PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	DEB, SP; MUNOZ, RM; BROWN, DR; SUBLER, MA; DEB, S				DEB, SP; MUNOZ, RM; BROWN, DR; SUBLER, MA; DEB, S			WILD-TYPE HUMAN P53 ACTIVATES THE HUMAN EPIDERMAL GROWTH-FACTOR RECEPTOR PROMOTER	ONCOGENE			English	Review							HUMAN PAPILLOMAVIRUS TYPE-16; PROTO-ONCOGENE; GENE-EXPRESSION; TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; RESPONSIVE ELEMENT; TRANSFORMED-CELLS; NUCLEAR-PROTEIN; BINDING PROTEIN; CARCINOMA-CELLS	We show that wild-type human p53 transactivates the human epidermal growth factor receptor (EGFR) promoter in vivo in a dose-dependent manner, implicating p53 in promotion of cell proliferation. This activation is sensitive to the expression of cellular oncoprotein MDM2 and human papillomavirus type 18 (HPV-18) E6 protein. The p53 response element is localized within -15 and -569 of the promoter. The EGFR promoter does not have a TATA box, and has low activity in Saos-2 cells in the absence of p53. Results from our in vivo transient transfection assays suggest that p53-binding sites, without any other known promoter element, can act as bidirectional promoters in the presence of wild-type p53. Gel retardation analyses suggest that p53 may serve to nucleate TBP on a promoter. We propose that p53 successfully nucleates the transcription complex, possibly via direct interaction with TFIID, and activates the EGFR promoter.	UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NIAID NIH HHS [AI31498-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031498] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARK AJL, 1985, P NATL ACAD SCI USA, V82, P8374, DOI 10.1073/pnas.82.24.8374; COLLINS VP, 1993, SEMIN CANCER BIOL, V4, P27; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V115, P185; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALEY J, 1987, ONCOGENE RES, V1, P375; HALEY JD, 1991, J BIOL CHEM, V266, P1746; HALL PA, 1993, ONCOGENE, V8, P203; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HUDSON LG, 1989, MOL ENDOCRINOL, V3, P400, DOI 10.1210/mend-3-2-400; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MAEKAWA T, 1989, J BIOL CHEM, V264, P5488; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MARTIN DW, 1993, BIOCHEM BIOPH RES CO, V195, P428, DOI 10.1006/bbrc.1993.2061; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MENDELSOHN J, 1992, NATL CANCER I MONOGR, V13, P125; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIETZ JA, 1992, EMBO J, V11, P5103; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NEAL DE, 1992, UROL INT, V48, P365, DOI 10.1159/000282357; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1981, MOL CELL BIOL, V1, P137; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SANTON JB, 1986, CANCER RES, V46, P4701; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHIO Y, 1992, P NATL ACAD SCI USA, V89, P5206; SHOBAT O, 1987, ONCOGENE, V1, P277; STOSCHECK CM, 1986, CANCER RES, V46, P1030; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUBLER MA, 1994, J VIROL, V68, P103, DOI 10.1128/JVI.68.1.103-110.1994; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; THOMPSON KL, 1992, MOL ENDOCRINOL, V6, P627, DOI 10.1210/me.6.4.627; Tripathy D, 1992, Cancer Treat Res, V63, P15; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1993, J CELL SCI, V105, P607; WANG WD, 1991, MOL CELL BIOL, V11, P4561, DOI 10.1128/MCB.11.9.4561; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHENG ZS, 1992, CELL GROWTH DIFFER, V3, P225	113	110	111	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1341	1349						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152794				2022-12-25	WOS:A1994NH40100005
J	BRANDT, R; LEE, G; TEPLOW, DB; SHALLOWAY, D; ABDELGHANY, M				BRANDT, R; LEE, G; TEPLOW, DB; SHALLOWAY, D; ABDELGHANY, M			DIFFERENTIAL EFFECT OF PHOSPHORYLATION AND SUBSTRATE MODULATION ON TAUS ABILITY TO PROMOTE MICROTUBULE GROWTH AND NUCLEATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TUBULIN BINDING DOMAIN; DEPENDENT PHOSPHORYLATION; MEDIATED PHOSPHORYLATION; DYNAMIC INSTABILITY; RAT-BRAIN; SEQUENCE; NEUROFILAMENTS; IDENTIFICATION; LOCALIZATION	The neuronal microtubule associated protein tau promotes microtubule assembly and has been implicated in the development of axonal morphology. To study the effect of phosphorylation and substrate modulation on tau's distinct activities to promote growth of existing microtubules and nucleation of new ones, we phosphorylated bacterially expressed human tau by cAMP-dependent protein kinase in the absence or presence of heparin, an acidic substrate modulator. We found that heparin increased phosphorylation of tau by a factor of more than 2 and produced tau bands with decreased electrophoretic mobility. We demonstrate that phosphorylation of tau in the absence or presence of heparin similarly reduced tau's activity to promote microtubule growth, whereas tau's activity to nucleate free microtubules was suppressed much more after phosphorylation in the presence of heparin. Using recombinant tau fragments we showed that heparin-induced phosphorylation caused a specific shift in electrophoretic mobility indicative of a change in tau's conformation. By aminoterminal sequencing of a tau fragment starting at residue 154 we provide evidence that phosphorylation of serine 156 is responsible for this mobility shift and for the effect on tau's nucleation activity. We conclude that tau's activities to promote growth of existing microtubules and nucleation of new ones are differentially affected by the phosphorylation of specific tau residues. Regulation of the phosphorylation state by substrate modulation may play an important role in regulating tau's function.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CTR NEUROL DIS,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,BIOPOLYMER LAB,BOSTON,MA 02115; CORNELL UNIV,DIV BIOL SCI,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Cornell University			Lee, Gloria/F-5965-2011	Lee, Gloria/0000-0002-8633-1534; Brandt, Roland/0000-0003-0101-1257	NATIONAL CANCER INSTITUTE [R01CA008964] Funding Source: NIH RePORTER; NCI NIH HHS [CA08964] Funding Source: Medline; NIGMS NIH HHS [GM39300] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELGHANY M, 1993, J BIOL CHEM, V268, P11976; ABDELGHANY M, 1990, P NATL ACAD SCI USA, V87, P7061, DOI 10.1073/pnas.87.18.7061; ABDELGHANY M, 1989, P NATL ACAD SCI USA, V86, P1761, DOI 10.1073/pnas.86.6.1761; ABDELGHANY M, 1992, BIOCHIM BIOPHYS ACTA, V1137, P349, DOI 10.1016/0167-4889(92)90156-6; ABDELGHANY M, 1987, P NATL ACAD SCI USA, V84, P8888, DOI 10.1073/pnas.84.24.8888; AIZAWA H, 1989, J BIOL CHEM, V264, P5885; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT R, 1993, J BIOL CHEM, V268, P3414; BRANDT R, 1993, J NEUROCHEM, V61, P997, DOI 10.1111/j.1471-4159.1993.tb03613.x; BRE MH, 1990, CELL MOTIL CYTOSKEL, V15, P88, DOI 10.1002/cm.970150205; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CACERES A, 1991, J NEUROSCI, V11, P1515; CORREAS I, 1992, J BIOL CHEM, V267, P15721; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; ENNULAT DJ, 1989, J BIOL CHEM, V264, P5327; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; FOLKMAN J, 1989, SCIENCE, V243, P1490, DOI 10.1126/science.2467380; GOEDERT M, 1991, TRENDS NEUROSCI, V14, P193, DOI 10.1016/0166-2236(91)90105-4; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HOSHI M, 1987, FEBS LETT, V217, P237, DOI 10.1016/0014-5793(87)80670-1; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; JOHNSON KA, 1977, J MOL BIOL, V117, P1, DOI 10.1016/0022-2836(77)90020-1; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEE G, 1990, CELL MOTIL CYTOSKEL, V15, P199, DOI 10.1002/cm.970150402; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEE G, 1992, J CELL SCI, V102, P227; Lee G, 1993, CURR OPIN CELL BIOL, V5, P88, DOI 10.1016/S0955-0674(05)80013-4; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; LU Q, 1993, J NEUROSCI, V13, P508; MACCIONI RB, 1989, ARCH BIOCHEM BIOPHYS, V275, P568, DOI 10.1016/0003-9861(89)90403-7; MAWALDEWAN M, 1992, J BIOL CHEM, V267, P19705; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MURPHY DB, 1977, J MOL BIOL, V117, P33, DOI 10.1016/0022-2836(77)90021-3; NESTLER EJ, 1984, PROTEIN PHOSPHORYLAT, P2; OUIMET CC, 1984, P NATL ACAD SCI-BIOL, V81, P5604, DOI 10.1073/pnas.81.17.5604; PIERRE M, 1983, BIOCHEM BIOPH RES CO, V115, P212, DOI 10.1016/0006-291X(83)90991-9; RACKER E, 1989, JNCI-J NATL CANCER I, V81, P247, DOI 10.1093/jnci/81.4.247; REED J, 1985, BIOCHEMISTRY-US, V24, P2967, DOI 10.1021/bi00333a024; REVISGUPTA S, 1991, P NATL ACAD SCI USA, V88, P5954, DOI 10.1073/pnas.88.14.5954; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TRINCZEK B, 1990, FEBS LETT, V277, P167, DOI 10.1016/0014-5793(90)80835-7; TUCKER RP, 1990, BRAIN RES REV, V15, P101, DOI 10.1016/0165-0173(90)90013-E; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WITMAN GB, 1976, P NATL ACAD SCI USA, V73, P4070, DOI 10.1073/pnas.73.11.4070; WRIGHT TC, 1989, HEPARIN CHEM BIOL PR, P295; YAMAMOTO H, 1988, J NEUROCHEM, V50, P1614, DOI 10.1111/j.1471-4159.1988.tb03051.x; YAMAMOTO H, 1985, J NEUROCHEM, V44, P759, DOI 10.1111/j.1471-4159.1985.tb12880.x; YAMAMOTO H, 1983, J NEUROCHEM, V41, P1119, DOI 10.1111/j.1471-4159.1983.tb09060.x	54	90	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11776	11782						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163474				2022-12-25	WOS:A1994NG37700018
J	MORRIS, L; CANNON, W; CLAVERIEMARTIN, F; AUSTIN, S; BUCK, M				MORRIS, L; CANNON, W; CLAVERIEMARTIN, F; AUSTIN, S; BUCK, M			DNA DISTORTION AND NUCLEATION OF LOCAL DNA UNWINDING WITHIN SIGMA-54 (SIGMA(N)) HOLOENZYME CLOSED PROMOTER COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-PNEUMONIAE-NIFL; BINDING-PROTEIN NTRC; TRANSCRIPTIONAL ACTIVATION; ATPASE ACTIVITY; A-DNA; INVIVO; CONFORMATION; INITIATION; POLYMERASE; MECHANISM	The sigma(N) (sigma54) RNA polymerase holoenzyme has the distinctive property of binding to promoters to form a closed promoter complex, which only isomerizes to the open complex when acted upon by an enhancer binding activator protein. We probed promoter complexes that form between sigma(N) and its holoenzyme with the conformationally sensitive footprinting reagents ortho-copper phenanthroline, potassium permanganate, and diethylpyrocarbonate. Results from these experiments indicate that the contacts sigma(N) makes at the -12 promoter element are necessary to promote a local DNA distortion immediately adjacent to this promoter element when the holoenzyme but not sigma(N) alone binds promoter DNA. Complexes in which this local distortion is not detected are not activatable, and the altered DNA conformation is diminished in the activated complex. We propose that a barrier to open complex formation in the sigma(N) holoenzyme closed complex is at some step or steps after the initial nucleation of DNA strand separation, which is detected as an altered DNA conformation stably maintained within the closed complex. Thus the activator protein may promote a conformational change in the sigma(N) holoenzyme to allow propagation of the altered DNA conformation, probably local unwinding, which we propose is necessary for formation of the melted DNA state, characteristic of the open promoter complex.	UNIV SUSSEX,AFRC,INST PLANT SCI RES,NITROGEN FIXAT LAB,BRIGHTON BN1 9RQ,E SUSSEX,ENGLAND; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	University of Sussex; Massachusetts Institute of Technology (MIT)				Claverie-Martin, Felix/0000-0003-2468-3267				AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; BUCK M, 1985, NUCLEIC ACIDS RES, V13, P7621, DOI 10.1093/nar/13.21.7621; BUCK M, 1992, NATURE, V358, P422, DOI 10.1038/358422a0; BUCK M, 1992, MOL MICROBIOL, V6, P1625, DOI 10.1111/j.1365-2958.1992.tb00887.x; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; CALLADINE CR, 1984, J MOL BIOL, V178, P773, DOI 10.1016/0022-2836(84)90251-1; CANNON W, 1993, MOL MICROBIOL, V8, P287, DOI 10.1111/j.1365-2958.1993.tb01573.x; CANNON W, 1992, J MOL BIOL, V225, P271, DOI 10.1016/0022-2836(92)90921-6; CANNON W, 1994, MOL MICROBIOL, V11, P227, DOI 10.1111/j.1365-2958.1994.tb00303.x; CHARLTON W, 1993, MOL MICROBIOL, V7, P1007, DOI 10.1111/j.1365-2958.1993.tb01192.x; CONNER BN, 1984, J MOL BIOL, V174, P663, DOI 10.1016/0022-2836(84)90089-5; DERVAN PB, 1986, SCIENCE, V232, P464, DOI 10.1126/science.2421408; DICKERSON RE, 1983, J MOL BIOL, V166, P419, DOI 10.1016/S0022-2836(83)80093-X; DRAPER DE, 1993, P NATL ACAD SCI USA, V90, P7429, DOI 10.1073/pnas.90.16.7429; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; GOTOH O, 1981, BIOPOLYMERS, V20, P1033, DOI 10.1002/bip.1981.360200513; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; LESSER DR, 1993, P NATL ACAD SCI USA, V90, P7548, DOI 10.1073/pnas.90.16.7548; MERRICK M, 1992, J BACTERIOL, V174, P7221, DOI 10.1128/jb.174.22.7221-7226.1992; MINCHIN SD, 1989, EMBO J, V8, P3491, DOI 10.1002/j.1460-2075.1989.tb08514.x; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; NORTH AK, 1993, J BACTERIOL, V175, P4267, DOI 10.1128/JB.175.14.4267-4273.1993; PEATTIE DA, 1980, P NATL ACAD SCI-BIOL, V77, P4679, DOI 10.1073/pnas.77.8.4679; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SEITZ TA, 1990, Q REV BIOPHYS, V23, P205; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; SPASSKY A, 1988, EMBO J, V7, P1871, DOI 10.1002/j.1460-2075.1988.tb03020.x; TRAVERS AA, 1993, PROTEIN DNA INTERACT; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WHITEHALL S, 1992, J MOL BIOL, V225, P591, DOI 10.1016/0022-2836(92)90388-Z; WONG CN, 1992, J BIOL CHEM, V267, P24762	37	75	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11563	11571						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157688				2022-12-25	WOS:A1994NF96600087
J	YAMITHEZI, A; PLAKSIN, D; EISENBACH, L				YAMITHEZI, A; PLAKSIN, D; EISENBACH, L			C-FOS AND C-JUN OVEREXPRESSION IN MALIGNANT-CELLS REDUCES THEIR TUMORIGENIC AND METASTATIC POTENTIAL, AND AFFECTS THEIR MHC CLASS-I GENE-EXPRESSION	ONCOGENE			English	Article							NF-KAPPA-B; EMBRYONAL CARCINOMA-CELLS; MAJOR HISTOCOMPATIBILITY GENE; TRANS-ACTING FACTOR; PROTO-ONCOGENE FOS; NEGATIVE REGULATION; TUMOR-CELLS; TRANSCRIPTION FACTORS; BINDING AFFINITIES; CANCER METASTASIS	Reduced co-expression of the c-fos and c-jun protooncogenes has been correlated with the down regulation of H-2K class I major histocompatibility antigens in high-metastatic cell lines from the Lewis lung carcinoma, B16 melanoma and the K1735 melanoma. Transfection of c-jun and c-fos genes into the high metastatic clones D122 (3LL) and F10.9 (B16 melanoma) resulted in activation of H-2 class I gene expression. D122 transfectants expressing high levels of c-jun and c-fos and F10.9 transfectants expressing high levels of c-fos exhibited markedly reduced tumorigenicity and were of low metastatic potential. In contrast, transfection of junB into the low metastatic, high H-2K(b), D(b) expressor clone A9 (3LL), reduced MHC class I gene expression, and converted the parental low, into high-metastatic cells. The data demonstrate the involvement of genes from the fos and jun family in regulation of MHC class I expression and consequently in regulation of immunogenicity and metastatic competence of tumor cells.	WEIZMANN INST SCI, DEPT CELL BIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science				Eisenbach, Lea R/0000-0002-4816-1968	NATIONAL CANCER INSTITUTE [R01CA028139] Funding Source: NIH RePORTER; NCI NIH HHS [CA 28139] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BARZILAY J, 1987, LEUKEMIA, V1, P198; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; EISENBACH L, 1983, INT J CANCER, V32, P113, DOI 10.1002/ijc.2910320118; Eisenbach L, 1991, Semin Cancer Biol, V2, P179; EISENBACH L, 1984, INT J CANCER, V34, P567, DOI 10.1002/ijc.2910340421; Eisenbach L, 1983, Symp Fundam Cancer Res, V36, P101; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; FIDLER IJ, 1990, J NATL CANCER I, V82, P166, DOI 10.1093/jnci/82.3.166; FLANAGAN JR, 1991, P NATL ACAD SCI USA, V88, P3145, DOI 10.1073/pnas.88.8.3145; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; HOWCROFT TK, 1993, EMBO J, V12, P3163, DOI 10.1002/j.1460-2075.1993.tb05985.x; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; ISRAEL A, 1987, P NATL ACAD SCI USA, V84, P2653, DOI 10.1073/pnas.84.9.2653; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; KRALOVA J, 1992, EMBO J, V11, P4591, DOI 10.1002/j.1460-2075.1992.tb05561.x; KRIPKE ML, 1979, JNCI-J NATL CANCER I, V63, P541, DOI 10.1093/jnci/63.3.541; KUSHTAI G, 1990, INT J CANCER, V45, P1131, DOI 10.1002/ijc.2910450624; KUSHTAI G, 1988, ONCOGENE, V2, P119; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MIYAZAKI J, 1986, P NATL ACAD SCI USA, V83, P9537, DOI 10.1073/pnas.83.24.9537; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; ONO SJ, 1991, P NATL ACAD SCI USA, V88, P4304, DOI 10.1073/pnas.88.10.4304; ONO SJ, 1991, P NATL ACAD SCI USA, V88, P4309, DOI 10.1073/pnas.88.10.4309; OZATO K, 1981, J IMMUNOL, V126, P317; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; PLAKSIN D, 1988, P NATL ACAD SCI USA, V85, P4463, DOI 10.1073/pnas.85.12.4463; PORGADOR A, 1989, J IMMUNOGENET, V16, P291; PORGADOR A, 1993, INT J CANCER, V53, P471, DOI 10.1002/ijc.2910530320; PORGADOR A, 1992, CANCER RES, V52, P3679; PORGADOR A, 1993, J IMMUNOL, V150, P1458; PORGADOR A, 1991, INT J CANCER, P54; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; RICCIO A, 1985, NUCLEIC ACIDS RES, V13, P2759, DOI 10.1093/nar/13.8.2759; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; RUTHER U, 1988, CELL, V53, P847, DOI 10.1016/S0092-8674(88)90289-9; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, COLD SPRING HARB SYM, V53, P749, DOI 10.1101/SQB.1988.053.01.085; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHIRAYOSHI Y, 1987, MOL CELL BIOL, V7, P4542, DOI 10.1128/MCB.7.12.4542; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; VERMA IM, 1990, CIBA F SYMP, V150, P128; VERMA IM, 1988, UCLA S MOL CELLULAR, V87; WALLICH R, 1985, NATURE, V315, P301, DOI 10.1038/315301a0; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x	80	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1065	1079						15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134110				2022-12-25	WOS:A1994NC04800009
J	MIQUEROL, L; LOPEZ, S; CARTIER, N; TULLIEZ, M; RAYMONDJEAN, M; KAHN, A				MIQUEROL, L; LOPEZ, S; CARTIER, N; TULLIEZ, M; RAYMONDJEAN, M; KAHN, A			EXPRESSION OF THE L-TYPE PYRUVATE-KINASE GENE AND THE HEPATOCYTE NUCLEAR FACTOR-4 TRANSCRIPTION FACTOR IN EXOCRINE AND ENDOCRINE PANCREAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR SUPERFAMILY; POLYMERASE CHAIN-REACTION; TRANSGENIC MICE; FACTOR-IV; LIVER; RAT; CELLS; PROMOTER; INSULIN; BINDING	The L-pyruvate kinase (L-PK) gene is slightly active in normal and tumoral endocrine pancreatic tissues while, in vivo, this gene is not transcribed in the exocrine pancreas. Nevertheless, the L-PK gene is re-expressed at a very low level in cultured 266.6 cells derived from an exocrine pancreas carcinoma. The L-PK gene is early activated in endodermal tissues, e.g. yolk sac and primitive intestine; it remains transcribed in fetal pancreas. In adult, L-PK gene expression is restricted to some endocrine cells. Hepatocyte nuclear factor (HNF) 1 and HNF4 are the main tissue restricted transcription factors involved in tissue specific expression of the L-PK gene. HNF1 concentration is similar in liver and all pan creatic cells. HNF4 concentration is high in liver, much lower in islets of Langerhans, endocrine pancreatic tumors, and cultured insulinoma cells, and is scarcely detectable in adult exocrine pancreas. This distribution of HNF4 parallels the expression of the L-PK gene. In vivo footprinting experiments show that the HNF1 binding site is similarly occupied in both adult liver and adult pancreas, in which this gene is practically inactive. In this latter tissue, however, the HNF4 binding site is differently occupied with respect to the liver. Since the chromatin structure remains open around the L-PK promoter in pancreas, the L-PK gene can probably be reexpressed under certain circumstances, for instance in cancerous pancreatic cells.	HOP ST VINCENT DE PAUL, INSERM, U342, F-75014 PARIS, FRANCE; HOP COCHIN, ANAT PATHOL LAB, F-75014 PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	MIQUEROL, L (corresponding author), CHU COCHIN, INST COCHIN GENET MOLEC, INSERM, U129, UNITE RECH GENET & PATHOL MOLEC, F-75014 PARIS, FRANCE.		cartier, nathalie/C-3103-2012	cartier, nathalie/0000-0003-2298-5261				AKLI S, 1991, GENOMICS, V11, P124, DOI 10.1016/0888-7543(91)90109-R; ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BLUMENFELD M, 1991, DEVELOPMENT, V113, P589; CARTIER N, 1992, ONCOGENE, V7, P1413; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CHELLY J, 1990, EUR J BIOCHEM, V187, P691, DOI 10.1111/j.1432-1033.1990.tb15355.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COGNET M, 1987, J MOL BIOL, V196, P11, DOI 10.1016/0022-2836(87)90507-9; COGNET M, 1991, J BIOL CHEM, V266, P7368; COSTA RH, 1990, P NATL ACAD SCI USA, V87, P6589, DOI 10.1073/pnas.87.17.6589; CUIF MH, 1993, J BIOL CHEM, V268, P13769; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMINGO M, 1992, J HISTOCHEM CYTOCHEM, V40, P665, DOI 10.1177/40.5.1374093; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; GAZDAR AF, 1980, P NATL ACAD SCI-BIOL, V77, P3519, DOI 10.1073/pnas.77.6.3519; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; HATA S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P211, DOI 10.1016/0167-4781(92)90080-J; IMMURA K, 1982, METHOD ENZYMOL, V90, P150; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KAHN A, 1982, METHOD ENZYMOL, V90, P131; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEDOUARIN NM, 1988, CELL, V53, P169, DOI 10.1016/0092-8674(88)90375-3; LIU ZR, 1993, J BIOL CHEM, V268, P12787; MEDLOCK ES, 1983, ANAT REC, V207, P31, DOI 10.1002/ar.1092070105; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; NOGUCHI T, 1991, BIOCHEM BIOPH RES CO, V181, P259, DOI 10.1016/S0006-291X(05)81411-1; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; PEARSE AGE, 1966, NATURE, V211, P598, DOI 10.1038/211598a0; PICTET RL, 1972, DEV BIOL, V29, P436, DOI 10.1016/0012-1606(72)90083-8; RAMJI DP, 1991, NUCLEIC ACIDS RES, V19, P1139, DOI 10.1093/nar/19.5.1139; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; SCHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90, DOI 10.1016/0003-2697(89)90019-5; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; TREMP GL, 1989, J BIOL CHEM, V264, P19904; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1986, J BIOL CHEM, V261, P7621; VAULONT S, 1989, MOL CELL BIOL, V9, P4409, DOI 10.1128/MCB.9.10.4409; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0	48	118	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8944	8951						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132632				2022-12-25	WOS:A1994NB41100050
J	DELGADO, A; RAMOS, JL				DELGADO, A; RAMOS, JL			GENETIC-EVIDENCE FOR ACTIVATION OF THE POSITIVE TRANSCRIPTIONAL REGULATOR XYLR, A MEMBER OF THE NTRC FAMILY OF REGULATORS, BY EFFECTOR-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS TOL PLASMID; INTEGRATION HOST FACTOR; ESCHERICHIA-COLI; KLEBSIELLA-PNEUMONIAE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; INITIATION SITE; UPPER PATHWAY; PROTEIN; OPERON	The XylR protein positively controls expression from the Pseudomonas putida TOL plasmid sigma(54)-dependent Pu and Ps promoters, in response to the presence of aromatic effecters such as m-xylene, m-methylbenzyl alcohol, and p-chlorobenzaldehyde in the culture medium. XylR also autoregulates its own synthesis. A mutant XylR regulator called XylR7 was isolated after nitrosoguanidine mutagenesis of the wild-type gene and phenotypic selection for mutants that had acquired the ability to recognize m-nitrotoluene, a nitroarene that is not an effector for the wild-type regulator. The mutant regulator exhibited a single point mutation that resulted in a change in codon 172 (GAA --> AAA), which should result in a Glu --> Lys change in the polypeptide chain, The effector profile of the mutant regulator was determined by measuring beta-galactosidase from a fusion of the Pu promoter to a promoterless lacZ gene. The results showed that the mutant regulator had acquired the ability to recognize m-nitrotoluene, and retained the wild type regulator's ability to recognize most of the wild type effecters. Full transcriptional activation of the Pu promoter by XylR7, as with the wild-type XylR protein, requires its full modular structure, namely the sigma 54 recognition site, the integration host factor binding site, and the upstream activation sequences. The XylR7 regulator did not stimulate transcription from the Ps promoter in response to the presence of its effecters, and autoregulated its own synthesis at low levels.	CONSEJO SUPER INVEST CIENT,ESTAC EXPTL ZAIDIN,DEPT PLANT BIOCHEM,E-18008 GRANADA,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ)			Delgado, Asunción/HGU-5527-2022	Ramos, Juan L./0000-0002-8731-7435				ABRIL MA, 1993, MOL GEN GENET, V239, P281, DOI 10.1007/BF00281629; ABRIL MA, 1991, J BIOL CHEM, V266, P15832; ABRIL MA, 1989, J BACTERIOL, V171, P6782, DOI 10.1128/jb.171.12.6782-6790.1989; BUCK M, 1987, MOL MICROBIOL, V1, P243, DOI 10.1111/j.1365-2958.1987.tb00518.x; DAYHOFF MO, 1978, ATLAS PROTEIN SEQUEN, V5, P1; DELORENZO V, 1991, EMBO J, V10, P1159, DOI 10.1002/j.1460-2075.1991.tb08056.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIXON R, 1986, MOL GEN GENET, V203, P129, DOI 10.1007/BF00330393; DRUMMOND M, 1986, EMBO J, V5, P441, DOI 10.1002/j.1460-2075.1986.tb04230.x; EGAN SM, 1990, J BACTERIOL, V172, P5020, DOI 10.1128/jb.172.9.5020-5029.1990; FRANKLIN FCH, 1983, J BACTERIOL, V154, P676, DOI 10.1128/JB.154.2.676-685.1983; FROST S, 1989, P NATL ACAD SCI USA, V86, P6052; GROSS R, 1989, MOL MICROBIOL, V3, P1661, DOI 10.1111/j.1365-2958.1989.tb00152.x; HARAYAMA S, 1989, GENETICS BACTERIAL D, P154; HOLTEL A, 1992, NUCLEIC ACIDS RES, V20, P1755, DOI 10.1093/nar/20.7.1755; INOUYE S, 1985, J BACTERIOL, V163, P863, DOI 10.1128/JB.163.3.863-869.1985; INOUYE S, 1981, J BACTERIOL, V148, P413, DOI 10.1128/JB.148.2.413-418.1981; INOUYE S, 1990, J MOL BIOL, V216, P251, DOI 10.1016/S0022-2836(05)80317-1; INOUYE S, 1987, P NATL ACAD SCI USA, V84, P5182, DOI 10.1073/pnas.84.15.5182; INOUYE S, 1983, J BACTERIOL, V155, P1192, DOI 10.1128/JB.155.3.1192-1199.1983; INOUYE S, 1988, GENE, V66, P301; INOUYE S, 1984, P NATL ACAD SCI-BIOL, V81, P1688, DOI 10.1073/pnas.81.6.1688; ISHIMOTO KS, 1992, J BACTERIOL, V174, P3514, DOI 10.1128/JB.174.11.3514-3521.1992; JOERGER RD, 1989, J BACTERIOL, V171, P3258, DOI 10.1128/jb.171.6.3258-3267.1989; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; MARQUES S, 1994, IN PRESS BIOCH BIOPH; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NORTH AK, 1993, J BACTERIOL, V175, P4267, DOI 10.1128/JB.175.14.4267-4273.1993; PITTARD AJ, 1991, MOL MICROBIOL, V5, P1585, DOI 10.1111/j.1365-2958.1991.tb01904.x; RAMAKRISHNAN G, 1990, P NATL ACAD SCI USA, V87, P2369, DOI 10.1073/pnas.87.6.2369; RAMOS JL, 1986, P NATL ACAD SCI USA, V83, P8467, DOI 10.1073/pnas.83.22.8467; RAMOS JL, 1987, MOL MICROBIOL, V1, P293, DOI 10.1111/j.1365-2958.1987.tb01935.x; RONSON CW, 1987, NUCLEIC ACIDS RES, V15, P7921, DOI 10.1093/nar/15.19.7921; SHINGLER V, 1993, J BACTERIOL, V175, P1596, DOI 10.1128/JB.175.6.1596-1604.1993; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; WORSEY MJ, 1975, J BACTERIOL, V124, P7, DOI 10.1128/JB.124.1.7-13.1975; WOZNIAK DJ, 1991, J BACTERIOL, V173, P1406, DOI 10.1128/jb.173.4.1406-1413.1991; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	40	64	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8059	8062						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132529				2022-12-25	WOS:A1994NB40900037
J	AHN, BY; GERSHON, PD; MOSS, B				AHN, BY; GERSHON, PD; MOSS, B			RNA POLYMERASE-ASSOCIATED PROTEIN RAP94 CONFERS PROMOTER SPECIFICITY FOR INITIATING TRANSCRIPTION OF VACCINIA VIRUS EARLY-STAGE GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTANTS; FACTOR-IIF; 2ND-LARGEST SUBUNIT; INTERMEDIATE GENE; TERNARY COMPLEXES; DNA; EXPRESSION; GENOME; IDENTIFICATION; COMPONENT	The association of a 94,000-Da viral polypeptide, called Rap94, with 30-40% of the multisubunit DNA-dependent RNA polymerase molecules purified from infectious vaccinia virus particles was established by immunoaffinity chromatography. The submolar amount of Rap94, relative to RNA polymerase, was confirmed by quantitative immunoblotting of total virion extracts. Only the RNA polymerase molecules containing Rap94 could functionally interact with VETF, the vaccinia virus early transcription factor, to transcribe a double-stranded DNA template regulated by a viral early stage promoter. Rap94 was required for the synthesis of short oligoribonucleotides and for the formation of stable ter nary transcription complexes. With a nonspecific single stranded DNA template, however, the Rap94-deficient polymerase had greater catalytic activity than the Rap94-containing polymerase. These data support a model in which Rap94 confers specificity to the RNA polymerase for promoters of early stage genes.	NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Moss, Bernard/0000-0002-2154-8564				AHN BY, 1992, P NATL ACAD SCI USA, V89, P3536, DOI 10.1073/pnas.89.8.3536; AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; AMEGADZIE BY, 1991, VIROLOGY, V180, P88, DOI 10.1016/0042-6822(91)90012-Z; AMEGADZIE BY, 1992, J VIROL, V66, P3003, DOI 10.1128/JVI.66.5.3003-3010.1992; BAROUDY BM, 1980, J BIOL CHEM, V255, P4372; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BROYLES SS, 1987, MOL CELL BIOL, V7, P7, DOI 10.1128/MCB.7.1.7; BROYLES SS, 1988, J BIOL CHEM, V263, P10761; BROYLES SS, 1991, J BIOL CHEM, V266, P15539; BROYLES SS, 1990, J VIROL, V64, P1523, DOI 10.1128/JVI.64.4.1523-1529.1990; BROYLES SS, 1986, P NATL ACAD SCI USA, V83, P3141, DOI 10.1073/pnas.83.10.3141; BURGESS RR, 1976, RNA POLYM; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; Chamberlin M.J., 1976, RNA POLYMERASE, P159; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONDIT RC, 1983, VIROLOGY, V128, P429, DOI 10.1016/0042-6822(83)90268-4; FLORES O, 1988, J BIOL CHEM, V263, P10812; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GERSHON PD, 1990, P NATL ACAD SCI USA, V87, P4401, DOI 10.1073/pnas.87.11.4401; GONG DW, 1992, NUCLEIC ACIDS RES, V20, P6414, DOI 10.1093/nar/20.23.6414; HAGLER J, 1992, J VIROL, V66, P2982, DOI 10.1128/JVI.66.5.2982-2989.1992; HAGLER J, 1992, J BIOL CHEM, V267, P7644; HARRIS N, 1993, P NATL ACAD SCI USA, V90, P2860, DOI 10.1073/pnas.90.7.2860; JONES EV, 1987, J VIROL, V61, P1765, DOI 10.1128/JVI.61.6.1765-1771.1987; KANE EM, 1992, J VIROL, V66, P5752, DOI 10.1128/JVI.66.10.5752-5762.1992; KECK JG, 1990, CELL, V61, P801, DOI 10.1016/0092-8674(90)90190-P; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; LI J, 1993, J BIOL CHEM, V268, P2773; LUSE DS, 1987, J BIOL CHEM, V262, P14990; MCCRACKEN S, 1991, SCIENCE, V253, P290; MOSS B, 1991, J BIOL CHEM, V266, P1355; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; PATEL DD, 1989, J VIROL, V63, P1076, DOI 10.1128/JVI.63.3.1076-1086.1989; ROSEL JL, 1986, J VIROL, V60, P436, DOI 10.1128/JVI.60.2.436-449.1986; STUNNENBERG HG, 1989, MOL BIOL RNA, P199; THOMPSON CL, 1986, VIROLOGY, V150, P10, DOI 10.1016/0042-6822(86)90261-8; TRAVERS AA, 1969, NATURE, V222, P537, DOI 10.1038/222537a0; VENKATESAN S, 1981, J VIROL, V37, P738, DOI 10.1128/JVI.37.2.738-747.1981; VOS JC, 1991, CELL, V65, P105, DOI 10.1016/0092-8674(91)90412-R; VOS JC, 1991, EMBO J, V10, P2553, DOI 10.1002/j.1460-2075.1991.tb07795.x; WRIGHT CF, 1989, J VIROL, V63, P4224, DOI 10.1128/JVI.63.10.4224-4233.1989; WRIGHT CF, 1991, J VIROL, V65, P3715, DOI 10.1128/JVI.65.7.3715-3720.1991; YUEN L, 1986, J VIROL, V60, P320, DOI 10.1128/JVI.60.1.320-323.1986; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6069, DOI 10.1073/pnas.84.17.6069; ZHANG Y, 1994, IN PRESS J VIROL, V68; ZHANG YF, 1992, J VIROL, V66, P6470, DOI 10.1128/JVI.66.11.6470-6479.1992	48	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7552	7557						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125977				2022-12-25	WOS:A1994NA03200082
J	XIA, Y; HWANG, L; COBB, MH; BAER, R				XIA, Y; HWANG, L; COBB, MH; BAER, R			PRODUCTS OF THE TAL2 ONCOGENE IN LEUKEMIC T-CELLS - BHLH PHOSPHOPROTEINS WITH DNA-BINDING ACTIVITY	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; LOOP-HELIX PROTEIN; GLUTATHIONE-S-TRANSFERASE; CHROMOSOMAL TRANSLOCATION; ESCHERICHIA-COLI; ENHANCER-BINDING; GENE; MOTIF; PURIFICATION; MYOD	The TAL2 gene is activated as a result of the (7;9) (q34;q32) translocation, a chromosome defect found in the malignant cells of some patients with T-cell acute lymphoblastic leukemia (T-ALL). TAL2 potentially encodes a basic helix-loop-helix motif that is highly related to those specified by TAL1 and LYL1, distinct genes that have also been implicated in T-ALL. In this report we show that leukemic cells bearing the (7;9) (q34;q32) translocation express a TAL2 gene product of 108 amino acids. In leukemic cells this product exists in both a phosphorylated (pp13(TAL2)) and an unphosphorylated (p12(TAL2)) form. Serine residue 100 is the major site of TAL2 phosphorylation in vivo, and it serves as an effective in vitro substrate for mitogen-activated protein (MAP) kinases such as ERK1. TAL2 polypeptides interact in vivo with the E2A gene products (E47 and E12) to form bHLH heterodimers that bind DNA in a sequence-specific manner. The TAL2 polypeptides do not bind DNA by themselves, however, suggesting that their functional properties may be contingent upon association with other bHLH proteins. Taken together, the properties of TAL2 evaluated here broadly resemble those described previously for TAL1, and therefore support the idea that both proteins promote T-ALL by a common mechanism.	UNIV TEXAS,SOUTHWESTERN MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; UNIV TEXAS,SOUTHWESTERN MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Cobb, Melanie/0000-0003-0833-5473	NCI NIH HHS [CA44016] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA044016] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; APLAN PD, 1992, BLOOD, V79, P1327; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; BASH RO, 1993, BLOOD, V81, P2110; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1992, J EXP MED, V176, P919, DOI 10.1084/jem.176.4.919; BERNARD O, 1991, ONCOGENE, V6, P1477; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARROLL AJ, 1990, BLOOD, V76, P1220; CHAKRABORTY T, 1992, J BIOL CHEM, V267, P17498; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CHENG JT, 1993, ONCOGENE, V8, P677; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FINKEL T, 1993, J BIOL CHEM, V268, P5; FITZGERALD TJ, 1991, BLOOD, V78, P2686; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HSU HL, 1994, UNPUB; HSU HL, 1994, IN PRESS P NATL ACAD, V91; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JONSSON OG, 1991, J CLIN INVEST, V87, P2029, DOI 10.1172/JCI115232; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; REYNOLDS TC, 1987, CELL, V50, P107, DOI 10.1016/0092-8674(87)90667-2; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SADOWSKI I, 1988, NATURE, V335, P559; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH SD, 1988, BLOOD, V71, P395; TYCKO B, 1989, J EXP MED, V169, P369, DOI 10.1084/jem.169.2.369; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WESTBROOK CA, 1987, P NATL ACAD SCI USA, V84, P251, DOI 10.1073/pnas.84.1.251; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; XIA Y, 1992, GENE CHROMOSOME CANC, V4, P211, DOI 10.1002/gcc.2870040304	54	31	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1437	1446						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152805				2022-12-25	WOS:A1994NH40100016
J	KATO, K; HASEGAWA, K; GOTO, S; INAGUMA, Y				KATO, K; HASEGAWA, K; GOTO, S; INAGUMA, Y			DISSOCIATION AS A RESULT OF PHOSPHORYLATION OF AN AGGREGATED FORM OF THE SMALL STRESS PROTEIN, HSP27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; TUMOR-NECROSIS-FACTOR; EHRLICH ASCITES TUMOR; ALPHA-B-CRYSTALLIN; RODENT CELLS; OKADAIC ACID; EXPRESSION; IDENTIFICATION; INTERLEUKIN-1; KINASE	We have found that the small stress protein, hsp27, exists in extracts of U251 MG human glioma cells in two forms: a large or aggregated form (L-hsp27, 300-400 kDa) and a small or dissociated form (S-hsp27, <70 kDa), as indicated by centrifugation on sucrose density gradients. Dissociation of L-hsp27 to S-hsp27 was enhanced by incubation of cells with phorbol 12-myristate-13 acetate, interleukin-1alpha, tumor necrosis factor alpha, or okadaic acid, all of which are known to enhance or mimic the effects of phosphorylation of hsp27 without stimulation of its synthesis. Exposure of cells to chemical stressors, namely, NaAsO2 and CdCl2, also enhanced the dissociation of L-hsp27. hsp27 that had been labeled with [P-32]H3PO4 in U251 MG cells was detected mostly in fractions that contained S-hsp27, and the incorporation of radioactivity to S-hsp27 was enhanced under conditions that stimulated the dissociation of L-hsp27. L-hsp27 present in the (NH4)2SO4 fraction (0-50% saturation) of cell extracts were dissociated to P-32-labeled hsp27 when incubated in the presence of [gamma-P-32]ATP and Mg. These results indicate that the molecular configuration of hsp27 in cells is determined in part by phosphorylation and dephosphorylation of this protein by protein kinase(s) and phosphatase(s) and, moreover, that the rapid dissociation of the aggregated form of hsp27 by phosphorylation might be involved in a cellular defense mechanism for protection against stress.			KATO, K (corresponding author), AICHI PREFECTURAL COLONY,INST DEV RES,DEPT BIOCHEM,KASUGAI,AICHI 48003,JAPAN.							ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; BENNDORF R, 1992, BIOCHIM BIOPHYS ACTA, V1136, P203, DOI 10.1016/0167-4889(92)90258-D; BEYSTEAD TAJ, 1989, NATURE, V337, P78; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; FORNACE AJ, 1986, NUCLEIC ACIDS RES, V14, P5793, DOI 10.1093/nar/14.14.5793; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; GAESTEL M, 1992, J BIOL CHEM, V267, P21607; GAESTEL M, 1989, EUR J BIOCHEM, V179, P209, DOI 10.1111/j.1432-1033.1989.tb14542.x; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUY GR, 1992, J BIOL CHEM, V267, P1846; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; KASAHARA K, 1993, EUR J BIOCHEM, V213, P1101, DOI 10.1111/j.1432-1033.1993.tb17859.x; KATO K, 1993, BIOCHIM BIOPHYS ACTA, V1175, P257, DOI 10.1016/0167-4889(93)90214-A; KATO K, 1993, J BIOCHEM-TOKYO, V114, P640, DOI 10.1093/oxfordjournals.jbchem.a124230; KATO K, 1992, J BIOL CHEM, V267, P7718; KIM YJ, 1983, J CELL BIOL, V96, P393, DOI 10.1083/jcb.96.2.393; KLEMENZ R, 1993, J CELL BIOL, V120, P639, DOI 10.1083/jcb.120.3.639; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; ROYAYE B, 1989, BIOCHEM BIOPH RES CO, V163, P301; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; TANGUAY RM, 1993, DEV GENET, V14, P112, DOI 10.1002/dvg.1020140205; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936; ZHOU M, 1993, J BIOL CHEM, V268, P325	28	218	221	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11274	11278						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157658				2022-12-25	WOS:A1994NF96600047
J	BEDOWS, E; NORTON, SE; HUTH, JR; SUGANUMA, N; BOIME, I; RUDDON, RW				BEDOWS, E; NORTON, SE; HUTH, JR; SUGANUMA, N; BOIME, I; RUDDON, RW			MISFOLDED HUMAN CHORIONIC-GONADOTROPIN BETA-SUBUNITS ARE SECRETED FROM TRANSFECTED CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; PROTEIN-DEGRADATION; HEMAGGLUTININ; FORM; KINETICS; HORMONE; INVITRO; DIMER	There are six intramolecular disulfide (S-S) bonds that form during intracellular folding of the human chorionic gonadotropin (hCG)-beta subunit. Site-directed mutagenesis of every pair of Cys residues involved in the formation of each S-S bond was used to examine the roles that S-S bonds play in beta subunit folding and secretion. Tryptic maps of secreted hCG-beta showed that only one S-S bond formed in all S-S bond mutants that failed to fold from the earliest detectable beta folding intermediate, p beta 1, into a second major intermediate, p beta 2 (C34A-C88A, C38-C57A or C9A-C90A mutants), whereas all 5 remaining S-S bonds formed in mutants when p beta 1 --> p beta 2 conversion occurred (C23A-C72A, C93A-C100A, or C26A-C110A mutants). Nonreducing SDS-polyacrylamide gel electrophoresis showed that beta multimers were secreted from cells expressing S-S bond mutations where the folding of p beta 1 --> p beta 2 was blocked. However, for mutations where p beta 1 --> p beta 2 conversion was efficient, beta monomers rather than multimers were secreted. For all cell lines studied, secreted hCG-beta migrated as monomeric beta during reducing SDS-polyacrylamide gel electrophoresis, indicating that hCG-beta multimers formed via intermolecular cross-linking of unpaired thiols. Tryptic maps of hCG-beta isolated from mutants lacking the 34-88 bond, where >80% turnover occurs, showed that only the 38-57 S-S bond formed. beta Subunits lacking the 9-90 linkage also have only S-S bond 38-57 formed, but <10% turnover of C9A-C90A hcg-beta occurs. Thus, subtle conformational differences between partially folded or misfolded beta subunits may determine whether hCG-beta is degraded, or undergoes intracellular translocation and secretion.	UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC & ALLIED DIS, OMAHA, NE 68198 USA; WASHINGTON UNIV, SCH MED, DEPT PHARMACOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT OBSTET & GYNECOL, ST LOUIS, MO 63110 USA; UNIV NEBRASKA, MED CTR, DEPT PHARMACOL, OMAHA, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; Washington University (WUSTL); Washington University (WUSTL); University of Nebraska System; University of Nebraska Medical Center					FIC NIH HHS [1F05TW-04124] Funding Source: Medline; NCI NIH HHS [CA32949] Funding Source: Medline; NICHD NIH HHS [HD23398] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023398] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [F05TW004124] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA032949] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BEDOWS E, 1993, J BIOL CHEM, V268, P11655; BEEBE JS, 1990, J BIOL CHEM, V265, P312; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; HUANG JN, 1993, MOL CELL ENDOCRINOL, V90, P211, DOI 10.1016/0303-7207(93)90154-C; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HUTH JR, 1992, J BIOL CHEM, V267, P21396; HUTH JR, 1992, J BIOL CHEM, V267, P8870; HUTH JR, 1993, J BIOL CHEM, V268, P16472; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JAENICKE R, 1993, CURR OPIN STRUC BIOL, V3, P104, DOI 10.1016/0959-440X(93)90209-4; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSTBADER JW, 1993, ENDOCR REV, V14, P291, DOI 10.1210/er.14.3.291; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MCGUIRE MC, 1989, P NATL ACAD SCI USA, V86, P953, DOI 10.1073/pnas.86.3.953; MULLENBACH R, 1989, TRENDS GENET, V5, P391; NG DTW, 1989, J CELL BIOL, V109, P3273, DOI 10.1083/jcb.109.6.3273; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PETERS BP, 1984, J BIOL CHEM, V259, P5123; RUDDON RW, 1987, J BIOL CHEM, V262, P12533; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; TOOZE J, 1989, J CELL BIOL, V109, P35, DOI 10.1083/jcb.109.1.35; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; YON JM, 1991, BIOL CELL, V71, P17, DOI 10.1016/0248-4900(91)90047-Q; YOUNG J, 1993, J BIOL CHEM, V268, P19810	36	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10574	10580						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144645				2022-12-25	WOS:A1994NF01700059
J	FIORELLA, PD; NAPOLI, JL				FIORELLA, PD; NAPOLI, JL			MICROSOMAL RETINOIC ACID METABOLISM - EFFECTS OF CELLULAR RETINOIC ACID-BINDING PROTEIN (TYPE-I) AND C18-HYDROXYLATION AS AN INITIAL STEP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; INVIVO METABOLISM; DIFFERENTIAL EXPRESSION; 13-CIS-RETINOIC ACID; ESCHERICHIA-COLI; RECEPTOR-ALPHA; RAT-LIVER; INVITRO; BETA; IDENTIFICATION	This report extends our observation that cellular retinoic acid-binding protein type I (CRABP) serves as substrate for retinoic acid metabolism by testis microsomes. Retinoic acid bound to excess CRABP was metabolized at 70% of the unbound retinoic acid rate with testis microsomes and at the same rates as unbound retinoic acid with kidney and lung microsomes. Chromatography of testis, lung, kidney, and liver microsomal incubations provided two sets of metabolites each, P1 and P2. The composition of P2 was characteristic of the individual tissue. CRABP had modest quantitative affects on P2 composition, but did not affect P2 qualitatively. Retinoids bound to CRABP, isolated from a testis microsomal incubation, consisted of 50% retinoic acid, 32% P1 and 17% P2, suggesting that CRABP may bind retinoic acid metabolites in vivo. The effect of CRABP on the rate of metabolism was retinoid specific. Two major components of P2, 4-hydroxy-retinoic acid and 4-oxo-retinoic acid, when bound to CRABP were metabolized slowly if at all, by testis microsomes, in contrast to CRABP-bound retinoic acid which had an elimination t(1/2) of 40 min. Unbound retinoic acid, 4-hydroxy-retinoic acid, and 4-oxo-retinoic acid had elimination t(1/2) values of 35, 40, and 9 min, respectively. Reduced metabolism of CRABP-bound C4-derivatized retinoids suggests pathways of retinoic acid metabolism besides the one initiated by C4-hydroxylation, This was corroborated by identification of 18-hydrexy-retinoic acid as a testis, lung, and liver microsomal retinoic acid metabolite. Ketoconazole inhibited the metabolism by testis microsomes of free and CRABP-bound retinoic acid with IC50 values of 2 and 0.7 mu M, respectively, denoting catalysis by cytochrome P-450. These results indicate that cloistering retinoic acid in CRABP, while permitting metabolism, may operate throughout CRABP-expressing tissues as a mechanism of controlling the concentrations of free retinoic acid.	SUNY BUFFALO, SCH MED & BIOMED SCI, DEPT BIOCHEM, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036870] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36870] Funding Source: Medline; NIEHS NIH HHS [ES09505] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAILEY JS, 1988, J BIOL CHEM, V263, P9326; BASHOR MM, 1973, P NATL ACAD SCI USA, V70, P3483, DOI 10.1073/pnas.70.12.3483; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BOYLAN JF, 1992, J BIOL CHEM, V267, P21486; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE SD, 1989, FASEB J, V3, P2480, DOI 10.1096/fasebj.3.13.2680704; COWAN SW, 1993, MOL BIOL, V230, P1225; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DUELL EA, 1992, J CLIN INVEST, V90, P1269, DOI 10.1172/JCI115990; DUNAGIN PE, 1965, SCIENCE, V148, P86, DOI 10.1126/science.148.3666.86; ERIKSSON U, 1987, J CELL PHYSIOL, V133, P482, DOI 10.1002/jcp.1041330308; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; FIORELLA PD, 1993, J BIOL CHEM, V268, P21545; FROLIK CA, 1980, J BIOL CHEM, V255, P8057; FROLIK CA, 1979, BIOCHEMISTRY-US, V18, P2092, DOI 10.1021/bi00577a039; HANNI R, 1977, HELV CHIM ACTA, V60, P881, DOI 10.1002/hlca.19770600317; HANNI R, 1976, HELV CHIM ACTA, V59, P2221, DOI 10.1002/hlca.19760590636; HAQ RU, 1992, J LIPID RES, V33, P381; HARNISH DC, 1990, DIFFERENTIATION, V45, P103, DOI 10.1111/j.1432-0436.1990.tb00463.x; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KOCHHAR DM, 1967, ACTA PATHOL MIC SC, V70, P398; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LI E, 1986, P NATL ACAD SCI USA, V83, P5779, DOI 10.1073/pnas.83.16.5779; LI E, 1991, J BIOL CHEM, V266, P3622; LOOSE DS, 1983, J CLIN INVEST, V71, P1495, DOI 10.1172/JCI110903; MARTINI R, 1993, ARCH BIOCHEM BIOPHYS, V303, P57, DOI 10.1006/abbi.1993.1255; MAURICE M, 1992, FASEB J, V6, P752, DOI 10.1096/fasebj.6.2.1371482; MCCORMICK AM, 1983, BIOCHEMISTRY-US, V22, P3933, DOI 10.1021/bi00285a032; MORRISSKAY G, 1992, CANCER SURV, V14, P181; NAPOLI JL, 1986, J BIOL CHEM, V261, P3592; NAPOLI JL, 1982, BIOCHEMISTRY-US, V21, P1942, DOI 10.1021/bi00537a038; NAPOLI JL, 1981, BIOCHIM BIOPHYS ACTA, V666, P165, DOI 10.1016/0005-2760(81)90102-8; ONG DE, 1982, J BIOL CHEM, V257, P13385; ONG DE, 1978, J BIOL CHEM, V253, P4551; ONG DE, 1988, J BIOL CHEM, V263, P5789; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; REES JL, 1989, BIOCHEM J, V259, P917, DOI 10.1042/bj2590917; RIAZULHAQ, 1991, P NATL ACAD SCI USA, V88, P8272, DOI 10.1073/pnas.88.18.8272; ROBERTS AB, 1979, J BIOL CHEM, V254, P6296; ROBERTS ES, 1992, MOL PHARMACOL, V41, P427; SAARI JC, 1982, J BIOL CHEM, V257, P13329; SANI BP, 1978, BIOCHEM J, V173, P643, DOI 10.1042/bj1730643; SOPRANO DR, 1993, J NUTR, V123, P367, DOI 10.1093/jn/123.suppl_2.367; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; SWART P, 1993, J CLIN ENDOCR METAB, V77, P98, DOI 10.1210/jc.77.1.98; Vanden Bossche H, 1988, Skin Pharmacol, V1, P176; VANWAUWE JP, 1990, J PHARMACOL EXP THER, V252, P365; VANWAUWE JP, 1988, J PHARMACOL EXP THER, V245, P718; WILLIAMS JB, 1987, ANAL BIOCHEM, V160, P267, DOI 10.1016/0003-2697(87)90046-7; WILLIAMS JB, 1987, BIOCHEM PHARMACOL, V36, P1386, DOI 10.1016/0006-2952(87)90102-X; WILLIAMS JB, 1985, P NATL ACAD SCI USA, V82, P4658, DOI 10.1073/pnas.82.14.4658; WINSTON JH, 1989, THESIS SW MED SCH DA; YOST RW, 1988, J BIOL CHEM, V263, P18693; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	55	101	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10538	10544						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144640				2022-12-25	WOS:A1994NF01700054
J	HURME, R; NAMORK, E; NURMIAHOLASSILA, EL; RHEN, M				HURME, R; NAMORK, E; NURMIAHOLASSILA, EL; RHEN, M			INTERMEDIATE FILAMENT-LIKE NETWORK FORMED IN-VITRO BY A BACTERIAL COILED-COIL PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE TROPOMYOSIN; TYPHIMURIUM VIRULENCE PLASMID; KERATIN-LIKE PROTEINS; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; DNA-BINDING; EPITHELIAL-CELLS; LEUCINE ZIPPER; CROSS-LINKING; ALPHA	The TlpA protein encoded by the virulence plasmid of Salmonella enterica is an alpha-helical 371-amino acid protein possessing characteristics similar to eukaryotic coiled coil proteins (Koski, P., Saarilahti, H., Sukupolvi, S., Taira, S., Rikkonen, P., Osterlund, K., Hurme, R., and Rhen, M. (1992) J. Biol. Chem. 267, 12258-12265). In this paper we have investigated inter- and intramolecular associations and the morphology of structures formed by TlpA. Dynamics and temperature stability of TlpA dimers were studied by examining the feasibility and conditions in which TlpA would form an artificial heterodimer with its truncated derivative. Formation of heterodimers, bridged by Cu2+-catalyzed air oxidation of adjacent Cys residues, showed that TlpA dimers are dynamic chain exchanging structures at 37 degrees C, whereas they were nonexchanging at room temperature or on ice. Chemical cross-linking suggested higher order interaction between TlpA dimers. Electron microscopy studies revealed two levels of TlpA organization in vitro: thin filaments and rods, 2-5 nm in diameter, and a higher ordered filament network consisting of tonofilament-like formations with a diameter of 8-15 nm. Electron microscopy of thin-sectioned Escherichia coli overproducing TlpA showed an extraordinary intracellular assembly of proteinacious lamellae with a striated appearance and a 38-nm periodicity. This study describes for the first time a bacterial protein capable of organizing itself into an ordered and suspectedly dynamic intermediate filament-like architecture.	NATL INST PUBL HLTH,N-0462 OSLO 4,NORWAY; UNIV HELSINKI,DEPT ELECTRON MICROSCOPY,SF-00014 HELSINKI,FINLAND	University of Helsinki	HURME, R (corresponding author), UNIV HELSINKI,DEPT BIOCHEM,POB 5,UNIONINKATU 35,SF-00014 HELSINKI,FINLAND.							ABDELLA PM, 1979, BIOCHEM BIOPH RES CO, V87, P734, DOI 10.1016/0006-291X(79)92020-5; AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMOFONSECA M, 1990, ELECTRON MICROSC REV, V3, P115, DOI 10.1016/0892-0354(90)90017-M; CERIN H, 1989, MICROB PATHOGENESIS, V7, P85, DOI 10.1016/0882-4010(89)90028-4; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; COULOMBE PA, 1990, J CELL BIOL, V111, P3049, DOI 10.1083/jcb.111.6.3049; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; COWGILL RW, 1974, BIOCHEMISTRY-US, V13, P2467, DOI 10.1021/bi00709a002; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ENGEL AM, 1992, EMBO J, V11, P4369, DOI 10.1002/j.1460-2075.1992.tb05537.x; FINLAY BB, 1991, J CELL SCI, V99, P283; FISCHETTI VA, 1991, SCI AM, V264, P32; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; GEISLER N, 1982, EMBO J, V1, P1649, DOI 10.1002/j.1460-2075.1982.tb01368.x; GEISLER N, 1992, EUR J BIOCHEM, V206, P841, DOI 10.1111/j.1432-1033.1992.tb16992.x; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; Gibson T. J., 1984, THESIS CAMBRIDGE U C; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; GOLDMAN AE, 1986, P NATL ACAD SCI USA, V83, P3839, DOI 10.1073/pnas.83.11.3839; GRACEFFA P, 1989, BIOCHEMISTRY-US, V28, P1282, DOI 10.1021/bi00429a050; GULIG PA, 1993, MOL MICROBIOL, V7, P825, DOI 10.1111/j.1365-2958.1993.tb01172.x; HARRINGTON WF, 1984, ANNU REV BIOCHEM, V53, P35, DOI 10.1146/annurev.bi.53.070184.000343; HATZFELD M, 1985, J CELL BIOL, V101, P1826, DOI 10.1083/jcb.101.5.1826; HATZFELD M, 1990, J CELL BIOL, V110, P1199, DOI 10.1083/jcb.110.4.1199; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; JAGURA-BURDZY G, 1992, J MOL BIOL, V225, P651, DOI 10.1016/0022-2836(92)90392-W; JANCSO A, 1991, J BIOL CHEM, V266, P5891; KOSKI P, 1992, J BIOL CHEM, V267, P12258; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCEFIELD RC, 1962, J IMMUNOL, V89, P307; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEHRER SS, 1990, J BIOL CHEM, V265, P1134; LEHRER SS, 1975, P NATL ACAD SCI USA, V72, P3377, DOI 10.1073/pnas.72.9.3377; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; LUPAS AN, 1992, FEBS LETT, V314, P105, DOI 10.1016/0014-5793(92)80952-D; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MCCORMICK MB, 1993, J CELL BIOL, V122, P395, DOI 10.1083/jcb.122.2.395; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MILLER RK, 1993, J CELL BIOL, V122, P123, DOI 10.1083/jcb.122.1.123; NAMORK E, 1982, ULTRAMICROSCOPY, V7, P321, DOI 10.1016/0304-3991(82)90257-1; NIKI H, 1992, EMBO J, V11, P5101, DOI 10.1002/j.1460-2075.1992.tb05617.x; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PARRY D A D, 1992, Current Opinion in Cell Biology, V4, P94, DOI 10.1016/0955-0674(92)90064-J; PARRY DAD, 1992, BIOPHYS J, V61, P858, DOI 10.1016/S0006-3495(92)81893-3; RHEN M, 1988, FEMS MICROBIOL LETT, V52, P145; RHEN M, 1986, J BACTERIOL, V168, P1234, DOI 10.1128/jb.168.3.1234-1242.1986; RHEN M, 1992, VIRULENCE FACTORS SA, P103; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SANDERS C, 1986, J BIOL CHEM, V261, P2774; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; STEINERT PM, 1993, J MOL BIOL, V230, P436, DOI 10.1006/jmbi.1993.1161; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; THOMAS CM, 1990, GENE, V89, P29, DOI 10.1016/0378-1119(90)90202-3; TINGE SA, 1990, J BACTERIOL, V172, P5266, DOI 10.1128/jb.172.9.5266-5277.1990; UBBEN D, 1986, GENE, V41, P145, DOI 10.1016/0378-1119(86)90093-4; WILLIAMS DR, 1992, J GEN MICROBIOL, V138, P1; YANG CH, 1992, J CELL BIOL, V116, P1303, DOI 10.1083/jcb.116.6.1303; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZACKROFF RV, 1984, J CELL BIOL, V98, P1231, DOI 10.1083/jcb.98.4.1231	72	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10675	10682						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144657				2022-12-25	WOS:A1994NF01700073
J	LUO, XN; MOOKERJEE, B; FERRARI, A; MISTRY, S; ATWEH, GF				LUO, XN; MOOKERJEE, B; FERRARI, A; MISTRY, S; ATWEH, GF			REGULATION OF PHOSPHOPROTEIN P18 IN LEUKEMIC-CELLS - CELL-CYCLE-REGULATED PHOSPHORYLATION BY P34(CDC2) KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PHOSPHORYLATION; LYMPHOCYTES-T; EXPRESSION; CDC2; GENE; STATHMIN; ELECTROPHORESIS; IDENTIFICATION; PURIFICATION; CONSERVATION	p18 is a phosphoprotein that is expressed at very high levels in leukemic cells, at moderately high levels in proliferating normal lymphocytes, and at low levels in quiescent lymphocytes. Induction of terminal differentiation of leukemic cells in culture results in a decrease in cellular proliferation. These phenotypic changes are associated with rapid phosphorylation of p18, followed by a more gradual decrease in the level of its mRNA expression. More than 12 different phosphorylation products of p18 have been identified in different cells by high resolution two-dimensional polyacrylamide gel electrophoresis. Previous studies have suggested that p18 may be a substrate for protein kinase C in some cellular processes and protein kinase A in others. In this report, we show that the phosphorylation of p18 increases as cells progress toward the G2-M phases of the cell cycle in proliferating leukemic cells. We have examined the hypothesis that the putative role of p18 in cellular proliferation may be mediated by its involvement in the p34(cdc2) kinase signal transduction pathway. We have produced recombinant p18 in bacterial cells and shown that it can be phosphorylated in vitro by purified p34(cdc2) kinase with a stoichiometry of 0.86 mol of PO4/mol of substrate. We have used site-directed mutagenesis to demonstrate that the site of p34(cdc2) phosphorylation is the serine at position 38. This same site has previously been shown to be phosphorylated in vivo in bovine brain along with another serine at position 25. The observation that p18 gets phosphorylated in the G2-M phases of the cell cycle and the demonstration that p18 is phosphorylated efficiently by p34(cdc2) kinase in vitro at a residue that is also phosphorylated in vivo support the hypothesis that p18 may be a physiologic substrate for p34(cdc2) kinase in vivo. We have also examined the effect of inhibiting the expression of p18 on cell cycle progression. These experiments demonstrated that antisense inhibition of the expression of p18 in K562 erythroleukemia cells is associated with a decrease in cellular proliferation and accumulation of cells in the G2-M phases of the cycle. The implications of these findings to the proposed role of p18 in the regulation of cellular proliferation are discussed.	MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042919] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42919] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNDTJOVIN DJ, 1977, J HISTOCHEM CYTOCHEM, V25, P585, DOI 10.1177/25.7.70450; ATWEH GF, 1988, MOL CELL BIOL, V8, P5047, DOI 10.1128/MCB.8.11.5047; BRICKNER HE, 1991, J BIOL CHEM, V266, P15363; COOPER HL, 1989, J IMMUNOL, V143, P956; COURVALIN JC, 1992, J BIOL CHEM, V267, P19035; DOYE V, 1989, J BIOL CHEM, V264, P12134; FEUERSTEIN N, 1983, J BIOL CHEM, V258, P786; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GHOSH PK, 1993, ONCOGENE, V8, P2869; GOBINDA S, 1990, BIOTECHNIQUES, V8, P404; GULLBERG M, 1990, J BIOL CHEM, V265, P17499; HANASH SM, 1988, J BIOL CHEM, V263, P12813; KOPPEL J, 1990, J BIOL CHEM, V265, P3703; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; LABDON JE, 1992, J BIOL CHEM, V267, P3506; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LOKEN MR, 1980, CYTOMETRY, V1, P136, DOI 10.1002/cyto.990010208; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUO XN, 1991, J BIOL CHEM, V266, P21004; MARKLUND U, 1993, J BIOL CHEM, V268, P15039; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MURRAY AW, 1989, NATURE, V342, P14, DOI 10.1038/342014a0; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PASMANTIER R, 1986, ENDOCRINOLOGY, V119, P1229, DOI 10.1210/endo-119-3-1229; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; TOUTANT M, 1987, DEV BIOL, V124, P370, DOI 10.1016/0012-1606(87)90489-1; Vindelov L, 1990, Methods Cell Biol, V33, P127; WANG YK, 1993, J BIOL CHEM, V268, P14269; ZHU XX, 1989, J BIOL CHEM, V264, P14556	38	104	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10312	10318						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144611				2022-12-25	WOS:A1994NF01700023
J	SCHRODER, B; REINHARDTMAELICKE, S; SCHRATTENHOLZ, A; MCLANE, KE; KRETSCHMER, A; CONTITRONCONI, BM; MAELICKE, A				SCHRODER, B; REINHARDTMAELICKE, S; SCHRATTENHOLZ, A; MCLANE, KE; KRETSCHMER, A; CONTITRONCONI, BM; MAELICKE, A			MONOCLONAL-ANTIBODIES FK1 AND WF6 DEFINE 2 NEIGHBORING LIGAND-BINDING SITES ON TORPEDO ACETYLCHOLINE-RECEPTOR ALPHA-POLYPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; H-3 CHLORPROMAZINE; AMINO-ACIDS; SYNTHETIC PEPTIDES; DELTA-SUBUNIT; NONCOMPETITIVE BLOCKERS; MOLECULAR-BIOLOGY; SOLID-PHASE; ION CHANNEL; BUNGAROTOXIN	Previous studies have identified the sequence region flanking the invariant vicinal cysteinyl residues at positions 192 and 193 of the nicotinic acetylcholine receptor alpha-subunit as containing major elements of the binding site for acetylcholine and its agonists and antagonists, including antibody WF6 (Conti-Tronconi, B. M., Diethelm, B. M., Wu, X., Tang, F., Bertazzon, T., Schroder, B., Reinhardt-Maelicke, A., and Maelicke, A (1991) Biochemistry 30, 2575-2584). Recently we have shown that the sequence region flanking lysine alpha 125 contains elements of the binding site for physostigmine and related ligands, including antibody FK1 (Schrattenholz, A., Godovac-Zimmerman, J., Schafer, H.-J., Albuquerque, E. X, and Maelicke, A. (1993) Eur. J. Biochem. 216, 671-677). Here we report the identification by enzyme-linked immunosorbent assay techniques, employing fragments of the Torpedo nicotinic acetylcholine receptor alpha-subunit N-terminal region and a panel of synthetic peptides matching in sequence preselected portions of this subunit, of the sequence regions alpha 118-145 and alpha 181-216 as contributing to the FK1 epitope. Of the synthetic peptides employed, alpha 118-137 displayed the highest affinity of FK1 binding. Binding of FK1 and WF6 to single residue-substituted analogs of the sequence alpha 181-200 indicated that the two antibodies have different attachment point patterns within this sequence region. These results, and those of ligand competition studies, suggest that the binding sites for FK1 and physostigmine, and those of WF6 and acetylcholine, are within the same general region of the receptor's three-dimensional structure. The sites neighbor each other, with limited overlap in the case of occupation by high molecular weight ligands.	UNIV MINNESOTA,COLL BIOL SCI,DEPT BIOCHEM,ST PAUL,MN 55108; BAYER AG,ZENT FORSCH,D-51375 LEVERKUSEN,GERMANY	University of Minnesota System; University of Minnesota Twin Cities; Bayer AG	SCHRODER, B (corresponding author), UNIV MAINZ,SCH MED,INST PHYSIOL CHEM & PATHOBIOCHEM,MOLEC NEUROBIOL LAB,DUESBERGWEG 6,D-55099 MAINZ,GERMANY.				NATIONAL INSTITUTE ON DRUG ABUSE [P01DA005695] Funding Source: NIH RePORTER; NIDA NIH HHS [5P01-DA05695] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; ARONHEIM A, 1988, J BIOL CHEM, V263, P9933; BARNARD EA, 1990, TRENDS PHARMACOL SCI, V11, P500, DOI 10.1016/0165-6147(90)90051-9; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; Catty D., 1989, ANTIBODIES PRACTICAL, VII, P97; CONTITRONCONI BM, 1990, BIOCHEMISTRY-US, V29, P6221, DOI 10.1021/bi00478a016; CONTITRONCONI BM, 1991, BIOCHEMISTRY-US, V30, P2575, DOI 10.1021/bi00224a003; CONTITRONCONI BM, 1982, SCIENCE, V218, P1277; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DENNIS M, 1986, FEBS LETT, V207, P2443; DUGUID JR, 1980, P NATL ACAD SCI USA, V77, P4509; DUNN SMJ, 1993, BIOCHEMISTRY-US, V32, P8608, DOI 10.1021/bi00084a031; FELS G, 1986, J BIOL CHEM, V261, P5746; FRIGUET B, 1983, J IMMUNOL METHODS, V60, P351, DOI 10.1016/0022-1759(83)90292-2; GALZI JL, 1990, J BIOL CHEM, V265, P1043; GERSHONI JM, 1987, P NATL ACAD SCI USA, V84, P4318, DOI 10.1073/pnas.84.12.4318; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GIRAUDAT J, 1989, FEBS LETT, V253, P190, DOI 10.1016/0014-5793(89)80957-3; GRIESMANN GE, 1990, J NEUROCHEM, V54, P1541, DOI 10.1111/j.1471-4159.1990.tb01202.x; GUAN C, 1987, GENE, V67, P21; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; KAO PN, 1984, J BIOL CHEM, V259, P1662; KELLERMANN OK, 1982, METHOD ENZYMOL, V90, P459; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGENBUCHCACHAT J, 1988, BIOCHEMISTRY-US, V27, P2337, DOI 10.1021/bi00407a015; LINDSTROM J, 1988, ADV IMMUNOL, V42, P233, DOI 10.1016/S0065-2776(08)60847-0; MAELICKE A, 1993, ANN NY ACAD SCI, V681, P140, DOI 10.1111/j.1749-6632.1993.tb22880.x; MAELICKE A, 1992, RECEPTOR SUBUNITS CO, P119; MAELICKE A, 1989, NATO ASI SERR H, V32, P221; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCLANE KE, 1992, J RECEPTOR RES, V12, P299, DOI 10.3109/10799899209074798; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; NEUMANN D, 1986, P NATL ACAD SCI USA, V83, P9250, DOI 10.1073/pnas.83.23.9250; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; OBERTHUR W, 1988, J PROTEIN CHEM, V7, P141, DOI 10.1007/BF01025243; OBERTHUR W, 1986, EMBO J, V5, P1815, DOI 10.1002/j.1460-2075.1986.tb04431.x; OHANA B, 1990, BIOCHEMISTRY-US, V29, P6409, DOI 10.1021/bi00479a011; OHANA B, 1991, BIOCHEM BIOPH RES CO, V179, P648, DOI 10.1016/0006-291X(91)91421-8; OKONJO KO, 1991, EUR J BIOCHEM, V200, P671, DOI 10.1111/j.1432-1033.1991.tb16231.x; PEDERSEN SE, 1986, J BIOL CHEM, V261, P3735; PEDERSEN SE, 1990, J BIOL CHEM, V265, P569; PEREIRA EFR, 1993, J PHARMACOL EXP THER, V265, P1474; PEREIRA EFR, 1993, J RECEPTOR RES, V13, P413, DOI 10.3109/10799899309073670; PLUMER R, 1984, FEBS LETT, V178, P204, DOI 10.1016/0014-5793(84)80601-8; RALSTON S, 1987, BIOCHEMISTRY-US, V26, P3261, DOI 10.1021/bi00386a004; REINHARDT S, 1984, FEBS LETT, V173, P217, DOI 10.1016/0014-5793(84)81050-9; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; SCHRATTENHOLZ A, 1993, J RECEPTOR RES, V13, P393, DOI 10.3109/10799899309073669; SCHRATTENHOLZ A, 1993, EUR J BIOCHEM, V216, P671, DOI 10.1111/j.1432-1033.1993.tb18187.x; SHAW KP, 1985, MOL PHARMACOL, V28, P527; SMART L, 1984, FEBS LETT, V178, P64, DOI 10.1016/0014-5793(84)81241-7; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001; SUMIKAWA K, 1981, NATURE, V292, P862, DOI 10.1038/292862a0; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; WAHLSTEN JL, 1993, J RECEPTOR RES, V13, P989, DOI 10.3109/10799899309073705; WATTERS D, 1983, BIOCHEMISTRY-US, V22, P1811, DOI 10.1021/bi00277a011; WHITING P, 1991, MOL PHARMACOL, V40, P463; WILSON PT, 1988, BIOCHEMISTRY-US, V27, P6667, DOI 10.1021/bi00418a004	62	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10407	10416						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144624				2022-12-25	WOS:A1994NF01700036
J	LIN, BF; SHANE, B				LIN, BF; SHANE, B			EXPRESSION OF ESCHERICHIA-COLI FOLYLPOLYGLUTAMATE SYNTHETASE IN THE CHINESE-HAMSTER OVARY CELL MITOCHONDRION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMATE SYNTHETASE; FOLATE-DEPENDENT ENZYMES; RAT-LIVER MITOCHONDRIA; ORNITHINE TRANSCARBAMYLASE; DIHYDROFOLATE SYNTHETASE; SUBCELLULAR-LOCALIZATION; FOLC GENE; PROTEINS; DNA; PURIFICATION	Chinese hamster ovary (CHO) cell transfectants expressing Escherichia coli folylpoly-gamma-glutamate synthetase (FPGS) activity solely in their cytosol lack mitochondrial folylpolyglutamates and are auxotrophic for glycine. Addition of a mammalian mitochondrial leader sequence targeted E. coli FPGS to the mitochondria of these cells. Mitochondrial expression of FPGS restored mitochondrial folylpolyglutamate pools and overcame the glycine requirement. Pteroyltriglutamates functioned as effectively as the longer glutamate chain length folates found in wild type CHO cells in the metabolic cycle of glycine synthesis provided they were located in the mitochondria. Although folylpolyglutamates cannot enter the mitochondria, mitochondrial folylpolyglutamates can be released without prior hydrolysis and CHO transfectants expressing E. coli FPGS activity solely in the mitochondria possessed normal cytosolic folylpolyglutamate pools. The proportion of cellular folate in the mitochondrion is governed by competition between mitochondrial and cytosolic FPGS activities.	UNIV CALIF BERKELEY, DEPT NUTR SCI, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley				LIN, BI-FONG/0000-0003-2260-6081	NATIONAL CANCER INSTITUTE [R01CA041991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042033] Funding Source: NIH RePORTER; NCI NIH HHS [CA41991] Funding Source: Medline; NIDDK NIH HHS [DK42033] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARLOWE C K, 1988, Biofactors, V1, P171; BOGNAR AL, 1987, J BIOL CHEM, V262, P12337; BOGNAR AL, 1985, J BIOL CHEM, V260, P5625; CHASIN LA, 1974, P NATL ACAD SCI USA, V71, P718, DOI 10.1073/pnas.71.3.718; CICHOWICZ DJ, 1987, BIOCHEMISTRY-US, V26, P504, DOI 10.1021/bi00376a024; CICHOWICZ DJ, 1987, BIOCHEMISTRY-US, V26, P513, DOI 10.1021/bi00376a025; COOK RJ, 1979, BIOCHEM J, V178, P651, DOI 10.1042/bj1780651; FOO SK, 1982, J BIOL CHEM, V257, P13587; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HAY R, 1984, BIOCHIM BIOPHYS ACTA, V779, P65, DOI 10.1016/0304-4157(84)90004-2; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HOFFBRAN.AV, 1969, BIOCHIM BIOPHYS ACTA, V192, P479, DOI 10.1016/0304-4165(69)90397-3; HORNE DW, 1992, J NUTR, V122, P2204, DOI 10.1093/jn/122.11.2204; HORWICH AL, 1984, SCIENCE, V224, P1068, DOI 10.1126/science.6372096; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; KIM JS, 1994, J BIOL CHEM, V269, P9714; KIM JS, 1993, J BIOL CHEM, V268, P21680; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN BF, 1993, J BIOL CHEM, V268, P21674; LOWE KE, 1993, J BIOL CHEM, V268, P21665; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; OSBORNE CB, 1993, J BIOL CHEM, V268, P21657; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schirch L. V., 1984, FOLATES PTERINS CHEM, V1, P399; SHANE B, 1989, VITAM HORM, V45, P263; SHIN YS, 1976, BIOCHIM BIOPHYS ACTA, V444, P794; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; SUSSMAN DJ, 1986, SOMAT CELL MOLEC GEN, V12, P531, DOI 10.1007/BF01671939; TAYLOR RT, 1977, ARCH BIOCHEM BIOPHYS, V181, P331, DOI 10.1016/0003-9861(77)90512-4; TAYLOR RT, 1982, ARCH BIOCHEM BIOPHYS, V217, P609, DOI 10.1016/0003-9861(82)90543-4	35	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9705	9713						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144561				2022-12-25	WOS:A1994NE05300050
J	THOMPSON, J; CHOUDHURY, S; KASHANCHI, F; DONIGER, J; BERNEMAN, Z; FRENKEL, N; ROSENTHAL, LJ				THOMPSON, J; CHOUDHURY, S; KASHANCHI, F; DONIGER, J; BERNEMAN, Z; FRENKEL, N; ROSENTHAL, LJ			A TRANSFORMING FRAGMENT WITHIN THE DIRECT REPEAT REGION OF HUMAN HERPESVIRUS TYPE-6 THAT TRANSACTIVATES HIV-1	ONCOGENE			English	Article							HUMAN CYTOMEGALO-VIRUS; HUMAN PAPILLOMAVIRUS TYPE-16; EPSTEIN-BARR-VIRUS; LYMPHOCYTES-T; EXANTHEM-SUBITUM; READING FRAME; STRAIN AD169; B VIRUS; DNA; IDENTIFICATION	HHV-6 infection has been associated with several malignancies including non-Hodgkin's lymphoma and Hodgkin's disease by the presence of high antibody titer and/or the presence of HHV-6 DNA. To understand their oncogenic potential, SalI restriction fragments from HHV-6 strain U1102 were transfected into NIH3T3 cells to assess transforming ability. A 3.9-kbp SalI-L DNA fragment spanning the junction of the direct repeat left (DR(L)) and unique long segment (U(L)) regions of HHV-6 induced foci of morphologically altered cells. The SalI-L transformed NIH3T3 focal lines induced tumors in nude mice within 2 weeks. The retention of HHV-6 specific DNA observed in SalI-L transformed cells and their tumor-derived lines suggest a possible maintenance function. Since both HHV-6 infection as well as transforming fragments from other DNA viruses have been shown to transactivate the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR), SalI-L was examined for transactivation activity. SalI-L up-regulated HIV-1 LTR CAT 10-15 fold in both monkey CV-1 and human T Jurkat cells. The further study of the SalI-L transforming fragment exhibiting transactivation of HIV-1 LTR will elucidate whether these two activities are encoded by a single gene and will aid in the understanding of the interaction between HHV-6 and HIV-1 as it relates to progression of AIDS and/or AIDS-related malignancies.	GEORGETOWN UNIV, SCH MED, DEPT MICROBIOL, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, DEPT IMMUNOL, WASHINGTON, DC 20007 USA; TEL AVIV UNIV, DEPT CELL RES & IMMUNOL, IL-69978 TEL AVIV, ISRAEL; NCI, TUMOR CELL BIOL LAB, BETHESDA, MD 20892 USA	Georgetown University; Georgetown University; Tel Aviv University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [CA37259-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA037259, R01CA037259] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABLASHI D, 1993, ARCH VIROL, V129, P363, DOI 10.1007/BF01316913; ABLASHI DV, 1987, NATURE, V329, P207, DOI 10.1038/329207a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERNEMAN ZN, 1992, HUMAN HERPESVIRUS, V6, P81; BERTRAM G, 1991, In Vivo (Attiki), V5, P271; BRADY J, 1983, CANCER CELL, V1, P105; CARRIGAN DR, 1991, LANCET, V338, P147, DOI 10.1016/0140-6736(91)90137-E; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DESAINTES C, 1992, J VIROL, V66, P325, DOI 10.1128/JVI.66.1.325-333.1992; DONIGER J, 1987, J BIOL CHEM, V262, P3813; ELBEIK T, 1986, J VIROL, V60, P645, DOI 10.1128/JVI.60.2.645-652.1986; ELLINGER K, 1992, HUMAN HERPESVIRUS, V6, P209; ENSOLI B, 1989, EMBO J, V8, P3019, DOI 10.1002/j.1460-2075.1989.tb08452.x; FRENKEL N, 1990, P NATL ACAD SCI USA, V87, P748, DOI 10.1073/pnas.87.2.748; GENG YQ, 1992, J VIROL, V66, P1564, DOI 10.1128/JVI.66.3.1564-1570.1992; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HORVAT RT, 1991, J VIROL, V65, P2895, DOI 10.1128/JVI.65.6.2895-2902.1991; ISHIGURO N, 1990, ACTA PAEDIATR SCAND, V79, P987, DOI 10.1111/j.1651-2227.1990.tb11369.x; JAHAN N, 1989, J VIROL, V63, P2866, DOI 10.1128/JVI.63.6.2866-2869.1989; JARIWALLA RJ, 1980, P NATL ACAD SCI-BIOL, V77, P2279, DOI 10.1073/pnas.77.4.2279; JARRETT RF, 1988, LEUKEMIA, V2, P496; JOSEPHS SF, 1988, LEUKEMIA, V2, P132; JOSEPHS SF, 1986, SCIENCE, V234, P601, DOI 10.1126/science.3020691; JOSEPHS SF, 1988, J VIROL METHODS, V21, P179, DOI 10.1016/0166-0934(88)90064-X; KELLER JM, 1984, CELL, V36, P381, DOI 10.1016/0092-8674(84)90231-9; KISHI M, 1988, J VIROL, V62, P4824, DOI 10.1128/JVI.62.12.4824-4827.1988; KOUZARIDES T, 1988, VIROLOGY, V165, P151, DOI 10.1016/0042-6822(88)90668-X; LINDQUESTER GJ, 1991, VIROLOGY, V182, P102, DOI 10.1016/0042-6822(91)90653-S; LUSSO P, 1991, NATURE, V349, P533, DOI 10.1038/349533a0; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; LUSSO P, 1988, J EXP MED, V167, P1659, DOI 10.1084/jem.167.5.1659; MARTIN MED, 1991, J GEN VIROL, V72, P157, DOI 10.1099/0022-1317-72-1-157; MARTIN MED, 1991, J VIROL, V65, P5381, DOI 10.1128/JVI.65.10.5381-5390.1991; MOCARSKI ES, 1988, J GEN VIROL, V69, P2613, DOI 10.1099/0022-1317-69-10-2613; NELSON JA, 1982, J VIROL, V43, P83, DOI 10.1128/JVI.43.1.83-91.1982; NIEDERMAN JC, 1988, LANCET, V2, P817; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; RAZZAQUE A, 1990, ONCOGENE, V5, P1365; RAZZAQUE A, 1988, P NATL ACAD SCI USA, V85, P5709, DOI 10.1073/pnas.85.15.5709; REYES GR, 1979, COLD SPRING HARB SYM, V44, P629; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIRMER EC, 1991, P NATL ACAD SCI USA, V88, P5922, DOI 10.1073/pnas.88.13.5922; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEEPER TA, 1990, AM J CLIN PATHOL, V93, P776, DOI 10.1093/ajcp/93.6.776; TAKAHASHI K, 1989, J VIROL, V63, P3161, DOI 10.1128/JVI.63.7.3161-3163.1989; TORELLI G, 1991, BLOOD, V77, P2251, DOI 10.1182/blood.V77.10.2251.2251; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; WANG F, 1987, P NATL ACAD SCI USA, V84, P3452, DOI 10.1073/pnas.84.10.3452; WESTON K, 1986, J MOL BIOL, V192, P177, DOI 10.1016/0022-2836(86)90359-1; YAMANISHI K, 1988, LANCET, V1, P1065; YASUMOTO S, 1986, J VIROL, V57, P572, DOI 10.1128/JVI.57.2.572-577.1986	56	40	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1167	1175						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134119				2022-12-25	WOS:A1994NC04800020
J	WATANABE, T; SHINTANI, A; NAKATA, M; SHING, Y; FOLKMAN, J; IGARASHI, K; SASADA, R				WATANABE, T; SHINTANI, A; NAKATA, M; SHING, Y; FOLKMAN, J; IGARASHI, K; SASADA, R			RECOMBINANT HUMAN BETACELLULIN - MOLECULAR-STRUCTURE, BIOLOGICAL-ACTIVITIES, AND RECEPTOR INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR-ALPHA; EGF RECEPTOR; SIGNAL TRANSDUCTION; FACTOR PRECURSOR; MYXOMA VIRUS; CELLS; BINDING; PROTEIN; SEQUENCE	Soluble forms of human betacellulin (BTC) were purified to homogeneity from the conditioned medium of mouse A9 cells transfected with the BTC precursor cDNA. Three types of soluble BTC, designated BTC-1a, BTC-1b and BTC-2, were resolved by cation-exchange and size-exclusion column chromatography. Physico-chemical analysis has revealed that BTC-1a represents the glycosylated, intact molecule composed of 80 amino acid residues (Asp32 to Tyr111 of the precursor molecule). BTC-1b appears to be a truncated molecule lacking 12 amino acid residues from the amino terminus of BTC-1a. BTC-2 was found to be a 50-amino acid molecule (Arg62 to Tyr111) that corresponds to the epidermal growth factor (EGF) structural unit. The biological activities of these BTC molecules were essentially identical as judged by their mitogenicity on Balb/c 3T3 fibroblasts. BTC and EGF were equipotent in stimulating Balb/c 3T3 cell proliferation and rat mesangial cell Ca2+ mobilization as well as in inhibiting the growth of human epidermoid carcinoma A431 cells. BTC and EGF antagonized each other with similar dose dependence for binding to A431 cells, indicating that these factors bind the same receptor molecules with equivalent avidity. The K(d) value of EGF receptor (EGFR) and BTC is 0.5 nM as determined on Balb/c 3T3 cells. In addition, human mammary carcinoma MDA-MB-453 cells, which express multiple members of the EGFR family, were found to possess 2.7 x 10(3) BTC binding sites/cell, and the binding was readily quenched by EGF. These results suggest that the primary receptor for BTC is EGFR.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT SURG,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School	WATANABE, T (corresponding author), TAKEDA CHEM IND LTD,DIV DISCOVERY,DEPT V,DISCOVERY RES LABS 2,OSAKA 532,JAPAN.							ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; Besner GE, 1992, GROWTH FACTORS, V7, P289, DOI 10.3109/08977199209046411; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; CHANG W, 1987, MOL CELL BIOL, V7, P535, DOI 10.1128/MCB.7.1.535; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JOLLY DJ, 1983, P NATL ACAD SCI-BIOL, V80, P477, DOI 10.1073/pnas.80.2.477; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN YZ, 1991, BIOCHEMISTRY-US, V30, P3310, DOI 10.1021/bi00227a020; LITTLEFIELD JW, 1964, SCIENCE, V145, P709, DOI 10.1126/science.145.3633.709; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MARQUARDT H, 1983, P NATL ACAD SCI-BIOL, V80, P4684; Marshall R D, 1974, Biochem Soc Symp, P17; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MONTELIONE GT, 1987, P NATL ACAD SCI USA, V84, P5226, DOI 10.1073/pnas.84.15.5226; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MROCZKOWSKI B, 1989, MOL CELL BIOL, V9, P2771, DOI 10.1128/MCB.9.7.2771; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; ORITA Y, 1985, FEBS LETT, V192, P155, DOI 10.1016/0014-5793(85)80063-6; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1992, ONCOGENE, V7, P1273; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; Sambrook J, 1989, MOL CLONING LABORATO; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SASADA R, 1988, CELL STRUCT FUNCT, V13, P129, DOI 10.1247/csf.13.129; SASADA R, 1987, CELL STRUCT FUNCT, V12, P205, DOI 10.1247/csf.12.205; SASADA R, 1993, BIOCHEM BIOPH RES CO, V190, P1173, DOI 10.1006/bbrc.1993.1173; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; STROOBANT P, 1985, CELL, V42, P383, DOI 10.1016/S0092-8674(85)80133-1; TAKAYASUOKISHIO M, 1990, BIOCHEM PHARMACOL, V40, P2713; UPTON C, 1987, J VIROL, V61, P1271, DOI 10.1128/JVI.61.4.1271-1275.1987; VENKATESAN S, 1982, J VIROL, V44, P637, DOI 10.1128/JVI.44.2.637-646.1982; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	57	96	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9966	9973						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144591				2022-12-25	WOS:A1994NE05300087
J	QUINTANA, J; HIPKIN, RW; ASCOLI, M; SANCHEZYAGUE, J				QUINTANA, J; HIPKIN, RW; ASCOLI, M; SANCHEZYAGUE, J			FOLLITROPIN (FSH) AND A PHORBOL ESTER STIMULATE THE PHOSPHORYLATION OF THE FSH RECEPTOR IN INTACT-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEYDIG TUMOR-CELLS; MUSCARINIC CHOLINERGIC RECEPTORS; HUMAN CHORIO-GONADOTROPIN; PROTEIN KINASE-C; ADENYLYL CYCLASE; CYCLIC-AMP; ADENOSINE-MONOPHOSPHATE; CAMP-PHOSPHODIESTERASE; SIGNALING PATHWAYS; CA2+ MOBILIZATION	Using a cell line stably transfected with the rat follitropin (FSH) receptor cDNA we demonstrate that the FSH receptor becomes phosphorylated when cells are exposed to FSH. Since binding of FSH to its receptor results in an increase in cAMP and inositol phosphate accumulation, we examined the potential involvement of protein kinase A and C in mediating receptor phosphorylation. Stimulation of protein kinase A does not appear to be necessary because hFSH-induced receptor phosphorylation was minimally impaired in a cell line that overexpresses cAMP phosphodiesterase. Moreover, stimulation of the protein kinase A pathway with other agonists result in minimal phosphorylation of the FSH receptor. Stimulation of the protein kinase C with a phorbol ester did result in an increase in receptor phosphorylation, and down-regulation of the protein kinase C decreased, but did not abolish, the FSH-induced receptor phosphorylation. The possible impact of phosphorylation on the functions of the receptor was examined by testing if conditions that lead to phosphorylation decrease the ability of FSH to stimulate cAMP synthesis. Our data show that as with the addition of FSH, addition of a phorbol ester also results in a decrease in the ability of FSH to stimulate cAMP synthesis.	UNIV IOWA,COLL MED,DEPT PHARMACOL,IOWA CITY,IA 52242	University of Iowa			Yague, Jesus Sanchez/B-7792-2008; Quintana, José/K-5709-2014	Quintana, José/0000-0001-8225-4538; Sanchez-Yague, Jesus/0000-0003-0409-3198	FIC NIH HHS [TW-04655] Funding Source: Medline; NICHD NIH HHS [HD28962] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028962] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [F05TW004655] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ASCOLI M, 1982, J BIOL CHEM, V257, P13306; ASCOLI M, 1989, J BIOL CHEM, V264, P6674; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BALLISTER R, 1987, J BIOL CHEM, V260, P15194; BOUVIER M, 1987, J BIOL CHEM, V262, P3106; Bradford M. M., 1976, ANAL BIOCHEM, V53, P304; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; EKSTROM RC, 1989, ENDOCRINOLOGY, V125, P2470, DOI 10.1210/endo-125-5-2470; GUDERMANN T, 1992, MOL ENDOCRINOL, V6, P272, DOI 10.1210/me.6.2.272; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HIPKIN RW, 1993, MOL ENDOCRINOL, V7, P823, DOI 10.1210/me.7.7.823; HIPKIN RW, 1992, MOL ENDOCRINOL, V6, P2210, DOI 10.1210/me.6.12.2210; HOELSCHER SR, 1993, ENDOCRINOLOGY, V132, P2229, DOI 10.1210/en.132.5.2229; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; QUINTANA J, 1993, ENDOCRINOLOGY, V133, P2098, DOI 10.1210/en.133.5.2098; REBOIS RV, 1986, ENDOCRINOLOGY, V118, P2340, DOI 10.1210/endo-118-6-2340; REBOIS RV, 1985, J BIOL CHEM, V260, P8026; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; RICHARDSON RM, 1992, J BIOL CHEM, V267, P10127; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; SANCHEZYAGUE J, 1992, J BIOL CHEM, V267, P7217; SANCHEZYAGUE J, 1993, ENDOCRINOLOGY, V132, P1007, DOI 10.1210/en.132.3.1007; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SHIBATA EF, 1992, ENDOCRINOLOGY, V131, P979, DOI 10.1210/en.131.2.979; SOLANKI V, 1981, P NATL ACAD SCI-BIOL, V78, P1722, DOI 10.1073/pnas.78.3.1722; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; SWINNEN JV, 1991, J BIOL CHEM, V266, P14383; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; WANG Z, 1993, MOL ENDOCRINOL, V7, P85, DOI 10.1210/me.7.1.85; ZHOU XM, 1991, J BIOL CHEM, V266, P7462	44	93	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8772	8779						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132609				2022-12-25	WOS:A1994NB41100026
J	TING, SM; DIGNAM, JD				TING, SM; DIGNAM, JD			POSTTRANSCRIPTIONAL REGULATION OF GLUTAMYL-PROLYL-TRANSFER-RNA SYNTHETASE IN RAT SALIVARY-GLAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; PROTEIN MULTIGENE FAMILIES; ALANYL-TRANSFER RNA; MESSENGER-RNA; ESCHERICHIA-COLI; BOMBYX-MORI; UNTRANSLATED REGION; GLYCYL-TRANSFER; HEAT-SHOCK; AMINOACYL	Treatment of rats with isoproterenol resulted in elevated levels of prolyl- and glutamyl-tRNA synthetase activities in the parotid and submandibular glands. This increase in enzyme activity was accompanied by an increase in the bi-functional glutamyl-prolyl-tRNA synthetase and of a low molecular weight form of prolyl-tRNA synthetase. Isoproterenol also induced the synthesis of proline-rich glycoproteins in the parotid and submandibular glands. Withdrawal from the drug was accompanied by a decline in prolyl- and glutamyl-tRNA synthetase activities and by a decline in the levels of proline-rich glycoproteins in the salivary gland. During the time course of isoproterenol treatment, little change in the levels of mRNA encoding the bi-functional glutamyl-prolyl-tRNA synthetase was detected by Northern blot analysis. These results indicate that the synthesis of glutamyl-prolyl-tRNA synthetase is regulated at a posttranscriptional step and that the synthesis of this bifunctional protein may be linked to the utilization of proline and glutamic acid in protein synthesis.	MED COLL OHIO, DEPT BIOCHEM & MOLEC BIOL, TOLEDO, OH 43699 USA						NIDCR NIH HHS [DE09669] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009669] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANN DK, 1987, J BIOL CHEM, V262, P899; AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNGRANT K, 1961, NATURE, V191, P1076, DOI 10.1038/1911076a0; CARLSON DM, 1991, PROG NUCLEIC ACID RE, V41, P1; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CERINI C, 1991, EMBO J, V10, P4267, DOI 10.1002/j.1460-2075.1991.tb05005.x; CHAPEVILLE F, 1962, P NATL ACAD SCI USA, V48, P1086, DOI 10.1073/pnas.48.6.1086; CHAVANCY G, 1979, BIOCHIMIE, V61, P71, DOI 10.1016/S0300-9084(79)80314-4; CHEUNG AY, 1985, J BACTERIOL, V161, P212, DOI 10.1128/JB.161.1.212-218.1985; CRICK F H, 1958, Symp Soc Exp Biol, V12, P138; DELMONTE U, 1975, FEBS LETT, V49, P380; DIGNAM SS, 1984, J BIOL CHEM, V259, P4043; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FETT R, 1991, J BIOL CHEM, V266, P1448; FREIST W, 1989, BIOCHEMISTRY-US, V28, P6787, DOI 10.1021/bi00443a001; GARRET M, 1991, BIOCHEMISTRY-US, V30, P7809, DOI 10.1021/bi00245a021; GILLAM IC, 1981, SELECTED METHODS ENZ, P43; HATFIELD D, 1982, J BIOL CHEM, V257, P3183; HENTZEN D, 1981, NATURE, V290, P267, DOI 10.1038/290267a0; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOAGLAND MB, 1956, J BIOL CHEM, V218, P345; JOHNSON RC, 1977, J BIOL CHEM, V252, P878; KAISER E, 1992, J MOL EVOL, V34, P45, DOI 10.1007/BF00163851; KELLERMANN O, 1982, J BIOL CHEM, V257, P1041; KERJAN P, 1992, BIOCHIMIE, V74, P195, DOI 10.1016/0300-9084(92)90046-H; KLEMENZ R, 1985, EMBO J, V4, P2053, DOI 10.1002/j.1460-2075.1985.tb03891.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKER S, 1992, CELL, V70, P647, DOI 10.1016/0092-8674(92)90433-D; LAZARD L, 1992, FEBS LETT, V216, P27; LAZARD M, 1987, J BIOL CHEM, V262, P3982; MAJIMA R, 1975, J BIOCHEM-TOKYO, V78, P391, DOI 10.1093/oxfordjournals.jbchem.a130919; MEHANSHO H, 1985, J BIOL CHEM, V260, P4418; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MISETA A, 1991, J BIOL CHEM, V266, P19158; MUELLER PP, 1987, P NATL ACAD SCI USA, V84, P2863, DOI 10.1073/pnas.84.9.2863; NADA S, 1993, J BIOL CHEM, V268, P7660; RABEN N, 1992, NUCLEIC ACIDS RES, V20, P1075, DOI 10.1093/nar/20.5.1075; REEH S, 1977, J BACTERIOL, V129, P702, DOI 10.1128/JB.129.2.702-706.1977; Sambrook J, 1989, MOL CLONING LABORATO; SANFACON H, 1983, GENE, V22, P175, DOI 10.1016/0378-1119(83)90101-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SCHRAY B, 1991, NUCLEIC ACIDS RES, V19, P5307, DOI 10.1093/nar/19.19.5307; SELYE H, 1961, GROWTH, V25, P243; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; SPRINGER M, 1989, EMBO J, V8, P2417, DOI 10.1002/j.1460-2075.1989.tb08372.x; TING SM, 1992, J BIOL CHEM, V267, P17701; VISWANATHAN S, 1988, DEV BIOL, V129, P350, DOI 10.1016/0012-1606(88)90382-X	51	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8993	8998						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132637				2022-12-25	WOS:A1994NB41100057
J	CHEN, Y; YU, L				CHEN, Y; YU, L			DIFFERENTIAL REGULATION BY CAMP-DEPENDENT PROTEIN-KINASE AND PROTEIN-KINASE-C OF THE MU-OPIOID RECEPTOR COUPLING TO A G-PROTEIN-ACTIVATED K+ CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INDUCED POTASSIUM CURRENT; GUINEA-PIG; RAT; NEURONS; FAMILY; CELLS; CONDUCTANCE; ANALGESIA; CALCIUM; NODE	A mu opioid receptor and a G protein-activated K+ channel were coexpressed in Xenopus oocytes. Stimulation of the mu opioid receptor induced an inwardly rectifying current that was blocked by opioid receptor antagonist naloxone, indicating that the mu opioid receptor is functionally coupled to the K+ channel. The coupling is mediated by G proteins, since pertussis toxin treatment reduced the K+ current and injection of GTP gamma S (guanosine 5'-O-(thiotriphosphate)) enhanced it. Repeated stimulation of the mu receptor leads to desensitization, as the K+ current from the second stimulation was reduced to 70% of that from the first one. Both cAMP-dependent protein kinase (PKA) and protein kinase C (PKC) regulate this process, but in opposite direction. Activation of PKC by treatment of the oocyte with phorbol ester potentiated the desensitization of the mu receptor-induced current. However, incubation of the cell with a membrane-permeable cAMP analog, 8-chlorophenylthio-cAMP, completely abolished the desensitization. The cAMP effect appears to be mediated by PKA, since injection of a PKA catalytic subunit showed the same effect as cAMP incubation. These results suggest that PKA and PKC differentially regulate the mu opioid receptor coupling to the G protein-activated K+ channel.	INDIANA UNIV,SCH MED,DEPT MED & MOLEC GENET,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis					NINDS NIH HHS [NS01557, NS28190] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K04NS001557, R29NS028190] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ATTALI B, 1989, J BIOL CHEM, V264, P347; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BOURINET E, 1992, FEBS LETT, V299, P5, DOI 10.1016/0014-5793(92)80087-W; CARIELLO NF, 1991, NUCLEIC ACIDS RES, V19, P4193, DOI 10.1093/nar/19.15.4193; CARTER BD, 1993, P NATL ACAD SCI USA, V90, P4062, DOI 10.1073/pnas.90.9.4062; CAUDLE RM, 1990, J PHARMACOL EXP THER, V252, P1361; CHAILLET P, 1984, EUR J PHARMACOL, V101, P83, DOI 10.1016/0014-2999(84)90033-5; CHEN Y, 1993, MOL PHARMACOL, V44, P8; CHEN Y, 1994, FEBS LETT, V336, P191; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P6596, DOI 10.1073/pnas.90.14.6596; EINHORN LC, 1991, J NEUROSCI, V11, P3727; GOLDSTEIN A, 1987, TRENDS PHARMACOL SCI, V8, P456, DOI 10.1016/0165-6147(87)90038-1; KREBS EG, 1989, JAMA-J AM MED ASSOC, V262, P1815, DOI 10.1001/jama.262.13.1815; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURTZ A, 1989, P NATL ACAD SCI USA, V86, P3423, DOI 10.1073/pnas.86.9.3423; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; MIHARA S, 1987, J PHYSIOL-LONDON, V390, P335, DOI 10.1113/jphysiol.1987.sp016704; MIYAKE M, 1989, P NATL ACAD SCI USA, V86, P3419, DOI 10.1073/pnas.86.9.3419; NOMA A, 1979, PFLUG ARCH EUR J PHY, V381, P255, DOI 10.1007/BF00583257; NOMA A, 1978, PFLUG ARCH EUR J PHY, V377, P193, DOI 10.1007/BF00584272; NORTH RA, 1987, P NATL ACAD SCI USA, V84, P5487, DOI 10.1073/pnas.84.15.5487; OFFERMANNS S, 1991, J BIOL CHEM, V266, P3365; PASTERNAK GW, 1980, SCIENCE, V208, P514, DOI 10.1126/science.6245448; PASTERNAK GW, 1988, OPIATE RECEPTORS; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SHEN KZ, 1992, J PHYSIOL-LONDON, V445, P581, DOI 10.1113/jphysiol.1992.sp018941; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; UEDA H, 1988, P NATL ACAD SCI USA, V85, P7013, DOI 10.1073/pnas.85.18.7013; WILLIAMS JT, 1988, J NEUROSCI, V8, P4299; WIMPEY TL, 1991, NEURON, V6, P281, DOI 10.1016/0896-6273(91)90363-5; YU L, 1991, MOL BRAIN RES, V11, P143, DOI 10.1016/0169-328X(91)90116-F	33	172	180	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7839	7842						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132498				2022-12-25	WOS:A1994NB40900002
J	LYNCH, JW; LEMOS, VS; BUCHER, B; STOCLET, JC; TAKEDA, K				LYNCH, JW; LEMOS, VS; BUCHER, B; STOCLET, JC; TAKEDA, K			PERTUSSIS TOXIN-INSENSITIVE CALCIUM INFLUX MEDIATED BY NEUROPEPTIDE Y-2 RECEPTORS IN A HUMAN NEUROBLASTOMA CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROLEUKEMIA-CELLS; ROOT GANGLION NEURONS; RAT SENSORY NEURONS; Y PEPTIDE-YY; N-MC CELLS; ADENYLATE-CYCLASE; G-PROTEIN; INTRACELLULAR CALCIUM; CA2+ INFLUX; CA-2+	Stimulation of neuropeptide Y (NPY) Y-2 receptors induced an intracellular free Ca2+ ([Ca2+](i)) increase in a human neuroblastoma cell line, CHP-234. When NPY in a Ca2+-free solution was applied, this increase was abolished. Depolarization with high KC1 evoked no response, suggesting that the responses were not mediated by voltage-gated Ca2+ channels. There was no evidence that the NPY response consisted of a capacitative Ca2+ entry sensitive to internal Ca2+ store levels. The [Ca2+](i) elevation was diminished by Ni2+, a blocker of Ca2+ entry. Mn2+ induced a quench of the fura-2 fluorescence, which ceased promptly upon the removal of NPY, indicating that Ca2+ entry was linked tightly to receptor activation. Although thapsigargin- and ryanodine-sensitive Ca2+ stores were present, NPY induced responses were not impaired by pretreatment with either drug. Further-more, NPY had no effect on the thapsigargin sensitive store. Pertussis toxin did not affect the NPY-stimulated [Ca2+](i) increase, although it abolished the NPY-dependent inhibition of cAMP production. It is concluded that the Y-2 receptors couple directly to receptor-operated Ca2+ channels without the involvement of intracellular Ca2+ stores. The results also indicate that Y-2 receptors can activate both pertussis toxin-sensitive and -insensitive mechanisms in the same cell.	UNIV LOUIS PASTEUR STRASBOURG,PHARMACOL CELLAIRE & MOLEC LAB,CNRS,URA 600,F-67401 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS)			Lemos, Virginia/B-7305-2018; Lynch, Joseph/C-8636-2009	Lemos, Virginia/0000-0003-1234-9325; 				AAKERLUND L, 1990, FEBS LETT, V260, P73, DOI 10.1016/0014-5793(90)80069-U; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLACKMORE PF, 1993, CELL CALCIUM, V14, P53, DOI 10.1016/0143-4160(93)90018-2; BLEAKMAN D, 1991, BRIT J PHARMACOL, V103, P1781, DOI 10.1111/j.1476-5381.1991.tb09863.x; Cochran W.G, 1957, STAT METHODS, V6th ed; COLMERS WF, 1989, BRAIN RES, V498, P99, DOI 10.1016/0006-8993(89)90403-4; DANGER JM, 1990, FUNDAM CLIN PHARM, V21, P5; DANIELS AJ, 1989, BIOCHEM BIOPH RES CO, V165, P1138, DOI 10.1016/0006-291X(89)92721-6; DANIELS AJ, 1992, MOL PHARMACOL, V41, P767; EDVINSSON L, 1987, TRENDS PHARMACOL SCI, V8, P231, DOI 10.1016/0165-6147(87)90069-1; EWALD DA, 1989, NEURON, V2, P1185, DOI 10.1016/0896-6273(89)90185-2; FETH F, 1992, BRIT J PHARMACOL, V105, P71, DOI 10.1111/j.1476-5381.1992.tb14212.x; FETH F, 1991, N-S ARCH PHARMACOL, V344, P1; FOUCART S, 1989, N-S ARCH PHARMACOL, V340, P658, DOI 10.1007/BF00717741; FREDHOLM BB, 1985, ACTA PHYSIOL SCAND, V124, P467, DOI 10.1111/j.1748-1716.1985.tb07683.x; FUHLENDORFF J, 1990, P NATL ACAD SCI USA, V87, P182, DOI 10.1073/pnas.87.1.182; GIMPL G, 1993, J NEUROSCI RES, V34, P198, DOI 10.1002/jnr.490340207; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEILIG M, 1990, ACTA PSYCHIAT SCAND, V82, P95, DOI 10.1111/j.1600-0447.1990.tb01366.x; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; KOCH B, 1991, MOL CELL ENDOCRINOL, V77, P57, DOI 10.1016/0303-7207(91)90058-Z; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LEHMANN J, 1990, DRUG DEVELOP RES, V19, P329, DOI 10.1002/ddr.430190402; LLOPIS J, 1992, BIOCHEM J, V284, P243, DOI 10.1042/bj2840243; LO TM, 1993, AM J PHYSIOL, V264, pC641, DOI 10.1152/ajpcell.1993.264.3.C641; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MICHEL MC, 1992, N-S ARCH PHARMACOL, V345, P370; MIHARA S, 1989, FEBS LETT, V259, P79, DOI 10.1016/0014-5793(89)81499-1; MISSIAEN L, 1992, J BIOL CHEM, V267, P22961; MOTULSKY HJ, 1988, AM J PHYSIOL, V255, pE880, DOI 10.1152/ajpendo.1988.255.6.E880; NEHER E, 1992, NATURE, V355, P298, DOI 10.1038/355298a0; NORENBERG W, 1991, PFLUG ARCH EUR J PHY, V418, P346, DOI 10.1007/BF00550872; PERNEY TM, 1989, J BIOL CHEM, V264, P7317; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SAGE SO, 1989, BIOCHEM J, V258, P923, DOI 10.1042/bj2580923; SHEIKH SP, 1989, J BIOL CHEM, V264, P6648; SPEDDING M, 1992, PHARMACOL REV, V44, P363; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; TAYLOR CW, 1990, TRENDS PHARMACOL SCI, V11, P269, DOI 10.1016/0165-6147(90)90003-Q; WAHLESTEDT C, 1992, LIFE SCI, V50, pPL7, DOI 10.1016/0024-3205(92)90342-M; WAHLESTEDT C, 1986, REGUL PEPTIDES, V13, P307, DOI 10.1016/0167-0115(86)90048-0; WAHLESTEDT C, 1993, ANN REV PHARM TOXICO, V32, P309; WALKER MW, 1988, J NEUROSCI, V8, P2438; WALKER P, 1991, TRENDS PHARMACOL SCI, V12, P111, DOI 10.1016/0165-6147(91)90518-W	44	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8226	8233						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132547				2022-12-25	WOS:A1994NB40900061
J	BREYTON, C; DEVITRY, C; POPOT, JL				BREYTON, C; DEVITRY, C; POPOT, JL			MEMBRANE ASSOCIATION OF CYTOCHROME B(6)F SUBUNITS - THE RIESKE IRON-SULFUR PROTEIN FROM CHLAMYDOMONAS-REINHARDTII IS AN EXTRINSIC PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; C REDUCTASE COMPLEX; THYLAKOID MEMBRANE; ELECTROPHORETIC TRANSFER; POLYACRYLAMIDE GELS; UBIQUINOL; MUTANTS; NITROCELLULOSE	The mode of membrane attachment of five subunits from Chlamydomonas reinhardtii cytochrome b(6) f complex has been studied using biochemical approaches. Antisera specific for cytochrome f, cytochrome b(6), the Rieske iron-sulfur protein, subunit IV, and a 4-kDa subunit (product of the petG gene) were used to quantify the degree of extraction of each of these polypeptides following various treatments. In contrast to the other four subunits, the Rieske protein was extracted to extents varying between 50 and 100% following two cycles of freezing and thawing in the presence of chaotropic agents (KSCN, urea, or NaI). The Rieske protein was not extracted by 2 M NaC1 and was rather resistant to alkaline treatments, being extracted by 20 mM 3-(cyclohexylamino)propanesulfonic acid buffer only at pH > 11.5. The hydrodynamic behavior of the isolated Rieske protein was examined in the absence and presence of detergent by ultracentrifugation and by molecular sieving. The extracted protein bound neither to laurylmaltoside nor to C(12)E(8) micelles. Its sedimentation coefficient (D-20,w = 9.6 x 10(-11) m(2.) s(-1), diffusion coefficient (s(20),(w) = 2 S), and deduced molecular mass (20.0 +/- 1.7 kDa) are those expected for the monomeric protein. We conclude that the Rieske protein is extrinsic and therefore does not cross the membrane, although its association with the rest of the complex involves primarily hydrophobic interactions, and that the other four subunits analyzed are intrinsic.	COLL FRANCE,CTR NATL RECH SCI,URA 1187,F-75005 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France	BREYTON, C (corresponding author), INST BIOL PHYSICOCHIM,13 RUE PIERRE & MARIE CURIE,F-75005 PARIS,FRANCE.							ATTEIA A, 1992, J BIOL CHEM, V267, P226; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BRUCE BD, 1991, PLANT CELL, V3, P203, DOI 10.1105/tpc.3.2.203; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; COCCO T, 1991, EUR J BIOCHEM, V195, P731, DOI 10.1111/j.1432-1033.1991.tb15760.x; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; DANDLIKER WB, 1971, CHEM BIOSURFACES, P1; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3351, DOI 10.1021/bi00128a007; DEVITRY C, 1994, J BIOL CHEM, V269, P7603; DEVITRY C, 1991, J BIOL CHEM, V266, P16614; DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991; DRAPIER D, 1992, PLANT CELL, V4, P283, DOI 10.2307/3869540; GAVEL Y, 1991, FEBS LETT, V282, P41, DOI 10.1016/0014-5793(91)80440-E; GONZALEZHALPHEN D, 1991, J BIOL CHEM, V266, P3870; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; GUTWENIGER H, 1981, J BIOL CHEM, V256, P1132; HALEY J, 1989, P NATL ACAD SCI USA, V86, P1534, DOI 10.1073/pnas.86.5.1534; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HOPE AB, 1993, BIOCHIM BIOPHYS ACTA, V1143, P1, DOI 10.1016/0005-2728(93)90210-7; KNAFF DB, 1993, PHOTOSYNTH RES, V35, P117, DOI 10.1007/BF00014743; Kuntz I D Jr, 1974, Adv Protein Chem, V28, P239, DOI 10.1016/S0065-3233(08)60232-6; LEMAIRE C, 1986, BIOCHIM BIOPHYS ACTA, V851, P229, DOI 10.1016/0005-2728(86)90130-1; LI Y, 1981, FEBS LETT, V135, P277, DOI 10.1016/0014-5793(81)80800-9; LINK TA, 1992, EUR J BIOCHEM, V208, P685, DOI 10.1111/j.1432-1033.1992.tb17235.x; MALKIN R, 1992, PHOTOSYNTH RES, V33, P121, DOI 10.1007/BF00039175; MOLLER JV, 1993, J BIOL CHEM, V268, P18659; PARADIES HH, 1983, COLLOID SURFACE, V6, P405, DOI 10.1016/0166-6622(83)80031-6; PIERRE Y, 1993, CR ACAD SCI III-VIE, P1404; POPOT, 1993, CURR OPIN STRUCT BIO, V3, P532; POPOT JL, 1990, ANNU REV BIOPHYS BIO, V19, P369; RIESKE JS, 1964, BIOCHEM BIOPH RES CO, V15, P338, DOI 10.1016/0006-291X(64)90171-8; ROBINSON NC, 1975, BIOCHEMISTRY-US, V14, P369, DOI 10.1021/bi00673a025; ROSEVEAR P, 1980, BIOCHEMISTRY-US, V19, P4108, DOI 10.1021/bi00558a032; SZCZEPANIAK A, 1991, EMBO J, V10, P2757, DOI 10.1002/j.1460-2075.1991.tb07824.x; Tanford C., 1961, PHYS CHEM MACROMOLEC, P710; TANNER MJA, 1979, CURR TOP MEMBR TRANS, V12, P1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDOREN SR, 1993, BIOCHEMISTRY-US, V32, P628, DOI 10.1021/bi00053a031	40	67	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7597	7602						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125983				2022-12-25	WOS:A1994NA03200089
J	KELMAN, DJ; DEGRAY, JA; MASON, RP				KELMAN, DJ; DEGRAY, JA; MASON, RP			REACTION OF MYOGLOBIN WITH HYDROGEN-PEROXIDE FORMS A PEROXYL RADICAL WHICH OXIDIZES SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; METMYOGLOBIN; RESONANCE; FERRYLMYOGLOBIN; TYR-151; SYSTEMS	Evidence is presented that the radical observed upon reaction of myoglobin with hydrogen peroxide is a peroxyl radical. Simulation of this spectrum gives principal values for the g tenser of g(x) = 2.0357, g(y) = 2.0082, and g(z) = 2.0016, which are consistent with those of a peroxyl radical. Use of molecular oxygen isotopically labeled with O-17 confirmed that the radical observed was a peroxyl radical. Removal of oxygen from the incubation by use of glucose and glucose oxidase revealed two radicals, one at g(iso) = 2.0028 and the other at g(iso) = 2.0073. Addition of various amounts of the spin trap 5,5-dimethyl-1-pyrroline N-oxide revealed that the spin trap and oxygen compete for the same radical site. Four model substrates, glutathione, styrene, arachidonic acid and linoleic acid, were individually added to both the aerobic and anoxic systems. Glutathione reacted with the peroxyl radical, reducing its intensity by 98%, and entirely eliminated the g(iso) = 2.0028 line from the spectrum of the anoxic incubation. Styrene, arachidonic acid and linoleic acid reacted with the peroxyl radical, reducing its amplitude by 84, 57, and 35%, respectively, but did not decrease the amplitude of either radical species in the anoxic incubation. The g(iso) = 2.0028 species detected in the anoxic incubation appears to be the original radical site to which molecular oxygen binds to form the peroxyl radical. This myoglobin-derived peroxyl radical species is responsible for the advent of lipid peroxidation as proposed in ischemia/repurfusion injury, as well as other reactions, as exemplified by the O-2-dependent epoxidation of styrene.	UNIV N CAROLINA, CURRICULUM TOXICOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	KELMAN, DJ (corresponding author), NIEHS, MOLEC BIOPHYS LAB, RES TRIANGLE PK, NC 27709 USA.		Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109				AMBROSIO G, 1992, AM J PHYSIOL, V262, pH23, DOI 10.1152/ajpheart.1992.262.1.H23; ARDUINI A, 1992, FREE RADICAL BIO MED, V13, P449, DOI 10.1016/0891-5849(92)90185-J; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; DAVIES MJ, 1990, FREE RADICAL RES COM, V10, P361, DOI 10.3109/10715769009149905; DAVIES MJ, 1991, BIOCHIM BIOPHYS ACTA, V1077, P86, DOI 10.1016/0167-4838(91)90529-9; DEGRAY JA, 1992, J BIOL CHEM, V267, P23583; DEGRAY JA, 1987, THESIS BROWN U PROVI; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; DIMMEY LJ, 1980, P NATL ACAD SCI-BIOL, V77, P343, DOI 10.1073/pnas.77.1.343; GALARIS D, 1990, ARCH BIOCHEM BIOPHYS, V281, P163, DOI 10.1016/0003-9861(90)90427-Z; GIBSON JF, 1958, NATURE, V181, P1398, DOI 10.1038/1811398a0; GRISHAM M B, 1985, Journal of Free Radicals in Biology and Medicine, V1, P227, DOI 10.1016/0748-5514(85)90122-9; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; HARADA K, 1987, J BIOCHEM, V101, P283, DOI 10.1093/oxfordjournals.jbchem.a121903; HONG S-J, 1989, Korean Biochemical Journal, V22, P196; INGOLD KU, 1969, ACCOUNTS CHEM RES, V2, P1, DOI 10.1021/ar50013a001; KELMAN DJ, 1992, FREE RADICAL RES COM, V16, P27, DOI 10.3109/10715769209049156; KING NK, 1967, BIOCHIM BIOPHYS ACTA, V133, P65; KING NK, 1963, J BIOL CHEM, V238, P1520; LOW W, 1957, PHYS REV, V105, P801, DOI 10.1103/PhysRev.105.801; MIKI H, 1989, ARCH BIOCHEM BIOPHYS, V275, P354, DOI 10.1016/0003-9861(89)90382-2; RAO SI, 1993, J BIOL CHEM, V268, P803; RIEGER PH, 1982, J MAGN RESON, V50, P485, DOI 10.1016/0022-2364(82)90013-0; ROBERTS JE, 1981, J BIOL CHEM, V256, P2118; ROMERO FJ, 1992, J BIOL CHEM, V267, P1680; SEVILLA MD, 1990, INT J RADIAT BIOL, V57, P65, DOI 10.1080/09553009014550351; SINCLAIR AJ, 1990, BRIT J HOSP MED, V43, P334; TEW D, 1988, J BIOL CHEM, V263, P17880; VANDERKOOI JM, 1987, J BIOL CHEM, V262, P5476; WILKS A, 1992, J BIOL CHEM, V267, P8827; XU Y, 1990, J AGR FOOD CHEM, V38, P1494, DOI 10.1021/jf00097a014	31	137	138	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7458	7463						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125965				2022-12-25	WOS:A1994NA03200068
J	RISTIMAKI, A; GARFINKEL, S; WESSENDORF, J; MACIAG, T; HLA, T				RISTIMAKI, A; GARFINKEL, S; WESSENDORF, J; MACIAG, T; HLA, T			INDUCTION OF CYCLOOXYGENASE-2 BY INTERLEUKIN-1-ALPHA - EVIDENCE FOR POSTTRANSCRIPTIONAL REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; MESSENGER-RNA; II PHOSPHOLIPASE-A2; COMPLEMENTARY-DNA; ENDOTHELIAL-CELLS; PROTEIN-SYNTHESIS; GENE-EXPRESSION; G/H SYNTHASE; CDNA CLONING; H SYNTHASE	Prostanoids, produced by diverse cell types, modulate a variety of pathophysiological processes. The rate of prostanoid synthesis is determined, in part, by the levels of prostanoid-synthetic enzymes, such as cyclooxygenase (Cox), a rate-limiting enzyme in the conversion of arachidonic acid to prostanoids. While two Cox genes have been identified, Cox-2 is unique because it is highly induced in response to cell activation processes including inflammation. We have studied the effect of interleukin-1 alpha (IL-1 alpha), a proinflammatory cytokine that facilitates its actions in part by inducing the synthesis of prostanoids, on the expression of Cox-2 in a human cell line (ECV304) and demonstrated that IL-1 alpha induces a sustained increase in the expression of the Cox-2 mRNA as well as the functional enzyme. Three mechanistically distinct inhibitors of translation stimulated the expression of the Cox-2 mRNA and potentiated the effect of IL-1 alpha. Furthermore, IL-1 alpha induced rapid but transient activation of Cox-2 transcription and, in the absence of transcription, prolonged the half-life of the Cox-2 mRNA Together, these data suggest that post-transcriptional mechanisms are important in the sustained induction of the Cox-2 mRNA and that IL-1 alpha may increase the stability of the Cox-2 transcript.	AMER RED CROSS, DEPT MOLEC BIOL, HOLLAND LAB, ROCKVILLE, MD 20855 USA	American Red Cross			Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065	FIC NIH HHS [FO5 TWO4963] Funding Source: Medline; NHLBI NIH HHS [HL49094, HL35627] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004963] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035627, R01HL049094] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; APPLEBY SB, 1994, IN PRESS BIOCH J; CELANO P, 1989, BIOTECHNIQUES, V7, P942; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; CROWL RM, 1991, J BIOL CHEM, V266, P2647; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DOCTROW SR, 1987, J CELL BIOL, V104, P679, DOI 10.1083/jcb.104.3.679; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAINES DS, 1992, BIOTECHNIQUES, V12, P736; HAMASAKI Y, 1993, ARCH BIOCHEM BIOPHYS, V304, P226, DOI 10.1006/abbi.1993.1343; HLA T, 1993, ANN NY ACAD SCI, V696, P197; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HUA JL, 1992, MOL ENDOCRINOL, V6, P1418, DOI 10.1210/me.6.9.1418; JONES DA, 1993, J BIOL CHEM, V268, P9049; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LEE SH, 1992, J BIOL CHEM, V267, P25934; LIN LL, 1992, J BIOL CHEM, V267, P23451; LYONSGIORDANO B, 1993, EXP CELL RES, V206, P58, DOI 10.1006/excr.1993.1120; MACIAG T, 1982, J CELL BIOL, V94, P511, DOI 10.1083/jcb.94.3.511; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NORIOKA K, 1987, BIOCHEM BIOPH RES CO, V145, P969, DOI 10.1016/0006-291X(87)91060-6; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OKA S, 1991, J BIOL CHEM, V266, P9956; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; RISTIMAKI A, 1992, PROSTAG LEUKOTR ESS, V47, P93, DOI 10.1016/0952-3278(92)90143-7; RYSECK RP, 1992, CELL GROWTH DIFFER, V3, P43; SANO H, 1992, J CLIN INVEST, V89, P97, DOI 10.1172/JCI115591; SEHGAL PB, 1976, SCIENCE, V194, P431, DOI 10.1126/science.982026; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; XIE W, 1991, P NATL ACAD SCI USA, V88, P2892; XIE WL, 1993, ARCH BIOCHEM BIOPHYS, V300, P247, DOI 10.1006/abbi.1993.1034; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0	49	431	436	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11769	11775						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163473				2022-12-25	WOS:A1994NG37700017
J	COVER, TL; TUMMURU, MKR; CAO, P; THOMPSON, SA; BLASER, MJ				COVER, TL; TUMMURU, MKR; CAO, P; THOMPSON, SA; BLASER, MJ			DIVERGENCE OF GENETIC SEQUENCES FOR THE VACUOLATING CYTOTOXIN AMONG HELICOBACTER-PYLORI STRAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MARCESCENS SERINE PROTEASE; TRANSFER RNA-SYNTHETASE; OUTER-MEMBRANE PROTEIN; ESCHERICHIA-COLI; RICKETTSIA-RICKETTSII; CAMPYLOBACTER-PYLORI; IGA PROTEASE; PRECURSOR; UREASE; TOXIN	Approximately 50% of Helicobacter pylori isolates produce a cytotoxin in vitro that induces vacuolation of eukaryotic cells. Screening a lambda ZapII library of H. pylori 60190 chromosomal fragments permitted the identification of a 3864-base pair (bp) open reading frame (vacA) that encoded the vacuolating cytotoxin, and a greater than or equal to 567-bp upstream gene that was homologous to Escherichia coli cysteinyl-tRNA synthetase. The sequence data suggest that a 33-amino-acid leader sequence and a C-terminal peptide are cleaved from a 139-kDa protoxin to yield the mature 87-kDa cytotoxin. The vacA gene product contains a C-terminal motif that is present in several other bacterial proteins that undergo C-terminal cleavage, including IgA proteases of Haemophilus influenzae and Neisseria gonorrhoeae. Isogenic H. pylori mutants with insertional mutation of the vacA gene lacked vacuolating cytotoxin activity and failed to produce the 87-kDa protein. Southern analysis of naturally occurring tox(-) H. pylori strains with vacA probes indicated the presence of hybridizing bands, but both Southern analysis and polymerase chain reaction studies suggested that the vacA sequences of tox(-) strains differed from those of tox(+) strains. Sequence analysis of a 1541-bp region of polymerase chain reaction-amplified vacA from tox(-) strain 87-203 indicated 64.8% amino acid identity with the corresponding region from tox(+) strain 60190. Thus, sequence divergence in vacA genes may explain the lack of functionally active cytotoxin production by some H. pylori isolates.	VANDERBILT UNIV, SCH MED, DEPT MICROBIOL, NASHVILLE, TN 37232 USA; DEPT VET AFFAIRS MED CTR, NASHVILLE, TN 37212 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	COVER, TL (corresponding author), VANDERBILT UNIV, SCH MED, DEPT MED, DIV INFECT DIS, MED CTR N A3310, NASHVILLE, TN 37232 USA.		Cover, Timothy/I-3814-2015	Cover, Timothy/0000-0001-8503-002X; Thompson, Stuart/0000-0002-0457-6926	NCI NIH HHS [R01 CA58834] Funding Source: Medline; NIDDK NIH HHS [R29 DK45293-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045293] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKOPYANZ N, 1992, NUCLEIC ACIDS RES, V20, P5137, DOI 10.1093/nar/20.19.5137; AVALOS J, 1991, FEBS LETT, V286, P176, DOI 10.1016/0014-5793(91)80968-9; BENZ I, 1992, MOL MICROBIOL, V6, P1539, DOI 10.1111/j.1365-2958.1992.tb00875.x; BUKANOV NO, 1994, MOL MICROBIOL, V11, P509, DOI 10.1111/j.1365-2958.1994.tb00332.x; CARL M, 1990, P NATL ACAD SCI USA, V87, P8237, DOI 10.1073/pnas.87.21.8237; CORREA P, 1992, CANCER RES, V52, P6735; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; COVER TL, 1991, INFECT IMMUN, V59, P1264, DOI 10.1128/IAI.59.4.1264-1270.1991; COVER TL, 1992, ANNU REV MED, V43, P135, DOI 10.1146/annurev.me.43.020192.001031; COVER TL, 1993, INFECT IMMUN, V61, P5008, DOI 10.1128/IAI.61.12.5008-5012.1993; COVER TL, 1992, J BIOL CHEM, V267, P10570; COVER TL, 1990, INFECT IMMUN, V58, P603, DOI 10.1128/IAI.58.3.603-610.1990; CRABTREE JE, 1991, LANCET, V338, P332, DOI 10.1016/0140-6736(91)90477-7; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FERRERO RL, 1992, J BACTERIOL, V174, P4212, DOI 10.1128/JB.174.13.4212-4217.1992; FIGURA N, 1989, J CLIN MICROBIOL, V27, P225, DOI 10.1128/JCM.27.1.225-226.1989; FOXALL PA, 1992, J CLIN MICROBIOL, V30, P739, DOI 10.1128/JCM.30.3.739-741.1992; GILMORE RD, 1989, MOL MICROBIOL, V3, P1579, DOI 10.1111/j.1365-2958.1989.tb00143.x; GILMORE RD, 1991, MOL MICROBIOL, V5, P2361, DOI 10.1111/j.1365-2958.1991.tb02082.x; GOOSSENS H, 1992, MED MICROBIOL LETT, V1, P153; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; KLAUSER T, 1990, EMBO J, V9, P1991, DOI 10.1002/j.1460-2075.1990.tb08327.x; LABIGNEROUSSEL A, 1988, J BACTERIOL, V170, P1704, DOI 10.1128/jb.170.4.1704-1708.1988; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; Maniatis T, 1989, MOL CLONING; MIYAZAKI H, 1989, J BACTERIOL, V171, P6566, DOI 10.1128/jb.171.12.6566-6572.1989; POHLNER J, 1987, NATURE, V325, P458, DOI 10.1038/325458a0; POLLOCK MR, 1962, NATURE, V194, P446, DOI 10.1038/194446a0; POULSEN K, 1989, INFECT IMMUN, V57, P3097, DOI 10.1128/IAI.57.10.3097-3105.1989; SANGER F, 1977, P NATL ACAD SCI USA, V71, P1342; SCHLEIF RF, 1981, PRACTICAL METHODS MO, P98; SHIKATA S, 1992, J BIOCHEM-TOKYO, V111, P627, DOI 10.1093/oxfordjournals.jbchem.a123809; STRUYVE M, 1991, J MOL BIOL, V218, P141, DOI 10.1016/0022-2836(91)90880-F; SUERBAUM S, 1993, J BACTERIOL, V175, P3278, DOI 10.1128/jb.175.11.3278-3288.1993; TEE W, 1993, GASTROENTEROLOGY, V104, pA789; TUMMURU MKR, 1993, INFECT IMMUN, V61, P1799, DOI 10.1128/IAI.61.5.1799-1809.1993; YANAGIDA N, 1986, J BACTERIOL, V166, P937, DOI 10.1128/jb.166.3.937-944.1986	40	429	456	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10566	10573						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144644				2022-12-25	WOS:A1994NF01700058
J	DOLCE, V; IACOBAZZI, V; PALMIERI, F; WALKER, JE				DOLCE, V; IACOBAZZI, V; PALMIERI, F; WALKER, JE			THE SEQUENCES OF HUMAN AND BOVINE GENES OF THE PHOSPHATE CARRIER FROM MITOCHONDRIA CONTAIN EVIDENCE OF ALTERNATIVELY SPLICED FORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP ATP TRANSLOCASE; COMPLEMENTARY-DNA SEQUENCE; BROWN FAT MITOCHONDRIA; UNCOUPLING PROTEIN; HEART-MITOCHONDRIA; STRUCTURAL RELATIONSHIP; TRANSPORT PROTEIN; CDNA; SYNTHASE; CLONING	The sequences of the human and bovine genes for the phosphate carrier from the inner membranes of mitochondria have been determined. The genes have similar structures and each is divided into nine exons. In both genes, two exons, named IIIA and IIIB, are closely related, and they appear to be alternatively spliced. The human exon IIIB sequence is found in a published human heart cDNA sequence, and bovine exon IIIA forms part of a published bovine heart cDNA sequence. By further examination of the human heart cDNA library, sequences arising from both alternatively spliced forms of the phosphate carrier have been characterized. Both forms were also found in several bovine tissues, but the ratios of expression of the two forms varied. The form containing exon IIIA was expressed most highly in bovine heart and liver, less highly in brain and kidney, and only in low amounts in lung. The opposite hierarchy was found for the form containing exon IIIB; it was most highly expressed in lung and least in heart and liver. The alternative splicing mechanism affects amino acids 4-45 of the mature phosphate carrier protein, which is believed to form one of six transmembrane segments of the phosphate carrier and to emerge into a large extramembranous loop. The alternative splicing mechanism changes 13 and 11 amino acids in the human and bovine carrier proteins, respectively. As the function of this region of the phosphate carrier is not known, the effects of the changes on carrier function are not understood at present.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; UNIV BARI,DEPT PHARMACOBIOL,BIOCHEM & MOLEC BIOL LAB,I-70125 BARI,ITALY	MRC Laboratory Molecular Biology; Universita degli Studi di Bari Aldo Moro			Iacobazzi, Vito/A-6106-2016	Iacobazzi, Vito/0000-0002-0470-2056; Dolce, Vincenza/0000-0003-2966-4866; Walker, John/0000-0001-7929-2162				AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; BATTINI R, 1987, J BIOL CHEM, V262, P4355; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BISACCIA F, 1984, BIOCHIM BIOPHYS ACTA, V766, P386, DOI 10.1016/0005-2728(84)90254-8; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CAPOBIANCO L, 1991, BIOCHEMISTRY-US, V30, P4963, DOI 10.1021/bi00234a018; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COZENS AL, 1989, J MOL BIOL, V206, P261, DOI 10.1016/0022-2836(89)90477-4; Dolce V, 1991, DNA Seq, V2, P133, DOI 10.3109/10425179109039683; DYER MR, 1993, BIOCHEM J, V293, P51, DOI 10.1042/bj2930051; FERREIRA GC, 1989, J BIOL CHEM, V264, P15628; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; GARBER RL, 1983, EMBO J, V2, P2027, DOI 10.1002/j.1460-2075.1983.tb01696.x; GAWAZ M, 1990, J BIOL CHEM, V265, P14202; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; Iacobazzi V, 1992, DNA Seq, V3, P79, DOI 10.3109/10425179209034000; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; KOLAROV J, 1990, J BIOL CHEM, V265, P12711; KOLBE HVJ, 1984, J BIOL CHEM, V259, P9115; KRAMER R, 1989, BIOCHIM BIOPHYS ACTA, V974, P1, DOI 10.1016/S0005-2728(89)80160-4; Krumer R., 1992, MOL MECHANISMS BIOEN, P359, DOI DOI 10.1016/50167-7306(08)60184-2; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; MATSUDA C, 1993, FEBS LETT, V325, P281, DOI 10.1016/0014-5793(93)81089-I; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; PALMIERI F, 1993, J BIOENERG BIOMEMBR, V25, P493, DOI 10.1007/BF01108406; PHELPS A, 1991, BIOCHEMISTRY-US, V30, P248, DOI 10.1021/bi00215a035; POWELL SJ, 1989, BIOCHEMISTRY-US, V28, P866, DOI 10.1021/bi00428a069; RICQUIER D, 1991, FASEB J, V5, P2237, DOI 10.1096/fasebj.5.9.1860614; RUNSWICK MJ, 1987, EMBO J, V6, P1367, DOI 10.1002/j.1460-2075.1987.tb02377.x; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; RUNSWICK MJ, 1994, IN PRESS DNA SEQUENC; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P4731, DOI 10.1093/nar/10.15.4731; VINAS O, 1990, BIOCHEM J, V265, P321, DOI 10.1042/bj2650321; Walker J.E., 1992, CURR OPIN STRUC BIOL, V2, P519, DOI DOI 10.1016/0959-440X(92)90081-H; WALKER JE, 1992, J MOL BIOL, V226, P1051, DOI 10.1016/0022-2836(92)91052-Q; WALKER JE, 1989, BIOCHEMISTRY-US, V28, P4702, DOI 10.1021/bi00437a029; WALKER JE, 1987, BIOCHEMISTRY-US, V26, P8613, DOI 10.1021/bi00400a018; WALKER JE, 1993, J BIOENERG BIOMEMBR, V25, P435, DOI 10.1007/BF01108401; WALKER JE, 1987, CHEM SCRIPTA, V27B, P97; ZARA V, 1992, J BIOL CHEM, V267, P12077	42	61	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10451	10460						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144629				2022-12-25	WOS:A1994NF01700042
J	DREVET, JR; SKEIKY, YAW; IATROU, K				DREVET, JR; SKEIKY, YAW; IATROU, K			GATA-TYPE ZINC-FINGER MOTIF-CONTAINING SEQUENCES AND CHORION GENE-TRANSCRIPTION FACTORS OF THE SILKWORM BOMBYX-MORI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIGENE FAMILY; DEVELOPMENTAL REGULATION; SILKMOTH; DNA; EXPRESSION; DROSOPHILA; PROTEIN; EVOLUTION; PROMOTER; ENCODES	To characterize a DNA-binding protein, BCFI, which regulates the expression of silkmoth chorion genes through binding to gene promoter elements identical to those recognized by the GATA family of transcription factors, we have carried out polymerase chain reaction amplifications of Bombyx mori genomic DNA using degenerate primers derived from the conserved DNA binding domain of mammalian GATA factors. Two single copy genes, BmGATA alpha and BmGATA beta, were identified, which encode sequences containing GATA-type zinc finger motifs. The BmGATA beta gene is expressed in follicular and Bm5 tissue culture cells, the two cell types that contain BCFI. No BmGATA alpha gene transcripts were detectable in the tissues that were tested. Upon overexpression in Escherichia coli, a peptide encompassing the BmGATA beta zinc finger motif was able to bind specifically to the BCFI recognition motif of the chorion gene promoters. A polyclonal antibody directed against the zinc finger domain of BmGATA beta was also used in gel retardation assays to confirm that factor BCFI is indeed encoded by the BmGATA beta gene. Conceptual translation of a complete cDNA clone encoding the BmGATA beta protein revealed that this protein has a size similar to that of an immunoreactive protein, presumably BCFI, which is present in follicular cell extracts.	UNIV CALGARY,FAC MED,DEPT MED BIOCHEM,CALGARY T2N 4N1,AB,CANADA	University of Calgary			Drevet, Joël/W-2692-2019	Drevet, Joël/0000-0003-3077-6558				ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BAILEY JM, 1976, ANAL BIOCHEM, V70, P75, DOI 10.1016/S0003-2697(76)80049-8; BALTZ R, 1992, PLANT J, V2, P713, DOI 10.1046/j.1365-313X.1992.t01-13-00999.x; BOCK SC, 1982, P NATL ACAD SCI-BIOL, V79, P1032, DOI 10.1073/pnas.79.4.1032; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BURKE WD, 1986, J MOL BIOL, V190, P343, DOI 10.1016/0022-2836(86)90006-9; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CUNNINGHAM TS, 1991, MOL CELL BIOL, V11, P6205, DOI 10.1128/MCB.11.12.6205; DESPLAN C, 1985, NATURE, V318, P630, DOI 10.1038/318630a0; EICKBUSH TH, 1982, CELL, V19, P633; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FU YH, 1990, MOL CELL BIOL, V10, P1056, DOI 10.1128/MCB.10.3.1056; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; HARLOW E, 1988, ANTIBODIES LABORATOR; HIBNER BL, 1988, DEV BIOL, V125, P423, DOI 10.1016/0012-1606(88)90223-0; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; IATROU K, 1980, CELL, V20, P659, DOI 10.1016/0092-8674(80)90312-8; IATROU K, 1982, J MOL BIOL, V157, P417, DOI 10.1016/0022-2836(82)90469-7; IATROU K, 1983, EMBO J, V2, P1431, DOI 10.1002/j.1460-2075.1983.tb01604.x; IATROU K, 1984, P NATL ACAD SCI-BIOL, V81, P4452, DOI 10.1073/pnas.81.14.4452; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; JONES CW, 1980, CELL, V22, P855; Kafatos F.C, 1977, Results Probl Cell Differ, V8, P45; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; MITSIALIS SA, 1987, P NATL ACAD SCI USA, V84, P7987, DOI 10.1073/pnas.84.22.7987; ORKIN SH, 1992, BLOOD, V80, P575; RODAKIS GC, 1982, P NATL ACAD SCI-BIOL, V79, P3551, DOI 10.1073/pnas.79.11.3551; RODAKIS GC, 1984, J MOL EVOL, V20, P265, DOI 10.1007/BF02104732; RODAKIS GC, 1982, MOL CELL BIOL, V2, P554, DOI 10.1128/MCB.2.5.554; SKEIKY YAW, 1987, J BIOL CHEM, V262, P6628; SKEIKY YAW, 1991, J MOL BIOL, V218, P517, DOI 10.1016/0022-2836(91)90698-6; SKEIKY YAW, 1990, J MOL BIOL, V213, P53, DOI 10.1016/S0022-2836(05)80121-4; SKEIKY YAW, 1991, MOL CELL BIOL, V11, P1954, DOI 10.1128/MCB.11.4.1954; SPIETH J, 1991, MOL CELL BIOL, V11, P4651, DOI 10.1128/MCB.11.9.4651; SPOEREL N, 1986, J MOL BIOL, V190, P23, DOI 10.1016/0022-2836(86)90072-0; SWEVERS L, 1992, DEV BIOL, V150, P12, DOI 10.1016/0012-1606(92)90003-Y; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10642, DOI 10.1073/pnas.88.23.10642; ZON LI, 1990, P NATL ACAD SCI USA, V87, P668, DOI 10.1073/pnas.87.2.668	41	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10660	10667						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144656				2022-12-25	WOS:A1994NF01700071
J	HAJNOCZKY, G; LIN, C; THOMAS, AP				HAJNOCZKY, G; LIN, C; THOMAS, AP			LUMINAL COMMUNICATION BETWEEN INTRACELLULAR CALCIUM STORES MODULATED BY GTP AND THE CYTOSKELETON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; INOSITOL 1,4,5-TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; CA2+ RELEASE; PERMEABILIZED HEPATOCYTES; GUANINE-NUCLEOTIDES; CELL-LINE; TRISPHOSPHATE; FEEDBACK; MOBILIZATION	The activation properties of inositol 1,4,5-trisphosphate (InsP(3)) sensitive Ca2+ stores in permeabilized and intact hepatocytes were investigated by monitoring Mn2+ quench of fura-2 compartmentalized within these stores, as Mn2+ passed through InsP(3)-activated channels in a retrograde manner. In cells permeabilized in suspension the InsP(3)-sensitive pool size was dependent on InsP(3) dose, and there was a large unresponsive compartment. By contrast, essentially all of the compartmentalized dye was accessible following activation of a small fraction of the InsP(3) receptors in carefully permeabilized attached cells. After loading the cytosol of intact hepatocytes with Mn2+, both submaximal and maximal vasopressin doses caused complete quench of the entire intracellular pool of compartmentalized fura-2. Vasopressin-induced Mn2+ quench occurred in a stepwise manner at doses that gave cytosolic Ca2+ oscillations, reflecting periodic opening of intracellular Ca2+ channels. Pretreatment with thapsigargin to eliminate feedback effects of Ca2+ fluxes converted the steps to a continuous quench. The data suggest that Ca2+ stores in attached permeabilized and intact hepatocytes are luminally connected, making the entire store accessible to InsP(3). In cells permeabilized in suspension, GTP increased InsP(3)-sensitive pool size, and this effect was inhibited by cytochalasin B. GTP did not change the initial rate of Mn2+ quench but increased the proportion of slowly accessible stores in the InsP(3)-sensitive compartment, apparently by recruitment of InsP(3)-insensitive stores. Preincubation on ice or with cytoskeletal inhibitors dissociated slowly accessible compartments from the InsP(3)-sensitive stores in both intact and subsequently permeabilized attached hepatocytes. Addition of GTP to permeabilized cells reversed this disruption of store continuity. It is suggested that GTP- and cytoskeleton-dependent luminal communication between Ca2+ stores is an important determinant of function, which could modulate the availability of Ca2+ for release.	THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, PHILADELPHIA, PA 19107 USA	Jefferson University			Thomas, Andrew/C-6755-2013	Thomas, Andrew/0000-0002-9026-7467	NIAAA NIH HHS [AA07215, AA07186] Funding Source: Medline; NIDDK NIH HHS [DK38422] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038422, R01DK038422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BORLE AB, 1982, J MEMBRANE BIOL, V68, P37, DOI 10.1007/BF01872252; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHUEH SH, 1986, J BIOL CHEM, V261, P13883; COMERFORD JG, 1989, BIOCHEM J, V258, P823, DOI 10.1042/bj2580823; COMERFORD JG, 1991, BIOCHEM J, V280, P335, DOI 10.1042/bj2800335; DAWSON AP, 1985, FEBS LETT, V185, P147, DOI 10.1016/0014-5793(85)80759-6; DOWNEY GP, 1991, J CELL BIOL, V114, P1179, DOI 10.1083/jcb.114.6.1179; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GLENNON MC, 1992, J BIOL CHEM, V267, P8230; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JOSEPH SK, 1984, J BIOL CHEM, V259, P3077; KACHAR B, 1988, J CELL BIOL, V106, P1545, DOI 10.1083/jcb.106.5.1545; KINDMAN LA, 1993, BIOCHEMISTRY-US, V32, P1270, DOI 10.1021/bi00056a011; KWAN CY, 1990, J BIOL CHEM, V265, P678; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; MELDOLESI J, 1990, BIOCHIM BIOPHYS ACTA, V1055, P130, DOI 10.1016/0167-4889(90)90113-R; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PAYNE R, 1988, PHILOS T ROY SOC B, V320, P359, DOI 10.1098/rstb.1988.0082; PRENTKI M, 1985, J BIOL CHEM, V260, P9185; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; SCHULZ I, 1989, CELL CALCIUM, V10, P325, DOI 10.1016/0143-4160(89)90058-4; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; Thomas A.P., 1991, CELLULAR CALCIUM PRA, P1; Thomas Andrew P., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P225; THOMAS AP, 1988, J BIOL CHEM, V263, P2704; TIMASHEFF SN, 1980, ANNU REV BIOCHEM, V49, P565, DOI 10.1146/annurev.bi.49.070180.003025; UEDA T, 1986, J BIOL CHEM, V261, P3184; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	50	78	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10280	10287						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144609				2022-12-25	WOS:A1994NF01700019
J	HANASAKI, K; VARKI, A; STAMENKOVIC, I; BEVILACQUA, MP				HANASAKI, K; VARKI, A; STAMENKOVIC, I; BEVILACQUA, MP			CYTOKINE-INDUCED BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE IN HUMAN ENDOTHELIAL-CELLS MEDIATES ALPHA-2,6-SIALYLATION OF ADHESION MOLECULES AND CD22 LIGANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; SIALIC-ACID; LINKED OLIGOSACCHARIDES; LEUKOCYTE ADHESION; ALPHA-1-ACID GLYCOPROTEIN; LIQUID-CHROMATOGRAPHY; RAT-LIVER; SIALYLTRANSFERASE; INFLAMMATION; EXPRESSION	Sialic acids decorating blood and cell surface proteins can play important roles in various biological processes. The inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-1, as well as bacterial lipopolysaccharide, can activate vascular endothelium, increasing expression of several surface glycoproteins. Here we show that treatment of cultured human endothelial cells (HEC) with TNF-alpha, interleukin-1, or lipopolysaccharide causes increased expression of the enzyme beta-galactoside alpha-2,6-sialyltransferase (alpha 2-6STN). TNF-alpha was most effective, inducing a 3.5-fold enhancement of cell-associated sialyltransferase activity by 72 h. In addition, activated HEC secreted a large portion of the induced sialyltransferase activity into the medium. Analysis of labeled HEC showed both a relative and an absolute increase of alpha 2,6-linked sialic acid on N-linked oligosaccharides after TNF-alpha stimulation. This coincided with increased expression of endothelial glycoproteins bearing N-linked glycans with alpha 2,6-linked sialic acid detected by the lectin Sambucus nigra agglutinin. The cytokine-inducible endothelial cell adhesion molecules E-selectin, ICAM-1, and VCAM-1 are among these glycoprotein substrates for alpha 2-6STN. These changes also correlated with a substantial increase in binding sites for CD22 beta, a mammalian lectin known to recognize oligosaccharides carrying multiple copies of alpha 2,6-linked sialic acid. Northern analysis revealed increased levels of mRNA encoding alpha 2-6STN. Thus, activation of endothelial cells during in flammatory and immunological processes may induce alpha 2-6STN, which can participate in sialylation of other activation-dependent molecules.	UNIV CALIF SAN DIEGO,CTR CANC,DIV CELLULAR & MOLEC MED,GLYCOBIOL PROGRAM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02129	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; Harvard University; Massachusetts General Hospital					NIGMS NIH HHS [R01GM32373] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGUSTINVOSS HG, 1992, J CELL BIOL, V119, P483, DOI 10.1083/jcb.119.2.483; BAST BJEG, 1992, J CELL BIOL, V116, P423, DOI 10.1083/jcb.116.2.423; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK EA, 1993, J IMMUNOL, V150, P4715; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; DRZENIEK R, 1973, HISTOCHEM J, V5, P271, DOI 10.1007/BF01004994; ENGEL P, 1993, J IMMUNOL, V150, P4719; ERIKSTEIN BK, 1992, EUR J IMMUNOL, V22, P1149, DOI 10.1002/eji.1830220507; FOURNET B, 1978, BIOCHEMISTRY-US, V17, P5206, DOI 10.1021/bi00617a021; GILLARD BK, 1990, ARCH BIOCHEM BIOPHYS, V279, P122, DOI 10.1016/0003-9861(90)90471-A; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; HAYES BK, 1993, J BIOL CHEM, V268, P16139; JAMIESON JC, 1987, COMP BIOCHEM PHYS B, V87, P11, DOI 10.1016/0305-0491(87)90463-9; JAMIESON JC, 1983, CAN J BIOCHEM CELL B, V61, P1041, DOI 10.1139/o83-133; KEPPLER OT, 1992, EUR J IMMUNOL, V22, P2777, DOI 10.1002/eji.1830221104; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS G, 1989, BIOCHEM J, V261, P389, DOI 10.1042/bj2610389; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; NILSSON B, 1979, J BIOL CHEM, V254, P4545; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1979, J BIOL CHEM, V254, P2120; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1994, J BIOL CHEM, V269, P10628; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SGROI D, 1993, J BIOL CHEM, V268, P7011; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SILVER HKB, 1979, CANCER RES, V39, P5036; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SPERTINI O, 1991, J IMMUNOL, V147, P2565; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; TAATJES DJ, 1988, J BIOL CHEM, V263, P6302; VANDAMME V, 1992, BIOCHIMIE, V74, P89, DOI 10.1016/0300-9084(92)90188-K; VANDENBERG TK, 1992, J EXP MED, V176, P647, DOI 10.1084/jem.176.3.647; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WANG WC, 1988, J BIOL CHEM, V263, P4576; WANG XC, 1989, J BIOL CHEM, V264, P1854; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WOLOSKI BMRNJ, 1986, BIOCHIM BIOPHYS ACTA, V885, P185, DOI 10.1016/0167-4889(86)90087-X; WOLOSKI BMRNJ, 1985, BIOCHEM BIOPH RES CO, V130, P30, DOI 10.1016/0006-291X(85)90377-8	56	121	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10637	10643						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144653				2022-12-25	WOS:A1994NF01700068
J	HENRY, R; KAPAZOGLOU, A; MCCAFFERY, M; CLINE, K				HENRY, R; KAPAZOGLOU, A; MCCAFFERY, M; CLINE, K			DIFFERENCES BETWEEN LUMEN TARGETING DOMAINS OF CHLOROPLAST TRANSIT PEPTIDES DETERMINE PATHWAY SPECIFICITY FOR THYLAKOID TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN; MEMBRANES; IMPORT; INSERTION; ATP	Nuclear encoded thylakoid lumen proteins are imported into the chloroplast stroma and further directed across thylakoid membranes by lumen targeting domains. Recently, we showed that there are two protein-specific pathways for transport into the lumen. This was unexpected in that lumen targeting domains have similar properties, all containing bacterial signal peptide motifs. Nevertheless, sequence homology analysis suggests that pathway specificity is determined by elements in the lumen targeting domain. To test this, we constructed and analyzed chimeric proteins in which transit peptides from proteins transported by one pathway were fused to the mature domains of proteins directed by the other. We also investigated the transport characteristics of a previously unexamined protein whose pathway was predicted by sequence similarity analysis. Our results confirm that lumen targeting domains contain pathway sorting elements and further indicate that distinct energy and stroma requirements for transport are pathway characteristics, unrelated to the passenger protein. These findings suggest the operation of two mechanistically different translocators.	UNIV FLORIDA,DEPT HORT SCI,PLANT MOLEC & CELLULAR BIOL PROGRAM,GAINESVILLE,FL 32611; UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602	State University System of Florida; University of Florida; University System of Georgia; University of Georgia			Cline, Kenneth/J-6238-2013; Kapazoglou, Aliki/AAV-6723-2021	Kapazoglou, Aliki/0000-0002-7584-5994	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046951] Funding Source: NIH RePORTER; NIGMS NIH HHS [1 R01 GM46951] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BASSHAMDC, 1991, J BIOL CHEM, V266, P23606; CLAUSMEYER S, 1993, J BIOL CHEM, V268, P13869; CLINE K, 1988, PLANT PHYSIOL, V86, P1120, DOI 10.1104/pp.86.4.1120; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CLINE K, 1989, J BIOL CHEM, V264, P14225; CLINE K, 1986, J BIOL CHEM, V261, P4804; CROWE JS, 1991, NUCLEIC ACIDS RES, V19, P184, DOI 10.1093/nar/19.1.184; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRIESSEN AJM, 1992, TRENDS BIOCHEM SCI, V17, P219, DOI 10.1016/0968-0004(92)90381-I; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; IKEUCHI M, 1992, BOT MAG TOKYO, V105, P327, DOI 10.1007/BF02489425; KNOETZEL J, 1993, PLANT MOL BIOL, V22, P337, DOI 10.1007/BF00014940; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; REED JE, 1990, EUR J BIOCHEM, V194, P33, DOI 10.1111/j.1432-1033.1990.tb19423.x; ROBINSON C, 1993, FEBS LETT, V325, P67, DOI 10.1016/0014-5793(93)81415-V; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIMPSON DJ, 1989, CARLSBERG RES COMMUN, V54, P55, DOI 10.1007/BF02907585	21	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10189	10192						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144595				2022-12-25	WOS:A1994NF01700002
J	COWLING, RT; BIRNBOIM, HC				COWLING, RT; BIRNBOIM, HC			INCORPORATION OF [P-32] ORTHOPHOSPHATE INTO INORGANIC POLYPHOSPHATES BY HUMAN GRANULOCYTES AND OTHER HUMAN CELL-TYPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANES; PROTEINS; KINASE	When human peripheral blood granulocytes were metabolically labeled at 37-degrees-C with [P-32] orthophosphate, inorganic polyphosphates became preferentially radiolabeled. Incorporation of radiolabel into the polymer appeared to be ATP-independent. [P-32]Polyphosphate was identified by its (i) characteristic lability to acid hydrolysis, (ii) insolubility in barium acetate (pH 4.5), (iii) conversion to [P-32]trimetaphosphate, (iv) hydrolysis to [P-32]orthophosphate by an exopolyphosphatase (Saccharomyces cerevisiae scPPX1), and (v) conversion to a ''phosphate ladder''which co-migrated on a polyacrylamide gel with a synthetic phosphate ladder. Also, indirect evidence suggested that the [P-32]polyphosphate was strongly, noncovalently associated with another unknown molecule. Particulate fractions (13,000 x g) from lysates of human granulocytes, skin fibroblasts, HL-60 and SK-N-SH cells, all demonstrated radiolabeling of polyphosphate when incubated at 37-degrees-C with [P-32] orthophosphate.	OTTAWA REG CANC CTR,OTTAWA K1H 8L6,ON,CANADA; UNIV OTTAWA,OTTAWA K1H 8L6,ON,CANADA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa				Birnboim, Hyman C./0000-0001-5830-4769				AHN KH, 1990, J BIOL CHEM, V265, P11734; AKIYAMA M, 1993, J BIOL CHEM, V268, P633; BIRNBOIM HC, 1990, METHOD ENZYMOL, V186, P550; CHEN JH, 1993, DNA CELL BIOL, V12, P177, DOI 10.1089/dna.1993.12.177; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; FITTSCHEN C, 1991, J LEUKOCYTE BIOL, V50, P517, DOI 10.1002/jlb.50.5.517; FURLONG NB, 1965, ANAL BIOCHEM, V12, P349, DOI 10.1016/0003-2697(65)90102-8; GABEL NW, 1971, J NEUROCHEM, V18, P1229, DOI 10.1111/j.1471-4159.1971.tb00222.x; GRIFFIN JB, 1965, J BIOL CHEM, V240, P4427; GURLAND J, 1971, AM STAT, V25, P30, DOI 10.2307/2682923; Hallet M. B., 1989, NEUTROPHIL CELLULAR, P1; HAROLD FM, 1966, BACTERIOL REV, V30, P772, DOI 10.1128/MMBR.30.4.772-794.1966; HAROLD FM, 1962, BIOCHIM BIOPHYS ACTA, V57, P48; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; HIRSCH JG, 1965, INFLAMMATORY PROCESS, P245; Kulaev I.S., 1958, P ACAD SCI USSR, V120, P128; KULAEV IS, 1983, ADV MICROB PHYSIOL, V24, P83, DOI 10.1016/S0065-2911(08)60385-9; KULAEV IS, 1975, REV PHYSIOL BIOCH P, V73, P131, DOI 10.1007/BFb0034661; LELOIR LF, 1957, METHOD ENZYMOL, V3, P840, DOI 10.1016/S0076-6879(57)03459-X; MCCORMICK JJ, 1981, DNA REPAIR LABORATOR, P501; Murphy P, 1976, NEUTROPHIL; OFFENBACHER S, 1984, ARCH BIOCHEM BIOPHYS, V231, P114, DOI 10.1016/0003-9861(84)90368-0; PARKER RP, 1970, CURRENT STATUS LIQUI, P00110; PENNIALL R, 1984, BIOSCIENCE REP, V4, P957, DOI 10.1007/BF01116894; PICK U, 1990, FEBS LETT, V274, P15, DOI 10.1016/0014-5793(90)81318-I; PISONI RL, 1992, J BIOL CHEM, V267, P3626; REUSCH RN, 1989, P SOC EXP BIOL MED, V191, P377; REUSCH RN, 1988, P NATL ACAD SCI USA, V85, P4176, DOI 10.1073/pnas.85.12.4176; ROBINSON NA, 1984, BIOCHEM INT, V8, P757; SKORKO R, 1989, BIOCHIMIE, V71, P1089, DOI 10.1016/0300-9084(89)90115-6; TAMAOKI T, 1967, BIOCHEMISTRY-US, V6, P3583, DOI 10.1021/bi00863a033; TINSLEY CR, 1993, INFECT IMMUN, V61, P3703, DOI 10.1128/IAI.61.9.3703-3710.1993; VOLLOCH VZ, 1979, NUCLEIC ACIDS RES, V6, P1521, DOI 10.1093/nar/6.4.1521; WOOD HG, 1985, CURR TOP CELL REGUL, V26, P355; WURST H, 1994, IN PRESS J BIOL CHEM, V269	35	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9480	9485						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144532				2022-12-25	WOS:A1994NE05300016
J	CROOK, T; FISHER, C; MASTERSON, PJ; VOUSDEN, KH				CROOK, T; FISHER, C; MASTERSON, PJ; VOUSDEN, KH			MODULATION OF TRANSCRIPTIONAL REGULATORY PROPERTIES OF P53 BY HPV-E6	ONCOGENE			English	Note							HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; CARCINOMA CELL-LINES; CERVICAL-CARCINOMA; E6 ONCOPROTEIN; RETINOBLASTOMA GENES; BINDING PROTEIN; DEGRADATION; PROMOTERS; TRANSACTIVATION	The E6 protein encoded by human papillomavirus type 16 (HPV16), a genital virus with oncogenic potential, can target cellular p53 for rapid degradation following the formation of a complex including the two proteins. Some studies suggest that the E6 proteins encoded by HPV6 and 11, viral types which are normally limited to benign lesions, may also interact with p53, although the association is weaker than that seen with HPV16 E6. The present study demonstrates that E6 proteins from HPV16 and HPV6 can modulate the transcriptional regulatory functions of p53 in several cell types. A series of E6 mutants was used to show that association between E6 and p53 is necessary for this activity and that E6 proteins which retain the ability to associate with p53 but show no detectable degradation activity in vitro can, to some extent, abrogate p53 mediated transcriptional trans-regulation. This activity is augmented, however, by the ability of the E6 protein to target bound p53 for rapid degradation. These results suggest that some degree of modulation of p53 function is necessary in the normal viral life cycle but also demonstrate a correlation between the efficiency of this activity and oncogenic potential of the virus.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,NORFOLK PL,LONDON W2 1PG,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research								BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARK Y, 1993, EMBO J, V12, P461; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHOO KB, 1993, VIROLOGY, V193, P1042; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1991, ONCOGENE, V6, P873; CROOK T, 1991, ONCOGENE, V6, P1251; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DESAINTES C, 1992, J VIROL, V66, P325, DOI 10.1128/JVI.66.1.325-333.1992; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FUJITA M, 1992, CANCER RES, V52, P5323; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JACKSON P, 1993, ONCOGENE, V8, P589; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SEGAWA K, 1993, ONCOGENE, V8, P543; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TRUANT R, 1993, J BIOL CHEM, V268, P2284; TUCK SP, 1989, ONCOGENE RES, V4, P81; VOUSDEN KH, 1991, SEMIN VIROL, V2, P307; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	51	63	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1225	1230						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134125				2022-12-25	WOS:A1994NC04800026
J	LAWRENCE, R; HARTMANN, DJ; SONENSHEIN, GE				LAWRENCE, R; HARTMANN, DJ; SONENSHEIN, GE			TRANSFORMING GROWTH-FACTOR-BETA-1 STIMULATES TYPE-V COLLAGEN EXPRESSION IN BOVINE VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRONECTIN MESSENGER-RNAS; FACTOR TYPE-BETA; RAT-KIDNEY; EXTRACELLULAR-MATRIX; CONNECTIVE-TISSUE; III COLLAGEN; XI COLLAGEN; I COLLAGEN; CHAIN; PROLIFERATION	Vascular smooth muscle cells (SMCs) produce the bulk of the connective tissue of major arteries, including collagen types I, III, and V. Recently, we have shown, they also have the capacity to synthesize the alpha1 chain of type XI, a collagen related to type V (Brown, K., Lawrence, R., and Sonenshein, G. (1991) J. Biol. Chem. 266, 23268-23273). Furthermore, expression of types V and XI collagen were coordinately regulated with respect to serum deprivation and cell density in a fashion distinct from that for types I and III. To begin to determine the factors that influence vascular SMC production of types V/XI collagen, we have examined the effects of transforming growth factor (TGF)-beta1, a major modulator of connective tissue expression. In serum-deprived confluent cultures of bovine pulmonary artery SMCs, TGF-beta1 treatment increased the steady-state levels of the mRNAs of collagen types V and XI, as well as of types I and III, elastin and fibronectin. The largest increase was seen for alpha2(V) procollagen. The increase in alpha2(V) mRNA was detectable by 12 h after addition of 2 ng/ml TGF-beta1, and concentrations as little as 0.5 ng/ml were effective. A similar increase in alpha2(V) mRNA levels was observed with SMCs derived from the aortic arch and carotid artery. Type V collagen protein was found to be elevated by TGF-beta1 treatment in both the conditioned media and the cell layer associated fraction of pulse-labeled cultures. A slight decrease in SMC proliferation as judged by DNA content, [H-3]thymidine incorporation, and steady-state levels of histone H3.2 mRNA resulted from TGF-beta1 treatment. These results suggest that the elevated levels of TGF-beta1 in the vessel wall during atherosclerosis may be, in part, responsible for the increase in type V collagen that typifies advanced fibrotic lesions.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; INST PASTEUR,CNRS,URA 1459,CTR RADIOANAL,F-69365 LYON,FRANCE	Boston University; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris					NHLBI NIH HHS [HL13262] Funding Source: Medline; NIA NIH HHS [AG00115] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI E, 1986, CONNECT TISSUE RES, V14, P257, DOI 10.3109/03008208609017469; ALTERMAN RBM, 1984, MOL CELL BIOL, V4, P123, DOI 10.1128/MCB.4.1.123; ASSOIAN RK, 1986, J CELL BIOL, V102, P1217, DOI 10.1083/jcb.102.4.1217; BARSKY SH, 1982, AM J PATHOL, V108, P276; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BELDEKAS JC, 1981, BIOCHEMISTRY-US, V20, P2162, DOI 10.1021/bi00511a014; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; BIRK DE, 1990, J CELL SCI, V95, P649; BROWN KE, 1991, J BIOL CHEM, V266, P23268; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHEN JK, 1987, P NATL ACAD SCI USA, V84, P5287, DOI 10.1073/pnas.84.15.5287; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5284; CHOE I, 1987, J BIOL CHEM, V262, P5408; CHUNG E, 1976, BIOCHEM BIOPH RES CO, V71, P1167, DOI 10.1016/0006-291X(76)90776-2; DEAN M, 1983, NATURE, V305, P443, DOI 10.1038/305443a0; Eyre D, 1987, STRUCTURE FUNCTION C, P261; FAVA RA, 1987, J CELL PHYSIOL, V131, P184, DOI 10.1002/jcp.1041310207; FESSLER JH, 1987, STRUCTURE FUNCTION C, P81; FINE A, 1987, J BIOL CHEM, V262, P3897; GRAHAM MF, 1988, GASTROENTEROLOGY, V94, P257, DOI 10.1016/0016-5085(88)90411-8; GRAHAM MF, 1987, GASTROENTEROLOGY, V92, P400, DOI 10.1016/0016-5085(87)90134-X; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; KINDY MS, 1986, J BIOL CHEM, V261, P2865; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; LIAU G, 1989, J BIOL CHEM, V264, P10315; LIU JM, 1988, BIOCHEM BIOPH RES CO, V154, P895, DOI 10.1016/0006-291X(88)90224-0; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MADRI JA, 1979, AM J PATHOL, V94, P323; MAJACK RA, 1987, J CELL BIOL, V105, P465, DOI 10.1083/jcb.105.1.465; MARTINEZHERNANDEZ A, 1982, J CELL BIOL, V92, P343, DOI 10.1083/jcb.92.2.343; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MORRIS NP, 1990, J BIOL CHEM, V265, P10081; MORTON LF, 1982, ATHEROSCLEROSIS, V42, P41, DOI 10.1016/0021-9150(82)90124-1; MOSS NS, 1970, LAB INVEST, V23, P231; MURATA K, 1986, ATHEROSCLEROSIS, V60, P251, DOI 10.1016/0021-9150(86)90172-3; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; NARAYANAN AS, 1983, J BIOL CHEM, V258, P1694; NARAYANAN AS, 1983, COLLAGEN REL RES, V3, P323; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; NUGENT MA, 1989, CANCER RES, V49, P3884; NUGENT MA, 1989, J BIOL CHEM, V264, P18060; OAKES BW, 1982, EUR J CELL BIOL, V27, P34; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; OOSHIMA A, 1981, SCIENCE, V213, P666, DOI 10.1126/science.7256267; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; RICH CB, 1989, ARCH BIOCHEM BIOPHYS, V268, P551, DOI 10.1016/0003-9861(89)90322-6; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; SAGE H, 1979, BIOCHEMISTRY-US, V18, P3815, DOI 10.1021/bi00584a027; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; SILVER MH, 1984, DIFFERENTIATION, V27, P205, DOI 10.1111/j.1432-0436.1984.tb01430.x; STEPP MA, 1985, ANN NY ACAD SCI, V460, P510, DOI 10.1111/j.1749-6632.1985.tb51225.x; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; VARGA J, 1987, BIOCHEM J, V247, P597, DOI 10.1042/bj2470597; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WEIL D, 1987, NUCLEIC ACIDS RES, V15, P181, DOI 10.1093/nar/15.1.181; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423	63	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9603	9609						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144547				2022-12-25	WOS:A1994NE05300034
J	LEE, TC; ZHANG, Y; SCHWARTZ, RJ				LEE, TC; ZHANG, Y; SCHWARTZ, RJ			BIFUNCTIONAL TRANSCRIPTIONAL PROPERTIES OF YY1 IN REGULATING MUSCLE ACTIN AND C-MYC GENE-EXPRESSION DURING MYOGENESIS	ONCOGENE			English	Article							ADENOVIRUS E1A PROTEIN; BINDING COMPLEXES; MESSENGER-RNA; PROMOTER; DIFFERENTIATION; ELEMENTS; ACTIVATION; MYOBLASTS; CELLS; IDENTIFICATION	Oncogene expression is generally incompatible with terminal cell differentiation as in myogenesis. We present evidence that this incompatibility can be caused in part by the dual activity of a Kruppel-related zinc finger, YY1 (formerly F-ACT1), in differentially regulating oncogene and muscle-specific gene expression. The c-myc and skeletal alpha-actin gene promoters contain YY1 binding sites thought to act either as positive or negative cis-acting elements. Through manipulating the intracellular level of YY1 by treating primary myoblasts with bromo-deoxyuridine (BrdU), which inhibited myogenesis and increased the YY1 protein content, or by transfecting YY1 cDNA expression vector, we show that it can simultaneously inhibit and activate expression of the skeletal alpha-actin and c-myc genes, respectively. The transrepression activity of YY1 solely depends on its C-terminal zinc finger region (amino acids 297-407) while its transactivation function requires an additional N-terminal domain (amino acids 1-90) normally masked in the full-length protein. We propose that the high level of YY1 in proliferating myoblasts might serve to maintain c-myc expression and suppress muscle actin expression, which can then be gradually reversed by downregulating YY1 activity toward myogenesis.	BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030; SUNY BUFFALO,DEPT BIOCHEM,BUFFALO,NY 14214	Baylor College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042267, P01HL049953] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50-HL42267, P01HL49953] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KAKKIS E, 1987, P NATL ACAD SCI USA, V84, P7031, DOI 10.1073/pnas.84.20.7031; KESSLER DJ, 1992, ONCOGENE, V7, P2447; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEE TC, 1992, NUCLEIC ACIDS RES, V20, P140, DOI 10.1093/nar/20.1.140; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LEE TC, 1992, BIOTECHNIQUES, V12, P486; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MEULIA T, 1992, MOL CELL BIOL, V12, P4590, DOI 10.1128/MCB.12.10.4590; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MOBERG KH, 1992, ONCOGENE, V7, P411; MODAK SP, 1993, ONCOGENE, V8, P645; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PIECHACZYK M, 1987, TRENDS GENET, V3, P47, DOI 10.1016/0168-9525(87)90166-1; PLET A, 1992, ONCOGENE, V7, P1847; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; SCHWARTZ RJ, 1981, BIOCHEMISTRY-US, V20, P4122, DOI 10.1021/bi00517a027; SEJERSEN T, 1985, J CELL PHYSIOL, V125, P465, DOI 10.1002/jcp.1041250315; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SPENCER CA, 1990, ADV CANCER RES, V56, P1; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WEINTRAUB H, 1972, J MOL BIOL, V70, P337, DOI 10.1016/0022-2836(72)90543-8; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0	38	110	117	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1047	1052						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134108				2022-12-25	WOS:A1994NC04800006
J	MARVEL, J; PERKINS, GR; RIVAS, AL; COLLINS, MKL				MARVEL, J; PERKINS, GR; RIVAS, AL; COLLINS, MKL			GROWTH-FACTOR STARVATION OF BCL-2 OVEREXPRESSING MURINE BONE-MARROW CELLS INDUCED REFRACTORINESS TO IL-3 STIMULATION OF PROLIFERATION	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; C-MYC; HEMATOPOIETIC-CELLS; CALCIUM IONOPHORES; GENE-EXPRESSION; GERMINAL CENTER; APOPTOSIS; DEATH; SURVIVAL	Murine bone-marrow derived BAF3 cells, overexpressing the human Bcl-2 gene product, showed considerably delayed onset of apoptosis when deprived of IL-3. Such Bcl-2-BAF3 cells arrested rapidly in the G1 phase of the cell cycle upon IL-3 removal, then became refractory to IL-3 re-stimulation. The delay in IL-3 induced proliferation of Bcl-2 over-expressing cells was due to down-regulation of a specific signalling pathway. In the refractory cells, IL-3 was able to stimulate protein tyrosine phosphorylation and c-myc mRNA accumulation, but not rapid Erk2 activation or cdc2 mRNA accumulation.	INST CANC RES,CHESTER BEATTY LABS,237 FULHAM RD,LONDON SW3 6JB,ENGLAND; CSIC,INST LOPEZ NEYRA PARASITOL,GRANADA,SPAIN	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)			marvel, jacqueline/H-8638-2014; Lopez-Rivas, Abelardo/E-5115-2015	marvel, jacqueline/0000-0001-6241-459X; Lopez-Rivas, Abelardo/0000-0002-9351-9690				ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; BARDON S, 1987, CANCER RES, V47, P1441; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS M, 1991, Current Biology, V1, P140, DOI 10.1016/0960-9822(91)90212-F; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KAWAKAMI M, 1991, EXP CELL RES, V193, P120, DOI 10.1016/0014-4827(91)90545-6; LEEVERS S, 1992, EMBO J, V11, P568; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NAKAMURA Y, 1992, SCIENCE, V257, P1138, DOI 10.1126/science.257.5073.1138; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PEZZELLA F, 1990, AM J PATHOL, V137, P225; POPPEMA S, 1992, IMMUNOL REV, V126, P163, DOI 10.1111/j.1600-065X.1992.tb00636.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V148, P1416; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Sambrook J, 1989, MOL CLONING LABORATO; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHIGII SM, 1980, SELECTED METHODS CEL; STERN M, 1992, J IMMUNOL, V148, P3543; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VONBOEHMER H, 1992, IMMUNOL TODAY, V13, P454, DOI 10.1016/0167-5699(92)90075-I; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	44	70	71	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1117	1122						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134114				2022-12-25	WOS:A1994NC04800014
J	YE, XH; KRALLI, A; GE, R; RICCIARDI, RP; KNOWLES, BB				YE, XH; KRALLI, A; GE, R; RICCIARDI, RP; KNOWLES, BB			DOWN-REGULATION OF MHC CLASS-I ANTIGEN IN INSULINOMA CELLS CONTROLLED BY THE R1 ELEMENT OF THE H-2 ENHANCER	ONCOGENE			English	Article							TRANSFORMED RAT-CELLS; PANCREATIC BETA-CELLS; GENE-EXPRESSION; NEGATIVE REGULATION; TRANSGENIC MICE; FACTOR BINDING; T-ANTIGEN; N-MYC; MOUSE; COMPLEX	Tumorigenesis in mice of the rat insulin promoter [RIP]-simian virus 40 tumor antigen [SV40 Tag] transgenic lineages, RIP1-Tag2 and RIP1-Tag4, is a process initiated by expression of SV40 Tag in pancreatic beta cells, evolution of islet cell hyperplasia and insulinoma appearance. Analysis of major histocompatibility complex [MHC] class I gene expression during this process revealed a normal level of MHC class I molecules at the surface of pancreatic islet cells of RIP1-Tag4 mice, while hyperplastic islets from the same mice contained cells expressing a normal level and cells expressing a low level of MHC class I antigen. Insulinomas themselves expressed very low levels or no MHC class I gene product. Thus, down-regulation of MHC class I gene appears to accompany tumor progression of SV40 Tag-transformed beta islet cells. MHC class I antigen expression in a series of clonally derived cell lines of beta cell origin from different SV40 Tag-induced insulinomas ranged from quite low to undetectable, although expression was inducible by interferon-gamma. Nuclear run-on and transient transfection analyses indicated that expression of the MHC class I gene in these cells is controlled at the transcriptional level, and that the decreased expression is paralleled by reduced binding of transcription factors to the R1 element of the H-2 enhancer.	WISTAR INST ANAT & BIOL, 36TH & SPRUCE ST, PHILADELPHIA, PA 19104 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; AMER CYANAMIDE, PEARL RIVER, NY 10965 USA; UNIV PENN, SCH DENT MED, DEPT MICROBIOL, PHILADELPHIA, PA 19104 USA	The Wistar Institute; University of California System; University of California San Francisco; University of Pennsylvania			Ge, Ruowen/D-8352-2012	Ge, Ruowen/0000-0002-0750-7336; Knowles, Barbara B./0000-0002-2597-5619	NATIONAL CANCER INSTITUTE [R01CA029797, P30CA010815, R01CA018470] Funding Source: NIH RePORTER; NCI NIH HHS [CA18470, CA10815, CA29797] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKRILL AM, 1988, ONCOGENE, V3, P483; ADAMS TE, 1987, NATURE, V325, P223, DOI 10.1038/325223a0; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BALDWIN AS, 1990, MOL CELL BIOL, V10, P1406, DOI 10.1128/MCB.10.4.1406; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BLIEDEN TM, 1991, INT J CANCER, P82; BURKE PA, 1989, J EXP MED, V169, P1309, DOI 10.1084/jem.169.4.1309; CAMPBELL IL, 1985, DIABETES, V34, P1205, DOI 10.2337/diabetes.34.11.1205; CHEN E, 1986, MOL CELL BIOL, V6, P1698, DOI 10.1128/MCB.6.5.1698; DAVID-WATINE B, 1990, IMMUNOL TODAY, V11, P286, DOI 10.1016/0167-5699(90)90114-O; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; GE R, 1992, THESIS U PENNSYLVANI; GE RW, 1992, J VIROL, V66, P6969, DOI 10.1128/JVI.66.12.6969-6978.1992; GILLIGAN A, 1989, DIABETES, V38, P1056, DOI 10.2337/diabetes.38.8.1056; GOODING LR, 1979, J IMMUNOL, V122, P1002; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HENSELING U, 1990, MOL CELL BIOL, V10, P4100, DOI 10.1128/MCB.10.8.4100; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; ISRAEL A, 1987, P NATL ACAD SCI USA, V84, P2653, DOI 10.1073/pnas.84.9.2653; ISRAEL A, 1989, NUCLEIC ACIDS RES, V17, P5245, DOI 10.1093/nar/17.13.5245; JEFFERIES WA, 1988, EMBO J, V7, P3423, DOI 10.1002/j.1460-2075.1988.tb03216.x; JONES B, 1981, NATURE, V292, P547, DOI 10.1038/292547a0; JUULMADSEN HR, 1990, APMIS, V98, P624, DOI 10.1111/j.1699-0463.1990.tb04980.x; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KNOWLES BB, 1979, J IMMUNOL, V122, P1798; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; KRALLI A, 1992, J VIROL, V66, P6979, DOI 10.1128/JVI.66.12.6979-6988.1992; KRALLI A, 1991, THESIS U PENNSYLVANI; LENARDO M, 1989, EMBO J, V8, P3351, DOI 10.1002/j.1460-2075.1989.tb08497.x; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LEW AM, 1986, IMMUNOLOGY, V57, P3; MIYAZAKI J, 1986, P NATL ACAD SCI USA, V83, P9537, DOI 10.1073/pnas.83.24.9537; OZATO K, 1985, P NATL ACAD SCI USA, V82, P2427, DOI 10.1073/pnas.82.8.2427; PAN S, 1982, J IMMUNOL, V128, P243; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; ROSA F, 1983, EMBO J, V2, P239, DOI 10.1002/j.1460-2075.1983.tb01412.x; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHIRAYOSHI Y, 1987, MOL CELL BIOL, V7, P4542, DOI 10.1128/MCB.7.12.4542; SOONG TW, 1991, CANCER DETECT PREV, V15, P231; TANAKA K, 1988, ANNU REV IMMUNOL, V6, P359; TEITELMAN G, 1988, CELL, V52, P97, DOI 10.1016/0092-8674(88)90534-X; TEVETHIA SS, 1990, J VIROL, V64, P1192, DOI 10.1128/JVI.64.3.1192-1200.1990; WEISSMAN JD, 1991, MOL CELL BIOL, V11, P4217, DOI 10.1128/MCB.11.8.4217; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x; YE X, 1994, IN PRESS P NATL ACAD; YE X, 1993, THESIS U PENNSYLVANI; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0	56	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1195	1204						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134122				2022-12-25	WOS:A1994NC04800023
J	COOK, WJ; MOSLEY, SP; AUDINO, DC; MULLANEY, DL; ROVELLI, A; STEWART, G; DENIS, CL				COOK, WJ; MOSLEY, SP; AUDINO, DC; MULLANEY, DL; ROVELLI, A; STEWART, G; DENIS, CL			MUTATIONS IN THE ZINC-FINGER REGION OF THE YEAST REGULATORY PROTEIN ADR1 AFFECT BOTH DNA-BINDING AND TRANSCRIPTIONAL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ALCOHOL-DEHYDROGENASE; ADH2 EXPRESSION; FACTOR-IIIA; GENE; SEQUENCE; MUTAGENESIS; KINASE; SPECIFICITY; KRUPPEL	The expression of the yeast ADH2 gene is controlled by the transcriptional activator ADR1, a zinc-finger pro- tein that binds to an upstream activating sequence (UAS1) in the ADH2 promoter. We report here the isolation of seven mutations in the ADR1-5(c) allele, defining five different amino acid changes, that suppress the enhanced ADH2 expression caused by the ADR1-5(c) allele. Each of the mutations was shown to reduce the activation of ADH2 by a wild-type ADR1 gene, suggesting the mutations disrupt a domain important to the function of both the ADR1 and ADR1-5(c) proteins. All five amino acid changes occurred within the DNA-binding domain of ADR1 and were shown to severely inhibit the ability of ADR1 to bind UAS1 in vitro. These mutations were found, however, to also affect the ability of ADR1 to activate transcription independent of its ability to bind DNA. These results indicate that the DNA-binding region of ADR1 is involved in both transactivation and DNA binding.	UNIV NEW HAMPSHIRE, DEPT BIOCHEM & MOLEC BIOL, DURHAM, NH 03824 USA	University System Of New Hampshire; University of New Hampshire	COOK, WJ (corresponding author), HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041215] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41215] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEMIS LT, 1988, MOL CELL BIOL, V8, P2125, DOI 10.1128/MCB.8.5.2125; BEMIS LT, 1989, YEAST, V5, P291, DOI 10.1002/yea.320050409; BLUMBERG H, 1987, NATURE, V328, P443, DOI 10.1038/328443a0; BRAM RJ, 1985, P NATL ACAD SCI USA, V82, P43, DOI 10.1073/pnas.82.1.43; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CAMIER S, 1992, MOL CELL BIOL, V12, P5758, DOI 10.1128/MCB.12.12.5758; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; CIRIACY M, 1975, MOL GEN GENET, V138, P157, DOI 10.1007/BF02428119; COOK WJ, 1993, CURR GENET, V23, P192, DOI 10.1007/BF00351495; COOK WJ, 1994, MOL CELL BIOL, V14, P629, DOI 10.1128/MCB.14.1.629; DELRIO S, 1993, P NATL ACAD SCI USA, V90, P168, DOI 10.1073/pnas.90.1.168; DENIS CL, 1983, MOL CELL BIOL, V3, P360, DOI 10.1128/MCB.3.3.360; DENIS CL, 1986, MOL CELL BIOL, V6, P4026, DOI 10.1128/MCB.6.11.4026; DENIS CL, 1991, MOL GEN GENET, V229, P395, DOI 10.1007/BF00267461; DENIS CL, 1992, MOL CELL BIOL, V12, P1507, DOI 10.1128/MCB.12.4.1507; DENIS CL, 1987, MOL GEN GENET, V208, P101, DOI 10.1007/BF00330429; EISEN A, 1988, MOL CELL BIOL, V8, P4552, DOI 10.1128/MCB.8.10.4552; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; KIM KS, 1989, NATURE, V342, P200, DOI 10.1038/342200a0; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURET J, 1988, J BIOL CHEM, V263, P9149; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; Miller JH., 1972, EXPT MOL GENETICS; MILNE CA, 1993, J BIOL CHEM, V268, P11364; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; TAYLOR WE, 1990, P NATL ACAD SCI USA, V87, P4098, DOI 10.1073/pnas.87.11.4098; THUKRAL SK, 1991, P NATL ACAD SCI USA, V88, P9188, DOI 10.1073/pnas.88.20.9188; THUKRAL SK, 1992, MOL CELL BIOL, V12, P2784, DOI 10.1128/MCB.12.6.2784; THUKRAL SK, 1991, MOL CELL BIOL, V11, P1566, DOI 10.1128/MCB.11.3.1566; THUKRAL SK, 1989, MOL CELL BIOL, V9, P2360, DOI 10.1128/MCB.9.6.2360; THUKRAL SK, 1993, P NATL ACAD SCI USA, V90, P7908; VALLARI RC, 1992, MOL CELL BIOL, V12, P1663, DOI 10.1128/MCB.12.4.1663; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; YU J, 1989, MOL CELL BIOL, V9, P34, DOI 10.1128/MCB.9.1.34	46	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9374	9379						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132676				2022-12-25	WOS:A1994NB41100109
J	GULLIVER, GA; BEDZYK, WD; SMITH, RG; BODE, SL; TETIN, SY; VOSS, EW				GULLIVER, GA; BEDZYK, WD; SMITH, RG; BODE, SL; TETIN, SY; VOSS, EW			CONVERSION OF AN ANTI-SINGLE-STRANDED DNA ACTIVE-SITE TO AN ANTIFLUORESCEIN ACTIVE-SITE THROUGH HEAVY-CHAIN COMPLEMENTARITY-DETERMINING REGION TRANSPLANTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; FAB COMPLEX; BINDING; AUTOANTIBODY; CLONING	Complementarity determining region (CDR) transplant studies were conducted between two monoclonal antibodies of distinctly different specificities (anti-fluorescein monoclonal antibody (mAb) 4-4-20 and anti-single-stranded DNA (ssDNA) mAb 04-01) which possessed nearly identical light chains but dissimilar heavy chains. The variations in binding specificities between the two immunoglobulins suggested that the active-site features of anti fluorescein antibodies were dictated by characteristics intrinsic to the heavy chain (H-chain). To identify specific regions of the H-chain which influence the structure and function of an anti-fluorescein active site, CDR transplantation was systematically employed to convert the anti-ssDNA 04-01 antibody active site to an active site with anti-fluorescein activity. Each mAb 4-4-20 H-chain CDR (HCDR) was transplanted into the H-chain of a single-chain derivative of the 04-01 molecule. A fluorescence polarization ligand binding assay was utilized to determine the equilibrium dissociation constant, K-d, Of hybrid transplant single-chain antibody HCDR1-HCDR2-HCDR3(4.4.20) for fluorescein (3.8 x 10(-7) M), indicating successful conversion of an anti-ssDNA active site to an anti-fluorescein binding site. A similar K-d (6.3 x 10(-7) M) was determined using a fluorescein fluorescence quenching assay. The transplantation results are discussed in terms of the relative contribution of each HCDR to a successful conversion in antibody specificity.	UNIV ILLINOIS, DEPT MICROBIOL, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign								BALLARD DW, 1984, J BIOL CHEM, V259, P3492; BATES RM, 1985, MOL IMMUNOL, V22, P871, DOI 10.1016/0161-5890(85)90072-0; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BEDZYK WD, 1986, MOL IMMUNOL, V23, P1319, DOI 10.1016/0161-5890(86)90017-9; BEDZYK WD, 1990, J BIOL CHEM, V265, P133; BEDZYK WD, 1990, J BIOL CHEM, V265, P18615; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; CHAMBERS SP, 1988, GENE, V68, P139, DOI 10.1016/0378-1119(88)90606-3; DENZIN LK, 1993, MOL IMMUNOL, V30, P1331, DOI 10.1016/0161-5890(93)90094-R; DENZIN LK, 1991, J BIOL CHEM, V266, P14095; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; GUSSOW D, 1991, METHOD ENZYMOL, V203, P99; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HERRON JN, 1984, FLUORESCEIN HAPTEN I, P49; KRANZ DM, 1981, P NATL ACAD SCI-BIOL, V78, P5807, DOI 10.1073/pnas.78.9.5807; KRANZ DM, 1982, J BIOL CHEM, V257, P6987; KRANZ DM, 1981, MOL IMMUNOL, V18, P889, DOI 10.1016/0161-5890(81)90012-2; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; REINITZ DM, 1985, J IMMUNOL, V135, P3365; RUMBLEY CA, 1993, J BIOL CHEM, V268, P13667; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCANDELLA D, 1985, J CELL BIOCH B, V9, P203; SMITH R G, 1989, Journal of the Indian Institute of Science, V69, P25; SMITH RG, 1990, MOL IMMUNOL, V27, P463, DOI 10.1016/0161-5890(90)90171-U; SWINDLEHURST CA, 1991, BIOPHYS J, V59, P619, DOI 10.1016/S0006-3495(91)82277-9	27	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7934	7940						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132513				2022-12-25	WOS:A1994NB40900019
J	AMIN, AA; MURAKAMI, Y; HURWITZ, J				AMIN, AA; MURAKAMI, Y; HURWITZ, J			INITIATION OF DNA-REPLICATION BY SIMIAN-VIRUS-40 T-ANTIGEN IS INHIBITED BY THE P107 PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE TUMOR-ANTIGEN; RETINOBLASTOMA GENE-PRODUCT; SV40 LARGE-T; E2F TRANSCRIPTION FACTOR; CELL-CYCLE; SUSCEPTIBILITY GENE; INVITRO REPLICATION; POLYMERASE-ALPHA; PURIFIED PROTEINS; BINDING ACTIVITY	The p107 protein is related to the Rb protein by a 60-kDa region of homology called the pocket domain that binds cellular proteins such as E2F and cyclins A and E as well as the viral oncoproteins E1A, E7, and SV40 T antigen. The p107 and Rb proteins have both been implicated as negative regulators of cell growth. We have examined the effect of the unphosphorylated pocket domain of p107 on specific stages of the T antigen-mediated replication of SV40 DNA in vitro. The pocket domain inhibited replication by preventing the assembly of T antigen at the SV40 core origin DNA containing binding site II. However, both proteins formed a ternary complex with DNA containing T antigen-binding site I. The pocket domain of p107 did not inhibit the oligomerization of T antigen in the absence of DNA, and the p107 derivative is bound to the intermediates of this reaction. In the unwinding assay, once T antigen was preassembled as hexamers at the core origin, the pocket domain bound to and stabilized the complex, resulting in an increase in the yield of unwound product. Preformed T antigen hexamers complexed with the pocket domain bind to a synthetic replication fork, and this complex supported unwinding. Consistent with this, the p107 pocket domain had no effect on the helicase activity of T antigen in an assay using a partial duplex substrate. However, a complex containing p107 and T antigen assembled at the core origin did not support SV40 DNA replication in HeLa cell crude extracts or in the monopolymerase reaction. This inhibition is due to the inability of the complex to bind to DNA polymerase alpha, which is required for the initiation of DNA synthesis. The data suggest pathways by which the pocket domain of p107 can negatively regulate T antigen-mediated replication in vitro. The binding of T antigen to p107 is discussed with respect to its role in mitigating negative cell growth control, resulting in viral mediated transformation.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center								AMIN AA, 1992, J BIOL CHEM, V267, P18612; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOROWIEC JA, 1988, P NATL ACAD SCI USA, V85, P64, DOI 10.1073/pnas.85.1.64; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DEAN FB, 1992, J BIOL CHEM, V267, P14129; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EKI T, 1992, J BIOL CHEM, V267, P7284; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOETZ GS, 1988, J BIOL CHEM, V263, P383; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; IISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KATO J, 1993, GENE DEV, V7, P331; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1991, J BIOL CHEM, V266, P594; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LOEBER G, 1991, J VIROL, V65, P3167, DOI 10.1128/JVI.65.6.3167-3174.1991; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MCVEY D, 1993, J VIROL, V67, P5206, DOI 10.1128/JVI.67.9.5206-5215.1993; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11018; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; MURAKAMI Y, 1993, J BIOL CHEM, V268, P1108; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARSONS RE, 1991, J VIROL, V65, P2798, DOI 10.1128/JVI.65.6.2798-2806.1991; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; SCHEIDTMANN KH, 1991, J VIROL, V65, P2098, DOI 10.1128/JVI.65.4.2098-2101.1991; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SENGUPTA DJ, 1992, SCIENCE, V256, P1656, DOI 10.1126/science.256.5064.1656; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; STAHL MH, 1988, EMBO J, V7, P3149; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TACK LC, 1987, J BIOL CHEM, V262, P6339; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; VIRSHUP DM, 1992, MOL CELL BIOL, V12, P4883, DOI 10.1128/MCB.12.11.4883; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; WOBBE CR, 1987, PHILOS T ROY SOC B, V317, P439, DOI 10.1098/rstb.1987.0071; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	84	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7735	7743						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8126000				2022-12-25	WOS:A1994NA03200108
J	BOLIN, DJ; JONAS, A				BOLIN, DJ; JONAS, A			BINDING OF LECITHIN-CHOLESTEROL ACYLTRANSFERASE TO RECONSTITUTED HIGH-DENSITY-LIPOPROTEINS IS AFFECTED BY THEIR LIPID BUT NOT APOLIPOPROTEIN COMPOSITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-I; DISCOIDAL COMPLEXES; MICELLAR COMPLEXES; MODEL MEMBRANES; HUMAN-PLASMA; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLETHANOLAMINE; VESICLES; LIPASE; ACID	The reaction of lecithin:cholesterol acyltransferase (LCAT) with high density lipoproteins (HDL) is of critical importance in reverse cholesterol transport. We studied the relationship between LCAT binding and HDL composition using two assays to determine LCAT binding affinity for discoidal reconstituted HDL (rHDL). We prepared rHDL with egg phosphatidylcholine (egg-PC), cholesterol, and either apolipoprotein (apo) A-I or apoA-II. The rHDL, identical in lipid content, had sizes of 96 and 100 Angstrom, respectively. Binding constants (K-d)determined by the activity-inhibition method were 2.2 +/- 0.3 x 10(-7) and 1.1 +/- 0.3 x 10(-6) M, whereas those determined by a solid-phase method were 3.3 +/- 0.9 x 10(-7) and 3.7 +/- 0.9 x 10(-7) M for apoA-I and apoA-II rHDL, respectively. The stoichiometry was 1 LCAT bound/rHDL. The appV(max)/appK(m) for apoA-I was 80 fold higher than for apoA-II rHDL. The large difference between LCAT-binding constants and enzymatic activity measurements for the two particles suggests that LCAT binding and activation by apolipoproteins are independent events. To determine the effects of phospholipid headgroup on LCAT binding affinity, we tested rHDL containing up to 16 mol % of egg phosphatidylethanolamine (egg-PE), egg phosphatidic acid (egg-PA), or bovine phosphatidylserine (PS). K-d was unchanged for PS rHDL, but increased 6-fold with increasing PE content. AppV(max) increased with PE content, but decreased with PS or PA relative to egg-PC controls. AppK(m) increased in PE rHDL, but remained unchanged in rHDL with PA or PS. Fluorescence characterization of the lipid domains of rHDL shows small differences in the polarity of the headgroup region of PE rHDL. Thus, LCAT binding is influenced by the lipid, but not the protein composition of rHDL. AppV(max) values reflect active site preferences, while appK(m) values reflect interfacial binding affinity.	UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign					NHLBI NIH HHS [HL 16059, HL 29939] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016059, R01HL029939] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANERJEE D, 1983, J CELL BIOL, V96, P651, DOI 10.1083/jcb.96.3.651; BONELLI FS, 1989, J BIOL CHEM, V264, P14723; BONOMO EA, 1990, BIOCHEMISTRY-US, V29, P5094, DOI 10.1021/bi00473a014; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHRISTNER JE, 1990, ANAL BIOCHEM, V184, P388, DOI 10.1016/0003-2697(90)90698-9; CULLIS PR, 1986, CHEM PHYS LIPIDS, V40, P127, DOI 10.1016/0009-3084(86)90067-8; DOBIASOVA M, 1983, ADV LIPID RES, V20, P107; EDELSTEIN C, 1972, J BIOL CHEM, V247, P5841; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; FIELDING PE, 1986, J BIOL CHEM, V261, P5233; GLOMSET JA, 1972, BLOOD LIPIDS LIPOPRO, P745; GWYNNE J, 1974, J BIOL CHEM, V249, P2411; HOWELL KE, 1982, J CELL BIOL, V92, P833, DOI 10.1083/jcb.92.3.833; JAIN MK, 1986, BIOCHIM BIOPHYS ACTA, V860, P435, DOI 10.1016/0005-2736(86)90541-9; JONAS A, 1983, J BIOL CHEM, V258, P335; JONAS A, 1987, J BIOL CHEM, V262, P3969; JONAS A, 1984, J BIOL CHEM, V259, P6369; JONAS A, 1982, BIOCHEMISTRY-US, V21, P6867, DOI 10.1021/bi00269a037; JONAS A, 1986, J LIPID RES, V27, P689; JONAS A, 1987, PLASMA LIPOPROTEINS, P299; JONAS A, 1992, HIGH DENSITY LIPOPRO, V3, P67; LEROY A, 1993, J BIOL CHEM, V268, P4798; LITMAN BJ, 1973, BIOCHEMISTRY-US, V12, P2545, DOI 10.1021/bi00737a028; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASSEY JB, 1985, BIOCHEMISTRY-US, V24, P6973, DOI 10.1021/bi00345a033; MATZ CE, 1982, J BIOL CHEM, V257, P4541; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MILLER AL, 1973, J BIOL CHEM, V248, P3359; NICHOLS AV, 1971, BIOCHIM BIOPHYS ACTA, V231, P75; POWNALL HJ, 1985, J BIOL CHEM, V260, P2146; POWNALL HJ, 1986, METHOD ENZYMOL, V128, P515; Quinn D., 1982, Progress in Lipid Research, V22, P35, DOI 10.1016/0163-7827(83)90003-6; SLATER SJ, 1993, BIOCHEMISTRY-US, V32, P3714, DOI 10.1021/bi00065a025; STOKKE KT, 1971, SCAND J CLIN LAB INV, V27, P21, DOI 10.3109/00365517109080184; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; VERGER R, 1973, J BIOL CHEM, V248, P4023; WALD JH, 1990, J BIOL CHEM, V265, P20044; WEBER G, 1979, BIOCHEMISTRY-US, V18, P3075, DOI 10.1021/bi00581a025; YANG CY, 1987, J BIOL CHEM, V262, P3086; ZORICH NL, 1987, BIOCHIM BIOPHYS ACTA, V919, P181, DOI 10.1016/0005-2760(87)90206-2	40	54	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7429	7434						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125962				2022-12-25	WOS:A1994NA03200063
J	PETERS, JM; FRANKE, WW; KLEINSCHMIDT, JA				PETERS, JM; FRANKE, WW; KLEINSCHMIDT, JA			DISTINCT 19-S AND 20-S SUBCOMPLEXES OF THE 26-S PROTEASOME AND THEIR DISTRIBUTION IN THE NUCLEUS AND THE CYTOPLASM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH MOLECULAR-WEIGHT; IMMUNOELECTRON MICROSCOPIC LOCALIZATION; MULTICATALYTIC PROTEINASE PROTEASOME; UBIQUITIN-ACTIVATING ENZYME; RABBIT RETICULOCYTE LYSATE; ATP-DEPENDENT PROTEASES; 22-S CYLINDER PARTICLES; XENOPUS-LAEVIS; CULTURED-CELLS; IMMUNOCYTOCHEMICAL LOCALIZATION	The 26 S proteolytic complex (''26 S proteasome'') is a macromolecular assembly thought to be involved in ATP- and ubiquitin-dependent protein degradation in the cytoplasm of higher eukaryotic cells. This complex is composed of one 20 S cylinder particle (multicatalytic proteinase, 20 S proteasome) and two cap-shaped 19 S particles comprising a set of polypeptides in the M(r) range of 35,000-110,000. Here we show that cell supernatant fractions contain both these two subunit complexes as distinct particles as well as assembled to 26 S proteasomes. We have separated and purified all three forms from Xenopus laevis oocytes and have determined their peptidase and protease activities. Using various antibodies specific for either a constitutive p52 polypeptide of the 19 S cap complex or for proteins of the 20 S cylinder der particle, we have immunolocalized these complexes in both the cytoplasm and the nucleus of diverse species and cell types. The occurrence of all three forms, the 26 S proteasome, the 20 S cylinder particle, and the 19 S cap complex in the nucleoplasm has also been demonstrated in analyses of isolated giant nuclei from Xenopus oocytes. In addition, we show that the 19 S and 20 S subcomplexes can be released from 26 S proteasomes by ATP depletion and that readdition of ATP to 19 S and 20 S particles in cell extracts leads to the reformation of 26 S proteasomes. We discuss that all three particles (19 S, 20 S, and 26 S) exist in a dynamic equilibrium in both cell compartments and serve cytoplasmic as well as nucleus-specific functions.	GERMAN CANC RES CTR,DIV CELL BIOL,D-69120 HEIDELBERG,GERMANY; GERMAN CANC RES CTR,DIV APPL TUMOR VIROL,D-69120 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)				Franke, Werner W./0000-0002-4873-8448				AKHAYAT O, 1987, P NATL ACAD SCI USA, V84, P1595, DOI 10.1073/pnas.84.6.1595; AMSTERDAM A, 1993, P NATL ACAD SCI USA, V90, P99, DOI 10.1073/pnas.90.1.99; ANKENBAUER T, 1989, NATURE, V342, P822, DOI 10.1038/342822a0; ARRIGO AP, 1988, NATURE, V331, P192, DOI 10.1038/331192a0; BARRETT AJ, 1980, BIOCHEM J, V187, P909, DOI 10.1042/bj1870909; BEYETTE JR, 1992, MUSCLE NERVE, V15, P1023, DOI 10.1002/mus.880150907; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRIANE D, 1992, EUR J CELL BIOL, V57, P30; CARLSON N, 1987, J CELL BIOL, V104, P537, DOI 10.1083/jcb.104.3.537; CHI XS, 1992, BIOCHEMISTRY-US, V31, P11963; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; COOK JC, 1991, BIOCHEM BIOPH RES CO, V174, P564, DOI 10.1016/0006-291X(91)91454-K; DABAUVALLE MC, 1982, P NATL ACAD SCI-BIOL, V79, P5302, DOI 10.1073/pnas.79.17.5302; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DEROBERTIS EM, 1983, CELL, V32, P1021, DOI 10.1016/0092-8674(83)90285-4; DESA MFG, 1988, J CELL BIOL, V107, P1517, DOI 10.1083/jcb.107.4.1517; DESA MFG, 1988, J CELL SCI, V89, P151; DRISCOLL J, 1992, P NATL ACAD SCI USA, V89, P4986, DOI 10.1073/pnas.89.11.4986; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FRANKE WW, 1979, EXP CELL RES, V123, P25, DOI 10.1016/0014-4827(79)90418-X; GANOTH D, 1988, J BIOL CHEM, V263, P12412; GAUTIER J, 1988, J CELL SCI, V90, P543; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GRZIWA A, 1992, J STRUCT BIOL, V109, P168, DOI 10.1016/1047-8477(92)90048-F; HAASS C, 1989, EMBO J, V8, P2373, DOI 10.1002/j.1460-2075.1989.tb08366.x; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HILT W, 1993, J BIOL CHEM, V268, P3479; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOUGH R, 1986, J BIOL CHEM, V261, P2400; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HUGLE B, 1983, EUR J CELL BIOL, V32, P157; IKAI A, 1991, FEBS LETT, V292, P21, DOI 10.1016/0014-5793(91)80824-M; INABA K, 1993, J CELL SCI, V104, P907; ISHIDA N, 1993, FEBS LETT, V324, P345, DOI 10.1016/0014-5793(93)80148-N; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KANAYAMA HO, 1992, EUR J BIOCHEM, V206, P567, DOI 10.1111/j.1432-1033.1992.tb16961.x; KAWAHARA H, 1992, DEV BIOL, V151, P27, DOI 10.1016/0012-1606(92)90210-8; KLEIN U, 1990, J CELL BIOL, V111, P2275, DOI 10.1083/jcb.111.6.2275; KLEINSCHMIDT JA, 1982, CELL, V29, P799, DOI 10.1016/0092-8674(82)90442-1; KLEINSCHMIDT JA, 1983, EUR J CELL BIOL, V32, P143; KLOETZEL PM, 1987, EXP CELL RES, V170, P204, DOI 10.1016/0014-4827(87)90130-3; KNAPP AC, 1989, CELL, V59, P67, DOI 10.1016/0092-8674(89)90870-2; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KROHNE G, 1989, J CELL BIOL, V109, P2003, DOI 10.1083/jcb.109.5.2003; KROHNE G, 1980, EXP CELL RES, V129, P167, DOI 10.1016/0014-4827(80)90341-9; KUEHN L, 1992, ARCH BIOCHEM BIOPHYS, V295, P55, DOI 10.1016/0003-9861(92)90487-H; KUMATORI A, 1990, P NATL ACAD SCI USA, V87, P7071, DOI 10.1073/pnas.87.18.7071; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MURAKAMI K, 1986, P NATL ACAD SCI USA, V83, P7588, DOI 10.1073/pnas.83.20.7588; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OLINKCOUX M, 1992, EUR J CELL BIOL, V59, P148; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; PAINE PL, 1984, J CELL BIOL, V99, pS188, DOI 10.1083/jcb.99.1.188s; PAL JK, 1988, J CELL SCI, V90, P555; PETERS JM, 1991, EUR J CELL BIOL, V56, P422; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RICHTERRUOFF B, 1992, FEBS LETT, V302, P192, DOI 10.1016/0014-5793(92)80438-M; RIVETT AJ, 1993, CURR BIOL, V3, P127, DOI 10.1016/0960-9822(93)90173-L; RIVETT AJ, 1993, BIOCHEM J, V291, P1; RIVETT AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1165, DOI 10.1177/40.8.1619280; SCALENGHE F, 1978, CHROMOSOMA, V66, P299, DOI 10.1007/BF00328531; SCHMIDTZACHMANN MS, 1984, EXP CELL RES, V153, P327, DOI 10.1016/0014-4827(84)90604-9; SCHWARTZ AL, 1992, P NATL ACAD SCI USA, V89, P5542, DOI 10.1073/pnas.89.12.5542; SCHWARTZ AL, 1988, EMBO J, V7, P2961, DOI 10.1002/j.1460-2075.1988.tb03158.x; SEELIG A, 1991, BIOCHEM J, V280, P225, DOI 10.1042/bj2800225; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SHIMBARA N, 1992, J BIOL CHEM, V267, P18100; TANAKA K, 1990, FEBS LETT, V271, P41, DOI 10.1016/0014-5793(90)80367-R; TANAKA K, 1992, NEW BIOL, V4, P173; TANAKA K, 1989, J CELL PHYSIOL, V139, P34, DOI 10.1002/jcp.1041390107; THOMAS JO, 1975, P NATL ACAD SCI USA, V72, P2626, DOI 10.1073/pnas.72.7.2626; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; UGAI S, 1993, J BIOCHEM, V113, P754, DOI 10.1093/oxfordjournals.jbchem.a124116; van Holde KE., 1989, SPRINGER SERIES MOL; WAXMAN L, 1987, J BIOL CHEM, V262, P2451; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	93	335	344	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7709	7718						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125997				2022-12-25	WOS:A1994NA03200105
J	REILLY, BD; MAKRIDES, SC; FORD, PJ; MARSH, HC; MOLD, C				REILLY, BD; MAKRIDES, SC; FORD, PJ; MARSH, HC; MOLD, C			QUANTITATIVE-ANALYSIS OF C4B DIMER BINDING TO DISTINCT SITES ON THE C3B/C4B RECEPTOR (CR-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-COMPLEMENT; REPEATING DOMAINS; IMMUNE-COMPLEXES; LIGAND-BINDING; C5 CONVERTASE; CR-1; C3B; INHIBITOR; MEMBRANE; PATHWAY	The complement receptor CR1 (CD35) is a transmembrame protein composed in its extracellular portion of short consensus repeats (SCR 1-30) organized into four long homologous repeats (LHR-A, LHR-B, LHR-C, and LHR-D). Each LHR, except LHR-D, contains a binding site for C3b and/or C4b within its first four SCR. The binding reaction between CR1 and soluble dimers of C4b (C4b(2)) was analyzed using the native receptor on human erythrocytes and full-length recombinant CR1 expressed in stably transfected Chinese hamster ovary (CHO) cells. CR1 mutants expressed similarly were used to determine the SCR of LHR-A required for C4b(2) binding and the potential of C3b binding sites in CR1 to bind C4b(2). Erythrocyte CR1, CHO cells expressing full-length recombinant CR1 (ABCD), constructs ACD, and SCR(1-4)D each bound C4b(2) with similar affinities (K-d, similar to 4 x 10(-7) M). Construct SCR(1-2)D bound C4b(2) with lower affinity (K-d, 1.4 x 10(-6) M) indicating that SCR(1-4) are required for a fully functional C4b(2) binding site. Construct SCR(15-18)D, which contains a C3b site, also bound C4b(2) with lower affinity (K-d 1.2 x 10(-6) M) than its binding to C3b dimers. Constructs SCR(15-16)D and D did not bind C4b(2). Each CR1 construct that bound C4b(2) functioned as a cofactor for factor I-mediated cleavage to C4d.	UNIV NEW MEXICO,SCH MED,DEPT MICROBIOL,ALBUQUERQUE,NM 87131; T CELL SCI INC,CAMBRIDGE,MA 02139	University of New Mexico				Marsh, Henry/0000-0001-5637-6013	NIAID NIH HHS [AI 08152, AI 24720] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024720, F32AI008152] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS EM, 1991, J IMMUNOL, V147, P3005; CLEMENZA L, 1993, J IMMUNOL, V150, pA14; FEARON DT, 1979, P NATL ACAD SCI USA, V76, P5867, DOI 10.1073/pnas.76.11.5867; HAMMER CH, 1981, J BIOL CHEM, V256, P3995; IIDA K, 1981, J EXP MED, V153, P1138, DOI 10.1084/jem.153.5.1138; ISENMAN DE, 1982, BIOCHEMISTRY-US, V21, P1109, DOI 10.1021/bi00535a001; KALLI KR, 1991, J EXP MED, V174, P1451, DOI 10.1084/jem.174.6.1451; KINOSHITA T, 1988, J IMMUNOL, V141, P3895; KLICKSTEIN LB, 1988, J EXP MED, V168, P1699, DOI 10.1084/jem.168.5.1699; KLICKSTEIN LB, 1987, J EXP MED, V165, P1095, DOI 10.1084/jem.165.4.1095; KRYCH M, 1991, P NATL ACAD SCI USA, V88, P4353, DOI 10.1073/pnas.88.10.4353; MAKRIDES SC, 1992, J BIOL CHEM, V267, P24754; MEDOF ME, 1984, J EXP MED, V159, P1669, DOI 10.1084/jem.159.6.1669; MEDOF ME, 1982, J EXP MED, V156, P1739, DOI 10.1084/jem.156.6.1739; MEDOF ME, 1983, J IMMUNOL, V130, P1336; MEDOF ME, 1982, J LAB CLIN IMMUNOL, V7, P1; ROSS GD, 1985, ADV IMMUNOL, V37, P217, DOI 10.1016/S0065-2776(08)60341-7; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHREIBER RD, 1984, SPRINGER SEMIN IMMUN, V7, P221, DOI 10.1007/BF01893021; SPINELLA D G, 1984, Complement, V1, P187; TAKATA Y, 1987, J EXP MED, V165, P1494, DOI 10.1084/jem.165.6.1494; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; YOON SH, 1985, J IMMUNOL, V134, P3332	23	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7696	7701						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125996				2022-12-25	WOS:A1994NA03200103
J	TAWFIC, S; AHMED, K				TAWFIC, S; AHMED, K			ASSOCIATION OF CASEIN KINASE-2 WITH NUCLEAR MATRIX - POSSIBLE ROLE IN NUCLEAR MATRIX PROTEIN-PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE-II; HORMONE ACTION; CELL-CYCLE; IDENTIFICATION; ORGANIZATION; STIMULATION; ANTIBODIES; INTERPHASE; INVITRO; LAMINA	The nuclear matrix is thought to play a fundamental role in the nuclear structure and functions relating to cell proliferation and regulation of gene activity. Phosphorylation of nuclear matrix proteins has been observed, and multiple protein kinases may be involved in this process. Casein kinase 2 is a ubiquitous messenger-independent serine/threonine protein kinase that has been implicated in cellular growth and proliferation. The presence of immunoreactive casein kinase 2 in purified nuclear matrix preparations was demonstrated in rat liver and prostate tissues by employing specific antibodies. The enzyme was active toward the specific decapeptide substrate Arg-Arg-Arg-Glu-Glu-Glu-Thr-Glu-Glu-Glu and exhibited other properties characteristic of casein kinase 2. Phosphorylation of nuclear matrix proteins catalyzed by intrinsic protein kinase activity in intact nuclei was also observed, and the results suggested that this reaction was at least in part catalyzed by casein kinase 2. The profile of nuclear matrix proteins labeled with (32)p(i) in situ in intact liver cells was similar to that observed in nuclear matrix proteins isolated from nuclei labeled with [gamma-P-32]ATP in vitro. Association of casein kinase 2 with the nuclear matrix may be of significance in the post-translational modification of certain proteins in this fraction.	DEPT VET AFFAIRS MED CTR, CELLULAR & MOLEC BIOCHEM RES LAB 151, MINNEAPOLIS, MN 55417 USA; UNIV MINNESOTA, DEPT LAB MED & PATHOL, CELLULAR & MOLEC BIOCHEM RES LAB 151, MINNEAPOLIS, MN 55417 USA	University of Minnesota System; University of Minnesota Twin Cities					NCI NIH HHS [CA-15062] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA015062, U01CA015062, R37CA015062] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; AGOSTINIS P, 1989, FEBS LETT, V259, P75, DOI 10.1016/0014-5793(89)81498-X; AHMED K, 1993, P NATL ACAD SCI USA, V90, P4426, DOI 10.1073/pnas.90.10.4426; AHMED K, 1986, ADV ENZYME REGUL, V25, P401, DOI 10.1016/0065-2571(86)90026-9; AHMED K, 1982, 2ND P WIST S NUCL EN, P31; AHMED K, 1992, RECENT ADV CELLULAR, V4, P7; ALLEN SL, 1977, BIOCHEM BIOPH RES CO, V75, P111, DOI 10.1016/0006-291X(77)91296-7; BEREZNEY R, 1991, J CELL BIOCHEM, V47, P109, DOI 10.1002/jcb.240470204; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BEREZNEY R, 1984, CHROMOSOMAL NONHISTO, V4, P119; CARDENAS ME, 1993, J CELL SCI, V104, P219; CHRISTMANN JL, 1981, J BIOL CHEM, V256, P3326; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; DESSEV G, 1988, P NATL ACAD SCI USA, V85, P2994, DOI 10.1073/pnas.85.9.2994; DUMBAR TS, 1989, THESIS U MISSISSIPPI; EBERHARTER A, 1993, EUR J BIOCHEM, V212, P573, DOI 10.1111/j.1432-1033.1993.tb17695.x; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FEY E G, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P127; FEY EG, 1988, P NATL ACAD SCI USA, V85, P121, DOI 10.1073/pnas.85.1.121; GETZENBERG RH, 1991, J CELL BIOCHEM, V47, P289, DOI 10.1002/jcb.240470402; GETZENBERG RH, 1990, ENDOCR REV, V11, P399, DOI 10.1210/edrv-11-3-399; GOUELI SA, 1990, BIOCHEM INT, V21, P685; GOUELI SA, 1984, ARCH BIOCHEM BIOPHYS, V234, P646, DOI 10.1016/0003-9861(84)90315-1; GOUELI SA, 1985, BIOCHEM J, V230, P293, DOI 10.1042/bj2300293; GOUELI SA, 1991, MOL CELL BIOCHEM, V101, P145; GOUELI SA, 1986, INT J BIOCHEM, V18, P861, DOI 10.1016/0020-711X(86)90067-4; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HENRY SM, 1983, EUR J BIOCHEM, V133, P23, DOI 10.1111/j.1432-1033.1983.tb07425.x; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LI HM, 1992, P NATL ACAD SCI USA, V89, P8434, DOI 10.1073/pnas.89.18.8434; LORENZ P, 1993, J BIOL CHEM, V268, P2733; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; MEEK DW, 1992, BIOCHEM J, V287, P1; MEGGIO F, 1989, BIOCHIM BIOPHYS ACTA, V1010, P128, DOI 10.1016/0167-4889(89)90193-6; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MOY BC, 1986, CANCER RES, V46, P4672; NAKAYASU H, 1991, P NATL ACAD SCI USA, V88, P10312, DOI 10.1073/pnas.88.22.10312; NEGRI C, 1992, EXP CELL RES, V200, P452, DOI 10.1016/0014-4827(92)90195-E; NICKERSON JA, 1990, EUKARYOTIC NUCLEUS M, V2, P763; OLSON MOJ, 1990, EUKARYOTIC NUCLEUS M, V2, P520; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; PALEN E, 1991, BIOCHEMISTRY-US, V30, P5586, DOI 10.1021/bi00236a035; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; SEVALJEVIC L, 1982, MOL BIOL REP, V8, P225, DOI 10.1007/BF00776584; STEER RC, 1979, EXP CELL RES, V119, P403, DOI 10.1016/0014-4827(79)90372-0; STUURMAN N, 1990, J BIOL CHEM, V265, P5460; TAWFIC S, 1993, CELL MOL BIOL RES, V39, P43; TOMMASINO M, 1992, GENE, V111, P93, DOI 10.1016/0378-1119(92)90607-Q; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; XING YG, 1991, J CELL BIOL, V112, P1055, DOI 10.1083/jcb.112.6.1055	54	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7489	7493						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125967				2022-12-25	WOS:A1994NA03200072
J	PARSEK, MR; YE, RW; PUN, P; CHAKRABARTY, AM				PARSEK, MR; YE, RW; PUN, P; CHAKRABARTY, AM			CRITICAL NUCLEOTIDES IN THE INTERACTION OF A LYSR-TYPE REGULATOR WITH ITS TARGET PROMOTER REGION - CATBC PROMOTER ACTIVATION BY CATR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RPOA; PSEUDOMONAS-PUTIDA; BINDING-SITE; TRANSCRIPTIONAL ACTIVATOR; GEL-ELECTROPHORESIS; RNA-POLYMERASE; DNA; PROTEIN; MUTATIONS; SEQUENCE	We have used site-directed mutagenesis to analyze the importance of nucleotides in the catBC promoter region for the binding of CatR, a member of the LysR family of DNA-binding proteins and for the in vivo activation of the catBC operon. The binding affinity of CatR for its binding site in the catBC promoter region was shown to increase about 2.2-fold in the presence of the inducer, cis,cis-muconate. Nucleotides were targeted for mutagenesis on the basis of previous footprinting data and sequence analysis of CatR binding sites. Critical nucleotides for CatR binding were found within an imperfect inverted repeat. Previous studies have indicated that the LysR family of DNA-binding proteins shares a consensus T-N-11-A binding motif (Goethals, K., Van Montagu, M., and Holsters, M. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 1646-1650), but the CatR binding site sequence has located within the imperfect inverted repeat a G-N-11-A instead of the predicted T. Mutagenesis of the G to a T resulted in an increase in both the binding of CatR to the catBC promoter and in the in vivo activation. Nucleotides within the -35 and -10 regions of the catBC promoter were found to be important for promoter activity but not for CatR binding.	UNIV ILLINOIS, COLL MED,DEPT MICROBIOL & IMMUNOL,M-C 790,BOX 6998, CHICAGO, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004050] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 04050-07] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALDRICH TL, 1989, MOL GEN GENET, V218, P266, DOI 10.1007/BF00331277; ALDRICH TL, 1988, J BACTERIOL, V170, P1297, DOI 10.1128/jb.170.3.1297-1304.1988; AYERS DG, 1989, J MOL BIOL, V207, P749, DOI 10.1016/0022-2836(89)90241-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYERLY KA, 1991, J BACTERIOL, V173, P3547, DOI 10.1128/jb.173.11.3547-3553.1991; CHANG M, 1990, NUCLEIC ACIDS RES, V18, P979, DOI 10.1093/nar/18.4.979; COCO WM, 1993, J BACTERIOL, V175, P417, DOI 10.1128/JB.175.2.417-427.1993; FARINHA MA, 1990, J BACTERIOL, V172, P3496, DOI 10.1128/jb.172.6.3496-3499.1990; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GAO J, 1991, EMBO J, V10, P4137, DOI 10.1002/j.1460-2075.1991.tb04991.x; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GOETHALS K, 1992, P NATL ACAD SCI USA, V89, P1646, DOI 10.1073/pnas.89.5.1646; GUSSIN GN, 1992, J BACTERIOL, V174, P5156, DOI 10.1128/JB.174.15.5156-5160.1992; HENIKOFF SJC, 1990, METHOD ENZYMOL, V183, P111; HUANG JZ, 1991, J BIOL CHEM, V266, P10830; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; Maniatis T, 1989, MOL CLONING; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; Miller JH., 1972, EXPT MOL GENETICS; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; PARSEK MR, 1992, J BACTERIOL, V174, P7798, DOI 10.1128/JB.174.23.7798-7806.1992; PARSEK MR, 1994, METH MOL G, V3, P273; REZNIKOFF WS, 1985, ANNU REV GENET, V19, P355, DOI 10.1146/annurev.genet.19.1.355; ROGOWSKY PM, 1987, J BACTERIOL, V169, P5101, DOI 10.1128/jb.169.11.5101-5112.1987; ROTHMEL RK, 1991, J BACTERIOL, V173, P4717, DOI 10.1128/jb.173.15.4717-4724.1991; SCHELL MA, 1993, ANNU REV MICROBIOL, V47, P597, DOI 10.1146/annurev.micro.47.1.597; SCHELL MA, 1989, J BACTERIOL, V171, P837, DOI 10.1128/jb.171.2.837-846.1989; Stanier R Y, 1973, Adv Microb Physiol, V9, P89; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; THOMAS MS, 1991, MOL MICROBIOL, V5, P2719, DOI 10.1111/j.1365-2958.1991.tb01980.x; VIERA J, 1988, METHOD ENZYMOL, V153, P3; WANG L, 1992, CELL, V69, P659, DOI 10.1016/0092-8674(92)90229-6; WEK RC, 1988, J MOL BIOL, V203, P643, DOI 10.1016/0022-2836(88)90199-4; WEREL W, 1991, EMBO J, V10, P2589, DOI 10.1002/j.1460-2075.1991.tb07800.x; WHEELIS ML, 1972, J BACTERIOL, V109, P790, DOI 10.1128/JB.109.2.790-795.1972; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	37	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11279	11284						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157659				2022-12-25	WOS:A1994NF96600048
J	CARMEN, AA; HOLLAND, MJ				CARMEN, AA; HOLLAND, MJ			THE UPSTREAM REPRESSION SEQUENCE FROM THE YEAST ENOLASE GENE ENO1 IS A COMPLEX REGULATORY ELEMENT THAT BINDS MULTIPLE TRANS-ACTING FACTORS INCLUDING REB1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ACTIVATING SEQUENCES; MODULATE REPRESSION; PROTEIN-BINDING; IDENTIFICATION; TRANSCRIPTION; EXPRESSION; DNA; SITE; ENHANCER	Cis-acting sequences that modulate ENO1 URS (upstream repression site) element activity were identified by base pair substitution mutagenesis. Base substitution mutations within three distinct regions of the 125-base pair URS element caused partial loss of URS activity in vivo. A URS element containing all three mutations was inactive. A binding site for the yeast REB1 protein was identified near the 5' terminus of the ENO1 URS element. Base substitution mutations that disrupted REB1 binding in vitro caused a 30% loss of URS activity in vivo. A second DNA binding activity was identified which also bound near the 5' terminus of the URS element. This latter binding activity was not antigenically related to REB1 nor was binding of this activity affected by base substitution mutations that abolished REB1 binding. Base substitution mutations within a second region of the ENO1 URS element caused a 38% loss of URS activity in vivo. The nucleotide sequence of this latter region is very similar to essential sequences within the URS elements from the yeast CAR1 and SSA1 genes, respectively. Base substitution mutations within a third region near the 3' terminus of the ENO1 URS element caused a 70% loss of URS activity in vivo. These latter sequences bound a partially purified factor that was distinct from REB1. These results showed that ENO1 URS element activity was modulated by multiple cis-acting sequences that bound distinct trans-acting factors.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616	University of California System; University of California Davis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R35GM130307, R01GM030307] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30307] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BRINDLE PK, 1990, MOL CELL BIOL, V10, P4872, DOI 10.1128/MCB.10.9.4872; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CHEN W, 1989, EMBO J, V8, P261, DOI 10.1002/j.1460-2075.1989.tb03372.x; COHEN R, 1987, MOL CELL BIOL, V7, P2753, DOI 10.1128/MCB.7.8.2753; COHEN R, 1986, MOL CELL BIOL, V6, P2287, DOI 10.1128/MCB.6.7.2287; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; HOLLAND JP, 1990, MOL CELL BIOL, V10, P4863, DOI 10.1128/MCB.10.9.4863; HUET J, 1987, P NATL ACAD SCI USA, V84, P3648, DOI 10.1073/pnas.84.11.3648; INNIS MA, 1986, METHOD ENZYMOL, V119, P397; JARVIS EE, 1989, GENE DEV, V3, P936, DOI 10.1101/gad.3.7.936; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; LANG WH, 1993, MOL CELL BIOL, V13, P649, DOI 10.1128/MCB.13.1.649; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LUCHE RM, 1990, MOL CELL BIOL, V10, P3884, DOI 10.1128/MCB.10.8.3884; Maxam A M, 1980, Methods Enzymol, V65, P499; MCALISTER L, 1982, J BIOL CHEM, V257, P7181; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MESTEL R, 1989, MOL CELL BIOL, V9, P1243, DOI 10.1128/MCB.9.3.1243; MORROW BE, 1989, J BIOL CHEM, V264, P9061; MORROW BE, 1990, J BIOL CHEM, V265, P20778; NISHIZAWA M, 1989, MOL CELL BIOL, V9, P442, DOI 10.1128/MCB.9.2.442; PARK HO, 1989, MOL CELL BIOL, V9, P2025, DOI 10.1128/MCB.9.5.2025; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT EW, 1990, NUCLEIC ACIDS RES, V18, P7099, DOI 10.1093/nar/18.23.7099; SUMRADA RA, 1987, P NATL ACAD SCI USA, V84, P3997, DOI 10.1073/pnas.84.12.3997; SWANSON ME, 1983, J BIOL CHEM, V258, P3242	29	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9790	9797						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144571				2022-12-25	WOS:A1994NE05300062
J	MARTI, A; JEHN, B; COSTELLO, E; KEON, N; KE, G; MARTIN, F; JAGGI, R				MARTI, A; JEHN, B; COSTELLO, E; KEON, N; KE, G; MARTIN, F; JAGGI, R			PROTEIN KINASE-A AND AP-1 (C-FOS/JUND) ARE INDUCED DURING APOPTOSIS OF MOUSE MAMMARY EPITHELIAL-CELLS	ONCOGENE			English	Article							GENE-EXPRESSION; NUCLEAR FACTOR; BETA-CASEIN; TISSUE TRANSGLUTAMINASE; TRANSGENIC MICE; FOS EXPRESSION; ONCOGENE FOS; DEATH; JUN; INDUCTION	At weaning the mammary gland undergoes a reductive remodelling process (involution) which is associated with the cessation of milk protein gene expression and programmed cell death of milk-producing epithelial cells. Elevated nuclear protein kinase A (PKA) activity was observed from one day post-lactation, paralleled by increased c-fos, junB, junD and to a lesser extent c-jun mRNA levels. AP-1 DNA binding activity was transiently induced and the AP-1 complex was shown to consist principally of cFos/JunD. Oct-1 DNA binding activity and Oct-1 protein were gradually lost from the gland over the first 4 days of involution, whereas Oct-1 mRNA levels remained unchanged. Comparing nuclear extracts from normal mammary glands with nuclear extracts from glands which had been cleared of all epithelial cells 3 weeks after birth, revealed that PKA activation, AP-1 induction and Oct-1 inactivation all are dependent on the presence of the epithelial compartment. The increased Fos/Jun expression and the inactivation of Oct-1 may be consequences of the increased PKA activity. A similar induction of AP-1 (cFos/JunD) was also observed in the involuting rat ventral prostate pointing to a possible role for AP-1 in programmed cell death.	UNIV BERN,CLIN & EXPTL RES LAB,TIEFENAUSTR 120,CH-3004 BERN,SWITZERLAND; ISREC,CH-1066 EPALINGES,SWITZERLAND; NATL UNIV IRELAND UNIV COLL DUBLIN,DEPT PHARMACOL,DUBLIN 4,IRELAND	University of Bern; Swiss Institute Experimental Cancer Research; University College Dublin				Costello, Eithne/0000-0002-0104-8992				ABATE C, 1991, ONCOGENE, V6, P2179; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; Angel P, 1992, Matrix Suppl, V1, P156; BANDYK MG, 1990, J UROLOGY, V143, P407, DOI 10.1016/S0022-5347(17)39975-5; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; COHEN JJ, 1984, J IMMUNOL, V132, P38; COLLARD MW, 1987, BIOCHEMISTRY-US, V26, P3297, DOI 10.1021/bi00386a008; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; COMPTON MM, 1987, J BIOL CHEM, V262, P8288; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DEGROOT RP, 1992, ONCOGENE, V7, P2281; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; DOWD DR, 1992, MOL CELL BIOL, V12, P3600, DOI 10.1128/MCB.12.8.3600; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GINZBURG I, 1980, NUCLEIC ACIDS RES, V8, P3553, DOI 10.1093/nar/8.16.3553; GONZALEZMARTIN C, 1992, DEV BRAIN RES, V68, P83, DOI 10.1016/0165-3806(92)90250-Z; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HENNIGHAUSEN LG, 1982, EUR J BIOCHEM, V125, P131, DOI 10.1111/j.1432-1033.1982.tb06660.x; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; KERR JFR, 1991, APOPTOSIS MOL BASIS, P5; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MEDINA D, 1978, BREAST CANCER PLENUM, P47; MELLSTROM B, 1991, ONCOGENE, V6, P1959; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PIACENTINI M, 1991, CELL TISSUE RES, V263, P227, DOI 10.1007/BF00318764; ROBERTS SB, 1991, SCIENCE, V253, P1022, DOI 10.1126/science.1887216; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHMIDHAUSER C, 1992, MOL BIOL CELL, V3, P699, DOI 10.1091/mbc.3.6.699; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STRANGE R, 1992, DEVELOPMENT, V115, P49; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064; THOMPSON HJ, 1992, CANCER EPIDEM BIOMAR, V1, P597; TOURAY M, 1991, ONCOGENE, V6, P211; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WAKAO H, 1992, J BIOL CHEM, V267, P16365; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	70	198	198	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1213	1223						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134124				2022-12-25	WOS:A1994NC04800025
J	NOVOTNY, WF; CHASSANDE, O; BAKER, M; LAZDUNSKI, M; BARBRY, P				NOVOTNY, WF; CHASSANDE, O; BAKER, M; LAZDUNSKI, M; BARBRY, P			DIAMINE OXIDASE IS THE AMILORIDE-BINDING PROTEIN AND IS INHIBITED BY AMILORIDE ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; AMINE OXIDASE; CULTURED-CELLS; SEQUENCE; BLASTOCYST; CHANNEL; SITE	Diamine oxidase (histaminase), an enzyme that oxidatively deaminates putrescine and histamine, was purified from human placenta and from pig kidney. Both NH2-terminal sequences are highly homologous to the human kidney amiloride-binding protein, previously thought to be a component of the amiloride-sensitive Na+ channel. Monoclonal antibodies raised against the pig kidney amiloride-binding protein immunoprecipitate a polypeptide with the same M(r) (105,000) as that of pig kidney diamine oxidase. That polypeptide has both diamine oxidase activity and the capacity to bind [H-3]phenamil, a tritiated amiloride derivative. Cells stably transfected with human kidney amiloride-binding protein cDNA express a high diamine oxidase activity. In transfected cells as well as with the purified enzyme, this activity was inhibited by amiloride and by some of its derivatives, such as phenamil and ethylpropylamiloride. Amiloride inhibition seems to be due to drug binding at the active site of the enzyme. These data indicate that human placental diamine oxidase is identical to the human kidney amiloride-binding protein and that amiloride analogues may have wider physiological effects besides those on epithelial ion transport.	INST PHARMACOL MOLEC & CELLULAIRE, F-06560 VALBONNE, FRANCE		NOVOTNY, WF (corresponding author), UNIV CALIF SAN DIEGO, MED CTR, DEPT MED, DIV HEMATOL ONCOL, SAN DIEGO, CA 92103 USA.		Barbry, Pascal/O-5021-2016	Barbry, Pascal/0000-0001-9632-6483				BACHRACH U, 1987, TISSUE CELL, V19, P39, DOI 10.1016/0040-8166(87)90055-3; BACHRACH U, 1987, J CELL PHYSIOL, V131, P92, DOI 10.1002/jcp.1041310114; BARBRY P, 1990, BIOCHEMISTRY-US, V29, P1039, DOI 10.1021/bi00456a028; BARBRY P, 1990, P NATL ACAD SCI USA, V87, P7347, DOI 10.1073/pnas.87.19.7347; BAYLIN SB, 1977, P NATL ACAD SCI USA, V74, P883, DOI 10.1073/pnas.74.3.883; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; BRUINENBERG PG, 1989, BIOCHIM BIOPHYS ACTA, V1008, P157, DOI 10.1016/0167-4781(80)90003-2; BUFFONI F, 1966, PHARMACOL REV, V18, P1163; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; COUNILLON L, 1993, P NATL ACAD SCI USA, V90, P4508, DOI 10.1073/pnas.90.10.4508; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DOWLING RH, 1990, DIGESTION, V46, P331, DOI 10.1159/000200406; FRELIN C, 1987, KIDNEY INT, V32, P785, DOI 10.1038/ki.1987.277; GOLDSTEIN O, 1993, J BIOL CHEM, V268, P7856; HANSSON R, 1966, ACTA MED SCAND, V180, P533; HARLOW E, 1988, ANTIBODIES LABORATOR; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; LINGUEGLIA E, 1993, EUR J BIOCHEM, V216, P679, DOI 10.1111/j.1432-1033.1993.tb18188.x; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; NOVOTNY WF, 1991, BLOOD, V78, P387; OKUYAMA T, 1961, ARCH BIOCHEM BIOPHYS, V95, P242, DOI 10.1016/0003-9861(61)90141-2; PARCHMENT RE, 1989, CANCER RES, V49, P6680; PIERCE GB, 1991, DIFFERENTIATION, V46, P181, DOI 10.1111/j.1432-0436.1991.tb00880.x; PIERCE GB, 1989, P NATL ACAD SCI USA, V86, P3654, DOI 10.1073/pnas.86.10.3654; ROBINSONWHITE A, 1985, J CLIN INVEST, V76, P93, DOI 10.1172/JCI111983; ROSSI A, 1992, FEBS LETT, V301, P253, DOI 10.1016/0014-5793(92)80251-B; SATTLER J, 1990, J NEUR TR S, P291; SOLOMON EI, 1993, SCIENCE, V259, P1575, DOI 10.1126/science.8384374; THESTRUP PK, 1987, DAN MED B, V34, P3	32	87	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9921	9925						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144586				2022-12-25	WOS:A1994NE05300080
J	HIGGINS, JB; CASEY, PJ				HIGGINS, JB; CASEY, PJ			IN-VITRO PROCESSING OF RECOMBINANT G-PROTEIN GAMMA-SUBUNITS - REQUIREMENTS FOR ASSEMBLY OF AN ACTIVE BETA-GAMMA COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; ALPHA-SUBUNITS; PERTUSSIS TOXIN; BOVINE BRAIN; PRENYLATION; EXPRESSION; DIMERS; CELLS; MYRISTOYLATION; ASSOCIATION	The gamma subunits of the heterotrimeric G proteins (G(gamma)) are subject to carboxyl-terminal processing. This processing involves prenylation of a cysteine residue initially 4 amino acids from the carboxyl terminus, endoproteolytic truncation of the 3 terminal amino acids, and methylation of the now carboxyl-terminal prenylcysteine residue. The significance of each of these modifications in the ultimate properties of G proteins is not yet clear. We have developed in vitro systems for the production of the three processing intermediates (unmodified, prenylated, and truncated-prenylated) for two G(gamma) subunits, one which is subject to farnesylation (G(gamma 1)) and one which is geranylgeranylated (G(gamma 2)). Assessment of the functional consequences of the processing of G(gamma) was found to require reconstitution of the polypeptides with a G protein beta subunit (G(beta)) The ability of recombinant G(beta), produced in Sf9 cells, to assemble into stable beta gamma complexes (G(beta gamma)) with each of the G(gamma) processing intermediates was assessed. Both prenylated and unprenylated G gamma subunits formed stable complexes with G(beta), but surprisingly, neither of the truncated-prenylated G(gamma) subunits were competent for this assembly. The G(beta gamma) complexes which were formed were examined for their ability to interact with a G protein alpha subunit (G(alpha)). Only those G(beta gamma) complexes containing a prenylated G(gamma) subunit were functional in this assay. These data indicate that: 1) prenylation of G(gamma) is not required for G(beta gamma) assembly; 2) assembly of the G(beta gamma) complex occurs prior to the proteolytic processing of G(gamma); and 3) G(beta gamma) complexes require prenylated G(gamma) for interaction with G(alpha).	DUKE UNIV,MED CTR,DEPT MOLEC CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University				Casey, Patrick/0000-0002-7366-9309				BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CASEY PJ, 1992, J LIPID RES, V33, P1731; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GRABER SG, 1992, J BIOL CHEM, V267, P13123; GRAZIANO MP, 1987, J BIOL CHEM, V262, P11375; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KATADA T, 1986, J BIOL CHEM, V261, P8182; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; O'Reilly D. R., 1992, BACULOVIRUS EXPRESSI, P1; OHGURO H, 1991, EMBO J, V10, P3669, DOI 10.1002/j.1460-2075.1991.tb04934.x; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROBISHAW JD, 1992, BIOCHEM J, V286, P677, DOI 10.1042/bj2860677; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; SUMMERS MD, 1987, MANUAL METHODS BACUL, P1; THISSEN JA, 1993, J BIOL CHEM, V268, P13780; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	36	90	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9067	9073						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132644				2022-12-25	WOS:A1994NB41100068
J	OSTANIN, K; SAEED, A; VANETTEN, RL				OSTANIN, K; SAEED, A; VANETTEN, RL			HETEROLOGOUS EXPRESSION OF HUMAN PROSTATIC ACID-PHOSPHATASE AND SITE-DIRECTED MUTAGENESIS OF THE ENZYME ACTIVE-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPRO-ALPHA-FACTOR; PHOSPHOTYROSYL PROTEIN PHOSPHATASE; 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; SACCHAROMYCES-CEREVISIAE; STRUCTURAL GENE; BOVINE HEART; YEAST; INTERMEDIATE; PHOSPHORYLATION; DEPENDENCE	Earlier covalent modification experiments indicated that histidine, arginine, and carboxylic acid residues were involved in the catalytic mechanism of the acid phosphatase enzyme from human prostate. The present study utilizes site-directed mutagenesis to evaluate the catalytic importance of 7 residues of human prostatic phosphatase, namely His(12), His(257), Asp(258), Arg(11), Arg(15), Arg(54), and Arg(79), which are highly conserved in the sequences of high molecular weight acid phosphatases. Both wild type and mutant enzymes were expressed in the yeast Saccharomyces cerevisiae as fusions to a leader peptide of prepro-alpha-factor, which resulted in the secretion of processed proteins into the culture media. The kinetic parameters of the recombinant wild type enzyme were shown to be effectively identical with those of the native protein. The circular dichroism spectra of wild type and mutant proteins were effectively superimposable. Replacement of His(12), which was previously shown to be transiently phosphorylated during catalysis, as well as the adjacent Arg(11), both resulted in >10(4) reductions of enzyme activity. Consistent with a postu lated involvement of arginine residues in substrate binding, large reductions in V-max caused by the R15A and R79A mutations were accompanied by marked increases in K-m. However, the mutation R54A had only small effects on kinetic parameters. Essential roles for both His(257) and Asp(258) were also established. The D258A mutation not only caused larger decreases of V-max toward p-nitrophenyl phosphate compared to the effect of the H257A mutation, but it also caused the reaction to become more sensitive to the nature of the leaving group. It is concluded that His(12) and Asp(258) are involved in the formation of the phosphoenzyme intermediate as an acceptor of the phospho group and a proton donor for the substrate leaving group, respectively, while His(257) may participate in substrate binding or may facilitate the breakdown of the phosphoenzyme by maintaining the protonated state of the phosphorylated His(12) residue.	PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIAID NIH HHS [AI 27713] Funding Source: Medline; NIGMS NIH HHS [GM 27003] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027003] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHSTETTER T, 1985, EMBO J, V4, P173, DOI 10.1002/j.1460-2075.1985.tb02333.x; BAJWA W, 1984, NUCLEIC ACIDS RES, V12, P7721, DOI 10.1093/nar/12.20.7721; BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; BEGGS JD, 1981, A BENZON S, V16, P383; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAKE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P4642, DOI 10.1073/pnas.81.15.4642; BRAKE AJ, 1989, YEAST GENETIC ENG, P269; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; DAVIDSON RE, 1990, THESIS PURDUE U W LA; DUNCAN PH, 1984, CLIN CHEM, V30, P1327; GUAN KL, 1991, J BIOL CHEM, V266, P17026; Huggins C, 1941, CANCER RES, V1, P293; HULTQUIS.DE, 1968, BIOCHIM BIOPHYS ACTA, V153, P329, DOI 10.1016/0005-2728(68)90078-9; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN K, 1992, J BIOL CHEM, V267, P19163; LINDQVIST Y, 1993, J BIOL CHEM, V268, P20744; MCTIGUE JJ, 1978, BIOCHIM BIOPHYS ACTA, V523, P422, DOI 10.1016/0005-2744(78)90044-X; MCTIGUE JJ, 1978, BIOCHIM BIOPHYS ACTA, V523, P407, DOI 10.1016/0005-2744(78)90043-8; MYASNIKOV AN, 1991, CHEM ABSTR P43519M, V115; OSTANIN K, 1993, J BIOL CHEM, V268, P20778; OSTANIN K, 1992, J BIOL CHEM, V267, P22830; OSTANIN K, 1989, Patent No. 4698215; OSTROWSKI W, 1978, BIOCHIM BIOPHYS ACTA, V526, P147, DOI 10.1016/0005-2744(78)90299-1; OSTROWSKI W, 1980, MALE ACCESSORY SEX G, P197; PILKIS SJ, 1987, J BIOL CHEM, V262, P12672; RISLEY J M, 1990, Journal of Protein Chemistry, V9, P366; Rose Z B, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P211; ROTHMAN JH, 1986, P NATL ACAD SCI USA, V83, P3248, DOI 10.1073/pnas.83.10.3248; SAINI MS, 1979, BIOCHIM BIOPHYS ACTA, V568, P370, DOI 10.1016/0005-2744(79)90305-X; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER G, 1993, EMBO J, V12, P2609, DOI 10.1002/j.1460-2075.1993.tb05921.x; SCHWARTZ JH, 1961, P NATL ACAD SCI USA, V47, P1996, DOI 10.1073/pnas.47.12.1996; SHERMAN F, 1978, COLD SPRING HARBOR L; TAULER A, 1990, J BIOL CHEM, V265, P15617; VANETTEN RL, 1977, BIOCHIM BIOPHYS ACTA, V484, P386, DOI 10.1016/0005-2744(77)90094-8; VANETTEN RL, 1991, J BIOL CHEM, V266, P2313; VANETTEN RL, 1982, ANN NY ACAD SCI, V390, P27; VINCENT JB, 1992, TRENDS BIOCHEM SCI, V17, P105, DOI 10.1016/0968-0004(92)90246-6; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; ZHANG ZY, 1991, BIOCHEMISTRY-US, V30, P8954, DOI 10.1021/bi00101a006; ZSEBO KM, 1986, J BIOL CHEM, V261, P5858	50	57	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8971	8978						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132635				2022-12-25	WOS:A1994NB41100054
J	SZWEDA, LI				SZWEDA, LI			AGE-RELATED INCREASE IN LIVER RETINYL PALMITATE - RELATIONSHIP TO LIPOFUSCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A; LIPID-PEROXIDATION; AGING RATS; FLUORESCENT; PRODUCTS; TISSUES; INVOLVEMENT; SUBSTANCES; STORAGE	Lipofuscin is a general term assigned to fluorescent material that accumulates in cells as they age. It is apparent from this study that the fluorescent intensity of detergent-solubilized liver from Fisher-344 rats increased as a function of age. The fluorophore responsible for this increase was extracted with methanol and could be resolved from other cellular components when the methanol extracts were chromatographed over a re verse phase column. This compound was identified as retinyl palmitate and was found to increase throughout the entire life of the Fisher-344 rat (2-24 months), from a value of 0.26-1.77 mg/g of liver. In addition, the results presented here demonstrate that concentration, time between extraction and analysis, exposure to light, and degree of purity affect the observed fluorescent properties of retinyl palmitate. These factors affect many fluorophores and are likely to be, at least in part, responsible for the multiplicity of reported properties of lipofuscin. As has been reported for lipofuscin, retinyl palmitate accumulates in intracellular granules and exhibits fluorescence between 450 and 600 nm. Due to these similarities, the relationship between retinyl palmitate and lipofuscin warrants further investigation.			SZWEDA, LI (corresponding author), NHLBI,BIOCHEM LAB,BLDG 3,RM 221,BETHESDA,MD 20892, USA.							BANKSON DD, 1989, EXP GERONTOL, V24, P127, DOI 10.1016/0531-5565(89)90023-5; BHAT PV, 1983, J CHROMATOGR, V272, P269, DOI 10.1016/S0378-4347(00)86129-0; CHIO KS, 1969, SCIENCE, V166, P1535, DOI 10.1126/science.166.3912.1535; CHIO KS, 1969, BIOCHEMISTRY-US, V8, P2821, DOI 10.1021/bi00835a019; CSALLANY AS, 1976, LIPIDS, V11, P412, DOI 10.1007/BF02532849; ELDRED GE, 1989, FREE RADICAL BIO MED, V7, P157, DOI 10.1016/0891-5849(89)90007-5; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FERLAND G, 1992, J GERONTOL, V47, pB3, DOI 10.1093/geronj/47.1.B3; FLETCHER BL, 1973, ANAL BIOCHEM, V52, P1, DOI 10.1016/0003-2697(73)90327-8; GANGULY J, 1989, BIOCH VITAMIN A; GUERRANT N. B., 1949, JOUR NUTRITION, V37, P37; HARMAN D, 1990, LIPOFUSCIN CEROID PI, P3; IVY GO, 1991, MECH AGEING DEV, V57, P213, DOI 10.1016/0047-6374(91)90048-5; KAHAN J, 1967, ACTA CHEM SCAND, V21, P2515, DOI 10.3891/acta.chem.scand.21-2515; KATZ ML, 1987, MECH AGEING DEV, V39, P81, DOI 10.1016/0047-6374(87)90088-1; KIKUGAWA K, 1987, CHEM PHYS LIPIDS, V44, P277, DOI 10.1016/0009-3084(87)90054-5; KIRK JE, 1962, VITAM HORM, V20, P67, DOI 10.1016/S0083-6729(08)60716-5; MOBARHAN S, 1991, J NUTR, V121, P510, DOI 10.1093/jn/121.4.510; Olson JA., 1991, HDB VITAMINS, P1; PLANTA CV, 1962, HELV CHIM ACTA, V45, P548, DOI 10.1002/hlca.19620450218; PORTA EA, 1991, ARCH GERONTOL GERIAT, V12, P303, DOI 10.1016/0167-4943(91)90036-P; Sobotka H, 1943, J AM CHEM SOC, V65, P1959, DOI 10.1021/ja01250a042; SUNDBOOM J, 1984, EXP GERONTOL, V19, P257, DOI 10.1016/0531-5565(84)90021-4; TOTARO EA, 1985, ADV AGE PIGMENTS RES, V64; TSUCHIDA M, 1987, CHEM PHYS LIPIDS, V44, P297, DOI 10.1016/0009-3084(87)90055-7; WOLFE LS, 1977, SCIENCE, V195, P1360, DOI 10.1126/science.841336; ZSNAGY I, 1988, INT C SERIES, V782	27	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8712	8715						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132600				2022-12-25	WOS:A1994NB41100017
J	SUCHARD, SJ; NAKAMURA, T; ABE, A; SHAYMAN, JA; BOXER, LA				SUCHARD, SJ; NAKAMURA, T; ABE, A; SHAYMAN, JA; BOXER, LA			PHOSPHOLIPASE D-MEDIATED DIRADYLGLYCEROL FORMATION COINCIDES WITH H2O2 AND LACTOFERRIN RELEASE IN ADHERENT HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; PROTEIN-KINASE-C; RESPIRATORY BURST; NADPH OXIDASE; PHOSPHATIDIC-ACID; SUBCELLULAR-LOCALIZATION; PHOSPHATIDYLCHOLINE HYDROLYSIS; SUPEROXIDE GENERATION; RECEPTOR EXPRESSION; B-CYTOCHROME	Polymorphonuclear leukocytes (PMNs) adherent to fibrinogen exhibit a delay in the onset of the respiratory burst in response to N-formyl-methionyl-leucyl-phenylalanine (fMLP). Previously, we demonstrated that H2O2 release in adherent PMNs coincides with the exocytosis of lactoferrin containing specific granules. Since diradylglycerol (DRG) has been implicated in PMN secretion and oxidant release, we measured DRG formation during PMN adhesion to fibrinogen. PMNs were added to fibrinogen-coated plastic in the presence of fMLP, and H2O2 release, lactoferrin release, and DRG formation measured over a time course of 120 min. H2O2 and lactoferrin release were not apparent until 45-60 min, reaching maximal levels by 120 min. In contrast, DRG concentration increased by 15-30 min, from 275 +/- 27 pmol/mg of protein in resting cells to 600 +/- 173 pmol/mg protein in cells exposed to fMLP. DRG levels returned to base line by 30-45 min (383 +/- 32 pmol/mg of protein) before increasing again between 60 and 120 min (944 +/- 230 pmol/mg of protein and 1632 +/- 351 pmol/mg of protein, respectively). Propranolol, an inhibitor of phosphatidate phosphohydrolase, caused a dose-dependent inhibition of both H2O2 and lactoferrin release, with maximal inhibition at 50-100 mu M. Propranolol also inhibited the second, but not the first phase of DRG formation. Similarly, ethanol treatment completely blocked H2O2 and lactoferrin release, and the second phase of DRG formation. In the presence of ethanol, phospholipase D (PLD)-mediated formation of [H-3] phosphatidylethanol from H-3-O-alkyl phosphatidylcholine corresponded to the second, but not the first, phase of DRG formation (23,169 +/- 2,017 cpm/mg protein, ethanol versus 2,696 +/- 261 cpm/mg protein, control). These data indicate that DRG, generated through the activation of PLD, plays an important role in degranulation and oxidant release in adherent PMNs.	UNIV MICHIGAN,DEPT INTERNAL MED,DIV NEPHROL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	SUCHARD, SJ (corresponding author), UNIV MICHIGAN,DEPT PEDIAT,DIV HEMATOL ONCOL,RM 7510B,MSRB-1,BOX 0684,ANN ARBOR,MI 48109, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020065, R29AI026863] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31963] Funding Source: Medline; NIAID NIH HHS [AI26863, AI20065] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; BABIOR BM, 1981, METHODS HEMATOLOGY L, P1; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BIRGENS HS, 1985, SCAND J HAEMATOL, V34, P326; BJERRUM OW, 1989, EUR J HAEMATOL, V43, P67; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BORREGAARD N, 1984, J BIOL CHEM, V259, P47; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BOXER LA, 1988, HEMATOL ONCOL CLIN N, V2, P101; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CLARK RA, 1987, J BIOL CHEM, V262, P4065; COX CC, 1986, J IMMUNOL, V136, P4611; CURNUTTE JT, 1979, J CLIN INVEST, V63, P637, DOI 10.1172/JCI109346; DELLABIANCA V, 1990, J IMMUNOL, V144, P1411; DELLABIANCA V, 1993, J LEUKOCYTE BIOL, V53, P427; DELLABIANCA V, 1991, BIOCHEM BIOPH RES CO, V177, P948, DOI 10.1016/0006-291X(91)90630-P; DOUGHERTY RW, 1989, J BIOL CHEM, V264, P11263; ENGLISH D, 1991, BLOOD, V77, P2746; FU T, 1992, BIOCHEM J, V283, P347, DOI 10.1042/bj2830347; HAINES KA, 1991, J CELL BIOL, V114, P433, DOI 10.1083/jcb.114.3.433; HUGHES BJ, 1992, J CLIN INVEST, V90, P1687, DOI 10.1172/JCI116041; JACONI MEE, 1991, J CELL BIOL, V112, P1249, DOI 10.1083/jcb.112.6.1249; KESSELS GCR, 1991, J BIOL CHEM, V266, P15870; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; MAHER RJ, 1993, J CELL PHYSIOL, V156, P226, DOI 10.1002/jcp.1041560203; MARTIN TW, 1988, BIOCHIM BIOPHYS ACTA, V962, P282, DOI 10.1016/0005-2760(88)90258-5; NATHAN C, 1990, J CELL BIOL, V111, P2171, DOI 10.1083/jcb.111.5.2171; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; O'SHEA JJ, 1985, J IMMUNOL, V134, P2580; PERRY DK, 1992, J IMMUNOL, V149, P2749; PREISS J, 1986, J BIOL CHEM, V261, P8597; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SCHLEIFFENBAUM B, 1989, J IMMUNOL, V142, P3537; SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; SINGER II, 1989, J CELL BIOL, V109, P3169, DOI 10.1083/jcb.109.6.3169; SOZZANI S, 1992, J BIOL CHEM, V267, P20481; SUCHARD SJ, 1991, J IMMUNOL, V146, P3945; SUCHARD SJ, 1994, J IMMUNOL, V152, P290; SUCHARD SJ, 1992, BIOCHEM J, V284, P513, DOI 10.1042/bj2840513; THOMPSON NT, 1990, BIOCHEM J, V271, P209, DOI 10.1042/bj2710209; TYAGI SR, 1988, J BIOL CHEM, V263, P13191; TYAGI SR, 1989, J BIOL CHEM, V264, P12977; VANVELDHOVEN PP, 1988, BIOCHIM BIOPHYS ACTA, V959, P185, DOI 10.1016/0005-2760(88)90030-6; YANG SF, 1967, J BIOL CHEM, V242, P477; YOON PS, 1987, J IMMUNOL, V138, P259	49	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8063	8068						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132530				2022-12-25	WOS:A1994NB40900038
J	BEG, AA; BALDWIN, AS				BEG, AA; BALDWIN, AS			ACTIVATION OF MULTIPLE NF-KAPPA-B/REL DNA-BINDING COMPLEXES BY TUMOR-NECROSIS-FACTOR	ONCOGENE			English	Note							B P50; SUBUNIT; REL; TRANSCRIPTION; PRECURSOR; PRODUCT; GENE; P65	NF-kappa B is an inducible transcription factor that regulates the expression of numerous genes involved in immune and inflammation responses and in cellular growth control. Typically, NF-kappa B is localized in the cytoplasm complexed with members of the I kappa B family. The most well characterized form of NF-kappa B is comprised of a heterodimer of a 50 kD (p50/NFKB1) and a 65 kD (p65/RelA) protein. This heterodimeric protein was thought to be primarily responsible for transcriptional regulation of target genes. However, recent studies have led to the identification of other kappa B binding proteins such as c-Rel, RelB and p52 (NFKB2/lyt-10) although their role in gene regulation has been less clear. Here, using gel mobility shift assays as well as a highly sensitive DNA-protein crosslinking assay, we provide evidence for the existence of multiple tumor necrosis factor (TNF)inducible kappa B binding complexes containing various members of the NF-kappa B/Rel family, namely p50 and p65 as well as the c-Rel and p52 oncoproteins. Dimeric complexes containing various combinations of these proteins appear rapidly in nuclei of TNF-alpha-stimulated cells and include, along with a p50-p65 heterodimer, p50-c-Rel, p65-c-Rel, p52-c-Rel and p52-p65 complexes. The presence of multiple inducible complexes containing distinct combinations of NF-kappa B/Rel family members indicate that specific kappa B responsive genes may be regulated in an NF-kappa B subunit-dependent manner.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NCI NIH HHS [CA52515] Funding Source: Medline; NIAID NIH HHS [AI35098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098, R01AI035098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GRILLI M, 1993, INT REV CYTOL, V143, P1; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SPRINGER TA, 1989, CURRENT PROTOCOLS MO, V2; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	25	58	63	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1487	1492						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152812				2022-12-25	WOS:A1994NH40100023
J	MONTANO, X; SHAMSHER, M; WHITEHEAD, P; DAWSON, K; NEWTON, J				MONTANO, X; SHAMSHER, M; WHITEHEAD, P; DAWSON, K; NEWTON, J			ANALYSIS OF P53 IN HUMAN CUTANEOUS MELANOMA CELL-LINES	ONCOGENE			English	Note							MALIGNANT-MELANOMA; SV40-TRANSFORMED CELLS; MELANOCYTIC LESIONS; METASTATIC CAPACITY; DYSPLASTIC NEVUS; EXPRESSION; PROTEIN; MUTATIONS; GENE; SUPPRESSOR	Mutations in the p53 tumour suppressor gene have been detected in a variety of human malignancies. Mutations have been found predominantly in conserved regions two to five. Our aim was to analyse p53 at the protein and DNA level in seven melanoma cell lines of cutaneous origin (HMB-2, DX3, LT5.1, MJM, SK23, A375P and A375M), including two parental/metastatic derivatives (A375P and A375M; DX3 and LT5.1). By immunohistochemical staining with three mouse monoclonal antibodies and a rabbit polyclonal serum, it was possible to observe differential nuclear expression of p53. The quantitation of p53 protein levels by ELISA correlated with the nuclear staining pattern. Western blotting showed an intact p53 protein in all cell lines; p53 was polymorphic in three cell lines (MJM, A375P and A375M). DNA sequencing studies showed that all cell lines had wild type p53. These results suggest that p53 is unlikely to play a significant role in the genesis of cutaneous melanoma.	LONDON HOSP,COLL MED,DEPT EXPTL DERMATOL,LONDON E1 2BL,ENGLAND	University of London; Queen Mary University London	MONTANO, X (corresponding author), LONDON HOSP,COLL MED,IMPERIAL CANC RES FUND,SKIN TUMOUR LAB,56 ASHFIELD ST,LONDON E1 2BL,ENGLAND.							ALBINO AP, 1991, J CUTAN PATHOL, V18, P273, DOI 10.1111/j.1600-0560.1991.tb01235.x; BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BEENKEN SW, 1991, NUCLEIC ACIDS RES, V19, P4747, DOI 10.1093/nar/19.17.4747; BERGMAN W, 1986, ANN HUM GENET, V50, P249, DOI 10.1111/j.1469-1809.1986.tb01046.x; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BURNS PA, 1991, ONCOGENE, V6, P2363; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CARBONE D, 1991, ONCOGENE, V6, P1691; CLARK WH, 1978, ARCH DERMATOL, V114, P732, DOI 10.1001/archderm.114.5.732; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HARLOW E, 1988, ANTIBODIES LABORATOR; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KOZLOWSKI JM, 1984, J NATL CANCER I, V72, P913; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LASSAM NJ, 1993, CANCER RES, V53, P2235; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MARSHALL JF, 1991, INT J CANCER, V49, P924, DOI 10.1002/ijc.2910490621; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MOLES JP, 1993, ONCOGENE, V8, P583; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MONTENARH M, 1992, ONCOGENE, V7, P1673; MUKAI S, 1986, CANCER GENET CYTOGEN, V22, P45, DOI 10.1016/0165-4608(86)90136-6; NEWTON JA, 1992, DIAGNOSIS MANAGEMENT, P53; ORMEROD EJ, 1986, CANCER RES, V46, P884; OSTERLIND A, 1988, INT J CANCER, V42, P319, DOI 10.1002/ijc.2910420303; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P445, DOI 10.1002/mc.2940040606; RADDY P, 1992, CANCER RES, V52, P3804; SANGER F, 1973, P NATL ACAD SCI USA, V70, P1209, DOI 10.1073/pnas.70.4.1209; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; STRETCH JR, 1991, CANCER RES, V51, P5976; TOBAL K, 1992, BRIT J CANCER, V66, P900, DOI 10.1038/bjc.1992.382; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOLKENANDT M, 1991, PIGM CELL RES, V4, P35, DOI 10.1111/j.1600-0749.1991.tb00311.x; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	46	61	62	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1455	1459						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152807				2022-12-25	WOS:A1994NH40100018
J	ZHU, GC; DECKER, SJ; MACLEAN, D; MCNAMARA, DJ; SINGH, J; SAWYER, TK; SALTIEL, AR				ZHU, GC; DECKER, SJ; MACLEAN, D; MCNAMARA, DJ; SINGH, J; SAWYER, TK; SALTIEL, AR			SEQUENCE SPECIFICITY IN THE RECOGNITION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR BY THE ABL SRC-HOMOLOGY-2 DOMAIN	ONCOGENE			English	Article							C-ABL; ONCOGENE PRODUCT; TYROSINE KINASES; PHOSPHOLIPASE-C; ABELSON VIRUS; CELL-LINE; PROTEINS; BINDING; SH2; TRANSFORMATION	The transforming activity of the abl gene product requires a functional src homology 2 (SH2) domain. An assay was developed to evaluate this function by examining binding of a bacterially-expressed abl SH2 domain to the activated EGF receptor, used as a surrogate tyrosine phosphorylated protein. The sequence specificity of this interaction has been explored with a series of point mutants of EGF receptor. Analysis of equilibrium binding reveals that substitution of Tyr(1086) for Phe in the EGF receptor produced a 10-fold reduced affinity for abl SH2 domain binding as compared to the wildtype receptor. Moreover, a phosphorylated peptide modeled on the sequences surrounding Tyr(1086) specifically inhibits abl SH2 binding, with an IC50 of approximately 10 mu M. Evaluation of a series of additional peptides, modeled on the Tyr(1086) sequence, revealed that the carboxy terminal residues directly next to the phosphotyrosine were particularly critical to this binding. Molecular modeling studies of the pTyr(1086) peptide revealed the potential hydrophobic, ionic and hydrogen bonding interactions involved in the functions of the abl SH2 domain.	WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES, DEPT SIGNAL TRANSDUCT, ANN ARBOR, MI 48105 USA; WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES, DEPT CHEM, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT MICROBIOL, ANN ARBOR, MI 48109 USA	Pfizer; Pfizer; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; HOLM L, 1992, PROTEINS, V14, P213, DOI 10.1002/prot.340140208; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MATUDA M, 1990, SCIENCE, V248, P1537; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, COLD SPRING HARB SYM, V53, P907, DOI 10.1101/SQB.1988.053.01.104; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; MITCHELL JBO, 1993, J CHEM SOC FARADAY T, V89, P2619, DOI 10.1039/ft9938902619; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; Saltiel A R, 1993, Curr Opin Neurobiol, V3, P352, DOI 10.1016/0959-4388(93)90128-L; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU G, 1993, J BIOL CHEM, V266, P12964; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559	32	11	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1994	9	5					1379	1385						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152798				2022-12-25	WOS:A1994NH40100009
J	SCHLOSSMANN, J; DIETMEIER, K; PFANNER, N; NEUPERT, W				SCHLOSSMANN, J; DIETMEIER, K; PFANNER, N; NEUPERT, W			SPECIFIC RECOGNITION OF MITOCHONDRIAL PREPROTEINS BY THE CYTOSOLIC DOMAIN OF THE IMPORT RECEPTOR MOM72	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-ATP CARRIER; PROTEIN IMPORT; SACCHAROMYCES-CEREVISIAE; PRECURSOR PROTEINS; ADP/ATP CARRIER; OUTER-MEMBRANE; YEAST MITOCHONDRIA; GENE; IDENTIFICATION; TRANSLOCATION	The import receptor MOM72 constitutes part of the protein translocation machinery of the outer mitochondrial membrane, the receptor general insertion pore complex. The protein contains a membrane anchor at the NH2 terminus and a large cytosolic domain. In yeast and Neurospora crassa the cytosolic domain comprises about 570-580 amino acid residues. The cytosolic domain of yeast MOM72 was purified after expression in Escherichia coli as a homogeneous monomeric protein. It can recognize precursor proteins as demonstrated by its ability to compete for binding and import into the mitochondria and to physically interact with preproteins. A subset of preproteins including the ADP/ATP carrier and the phosphate carrier interact with very high affinity, precursors that are known to be targeted via MOM72. Thus, the cytosolic domain of MOM72 plays a critical function in the recognition of preproteins by directly binding to precursor proteins and thereby facilitating their targeting to mitochondria.	UNIV MUNICH, INST PHYSIOL CHEM, D-80336 MUNICH, GERMANY	University of Munich			Schlossmann, Jens/I-7743-2016; Pfanner, Nikolaus/AAV-7878-2021	Schlossmann, Jens/0000-0002-2550-6839; 				BAKER KP, 1990, NATURE, V348, P6025; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAUM G, 1990, NATURE, V348, P605; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; DIETMEIER K, 1993, J BIOL CHEM, V268, P25958; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HARKNESS TAA, 1994, GENETICS, V136, P107; HARKNESS TAA, 1994, IN PRESS J CELL BIOL, V124; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HASE T, 1983, EMBO J, V2, P2169, DOI 10.1002/j.1460-2075.1983.tb01718.x; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HINES V, 1993, J BIOL CHEM, V268, P449; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HORST M, 1993, EMBO J, V12, P3035, DOI 10.1002/j.1460-2075.1993.tb05972.x; INIS MA, 1988, SCIENCE, V86, P8432; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Kyshe-Andersen J, 1984, J BIOCHEM BIOPH METH, V10, P203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; MAHLKE K, 1991, THESIS U MUNICH; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; MILLAR DG, 1993, J BIOL CHEM, V268, P18403; MOCZKO M, 1993, FEBS LETT, V326, P251, DOI 10.1016/0014-5793(93)81801-6; MOCZKO M, 1992, FEBS LETT, V310, P265, DOI 10.1016/0014-5793(92)81345-M; NEUPERT W, 1993, PHILOS T ROY SOC B, V339, P355, DOI 10.1098/rstb.1993.0034; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1987, J BIOL CHEM, V262, P14851; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; SCHULTZ J, 1987, MOL CELL BIOL, V7, P3637, DOI 10.1128/MCB.7.10.3637; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMAGULA CS, 1988, J CELL BIOCHEM, V36, P323, DOI 10.1002/jcb.240360402; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; VOOS W, 1993, J CELL BIOL, V123, P119, DOI 10.1083/jcb.123.1.119; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; ZIMMERMANN R, 1980, EUR J BIOCHEM, V109, P217, DOI 10.1111/j.1432-1033.1980.tb04787.x	52	74	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11893	11901						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163488				2022-12-25	WOS:A1994NG37700036
J	CAPPS, GG; ZUNIGA, MC				CAPPS, GG; ZUNIGA, MC			CLASS-I HISTOCOMPATIBILITY MOLECULE ASSOCIATION WITH PHOSPHORYLATED CALNEXIN - IMPLICATIONS FOR RATES OF INTRACELLULAR-TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; TRANSPLANTATION ANTIGENS; PEPTIDE BINDING; VIRAL PEPTIDES; CELL-SURFACE; T-CELLS; COMPLEX; PROTEIN; BETA-2-MICROGLOBULIN; CHAPERONE	Recent studies have shown that the endoplasmic reticulum (ER)-resident protein, calnexin, associates with class I major histocompatibility complex (MHC) molecules early in their biosynthesis. It has been suggested that calnexin participates in the assembly of class I MHC molecules or in the retention within the ER of unassembled class I molecules. We have examined the role of phosphorylation of calnexin in its association with mouse class I MHC molecules. We show that phosphocalnexin associates with H-2L(d) and H-2D(b) molecules but not with H-2K(b) and H-2D(d) molecules, although calnexin-H2K(b) association can be demonstrated. These observations are interesting in light of the fact that H-2K(b) and H-2D(d) molecules are transported out of the ER more rapidly than are H-2L(d) and H-2D(b) molecules. H-2L(d) and H-2D(b) molecules differ in amino acid sequence only in their membrane-distal alpha1 and alpha2 domains. Nevertheless, the affinity of phosphocalnexin for H-2L(d) is greater than its affinity for H-2D(b). Furthermore, H-2D(b) becomes endoglycosidase H-resistant more slowly in cells in which it associates with phosphocalnexin than in cells in which it does not. Ca2+ ionophore A23187 prevents association of phosphocalnexin with H-2L(d) molecules in vivo but does not cause the disruption of phosphocalnexin-H-2L(d) complexes after they have formed. A23187 does not prevent assembly of H-2L(d)-beta2-microglobulin (beta2-m) heterodimers. Furthermore, phosphocalnexin is found associated with H-2L(d) molecules regardless of their state of assembly with beta2-m and antigenic peptide. These results suggest that phosphocalnexin association with class I MHC molecules does not play a role in assembly of the class I MHC-beta2-m-peptide complex nor in preventing release of unassembled class I molecules from the ER but may otherwise influence their rate of transport through the ER.	UNIV CALIF SANTA CRUZ,SINSHEIMER LABS,DEPT BIOL,SANTA CRUZ,CA 95064	University of California System; University of California Santa Cruz								AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; BOYD LF, 1992, P NATL ACAD SCI USA, V89, P2242, DOI 10.1073/pnas.89.6.2242; BURKE T, 1989, MOL IMMUNOL, V26, P1095, DOI 10.1016/0161-5890(89)90053-9; CALA SE, 1993, J BIOL CHEM, V268, P2969; CAPPS GG, 1993, J BIOL CHEM, V268, P21263; CAPPS GG, 1990, BIOTECHNIQUES, V8, P62; CAPPS GG, 1993, J IMMUNOL, V151, P159; CAPPS GG, 1989, J CELL BIOL, V108, P1317, DOI 10.1083/jcb.108.4.1317; CORR M, 1992, J EXP MED, V176, P1681, DOI 10.1084/jem.176.6.1681; DAVID W, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DERES K, 1992, EUR J IMMUNOL, V22, P1603, DOI 10.1002/eji.1830220638; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; EVANS GA, 1982, NATURE, V300, P755, DOI 10.1038/300755a0; Falk K, 1993, Semin Immunol, V5, P81, DOI 10.1006/smim.1993.1012; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GALVIN K, 1992, P NATL ACAD SCI USA, V89, P8452, DOI 10.1073/pnas.89.18.8452; GILCHRIST JSC, 1993, J BIOL CHEM, V268, P4291; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; JONES PP, 1980, SELECTED METHODS CEL, P398; KAARIAINEN L, 1984, ANNU REV MICROBIOL, V38, P91, DOI 10.1146/annurev.mi.38.100184.000515; KLEIN J, 1986, NATURAL HIST MAJOR H, P609; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MILNER RE, 1991, J BIOL CHEM, V266, P7155; OU WJ, 1992, J BIOL CHEM, V267, P23789; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PARKER KC, 1992, J IMMUNOL, V149, P3580; PARKER KC, 1992, J IMMUNOL, V149, P1896; PULLEN JK, 1992, J IMMUNOL, V148, P953; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; ROCK KL, 1992, P NATL ACAD SCI USA, V89, P8918, DOI 10.1073/pnas.89.19.8918; SMITH JD, 1992, J EXP MED, V175, P191, DOI 10.1084/jem.175.1.191; TOWNSEND A, 1989, COLD SH Q B, V54, P299; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; WADA I, 1991, J BIOL CHEM, V266, P19599; WALLNY HJ, 1990, NATURE, V343, P275, DOI 10.1038/343275a0; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X; ZUNIGA MC, 1983, CELL, V34, P535, DOI 10.1016/0092-8674(83)90386-0; ZUNIGA MC, 1986, J CELL BIOL, V102, P1, DOI 10.1083/jcb.102.1.1	44	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11634	11639						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157696				2022-12-25	WOS:A1994NF96600098
J	KENNEDY, SP; WEED, SA; FORGET, BG; MORROW, JS				KENNEDY, SP; WEED, SA; FORGET, BG; MORROW, JS			A PARTIAL STRUCTURAL REPEAT FORMS THE HETERODIMER SELF-ASSOCIATION SITE OF ALL BETA-SPECTRINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE SPECTRIN; FUNCTIONAL DOMAINS; MEMBRANE-PROTEINS; IDENTIFICATION; CYTOSKELETON; OLIGOMERS; CDNA; ELLIPTOCYTOSIS; PEPTIDES; SEQUENCE	The self-polymerization of alphabeta-spectrin heterodimers to form tetramers and higher oligomers is central to its role as a membrane stabilizer and organizer. Mutations near the amino terminus of alphaISIGMA1-spectrin or the COOH terminus of betaISIGMA1-spectrin often lead to profound impairment of heterodimer polymerization and to hemolytic disease of varying severity. Previous studies using an 80-kDa univalent fragment of alphaISIGMA1-spectrin have established that the amino-terminal segment of alphaISIGMA1-spectrin mediates the association of the alpha subunit with either intact heterodimers or with isolated beta-spectrin (betaISIMGA1). However, the nature of the self-association site in beta-spectrin has remained unclear. In the present study, native beta-spectrin and recombinant beta-spectrin peptides representing COOH-terminal portions of two alternative transcripts of the gene on chromosome 2 (betaISIGMA1 or ''erythrocyte'' spectrin and betaISIGMA2 or ''muscle'' spectrin), and one transcript of the gene on chromosome 14 (betaIISIGMA1 or ''beta(G)-fodrin'') have been examined for their ability to bind either intact alphabeta-spectrin or the alphaI-spectrin 80-kDa univalent fragment. Deletion of the nonhomologous beta-spectrin sequence downstream of repeat 17 (spectrin domain III) had no discernible effect on binding. Truncations proximal to codon 2085 of betaISIGMA1-spectrin demonstrated a precipitous loss of activity, accounted for by a loss of both binding affinity and capacity. Further truncations to repeat 16 (codon 1979) restored binding activity to levels approximating that of the intact molecule. Repeat 16/17 and 17/16 chimeras displayed reduced binding activity. Collectively, these data indicate that the beta-subunit self-association site is highly sensitive to conformation, involves widespread interactions within the 17th repeat unit, is largely independent of sequences in domain III, and can be recreated by the deletion of all residues distal to the COOH end (codon 1979) of the 16th and presumably other spectrin sequence repeat units. All beta-spectrins appear to use this binding motif, regardless of the nature of the nonhomologous sequence in domain III.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University				Weed, Scott/0000-0001-7033-9999				CIANCI CD, 1988, J CELL BIOCHEM, V37, P301, DOI 10.1002/jcb.240370305; COLEMAN TR, 1989, CELL MOTIL CYTOSKEL, V12, P248, DOI 10.1002/cm.970120406; COLEMAN TR, 1989, CELL MOTIL CYTOSKEL, V12, P225, DOI 10.1002/cm.970120405; DELAUNAY J, 1993, SEMIN HEMATOL, V30, P21; DESILVA TM, 1992, BIOCHEMISTRY-US, V31, P10872, DOI 10.1021/bi00159a030; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GALLAGHER PG, 1993, SEMIN HEMATOL, V30, P4; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; HARRIS AS, 1988, J NEUROSCI, V8, P2640; HU RJ, 1992, J BIOL CHEM, V267, P18715; HU RJ, 1991, J BIOL CHEM, V266, P18200; KENNEDY S P, 1991, Journal of Cell Biology, V115, p42A; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; KENNEDY SP, 1994, IN PRESS FASEB J; KOTULA L, 1993, J BIOL CHEM, V268, P14788; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Maniatis T., 1982, MOL CLONING; MORROW JS, 1983, METHOD ENZYMOL, V96, P298; MORROW JS, 1981, J SUPRAMOL STR CELL, V17, P275, DOI 10.1002/jsscb.380170308; MORROW JS, 1980, P NATL ACAD SCI-BIOL, V77, P6592, DOI 10.1073/pnas.77.11.6592; MORROW JS, 1981, J CELL BIOL, V88, P463, DOI 10.1083/jcb.88.2.463; PALEK J, 1992, BLOOD, V80, P308; SPEICHER DW, 1983, J BIOL CHEM, V258, P4931; SPEICHER DW, 1992, J BIOL CHEM, V267, P14775; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SPEICHER DW, 1993, J BIOL CHEM, V268, P4227; SPEICHER DW, 1980, P NATL ACAD SCI-BIOL, V77, P5673, DOI 10.1073/pnas.77.10.5673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSE WT, 1990, J CLIN INVEST, V86, P909, DOI 10.1172/JCI114792; TSE WT, 1991, BLOOD, V78, P517; WEAVER DC, 1984, J BIOL CHEM, V259, P6170; WINKELMANN JC, 1993, BLOOD, V81, P3173; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; WINKELMANN JC, 1988, BLOOD, V72, P328; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YURCHENCO PD, 1982, J BIOL CHEM, V257, P9102	39	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11400	11408						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157672				2022-12-25	WOS:A1994NF96600064
J	CLARK, DP; DURELL, S; MALOY, WL; ZASLOFF, M				CLARK, DP; DURELL, S; MALOY, WL; ZASLOFF, M			RANALEXIN - A NOVEL ANTIMICROBIAL PEPTIDE FROM BULLFROG (RANA-CATESBEIANA) SKIN, STRUCTURALLY RELATED TO THE BACTERIAL ANTIBIOTIC, POLYMYXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ANTIBACTERIAL PEPTIDES; FROG-SKIN; BOVINE NEUTROPHILS; AMPHIBIAN SKIN; PIG INTESTINE; IMMUNITY; CDNA; DERMORPHIN; PRECURSOR	Antimicrobial peptides comprise a diverse class of molecules used in host defense by plants, insects, and animals. In this study we have isolated a novel antimicrobial peptide from the skin of the bullfrog, Rana catesbeiana. This 20 amino acid peptide, which we have termed Ranalexin, has the amino acid sequence: NH2-Phe-Leu-Gly-Gly-Leu-Ile-Lys-Ile-Val-Pro-Ala-Met-Ile- Cys-Ala-Val-Thr-Lys-Lys-Cys-COOH, and it contains a single intramolecular disulfide bond which forms a heptapeptide ring within the molecule. Structurally, Ranalexin resembles the bacterial antibiotic, polymyxin, which contains a similar heptapeptide ring. We have also cloned the cDNA for Ranalexin from a metamorphic R. catesbeiana tadpole cDNA library. Based on the cDNA sequence, it appears that Ranalexin is initially synthesized as a propeptide with a putative signal sequence and an acidic amino acid-rich region at its amino-terminal end. Interestingly, the putative signal sequence of the Ranalexin cDNA is strikingly similar to the signal sequence of opioid peptide precursors isolated from the skin of the South American frogs Phyllomedusa sauvagei and Phyllomedusa bicolor. Northern blot analysis and in situ hybridization experiments demonstrated that Ranalexin mRNA is first expressed in R. catesbeiana skin at metamorphosis and continues to be expressed into adulthood.	MAGAININ PHARMACEUT INC,MAGAININ RES INST,PLYMOUTH MEETING,PA 19462; HOSP UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; CHILDRENS HOSP,DIV HUMAN GENET & MOLEC BIOL,PHILADELPHIA,PA 19104; NCI,MATH BIOL LAB,BETHESDA,MD 20892	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; AINSWORTH GC, 1947, NATURE, V160, P263, DOI 10.1038/160263a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARTECZKO I, 1970, ZOOL POLONIAE, V20, P189; BENEDICT RG, 1947, J BACTERIOL, V54, P24; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; BOWLES DJ, 1990, ANNU REV BIOCHEM, V59, P873, DOI 10.1146/annurev.bi.59.070190.004301; CASTEELS P, 1989, EMBO J, V8, P2387, DOI 10.1002/j.1460-2075.1989.tb08368.x; CEVIKBAS A, 1978, TOXICON, V16, P195, DOI 10.1016/0041-0101(78)90038-7; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; DUNN PE, 1986, ANNU REV ENTOMOL, V31, P321, DOI 10.1146/annurev.en.31.010186.001541; ERSPAMER V, 1989, P NATL ACAD SCI USA, V86, P5188, DOI 10.1073/pnas.86.13.5188; FRANK RW, 1990, J BIOL CHEM, V265, P18871; GIBSON BW, 1991, J BIOL CHEM, V266, P23103; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; Helff OM, 1941, J MORPHOL, V68, P303, DOI 10.1002/jmor.1050680206; JONES DE, 1992, J BIOL CHEM, V267, P23216; KREIL G, 1989, EUR J PHARMACOL, V162, P123, DOI 10.1016/0014-2999(89)90611-0; KREIL G, 1984, CURR TOP CELL REGUL, V24, P261; KURIHARA T, 1972, YAKUGA ZASSHI, V92, P129, DOI 10.1248/yakushi1947.92.2_129; LAMBERT J, 1989, P NATL ACAD SCI USA, V86, P262, DOI 10.1073/pnas.86.1.262; LEE JY, 1989, P NATL ACAD SCI USA, V86, P9159, DOI 10.1073/pnas.86.23.9159; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; MATSUYAMA K, 1988, J BIOL CHEM, V263, P17117; MONTECUCCHI PC, 1981, INT J PEPT PROT RES, V17, P275; MOORE KS, 1991, J BIOL CHEM, V266, P19851; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; MORIKAWA N, 1992, BIOCHEM BIOPH RES CO, V189, P184, DOI 10.1016/0006-291X(92)91542-X; MORRIS HR, 1988, TRENDS BIOTECHNOL, V6, P140, DOI 10.1016/0167-7799(88)90083-2; NAKAJIMA K, 1967, CHEM PHARM BULL, V15, P1219; Nakajima T, 1989, Adv Exp Med Biol, V247A, P215; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; RICHTER K, 1990, P NATL ACAD SCI USA, V87, P4836, DOI 10.1073/pnas.87.12.4836; RICHTER K, 1987, SCIENCE, V238, P200, DOI 10.1126/science.3659910; ROMEO D, 1988, J BIOL CHEM, V263, P9573; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; SIANSLY PG, 1947, B J HOPKINS HOSP, V81, P43; SIMMACO M, 1993, FEBS LETT, V324, P159, DOI 10.1016/0014-5793(93)81384-C; SIMMACO M, 1991, EUR J BIOCHEM, V199, P217, DOI 10.1111/j.1432-1033.1991.tb16112.x; STORM DR, 1977, ANNU REV BIOCHEM, V46, P723, DOI 10.1146/annurev.bi.46.070177.003451; TEUBER M, 1970, Z NATURFORSCH PT B, VB 25, P117, DOI 10.1515/znb-1970-0137; VOGLER K, 1964, EXPERIENTIA, V20, P365, DOI 10.1007/BF02147959; VOGLER K, 1960, HELV CHIM ACTA, V43, P1751, DOI 10.1002/hlca.19600430638; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; ZASLOFF M, 1988, P NATL ACAD SCI USA, V85, P910, DOI 10.1073/pnas.85.3.910; ZASLOFF M, 1992, CURR OPIN IMMUNOL, V4, P3, DOI 10.1016/0952-7915(92)90115-U	52	199	213	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10849	10855						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144672				2022-12-25	WOS:A1994NF01700097
J	DAUM, G; REGENASS, S; SAP, J; SCHLESSINGER, J; FISCHER, EH				DAUM, G; REGENASS, S; SAP, J; SCHLESSINGER, J; FISCHER, EH			MULTIPLE FORMS OF THE HUMAN TYROSINE PHOSPHATASE RPTP-ALPHA - ISOZYMES AND DIFFERENCES IN GLYCOSYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROCELLULOSE SHEETS; CLONING; FAMILY; DROSOPHILA; EXPRESSION; TRANSFORMATION; CLEAVAGE; PROTEINS; DOMAINS; MEMBER	Among all the receptor-linked protein-tyrosine-phosphatase RPTP alpha clones described from mammalian tissues, one differed in that it encoded a 9-amino-acid insert 3 residues upstream from the transmembrane segment (Kaplan, R, Morse, B., Huebner, K, Croce, C., Howk, R. Ravera, M., Ricca, G., Jaye, M., and Schlessinger, J. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 7000-7004). Using the polymerase chain reaction technique, simultaneous expression of both isoforms was demonstrated in human T-cell and vascular smooth muscle libraries, as well as in the A431 human epidermal cancer cell Line. Following transient expression in COS-1 cells, each isoform gave rise to two proteins of 100 and 130 kDa, respectively. Endoglycosidase treatment showed that the 100-kDa species corresponded to a molecule exclusively glycosylated on N-residues, whereas the 130-kDa species contained both, N- and O-linked carbohydrates. Pulse-chase experiments demonstrated that the smaller RPTP alpha protein is a precursor of the larger one. A high affinity antibody was generated that recognizes the immature protein only; however, both proteins can be detected by Western blot analysis after a simple chemical hydrolysis. Following Superose 12 chromatography, the 100- and 130-kDa species of RPTP alpha emerged as 200- and 340-kDa proteins, respectively. Both species exhibited similar enzymatic activities as determined with a peptide substrate in immunoprecipitates.	UNIV WASHINGTON,DEPT PATHOL SM30,SEATTLE,WA 98195; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	University of Washington; University of Washington Seattle; New York University	DAUM, G (corresponding author), UNIV WASHINGTON,DEPT BIOCHEM SJ70,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK000709] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK0709] Funding Source: Medline; NIGMS NIH HHS [GM42508] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAUM G, 1991, J BIOL CHEM, V266, P12211; DAUM G, 1993, ANAL BIOCHEM, V211, P50, DOI 10.1006/abio.1993.1231; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; HATHCOCK KS, 1993, IMMUNOL RES, V12, P21, DOI 10.1007/BF02918366; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; JIRIK FR, 1990, FEBS LETT, V273, P239, DOI 10.1016/0014-5793(90)81094-5; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KIJIMOTOOCHIAI S, 1985, ANAL BIOCHEM, V147, P222, DOI 10.1016/0003-2697(85)90031-4; KORETZKY GA, 1993, FASEB J, V7, P420, DOI 10.1096/fasebj.7.5.8462784; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY JB, 1993, J BIOL CHEM, V268, P10573; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TAN XH, 1993, J BIOL CHEM, V268, P6835; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	35	52	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10524	10528						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144638				2022-12-25	WOS:A1994NF01700052
J	EWART, GD; CANNELL, D; COX, GB; HOWELLS, AJ				EWART, GD; CANNELL, D; COX, GB; HOWELLS, AJ			MUTATIONAL ANALYSIS OF THE TRAFFIC ATPASE (ABC) TRANSPORTERS INVOLVED IN UPTAKE OF EYE PIGMENT PRECURSORS IN DROSOPHILA-MELANOGASTER - IMPLICATIONS FOR STRUCTURE-FUNCTION-RELATIONSHIPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PERIPLASMIC PERMEASES; RESISTANT HUMAN-CELLS; MULTIDRUG RESISTANCE; ESCHERICHIA-COLI; CYSTIC-FIBROSIS; P-GLYCOPROTEIN; WHITE LOCUS; CHLORIDE CHANNEL; GENE; DNA	The white, brown, and scarlet genes of Drosophila melanogaster encode three proteins that belong to the Traffic ATPase superfamily of transmembrane permeases and are involved in the transport of guanine and tryptophan (precursors of the red and brown eye pigments). We have determined the nucleotide sequences of two mutant white alleles (w(co2) and w(Bwx)) that cause reduced red pigmentation but have no effect on brown pigmentation. In w(co2) the effect is only observed when interacting with the bw(6) allele or a newly isolated allele (bW(T50)). These alleles of the brown gene were cloned and sequenced. In w(co2) the codon for glycine 588 is changed to encode serine; in w(Bwx) the triplet ATC encoding isoleucine 581 is deleted; asparagine 638 is changed to threonine in bW(6), and glycine 578 is changed to aspartate in bW(T50). NO Other relevant changes to the gene structures were detected. P-element-mediated germline transduction was used to construct a fly strain containing a white gene with a mutation of the nucleotide binding domain. Such flies had white eyes, indicating that the mutated white gene was unable to support either guanine or tryptophan transport. The implications of these mutations are discussed in terms of a model of the Drosophila pigment precursor transport system.	AUSTRALIAN NATL UNIV,FAC SCI,DIV BIOCHEM & MOLEC BIOL,CANBERRA 2600,AUSTRALIA	Australian National University	EWART, GD (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV BIOCHEM & MOLEC BIOL,POB 4,CANBERRA 2600,AUSTRALIA.							AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; AMES GFL, 1990, J BACTERIOL, V172, P4133, DOI 10.1128/jb.172.8.4133-4137.1990; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BENDER W, 1983, J MOL BIOL, V168, P17, DOI 10.1016/S0022-2836(83)80320-9; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; COX GB, 1989, J BACTERIOL, V171, P1531, DOI 10.1128/jb.171.3.1531-1534.1989; COX GB, 1988, J BACTERIOL, V170, P2283, DOI 10.1128/jb.170.5.2283-2286.1988; DASSA E, 1985, EMBO J, V4, P2287, DOI 10.1002/j.1460-2075.1985.tb03928.x; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; DREESEN TD, 1988, MOL CELL BIOL, V8, P5206, DOI 10.1128/MCB.8.12.5206; FARMER JL, 1977, HEREDITY, V39, P297, DOI 10.1038/hdy.1977.70; FARMER JL, 1986, DROSOPHILA INFO SERV, V63, P50; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HAZELRIGG T, 1984, CELL, V36, P469, DOI 10.1016/0092-8674(84)90240-X; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JOWETT T, 1986, DROSOPHILA PRACTICAL, P278; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; LINDSAY DL, 1968, PUBLICATION, V627; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; OHARE K, 1984, J MOL BIOL, V180, P437, DOI 10.1016/0022-2836(84)90021-4; PARSONAGE D, 1987, J BIOL CHEM, V262, P8022; PEPLING M, 1990, NUCLEIC ACIDS RES, V18, P1633, DOI 10.1093/nar/18.6.1633; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; SULLIVAN DT, 1980, BIOCHEM GENET, V18, P1109, DOI 10.1007/BF00484342; SULLIVAN DT, 1979, BIOCHEM GENET, V17, P565, DOI 10.1007/BF00498891; SULLIVAN DT, 1975, BIOCHEM GENET, V13, P603, DOI 10.1007/BF00484918; SUMMERS KM, 1982, ADV INSECT PHYSIOL, V16, P119, DOI 10.1016/S0065-2806(08)60153-8; TEARLE RG, 1989, GENETICS, V122, P595; Tsui Lap-Chee, 1992, Human Mutation, V1, P197, DOI 10.1002/humu.1380010304; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBB DC, 1992, J BIOL CHEM, V267, P24661; ZACHAR Z, 1982, CELL, V30, P529, DOI 10.1016/0092-8674(82)90250-1	47	143	148	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10370	10377						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144619				2022-12-25	WOS:A1994NF01700031
J	KUNAPULI, P; GUREVICH, VV; BENOVIC, JL				KUNAPULI, P; GUREVICH, VV; BENOVIC, JL			PHOSPHOLIPID-STIMULATED AUTOPHOSPHORYLATION ACTIVATES THE G-PROTEIN-COUPLED RECEPTOR KINASE GRK5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-ADRENERGIC-RECEPTOR; RHODOPSIN KINASE; PHOSPHORYLATION; FAMILY; IDENTIFICATION; ISOPRENYLATION; MUSCLE; LIGHT	G protein-coupled receptor kinases (GRKs) play an important role in mediating agonist-specific desensitization of numerous G protein-coupled receptors. GRK5, a recently identified member of the GRK family, undergoes a rapid phospholipid-stimulated autophosphorylation to a stoichiometry of similar to 2 mol of phosphate/mol of GRK5. The ability of phospholipids to stimulate autophosphorylation is largely blocked by a glutathione S-transferase fusion protein containing the last 102 amino acids of GRK5 (amino acids 489-590), suggesting that this is a primary region involved in GRK5/phospholipid interaction. Phosphoamino acid determination and mutagenesis studies demonstrate that autophosphorylation of GRK5 occurs primarily at residues Ser-484 and Thr-485. Expression and characterization of a mutant GRK5 that does not autophosphorylate (S484A and T485A) reveals that the mutant has a similar to 15-20-fold reduced ability to phosphorylate the beta(2)-adrenerse receptor and rhodopsin compared to wild type GRK5. These results suggest that phospholipid-stimulated autophosphorylation may represent a novel mechanism for membrane association and regulation of GRK5 activity,	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107	Jefferson University			Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NIGMS NIH HHS [GM44944] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BOEKHOFF I, 1994, J BIOL CHEM, V269, P37; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; BUCZYLKO J, 1991, P NATL ACAD SCI USA, V88, P2568, DOI 10.1073/pnas.88.6.2568; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CERIONE RA, 1983, NATURE, V306, P562, DOI 10.1038/306562a0; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; GOMEZ J, 1992, MOL BIOL RECEPTORS T, P1; HAGA T, 1992, J BIOL CHEM, V26, P2222; HARGRAVE PA, 1992, MOL BIOL RECEPTORS T, P49; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KIM CM, 1993, J BIOL CHEM, V268, P15412; KIM CM, 1993, RECEPTOR, V3, P39; KUHN H, 1972, FEBS LETT, V20, P1, DOI 10.1016/0014-5793(72)80002-4; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; KURET J, 1985, J BIOL CHEM, V260, P6427; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PALCZEWSKI K, 1992, J BIOL CHEM, V267, P18991; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RANGELALDAO R, 1976, J BIOL CHEM, V251, P3375; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WANG JH, 1976, J BIOL CHEM, V251, P4521	35	90	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10209	10212						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144599				2022-12-25	WOS:A1994NF01700007
J	RYE, KA; BARTER, PJ				RYE, KA; BARTER, PJ			THE INFLUENCE OF APOLIPOPROTEINS ON THE STRUCTURE AND FUNCTION OF SPHEROIDAL, RECONSTITUTED HIGH-DENSITY-LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA-LIPOPROTEINS; A-II PARTICLES; CHOLESTEROL ACYLTRANSFERASE; EGG PHOSPHATIDYLCHOLINE; RICH LIPOPROTEINS; CONVERSION FACTOR; INVITRO; TRIGLYCERIDE; PROTEIN; SURFACE	This study investigates the influence of apolipoproteins on the structure and function of spheroidal, reconstituted high density lipoproteins (rHDL). Spheroidal rHDL containing apolipoprotein (apo) A-I, (A-I)rHDL, were prepared by incubating discoidal rHDL with low density lipoproteins and lecithin:cholesterol acyltransferase. Spheroidal rHDL containing apoA-II, (A-II)rHDL, were prepared by displacing apoA-I from (A-I)rHDL with apoA-II. When the (A-I)rHDL were subjected to agarose gel electrophoresis, their migration was retarded relative to native HDL. The (A-II)rHDL migrated slower than either the (A-I)rHDL or native HDL. Spectroscopic studies showed that the packing order of the rHDL phospholipids was independent of apolipoprotein composition and that the polarity, or hydration, of the lipid-water interface of the (A-I)rHDL was greater than that of the (A-II)rHDL. When the rHDL were incubated with very low density lipoproteins (VLDL) and cholesteryl ester transfer protein, comparable amounts of cholesteryl ester (CE) were transferred from (A-I)rHDL and (A-II)rHDL to VLDL, The transfer of triglyceride (TG) from VLDL to (A-I)rHDL and (A-II)rHDL was also comparable. Similar results were obtained when Intralipid was substituted for VLDL. It is concluded that (i) apolipoproteins influence the surface charge of spheroidal rHDL, (ii) the hydration of the lipid-water interface of (A-I)rHDL is greater than that of (A-II)rHDL and (ii) cholesteryl ester transfer protein-mediated transfers of CE and TG between spheroidal rHDL and TG-rich particles are independent of rHDL apolipoprotein composition.	UNIV ADELAIDE,DEPT MED,ADELAIDE,SA 5000,AUSTRALIA	University of Adelaide								ATMEH RF, 1983, BIOCHIM BIOPHYS ACTA, V751, P175, DOI 10.1016/0005-2760(83)90172-8; BARTER PJ, 1988, BIOCHEM J, V254, P179, DOI 10.1042/bj2540179; BARTER PJ, 1990, BIOCHIM BIOPHYS ACTA, V1047, P294, DOI 10.1016/0005-2760(90)90529-7; BARTER PJ, 1990, BIOCHIM BIOPHYS ACTA, V1045, P81, DOI 10.1016/0005-2760(90)90206-D; BEKAERT ED, 1991, J LIPID RES, V32, P1587; BEKAERT ED, 1992, BIOCHIM BIOPHYS ACTA, V1126, P105, DOI 10.1016/0005-2760(92)90223-I; BENYASHAR V, 1991, CHEM PHYS LIPIDS, V60, P1, DOI 10.1016/0009-3084(91)90009-Z; BURSTEIN M, 1970, J LIPID RES, V11, P583; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; CHEUNG MC, 1991, J LIPID RES, V32, P383; HOPKINS GJ, 1980, METABOLISM, V29, P546, DOI 10.1016/0026-0495(80)90080-3; HOPKINS GJ, 1989, ATHEROSCLEROSIS, V75, P73, DOI 10.1016/0021-9150(89)90209-8; JAMES RW, 1989, BIOCHIM BIOPHYS ACTA, V1002, P292, DOI 10.1016/0005-2760(89)90343-3; JAMES RW, 1988, J LIPID RES, V29, P1557; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1989, J BIOL CHEM, V264, P4818; KILSDONK EPC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P205, DOI 10.1016/0005-2760(90)90121-D; KINOSHITA M, 1993, J LIPID RES, V34, P261; KREBS KE, 1988, BIOCHIM BIOPHYS ACTA, V959, P229, DOI 10.1016/0005-2760(88)90195-6; LAGOCKI PA, 1980, J BIOL CHEM, V255, P3701; MAHADEVAN V, 1983, BIOCHIM BIOPHYS ACTA, V752, P89, DOI 10.1016/0005-2760(83)90236-9; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MOWRI HO, 1992, J LIPID RES, V33, P1269; OHNISHI T, 1993, BIOCHEMISTRY-US, V32, P5029, DOI 10.1021/bi00070a009; OSBORNE JC, 1986, METHOD ENZYMOL, V128, P213; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; PIRAN U, 1979, J LIPID RES, V20, P1040; RADER DJ, 1991, J LIPID RES, V32, P1849; RAJARAM OV, 1985, BIOCHIM BIOPHYS ACTA, V835, P41, DOI 10.1016/0005-2760(85)90028-1; RYE KA, 1990, BIOCHIM BIOPHYS ACTA, V1042, P227, DOI 10.1016/0005-2760(90)90013-N; RYE KA, 1989, J LIPID RES, V30, P335; RYE KA, 1993, BIOCHIM BIOPHYS ACTA, V1167, P316, DOI 10.1016/0005-2760(93)90235-2; SATA T, 1972, J LIPID RES, V13, P757; SPARKS DL, 1992, J LIPID RES, V33, P123; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; STUART WD, 1992, BIOCHEMISTRY-US, V31, P8552, DOI 10.1021/bi00151a024; TOLLEFSON JH, 1988, AM J PHYSIOL, V255, pE894, DOI 10.1152/ajpendo.1988.255.6.E894; VANTORNOUT P, 1981, BIOCHIM BIOPHYS ACTA, V663, P630, DOI 10.1016/0005-2760(81)90073-4; WEINBERG RB, 1982, ATHEROSCLEROSIS, V44, P141, DOI 10.1016/0021-9150(82)90109-5	39	64	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10298	10303						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144610				2022-12-25	WOS:A1994NF01700021
J	VERES, Z; KIM, IY; SCHOLZ, TD; STADTMAN, TC				VERES, Z; KIM, IY; SCHOLZ, TD; STADTMAN, TC			SELENOPHOSPHATE SYNTHETASE - ENZYME PROPERTIES AND CATALYTIC REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE PHOSPHATE DIKINASE; SELD GENE-PRODUCT; ESCHERICHIA-COLI; SELENIUM METABOLISM; TRANSFER-RNAS; NUCLEOSIDE; MUTANT; 5-METHYLAMINOMETHYL-2-SELENOURIDINE; INTERMEDIATE; GENISTEIN	Selenophosphate synthetase, the product of the selD gene, produces the biologically active selenium donor compound, monoselenophosphate, from ATP and selenide. Isolation of the enzyme and characterization of some of its physical and catalytic properties are described. Magnesium ion and a monovalent cation, K+, NH4+ , or Rb+, are required for catalytic activity. Polyphosphates and other common nucleotide triphosphates do not replace ATP as substrate. The stoichiometry of the catalytic reaction (Reaction 1) was established using P-31 NMR, anaerobic molecular sieve chromatography, and radiochemical labeling procedures. ATP + selenide + H2O --> selenophosphate + P-i + AMP In the absence of selenide, ATP is converted completely to AMP and orthophosphate upon prolonged incubation with elevated levels of enzyme. AMP is a competitive inhibitor of ATP, K-i = 170 mu m, whereas selenophosphate and orthophosphate are weak inhibitors indicating a multistep reaction. Attempts to obtain direct evidence for a postulated enzyme-pyrophosphate intermediate using several experimental approaches are described. No exchange of [C-14]AMP with ATP could be detected after the enzyme was freed of traces of contaminating adenylate kinase by chromatography on phenyl-Sepharose.	NHLBI,BIOCHEM LAB,BETHESDA,MD 20892; HUNGARIAN ACAD SCI,CENT RES INST CHEM,H-1025 BUDAPEST,HUNGARY; UNIV IOWA,DEPT PEDIAT,IOWA CITY,IA 52242	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; University of Iowa				Scholz, Thomas/0000-0003-0759-2486				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BAGNARA AS, 1972, ANAL BIOCHEM, V45, P24, DOI 10.1016/0003-2697(72)90004-8; Bock A, 1988, Biofactors, V1, P245; Boyer Paul D., 1942, JOUR BIOL CHEM, V146, P673; BUTLERRANSOHOFF JE, 1988, BIOCHEMISTRY-US, V27, P4777, DOI 10.1021/bi00413a029; CARROLL LJ, 1989, J AM CHEM SOC, V111, P5965, DOI 10.1021/ja00197a081; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CASHEL M, 1975, ANNU REV MICROBIOL, V29, P301, DOI 10.1146/annurev.mi.29.100175.001505; CHING WM, 1985, P NATL ACAD SCI USA, V82, P347, DOI 10.1073/pnas.82.2.347; CHING WM, 1982, P NATL ACAD SCI-BIOL, V79, P374, DOI 10.1073/pnas.79.2.374; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; COOPERMAN BS, 1992, TRENDS BIOCHEM SCI, V17, P262, DOI 10.1016/0968-0004(92)90406-Y; EHRENREICH A, 1992, EUR J BIOCHEM, V206, P767, DOI 10.1111/j.1432-1033.1992.tb16983.x; GLASS RS, 1993, BIOCHEMISTRY-US, V32, P12555, DOI 10.1021/bi00210a001; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HUANG JM, 1992, J BIOL CHEM, V267, P15511; KIM IY, 1992, J BIOL CHEM, V267, P19650; KIM IY, 1993, J BIOL CHEM, V268, P27020; KRAMER GF, 1988, J BACTERIOL, V170, P736, DOI 10.1128/jb.170.2.736-743.1988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEINFELDER W, 1988, J BACTERIOL, V170, P540, DOI 10.1128/jb.170.2.540-546.1988; LEINFELDER W, 1990, P NATL ACAD SCI USA, V87, P543, DOI 10.1073/pnas.87.2.543; MILNER Y, 1978, J BIOL CHEM, V253, P878; MILNER Y, 1976, J BIOL CHEM, V251, P7920; PHILLIPS NFB, 1986, BIOCHEMISTRY-US, V25, P1644, DOI 10.1021/bi00355a030; REUBEN J, 1971, J BIOL CHEM, V246, P6227; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THRALL SH, 1993, BIOCHEMISTRY-US, V32, P1803, DOI 10.1021/bi00058a014; VERES Z, 1992, P NATL ACAD SCI USA, V89, P2975, DOI 10.1073/pnas.89.7.2975; WITTWER AJ, 1986, ARCH BIOCHEM BIOPHYS, V248, P540, DOI 10.1016/0003-9861(86)90507-2; WITTWER AJ, 1984, BIOCHEMISTRY-US, V23, P4650, DOI 10.1021/bi00315a021	32	118	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10597	10603						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144648				2022-12-25	WOS:A1994NF01700062
J	ALBERTS, GF; PEIFLEY, KA; JOHNS, A; KLEHA, JF; WINKLES, JA				ALBERTS, GF; PEIFLEY, KA; JOHNS, A; KLEHA, JF; WINKLES, JA			CONSTITUTIVE ENDOTHELIN-1 OVEREXPRESSION PROMOTES SMOOTH-MUSCLE CELL-PROLIFERATION VIA AN EXTERNAL AUTOCRINE LOOP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-SYNTHESIS; GROWTH-FACTOR; MESSENGER-RNA; VASOCONSTRICTOR PEPTIDE; SEQUENCE-ANALYSIS; EXPRESSION; RECEPTOR; CLONING; CDNA; SECRETION	Endothelin-1 (ET-1) is a potent vasoconstrictor peptide originally purified from endothelial cell-conditioned medium. It has multiple biological activities and has been implicated in a number of human diseases, including hypertension and atherosclerosis. Contradictory reports have been published regarding whether ET-1 is a mitogen for vascular smooth muscle cells (SMC); thus, this issue is presently unresolved. In this study, we demonstrate that rat aortic SMC express functional endothelin cell surface receptors but do not proliferate when ET-1 is added to serum-free culture medium on every other day for a period of 1 week. To determine whether ET-1 could function in an autocrine manner to promote SMC growth, we transfected this same cell line with an ET-1 expression plasmid. Several independent lines expressing variable levels of ET-1 mRNA and biologically active ET-1 were obtained. Cell proliferation assays indicated that the transfected SMC line secreting the highest level of ET-1 had an enhanced growth rate when compared with untransfected or vector-alone transfected cells. The growth rate of this SMC line, but not of untransfected cells, was significantly reduced when the ET(A) receptor subtype-selective antagonist BQ-123 was included in the culture medium. These results indicate that constitutive ET-1 overexpression can promote SMC proliferation. Therefore, it is possible that under certain conditions ET-1 could be an important factor controlling SMC replication in vivo.	AMER RED CROSS,HOLLAND LAB,DEPT MOLEC BIOL,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855; BERLEX BIOSCI,DEPT CARDIOVASC RES,RICHMOND,CA 94804	American Red Cross								ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BAGBY SP, 1992, AM J PHYSIOL, V262, pC578, DOI 10.1152/ajpcell.1992.262.3.C578; BATTISTINI B, 1993, PEPTIDES, V14, P385, DOI 10.1016/0196-9781(93)90057-N; CADE C, 1991, J CARDIOVASC PHARM, V17, pS71, DOI 10.1097/00005344-199100177-00020; CHUA BHL, 1992, AM J PHYSIOL, V262, pE412, DOI 10.1152/ajpendo.1992.262.4.E412; DICKSON RB, 1987, METHOD ENZYMOL, V146, P329; Dubin D, 1989, J VASC MED BIOL, V1, P150; EGUCHI S, 1992, FEBS LETT, V302, P243, DOI 10.1016/0014-5793(92)80451-L; ELSHOURBAGY NA, 1993, J BIOL CHEM, V268, P3873; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; GAY CG, 1991, J CELL PHYSIOL, V147, P121, DOI 10.1002/jcp.1041470116; HAHN AWA, 1990, CELL REGUL, V1, P649, DOI 10.1091/mbc.1.9.649; HECHLER U, 1993, BIOCHEM BIOPH RES CO, V194, P1305, DOI 10.1006/bbrc.1993.1966; HIRATA Y, 1989, ATHEROSCLEROSIS, V78, P225, DOI 10.1016/0021-9150(89)90227-X; HOSODA K, 1991, FEBS LETT, V287, P23, DOI 10.1016/0014-5793(91)80007-P; HSU DKW, 1993, BIOCHEM BIOPH RES CO, V197, P1483, DOI 10.1006/bbrc.1993.2644; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; ITOH Y, 1988, FEBS LETT, V231, P440, DOI 10.1016/0014-5793(88)80867-6; KIMES BW, 1976, EXP CELL RES, V98, P349, DOI 10.1016/0014-4827(76)90446-8; KOIDE M, 1992, ATHEROSCLEROSIS, V92, P1, DOI 10.1016/0021-9150(92)90003-Y; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; LEPPALUOTO J, 1992, ANN MED, V24, P153, DOI 10.3109/07853899209147813; LERMAN A, 1991, NEW ENGL J MED, V325, P9957; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; MARTIN ER, 1990, J BIOL CHEM, V265, P14044; MASAKI T, 1992, MED RES REV, V12, P391, DOI 10.1002/med.2610120405; MAURER HR, 1981, CELL TISSUE KINET, V14, P111, DOI 10.1111/j.1365-2184.1981.tb00516.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAMBI P, 1992, J BIOL CHEM, V267, P19555; OGAWA Y, 1991, BIOCHEM BIOPH RES CO, V178, P248, DOI 10.1016/0006-291X(91)91806-N; OHLSTEIN EH, 1992, EUR J PHARM-MOLEC PH, V225, P347, DOI 10.1016/0922-4106(92)90109-9; RESINK TJ, 1990, BIOCHEM BIOPH RES CO, V168, P1303, DOI 10.1016/0006-291X(90)91171-N; ROUBERT P, 1993, J VASC RES, V30, P139; ROUBERT P, 1991, J CARDIOVASC PHARM, V17, pS104, DOI 10.1097/00005344-199100177-00027; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAKURAI T, 1991, BIOCHEM BIOPH RES CO, V175, P44, DOI 10.1016/S0006-291X(05)81197-0; SCOTTBURDEN T, 1991, J CARDIOVASC PHARM, V17, pS96, DOI 10.1097/00005344-199100177-00025; SHICHIRI M, 1991, J CLIN INVEST, V87, P1867, DOI 10.1172/JCI115210; SOKOLOVSKY M, 1992, J NEUROCHEM, V59, P809, DOI 10.1111/j.1471-4159.1992.tb08318.x; TAKAGI Y, 1990, BIOCHEM BIOPH RES CO, V168, P537, DOI 10.1016/0006-291X(90)92354-3; WEISSBERG PL, 1990, ATHEROSCLEROSIS, V85, P257, DOI 10.1016/0021-9150(90)90118-3; WINKLES JA, 1993, BIOCHEM BIOPH RES CO, V191, P1081, DOI 10.1006/bbrc.1993.1327; WINKLES JA, 1991, CELL GROWTH DIFFER, V2, P531; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	44	123	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					10112	10118						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144511				2022-12-25	WOS:A1994NE05300107
J	BABA, T; NIIDA, Y; MICHIKAWA, Y; KASHIWABARA, S; KODAIRA, K; TAKENAKA, M; KOHNO, N; GERTON, GL; ARAI, Y				BABA, T; NIIDA, Y; MICHIKAWA, Y; KASHIWABARA, S; KODAIRA, K; TAKENAKA, M; KOHNO, N; GERTON, GL; ARAI, Y			AN ACROSOMAL PROTEIN, SP32, IN MAMMALIAN SPERM IS A BINDING-PROTEIN SPECIFIC FOR 2 PROACROSINS AND AN ACROSIN INTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG SPERMATOGENESIS; MOLECULAR-WEIGHT FORM; BOAR PROACROSIN; ZYMOGEN GRANULES; GOLGI-APPARATUS; ACTIVATION; PURIFICATION; SPERMATOZOA; AGGREGATION; BIOGENESIS	An acrosomal protein, sp32, was completely purified from acid extracts of ejaculated porcine sperm. Purified sp32 gave a single 32-kDa protein band on SDS-polyacrylamide gel electrophoresis and was characterized as a binding protein specific for 55-, 53-, and 49-kDa forms of (pro)acrosin. This protein was not capable of binding a 43-kDa acrosin intermediate and 35-kDa mature acrosin. sp32 significantly accelerated autoactivation of proacrosin at a basic pH in vitro and affected the maturation pathway of proacrosin. In the presence of sp32, the 49-kDa acrosin intermediate from the 55- and 53-kDa proacrosins was accumulated, instead of the 43-kDa acrosin intermediate. These results suggest that sp32 interacts with both the amino- and carboxyl-terminal sequences of the 53-kDa proacrosin. The cDNA clones coding for porcine and guinea pig sp32 have been identified from testis cDNA libraries in lambdagt11. The deduced amino acid sequence indicates that sp32 is initially synthesized as a 61-kDa precursor protein with a putative signal peptide at the amino terminus. The carboxyl-terminal half of the precursor molecule corresponds to the mature sp32. Thus, sp32 is produced by post-translational modification of the precursor. The binding of sp32 to proacrosin may be involved in packaging the acrosin zymogen into the acrosomal matrix.	UNIV PENN,SCH MED,DEPT OBSTET & GYNECOL,PHILADELPHIA,PA 19104	University of Pennsylvania	BABA, T (corresponding author), UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA SCI CITY,TSUKUBA,IBARAKI 305,JAPAN.		Gerton, George L/A-1039-2007	Gerton, George L/0000-0001-9894-5640	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD006274, R01HD022899] Funding Source: NIH RePORTER; NICHD NIH HHS [P01-HD-06274, R01-HD-22899] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANAKWE OO, 1990, BIOL REPROD, V42, P317, DOI 10.1095/biolreprod42.2.317; ANDERSON RA, 1981, BIOCHEM J, V199, P307, DOI 10.1042/bj1990307; ARBOLEDA CE, 1988, DEV BIOL, V125, P217, DOI 10.1016/0012-1606(88)90075-9; BABA T, 1989, J BIOL CHEM, V264, P11920; BABA T, 1993, MOL REPROD DEV, V34, P233, DOI 10.1002/mrd.1080340302; BABA T, 1989, FEBS LETT, V244, P132, DOI 10.1016/0014-5793(89)81178-0; BABA T, 1989, FEBS LETT, V244, P296, DOI 10.1016/0014-5793(89)80549-6; BABA T, 1989, BIOCHEM BIOPH RES CO, V160, P1026, DOI 10.1016/S0006-291X(89)80105-6; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURGOS MH, 1986, ANAT REC, V216, P139, DOI 10.1002/ar.1092160205; ESCALIER D, 1991, DEVELOPMENT, V113, P779; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FULLER SA, 1991, CURRENT PROTCOLS MOL; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GREEN DPL, 1978, J CELL SCI, V32, P153; HARDY DM, 1991, BIOCHEM J, V275, P759, DOI 10.1042/bj2750759; HARRISON RAP, 1982, J REPROD IMMUNOL, V4, P231, DOI 10.1016/0165-0378(82)90029-8; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; Hayashi R, 1977, Methods Enzymol, V47, P84; HEDRICK JL, 1989, BIOCATALYSIS AGR BIO, P215; HERMO L, 1980, AM J ANAT, V157, P357, DOI 10.1002/aja.1001570405; HSU SM, 1982, J HISTOCHEM CYTOCHEM, V30, P1079, DOI 10.1177/30.10.6182185; JONES R, 1987, EXP CELL RES, V171, P503, DOI 10.1016/0014-4827(87)90182-0; KASHIWABARA S, 1990, BIOCHEM BIOPH RES CO, V173, P240, DOI 10.1016/S0006-291X(05)81047-2; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KLEMM U, 1991, HUM GENET, V87, P635; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOOS J, 1993, BIOL REPROD, V49, P408, DOI 10.1095/biolreprod49.2.408; MULLERESTERL W, 1980, H-S Z PHYSIOL CHEM, V361, P1811, DOI 10.1515/bchm2.1980.361.2.1811; MULLERESTERL W, 1981, METHOD ENZYMOL, V80, P621; PARRISH RF, 1978, ANAL BIOCHEM, V87, P108, DOI 10.1016/0003-2697(78)90574-2; PARRISH RF, 1978, J BIOL CHEM, V253, P8428; POLAKOSKI KL, 1977, J BIOL CHEM, V252, P1888; REGGIO H, 1978, J CELL BIOL, V78, P951, DOI 10.1083/jcb.78.3.951; REGGIO HA, 1978, J CELL BIOL, V77, P288, DOI 10.1083/jcb.77.2.288; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUSI FR, 1971, AM J ANAT, V130, P251, DOI 10.1002/aja.1001300302; TARTAKOFF A, 1974, J BIOL CHEM, V249, P7420; URCH UA, 1991, DEVELOPMENT, V111, P1165; URCH UA, 1991, BIOL CHEM MAMMALIAN, P233; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; YI LSH, 1992, BIOCHEM BIOPH RES CO, V184, P760, DOI 10.1016/0006-291X(92)90655-5; YI LSH, 1992, J REPROD IMMUNOL, V21, P309, DOI 10.1016/0165-0378(92)90033-Z; YI LSH, 1992, ANDROLOGIA, V24, P41	47	124	136	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					10133	10140						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144514				2022-12-25	WOS:A1994NE05300110
J	ELBERG, G; LI, JP; SHECHTER, Y				ELBERG, G; LI, JP; SHECHTER, Y			VANADIUM ACTIVATES OR INHIBITS RECEPTOR AND NONRECEPTOR PROTEIN-TYROSINE KINASES IN CELL-FREE EXPERIMENTS, DEPENDING ON ITS OXIDATION-STATE - POSSIBLE ROLE OF ENDOGENOUS VANADIUM IN CONTROLLING CELLULAR PROTEIN-TYROSINE KINASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR; RAT ADIPOCYTES; BLOOD-GLUCOSE; DIABETIC RATS; FA/FA RATS; HL60 CELLS; VANADATE; PHOSPHORYLATION; PHOSPHATASE; MECHANISM	We have shown that vanadium mimics several insulin effects in rat adipocytes, via a staurosporine sensitive cytosolic protein tyrosine kinase (CytPTK; Shisheva, A., and Shechter, Y. (1993) J. Biol. Chem. 268, 6463). Here we demonstrate that vanadium effects on protein tyrosine kinases are preserved after cell disintegration. Vanadium inhibits or activates protein tyrosine kinases depending on its oxidation state and the tyrosine kinase studied. Vanadyl (4+) but not vanadate (5+) inhibits receptor tyrosine kinases such as the insulin receptor (IC50 value = 23 +/- 4 muM) and the insulin-like growth factor-I receptor (IC50 = 19 +/- 3 muM). Inhibition is non-competitive with respect to ATP, Mn2+, or substrate concentrations. Preincubation of adipocytes with vanadyl (0.4 mm), and staurosporine (which arrests the cytosolic enzyme) substantially inhibited insulin-stimulated lipogenesis. Vanadyl is readily oxidized to vanadate by hydrogen peroxide. In contrast, CytPTKs were poorly inhibited by vanadyl, and vanadate stimulated several CytPTKs 2-6-fold. CytPTK derived from rat adipocytes, liver and brain were activated, and CytPTK from Nb2 lymphoma cells was not affected. CytPTK extracted from insulin-responsive tissues are more sensitive to vanadate activation (ED50 = 3 +/- 0.7 muM), whereas the brain enzyme is less sensitive (ED50 = 27 +/- 3 muM). Tungstate, molybdate, and phenylarsine oxide also stimulate CytPTK, suggesting that the vanadate effect is secondary to inhibiting protein phosphotyrosine phosphatases. This study supports a working hypothesis implicating the intracellular vanadyl pool in modulating CytPTK activity. Any physiological conditions converting vanadyl to vanadate (i.e. H2O2 Production) will activate CytPTK and consequently CytPTK-dependent bioeffects.			ELBERG, G (corresponding author), WEIZMANN INST SCI, DEPT HORMONE RES, IL-76100 REHOVOT, ISRAEL.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICHARD SM, 1989, ENDOCRINOLOGY, V125, P2510, DOI 10.1210/endo-125-5-2510; BRICHARD SM, 1992, ENDOCRINOLOGY, V131, P311, DOI 10.1210/en.131.1.311; BRUNATI AM, 1985, BIOCHEM BIOPH RES CO, V133, P929, DOI 10.1016/0006-291X(85)91225-2; DEGANI H, 1981, BIOCHEMISTRY-US, V20, P5795, DOI 10.1021/bi00523a023; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GIL J, 1988, J BIOL CHEM, V263, P1868; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; GOLDMAN R, 1992, FEBS LETT, V309, P190, DOI 10.1016/0014-5793(92)81092-Z; GRINSTEIN S, 1990, J BIOL CHEM, V265, P318; HEYLIGER CE, 1985, SCIENCE, V227, P1474, DOI 10.1126/science.3156405; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LAU KHW, 1989, BIOCHEM J, V257, P23, DOI 10.1042/bj2570023; LINDQUIST RN, 1973, J AM CHEM SOC, V95, P8762, DOI 10.1021/ja00807a043; LIOCHEV S, 1987, ARCH BIOCHEM BIOPHYS, V255, P274, DOI 10.1016/0003-9861(87)90394-8; LOPEZ V, 1976, ANN REV PHARM TOXICO, V24, P501; MACARA IG, 1980, TRENDS BIOCHEM SCI, V5, P92, DOI 10.1016/0968-0004(80)90256-X; MCCLAIN DA, 1989, MOL CELLULAR BIOL DI, V2, P53; MEYEROVITCH J, 1987, J BIOL CHEM, V262, P6658; MEYEROVITCH J, 1990, BIOCHEMISTRY-US, V29, P3654, DOI 10.1021/bi00467a010; MEYEROVITCH J, 1991, J CLIN INVEST, V87, P1286, DOI 10.1172/JCI115131; MEYEROVITCH J, 1992, BIOCHEMISTRY, V31; MOONEY RA, 1989, ENDOCRINOLOGY, V124, P422, DOI 10.1210/endo-124-1-422; NECHAY BR, 1984, ANNU REV PHARMACOL, V24, P501; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SCHECHTER Y, 1989, EMBO J, V8, P1671, DOI 10.1002/j.1460-2075.1989.tb03558.x; SHECHTER Y, 1990, DIABETES, V39, P1, DOI 10.2337/diabetes.39.1.1; SHISHEVA A, 1991, J BIOCHEM BIOPH METH, V23, P307, DOI 10.1016/0165-022X(91)90006-I; SHISHEVA A, 1992, FEBS LETT, V300, P93, DOI 10.1016/0014-5793(92)80171-C; SHISHEVA A, 1993, J BIOL CHEM, V268, P6463; SHISHEVA A, 1992, BIOCHEMISTRY-US, V31, P8059, DOI 10.1021/bi00149a041; SHOELSON SE, 1989, MOL CELLULAR BIOL DI, V2, P23; SIMONS TJB, 1979, NATURE, V281, P337, DOI 10.1038/281337a0; SRIVASTAVA AK, 1990, INT J BIOCHEM, V22, P1229, DOI 10.1016/0020-711X(90)90303-K; STANKIEWICZ PJ, 1988, BIOCHEMISTRY-US, V27, P206, DOI 10.1021/bi00401a031; STROUT HV, 1989, ENDOCRINOLOGY, V124, P1918, DOI 10.1210/endo-124-4-1918; SWARUP G, 1982, J BIOL CHEM, V257, P7298; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUDEL S, 1991, BIOCHEM J, V276, P611, DOI 10.1042/bj2760611; TRUDEL S, 1990, BIOCHEM J, V269, P127, DOI 10.1042/bj2690127; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VENKATESAN N, 1991, DIABETES, V40, P492, DOI 10.2337/diabetes.40.4.492; WHITE MF, 1987, J BIOL CHEM, V262, P9769	46	92	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9521	9527						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144537				2022-12-25	WOS:A1994NE05300022
J	JANIAK, F; LEBER, B; ANDREWS, DW				JANIAK, F; LEBER, B; ANDREWS, DW			ASSEMBLY OF BCL-2 INTO MICROSOMAL AND OUTER MITOCHONDRIAL-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; HUMAN FOLLICULAR LYMPHOMA; ENDOPLASMIC-RETICULUM; PHOTOACTIVATABLE PHOSPHOLIPIDS; EMBEDDED SEGMENT; CROSS-LINKING; RAT-LIVER; PROTEIN-A; CYTOCHROME-B5; CELL	Bcl-2 is thought to associate spontaneously with membranes via a carboxyl-terminal hydrophobic domain by a mechanism analogous to that of cytochrome b5. We have examined the association of Bcl-2 with a variety of highly purified intracellular membranes in vitro. Fusion proteins were used to assess directly the role of the carboxyl-terminal hydrophobic domain of Bcl-2 in membrane association. Although this domain of Bcl-2 was sufficient to promote the association of a normally cytosolic polypeptide with either microsomal or mitochondrial membranes additional nonhydrophobic amino-terminal residues were required for membrane integration. Furthermore, direct comparison of membrane binding of Bcl-2 and cytochrome b5 revealed that similar to cytochrome b5, membrane targeting of Bcl-2 was not dependent on protease-sensitive components of the recipient membranes. In competition experiments, cytochrome b5 demonstrated the expected preference for integration into endoplasmic reticulum membranes. In contrast, the data presented here suggest that Bcl-2 is targeted to the cytoplasmic surface of multiple intracellular membranes, both in vitro and in human leukemic cells.	MCMASTER UNIV, DEPT BIOCHEM, HAMILTON L8N 3Z5, ONTARIO, CANADA; MCMASTER UNIV, DEPT MED, HAMILTON L8N 3Z5, ONTARIO, CANADA	McMaster University; McMaster University				Andrews, David/0000-0002-9266-7157; Leber, Brian/0000-0001-5502-1480				ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; ANDERSON DJ, 1983, P NATL ACAD SCI-BIOL, V80, P7249, DOI 10.1073/pnas.80.23.7249; ANDREWS DW, 1992, J BIOL CHEM, V267, P7761; ANDREWS DW, 1993, MOL CELL BIOL, V13, P4703, DOI 10.1128/MCB.13.8.4703; ANDREWS DW, 1989, J CELL BIOL, V108, P797, DOI 10.1083/jcb.108.3.797; AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; ARGAN C, 1983, J BIOL CHEM, V258, P6667; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; COLLINS MKL, 1993, TRENDS BIOCHEM SCI, V18, P307, DOI 10.1016/0968-0004(93)90042-L; ENOCH HG, 1979, J BIOL CHEM, V254, P6483; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GRAHAM JM, 1990, ANAL BIOCHEM, V187, P318, DOI 10.1016/0003-2697(90)90463-J; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; JANIAK F, 1994, IN PRESS BIOCH J; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; LEDERER F, 1983, EUR J BIOCHEM, V132, P95, DOI 10.1111/j.1432-1033.1983.tb07330.x; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; Martin Seamus J., 1993, Trends in Cell Biology, V3, P141, DOI 10.1016/0962-8924(93)90128-N; MITOMA JY, 1992, EMBO J, V11, P4197, DOI 10.1002/j.1460-2075.1992.tb05513.x; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OZOLS J, 1989, BIOCHIM BIOPHYS ACTA, V997, P121, DOI 10.1016/0167-4838(89)90143-X; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SHORE GC, 1983, METHOD ENZYMOL, V97, P396; Sottocasa G. L., 1967, METHOD ENZYMOL, V10, P448; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; STRITTMATTER P, 1960, J BIOL CHEM, V235, P2492; TAKAGAKI Y, 1983, J BIOL CHEM, V258, P9128; TAKAGAKI Y, 1983, J BIOL CHEM, V258, P9136; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; UHLEN M, 1984, J BIOL CHEM, V259, P1695; WALTER P, 1983, METHOD ENZYMOL, V96, P84; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929	41	110	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9842	9849						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144576				2022-12-25	WOS:A1994NE05300070
J	KAUR, P; ROSEN, BP				KAUR, P; ROSEN, BP			IN-VITRO ASSEMBLY OF AN ANION-STIMULATED ATPASE FROM PEPTIDE-FRAGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTALLINE ADENYLATE KINASE; NUCLEOTIDE-BINDING SITE; 2 OVERLAPPING FRAGMENTS; ESCHERICHIA-COLI; MOLECULAR CHARACTERIZATION; TRANSLOCATING ATPASE; CATALYTIC SUBUNIT; ARSA PROTEIN; PUMP; RESISTANCE	The oxyanion-translocating ATPase encoded by the ars operon of plasmid R 773 confers resistance to anti-monials and arsenicals in Escherichia coli by extrusion of the oxyanions from the cells. The catalytic subunit, the ArsA protein, is an oxyanion-stimulated ATPase with two nucleotide binding consensus sequences, one in the N-terminal half and one in the C-terminal half of the protein. In this report subclones of the arsA gene were constructed to produce polypeptide fragments of the ArsA protein. By themselves none of the fragments exhibited anion-stimulated ATPase activity. Denaturation and renaturation of mixtures of N- and C-terminal polypeptides that between them comprised an entire ArsA protein resulted in active ATPase complexes.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, DETROIT, MI 48201 USA	Wayne State University				Rosen, Barry P./0000-0002-5230-4271	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019793] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19793] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHEN CM, 1986, J BIOL CHEM, V261, P5030; DHARMAVARAM RM, 1987, J BACTERIOL, V169, P3921, DOI 10.1128/jb.169.9.3921-3925.1987; FRANCISCO MJDS, 1989, MOL MICROBIOL, V3, P15, DOI 10.1111/j.1365-2958.1989.tb00098.x; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; HSU CM, 1989, J BIOL CHEM, V264, P17349; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KARKARIA CE, 1991, ARCH BIOCHEM BIOPHYS, V288, P107, DOI 10.1016/0003-9861(91)90170-N; KATO I, 1969, J BIOL CHEM, V244, P1004; KAUR P, 1993, J BACTERIOL, V175, P351, DOI 10.1128/JB.175.2.351-357.1993; KAUR P, 1992, J BIOL CHEM, V267, P19272; KAUR P, 1992, PLASMID, V27, P29, DOI 10.1016/0147-619X(92)90004-T; KIERDASZUK B, 1988, BIOCHEMISTRY-US, V27, P4952, DOI 10.1021/bi00413a054; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; MEI-HSU C, 1991, Journal of Biological Chemistry, V266, P2327; MOBLEY HLT, 1982, P NATL ACAD SCI-BIOL, V79, P6119, DOI 10.1073/pnas.79.20.6119; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; ROSEN BP, 1992, ANN NY ACAD SCI, V671, P257, DOI 10.1111/j.1749-6632.1992.tb43801.x; ROSEN BP, 1984, BIOCHEM BIOPH RES CO, V124, P760, DOI 10.1016/0006-291X(84)91023-4; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SACHSENHEIMER W, 1977, J MOL BIOL, V114, P23, DOI 10.1016/0022-2836(77)90280-7; SAMBROOK J, 1989, MOL CLONING CLONING; SILVER S, 1982, P NATL ACAD SCI-BIOL, V79, P6114, DOI 10.1073/pnas.79.20.6114; TANIUCHI H, 1971, J BIOL CHEM, V246, P2291; TISA LS, 1990, J BIOL CHEM, V265, P190; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WU J, 1991, MOL MICROBIOL, V5, P1331, DOI 10.1111/j.1365-2958.1991.tb00779.x; WU JH, 1992, J BIOL CHEM, V267, P12570; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YUE VT, 1977, BIOCHEMISTRY-US, V16, P4678, DOI 10.1021/bi00640a023	35	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9698	9704						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144560				2022-12-25	WOS:A1994NE05300049
J	SINGH, H; BECKMAN, K; POULOS, A				SINGH, H; BECKMAN, K; POULOS, A			PEROXISOMAL BETA-OXIDATION OF BRANCHED-CHAIN FATTY-ACIDS IN RAT-LIVER - EVIDENCE THAT CARNITINE PALMITOYLTRANSFERASE-I PREVENTS TRANSPORT OF BRANCHED-CHAIN FATTY-ACIDS INTO MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SKIN FIBROBLASTS; PRISTANOYL-COA OXIDASE; PHYTANIC ACID; ACYL-COA; REFSUMS DISEASE; LONG-CHAIN; TRIHYDROXYCOPROSTANOYL-COA; ZELLWEGERS SYNDROME; ALPHA-OXIDATION; LIGNOCERIC ACID	Fatty acid beta-oxidation was investigated in highly purified mitochondrial and peroxisomal preparations from rat liver. Under isotonic conditions, pristanic and homophytanic acid beta-oxidation in purified peroxisomes was severalfold greater compared to the oxidation in purified mitochondria. Branched chain fatty acid beta-oxidation in purified mitochondria was very low, and the oxidation was not stimulated by exogenous L-carnitine or L-malate. In contrast, stearic acid beta-oxidation by purified mitochondria depended upon exogenous L-Carnitine, and the oxidation was stimulated by L-malate. Both mitochondrial and peroxisomal beta-oxidation of branched chain fatty acids was strongly inhibited by fatty acid-free bovine serum albumin, whereas stearic acid oxidation was either unaffected or slightly inhibited by bovine serum albumin. The results presented clearly indicate that branched chain fatty acids are mainly degraded in peroxisomes in rat liver. Branched chain fatty acids were efficiently converted to coenzyme A thioesters by purified mitochondria, peroxisomes, and microsomes. Although pristanic and phytanic acids were rapidly converted to pristanoyl-CoA and phytanoyl-CoA, respectively, they were not converted to carnitine esters by mitochondrial outer membranes. The results indicate that acyl-CoA synthetase and carnitine acyltransferase located at the mitochondrial outer membranes regulate entry of branched chain fatty acids into mitochondria. Mitochondrial carnitine acyltransferase I appears to be highly specific for straight chain fatty acids and restricts entry of branched chain fatty acids into mitochondria. Thus, branched chain fatty acids which cannot be transported across the mitochondrial membranes via the carnitine acyltransferase system are directed to peroxisomes for beta-oxidation. The results reported indicate that phytanic acid, the fatty acid which can be initially degraded by alpha-oxidation due to the presence of a beta-methyl group in the molecule, cannot be transported across the mitochondrial membranes. The data presented strongly suggest that phytanic acid alpha-oxidation occurs in organelles other than mitochondria and possibly in peroxisomes.			SINGH, H (corresponding author), WOMENS & CHILDRENS HOSP,DEPT CHEM PATHOL,ADELAIDE,SA 5006,AUSTRALIA.							Bergmeyer HU, 1974, METHODS ENZYMATIC AN; BHUIYAN AKMJ, 1992, LIPIDS, V27, P392; BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; BREMER J, 1983, PHYSIOL REV, V63, P1420, DOI 10.1152/physrev.1983.63.4.1420; BUECHLER KF, 1990, ARCH BIOCHEM BIOPHYS, V281, P233, DOI 10.1016/0003-9861(90)90437-4; CASTEELS M, 1990, J LIPID RES, V31, P1865; DERRICK JP, 1989, BIOCHEM J, V262, P801, DOI 10.1042/bj2620801; FARRELL SO, 1984, J BIOL CHEM, V259, P3089; GARLAND PB, 1970, BIOCHEM J, V119, P553, DOI 10.1042/bj1190553; GUILBAULT GG, 1968, ANAL CHEM, V40, P190, DOI 10.1021/ac60257a002; HERNDON JH, 1969, J CLIN INVEST, V48, P1017, DOI 10.1172/JCI106058; HUANG S, 1992, ARCH BIOCHEM BIOPHYS, V296, P214, DOI 10.1016/0003-9861(92)90565-E; JOHNSON DW, 1989, BIOMED ENVIRON MASS, V18, P603, DOI 10.1002/bms.1200180816; KASHFI K, 1992, BIOCHEM J, V282, P909, DOI 10.1042/bj2820909; KOLODNY EH, 1976, CLIN CHIM ACTA, V70, P247, DOI 10.1016/0009-8981(76)90426-5; KORNBERG A, 1953, J BIOL CHEM, V204, P329; KRISANS SK, 1980, J BIOL CHEM, V255, P9599; LAZAROW PB, 1978, J BIOL CHEM, V253, P1522; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; MANNAERTS GP, 1979, J BIOL CHEM, V254, P4585; MIYAZAWA S, 1983, J BIOCHEM, V94, P529, DOI 10.1093/oxfordjournals.jbchem.a134384; MORRE DJ, 1971, METHOD ENZYMOL, V22, P130; MURALIDHARAN VB, 1984, J BIOL CHEM, V259, P3021; MURTHY MSR, 1987, P NATL ACAD SCI USA, V84, P378, DOI 10.1073/pnas.84.2.378; NORUM KR, 1966, BIOCHEM BIOPH RES CO, V24, P797, DOI 10.1016/0006-291X(66)90397-4; POULOS A, 1980, LIPIDS, V15, P19, DOI 10.1007/BF02534112; POULOS A, 1989, PROG LIPID RES, V28, P35, DOI 10.1016/0163-7827(89)90006-4; POULOS A, 1993, BIOCHEM J, V292, P457, DOI 10.1042/bj2920457; POULOS A, 1985, HUM GENET, V70, P172, DOI 10.1007/BF00273077; POULOS A, 1981, CLIN GENET, V20, P247; POULOS A, 1984, CLIN GENET, V26, P579; POULOS A, 1986, CLIN GENET, V29, P397; POULOS A, 1988, EUR J PEDIATR, V147, P143, DOI 10.1007/BF00442211; RAMSAY RR, 1988, BIOCHEM J, V249, P239, DOI 10.1042/bj2490239; SCHEPERS L, 1990, J BIOL CHEM, V265, P5242; SHINDO Y, 1978, J BIOCH, V84, P1171; SINGH H, 1988, ARCH BIOCHEM BIOPHYS, V266, P486, DOI 10.1016/0003-9861(88)90281-0; SINGH H, 1992, J LIPID RES, V33, P1597; SINGH H, 1989, ARCH BIOCHEM BIOPHYS, V268, P676, DOI 10.1016/0003-9861(89)90336-6; SINGH H, 1990, J LIPID RES, V31, P217; SINGH H, 1987, ARCH BIOCHEM BIOPHYS, V259, P382, DOI 10.1016/0003-9861(87)90504-2; SINGH H, 1986, ARCH BIOCHEM BIOPHYS, V250, P171, DOI 10.1016/0003-9861(86)90714-9; SINGH H, 1987, ARCH BIOCHEM BIOPHYS, V254, P526, DOI 10.1016/0003-9861(87)90133-0; SINGH H, 1993, J LIPID RES, V34, P467; SINGH I, 1984, P NATL ACAD SCI-BIOL, V81, P4203, DOI 10.1073/pnas.81.13.4203; SKJELDAL OH, 1987, BIOCHIM BIOPHYS ACTA, V921, P38, DOI 10.1016/0005-2760(87)90167-6; TENBRINK HJ, 1992, J LIPID RES, V33, P41; TSAI SC, 1969, J BIOL CHEM, V244, P2682; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; VANHOVE G, 1991, J BIOL CHEM, V266, P24670; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P24676; VANVELDHOVEN PP, 1992, J BIOL CHEM, V267, P20065; WANDERS RJA, 1991, J INHERIT METAB DIS, V14, P349, DOI 10.1007/BF01811700; WANDERS RJA, 1992, BIOCHIM BIOPHYS ACTA, V1124, P199, DOI 10.1016/0005-2760(92)90099-H; WATKINS PA, 1990, BIOCHEM BIOPH RES CO, V167, P580, DOI 10.1016/0006-291X(90)92064-7; WATMOUGH NJ, 1989, BIOCHEM J, V262, P261, DOI 10.1042/bj2620261	56	43	43	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9514	9520						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144536				2022-12-25	WOS:A1994NE05300021
J	SOROKIN, A; LEMMON, MA; ULLRICH, A; SCHLESSINGER, J				SOROKIN, A; LEMMON, MA; ULLRICH, A; SCHLESSINGER, J			STABILIZATION OF AN ACTIVE DIMERIC FORM OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR BY INTRODUCTION OF AN INTER-RECEPTOR DISULFIDE BOND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; CROSS-LINKING; SIGNAL TRANSDUCTION; SENSORY RECEPTOR; ESCHERICHIA-COLI; AUTOPHOSPHORYLATION; PHOSPHORYLATION; BINDING; INSULIN; DIMERIZATION	Populations of the epidermal growth factor receptor (EGFR) with both high and low affinity for EGF are found on the surface of cells. It has been hypothesized that the high-affinity state of the EGFR represents the receptor dimer and that this is also the kinase-active form. We describe here studies aimed at addressing this question directly. To stabilize homodimers of EGFR, we have generated a mutated form of the receptor by inserting a cysteine residue in the extracellular juxtamembranous region, in order to cross-link the extracellular domains of two receptors via disulfide bond formation. The mutation resulted in ligand-induced appearance of covalently linked EGF receptor dimers and, in parallel, increased the number of high-affinity receptors present on the surface of cells expressing the mutated EGFR. Comparison of the tyrosine kinase activity of the covalently linked dimeric and the monomeric forms of the EGF receptor, separated by sucrose density gradient centrifugation, showed that the dimer was significantly more active than monomer in the phosphorylation of exogenous substrate. We conclude that the dimeric form of the EGF-receptor represents the active form, and that dimer formation is associated with the appearance of high-affinity binding EGF receptors on the cell surface.	NYU MED CTR,DEPT PHARMACOL,550 1ST AVE,NEW YORK,NY 10016; MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,W-8033 MARTINSRIED,GERMANY	New York University; Max Planck Society				Sorokin, Andrey/0000-0002-5660-0190; Lemmon, Mark/0000-0002-3379-5319				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BELLOT F, 1990, J CELL BIOL, V110, P491, DOI 10.1083/jcb.110.2.491; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CAO HN, 1992, J BIOL CHEM, V267, P20489; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; HENEGOUWEN PMP, 1989, J CELL BIOCHEM, V39, P455; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; JACOBS S, 1983, ANNU REV PHARMACOL, V23, P461, DOI 10.1146/annurev.pa.23.040183.002333; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KOBASHI K, 1968, BIOCHIM BIOPHYS ACTA, V158, P239, DOI 10.1016/0304-4165(68)90136-0; LONARDO F, 1990, New Biologist, V2, P992; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MOHAMMADI M, 1993, BIOCHEMISTRY-US, V32, P8742, DOI 10.1021/bi00085a004; NORTHWOOD IC, 1989, J BIOL CHEM, V264, P5746; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PESSIN JE, 1985, MOL BASIS INSULIN AC, P3; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHREIBER AB, 1983, J BIOL CHEM, V258, P846; SCHREIBER AB, 1981, J BIOL CHEM, V256, P716; SORKIN A, 1991, J BIOL CHEM, V266, P23453; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1733; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; WALKER F, 1991, J BIOL CHEM, V266, P2746; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WILEY HS, 1989, J BIOL CHEM, V264, P18912; WINSTON JT, 1991, J CELL BIOCHEM, V47, P79, DOI 10.1002/jcb.240470110; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; ZHOU M, 1993, BIOCHEMISTRY-US, V32, P8193, DOI 10.1021/bi00083a020	40	102	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9752	9759						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144568				2022-12-25	WOS:A1994NE05300057
J	STACK, MS; JOHNSON, DA				STACK, MS; JOHNSON, DA			HUMAN MAST-CELL TRYPTASE ACTIVATES SINGLE-CHAIN URINARY-TYPE PLASMINOGEN-ACTIVATOR (PROUROKINASE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PURIFICATION; PROENZYME; SEQUENCE; THROMBIN; FORM; INACTIVATION; PROTEINS; INVITRO; PLASMA; TUMOR	Human lung mast cell tryptase is a trypsin-like serine proteinase that is stored in mast cell granules and released by activated mast cells. Here we report that mast cell tryptase is a potent activator of single-chain urinary-type plasminogen activator (scu-PA, or pro-urokinase), the zymogen form of urinary-type plasminogen activator (u-PA). Activation was complete within 75 min using an enzyme:substrate molar ratio of 1:50 and was accompanied by cleavage of scu-PA at Lys158-Ile159, generating active two-chain u-PA. The reaction was dependent on enzyme concentration and obeyed Michaelis-Menten kinetics. Kinetic constants calculated for scu-PA activation by mast cell tryptase are K(m) = 34 muM, V(max) = 3.6 pmol of u-PA/min, and k(cat) = 0.08 s-1. These data suggest that tryptase from tumor-associated mast cells may participate in the activation of scu-PA.	E TENNESSEE STATE UNIV,COLL MED,DEPT BIOCHEM,JOHNSON CITY,TN 37614	East Tennessee State University	STACK, MS (corresponding author), DUKE UNIV,MED CTR,DEPT PATHOL,BOX 3712,DURHAM,NC 27710, USA.				NATIONAL CANCER INSTITUTE [R01CA058900, R55CA058900, P30CA014236] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R15HL042623] Funding Source: NIH RePORTER; NCI NIH HHS [CA-14236, CA-58900] Funding Source: Medline; NHLBI NIH HHS [HL-42623] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTER SC, 1987, BIOCHEM J, V248, P821, DOI 10.1042/bj2480821; BRUNNER G, 1990, FEBS LETT, V260, P141, DOI 10.1016/0014-5793(90)80087-Y; CROWLE PK, 1989, MAST CELL BASOPHIL D, P307; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ETO I, 1992, BIOCHEM J, V283, P209, DOI 10.1042/bj2830209; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FRIEDMAN MM, 1987, AM REV RESPIR DIS, V135, P1157; GLENNER GG, 1960, NATURE, V185, P846, DOI 10.1038/185846a0; GONZALEZGRONOW M, 1984, BIOCHEMISTRY-US, V23, P190, DOI 10.1021/bi00297a003; GUREWICH V, 1987, BLOOD, V69, P769; GUREWICH V, 1984, J CLIN INVEST, V73, P1731, DOI 10.1172/JCI111381; HOLMES WE, 1985, BIO-TECHNOL, V3, P923, DOI 10.1038/nbt1085-923; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; LIJNEN HR, 1987, SEMIN THROMB HEMOST, V13, P152, DOI 10.1055/s-2007-1003486; LIJNEN HR, 1987, EUR J BIOCHEM, V169, P359, DOI 10.1111/j.1432-1033.1987.tb13620.x; LITTLE SS, 1993, THESIS E TENNESSEE S; LOHI J, 1992, J CELL BIOCHEM, V50, P337, DOI 10.1002/jcb.240500402; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUO O, 1981, NATURE, V291, P590, DOI 10.1038/291590a0; NOLAN C, 1977, BIOCHIM BIOPHYS ACTA, V496, P384, DOI 10.1016/0304-4165(77)90321-X; RIFKIN DB, 1989, AM REV RESPIR DIS, V140, P1112, DOI 10.1164/ajrccm/140.4.1112; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; SCHARTZ LB, 1981, J BIOL CHEM, V256, P11939; SCHWARTZ LB, 1981, J IMMUNOL, V126, P1290; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; SKRIVER L, 1982, EUR J BIOCHEM, V124, P409; SMITH TJ, 1984, J BIOL CHEM, V259, P1046; SMITH TJ, 1984, FED PROC, V43, P1760; TAPIOVAARA H, 1993, INT J CANCER, V53, P499, DOI 10.1002/ijc.2910530324; WASSERMAN SI, 1990, J ALLERGY CLIN IMMUN, V86, P590, DOI 10.1016/S0091-6749(05)80221-0; WUN TC, 1982, J BIOL CHEM, V257, P7262	38	203	213	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9416	9419						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144524				2022-12-25	WOS:A1994NE05300006
J	WEISEL, JW; NAGASWAMI, C; WOODHEAD, JL; DELACADENA, RA; PAGE, JD; COLMAN, RW				WEISEL, JW; NAGASWAMI, C; WOODHEAD, JL; DELACADENA, RA; PAGE, JD; COLMAN, RW			THE SHAPE OF HIGH-MOLECULAR-WEIGHT KININOGEN - ORGANIZATION INTO STRUCTURAL DOMAINS, CHANGES WITH ACTIVATION, AND INTERACTIONS WITH PREKALLIKREIN, AS DETERMINED BY ELECTRON-MICROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA PREKALLIKREIN; DISTINCT FUNCTIONAL DOMAINS; AMINO-ACID-SEQUENCE; HAGEMAN-FACTOR; LIGHT CHAIN; HMW-KININOGEN; HEAVY-CHAIN; FACTOR-XII; KALLIKREIN; FIBRINOGEN	Knowledge of the organization of the kininogen gene and protein structure and function correlations has allowed the development of a model of high molecular weight kininogen. Domains 1-3 on the heavy chain are evolutionarily related to cystatin and the latter two are inhibitors of cysteine proteases. Proteolytic cleavage in domain 4 to release bradykinin causes a conformational change, exposing a surface-binding region (domain 5) on the disulfide-linked light chain. The carboxyl-terminal domain 6 contains a zymogen binding sequence for factor XI and prekallikrein which, with domain 5, accounts for its cofactor activity. To explore further the domain structure, we have determined the shapes of high molecular weight kininogen and prekallikrein by electron microscopy of rotary shadowed preparations and computer image processing. High molecular weight kininogen appears to be a linear array of three linked globular regions about 16 nm long, with the two ends also connected by another thin strand. Both prekallikrein and kallikrein have a compact globular shape, with a subdivision that is sometimes visible. Different functional domains of high molecular weight kininogen were identified by monoclonal antibodies against these regions, as well as ligand binding of prekallikrein. These studies indicate that one end globular region is the prekallikrein-binding domain, the other comprises the cysteine protease inhibitor domains and the smaller central nodule is the surface-binding domain. Cleavage of high molecular weight kininogen with plasma kallikrein to yield two-chain high molecular weight kininogen results in a striking change in conformation: the central surface-binding domain swings out so that it is still adjacent to the prekallikrein-binding domain but no longer in the middle. These structural studies provide insight into the interactions of these proteins and aspects of the mechanisms of their actions.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,SOL SHERRY THROMBOSIS RES CTR,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT MED,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	WEISEL, JW (corresponding author), UNIV PENN,SCH MED,DEPT CELL & DEV BIOL,PHILADELPHIA,PA 19104, USA.				NHLBI NIH HHS [HL45486, HL30954, HL02681] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL045486, K08HL002681, R01HL030954] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASAKURA S, 1992, J CELL BIOL, V116, P465, DOI 10.1083/jcb.116.2.465; BAGDASARIAN A, 1974, J CLIN INVEST, V54, P1444, DOI 10.1172/JCI107892; BRADFORD HN, 1993, J BIOL CHEM, V268, P26546; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DELACADENA RA, 1988, BLOOD, V72, P1748; DELACADENA RA, 1987, J LAB CLIN MED, V109, P601; DELACADENA RA, 1992, PROTEIN SCI, V1, P151; DELACADENA RA, 1991, THROMB HAEMOSTASIS, V65, P699; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; FOWLER WE, 1983, J ULTRA MOL STRUCT R, V83, P319, DOI 10.1016/S0022-5320(83)90139-9; FUJIKAWA K, 1980, BIOCHEMISTRY-US, V19, P1322, DOI 10.1021/bi00548a010; Goding J., 1986, MONOCLONAL ANTIBODIE, P108; GUSTAFSON EJ, 1989, J CLIN INVEST, V84, P28, DOI 10.1172/JCI114151; KELLERMANN J, 1986, EUR J BIOCHEM, V154, P471, DOI 10.1111/j.1432-1033.1986.tb09421.x; KERBIRIOU DM, 1979, J BIOL CHEM, V254, P2020; KUNAPULI SP, 1992, THROMB HAEMOSTASIS, V67, P428; KUNAPULI SP, 1993, J BIOL CHEM, V268, P2486; MANDLE R, 1977, J BIOL CHEM, V252, P6097; MANDLE RJ, 1976, P NATL ACAD SCI USA, V73, P4179, DOI 10.1073/pnas.73.11.4179; MORI K, 1981, J BIOCHEM-TOKYO, V89, P1465, DOI 10.1093/oxfordjournals.jbchem.a133339; PAGE JD, 1991, J BIOL CHEM, V266, P8143; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; SCHMAIER AH, 1987, J BIOL CHEM, V262, P1405; SCOTT CF, 1979, EUR J BIOCHEM, V100, P77, DOI 10.1111/j.1432-1033.1979.tb02035.x; SCOTT CF, 1985, J BIOL CHEM, V260, P856; SCOTT CF, 1980, J CLIN INVEST, V65, P413, DOI 10.1172/JCI109684; SCOTT CF, 1984, J CLIN INVEST, V73, P954, DOI 10.1172/JCI111319; SILVERBERG M, 1980, THROMB RES, V20, P173, DOI 10.1016/0049-3848(80)90383-7; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; VILLANUEVA GB, 1989, BIOCHEM BIOPH RES CO, V158, P72, DOI 10.1016/S0006-291X(89)80178-0; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058	32	75	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					10100	10106						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144509				2022-12-25	WOS:A1994NE05300105
J	GOMEZMUNOZ, A; MARTIN, A; OBRIEN, L; BRINDLEY, DN				GOMEZMUNOZ, A; MARTIN, A; OBRIEN, L; BRINDLEY, DN			CELL-PERMEABLE CERAMIDES INHIBIT THE STIMULATION OF DNA-SYNTHESIS AND PHOSPHOLIPASE-D ACTIVITY BY PHOSPHATIDATE AND LYSOPHOSPHATIDATE IN RAT FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; PROTEIN KINASE-C; HL-60 CELLS; PHOSPHATIDYLCHOLINE BREAKDOWN; SPHINGOMYELIN METABOLISM; SIGNAL TRANSDUCTION; HUMAN NEUTROPHILS; ACID; DIFFERENTIATION; SPHINGOSINE	The interactions of ceramides with phosphatidate and lysophosphatidate in the regulation of signal transduction in rat fibroblasts were examined. C-2- and C-6-ceramides (N-acetylsphingosine and N-hexanoylsphingosine, respectively) at 10 mu M inhibited the stimulation of DNA synthesis that was produced by 50-100 mu M phosphatidate, or lysophosphatidate, or by exogenous phospholipase D. Sphingosine (10 mu M) had the opposite effect to the ceramides on DNA synthesis. C-2- or C-6-ceramides failed to inhibit the stimulation of DNA synthesis by insulin or serum. The ceramides did not modify the actions of phosphatidate, or lysophosphatidate, in decreasing the forskolin-induced increase in cAMP. C-2- and C-6-ceramides inhibited the stimulation of phospholipase D activity by: (a) phosphatidate, lysophosphatidate, phorbol ester, thrombin, or serum in intact fibroblasts and (b) phorbol ester or guanosine 5'-3-O-(thio)triphosphate in permeabilized fibroblasts. The ceramides can therefore modify cell signaling via phospholipase D, but this effect alone could not explain the decreased DNA synthesis. Incubation of fibroblasts with C-2- or Cs-ceramides or sphingomyelinase inhibited the interaction of exogenous phosphatidate or lysophosphatidate with the fibroblasts by 42 and 53%, respectively. Furthermore, a greater proportion of the phosphatidate, or lysophosphatidate, that was associated with the fibroblasts was metabolized further when the cells were pretreated with ceramides or sphingomyelinase. This effect was accompanied by an increased activity of N-ethylmaleimide-insensitive phosphatidate phosphohydrolase. Ceramides may therefore produce part of their growth inhibitory effects by blocking some of the signal transducing effects of phosphatidate and lysophosphatidate.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,AB,CANADA; UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON T6G 2S2,AB,CANADA	University of Alberta; University of Alberta				GOMEZ MUNOZ, ANTONIO/0000-0002-2539-016X				ABE A, 1992, EUR J BIOCHEM, V210, P765, DOI 10.1111/j.1432-1033.1992.tb17479.x; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; CHATTERJEE S, 1993, J BIOL CHEM, V268, P3401; CHEN H, 1992, BIOCHEM J, V286, P771, DOI 10.1042/bj2860771; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; EXTON JH, 1990, J BIOL CHEM, V265, P1; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; FLORINCHRISTENSEN J, 1992, J BIOL CHEM, V267, P14783; FRANSON RC, 1992, BIOCHIM BIOPHYS ACTA, V1136, P169, DOI 10.1016/0167-4889(92)90253-8; GODLKORN T, 1991, J BIOL CHEM, V266, P16092; GOMEZMUNOZ A, 1992, BIOCHIM BIOPHYS ACTA, V1127, P49, DOI 10.1016/0005-2760(92)90200-F; GUPTA AK, 1991, J LIPID RES, V32, P125; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HUANG CF, 1990, J BIOL CHEM, V265, P17468; JALINK K, 1993, P NATL ACAD SCI USA, V90, P1857, DOI 10.1073/pnas.90.5.1857; JALINK K, 1990, J BIOL CHEM, V265, P12232; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; KALEN A, 1992, BIOCHIM BIOPHYS ACTA, V1125, P90, DOI 10.1016/0005-2760(92)90160-W; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK RN, 1989, J BIOL CHEM, V264, P7617; LISCOVITCH M, 1991, BIOCHEM J, V279, P319, DOI 10.1042/bj2790319; MARTIN A, 1987, BIOCHEM J, V245, P347, DOI 10.1042/bj2450347; MARTIN A, 1993, J BIOL CHEM, V268; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1992, NUTR REV, V50, P78; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; VANDERBEND RL, 1992, BIOCHIM BIOPHYS ACTA, V1125, P110, DOI 10.1016/0005-2760(92)90163-P; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; YOUNES A, 1992, J BIOL CHEM, V267, P842; ZHANG H, 1990, J BIOL CHEM, V265, P76	49	186	187	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8937	8943						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132631				2022-12-25	WOS:A1994NB41100049
J	GUREVICH, VV; CHEN, CY; KIM, CM; BENOVIC, JL				GUREVICH, VV; CHEN, CY; KIM, CM; BENOVIC, JL			VISUAL ARRESTIN BINDING TO RHODOPSIN - INTRAMOLECULAR INTERACTION BETWEEN THE BASIC N-TERMINUS AND ACIDIC C-TERMINUS OF ARRESTIN MAY REGULATE BINDING SELECTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							48-KDA PROTEIN; PHOTOEXCITED RHODOPSIN; ACTIVATION; PHOSPHORYLATION; EXPRESSION; KINASE; SITES	Visual arrestin plays an important role in quenching phototransduction via its ability to preferentially bind to phosphorylated light-activated rhodopsin (P-Rh*). Recently we proposed a mechanism for the binding of visual arrestin to P-Rh* that helps to explain the nature of the conformational changes in arrestin observed upon binding. This mechanism involves a multisite interaction between arrestin and P-Rh* and implies an interaction between the C-terminal and N-terminal domains of arrestin. To obtain further insight into the mechanism of arrestin-rhodopsin interaction we have characterized the ability of polyanions to inhibit the interaction of wild type and mutant arrestins to different functional forms of rhodopsin. These studies reveal that: 1) heparin is most potent at inhibiting arrestin binding to dark phosphorylated rhodopsin > light-activated rhodopsin > P-Rh*; 2) C-terminal deletions in arrestin increase arrestin sensitivity to heparin inhibition while an N-terminal deletion (residues 2-16) decreases heparin inhibition; 3) the sensitivity of chimeric arrestins to heparin inhibition is determined by the origin of the N terminus of the chimera; and 4) heparin also inhibits arrestin binding to truncated (329)G-Rh*, suggesting it does not mimic the phosphorylated C terminus of rhodopsin. Taken together, these data suggest that heparin mimics the regulatory acidic C terminus of arrestin. Since the basic N terminal region of arrestin appears to serve as a site of heparin binding it is a likely candidate to be involved in the intramolecular interaction with the C-terminal region. The interaction of the N- and C-terminal domains of arrestin may control the conformational rearrangements in arrestin that occur upon binding to P-Rh*.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107	Jefferson University			Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NHLBI NIH HHS [HL45964] Funding Source: Medline; NIGMS NIH HHS [GM44944] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; CHEN CY, 1993, J BIOL CHEM, V268, P7825; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; HARGRAVE PA, 1992, MOL BIOL RECEPTORS T, P49; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; KIM CM, 1993, RECEPTOR, V3, P39; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; THOMPSON P, 1984, BIOCHEM J, V220, P773, DOI 10.1042/bj2200773; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; ZOZULYA SA, 1990, PROTEIN ENG, V3, P453, DOI 10.1093/protein/3.5.453	21	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8721	8727						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132602				2022-12-25	WOS:A1994NB41100019
J	SHIGERI, Y; FUJIMOTO, M				SHIGERI, Y; FUJIMOTO, M			Y2 RECEPTORS FOR NEUROPEPTIDE-Y ARE COUPLED TO 3 INTRACELLULAR SIGNAL-TRANSDUCTION PATHWAYS IN A HUMAN NEUROBLASTOMA CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ROOT GANGLION NEURONS; RAT SENSORY NEURONS; NEUROTRANSMITTER RELEASE; ADENYLATE-CYCLASE; CALCIUM CHANNELS; PEPTIDE-YY; PRESYNAPTIC INHIBITION; CA-2+ CHANNELS; BRAIN PEPTIDE	Neuropeptide Y (NPY) attenuated angiotensin II (AII)- or bradykinin (BK)-induced Ca2+ release from intracellular stores and inhibited forskolin-stimulated cAMP accumulation and omega conotoxin-sensitive high K+-induced Ca2+ influx in the human neuroblastoma cell line SMS- KAN. All three NPY actions were mediated via Y2 receptors. Pretreatment with pertussis toxin completely abolished all of the NPY actions. Activation or downregulation of protein kinase C had no effect on any NPY-mediated effect; herbimycin A, a tyrosine kinase inhibitor, only abolished the inhibitory effect of NPY on AII- or BK-induced Ca2+ mobilization. Herbimycin A also blocked platelet derived growth factor-induced Ca2+ mobilization, which involves tyrosine kinase activation, and there was a good correlation in the concentration dependency between the two effects of herbimycin A, strongly suggesting that its ability to cancel the NPY effect is due to inhibition of tyrosine kinase activity. NPY attenuated AII or BK-induced inositol 1,4,5-trisphosphate production, and herbimycin A reversed this NPY effect. These results provide the first evidence that Y2 receptors negatively couple to AII- or BK-induced phosphoinositide turnover leading to Ca2+ mobilization through pertussis toxin sensitive GTP-binding protein(s). Inhibition of phospholipase C-beta activity by NPY seems to be mediated by activation of protein-tyro sine kinase or phosphotyrosine-containing protein(s).			SHIGERI, Y (corresponding author), SHIONOGI & CO LTD, SHIONOGI RES LABS, FUKUSHIMA KU, OSAKA 553, JAPAN.							AAKERLUND L, 1990, FEBS LETT, V260, P73, DOI 10.1016/0014-5793(90)80069-U; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BIZZARRI C, 1990, P NATL ACAD SCI USA, V87, P4889, DOI 10.1073/pnas.87.12.4889; BLEAKMAN D, 1992, BRIT J PHARMACOL, V107, P334, DOI 10.1111/j.1476-5381.1992.tb12747.x; BLEAKMAN D, 1991, BRIT J PHARMACOL, V103, P1781, DOI 10.1111/j.1476-5381.1991.tb09863.x; COLMERS WF, 1989, BRAIN RES, V498, P99, DOI 10.1016/0006-8993(89)90403-4; DELAHUNTY TM, 1988, BIOCHEM J, V255, P69, DOI 10.1042/bj2550069; DUMONT Y, 1992, PROG NEUROBIOL, V38, P125, DOI 10.1016/0301-0082(92)90038-G; ENJALBERT A, 1990, J BIOL CHEM, V265, P18816; EWALD DA, 1988, P NATL ACAD SCI USA, V85, P3633, DOI 10.1073/pnas.85.10.3633; EWALD DA, 1988, J NEUROSCI, V8, P2447; EWALD DA, 1989, NEURON, V2, P1185, DOI 10.1016/0896-6273(89)90185-2; FOUCART S, 1993, J PHARMACOL EXP THER, V265, P903; FOUCART S, 1989, N-S ARCH PHARMACOL, V340, P658, DOI 10.1007/BF00717741; FUHLENDORFF J, 1990, P NATL ACAD SCI USA, V87, P182, DOI 10.1073/pnas.87.1.182; FUJIMOTO M, 1991, NEUROSCI LETT, V122, P9, DOI 10.1016/0304-3940(91)90180-2; HIRNING LD, 1990, BRAIN RES, V532, P120, DOI 10.1016/0006-8993(90)91751-2; INUI A, 1992, ENDOCRINOLOGY, V131, P2090, DOI 10.1210/en.131.5.2090; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; LEE KM, 1993, J BIOL CHEM, V268, P9945; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MICHEL MC, 1991, TRENDS PHARMACOL SCI, V12, P389, DOI 10.1016/0165-6147(91)90610-5; MIHARA S, 1989, FEBS LETT, V259, P79, DOI 10.1016/0014-5793(89)81499-1; MIHARA S, 1990, BIOCHEM INT, V22, P205; MILLER RJ, 1990, FASEB J, V4, P3291, DOI 10.1096/fasebj.4.15.1979294; MOTULSKY HJ, 1988, AM J PHYSIOL, V255, pE880, DOI 10.1152/ajpendo.1988.255.6.E880; PERNEY TM, 1989, J BIOL CHEM, V264, P7317; PLUMMER MR, 1991, J NEUROSCI, V11, P2339; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; ROSS RA, 1981, CELL MOL NEUROBIOL, V1, P301, DOI 10.1007/BF00710685; SHEIKH SP, 1989, J BIOL CHEM, V264, P6648; SHIGERI Y, 1992, BIOCHEM BIOPH RES CO, V187, P1565, DOI 10.1016/0006-291X(92)90481-Y; TADDEI S, 1991, HYPERTENSION, V18, P266, DOI 10.1161/01.HYP.18.3.266; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; TATEMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P5485, DOI 10.1073/pnas.79.18.5485; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; WAHLESTEDT C, 1990, ANN NY ACAD SCI, V611, P7; WAHLESTEDT C, 1992, LIFE SCI, V50, pPL7, DOI 10.1016/0024-3205(92)90342-M; WAHLESTEDT C, 1986, REGUL PEPTIDES, V13, P307, DOI 10.1016/0167-0115(86)90048-0; WAHLESTEDT C, 1993, ANNU REV PHARMACOL, V33, P309, DOI 10.1146/annurev.pa.33.040193.001521; WALKER MW, 1988, J NEUROSCI, V8, P2438; WEISS C, 1991, BRAIN RES, V543, P102, DOI 10.1016/0006-8993(91)91053-4; WEISS RH, 1992, J BIOL CHEM, V267, P5608; WILEY JW, 1990, J NEUROPHYSIOL, V63, P1499, DOI 10.1152/jn.1990.63.6.1499	45	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8842	8848						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132619				2022-12-25	WOS:A1994NB41100036
J	CHAIKIN, E; HAKEEM, I; RAZIN, E				CHAIKIN, E; HAKEEM, I; RAZIN, E			ENHANCEMENT OF INTERLEUKIN-3-DEPENDENT MAST-CELL PROLIFERATION BY SUPPRESSION OF C-JUN EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GROWTH-FACTOR; GENE-EXPRESSION; FOS; PHOSPHORYLATION; ACTIVATION; CLONING; ELEMENT; DIFFERENTIATION; IDENTIFICATION	We have previously shown that protein kinase C (PKC) depletion is associated with an increase in the proliferation of interleukin 3 (IL-3)-induced mast cells. Here we show that the AP-1 components c-Jun and c-Fos are induced by IL-3. While c-Jun's induction by IL-3 is totally dependent on PKC, c-Fos induction by IL-3 is only attenuated by PKC depletion. AP-1 binding activity was also induced by IL-3 but this induction was PKC independent. These results indicated a possible involvement of c-Jun in the inhibition of IL-3-induced growth regulation. A support for this assumption came from experiments in which an increase in thymidine incorporation into mast cells was noted when c-jun antisense oligomers were administered to IL-3-treated cells. Since the only known effect of direct inhibition of c-Jun on proliferation rates in several cellular systems was a reduction of proliferation, we verified that our c-jun antisense oligomer could also inhibit proliferation rates in fibroblasts where such a repression was previously reported. Thus c-Jun has an inhibitory effect on IL-3 induction of mast cells proliferation that is distinct from its role in several other cellular environments. These observations reveal the involvement of AP-1 and its components in IL-3-induced signal transduction and the importance of the mast cell environment in determining their specific cellular function.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,INST BIOCHEM,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem								ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BERGMEYER HU, 1974, METHOD ENZYMAT AN, P574; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CARSTEN J, 1990, CELL, V62, P1189; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHAIKIN E, 1990, J BIOL CHEM, V265, P22109; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; FARRAR WL, 1985, NATURE, V315, P235, DOI 10.1038/315235a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOLDWASER E, 1983, UCLA S MOL CELL BIOL, V1, P301; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HOLGATE ST, 1993, ALLERGY; HORIE M, 1993, J BIOL CHEM, V268, P968; HUANG CL, 1987, NATURE, V329, P849, DOI 10.1038/329849a0; IHLE JN, 1983, J IMMUNOL, V131, P282; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; KOIKE K, 1986, BLOOD, V67, P859; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LEWIN I, 1993, BLOOD, V82, P3745; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MECHTA F, 1989, New Biologist, V1, P297; MILLS GB, 1988, CELL, V55, P91, DOI 10.1016/0092-8674(88)90012-8; MOORE MAS, 1988, LYMPHOKINES, V15, P219; NABEL G, 1981, NATURE, V291, P332, DOI 10.1038/291332a0; NEL AE, 1986, BIOCHEM J, V233, P145, DOI 10.1042/bj2330145; NICOLAIDES NC, 1992, J BIOL CHEM, V267, P19665; NISHIZUKA Y, 1992, SCIENCE, V258, P604; OKAZAKI T, 1988, EXP HEMATOL, V16, P42; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; RAZIN E, 1984, J IMMUNOL, V132, P1479; SAGHER F, 1967, MASTOCYTOSIS MAST CE; Sambrook J, 1989, MOL CLONING LABORATO; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SMITH MJ, 1992, BLOOD, V79, P2107; SOPRANO KJ, 1993, ANN NY ACAD SCI, V666, P231; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0	45	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8498	8503						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132577				2022-12-25	WOS:A1994NB40900100
J	CHAKRABARTI, R; BUXTON, J; JOLY, M; CORVERA, S				CHAKRABARTI, R; BUXTON, J; JOLY, M; CORVERA, S			INSULIN-SENSITIVE ASSOCIATION OF GLUT-4 WITH ENDOCYTIC CLATHRIN-COATED VESICLES REVEALED WITH THE USE OF BREFELDIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATABLE GLUCOSE TRANSPORTER; TRANS-GOLGI NETWORK; ORGANELLE STRUCTURE; PLASMA-MEMBRANE; RAT ADIPOCYTES; TRANSLOCATION; PROTEINS; ENDOSOMES; LOCALIZATION; MECHANISM	The interaction of the adipocyte/skeletal muscle glucose transporter (GLUT-4) with clathrin lattices may be important in maintaining its intracellular distribution. To better understand the role of clathrin lattices in the sorting of GLUT-4, we have attempted to determine the cellular origin of clathrin-coated vesicles (CCVs) that contain this transporter. The fungal toxin brefeldin A (BFA) causes the selective disassembly of clathrin lattices at the trans-Golgi network (TGN), but not at the plasma membrane (PM), thus providing a way of estimating the proportion of GLUT-4 in PM- versus TGN-derived clathrin lattices. Exposure of 3T3-L1 adipocytes to BFA resulted in a rapid disassembly of clathrin lattices at the TGN, observed by optical sectioning microscopy, and to a pronounced decrease in the yield of CCVs purified from these cells. Thus, CCVs isolated from BFA-treated cells are likely to be derived from the PM. Immunoblotting experiments revealed the presence of GLUT-4 in such CCVs, suggesting that under basal conditions the transporter is continually retrieved from the PM through the CCV pathway. Exposure of both BFA-treated or non-treated cells to insulin resulted in a 4-6-fold increase in the concentration of GLUT-4 at the PM. In parallel, the concentration of GLUT-4 in PM-derived CCVs decreased by 60%. These results suggest (a) that the effect of insulin to increase the cell surface concentration of GLUT-4 is not inhibited by BFA, and (b) that a decreased association of GLUT-4 with endocytic CCVs may be important in facilitating its increased cell surface concentration in response to the hormone.	UNIV MASSACHUSETTS, SCH MED, DEPT CELL BIOL, WORCESTER, MA 01655 USA; UNIV MASSACHUSETTS, SCH MED, PROGRAM MOLEC MED, WORCESTER, MA 01655 USA; UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester								BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; BROWN WJ, 1989, P NATL ACAD SCI USA, V81, P5135; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; CARRINGTON WA, 1990, NONINVASIVE TECHNIQU, P53; CORVERA S, 1990, J BIOL CHEM, V265, P15963; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J BIOL CHEM, V268, P9187; DAMKE H, 1991, J BIOL CHEM, V266, P29829; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KEDERSHA NL, 1986, ANAL BIOCHEM, V156, P161, DOI 10.1016/0003-2697(86)90168-5; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; RUBINSTEIN JR, 1981, J CELL BIOL, V89, P357; SEEGER M, 1992, EMBO J, V11, P2811, DOI 10.1002/j.1460-2075.1992.tb05348.x; SEEGER M, 1992, J CELL BIOL, V118, P531, DOI 10.1083/jcb.118.3.531; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WONG DH, 1992, J CELL BIOL, V117, P1171, DOI 10.1083/jcb.117.6.1171; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; YANG J, 1993, J BIOL CHEM, V268, P4600	26	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7926	7933						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132512				2022-12-25	WOS:A1994NB40900018
J	CHALMERS, RM; KLECKNER, N				CHALMERS, RM; KLECKNER, N			TN10/IS10 TRANSPOSASE PURIFICATION, ACTIVATION, AND IN-VITRO REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TN10 TRANSPOSITION; STRAND TRANSFER; DNA-SEQUENCE; PROTEIN; INVITRO; INTEGRATION; MECHANISM; CLEAVAGE; BINDING; SITE	We describe a method for the purification of Tn10/IS10 transposase that relies on the aggregation of the protein after overexpression in Escherichia coli. Aggregated transposase was solubilized before the final purification step, a gel-filtration column, using a combination of salt and detergent. This procedure is the first reported for the preparation of concentrated and active transposase from any IS element. The yield is 11 mg of purified protein at a concentration of 1 mg/ml from 2.5 g of cells. The procedure can be scaled up with ease. We also describe a treatment that activates transposase in either a crude or purified state. This involves dilution into a solution of salt plus organic solvent. In transposition reactions using supercoiled substrate plasmid, the activity was directly proportional to the amount of transposase added over a wide range of transposase/DNA ratios (0.2-2.0 molecules/DNA substrate molecule). In this range 8 transposase molecules were added per transposition event. Maximum conversion of substrate to product (40%) was with 18 transposase molecules/transposition event. At higher levels of transposase with a constant amount of substrate, activity was reduced but could be restored by addition of nonspecific DNA. Both the specific activity of transposase and the type of products generated can be altered by changing in vitro assay conditions. The effects of salts, solvents, and pH value on the reaction are described.			CHALMERS, RM (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.			chalmers, ronald/0000-0002-1395-7173	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025326, R37GM025326] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25326] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKMAN K, 1976, P NATL ACAD SCI USA, V73, P4174, DOI 10.1073/pnas.73.11.4174; BENDER J, 1986, CELL, V45, P801, DOI 10.1016/0092-8674(86)90555-6; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; BENJAMIN HW, 1992, P NATL ACAD SCI USA, V89, P4648, DOI 10.1073/pnas.89.10.4648; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CHALMERS RM, 1989, BIOCHEM J, V263, P913, DOI 10.1042/bj2630913; DELACRUZ NB, 1993, J BACTERIOL, V175, P6932, DOI 10.1128/jb.175.21.6932-6938.1993; DERBYSHIRE KM, 1992, EMBO J, V11, P3449, DOI 10.1002/j.1460-2075.1992.tb05424.x; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P155; HALLING SM, 1982, P NATL ACAD SCI-BIOL, V79, P2608, DOI 10.1073/pnas.79.8.2608; HANIFORD DB, 1991, CELL, V64, P171; HANIFORD DB, 1989, CELL, V59, P385, DOI 10.1016/0092-8674(89)90299-7; ICHIKAWA H, 1987, P NATL ACAD SCI USA, V84, P8220, DOI 10.1073/pnas.84.23.8220; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; REED RR, 1981, CELL, V25, P713, DOI 10.1016/0092-8674(81)90178-1; ROBERTS DE, 1991, GENETICS, V128, P37; Sambrook J, 1989, MOL CLONING LABORATO; SCHUKKINK RF, 1990, NUCLEIC ACIDS RES, V18, P859; SEN J, 1988, NUCLEIC ACIDS RES, V16, P4730, DOI 10.1093/nar/16.10.4730; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; [No title captured]	27	71	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8029	8035						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132525				2022-12-25	WOS:A1994NB40900033
J	CHAUDHURI, A; ZBRZEZNA, V; POLYAKOVA, J; POGO, AO; HESSELGESSER, J; HORUK, R				CHAUDHURI, A; ZBRZEZNA, V; POLYAKOVA, J; POGO, AO; HESSELGESSER, J; HORUK, R			EXPRESSION OF THE DUFFY ANTIGEN IN K562 CELLS - EVIDENCE THAT IT IS THE HUMAN ERYTHROCYTE CHEMOKINE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN INTERLEUKIN-8 RECEPTOR; CYTOKINE FAMILY; BIOLOGY	The human malarial parasite Plasmodium vivax invades erythrocytes by binding to a cell surface protein identified as the Duffy blood group antigen. The molecular properties of the Duffy antigen, which was recently cloned, are very similar to those of a chemokine binding protein known as the human erythrocyte chemokine receptor. This has led to the suggestion that these two molecules are the same protein. To further investigate the suspected double identity of the Duffy antigen we have transfected it into a human erythroleukemic cell line, K562. Cells stably expressing the Duffy antigen were isolated and used to characterize the protein. K562 cells transfected with the Duffy antigen displayed specific I-125-melanoma growth-stimulating activity (MGSA) binding while mock transfected cells did not. Comparison of I-125-MGSA binding to the Duffy antigen and the human erythrocyte chemokine receptor showed that the specific I-125-MGSA binding to both proteins was displaced by excess unlabeled MGSA, interleukin-8, RANTES, monocyte chemotactic peptide-1, and platelet factor 4, but not by macrophage inflammatory protein-1 alpha or -1 beta. Scatchard analysis of competition binding studies with these unlabeled chemokines revealed high affinity binding to the Duffy antigen with K-D binding values of 24 +/- 4.9, 20 +/- 4.7, 41.9 +/- 12.8, and 33.9 +/- 7 nM for MGSA, interleukin-8, RANTES, and monocyte chemotactic peptide l, respectively. A monoclonal antibody, Fy6, to the Duffy antigen inhibited I-125-MGSA binding to K562 cells expressing the Duffy antigen. Cell membranes from K562 cells permanently expressing the Duffy antigen were chemically cross-linked with I-125-MGSA. SDS-polyacrylamide gel electrophoresis analysis of the cross-linked products showed covalent incorporation of radiolabeled MGSA into a protein of molecular mass 47 kDa, and cross linking was inhibited in the presence of unlabeled MGSA. These studies provide evidence that the Duffy blood group antigen is the same protein as the human erythrocyte chemokine receptor.	GENENTECH INC,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech	CHAUDHURI, A (corresponding author), NEW YORK BLOOD CTR,NEW YORK,NY 10021, USA.							CHAUDHURI A, 1993, P NATL ACAD SCI USA, V90, P10793, DOI 10.1073/pnas.90.22.10793; CHAUDHURI A, 1994, BLOOD CELL BIOCH; DARBONNE WC, 1991, J CLIN INVEST, V88, P1362, DOI 10.1172/JCI115442; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORUK R, 1993, BIOCHEMISTRY-US, V32, P5733, DOI 10.1021/bi00073a002; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; HORUK R, 1993, J BIOL CHEM, V268, P541; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, J BIOL CHEM, V268, P12247; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NICHOLS ME, 1987, J EXP MED, V166, P776, DOI 10.1084/jem.166.3.776; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; TANNER MJA, 1972, BIOCHEM J, V129, P333, DOI 10.1042/bj1290333; WASNIOWSKA K, 1993, BIOCHEM BIOPH RES CO, V192, P366, DOI 10.1006/bbrc.1993.1424	19	142	150	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7835	7838						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132497				2022-12-25	WOS:A1994NB40900001
J	DEVASKAR, SU; GIDDINGS, SJ; RAJAKUMAR, PA; CARNAGHI, LR; MENON, RK; ZAHM, DS				DEVASKAR, SU; GIDDINGS, SJ; RAJAKUMAR, PA; CARNAGHI, LR; MENON, RK; ZAHM, DS			INSULIN GENE-EXPRESSION AND INSULIN SYNTHESIS IN MAMMALIAN NEURONAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN GLUCOSE TRANSPORTER; RAT-BRAIN; DEVELOPMENTAL REGULATION; GLUCOKINASE GENE; MESSENGER-RNA; BINDING; INVIVO; IDENTIFICATION; MICROVESSELS; LOCALIZATION	To demonstrate the presence of de novo synthesis in central mammalian neurons, we cloned and sequenced a rabbit insulin cDNA from pancreas and used it to define sequences encoding insulin mRNA from postnatal rabbit brain. We observed transcription/elongation of nascent insulin transcripts, characterized the size of these transcripts, and localized them to specific neurons in certain catecholaminergic-rich areas of the central nervous system. RNase protection assays using a rabbit probe spanning a region from 14 bases 5' to the translation start site through all but 18 bases of the sequence encoding the A-chain of insulin showed two bands in rabbit brain RNA and only one band in pancreas. The larger band in brain was the same size as that in pancreatic RNA; the other was approximately 10 bases shorter. Because the sequence of a reverse transcription-polymerase chain reaction product from brain RNA was identical to pancreatic RNA sequence in the region corresponding to the 3' region of the probe, the smaller band in brain is most consistent with a sequence mismatch in some brain mRNA in the region corresponding to the 5'-end of the probe, In situ hybridization localized insulin mRNA to anatomical regions involved with olfaction and higher association of the limbic system. High performance liquid chromatography, radioimmunoassay, and [S-35]cysteine metabolic labeling of cultured neuronal and glial cells indicated extracellular secretion of immunoprecipitable insulin by neurons only. Presence of insulin transcripts within specific neurons with extracellular secretion of the peptide suggests a specialized biological role.	ST LOUIS UNIV, SCH MED,CARDINAL GLENNON CHILDRENS HOSP, PEDIAT RES INST,DEPT PEDIAT, ST LOUIS, MO 63110 USA; ST LOUIS UNIV, SCH MED,CARDINAL GLENNON CHILDRENS HOSP, PEDIAT RES INST,DEPT ANAT, ST LOUIS, MO 63110 USA; ST LOUIS UNIV, SCH MED,CARDINAL GLENNON CHILDRENS HOSP, PEDIAT RES INST,DEPT NEUROBIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, DEPT VET AFFAIRS MED CTR, MED SERV 111JC, ST LOUIS, MO 63106 USA; UNIV PITTSBURGH, CHILDRENS HOSP PITTSBURGH, DEPT PEDIAT, DIV ENDOCRINOL, PITTSBURGH, PA 15213 USA	Saint Louis University; Saint Louis University; Saint Louis University; Washington University (WUSTL); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	DEVASKAR, SU (corresponding author), ST LOUIS UNIV, SCH MED,CARDINAL GLENNON CHILDRENS HOSP, PEDIAT RES INST,DEPT PEDIAT, DIV NEONATOL, ST LOUIS, MO 63110 USA.			Zahm, Daniel/0000-0002-2943-7906	NICHD NIH HHS [HD25024] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025024, R29HD025024] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BELL GI, 1980, NATURE, V284, P26, DOI 10.1038/284026a0; BOYD FT, 1985, J BIOL CHEM, V260, P5880; COHEN RM, 1986, METABOLISM, V35, P1137, DOI 10.1016/0026-0495(86)90027-2; COKER GT, 1990, MOL BRAIN RES, V8, P93, DOI 10.1016/0169-328X(90)90052-F; COLWELL N, 1992, BIOCHIM BIOPHYS ACTA, V1172, P175; CORDELL B, 1979, CELL, V18, P533, DOI 10.1016/0092-8674(79)90070-9; DEHAEN C, 1976, J MOL BIOL, V106, P639, DOI 10.1016/0022-2836(76)90256-4; DELTOUR L, 1993, P NATL ACAD SCI USA, V90, P527, DOI 10.1073/pnas.90.2.527; DEVASKAR S, 1989, MOLECULAR AND CELLULAR BIOLOGY OF INSULIN-LIKE GROWTH FACTORS AND THEIR RECEPTORS, P231; DEVASKAR S, 1991, ENDOCRINOLOGY, V129, P1530, DOI 10.1210/endo-129-3-1530; DEVASKAR S, 1992, DEV BRAIN RES, V67, P95, DOI 10.1016/0165-3806(92)90029-V; DEVASKAR SU, 1993, REGUL PEPTIDES, V48, P55, DOI 10.1016/0167-0115(93)90335-6; DEVASKAR SU, 1985, BIOCHEM BIOPH RES CO, V133, P670, DOI 10.1016/0006-291X(85)90957-X; DEVASKAR SU, 1993, BRAIN RES, V605, P101, DOI 10.1016/0006-8993(93)91361-U; DICKINSON CJ, 1993, AM J PHYSIOL, V264, pG553, DOI 10.1152/ajpgi.1993.264.3.G553; DUFFY KR, 1987, BRAIN RES, V420, P32, DOI 10.1016/0006-8993(87)90236-8; FRANK HJL, 1985, DIABETES, V34, P728, DOI 10.2337/diabetes.34.8.728; FRANK HJL, 1986, DIABETES, V35, P654, DOI 10.2337/diabetes.35.6.654; GIDDINGS SJ, 1988, J BIOL CHEM, V263, P3845; GIDDINGS SJ, 1989, J BIOL CHEM, V264, P9462; GIDDINGS SJ, 1985, DIABETOLOGIA, V28, P343; HAVRANKOVA J, 1978, P NATL ACAD SCI USA, V75, P5737, DOI 10.1073/pnas.75.11.5737; JANSEN E, 1991, MOL CELL ENDOCRINOL, V78, P115, DOI 10.1016/0303-7207(91)90192-U; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; LOMEDICO P, 1979, CELL, V18, P545, DOI 10.1016/0092-8674(79)90071-0; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MARKS JL, 1990, ENDOCRINOLOGY, V127, P3234, DOI 10.1210/endo-127-6-3234; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MUKAI T, 1991, EUR J BIOCHEM, V195, P781, DOI 10.1111/j.1432-1033.1991.tb15766.x; SADIQ F, 1990, ENDOCRINOLOGY, V126, P2417, DOI 10.1210/endo-126-5-2417; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECHTER R, 1990, J HISTOCHEM CYTOCHEM, V38, P829, DOI 10.1177/38.6.2186089; SCHECHTER R, 1988, ENDOCRINOLOGY, V123, P505, DOI 10.1210/endo-123-1-505; SCHECHTER R, 1992, BRAIN RES, V582, P27, DOI 10.1016/0006-8993(92)90313-X; SCHWARTZ MW, 1991, J CLIN INVEST, V88, P1272, DOI 10.1172/JCI115431; SCHWARTZ MW, 1992, ENDOCR REV, V13, P387, DOI 10.1210/er.13.3.387; THOMPSON RJ, 1973, J NEUROCHEM, V21, P19, DOI 10.1111/j.1471-4159.1973.tb04222.x; VANHOUTEN M, 1979, ENDOCRINOLOGY, V105, P666; YALOW R, 1986, PEPTIDES S20, V7, P17	42	261	270	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8445	8454						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132571				2022-12-25	WOS:A1994NB40900092
J	MUH, U; WILLIAMS, CH; MASSEY, V				MUH, U; WILLIAMS, CH; MASSEY, V			LACTATE MONOOXYGENASE .2. SITE-DIRECTED MUTAGENESIS OF THE POSTULATED ACTIVE-SITE BASE HISTIDINE-290	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINACH GLYCOLATE OXIDASE; BAKERS-YEAST; MECHANISM; FLAVOCYTOCHROME-B2; SEQUENCE; INACTIVATION; RESOLUTION; PROTEINS; BINDING	Lactate monooxygenase catalyzes the oxidation of L-lactate with molecular oxygen to acetate, CO2, and water. Histidine 290 has been proposed to be the active site base in lactate monooxygenase (Giegel, D. A., Williams, C. H., Jr, and Massey, V. (1990) J. Biol. Chem. 265, 6626-6632) and was mutated to a glutamine (H290Q). The mutant enzyme shows properties that support strongly the postulated function of the histidine. The ability of L-lactate to reduce the enzyme flavin is essentially abolished, whereas reoxidation of reduced enzyme with oxygen proceeds at 1.4 x 10(4) M(-1) S-1, a rate essentially like that found in the wild type enzyme. The substrate, L-lactate, is bound with a K-d equal to 2.0 x 10(-2) M, and D-lactate, a competitive inhibitor with a K-d of 3.1 X 10(-3) M. Both values are similar to binding measured in the wild type enzyme. Unlike the situation with wild type enzyme, where the transition state analog oxalate is bound tightly in a two-step reaction involving proton uptake from solution (Ghisla, S., and Massey, V. (1977) J. Biol. Chem. 252, 6729-6735), the mutant enzyme binds oxalate weakly, in a single step reaction, with a K-d in the order of 0.1 M. No effect was observed upon varying the pH, indicating that binding does not include a protonation step. Replacing the histidine also has a significant effect on the ability of the enzyme to stabilize the flavin N(5)-sulfite adduct. Sulfite is bound at least 1000-fold weaker than it is in the wild type enzyme.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; DEPT VET AFFAIRS MED CTR,ANN ARBOR,MI 48105	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011106, R37GM011106] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21444, GM-11106] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bevington P. R., 1969, DATA REDUCTION ERROR, P235; CEDERLUND E, 1988, EUR J BIOCHEM, V173, P523, DOI 10.1111/j.1432-1033.1988.tb14029.x; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P6030, DOI 10.1021/bi00393a013; GHISLA S, 1976, BIOCHEMISTRY-US, V15, P1791, DOI 10.1021/bi00654a002; GHISLA S, 1975, J BIOL CHEM, V250, P577; GHISLA S, 1977, J BIOL CHEM, V252, P6729; Ghisla S., 1991, CHEM BIOCH FLAVOENZY, P243; GIEGEL DA, 1990, J BIOL CHEM, V265, P6626; HAYAISHI O, 1957, J AM CHEM SOC, V79, P4809, DOI 10.1021/ja01574a060; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDERER F, 1985, EUR J BIOCHEM, V152, P419, DOI 10.1111/j.1432-1033.1985.tb09213.x; LINDQVIST Y, 1989, J BIOL CHEM, V264, P3624; LOCKRIDGE O, 1972, J BIOL CHEM, V247, P8097; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; MASSEY V, 1977, J BIOL CHEM, V252, P5562; MUH U, 1994, J BIOL CHEM, V269, P7982; MUH U, 1994, J BIOL CHEM, V269, P7994; SCHONBRUNN A, 1976, BIOCHEMISTRY-US, V15, P1798, DOI 10.1021/bi00654a003; VOLOKITA M, 1987, J BIOL CHEM, V262, P15825; WALSH C, 1973, J BIOL CHEM, V248, P7049; WALSH CT, 1972, J BIOL CHEM, V247, P6004; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M; XIA ZX, 1987, P NATL ACAD SCI USA, V84, P2629, DOI 10.1073/pnas.84.9.2629	24	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7989	7993						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132519				2022-12-25	WOS:A1994NB40900027
J	JIANG, HP; WU, DQ; SIMON, MI				JIANG, HP; WU, DQ; SIMON, MI			ACTIVATION OF PHOSPHOLIPASE-C BETA-4 BY HETEROTRIMERIC GTP-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNITS; GQ; ISOZYMES; FAMILY; GENE; EXPRESSION; DIVERSITY; CELLS	Transient transfection assays were used to determine how the activity of phospholipase C beta 4, which is preferentially expressed in retina, was regulated. An expression vector carrying the full-length cDNA corresponding to phospholipase C beta 4 was constructed and co-trans- fected into COS -7 cells together with cDNA encoding the alpha subunits of the Gq class and various beta and gamma subunits corresponding to the heterotrimeric GTP-binding proteins. We found that all the alpha subunits of the Gq class, including G alpha q, G alpha 11, G alpha 14, G alpha 15, and G alpha 16 could activate PLC beta 4 and that none of the G beta gamma subunits that we tested including G beta 1 gamma 1, G beta 1 gamma 2, G beta 1 gamma 3, or G beta 2 gamma 2 activated phospholipase C beta 4. In control experiments, cotransfection with cDNA encoding the alpha subunit of transducin or Gi2 gave no activation of PLC beta 4. These results indicate that phospholipase C beta 4 is activated by G alpha subunits that are members of the Gq class, and, like the phospholipase C beta 1 isoform, it is refractory to activation in the transfection assay by many of the combinations of beta and gamma subunits found in the heterotrimeric G-proteins.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034236, R37GM034236] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34236] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAROZZI A, 1993, FEBS LETT, V315, P340, DOI 10.1016/0014-5793(93)81190-B; FERREIRA PA, 1993, P NATL ACAD SCI USA, V90, P6042, DOI 10.1073/pnas.90.13.6042; FOECKING MK, 1986, GENE, V45, P101, DOI 10.1016/0378-1119(86)90137-X; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; JHON DY, 1993, J BIOL CHEM, V268, P6654; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRIZ R, 1990, CIBA F SYMP, V150, P112; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEE CW, 1993, J BIOL CHEM, V268, P21318; MIN DS, 1993, J BIOL CHEM, V268, P12207; PARK D, 1992, J BIOL CHEM, V267, P16048; PARK DG, 1993, J BIOL CHEM, V268, P4573; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; WU DQ, 1993, J BIOL CHEM, V268, P3704; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811	34	102	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7593	7596						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125982				2022-12-25	WOS:A1994NA03200088
J	LE, AQ; STEINER, JL; FERRELL, GA; SHAKER, JC; SIFERS, RN				LE, AQ; STEINER, JL; FERRELL, GA; SHAKER, JC; SIFERS, RN			ASSOCIATION BETWEEN CALNEXIN AND A SECRETION-INCOMPETENT VARIANT OF HUMAN ALPHA(1)-ANTITRYPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; ALPHA-1-PROTEINASE INHIBITOR; HUMAN ALPHA-1-ANTITRYPSIN; TRANSGENIC MICE; PROTEIN; TISSUE; ACCUMULATION; DEGRADATION; TRANSPORT; EMPHYSEMA	The naturally occurring null(Hong Kong) variant of human alpha 1-antitrypsin is truncated at its carboxyl terminus, and is retained and degraded in a pre-Gels compartment of stably transfected murine hepatoma cells (Le, A., Graham, K. S., and Sifers, R. N. (1990) J. Biol. Chen. 265, 14001-14007). Long-term metabolic radiolabeling with [S-35]methionine or [P-32]orthophosphate in combination with low stringency immunoprecipitation of the null(Hong Kong) variant has resulted in the co-precipitation of a radiolabeled 90-kDa protein designated p90. Several criteria, including mobility in SDS-polyacrylamide gel electrophoresis, absence of asparagine-linked oligosaccharides, and immunoreactivity with peptide-specific antiserum, have indicated that co-precipitating p90 is identical to calnexin, a calcium-binding phosphoprotein of the endoplasmic reticulum membrane (Wada, I. W., Rindress, P. H., Ou, W. J., Doherty, J. J., Louvard, D., Bell, A. W., Dignard, D., Thomas, D. Y., and Bergeron, J. J. M. (1991) J. Biol. Chem. 266, 19599-19610). Finally, results from co-immunoprecipitation analyses and velocity sedimentation experiments have verified that approximately 30% of the retained null(Hong Kong) variant polypeptides are associated with calnexin in a 1:1 molar ratio and can be dissociated with either deoxycholate or chelation of calcium ions at 37 degrees C. Overall, these findings may extend our current understanding of the molecular pathogenesis of serum alpha 1-antitrypsin deficiency.	BAYLOR COLL MED, DEPT PATHOL, MOLEC PATHOBIOL SECT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine			Sifers, Richard Norman/AGQ-7262-2022		NIDDK NIH HHS [DK42806] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042806] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; BRANTLY M, 1988, AM J MED, V84, P13; BRODBECK RM, 1992, J BIOL CHEM, V267, P294; CALA SE, 1993, J BIOL CHEM, V268, P2969; CARLSON JA, 1988, J CLIN INVEST, V82, P26, DOI 10.1172/JCI113580; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; FABBRETTI G, 1992, LIVER, V12, P296; GADEK JE, 1981, J CLIN INVEST, V68, P889, DOI 10.1172/JCI110344; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAHAM KS, 1990, J BIOL CHEM, V265, P20463; HANCE AJ, 1975, AM REV RESPIR DIS, V112, P657; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; JANOFF A, 1977, AM REV RESPIR DIS, V115, P461; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LE A, 1990, J BIOL CHEM, V265, P14001; LE AQ, 1992, J BIOL CHEM, V267, P1072; LODISH HF, 1987, J CELL BIOL, V104, P221, DOI 10.1083/jcb.104.2.221; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; LONG GL, 1984, BIOCHEMISTRY-US, V23, P4828, DOI 10.1021/bi00316a003; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; OU WJ, 1992, J BIOL CHEM, V267, P23789; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; ROTHMAN JE, 1987, CELL, V50, P521, DOI 10.1016/0092-8674(87)90024-9; SENIOR RM, 1977, AM REV RESPIR DIS, V116, P469, DOI 10.1164/arrd.1977.116.3.469; SIFERS RN, 1992, NATURE, V357, P541, DOI 10.1038/357541a0; SIFERS RN, 1987, NUCLEIC ACIDS RES, V15, P1459, DOI 10.1093/nar/15.4.1459; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; SIFERS RN, 1989, AM J RESP CELL MOL, V1, P341, DOI 10.1165/ajrcmb/1.5.341; WADA I, 1991, J BIOL CHEM, V266, P19599; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8	35	105	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7514	7519						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125971				2022-12-25	WOS:A1994NA03200076
J	RENAULD, JC; VANDERLUGT, N; VINK, A; VANROON, M; GODFRAIND, C; WARNIER, G; MERZ, H; FELLER, A; BERNS, A; VANSNICK, J				RENAULD, JC; VANDERLUGT, N; VINK, A; VANROON, M; GODFRAIND, C; WARNIER, G; MERZ, H; FELLER, A; BERNS, A; VANSNICK, J			THYMIC LYMPHOMAS IN INTERLEUKIN-9 TRANSGENIC MICE	ONCOGENE			English	Article							CELL GROWTH-FACTOR; ENHANCING ACTIVITY MEA; CD4+ T-CELLS; FACTOR P40; EXPRESSION; CDNA; PROLIFERATION; GLYCOPROTEIN; SEQUENCES; P40/IL-9	Transgenic mice overexpressing the interleukin 9 gene were generated to study the biological activity of this cytokine in vivo. Although no major histological or morphological modifications of the lymphoid system were observed in most animals, similar to 7% of transgenic mice developed thymic lymphomas at the age of 3-9 months. The tumor cells, which were clonal, with unique T cell rearrangements, were double positive for the expression of CD4 and CD8. The need for additional transforming events, suggested by the low incidence of spontaneous tumors, was further indicated by the high susceptibility of the transgenic animals to injections of low doses of N-methyl-N-nitrosourea, a chemical carcinogen with a thymic tropism. Expression of interleukin 9 was required for optimal tumor growth in vivo, as one of the tumors studied, which had lost the transgene, was much more efficiently transplanted into transgenic than in normal mice. Moreover, the in vitro proliferative activity of interleukin 9 on cell lines derived from such transgene-negative tumors suggests that an autocrine loop mediates the proliferation of these cells in vivo. Taken together, these results indicate that dysregulated IL-9 expression could be involved in the development of some T cell malignancies.	UNIV CATHOLIQUE LOUVAIN,DEPT PATHOL,B-1200 BRUSSELS,BELGIUM; UNIV LUBECK,INST PATHOL,W-2400 LUBECK,GERMANY; NETHERLANDS CANC INST,AMSTERDAM,NETHERLANDS	Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; University of Lubeck; Netherlands Cancer Institute	RENAULD, JC (corresponding author), UNIV CATHOLIQUE LOUVAIN,LUDWIG INST CANC RES,BRUSSELS BRANCH & EXPTL MED,B-1200 BRUSSELS,BELGIUM.		Feller, Alfred/E-3853-2010; Renauld, Jean-Christophe/B-7268-2012	Renauld, Jean-Christophe/0000-0003-1736-2131				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; BRUCE J, 1981, J IMMUNOL, V127, P2496; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; DONAHUE RE, 1990, BLOOD, V75, P2271; DRUEZ C, 1990, J IMMUNOL, V145, P2494; DUGAS B, 1993, EUR J IMMUNOL, V23, P1687, DOI 10.1002/eji.1830230743; GRUSS HJ, 1992, CANCER RES, V52, P1026; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HOUSSIAU FA, 1992, J IMMUNOL, V148, P3147; HOUSSIAU FA, 1993, J IMMUNOL, V150, P2634; HULTNER L, 1990, EXP HEMATOL, V18, P873; HULTNER L, 1990, EUR J IMMUNOL, V20, P1413, DOI 10.1002/eji.1830200632; KELLEHER K, 1991, BLOOD, V77, P1436; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MEHLER MF, 1993, NATURE, V362, P62, DOI 10.1038/362062a0; MERZ H, 1991, BLOOD, V78, P1311; PETITFRERE C, 1993, IMMUNOLOGY, V79, P146; RENAULD J-C, 1990, Cytokine, V2, P9, DOI 10.1016/1043-4666(90)90037-T; RENAULD JC, 1990, J IMMUNOL, V144, P4235; RENAULD JC, 1993, ADV IMMUNOL, V54, P79, DOI 10.1016/S0065-2776(08)60533-7; RICH BE, 1993, J EXP MED, V177, P305, DOI 10.1084/jem.177.2.305; SCHMITT E, 1989, EUR J IMMUNOL, V19, P2167, DOI 10.1002/eji.1830191130; SIU G, 1984, NATURE, V311, P344, DOI 10.1038/311344a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUDA T, 1990, J IMMUNOL, V144, P1783; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; UYTTENHOVE C, 1988, P NATL ACAD SCI USA, V85, P6934, DOI 10.1073/pnas.85.18.6934; UYTTENHOVE C, 1991, J EXP MED, V173, P519, DOI 10.1084/jem.173.2.519; VANSNICK J, 1989, J EXP MED, V169, P363, DOI 10.1084/jem.169.1.363; VINK A, 1993, EUR J IMMUNOL, V23, P1134, DOI 10.1002/eji.1830230523; WILDE D, 1982, J IMMUNOL, V131, P2178; WILLIAMS DE, 1990, BLOOD, V76, P906; YANG YC, 1989, BLOOD, V74, P1880	36	131	134	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1327	1332						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152793				2022-12-25	WOS:A1994NH40100003
J	KOZYAVKIN, SA; KRAH, R; GELLERT, M; STETTER, KO; LAKE, JA; SLESAREV, AI				KOZYAVKIN, SA; KRAH, R; GELLERT, M; STETTER, KO; LAKE, JA; SLESAREV, AI			A REVERSE GYRASE WITH AN UNUSUAL STRUCTURE - A TYPE-I DNA TOPOISOMERASE FROM THE HYPERTHERMOPHILE METHANOPYRUS-KANDLERI IS A 2-SUBUNIT PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ESCHERICHIA-COLI; DESULFUROCOCCUS-AMYLOLYTICUS; SUPERHELICAL TURNS; CLEAVAGE REACTION; SUPERCOILED DNA; ATPASE ACTIVITY; NALIDIXIC-ACID; GENE-PRODUCT; DUPLEX DNA	Reverse gyrase, an ATP-dependent topoisomerase that positively supercoils DNA, has been purified to near-homogeneity from the hyperthermophile Methanopyrus kandleri. It migrates on SDS-polyacrylamide gel electrophoresis as two principal bands with apparent molecular masses of 150 and 50 kDa. Both proteins remain associated throughout all chromatographic steps. Transfer of a radioactive phosphate from DNA to the 50-kDa protein and gel retardation experiments indicate that this protein forms the covalent complex with DNA. A blot overlay assay identifies the 150-kDa protein as the potential ATPase. This is the first evidence that a reverse gyrase can be a topoisomerase consisting of two protomers. In analogy with the DNA gyrase A subunit (DNA breakage and reunion activity) and the B subunit (ATPase), the 50- and 150-kDa components of Mka reverse gyrase have been designated the A and B subunits, respectively. Methanopyrus reverse gyrase changes DNA linking number in steps of one and its A subunit covalently binds to the 5'-DNA phosphoryl group. It nicks DNA at sites that predominantly have a cytosine at the -4-position. The same rule was derived previously for monomeric reverse gyrase from sulfur-metabolizing hyperthermophiles and for topoisomerase I from mesophilic bacteria. Based on these results, Mka reverse gyrase is classified as belonging to group A of type I topoisomerases. The structural diversity of type I group A topoisomerases parallels the diversity of type II enzymes and suggests the evolution of an essential function by gene fusion.	UNIV REGENSBURG, W-8400 REGENSBURG, GERMANY; UNIV CALIF LOS ANGELES, INST MICROBIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT BIOL, LOS ANGELES, CA 90024 USA	University of Regensburg; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	KOZYAVKIN, SA (corresponding author), NIDDKD, MOLEC BIOL LAB, BLDG 5, RM 238, BETHESDA, MD 20892 USA.			Kozyavkin, Sergei/0000-0001-5605-5113				ACHENBACHRICHTER L, 1987, SYST APPL MICROBIOL, V9, P34, DOI 10.1016/S0723-2020(87)80053-X; AGHAAMIRI K, 1993, NUCLEIC ACIDS RES, V21, P1491, DOI 10.1093/nar/21.6.1491; ANDERA L, 1993, FEMS MICROBIOL LETT, V110, P107, DOI 10.1111/j.1574-6968.1993.tb06303.x; ANDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P6237, DOI 10.1021/bi00441a015; BAUER WR, 1990, CHROMOSOMES EUKARYOT, V1, P87; BONCHOSMOLOVSKAIA EA, 1986, DOKL AKAD NAUK SSSR+, V290, P1259; BONCHOSMOLOVSKAYA EA, 1988, MICROBIOLOGY+, V57, P78; BROCK TD, 1972, ARCH MIKROBIOL, V84, P54, DOI 10.1007/BF00408082; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; BURGGRAF S, 1991, SYST APPL MICROBIOL, V14, P346, DOI 10.1016/S0723-2020(11)80308-5; CHAMPOUX JJ, 1976, P NATL ACAD SCI USA, V73, P3488, DOI 10.1073/pnas.73.10.3488; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CONFALONIERI F, 1993, P NATL ACAD SCI USA, V90, P4753, DOI 10.1073/pnas.90.10.4753; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; DEAN FB, 1985, J BIOL CHEM, V260, P4984; DELATOUR CB, 1990, J BACTERIOL, V172, P6803, DOI 10.1128/jb.172.12.6803-6808.1990; DELATOUR CB, 1991, J BACTERIOL, V173, P3921, DOI 10.1128/JB.173.12.3921-3923.1991; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; DOOLITTLE WF, 1992, BIOCHEM SOC SYMP, P1; FELSENFELD G, 1977, ORG EXPRESSION EUKAR, P157; Forterre P, 1992, Biochem Soc Symp, V58, P99; FORTERRE P, 1992, BIOSYSTEMS, V28, P15, DOI 10.1016/0303-2647(92)90004-I; FORTERRE P, 1985, EMBO J, V4, P2123, DOI 10.1002/j.1460-2075.1985.tb03902.x; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; HIGGINS NP, 1978, P NATL ACAD SCI USA, V75, P1773, DOI 10.1073/pnas.75.4.1773; Hsieh TS, 1990, DNA TOPOLOGY ITS BIO, P243; HUBER R, 1989, NATURE, V342, P833, DOI 10.1038/342833a0; JAXEL C, 1989, EMBO J, V8, P3135, DOI 10.1002/j.1460-2075.1989.tb08466.x; Kandler O, 1992, Biochem Soc Symp, V58, P195; KIKUCHI A, 1986, SYST APPL MICROBIOL, V7, P72, DOI 10.1016/S0723-2020(86)80126-6; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; Kikuchi A, 1990, DNA TOPOLOGY ITS BIO, P285; KIM RA, 1992, J BIOL CHEM, V267, P17178; KLETZIN A, 1992, NUCLEIC ACIDS RES, V20, P5389, DOI 10.1093/nar/20.20.5389; KLEVAN L, 1980, BIOCHEMISTRY-US, V19, P5229, DOI 10.1021/bi00564a012; KORNBERG A, 1992, DNA REPLICATION, P379; KOVALSKY OI, 1990, NUCLEIC ACIDS RES, V18, P2801, DOI 10.1093/nar/18.9.2801; Kristjansson Jakob K., 1992, P1; KURR M, 1991, ARCH MICROBIOL, V156, P239, DOI 10.1007/BF00262992; LAKE JA, 1988, NATURE, V331, P184, DOI 10.1038/331184a0; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LEE MP, 1992, NUCLEIC ACIDS RES, V20, P5027, DOI 10.1093/nar/20.19.5027; LEE MP, 1989, J BIOL CHEM, V264, P13510; LIU LF, 1979, J BIOL CHEM, V254, P1082; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; LYUBCHENKO YL, 1988, NUCLEIC ACIDS RES, V16, P3269, DOI 10.1093/nar/16.8.3269; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MENZEL R, 1983, CELL, V34, P105, DOI 10.1016/0092-8674(83)90140-X; MIZUUCHI K, 1978, P NATL ACAD SCI USA, V75, P5960, DOI 10.1073/pnas.75.12.5960; MUKHERJEE A, 1993, P NATL ACAD SCI USA, V90, P1053, DOI 10.1073/pnas.90.3.1053; MUSGRAVE DR, 1991, P NATL ACAD SCI USA, V88, P10397, DOI 10.1073/pnas.88.23.10397; NADAL M, 1988, BIOCHEMISTRY-US, V27, P9102, DOI 10.1021/bi00426a006; NAKASU S, 1985, EMBO J, V4, P2705, DOI 10.1002/j.1460-2075.1985.tb03990.x; ORR E, 1982, J BACTERIOL, V151, P524, DOI 10.1128/JB.151.1.524-527.1982; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; OUZOUNIS C, 1992, CELL, V71, P189, DOI 10.1016/0092-8674(92)90347-F; PACE NR, 1991, CELL, V65, P531, DOI 10.1016/0092-8674(91)90082-A; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; RAYCHAUDHURI D, 1992, NATURE, V359, P251, DOI 10.1038/359251a0; RIVERA MC, 1992, SCIENCE, V257, P74, DOI 10.1126/science.1621096; SANDMAN K, 1990, P NATL ACAD SCI USA, V87, P5788, DOI 10.1073/pnas.87.15.5788; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SEASHOLTZ AF, 1983, J BIOL CHEM, V258, P1221; SEGERER A, 1985, NATURE, V313, P787, DOI 10.1038/313787a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SHIBATA T, 1987, J BIOL CHEM, V262, P10419; SINDEN RR, 1980, CELL, V21, P773, DOI 10.1016/0092-8674(80)90440-7; SLESAREV A I, 1988, Biopolimery i Kletka, V4, P119; SLESAREV AI, 1994, J BIOL CHEM, V269, P3295; SLESAREV AI, 1990, J BIOMOL STRUCT DYN, V7, P935, DOI 10.1080/07391102.1990.10508533; SLESAREV AI, 1988, EUR J BIOCHEM, V173, P395, DOI 10.1111/j.1432-1033.1988.tb14012.x; SLESAREV AI, 1993, NATURE, V364, P735, DOI 10.1038/364735a0; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; STETTER KO, 1986, SYST APPL MICROBIOL, V7, P393; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; TABASSUM R, 1992, J BACTERIOL, V174, P7890, DOI 10.1128/JB.174.24.7890-7895.1992; TSE YC, 1980, J BIOL CHEM, V255, P5560; TU J, 1982, J MOL EVOL, V18, P109, DOI 10.1007/BF01810829; van Holde K.E., 1988, CHROMATIN; VOLOSHIN ON, 1989, FEBS LETT, V243, P377, DOI 10.1016/0014-5793(89)80165-6; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; Wang J C, 1985, Harvey Lect, V81, P93; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG JC, 1987, NATL CANCER I MONOGR, V4, P3; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014	90	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11081	11089						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157633				2022-12-25	WOS:A1994NF96600020
J	FELDMAN, GM; PETRICOIN, EF; DAVID, M; LARNER, AC; FINBLOOM, DS				FELDMAN, GM; PETRICOIN, EF; DAVID, M; LARNER, AC; FINBLOOM, DS			CYTOKINES THAT ASSOCIATE WITH THE SIGNAL TRANSDUCER GP130 ACTIVATE THE INTERFERON-INDUCED TRANSCRIPTION FACTOR P91 BY TYROSINE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-INHIBITORY FACTOR; DNA-BINDING PROTEIN; FC-GAMMA RECEPTOR; ONCOSTATIN-M; STIMULATED TRANSCRIPTION; CYTOPLASMIC ACTIVATION; RESPONSE ELEMENTS; IFN-GAMMA; CELLS; ALPHA	Interleukin-6, leukemia inhibitory factor, and oncostatin M exert a broad range of similar biological activities through association of their receptors with the signal-transducing component gp130. Although it is known that these cytokines trigger rapid tyrosine phosphorylation of a common set of cellular proteins as well as induction of several of the same early response genes, the mechanisms by which these genes are activated is not well understood. In this report, we show that interleukin-6 leukemia inhibitory factor, and oncostatin M stimulate the assembly of protein complexes that recognize conserved sequences within the enhancers of two genes (interferon regulatory factor 1 and Fc gamma receptor type I) that are rapidly activated by these cytokines. These enhancers are known to be required for transcriptional induction of these genes by interferon-gamma. Assembly of the DNA-binding protein complexes occurs within minutes after ligand addition and depends upon tyrosine phosphorylation. These complexes contain the p91 transcription factor, which is tyrosine-phosphorylated in response to these cytokines. An additional tyrosine-phosphorylated protein of 93 kDa can be coimmunoprecipitated with antibodies against p91. These findings further expand the network of cytokines known to activate p91 and, in addition, support the concept that sets of tyrosine-phosphorylated proteins may be responsible for the cytokine-regulated expression of early response genes.	US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892	US Food & Drug Administration (FDA)								ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BENECH PD, 1992, J EXP MED, V176, P1115, DOI 10.1084/jem.176.4.1115; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DAVID M, 1993, J BIOL CHEM, V268, P6593; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GROVE RI, 1991, J BIOL CHEM, V266, P18194; GROVE RI, 1993, P NATL ACAD SCI USA, V90, P823, DOI 10.1073/pnas.90.3.823; GUAN KL, 1991, J BIOL CHEM, V266, P17026; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARROCH S, 1993, J BIOL CHEM, V268, P9092; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PETRICOIN EF, 1992, MOL CELL BIOL, V12, P4486, DOI 10.1128/MCB.12.10.4486; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUHL S, 1993, BLOOD, V82, P2641; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHIEVEN GL, 1992, J IMMUNOL, V149, P1676; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEARS DW, 1990, J IMMUNOL, V144, P371; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964	51	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10747	10752						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144663				2022-12-25	WOS:A1994NF01700083
J	HOU, CF; GILBERT, RL; BARBER, DL				HOU, CF; GILBERT, RL; BARBER, DL			SUBTYPE-SPECIFIC SIGNALING MECHANISMS OF SOMATOSTATIN RECEPTORS SSTR1 AND SSTR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA-H EXCHANGE; BETA-ADRENERGIC-RECEPTOR; ADENYLATE-CYCLASE; BINDING PROTEINS; TUMOR-CELLS; INHIBITION; CLONING; BRAIN; ACTIVATION; CALCIUM	Somatostatin regulates diverse cellular effecters, including adenylyl cyclase, ion channels, and ion exchangers. We expressed two somatostatin receptor subtypes, SSTR1 and SSTR2, stably in mouse fibroblast Ltk(-) cells and transiently in human embryonic kidney HEK293 cells to investigate subtype-specific pharmacological and functional properties. The effects of GTP gamma S and pertussis toxin on [I-125-Tyr(11)]somatostatin-14 binding indicated that SSTR2 may couple exclusively to pertussis toxin sensitive G proteins, whereas SSTR1 may couple to both pertussis-sensitive and -insensitive G proteins. When expressed either stably or transiently, both receptor subtypes mediated somatostatin inhibition of cAMP accumulation by a pertussis toxin-sensitive mechanism. In contrast, only SSTR1 mediated somatostatin inhibition of Na+-H+ exchange activity, and this action was insensitive to pertussis toxin. We generated two chimeric receptors by replacing sequential residues of SSTR2 with cognate sequences of SSTR1 to identify molecular determinants unique to SSTR1 that may confer coupling to the exchanger. SSTCR4 included a SSTR1 segment encompassing determinants within the fifth and sixth hydrophobic domains and the entire third cytoplasmic loop, while SSTCRS5 contained a SSTR1 segment spanning the second through sixth hydrophobic domains, including both second and third cytoplasmic loops. Although both chimeric receptors mediated somatostatin inhibition of cAMP accumulation, only SSTCR5 mediated the inhibition of Na+-H+ exchange activity, and this effect was pertussis-insensitive. These findings demonstrate both pharmacological and functional differences between SSTR1 and SSTR2. The ability of SSTR1 to selectively attenuate Na+-H+ exchange activity requires determinants outside the third cytoplasmic domain.	UNIV CALIF SAN FRANCISCO,DEPT STOMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040259, R29DK040259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047413] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40259] Funding Source: Medline; NIGMS NIH HHS [GM47413] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER DL, 1989, J BIOL CHEM, V264, P21038; BARBER DL, 1992, J BIOL CHEM, V267, P20607; BARBER DL, 1992, MOL PHARMACOL, V41, P1056; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BROWN PJ, 1993, J BIOL CHEM, V268, P6668; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; GANZ MB, 1990, J BIOL CHEM, V265, P8989; JAKOBS KH, 1983, NATURE, V303, P177, DOI 10.1038/303177a0; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOCH BD, 1985, J BIOL CHEM, V260, P3138; LAW SF, 1993, J BIOL CHEM, V268, P10721; LAW SF, 1991, J BIOL CHEM, V266, P17885; LEWIS DL, 1986, P NATL ACAD SCI USA, V83, P9035, DOI 10.1073/pnas.83.23.9035; LI XJ, 1992, J BIOL CHEM, V267, P21307; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; LUTHIN DR, 1993, J BIOL CHEM, V268, P5990; MURRAYWHELAN R, 1992, J BIOL CHEM, V267, P2960; OCARROLL AM, 1992, MOL PHARMACOL, V42, P939; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; RAYNOR K, 1993, MOL PHARMACOL, V44, P385; RAYNOR K, 1993, MOL PHARMACOL, V43, P838; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; ROHRER L, 1993, P NATL ACAD SCI USA, V90, P4196, DOI 10.1073/pnas.90.9.4196; SOLOMON Y, 1974, ANAL BIOCHEM, V58, P541; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; STRNAD J, 1993, BIOCHEM BIOPH RES CO, V191, P968, DOI 10.1006/bbrc.1993.1312; TALLENT M, 1992, MOL PHARMACOL, V41, P452; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VIGUERIE N, 1989, ENDOCRINOLOGY, V124, P1017, DOI 10.1210/endo-124-2-1017; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; WESS J, 1990, MOL PHARMACOL, V38, P517; WONG SKF, 1990, J BIOL CHEM, V265, P6219; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YAMASHITA N, 1986, P NATL ACAD SCI USA, V83, P6198, DOI 10.1073/pnas.83.16.6198; YASUDA K, 1992, J BIOL CHEM, V267, P20422; YATANI A, 1987, MOL ENDOCRINOL, V1, P283, DOI 10.1210/mend-1-4-283	40	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10357	10362						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144617				2022-12-25	WOS:A1994NF01700029
J	SASAOKA, T; DRAZNIN, B; LEITNER, JW; LANGLOIS, WJ; OLEFSKY, JM				SASAOKA, T; DRAZNIN, B; LEITNER, JW; LANGLOIS, WJ; OLEFSKY, JM			SHC IS THE PREDOMINANT SIGNALING MOLECULE COUPLING INSULIN-RECEPTORS TO ACTIVATION OF GUANINE-NUCLEOTIDE RELEASING-FACTOR AND P21(RAS)-GTP FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; RAS P21; PROTEIN; TRANSDUCTION; STIMULATION; ASSOCIATION; EXPRESSION; ONCOGENES; DOMAIN; GROWTH	Insulin stimulates tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) and She in Rat1 fibroblasts overexpressing wild type insulin receptors. We investigated the relative role of IRS-1 and She in insulin activation of guanine nucleotide releasing factor (GNRF) and p21(ras)-GTP formation. The time course of insulin stimulated tyrosine phosphorylation of IRS-1 was rapid, whereas She phosphorylation was relatively slow. Growth factor receptor bound protein-2 (Grb2) associated with IRS-1 rapidly and gradually dissociated after 5 min, whereas Grb2 association with She was slower and reached a maximum at 10 min after insulin stimulation. Thus, the kinetics of Grb2 association with IRS-1 and She corresponded closely to the time course of tyrosine phosphorylation of IRS-1 and Shc, respectively. Importantly, 3-13-fold more Grb2 was associated with Shc than with IRS-1. In addition, the kinetics of insulin-stimulated GNRF activity and p21(ras)-GTP formation corresponded more closely to the time course of She phosphorylation than to the kinetics of IRS-1 phosphorylation. Furthermore, immunoprecipitation of She proteins from cell lysates of insulin-stimulated cells removed 67% of the GNRF activity, whereas precipitation of IRS-1 had a negligible effect on GNRF activity. Thus, although both IRS-1 and She associate with Grb2, the current results indicate that She plays a more important role than IRS-1 in insulin stimulation of GNRF activity and subsequent p21(ras)-GTP formation.	UNIV CALIF SAN DIEGO,DEPT MED,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; VET ADM MED CTR,MED RES SERV,SAN DIEGO,CA 92161; VET AFFAIRS MED CTR,MED RES SERV,DENVER,CO 80220; VET AFFAIRS MED CTR,DEPT MED,DENVER,CO 80220; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80220	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI BQ, 1993, P NATL ACAD SCI USA, V90, P8504, DOI 10.1073/pnas.90.18.8504; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597	39	186	187	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10734	10738						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144662				2022-12-25	WOS:A1994NF01700081
J	BOUWMEESTER, T; VANWIJK, I; WEDLICH, D; PIELER, T				BOUWMEESTER, T; VANWIJK, I; WEDLICH, D; PIELER, T			FUNCTIONAL-ASPECTS OF B-MYB IN EARLY XENOPUS DEVELOPMENT	ONCOGENE			English	Article							C-MYB; DNA-BINDING; A-MYB; EXPRESSION; PROTEIN; DIFFERENTIATION; PHOSPHORYLATION; TRANSCRIPTION; ACTIVATION; INVITRO	The gene encoding Xenopus B-Myb (XB-Myb), a protein structurally related to the nuclear protooncogene product c-Myb, is expressed in early Xenopus embryogenesis. We report on developmental alterations in the nucleocytoplasmic distribution and phosphorylation of XB-Myb in Xenopus oocytes and embryos, as well as on a negative regulatory role of the carboxyl terminus in sequence specific DNA binding. In growing oocytes and early embryonic stages the protein is primarily located in the nucleus; in the full-grown oocyte, however, it remains sequestered in the cytoplasmic compartment. Upon meiotic maturation of the oocyte, XB-Myb becomes hyperphosphorylated. Oocyte/egg isolates of XB-Myb are inhibited in their specific DNA binding activity; truncation of the carboxyl terminal region relieves this block in nucleic acid recognition. Furthermore, we have used overexpression of XB-Myb in Xenopus embryos by means of mRNA injection as an assay for gene function in vivo. Overexpression of full-length XB-Myb, not of the carboxyl terminal deletion mutant, results in an altered morphology of lateral plate mesoderm.	MAX PLANCK INST MOLEC GENET,OTTO WARBURG LAB,D-14195 BERLIN,GERMANY; UNIV ULM,BIOCHEM ABT,D-89081 ULM,GERMANY	Max Planck Society; Ulm University								ARSURA M, 1992, BLOOD, V79, P2708; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DANKER K, 1992, DEV DYNAM, V193, P136, DOI 10.1002/aja.1001930205; DENT JA, 1989, DEVELOPMENT, V105, P61; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GARCIA A, 1991, ONCOGENE, V6, P265; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; HARLOW E, 1988, ANTIBODIES LABORATOR; HERZBERG F, 1991, MECH DEVELOP, V35, P33, DOI 10.1016/0925-4773(91)90039-9; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KIMELMAN D, 1992, DEVELOPMENT, V114, P261; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MCMAHON J, 1988, ONCOGENE, V3, P717; MILLER M, 1991, DEVELOPMENT, V113, P569; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; NIETFELD W, 1993, J MOL BIOL, V230, P400, DOI 10.1006/jmbi.1993.1158; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; RAMSAY RG, 1992, J BIOL CHEM, V267, P5656; RAMSAY RG, 1991, ONCOGENE, V6, P1875; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; VIZE PD, 1991, METHOD CELL BIOL, V36, P367; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	44	10	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1029	1038						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134106				2022-12-25	WOS:A1994NC04800004
J	GOSS, GG; WOODSIDE, M; WAKABAYASHI, S; POUYSSEGUR, J; WADDELL, T; DOWNEY, GP; GRINSTEIN, S				GOSS, GG; WOODSIDE, M; WAKABAYASHI, S; POUYSSEGUR, J; WADDELL, T; DOWNEY, GP; GRINSTEIN, S			ATP DEPENDENCE OF NHE-1, THE UBIQUITOUS ISOFORM OF THE NA+/H+ ANTIPORTER - ANALYSIS OF PHOSPHORYLATION AND SUBCELLULAR-LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; GROWTH-FACTOR; MOLECULAR-CLONING; VOLUME REGULATION; INTRACELLULAR PH; OKADAIC ACID; ACTIVATION; CELLS; DEPLETION; PROTEINS	ATP is not hydrolyzed during the transport cycle of the Na+/H+ exchanger (NHE), yet depletion of the nucleotide drastically reduces the rate of cation exchange. The mechanism underlying this inhibition was investigated in fibroblasts transfected with NHE-1, the growth factor-sensitive isoform of the antiport. NHE-1 was found to be phosphorylated in serum-starved, unstimulated cells. Acute ATP depletion induced a profound inhibition of transport without detectable changes in NHE-1 phosphorylation. Analysis of cells transfected with truncated mutants of NHE-1 indicated that the carboxyl-terminal cytosolic domain of the antiport is required for expression of its ATP dependence. To define whether inhibition of Na+/H+ exchange resulted from internalization of NHE-1, extracellularly exposed proteins were labeled with impermeant biotin derivatives. The proportion of NHE-1 exposed to the surface was comparable before and after ATP depletion. Immunofluorescence determinations revealed focal accumulations of NHE-1 on the membrane of untreated cells. NHE-1 redistributed following ATP depletion, showing a more homogeneous localization. F-actin, which co-localizes with the antiport in untreated cells, also redistributed when cells were ATP depleted. These findings suggest an interaction of NHE-1 with the cytoskeleton. Accordingly, disassembly of actin filaments with cytochalasin D induced redistribution of the antiport. However, Na+/H+ exchange activity was unaltered by cytochalasin D. We propose that ancillary proteins confer ATP sensitivity to the antiporter and may also mediate its association with the cytoskeleton. Depletion of the nucleotide would alter the interaction between NHE-1 and the putative regulator, inhibiting Na+/H+ exchange and inducing subcellular redistribution. However, disruption of the cytoskeleton at distal sites, such as induced by cytochalasins, is insufficient to inactivate the antiport.	HOSP SICK CHILDREN,DIV CELL BIOL,TORONTO M5G 1X8,ON,CANADA; UNIV NICE,CTR NATL RECH SCI,CTR BIOCHIM,F-06034 NICE,FRANCE; UNIV TORONTO,DEPT MED,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Toronto			; Goss, Greg/D-2723-2015	Downey, Gregory P/0000-0003-3253-5862; Goss, Greg/0000-0003-0786-8868				BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; CASSEL D, 1986, J BIOL CHEM, V261, P5460; CHEN LK, 1991, KIDNEY INT, V40, pS11; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAVIS BA, 1992, AM J PHYSIOL, V262, pC533, DOI 10.1152/ajpcell.1992.262.2.C533; GABAI VL, 1992, TISSUE CELL, V24, P171, DOI 10.1016/0040-8166(92)90090-T; GLASCOTT PA, 1987, CELL MOTIL CYTOSKEL, V8, P118, DOI 10.1002/cm.970080204; GREEN J, 1993, AM J PHYSIOL, V265, pF440, DOI 10.1152/ajprenal.1993.265.3.F440; GRINSTEIN S, 1993, EMBO J, V12, P5209, DOI 10.1002/j.1460-2075.1993.tb06216.x; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GRINSTEIN S, 1985, J CELL BIOL, V101, P269, DOI 10.1083/jcb.101.1.269; HILGEMANN DW, 1992, J PHYSIOL-LONDON, V454, P59, DOI 10.1113/jphysiol.1992.sp019254; JOHNSON BD, 1993, NEURON, V10, P797, DOI 10.1016/0896-6273(93)90196-X; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; LITTLE PJ, 1988, J BIOL CHEM, V263, P16780; MACHEN TE, 1987, ANNU REV PHYSIOL, V49, P19, DOI 10.1146/annurev.ph.49.030187.000315; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; NG LL, 1992, KIDNEY INT, V41, P872, DOI 10.1038/ki.1992.133; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARDET C, 1991, J BIOL CHEM, V266, P19166; TSE CM, 1993, J BIOL CHEM, V268, P11917; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WANG YL, 1986, EXP CELL RES, V167, P16, DOI 10.1016/0014-4827(86)90200-4; WANG Z, 1993, J BIOL CHEM, V268, P11925	28	103	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8741	8748						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132605				2022-12-25	WOS:A1994NB41100022
J	SVAREN, J; KLEBANOW, E; SEALY, L; CHALKLEY, R				SVAREN, J; KLEBANOW, E; SEALY, L; CHALKLEY, R			ANALYSIS OF THE COMPETITION BETWEEN NUCLEOSOME FORMATION AND TRANSCRIPTION FACTOR-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEWLY SYNTHESIZED HISTONES; VIRUS INTERNAL ENHANCER; NUCLEAR FACTOR-I; 5-S RNA GENE; ASSEMBLY INVITRO; DNA-REPLICATION; FACTOR-IIIA; CHROMATIN; CORE; PURIFICATION	We have studied the competitive binding of histones and the Rous sarcoma virus internal enhancer binding factor (IBF) factor (which recent studies indicate is almost certainly cEBP beta). We find that histones and IBF are incapable of forming a ternary complex with a 159- base pair (bp) fragment of DNA containing a single IBF binding site and that histones and factor are mutually exclusive in binding. We have analyzed the various physical parameters of binding, in an attempt to understand how the factor might establish an exclusive binding in the cell. The stability of the nucleosome and the factor-DNA complex have been determined, and in addition a minimum value for the affinity of the histone octamer has been computed. We find that in simple competition the IBF can successfully compete, only if the substrate DNA is shorter than 140 bp. The relevance of these results is discussed in terms of a kinetic model for successful factor competition during the replication of the factor binding site in the cell.	VANDERBILT UNIV, SCH MED, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA	Vanderbilt University			Svaren, John/A-1605-2010	Svaren, John/0000-0003-2963-7921				ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BAKER RE, 1986, J BIOL CHEM, V261, P5275; BARTLEY JA, 1972, J BIOL CHEM, V247, P3647; BINASTEIN M, 1977, CELL, V11, P609, DOI 10.1016/0092-8674(77)90078-2; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CALZONE FJ, 1988, GENE DEV, V2, P1074, DOI 10.1101/gad.2.9.1074; CHATTORAJ DK, 1972, ARCH BIOCHEM BIOPHYS, V152, P778, DOI 10.1016/0003-9861(72)90273-1; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; COTTEN M, 1987, EMBO J, V6, P3945, DOI 10.1002/j.1460-2075.1987.tb02736.x; COTTEN M, 1985, NUCLEIC ACIDS RES, V13, P401, DOI 10.1093/nar/13.2.401; DREW HR, 1991, J MOL BIOL, V219, P391, DOI 10.1016/0022-2836(91)90179-A; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; EMERSON BM, 1985, CELL, V41, P21, DOI 10.1016/0092-8674(85)90057-1; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FELTS SJ, 1990, MOL CELL BIOL, V10, P2390, DOI 10.1128/MCB.10.5.2390; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; JACKSON V, 1988, BIOCHEMISTRY-US, V27, P2109, DOI 10.1021/bi00406a044; JACKSON V, 1987, BIOCHEMISTRY-US, V26, P2315, DOI 10.1021/bi00382a037; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; KARNITZ L, 1987, NUCLEIC ACIDS RES, V15, P9841, DOI 10.1093/nar/15.23.9841; KARNITZ L, 1989, MOL CELL BIOL, V9, P1929, DOI 10.1128/MCB.9.5.1929; KARNITZ L, 1988, CIS TRANSACTING ELEM; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; KLEVAN L, 1978, BIOCHEMISTRY-US, V17, P4533, DOI 10.1021/bi00614a027; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LINXWEILER W, 1984, NUCLEIC ACIDS RES, V12, P9395, DOI 10.1093/nar/12.24.9395; LORCH Y, 1992, GENE DEV, V6, P2282, DOI 10.1101/gad.6.12a.2282; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MEISTERERNST M, 1988, NUCLEIC ACIDS RES, V16, P4419, DOI 10.1093/nar/16.10.4419; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PETERSON CL, 1988, MOL CELL BIOL, V8, P4972, DOI 10.1128/MCB.8.11.4972; PFAFFLE P, 1990, J BIOL CHEM, V265, P16821; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; READ CM, 1985, BIOCHEMISTRY-US, V24, P4435, DOI 10.1021/bi00337a027; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROMANIUK PJ, 1990, J BIOL CHEM, V265, P17593; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; RUIZCARRILLO A, 1979, P NATL ACAD SCI USA, V76, P3284, DOI 10.1073/pnas.76.7.3284; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SOLLNERWEBB B, 1976, CELL, V9, P179, DOI 10.1016/0092-8674(76)90063-5; STOCKLEY PG, 1979, FEBS LETT, V99, P129, DOI 10.1016/0014-5793(79)80264-1; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; TAN S, 1988, EMBO J, V7, P4255, DOI 10.1002/j.1460-2075.1988.tb03323.x; TATCHELL K, 1979, BIOCHEMISTRY-US, V18, P2870, DOI 10.1021/bi00580a031; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREMETHICK D, 1990, J BIOL CHEM, V265, P5014; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WOLFFE AP, 1986, CELL, V47, P217, DOI 10.1016/0092-8674(86)90444-7; WOLFFE AP, 1991, J CELL SCI, V99, P201; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZUCKER K, 1990, J BIOL CHEM, V265, P14487	62	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9335	9344						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132673				2022-12-25	WOS:A1994NB41100104
J	SUNG, P; WATKINS, JF; PRAKASH, L; PRAKASH, S				SUNG, P; WATKINS, JF; PRAKASH, L; PRAKASH, S			NEGATIVE SUPERHELICITY PROMOTES ATP-DEPENDENT BINDING OF YEAST RAD3 PROTEIN TO ULTRAVIOLET-DAMAGED DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOBUTANE PYRIMIDINE DIMERS; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; DHFR GENE; REPAIR; CELLS; HELICASE; PHOTOPRODUCTS; REPLICATION; REMOVAL	The RAD3 gene of Saccharomyces cereuisiae is required for excision repair of UV-damaged DNA and is essential for cell viability. Remarkable homology exists between RAD3 and the human excision repair gene XPD, whose mutational inactivation underlies the cancer-prone disorder in xeroderma pigmentosum group D patients. Our previous work demonstrated that RAD3-encoded protein contains a DNA helicase activity. Here, we show that RAD3 binds preferentially to UV-damaged DNA over nondamaged DNA. Removal of pyrimidine dimers from damaged DNA by enzymatic photoreactivation does not affect binding, suggesting an affinity of RAD3 for pyrimidine (6-4) pyrimidone photoproducts. Damage-specific binding by RADS is strongly dependent on ATP and on the degree of negative superhelicity in DNA. The requirement of superhelicity in damage binding may target RAD3 to regions of DNA undergoing transcription, resulting in the preferential repair of these regions. The rad3 Arg-48 mutant protein, which lacks the DNA helicase activity, also binds UV-damaged DNA preferentially, indicating that DNA helicase and damage binding are two distinct and separable functional entities in RAD3.	UNIV TEXAS,SEALY CTR MOLEC SCI,MED BRANCH,GALVESTON,TX 77555; UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT BIOPHYS,ROCHESTER,NY 14642	University of Texas System; University of Texas Medical Branch Galveston; University of Rochester; University of Rochester			Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NCI NIH HHS [CA35035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA035035, R01CA035035] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BROWN WC, 1989, J BIOL CHEM, V264, P6748; DOETSCH PW, 1985, NUCLEIC ACIDS RES, V13, P3285, DOI 10.1093/nar/13.9.3285; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FUNNELL BE, 1986, J BIOL CHEM, V261, P5616; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; LIM HM, 1992, J BIOL CHEM, V267, P11176; LJUNGMAN M, 1992, P NATL ACAD SCI USA, V89, P6055, DOI 10.1073/pnas.89.13.6055; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MITCHELL DL, 1985, MUTAT RES, V143, P109, DOI 10.1016/S0165-7992(85)80018-X; MIZUTANI M, 1991, P NATL ACAD SCI USA, V88, P718, DOI 10.1073/pnas.88.3.718; NAEGELI H, 1992, J BIOL CHEM, V267, P392; NORANELLI F, 1980, P NATL ACAD SCI USA, V77, P3201; ODAY CL, 1992, NUCLEIC ACIDS RES, V20, P5403, DOI 10.1093/nar/20.20.5403; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; SEEBERG E, 1982, P NATL ACAD SCI-BIOL, V79, P988, DOI 10.1073/pnas.79.4.988; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; WOOD RD, 1989, BIOCHEMISTRY-US, V28, P8287, DOI 10.1021/bi00447a005; ZDZIENICKA MZ, 1992, MUTAT RES, V273, P73, DOI 10.1016/0921-8777(92)90051-4	25	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8303	8308						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132553				2022-12-25	WOS:A1994NB40900071
J	TODA, K; SHIZUTA, Y				TODA, K; SHIZUTA, Y			IDENTIFICATION AND CHARACTERIZATION OF CIS-ACTING REGULATORY ELEMENTS FOR THE EXPRESSION OF THE HUMAN AROMATASE CYTOCHROME-P-450 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODING HUMAN AROMATASE; HUMAN PLACENTAL AROMATASE; ADIPOSE STROMAL CELLS; ESTROGEN BIOSYNTHESIS; ENHANCER ELEMENTS; MAMMALIAN-CELLS; PHORBOL ESTERS; DNA; AROMATIZATION; BINDING	CYP19, the human aromatase cytochrome P-450 (P450arom) gene, encodes an enzyme which converts androgens to estrogens by three successive hydroxylation reactions by coupling with NADPH-cytochrome P-450 reductase. In the present study, we have characterized two cis-acting transcriptional regulatory elements of CYP19, termed as hATRE-1 (human aromatase cytochrome P-450 gene transcriptional regulatory element-1) (5'-CTTTCTGGCCTAAGGGTTGGAGAGC-3') and hATRE-2 (5'-CTTTTATGTTGCCCAATACCTGCTCTGCCTCGAGGGTCACTGTC-3'). These sequences are located between -2238 and -2214, and between -2141 and -2098 relative to the major cap site of the gene, respectively. Transient expression analysis in human BeWo choriocarcinoma cells, in which CYP19 is expressed, shows that hATRE-1 represses the expression of the bacterial chloramphenicol acetyltransferase reporter gene driven by the promoter of CYP19, whereas hATRE-2 enhances the reporter gene expression in response to 12-O-tetradecanoylphorbol 13-acetate. Electrophoretic mobility shift analysis indicates that nuclear binding factors specific to hATRE-1 are present in BeWo cells, but not in HeLa cells nor in TYK-nu cells that lack the expression of CYP19. In contrast, nuclear binding factors to hATRE-2 are present not only in BeWo cells but also in the latter two types of cells. Nevertheless, hATRE-2 does not affect the reporter gene expression in HeLa cells and TYK-nu cells. These results indicate that hATRE-1 and hATRE-2 are cis-acting transcriptional regulatory elements involving in the regulation of the cell type-specific expression of CYP19.	KOCHI MED SCH, DEPT MED CHEM, NANKO KU, KOCHI 783, JAPAN	Kochi University								AKHTAR M, 1982, BIOCHEM J, V201, P569, DOI 10.1042/bj2010569; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERKOVITZ GD, 1992, J CLIN ENDOCR METAB, V74, P629, DOI 10.1210/jc.74.3.629; CORBIN CJ, 1988, P NATL ACAD SCI USA, V85, P8948, DOI 10.1073/pnas.85.23.8948; EVANS CT, 1987, J BIOL CHEM, V262, P6914; FISHMAN J, 1981, J BIOL CHEM, V256, P4466; FOSTER R, 1988, J BIOL CHEM, V263, P11528; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAMLORENCE S, 1991, J BIOL CHEM, V266, P11939; HAGERMAN DD, 1987, J BIOL CHEM, V262, P2398; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HARADA N, 1988, BIOCHEM BIOPH RES CO, V156, P725, DOI 10.1016/S0006-291X(88)80903-3; HARADA N, 1990, BIOCHEM BIOPH RES CO, V166, P365, DOI 10.1016/0006-291X(90)91954-Q; HERBST RS, 1990, MOL CELL BIOL, V10, P3896, DOI 10.1128/MCB.10.8.3896; JUNGMANN RA, 1966, STEROIDS, V8, P977, DOI 10.1016/0039-128X(66)91022-1; KELLIS JT, 1987, J BIOL CHEM, V262, P4413; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; LANOUX MJ, 1985, ENDOCRINOLOGY, V117, P361, DOI 10.1210/endo-117-1-361; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOBO JO, 1989, J CLIN ENDOCR METAB, V69, P868, DOI 10.1210/jcem-69-4-868; LONGCOPE C, 1978, J CLIN ENDOCR METAB, V46, P146, DOI 10.1210/jcem-46-1-146; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHENDROO MS, 1991, J BIOL CHEM, V266, P11276; Maxam A M, 1980, Methods Enzymol, V65, P499; MEANS GD, 1989, J BIOL CHEM, V264, P19385; MENDELSON CR, 1986, ENDOCRINOLOGY, V118, P968, DOI 10.1210/endo-118-3-968; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; POMPON D, 1989, MOL ENDOCRINOL, V3, P1477, DOI 10.1210/mend-3-9-1477; PRICE T, 1992, J CLIN ENDOCR METAB, V74, P879, DOI 10.1210/jc.74.4.879; RICE DA, 1991, MOL ENDOCRINOL, V5, P1552, DOI 10.1210/mend-5-10-1552; RITVOS O, 1992, ENDOCRINOLOGY, V130, P61, DOI 10.1210/en.130.1.61; RYAN KJ, 1966, J CLIN ENDOCR METAB, V26, P46, DOI 10.1210/jcem-26-1-46; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMPSON ER, 1981, P NATL ACAD SCI-BIOL, V78, P5690, DOI 10.1073/pnas.78.9.5690; SMUK M, 1977, J CLIN ENDOCR METAB, V45, P1009, DOI 10.1210/jcem-45-5-1009; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; THOMPSON EA, 1974, J BIOL CHEM, V249, P5373; TODA K, 1989, FEBS LETT, V247, P371, DOI 10.1016/0014-5793(89)81373-0; TODA K, 1992, EUR J BIOCHEM, V205, P303, DOI 10.1111/j.1432-1033.1992.tb16781.x; TODA K, 1993, EUR J BIOCHEM, V213, P383, DOI 10.1111/j.1432-1033.1993.tb17772.x; TODA K, 1990, EUR J BIOCHEM, V193, P559, DOI 10.1111/j.1432-1033.1990.tb19372.x; YOSHIDA N, 1991, BIOCHEMISTRY-US, V30, P3003, DOI 10.1021/bi00226a004	45	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8099	8107						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132535				2022-12-25	WOS:A1994NB40900043
J	ANDRES, AC; REID, HH; ZURCHER, G; BLASCHKE, RJ; ALBRECHT, D; ZIEMIECKI, A				ANDRES, AC; REID, HH; ZURCHER, G; BLASCHKE, RJ; ALBRECHT, D; ZIEMIECKI, A			EXPRESSION OF 2 NOVEL EPH-RELATED RECEPTOR PROTEIN-TYROSINE KINASES IN MAMMARY-GLAND DEVELOPMENT AND CARCINOGENESIS	ONCOGENE			English	Note							GROWTH-FACTOR RECEPTOR; BREAST-CANCER; MEDICAL PROGRESS; FAMILY; GENE; MOUSE; IDENTIFICATION; RNA; ONCOGENE; CLONING	To investigate the involvement of protein tyrosine kinases (PTKs) in the growth control of mammary epithelial cells, we have used PCR based cloning to identify PTKs expressed in a mouse mammary epithelial cell line. This approach led to the isolation of two receptor PTKs of the eph-related subfamily; myk-1, a novel member expressed predominantly in lung, heart and mammary gland and myk-2, a close relative of the human eck gene. Northern blot analysis of RNA from mouse mammary glands at different stages of development revealed that myk-1 and myk-2 expression is induced at puberty and differentially regulated during the estrus cycle. myk-1 and myk-2 expression was downregulated during the pregnancy induced differentiation of the mammary gland. Over-expression of myk-1 and myk-2 was found in the undifferentiated and invasive mammary tumors of transgenic mice expressing the Haras oncogene. In contrast, no elevated expression of either gene could be detected in the well differentiated and non-metastatic mammary tumors of c-myc expressing transgenic mice. These results indicate that myk-1 and myk-2 expression is induced during the proliferation of the mammary gland and down-regulated by its differentiation.	UNIV BERN, CLIN & EXPTL RES LAB, CH-3004 BERN, SWITZERLAND	University of Bern								ANDRES AC, 1991, ONCOGENE, V6, P771; BERNS LMJ, 1992, CANCER RES, V52, P1036; Boehme Beatrix, 1993, Oncogene, V8, P2857; CANTLEY LC, 1991, CELL, V64, P235; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESANTES K, 1992, CANCER RES, V52, P1961; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HARRIS JR, 1992, NEW ENGL J MED, V327, P390, DOI 10.1056/NEJM199208063270606; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRATOCHWIL K, 1969, DEV BIOL, V20, P46, DOI 10.1016/0012-1606(69)90004-9; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; Lofts F J, 1992, Cancer Treat Res, V61, P161; Maniatis T., 1982, MOL CLONING; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; RUSSO J, 1989, DEV ONCOL, V58, P133; SAINSBURY JRC, 1987, LANCET, V1, P1398; SAJJADI FG, 1991, NEW BIOL, V3, P769; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; Vonderhaar B K, 1988, Cancer Treat Res, V40, P251; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603	38	135	152	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1994	9	5					1461	1467						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152808				2022-12-25	WOS:A1994NH40100019
J	BLUML, K; MUTSCHLER, E; WESS, J				BLUML, K; MUTSCHLER, E; WESS, J			FUNCTIONAL-ROLE OF A CYTOPLASMIC AROMATIC AMINO-ACID IN MUSCARINIC RECEPTOR-MEDIATED ACTIVATION OF PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; ACETYLCHOLINE-RECEPTOR; LIGAND-BINDING; PHOSPHATIDYLINOSITOL HYDROLYSIS; INTRACELLULAR LOOP; DOMAINS; GS; SUBTYPES; SELECTIVITY; IDENTIFICATION	The N-terminal portion of the third intracellular loop (i3) of muscarinic acetylcholine and other G protein-coupled receptors has been shown to largely determine the G protein coupling profile of a given receptor subtype. Using the rat m3 muscarinic receptor as a model system, we have recently demonstrated that a tyrosine residue (Tyr-254), located at the beginning of the i3 domain, is critically involved in muscarinic receptor-mediated stimulation of phosphatidylinositol (PI) hydrolysis (Bluml, K., Mutschler, E., and Wess, J. (1994) J. Biol. Chem. 269, 402-405). This study was designed to investigate the functional role of this amino acid in further molecular detail. Replacement of Tyr-254 (rat m3 receptor) with alanine or exchange of its position with Ile-253 virtually abolished receptor-mediated stimulation of PI hydrolysis studied in transfected COS-7 cells. In contrast, substitution of Tyr-254 by other aromatic residues such as phenylalanine or tryptophan resulted in mutant receptors that behaved functionally similar to the wild type m3 receptor. Introduction of Tyr-254 into the corresponding position (Ser-210) of the m2 muscarinic receptor (which is only poorly coupled to PI turnover) did not result in an enhanced PI response. However, ''reinsertion'' of Tyr-254 into a functionally inactive chimeric m3/m2 muscarinic receptor (containing m2 receptor sequence at the N terminus of the i3 loop) yielded a mutant receptor that was able to stimulate PI hydrolysis to a similar maximum extent as the wild type m3 receptor. Taken together, our data provide strong evidence that muscarinic receptor-mediated stimulation of PI metabolism is critically dependent on the presence and proper positioning of an aromatic residue at the beginning of the i3 loop.	NIDDKD,BIOORGAN CHEM LAB,BLDG 8A,RM B1A-09,BETHESDA,MD 20892; UNIV FRANKFURT,DEPT PHARMACOL,D-60053 FRANKFURT,GERMANY	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Goethe University Frankfurt								ARDEN JR, 1992, BIOCHEM BIOPH RES CO, V188, P1111, DOI 10.1016/0006-291X(92)91346-R; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLUML K, 1994, J BIOL CHEM, V269, P402; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; CONKLIN RB, 1993, NATURE, V363, P274; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; Higuchi R., 1989, PCR TECHNOLOGY, P61; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; PARKER EM, 1991, J BIOL CHEM, V266, P519; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO RA, 1989, P NATL ACAD SCI USA, V86, P9039, DOI 10.1073/pnas.86.22.9039; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; VOSS T, 1993, J BIOL CHEM, V268, P4637; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3; WESS J, 1990, MOL PHARMACOL, V38, P517; WESS J, 1990, MOL PHARMACOL, V38, P872; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; WONG SKF, 1990, J BIOL CHEM, V265, P6219	36	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11537	11541						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157684				2022-12-25	WOS:A1994NF96600083
J	WURST, H; KORNBERG, A				WURST, H; KORNBERG, A			A SOLUBLE EXOPOLYPHOSPHATASE OF SACCHAROMYCES-CEREVISIAE - PURIFICATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; POLYPHOSPHATE; VACUOLES; ENZYMES	A soluble polyphosphatase of Saccharomyces cerevisiae, purified to apparent homogeneity, is monomeric with a molecular mass of 40 kDa. It acts as an exoenzyme in a processive mode releasing orthophosphate residues from long polyphosphate chains until pyrophosphate is reached. Polyphosphates of all the lengths examined are used as substrates with a preference for those of about 250 residues. These are degraded with a k(cat)/K(m) near the limit for diffusion-controlled reactions. At 37-degrees-C, the enzyme releases about 500 phosphate residues/s. It does not act on pyrophosphate, ATP, or the cyclic form of tripolyphosphate. For optimal activity the enzyme requires magnesium, manganese, or cobalt.	STANFORD UNIV, MED CTR, SCH MED, DEPT BIOCHEM, STANFORD, CA 94305 USA	Stanford University								AHN KH, 1990, J BIOL CHEM, V265, P11734; AKIYAMA M, 1993, J BIOL CHEM, V268, P633; ANDREEVA NA, 1993, YEAST, V9, P127, DOI 10.1002/yea.320090204; BEAUVOIT B, 1989, FEBS LETT, V252, P17, DOI 10.1016/0014-5793(89)80882-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK JE, 1987, ANAL BIOCHEM, V161, P280, DOI 10.1016/0003-2697(87)90452-0; DURR M, 1979, ARCH MICROBIOL, V121, P169, DOI 10.1007/BF00689982; FELTER S, 1973, BIOCHIMIE, V55, P245, DOI 10.1016/S0300-9084(73)80122-1; FELTER S, 1970, B SOC CHIM BIOL, V52, P433; GOOD NE, 1966, BIOCHEMISTRY-US, V5, P467, DOI 10.1021/bi00866a011; HANES CS, 1949, NATURE, V164, P1107, DOI 10.1038/1641107a0; JACOBSON L, 1982, BIOCHEM J, V201, P473, DOI 10.1042/bj2010473; JAZWINSKI SM, 1990, METHOD ENZYMOL, V182, P154; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGEN P, 1958, BIOCHEM Z, V330, P455; LANGEN P, 1962, ACIDES RIBONUCLEIQUE, P603; LUSBY EW, 1980, MOL GEN GENET, V178, P69, DOI 10.1007/BF00267214; MATSUHASHL MICHIO, 1963, ZEIT PHYSIOL CHEM, V333, P28; MATTENHEIMER H, 1951, BIOCHEM Z, V322, P36; SCHUDDEMAT J, 1989, BIOCHIM BIOPHYS ACTA, V1010, P191, DOI 10.1016/0167-4889(89)90160-2; URECH K, 1978, ARCH MICROBIOL, V116, P275, DOI 10.1007/BF00417851; WIEMKEN A, 1979, ARCH MICROBIOL, V123, P23, DOI 10.1007/BF00403499; WIEMKEN A, 1974, ARCH MICROBIOL, V101, P45, DOI 10.1007/BF00455924	23	139	140	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					10996	11001						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157625				2022-12-25	WOS:A1994NF96600008
J	BANERJEE, A; DHOORE, A; ENGELBORGHS, Y				BANERJEE, A; DHOORE, A; ENGELBORGHS, Y			INTERACTION OF DESACETAMIDOCOLCHICINE, A FAST BINDING ANALOG OF COLCHICINE WITH ISOTYPICALLY PURE TUBULIN DIMERS ALPHA-BETA(II), ALPHA-BETA(III) AND ALPHA-BETA(IV)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE STOPPED FLOW; BETA-TUBULIN; BOVINE BRAIN; B-RING; MONOCLONAL-ANTIBODY; KINETICS; COMPLEX; ISOTYPE; AFFINITY; 2-METHOXY-5-(2'	Desacetamidocolchicine (DAAC) is a colchicine analogue that lacks the acetamido side chain in the ring-B of colchicine. Unlike colchicine, it binds to tubulin very quickly, and yet it has powerful antimitotic properties. It has been demonstrated that the beta-tubulin isoforms differ significantly in their interactions with colchicine. In an effort to understand the role of the ring-B of colchicine, we have studied the interaction of DAAC with purified beta-tubulin isoforms. The association was studied fluorometrically using a stopped-now instrument under pseudo-first order conditions in the presence of a large excess of drug. The observed pseudo-first-order rate constants increased in a nonlinear way with the drug concentration, indicating that the binding of DAAC to tubulin isoforms occur in two steps as is true for the binding of colchicine to tubulin (Garland, D. L. (1978) Biochemistry 17, 4266-4272), [GRAPHICS] where the first step is a fast reversible binding and the second step is a slow conformational change leading to the formation of the stable complex (T.DAAC)*. Kinetic analysis shows that the tubulin isoforms exhibit very little differences in their K-1 values, which are 5794 +/- 670, 7109 +/- 1800, and 8993 +/- 1780 M(-1) for alpha beta(II), alpha beta(III), and alpha beta(IV), respectively. The k(2) values for alpha beta(II), alpha beta(III), and alpha beta(IV) are 0.67 +/- 0.05, 0.05 +/- 0.006, and 0.59 +/- 0.07 s(-1), respectively. The apparent on-rate constants (k(on,app) = K(1)k(2)) for alpha beta(II), alpha beta(III), and alpha beta(IV) are 3907 +/- 530, 376 +/- 80, and 5305 +/- 1200 M(-1) s(-1), respectively. The off-rate constants as measured by the loss of fluorescence of drug-tubulin complexes in the presence of a large excess of podophyllotoxin are 6.3 x 10(-4), 5.2 x 10(-4), and 5.7 x 10(-4) s(-1), respectively, for alpha beta(II), alpha beta(III), and alpha beta(IV). The affinity constants as determined by Scatchard analyses are 2.5 x 10(6), 1.5 x 10(6), and 4 x 10(6) M(-1) for alpha beta(II), alpha beta(III), and alpha beta(IV), respectively. The results indicate that the colchicine-binding domain on the alpha beta(III) isoform may differ from that of alpha beta(II) or alpha beta(IV) isoforms in a small region that might accommodate the ring-B of colchicine; and furthermore, this region is much less flexible in alpha beta(III) than in alpha beta(II) or alpha beta(IV) isoforms.	KATHOLIC UNIV LEUVEN, CHEM & BIOL DYNAM LAB, B-3001 LOUVAIN, BELGIUM	KU Leuven	BANERJEE, A (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA.				NCI NIH HHS [CA 26376, CA 59711] Funding Source: Medline; NIGMS NIH HHS [GM 23476] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026376, R29CA059711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023476] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREU JM, 1991, BIOCHEMISTRY-US, V30, P3777, DOI 10.1021/bi00229a027; ANDREU JM, 1982, BIOCHEMISTRY-US, V21, P534, DOI 10.1021/bi00532a019; ARAI T, 1975, ANAL BIOCHEM, V69, P443, DOI 10.1016/0003-2697(75)90146-3; BANE S, 1984, J BIOL CHEM, V259, P7391; BANERJEE A, 1992, J BIOL CHEM, V267, P5625; BANERJEE A, 1987, FEBS LETT, V219, P103, DOI 10.1016/0014-5793(87)81199-7; BANERJEE A, 1988, J BIOL CHEM, V263, P3029; BANERJEE A, 1992, J BIOL CHEM, V267, P13335; BANERJEE A, 1991, J BIOL CHEM, V266, P1689; BANERJEE A, 1987, BIOCHIM BIOPHYS ACTA, V913, P138, DOI 10.1016/0167-4838(87)90322-0; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; BHATTACH.B, 1974, P NATL ACAD SCI USA, V71, P2627, DOI 10.1073/pnas.71.7.2627; CHOUDHURY GG, 1983, FEBS LETT, V161, P55, DOI 10.1016/0014-5793(83)80729-7; DETRICH HW, 1981, BIOCHEMISTRY-US, V20, P5999, DOI 10.1021/bi00524a012; DIAZ JF, 1991, J BIOL CHEM, V266, P2890; Dustin P., 1978, MICROTUBULES; ENGELBORGHS Y, 1987, J BIOL CHEM, V262, P5204; ENGELBORGHS Y, 1986, ANN NY ACAD SCI, V466, P709, DOI 10.1111/j.1749-6632.1986.tb38453.x; ENGELBORGHS Y, 1993, J BIOL CHEM, V268, P107; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; FLOYD LJ, 1989, BIOCHEMISTRY-US, V28, P8515, DOI 10.1021/bi00447a037; GARLAND DL, 1978, BIOCHEMISTRY-US, V17, P4266, DOI 10.1021/bi00613a024; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P1; LAMBEIR A, 1981, J BIOL CHEM, V256, P3279; MAITY SN, 1987, FEBS LETT, V218, P102, DOI 10.1016/0014-5793(87)81027-X; MUKHOPADHYAY K, 1990, BIOCHEMISTRY-US, V29, P6845, DOI 10.1021/bi00481a013; OLMSTED JB, 1973, ANNU REV BIOCHEM, V42, P507, DOI 10.1146/annurev.bi.42.070173.002451; PYLES EA, 1993, BIOCHEMISTRY-US, V32, P2329, DOI 10.1021/bi00060a026; RAY K, 1981, J BIOL CHEM, V256, P6241; RAY K, 1984, EUR J BIOCHEM, V142, P577, DOI 10.1111/j.1432-1033.1984.tb08325.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMITT H, 1976, J MOL BIOL, V102, P743, DOI 10.1016/0022-2836(76)90289-8; SERRANO L, 1984, J BIOL CHEM, V259, P6607; SHERLINE P, 1975, J BIOL CHEM, V250, P5481; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; WILLIAMS RF, 1985, J BIOL CHEM, V260, P3794; WILSON L, 1966, BIOCHEMISTRY-US, V5, P2463, DOI 10.1021/bi00871a042; Wilson L., 1973, ADV CELL MOLECULAR B, V3, P21; WOLFF J, 1991, P NATL ACAD SCI USA, V88, P2820, DOI 10.1073/pnas.88.7.2820	41	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10324	10329						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144613				2022-12-25	WOS:A1994NF01700025
J	GOWDA, DC; JACKSON, CM; HENSLEY, P; DAVIDSON, EA				GOWDA, DC; JACKSON, CM; HENSLEY, P; DAVIDSON, EA			FACTOR X-ACTIVATING GLYCOPROTEIN OF RUSSELLS VIPER VENOM - POLYPEPTIDE COMPOSITION AND CHARACTERIZATION OF THE CARBOHYDRATE MOIETIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED SUGAR CHAINS; AFFINITY-CHROMATOGRAPHY; OLIGOSACCHARIDES; ENZYME; FRACTIONATION; GLYCOPEPTIDES; COAGULATION; PROTEINS	There is contradictory information regarding the molecular weight and polypeptide chain composition of RVV-X, a glycoprotein in Russell's viper venom that is capable of activating factor X to Xa. We show that RVV-X is a 92,880-Da glycoprotein. It consists of three disulfide-linked polypeptide chains, one heavy chain (alpha-chain, M(r) 57,600) and two light chains (beta- and gamma-chains, M(r) 19,400 and 16,400, respectively). The two light chains seen on SDS-polyacrylamide gel electrophoresis under reducing conditions are two distinct components of the molecule, rather than a heterogeneous mixture of a single chain as previously reported (Takeya, H., Nishida, S., Miyata, T., Kawada, S., Saisaka, Y., Morita, T., and Iwanaga, S. (1992) J. Biol. Chem. 267, 14109-14117). The following evidence supports this conclusion. (i) The two light chains of RVV-X are present in equal proportion. (ii) The estimated molecular weight of an alpha(1) beta(1) gamma(1)-structure closely matches the molecular weight determined by matrix-assisted laser desorption mass spectrometry. (iii) The amino acid compositions and NH2-terminal sequences of the beta- and gamma-chains are different. (iv) Although both the beta- and gamma-chains contain one N-linked oligosaccharide chain each, they are glycosylated differentially. RVV-X contains six N-linked oligosaccharides, four in the alpha-chain and one in each of the beta- and gamma-chains. The carbohydrate structures are different from those known for other snake venom glycoproteins, and they resemble closely those in various mammalian glycoproteins. The majority of the oligosaccharides are complex bi-, tri-, and tetraantennary structures, with a small proportion of multiantennary and high mannose-type structures. Two notable structural features of RVV-X oligosaccharides are as follows. (i) Sialic acid residues are linked to beta-galactosyl residues solely by alpha 2,3-linkages, and (ii) bisecting N-acetylglucosamine residues are present in the majority of the oligosaccharides.	AMER RED CROSS, DETROIT, MI 48232 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT MACROMOLEC SCI, KING OF PRUSSIA, PA 19406 USA	American Red Cross; GlaxoSmithKline	GOWDA, DC (corresponding author), GEORGETOWN UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, 3900 RESERVOIR RD NW, WASHINGTON, DC 20007 USA.		Jackson, Craig M/AAC-6338-2020	Jackson, Craig/0000-0001-9484-4420; Gowda, Channe/0000-0002-6860-5108	NCRR NIH HHS [1-P41-RR05351-04] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR005351] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AMPHLETT GW, 1982, BIOCHEMISTRY-US, V21, P125, DOI 10.1021/bi00530a022; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; FINNE J, 1982, METHOD ENZYMOL, V83, P269; FUKUDA M, 1984, J BIOL CHEM, V259, P4782; Furie B.C., 1976, Methods Enzymol, V45, P191; Gowda D. Channe, 1992, Glycobiology, V2, P475; GOWDA DC, 1992, MOL IMMUNOL, V29, P335, DOI 10.1016/0161-5890(92)90020-X; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HARADA H, 1987, ANAL BIOCHEM, V164, P374, DOI 10.1016/0003-2697(87)90507-0; HARDY MR, 1989, METHOD ENZYMOL, V179, P76; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MATSUI T, 1992, J BIOL CHEM, V267, P8723; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; MIZOGUCHI A, 1984, J BIOL CHEM, V259, P1943; NOSE M, 1990, J IMMUNOL, V145, P910; PFEIFFER G, 1992, EUR J BIOCHEM, V205, P961, DOI 10.1111/j.1432-1033.1992.tb16863.x; PIERCECRETEL A, 1984, EUR J BIOCHEM, V139, P337, DOI 10.1111/j.1432-1033.1984.tb08012.x; SCHIFFMAN S, 1969, BIOCHEMISTRY-US, V8, P1397, DOI 10.1021/bi00832a014; SIEFTER S, 1950, ARCH BIOCH, V25, P191; Stocker K., 1990, P97; TAKEYA H, 1992, J BIOL CHEM, V267, P14109; TANAKA N, 1992, J BIOCHEM-TOKYO, V112, P68, DOI 10.1093/oxfordjournals.jbchem.a123867; WEINBERGER SR, 1992, AM LAB SHELTON CONN, P54; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WILLIAMS WJ, 1962, BIOCHEM J, V84, P52, DOI 10.1042/bj0840052; YAMASHITA K, 1983, CANCER RES, V43, P4691; YAMASHITA K, 1983, J BIOL CHEM, V258, P1098; YAMASHITA K, 1982, J BIOL CHEM, V257, P2809; YORK WS, 1984, METHOD ENZYMOL, V118, P3; YOSHIMA H, 1980, J BIOL CHEM, V255, P9713	33	68	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10644	10650						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144654				2022-12-25	WOS:A1994NF01700069
J	RANDAZZO, PA; KAHN, RA				RANDAZZO, PA; KAHN, RA			GTP HYDROLYSIS BY ADP-RIBOSYLATION FACTOR IS DEPENDENT ON BOTH AN ADP-RIBOSYLATION FACTOR GTPASE-ACTIVATING PROTEIN AND ACID PHOSPHOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; RAS GTPASE; BINDING-PROTEIN; ENDOSOME FUSION; CHOLERA-TOXIN; GENE; COFACTOR; ENCODES; DOMAIN; TRANSPORT	ADP-ribosylation factor (ARF) is a 21-kDa GTP binding protein that regulates eukaryotic membrane traffic. Both the binding and hydrolysis of GTP by ARF have been shown to be necessary for this function. However, purified mammalian ARF lacks intrinsic GTPase activity (<0.0015 min(-1)). We document the presence, in bovine brain extracts, of a protein with the predicted properties for an ARF GTPase activating protein (ARF GAP). This activity was highly dependent on phospholipids. An acid phospholipid fraction from bovine brain (containing primarily phosphatidylinositol 4,5-bisphosphate (PIP2), phosphatidylinositol 4-phosphate, phosphatidylinositol, and phosphatidylserine) had no effect on intrinsic GTPase activity of purified ARF but increased the ARF GAP activity of bovine brain homogenates about 8-fold. This dependence on acid phospholipids was retained after >100-fold purification of ARF GAP, making it, likely, an inherent property of this reaction. PIP2 alone stimulated ARF GAP activity up to 30-fold with a half-maxmal effect at 100-300 mu M but had no effect on the GTPase rate of ARF alone. Phosphatidylinositol 4-phosphate was also active but had only 50% of the maximal effect and twice the EC(50) of PIP2. Phosphatidylserine, phosphatidylethanolamine, phosphatidylcholine, phosphatidylinositol, and diacylglycerol either alone or in the presence of ARF GAP do not stimulate ARF GTPase activity. ARF proteins have been identified recently as regulators of phospholipase D. The product of the phospholipase D reaction, phosphatidic acid, stimulated ARF GAP approximately 5-fold and reduced the PIP2 concentration needed for GAP stimulation about 6-fold. The substrate of phospholipase D, phosphatidylcholine, inhibited ARF GAP activity, but this inhibition seen with phosphatidylcholine was partially reversed by phosphatidic acid. A feedback loop for the coordinate regulation of phospholipase D and ARF activities is proposed.			RANDAZZO, PA (corresponding author), NCI, DIV CANC TREATMENT, DEV THERAPEUT PROGRAM, BIOL CHEM LAB, BETHESDA, MD 20892 USA.		Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				BALCH WE, 1992, J BIOL CHEM, V267, P13053; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; JONES GA, 1993, J BIOL CHEM, V268, P20845; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1993, GTPASES BIOL, P529; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAEKAWA M, 1993, J BIOL CHEM, V268, P22948; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MORITZ A, 1992, J BIOL CHEM, V267, P7207; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; ROSENWALD AG, 1994, IN PRESS GTPASE CONT; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SALAMA SR, 1990, J BACTERIOL, V172, P4510, DOI 10.1128/jb.172.8.4510-4521.1990; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; WEISS O, 1989, J BIOL CHEM, V264, P21066; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683; ZHANG CJ, 1994, IN PRESS J CELL BIOL	45	179	181	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10758	10763						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144664				2022-12-25	WOS:A1994NF01700085
J	TAVARES, P; RAVI, N; MOURA, JJG; LEGALL, J; HUANG, YH; CROUSE, BR; JOHNSON, MK; HUYNH, BH; MOURA, I				TAVARES, P; RAVI, N; MOURA, JJG; LEGALL, J; HUANG, YH; CROUSE, BR; JOHNSON, MK; HUYNH, BH; MOURA, I			SPECTROSCOPIC PROPERTIES OF DESULFOFERRODOXIN FROM DESULFOVIBRIO-DESULFURICANS (ATCC-27774)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; RESONANCE RAMAN-SPECTRA; BLUE COPPER PROTEINS; MOSSBAUER-SPECTROSCOPY; RUBREDOXIN; DESULFOREDOXIN; HILDENBOROUGH; PURIFICATION; ENVIRONMENT; CYTOCHROME	Desulfoferrodoxin, a non-heme iron protein, was purified previously from extracts of Desulfovibrio desulfuricans (ATCC 27774) (Moura, I., Tavares, P., Moura, J. J. G., Ravi, N., Huynh, B. H., Liu, M.-Y., and LeGall, J. (1990) J. Biol. Chem. 265, 21596-21602). The as-isolated protein displays a pink color (pink form) and contains two mononuclear iron sites in different oxidation states: a ferric site (center I) with a distorted tetrahedral sulfur coordination similar to that found in desulforedoxin from Desulfovibrio gigas and a ferrous site (center II) octahedrally coordinated with predominantly nitrogen/ oxygen-containing ligands. A new form of desulfoferrodoxin which displays a gray color (gray form) has now been purified. Optical, electron paramagnetic resonance (EPR), and Mossbauer data of the gray desulfoferrodoxin indicate that both iron centers are in the high-spin ferric states. In addition to the EPR signals originating from center I at g = 7.7, 5.7, 4.1, and 1.8, the gray form of desulfoferrodoxin exhibits a signal atg = 4.3 and a shoulder at g = 9.6, indicating a high-spin ferric state with E/D approximate to 1/3 for the oxidized center II. Redox titrations of the gray form of the protein monitored by optical spectroscopy indicate midpoint potentials of +4 +/- 10 and +240 +/- 10 mV for centers I and II, respectively. Mossbauer spectra of the gray form of the protein are consistent with the EPR finding that both centers are high-spin ferric and can be analyzed in terms of the EPR-determined spin Hamiltonian parameters. The Mossbauer parameters for both the ferric and ferrous forms of center II are indicative of a mononuclear high spin iron site with octahedral coordination and predominantly nitrogen/oxygen-containing ligands. Resonance Raman studies confirm the structural similarity of center I and the distorted tetrahedral FeS4 center in desulforedoxin and provide evidence for one or two cysteinyl-S ligands for center II. On the basis of the resonance Raman results, the 635 nm absorption band that is responsible for the gray color of the oxidized protein is assigned to a cysteinyl-S --> Fe(III) charge transfer transition localized on center II. The novel properties and possible function of center II are discussed in relation to those of mononuclear iron centers in other enzymes.	UNIV GEORGIA,DEPT CHEM,ATHENS,GA 30602; UNIV NOVA LISBOA,INST TECNOL QUIM & BIOL,P-2780 OEIRAS,PORTUGAL; EMORY UNIV,DEPT PHYS,ATLANTA,GA 30322; UNIV NOVA LISBOA,FAC CIENCIAS & TECNOL,DEPT QUIM,P-2825 MONTE DE CAPARICA,PORTUGAL; UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; UNIV GEORGIA,CTR METALLOENZYME STUDIES,ATHENS,GA 30602	University System of Georgia; University of Georgia; Universidade Nova de Lisboa; Emory University; Universidade Nova de Lisboa; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia			Tavares, Pedro/B-3654-2008; Moura, Isabel/D-6339-2013; Moura, José J G/D-6426-2013	Tavares, Pedro/0000-0002-7398-2661; Moura, Isabel/0000-0003-0971-4977; Moura, José J G/0000-0002-4726-2388	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047295, R01GM041482, R01GM033806] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33806, GM-41482, GM-47295] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCIERO DM, 1983, J BIOL CHEM, V258, P4981; BLAIR DF, 1985, J AM CHEM SOC, V107, P5755, DOI 10.1021/ja00306a025; BRUMLIK MJ, 1989, J BACTERIOL, V171, P4996, DOI 10.1128/jb.171.9.4996-5004.1989; CZERNUSZEWICZ RS, 1986, INORG CHEM, V25, P696, DOI 10.1021/ic00225a022; DUNHAM WR, 1990, EUR J BIOCHEM, V190, P611, DOI 10.1111/j.1432-1033.1990.tb15616.x; FU WG, 1992, J BIOL CHEM, V267, P15502; HAN J, 1991, BIOCHEMISTRY-US, V30, P10904, DOI 10.1021/bi00109a014; JIN HY, 1993, J AM CHEM SOC, V115, P5290, DOI 10.1021/ja00065a048; KENT TA, 1987, INORG CHEM, V26, P1402, DOI 10.1021/ic00256a014; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; Kretchmar S A, 1988, Biol Met, V1, P26, DOI 10.1007/BF01128014; KUILA D, 1992, BIOCHIM BIOPHYS ACTA, V1140, P175, DOI 10.1016/0005-2728(92)90007-O; LIU MC, 1981, J BIOL CHEM, V256, P3159; MINOR W, 1993, BIOCHEMISTRY-US, V32, P6320, DOI 10.1021/bi00076a003; MOORE S, 1963, METHOD ENZYMOL, V46, P41; MOURA I, 1977, BIOCHEM BIOPH RES CO, V75, P1037, DOI 10.1016/0006-291X(77)91486-3; MOURA I, 1980, J BIOL CHEM, V255, P2493; MOURA I, 1990, J BIOL CHEM, V265, P21596; NELSON MJ, 1991, J AM CHEM SOC, V113, P7072, DOI 10.1021/ja00018a074; ORVILLE AM, 1992, BIOCHEMISTRY-US, V31, P4602, DOI 10.1021/bi00134a010; QUE L, 1983, COORDIN CHEM REV, V50, P73, DOI 10.1016/0010-8545(83)85027-9; Que L, 1988, BIOL APPLICATIONS RA, P491; ROTTMAN GA, 1989, J AM CHEM SOC, V111, P8613, DOI 10.1021/ja00205a009; SHELNUTT JA, 1979, P NATL ACAD SCI USA, V76, P3865, DOI 10.1073/pnas.76.8.3865; Spiro T. G., 1988, BIOL APPLICATIONS RA, P523; WHITTAKER JW, 1984, J BIOL CHEM, V259, P4466; YACHANDRA VK, 1983, J AM CHEM SOC, V105, P6455, DOI 10.1021/ja00359a015; YANG CY, 1987, BIOCHEMISTRY-US, V26, P497, DOI 10.1021/bi00376a023	28	89	90	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10504	10510						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144635				2022-12-25	WOS:A1994NF01700049
J	WOOTAN, MG; STORCH, J				WOOTAN, MG; STORCH, J			REGULATION OF FLUORESCENT FATTY-ACID TRANSFER FROM ADIPOCYTE AND HEART FATTY-ACID-BINDING PROTEINS BY ACCEPTOR MEMBRANE LIPID-COMPOSITION AND STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNILAMELLAR VESICLES; RAT-HEART; 3-DIMENSIONAL STRUCTURE; MAGNETIC-RESONANCE; BILAYER-MEMBRANES; MODEL MEMBRANES; MESSENGER-RNAS; LIVER; CHOLESTEROL; CARDIOLIPIN	Adipocyte and heart fatty acid binding proteins (A-FABP and H-FABP) are closely related members of the FABP family. Unlike the more distantly related liver FABP, these FABP have been proposed to transfer free fatty acids to model membranes by a collisional mechanism (Wootan, M. G., Bernlohr, D.A,, and Storch, J. (1993) Biochemistry 32, 8622-8627; Kim, H. K., and Storch, J. (1992) J. Biol. Chen. 267, 20051-20056). Collisional transfer requires that the acceptor membranes interact with FABP during the transfer process. We, therefore, examined whether the acceptor membrane structure and lipid composition regulate the rate of anthroyloxy-labeled palmitate (2AP) transfer from A- and H-FABP, using a fluorescence resonance energy transfer assay. The results showed that 2AP transfer from A and H-FABP was more rapid to acceptor vesicles containing acidic phospholipids and was slower to positively charged membranes. In addition, the rate of 2AP transfer from A- and H-FABP was enhanced by unsaturation of the phosphatidylcholine acyl chains and was slowed by the presence of cholesterol or sphingomyelin in the acceptor membranes. These latter changes were small but of a similar magnitude and together suggest that fatty acid transfer from A- and H-FABP was slower to membranes of greater lipid order. Since transfer by an aqueous diffusion mechanism would be unaffected by acceptor membrane properties, these studies strengthen the hypothesis that free fatty acid transfer from A- and H-FABP to membranes occurs via a collisional mechanism.	RUTGERS STATE UNIV, COOK COLL, DEPT NUTR SCI, NEW BRUNSWICK, NJ 08903 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA	Rutgers State University New Brunswick; Harvard University; Harvard T.H. Chan School of Public Health				Storch, Judith/0000-0001-5482-1777	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038389, R29DK038389] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK038389, DK38389] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEGRINI PR, 1984, BIOCHEMISTRY-US, V23, P6452, DOI 10.1021/bi00321a027; BAR LK, 1987, BIOCHEMISTRY-US, V26, P5460, DOI 10.1021/bi00391a037; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BLOCH K, 1985, BIOCH LIPIDS MEMBRAN, P1; BOGGS JM, 1987, BIOCHIM BIOPHYS ACTA, V906, P353, DOI 10.1016/0304-4157(87)90017-7; BRECHER P, 1984, J BIOL CHEM, V259, P3395; COLBEAU A, 1971, BIOCHIM BIOPHYS ACTA, V249, P462, DOI 10.1016/0005-2736(71)90123-4; COOK KS, 1985, J CELL BIOL, V100, P514, DOI 10.1083/jcb.100.2.514; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5873, DOI 10.1021/bi00238a010; CULLIS PR, 1985, BIOCH LIPIDS MEMBRAN, P25; DAEL HV, 1982, BIOCHEM BIOPH RES CO, V104, P173; DECUYPER M, 1984, COLLOID SURFACE, V10, P313, DOI 10.1016/0166-6622(84)80032-3; EASTMAN SJ, 1989, BIOCHIM BIOPHYS ACTA, V981, P178, DOI 10.1016/0005-2736(89)90026-6; Gomori G, 1942, J LAB CLIN MED, V27, P955; GRINSTEAD GF, 1983, BIOCHIM BIOPHYS ACTA, V751, P41, DOI 10.1016/0005-2760(83)90255-2; Huang C, 1974, Methods Enzymol, V32, P485; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; IOANNOU P V, 1979, Progress in Lipid Research, V17, P279, DOI 10.1016/0079-6832(79)90010-7; JONES JD, 1989, BIOCHEMISTRY-US, V28, P129, DOI 10.1021/bi00427a019; KEENAN TW, 1970, BIOCHEMISTRY-US, V9, P19, DOI 10.1021/bi00803a003; KIM HK, 1992, J BIOL CHEM, V267, P20051; KIM HK, 1992, J BIOL CHEM, V267, P77; KUTCHAI H, 1983, BIOCHIM BIOPHYS ACTA, V736, P137, DOI 10.1016/0005-2736(83)90277-8; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LEE A G, 1975, Progress in Biophysics and Molecular Biology, V29, P3; LEE AG, 1972, BIOCHIM BIOPHYS ACTA, V255, P43, DOI 10.1016/0005-2736(72)90006-5; LEVINE YK, 1972, BIOCHEMISTRY-US, V11, P1416, DOI 10.1021/bi00758a014; LIS LJ, 1982, BIOPHYS J, V37, P667; LUNZER MA, 1977, J BIOL CHEM, V252, P5483; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MATARESE V, 1988, J BIOL CHEM, V263, P14544; MULLERFAHRNOW A, 1991, EUR J BIOCHEM, V199, P271, DOI 10.1111/j.1432-1033.1991.tb16120.x; NICHOLS JW, 1982, BIOCHEMISTRY-US, V21, P1720, DOI 10.1021/bi00537a003; NICHOLS JW, 1981, BIOCHEMISTRY-US, V20, P2783, DOI 10.1021/bi00513a012; POWELL GL, 1985, BIOCHEMISTRY-US, V24, P2902, DOI 10.1021/bi00333a013; ROSEMAN MA, 1980, BIOCHEMISTRY-US, V19, P439, DOI 10.1021/bi00544a006; ROSING J, 1988, BIOCHEMISTRY-US, V27, P9048, DOI 10.1021/bi00425a025; SACCHETTINI JC, 1986, J BIOL CHEM, V261, P8218; SAID B, 1984, J BIOL CHEM, V259, P1155; SALSBURY NJ, 1970, T FARADAY SOC, V66, P1554, DOI 10.1039/tf9706601554; SANKARAM MB, 1989, BIOCHIM BIOPHYS ACTA, V980, P389, DOI 10.1016/0005-2736(89)90331-3; SCHLAME M, 1990, BIOCHEM J, V265, P79, DOI 10.1042/bj2650079; SHEETZ MP, 1972, BIOCHEMISTRY-US, V11, P4573, DOI 10.1021/bi00774a024; SQUIER TC, 1991, BIOPHYS J, V59, P654, DOI 10.1016/S0006-3495(91)82281-0; STORCH J, 1990, J BIOL CHEM, V265, P7827; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; STORCH J, 1989, J BIOL CHEM, V264, P8708; SWEELEY CC, 1985, BIOCH LIPIDS MEMBRAN, P371; TANFORD C, 1961, PHYSICAL CHEM MACROM, P346; THILO L, 1977, BIOCHIM BIOPHYS ACTA, V469, P326, DOI 10.1016/0005-2736(77)90168-7; VINCENT SH, 1985, J BIOL CHEM, V260, P4521; WOOTAN MG, 1993, BIOCHEMISTRY-US, V32, P8622, DOI 10.1021/bi00084a033; WOOTAN MG, 1990, BIOCHEMISTRY-US, V29, P9305, DOI 10.1021/bi00492a001; XU ZH, 1992, BIOCHEMISTRY-US, V31, P3484, DOI 10.1021/bi00128a024; XU ZH, 1991, J BIOL CHEM, V266, P14367; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541	57	60	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10517	10523						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144637				2022-12-25	WOS:A1994NF01700051
J	ZHANG, WG; GUSTAFSON, TA; RUTTER, WJ; JOHNSON, JD				ZHANG, WG; GUSTAFSON, TA; RUTTER, WJ; JOHNSON, JD			POSITIVELY CHARGED SIDE-CHAINS IN THE INSULIN-LIKE GROWTH-FACTOR-I C-REGIONS AND D-REGIONS DETERMINE RECEPTOR-BINDING SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR	Human insulin-like growth factor-1 (hIGF-1) contains seven positively charged residues in the A-, C-, and D-regions that are not present in similar positions in insulin. To determine whether these residues contribute to receptor binding specificity for the insulin-like growth factor-1 receptor (IGF-1R) relative to the insulin receptor (IR) we examined the binding of hIGF-1 analogs in which these residues have been replaced with either alanine or the corresponding residue of insulin. To improve expression and facilitate purification we employed insulin-like growth factor (IGF-1) analogs modified with an N-terminal 8 amino acid epitope. This additional epitope did not alter receptor binding specificity. Alanine substitution for the positively charged residues in the C- and D-regions of IGF-1 led to 15- and 10-fold losses, respectively, in binding potency for the human IGF-1R, but they increased the potency of binding to the human IR 29 and 6-fold, respectively. In contrast, substitution of the positively charged side chains in the A-region with the corresponding uncharged residues of insulin had little effect on binding to either receptor. These data suggest that the positive charges in the C- and D-regions of IGF-1 contribute significantly to the binding preference of the IGF-1R for IGF-1. In complementary experiments using chimeric receptors we have also shown that the IGF-1 receptor elements required to discriminate in favor of the positive charges in the C- and D-regions are contained in the N-terminal 283 amino acids of the alpha-subunit. Insulin receptor elements that discriminate against these charges are within the N-terminal 225 amino acids of its alpha-subunit.	UNIV CALIF SAN FRANCISCO,HORMONE RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV MARYLAND,DEPT PHYSIOL,BALTIMORE,MD 21201	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University System of Maryland; University of Maryland Baltimore					NIDDK NIH HHS [DK37661, DK44093] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044093] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAYNE ML, 1989, J BIOL CHEM, V264, P11004; BLUNDELL TL, 1978, P NATL ACAD SCI USA, V75, P180, DOI 10.1073/pnas.75.1.180; CARA JF, 1990, J BIOL CHEM, V265, P17820; CASCIERI MA, 1989, J BIOL CHEM, V264, P2199; COOKE RM, 1991, BIOCHEMISTRY-US, V30, P5484, DOI 10.1021/bi00236a022; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FRANKEL AD, 1992, P NATL ACAD SCI USA, V89, P11653, DOI 10.1073/pnas.89.24.11653; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; PHILLIPS MA, 1990, J BIOL CHEM, V265, P20692; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; RUTTER W, 1991, MODERN CONCEPTS INSU, P541; SCHAFFER L, 1993, J BIOL CHEM, V268, P3044; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0	20	42	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10609	10613						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144650				2022-12-25	WOS:A1994NF01700064
J	BERNSTEIN, LR; FERRIS, DK; COLBURN, NH; SOBEL, ME				BERNSTEIN, LR; FERRIS, DK; COLBURN, NH; SOBEL, ME			A FAMILY OF MITOGEN-ACTIVATED PROTEIN KINASE-RELATED PROTEINS INTERACTS IN-VIVO WITH ACTIVATOR PROTEIN-1 TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							C-JUN; TYROSINE KINASE; DNA-BINDING; MAP KINASES; FACTOR AP-1; JB6 CELLS; PHOSPHORYLATION; FOS; RESISTANT; THREONINE	The activator protein-1 (AP-1) transcription factor modulates expression of genes involved in growth regulation, differentiation, and neoplastic transformation. Several mitogen-activated protein kinases (MAP kinases) as well as other kinases phosphorylate c-Jun and c-Fos in vitro and are postulated to control AP-1 activity. However, since many protein kinases phosphorylate substrates in vitro with which they have no association in vivo, we sought evidence for interaction in vivo between AP-1 and MAP kinase proteins. We now report detection of an association in vivo of MAP kinase-related proteins with c-Jun and AP-1 dimers by peptide mapping and two-dimensional electrophoretic analyses of proteins co-immunoprecipitated with AP-1 antigens. Extracellular signal-regulated kinase-2 and several apparently novel MAP kinase-related proteins are among the species that bind to AP-1. The large number of MAP kinase-related proteins associated with AP-1 implicates them on an important gene regulation pathway. Combinatorial association between MAP kinase-related proteins and AP-1 dimers could potentially create numerous distinct complexes that could regulate diverse genes.	NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	BERNSTEIN, LR (corresponding author), NCI,PATHOL LAB,BLDG 10,RM 2A33,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAIROCH A, 1992, PC GENE SEQUENCE ANA; BARABAN JM, 1993, J NEUROCHEM, V60, P330, DOI 10.1111/j.1471-4159.1993.tb05855.x; BASKER SJ, 1992, MOL CELL BIOL, P4694; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BERNSTEIN LR, 1992, MOL CARCINOGEN, V6, P221, DOI 10.1002/mc.2940060308; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHENG HC, 1991, J BIOL CHEM, V266, P17919; CHOU S, 1991, MOL CELL BIOL, V3, P1117; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1984, CELL, V36, P259; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; FRAME MC, 1991, ONCOGENE, V6, P205; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LEE H, 1993, J BIOL CHEM, V268, P8181; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEE W, 1987, CELL, V49, P35; LEVINE RA, 1990, CELL REGUL, V1, P215, DOI 10.1091/mbc.1.2.215; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; 1993, ECL DETECTION W BLOT, P10	34	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9401	9404						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144522				2022-12-25	WOS:A1994NE05300002
J	KRAMER, RH; LENFERINK, AEG; VANBUERENKOORNNEEF, IL; VANDERMEER, A; VANDEPOLL, MLM; VANZOELEN, EJJ				KRAMER, RH; LENFERINK, AEG; VANBUERENKOORNNEEF, IL; VANDERMEER, A; VANDEPOLL, MLM; VANZOELEN, EJJ			IDENTIFICATION OF THE HIGH-AFFINITY BINDING-SITE OF TRANSFORMING GROWTH-FACTOR-ALPHA (TGF-ALPHA) FOR THE CHICKEN EPIDERMAL GROWTH-FACTOR (EGF) RECEPTOR USING EGF/TGF-ALPHA CHIMERAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LIGAND; PROTEOLYSIS; ANTIBODIES; MOLECULES; PROTEINS	Human epidermal growth factor (hEGF) and human transforming growth factor-alpha (hTGF-alpha) are structurally related growth factors that share relatively little sequence homology. They both exert their biological action by binding to the cell-surface EGF receptor. hEGF and hTGF-alpha bind with similar affinity to the hEGF re receptor, but hEGF binds with an similar to 100-fold lower affinity to the chicken EGF receptor compared with hTGF-alpha. To map the region in hTGF-alpha that confers its ability to bind with high affinity to the chicken EGF receptor, 10 hybrids of hEGF and hTGF-alpha were constructed by exchanging domains bordered by the third, fourth, and sixth conserved cysteine residues. The activity of the expressed chimeric proteins was determined by their ability to compete with I-125-labeled mouse EGF for bind binding to NIH-3T3 cells transfected with the hEGF receptor. Subsequent binding competition studies of NIH-3T3 cells transfected with the chicken EGF receptor showed that chimeras carrying TGF-alpha sequences COOH-terminal of the sixth cysteine have a high affinity for this receptor, similar to hTGF-alpha. In contrast, chimeras with EGF sequences in this COOH-terminal domain have only low binding affinity, similar to hEGF. We conclude that the COOH-terminal linear region of hTGF-alpha is important for its high affinity interaction with the chicken EGF receptor.	UNIV NIJMEGEN, DEPT CELL BIOL, 6525 ED NIJMEGEN, NETHERLANDS	Radboud University Nijmegen			van der Meer, Arnold/M-1693-2016	van der Meer, Arnold/0000-0001-8274-414X				AVIVI A, 1991, ONCOGENE, V6, P673; BURGESS AW, 1988, BIOCHEMISTRY-US, V27, P4977, DOI 10.1021/bi00414a005; BUTTERWITH SC, 1992, J ENDOCRINOL, V134, P163, DOI 10.1677/joe.0.1340163; Campbell I D, 1989, Prog Growth Factor Res, V1, P13, DOI 10.1016/0955-2235(89)90038-0; CAMPION SR, 1992, J CELL BIOCHEM, V50, P35; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1991, PEPTIDE GROWTH FACTO, V1, P69; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; ENGEL H, 1992, PROTEIN EXPRES PURIF, V3, P108, DOI 10.1016/S1046-5928(05)80026-9; FIELD JA, 1992, BIOCHEM J, V283, P91; HOEPRICH PD, 1989, J BIOL CHEM, V264, P19086; KATSUURA M, 1989, J BIOCHEM-TOKYO, V106, P87, DOI 10.1093/oxfordjournals.jbchem.a122826; KAUSHANSKY K, 1992, PROTEINS, V12, P1, DOI 10.1002/prot.340120102; KIENHUIS CBM, 1991, CLIN CHEM, V37, P1749; KING IC, 1990, ANAL BIOCHEM, V188, P97, DOI 10.1016/0003-2697(90)90533-F; KOHDA D, 1992, BIOCHEMISTRY-US, V31, P11928, DOI 10.1021/bi00162a036; LAROCHELLE WJ, 1992, J BIOL CHEM, V267, P17074; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; MCKENZIE ANJ, 1991, EMBO J, V10, P1193, DOI 10.1002/j.1460-2075.1991.tb08060.x; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NILSSON B, 1990, METHOD ENZYMOL, V185, P144; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; PURCHIO AF, 1987, GENE, V60, P175, DOI 10.1016/0378-1119(87)90225-3; SCHULTZ G, 1991, METHOD ENZYMOL, V198, P200; SORVILLO JM, 1990, ONCOGENE, V5, P377; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; van Zoelen E J, 1990, Prog Growth Factor Res, V2, P131, DOI 10.1016/0955-2235(90)90001-Z; VANZOELEN EJJ, 1993, BIOCHEMISTRY-US, V32, P6275, DOI 10.1021/bi00075a022; VIOLAND BN, 1991, INT J PEPT PROT RES, V37, P463; WALKER F, 1990, BIOCHEMISTRY-US, V29, P10635, DOI 10.1021/bi00499a009	30	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8708	8711						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132599				2022-12-25	WOS:A1994NB41100016
J	BAFFY, G; YANG, LJ; RAJ, S; MANNING, DR; WILLIAMSON, JR				BAFFY, G; YANG, LJ; RAJ, S; MANNING, DR; WILLIAMSON, JR			G-PROTEIN COUPLING TO THE THROMBIN RECEPTOR IN CHINESE-HAMSTER LUNG FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERTUSSIS TOXIN; PHOSPHOLIPASE-C; PROTEOLYTIC MECHANISM; RAT HEPATOCYTES; HUMAN-PLATELETS; GROWTH-FACTORS; ALPHA-SUBUNIT; ACTIVATION; PHOSPHORYLATION; CELLS	The specific involvement of G proteins in thrombin receptor-mediated Ca2+ mobilization and DNA synthesis has been studied in single Chinese hamster lung fibroblasts (CCL39 cells) activated by the hexapeptide SFLLRN. Immunoblots performed with antibodies directed against the COOH terminus of G protein cu subunits revealed that alpha(q), alpha(i), and alpha(o), were each present in CCL39 cells. The Ca2+ response to SFLLRN was measured after microinjection of anti-alpha(q) or anti-alpha(o) antibodies, which produced a total blockade in 71 and 46% of cells, respectively. A partial inhibition of the SFLLRN-induced Ca2+ response was observed in the remaining cells. The lag time between exposure of the cells to SFLLRN and the onset of Ca2+ mobilization was significantly longer (20-24 s) in cells microinjected with anti-alpha(q)- or anti-alpha(o)-antibodies than in control cells microinjected with preimmune serum (9 +/- 1 s). Moreover, the peak height of the Ca2+ response to SFLLRN was de creased by 36 and 73%, respectively in cells microinjected with anti-alpha(q) or anti-alpha(o) antibodies. SFLLRN-induced DNA synthesis in growth arrested CCL39 cells was also inhibited (44-78%) by prior microinjection of anti-alpha(q) or anti-alpha(o) antibodies. Anti-alpha(i) antibodies had no effect on the SFLLRN-induced Ca2+ response or on DNA synthesis. These results provide direct evidence that the thrombin receptor in CCL39 cells is coupled to two different types of G proteins, G(q) and G(o), both causing Ca2+ mobilization and mitogenesis.	UNIV PENN,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PHARMACOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania			Baffy, Gyorgy/P-7986-2018	Baffy, Gyorgy/0000-0002-8334-0400	NIDDK NIH HHS [DK-15120, DK-19525] Funding Source: Medline; NIMH NIH HHS [MH-48125] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015120, P30DK019525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH048125] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAFFY G, 1993, DIABETES, V42, P1878, DOI 10.2337/diabetes.42.12.1878; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BRASS LF, 1991, J BIOL CHEM, V266, P958; BRASS LF, 1992, J BIOL CHEM, V267, P6044; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANSEN CA, 1991, J BIOL CHEM, V266, P18573; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; JHON DY, 1993, J BIOL CHEM, V268, P6654; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KROLL SD, 1991, P NATL ACAD SCI USA, V88, P5182, DOI 10.1073/pnas.88.12.5182; KROLL SD, 1992, J BIOL CHEM, V267, P23183; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; LAW SF, 1991, J BIOL CHEM, V266, P17885; LEE CH, 1992, J BIOL CHEM, V267, P16044; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; NEER EJ, 1990, SOC GEN PHY, V45, P143; NEYLON CB, 1992, J BIOL CHEM, V267, P7295; OFFERMANNS S, 1993, BIOCHEM J, V290, P27, DOI 10.1042/bj2900027; PANDRELL E, 1991, J BIOL CHEM, V266, P9771; PEREZRODRIGUEZ R, 1981, CELL BIOL INT REP, V5, P347, DOI 10.1016/0309-1651(81)90004-7; REILLY CF, 1993, BIOCHEM BIOPH RES CO, V190, P1001, DOI 10.1006/bbrc.1993.1148; SHEARS SB, 1989, J BIOL CHEM, V264, P19879; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPIEGEL A M, 1992, Current Opinion in Cell Biology, V4, P203, DOI 10.1016/0955-0674(92)90034-A; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; YANG LJ, 1991, J BIOL CHEM, V266, P22451; YANG LJ, 1993, J BIOL CHEM, V268, P3739	37	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8483	8487						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132575				2022-12-25	WOS:A1994NB40900097
J	KNOTT, TG; ROBINSON, C				KNOTT, TG; ROBINSON, C			THE SECA INHIBITOR, AZIDE, REVERSIBLY BLOCKS THE TRANSLOCATION OF A SUBSET OF PROTEINS ACROSS THE CHLOROPLAST THYLAKOID MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							OXYGEN-EVOLVING COMPLEX; COLI PLASMA-MEMBRANE; ESCHERICHIA-COLI; PRECURSOR PROTEIN; PROTON GRADIENT; TRANSIT PEPTIDE; FULL PRECURSOR; TRANSPORT; IMPORT; GENE	The presence of secA and secY gene homologues in the plastid genomes of red algae and cyanophytes has raised the possibility that the products of these genes are involved in protein translocation across the thylakoid membrane. Bacterial SecA proteins are effectively inhibited by azide, and we have tested the effects of this compound on the transport of lumenal proteins across the thylakoid membrane in pea chloroplasts. Recent studies have shown that lumenal proteins are transported by two different mechanisms, one dependent on the thylakoidal Delta pH and the other requiring the presence of a stromal protein factor and ATP. In this report we show that azide inhibits the transport across the thylakoid membrane of the latter group of proteins, which includes plastocyanin and the lumenal 33-kDa protein of photosystem II; translocation of proteins by the Delta pH-dependent pathway is unaffected. Following import into isolated chloroplasts in the presence of azide, a substantial proportion of plastocyanin and the 33-kDa protein is found as the stromal intermediate form; the proportion increases with lower ATP concentrations, suggesting that azide and ATP may compete for a single site. The presence of azide completely inhibits the import of the 33-kDa protein by isolated thylakoids, but import is restored if the azide is removed from the stromal extract or thylakoids, prior to the import incubation. The data thus indicate that azide reversibly inhibits the transport of a subset of proteins across the thylakoid membrane, consistent with the involvement of a SecA homolog. The results also indicate that azide is potentially a valuable tool for the future assignment of novel lumenal proteins to one of the thylakoidal protein transport mechanisms.	UNIV WARWICK, DEPT BIOL SCI, COVENTRY CV4 7AL, W MIDLANDS, ENGLAND	University of Warwick								BRIGGS LM, 1990, PLANT MOL BIOL, V15, P633, DOI 10.1007/BF00017837; CAI D, 1993, PLANT J, V3, P383, DOI 10.1046/j.1365-313X.1993.t01-21-00999.x; CHITNIS PR, 1987, PLANT MOL BIOL, V10, P3, DOI 10.1007/BF00014181; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; DOUGLAS SE, 1992, FEBS LETT, V298, P93, DOI 10.1016/0014-5793(92)80029-G; FLACHMANN R, 1993, J BIOL CHEM, V268, P7514; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; HALPIN C, 1989, EMBO J, V8, P3917, DOI 10.1002/j.1460-2075.1989.tb08572.x; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HULFORD A, 1994, J BIOL CHEM, V269, P3251; JAMES HE, 1989, J BIOL CHEM, V264, P19573; KLOSGEN RB, 1992, PLANT MOL BIOL, V18, P1031, DOI 10.1007/BF00019226; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; MEADOWS JW, 1991, PLANT MOL BIOL, V17, P1241, DOI 10.1007/BF00028739; MOULD RM, 1991, J BIOL CHEM, V266, P17286; MOULD RM, 1991, J BIOL CHEM, V266, P12189; NIELSEN VS, 1994, J BIOL CHEM, V269, P3762; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PFANNER N, 1987, EUR J BIOCHEM, V169, P289, DOI 10.1111/j.1432-1033.1987.tb13610.x; ROBINSON C, 1994, EMBO J, V13, P279, DOI 10.1002/j.1460-2075.1994.tb06260.x; SCARAMUZZI CD, 1992, CURR GENET, V22, P421, DOI 10.1007/BF00352444; SEIDLER A, 1990, EMBO J, V9, P1743, DOI 10.1002/j.1460-2075.1990.tb08298.x; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; VALENTIN K, 1993, MOL GEN GENET, V236, P245, DOI 10.1007/BF00277119; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P1165	28	69	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7843	7846						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132499				2022-12-25	WOS:A1994NB40900003
J	FRAGA, D; HERMOLIN, J; OLDENBURG, M; MILLER, MJ; FILLINGAME, RH				FRAGA, D; HERMOLIN, J; OLDENBURG, M; MILLER, MJ; FILLINGAME, RH			ARGININE-41 OF SUBUNIT-C OF ESCHERICHIA-COLI H+-ATP SYNTHASE IS ESSENTIAL IN BINDING AND COUPLING OF F1 TO F-0	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLAR LOOP REGION; OXIDATIVE-PHOSPHORYLATION; UNCE PROTEIN; F0 SECTOR; MUTATIONS; F1; TRANSLOCATION; MEMBRANE; COMPLEX; ALTER	Two substitutions were made for Arg(41) in the polar loop of subunit c of the Escherichia coli F1F0 H+-transporting ATP synthase. The R41K and R41H mutants were initially studied by use of a plasmid carrying the complete c R41K or c R41H unc (F1F0) operon in a chromosomal strain deleted for the unc operon. The extent of F-0 incorporation into membranes of these cells was quite variable, and the system was concluded to be unsuitable for biochemical characterization. Ultimately, the mutant genes were recombined into the chromosome using a novel method for the unc system. The biochemical phenotype of the chromosomally expressed mutants proved to be reproducible. The c R41H mutation causes a specific defect in assembly of F-0, i.e. subunit alpha was not incorporated into the membrane despite near normal incorporation of subunits b and c. On the other hand, c R41K mutant F-0 assembled normally in one of two background strains studied. (In the second genetic background, subunit alpha was inefficiently incorporated into the c R41K membrane.) In membranes prepared from a c R41K strain assembling a complete F-0, R41K F-0 was found to bind F-1 with near normal affinity and to transport H+ at near normal rates. Although R41K F-0 binds F-1, F-1-ATPase activity and H+ transport remained uncoupled. The uncoupling was indicated by a lack of ATP-driven H+ translocation and by the high proton permeability of membranes with F-1 bound to F-0. The uncoupled phenotype of the R41K mutant closely resembles that previously reported for the c Q42E mutant.	UNIV WISCONSIN,SCH MED,DEPT BIOMOLEC CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Fraga, Dean/0000-0002-9933-665X	NIGMS NIH HHS [GM23105] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023105, R01GM023105] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; DECKERSHEBESTREIT G, 1986, EUR J BIOCHEM, V161, P225, DOI 10.1111/j.1432-1033.1986.tb10146.x; FELTON J, 1980, J BACTERIOL, V142, P221, DOI 10.1128/JB.142.1.221-228.1980; FILLINGAME RH, 1986, J BACTERIOL, V165, P244, DOI 10.1128/jb.165.1.244-251.1986; FILLINGAME RH, 1984, J BACTERIOL, V158, P1078, DOI 10.1128/JB.158.3.1078-1083.1984; FILLINGAME RH, 1983, J BIOL CHEM, V258, P604; FILLINGAME RH, 1975, J BACTERIOL, V124, P870, DOI 10.1128/JB.124.2.870-883.1975; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FRAGA D, 1991, J BACTERIOL, V173, P2639, DOI 10.1128/jb.173.8.2639-2643.1991; FRAGA D, 1989, J BIOL CHEM, V264, P6797; FRAGA D, 1994, J BIOL CHEM, V269, P2562; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; GIBSON F, 1977, BIOCHEM J, V162, P665, DOI 10.1042/bj1620665; GIRVIN ME, 1989, BIOCHEMISTRY-US, V28, P4340, DOI 10.1021/bi00436a032; GUNSALUS RP, 1982, P NATL ACAD SCI-BIOL, V79, P320, DOI 10.1073/pnas.79.2.320; Haddock B A, 1974, Biochem J, V142, P703; HATCH L, 1993, BIOCHIM BIOPHYS ACTA, V1141, P183, DOI 10.1016/0005-2728(93)90041-D; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; Maniatis T., 1982, MOL CLONING; Miller J.H., 1972, EXPT MOL GENETICS; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MILLER MJ, 1989, J BIOL CHEM, V264, P305; MITRA B, 1990, BIOCHEMISTRY-US, V29, P9879, DOI 10.1021/bi00494a018; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; MOSHER ME, 1983, J BACTERIOL, V156, P1078, DOI 10.1128/JB.156.3.1078-1092.1983; PAULE CR, 1989, ARCH BIOCHEM BIOPHYS, V274, P270, DOI 10.1016/0003-9861(89)90439-6; PERLIN DS, 1985, ARCH BIOCHEM BIOPHYS, V236, P603, DOI 10.1016/0003-9861(85)90664-2; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; ZHANG Y, 1994, J BIOL CHEM, V269, P5473	35	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7532	7537						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125974				2022-12-25	WOS:A1994NA03200079
J	SUBLER, MA; MARTIN, DW; DEB, S				SUBLER, MA; MARTIN, DW; DEB, S			OVERLAPPING DOMAINS ON THE P53 PROTEIN REGULATE ITS TRANSCRIPTIONAL ACTIVATION AND REPRESSION FUNCTIONS	ONCOGENE			English	Article							WILD-TYPE P53; TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; RESPONSIVE ELEMENT; TRANSFORMED-CELLS; BINDING PROTEIN; GENE-EXPRESSION; T-ANTIGEN; MUTANT; ONCOGENE	Wild-type p53 has been shown to inhibit transcription from several viral and cellular promoters without known p53-binding sites, while transactivating promoters with p53-binding sites. Using a series of N- and C-terminal p53 deletion mutants and wild-type p53, we have defined the domains on p53 responsible for its transcriptional functions. To test transcriptional activation by p53 we have used a promoter-chloramphenicol acetyltransferase (CAT) construct containing synthetic p53-binding sites. To check transcriptional inhibition by p53 we have used a human cytomegalovirus immediate-early promoter construct, CMV-CAT. Using transient transfection-transcription assays in Saos-2 cells, we determined that the p53 transcriptional activation and repression domains overlap at the N-terminus. This suggests the possibility that the same transcriptional machinery is involved in both functions. A C-terminal deletion up to amino acid 327 (del 393-327) eliminated repression of CMV-CAT, while preserving the transactivation function to a large extent. Using gluteraldehyde cross-linking experiments, we observed that the mutant del 393-327, which is transactivation-competent, but repression-defective, could not oligomerize. Thus, oligomerization of p53 is not required for transactivation, but may be essential for repression. Interestingly, transactivation by the oligomerization-defective mutant could be inhibited by cotransfection with a plasmid expressing the transforming mutant p53-175H.	UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio								AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IWABUCHI K, 1993, ONCOGENE, V8, P1693; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MARTIN DW, 1993, BIOCHEM BIOPH RES CO, V195, P428, DOI 10.1006/bbrc.1993.2061; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUBLER MA, 1994, J VIROL, V68, P103, DOI 10.1128/JVI.68.1.103-110.1994; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHANG W, 1993, ONCOGENE, V8, P2555	73	72	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1351	1359						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152795				2022-12-25	WOS:A1994NH40100006
J	ARUNACHALAM, U; MASSEY, V				ARUNACHALAM, U; MASSEY, V			STUDIES ON THE OXIDATIVE HALF-REACTION OF P-HYDROXYPHENYLACETATE 3-HYDROXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARA-HYDROXYBENZOATE HYDROXYLASE; CONTAINING MONO-OXYGENASE; PHENOL HYDROXYLASE; INTERMEDIATE; DERIVATIVES; TEMPERATURE	The oxidative half-reaction of the two-protein enzyme, p-hydroxyphenylacetate 3-hydroxylase from Pseudomonas putida, has been studied by absorbance stopped-flow techniques. The formation of three flavin-oxygen intermediates, the anionic and protonated forms of the flavin hydroperoxide (intermediates I and I*) and the hydroxyflavin (intermediate III), was observed during the course of the oxygen reaction with the reduced flavoprotein-coupling protein complex. The flavin hydroperoxide, which is formed in a second-order reaction with oxygen, is in rapid equilibrium with the aromatic substrate, p-hydroxyphenylacetate. Due to this rapid equilibrium, p-hydroxyphenylacetate effectively competes with other ligands, such as p-chlorophenylacetate and p-aminophenylacetate and proceeds through the hydroxylation pathway. Furthermore, dehydration of intermediate III is subjected to severe inhibition in the presence of excess p-hydroxyphenylacetate, similar to the observations made with phenol hydroxylase. A reaction mechanism for the oxidative half-reaction in the presence of the aromatic substrate, p-hydroxyphenylacetate, is proposed.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM011106, R01GM011106] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-11106] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUNACHALAM U, 1994, J BIOL CHEM, V269, P150; ARUNACHALAM U, 1992, J BIOL CHEM, V267, P25848; BEATY NB, 1981, J BIOL CHEM, V256, P4619; BEATY NB, 1981, J BIOL CHEM, V256, P4611; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; BRISSETTE P, 1987, FLAVINS FLAVOPROTEIN, P573; DAGLEY S, 1982, FLAVINS FLAVOPROTEIN, P311; DETMER K, 1985, J BIOL CHEM, V260, P5998; ENTSCH B, 1991, J BIOL CHEM, V266, P17341; ENTSCH B, 1989, BIOCHIM BIOPHYS ACTA, V999, P313, DOI 10.1016/0167-4838(89)90014-9; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; GHISLA S, 1977, EUR J BIOCHEM, V76, P139, DOI 10.1111/j.1432-1033.1977.tb11579.x; HASTINGS JW, 1973, P NATL ACAD SCI USA, V70, P3468, DOI 10.1073/pnas.70.12.3468; MAEDAYORITA K, 1993, J BIOL CHEM, V268, P4134; POWLOWSKI J, 1990, J BIOL CHEM, V265, P4969; RYERSON CC, 1982, BIOCHEMISTRY-US, V21, P2644, DOI 10.1021/bi00540a011; SCHOPFER LM, 1991, J BIOL CHEM, V266, P13080; SCHOPFER LM, 1980, J BIOL CHEM, V255, P5355; TAYLOR MG, 1990, J BIOL CHEM, V265, P13687; TAYLOR MG, 1991, J BIOL CHEM, V266, P8291; VANBERKEL WJH, 1989, EUR J BIOCHEM, V179, P307; VERVOORT J, 1992, EUR J BIOCHEM, V206, P479, DOI 10.1111/j.1432-1033.1992.tb16950.x	22	15	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11795	11801						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163477				2022-12-25	WOS:A1994NG37700021
J	SAHLIN, M; LASSMANN, G; POTSCH, S; SLABY, A; SJOBERG, BM; GRASLUND, A				SAHLIN, M; LASSMANN, G; POTSCH, S; SLABY, A; SJOBERG, BM; GRASLUND, A			TRYPTOPHAN RADICALS FORMED BY IRON/OXYGEN REACTION WITH ESCHERICHIA-COLI RIBONUCLEOTIDE REDUCTASE PROTEIN R2 MUTANT Y122F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYTOCHROME-C PEROXIDASE; IDENTIFICATION; COMPOUND; SUBUNIT; SITE	The active state of the small subunit, protein R2, of ribonucleotide reductase is formed by the reaction of apoprotein with Fe2+ and O-2, whereby the diferric site and a stable phenoxy free radical on a tyrosyl residue (Tyr(122)) is formed. The corresponding reaction was studied in the mutant Y122F R2. It leads to a normal iron site, but the reduction equivalent from Tyr(122) now has to be supplied from elsewhere. EPR spectroscopy shows formation of several paramagnetic species on different time scales. Using apoprotein with deuterium-labeled tryptophan residues, at least two species could be assigned to tryptophan free radicals. This is the first EPR observation of relatively stable protein-linked tryptophan radicals at room temperature and at 77 K. These tryptophan radicals may be involved as redox intermediates in long range electron transfer within the protein structure.	UNIV STOCKHOLM, DEPT BIOPHYS, ARRHENIUS LAB, S-10691 STOCKHOLM, SWEDEN; UNIV STOCKHOLM, DEPT MOLEC BIOL, S-10691 STOCKHOLM, SWEDEN; MAX DELBRUCK CTR MOLEC MED, D-13125 BERLIN, GERMANY; TECH UNIV BERLIN, MAX VOLMER INST BIOPHYS & PHYS CHEM, D-10623 BERLIN, GERMANY	Stockholm University; Stockholm University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Technical University of Berlin				Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1993, BIOCHEMISTRY-US, V32, P9845; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BOLLINGER JM, 1993, J INORG BIOCHEM, V51, P6; FLOSSMANN W, 1978, RADIAT RES, V73, P75, DOI 10.2307/3574574; GRASLUND A, 1985, ENVIRON HEALTH PERSP, V64, P139, DOI 10.2307/3430005; HELLWEGE KH, 1979, LANDOLTBORNSTEIN C2, V9, P8; HOFFMAN BM, 1981, J BIOL CHEM, V256, P6556; HOUSEMAN ALP, 1993, BIOCHEMISTRY-US, V32, P4430, DOI 10.1021/bi00067a036; KIM ST, 1993, P NATL ACAD SCI USA, V90, P8023, DOI 10.1073/pnas.90.17.8023; LAM KY, 1993, J CHEM SOC DALTON, P2797, DOI 10.1039/dt9930002797; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LASSMANN G, 1992, BIOCHEM BIOPH RES CO, V188, P879, DOI 10.1016/0006-291X(92)91138-G; LING JS, 1994, J BIOL CHEM, V269, P5595; MOTTLEY C, 1989, BIOL MAGN RESON, V8, P521; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; OCHIAI EI, 1990, J BIOL CHEM, V265, P15758; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; SJOBERG BM, 1987, J BIOL CHEM, V262, P9736; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; THELANDER L, 1994, MET IONS BIOL SYST, V30, P109; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025	25	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11699	11702						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163466				2022-12-25	WOS:A1994NG37700007
J	CZAR, MJ; OWENSGRILLO, JK; DITTMAR, KD; HUTCHISON, KA; ZACHAREK, AM; LEACH, KL; DEIBEL, MR; PRATT, WB				CZAR, MJ; OWENSGRILLO, JK; DITTMAR, KD; HUTCHISON, KA; ZACHAREK, AM; LEACH, KL; DEIBEL, MR; PRATT, WB			CHARACTERIZATION OF THE PROTEIN-PROTEIN INTERACTIONS DETERMINING THE HEAT-SHOCK PROTEIN (HSP90-CENTER-DOT-HSP70-CENTER-DOT-HSP56) HETEROCOMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COMPLEXES; CELL GLUCOCORTICOID RECEPTOR; ROUS-SARCOMA VIRUS; PROGESTERONE-RECEPTOR; 59-KILODALTON PROTEIN; POLYCLONAL ANTIBODY; HSP90; RECONSTITUTION; TRANSFORMATION; MOLYBDATE	We have reported previously that the three heat shock proteins hsp56, hsp70, and hsp90 exist together in a heterocomplex in human lymphocyte cytosol (Sanchez, E. R., Faber, L. E., Henzel, W. J., and Pratt, W. B. (1990) Biochemistry 29, 5145-5152). All three of these proteins also exist in the native glucocorticoid receptor heterocomplex isolated from WCL2 cell cytosol and we have recently shown that the three heat shock proteins are present when immunopurified mouse glucocorticoid receptor is reconstituted into a heterocomplex by rabbit reticulocyte lysate (Hutchison, K. A., Scherrer, L. C., Czar, M. J., Ning, Y., Sanchez, E. R., Leach, K. L., Deibel, M. R., Jr., and Pratt, W. B. (1993) Biochemistry 32,3953-3957). In this work, we show that highly purified mouse hsp90 binds in a reversible equilibrium to immunopurified rabbit hsp56, but hsp56 does not bind to purified mouse hsp70. In contrast to the equilibrium binding of hsp90 to hsp56, purified hsp90 binds poorly or not at all to purified hsp70 unless a third factor from reticulocyte lysate is present to permit complex formation. This hsp70-hsp90 complex-forming factor is heat-labile, and in the presence of this factor and ATP, a heat shock protein heterocomplex can be reconstituted from purified mouse hsp90 and hsp70 and rabbit hsp56 that is present in the factor preparation. Our data are consistent with a model in which hsp56 and hsp70 bind to different sites on hsp90 but do not interact with each other. The presence of hsp56 in the heat shock protein heterocomplex is not stabilized by molybdate but hsp56 is stabilized if the glucocorticoid receptor is present in addition to hsp90 and hsp70.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,6448 MED SCI BLDG 1,ANN ARBOR,MI 48109; UPJOHN CO,DEPT CELL BIOL & BIOCHEM,KALAMAZOO,MI 49001	University of Michigan System; University of Michigan; Pfizer					NCI NIH HHS [CA28010] Funding Source: Medline; NIDDK NIH HHS [DK31573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXIS MN, 1992, EUR J BIOCHEM, V204, P75, DOI 10.1111/j.1432-1033.1992.tb16607.x; BRESNICK EH, 1990, BIOCHEMISTRY-US, V29, P520, DOI 10.1021/bi00454a028; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; DAHMER MK, 1984, ANNU REV PHYSIOL, V46, P67; HIRST MA, 1990, MOL ENDOCRINOL, V4, P162, DOI 10.1210/mend-4-1-162; HUTCHISON KA, 1992, J BIOL CHEM, V267, P13952; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; LEACH KL, 1979, J BIOL CHEM, V254, P1884; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MESHINCHI S, 1990, J BIOL CHEM, V265, P4863; MINAMI Y, 1991, J BIOL CHEM, V266, P10099; NADEAU K, 1993, J BIOL CHEM, V268, P1479; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PELHAM H, 1988, NATURE, V332, P776, DOI 10.1038/332776a0; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PRATT WB, 1992, BIOESSAYS, V14, P841, DOI 10.1002/bies.950141209; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PRATT WB, 1992, TRENDS ENDOCRIN MET, V3, P326, DOI 10.1016/1043-2760(92)90111-D; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; REXIN M, 1991, J BIOL CHEM, V266, P24601; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P7325, DOI 10.1021/bi00147a017; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; ULLRICH SJ, 1986, P NATL ACAD SCI USA, V83, P3121, DOI 10.1073/pnas.83.10.3121; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; YEM AW, 1992, J BIOL CHEM, V267, P2868	43	83	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11155	11161						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157642				2022-12-25	WOS:A1994NF96600030
J	RODEN, L; ANANTH, S; CAMPBELL, P; MANZELLA, S; MEEZAN, E				RODEN, L; ANANTH, S; CAMPBELL, P; MANZELLA, S; MEEZAN, E			XYLOSYL TRANSFER TO AN ENDOGENOUS RENAL ACCEPTOR - PURIFICATION OF THE TRANSFERASE AND THE ACCEPTOR AND THEIR IDENTIFICATION AS GLYCOGENIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE GLYCOGENIN; PROTEIN; BIOSYNTHESIS; INITIATION; BIOGENESIS; PRIMER	A xylosyltransferase in rat kidney, tentatively identified as glycogenin (Meezan, E., Ananth, S., Manzella, S., Campbell, P., Siegal, S., Pillion, D. J., and Roden, L. (1994) J. Biol. Chem. 269,11503-11508), was purified by a procedure in which affinity chromatography on UDP-glucuronic acid-agarose was a particularly useful step. The purified material was nearly homogeneous, as shown by SDS-polyacrylamide gel electrophoresis and silver staining, and had an electrophoretic mobility corresponding to a M(r) of 32,000. The purified enzyme possessed both glucosyl- and xylosyltransferase activity, and incubation with UDP-[H-3]xylose or UDP-[H-3]glucose yielded a single macromolecular product, which had the same electrophoretic mobility as the major silver-stained component. These results indicate that the kidney transferase was indeed glycogenin and that it was functionally analogous to the larger glycogenin species previously isolated from rabbit muscle. Further examination of the properties of the rat kidney enzyme showed, i.a., that it was inhibited strongly by cytidine 5'-diphosphate. This effect was used to advantage in an alternative purification procedure, which was applied to beef kidney and involved adsorption of the enzyme to UDP-glucuronic acid-agarose and subsequent elution with cytidine 5'-diphosphate. In contrast to glycogenin, glycogen synthase did not catalyze transfer from UDP-xylose, and it is suggested that the incorporation of xylose into glycogen observed by other investigators was due to glycogenin-catalyzed xylosyl transfer and subsequent chain elongation by glycogen synthase.	UNIV ALABAMA,DEPT PHARMACOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NIDCR NIH HHS [DE 08252] Funding Source: Medline; NIDDK NIH HHS [DK 39877] Funding Source: Medline; NINDS NIH HHS [NS 27353] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039877] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027353] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANTTINEN H, 1978, BIOCHEM J, V175, P737, DOI 10.1042/bj1750737; BLUMENFELD ML, 1985, J BIOL CHEM, V260, P1560; CAMPBELL DG, 1989, EUR J BIOCHEM, V185, P119, DOI 10.1111/j.1432-1033.1989.tb15090.x; CAO YJ, 1993, J BIOL CHEM, V268, P14687; GREBNER EE, 1966, BIOCHEM BIOPH RES CO, V22, P672, DOI 10.1016/0006-291X(66)90199-9; GREBNER EE, 1966, ARCH BIOCHEM BIOPHYS, V116, P391, DOI 10.1016/0003-9861(66)90045-2; KIMURA JH, 1978, ARCH BIOCHEM BIOPHYS, V191, P687, DOI 10.1016/0003-9861(78)90408-3; LOMAKO J, 1990, BIOCHEM INT, V21, P251; LOMAKO J, 1990, FEBS LETT, V264, P13, DOI 10.1016/0014-5793(90)80752-5; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; MEEZAN E, 1994, J BIOL CHEM, V269, P11503; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MYLLYLA R, 1977, BIOCHIM BIOPHYS ACTA, V480, P113, DOI 10.1016/0005-2744(77)90326-6; PARK JT, 1949, J BIOL CHEM, V181, P149; PARTRIDGE SM, 1949, NATURE, V164, P443, DOI 10.1038/164443a0; PITCHER J, 1987, EUR J BIOCHEM, V169, P497, DOI 10.1111/j.1432-1033.1987.tb13637.x; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; RODRIGUEZ IR, 1985, BIOCHEM BIOPH RES CO, V132, P829, DOI 10.1016/0006-291X(85)91206-9; SMYTHE C, 1989, EUR J BIOCHEM, V183, P205, DOI 10.1111/j.1432-1033.1989.tb14914.x; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; VISKUPIC E, 1992, J BIOL CHEM, V267, P25759; WHELAN WJ, 1986, BIOESSAYS, V5, P136, DOI 10.1002/bies.950050312	22	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11509	11513						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157680				2022-12-25	WOS:A1994NF96600079
J	SOLIS, D; FEIZI, T; YUEN, CT; LAWSON, AM; HARRISON, RA; LOVELESS, RW				SOLIS, D; FEIZI, T; YUEN, CT; LAWSON, AM; HARRISON, RA; LOVELESS, RW			DIFFERENTIAL RECOGNITION BY CONGLUTININ AND MANNAN-BINDING PROTEIN OF N-GLYCANS PRESENTED ON NEOGLYCOLIPIDS AND GLYCOPROTEINS WITH SPECIAL REFERENCE TO COMPLEMENT GLYCOPROTEIN C3 AND RIBONUCLEASE-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOSACCHARIDE PROBES NEOGLYCOLIPIDS; 3RD COMPONENT; STRUCTURAL-ANALYSIS; CONFORMATIONAL-CHANGES; BOVINE SERUM; MANNOSE; C-3; CHAINS; LECTIN; EXTENT	Conglutinin and mannan-binding protein are serum proteins that have similar carbohydrate binding specificities toward high mannose-type oligosaccharides, and yet only conglutinin binds the complement glycoprotein iC3b, which contains oligosaccharides of this type. In the present study, the interactions of conglutinin and mannan-binding protein were evaluated with the complement glycoprotein C3, including various physiologically derived fragments of this glycoprotein, and neoglycolipids prepared from oligosaccharides released from C3 and its isolated alpha and beta chains. Several conclusions can be drawn. First, the interaction of conglutinin is profoundly influenced by the state of the protein moiety of the a chain in the vicinity of the glycosylation site Asn-917. Second, the binding to the C3-derived glycoprotein iC3b appears to be exclusively mediated through the Man8 or Man9 oligosaccharide on the a chain; there is no evidence for other N-linked oligosaccharides on C3 that are uniquely bound by conglutinin. Third, although conglutinin shows a more restricted binding relative to mannan-binding protein toward the oligosaccharides free of protein, it has a broader binding pattern toward the oligosaccharides as presented on C3-derived glycoproteins. From these and additional observations with RNase B, which contains high mannose-type oligosaccharides at Asn-34, it is clear that the protein moieties of these glycoproteins markedly influence the presentation of the oligosaccharides such that biological specificity is mediated by the commonly occurring high mannose-type oligosaccharides in the context of specific carrier proteins.	MRC, MOLEC IMMUNOPATHOL UNIT, CAMBRIDGE CB2 2QH, ENGLAND; MRC, CLIN RES CTR, CLIN MASS SPECT SECT, HARROW HA1 3UJ, MIDDX, ENGLAND	Medical Research Council Clinical Trials Unit	SOLIS, D (corresponding author), MRC, CLIN RES CTR, GLYCOCONJUGATES SECT, WATFORD RD, HARROW HA1 3UJ, MIDDX, ENGLAND.		Solís, Dolores/E-5992-2015	Solís, Dolores/0000-0002-8148-1875; Feizi, Ten/0000-0001-6495-0329; Harrison, Richard Alexander/0000-0002-2408-6043				BARNUM SR, 1990, YEAR IMMUNOLOGY 1989, P208; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BROWN EJ, 1982, J IMMUNOL, V128, P860; CARVER JP, 1993, PURE APPL CHEM, V65, P763, DOI 10.1351/pac199365040763; CHILDS RA, 1989, BIOCHEM J, V262, P131, DOI 10.1042/bj2620131; DAVIS AE, 1981, FEBS LETT, V134, P147, DOI 10.1016/0014-5793(81)80588-1; DAVIS AE, 1984, J IMMUNOL, V132, P1960; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; EDGE CJ, 1993, BIOCHEM SOC T, V21, P452; HARRISON RA, 1979, MOL IMMUNOL, V16, P767, DOI 10.1016/0161-5890(79)90154-8; HARRISON RA, 1980, MOL IMMUNOL, V17, P9, DOI 10.1016/0161-5890(80)90119-4; HASE S, 1985, J BIOCHEM-TOKYO, V98, P863, DOI 10.1093/oxfordjournals.jbchem.a135366; HIRANI S, 1985, J IMMUNOL, V134, P1105; HIRANI S, 1986, BIOCHEM J, V233, P613, DOI 10.1042/bj2330613; Holmskov U, 1993, Behring Inst Mitt, P224; ISENMAN DE, 1981, BIOCHEMISTRY-US, V20, P4458, DOI 10.1021/bi00518a034; ISENMAN DE, 1981, MOL IMMUNOL, V18, P331, DOI 10.1016/0161-5890(81)90057-2; KAWASAKI N, 1985, J BIOCHEM-TOKYO, V98, P1309, DOI 10.1093/oxfordjournals.jbchem.a135398; LACHMANN PJ, 1962, IMMUNOLOGY, V5, P687; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON AM, 1990, CARBOHYD RES, V200, P47, DOI 10.1016/0008-6215(90)84181-S; LEON MA, 1964, SCIENCE, V143, P1327, DOI 10.1126/science.143.3612.1327; LINSCOTT WD, 1978, J IMMUNOL, V121, P658; LOVELESS RW, 1989, BIOCHEM J, V258, P109, DOI 10.1042/bj2580109; LOVELESS RW, 1992, EMBO J, V11, P813, DOI 10.1002/j.1460-2075.1992.tb05118.x; LU JH, 1993, BIOCHEM J, V292, P157, DOI 10.1042/bj2920157; MIZUOCHI T, 1989, J BIOL CHEM, V264, P13834; NILSSON B, 1985, SCAND J IMMUNOL, V22, P703, DOI 10.1111/j.1365-3083.1985.tb01933.x; NILSSON B, 1992, BIOCHEM J, V282, P715, DOI 10.1042/bj2820715; SANCHEZCORRAL P, 1989, J IMMUNOL METHODS, V122, P105, DOI 10.1016/0022-1759(89)90340-2; SOLIS D, 1987, EUR J BIOCHEM, V165, P131, DOI 10.1111/j.1432-1033.1987.tb11203.x; SOLIS D, 1993, EUR J BIOCHEM, V214, P677, DOI 10.1111/j.1432-1033.1993.tb17968.x; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; TACK BF, 1979, BIOCHEMISTRY-US, V18, P1497, DOI 10.1021/bi00575a017; TAYLOR ME, 1987, BIOCHIM BIOPHYS ACTA, V915, P60, DOI 10.1016/0167-4838(87)90125-7; TOMANA M, 1985, MOL IMMUNOL, V22, P107, DOI 10.1016/S0161-5890(85)80004-3; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WILLIAMS DB, 1984, J BIOL CHEM, V259, P5105; YOUNG NM, 1987, BIOCHEM BIOPH RES CO, V143, P645, DOI 10.1016/0006-291X(87)91402-1	40	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11555	11562						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157687				2022-12-25	WOS:A1994NF96600086
J	CURNUTTE, JT; ERICKSON, RW; DING, JB; BADWEY, JA				CURNUTTE, JT; ERICKSON, RW; DING, JB; BADWEY, JA			RECIPROCAL INTERACTIONS BETWEEN PROTEIN-KINASE-C AND COMPONENTS OF THE NADPH OXIDASE COMPLEX MAY REGULATE SUPEROXIDE PRODUCTION BY NEUTROPHILS STIMULATED WITH A PHORBOL ESTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; PLASMA-MEMBRANE; OKADAIC ACID; RABBIT NEUTROPHILS; MYRISTATE ACETATE; CYTOCHALASIN-B; ACTIVATION; PHOSPHORYLATION; CALCIUM	The 47-kDa subunit of the NADPH oxidase system (p47-phox) of neutrophils undergoes an association with proteins in the Triton X-100-insoluble fraction upon stimulation of the cells with 4 beta-phorbol 12-myristate 13-acetate. This fraction contains the assembled oxidase that catalyzes the generation of superoxide by stimulated cells. In this paper, we report that the addition of an inhibitor of protein kinases (1-(5-isoquinolinylsulfonyl-2-methylpiperazine) to neutrophils that are already stimulated results in the dissociation of p47-phox from this fraction. Antagonists of type 1 and 2A protein phosphatases (calyculin A, okadaic acid) prevented this phenomenon. In contrast, norokadanone, an inactive analog of okadaic acid, did not affect this response. These observations are correlated with previous studies on the phosphorylation of p47-phox and superoxide release. In addition, we show that protein kinase C (PKC) also undergoes an extensive redistribution to the Triton X-100-insoluble fraction in 4 beta-phorbol 12-myristate 13-acetate-stimulated cells, the extent of which is diminished significantly in neutrophils from chronic granulomatous disease patients who lack either p47-phox or cytochrome b(558). These studies strongly indicate that PKC and type 1 and/or 2A protein phosphatases are involved in a continuous phosphorylation reaction that maintains the oxidase in the assembled/active state. Moreover, components of the oxidase may target and facilitate the translocation of PKC to a cellular site in close apposition to the oxidase.	BOSTON BIOMED RES INST, BOSTON, MA 02114 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Boston Biomedical Research Institute; Scripps Research Institute; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023323, R01AI028342, R01AI024838] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28342, AI-24838, AI23323] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BADWEY JA, 1988, J BIOL CHEM, V263, P2779; BADWEY JA, 1982, BIOCHEM BIOPH RES CO, V106, P170, DOI 10.1016/0006-291X(82)92073-3; BAZZI MD, 1992, J BIOL CHEM, V267, P22891; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CALDWELL SE, 1988, J CLIN INVEST, V81, P1485, DOI 10.1172/JCI113480; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CURNUTTE JT, 1984, J BIOL CHEM, V259, P1851; CURNUTTE JT, 1993, CLIN IMMUNOL IMMUNOP, V67, pS2; DING JB, 1993, BLOOD, V82, P940; DING JB, 1992, J BIOL CHEM, V267, P6442; DOWNEY GP, 1992, J CELL BIOL, V116, P695, DOI 10.1083/jcb.116.3.695; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; ERICKSON RW, 1992, J CLIN INVEST, V89, P1587, DOI 10.1172/JCI115753; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P6438; HEYWORTH PG, 1990, BIOCHIM BIOPHYS ACTA, V1052, P299, DOI 10.1016/0167-4889(90)90225-3; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1992, CELLULAR MOL MECHANI, V4, P43; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; ISHIHARA H, 1989, J PHARMACOL EXP THER, V250, P388; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMEYER JE, 1979, BLOOD, V54, P35; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LEVENTHAL PS, 1993, J BIOL CHEM, V268, P13906; LU DJ, 1992, AM J PHYSIOL, V262, pC39; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MAJUMDAR S, 1993, BIOCHIM BIOPHYS ACTA, V1176, P276, DOI 10.1016/0167-4889(93)90056-U; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; NAKANISHI A, 1992, J BIOL CHEM, V267, P19072; NAUSEEF WM, 1990, BLOOD, V76, P2622; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; NISHIWAKI S, 1990, CARCINOGENESIS, V11, P1837, DOI 10.1093/carcin/11.10.1837; OKAMURA N, 1988, BLOOD, V72, P811; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERRY DK, 1992, J IMMUNOL, V149, P2749; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PONTREMOLI S, 1990, J BIOL CHEM, V265, P706; QUINN MT, 1989, BIOCHIM BIOPHYS ACTA, V987, P83, DOI 10.1016/0005-2736(89)90458-6; QUINN MT, 1992, J BIOL CHEM, V267, P7303; ROBINSON JM, 1985, J CELL BIOL, V101, P1052, DOI 10.1083/jcb.101.3.1052; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; ROTROSEN D, 1990, J BIOL CHEM, V265, P8475; SHAAFI RI, 1988, J LEUKOCYTE BIOL, V43, P18, DOI 10.1002/jlb.43.1.18; STEVENSON KB, 1989, BLOOD, V74, P2136; UHLINGER DJ, 1993, J BIOL CHEM, V268, P8624; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P9563; WHITE JR, 1984, J BIOL CHEM, V259, P8605; WHITE JR, 1983, J BIOL CHEM, V258, P4041; WOLF M, 1986, J BIOL CHEM, V261, P3327; WOLFSON M, 1985, J IMMUNOL, V135, P2057; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138	57	102	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10813	10819						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144669				2022-12-25	WOS:A1994NF01700093
J	STEWART, MJ; COX, G; REIFELMILLER, A; KIM, SY; WESTBROOK, CA; LEIBOWITZ, DS				STEWART, MJ; COX, G; REIFELMILLER, A; KIM, SY; WESTBROOK, CA; LEIBOWITZ, DS			A NOVEL TRANSCRIPTIONAL SUPPRESSOR LOCATED WITHIN A DOWNSTREAM INTRON OF THE BCR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; HYBRID MESSENGER-RNA; ABL TYROSINE KINASE; CLUSTER REGION BCR; BETA-GLOBIN; CHRONIC PHASE; BLAST CRISIS; CML PATIENTS; C-ABL	A reciprocal translocation between chromosomes 9 and 22 creates the Philadelphia (Ph(1)) chromosome in chronic myelogenous leukemia. This translocation results in the fusion of the ABL and the BCR genes to form a BCR/ABL fusion gene, the product of which has a greatly increased protein tyrosine kinase activity in comparison with the normal ABL protein. The chromosome 22 translocation breakpoints are concentrated within a 5.8-kilobase region named the major breakpoint cluster region (Mbcr). Gel mobility shift and DNase I footprinting assays have defined binding sites for three proteins, BIF 1-3 (BCR intron factors 1-3), lying within a 427-base pair fragment of the Mbcr. This 427-base pair fragment functions as a transcriptional silencer with both the BCR as well as a heterologous promoter. The silencing is position- and orientation-independent. The transcriptional effects are greatest in chronic myelogenous leukemia cells, decreased in HeLa and B-cells, and absent in T-lymphocytes. Gel mobility shift assays show a corresponding difference in pattern when the T-lymphocyte nuclear extract is compared with other cell Lines. The Mbcr appears to contain a novel group of transcriptional silencers that share a common binding motif with a recently described suppresser in the mouse Adh-1 gene.	INDIANA UNIV, DEPT MED, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, DEPT MOLEC & MED GENET, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, VET ADM MED CTR, INDIANAPOLIS, IN 46202 USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Chicago								AMOUYAL M, 1991, BIOCHIMIE, V73, P1261, DOI 10.1016/0300-9084(91)90086-G; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; AYER DE, 1990, MOL CELL BIOL, V10, P3635, DOI 10.1128/MCB.10.7.3635; BAUKNECHT T, 1992, EMBO J, V11, P4607, DOI 10.1002/j.1460-2075.1992.tb05563.x; BEDI A, 1993, BLOOD, V81, P2898; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERNARDS A, 1988, ONCOGENE, V2, P297; BERNARDS A, 1987, MOL CELL BIOL, V12, P721; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; CHARNAY P, 1984, CELL, V38, P251, DOI 10.1016/0092-8674(84)90547-6; CHEN XR, 1992, ONCOGENE, V7, P1805; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREAZEN O, 1988, BLOOD, V71, P797; DYCK JA, 1989, BRIT J HAEMATOL, V72, P64, DOI 10.1111/j.1365-2141.1989.tb07653.x; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EISENBERG A, 1988, LEUKEMIA, V2, P642; ENVER T, 1991, DEV BIOL, V148, P129, DOI 10.1016/0012-1606(91)90323-U; FAINSTEIN E, 1989, ONCOGENE, V4, P1477; FARNHAM PJ, 1990, MOL CELL BIOL, V10, P1390, DOI 10.1128/MCB.10.4.1390; FOLEY KP, 1992, GENE DEV, V6, P730, DOI 10.1101/gad.6.5.730; FUTAKI M, 1992, LEUKEMIA RES, V16, P1071, DOI 10.1016/0145-2126(92)90045-9; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GOLDMAN JM, 1990, LEUKEMIA, V4, P163; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROSSMAN A, 1989, AM J HUM GENET, V45, P729; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Higuchi R., 1989, PCR TECHNOLOGY, P61; HUANG JD, 1993, GENE DEV, V7, P694, DOI 10.1101/gad.7.4.694; INOKUCHI K, 1991, LEUKEMIA RES, V15, P1067, DOI 10.1016/0145-2126(91)90113-8; INOKUCHI K, 1991, BLOOD, V78, P3125; JAUBERT J, 1990, BRIT J HAEMATOL, V74, P30, DOI 10.1111/j.1365-2141.1990.tb02534.x; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; JIANG J, 1991, GENE DEV, V5, P265, DOI 10.1101/gad.5.2.265; JIANG XY, 1990, BLOOD, V76, P597; KEATING A, 1991, EXP HEMATOL, V19, P539; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LEIBOWITZ D, 1989, CANCER INVEST, V7, P195, DOI 10.3109/07357908909038285; LEIBOWITZ D, 1991, GENE CHROMOSOME CANC, V3, P308, DOI 10.1002/gcc.2870030410; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LEY TJ, 1991, BLOOD, V77, P1146; LIN ZH, 1993, J BIOL CHEM, V268, P10260; LINDENBAUM MH, 1990, GENE DEV, V4, P2075, DOI 10.1101/gad.4.12a.2075; LLOYD JA, 1992, MOL CELL BIOL, V12, P1561, DOI 10.1128/MCB.12.4.1561; MANDANAS RA, 1992, LEUKEMIA, V6, P796; MANDANAS RA, 1993, BLOOD, V82, P1838; Maxam A M, 1980, Methods Enzymol, V65, P499; MILLS KI, 1988, BLOOD, V72, P1237; MILLS KI, 1991, BLOOD, V78, P1155; MOON AM, 1991, BLOOD, V77, P2272; MORGAN GJ, 1990, BRIT J HAEMATOL, V76, P33, DOI 10.1111/j.1365-2141.1990.tb07833.x; MORRIS SW, 1990, BLOOD, V75, P2035; MUGLIA L, 1986, P NATL ACAD SCI USA, V83, P7653, DOI 10.1073/pnas.83.20.7653; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MULLER J, 1991, EMBO J, V10, P3147, DOI 10.1002/j.1460-2075.1991.tb04876.x; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; OGAWA H, 1989, LEUKEMIA, V3, P492; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PAULWEBER B, 1993, MOL CELL BIOL, V13, P1534, DOI 10.1128/MCB.13.3.1534; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; POPENOE DW, 1986, BLOOD, V68, P1123; PRZEPIORKA D, 1988, CANCER GENET CYTOGEN, V36, P117, DOI 10.1016/0165-4608(88)90081-7; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RAHUEL C, 1992, EMBO J, V11, P4095, DOI 10.1002/j.1460-2075.1992.tb05502.x; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; SCHAEFERREGO K, 1987, BLOOD, V70, P448; SCHEUERMANN RH, 1989, GENE DEV, V3, P1255, DOI 10.1101/gad.3.8.1255; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHAH NP, 1991, MOL CELL BIOL, V11, P1854, DOI 10.1128/MCB.11.4.1854; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHTALRID M, 1988, BLOOD, V72, P485; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; STAMATOYANNOPOULOS G, 1991, SCIENCE, V252, P383, DOI 10.1126/science.2017679; TAPSCOTT SJ, 1992, MOL CELL BIOL, V12, P4994, DOI 10.1128/MCB.12.11.4994; TENHARMSEL A, 1993, MOL CELL BIOL, V13, P2742, DOI 10.1128/MCB.13.5.2742; TIEN HF, 1990, BRIT J HAEMATOL, V75, P469, DOI 10.1111/j.1365-2141.1990.tb07784.x; TOWNES TM, 1985, EMBO J, V4, P1715, DOI 10.1002/j.1460-2075.1985.tb03841.x; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; WITTE ON, 1993, CANCER RES, V53, P485; WOOD J, 1990, MASTER DRAWINGS, V28, P3; ZHU QS, 1990, ONCOGENE, V5, P885	94	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10820	10829						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144670				2022-12-25	WOS:A1994NF01700094
J	SCHMIDT, AM; MORA, R; CAO, R; YAN, SD; BRETT, J; RAMAKRISHNAN, R; TSANG, TC; SIMIONESCU, M; STERN, D				SCHMIDT, AM; MORA, R; CAO, R; YAN, SD; BRETT, J; RAMAKRISHNAN, R; TSANG, TC; SIMIONESCU, M; STERN, D			THE ENDOTHELIAL-CELL BINDING-SITE FOR ADVANCED GLYCATION END-PRODUCTS CONSISTS OF A COMPLEX - AN INTEGRAL MEMBRANE-PROTEIN AND A LACTOFERRIN-LIKE POLYPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR; GLUCOSE; SURFACE; BOVINE; COMPLICATIONS; TRANSFERRIN	Advanced glycation end products (AGEs), formed as the result of the extended interaction of proteins with ketoses, modulate central properties of endothelial cells and mononuclear phagocytes by interacting with a cell surface binding site comprised of a novel integral membrane protein (receptor for AGE = RAGE) and a lactoferrin-like polypeptide (LF-L), the latter having sequence identity to lactoferrin (LF). To further understand this cellular binding site, the interaction of RAGE with LF-L and LF was characterized. By ligand blotting and a solid state competitive binding assay, I-125-LF-L and I-125-LF bound to RAGE immobilized on nitrocellulose membranes or polypropylene tubes in a time-dependent and reversible manner, demonstrating a high affinity component with K(d) almost-equal-to 100 pm. The interaction of I-125-LF-L and I-125-LF with RAGE was independent of iron in LF and was competed by addition of an excess of unlabeled carboxyl-terminal portion of LF. Cross-linking studies with purified I-125-LF-L and RAGE, in the presence of disuccinimidyl suberate, showed a new, slowly migrating band, corresponding to a complex of RAGE and LF-L, and cross-linking on mouse aortic endothelial cells showed two new slowly migrating bands on immunoblotting visualized with both anti-RAGE IgG and anti-LF-L IgG. These data lead us to propose that the endothelial cell surface binding site for AGEs consists of LF-L bound noncovalently to RAGE anchored in the cell membrane.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT MOLEC GENET,NUTLEY,NJ 07110; INST CELL BIOL & PATHOL,BUCHAREST,ROMANIA	Columbia University; Roche Holding; Romanian Academy of Sciences; Nicolae Simionescu Institute of Cellular Biology & Pathology	SCHMIDT, AM (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL,P&S 11-518,NEW YORK,NY 10032, USA.		Simionescu, Maya/C-4794-2011		NHLBI NIH HHS [HL21006, HL42833] Funding Source: Medline; NIA NIH HHS [AG00602] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006, R01HL042833] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; BATES GW, 1973, J BIOL CHEM, V248, P3228; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; FRENS G, 1973, NATURE-PHYS SCI, V241, P120; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINEBACKZINS J, 1980, J BIOL CHEM, V255, P708; MEAD PE, 1990, NUCLEIC ACIDS RES, V18, P7167, DOI 10.1093/nar/18.23.7167; MONTESANO L, 1982, BIOCHEM BIOPH RES CO, V109, P7, DOI 10.1016/0006-291X(82)91558-3; NEEPER M, 1992, J BIOL CHEM, V267, P14998; OBESO J, 1990, LAB INVEST, V63, P259; REHMAN J, 1989, COMP BIOCH PHYSL B, V93, P929; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; SCATCHARD G, 1957, J AM CHEM SOC, V79, P12, DOI 10.1021/ja01558a003; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SCHMIDT AM, 1993, J CLIN INVEST, V92, P2155; SHIMAZAKI K, 1991, COMP BIOCHEM PHYS B, V98, P417, DOI 10.1016/0305-0491(91)90199-N; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSANG T, 1991, FASEB J, V6, pA233; YAN SD, 1994, J BIOL CHEM, V269, P9889; YANG Z, 1991, J EXP MED, V174, P515, DOI 10.1084/jem.174.3.515	24	111	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9882	9888						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144581				2022-12-25	WOS:A1994NE05300075
J	THNG, JPH; GUO, XW; SWANK, RA; CRISSMAN, HA; BRADBURY, EM				THNG, JPH; GUO, XW; SWANK, RA; CRISSMAN, HA; BRADBURY, EM			INHIBITION OF HISTONE PHOSPHORYLATION BY STAUROSPORINE LEADS TO CHROMOSOME DECONDENSATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; LYSINE-RICH HISTONE; CELL-CYCLE; POTENT INHIBITOR; G2 PHASE; PHYSARUM-POLYCEPHALUM; H3 PHOSPHORYLATION; MAMMALIAN-CELLS; CDC2 KINASE; CONDENSATION	In mammalian cells, hyperphosphorylation of histone H1 and phosphorylation of histone H3 correlate well with the G2 phase to metaphase condensation of chromosomes, and these phosphorylations most probably have a role in initiating and controlling the entry into mitosis. The protein kinase inhibitor staurosporine has been used to examine the role of H1 and H3 phosphorylations in controlling chromosome condensation in the mouse FM3A cell line. We present evidence that (i) staurosporine inhibits the protein kinases that phosphorylate histone H1 during mitosis, (ii) staurosporine also inhibits the histone H3-specific kinase, (iii) the inhibition of these kinase activities prevent cells from entering mitosis, and (iv) addition of staurosporine to cells already arrested at metaphase by nocodazole causes a rapid dephosphorylation of histones H1 and H3 and the decondensation of the metaphase chromosomes. The results show that the hyperphosphorylation of histone H1 and phosphorylation of histone H3 are required to maintain metaphase chromosomes in their condensed state.	LOS ALAMOS NATL LAB,DIV LIFE SCI,LOS ALAMOS,NM 87545	United States Department of Energy (DOE); Los Alamos National Laboratory	THNG, JPH (corresponding author), UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045890] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45890-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE K, 1991, EXP CELL RES, V192, P122, DOI 10.1016/0014-4827(91)90166-R; AJIRO K, 1983, J BIOL CHEM, V258, P4534; BRADBURY EM, 1973, EUR J BIOCHEM, V33, P131, DOI 10.1111/j.1432-1033.1973.tb02664.x; BRADBURY EM, 1974, NATURE, V249, P553, DOI 10.1038/249553a0; BRADBURY EM, 1974, NATURE, V247, P257, DOI 10.1038/247257a0; BRADBURY EM, 1992, BIOESSAYS, V14, P9; CHAMBERS TC, 1990, J BIOL CHEM, V265, P16940; CRISSMAN HA, 1991, P NATL ACAD SCI USA, V88, P7580, DOI 10.1073/pnas.88.17.7580; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; ENOCH T, 1991, J CELL BIOL, V112, P797, DOI 10.1083/jcb.112.5.797; FALLON RJ, 1990, BIOCHEM BIOPH RES CO, V170, P1191, DOI 10.1016/0006-291X(90)90519-S; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FINE RL, 1988, P AM ASSOC CANC RES, V29, P301; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; GROSS JL, 1990, BIOCHEM PHARMACOL, V40, P343, DOI 10.1016/0006-2952(90)90697-J; GURLEY LR, 1975, J BIOL CHEM, V250, P3936; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; HANKS SK, 1983, EXP CELL RES, V148, P293, DOI 10.1016/0014-4827(83)90153-2; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V171, P189, DOI 10.1016/0006-291X(90)91375-3; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MITCHELSON K, 1978, FEBS LETT, V92, P339, DOI 10.1016/0014-5793(78)80782-0; NAKANO H, 1987, J ANTIBIOT, V40, P706, DOI 10.7164/antibiotics.40.706; NIGGLI V, 1991, J BIOL CHEM, V266, P7927; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PAGANO M, 1992, EMBO J, V11, P761; PANYIM S, 1969, BIOCHEM BIOPH RES CO, V37, P1042, DOI 10.1016/0006-291X(69)90237-X; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROBERGE M, 1990, J CELL BIOL, V111, P1753, DOI 10.1083/jcb.111.5.1753; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SHOEMAKER CB, 1980, J BIOL CHEM, V255, P1048; SHOEMAKER CB, 1978, J BIOL CHEM, V253, P5802; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; Tobey R A, 1973, Methods Cell Biol, V6, P67, DOI 10.1016/S0091-679X(08)60048-5; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577; VEGESNA RVK, 1988, MOL PHARMACOL, V33, P537	43	78	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9568	9573						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144543				2022-12-25	WOS:A1994NE05300029
J	CHARNESS, ME; SAFRAN, RM; PERIDES, G				CHARNESS, ME; SAFRAN, RM; PERIDES, G			ETHANOL INHIBITS NEURAL CELL-CELL ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL ALCOHOL SYNDROME; OSTEOGENIC PROTEIN-1; HOMOPHILIC BINDING; PRENATAL EXPOSURE; NERVOUS-SYSTEM; MESSENGER-RNA; MOLECULE; INVITRO; MIGRATION; SURFACE	Gestational exposure to ethanol causes defects in neuronal migration, fasciculation, and synaptogenesis, developmental events that depend on the patterned expression and function of cell adhesion molecules (CAMs). Recombinant human osteogenic protein-1 (hOP-1) increases cell-cell adhesion and promotes cell clustering in proliferating neuroblastoma x glioma hybrid NG108-15 cells by strongly inducing N-CAM and L1. Here we show that concentrations of ethanol achieved during social drinking inhibit hOP-1-induced cell clustering without affecting cell proliferation, the induction and cell surface expression of N-CAM and L1, or the alternative splicing and sialylation of N-CAM. This inhibition was reproduced by other alcohols in proportion to their chain length, but not by teratogenic anticonvulsants or phenylalanine. Ethanol inhibition of hOP-1 morphogenesis was inversely proportional to the concentration of hOP-1 and, hence, to the levels of N-CAM and L1. Low concentrations of ethanol (IC50 5-10 mM) inhibited cell-cell adhesion in hOP-1-treated cells, and this action too was reproduced more potently by propa- nol and butanol. Ethanol may perturb brain and skeletal development by inhibiting CAM-mediated cell-cell interactions.	HARVARD UNIV,SCH MED,DEPT NEUROSCI,BOSTON,MA; BRIGHAM & WOMENS HOSP,DIV NEUROL,BOSTON,MA 02115; W ROXBURY VET ADM MED CTR,NEUROL SECT 127,BOSTON,MA 02132; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA; W ROXBURY VET ADM MED CTR,SPINAL CORD INJURY RES LAB,BOSTON,MA 02132	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	CHARNESS, ME (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROL 127,1400 VFW PKWY,BOSTON,MA 02132, USA.			Charness, Michael/0000-0002-3301-8966	NIAAA NIH HHS [AA06662] Funding Source: Medline; NINDS NIH HHS [NS13034] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006662] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ABEL EL, 1987, DRUG ALCOHOL DEPEN, V19, P51, DOI 10.1016/0376-8716(87)90087-1; BHAT S, 1988, BRAIN RES, V452, P373, DOI 10.1016/0006-8993(88)90042-X; CHANG S, 1987, J CELL BIOL, V104, P355, DOI 10.1083/jcb.104.2.355; CHARNESS ME, 1989, NEW ENGL J MED, V321, P442, DOI 10.1056/NEJM198908173210706; CHARNESS ME, 1992, DIAGNOSIS TREATMENT, P155; CLARREN SK, 1978, J PEDIATR-US, V92, P64, DOI 10.1016/S0022-3476(78)80072-9; CLODE AM, 1987, TERATOLOGY, V35, P395, DOI 10.1002/tera.1420350313; COLE GJ, 1986, NATURE, V320, P445, DOI 10.1038/320445a0; DEITRICH RA, 1989, PHARMACOL REV, V41, P489; DOHERTY P, 1992, J NEUROCHEM, V58, P2338, DOI 10.1111/j.1471-4159.1992.tb10984.x; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; EDELMAN GM, 1982, P NATL ACAD SCI-BIOL, V79, P7036, DOI 10.1073/pnas.79.22.7036; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; GRESSENS P, 1992, ALCOHOL ALCOHOLISM, V27, P219; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; HU G, 1993, J BIOL CHEM, V268, P23441; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JONES KL, 1973, LANCET, V2, P999; KOCH R, 1991, J NIH RES, V3, P61; KOERKER RL, 1976, TOXICOL APPL PHARM, V37, P281, DOI 10.1016/0041-008X(76)90091-0; LEE YS, 1992, J BONE MINER RES, V7, P1435; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; LINNEMANN D, 1989, DEV NEUROSCI-BASEL, V11, P149, DOI 10.1159/000111896; MACGREGOR RR, 1974, NEW ENGL J MED, V291, P642, DOI 10.1056/NEJM197409262911302; MAGUIRE C, 1991, INT J DEV NEUROSCI, V9, P581, DOI 10.1016/0736-5748(91)90019-I; MILES MF, 1992, BIOCHIM BIOPHYS ACTA, V1138, P268, DOI 10.1016/0925-4439(92)90003-6; MILLER MW, 1993, J COMP NEUROL, V337, P253, DOI 10.1002/cne.903370206; MILLER MW, 1986, SCIENCE, V233, P1308, DOI 10.1126/science.3749878; MIURA M, 1992, J BIOL CHEM, V267, P10752; MOCHLYROSEN D, 1988, NATURE, V333, P848, DOI 10.1038/333848a0; MODELL JG, 1990, NEW ENGL J MED, V323, P455, DOI 10.1056/NEJM199008163230706; MORLAND B, 1985, ALCOHOL, V2, P425, DOI 10.1016/0741-8329(85)90108-9; PENTNEY RJ, 1992, DEV CENTRAL NERVOUS, P71; PERIDES G, 1993, J BIOL CHEM, V268, P25197; PERIDES G, 1992, P NATL ACAD SCI USA, V89, P10326, DOI 10.1073/pnas.89.21.10326; PERIDES G, 1994, J BIOL CHEM, V269, P765; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; RATHJEN FG, 1984, EMBO J, V3, P1; ROSENTHAL A, 1992, NAT GENET, V2, P107, DOI 10.1038/ng1092-107; RUTISHAUSER U, 1991, TRENDS NEUROSCI, V14, P528, DOI 10.1016/0166-2236(91)90006-G; RUTISHAUSER U, 1984, NATURE, V310, P549, DOI 10.1038/310549a0; SAMPATH TK, 1992, J BIOL CHEM, V267, P20352; SCHENKER S, 1990, ALCOHOL CLIN EXP RES, V14, P635, DOI 10.1111/j.1530-0277.1990.tb01220.x; SHETTY AK, 1992, J COMP NEUROL, V321, P19, DOI 10.1002/cne.903210103; STREISSGUTH AP, 1980, SCIENCE, V209, P353, DOI 10.1126/science.6992275; SULIK KK, 1981, SCIENCE, V214, P936, DOI 10.1126/science.6795717; WEST JR, 1981, SCIENCE, V211, P957; WOOD PM, 1990, J NEUROSCI, V10, P3635	50	121	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9304	9309						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132668				2022-12-25	WOS:A1994NB41100099
J	FRAIZER, GC; WU, YJ; HEWITT, SM; MAITY, T; TON, CCT; HUFF, V; SAUNDERS, GF				FRAIZER, GC; WU, YJ; HEWITT, SM; MAITY, T; TON, CCT; HUFF, V; SAUNDERS, GF			TRANSCRIPTIONAL REGULATION OF THE HUMAN WILMS-TUMOR GENE (WT1) - CELL-TYPE-SPECIFIC ENHANCER AND PROMISCUOUS PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-A-CHAIN; RETINOBLASTOMA GENE; MAMMALIAN-CELLS; SUPPRESSOR WT1; EXPRESSION; DNA; DELETION; BINDING; PROTEIN; MUTATIONS	The Wilms' tumor gene, WT1, is expressed in few tissues, mainly the developing kidney, genitourinary system, and mesothelium, and in immature hematopoietic cells. To develop an understanding of the role of WT1 in development and tumorigenesis, we have identified transcriptional regulatory elements that function in transient reporter gene constructs transfected into kid ney and hematopoietic cell lines. We found three transcription start sites of the WT1 gene and have identified an essential promoter region by deletion analysis. The WT1 promoter is a member of the GC-rich, TATA-less, and CCAAT-less class of polymerase II promoters. Whereas the WT1 promoter is similar to other tumor suppressor gene promoters, the WT1 expression pattern (unlike Rb and p53) is tissue-restricted. The WT1 GC-rich promoter is promiscuous, functioning in all cell lines tested, independent of WT1 expression. This finding suggests that the promoter is not tissue-specific, but that tissue-specific expression of WT1 is modulated by additional regulatory elements. Indeed, we have identified a transcriptional enhancer located 3' of the WT1 gene >50 kilobases downstream from the promoter. This orientation-independent enhancer increases the basal transcription rate of the WT1 promoter in the human erythroleukemia cell line K562, but not in any of the other cell lines tested.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center				Hewitt, Stephen/0000-0001-8283-1788	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA046720, P01CA034936] Funding Source: NIH RePORTER; NCI NIH HHS [CA 46720, CA 16672, CA 34936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKWITH J B, 1990, Pediatric Pathology, V10, P1; Bennington JI, 1975, TUMORS KIDNEY RENAL; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; COMPTON DA, 1990, GENOMICS, V6, P309, DOI 10.1016/0888-7543(90)90571-B; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ECCLES MR, 1992, CELL GROWTH DIFFER, V3, P279; EVANS GA, 1987, METHOD ENZYMOL, V152, P604; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GARVIN AJ, 1993, AM J PATHOL, V142, P375; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; HOFMANN W, 1993, ONCOGENE, V8, P3123; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1991, AM J HUM GENET, V48, P997; HUFF V, 1993, BIOCHIM BIOPHYS ACTA, V1155, P295, DOI 10.1016/0304-419X(93)90011-Z; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; KANEKO Y, 1981, CANCER RES, V42, P4577; KIDD JM, 1984, TUMOR, P265; KINGSTON RE, 1990, CURRENT PROTOCOLS MO; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MANIATIS T, 1982, MOL CLONING LABORATO, P309; MIWA H, 1992, LEUKEMIA, V6, P405; OKA T, 1991, ONCOGENE, V6, P2077; PASTAN I, 1985, P NATL ACAD SCI USA, V82, P4920; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RICCARDI VM, 1978, PEDIATRICS, V61, P604; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; TADAKORO K, 1992, JPN J CANCER RES, V83, P1198; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; YOUNG JL, 1975, J PEDIATR-US, V86, P254, DOI 10.1016/S0022-3476(75)80484-7; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; 1991, PROGRAM MANUAL GCG P	57	80	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8892	8900						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132626				2022-12-25	WOS:A1994NB41100043
J	JAIN, R; GOMER, RH				JAIN, R; GOMER, RH			A DEVELOPMENTALLY-REGULATED CELL-SURFACE RECEPTOR FOR A DENSITY-SENSING FACTOR IN DICTYOSTELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA PROTEIN SUBUNITS; SIGNAL TRANSDUCTION; GROWTH-FACTOR; DISCOIDEUM; BINDING; GENES	Conditioned medium factor (CMF) is an 80-kDa glycoprotein which is the signal in a cell density sensing system used by developing Dictyostelium cells. CMF is slowly secreted by cells when they starve, and the extracellular level of CMF then becomes an indicator of the density of starving cells. To examine how CMF is sensed, we have made bacterially synthesized recombinant CMF and found that it has as much activity as native CMF, indicating that glycosylation is not part of the active site of CMF. Expression of recombinant fragments of CMF indicates that the active site lies within an 88-amino acid region near the N terminus. To determine whether CMF is sensed by cell surface receptors, we examined binding of iodinated recombinant CMF to live cells. We found saturable binding to 6-h starved cells at 3.9 x 10(4) molecules/cell with a K-D of 2.1 nM. The binding saturates in 30 min, and a Scatchard plot indicates that there is only one class of receptor, The binding is competed off by the addition of either the native or recombinant CMF, or the 88-amino acid active fragment region; no binding competition is seen from the nonactive regions or other proteins. Very little binding to vegetative cells is seen, with maximal binding seen in cells starved for 6-8 h. The amount of cell surface CMF binding then decreases during later development. Normal levels of CMF binding are seen to CMF(-) cells, indicating that CMF is not required for the accumulation of its own receptor.	RICE UNIV, DEPT BIOCHEM & CELL BIOL, HOUSTON, TX 77251 USA; RICE UNIV, HOWARD HUGHES MED INST, HOUSTON, TX 77251 USA	Rice University; Howard Hughes Medical Institute; Rice University				Gomer, Richard/0000-0003-2361-4307	NIGMS NIH HHS [GM42604] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042604] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERA T, 1977, BIOCHIM BIOPHYS ACTA, V470, P412, DOI 10.1016/0005-2736(77)90132-8; BYLUND DB, 1980, RECEPTOR BINDING TEC, P70; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CATERINA MJ, 1991, FASEB J, V5, P3078, DOI 10.1096/fasebj.5.15.1743439; CLARKE M, 1992, DEV BIOL, V152, P403, DOI 10.1016/0012-1606(92)90147-9; DEVREOTES PN, 1982, DEV DICTYOSTELIUM DI, P117; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; FIRTEL RA, 1991, TRENDS GENET, V7, P381, DOI 10.1016/0168-9525(91)90260-W; GOMER RH, 1983, J CELL BIOL, V96, P321, DOI 10.1083/jcb.96.2.321; GOMER RH, 1987, METHOD CELL BIOL, V28, P471; GOMER RH, 1987, SCIENCE, V237, P758, DOI 10.1126/science.3039657; GOMER RH, 1986, J CELL BIOL, V103, P1999, DOI 10.1083/jcb.103.5.1999; GOMER RH, 1991, DEV BIOL, V64, P203; GRABEL L, 1978, DEV BIOL, V64, P203, DOI 10.1016/0012-1606(78)90072-6; GREEN AA, 1975, CELL, V6, P129, DOI 10.1016/0092-8674(75)90003-3; GREINER RA, 1992, J BIOL CHEM, V267, P5096; HARLOW E, 1988, ANTIBODIES LABORATOR; HELDIN CH, 1981, P NATL ACAD SCI-BIOL, V78, P3664, DOI 10.1073/pnas.78.6.3664; INSALL R, 1990, EMBO J, V9, P3323, DOI 10.1002/j.1460-2075.1990.tb07532.x; JAIN R, 1992, GENE DEV, V6, P390, DOI 10.1101/gad.6.3.390; JANSSENS PMW, 1987, MICROBIOL REV, V51, P396, DOI 10.1128/MMBR.51.4.396-418.1987; KLEIN C, 1976, P NATL ACAD SCI USA, V73, P1250, DOI 10.1073/pnas.73.4.1250; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KNECHT DA, 1986, MOL CELL BIOL, V6, P3973, DOI 10.1128/MCB.6.11.3973; KNECHT DA, 1990, DEV GENET, V11, P403, DOI 10.1002/dvg.1020110513; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; Loomis WF., 1975, DICTYOSTELIUM DISCOI; MALCHOW D, 1974, P NATL ACAD SCI USA, V71, P2423, DOI 10.1073/pnas.71.6.2423; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MEHDY MC, 1985, MOL CELL BIOL, V5, P705, DOI 10.1128/MCB.5.4.705; MEHDY MC, 1983, CELL, V32, P763, DOI 10.1016/0092-8674(83)90062-4; NANDINIKISHORE SG, 1981, P NATL ACAD SCI-BIOL, V78, P7299, DOI 10.1073/pnas.78.12.7299; NEWELL PC, 1977, RECEPTORS RECOGNIT B, V3, P3; Sambrook J, 1989, MOL CLONING LABORATO; SAXE CL, 1991, DEV GENET, V12, P6, DOI 10.1002/dvg.1020120104; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; VANHAASTERT PJM, 1991, EUR J BIOCHEM, V195, P289; WURSTER B, 1980, EUR J BIOCHEM, V109, P613, DOI 10.1111/j.1432-1033.1980.tb04834.x; WURSTER B, 1983, FEMS MICROBIOL LETT, V18, P139; YUEN IS, 1991, DEVELOPMENT, V113, P1375; YUEN IS, 1994, IN PRESS J THEOR BIO	42	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9128	9136						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132650				2022-12-25	WOS:A1994NB41100077
J	KUAN, CT; WANG, QC; PASTAN, I				KUAN, CT; WANG, QC; PASTAN, I			PSEUDOMONAS EXOTOXIN-A MUTANTS - REPLACEMENT OF SURFACE-EXPOSED RESIDUES IN DOMAIN-II WITH CYSTEINE RESIDUES THAT CAN BE MODIFIED WITH POLYETHYLENE-GLYCOL IN A SITE-SPECIFIC MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT INTERLEUKIN-2; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; AERUGINOSA; PROTEIN; TOXIN; GENE; CONJUGATION; MUTAGENESIS; EXPRESSION	Pseudomonas exotoxin A (PE) is a three-domain protein in which domain Ia is involved in recognition of receptors on eukaryotic target cells, domain II promotes translocation of PE into the cytosol, and domain III en- zymatically ADP-ribosylates elongation factor 2. Modification of proteins with polyethylene glycol (PEG) has been shown to prolong circulating plasma lifetime and may reduce or eliminate immunogenicity. However, in the case of toxins, PEG may interfere with or block toxin activity. To investigate the effect of polyethylene glycolation on specific residues located on the surface of PE domain II, we substituted cysteine, for each of the five most exposed surface amino acids (H276, E282, N306, R313, and E327) in domain II. These cysteines can serve as unique sites for PEG modification. The PE-Cys proteins retained most of their cytotoxicity even when the free sulfhydryl group was blocked by 5,5'-dithiobis(nitrobenzoic acid) or glutathione. When the PE-Cys proteins were conjugated with ovalbumin using a cleavable disulfide linkage, cytotoxicity was retained, but it was lost with a non-cleavable thioether linkage. In contrast, cytotoxicity was maintained when PE-Cys mutants were coupled to 5- or 20-kDa mPEG, using either a disulfide or a thioether linkage. Unexpectedly in some cases, the thioether conjugate was more active than the disulfide linkage. Pharmacokinetic studies on one of the polyethylene glycolated molecules (R313C) showed that the mean residence time (t(1/2) was prolonged to 72 min, compared to 20 min for unpolyethylene glycolated PECys(R313C). These studies show it is possible to derivatize PE at specific residues in domain II, maintain significant cytotoxic activity, and alter pharmacokinetics. These studies also suggest that large mPEG molecules can be translocated to the cytosol while still attached to domain II of PE.	NCI,DIV CANC BIOL DIAG & CTR,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BATRA JK, 1989, P NATL ACAD SCI USA, V86, P8545, DOI 10.1073/pnas.86.21.8545; BRINKMANN U, 1992, P NATL ACAD SCI USA, V89, P3065, DOI 10.1073/pnas.89.7.3065; BUCHNER J, 1991, CURR OPIN BIOTECH, V2, P532, DOI 10.1016/0958-1669(91)90077-I; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; CHAUDHARY VK, 1987, P NATL ACAD SCI USA, V84, P4538, DOI 10.1073/pnas.84.13.4538; CHILDS CE, 1975, MICROCHEM J, V20, P190, DOI 10.1016/0026-265X(75)90038-7; ELLISON JW, 1982, NUCLEIC ACIDS RES, V10, P4071, DOI 10.1093/nar/10.13.4071; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FitzGerald D J, 1987, Methods Enzymol, V151, P139, DOI 10.1016/S0076-6879(87)51015-1; GOODSON RJ, 1990, BIO-TECHNOL, V8, P343, DOI 10.1038/nbt0490-343; GRAY GL, 1984, P NATL ACAD SCI-BIOL, V81, P2645, DOI 10.1073/pnas.81.9.2645; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; JINNO Y, 1989, J BIOL CHEM, V264, P15953; JINNO Y, 1988, J BIOL CHEM, V263, P13203; KASTURI S, 1992, J BIOL CHEM, V267, P23427; KATRE NV, 1987, P NATL ACAD SCI USA, V84, P1487, DOI 10.1073/pnas.84.6.1487; KATRE NV, 1990, J IMMUNOL, V144, P209; KNAUF MJ, 1988, J BIOL CHEM, V263, P15064; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISI PL, 1982, J APPL BIOCHEM, V4, P1933; MAACK T, 1979, KIDNEY INT, V16, P251, DOI 10.1038/ki.1979.128; OGATA M, 1992, J BIOL CHEM, V267, P25396; OLSON JC, 1990, MOL IMMUNOL, V27, P981, DOI 10.1016/0161-5890(90)90121-F; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; PRIOR TI, 1991, CELL, V64, P1017, DOI 10.1016/0092-8674(91)90325-S; SIMS GEC, 1980, ANAL BIOCHEM, V107, P60, DOI 10.1016/0003-2697(80)90492-3; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THEUER CP, 1992, CANCER RES, V53, P1; WANG QC, 1993, CANCER RES, V53, P4588; WAWRZYNCZAK EJ, 1992, ANTI-CANCER DRUG DES, V7, P427; YOSHITAKE S, 1982, J BIOCHEM-TOKYO, V92, P1413, DOI 10.1093/oxfordjournals.jbchem.a134065	36	64	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7610	7616						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125985				2022-12-25	WOS:A1994NA03200091
J	HUANG, RP; DARLAND, T; OKAMURA, D; MERCOLA, D; ADAMSON, ED				HUANG, RP; DARLAND, T; OKAMURA, D; MERCOLA, D; ADAMSON, ED			SUPPRESSION OF V-SIS-DEPENDENT TRANSFORMATION BY THE TRANSCRIPTION FACTOR, EGR-1	ONCOGENE			English	Article							WILMS-TUMOR GENE; EMBRYONAL CARCINOMA-CELLS; DNA-BINDING DOMAINS; C-FOS; CULTURED-CELLS; GROWTH-FACTORS; RETINOIC ACID; CHAIN GENE; PROTEIN; EXPRESSION	The transcription factor Egr-1, stimulates the activity of a number of genes and inhibits other genes, by binding to the sequence GCGGGGGCG in 5' enhancer regions, However, the functions of Egr-1 are obscure in spite of its rather ubiquitous expression. Egr-1 may play a role in proliferation in mitogen-stimulated cells but its expression is also correlated with the differentiated state in teratocarcinoma cells. The constitutive expression of Egr-1 appears to have little effect on the growth rate of normal immortalized cell-lines. We show that in NIH3T3 cells that are conditionally transformed by the expression of v-sis, the presence of Egr-1 is inhibitory to the production of transformed colonies (foci) and to growth in soft agar. In addition, the first appearance of tumors in nu/nu mice is delayed in tumorigenicity tests with cells that over-express Egr-1 and tumor growth is suppressed compared to control cells. We used a series of fragments of Egr-1 cloned into expression vectors to show that not only full length, but also truncated Egr-1 fragments inhibit colony formation. Using deletion mutants, we observed that this inhibitory activity is dependent on the presence of the DNA-binding 'zinc-finger' region. Wilm's tumor protein, WT1, (known to be a tumor suppressor gene) that exhibits the same DNA binding activity is also inhibitory. In contrast, colony formation is stimulated by an Egr-1 antisense RNA-expressing plasmid, since colonies grow rapidly and the colony-forming frequency is higher than in the presence of v-sis alone. We conclude that proteins containing the Egr-1 'zinc-finger' domain can bind to the regulatory regions of one or more genes that are required for the transformation of fibroblasts by v-sis thus inhibiting transformation. One function for Egr-1 implied by these results is the restraint of transformed growth in mitogen-stimulated cells.	LA JOLLA CANC RES FDN,LA JOLLA,CA 92037; SAN DIEGO REG CANC CTR,SAN DIEGO,CA; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego			mercola, dan/L-4182-2013	mercola, dan/0000-0002-0281-9840	NCI NIH HHS [CA 49963] Funding Source: Medline; NICHD NIH HHS [HD 28025, HD 21957] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028025, R01HD021957] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA049963] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DARLAND T, 1991, ONCOGENE, V6, P1367; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DEWALD GW, 1985, BLOOD, V66, P189; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDWARDS SA, 1991, DEV BIOL, V148, P165, DOI 10.1016/0012-1606(91)90327-Y; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GINSBERG D, 1991, ONCOGENE, V6, P669; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; HUANG RP, 1993, DNA CELL BIOL, V12, P265, DOI 10.1089/dna.1993.12.265; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KADOMATSU K, 1990, J CELL BIOL, V110, P607, DOI 10.1083/jcb.110.3.607; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEVIIN WJ, 1992, J CELL BIOCHEM, V16, pA240; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MERCOLA D, 1993, FRONTIERS OF OSTEOSARCOMA RESEARCH, P375; MERCOLA D, 1992, ONCOGENE, V7, P1793; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NGUYEN TV, 1992, P NATL ACAD SCI USA, V89, P4270, DOI 10.1073/pnas.89.10.4270; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAGONA G, 1991, DNA CELL BIOL, V10, P61, DOI 10.1089/dna.1991.10.61; Sambrook J., 1989, MOL CLONING, V1; Sambrook J, 1989, MOL CLONING, V2; Sambrook J, 1989, MOL CLONING, V3; SHAM MH, 1993, CELL, V72, P83; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; VANDENBERGHE H, 1985, CANCER GENET CYTOGEN, V17, P189, DOI 10.1016/0165-4608(85)90016-0; VESQUE C, 1992, NUCLEIC ACIDS RES, V20, P2485, DOI 10.1093/nar/20.10.2485; WANG ZY, 1992, J BIOL CHEM, V267, P21999	47	77	82	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1367	1377						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152797				2022-12-25	WOS:A1994NH40100008
J	MANDON, E; KEMPNER, ES; ISHIHARA, M; HIRSCHBERG, CB				MANDON, E; KEMPNER, ES; ISHIHARA, M; HIRSCHBERG, CB			A MONOMERIC PROTEIN IN THE GOLGI MEMBRANE CATALYZES BOTH N-DEACETYLATION AND N-SULFATION OF HEPARAN-SULFATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; RADIATION-INACTIVATION; RAT-LIVER; TARGET ANALYSIS; MOLECULAR-SIZE; CELL-SURFACE; SULFOTRANSFERASE; PROTEOGLYCANS; RECEPTOR; BINDING	Recent studies have shown that the rat liver heparan sulfate N-deacetylase/N-sulfotransferase is a glycoprotein encoded by a single polypeptide chain of 882 amino acids. Using radiation inactivation analyses, we have now determined that in rat liver Golgi vesicles the target size for the N-deacetylase is 88 +/- 14 kDa, whereas that of the N-sulfotransferase is 92 +/- 8 kDa. These results, together with previous biochemical and molecular cloning approaches, demonstrate that 1) in rat Liver Golgi membranes there exists only one population of molecules expressing both activities, 2) the active protein in the Golgi membrane functions as a monomer, and 3) there is no evidence that a large independent protein acts as a regulator of either activity.	UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01655 USA; NIAMSD, PHYS BIOL LAB, BETHESDA, MD 20892 USA; GLYCOMED INC, ALAMEDA, CA 94501 USA	University of Massachusetts System; University of Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)				Hirschberg, Carlos/0000-0003-2299-7721	NIGMS NIH HHS [GM34396] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034396] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAME KJ, 1991, J BIOL CHEM, V266, P12461; BENYOSEPH Y, 1986, BIOCHEM J, V235, P883, DOI 10.1042/bj2350883; BOLGER GT, 1989, MOL PHARMACOL, V36, P327; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Burchell B, 1981, Methods Enzymol, V77, P188; CAREY DJ, 1981, J BIOL CHEM, V256, P989; FLEISCHER B, 1993, BIOCHEMISTRY-US, V32, P2076, DOI 10.1021/bi00059a027; HARMON JT, 1985, METHOD ENZYMOL, V117, P65; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HOOGEWERF AJ, 1991, J BIOL CHEM, V266, P16564; ISHIHARA M, 1993, J BIOL CHEM, V268, P20091; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; KEMPNER ES, 1988, ADV ENZYMOL RAMB, V61, P107; KEMPNER ES, 1993, TRENDS BIOCHEM SCI, V18, P236, DOI 10.1016/0968-0004(93)90169-N; KEMPNER ES, 1986, ANAL BIOCHEM, V156, P140, DOI 10.1016/0003-2697(86)90165-X; KEMPNER ES, 1989, METHOD ENZYMOL, V172, P410; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KORNFELD SA, 1992, J BIOL CLIN, V267, P11645; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; LEBARON RG, 1988, J CELL BIOL, V106, P945, DOI 10.1083/jcb.106.3.945; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LINDSTEDT KA, 1992, J LIPID RES, V33, P65; LUPA MT, 1990, DEV BIOL, V142, P31, DOI 10.1016/0012-1606(90)90148-C; MATERN H, 1982, J BIOL CHEM, V257, P7422; MCINTYRE JO, 1985, ANAL BIOCHEM, V147, P468, DOI 10.1016/0003-2697(85)90300-8; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; OTT S, 1988, J BIOL CHEM, V263, P10524; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SCHWARZ JK, 1984, J BIOL CHEM, V259, P354; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; SOMMERS LW, 1982, J BIOL CHEM, V257, P811; STEVENS BR, 1990, P NATL ACAD SCI USA, V87, P1456, DOI 10.1073/pnas.87.4.1456; TYRELL DJ, 1993, J BIOL CHEM, V268, P4684; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	40	33	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11729	11733						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163470				2022-12-25	WOS:A1994NG37700012
J	HUANG, CH; REID, ME; BLUMENFELD, OO				HUANG, CH; REID, ME; BLUMENFELD, OO			REMODELING OF THE TRANSMEMBRANE SEGMENT IN HUMAN GLYCOPHORIN BY ABERRANT RNA SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE MEMBRANES; AMINO-ACID SEQUENCE; BLOOD-GROUP; MOLECULAR ANALYSIS; GENE CONVERSION; HEREDITARY ELLIPTOCYTOSIS; NUCLEOTIDE-SEQUENCE; BETA-THALASSEMIA; SITE SELECTION; CELL MEMBRANE	This paper describes the identification in S-s-U-erythrocytes of a novel glycophorin (GP), He(P-2), with structural variations in both its extracellular and transmembrane domains, In the exon II-intron 2 region, a sequence transfer from GPA to GPB, probably via the mechanism of gene conversion, was associated with the induction of multiple untemplated nucleotide replacements. These changes defined the sequence for the He epitope while concomitantly abolishing GPB-associated N antigenicity. Moreover, the GPHe(P-2) gene carries two splice site mutations that coordinately affect the processing of exon V coding for the transmembrane segment. The C --> G transversion at the 3' end of exon V created a cryptic acceptor splice site, whereas the G --> T transversion at the +5 position of intron 5 altered the consensus of the donor splice site. Transcript sequencing revealed that neither site was utilized in the splicing of GPHe(P-2) pre-mRNA Rather, complete skipping of exon V and subsequent joining of exon IV to exon VI caused a shift in the open reading frame, which remodeled GPHe(P-2) with an elongated new hydrophobic sequence for membrane anchoring. As a result, GPHe(P-2) does not display the S and U epitopes although it still contains an intact linear sequence for the two antigens. These findings illustrate how exon and intron sequences concertedly determine the specificity of in vivo splice site selection. In addition, they pinpoint the conformational dependence of the S, s, and U antigens and the importance of the hinge region for their presentation.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	HUANG, CH (corresponding author), NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM016389] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 16389] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATWEH GF, 1987, BLOOD, V70, P147; BLANCHARD D, 1987, J BIOL CHEM, V262, P5808; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CARTRON JP, 1990, BLOOD CELL BIOCH, V1, P299; DAHR W, 1980, H-S Z PHYSIOL CHEM, V361, P895, DOI 10.1515/bchm2.1980.361.1.895; DAHR W, 1984, EUR J BIOCHEM, V141, P51, DOI 10.1111/j.1432-1033.1984.tb08155.x; DAHR W, 1986, RECENT ADV BLOOD GRO, V19, P23; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FURTHMAYR H, 1981, P NATL ACAD SCI-BIOL, V78, P631, DOI 10.1073/pnas.78.1.631; GALLAGHER PG, 1991, J BIOL CHEM, V266, P15154; Goossens M, 1981, Methods Enzymol, V76, P805; GOTODA T, 1991, J BIOL CHEM, V266, P24757; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; Huang C H, 1991, Baillieres Clin Haematol, V4, P821, DOI 10.1016/S0950-3536(06)80032-6; HUANG CH, 1988, P NATL ACAD SCI USA, V85, P9640, DOI 10.1073/pnas.85.24.9640; HUANG CH, 1987, BLOOD, V70, P1830; HUANG CH, 1991, BLOOD, V77, P381; HUANG CH, 1992, BLOOD, V80, P2379; HUANG CH, 1992, J BIOL CHEM, V267, P3336; HUANG CH, 1992, BLOOD, V80, P257; HUANG CH, 1991, BLOOD, V77, P1813; HUANG CH, 1991, J BIOL CHEM, V266, P7248; HUANG CH, 1991, J BIOL CHEM, V266, P23306; HUANG CH, 1993, J BIOL CHEM, V268, P4945; HUANG CH, 1993, J BIOL CHEM, V268, P25902; HUANG CH, 1992, BLOOD S, V80, pA274; HUANG CH, 1986, CHIN BIOCH J, V2, P9; JOHE KK, 1989, J BIOL CHEM, V264, P17486; KAPPES D, 1988, ANNU REV BIOCHEM, V57, P991, DOI 10.1146/annurev.bi.57.070188.005015; KAZAZIAN HH, 1990, SEMIN HEMATOL, V27, P209; KUDO S, 1990, J BIOL CHEM, V265, P13825; KUDO S, 1990, J BIOL CHEM, V265, P1102; KUDO S, 1989, P NATL ACAD SCI USA, V86, P4619, DOI 10.1073/pnas.86.12.4619; KUIVANIEMI H, 1990, J BIOL CHEM, V265, P12067; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; LOWE RF, 1972, HUM HERED, V22, P344, DOI 10.1159/000152509; LU YQ, 1987, BLOOD, V69, P618; MAIZELS N, 1989, TRENDS GENET, V5, P4, DOI 10.1016/0168-9525(89)90004-8; Maniatis T., 1982, MOL CLONING; MARCHESI VT, 1979, SEMIN HEMATOL, V16, P3; MARVIT J, 1987, NUCLEIC ACIDS RES, V15, P5613, DOI 10.1093/nar/15.14.5613; MITCHELL PJ, 1986, MOL CELL BIOL, V6, P1926, DOI 10.1128/MCB.6.6.1926; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NELSON KK, 1988, GENE DEV, V2, P319, DOI 10.1101/gad.2.3.319; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P119; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; RACE RR, 1975, BLOOD GROUPS MAN, P92; RAHUEL C, 1991, AM J HEMATOL, V37, P57, DOI 10.1002/ajh.2830370115; REARDEN A, 1990, J BIOL CHEM, V265, P9259; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SIEBERT PD, 1987, P NATL ACAD SCI USA, V84, P6735, DOI 10.1073/pnas.84.19.6735; SIEBERT PD, 1986, P NATL ACAD SCI USA, V83, P1665, DOI 10.1073/pnas.83.6.1665; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TATE CG, 1989, BIOCHEM J, V263, P993, DOI 10.1042/bj2630993; THOMAS KR, 1986, NATURE, V324, P34, DOI 10.1038/324034a0; TOMITA M, 1978, BIOCHEMISTRY-US, V17, P4756, DOI 10.1021/bi00615a025; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; VIGNAL A, 1990, GENE, V95, P289, DOI 10.1016/0378-1119(90)90374-Z; VIGNAL A, 1989, EUR J BIOCHEM, V184, P337, DOI 10.1111/j.1432-1033.1989.tb15024.x; VIGNAL A, 1990, EUR J BIOCHEM, V191, P619, DOI 10.1111/j.1432-1033.1990.tb19166.x; VULLIAMY T, 1992, TRENDS GENET, V8, P138, DOI 10.1016/0168-9525(92)90372-B; WEIL D, 1988, J BIOL CHEM, V263, P8561; YOON SH, 1991, J BIOL CHEM, V266, P8490	71	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10804	10812						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144668				2022-12-25	WOS:A1994NF01700092
J	CHRISTNER, RB; MORTENSEN, RF				CHRISTNER, RB; MORTENSEN, RF			SPECIFICITY OF THE BINDING INTERACTION BETWEEN HUMAN SERUM AMYLOID P-COMPONENT AND IMMOBILIZED HUMAN C-REACTIVE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; DNA-SEQUENCE; CALCIUM; FIBRONECTIN; COMPLEMENT; CHROMATIN; HISTONES; PEPTIDES; REGION; LOCALIZATION	C-reactive protein (CRP) and serum amyloid P-component (SAP) are two members of a group of plasma proteins termed pentraxins, which are composed of five identical noncovalently linked subunits that display Ca2+-dependent binding to a wide variety of substrates. Purified human SAP binds to CRP, only when the latter is immobilized, in a Ca2+-dependent manner under physiological conditions. Externally labeled SAP rapidly binds to two distinct forms of immobilized CRP (direct and phosphorylcholine captured) with a relatively high affinity (K(D) = 5 nM) at a molar ratio of specifically bound SAP/CRP = 0.3. Studies of binding inhibition using monoclonal antibodies to CRP or synthetic peptides of CRP revealed that residues 134-148 and the COOH-terminal region (residues 191-206) were recognized by SAP. A fragment of CRP consisting of the COOH-terminal 60 residues within each subunit was also selectively bound by SAP. The ability of immobilized CRP to bind SAP was distinguished from CRPs lectin-like binding reactivity since deglycosylated SAP retained its binding reactivity for CRP and sugars that inhibit CRP's lectin-like binding activity failed to inhibit binding. A peptide from trypsin digested SAP composed of residues 144-199 retained CRP binding activity, implicating the COOH-terminal region of SAP as the CRP recognition site.	OHIO STATE UNIV,DEPT MICROBIOL,484 W 12TH AVE,COLUMBUS,OH 43210	Ohio State University					NATIONAL CANCER INSTITUTE [P30CA016058, R01CA030015] Funding Source: NIH RePORTER; NCI NIH HHS [2 P30 CA 16058, CA 30015] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLOU SP, 1992, ADV INTERNAL MED, V37, P313; BALTZ ML, 1982, BIOCHIM BIOPHYS ACTA, V701, P229, DOI 10.1016/0167-4838(82)90118-2; BALTZ ML, 1980, IMMUNOLOGY, V41, P59; BUTLER PJG, 1990, J EXP MED, V172, P13, DOI 10.1084/jem.172.1.13; CATHCART ES, 1965, NEW ENGL J MED, V273, P143, DOI 10.1056/NEJM196507152730306; DEBEER FC, 1981, J EXP MED, V154, P1134, DOI 10.1084/jem.154.4.1134; DUCLOS TW, 1988, J IMMUNOL, V141, P4266; DUCLOS TW, 1989, J IMMUNOL, V143, P2553; FERNANDEZ MC, 1992, J CELL BIOCHEM, V50, P83, DOI 10.1002/jcb.240500113; HAMAZAKI H, 1990, BIOCHIM BIOPHYS ACTA, V1037, P435, DOI 10.1016/0167-4838(90)90047-J; HAMAZAKI H, 1987, J BIOL CHEM, V262, P1456; HICKS PS, 1992, J IMMUNOL, V149, P3689; INOUE S, 1991, CELL TISSUE RES, V263, P431, DOI 10.1007/BF00327277; JIANG HX, 1991, J IMMUNOL, V146, P2324; KILPATRICK JM, 1982, MOL IMMUNOL, V19, P1159, DOI 10.1016/0161-5890(82)90326-1; KILPATRICK JM, 1991, IMMUNOL RES, V10, P43, DOI 10.1007/BF02918166; KINOSHITA CM, 1989, BIOCHEMISTRY-US, V28, P9840, DOI 10.1021/bi00451a044; KOTTGEN E, 1992, J IMMUNOL, V149, P445; KUBAK BM, 1988, MOL IMMUNOL, V25, P851, DOI 10.1016/0161-5890(88)90121-6; KUSHNER I, 1963, J CLIN INVEST, V42, P286, DOI 10.1172/JCI104715; LEI KJ, 1985, J BIOL CHEM, V260, P3377; LIU T, 1985, J PROTEIN CHEM, V6, P263; LOVELESS RW, 1992, EMBO J, V11, P813, DOI 10.1002/j.1460-2075.1992.tb05118.x; MANTZOURANIS EC, 1985, J BIOL CHEM, V260, P7752; MOYLE WR, 1975, J BIOL CHEM, V250, P9163; OSMAND A, 1977, P NATL ACAD SCI USA, V54, P739; PEPYS MB, 1977, LANCET, V1, P1029; PEPYS MB, 1979, CLIN EXP IMMUNOL, V38, P284; PEPYS MB, 1978, CLIN EXP IMMUNOL, V32, P119; PEPYS MB, 1987, BIOCHEM BIOPH RES CO, V148, P308, DOI 10.1016/0006-291X(87)91111-9; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; POTEMPA L, 1985, J BIOL CHEM, V260, P1242; REES RF, 1988, CLIN IMMUNOL IMMUNOP, V48, P95, DOI 10.1016/0090-1229(88)90160-2; ROBEY FA, 1987, J BIOL CHEM, V262, P7053; ROBEY FA, 1984, J BIOL CHEM, V259, P7311; SALONEN EM, 1984, J BIOL CHEM, V259, P1496; SHEPHARD EG, 1990, J IMMUNOL, V145, P1469; SHIELDS MJ, 1993, IMMUNOL RES, V12, P37, DOI 10.1007/BF02918367; SOELTER J, 1986, IMMUNOLOGY, V58, P139; SWANSON SJ, 1990, MOL IMMUNOL, V27, P679, DOI 10.1016/0161-5890(90)90011-N; SWANSON SJ, 1992, BIOCHIM BIOPHYS ACTA, V1160, P309, DOI 10.1016/0167-4838(92)90093-S; SWANSON SJ, 1991, J IMMUNOL, V147, P2248; TEBO JM, 1991, BIOCHIM BIOPHYS ACTA, V1095, P210, DOI 10.1016/0167-4889(91)90101-3; TEBO JM, 1990, J IMMUNOL, V144, P231; TSENG J, 1988, MOL IMMUNOL, V25, P679, DOI 10.1016/0161-5890(88)90103-4; VOLANAKI.JE, 1971, P SOC EXP BIOL MED, V136, P612; VOLANAKIS JE, 1981, J IMMUNOL, V126, P1820; WOO P, 1985, J BIOL CHEM, V260, P3384; YING SC, 1992, MOL IMMUNOL, V29, P677, DOI 10.1016/0161-5890(92)90205-C; YING SC, 1993, J IMMUNOL, V150, P169; YING SC, 1989, J IMMUNOL, V143, P221; YOUNG NM, 1978, J IMMUNOL, V121, P1893	52	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9760	9766						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144569				2022-12-25	WOS:A1994NE05300058
J	LIM, F; SPINGOLA, M; PEABODY, DS				LIM, F; SPINGOLA, M; PEABODY, DS			ALTERING THE RNA-BINDING SPECIFICITY OF A TRANSLATIONAL REPRESSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAT PROTEIN; SITE; SEQUENCE; PLASMID; DNA; GA	The coat proteins of RNA phages MS2 and GA are specific RNA-binding proteins which function to encapsidate viral RNA and to translationally repress synthesis of the viral replicase. The two proteins have highly ho mologous amino acid sequences, yet they show different RNA binding specificities, recognizing RNA stem-loop structures which differ primarily in the nucleotide sequences of their loops. We sought to convert MS2 coat protein to the RNA binding specificity of GA through the introduction of GA-like amino acid substitutions into the MS2 coat protein RNA-binding site. The effects of the mutations were determined by measuring the affinity of the coat protein variants for RNA in vitro and by measuring translational repression in vivo. We found five substitutions that affect RNA binding. One dramatically reduces binding of MS2 coat protein to both operators. Three others compensate for this defect by nonspecifically strengthening the interaction. Another substitution accounts for the ability to recognize the differences in the RNA loop sequence.	UNIV NEW MEXICO, SCH MED, CTR CANC RES & TREATMENT, DEPT CELL BIOL, ALBUQUERQUE, NM 87131 USA	University of New Mexico								BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; DRAPER DE, 1988, METHOD ENZYMOL, V164, P221; GOTT JM, 1991, NUCLEIC ACIDS RES, V19, P6499, DOI 10.1093/nar/19.23.6499; INOKUCHI Y, 1986, J BIOCHEM-TOKYO, V99, P1169, DOI 10.1093/oxfordjournals.jbchem.a135580; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; PEABODY DS, 1990, J BIOL CHEM, V265, P5684; PEABODY DS, 1993, EMBO J, V12, P595, DOI 10.1002/j.1460-2075.1993.tb05691.x; ROMANIUK PJ, 1987, BIOCHEMISTRY-US, V26, P1563, DOI 10.1021/bi00380a011; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; VALEGARD K, 1990, NATURE, V345, P36, DOI 10.1038/345036a0; WEBER H, 1983, NUCLEIC ACIDS RES, V11, P5661, DOI 10.1093/nar/11.16.5661	13	49	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9006	9010						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132638				2022-12-25	WOS:A1994NB41100059
J	VERGHESE, GM; JOHNSON, JD; VASULKA, C; HAUPT, DM; STUMPO, DJ; BLACKSHEAR, PJ				VERGHESE, GM; JOHNSON, JD; VASULKA, C; HAUPT, DM; STUMPO, DJ; BLACKSHEAR, PJ			PROTEIN-KINASE C-MEDIATED PHOSPHORYLATION AND CALMODULIN-BINDING OF RECOMBINANT MYRISTOYLATED ALANINE-RICH C-KINASE SUBSTRATE (MARCKS) AND MARCKS-RELATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMINENT CELLULAR SUBSTRATE; DEPENDENT BINDING; SITE DOMAIN; PEPTIDES; IDENTIFICATION; MYOCYTES; ABSENCE; DESIGN	The myristoylated alanine-rich C kinase substrate (MARCKS) and the MARCKS-related protein (MRP) are members of a distinct family of protein kinase C (PKC) substrates that also bind calmodulin in a manner regulated by phosphorylation by PKC. The kinetics of PKC-mediated phosphorylation and the calmodulin binding properties of intact, recombinant MARCKS and MRP were investigated and compared with previous studies of synthetic peptides spanning the PKC phosphorylation site/calmodulin binding domains (PSCBD) of these proteins. Both MARCKS and MRP were high affinity substrates for the catalytic fragment of PKC, and their phosphorylation occurred with positive cooperativity (MARCKS: S-0.5 = 100 nM, K-H = 1.43; MRP: S-0.5 = 238 nM, K-H = 1.72). These affinities are similar to the values determined from studies of their respective PSCBD peptides. Two-dimensional mapping of MRP and its synthetic PSCBD peptide yielded identical patterns of tryptic phosphopeptides, indicating that, as in the case of MARCKS, all of the PKC phosphorylation sites in MRP lie within the 24-amino acid PSCBD. Sequence analysis of tryptic phosphopeptides revealed that the first and third, but not the second, serines in the MRP PSCBD were phosphorylated by PKC. Both MARCKS and MRP bound dansyl-calmodulin with high affinity, with a K-app of 4.6 and 9.5 nM, respectively. Phosphorylation of MARCKS and MRP by PKC disrupted the protein-calmodulin complexes, with half-lives of 4.0 and 3.5 min, respectively. These studies suggest that intact, recombinant MARCKS and MRP are accurately modeled by their synthetic PSCBD peptides with respect to PKC phosphorylation kinetics and their phosphorylation-dependent calmodulin binding properties.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR,DEPT MED,DIV ENDOCRINOL METAB & NUTR, DIABET & METAB SECT, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; OHIO STATE UNIV, DEPT MED BIOCHEM, COLUMBUS, OH 43210 USA	Duke University; Duke University; Duke University; University System of Ohio; Ohio State University			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; AMESS B, 1992, FEBS LETT, V297, P285; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CLARKE PR, 1993, FEBS LETT, V336, P37, DOI 10.1016/0014-5793(93)81604-X; COBURN C, 1993, BIOPHYS J, V64, pA60; DEGRADO WF, 1988, ADV PROTEIN CHEM, V39, P51; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HEEMSKERK FMJ, 1993, BIOCHEM BIOPH RES CO, V190, P236, DOI 10.1006/bbrc.1993.1036; JAMES G, 1989, J BIOL CHEM, V264, P20928; JOHNSON JD, 1983, BIOCHEM J, V211, P473, DOI 10.1042/bj2110473; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALENCIK DA, 1982, BIOCHEMISTRY-US, V21, P3480, DOI 10.1021/bi00257a035; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; ROACH PJ, 1991, METHOD ENZYMOL, V201, P200; Segel IH, 1975, ENZYME KINETICS, P346; SPACH DH, 1986, J BIOL CHEM, V261, P2750; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; UMEKAGE T, 1991, FEBS LETT, V286, P147, DOI 10.1016/0014-5793(91)80961-2	31	88	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9361	9367						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132675				2022-12-25	WOS:A1994NB41100107
J	LEMAIRE, S; DERAPPE, C; MICHALSKI, JC; AUBERY, M; NEEL, D				LEMAIRE, S; DERAPPE, C; MICHALSKI, JC; AUBERY, M; NEEL, D			EXPRESSION OF BETA-1-6-BRANCHED N-LINKED OLIGOSACCHARIDES IS ASSOCIATED WITH ACTIVATION IN HUMAN T4 AND T8 CELL-POPULATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAS-LIQUID-CHROMATOGRAPHY; METASTATIC TUMOR-CELLS; MEMBRANE-GLYCOPROTEINS; METHYL GLYCOSIDES; GLYCOSYLATION; LINES; DIFFERENTIATION; PROTEINS; BINDING; IDENTIFICATION	Activation of human T lymphocytes by phorbol 12-myristate 13-acetate and leukoagglutinin from Phaseolus vulgaris (L PHA) results in important changes in N-glycosylation. The most important event is the increase, in both T4 and T8 cells (especially the latter), of L-PHA(+) structures characterized by beta 1-6-branching of complex-type oligosaccharides. Moreover, the existence of a CD4-mediated increase of these beta 1-6-branched structures on positively selected T4 cells, as compared with the negatively selected ones, suggests that the presence of these structures, not detectable on T8 resting cells, could be related to stimulation events triggered by both selection methods. This beta 1-6-branching on N-glycans, strongly associated with a metastatic phenotype in human and rodent tumors, is exhibited by numerous glycoproteins on stimulated cells, as shown by blot analysis.	UNIV PARIS 05,INSERM,U180,F-75006 PARIS,FRANCE; UNIV SCI & TECHNOL LILLE 1,CNRS,UMR 111,CHIM BIOL LAB,F-59655 VILLENEUVE DASCQ,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille								BISSON JR, 1983, BIOCHEMISTRY-US, V22, P3680; BOLSCHER JGM, 1988, EMBO J, V7, P3361, DOI 10.1002/j.1460-2075.1988.tb03208.x; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CONZELMANN A, 1980, EUR J IMMUNOL, V10, P860, DOI 10.1002/eji.1830101111; CONZELMANN A, 1984, J BIOL CHEM, V259, P2528; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; FOURNET B, 1981, ANAL BIOCHEM, V116, P489, DOI 10.1016/0003-2697(81)90393-6; GOULUTCHASSAING C, 1992, BIOCHIMIE, V74, P101, DOI 10.1016/0300-9084(92)90189-L; HAMANN A, 1989, IMMUNOL REV, V108, P19, DOI 10.1111/j.1600-065X.1989.tb00011.x; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOVDENES J, 1989, SCAND J IMMUNOL, V29, P641, DOI 10.1111/j.1365-3083.1989.tb01168.x; KHAN SH, 1993, J BIOL CHEM, V268, P2468; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFERTE S, 1989, BIOCHEM J, V259, P569, DOI 10.1042/bj2590569; LAFERTE S, 1992, BIOCHEM J, V283, P193, DOI 10.1042/bj2830193; LAFERTE S, 1988, CANCER RES, V48, P4743; LEFRANCOIS L, 1985, J EXP MED, V162, P1275, DOI 10.1084/jem.162.4.1275; LEIVESTAD T, 1987, TRANSPLANT P, V19, P265; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; MERLU B, 1989, EUR J BIOCHEM, V181, P755, DOI 10.1111/j.1432-1033.1989.tb14788.x; MONTREUIL J, 1984, BIOL CELL, V51, P115, DOI 10.1111/j.1768-322X.1984.tb00291.x; NEEL D, 1987, BIOCHEM J, V244, P433, DOI 10.1042/bj2440433; OGIERDENIS E, 1988, J BIOL CHEM, V263, P6031; PALCIC MM, 1990, J BIOL CHEM, V265, P6759; PIERCE M, 1986, J BIOL CHEM, V261, P772; PILLER F, 1988, J BIOL CHEM, V263, P15146; SHIMIZU Y, 1991, FASEB J, V5, P2292, DOI 10.1096/fasebj.5.9.1860621; SUTTON P, 1992, IMMUNOLOGY, V76, P472; TAKASAKI S, 1982, METHOD ENZYMOL, V83, P263; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISS A, 1986, ANNU REV IMMUNOL, V44, P313; YAGEL S, 1989, INT J CANCER, V44, P685, DOI 10.1002/ijc.2910440422; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772; ZANETTA JP, 1972, J CHROMATOGR, V69, P291, DOI 10.1016/S0021-9673(00)92897-8	38	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8069	8074						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132531				2022-12-25	WOS:A1994NB40900039
J	MANENTI, S; SOROKINE, O; VANDORSSELAER, A; TANIGUCHI, H				MANENTI, S; SOROKINE, O; VANDORSSELAER, A; TANIGUCHI, H			DEMYRISTOYLATION OF THE MAJOR SUBSTRATE OF PROTEIN-KINASE-C (MARCKS) BY THE CYTOPLASMIC FRACTION OF BRAIN SYNAPTOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CELLULAR SUBSTRATE; RAT-BRAIN; PHOSPHORYLATION; 80-KDA; MYRISTOYLATION; CALMODULIN; BINDING; EXPRESSION; MEMBRANE	Myristoylated alanine-rich C kinase substrate (MARCKS) is a major substrate of protein kinase C, whose interaction with the plasma membrane is dependent on its phosphorylation by protein kinase C and on its N-terminal myristoylation. We describe a hitherto undescribed demyristoylation activity of the protein in cytoplasmic fraction of synaptosomes from bovine brain. The activity is dependent on ATP but independent from calcium. The formation of the demyristoylated form, characterized by an increased mobility on SDS gel (70 kDa instead of 85 kDa), was confirmed by mass spectrometry and amino acid sequencing. The molecular mass of the demyristoylated protein as well as the incorporation of radioactive phosphate from [gamma-P-32]ATP indicated that one phosphoryl group was incorporated during the demyristoylation process. Calmodulin, which binds to the protein kinase C phosphorylation domain of MARCKS, inhibited the reaction in a calcium-dependent manner. These data suggest that the demyristoylation is regulated by the signal transduction pathways and that the two conserved domains of the protein, namely the N-terminal myristoylated region and the phosphorylation site domain, are functionally interdependent. The localization of MARCKS in the cells may be regulated not only by its phosphorylation with protein kinase C but also by a reversible myristoylation of the protein in situ.	CHIM ORGAN SUBST NAT LAB,CNRS,URA 31,F-67084 STRASBOURG,FRANCE; FUJITA HLTH UNIV,INST COMPREHENS MED SCI,DIV BIOPOLYMER SCI,TOYOAKE,AICHI 47011,JAPAN	Centre National de la Recherche Scientifique (CNRS); Fujita Health University	MANENTI, S (corresponding author), UNIV BASEL,BIOCTR,DEPT BIOPHYS CHEM,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.		manenti, stephane/P-1518-2014	manenti, stephane/0000-0002-4793-3196				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DASILVA AM, 1990, J CELL BIOL, V111, P401, DOI 10.1083/jcb.111.2.401; DODD PR, 1981, BRAIN RES, V226, P107, DOI 10.1016/0006-8993(81)91086-6; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HINRICHSEN RD, 1993, P NATL ACAD SCI USA, V90, P1585, DOI 10.1073/pnas.90.4.1585; JAMES G, 1989, J BIOL CHEM, V264, P20928; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANENTI S, 1993, J BIOL CHEM, V268, P6878; MANENTI S, 1992, J BIOL CHEM, V267, P22310; MCILHINNEY RAJ, 1990, BIOCHEM J, V271, P681, DOI 10.1042/bj2710681; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	27	57	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8309	8313						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132554				2022-12-25	WOS:A1994NB40900072
J	SIEGFRIED, JM; HAN, YH; DEMICHELE, MAA; HUNT, JD; GAITHER, AL; CUTTITTA, F				SIEGFRIED, JM; HAN, YH; DEMICHELE, MAA; HUNT, JD; GAITHER, AL; CUTTITTA, F			PRODUCTION OF GASTRIN-RELEASING PEPTIDE BY A NONSMALL CELL LUNG-CARCINOMA CELL-LINE ADAPTED TO SERUM-FREE AND GROWTH FACTOR-FREE CONDITIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRONCHIAL EPITHELIAL-CELLS; BOMBESIN-LIKE PEPTIDES; TUMOR PROGRESSION; ENDOCRINE TUMORS; FACTOR RECEPTOR; FETAL LUNG; CANCER; EXPRESSION; CULTURE; ORIGIN	Gastrin-releasing peptide is an important growth-modulating factor in developing lung epithelium. It is known to be produced by small cell carcinomas of the lung, and an autocrine loop involving gastrin-releasing peptide and its receptor has been demonstrated in many small cell lung tumors. We investigated whether such an autocrine loop could also be demonstrated in non-small cell lung carcinoma, since gastrin-releasing peptide is known to stimulate human bronchial epithelial cells, from which non-small cell tumors should emerge. We report here that gastrin-releasing peptide is produced by a bronchiolo-alveolar carcinoma cell line (A549) adapted to serum-free and growth factor-free conditions. A549 cells adapted to these conditions, termed A549-R(0) cells, display extensive membrane interdigitations, Gels apparatus, and secretory-like granules, and grow as a mixture of attached colonies and floating cells. Gastrin-releasing peptide is present in the conditioned medium produced by A549-R(0) cells. Colony formation of cells derived from a squamous cell carcinoma of the lung, 239T, was stimulated 9-fold by A549-R(0) conditioned medium or by authentic gastrin-releasing peptide, measured in serum-free conditions. The growth stimulatory activity was inhibited by a monoclonal antibody to gastrin-releasing peptide. Transcripts for receptors for the bombesin family of peptides were also demonstrated in A549-R(0) cells and 239T cells. These results demonstrate that non-small cell lung carcinomas can secrete gastrin-releasing peptide and can also respond to the peptide.	UNIV PITTSBURGH,PITTSBURGH CANC INST,PITTSBURGH,PA 15261; NCI,BIOMARKERS & PREVENT BRANCH,ROCKVILLE,MD 20850	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SIEGFRIED, JM (corresponding author), UNIV PITTSBURGH,DEPT PHARMACOL,E1347 BIOMED SCI TOWER,PITTSBURGH,PA 15261, USA.			Hunt, Jay/0000-0002-8838-201X	NCI NIH HHS [CA-09033, CA-50694] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA009033, R01CA050694] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADRIAENSEN D, 1993, ANAT RECORD, V236, P70, DOI 10.1002/ar.1092360111; AGUAYO SM, 1989, J CLIN INVEST, V84, P1105, DOI 10.1172/JCI114273; BAYLIN SB, 1985, PEPTIDE HORMONES MED, P1; BERGER CL, 1981, J CLIN ENDOCR METAB, V53, P422, DOI 10.1210/jcem-53-2-422; CARNEY DN, 1985, CANCER RES, V45, P2913; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN MH, 1978, SEMIN ONCOL, V5, P234; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; COY DH, 1989, J BIOL CHEM, V264, P14691; CUTTITTA F, 1988, J CLIN ENDOCR METAB, V67, P576, DOI 10.1210/jcem-67-3-576; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DAMSTRUP L, 1992, CANCER RES, V52, P3089; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; FALCO JP, 1990, J CLIN INVEST, V85, P1740, DOI 10.1172/JCI114630; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GAZDAR AF, 1988, CANCER RES, V48, P4078; GOSNEY JR, 1989, J PATHOL, V157, P127, DOI 10.1002/path.1711570207; HAEDER M, 1988, CANCER RES, V48, P1132; HIRSCH FR, 1989, CHEST, V96, pS34; HIRSCH FR, 1993, LUNG CANCER, V9, P89; HOYT RF, 1990, ANAT REC, V227, P340, DOI 10.1002/ar.1092270309; HOYT RF, 1993, ANAT REC, V236, P15, DOI 10.1002/ar.1092360106; JOHNSON DE, 1982, PEDIATR RES, V16, P446, DOI 10.1203/00006450-198206000-00009; KANE M, 1988, P AM ASSOC CANC RES, V29, P47; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; MABRY M, 1988, P NATL ACAD SCI USA, V85, P6523, DOI 10.1073/pnas.85.17.6523; MABRY M, 1991, CANCER CELL-MON REV, V3, P53; MCDOWELL EM, 1993, ANAT REC, V236, P11; MCDOWELL EM, 1981, ARCH PATHOL LAB MED, V105, P20; PEARSE AGE, 1974, MED BIOL, V52, P3; PEARSE AGE, 1969, J HISTOCHEM CYTOCHEM, V17, P303, DOI 10.1177/17.5.303; PEARSE AGE, 1977, MED BIOL, V55, P115; SIEGFRIED JM, 1993, ANAT RECORD, V236, P241, DOI 10.1002/ar.1092360129; SIEGFRIED JM, 1988, CANCER RES, V48, P4976; SIEGFRIED JM, 1987, CANCER RES, V47, P2903; SIEGFRIED JM, 1984, CARCINOGENESIS, V5, P1317, DOI 10.1093/carcin/5.10.1317; SODERDAHL G, 1988, INT J CANCER, V41, P636, DOI 10.1002/ijc.2910410426; SUNDAY ME, 1990, AM J RESP CELL MOL, V3, P199, DOI 10.1165/ajrcmb/3.3.199; VEALE D, 1987, BRIT J CANCER, V55, P513, DOI 10.1038/bjc.1987.104; WILLEY JC, 1984, EXP CELL RES, V153, P245, DOI 10.1016/0014-4827(84)90466-X	40	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8596	8603						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132585				2022-12-25	WOS:A1994NB40900114
J	FIJNEMAN, RJA; OPHOFF, RA; HART, AAM; DEMANT, P				FIJNEMAN, RJA; OPHOFF, RA; HART, AAM; DEMANT, P			KRAS-2 ALLELES, MUTATIONS, AND LUNG TURNER SUSCEPTIBILITY IN THE MOUSE - AN EVALUATION	ONCOGENE			English	Article							RECOMBINANT CONGENIC STRAINS; ETHYL-N-NITROSOUREA; TUMOR SUSCEPTIBILITY; MICE; TRAITS; GENES; TOOL	Lung Tumor Susceptibility (LTS) in the mouse has been shown to be influenced by loci within the Major Histocompatibility Complex (MHC) and the Kras-2 regions. In crosses between susceptible and resistant strains, one allele of Kras-2 has been linked with a high LTS, whereas the other allele has been linked with a low LTS. Furthermore, these Kras-2 alleles affect differently the occurrence of Kras-2 mutations in lung tumors. In this study we evaluated the relationship between LTS, Kras-2 alleles and Kras-2 mutations, using Recombinant Congenic Strains with identical MHC haplotypes. The Kras-2 region indeed influences the frequency of Kras-2 mutations in N-ethyl-N-nitrosourea-induced lung tumors. These mutations are associated with larger tumors. However, Kras-2 affects LTS only marginally. Several strains with identical Kras-2 alleles and mutation frequency differ widely in LTS, while some strains with different alleles and mutation frequency do not. We conclude that a considerable part of the genetic variability in LTS is caused by LTS-loci other than Kras-2 and MHC.	NETHERLANDS CANC INST,DIV MOLEC GENET,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute			Fijneman, Remond/X-4199-2019	Fijneman, Remond/0000-0003-2076-5521				Cochran WG., 1963, SAMPLING TECHNIQUES; CRAXTON M, 1991, Methods (Orlando), V3, P20, DOI 10.1016/S1046-2023(05)80159-8; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; DIETRICH W, 1992, GENETICS, V131, P423; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; GROOT PC, 1992, FASEB J, V6, P2826, DOI 10.1096/fasebj.6.10.1634045; MALKINSON AM, 1991, ENVIRON HEALTH PERSP, V93, P149, DOI 10.2307/3431183; MALKINSON AM, 1992, CANCER RES, V52, pS2670; MOEN CJA, 1992, ONCOGENE, V7, P563; MOEN CJA, 1991, MAMM GENOME, V1, P217, DOI 10.1007/BF00352328; NUZUM EO, 1990, MOL CARCINOGEN, V3, P287, DOI 10.1002/mc.2940030509; OOMEN LCJM, 1983, INT J CANCER, V31, P447, DOI 10.1002/ijc.2910310409; OOMEN LCJM, 1991, EXP LUNG RES, V17, P283, DOI 10.3109/01902149109064419; RYAN J, 1987, J NATL CANCER I, V79, P1351; SKOPEK TR, 1992, P NATL ACAD SCI USA, V89, P7866, DOI 10.1073/pnas.89.17.7866; Slebos R J, 1992, Diagn Mol Pathol, V1, P136, DOI 10.1097/00019606-199206000-00007; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; WRIGHT SP, 1992, BIOMETRICS, V48, P1005, DOI 10.2307/2532694; YOU M, 1992, CARCINOGENESIS, V13, P1583, DOI 10.1093/carcin/13.9.1583; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804	21	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1417	1421						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152802				2022-12-25	WOS:A1994NH40100013
J	SASSANO, M; GRANUCCI, F; SEVESO, M; MARCONI, G; FOTI, M; RICCIARDICASTAGNOLI, P				SASSANO, M; GRANUCCI, F; SEVESO, M; MARCONI, G; FOTI, M; RICCIARDICASTAGNOLI, P			MOLECULAR-CLONING OF A RECOMBINANT RETROVIRUS CARRYING A MUTATED ENV(AKR)-MYC(MH2) FUSION GENE IMMORTALIZING CELLS OF THE MONOCYTIC-MACROPHAGE LINEAGE	ONCOGENE			English	Note							V-MYC; DNA-BINDING; MYELOMONOCYTIC CELLS; NUCLEOTIDE-SEQUENCE; MURINE RETROVIRUSES; MOUSE MACROPHAGE; LEUKEMIA VIRUSES; TARGET-CELLS; DIFFERENTIATION; ACTIVATION	The VN-11 recombinant retroviruses, originally generated by co-transfection of the avian MH2 and AKRv viral genomes, were molecularly cloned from an infected mouse cell line named N11. The analysis of the proviral genome sequence from one of these recombinants showed a possible env(AKR)-myc(MH2) fusion. Point mutations were also found in this env(AKR)-myc(MH2) gene. The cloned viral genome was co-transfected with the neo gene into the psi 2 packaging cell line. Selected clones were shown to transcribe the viral genome and supernatants from these cultures, containing C-type particles, were used to infect primary cultures from mouse lymphoid tissues and brain. Proliferating macrophages and microglial cell clones were obtained, indicating that various types of cells of the mouse monocytic-macrophage lineage can be immortalized in spite of the absence of selection or special growth conditions.	UNIV MILAN,CTR CYTOPHARMACOL,CNR,I-20129 MILAN,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Milan			GRANUCCI, Francesca/K-6150-2019	FOTI, MARIA/0000-0002-4481-1900; granucci, francesca/0000-0002-7046-4914				ANDERSON SM, 1985, MOL CELL BIOL, V5, P3369, DOI 10.1128/MCB.5.12.3369; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BEUG H, 1979, CELL, V18, P559; BICHENALLROBERT.MC, 1989, ONCOGENE, V4, P731; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; CHISHOLM O, 1992, ONCOGENE, V7, P1827; DUESBERG PH, 1979, P NATL ACAD SCI USA, V76, P1633, DOI 10.1073/pnas.76.4.1633; GAZZOLO L, 1979, CELL, V16, P627, DOI 10.1016/0092-8674(79)90036-9; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; KAN NC, 1984, P NATL ACAD SCI-BIOL, V81, P3000, DOI 10.1073/pnas.81.10.3000; KERKHOFF E, 1991, ONCOGENE, V6, P93; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, EMBO J, V10, P837, DOI 10.1002/j.1460-2075.1991.tb08016.x; MIN SY, 1992, ONCOGENE, V7, P1531; PIRAMI L, 1991, P NATL ACAD SCI USA, V88, P7543, DOI 10.1073/pnas.88.17.7543; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RICCIARDICASTAGNOLI P, 1992, RES IMMUNOL, V143, P101, DOI 10.1016/0923-2494(92)80086-Z; RIGHI M, 1989, ONCOGENE, V4, P223; RIGHI M, 1991, ONCOGENE, V6, P103; SYMONDS G, 1989, ONCOGENE, V4, P285; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7	27	24	25	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1473	1477						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152810				2022-12-25	WOS:A1994NH40100021
J	WU, GY; ZHAN, PL; SZE, LL; ROSENBERG, AR; WU, CH				WU, GY; ZHAN, PL; SZE, LL; ROSENBERG, AR; WU, CH			INCORPORATION OF ADENOVIRUS INTO A LIGAND-BASED DNA CARRIER SYSTEM RESULTS IN RETENTION OF ORIGINAL RECEPTOR SPECIFICITY AND ENHANCES TARGETED GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MEDIATED ENDOCYTOSIS; CELLS; DELIVERY; RELEASE; TYPE-5; EMBRYO; MARKER	Adenovirus type 5 was modified by coupling an asialoglycoprotein-polylysine conjugate to the virus by reactions that activate carbohydrate residues. Wild-type virus modified in this manner had greatly decreased infectivity toward normally susceptible HeLa S3, (asialoglycoprotein receptor (-)) and SK Hep1 (asialoglycoprotein receptor (-)) cels leaving 91 and 86% viable, respectively, after 48 h. However, with Huh 7 (asialoglycoprotein receptor (+)) cells, modified virus retained its infectivity leaving only 19% of cells viable under identical conditions. Modified virus was complexed to DNA in the form of a plasmid, pSVHBVsurf, containing the gene for hepatitis B surface antigen as a marker of gene expression. Huh 7, receptor (+), cells treated with modified wild type, and modified replication-defective dl312 virus complexed to DNA raised antigen levels by approximately 13- and 30-fold, respectively, compared with asialoglycoprotein-polylysine DNA complex alone. Competition with a large excess of an asialoglycoprotein blocked the enhancement by more than 95%. Using a beta-galactosidase marker gene, the number of cells transfected by modified virus was found to be 200-fold higher than complex alone. Yet, specificity was retained exclusively for asialoglycoprotein receptor-bearing cells. These data indicate that adenovirus can be chemically modified by coupling ligands resulting in targeted gene expression dictated specifically by receptor recognition of the attached ligand.	HOP NECKER ENFANTS MALAD,FAC MED,INSERM,U370,F-75730 PARIS 15,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	WU, GY (corresponding author), UNIV CONNECTICUT,SCH MED,DEPT MED,DIV GASTROENTEROL HEPATOL,RM AM-044,263 FARMINGTON AVE,FARMINGTON,CT 06030, USA.				NIDDK NIH HHS [NIDDK DK-42182] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042182] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEDDINGTON RSP, 1989, DEVELOPMENT, V106, P37; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; CHARDONN.Y, 1970, VIROLOGY, V40, P462, DOI 10.1016/0042-6822(70)90189-3; CRISTIANO RJ, 1993, P NATL ACAD SCI USA, V90, P2122, DOI 10.1073/pnas.90.6.2122; CURIEL DT, 1992, AM J RESP CELL MOL, V6, P247, DOI 10.1165/ajrcmb/6.3.247; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; FITZGERALD DJP, 1983, CELL, V32, P607, DOI 10.1016/0092-8674(83)90480-4; GRAYSTON JT, 1958, J INFECT DIS, V103, P86, DOI 10.1093/infdis/103.1.86; GREEN M, 1963, VIROLOGY, V20, P199, DOI 10.1016/0042-6822(63)90157-0; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HENNACHE B, 1977, BIOCHEM J, V166, P237, DOI 10.1042/bj1660237; HUEBNER RJ, 1954, NEW ENGL J MED, V251, P1077, DOI 10.1056/NEJM195412302512701; HUGHES G, 1948, J CHEM SOC FARADAY T, V44, P941; ISHIBASHI M, 1974, VIROLOGY, V58, P345, DOI 10.1016/0042-6822(74)90070-1; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; LANE CF, 1975, SYNTHESIS-STUTTGART, V3, P135; LAWRENCE WILLIAM C., 1967, J VIROL, V1, P851; LIANG TJ, 1993, J CLIN INVEST, V91, P1241, DOI 10.1172/JCI116287; MICHAEL SI, 1993, J BIOL CHEM, V268, P6866; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PEREIRA HG, 1963, VIROLOGY, V20, P613, DOI 10.1016/0042-6822(63)90286-1; PHILIPSON L, 1968, J VIROL, V2, P1064, DOI 10.1128/JVI.2.10.1064-1075.1968; Precious B., 1985, VIROLOGY PRACTICAL A, P193; ROWE DW, 1978, BIOCHEMISTRY-US, V17, P1581, DOI 10.1021/bi00602a001; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SETH P, 1984, MOL CELL BIOL, V4, P1528, DOI 10.1128/MCB.4.8.1528; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1988, J BIOL CHEM, V263, P14621	30	89	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11542	11546						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157685				2022-12-25	WOS:A1994NF96600084
J	APPLEGATE, D; FENG, W; GREEN, RS; TAUBMAN, MB				APPLEGATE, D; FENG, W; GREEN, RS; TAUBMAN, MB			CLONING AND EXPRESSION OF A NOVEL ACIDIC CALPONIN ISOFORM FROM RAT AORTIC VASCULAR SMOOTH-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAINS; NONMUSCLE CALDESMON; THIN-FILAMENTS; MESSENGER-RNA; PHOSPHORYLATION; ACTIN; CELLS; SEQUENCE; PROTEIN; FIBROBLASTS	The actin-binding protein calponin has been implicated in the regulation of smooth muscle contraction. We have isolated cDNA clones encoding a novel acidic calponin isoform from rat aortic vascular smooth muscle cells. The initial 273 residues of the deduced 330 amino acid polypeptide (M(r) 36,377) are highly homologous to basic smooth muscle calponin isoforms, but the remaining 57 residues at the carboxyl terminus comprise a unique and strongly acidic domain. The sequence of the acidic domain shows high homology (93.3% identity) to the partial sequence of HUMXT01244, an unidentified human hippocampal gene product (Adams, M., Dubnick, M., Kerlavgne, A. R., Moreno, R., Kelly, J. M., Utterback, T. R., Nagle, J. W., Fields, C., and Venter, J. C. (1992) Nature 355, 632-634). Transcripts encoding acidic calponin are expressed in cultured rat aortic vascular smooth muscle cells and in non-muscle and smooth muscle tissues of adult rat. Based on its calculated M(r) and the tissue distribution of its expression, acidic calponin is an excellent candidate for a previously detected non-muscle calponin homolog (Takeuchi, K., Takahashi, It., Abe, M., Nishida, W, Hiwada, K., Nabeya, T, and Maruyama, It. (1991) J. Biochem. (Tokyo) 109, 311-316). Like basic calponin isoforms, acidic calponin synthesized in a bacterial expression system bound F-actin. However, unlike basic calponin, the acidic isoform did not interact with Ca2+/calmodulin, indicating a functional distinction between the muscle and non-muscle forms.	CUNY MT SINAI SCH MED,DEPT MED,MED MOLEC BIOL UNIT,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT PEDIAT,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	APPLEGATE, D (corresponding author), CUNY MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,BOX 1218,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040154] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43302] Funding Source: Medline; NIDDK NIH HHS [DK-40154] Funding Source: Medline; NIGMS NIH HHS [GM-41373] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE M, 1990, J BIOCHEM-TOKYO, V108, P835, DOI 10.1093/oxfordjournals.jbchem.a123289; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DRAEGER A, 1991, FEBS LETT, V291, P24, DOI 10.1016/0014-5793(91)81095-P; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FURST DO, 1986, EMBO J, V5, P251, DOI 10.1002/j.1460-2075.1986.tb04206.x; GABBIANI G, 1984, J CLIN INVEST, V73, P148, DOI 10.1172/JCI111185; GILMAN M, 1987, CURRENT PROTOCOLS MO, V1; GIMONA M, 1992, EUR J BIOCHEM, V205, P1067, DOI 10.1111/j.1432-1033.1992.tb16875.x; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; GRIENDLING KK, 1991, J BIOL CHEM, V266, P15498; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; KAWAMOTO S, 1987, J BIOL CHEM, V262, P7282; KAWASAKI ES, 1992, PCR TECHNOLOGY, P89; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN W, 1991, J MUSCLE RES CELL M, V12, P221, DOI 10.1007/BF01745110; MAKUCH R, 1991, BIOCHEM J, V280, P31; MARSTON SB, 1985, BIOCHEM J, V231, P517, DOI 10.1042/bj2310517; MARSTON SB, 1991, BIOCHEM J, V279, P1; MEZGUELDI M, 1992, J BIOL CHEM, V267, P15943; NISHIDA W, 1991, BIOCHEM INT, V23, P663; OWENS GK, 1987, VASCULAR SMOOTH MUSC, V1, P57; PEARLSTONE JR, 1987, J BIOL CHEM, V262, P5985; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; SHIRINSKY VP, 1992, J BIOL CHEM, V267, P15886; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAKAHASHI K, 1987, LIFE SCI, V41, P291, DOI 10.1016/0024-3205(87)90151-2; TAKAHASHI K, 1991, J BIOL CHEM, V266, P13284; TAKEUCHI K, 1991, J BIOCHEM, V109, P311; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; THWEATT R, 1992, BIOCHEM BIOPH RES CO, V187, P1, DOI 10.1016/S0006-291X(05)81449-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAVO P, 1980, BLOOD VESSELS, V17, P110; UEKI N, 1987, P NATL ACAD SCI USA, V84, P9049, DOI 10.1073/pnas.84.24.9049; WILLS FL, 1993, BIOCHEMISTRY-US, V32, P2321, DOI 10.1021/bi00060a025; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0	43	120	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10683	10690						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144658				2022-12-25	WOS:A1994NF01700074
J	LEUNG, S; ODONNELL, ME; MARTINEZ, A; PALFREY, HC				LEUNG, S; ODONNELL, ME; MARTINEZ, A; PALFREY, HC			REGULATION BY NERVE GROWTH-FACTOR AND PROTEIN-PHOSPHORYLATION OF NA/K/2CL COTRANSPORT AND CELL-VOLUME IN PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORT; PHEOCHROMOCYTOMA CELLS; OKADAIC ACID; NA+/K+/CL COTRANSPORT; EPITHELIAL TISSUES; BUMETANIDE BINDING; AVIAN ERYTHROCYTES; TRANSPORT; KINASE; STIMULATION	PC12 cells possess a bumetanide sensitive Na/K/2Cl cotransport system similar to that found in other cell types. Between 10-15% of the total Rb-86 influx in these cells is mediated by this pathway under normal conditions. The cotransporter has affinities of 16.5 mM for Na-o and 0.7 mM for K-o, is absolutely dependent on Cl-o and is loop diuretic inhibitable (benzmetanide > bumetanide > piretanide > furosemide). The cotransporter can be activated (up to 8-fold) by cell shrinkage or (up to 4-fold) by treatment with the protein phosphatase inhibitors okadaic acid (EC(50) similar to 650 nM) or calyculin A (EC(50) similar to 8 nM). Cell shrinkage is followed by a bumetanide-sensitive regulatory volume increase as determined in cell sizing experiments. Calyculin A rapidly elevates normal cell volume in a diuretic-inhibitable manner. Cotransport activity and cell volume are also increased by nerve growth factor (NGF) treatment. The effect of NGF on cotransport rate is biphasic, with an initial rapid similar to 2.5-fold increase followed by a prolonged plateau, and is blocked by pretreatment of the cells with K252a (IC50 similar to 30 nM). By contrast, agents that raise cAMP or phorbol esters lead to an inhibition of cotransport, indicating that the NGF effect is not mediated by stimulation of either cAMP dependent protein kinase or protein kinase C. Long term NGF treatment (>2 days) leads to neurite formation and a maintained similar to 2-fold increase in cotransport activity. Bumetanide treatment does not affect the ability of cells to extend neurites, nor is the growth rate of cells in normal medium affected by the diuretic. These results suggest that the cotransport system in PC12 cells is acutely regulated by protein phosphorylation and dephosphorylation as well as cell shrinkage and that cotransport activity may be up-regulated during neuronotypic differentiation.	UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA; LAWRENCE LIVERMORE NATL LAB, DEPT HUMAN PHYSIOL, DAVIS, CA 95616 USA	University of Chicago; United States Department of Energy (DOE); Lawrence Livermore National Laboratory								ALTIN JG, 1990, J NEUROCHEM, V54, P1666, DOI 10.1111/j.1471-4159.1990.tb01220.x; ALVAREZLEEFMANS FJ, 1990, CHLORIDE CHANNELS AND CARRIERS IN NERVE, MUSCLE, AND GLIAL CELLS, P109; AMSLER K, 1985, J CELL PHYSIOL, V123, P257, DOI 10.1002/jcp.1041230216; BALLANYI K, 1988, RENAL PHYSIOL BIOCH, V11, P142; BARBACID M, 1993, ONCOGENE, V8, P2033; BOONSTRA J, 1983, J CELL BIOL, V97, P92, DOI 10.1083/jcb.97.1.92; BOONSTRA J, 1981, EXP CELL RES, V131, P452, DOI 10.1016/0014-4827(81)90255-X; CHANDLER CE, 1985, J CELL PHYSIOL, V125, P367, DOI 10.1002/jcp.1041250303; CHASSANDE O, 1988, EUR J BIOCHEM, V171, P425, DOI 10.1111/j.1432-1033.1988.tb13807.x; DAMON DH, 1990, J CELL BIOL, V110, P1333, DOI 10.1083/jcb.110.4.1333; DELPIRE E, 1991, ARCH INT PHYSIOL BIO, V99, P71, DOI 10.3109/13813459109145906; FRIZZELL RA, 1979, AM J PHYSIOL, V236, pF1, DOI 10.1152/ajprenal.1979.236.1.F1; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; GAMBA G, 1994, IN PRESS J BIOL CHEM; GARGUS JJ, 1980, J MEMBRANE BIOL, V52, P245, DOI 10.1007/BF01869193; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HEGDE RS, 1992, J MEMBRANE BIOL, V126, P27; HEUMANN R, 1983, EXP CELL RES, V145, P179, DOI 10.1016/S0014-4827(83)80019-6; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JAYME DW, 1981, P NATL ACAD SCI-BIOL, V78, P1057, DOI 10.1073/pnas.78.2.1057; JOHNSON JH, 1982, BIOCHEM BIOPH RES CO, V109, P100, DOI 10.1016/0006-291X(82)91571-6; KALMAN D, 1990, NEURON, V4, P355, DOI 10.1016/0896-6273(90)90048-K; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN JD, 1993, J MEMBRANE BIOL, V132, P243; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KORT JJ, 1989, J CELL PHYSIOL, V141, P181, DOI 10.1002/jcp.1041410126; KREGENOW FM, 1981, ANNU REV PHYSIOL, V43, P493, DOI 10.1146/annurev.ph.43.030181.002425; LAUF PK, 1992, AM J PHYSIOL, V263, pC917, DOI 10.1152/ajpcell.1992.263.5.C917; LYTLE C, 1992, J BIOL CHEM, V267, P25438; MANDEL G, 1988, P NATL ACAD SCI USA, V85, P924, DOI 10.1073/pnas.85.3.924; MCGUIRE JC, 1979, J BIOL CHEM, V254, P3362; MCROBERTS JA, 1983, J BIOL CHEM, V258, P2320; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MIYASAKA T, 1990, BIOCHEM BIOPH RES CO, V168, P1237, DOI 10.1016/0006-291X(90)91161-K; ODONNELL ME, 1993, AM J PHYSIOL, V264, pC1316, DOI 10.1152/ajpcell.1993.264.5.C1316; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; OWEN NE, 1985, J CELL BIOL, V101, P454, DOI 10.1083/jcb.101.2.454; Palfrey H C, 1981, Ann N Y Acad Sci, V372, P291, DOI 10.1111/j.1749-6632.1981.tb15482.x; Palfrey H. Clive, 1992, Cellular Physiology and Biochemistry, V2, P293; PALFREY HC, 1980, AM J PHYSIOL, V238, pC139, DOI 10.1152/ajpcell.1980.238.3.C139; PALFREY HC, 1993, AM J PHYSIOL, V264, pC1270, DOI 10.1152/ajpcell.1993.264.5.C1270; PALFREY HC, 1993, CELL MOL BIOL VOLUME, P129; PARIS S, 1986, J BIOL CHEM, V261, P6177; PEWITT EB, 1990, J BIOL CHEM, V265, P20747; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RUSSELL JM, 1990, REGULATION K TRANSPO; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; STRANGE K, 1992, J AM SOC NEPHROL, V3, P12; STRANGE K, 1993, CELL MOL BIOL VOLUME; TAPLEY P, 1992, ONCOGENE, V7, P371; TAS PWL, 1987, BIOCHIM BIOPHYS ACTA, V903, P411, DOI 10.1016/0005-2736(87)90047-2; TORCHIA J, 1992, J BIOL CHEM, V267, P25444	53	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10581	10589						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144646				2022-12-25	WOS:A1994NF01700060
J	NAKAGAWA, Y; KOSUGI, H; MIYAJIMA, A; ARAI, K; YOKOTA, T				NAKAGAWA, Y; KOSUGI, H; MIYAJIMA, A; ARAI, K; YOKOTA, T			STRUCTURE OF THE GENE ENCODING THE ALPHA-SUBUNIT OF THE HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-RECEPTOR - IMPLICATIONS FOR THE EVOLUTION OF THE CYTOKINE RECEPTOR SUPERFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GM-CSF RECEPTOR; Y-PSEUDOAUTOSOMAL REGION; HUMAN GROWTH-HORMONE; BETA-CHAIN GENE; TRANSCRIPTION FACTOR; EXTRACELLULAR DOMAIN; EXPRESSION CLONING; MOLECULAR-CLONING; CELL-LINE; ORGANIZATION	The receptor for granulocyte-macrophage colony-stimulating factor (GM-CSF) is composed of at least two subunits, alpha and beta. In addition to the conserved cysteine residues and a ''WSxWS'' motif, the extracellular segments of both subunits have domains that are structurally related to a fibronectin type III domain. This structure is conserved in all members of the cytokine receptor superfamily. We isolated and characterized genomic DNA clones containing the entire coding sequences of the alpha subunit of the human GM-CSF receptor (hGMR alpha). The gene spans approximately 44 kilobases and has 13 exons. The major transcription initiation site was determined to be 195 base pairs upstream of the translation initiation site. The putative promoter region lacks a typical TATA motif and an Sp1 binding site, but contains a purine-rich stretch about 30 base pairs upstream of the transcription initiation site. This stretch is also found in the human interleukin 2 receptor gamma subunit and granulocyte colony-stimulating factor receptor genes. We compared the exon-intron organization of the hGMR alpha gene with other members of the cytokine receptor superfamily and found the genomic organizations to be remarkably well conserved. On the basis of these observations, we propose a model for evolution of this gene family.	UNIV TOKYO,INST MED SCI,DEPT MOLEC & DEV BIOL,MINATO KU,TOKYO 108,JAPAN; DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT MOLEC BIOL,PALO ALTO,CA 94304	University of Tokyo; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Yokota, Takashi/F-6021-2011; Yokota, Takashi/J-8483-2015					AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ASHWORTH A, 1990, NUCLEIC ACIDS RES, V18, P7178, DOI 10.1093/nar/18.23.7178; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CROSIER KE, 1991, P NATL ACAD SCI USA, V88, P7744, DOI 10.1073/pnas.88.17.7744; DELCASTILLO I, 1992, NAT GENET, V2, P305, DOI 10.1038/ng1292-305; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; GORMAN DM, 1992, J BIOL CHEM, V267, P15842; GOUGH NM, 1990, NATURE, V345, P734, DOI 10.1038/345734a0; GULCHER JR, 1991, P NATL ACAD SCI USA, V88, P9438, DOI 10.1073/pnas.88.21.9438; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; IMAMURA F, 1994, IN PRESS DNA CELL BI; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KREMER E, 1993, BLOOD, V82, P22, DOI 10.1182/blood.V82.1.22.bloodjournal82122; KURATA H, 1993, IN PRESS SIGNAL TRAN; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LEARY AG, 1992, P NATL ACAD SCI USA, V89, P4013, DOI 10.1073/pnas.89.9.4013; LUTFALLA G, 1992, J BIOL CHEM, V267, P2802; MACKMAN N, 1989, BIOCHEMISTRY-US, V28, P1755, DOI 10.1021/bi00430a050; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MCLACHLAN AD, 1987, COLD SPRING HARB SYM, V52, P411, DOI 10.1101/SQB.1987.052.01.048; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MILATOVICH A, 1992, AM J HUM GENET, V51, P4; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NOGUCHI M, 1993, J BIOL CHEM, V268, P13601; ODERMATT E, 1985, P NATL ACAD SCI USA, V82, P6571, DOI 10.1073/pnas.82.19.6571; OGAWA M, 1993, BLOOD, V81, P2844; OWENS GC, 1987, P NATL ACAD SCI USA, V84, P294, DOI 10.1073/pnas.84.1.294; PATTHY L, 1987, FEBS LETT, V214, P1, DOI 10.1016/0014-5793(87)80002-9; PERKINS KK, 1988, GENE DEV, V2, P1615, DOI 10.1101/gad.2.12a.1615; PLEIMAN CM, 1991, MOL CELL BIOL, V11, P3052, DOI 10.1128/MCB.11.6.3052; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RAINES MA, 1991, P NATL ACAD SCI USA, V88, P8203, DOI 10.1073/pnas.88.18.8203; RAPPOLD G, 1992, GENOMICS, V14, P455, DOI 10.1016/S0888-7543(05)80241-1; SAMBOROK J, 1989, MOL CLONING LABORATO; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SETO Y, 1992, J IMMUNOL, V148, P259; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SHELLEY CS, 1993, P NATL ACAD SCI USA, V90, P5364, DOI 10.1073/pnas.90.11.5364; SHEN Y, 1992, CYTOGENET CELL GENET, V61, P175, DOI 10.1159/000133401; SHIBUYA H, 1990, NUCLEIC ACIDS RES, V18, P3697, DOI 10.1093/nar/18.13.3697; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STEWART CB, 1993, CURR BIOL, V3, P158, DOI 10.1016/0960-9822(93)90259-Q; TAUTZ D, 1984, NUCLEIC ACIDS RES, V12, P4127, DOI 10.1093/nar/12.10.4127; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WINKELMANN JC, 1990, BLOOD, V76, P24; Wrighton N, 1992, GROWTH FACTORS, V6, P103, DOI 10.3109/08977199209011014	64	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10905	10912						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144676				2022-12-25	WOS:A1994NF01700105
J	WANG, JT; MUELLER, KL; GROSSMAN, L				WANG, JT; MUELLER, KL; GROSSMAN, L			A MUTATIONAL STUDY OF THE C-TERMINAL ZINC-FINGER MOTIF OF THE ESCHERICHIA-COLI UVRA PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION REPAIR; SITE-SPECIFIC MUTAGENESIS; TRANSCRIPTION FACTOR; GLUCOCORTICOID RECEPTOR; BINDING DOMAINS; DNA-BINDING; RNA GENE; COMPLEX; EXCINUCLEASE; RECOGNITION	The cysteine 763 residue in the C-terminal zinc-finger region of Escherichia coli UvrA protein was subjected to random mutagenesis, and the results suggested that the UvrA mutants with a small amino acid (Ser, Ala, or Gly) substituting for the cysteine 763 were almost as active as the wild-type in supporting nucleotide excision repair, but its replacement with a large, bulky amino acid (Tyr, Trp, or Phe) rendered the mutants inactive. The C763F mutant UvrA protein was purified for further characterization, and it was found this mutant UvrA protein lost its DNA binding (single-stranded or double-stranded DNA) activity and those other activities dependent on DNA binding, such as formation of damage-specific UvrA(2)B complexes and the supercoiling reaction. However, this mutant protein retained vigorous ATPase activity and was capable of negatively complementing the wild-type UvrA in JM109 strain. The purified C763F mutant UvrA protein contains a single zinc ion/molecule, half that of the wild-type. It appears that the C763F mutation destabilizes the zinc-anchored structure in the C-terminal zinc finger region, and as a result, the C763F mutant UvrA protein lost its ability to bind DNA.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21218	Johns Hopkins University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031110, R01GM022846, R37GM022846] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES03819] Funding Source: Medline; NIGMS NIH HHS [GM 22846, GM 31110] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG JM, 1990, J BIOL CHEM, V265, P6513; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYANT FR, 1988, J BIOL CHEM, V263, P8716; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11388; DOOLITTLE RF, 1986, NATURE, V323, P451, DOI 10.1038/323451a0; FRIEDBERG EC, 1985, DNA REPAIR, P248; HANAS JS, 1983, J BIOL CHEM, V258, P4120; HUSAIN I, 1986, J BIOL CHEM, V261, P4895; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; KIM KS, 1989, NATURE, V342, P200, DOI 10.1038/342200a0; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1973, J MOL BIOL, V80, P545; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3834, DOI 10.1021/bi00230a005; NAVARATNAM S, 1989, J BIOL CHEM, V264, P16067; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; REDEMANN N, 1988, NATURE, V332, P90, DOI 10.1038/332090a0; SAKONJU S, 1981, CELL, V23, P665, DOI 10.1016/0092-8674(81)90429-3; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; TSEDINH YC, 1991, J BIOL CHEM, V266, P14317; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VISSE R, 1991, J BIOL CHEM, V266, P7609; VOIGT JM, 1989, J BIOL CHEM, V264, P5172; WANG JT, 1993, J BIOL CHEM, V268, P5323; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P2567, DOI 10.1093/nar/14.6.2567; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157	35	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10771	10775						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144665				2022-12-25	WOS:A1994NF01700087
J	WIECKOWSKI, EU; WNEK, AP; MCCLANE, BA				WIECKOWSKI, EU; WNEK, AP; MCCLANE, BA			EVIDENCE THAT AN APPROXIMATE-TO-50-KDA MAMMALIAN PLASMA-MEMBRANE PROTEIN WITH RECEPTOR-LIKE PROPERTIES MEDIATES THE AMPHIPHILICITY OF SPECIFICALLY BOUND CLOSTRIDIUM-PERFRINGENS ENTEROTOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANES; VERO CELLS; A ENTEROTOXIN; ALPHA-TOXIN; PERMEABILITY; BINDING; COMPLEX; CYTOTOXICITY; DAMAGE; ASSAY	Previous studies suggest that Clostridium perfringens enterotoxin (CPE) inserts into mammalian membranes. Using Triton X-114 phase separation analysis and charge-shift electrophoresis, this study demonstrates that CPE exhibits the amphiphilicity required for membrane insertion, but this behavior develops only after exposure of CPE to membranes. This effect does not require proteolytic or covalent CPE modifications or formation of a previously reported 160-kDa CPE-containing complex. A novel 90-kDa CPE containing complex with amphiphilic properties was detected in intestinal brush-border membranes and in CPE-sensitive, but not CPE-insensitive, cell lines using nondenaturing Triton X-100 electrophoresis. Immunoprecipitation analysis suggested that the 90-kDa complex is composed of CPE and a 45-50-kDa membrane protein. Since the 90-kDa complex is formed only in cells that bind and respond to CPE, these results are consistent with the 45-50-kDa protein mediating CPE amphiphilicity and serving as a functional CPE receptor. A four-step model for CPE action is proposed. 1) CPE binds to the 45-50-kDa protein to form a 90-kDa complex. 2) The 90-kDa complex undergoes some physical change corresponding to insertion or a conformational change. 3) The 90-kDa complex and a 70-kDa membrane protein interact to form a 160-kDa complex. 4) Formation of the 160-kDa complex leads to permeability alterations.	UNIV PITTSBURGH, SCH MED, DEPT MOLEC GENET & BIOCHEM, PITTSBURGH, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI019844, R01AI019844] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19844-11] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alouf JE, 1991, SOURCEBOOK BACTERIAL, P147; BHAKDI S, 1986, MICROB PATHOGENESIS, V1, P5, DOI 10.1016/0882-4010(86)90027-6; BHAKDI S, 1977, BIOCHIM BIOPHYS ACTA, V470, P35, DOI 10.1016/0005-2736(77)90059-1; BHAKDI S, 1987, REV PHYSIOL BIOCH P, V107, P147, DOI 10.1007/BFb0027646; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BHAKDI S, 1988, BACTERIAL PROTEIN TO, P71; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CZECZULIN JR, 1993, INFECT IMMUN, V61, P3429, DOI 10.1128/IAI.61.8.3429-3439.1993; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; GRANUM PE, 1985, J FOOD BIOCHEM, V9, P137, DOI 10.1111/j.1745-4514.1985.tb00344.x; GRANUM PE, 1985, ACTA PATH MICRO IM B, V93, P41; GRANUM PE, 1986, 2ND P EUR WORKSH BAC, P327; HANNA PC, 1991, MOL MICROBIOL, V5, P225, DOI 10.1111/j.1365-2958.1991.tb01843.x; HANNA PC, 1991, J BIOL CHEM, V266, P11037; HANNA PC, 1992, INFECT IMMUN, V60, P2110, DOI 10.1128/IAI.60.5.2110-2114.1992; HARSHMAN S, 1989, J BIOL CHEM, V264, P14978; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HELENIUS A, 1977, P NATL ACAD SCI USA, V74, P529, DOI 10.1073/pnas.74.2.529; HORIGUCHI Y, 1985, FEMS MICROBIOL LETT, V28, P131; HULKOWER KI, 1989, J CELL PHYSIOL, V140, P498, DOI 10.1002/jcp.1041400314; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADSHUS IH, 1989, INFECT IMMUN, V57, P1873, DOI 10.1128/IAI.57.7.1873-1878.1989; MATSUDA M, 1986, BIOCHEM BIOPH RES CO, V141, P704, DOI 10.1016/S0006-291X(86)80229-7; MCCLANE BA, 1988, MICROB PATHOGENESIS, V4, P317, DOI 10.1016/0882-4010(88)90059-9; MCCLANE BA, 1990, INFECT IMMUN, V58, P3109, DOI 10.1128/IAI.58.9.3109-3115.1990; MCCLANE BA, 1984, BIOCHIM BIOPHYS ACTA, V777, P99, DOI 10.1016/0005-2736(84)90501-7; MCCLANE BA, 1988, J BIOL CHEM, V263, P2423; MCCLANE BA, 1994, TOXICOLOGY, V87, P43, DOI 10.1016/0300-483X(94)90154-6; McDonel J. L., 1986, Pharmacology of bacterial toxins, P477; MCDONEL JL, 1979, BIOCHEM BIOPH RES CO, V87, P497, DOI 10.1016/0006-291X(79)91823-0; MCDONEL JL, 1988, METHOD ENZYMOL, V165, P94; MCDONEL JL, 1980, BIOCHEMISTRY-US, V19, P4801, DOI 10.1021/bi00562a014; MENESTRINA G, 1992, FEMS MICROBIOL IMMUN, V105, P19; ROLFE RD, 1993, CLIN INFECT DIS, V16, pS219, DOI 10.1093/clinids/16.Supplement_4.S219; SALINOVICH O, 1982, BIOCHIM BIOPHYS ACTA, V707, P147, DOI 10.1016/0167-4838(82)90408-3; SIGRIST H, 1975, BIOCHIM BIOPHYS ACTA, V406, P433, DOI 10.1016/0005-2736(75)90022-X; SUGII S, 1988, FEMS MICROBIOL LETT, V52, P85; SUGIMOTO N, 1988, BIOCHEM BIOPH RES CO, V156, P551, DOI 10.1016/S0006-291X(88)80877-5; THELESTAM M, 1975, INFECT IMMUN, V12, P225, DOI 10.1128/IAI.12.2.225-232.1975; VANDERGOOT FG, 1993, BIOCHEMISTRY-US, V32, P2636, DOI 10.1021/bi00061a023; WNEK AP, 1986, MICROB PATHOGENESIS, V1, P89, DOI 10.1016/0882-4010(86)90035-5; WNEK AP, 1983, BIOCHEM BIOPH RES CO, V112, P1099, DOI 10.1016/0006-291X(83)91731-X; WNEK AP, 1989, INFECT IMMUN, V57, P574, DOI 10.1128/IAI.57.2.574-581.1989; WNEK AP, 1985, INFECT IMMUN, V50, P442, DOI 10.1128/IAI.50.2.442-448.1985	45	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10838	10848						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144671				2022-12-25	WOS:A1994NF01700096
J	JANKOWSKI, SA; MITCHELL, DS; SMITH, SH; TRENT, JM; MELTZER, PS				JANKOWSKI, SA; MITCHELL, DS; SMITH, SH; TRENT, JM; MELTZER, PS			SAS, A GENE AMPLIFIED IN HUMAN SARCOMAS, ENCODES A NEW MEMBER OF THE TRANSMEMBRANE-4-SUPERFAMILY OF PROTEINS	ONCOGENE			English	Article							TUMOR-ASSOCIATED ANTIGEN; CELL-SURFACE PROTEINS; MOLECULAR-CLONING; CD9 ANTIGEN; MRC OX-44; N-MYC; C-MYC; AMPLIFICATION; FAMILY; IDENTIFICATION	Amplification of 12q13-14 occurs in a subset of human sarcomas including malignant fibrous histiocytoma and liposarcoma. This chromosomal region has previously been found to include a number of growth-related genes including the GLI proto-oncogene and the p53-associated protein, MDM2. We now report the characterization of SAS (sarcoma amplified sequence), a novel transcript found in this region. Sequence analysis demonstrates that SAS is a novel member of a transmembrane protein family (transmembrane 4 superfamily or TM4SF) thought to be involved in growth-related cellular processes. This observation adds a TM4SF protein to the cluster of genes at 12q13-14 frequently amplified in human sarcomas.	UNIV MICHIGAN, DEPT PEDIAT,MED SCI RES BLDG 2,RM C560B, 1150 W MED CTR DR, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT RADIAT ONCOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NCI NIH HHS [CA-09676, CA-56725, CA-09205] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009676, R01CA056725] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; AMIOT M, 1990, J IMMUNOL, V145, P4322; ANDRIA ML, 1991, J IMMUNOL, V147, P1030; ANGELISOVA P, 1990, IMMUNOGENETICS, V32, P281, DOI 10.1007/BF00187099; AZORSA DO, 1991, BLOOD, V78, P280; BELL GM, 1992, J EXP MED, V175, P527, DOI 10.1084/jem.175.2.527; BELLACOSA A, 1991, MOL CELL BIOL, V11, P2864, DOI 10.1128/MCB.11.5.2864; BENOIT P, 1991, HUM GENET, V86, P268, DOI 10.1007/BF00202407; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEMETRICK DJ, 1992, J NATL CANCER I, V84, P422, DOI 10.1093/jnci/84.6.422; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EMI N, 1993, IMMUNOGENETICS, V37, P193; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HOREJSI V, 1991, FEBS LETT, V288, P1, DOI 10.1016/0014-5793(91)80988-F; HOTTA H, 1988, CANCER RES, V48, P2955; KHATIB ZA, 1993, CANCER RES, V53, P5535; LEACH FS, 1993, CANCER RES, V53, P2231; LEVY S, 1991, J BIOL CHEM, V266, P14597; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MARKEN JS, 1992, P NATL ACAD SCI USA, V89, P503; MELTZER PS, 1991, CELL GROWTH DIFFER, V2, P495; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NISHIBORI M, 1993, J CLIN INVEST, V91, P1775, DOI 10.1172/JCI116388; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; ROBERTS WM, 1989, CANCER RES, V49, P5407; Sambrook J, 1989, MOL CLONING LABORATO; SCHWAB M, 1984, NATURE, V308, P288, DOI 10.1038/308288a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEHAFER JG, 1991, BIOCHEM BIOPH RES CO, V179, P401, DOI 10.1016/0006-291X(91)91384-O; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH SH, 1992, CANCER RES, V52, P3746; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; TOMLINSON MG, 1993, EUR J IMMUNOL, V23, P136, DOI 10.1002/eji.1830230122; TRENT JM, 1984, CANCER RES, V44, P233; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659; WRIGHT MD, 1990, J IMMUNOL, V144, P3195	44	75	81	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1205	1211						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134123				2022-12-25	WOS:A1994NC04800024
J	KATZ, RW; KOENIG, RJ				KATZ, RW; KOENIG, RJ			NUCLEOTIDE SUBSTITUTIONS DIFFERENTIALLY AFFECT DIRECT REPEAT AND PALINDROMIC THYROID-HORMONE RESPONSE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; NUCLEAR RECEPTORS; AUXILIARY PROTEIN; ACID RECEPTORS; BINDING-SITE; T3 RECEPTOR; DNA-BINDING; RXR-BETA; PROMOTER; TRANSACTIVATION	Thyroid hormone receptors are transcription factors that bind to specific DNA sequences and regulate gene expression in a ligand-dependent manner. Thyroid hormone response elements can be composed of direct repeat or palindromic arrangements of half-sites. The traditional half-site has been considered to be the sequence 5'-AGGTCA, although we recently demonstrated that the optimal monomer-binding site is 2 base pairs larger, 5'-TAAGGTCA. It has generally been presumed that alterations in half-site sequence have commensurate effects on gene expression from direct repeat and palindromic response elements. However, in the present studies we demonstrate that palindromic elements are highly dependent on the presence of the two 5'-nucleotides (TA) for function, whereas this portion of the response element has minimal influence on hormone induction from direct repeat elements. Hormone induction correlates poorly with binding affinity for thyroid hormone receptor monomers, homodimers, or heterodimers with retinoid X receptors, either in the absence or presence of ligands. We speculate that the magnitude of hormone induction may reflect protein conformation differences induced by a combination of the presence of the appropriate 5'-nucleotides plus half-site orientation.	UNIV MICHIGAN,MED CTR,5560 MSRB II,1150 W MED CTR DR,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K11DE000301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044155] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE00301] Funding Source: Medline; NIDDK NIH HHS [DK44155] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; FLINK IL, 1990, J BIOL CHEM, V265, P11233; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MITSUHASHI T, 1990, J BIOL CHEM, V265, P7395; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MOORE DD, 1986, GENE AMST, V45, P107; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; PROST E, 1988, NUCLEIC ACIDS RES, V16, P6248, DOI 10.1093/nar/16.13.6248; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILLIAMS GR, 1991, J BIOL CHEM, V266, P19636; WILLIAMS GR, 1992, MOL ENDOCRINOL, V6, P1527, DOI 10.1210/me.6.10.1527; YEN PM, 1992, J BIOL CHEM, V267, P3565; YEN PM, 1992, J BIOL CHEM, V267, P23248; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	31	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9500	9505						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144535				2022-12-25	WOS:A1994NE05300019
J	IWASAKI, M; DARDEN, TA; PARKER, CE; TOMER, KB; PEDERSEN, LG; NEGISHI, M				IWASAKI, M; DARDEN, TA; PARKER, CE; TOMER, KB; PEDERSEN, LG; NEGISHI, M			INHERENT VERSATILITY OF P-450 OXYGENASE - CONFERRING DEHYDROEPIANDROSTERONE HYDROXYLASE-ACTIVITY TO P-450 2A-4 BY A SINGLE AMINO-ACID MUTATION AT POSITION-117	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE; PROTEINS	Mouse steroid 15 alpha hydroxylase P-450 2a-4 is restricted in its substrate specificity to the Delta(4), 3-ketone steroids such as androstenedione. As a result, the P-450 exhibits little hydroxylase activity toward Delta(5), 3 hydroxysteroids including dehydroepiandrosterone (DHEA). A single amino acid mutation of Ala at position 117 to Val, however, is enough to confer a high DHEA hydroxylase activity to P-450 2a-4 with 7 alpha-OH DHEA as one of the two major hydroxylated metabolites. Mouse coumarin 7-hydroxylase P-450 2a-5 contains Val at position 117, but it exhibits very low DHEA hydroxylase activity. P-450 2a-5 acquires high DHEA hydroxylase activity, however, by a mutation of Phe-209 to Asn. Moreover, the mutant P-450 2a-5 loses its activity when Val is replaced by Ala at position 117. The residue at position 117, therefore, plays the principal role in the determination of the DHEA hydroxylase activity of the P-450s. Conversely, mutations at residue 117 have little effect on the androstenedione hydroxylase activities of the P-450s. Further modeling of the DHEA binding orientation in the substrate-heme pocket of bacterial P-450cam (Iwasaki, M., Darden, T., Pedersen, L., Davis, D. G., Juvonen, R. O., Sueyoshi, T., and Negishi, M. (1993) J. Biol. Chem. 268, 759-762) provides support for the hypothesis that the type of residue at position 117 determines the steroid-substrate speci ficity of the P-450 depending on the substituent at the C3 position of steroid molecule.	NIEHS, REPROD & DEV TOXICOL LAB, PHARMACOGENET SECT, RES TRIANGLE PK, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Pedersen, Lee G/E-3405-2013; Negishi, Masahiko/F-7805-2019; Tomer, Kenneth B/E-8018-2013	Pedersen, Lee G/0000-0003-1262-9861; Negishi, Masahiko/0000-0002-2076-8928; 				AKWA Y, 1992, BIOCHEM J, V288, P959, DOI 10.1042/bj2880959; BUSETTA B, 1972, CRYST STRUCT COMMUN, V1, P129; Duax W. L., 1975, ATLAS STEROID STRUCT; DUAX WL, 1975, CRYST STRUCT COMMUN, V4, P249; GOTOH O, 1992, J BIOL CHEM, V267, P83; HALPERT JR, 1993, J BIOL CHEM, V268, P4453; HARADA N, 1988, BIOCHEM PHARMACOL, V37, P4778; HARADA N, 1984, J BIOL CHEM, V259, P2285; IWASAKI M, 1993, J BIOL CHEM, V268, P759; IWASAKI M, 1991, J BIOL CHEM, V266, P3380; IWASAKI M, 1993, BIOCHEM J, V291, P569, DOI 10.1042/bj2910569; JOHNSON EF, 1992, TRENDS PHARMACOL SCI, V13, P122, DOI 10.1016/0165-6147(92)90042-5; KEDZIE KM, 1991, J BIOL CHEM, V266, P22515; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; LOIDA PJ, 1993, PROTEIN ENG, V6, P207, DOI 10.1093/protein/6.2.207; NEGISHI M, 1992, J STEROID BIOCHEM, V43, P1031, DOI 10.1016/0960-0760(92)90330-L; POULOS TL, 1991, METHOD ENZYMOL, V206, P11; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; WATERMAN MR, 1992, CURR OPIN STRUC BIOL, V2, P384; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051	21	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9079	9083						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132645				2022-12-25	WOS:A1994NB41100070
J	KAWANO, T; KOZUTSUMI, Y; KAWASAKI, T; SUZUKI, A				KAWANO, T; KOZUTSUMI, Y; KAWASAKI, T; SUZUKI, A			BIOSYNTHESIS OF N-GLYCOLYLNEURAMINIC ACID-CONTAINING GLYCOCONJUGATES - PURIFICATION AND CHARACTERIZATION OF THE KEY ENZYME OF THE CYTIDINE MONOPHOSPHO-N-ACETYLNEURAMINIC ACID HYDROXYLATION SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HANGANUTZIU-DEICHER ANTIGEN; MOUSE-LIVER CYTOSOL; NADH-CYTOCHROME-B5 REDUCTASE; EXPRESSION CLONING; MOLECULAR-CLONING; SMALL-INTESTINE; SIALIC ACIDS; RAT-KIDNEY; CELL-LINE; GANGLIOSIDE	We have proposed that cytidine monophospho-N-acetylneuraminic acid (CMP-NeuAc) hydroxylation is carried out by a multienzyme system involving CMP-NeuAc hydroxylase (the terminal enzyme of the system), cytochrome b(5), and an NADH dependent cytochrome b(5)-reducing factor (Kozutsumi, Y., Kawano, T, Yamakawa, T, and Suzuki, A. (1990) J. Biochem. 108, 704-706). The CMP-NeuAc hydroxylase was purified to homogeneity from the cytosolic fraction of mouse liver, using ion exchange columns, a Red-Sepharose column, and a soluble cytochrome b(5)-immobilized Sepharose column. The purified enzyme exhibited a single band (64 kDa) on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and a single peak (58 kDa) on gel permeation chromatography, indicating that it is composed of a single polypeptide chain. The absorption spectrum did not indicate the presence of a heme prosthetic group in the enzyme. Atomic absorption spectrometry and an inhibition test using an iron chelator indicate that the enzyme contains non-heme iron as an electron acceptor. A reconstitution experiment with the purified CMP-NeuAc hydroxylase, soluble cytochrome b(5), and recombinant NADH-cytochrome b(5) reductase revealed that these three factors are essential for the reaction. The hydroxylase exhibited high affinity to CMP-NeuAc (K-m = 5 mu M) and was greatly stabilized by CMP-NeuAc. The molecular activity of the enzyme (similar to 500/min) is much lower than that reported for NADH-cytochrome b(5) reductase, suggesting that the activity or amount of hydroxylase is rate-limiting in CMP-N-glycolylneuraminic acid (NeuGc) biosynthesis. These results, together with the previous observation that the level of CMP-NeuAc hydroxylase activity was associated with the expression of NeuGc in various tissues, support the notion that the enzyme is the key for regulation of the overall velocity of CMP-NeuAc hydroxylation and consequently for the expression of NeuGc-containing glycoconjugates.	TOKYO METROPOLITAN INST MED SCI, DEPT MEMBRANE BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN; KYOTO UNIV, FAC PHARMACEUT SCI, DEPT BIOL CHEM, SAKYO KU, KYOTO 606, JAPAN	Tokyo Metropolitan Institute of Medical Science; Kyoto University			Kawano, Takehiro/A-3080-2016					BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BOUHOURS JF, 1989, J BIOL CHEM, V264, P16992; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FUKUI Y, 1989, BIOCHEM BIOPH RES CO, V160, P1149, DOI 10.1016/S0006-291X(89)80123-8; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; HIGASHI H, 1984, J BIOCHEM, V95, P785, DOI 10.1093/oxfordjournals.jbchem.a134670; HIGASHI H, 1985, CANCER RES, V45, P3796; HIGASHI H, 1977, BIOCHEM BIOPH RES CO, V79, P388, DOI 10.1016/0006-291X(77)90169-3; HIRABAYASHI Y, 1987, JPN J CANCER RES, V78, P614; HIRABAYASHI Y, 1987, JPN J CANCER RES, V78, P251; HOKKE CH, 1990, FEBS LETT, V275, P9, DOI 10.1016/0014-5793(90)81427-P; IWAMORI M, 1978, BIOCHIM BIOPHYS ACTA, V528, P257; KAWANO T, 1993, GLYCOCONJUGATE J, V10, P109, DOI 10.1007/BF00731194; KOHN J, 1982, BIOCHEM BIOPH RES CO, V107, P878, DOI 10.1016/0006-291X(82)90604-0; KOZUTSUMI Y, 1991, J BIOCHEM, V110, P429, DOI 10.1093/oxfordjournals.jbchem.a123598; KOZUTSUMI Y, 1990, J BIOCHEM, V108, P704, DOI 10.1093/oxfordjournals.jbchem.a123268; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPERS A, 1990, EUR J BIOCHEM, V193, P715, DOI 10.1111/j.1432-1033.1990.tb19391.x; MIYAKE M, 1990, CANCER, V65, P499, DOI 10.1002/1097-0142(19900201)65:3<499::AID-CNCR2820650321>3.0.CO;2-P; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NAKAMURA K, 1988, J BIOCHEM-TOKYO, V103, P201, DOI 10.1093/oxfordjournals.jbchem.a122232; NELSON DR, 1989, BIOCHEMISTRY-US, V28, P656, DOI 10.1021/bi00428a036; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; OHASHI Y, 1983, AM J OPHTHALMOL, V96, P321, DOI 10.1016/S0002-9394(14)77822-5; OSHINO N, 1966, BIOCHIM BIOPHYS ACTA, V128, P13, DOI 10.1016/0926-6593(66)90137-8; PALTAUF F, 1973, J BIOL CHEM, V248, P1609; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; SCHAUER R, 1991, CARBOHYD RES, V213, P353, DOI 10.1016/S0008-6215(00)90623-2; Schauer R., 1982, SIALIC ACIDS CHEM ME; SHAW L, 1992, EUR J BIOCHEM, V206, P269, DOI 10.1111/j.1432-1033.1992.tb16925.x; SHAW L, 1988, BIOL CHEM H-S, V369, P477, DOI 10.1515/bchm3.1988.369.1.477; SHAW L, 1989, BIOCHEM J, V263, P355, DOI 10.1042/bj2630355; SHIRABE K, 1989, BIOCHIM BIOPHYS ACTA, V1008, P189, DOI 10.1016/0167-4781(80)90007-X; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; TAKEMATSU H, 1994, IN PRESS J BIOCH, V115; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; WANG YC, 1992, J BIOL CHEM, V267, P2728; WEN DX, 1992, J BIOL CHEM, V267, P21011; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146; YUBISUI T, 1982, J BIOCHEM, V91, P1467, DOI 10.1093/oxfordjournals.jbchem.a133838; YUBISUI T, 1987, P NATL ACAD SCI USA, V84, P3609, DOI 10.1073/pnas.84.11.3609	43	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9024	9029						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132639				2022-12-25	WOS:A1994NB41100062
J	KIM, ST; MALHOTRA, K; SMITH, CA; TAYLOR, JS; SANCAR, A				KIM, ST; MALHOTRA, K; SMITH, CA; TAYLOR, JS; SANCAR, A			CHARACTERIZATION OF (6-4)-PHOTOPRODUCT DNA PHOTOLYASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOBUTANE PYRIMIDINE DIMERS; COLI DNA; LIGHT; CELLS	Pyrimidine (6-4) pyrimidone photoproduct is the second most abundant UV photoproduct in DNA. Recently, it was reported that Drosophila melanogaster cell-free extracts restored the biological activity of (6-4) photoproduct-containing DNA in a light-dependent reaction (Todo, T., Takemori, H., Rye, H., Ihara, M., Matsunaga, T., Nikaido, O., Sate, K., and Nomura, T. (1993) Nature 361, 372-374) concomitant with the loss of (6-4) photoproduct antigenic sites and (6-4) photoproduct-caused alkali-labile sites. In the present study we show that the (6-4) photoproduct but not its Dewar isomer is the substrate for the enzyme, that the enzyme has an action spectrum peak at 400 nm, and that the efficiency of repair per incident photon is very low compared with cyclobutane pyrimidine dimer photolyases. Furthermore, we provide evidence that the (6-4) photoproduct photolyase converts the photoproduct to unmodified bases probably through an oxetane intermediate.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; WASHINGTON UNIV,DEPT CHEM,ST LOUIS,MO 63130	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Washington University (WUSTL)			Taylor, John-Stephen/AAA-3218-2020	Taylor, John-Stephen/0000-0002-8615-7257; Smith, Colin/0000-0001-5652-0855	NATIONAL CANCER INSTITUTE [R01CA040463, R37CA040463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031082, R01GM031082] Funding Source: NIH RePORTER; NCI NIH HHS [CA40463] Funding Source: Medline; NIEHS NIH HHS [ES5557] Funding Source: Medline; NIGMS NIH HHS [GM31082] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRASH DE, 1985, J BIOL CHEM, V260, P1438; CLIVIO P, 1991, J AM CHEM SOC, V113, P5481, DOI 10.1021/ja00014a065; FRANKLIN WA, 1982, J BIOL CHEM, V257, P13535; HIRSCHFELD S, 1990, MOL CELL BIOL, V10, P2041, DOI 10.1128/MCB.10.5.2041; IKENAGA M, 1970, PHOTOCHEM PHOTOBIOL, V11, P487, DOI 10.1111/j.1751-1097.1970.tb06019.x; IKENAGA M, 1971, PHOTOCHEM PHOTOBIOL, V14, P175, DOI 10.1111/j.1751-1097.1971.tb06161.x; JAGGER J, 1970, PHOTOCHEM PHOTOBIOL, V12, P185, DOI 10.1111/j.1751-1097.1970.tb06050.x; KATCHER HL, 1983, BIOCHEMISTRY-US, V22, P4071, DOI 10.1021/bi00286a013; KIM ST, 1993, PHOTOCHEM PHOTOBIOL, V57, P895, DOI 10.1111/j.1751-1097.1993.tb09232.x; MITCHELL DL, 1985, MUTAT RES, V143, P109, DOI 10.1016/S0165-7992(85)80018-X; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; NISHIO T, 1981, J CHEM SOC PERK T 1, P943, DOI 10.1039/p19810000943; PATRICK MH, 1970, PHOTOCHEM PHOTOBIOL, V11, P477, DOI 10.1111/j.1751-1097.1970.tb06018.x; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P7715, DOI 10.1021/bi00485a021; RAHN RO, 1969, PHOTOCHEM PHOTOBIOL, V10, P131, DOI 10.1111/j.1751-1097.1969.tb07230.x; REARDON JT, 1993, J BIOL CHEM, V268, P21301; RUPERT CS, 1962, J GEN PHYSIOL, V45, P725, DOI 10.1085/jgp.45.4.725; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SANCAR A, 1992, ADV ELECTRON TRANSFE, V2, P215; SMITH CA, 1993, J BIOL CHEM, V268, P11143; SVOBODA DL, 1993, J BIOL CHEM, V268, P10694; TAYLOR JS, 1988, BIOCHEMISTRY-US, V27, P7206, DOI 10.1021/bi00419a007; TAYLOR JS, 1987, J AM CHEM SOC, V109, P2834, DOI 10.1021/ja00243a052; TODO T, 1993, NATURE, V361, P371, DOI 10.1038/361371a0; TODO T, 1992, MUTAT RES, V273, P85, DOI 10.1016/0921-8777(92)90052-5; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P471; Wang S.Y., 1976, PHOTOCHEM PHOTOBIOL, P295	29	143	146	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8535	8540						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132580				2022-12-25	WOS:A1994NB40900106
J	ZANETTI, M; STORICI, P; TOSSI, A; SCOCCHI, M; GENNARO, R				ZANETTI, M; STORICI, P; TOSSI, A; SCOCCHI, M; GENNARO, R			MOLECULAR-CLONING AND CHEMICAL SYNTHESIS OF A NOVEL ANTIBACTERIAL PEPTIDE DERIVED FROM PIG MYELOID CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOVINE NEUTROPHILS; MEMBRANE PERMEABILIZATION; ANTIBIOTIC DODECAPEPTIDE; ANTIMICROBIAL PEPTIDES; BACTERICIDAL ACTIVITY; CDNA SEQUENCE; BACTENECINS; POLYPEPTIDES; INDOLICIDIN; PRECURSOR	A group of myeloid precursors of defense peptides has recently been shown to have highly homologous N-terminal regions. Using a strategy based on this homology, a novel cDNA was cloned from pig bone marrow RNA and found to encode a 153-residue polypeptide. This comprises a highly conserved region encompassing a 29-residue signal peptide and a 101-residue prosequence, followed by a unique, 23-residue, cationic, C-terminal sequence. A peptide corresponding to this C-terminal sequence was chemically synthesized and shown to exert antimicrobial activity against both Gram positive and negative bacteria at concentrations of 2-16 mu M. The activity of this potent and structurally novel antibacterial peptide appears to be mediated by its ability to damage bacterial membranes, as shown by the rapid permeabilization of the inner membrane of Escherichia coli.	UNIV UDINE,DIPARTIMENTO SCI & TECNOL BIOMED,I-33100 UDINE,ITALY; UNIV TRIESTE,DIPARTIMENTO BIOCHIM BIOFIS & CHIM MACROMOLEC,I-34127 TRIESTE,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; University of Trieste	ZANETTI, M (corresponding author), LAB NAZL CONSORZIO INTERUNIV BIOTECNOL,AREA SCI PK,PADRICIANO 99,I-34012 TRIESTE,ITALY.		Tossi, Alessandro/ABC-9061-2020; Gennaro, Renato/AAJ-2511-2021	storici, paola/0000-0002-2590-3332; Tossi, Alessandro/0000-0001-9087-5764; Gennaro, Renato/0000-0003-1331-3885				BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN SA, 1988, ANAL BIOCHEM, V174, P1, DOI 10.1016/0003-2697(88)90512-X; DAHER KA, 1988, P NATL ACAD SCI USA, V85, P7327, DOI 10.1073/pnas.85.19.7327; DELSAL G, 1992, BIOCHEM BIOPH RES CO, V187, P467, DOI 10.1016/S0006-291X(05)81517-7; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ELSBACH P, 1993, CURR OPIN IMMUNOL, V5, P103, DOI 10.1016/0952-7915(93)90088-A; FRANK RW, 1990, J BIOL CHEM, V265, P18871; GABAY JE, 1993, CURR OPIN IMMUNOL, V5, P97, DOI 10.1016/0952-7915(93)90087-9; GENNARO R, 1989, INFECT IMMUN, V57, P3142, DOI 10.1128/IAI.57.10.3142-3146.1989; GENNARO R, 1991, BLOOD CELL BIOCH, V3, P335; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; HOLAK TA, 1988, BIOCHEMISTRY-US, V27, P7620, DOI 10.1021/bi00420a008; JOINER KA, 1989, J CELL BIOL, V109, P2771, DOI 10.1083/jcb.109.6.2771; JONES DE, 1992, J BIOL CHEM, V267, P23216; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; KOKRYAKOV VN, 1993, FEBS LETT, V327, P231, DOI 10.1016/0014-5793(93)80175-T; LARRICK JW, 1991, BIOCHEM BIOPH RES CO, V179, P170, DOI 10.1016/0006-291X(91)91350-L; LEHER RI, 1993, ANNU REV IMMUNOL, V11, P105; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; LEVY O, 1993, J BIOL CHEM, V268, P6058; MARION D, 1988, FEBS LETT, V227, P21, DOI 10.1016/0014-5793(88)81405-4; RITONJA A, 1989, FEBS LETT, V255, P211, DOI 10.1016/0014-5793(89)81093-2; ROMEO D, 1988, J BIOL CHEM, V263, P9573; SCOCCHI M, 1992, EUR J BIOCHEM, V209, P589, DOI 10.1111/j.1432-1033.1992.tb17324.x; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; SKERLAVAJ B, 1990, INFECT IMMUN, V58, P3724, DOI 10.1128/IAI.58.11.3724-3730.1990; STORICI P, 1993, BIOCHEM BIOPH RES CO, V196, P1363, DOI 10.1006/bbrc.1993.2403; STORICI P, 1992, FEBS LETT, V314, P187, DOI 10.1016/0014-5793(92)80971-I; STORICI P, 1993, BIOCHEM BIOPH RES CO, V196, P1058, DOI 10.1006/bbrc.1993.2358; ZANETTI M, 1991, J IMMUNOL, V146, P4295; ZANETTI M, 1990, J CELL BIOL, V111, P1363, DOI 10.1083/jcb.111.4.1363; ZANETTI M, 1993, J BIOL CHEM, V268, P522; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; ZASLOFF M, 1992, CURR OPIN IMMUNOL, V4, P3, DOI 10.1016/0952-7915(92)90115-U	36	90	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7855	7858						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132502				2022-12-25	WOS:A1994NB40900006
J	HUANG, SL; CARLSON, GM; CHEUNG, WY				HUANG, SL; CARLSON, GM; CHEUNG, WY			CALMODULIN-DEPENDENT ENZYMES UNDERGO A PROTON-INDUCED CONFORMATIONAL CHANGE THAT IS ASSOCIATED WITH THEIR INTERACTIONS WITH CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; PHOSPHORYLASE-KINASE; INTRACELLULAR PH; BOVINE BRAIN; DOMAIN ORGANIZATION; PROTEIN PHOSPHATASE; LIMITED PROTEOLYSIS; CALCIUM-BINDING; PEPTIDE COMPLEX	The anionic hydrophobic (amphipathic) fluorescent probe 2-(p-toluidinyl)-naphthalene-6-sulfonate was used to investigate the surface hydrophobic properties of calmodulin (caM)-dependent enzymes as follows: calcineurin, myosin light chain kinase, cyclic nucleotide phosphodiesterase, CaM-dependent protein kinase II, and the gamma-subunit of phosphorylase kinase. We found that certain domains of these enzymes that interacted with 2-(p-toluidinyl)-naphthalene-6 sulfonate were exposed by a transient proton (H+) increase within the neutral pH range. This H+-induced exposure, which could be caused either by direct addition of H+ or by the release of H+ from metal chelators upon their binding of Ca2+, seemed to be more closely linked with a change in pH value (i.e. transient H+ increase) than with the actual equilibrium pH value of the system. Unlike the case with CaM-dependent enzymes, the H+-induced conformational change was uncommon in caM-independent enzymes. When CaM-binding domains were removed from calcineurin and smooth muscle myosin light chain kinase, the resultant enzymes no longer exposed new do mains in response to H+ increase. Using dansylated CaM to monitor the formation of CaM-enzyme complexes, we found that complex formation occurred with an uptake of H+ from solution. When caM-dependent enzymes were evaluated at suboptimal concentrations of Ca2+, addition of H+ enhanced both the formation of CaM-enzyme complexes and the caM-dependent catalytic activities, but this synergistic H+ effect occurred within only a narrow range of Ca2+ concentrations. These findings suggest that the H+-exposed domains in CaM-dependent enzymes are involved in the binding of CaM and that both conformational changes in caM and its enzyme targets are necessary for complex formation. Further, the findings are consistent with the notion that CaM-binding domains are masked in the nonactivated (uncomplexed) conformations of CaM-dependent enzymes. The interplay between H+ and Ca2+ is discussed in relation to other systems that display interdependent effects of these two ions.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center					NCI NIH HHS [CA 210765] Funding Source: Medline; NIDDK NIH HHS [DK 32953] Funding Source: Medline; NIGMS NIH HHS [GM 36734] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036734] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartfai T, 1979, Adv Cyclic Nucleotide Res, V10, P219; BAUER PJ, 1981, ANAL BIOCHEM, V110, P61, DOI 10.1016/0003-2697(81)90112-3; BESSEY OA, 1952, J BIOL CHEM, V196, P175; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BLUMENTHAL DK, 1982, BIOCHEMISTRY-US, V21, P2386, DOI 10.1021/bi00539a017; BUDUNOVA I, 1991, FEBS LETT, V279, P52, DOI 10.1016/0014-5793(91)80248-2; BULLEIT RF, 1988, NEURON, V1, P63, DOI 10.1016/0896-6273(88)90210-3; BUSA WB, 1984, AM J PHYSIOL, V246, pR409, DOI 10.1152/ajpregu.1984.246.4.R409; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CHARBONNEAU H, 1991, BIOCHEMISTRY-US, V30, P7931, DOI 10.1021/bi00246a009; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; GILLETTE R, 1990, BIOCHIM BIOPHYS ACTA, V1036, P207, DOI 10.1016/0304-4165(90)90036-V; GUERRIERO V, 1986, BIOCHEMISTRY-US, V25, P8372, DOI 10.1021/bi00374a007; HUANG S, 1990, FASEB J, V4, pA1960; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; IKEBE M, 1987, J BIOL CHEM, V262, P13828; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; ITO A, 1989, BIOCHEM BIOPH RES CO, V163, P1492, DOI 10.1016/0006-291X(89)91148-0; JARRETT HW, 1991, J BIOL CHEM, V266, P362; KEE SM, 1987, J BIOL CHEM, V262, P9448; KILHOFFER MC, 1992, BIOCHEMISTRY-US, V31, P8098, DOI 10.1021/bi00149a046; KINCAID RL, 1982, J BIOL CHEM, V257, P638; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KRAUSE KH, 1991, J BIOL CHEM, V266, P9453; LADOUX A, 1989, BIOCHIM BIOPHYS ACTA, V1013, P55, DOI 10.1016/0167-4889(89)90127-4; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; MALENCIK DA, 1982, CALCIUM CELL FUNCTIO, V3, P161; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; MARGOLIS LB, 1988, FEBS LETT, V234, P449, DOI 10.1016/0014-5793(88)80135-2; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MERAT DL, 1985, J BIOL CHEM, V260, P1053; MILOS M, 1986, BIOCHEMISTRY-US, V25, P6279, DOI 10.1021/bi00368a067; MILOS M, 1988, J BIOL CHEM, V263, P9218; Nuccitelli R., 1982, INTRACELLULAR PH ITS, P567; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PALLEN CJ, 1983, J BIOL CHEM, V258, P8550; PAUDEL HK, 1987, J BIOL CHEM, V262, P11912; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; ROTH SM, 1991, BIOCHEMISTRY-US, V30, P10078, DOI 10.1021/bi00106a003; SCHWERT GW, 1955, BIOCHIM BIOPHYS ACTA, V16, P570, DOI 10.1016/0006-3002(55)90280-8; SELLERS P, 1991, BIOPHYS CHEM, V39, P199, DOI 10.1016/0301-4622(91)85022-I; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; SLOTKI IN, 1989, AM J PHYSIOL, V257, pF210, DOI 10.1152/ajprenal.1989.257.2.F210; TALLANT EA, 1984, BIOCHEMISTRY-US, V23, P973, DOI 10.1021/bi00300a027; TANAKA T, 1980, J BIOL CHEM, V255, P1078; TKACHUK V A, 1981, Biokhimiya, V46, P963; WALLACE RW, 1980, CALCIUM CELL FUNCTIO, V1, P33; [No title captured]	49	17	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7631	7638						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125988				2022-12-25	WOS:A1994NA03200094
J	MAKITA, N; BENNETT, PB; GEORGE, AL				MAKITA, N; BENNETT, PB; GEORGE, AL			VOLTAGE-GATED NA+ CHANNEL BETA(1) SUBUNIT MESSENGER-RNA EXPRESSED IN ADULT HUMAN SKELETAL-MUSCLE, HEART, AND BRAIN IS ENCODED BY A SINGLE-GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT SODIUM-CHANNEL; RAT-BRAIN; CALCIUM-CHANNEL; FUNCTIONAL EXPRESSION; XENOPUS-OOCYTES; MESSENGER-RNA; MOLECULAR-CLONING; ALPHA-SUBUNIT; CLONED CDNA; MALIGNANT HYPERTHERMIA	Voltage-gated Na+ channels are heteromeric proteins consisting of alpha and beta subunits. Although alpha subunits alone are sufficient to encode functional channels, beta(1) subunits appear to modulate the kinetics of inactivation. We have used a cross-species reverse transcriptase polymerase chain reaction approach to isolate cDNAs encoding a Na+ channel beta(1) subunit from human heart and skeletal muscle. The deduced amino acid sequence of the human beta(1) subunit exhibits 96% identity with the rat brain beta(1) subunit. Human beta(1) mRNA transcripts are abundantly expressed in skeletal muscle, heart, and brain. Genomic Southern blot hybridization experiments suggest that a single gene located on chromosome 19 encodes the human beta(1) subunit that is expressed in all three of these tissues. Co-expression of the human beta(1) subunit with the recombinant human skeletal muscle alpha subunit (hSkM1) in Xenopus oocytes results in Na+ currents that inactivate rapidly. In contrast, the human beta(1) subunit has no effect on the function of the tetrodotoxin-insensitive human heart Na+ channel (hH1). These findings indicate that the human beta(1) subunit is widely expressed but does not functionally modify all Na+ channel isoforms.	VANDERBILT UNIV,SCH MED,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001862] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40608] Funding Source: Medline; NIAMS NIH HHS [AR01862] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARCHI RL, 1988, ANNU REV NEUROSCI, V11, P455, DOI 10.1146/annurev.ne.11.030188.002323; BENNETT PB, 1993, FEBS LETT, V326, P21, DOI 10.1016/0014-5793(93)81752-L; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CHAHINE M, 1993, BIOPHYS J, V64, pA4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAUTRON S, 1992, P NATL ACAD SCI USA, V89, P7272, DOI 10.1073/pnas.89.15.7272; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; GEORGE AL, 1992, P NATL ACAD SCI USA, V89, P4893, DOI 10.1073/pnas.89.11.4893; GEORGE AL, 1992, ANN NEUROL, V31, P131, DOI 10.1002/ana.410310203; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KIM HL, 1992, P NATL ACAD SCI USA, V89, P3251, DOI 10.1073/pnas.89.8.3251; KRAFTE DS, 1988, J NEUROSCI, V8, P2859; KRAFTE DS, 1990, J GEN PHYSIOL, V96, P689, DOI 10.1085/jgp.96.4.689; MACLENNAN DH, 1990, NATURE, V343, P559, DOI 10.1038/343559a0; MCCARTHY TV, 1990, NATURE, V343, P562, DOI 10.1038/343562a0; MCCLATCHEY AI, 1993, HUM MOL GENET, V2, P745, DOI 10.1093/hmg/2.6.745; MESSNER DJ, 1986, J BIOL CHEM, V261, P4882; MESSNER DJ, 1985, J BIOL CHEM, V260, P597; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PO S, 1993, CIRC RES, V72, P1326, DOI 10.1161/01.RES.72.6.1326; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; ROBERTS RH, 1987, J BIOL CHEM, V262, P2298; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; SATIN J, 1992, J MEMBRANE BIOL, V130, P11; SCHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90, DOI 10.1016/0003-2697(89)90019-5; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SUTKOWSKI EM, 1990, J BIOL CHEM, V265, P12393; SUZUKI H, 1988, FEBS LETT, V228, P195, DOI 10.1016/0014-5793(88)80615-X; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; WHITE MM, 1991, MOL PHARMACOL, V39, P604; YANG JS, 1993, NEURON, V11, P915, DOI 10.1016/0896-6273(93)90121-7; ZHOU JY, 1991, NEURON, V7, P775, DOI 10.1016/0896-6273(91)90280-D	47	141	150	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7571	7578						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125980				2022-12-25	WOS:A1994NA03200085
J	WERTHEIMER, E; BARBETTI, F; MUGGEO, M; ROTH, J; TAYLOR, SI				WERTHEIMER, E; BARBETTI, F; MUGGEO, M; ROTH, J; TAYLOR, SI			2 MUTATIONS IN A CONSERVED STRUCTURAL MOTIF IN THE INSULIN-RECEPTOR INHIBIT NORMAL FOLDING AND INTRACELLULAR-TRANSPORT OF THE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; GROWTH-FACTOR; CELL-SURFACE; EXTRACELLULAR DOMAIN; CATALYTIC SUBUNIT; IMPAIRS TRANSPORT; PROLINE MUTATION; MUTANT ALLELES; ALPHA-SUBUNIT; RESISTANCE	Insulin initiates its biological response by binding to the extracellular domain of the insulin receptor. The N-terminal half of the alpha-subunit contains several repeats of a loosely conserved motif consisting of a central glycine plus several hydrophobic amino acid residues upstream from the glycine, Hy phi Xaa-Xaa-Hy phi-Xaa-Hy phi Hy phi-Xaa-Gly (where Hy phi represents a hydrophobic amino acid residue). This structural motif has been proposed to be important in determining the three-dimensional structure of the insulin binding domain. We have identified two naturally occurring mutant alleles of the insulin receptor gene in an insulin-resistant patient, substitution of Ala for Val(28) and Arg for Gly(366). The mu- tations alter conserved amino acid residues in two distinct repeats of the structural motif described above, When mutant cDNAs were expressed in NIH-3T3 cells, both mutations severely impaired proteolytic processing of the proreceptor to mature alpha and beta-subunits. Transport of mutant receptors to the plasma membrane was also impaired. However, the minority (<1O%) of receptors that were eventually transported to the plasma membrane retained the ability to bind insulin with nor- mal affinity and to undergo insulin-stimulated phosphorylation. In conclusion, the effects of these naturally occurring mutations provide experimental support for the importance of the conserved glycine-containing structural motifs described above. By interrupting these structural motifs, the Ala(28) and Arg(366) mutations prevent normal folding of the insulin receptor alpha-subunit, thereby inhibiting post-translational processing and intracellular transport of the mutant receptors.	NIDDKD,DIABET BRANCH,BETHESDA,MD 20892; OSPED POLICLIN UNIV VERONA,DEPT METAB DIS,I-37134 VERONA,ITALY	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Barbetti, Fabrizio/I-7351-2018; Barbetti, Fabrizio/AAK-9106-2021	Barbetti, Fabrizio/0000-0003-4687-980X; Barbetti, Fabrizio/0000-0003-4687-980X				ACCILI D, 1992, J BIOL CHEM, V267, P586; ACCILI D, 1991, J BIOL CHEM, V266, P434; ACCILI D, 1989, EMBO J, V8, P2509, DOI 10.1002/j.1460-2075.1989.tb08388.x; ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; BARBETTI F, 1992, DIABETES, V41, P408, DOI 10.2337/diabetes.41.4.408; BARBETTI F, 1993, 75TH ANN M END SOC, V452; BONISCHNETZLER M, 1986, J BIOL CHEM, V261, P5281; BONISCHNETZLER M, 1988, J BIOL CHEM, V263, P6822; CAMA A, 1993, J BIOL CHEM, V268, P8060; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KADOWAKI T, 1990, J CLIN INVEST, V86, P254, DOI 10.1172/JCI114693; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KADOWAKI T, 1991, J BIOL CHEM, V266, P21224; KADOWAKI T, 1990, J BIOL CHEM, V265, P19143; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KLINKHAMER MP, 1989, EMBO J, V8, P2503, DOI 10.1002/j.1460-2075.1989.tb08387.x; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LEVITOLEDANO R, 1993, ENDOCRINOLOGY, V133, P1803; LONGO N, 1993, P NATL ACAD SCI USA, V90, P60, DOI 10.1073/pnas.90.1.60; MAASSEN JA, 1991, BIOCHEMISTRY-US, V30, P10778, DOI 10.1021/bi00108a024; MOLLER DE, 1990, J BIOL CHEM, V265, P14979; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; OLSON TS, 1988, J BIOL CHEM, V263, P7342; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SWEET LJ, 1987, J BIOL CHEM, V262, P16730; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDERVORM ER, 1992, J BIOL CHEM, V267, P66	31	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7587	7592						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125981				2022-12-25	WOS:A1994NA03200087
J	HOLLAND, EA; BEATON, SC; EDWARDS, BG; KEFFORD, RF; MANN, GJ				HOLLAND, EA; BEATON, SC; EDWARDS, BG; KEFFORD, RF; MANN, GJ			LOSS OF HETEROZYGOSITY AND HOMOZYGOUS DELETIONS ON 9P21-22 IN MELANOMA	ONCOGENE			English	Article							CYTOGENETIC ANALYSIS; LINKAGE MAP; SHORT ARM; CHROMOSOME-9; REGION; LOCUS; GENES	Recent studies have implicated chromosome 9p21-22 as a location for a gene involved in cutaneous melanoma (CM). Deletion mapping in 35 matched tumour-constitutional DNA pairs from metastatic melanomas (including one melanoma cell line) and one dysplastic naevus has been performed using six short tandem repeat polymorphic (STRP) markers (D9S157-D9S162-LFNA-D9S171-D9S126-D9S104) which span approximately 19 cM across the 9p21-22 region. Both heterozygous and homozygous deletions were observed across the region in melanomas from both sporadic and familial cases. Overall 57% (20/35) of the samples displayed some form of loss. A deletion map identifies two areas of common loss either side of the interferon gene cluster. Familial CM has previously been shown to link to the more proximal of these regions. The deleted region distal to IFNA has not been previously described in melanoma. The results imply the involvement of more than one tumour suppressor gene on 9p in CM.			HOLLAND, EA (corresponding author), UNIV SYDNEY,WESTMEAD CTR,DEPT MED ONCOL,WESTMEAD,NSW 2145,AUSTRALIA.		Mann, Graham J/G-4758-2014	Mann, Graham J/0000-0003-1301-405X; Kefford, Richard/0000-0001-9251-9229				ANDERSEN TI, 1992, GENE CHROMOSOME CANC, V4, P113, DOI 10.1002/gcc.2870040203; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CENTER R, 1993, GENE CHROMOSOME CANC, V7, P47, DOI 10.1002/gcc.2870070108; COLEMAN A, 1993, AM J HUM GENET S, V53, pA287; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; DRACOPOLI NC, 1985, P NATL ACAD SCI USA, V82, P1470, DOI 10.1073/pnas.82.5.1470; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; FOUNTAIN JW, 1992, GENOMICS, V14, P105, DOI 10.1016/S0888-7543(05)80290-3; FOUNTAIN JW, 1993, AM J HUM GENET S, V53, pA170; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; Greene MH, 1979, HUMAN MALIGNANT MELA, P139; HALUSKA FG, 1993, AM J HUM GENET S, V53, pA306; JAMES CD, 1993, CANCER RES, V53, P3674; JONASSON J, 1977, J CELL SCI, V24, P217; KARLBOM AE, 1993, HUM GENET, V92, P169; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KWIATKOWSKI DJ, 1992, HUM MOL GENET, V1, P658, DOI 10.1093/hmg/1.8.658-a; KWIATKOWSKI DJ, 1993, CYTOGENET CELL GENET, V64, P94; LINDBLOM A, 1993, HUM GENET, V91, P6; MACLENNAN R, 1992, J NATL CANCER I, V84, P1427, DOI 10.1093/jnci/84.18.1427; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OLOPADE OI, 1993, CANCER RES, V53, P2410; OLOPADE OI, 1992, CANCER RES, V52, P2523; PETTY EM, 1993, AM J HUM GENET, V53, P96; RUSTGI AK, 1992, ANNU REV MED, V43, P61, DOI 10.1146/annurev.me.43.020192.000425; Sambrook J, 1989, MOL CLONING LABORATO; SCHWECHHEIMER K, 1993, CLIN INVESTIGATOR, V71, P488; TAGUCHI T, 1993, CANCER RES, V53, P4349; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WILKIE PJ, 1992, GENOMICS, V12, P607, DOI 10.1016/0888-7543(92)90456-3; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488	37	84	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1361	1365						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152796				2022-12-25	WOS:A1994NH40100007
J	OBLONG, JE; BERGGREN, M; GASDASKA, PY; POWIS, G				OBLONG, JE; BERGGREN, M; GASDASKA, PY; POWIS, G			SITE-DIRECTED MUTAGENESIS OF ACTIVE-SITE CYSTEINES IN HUMAN THIOREDOXIN PRODUCES COMPETITIVE INHIBITORS OF HUMAN THIOREDOXIN REDUCTASE AND ELIMINATION OF MITOGENIC PROPERTIES OF THIOREDOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; PROTEIN DISULFIDE-ISOMERASE; DNA-BINDING ACTIVITY; RECOMBINANT HUMAN THIOREDOXIN; PURIFICATION; SUBSTITUTION; INVOLVEMENT; INVITRO; SYSTEMS	Thioredoxin and thioredoxin reductase comprise a redox system ubiquitous in all organisms. To better understand the thiol chemistry of the mammalian thioredoxin-thioredoxin reductase redox system, mutants of human thioredoxin were produced by site directed mutagenesis in which the two active site cysteines were replaced by serine residues, individually (C32S and C35S) and in combination (C32S/C35S). C35S and C32S/C35S were found to be competitive inhibitors of the reduction of human thioredoxin by human thioredoxin reductase with K-i values of 1.8 and 6.7 mu M, respectively. C32S did not inhibit thioredoxin reductase, apparently due to aggregation of the oxidized C32S species. Examination of the three mutant forms of thioredoxin by circular dichroism spectroscopy indicated that there were significant differences in the secondary structures when compared with thioredoxin. There were detectable changes in the circular dichroism spectra when thioredoxin, C35S, and C32S/C35S were bound to thioredoxin reductase, whereas C32S with thioredoxin reductase underwent only a small spectral change. Recombinant human thioredoxin stimulated DNA synthesis and the proliferation of murine fibroblasts. The ability of thioredoxin to stimulate cell proliferation could not be duplicated by either dithiothreitol or glutathione. C32S, C35S, and C32S/C35S failed to stimulate cell proliferation, showing that the redox active form of thioredoxin is necessary for eliciting growth stimulation.			OBLONG, JE (corresponding author), ARIZONA CANC CTR,1515 N CAMPBELL AVE,TUCSON,AZ 85724, USA.				NATIONAL CANCER INSTITUTE [R01CA042286, T32CA009213] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42286, CA 09213] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADAMS RLP, 1969, EXP CELL RES, V56, P49, DOI 10.1016/0014-4827(69)90392-9; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CROMLISH JA, 1989, J BIOL CHEM, V264, P18100; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P4129, DOI 10.1021/bi00469a016; FORMANKAY JD, 1989, BIOCHEMISTRY-US, V28, P7088, DOI 10.1021/bi00443a045; FORMANKAY JD, 1991, BIOCHEMISTRY-US, V30, P2685, DOI 10.1021/bi00224a017; FORMANKAY JD, 1992, BIOCHEMISTRY-US, V31, P3442, DOI 10.1021/bi00128a019; GASDASKA PY, 1994, IN PRESS BIOCH BIOPH; GRIPPO JF, 1983, J BIOL CHEM, V258, P3658; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HELLINGA HW, 1992, BIOCHEMISTRY-US, V31, P11203, DOI 10.1021/bi00160a034; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; KIMURA T, 1982, FLAVINS FLAVOPROTEIN, P695; KRAUSE G, 1991, J BIOL CHEM, V266, P4056; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MAU BL, 1992, BIOCHEM PHARMACOL, V43, P1613, DOI 10.1016/0006-2952(92)90220-D; MITSUI A, 1992, BIOCHEM BIOPH RES CO, V186, P1220, DOI 10.1016/S0006-291X(05)81536-0; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OBLONG JE, 1993, BIOCHEMISTRY-US, V32, P7271, DOI 10.1021/bi00079a025; OKUNO H, 1993, ONCOGENE, V8, P695; PELEG S, 1989, BIOCHEMISTRY-US, V28, P7373, DOI 10.1021/bi00444a034; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PORQUE PG, 1970, J BIOL CHEM, V245, P371; STRYER L, 1967, BIOCHEMISTRY-US, V6, P1016, DOI 10.1021/bi00856a009; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; WYNN R, 1993, PROTEIN SCI, V2, P395	36	120	127	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11714	11720						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163468				2022-12-25	WOS:A1994NG37700010
J	LARIMER, FW; HARPEL, MR; HARTMAN, FC				LARIMER, FW; HARPEL, MR; HARTMAN, FC			BETA-ELIMINATION OF PHOSPHATE FROM REACTION INTERMEDIATES BY SITE-DIRECTED MUTANTS OF RIBULOSE-BISPHOSPHATE CARBOXYLASE OXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; RIBULOSEBISPHOSPHATE CARBOXYLASE; RHODOSPIRILLUM-RUBRUM; ACTIVE-SITE; 1,5-BISPHOSPHATE CARBOXYLASE; TRIOSEPHOSPHATE ISOMERASE; CRYSTALLOGRAPHIC ANALYSIS; DIPHOSPHATE OXYGENASE; CRYSTAL-STRUCTURE; PYRUVATE-KINASE	Five residues (Thr-53, Asn-54, Gly-370, Gly-393, and Gly-394) of Rhodospirillum rubrum ribulose-bisphosphate carboxylase/oxygenase are positioned to serve as hydrogen-bond donors for the C1 phosphate of ribulose bisphosphate and thereby constrain conformational flexibility of the initial enediol(ate) intermediate (Knight, S., Andersson, I., and Branden, C.-I. (1990) J. Mol. Biol. 215, 113-160). To study the functional contributions of the residues implicated in ribulose bisphosphate binding and intermediate stabilization, we have replaced them individually with alanine, either to remove the H-bonding group (T53A, N54A) or to introduce bulk (G370A, G393A, G394A). Consequences of substitutions include diminution of carboxylase activity (with a lesser impact on enolization activity), increase of K(m) (ribulose bisphosphate), and decrease of carboxylation: oxygenation specificity. During catalytic turnover of ribulose bisphosphate by several mutants, substantial amounts of the substrate are diverted to 1-deoxy-D-glycero-2,3-pentodiulose 5-phosphate, reflecting beta-elimination of phosphate from the enediol(ate) intermediate. This side product is not observed with wild-type enzyme, nor has it been reported with mutant enzymes characterized previously. Another consequence of disruption of the phosphate binding site is enhanced production of pyruvate, relative to wild-type enzyme, by some of the mutants due to decomposition of the aci-carbanion of 3-phosphoglycerate (the terminal intermediate). These data provide direct evidence that phosphate ligands stabilize conformations of intermediates that favor productive turnover and mitigate beta-elimination at two stages of overall catalysis.			LARIMER, FW (corresponding author), OAK RIDGE NATL LAB,DIV BIOL,PROT ENGN PROGRAM,OAK RIDGE,TN 37831, USA.							ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; ANDRES J, 1992, CHEM PHYS LETT, V198, P515, DOI 10.1016/0009-2614(92)80037-C; ANDREWS TJ, 1991, J BIOL CHEM, V266, P9447; ANDREWS TJ, 1973, BIOCHEMISTRY-US, V12, P11, DOI 10.1021/bi00725a003; BLATTLER WA, 1979, BIOCHEMISTRY-US, V18, P3927, DOI 10.1021/bi00585a013; BOWES G, 1971, BIOCHEM BIOPH RES CO, V45, P716, DOI 10.1016/0006-291X(71)90475-X; DONNELLY MI, 1983, BIOCHEMISTRY-US, V22, P4346, DOI 10.1021/bi00287a028; EDMONDSON DL, 1990, FEBS LETT, V260, P62, DOI 10.1016/0014-5793(90)80066-R; EDMONDSON DL, 1990, PLANT PHYSIOL, V93, P1390, DOI 10.1104/pp.93.4.1390; FRANKVOORT W, 1978, THERMOCHIM ACTA, V25, P35, DOI 10.1016/0040-6031(78)80038-0; HARPEL MR, 1993, ANAL BIOCHEM, V209, P367, DOI 10.1006/abio.1993.1136; HARPEL MR, 1991, J BIOL CHEM, V266, P24734; HARTMAN FC, 1993, ADV ENZYMOL RAMB, V67, P1; HARTMAN FC, 1989, J BIOL CHEM, V264, P11784; Horecker B. L., 1958, BIOCHEM PREP, V6, P83; JAWOROWSKI A, 1984, J BIOL CHEM, V259, P6783; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KUEHN GD, 1978, BIOCHEM J, V175, P909, DOI 10.1042/bj1750909; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAING WA, 1974, PLANT PHYSIOL, V54, P678, DOI 10.1104/pp.54.5.678; LARIMER FW, 1987, J BIOL CHEM, V262, P15327; LARIMER FW, 1990, PROTEIN ENG, V3, P227, DOI 10.1093/protein/3.3.227; LEATHERBARROW RJ, 1985, P NATL ACAD SCI USA, V82, P7840, DOI 10.1073/pnas.82.23.7840; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6619, DOI 10.1021/bi00480a010; LORIMER GH, 1976, BIOCHEMISTRY-US, V15, P529, DOI 10.1021/bi00648a012; LORIMER GH, 1973, BIOCHEMISTRY-US, V12, P18, DOI 10.1021/bi00725a004; LUNDQVIST T, 1991, J BIOL CHEM, V266, P12604; MIZIORKO HM, 1980, BIOCHEMISTRY-US, V19, P1167, DOI 10.1021/bi00547a020; MORELL MK, 1992, AUST J BOT, V40, P431, DOI 10.1071/BT9920431; MURAL RJ, 1990, J BIOL CHEM, V265, P6501; NIYOGI SK, 1986, J BIOL CHEM, V261, P87; PAECH C, 1978, BIOCHEM BIOPH RES CO, V83, P1084, DOI 10.1016/0006-291X(78)91506-1; PIERCE J, 1980, BIOCHEMISTRY-US, V19, P934, DOI 10.1021/bi00546a018; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; RICHARD JP, 1991, BIOCHEMISTRY-US, V30, P4581, DOI 10.1021/bi00232a031; ROSE IA, 1981, PHILOS T ROY SOC B, V293, P131, DOI 10.1098/rstb.1981.0067; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLOSS JV, 1982, METHOD ENZYMOL, V90, P522; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; SUE JM, 1982, BIOCHEMISTRY-US, V21, P5404, DOI 10.1021/bi00265a004; Tapia O, 1992, MOL ENG, V2, P37, DOI [10.1007/BF00999521, DOI 10.1007/BF00999521]; VANDYK DE, 1986, BIOCHEMISTRY-US, V25, P5145, DOI 10.1021/bi00366a024; ZHU GH, 1991, PLANT PHYSIOL, V97, P1354, DOI 10.1104/pp.97.4.1354; ZHU GH, 1991, PLANT PHYSIOL, V97, P1348, DOI 10.1104/pp.97.4.1348	45	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11114	11120						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157638				2022-12-25	WOS:A1994NF96600025
J	PANG, L; MILARSKI, KL; OHMICHI, M; TAKATA, Y; OLEFSKY, JM; SALTIEL, AR				PANG, L; MILARSKI, KL; OHMICHI, M; TAKATA, Y; OLEFSKY, JM; SALTIEL, AR			MUTATION OF THE 2 CARBOXYL-TERMINAL TYROSINES IN THE INSULIN-RECEPTOR RESULTS IN ENHANCED ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; MICROTUBULE-ASSOCIATED PROTEIN-2; SRC HOMOLOGY-2 DOMAINS; MAP KINASE; PHOSPHATIDYLINOSITOL 3'-KINASE; THREONINE KINASE; 85-KDA SUBUNIT; GENE-PRODUCT; CELLS; PHOSPHORYLATION	Activation of mitogen-activated protein (MAP) kinase represents an important mechanism in hormonal regulation. To clarify the role of MAP kinase activation in insulin action, we compared the activation of the enzyme in Rat-1 cells transfected with Wild-type (Hire) and mutant insulin receptors in which the 2 carboxyl-terminal tyrosines were substituted with phenylalanine (Y/F2). Expression of the Y/F2 mutant receptor enhanced the responsiveness of MAP kinase to insulin. Moreover, the insulin responsiveness of the activator of this enzyme, MAP kinase kinase, was also increased in these cells. To explore the early signaling events that might account for this increase in responsiveness, we evaluated the tyrosine phosphorylation of the insulin receptor substrate, IRS-1, and its subsequent association with phosphatidylinositol (PI)-3 kinase. In both cell types, insulin led to a dose dependent increase in the association of tyrosine phosphorylated IRS-1 with the SH2 domain of the p85 regulatory subunit of PI-3 kinase, and also increased the amount of PI kinase activity detected in anti-IRS-1 immunoprecipitates. The effect of insulin was significantly greater in Y/F2 cells, as determined in both assays. In previous studies, cells bearing this receptor mutant exhibited an identical metabolic response but enhanced mitogenic response to insulin when compared with wild-type receptor. These data provide further evidence for divergence of the mitogenic and metabolic signaling pathways at or near the insulin receptor.	UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; VET AFFAIRS MED CTR,MED RES SERV,SAN DIEGO,CA 92093; VET AFFAIRS MED CTR,DEPT MED,SAN DIEGO,CA 92093; UNIV CALIF SAN DIEGO,SAN DIEGO,CA 92093	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	PHS HHS [33651] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS PD, 1992, J BIOL CHEM, V267, P13135; AHN NG, 1990, J BIOL CHEM, V265, P11487; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CAHILL AL, 1991, J NEUROCHEM, V57, P1832, DOI 10.1111/j.1471-4159.1991.tb06392.x; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CHEATHAM B, 1993, P NATL ACAD SCI USA, V90, P7336, DOI 10.1073/pnas.90.15.7336; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DECKER SJ, 1984, MOL CELL BIOL, V4, P571, DOI 10.1128/MCB.4.4.571; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; GIOGETTI S, 1992, EUR J BIOCHEM, V207, P599; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GOTTSCHALK WK, 1992, BIOCHEM BIOPH RES CO, V189, P906; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HOSHI M, 1988, J BIOL CHEM, V263, P5396; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; MOLLER DE, 1990, MOL ENDOCRINOL, V4, P1183, DOI 10.1210/mend-4-8-1183; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; OSTEROP APRM, 1992, J BIOL CHEM, V267, P14647; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PANG L, 1993, BIOCHEM BIOPH RES CO, V196, P301, DOI 10.1006/bbrc.1993.2249; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; REYNET C, 1990, MOL ENDOCRINOL, V4, P304, DOI 10.1210/mend-4-2-304; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIRAKABE K, 1992, J BIOL CHEM, V267, P16685; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUNG CK, 1989, J BIOL CHEM, V264, P18951; TAKATA Y, 1992, J BIOL CHEM, V267, P9065; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; ZHANG B, 1992, J BIOL CHEM, V267, P18320	54	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10604	10608						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144649				2022-12-25	WOS:A1994NF01700063
J	ZHANG, GH; MELVIN, JE				ZHANG, GH; MELVIN, JE			INTRACELLULAR MG2+ MOVEMENT DURING MUSCARINIC STIMULATION - MG2+ UPTAKE BY THE INTRACELLULAR CA2+ STORE IN RAT SUBLINGUAL MUCOUS ACINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE MAGNESIUM; CHICKEN HEART-CELLS; CALCIUM RELEASE; SARCOPLASMIC-RETICULUM; ELECTRON-PROBE; FLUORESCENT INDICATOR; PLASMA-MEMBRANE; CA-2+; SECRETION; CHANNELS	The muscarinic agonist carbachol produces a sustained elevation in the cytosolic free Mg2+ concentration ([Mg2+](i)) by mobilizing an intracellular Mg2+ pool in rat sublingual mucous acini (Zhang, G. H., and Melvin, J. E. (1992) J. Biol. Chem. 267, 20721-20727). In the present study, we investigated the relationship between the agonist-induced mobilization of the intracellular Ca2+ store and Mg2+ movement in acini loaded with the Ca2+-selective chelator bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA) by monitoring [Mg2+](i) using dual wavelength microfluorometry of the Mg2+-sensitive fluorescent indicator mag-fura-2. The resting [Mg2+](i) in BAPTA-loaded acini was comparable to unloaded acini (0.36 +/- 0.01 mM (n = 29) Dersus 0.35 +/- 0.01 mM (n = 119)). In contrast to the >40% sustained increase in [Mg2+](i) in unloaded acini, carbachol stimulation of BAPTA-loaded acini induced a rapid transient [Mg2+](i) decrease (similar to 30%), followed by a slower recovery to the prestimulated [Mg2+](i). in 3-4 min. Furthermore, in Ca2+-free medium or when Ca2+ influx was blocked with La3+ or Ni2+, carbachol induced a sustained decrease in [Mg2+](i) (similar to 40%). Reintroducing extracellular Ca2+ resulted in recovery of [Mg2+](i), even in the absence of extracellular Mg2+. 8-(Diethylamino)octyl 3,4,5-trimethoxybenzoate, an inhibitor of the inositol 1,4,5-trisphosphate-sensitive intracellular Ca2+ release pathway, completely blocked the carbachol-induced decrease in [Mg2+](i), whereas thapsigargin, a Ca2+-ATPase inhibitor that empties the inositol 1,4,5-trisphosphate-sensitive intracellular Ca2+ store, stimulated a decrease in [Mg2+](i). The thapsigargin-induced Mg2+ uptake was into the same intracellular pool as that activated by carbachol because stimulation with thapsigargin after carbachol did not induce a further decrease in [Mg2+](i). Taken together, these results strongly suggest that depletion of the inositol 1,4,5-trisphosphate-sensitive Ca2+ store activates Mg2+ uptake, most Likely to maintain charge balance of the intracellular Ca2+ pool.	UNIV ROCHESTER, DEPT DENT RES, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, DEPT NEUROBIOL & ANAT, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester					NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE007003, R37DE008921, R03DE010655] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE07003, DE08921, DE10655] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADAMS SR, 1989, J AM CHEM SOC, V111, P7957, DOI 10.1021/ja00202a042; AGUS ZS, 1989, AM J PHYSIOL, V256, pC452, DOI 10.1152/ajpcell.1989.256.2.C452; BAUMANN O, 1991, P NATL ACAD SCI USA, V88, P741, DOI 10.1073/pnas.88.3.741; DUCHATELLEGOURDON I, 1989, J PHYSIOL-LONDON, V415, P251, DOI 10.1113/jphysiol.1989.sp017721; FLATMAN PW, 1991, ANNU REV PHYSIOL, V53, P259, DOI 10.1146/annurev.ph.53.030191.001355; FOSKETT JK, 1989, SCIENCE, V244, P1582, DOI 10.1126/science.2500708; FREUDENRICH CC, 1992, AM J PHYSIOL, V262, pC1024, DOI 10.1152/ajpcell.1992.262.4.C1024; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYLFE E, 1990, BIOCHIM BIOPHYS ACTA, V1055, P82, DOI 10.1016/0167-4889(90)90094-T; HALLAM TJ, 1985, FEBS LETT, V186, P175, DOI 10.1016/0014-5793(85)80703-1; HARTZELL HC, 1989, J GEN PHYSIOL, V94, P745, DOI 10.1085/jgp.94.4.745; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; MAIRBAURL H, 1992, J GEN PHYSIOL, V99, P721, DOI 10.1085/jgp.99.5.721; MASON MJ, 1991, J BIOL CHEM, V266, P10872; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; MATSUKAWA R, 1990, ARCH BIOCHEM BIOPHYS, V280, P362, DOI 10.1016/0003-9861(90)90343-W; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MELVIN JE, 1991, AM J PHYSIOL, V261, pG1043, DOI 10.1152/ajpgi.1991.261.6.G1043; MERRITT JE, 1987, J BIOL CHEM, V262, P17362; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; MUALLEM S, 1988, AM J PHYSIOL, V255, pG221, DOI 10.1152/ajpgi.1988.255.2.G221; MURPHY E, 1989, P NATL ACAD SCI USA, V86, P2981, DOI 10.1073/pnas.86.8.2981; Parker J. C., 1989, American Journal of Physiology, V257, P1038; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; QUAMME GA, 1993, AM J PHYSIOL, V265, pH281, DOI 10.1152/ajpheart.1993.265.1.H281; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; ROMANI A, 1991, J BIOL CHEM, V266, P24376; ROMANI A, 1993, J BIOL CHEM, V268, P15489; ROMANI A, 1992, ARCH BIOCHEM BIOPHYS, V298, P1, DOI 10.1016/0003-9861(92)90086-C; ROTEVATN S, 1991, ACTA PHYSIOL SCAND, V142, P125; RUBBS RD, 1991, AM J PHYSIOL, V260, pC1158; SHUTTLEWORTH TJ, 1992, CELL CALCIUM, V13, P541, DOI 10.1016/0143-4160(92)90034-P; SOMLYO AV, 1985, J BIOL CHEM, V260, P6801; SOMLYO AV, 1981, J CELL BIOL, V90, P577, DOI 10.1083/jcb.90.3.577; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; ZHANG GH, 1993, AM J PHYSIOL, V264, pC54, DOI 10.1152/ajpcell.1993.264.1.C54; ZHANG GH, 1992, J BIOL CHEM, V267, P20721; ZHANG GH, 1992, J MEMBRANE BIOL, V129, P311; ZHANG GH, 1993, FEBS LETT, V327, P1, DOI 10.1016/0014-5793(93)81026-V	41	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10352	10356						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144616				2022-12-25	WOS:A1994NF01700028
J	KMIEC, EB; HOLLOMAN, WK				KMIEC, EB; HOLLOMAN, WK			DNA STRAND EXCHANGE IN THE ABSENCE OF HOMOLOGOUS PAIRING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER PROTEIN-ALPHA; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; RECA PROTEIN; BRANCH MIGRATION; PARTIAL-PURIFICATION; ELECTRON-MICROSCOPY; POLYMER-SOLUTIONS; HUMAN-CELLS; GENE	The strand exchange reaction that is widely used for in vitro studies on recombination of DNA molecules is generally presumed to result from a preceding homologous pairing step. With the use of a single-stranded circular DNA and a short homologous linear duplex fragment as substrates in a model strand exchange reaction, it was found that modest concentrations of polyethylene glycol or salt promote formation of heteroduplex molecules and strand exchange. When the duplex fragment was partially resected with an exonuclease exposing a short single-stranded stretch on the ends, the reaction was promoted by the addition of commercial bovine serum albumin. The transcription factor TFIIIA promoted strand exchange when the DNA substrates contained the cognate DNA binding sequence recognized by the protein. These observations suggest that detection of strand exchange in vitro does not necessarily imply a preceding homologous pairing step.	CORNELL UNIV,MED CTR,COLL MED,DEPT MICROBIOL,BOX 62,1300 YORK AVE,NEW YORK,NY 10021; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107	Cornell University; Jefferson University								ALBERTY RA, 1949, J PHYS COLLOID CHEM, V53, P114, DOI 10.1021/j150466a009; BAKER RT, 1992, CELL, V70, P877, DOI 10.1016/0092-8674(92)90238-8; BAZETTJONES DP, 1989, MOL CELL BIOL, V9, P336, DOI 10.1128/MCB.9.1.336; BOGENHAGEN DF, 1980, CELL, V19, P27, DOI 10.1016/0092-8674(80)90385-2; BORTNER C, 1993, J MOL BIOL, V231, P241, DOI 10.1006/jmbi.1993.1279; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTIANSEN C, 1977, J MOL BIOL, V115, P441, DOI 10.1016/0022-2836(77)90164-4; CLARK AB, 1991, MOL CELL BIOL, V11, P2576, DOI 10.1128/MCB.11.5.2576; COX MM, 1981, NUCLEIC ACIDS RES, V9, P389, DOI 10.1093/nar/9.2.389; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; CRAIG ME, 1971, J MOL BIOL, V62, P383, DOI 10.1016/0022-2836(71)90434-7; DONELSON JE, 1972, J BIOL CHEM, V247, P4661; DYKSTRA CC, 1991, MOL CELL BIOL, V11, P2583, DOI 10.1128/MCB.11.5.2583; EISEN A, 1988, P NATL ACAD SCI USA, V85, P7481, DOI 10.1073/pnas.85.20.7481; EVDOKIMOV YM, 1972, FEBS LETT, V23, P180, DOI 10.1016/0014-5793(72)80335-1; FISERLITTELL RM, 1988, J BIOL CHEM, V263, P17136; FISHEL RA, 1988, P NATL ACAD SCI USA, V85, P36, DOI 10.1073/pnas.85.1.36; GRALLA J, 1973, J MOL BIOL, V78, P301, DOI 10.1016/0022-2836(73)90118-6; HALBROOK J, 1989, J BIOL CHEM, V264, P21403; HAYES JJ, 1992, J MOL BIOL, V227, P407, DOI 10.1016/0022-2836(92)90897-S; HEYER WD, 1993, PROG NUCLEIC ACID RE, V46, P221, DOI 10.1016/S0079-6603(08)61023-5; HSIEH P, 1989, J BIOL CHEM, V264, P5089; HSIEH P, 1986, CELL, V44, P885, DOI 10.1016/0092-8674(86)90011-5; JENSEN DE, 1976, J BIOL CHEM, V251, P7198; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; JORDAN CF, 1972, NATURE-NEW BIOL, V236, P67, DOI 10.1038/newbio236067a0; KIM JM, 1990, GENETICS, V126, P799; KIPLING D, 1991, NUCLEIC ACIDS RES, V19, P1385, DOI 10.1093/nar/19.7.1385; KIPLING D, 1991, NATURE, V353, P509, DOI 10.1038/353509a0; KMIEC E, 1982, CELL, V29, P367, DOI 10.1016/0092-8674(82)90153-2; KMIEC EB, 1983, CELL, V33, P857, DOI 10.1016/0092-8674(83)90028-4; KMIEC EB, 1983, CELL, V34, P919, DOI 10.1016/0092-8674(83)90549-4; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; KOLODNER RD, 1992, MECHANISMS EUKARYOTI, P127; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LAEMMLI UK, 1975, P NATL ACAD SCI USA, V72, P4288, DOI 10.1073/pnas.72.11.4288; LARIMER FW, 1990, GENE, V95, P85, DOI 10.1016/0378-1119(90)90417-P; LEE CS, 1970, J MOL BIOL, V48, P1, DOI 10.1016/0022-2836(70)90215-9; LERMAN LS, 1971, P NATL ACAD SCI USA, V68, P1886, DOI 10.1073/pnas.68.8.1886; MCCARTHY JG, 1988, P NATL ACAD SCI USA, V85, P5854, DOI 10.1073/pnas.85.16.5854; MCGHEE JD, 1977, BIOCHEMISTRY-US, V16, P3276, DOI 10.1021/bi00634a002; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MINTON AP, 1981, BIOPOLYMERS, V20, P2093, DOI 10.1002/bip.1981.360201006; MOORE SP, 1990, J BIOL CHEM, V265, P11108; POINTIUS BW, 1991, P NATL ACAD SCI USA, V88, P8237; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; PORSCHKE D, 1971, J MOL BIOL, V62, P361, DOI 10.1016/0022-2836(71)90433-5; QUARTIN RS, 1989, BIOCHEMISTRY-US, V28, P8676, DOI 10.1021/bi00448a002; RADDING CM, 1977, J MOL BIOL, V116, P825, DOI 10.1016/0022-2836(77)90273-X; RADDING CM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P131, DOI 10.1016/0167-4781(80)90001-9; RAVZI E, 1983, GENE AMST, V23, P175; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROSS PD, 1962, J AM CHEM SOC, V84, P4503, DOI 10.1021/ja00882a026; SANDER M, 1991, NUCLEIC ACIDS RES, V19, P4523, DOI 10.1093/nar/19.16.4523; SCHROTH GP, 1989, NATURE, V340, P487, DOI 10.1038/340487a0; SIKORAV JL, 1991, J MOL BIOL, V222, P1085, DOI 10.1016/0022-2836(91)90595-W; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; STEVENS A, 1980, J BIOL CHEM, V255, P3080; SUGINO A, 1988, P NATL ACAD SCI USA, V85, P3683, DOI 10.1073/pnas.85.11.3683; TISHKOFF DX, 1991, MOL CELL BIOL, V11, P2593, DOI 10.1128/MCB.11.5.2593; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WETMUR JG, 1968, J MOL BIOL, V31, P349, DOI 10.1016/0022-2836(68)90414-2; WETMUR JG, 1975, BIOPOLYMERS, V14, P2517, DOI 10.1002/bip.1975.360141208; WETMUR JG, 1991, CRIT REV BIOCHEM MOL, V26, P227, DOI 10.3109/10409239109114069; ZHANG WD, 1993, J VIROL, V67, P204, DOI 10.1128/JVI.67.1.204-212.1993	65	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					10163	10168						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144518				2022-12-25	WOS:A1994NE05300114
J	FAIRCHILD, CD; GLAZER, AN				FAIRCHILD, CD; GLAZER, AN			OLIGOMERIC STRUCTURE, ENZYME-KINETICS, AND SUBSTRATE-SPECIFICITY OF THE PHYCOCYANIN ALPHA-SUBUNIT PHYCOCYANOBILIN LYASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIVERDIN-IX-ALPHA; INVITRO ATTACHMENT; BILIN ATTACHMENT; C-PHYCOCYANIN; APOPHYCOCYANIN; PURIFICATION; ADDUCT; PHYCOERYTHROBILIN; PHYCOBILIPROTEINS; IDENTIFICATION	Phycobiliproteins carry linear tetrapyrrole chromophores (bilins) thioether linked to specific cysteine residues. The process of bilin attachment to apoprotein in vivo has been characterized for only one bilin attachment site on one phycobiliprotein, that on the alpha subunit of phycocyanin (alpha(PC)). In the cyanobacterium Synechococcus sp. PCC 7002, the addition of phycocyanobilin to apo-alpha(PC) is catalyzed by the protein products of the cpcE and cpcF genes. We have purified and further characterized the recombinant CpcE and CpcF proteins. CpcE and CpcF form an enzymatically active 1:1 complex (Cp -cEF), stable to size exclusion chromatography CpcEF causes a reduction in alpha(PC) fluorescence and strongly affects its absorption spectrum but has no effect on the beta subunit. The CpcEF bilin addition activity exhibits simple Michaelis-Menten kinetics with respect to the apo-alpha(PC) and to bilin. CpcEF also catalyzes the addition of phycoerythrobilin to apo-alpha(PC); phycoerythrobilin is thought to be on the biosynthetic pathway of phycocyanobilin. CpcEF shows a preference for phycocyanobilin relative to phycoerythrobilin, both in binding affinity and in the rate of catalysis, sufficient to account for selective attachment of phycocyanobilin to apo-alpha(PC).	UNIV CALIF BERKELEY, DEPT MOLEC & CELLULAR BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028994] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28994] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], [No title captured]; ARCIERO DM, 1988, J BIOL CHEM, V263, P18343; ARCIERO DM, 1988, J BIOL CHEM, V263, P18358; ARCIERO DM, 1988, J BIOL CHEM, V263, P18350; BEALE SI, 1991, J BIOL CHEM, V266, P22333; BEALE SI, 1991, J BIOL CHEM, V266, P22341; BRASLAVSKY SE, 1991, J AM CHEM SOC, V113, P7322, DOI 10.1021/ja00019a033; CHAPMAN DJ, 1967, J AM CHEM SOC, V89, P5976, DOI 10.1021/ja00999a058; Cohen-Bazire G., 1982, BIOL CYANOBACTERIA, P143; COLE WJ, 1967, J AM CHEM SOC, V89, P3643, DOI 10.1021/ja00990a055; DICERA E, 1992, METHOD ENZYMOL, V210, P68; FAIRCHILD CD, 1992, P NATL ACAD SCI USA, V89, P7017, DOI 10.1073/pnas.89.15.7017; FU E, 1979, BIOCHEM J, V179, P1; GARDNER EE, 1980, BIOCHIM BIOPHYS ACTA, V624, P187; GLAZER AN, 1989, J BIOL CHEM, V264, P1; GLAZER AN, 1973, J BIOL CHEM, V248, P659; HOLZWARTH AR, 1978, LIEBIGS ANN CHEM, P2002; KLOTZ AV, 1985, J BIOL CHEM, V260, P4856; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCHINS J, 1978, SCIENCE, V199, P425, DOI 10.1126/science.619462; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; SCHIRMER T, 1987, J MOL BIOL, V196, P677, DOI 10.1016/0022-2836(87)90040-4; SWANSON RV, 1992, J BIOL CHEM, V267, P16146; SWANSON RV, 1990, ANAL BIOCHEM, V188, P295, DOI 10.1016/0003-2697(90)90609-D; WILBANKS SM, 1993, J BIOL CHEM, V268, P1226; ZHOU JH, 1992, J BIOL CHEM, V267, P16138	27	95	102	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8686	8694						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132596				2022-12-25	WOS:A1994NB41100013
J	BERLINER, E; MAHTANI, HK; KARKI, S; CHU, LF; CRONAN, JE; GELLES, J				BERLINER, E; MAHTANI, HK; KARKI, S; CHU, LF; CRONAN, JE; GELLES, J			MICROTUBULE MOVEMENT BY A BIOTINATED KINESIN BOUND TO A STREPTAVIDIN-COATED SURFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUID GIANT-AXON; DROSOPHILA KINESIN; EXPRESSION SYSTEM; LIGHT-MICROSCOPY; HEAVY-CHAIN; PROTEIN; MOLECULES; MOTILITY; ATPASE; IDENTIFICATION	Kinesin, an ATP-dependent microtubule motor, can be studied in vitro in motility assays where the kinesin is nonspecifically adsorbed to a surface. However, adsorption can inactivate kinesin and may alter its reaction kinetics. We therefore prepared a biotinated kinesin derivative, K612-BIO, and characterized its activity in solution and when bound to streptavidin-coated surfaces. K612-BIO consists of the N-terminal 612 amino acids of the Drosophila kinesin alpha subunit linked to the 87-amino acid C-terminal domain of the biotin carboxyl carrier protein subunit of Escherichia coli acetyl-CoA carboxylase. The C-terminal domain directs the efficient posttranslational biotination of the protein. We expressed K612-BIO at high levels using the baculovirus expression vector system and purified it to near-homogeneity. The expressed protein is completely soluble, and >90% is bound by streptavidin. K612-BIO steady-state ATPase kinetics (K-M,K-ATP = 24 mu M, K-0.5,K-microtubule = 0.61 mg ml(-1),V-max = similar to 25 s(-1) head(-1), 25 degrees C) are similar to those reported for intact kinesin. ATPase kinetics are not affected by the addition of streptavidin. Enzyme bound to a surface coated with streptavidin drove microtubule gliding in the presence of 2 mM ATP at 750 +/- 130 nm s(-1) (26 degrees C). Activity was abolished by pretreatment of the surface with biotin, indicating that the microtubule movements are due to specifically bound enzyme. Motility assays based on specific attachment of biotinated enzyme to streptavidin coated surfaces will be useful for quantitative analysis of kinesin motility and may provide a way to detect activity in kinesin derivatives or kinesin-like proteins that have not yet been shown to move microtubules.	BRANDEIS UNIV, GRAD DEPT BIOCHEM, WALTHAM, MA 02254 USA; BRANDEIS UNIV, BIOPHYS PROGRAM, WALTHAM, MA 02254 USA; BRANDEIS UNIV, CTR COMPLEX SYST, WALTHAM, MA 02254 USA; UNIV ILLINOIS, DEPT MICROBIOL, URBANA, IL 61801 USA; UNIV ILLINOIS, DEPT BIOCHEM, URBANA, IL 61801 USA	Brandeis University; Brandeis University; Brandeis University; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			Cronan, John/V-6626-2019; Chu, Larry/B-5324-2008	Chu, Larry/0000-0003-0814-6402				ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; ALLEN RD, 1982, SCIENCE, V218, P1127, DOI 10.1126/science.6183744; AMARATUNGA A, 1993, J BIOL CHEM, V268, P17427; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DECUEVAS M, 1992, J CELL BIOL, V116, P957, DOI 10.1083/jcb.116.4.957; FALL RR, 1973, J BIOL CHEM, V248, P2078; FASMAN GD, 1976, HDB BIOCH MOL BIOL; FRANKEL S, 1991, P NATL ACAD SCI USA, V88, P1192, DOI 10.1073/pnas.88.4.1192; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GILBERT S P, 1990, Journal of Cell Biology, V111, p416A; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; GREEN NM, 1965, BIOCHEM J, V94, pC23, DOI 10.1042/bj0940023C; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HACKNEY DD, 1991, BIOCHEM BIOPH RES CO, V174, P810, DOI 10.1016/0006-291X(91)91490-4; HALL K, 1993, NATURE, V364, P457, DOI 10.1038/364457a0; HINK WF, 1970, NATURE, V226, P466, DOI 10.1038/226466b0; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUNT A, 1993, BIOPHYS J, V64, pA263; KACHAR B, 1987, J BIOL CHEM, V262, P16180; KUO SC, 1993, SCIENCE, V260, P232, DOI 10.1126/science.8469975; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SJ, 1992, J BIOL CHEM, V267, P855; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; NA GC, 1980, BIOCHEMISTRY-US, V19, P1347, DOI 10.1021/bi00548a013; NERVI AM, 1971, ARCH BIOCHEM BIOPHYS, V143, P401, DOI 10.1016/0003-9861(71)90227-X; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; Sambrook J, 1989, MOL CLONING LABORATO; SARVARI M, 1990, BIOCHEM BIOPH RES CO, V167, P1154, DOI 10.1016/0006-291X(90)90644-3; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; SCHNAPP B J, 1991, Biophysical Journal, V59, p567A; SCHNAPP BJ, 1986, METHOD ENZYMOL, V134, P561; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; Summers MD, 1987, MANUAL METHODS BACUL; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V40, P559, DOI 10.1016/0092-8674(85)90204-1; WAGNER MC, 1989, CELL MOTIL CYTOSKEL, V12, P195, DOI 10.1002/cm.970120403; WEISENBERG RC, 1968, BIOCHEMISTRY-US, V7, P4466, DOI 10.1021/bi00852a043; WILCHEK M, 1988, ANAL BIOCHEM, V171, P1, DOI 10.1016/0003-2697(88)90120-0; YANG JT, 1988, P NATL ACAD SCI USA, V85, P1864, DOI 10.1073/pnas.85.6.1864; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	52	64	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8610	8615						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132586				2022-12-25	WOS:A1994NB40900116
J	LI, BY; ADAMS, CC; WORKMAN, JL				LI, BY; ADAMS, CC; WORKMAN, JL			NUCLEOSOME BINDING BY THE CONSTITUTIVE TRANSCRIPTION FACTOR SP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; SIMIAN VIRUS-40 ENHANCER; POSITIONED NUCLEOSOMES; HYPERSENSITIVE SITES; CHROMATIN TEMPLATES; ACTIVATION DOMAINS; PROMOTER ELEMENTS; DNA-REPLICATION; MMTV PROMOTER; INVITRO	The constitutive transcription factor Sp1 plays a role in the transcription of numerous viral and cellular genes including constitutive ''housekeeping'' genes and inducible genes. Sp1 has also been implicated in the formation of a nucleosome free region in Simian virus 40 (SV40) minichromosomes. To investigate the potential functions of Sp1 in remodeling chromatin structures, Sp1 was analyzed for the ability to bind its recognition sites (GC boxes) in DNA fragments reconstituted into nucleosome cores. Sp1 was found to bind to the GC boxes of the SV40 early promoter when this element was reconstituted into nucleosome cores. The affinity of Sp1 for the nucleosomal SV40 early promoter DNA was reduced approximately 10-20-fold relative to naked DNA. A peptide containing only the zinc fingers of Sp1 was also capable of binding nucleosomal DNA, indicating that the glutamine rich and serine/threonine-rich domains of Sp1 are not required for nucleosome binding. The binding of Sp1 to nucleosome cores resulted in the formation of a ternary Sp1-nucleosome complex.	PENN STATE UNIV,ALTHOUSE LAB 301,DEPT BIOCHEM & MOLEC BIOL,UNIV PK,PA 16802; PENN STATE UNIV,CTR GENE REGULAT,UNIV PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015861, R01GM047867, R37GM047867] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM15861, GM47867] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; AMBROSE C, 1990, J MOL BIOL, V214, P875, DOI 10.1016/0022-2836(90)90342-J; AMBROSE C, 1989, J MOL BIOL, V210, P255, DOI 10.1016/0022-2836(89)90328-8; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BATSON SC, 1993, NUCLEIC ACIDS RES, V21, P3459; BATSON SC, 1992, MOL CELL BIOL, V12, P1639, DOI 10.1128/MCB.12.4.1639; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; BUCHANAN RL, 1987, MOL CELL BIOL, V7, P1554, DOI 10.1128/MCB.7.4.1554; CARR KD, 1990, P NATL ACAD SCI USA, V87, P9300, DOI 10.1073/pnas.87.23.9300; CHEN H, 1994, IN PRESS EMBO J; CLARKE MF, 1985, J BIOL CHEM, V260, P2394; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JONGSTRA J, 1984, NATURE, V307, P708, DOI 10.1038/307708a0; JUAN L, 1994, IN PRESS COLD SPRING, V58; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LI Q, 1993, GENE DEV, V7, P2471, DOI 10.1101/gad.7.12a.2471; LORCH Y, 1992, GENE DEV, V6, P2282, DOI 10.1101/gad.6.12a.2282; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PERLMANN T, 1992, P NATL ACAD SCI USA, V89, P3884, DOI 10.1073/pnas.89.9.3884; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RHODES D, 1985, EMBO J, V4, P3473, DOI 10.1002/j.1460-2075.1985.tb04106.x; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; SOLOMON MJ, 1987, MOL CELL BIOL, V7, P3822, DOI 10.1128/MCB.7.10.3822; STEIN A, 1987, J BIOL CHEM, V262, P3872; SVAREN J, 1993, CURR OPIN GENET DEV, V3, P219, DOI 10.1016/0959-437X(93)90026-L; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; WOLFFE AP, 1991, J CELL SCI, V99, P201; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613	47	84	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7756	7763						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8126002				2022-12-25	WOS:A1994NA03200111
J	BENYA, RV; KUSUI, T; SHIKADO, F; BATTEY, JF; JENSEN, RT				BENYA, RV; KUSUI, T; SHIKADO, F; BATTEY, JF; JENSEN, RT			DESENSITIZATION OF NEUROMEDIN-B RECEPTORS (NMB-R) ON NATIVE AND NMB-R-TRANSFECTED CELLS INVOLVES DOWN-REGULATION AND INTERNALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOMBESIN-LIKE PEPTIDES; PANCREATIC ACINAR-CELLS; EPIDERMAL GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; PROTEIN-KINASE-C; SWISS 3T3 CELLS; PHOSPHOINOSITIDE HYDROLYSIS; GASTROINTESTINAL-TRACT; INOSITOL PHOSPHATES; LIGAND-BINDING	The receptor for neuromedin B (NMB-R), a mammalian bombesin-related peptide, is widely distributed in the central nervous system and gastrointestinal tract. While it is known that this receptor is coupled to phospholipase C, like many other phospholipase C-activating receptors, little is known about regulation of the NMB-R subsequent to agonist stimulation. We studied both native NMB-R on C-6 rat glioblastoma cells and wild type NMB-R cloned from rat esophageal muscle which was stably transfected into Balb/3T3 fibroblasts. Both cell types rapidly increased [H-3]inositol phosphates and [Ca2+](i) in response to 1 mu M NMB, whereas preincubation with 3 nM NMB for 3 h markedly attenuated the ability of 1 mu M NMB, but not 1 mu M endothelin-1, to alter either cell type's biological activity. Prolonged exposure to 3 nM NMB caused a rapid decrease in the number of NMB-R, with the maximal receptor down-regulation seen at 24 h due to NMB-R internalization. After maximal downregulation, removal of agonist resulted in a rapid restoration of NMB-R to the cell surface of both cell types. NMB-R recovery at 6 h was blocked by monensin, an inhibitor of receptor recycling, but was not affected by cycloheximide, a protein synthesis inhibitor. Resensitization to agonist paralleled the recovery of MMB-R in both cell types, and resensitization likewise was blocked by monensin. Our data demonstrate that the NMB-R undergoes rapid homologous desensitization consequent to agonist stimulation, which is mediated by receptor down-regulation and which, in turn, is regulated by internalization. During resensitization, NMB-R reappearance on the cell surface membrane is independent of protein synthesis and is due to a recycling from an intracellular site.	NCI, BIOL CHEM LAB, DEV THERAPEUT PROGRAM, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	BENYA, RV (corresponding author), NIDDKD, DIGEST DIS BRANCH, BETHESDA, MD 20892 USA.							ALBERS HE, 1991, J NEUROSCI, V11, P846; ASSELIN J, 1987, AM J PHYSIOL, V252, pG392, DOI 10.1152/ajpgi.1987.252.3.G392; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BATTEY J, 1991, TRENDS NEUROSCI, V14, P524, DOI 10.1016/0166-2236(91)90005-F; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BENYA RV, 1992, MOL PHARMACOL, V42, P1058; BENYA RV, 1993, GASTROENTEROLOGY, V104, pA812; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BOLOGNA M, 1989, CANCER, V63, P1714; BROWN KD, 1988, BIOCHEM J, V252, P227, DOI 10.1042/bj2520227; BROWN MR, 1988, ANN NY ACAD SCI, V547, P174, DOI 10.1111/j.1749-6632.1988.tb23885.x; CARPENTIER JL, 1984, J BIOL CHEM, V259, P4190; CHAU LY, 1991, LIPIDS, V26, P1076, DOI 10.1007/BF02536505; COLLINS S, 1990, BIOCHEM SOC T, V18, P541, DOI 10.1042/bst0180541; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; ERSPAMER GF, 1988, REGUL PEPTIDES, V21, P1; GHATEI MA, 1982, J CLIN ENDOCR METAB, V54, P980, DOI 10.1210/jcem-54-5-980; GLADHAUG IP, 1988, J BIOL CHEM, V263, P12199; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HOOTMAN SR, 1991, AM J PHYSIOL, V261, pG128, DOI 10.1152/ajpgi.1991.261.1.G128; HU JR, 1991, J PHARMACOL EXP THER, V257, P938; JENSEN RT, 1988, ANN NY ACAD SCI, V547, P138, DOI 10.1111/j.1749-6632.1988.tb23882.x; KANETO A, 1978, METABOLISM, V27, P549, DOI 10.1016/0026-0495(78)90021-5; KLEIN WL, 1979, BIOCHEM BIOPH RES CO, V90, P506, DOI 10.1016/0006-291X(79)91264-6; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LADENHEIM EE, 1990, BRAIN RES, V537, P233, DOI 10.1016/0006-8993(90)90363-G; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROSE L, 1983, EUR J PHARMACOL, V95, P215, DOI 10.1016/0014-2999(83)90637-4; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; MANTEY S, 1993, MOL PHARMACOL, V43, P762; MASTERS SB, 1985, MOL PHARMACOL, V27, P325; MENOZZI D, 1991, J BIOL CHEM, V266, P10385; MILLAR JBA, 1990, J BIOL CHEM, V265, P12052; MORAN TH, 1988, PEPTIDES, V9, P643, DOI 10.1016/0196-9781(88)90177-5; MORRISON WJ, 1988, MOL PHARMACOL, V33, P58; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAHATA N, 1987, BIOCHEM J, V241, P337, DOI 10.1042/bj2410337; PANDOL SJ, 1982, J BIOL CHEM, V257, P2024; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; RETTORI V, 1992, P NATL ACAD SCI USA, V89, P3035, DOI 10.1073/pnas.89.7.3035; ROWLEY WH, 1990, AM J PHYSIOL, V259, pG655, DOI 10.1152/ajpgi.1990.259.4.G655; ROZENGURT E, 1988, ANN NY ACAD SCI, V547, P277, DOI 10.1111/j.1749-6632.1988.tb23896.x; SCHWARTZ AL, 1984, J CELL BIOL, V98, P732, DOI 10.1083/jcb.98.2.732; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; STEIN BS, 1984, J BIOL CHEM, V259, P4762; SUGIYA H, 1987, BIOCHEM J, V244, P647, DOI 10.1042/bj2440647; SWOPE SL, 1990, MOL PHARMACOL, V37, P758; SWOPE SL, 1987, BIOCHEM J, V247, P731, DOI 10.1042/bj2470731; TACHE Y, 1988, ANN NY ACAD SCI, V547, P183, DOI 10.1111/j.1749-6632.1988.tb23886.x; TAYLOR JE, 1979, LIFE SCI, V25, P2181, DOI 10.1016/0024-3205(79)90090-0; THOMPSON AK, 1990, J PHARMACOL EXP THER, V252, P744; VIGNA SR, 1987, GASTROENTEROLOGY, V93, P1287, DOI 10.1016/0016-5085(87)90257-5; VINAYEK R, 1990, DIGESTION, V46, P112, DOI 10.1159/000200374; VINAYEK R, 1990, AM J PHYSIOL, V258, pG107, DOI 10.1152/ajpgi.1990.258.1.G107; VONSCHRENCK T, 1989, AM J PHYSIOL, V256, pG747, DOI 10.1152/ajpgi.1989.256.4.G747; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4; WANG LH, 1993, BIOCHIM BIOPHYS ACTA, V1175, P232, DOI 10.1016/0167-4889(93)90028-N; WANG LH, 1992, BIOCHEM J, V286, P641, DOI 10.1042/bj2860641; ZACHARY I, 1987, EMBO J, V6, P2233, DOI 10.1002/j.1460-2075.1987.tb02495.x; ZHU WY, 1991, AM J PHYSIOL, V261, pG57, DOI 10.1152/ajpgi.1991.261.1.G57	65	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11721	11728						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163469				2022-12-25	WOS:A1994NG37700011
J	GOROSPE, M; BAGLIONI, C				GOROSPE, M; BAGLIONI, C			DEGRADATION OF UNSTABLE INTERLEUKIN-1-ALPHA MESSENGER-RNA IN A RABBIT RETICULOCYTE CELL-FREE SYSTEM - LOCALIZATION OF AN INSTABILITY DETERMINANT TO A CLUSTER OF AUUUA MOTIFS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; URIDINE BINDING-FACTOR; RICH SEQUENCES; C-FOS; REGION; IDENTIFICATION; LYMPHOKINE; REMOVAL; PROTEIN; POLY(A)	Labeled transcripts of interleukin-1 alpha (IL-1 alpha) cDNA were rapidly degraded in incubations with rabbit reticulocyte lysate (RRL). In contrast, a transcript of superoxide dismutase cDNA was stable in control incubations. A transcript of the 3'-untranslated region (UTR) of IL-1 alpha was rapidly degraded while that of the 5'-UTR and coding region was stable. This degradative activity was present in the post-ribosomal supernatant. Degradation of the 3'-UTR transcript was inhibited by the addition of a large excess of an 80-base RNA containing four AUUUA repeats, but not by the same RNA without such repeats. This suggested that AUUUA motifs were responsible for the instability of the 3'-UTR transcript. The 80-base RNA did not act as a competitive substrate for a nuclease since it was not degraded. Partial transcripts of IL-1 alpha 3'-UTR were incubated with RRL to localize instability determinants. Transcripts containing at least three clustered AUUUA motifs were rapidly degraded, while transcripts containing four scattered AUUUA motifs were stable. To study the mechanism of RNA degradation, the RRL was passed through an affinity column that retained AUUUA-binding proteins. The flow-through or the fraction eluted from such a column were inactive, but the two fractions together degraded the 3'-UTR transcript. This indicated that proteins bound by the affinity column did not have nuclease activity but targeted this RNA for degradation.	SUNY ALBANY,DEPT BIOL SCI,ALBANY,NY 12222	State University of New York (SUNY) System; State University of New York (SUNY) Albany					NATIONAL CANCER INSTITUTE [R01CA029895] Funding Source: NIH RePORTER; NCI NIH HHS [CA-29895] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATWATER JA, 1990, ANNU REV GENET, V24, P519; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GOROSPE M, 1993, J BIOL CHEM, V268, P6214; GUBLER U, 1986, J IMMUNOL, V136, P2492; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HEPLER JE, 1990, ENDOCRINOLOGY, V127, P1550, DOI 10.1210/endo-127-3-1550; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MELENDEZ JA, 1993, FREE RADICAL BIO MED, V14, P601, DOI 10.1016/0891-5849(93)90141-G; RAYMOND V, 1989, ONCOGENE RES, V5, P1; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; WEBER LA, 1978, METHODS ENZYMOLOGY N, P351; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WRESCHNER DH, 1988, EUR J BIOCHEM, V172, P333, DOI 10.1111/j.1432-1033.1988.tb13891.x	24	38	38	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11845	11851						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163483				2022-12-25	WOS:A1994NG37700029
J	JENKINS, GH; FISETTE, PL; ANDERSON, RA				JENKINS, GH; FISETTE, PL; ANDERSON, RA			TYPE-I PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE ISOFORMS ARE SPECIFICALLY STIMULATED BY PHOSPHATIDIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PHOSPHOLIPASE-D; GROWTH-FACTOR; POLYACRYLAMIDE GELS; RAT-BRAIN; KINASE; PURIFICATION; MEMBRANES; PROTEINS; DIACYLGLYCEROL	A phosphatidylinositol 4-phosphate (PIP) kinase was isolated and purified to near homogeneity from bovine erythrocyte membranes. The PIP kinase was extracted from bovine erythrocyte membranes with a high salt wash, followed by phosphocellulose and phenyl-Sepharose chromatography. The predominant protein after phenyl-Sepharose purification had a molecular size of 68 kDa. Renaturation of PIP kinase activity after SDS-PAGE showed that a 68-kDa protein was able to phosphorylate PIP. An antibody developed against the 68-kDa protein Western blots the 68-kDa protein and is able to immunoprecipitate the 68-kDa protein and PIP kinase activity from membrane extracts. Based on functional studies, the 68-kDa protein is indistinguishable from the type I PIP kinase previously characterized from human erythrocyte membranes (Bazenet, C. E., Ruano, A. R., Brockman, J. L., and Anderson, R. A. (1990) J. Biol. Chem. 265,18012-18022). These studies also show that the type I PIP kinases, but not the type II PIP kinase, are stimulated by phosphatidic acid, suggesting alternative roles for these enzymes. Two immunoreactive isoforms of the type I PIP kinase, of 68 and 90 kDa, were identified in rat brain and partially purified. Both of these isoforms are also stimulated by phosphatidic acid.	UNIV WISCONSIN,SCH MED,DEPT PHARMACOL,1300 UNIV AVE,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,CELL & MOLEC BIOL PROGRAM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Anderson, Richard/0000-0001-6265-8359	NIGMS NIH HHS [GM38906] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038906, R29GM038906] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11156; COCCO L, 1987, BIOCHEM J, V248, P765, DOI 10.1042/bj2480765; COCHET C, 1991, J BIOL CHEM, V266, P637; COCHET C, 1986, BIOCHEM J, V237, P25, DOI 10.1042/bj2370025; DIVECHA N, 1993, BIOCHEM J, V289, P617, DOI 10.1042/bj2890617; DIVECHA N, 1992, BIOCHEM J, V288, P637, DOI 10.1042/bj2880637; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JACKOWSKI S, 1989, ARCH BIOCHEM BIOPHYS, V268, P516, DOI 10.1016/0003-9861(89)90318-4; JENKINS GH, 1991, BIOCHIM BIOPHYS ACTA, V1080, P11, DOI 10.1016/0167-4838(91)90105-9; JONES GA, 1993, J BIOL CHEM, V268, P20845; KONDO T, 1992, J BIOL CHEM, V267, P23609; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING LE, 1989, J BIOL CHEM, V264, P5080; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MORITZ A, 1990, J NEUROCHEM, V54, P351, DOI 10.1111/j.1471-4159.1990.tb13322.x; MORITZ A, 1992, J BIOL CHEM, V267, P7207; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; SMITH CD, 1992, BIOCHEM J, V281, P803, DOI 10.1042/bj2810803; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URUMOW T, 1990, BIOCHIM BIOPHYS ACTA, V1052, P152, DOI 10.1016/0167-4889(90)90070-T; URUMOW T, 1986, FEBS LETT, V207, P253, DOI 10.1016/0014-5793(86)81499-5; VANDONGEN CJ, 1984, BIOCHEM J, V223, P197, DOI 10.1042/bj2230197	33	374	380	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11547	11554						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157686				2022-12-25	WOS:A1994NF96600085
J	TARTARE, S; MOTHE, I; KOWALSKICHAUVEL, A; BREITTMAYER, JP; BALLOTTI, R; VANOBBERGHEN, E				TARTARE, S; MOTHE, I; KOWALSKICHAUVEL, A; BREITTMAYER, JP; BALLOTTI, R; VANOBBERGHEN, E			SIGNAL-TRANSDUCTION BY A CHIMERIC INSULIN-LIKE GROWTH-FACTOR-I (IGF-1) RECEPTOR HAVING THE CARBOXYL-TERMINAL DOMAIN OF THE INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; FACTOR-I; PHOSPHATIDYLINOSITOL 3'-KINASE; MOLECULAR MECHANISM; INTACT-CELLS; PROTEIN; BINDING; IRS-1; PHOSPHORYLATION; STIMULATION	Insulin-like growth factor-1 receptors (IGF-1R) and insulin receptors (IR) are closely related tyrosine kinases. However, the IR plays a major role in metabolism control, whereas the IGF-1R is mainly involved in growth and differentiation. With these observations in mind, we wished to define the regions of IR and IGF-1R responsible for generation of biological specificity. We constructed a chimeric IGF-1R in which the carboxyl-terminal domain was replaced by that of IR. This receptor (IGF/(CT)IR) was expressed in NIH3T3 cells, and we compared its biological activity with that of wild-type receptors. The IGF/(CT)IR was fully functional regarding kinase activity and biological properties. Comparison of insulin and IGF-1 effects on IR and IGF-1R cells, respectively, indicated that the IR is more efficient in stimulating glycogen synthesis and p44mapk activity than is the IGF-1R. Interestingly, in IGF/(CT)IR16 cells expressing only 250,000 receptors glycogen synthesis was better stimulated than in IGF-1R cells with 600,000 receptors. Similarly, p44mapk activation was slightly higher in IGF/(CT)IR16 cells than in IGF-1R cells. These results suggest that the carboxyl-terminal domain of IR is more tightly coupled to the stimulation of glycogen synthesis and to the p44mapk pathway than is that of IGF-1R. We propose that this domain plays a crucial role in the transmission of biological effects and could account, at least in part, for receptor specificity.	FAC MED NICE,INSERM,U145,AVE VALOMBROSE,F-06107 NICE 2,FRANCE; FAC MED NICE,INSERM,U343,F-06107 NICE 2,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur			Kowalski-Chauvel, Aline/O-9212-2014; BALLOTTI, Robert/F-8825-2013; TARTARE-DECKERT, Sophie/P-6057-2015; MOTHE-SATNEY, ISABELLE/Q-6377-2016	TARTARE-DECKERT, Sophie/0000-0001-8680-5720; BALLOTTI, Robert/0000-0002-7322-4908; MOTHE-SATNEY, ISABELLE/0000-0002-2693-8385				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALLOTTI R, 1991, EXP CELL RES, V197, P300, DOI 10.1016/0014-4827(91)90436-X; BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; BOULTON TG, 1990, J BIOL CHEM, V265, P2713; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOU CK, 1987, J BIOL CHEM, V262, P1842; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FLIER JS, 1986, P NATL ACAD SCI USA, V83, P664, DOI 10.1073/pnas.83.3.664; FREYCHET P, 1971, P NATL ACAD SCI USA, V68, P1833, DOI 10.1073/pnas.68.8.1833; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GIORGETTI S, 1992, EUR J BIOCHEM, V207, P599; GOTTSCHALK WK, 1992, BIOCHEM BIOPH RES CO, V189, P906; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; IZUMI T, 1987, J BIOL CHEM, V262, P1282; KAHN CR, 1985, ANNU REV MED, V36, P429; KATO H, 1993, J BIOL CHEM, V268, P2655; KHUNE MR, 1993, J BIOL CHEM, V268, P11479; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MAMOUNAS M, 1989, P NATL ACAD SCI USA, V86, P9294, DOI 10.1073/pnas.86.23.9294; MASSAGUE J, 1982, J BIOL CHEM, V257, P3958; MOTHE I, 1993, MOL BIOL CELL, V4, P737, DOI 10.1091/mbc.4.7.737; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; POGGI C, 1979, ENDOCRINOLOGY, V105, P723, DOI 10.1210/endo-105-3-723; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; SAHAL D, 1988, ARCH BIOCHEM BIOPHYS, V260, P416, DOI 10.1016/0003-9861(88)90465-1; SASAKI N, 1985, J BIOL CHEM, V260, P9793; SCIMECA JC, 1991, BIOCHEMISTRY-US, V30, P913; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SOSS MA, 1992, J BIOL CHEM, V267, P12955; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANOBBERGHEN E, 1981, P NATL ACAD SCI-BIOL, V78, P1052; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	44	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11449	11455						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157675				2022-12-25	WOS:A1994NF96600070
J	POWELL, LD; VARKI, A				POWELL, LD; VARKI, A			THE OLIGOSACCHARIDE BINDING SPECIFICITIES OF CD22-BETA, A SIALIC ACID-SPECIFIC LECTIN OF B-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-MUCUS GLYCOPROTEINS; BOMBARDMENT MASS-SPECTROMETRY; 500-MHZ H-1-NMR SPECTROSCOPY; QUANTITATIVE SUGAR ANALYSIS; SIALYLATED OLIGOSACCHARIDES; LINKED OLIGOSACCHARIDES; AFFINITY-CHROMATOGRAPHY; BOVINE COLOSTRUM; T-CELLS; ANTIGEN	CD22 beta is a B cell surface glycoprotein involved in cell adhesion and activation, We previously reported that a recombinant soluble form termed CD22 beta Rg is capable of binding alpha 2-6 sialylated complex N-linked oligosaccharides purified from lymphocyte glycoprotein ligands (Powell, L. D., Sgroi, D., Sjoberg, E. R, Stamenkovic, I., and Varki, A. (1993) J. Biol. Chem. 268, 7019-7027). Here, we utilize a number of naturally and enzymatically sialylated oligosaccharides and sialoglycoproteins to further define its lectin specificity and demonstrate that the minimal structure recognized is Neu5Ac alpha 2-6Gal beta 1-4Glc(NAc). Reduction of the glucose residue of Neu5Ac alpha 2-6Gal beta 1-4Glc diminishes the interaction, while truncation of the sialic acid side chain by mild periodate oxidation abolishes it. Branched oligosaccharides with two alpha 2-6 sialyl residues bind better, regardless of whether they were derived from N- or O-Linked oligosaccharides or from gangliosides. alpha 2-3-Sialyl residues have no effect on binding, whereas increasing the number of alpha 2-6-sialyl residues on multiantennary oligosaccharides progressively improves binding. No specific feature of the core region affects binding, although the spacing of the alpha 2-6-sialyl residues on tetraantennary chains appears to have a significant effect. Of several model sialoglycoproteins examined, fetuin and transferrin had an apparent affinity no greater than that observed with free sialylated N-linked oligosaccharides. Some subfractions of these proteins displayed unexpectedly weak binding, suggesting that the protein backbone can exert a negative effect. In contrast, a subfraction of alpha(1)-acid glycoprotein was identified as having a substantially higher apparent affinity than free oligosaccharides derived from it, indicating that multiple glycosylation sites may increase the apparent binding affinity. Thus, CD22 beta Rg contains a lectin activity specific for the minimal motif Neu5Ac alpha 2-6Gal beta 1-4Glc(NAc), and branched, multisialylated oligosaccharides are better ligands, regardless of the core sequences. Intact sialoglycoproteins can also interact, although with a variable affinity not directly predictable from the precise structure of their sialylated oligosaccharides chains. These data may help to explain why certain T and B cell surface sialoglycoproteins with the Neu5Ac alpha 2-6Gal beta 1-4Glc(NAc) motif are superior ligands, capable of mediating CD22 beta-mediated adhesion and activation events.	UNIV CALIF SAN DIEGO,SCH MED,CTR CANC,GLYCOBIOL PROGRAM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [KO1 CA01649] Funding Source: Medline; NIGMS NIH HHS [R01-GM32373] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P10242, DOI 10.1073/pnas.89.21.10242; BARCLAY AN, 1987, EMBO J, V6, P1259, DOI 10.1002/j.1460-2075.1987.tb02362.x; BAST BJEG, 1992, J CELL BIOL, V116, P423, DOI 10.1083/jcb.116.2.423; BERZOFSKY JA, 1989, FUNDAMENTAL IMMUNOLO, P315; BREG J, 1989, EUR J BIOCHEM, V178, P727, DOI 10.1111/j.1432-1033.1989.tb14504.x; BREG J, 1988, EUR J BIOCHEM, V171, P643, DOI 10.1111/j.1432-1033.1988.tb13835.x; DELAU WBM, 1993, J IMMUNOL, V150, P4911; DZIEGIELEWSKA KM, 1990, J BIOL CHEM, V265, P4354; EDGE ASB, 1987, J BIOL CHEM, V262, P16135; ENGEL P, 1993, J IMMUNOL, V150, P4719; FU DT, 1992, ANAL BIOCHEM, V206, P53, DOI 10.1016/S0003-2697(05)80010-7; Fukuda M., 1992, CELL SURFACE CARBOHY, P127; FUKUDA MN, 1986, J BIOL CHEM, V261, P5145; GREEN ED, 1988, J BIOL CHEM, V263, P25; GUY K, 1991, IMMUNOLOGY, V74, P206; HANASAKI K, 1994, J BIOL CHEM, V269, P10637; Hynes RO, 1990, FIBRONECTINS; JOZIASSE DH, 1987, J BIOL CHEM, V262, P2025; KEPPLER OT, 1992, EUR J IMMUNOL, V22, P2777, DOI 10.1002/eji.1830221104; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KLEIN A, 1988, EUR J BIOCHEM, V171, P631, DOI 10.1111/j.1432-1033.1988.tb13834.x; KNIEP B, 1990, FEBS LETT, V261, P347, DOI 10.1016/0014-5793(90)80588-A; LEE RT, 1988, BIOCHEM BIOPH RES CO, V155, P1444, DOI 10.1016/S0006-291X(88)81303-2; LEE YC, 1983, J BIOL CHEM, V258, P199; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; MANZI AE, 1990, J BIOL CHEM, V265, P8094; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1978, J BIOL CHEM, V253, P5617; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; POWELL LD, 1993, J BIOL CHEM, V268, P7019; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; SCHWARTZALBIEZ R, 1991, INT IMMUNOL, V3, P623, DOI 10.1093/intimm/3.7.623; SGROI D, 1993, J BIOL CHEM, V268, P7011; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; TAI GH, 1992, BIOCHEM J, V286, P231, DOI 10.1042/bj2860231; TAKI T, 1992, CANCER RES, V52, P4805; TONG PY, 1989, J BIOL CHEM, V264, P7970; TOWNSEND RR, 1989, ANAL BIOCHEM, V182, P1; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; VARKI A, 1983, J BIOL CHEM, V258, P2808; WANG XC, 1993, J BIOL CHEM, V268, P4355; WARREN L, 1959, J BIOL CHEM, V234, P1971; WEN DX, 1992, J BIOL CHEM, V267, P2512; WHITEHEART SW, 1987, ANAL BIOCHEM, V163, P123, DOI 10.1016/0003-2697(87)90102-3; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476	49	149	155	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10628	10636						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144652				2022-12-25	WOS:A1994NF01700067
J	TOMIYAMA, T; ASANO, S; FURIYA, Y; SHIRASAWA, T; ENDO, N; MORI, H				TOMIYAMA, T; ASANO, S; FURIYA, Y; SHIRASAWA, T; ENDO, N; MORI, H			RACEMIZATION OF ASP(23) RESIDUE AFFECTS THE AGGREGATION PROPERTIES OF ALZHEIMER AMYLOID-BETA PROTEIN ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ASPARTYL RESIDUES; FIBRIL FORMATION; DISEASE; PEPTIDES; PRECURSOR; METHYLTRANSFERASE; ASPARAGINYL; DEGRADATION; MODEL	The beta proteins in amyloid deposits of Alzheimer's disease have been found to be racemized and/or isomerized at their Asp residues (Roher, A. E., Lowenson, J. D., Clarke, S., Wolkow, C., Wang, R., Cotter, R. J., Reardon, I. M., Zurcher-Neely, H. A., Heinrikson, R. L., Ball, M. J., and Greenberg, B. D. (1993) J. Biol. Chem. 268, 3072-3083). To elucidate the effect of racemization on the aggregation properties of beta proteins, we synthesized four beta protein analogues in which D-Asp was substituted for L-Asp residues, i.e. normal beta 1-35, [D-Asp(7)]beta 1-35, [D-Asp(23)]beta 135, and [D-Asp(7),D-Asp(23)]beta 1-35. The aggregation and fibril formation of the peptides were examined by means of spectrophotometry, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and electron microscopy. Of the four peptides, [D-Asp(23)]beta 1-35 showed the earliest increase in turbidity and appearance of a smear in SDS-PAGE. This was followed by [D-Asp(7),D-Asp(23)]beta 1-35 and normal beta 1-35. [D-Asp(7)]beta 1-35 was considerably delayed in showing these signs of aggregation. Corresponding with the increase in turbidity and the appearance of a smear in SDS-PAGE, fibril formation was observed in electron microscopy. These results reveal that the aggregation properties of beta 1-35 peptides are affected by racemization of their Asp residues depending on their position. Racemization at amino acid position 23 accelerated the peptide aggregation and fibril formation, while that at position 7 slowed down this reaction. This suggests that the site specific racemization of p protein may be involved in the amyloid fibril formation in Alzheimer's disease.	TEIJIN INST BIOMED RES,HINO,TOKYO 191,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERENTOL,ITABASHI KU,TOKYO 173,TOKYO,JAPAN		TOMIYAMA, T (corresponding author), TOKYO INST PSYCHIAT,DEPT MOLEC BIOL,SETAGAYA KU,2-1-8 KAMIKITAZAWA,TOKYO 156,JAPAN.							BADA JL, 1984, METHOD ENZYMOL, V106, P98; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BURDICK D, 1992, J BIOL CHEM, V267, P546; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CONNOR JR, 1992, J NEUROSCI RES, V31, P75, DOI 10.1002/jnr.490310111; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DYRKS T, 1992, J BIOL CHEM, V267, P18210; DYRKS T, 1993, FEBS LETT, V324, P231, DOI 10.1016/0014-5793(93)81399-K; EMRE M, 1992, NEUROBIOL AGING, V13, P553, DOI 10.1016/0197-4580(92)90055-3; FISHER GH, 1992, BRAIN RES BULL, V28, P127, DOI 10.1016/0361-9230(92)90239-T; FRASER PE, 1992, BIOCHEMISTRY-US, V31, P10716, DOI 10.1021/bi00159a011; GEIGER T, 1987, J BIOL CHEM, V262, P785; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KOWALL NW, 1991, P NATL ACAD SCI USA, V88, P7247, DOI 10.1073/pnas.88.16.7247; LOWENSON JD, 1992, J BIOL CHEM, V267, P5985; MARSHALL T, 1988, BIOCHEM SOC T, V16, P640, DOI 10.1042/bst0160640; MASTERS PM, 1983, J AM GERIATR SOC, V31, P426, DOI 10.1111/j.1532-5415.1983.tb03719.x; MORI H, 1992, J BIOL CHEM, V267, P17082; PIKE CJ, 1993, J NEUROSCI, V13, P1676; ROHER AE, 1993, J BIOL CHEM, V268, P3072; RUSH DK, 1992, NEUROBIOL AGING, V13, P591, DOI 10.1016/0197-4580(92)90061-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHAPIRA R, 1988, J NEUROCHEM, V50, P69, DOI 10.1111/j.1471-4159.1988.tb13231.x; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	32	146	152	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10205	10208						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144598				2022-12-25	WOS:A1994NF01700006
J	KOBAYASHI, T; HONKE, K; MIYAZAKI, T; MATSUMOTO, K; NAKAMURA, T; ISHIZUKA, I; MAKITA, A				KOBAYASHI, T; HONKE, K; MIYAZAKI, T; MATSUMOTO, K; NAKAMURA, T; ISHIZUKA, I; MAKITA, A			HEPATOCYTE GROWTH-FACTOR SPECIFICALLY BINDS TO SULFOGLYCOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; RENAL-CELL CARCINOMA; SULFATED GLYCOLIPIDS; VONWILLEBRAND-FACTOR; SEQUENCE HOMOLOGY; RAT HEPATOCYTES; IDENTIFICATION; LAMININ; THROMBOSPONDIN; EXPRESSION	Hepatocyte growth factor (HGF) is a heparin-binding pleiotropic factor that acts on a variety of epithelial cells. The interaction of human HGF with glycolipids was studied by overlaying them with I-125-HGF on thin layer chromatograms and by a solid-phase assay using lipids adsorbed on microtiter plates. Among various glycolipids tested, HGF was found to bind to sulfoglycolipids, including galactosylceramide sulfate (SM4), lactosylceramide sulfate (SM3), and gangliotriaosylceramide bis-sulfate. In contrast, HGF failed to bind to gangliosides or neutral glycolipids. HGF binding to SM4 was strongly inhibited by dextran sulfate, heparin, and fucoidan, whereas neither keratan sulfate nor hyaluronic acid had any inhibitory activity. When glycolipids from a renal cancer cell line, SMKT-R3, which overexpresses sulfoglycolipids, were developed on a thin layer chromatogram, SM4 and SM3 were the only glycolipids that bound HGF. We further examined the effect of the incorporation of glycolipids into SMKT-R3 cells on HGF binding to the cells. The incorporation of SM4 into the cells enhanced HGF binding to SMKT-R3 cells, while that of galactosylceramide, a precursor of SM4, had no effect. These observations indicated that SM4 exogenously incorporated into the cell membranes could react with HGF and suggested that endogenous sulfoglycolipids on SMKT-R3 cells might function as reservoirs for HGF.	HOKKAIDO UNIV, SCH MED, INST CANC, BIOCHEM LAB, KITA KU, N15W7, SAPPORO, HOKKAIDO 060, JAPAN; HOKKAIDO UNIV, SCH MED, DEPT INTERNAL MED 3, SAPPORO, HOKKAIDO 060, JAPAN; OSAKA UNIV, SCH MED, BIOMED RES CTR, DEPT BIOCHEM, SUITA, OSAKA 565, JAPAN; TEIKYO UNIV, SCH MED, DEPT BIOCHEM, TOKYO 173, JAPAN	Hokkaido University; Hokkaido University; Osaka University; Teikyo University								ARAKAKI N, 1992, J BIOL CHEM, V267, P7101; BRANKAMP RG, 1991, BIOCHEM BIOPH RES CO, V181, P245; CHRISTOPHE O, 1991, BLOOD, V78, P2310; FAROOQUI AA, 1985, MOL CELL BIOCHEM, V66, P87; FREDMAN P, 1988, BIOCHEM J, V251, P17, DOI 10.1042/bj2510017; HIGUCHI O, 1991, BIOCHEM BIOPH RES CO, V176, P599, DOI 10.1016/S0006-291X(05)80226-8; HIGUCHI O, 1992, FEBS LETT, V301, P282, DOI 10.1016/0014-5793(92)80257-H; HOLT GD, 1989, J BIOL CHEM, V264, P12138; HOLT GD, 1990, J BIOL CHEM, V265, P2852; KOBAYASHI T, 1993, BRIT J CANCER, V67, P76, DOI 10.1038/bjc.1993.12; KOMADA M, 1992, EUR J BIOCHEM, V204, P857, DOI 10.1111/j.1432-1033.1992.tb16705.x; LAINE RA, 1973, BIOCHEM BIOPH RES CO, V54, P1039, DOI 10.1016/0006-291X(73)90798-5; MAKITA A, 1985, NEW COMPREHENSIVE BI, V10, P1; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V181, P691, DOI 10.1016/0006-291X(91)91246-9; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MIYAO N, 1989, UROL RES, V17, P317; MOHAN PS, 1992, BIOCHEM BIOPH RES CO, V182, P689, DOI 10.1016/0006-291X(92)91787-Q; MOHAN PS, 1990, J NEUROCHEM, V54, P2024, DOI 10.1111/j.1471-4159.1990.tb04907.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; OHKUBO I, 1991, BIOCHEM BIOPH RES CO, V174, P1133, DOI 10.1016/0006-291X(91)91538-N; ROBERTS DD, 1988, CANCER RES, V48, P6785; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; ROBERTS DD, 1987, METHOD ENZYMOL, V138, P473; ROBERTS DD, 1985, P NATL ACAD SCI USA, V82, P1306, DOI 10.1073/pnas.82.5.1306; ROBERTS DD, 1986, J BIOL CHEM, V261, P6872; ROBERTS DD, 1986, J BIOL CHEM, V261, P3306; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAKAKIBARA N, 1989, CANCER RES, V49, P335; SVENNERHOLM L, 1956, J NEUROCHEM, V1, P42, DOI 10.1111/j.1471-4159.1956.tb12053.x; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; TARABOLETTI G, 1990, J BIOL CHEM, V265, P12253; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZARNEGAR R, 1990, BIOCHEM BIOPH RES CO, V173, P1179, DOI 10.1016/S0006-291X(05)80910-6	36	54	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9817	9821						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144574				2022-12-25	WOS:A1994NE05300066
J	IMAGAWA, S; IZUMI, T; MIURA, Y				IMAGAWA, S; IZUMI, T; MIURA, Y			POSITIVE AND NEGATIVE REGULATION OF THE ERYTHROPOIETIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE HELIX FORMATION; EXPRESSION; TRANSCRIPTION; DNA; ENHANCER; PROTEIN; OLIGONUCLEOTIDES; ANTISENSE; ELEMENTS; CONTAINS	In order to investigate positive and negative regulatory elements of the erythropoietin (Epo) gene, synthetic oligonucleotides were designed to control Epo transcription by means of an antigene strategy. We devised a new method for detecting regulatory elements of genes that have a weak promoter. Synthetic oligonucleotides were incubated with Hep3B cells in the presence or absence of CoCl2 or hypoxia. To exclude the effect of translational regulation, Epo mRNA concentration was determined by competitive polymerase chain reaction. The addition of antisense oligonucleotide for CACCC elements decreased the production of Epo mRNA in a dose-dependent fashion when cells were stimulated by CoCl2 or hypoxia. In contrast, the addition of antisense oligonucleotide for the GATA element caused a dose dependent stimulation of Epo mRNA production either in the presence or absence of CoCl2 or hypoxia. Triple helix formation was revealed by electrophoresis. CACCC elements were demonstrated to be positive regulatory elements of the Epo gene, whereas the GATA element was a negative regulatory element. Furthermore, by gel mobility shift assays, we demonstrated evidence for the presence of factors in Hep3B cell nuclear extract that spe cifically bind to CACCC or GATA elements. Based on these observations, we presented the possibility that triple helix formation could serve as a novel means for transcriptional regulation of the gene.			IMAGAWA, S (corresponding author), JICHI MED SCH, DEPT MED, DIV HEMATOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN.							BERU N, 1990, J BIOL CHEM, V265, P14100; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; COSTAGIOMI P, 1990, J BIOL CHEM, V265, P10185; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GILMAN M, 1988, CURRENT PROTOCOLS MO, V1; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GOLDWASSER E, 1958, BLOOD, V13, P55, DOI 10.1182/blood.V13.1.55.55; GRABER SE, 1989, HEMATOL ONCOL CLIN N, V3, P369; HELENE C, 1991, ANTI-CANCER DRUG DES, V6, P569; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HELENE C, 1991, EUR J CANCER, V27, P1466, DOI 10.1016/0277-5379(91)90033-A; HERBST RS, 1990, MOL CELL BIOL, V10, P3896, DOI 10.1128/MCB.10.8.3896; HOOGSTEEN K, 1959, ACTA CRYSTALLOGR, V12, P822, DOI 10.1107/S0365110X59002389; IMAGAWA S, 1991, BLOOD, V77, P278; LEDOAN T, 1987, NUCLEIC ACIDS RES, V15, P8643, DOI 10.1093/nar/15.21.8643; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MERGNY JL, 1992, SCIENCE, V256, P1681, DOI 10.1126/science.256.5064.1681; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SHOEMAKER CB, 1986, MOL CELL BIOL, V6, P849, DOI 10.1128/MCB.6.3.849; TSUCHIYA M, 1987, EUR J BIOCHEM, V165, P7, DOI 10.1111/j.1432-1033.1987.tb11187.x; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	27	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9038	9044						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132641				2022-12-25	WOS:A1994NB41100064
J	MENDOZA, I; RUBIO, F; RODRIGUEZNAVARRO, A; PARDO, JM				MENDOZA, I; RUBIO, F; RODRIGUEZNAVARRO, A; PARDO, JM			THE PROTEIN PHOSPHATASE CALCINEURIN IS ESSENTIAL FOR NACL TOLERANCE OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM-TRANSPORT; LACZ FUSIONS; YEAST; GENE; ACTIVATION; HOMOLOGS; KINASE	NaCl-sensitive yeast mutants were isolated to identify genes essential for NaCl tolerance. Complementation of a mutant highly sensitive to Na+ and Li+ led to the isolation of the CNB1 gene. This gene encodes the regulatory subunit (CNB) of the Ca2+/calmodulin-dependent protein phosphatase calcineurin. Cells deficient in CNB accumulated Li+ due to reduced expression of ENA1, a gene encoding a P-type ATPase involved in Na+ and Li+ efflux. In addition, the K+ transport system of cnb1 Delta cells was not converted to the high affinity state that facilitates better discrimination of K+ over Na+. Thus the cnb1 Delta strain resembled a trk1 mutant. These results indicate that adaptation to NaCl stress in Saccharomyces cerevisiae requires a signal transduction pathway involving Ca2+ and protein phosphorylation-dephosphorylation. In this pathway, calcineurin would coordinate gene expression and activity of ion transporters to facilitate ion homeostasis.	CSIC, INST RECURSOS NAT & AGROBIOL, E-41080 SEVILLE, SPAIN; ESCUELA TECN SUPER INGN AGRON, DEPT MICROBIOL, E-28040 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS)			Pardo, Jose M./B-4652-2009; Rodriguez-Navarro, Alonso/AAB-4574-2019; Rubio, Francisco/K-2854-2014; Mendoza, Imelda/I-2864-2015; Rubio, Francisco/ABF-8662-2020	Pardo, Jose M./0000-0003-4510-8624; Rodriguez-Navarro, Alonso/0000-0003-0462-223X; Rubio, Francisco/0000-0001-7640-9548; Mendoza, Imelda/0000-0002-2673-3961; Rubio, Francisco/0000-0001-7640-9548				ARMSTRONG DL, 1989, TRENDS NEUROSCI, V12, P117, DOI 10.1016/0166-2236(89)90168-9; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BORSTPAUWELS GWFH, 1981, BIOCHIM BIOPHYS ACTA, V650, P88, DOI 10.1016/0304-4157(81)90002-2; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; DELCASSOTREMOUSAYGUE D, 1988, EUR J BIOCHEM, V172, P767, DOI 10.1111/j.1432-1033.1988.tb13956.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HARO R, 1993, PHYSIOL PLANTARUM, V89, P868, DOI 10.1111/j.1399-3054.1993.tb05298.x; HSIAO KC, 1991, NUCLEIC ACIDS RES, V19, P2787, DOI 10.1093/nar/19.10.2787; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; LUAN S, 1993, P NATL ACAD SCI USA, V90, P2202, DOI 10.1073/pnas.90.6.2202; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; RAMOS J, 1985, ARCH MICROBIOL, V143, P88, DOI 10.1007/BF00414774; RAMOS J, 1990, BIOCHIM BIOPHYS ACTA, V1029, P211, DOI 10.1016/0005-2736(90)90156-I; RAMOS J, 1986, EUR J BIOCHEM, V154, P307, DOI 10.1111/j.1432-1033.1986.tb09398.x; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; RODRIGUEZNAVARRO A, 1984, J BACTERIOL, V159, P940; RODRIGUEZNAVARRO A, 1982, FEBS LETT, V138, P205, DOI 10.1016/0014-5793(82)80442-0; Sambrook J, 1989, MOL CLONING LABORATO; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SKALA J, 1991, YEAST, V7, P651, DOI 10.1002/yea.320070614; UEKI K, 1993, J BIOL CHEM, V268, P6554	32	288	296	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8792	8796						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132612				2022-12-25	WOS:A1994NB41100029
J	MICHIKAWA, T; HAMANAKA, H; OTSU, H; YAMAMOTO, A; MIYAWAKI, A; FURUICHI, T; TASHIRO, Y; MIKOSHIBA, K				MICHIKAWA, T; HAMANAKA, H; OTSU, H; YAMAMOTO, A; MIYAWAKI, A; FURUICHI, T; TASHIRO, Y; MIKOSHIBA, K			TRANSMEMBRANE TOPOLOGY AND SITES OF N-GLYCOSYLATION OF INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE CEREBELLUM; RYANODINE RECEPTOR; MOLECULAR-CLONING; INSP3 RECEPTOR; P-400 PROTEIN; PURKINJE-CELL; TRISPHOSPHATE RECEPTOR; MONOCLONAL-ANTIBODIES; SODIUM-CHANNELS; P400 PROTEIN	To define the transmembrane topology of the inositol 1,4,5-trisphosphate receptor (InsP(3)R), we determined the subcellular location of the hydrophilic segment (residues 2463-2529 of mouse type 1 InsP(3)R) believed to be located at the luminal side of the endoplasmic reticulum (ER) in the six-transmembrane model but at the cytoplasmic side in the eight-transmembrane model. This hydrophilic segment includes two consensus sites for N-glycosylation (Asn-2475 and Asn-2503). We prepared an anti-peptide antibody against residues 2504-2523. Electron microscope immunocytochemical studies of mouse cerebellar Purkinje cells showed that binding of this antibody frequently occurs in the intracisternal space of the ER. We constructed three mutant receptors by site-directed mutagenesis of Asn to Gin (N2475Q, N2503Q, and N2475and/N2503Q), By concanavalin A column chromatography of these receptors, we found that both Asn-2475 and Asn-2503 are glycosylated. These results indicate that residues 2504-2523, Asn-2475, and Asn-2503 are exposed to the ER lumen. We therefore propose that InsP(3)R has six membrane spanning segments. Based on the transmembrane topology and subunit organization, we suggest that InsP(3)R is a member of the superfamily that includes the voltage- and second messenger-gated ion channels on the plasma membrane.	UNIV TOKYO,INST MED SCI,DEPT MOLEC NEUROBIOL,MINATO KU,TOKYO,TOKYO 108,JAPAN; KANSAI MED UNIV,DEPT MED 3,MORIGUCHI,OSAKA 570,JAPAN; KANSAI MED UNIV,DEPT PHYSIOL,MORIGUCHI,OSAKA 570,JAPAN; RIKEN,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN	University of Tokyo; Kansai Medical University; Kansai Medical University; RIKEN			Mikoshiba, Katsuhiko/N-7943-2015; Miyawaki, Atsushi/K-3569-2014	Miyawaki, Atsushi/0000-0002-2329-3235; Furuichi, Teiichi/0000-0002-9676-1888				BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DECAMILLI P, 1983, J CELL BIOL, V96, P1355, DOI 10.1083/jcb.96.5.1355; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NUCLEIC ACIDS RES, V17, P5385, DOI 10.1093/nar/17.13.5385; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GILLY WF, 1990, NEURON, V5, P633; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; KUWAJIMA G, 1992, NEURON, V9, P1133, DOI 10.1016/0896-6273(92)90071-K; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; MAEDA N, 1989, DEV BIOL, V133, P67, DOI 10.1016/0012-1606(89)90297-2; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MIKOSHIBA K, 1979, DEV NEUROSCI-BASEL, V2, P254, DOI 10.1159/000112489; Miller Christopher, 1992, Current Biology, V2, P573, DOI 10.1016/0960-9822(92)90146-2; MISHINA M, 1985, NATURE, V313, P364, DOI 10.1038/313364a0; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; NAKADE S, 1991, BIOCHEM J, V277, P125, DOI 10.1042/bj2770125; OTSU H, 1990, CELL STRUCT FUNCT, V15, P163, DOI 10.1247/csf.15.163; RECIOPINTO E, 1990, NEURON, V5, P675, DOI 10.1016/0896-6273(90)90221-Z; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; RYO Y, 1993, J NEUROSCI RES, V36, P19, DOI 10.1002/jnr.490360104; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WAECHTER CJ, 1983, J BIOL CHEM, V258, P5117; WATRAS J, 1991, J NEUROSCI, V11, P3239; YAMAMOTOHINO M, 1994, IN PRESS RECEPORS CH; YOSHIKAWA S, 1992, J BIOL CHEM, V267, P16613; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	44	121	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9184	9189						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132655				2022-12-25	WOS:A1994NB41100083
J	SHANI, N; ROSENBERG, N; KASARDA, DD; GALILI, G				SHANI, N; ROSENBERG, N; KASARDA, DD; GALILI, G			MECHANISMS OF ASSEMBLY OF WHEAT HIGH-MOLECULAR-WEIGHT GLUTENINS INFERRED FROM EXPRESSION OF WILD-TYPE AND MUTANT SUBUNITS IN TRANSGENIC TOBACCO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRITICUM-AESTIVUM L; GEL-ELECTROPHORESIS; NUCLEOTIDE-SEQUENCE; DISULFIDE BONDS; PROTEIN BODIES; GENERAL-METHOD; BREAD WHEAT; ENDOSPERM; REVEALS; VECTORS	Following sequestration into the endoplasmic reticulum, wheat high molecular weight glutenin subunits (HMW-GS) assemble into polymers through intermolecular disulfide bond formation. These polymers, which also include low molecular weight glutenin subunits (HMW-GS), have a broad distribution of molecular mass reaching up to several million daltons. To study the mechanism of assembly of the HMW-GS, we have expressed x- and y-type HMW-GS in transgenic tobacco plants. Both types, when expressed individually or in combination, were incorporated into polymers. Partial reduction of polymers formed by different subunits re suited in different patterns of release of homodimers, heterodimers, and monomers. This suggested different arrangements of intermolecular disulfide bonds or different peptide conformations in the vicinity of the disulfide bonds linking x-x, y-y, and x-y type HMW-GS. A mutant of the x type subunit, lacking a conserved cysteine in the C-terminal domain, assembled into oligomers linked by intermolecular disulfide bonds, but not into large polymers. This mutant was deposited, however, in dense protein bodies, similar to those formed by the native HMW-GS, suggesting that polymer formation and packaging into protein bodies may be the result of different types of interactions. Pulse-chase labeling of proteins in wheat endosperm showed that the assembly of the HMW-GS into insoluble polymers occurs by a slow process which apparently continues after the initiation of protein body formation.	WEIZMANN INST SCI,DEPT PLANT GENET,IL-76100 REHOVOT,ISRAEL; USDA ARS,WESTERN REG RES CTR,ALBANY,CA 94710	Weizmann Institute of Science; United States Department of Agriculture (USDA)								AN GH, 1986, PLANT PHYSIOL, V81, P86, DOI 10.1104/pp.81.1.86; ANDERSON OD, 1989, THEOR APPL GENET, V77, P689, DOI 10.1007/BF00261246; COLMAN A, 1984, BIOCHEM SOC T, V12, P932, DOI 10.1042/bst0120932; EWART JAD, 1979, J SCI FOOD AGR, V30, P482, DOI 10.1002/jsfa.2740300507; EWART JAD, 1968, J SCI FOOD AGR, V19, P617, DOI 10.1002/jsfa.2740191101; EWART JAD, 1987, J SCI FOOD AGR, V38, P277, DOI 10.1002/jsfa.2740380312; EWART JAD, 1988, CEREAL CHEM, V65, P95; FORDE J, 1985, NUCLEIC ACIDS RES, V13, P6817, DOI 10.1093/nar/13.19.6817; GALILI G, 1983, THEOR APPL GENET, V66, P77, DOI 10.1007/BF00281853; GALLIE DR, 1989, PLANT CELL, V1, P301, DOI 10.1105/tpc.1.3.301; GAO L, 1992, CEREAL CHEM, V69, P452; GRAVELAND A, 1985, J CEREAL SCI, V3, P1, DOI 10.1016/S0733-5210(85)80029-1; HALFORD NG, 1987, THEOR APPL GENET, V75, P117, DOI 10.1007/BF00249151; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Kasarda D.D., 1989, WHEAT UNIQUE, V277, P302; KHAN K, 1979, CEREAL CHEM, V56, P63; KOHLER P, 1991, Z LEBENSM UNTERS FOR, V192, P234, DOI 10.1007/BF01202885; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE GJ, 1988, J CEREAL SCI, V7, P109, DOI [10.1016/S0733-5210(88)80012-2, 10.1006/jcrs.1997.0158]; LAWRENCE GJ, 1983, J EXP BOT, V34, P254, DOI 10.1093/jxb/34.3.254; MATSUSHIMA N, 1992, BIOCHEM BIOPH RES CO, V186, P1057, DOI 10.1016/0006-291X(92)90854-E; Miflin B. J., 1983, Seed proteins, P255; MILLET E, 1991, PHYSIOL PLANTARUM, V83, P591, DOI 10.1111/j.1399-3054.1991.tb02473.x; PAYNE PI, 1981, THEOR APPL GENET, V60, P229, DOI 10.1007/BF02342544; PAYNE PI, 1984, PHILOS T R SOC B, V304, P359, DOI 10.1098/rstb.1984.0031; ROBERT LS, 1989, PLANT CELL, V1, P569, DOI 10.1105/tpc.1.6.569; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUBIN R, 1992, PLANT PHYSIOL, V99, P718, DOI 10.1104/pp.99.2.718; SHANI N, 1992, PLANT PHYSIOL, V98, P433, DOI 10.1104/pp.98.2.433; SHEWRY PR, 1989, OXFORD SURV PLANT MO, V6, P163; SHOTWELL MA, 1988, BIOCH PLANTS, P297; SUGIYAMA T, 1985, NUCLEIC ACIDS RES, V13, P8729, DOI 10.1093/nar/13.24.8729; TAO HP, 1992, BIOCHIM BIOPHYS ACTA, V1159, P13; TATHAM AS, 1984, FEBS LETT, V177, P205, DOI 10.1016/0014-5793(84)81284-3; THOMPSON RD, 1985, NUCLEIC ACIDS RES, V13, P6833, DOI 10.1093/nar/13.19.6833; WALLACE JC, 1988, SCIENCE, V240, P662, DOI 10.1126/science.2834822; WERNER WE, 1992, CEREAL CHEM, V69, P535	38	36	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8924	8930						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132629				2022-12-25	WOS:A1994NB41100047
J	WHITE, AL; HIXSON, JE; RAINWATER, DL; LANFORD, RE				WHITE, AL; HIXSON, JE; RAINWATER, DL; LANFORD, RE			MOLECULAR-BASIS FOR NULL LIPOPROTEIN(A) PHENOTYPES AND THE INFLUENCE OF APOLIPOPROTEIN(A) SIZE ON PLASMA LIPOPROTEIN(A) LEVEL IN THE BABOON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APO(A) MESSENGER-RNA; PROTEIN; CELL; OLIGOSACCHARIDES; HETEROGENEITY; POLYMORPHISM; HEPATOCYTES; INHERITANCE; SEQUENCE; ISOFORMS	High plasma levels of lipoprotein(a) (Lp(a)) and its unique apolipoprotein, apo(a), are an independent risk factor for cardiovascular disease. Plasma Lp(a) levels vary over a 1000-fold range and are determined by the apo(a) locus, which has at least 34 alleles expressing apo(a) isoforms with molecular weights from <300,000 to >800,000. In addition, ''null'' apo(a) alleles produce no detectable plasma apo(a). We used primary cultures of baboon hepatocytes to investigate the molecular basis for null apo(a) phenotypes. Immunoprecipitation of apo(a) after radiolabeling of hepatocytes revealed that some null alleles gave rise to intracellular protein products that were not secreted. Pulse chase analysis and endoglycosidase digests demonstrated that these proteins were retained in the endoplasmic reticulum. We also examined the molecular basis for the documented inverse correlation between apo(a) size and plasma Lp(a) concentration. Steady-state labeling and pulse-chase analysis of hepatocytes from animals expressing two isoforms of apo(a) revealed that the endoplasmic reticulum residence time of secreted apo(a) isoforms was determined by their size. This accounted for the inverse relationship between isoform size and level of secretion. We conclude that the efficiency of post-translational processing of apo(a) is a major determinant of plasma Lp(a) concentration.	SW FDN BIOMED RES,DEPT VIROL & IMMUNOL,SAN ANTONIO,TX 78228; SW FDN BIOMED RES,DEPT GENET,SAN ANTONIO,TX 78228	Texas Biomedical Research Institute; Texas Biomedical Research Institute				Hixson, James/0000-0002-0849-9315	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040637, P01HL028972] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40637, HL28972] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERS JJ, 1977, J LIPID RES, V18, P331; Amara J F, 1992, Trends Cell Biol, V2, P145, DOI 10.1016/0962-8924(92)90101-R; AZROLAN N, 1991, J BIOL CHEM, V266, P13866; BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; COHEN JC, 1993, J CLIN INVEST, V91, P1630, DOI 10.1172/JCI116370; FLESS GM, 1986, J BIOL CHEM, V261, P8712; Gaubatz J W, 1986, Methods Enzymol, V129, P167; GAUBATZ JW, 1990, J LIPID RES, V31, P603; GAVISH D, 1989, J CLIN INVEST, V84, P2021, DOI 10.1172/JCI114395; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HERBERT PN, 1983, METABOLIC BASIS INHE, P589; HIXSON JE, 1989, J BIOL CHEM, V264, P6013; HUGHES RC, 1964, BIOCHEMISTRY-US, V3, P1535, DOI 10.1021/bi00898a025; KAMBOH MI, 1991, AM J HUM GENET, V49, P1063; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; KREMPLER F, 1980, J CLIN INVEST, V65, P1483, DOI 10.1172/JCI109813; LACKNER C, 1993, HUM MOL GENET, V2, P933, DOI 10.1093/hmg/2.7.933; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; LANFORD RE, 1989, IN VITRO CELL DEV B, V25, P174; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; MARCOVINA SM, 1993, BIOCHEM BIOPH RES CO, V191, P1192, DOI 10.1006/bbrc.1993.1343; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; RAINWATER DL, 1989, BIOCHIM BIOPHYS ACTA, V1003, P30, DOI 10.1016/0005-2760(89)90094-5; RAINWATER DL, 1986, BIOCHIM BIOPHYS ACTA, V877, P75, DOI 10.1016/0005-2760(86)90120-7; RAINWATER DL, 1989, J LIPID RES, V30, P549; RAINWATER DL, 1988, ATHEROSCLEROSIS, V73, P23, DOI 10.1016/0021-9150(88)90159-1; SANDHOLZER C, 1991, HUM GENET, V86, P607; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; TANABE S, 1989, IN VITRO CELL DEV B, V25, P1129; TARENTINO AL, 1974, J BIOL CHEM, V249, P818; TOMLINSON JE, 1989, J BIOL CHEM, V264, P5957; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; WETTESTEN M, 1985, EUR J BIOCHEM, V149, P461, DOI 10.1111/j.1432-1033.1985.tb08947.x; WHITE AL, 1993, J LIPID RES, V34, P509; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WHITE AL, 1994, IN PRESS CHEM PHYS L	40	89	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9060	9066						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132643				2022-12-25	WOS:A1994NB41100067
J	CAZAUX, C; LARMINAT, F; VILLANI, G; JOHNSON, NP; SCHNARR, M; DEFAIS, M				CAZAUX, C; LARMINAT, F; VILLANI, G; JOHNSON, NP; SCHNARR, M; DEFAIS, M			PURIFICATION AND BIOCHEMICAL-CHARACTERIZATION OF ESCHERICHIA-COLI RECA PROTEINS MUTATED IN THE PUTATIVE DNA-BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; LARGE-SCALE PURIFICATION; MUTAGENESIS PROTEIN; LAMBDA-REPRESSOR; DEPENDENT ATPASE; LEXA REPRESSOR; SSB PROTEIN; EXCHANGE; RECOMBINATION; CLEAVAGE	Escherichia coli RecA protein plays a central role both in DNA repair and in recombination. We report biochemical properties of three new RecA proteins mutated at positions 199 (RecA694), 207 (RecA659), and 211 (RecA611) in the putative DNA binding site. RecA694 had a wild-type phenotype, whereas RecA611 and RecA659 were deficient in promoting both the self-cleavage of LexA repressor and the DNA-strand exchange reaction. In order to determine the origin of this inhibition, we examined the capacity of wild-type and mutant proteins to bind to single-stranded DNA (with and without single- stranded binding protein, SSB), double-stranded DNA, and ATP. DNA strand exchange defects were correlated with the inability of mutant proteins to displace SSB from DNA. For the recA659 mutation this inhibition was reversed by equimolar wild-type protein. In contrast, mixtures of either wild-type/RecA659 or wild-type/ RecA611 proteins remained deficient in LexA cleavage, suggesting that the dominant negative phenotype of the mutant proteins may be a consequence of the formation heterologous RecA complexes. Various mutations in the putative DNA binding site of RecA protein altered ATP binding, ATPase activity, displacement of SSB from single-stranded DNA, and protein-protein interactions. These results are consistent with the hypothesis that DNA binding to this site of RecA relays allosteric effects to several functional domains throughout the protein.	LAB PHARMACOL & TOXICOL FONDAMENTALES,CNRS,UPR 8221,F-31077 TOULOUSE,FRANCE	Centre National de la Recherche Scientifique (CNRS)								BEDALE WA, 1991, J BIOL CHEM, V266, P6499; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BLANCO M, 1975, MOL MECHANISMS REPAI, P379; BRYANT FR, 1985, J BIOL CHEM, V260, P1196; BURCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1811, DOI 10.1073/pnas.85.6.1811; CALSOU P, 1987, J BACTERIOL, V169, P4816, DOI 10.1128/jb.169.10.4816-4821.1987; CALSOU P, 1985, MOL GEN GENET, V201, P1162; CAZAUX C, 1991, BIOCHIMIE, V73, P281, DOI 10.1016/0300-9084(91)90214-L; CAZAUX C, 1992, J MOL BIOL, V223, P823, DOI 10.1016/0022-2836(92)90243-D; COX MM, 1983, J BIOL CHEM, V258, P2577; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; DICAPUA E, 1992, J MOL BIOL, V226, P707, DOI 10.1016/0022-2836(92)90627-V; DONNELLY CE, 1989, J BACTERIOL, V171, P6117, DOI 10.1128/jb.171.11.6117-6125.1989; DUTREIX M, 1989, J BACTERIOL, V171, P2415, DOI 10.1128/jb.171.5.2415-2423.1989; GUDAS LJ, 1977, P NATL ACAD SCI USA, V74, P5280, DOI 10.1073/pnas.74.12.5280; HONIGBERG SM, 1985, J BIOL CHEM, V260, P1845; HOWARDFLANDERS P, 1987, DNA REPLICATION RECO, P609; IWABUCHI MA, 1983, J BIOL CHEM, V258, P2394; JWANG BR, 1992, P NATL ACAD SCI USA, V89, P7596, DOI 10.1073/pnas.89.16.7596; KNIGHT KL, 1985, J BIOL CHEM, V260, P177; KNIGHT KL, 1985, J BIOL CHEM, V260, P185; KOWALCZYKOWSKI SC, 1987, TRENDS BIOCHEM SCI, V12, P141, DOI 10.1016/0968-0004(87)90070-3; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; KRUEGER JH, 1984, P NATL ACAD SCI-BIOL, V81, P1499, DOI 10.1073/pnas.81.5.1499; LARMINAT F, 1989, MOL GEN GENET, V216, P106, DOI 10.1007/BF00332237; LARMINAT F, 1992, J BACTERIOL, V174, P6264, DOI 10.1128/JB.174.19.6264-6269.1992; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LU C, 1987, J MOL BIOL, V196, P497, DOI 10.1016/0022-2836(87)90027-1; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MENETSKI JP, 1990, J MOL BIOL, V211, P845, DOI 10.1016/0022-2836(90)90078-Z; MENETSKI JP, 1988, BIOCHEMISTRY-US, V27, P1205, DOI 10.1021/bi00404a021; MOREAU PL, 1984, MOL GEN GENET, V198, P25, DOI 10.1007/BF00328696; MORRICAL SW, 1990, BIOCHEMISTRY-US, V29, P837, DOI 10.1021/bi00455a034; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; Ogawa H, 1986, Adv Biophys, V21, P135, DOI 10.1016/0065-227X(86)90019-5; OGAWA T, 1979, COLD SPRING HARB SYM, V43, P909, DOI 10.1101/SQB.1979.043.01.099; PANUSKA JR, 1980, J BIOL CHEM, V255, P5208; Radding C.M., 1988, GENETIC RECOMBINATIO, P193; REBOLLO JE, 1984, MOL GEN GENET, V195, P83, DOI 10.1007/BF00332728; RIDDLES PW, 1985, J BIOL CHEM, V260, P170; ROBERTS JW, 1983, LAMBDA, V2, P123; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROSSELLI W, 1990, J MOL BIOL, V216, P335, DOI 10.1016/S0022-2836(05)80325-0; ROSSELLI W, 1991, EMBO J, V10, P4391, DOI 10.1002/j.1460-2075.1991.tb05017.x; RUPP WD, 1968, J MOL BIOL, V31, P291, DOI 10.1016/0022-2836(68)90445-2; RYDBERG B, 1990, J BIOL CHEM, V265, P9563; SCHNARR M, 1985, BIOCHEMISTRY-US, V24, P2812, DOI 10.1021/bi00332a032; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; WANG TV, 1986, MUTAT RES, V165, P39, DOI 10.1016/0167-8817(86)90007-6; WANG WB, 1986, J BACTERIOL, V168, P901, DOI 10.1128/jb.168.2.901-910.1986; WEST SC, 1981, NATURE, V294, P659, DOI 10.1038/294659a0; WOODGATE R, 1989, P NATL ACAD SCI USA, V86, P7301, DOI 10.1073/pnas.86.19.7301; YANCEY SD, 1984, MOL GEN GENET, V193, P53, DOI 10.1007/BF00327413	61	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8246	8254						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132549				2022-12-25	WOS:A1994NB40900064
J	JACOBSEN, JS; SPRUYT, MA; BROWN, AM; SAHASRABUDHE, SR; BLUME, AJ; VITEK, MP; MUENKEL, HA; SONNENBERGREINES, J				JACOBSEN, JS; SPRUYT, MA; BROWN, AM; SAHASRABUDHE, SR; BLUME, AJ; VITEK, MP; MUENKEL, HA; SONNENBERGREINES, J			THE RELEASE OF ALZHEIMERS-DISEASE BETA-AMYLOID PEPTIDE IS REDUCED BY PHORBOL TREATMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PRECURSOR PROTEIN; INDEPENDENT MECHANISMS; MANNOSE 6-PHOSPHATE; PHOSPHORYLATION; RECEPTOR; CLEAVAGE; DERIVATIVES; SECRETION; MEMBRANE	Amyloid precursor protein (APP) is cleaved predominantly within the beta amyloid peptide (BAP) domain to release a non-amyloidogenic amino-terminal PN2 fragment. Treatment of cells with phorbol dibutyrate, an agent which activates protein kinase C, has been shown to increase the release of an amino-terminal fragment. A panel of mutant APP reporter constructs was expressed in which each of the potential phosphorylation sites located within the cytoplasmic domain of APP was replaced with alanine residues. Phorbol response patterns were unchanged for each of these mutants, suggesting that induced cleavage occurs independently of APP substrate phosphorylation. We find that phorbol (a) increases the release of a PN2 fragment that is consistent with the normal secretase activity, (b) decreases the release of a shorter amino terminal APP fragment that is cleaved near the amino terminus of BAP, and (c) decreases the release of BAP which was identified based on electrophoretic mobility, epitope mapping, and radiosequencing. These data demonstrate that pharmacological treatment can reduce the formation of BAP and suggests that protein kinase C activators could be developed as therapeutic agents to block BAP formation.	AMER CYANAMID CO, LEDERLE LABS, DIV MED RES, DEPT MOLEC PHARMACOL, PEARL RIVER, NY 10965 USA		JACOBSEN, JS (corresponding author), AMER CYANAMID CO, LEDERLE LABS, DIV MED RES, DEPT CENT NERVOUS SYST BIOL RES, BLDG 200, PEARL RIVER, NY 10965 USA.		brown, abraham/R-8823-2019	Vitek, Michael/0000-0001-8140-8048				ANDERSON JP, 1992, J NEUROCHEM, V59, P2328; BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; BRAULKE T, 1990, EUR J BIOCHEM, V189, P609, DOI 10.1111/j.1432-1033.1990.tb15529.x; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DAMKE H, 1992, BIOCHEM J, V281, P225, DOI 10.1042/bj2810225; DESTROOPER B, 1992, FEBS LETT, V308, P50, DOI 10.1016/0014-5793(92)81048-Q; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FLOOD JF, 1991, P NATL ACAD SCI USA, V88, P3363, DOI 10.1073/pnas.88.8.3363; GANDY S, 1988, P NATL ACAD SCI USA, V85, P6218, DOI 10.1073/pnas.85.16.6218; GILLESPIE SL, 1992, BIOCHEM BIOPH RES CO, V187, P1285, DOI 10.1016/0006-291X(92)90442-N; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HARDY J, 1992, SCIENCE, V359, P268; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; ISHIURA S, 1991, J NEUROCHEM, V56, P363, DOI 10.1111/j.1471-4159.1991.tb08160.x; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KOWALL NW, 1991, P NATL ACAD SCI USA, V88, P7247, DOI 10.1073/pnas.88.16.7247; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANTZ M, 1990, J CLIN INVEST, V86, P1396, DOI 10.1172/JCI114853; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; NORDSTEDT C, 1993, J BIOL CHEM, V268, P608; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PALMERT MR, 1989, BIOCHEM BIOPH RES CO, V165, P182, DOI 10.1016/0006-291X(89)91052-8; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; SAHASRABUDHE SR, 1992, J BIOL CHEM, V267, P25602; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SELKOE DJ, 1989, CELL, V58, P611, DOI 10.1016/0092-8674(89)90093-7; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, ANN NY ACAD SCI, V674, P53, DOI 10.1111/j.1749-6632.1992.tb27476.x; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SUZUKI T, 1992, NEUROSCIENCE, V48, P755, DOI 10.1016/0306-4522(92)90264-3; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	55	88	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8376	8382						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132561				2022-12-25	WOS:A1994NB40900082
J	MIURA, S; ICHIKAWA, Y				MIURA, S; ICHIKAWA, Y			INTERACTION OF NADPH-ADRENOFERREDOXIN REDUCTASE WITH NADP(+) AND ADRENOFERREDOXIN - EQUILIBRIUM AND DYNAMIC PROPERTIES INVESTIGATED BY PROTON NUCLEAR-MAGNETIC-RESONANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROIDOGENIC ELECTRON-TRANSPORT; BOVINE ADRENOCORTICAL MITOCHONDRIA; ADRENODOXIN REDUCTASE; ADRENAL-CORTEX; GLUTATHIONE-REDUCTASE; CONFORMATIONAL CHANGE; SEQUENCE-ANALYSIS; FERREDOXIN; PROTEINS; COMPLEX	NADPH-adrenoferredoxin reductase, a flavoprotein from bovine adrenocortical mitochondria, has been investigated to elucidate the equilibrium and dynamic properties of the interaction with NADP(+) and adrenoferredoxin (adrenodoxin) using proton NMR spectroscopy. The line width of the signals from NADP(+) depends on the presence of the reductase. The off rate constant of NADP(+) from the reductase is estimated to be about 15 similar to 20 s(-1) on the basis of line width measurements. No appreciable difference in off rate is detected between adenine and nicotinamide moieties of NADP(+). Transferred nuclear Overhauser effect experiments for NADP(+) indicate the time-dependent magnetization transfer profiles with a long lag phase. The proton NMR spectra during the titration of the reductase with adrenodoxin reveal that the reductase possesses distinct binding sites for both NADP(+) and adrenodoxin. The sharp resonances in the aromatic region due to His-10 and His-62 of adrenodoxin were utilized as a probe to explore the interaction with the reductase. In the mixture of adrenodoxin and the reductase at the mol ratio of 6:1, T-1 values of the histidine residue in adrenodoxin were measured by the inversion recovery method. At low ionic strength, T-1 values of the resonances are not affected in the presence or absence of the reductase, In the presence of the reductase, T-1 values of resonances resulting from the histidine residues become shorter as the concentration of KCl increases because of rapid exchange between bound and free states. At low ionic strength (10 mM phosphate buffer), the off rate from the reductase is estimated to be less than about 4 s(-1). The off rate of adrenodoxin from the reductase could be the rate-limiting step in cytochrome c reductase activity at low ionic strength.			MIURA, S (corresponding author), KAGAWA MED SCH,DEPT BIOCHEM,MIKI,KAGAWA 76107,JAPAN.							BANERJEE A, 1987, BIOCHEMISTRY-US, V26, P8443, DOI 10.1021/bi00399a062; CHU JW, 1973, J BIOL CHEM, V248, P5183; CLORE GM, 1983, J MAGN RESON, V53, P423, DOI 10.1016/0022-2364(83)90215-9; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; COGHLAN VM, 1991, J BIOL CHEM, V266, P18606; COGHLAN VM, 1992, J BIOL CHEM, V267, P8932; FERRIN LJ, 1985, BIOCHEMISTRY-US, V24, P6904, DOI 10.1021/bi00345a024; GEREN LM, 1984, J BIOL CHEM, V261, P15491; HIWATASHI A, 1976, BIOCHEMISTRY-US, V15, P3082, DOI 10.1021/bi00659a023; HIWATASHI A, 1986, FEBS LETT, V209, P311, DOI 10.1016/0014-5793(86)81133-4; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAMIN H, 1982, FLAVINS FLAVOPROTEIN, P655; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KOUDA D, 1987, BIOCHEMISTRY-US, V26, P6531; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBETH JD, 1980, J BIOL CHEM, V255, P4667; LAMBETH JD, 1979, J BIOL CHEM, V254, P7255; LAMBETH JD, 1981, J BIOL CHEM, V256, P3674; LAMBETH JD, 1982, MOL CELL BIOCHEM, V45, P13, DOI 10.1007/BF01283159; LIGHT DR, 1980, J BIOL CHEM, V255, P4264; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MIURA S, 1991, EUR J BIOCHEM, V197, P747, DOI 10.1111/j.1432-1033.1991.tb15967.x; MIURA S, 1991, J BIOL CHEM, V266, P19212; MIURA S, 1991, J BIOL CHEM, V266, P6252; NONAKA Y, 1987, BIOCHEM BIOPH RES CO, V145, P1239, DOI 10.1016/0006-291X(87)91570-1; NONAKA Y, 1985, J BIOCHEM-TOKYO, V97, P1263, DOI 10.1093/oxfordjournals.jbchem.a135177; OMURA T, 1966, ARCH BIOCHEM BIOPHYS, V117, P660, DOI 10.1016/0003-9861(66)90108-1; PAI EF, 1988, BIOCHEMISTRY-US, V27, P4465, DOI 10.1021/bi00412a038; PUEYO JJ, 1989, EUR J BIOCHEM, V183, P539, DOI 10.1111/j.1432-1033.1989.tb21082.x; ROSEVEAR PR, 1987, BIOCHEMISTRY-US, V26, P5338, DOI 10.1021/bi00391a018; SAGARA Y, 1987, J BIOCHEM-TOKYO, V102, P1333, DOI 10.1093/oxfordjournals.jbchem.a122178; SANDSTROM J, 1982, DYNAMIC NMR SPECTROS, P6; SHIN M, 1968, FLAVINS FLAVOPROTEIN, P1; SUHARA K, 1972, FEBS LETT, V28, P45, DOI 10.1016/0014-5793(72)80673-2; WEBER DJ, 1991, BIOCHEMISTRY-US, V30, P7425, DOI 10.1021/bi00244a009; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P93; ZUIDERWEG ERP, 1986, J MAGN RESON, V70, P336, DOI 10.1016/0022-2364(86)90020-X	39	5	5	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8001	8006						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132521				2022-12-25	WOS:A1994NB40900029
J	ASTURIAS, JA; ELTIS, LD; PRUCHA, M; TIMMIS, KN				ASTURIAS, JA; ELTIS, LD; PRUCHA, M; TIMMIS, KN			ANALYSIS OF 3,2,3-DIHYDROXYBIPHENYL 1,2-DIOXYGENASES FOUND IN RHODOCOCCUS-GLOBERULUS P6 - IDENTIFICATION OF A NEW FAMILY OF EXTRADIOL DIOXYGENASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCHLORINATED BIPHENYL DEGRADATION; CATECHOL 2,3-OXYGENASE GENES; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; PSEUDOMONAS-PSEUDOALCALIGENES; ENCODING BIPHENYL; TOL PLASMID; EXPRESSION; CLONING; DNA	The polychlorobiphenyl-degrading bacterium Rhodococcus globerulus P6 contains three bphC genes encoding 2,3-dihydroxybiphenyl 1,2-dioxygenases. One of them, bphC1, is clustered with the bphB gene which encodes 2,3-dihydroxy-4-phenylhexa-4,6-diene dehydrogenase and constitutes part of the bph operon specifying the degradation of biphenyl. The nucleotide sequence of bphB and the three bphC genes has been determined. The protein products of the bphBC1 gene cluster were found to exhibit significant homology with the corresponding proteins of analogous degradative pathways in Gram-negative bacteria; the highest homology was in those of the toluene degradation pathway of Pseudomonas putida strain F1. No homology was found between bphC2 and bphC3 and any other sequence in the database. At least two of the three meta cleavage enzymes are inducible by biphenyl. 2,3-Dihydroxybiphenyl 1,2-dioxygenase II, encoded by the bphC2 gene, was purified to apparent homogeneity from a recombinant Escherichia coli strain. The enzyme differed from other extradiol dioxygenases in having a subunit molecular mass of 21 kDa and a hexameric structure. The enzyme contains one tightly bound iron per subunit. These characteristics demonstrate that the 2,3-dihydroxybiphenyl 1,2-dioxygenases encoded by bphC2 and bphC3 belong to a new class of extradiol dioxygenases.	GESELL BIOTECHNOL FORSCH MBH,NATL RES CTR BIOTECHNOL,DEPT MICROBIOL,D-38124 BRAUNSCHWEIG,GERMANY	Gesellschaft fur Biotechnologische Forschung mbH			Eltis, Lindsay D/J-8272-2015	Eltis, Lindsay D/0000-0002-6774-8158; Asturias, Juan/0000-0001-9570-522X				ABRAMOWICZ DA, 1990, CRIT REV BIOTECHNOL, V10, P241, DOI 10.3109/07388559009038210; ADAMS RH, 1992, APPL ENVIRON MICROB, V58, P647, DOI 10.1128/AEM.58.2.647-654.1992; AHMAD D, 1990, GENE, V86, P53, DOI 10.1016/0378-1119(90)90113-6; AHMED M, 1973, CAN J MICROBIOL, V19, P47, DOI 10.1139/m73-007; ASTURIAS JA, 1993, J BACTERIOL, V175, P4631, DOI 10.1128/JB.175.15.4631-4640.1993; BLOCK DW, 1992, BIOL CHEM H-S, V373, P343, DOI 10.1515/bchm3.1992.373.1.343; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATFIELD LK, 1986, J BACTERIOL, V168, P878, DOI 10.1128/jb.168.2.878-885.1986; CHEN CM, 1991, APPL ENVIRON MICROB, V57, P2217, DOI 10.1128/AEM.57.8.2217-2222.1991; CRESPI M, 1992, EMBO J, V11, P795, DOI 10.1002/j.1460-2075.1992.tb05116.x; DESOMER J, 1992, MOL MICROBIOL, V6, P2377, DOI 10.1111/j.1365-2958.1992.tb01412.x; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; ELTIS LD, 1993, J BIOL CHEM, V268, P2727; ERICKSON BD, 1992, J BACTERIOL, V174, P2903, DOI 10.1128/JB.174.9.2903-2912.1992; FINNERTY WR, 1992, ANNU REV MICROBIOL, V46, P193, DOI 10.1146/annurev.mi.46.100192.001205; FURUKAWA K, 1987, J BACTERIOL, V169, P427, DOI 10.1128/jb.169.1.427-429.1987; FURUKAWA K, 1986, J BACTERIOL, V166, P392, DOI 10.1128/jb.166.2.392-398.1986; FURUKAWA K, 1987, J BACTERIOL, V169, P924, DOI 10.1128/jb.169.2.924-927.1987; GHOSAL D, 1987, GENE, V55, P19, DOI 10.1016/0378-1119(87)90244-7; HAPPE B, 1993, J BACTERIOL, V175, P7313, DOI 10.1128/JB.175.22.7313-7320.1993; HARAYAMA S, 1993, MOL GEN GENET, V239, P81, DOI 10.1007/BF00281605; HARAYAMA S, 1992, ANNU REV MICROBIOL, V46, P565, DOI 10.1146/annurev.micro.46.1.565; HARAYAMA S, 1989, J BIOL CHEM, V264, P15328; HART S, 1960, J GEN MICROBIOL, V136, P1357; HAYASE N, 1990, J BACTERIOL, V172, P1160, DOI 10.1128/jb.172.2.1160-1164.1990; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOFER B, 1993, GENE, V130, P47, DOI 10.1016/0378-1119(93)90345-4; IKEHATA O, 1989, EUR J BIOCHEM, V181, P563, DOI 10.1111/j.1432-1033.1989.tb14761.x; KABISCH M, 1990, NUCLEIC ACIDS RES, V18, P5543, DOI 10.1093/nar/18.18.5543; KEIL H, 1985, J BACTERIOL, V163, P248, DOI 10.1128/JB.163.1.248-255.1985; KHAN A, 1989, APPL ENVIRON MICROB, V55, P798, DOI 10.1128/AEM.55.4.798-805.1989; KIMBARA K, 1989, J BACTERIOL, V171, P2740, DOI 10.1128/jb.171.5.2740-2747.1989; Kuhm A E, 1991, Biodegradation, V2, P115, DOI 10.1007/BF00114601; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miller J.H., 1972, EXPT MOL GENETICS; MONDELLO FJ, 1989, J BACTERIOL, V171, P1725, DOI 10.1128/jb.171.3.1725-1732.1989; NAKAI C, 1983, J BIOL CHEM, V258, P2923; NEIDLE EL, 1991, EUR J BIOCHEM, V204, P113; NOZAKI M, 1963, BIOCHEM Z, V338, P582; OLSON PE, 1992, APPL ENVIRON MICROB, V58, P2820, DOI 10.1128/AEM.58.9.2820-2826.1992; PELOQUIN L, 1993, GENE, V125, P35, DOI 10.1016/0378-1119(93)90742-L; RAMOS JL, 1987, SCIENCE, V235, P593, DOI 10.1126/science.3468623; RUSSEL M, 1984, J BACTERIOL, V159, P1034, DOI 10.1128/JB.159.3.1034-1039.1984; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SHINGLER V, 1992, J BACTERIOL, V174, P711, DOI 10.1128/jb.174.3.711-724.1992; STROHL WR, 1992, NUCLEIC ACIDS RES, V20, P961, DOI 10.1093/nar/20.5.961; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAIRA K, 1992, J BIOL CHEM, V267, P4844; TAIRA K, 1988, BIOCHEMISTRY-US, V27, P3990, DOI 10.1021/bi00411a015; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WIERENGA RK, 1986, J MOL BIOL, V187, P105; ZYLSTRA GJ, 1989, J BIOL CHEM, V264, P14940	54	90	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7807	7815						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8126007				2022-12-25	WOS:A1994NA03200118
J	FROELICHAMMON, SJ; GALE, KC; OSHEROFF, N				FROELICHAMMON, SJ; GALE, KC; OSHEROFF, N			SITE-SPECIFIC CLEAVAGE OF A DNA HAIRPIN BY TOPOISOMERASE-II - DNA SECONDARY STRUCTURE AS A DETERMINANT OF ENZYME RECOGNITION/CLEAVAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER CHROMATID EXCHANGES; CHINESE-HAMSTER CELLS; EUKARYOTIC TOPOISOMERASE; ILLEGITIMATE RECOMBINATION; STRANDED-DNA; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; NUCLEOTIDE-SEQUENCE; MITOCHONDRIAL-DNA; INVITRO	To further define the nucleic acid determinants that govern the recognition of DNA by topoisomerase II, the ability of the enzyme to cleave a 51-base oligonucleotide that contained a centrally located 19-base hairpin was characterized. Topoisomerase II cleaved the 51-mer in a site-specific fashion, within the hairpin, one nucleotide from the 3'-base of the stem. Protein denaturants were not required to trap cleavage products. Although the sequence of the oligonucleotide influenced levels of enzyme-mediated DNA scission, it did not affect the spatial location of cleavage. DNA scission required a doublestranded/single-stranded junction at the 3'-base of the hairpin and a tail (either single- or double-stranded) at least 8 bases in length on the 5'-side. Cleavage was not observed when base-pairing within the oligonucleotide was eliminated or when the hairpin was extended to produce a completely double stranded substrate. Finally, the enzyme displayed a size constraint for both the stem and loop structures of the hairpin. These results indicate that topoisomerase II is capable of recognizing secondary structure within nucleic acids and identifies the first secondary structure-specific DNA recognition/cleavage site for the type II enzyme.	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232	Vanderbilt University					NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA09582] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; AKINS RA, 1990, CURR GENET, V18, P365, DOI 10.1007/BF00318218; ALMASAN A, 1991, P NATL ACAD SCI USA, V88, P7684, DOI 10.1073/pnas.88.17.7684; ANDERSEN AH, 1991, J BIOL CHEM, V266, P9203; ANDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P6237, DOI 10.1021/bi00441a015; ANDERSSON HC, 1989, CARCINOGENESIS, V10, P123, DOI 10.1093/carcin/10.1.123; BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; BAE YS, 1991, GENE, V101, P285; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BULLOCK P, 1985, SCIENCE, V230, P954, DOI 10.1126/science.2997924; CHARRON M, 1991, CHROMOSOMA, V100, P97, DOI 10.1007/BF00418242; CHARTRAND P, 1991, DNA TOPOISOMERASES C, P240; CHATTERJEE S, 1990, CANCER RES, V50, P2713; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; CORBETT AH, 1992, J BIOL CHEM, V267, P683; Cox M. M., 1989, MOBILE DNA, P661; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DALE EC, 1990, GENE, V91, P79, DOI 10.1016/0378-1119(90)90165-N; DEGRASSI F, 1989, MUTAT RES, V211, P125, DOI 10.1016/0027-5107(89)90112-7; DEVORE R, 1989, ANN INTERN MED, V110, P704, DOI 10.7326/0003-4819-110-9-740; DILLEHAY LE, 1989, MUTAT RES, V215, P15, DOI 10.1016/0027-5107(89)90213-3; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; FRANZ B, 1990, J MOL BIOL, V215, P523, DOI 10.1016/S0022-2836(05)80165-2; FREUDENREICH CH, 1993, EMBO J, V12, P2085, DOI 10.1002/j.1460-2075.1993.tb05857.x; GALE KC, 1990, BIOCHEMISTRY-US, V29, P9538, DOI 10.1021/bi00493a007; GALE KC, 1992, J BIOL CHEM, V267, P12090; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GELLERT M, 1992, TRENDS GENET, V8, P408, DOI 10.1016/0168-9525(92)90322-U; GODSON GN, 1978, SINGLE STRANDED DNA, P51; HANYH, 1993, J MOL BIOL, V229, P52; HIRANO T, 1991, J CELL BIOL, V115, P1479, DOI 10.1083/jcb.115.6.1479; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HUANG WM, 1990, DNA TOPOLOGY ITS BIO, P409; IKEDA H, 1986, P NATL ACAD SCI USA, V83, P922, DOI 10.1073/pnas.83.4.922; KREUZER KN, 1984, J BIOL CHEM, V259, P5347; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LEE MP, 1989, J BIOL CHEM, V264, P21779; LIM M, 1986, CELL BIOL TOXICOL, V2, P485, DOI 10.1007/BF00117850; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1983, J BIOL CHEM, V258, P5365; LONN U, 1989, CANCER RES, V49, P6202; MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561; MULLER MT, 1988, BIOCHEMISTRY-US, V27, P8369, DOI 10.1021/bi00422a012; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; PEDERSENBJERGAARD J, 1992, LEUKEMIA RES, V16, P733, DOI 10.1016/0145-2126(92)90150-6; POMMIER Y, 1991, NUCLEIC ACIDS RES, V19, P5973, DOI 10.1093/nar/19.21.5973; POMMIER Y, 1985, CANCER RES, V45, P3143; RENAULT G, 1987, TOXICOL APPL PHARM, V89, P281, DOI 10.1016/0041-008X(87)90049-4; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROSE D, 1990, CELL, V60, P1009, DOI 10.1016/0092-8674(90)90349-J; ROWE TC, 1984, J BIOL CHEM, V259, P9177; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SANDER M, 1983, J BIOL CHEM, V258, P8421; SANGER F, 1978, J MOL BIOL, V125, P225, DOI 10.1016/0022-2836(78)90346-7; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; THOMSEN B, 1990, J MOL BIOL, V215, P237, DOI 10.1016/S0022-2836(05)80342-0; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WINICK NJ, 1993, J CLIN ONCOL, V11, P209, DOI 10.1200/JCO.1993.11.2.209; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	83	81	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7719	7725						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125998				2022-12-25	WOS:A1994NA03200106
J	BALDWIN, AN; SHOOTER, EM				BALDWIN, AN; SHOOTER, EM			DISULFIDE MUTANTS OF THE BINDING DOMAIN OF THE RAT LOW-AFFINITY NERVE GROWTH-FACTOR RECEPTOR (P75(NGFR))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NUCLEAR MAGNETIC-RESONANCE; MONOCLONAL-ANTIBODY 217C; MOLECULAR-CLONING; NGF RECEPTOR; EXPRESSION; PROTEINS; CONFORMATION; ANTIGEN; CELLS	The binding domain of the low affinity nerve growth factor receptor (p75NGFR) is built from four ''cysteine repeats,'' with almost identical patterns of half-cystine residues. To study the pattern of disulfide bridging within each cysteine repeat, we have mutated pairs of cysteine residues, primarily in the fourth repeat, and have tested the relative ability of each mutant to be cross-linked to the nerve growth factor after transient expression in COS 7 cells. The results give an indication of the relative importance of different disulfide bonds for the stability of the active conformation. Immunofluorescent staining shows that all of these proteins, even those that may be partially misfolded, are expressed to varying degrees on the surface of COS cells. They can also be detected by the monoclonal antibody MC192 on a Western blot following electrophoresis on a nondenaturing gel. Some cannot, however, be detected by MC192 on a Western blot after heat denaturation in SDS. The ability to refold under these conditions correlates in general with the ability of the mutant protein to bind nerve growth factor on the surface of COS cells.			BALDWIN, AN (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305, USA.				NINDS NIH HHS [NS04270] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS004270] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHARYA AS, 1977, P NATL ACAD SCI USA, V74, P2362, DOI 10.1073/pnas.74.6.2362; BALDWIN AN, 1992, J BIOL CHEM, V267, P8352; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CHRAMBACH A, 1976, METHODS PROTEIN SEPA, V2, P27; CLORE GM, 1987, EMBO J, V6, P529, DOI 10.1002/j.1460-2075.1987.tb04785.x; CREIGHTON TE, 1980, FEBS LETT, V118, P283, DOI 10.1016/0014-5793(80)80239-0; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; CREIGHTON TE, 1975, J MOL BIOL, V96, P767, DOI 10.1016/0022-2836(75)90151-5; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ELLIOTT JF, 1990, P NATL ACAD SCI USA, V87, P6363, DOI 10.1073/pnas.87.16.6363; FERRARI G, 1991, EXP NEUROL, V112, P183, DOI 10.1016/0014-4886(91)90068-N; FLORY PJ, 1956, J AM CHEM SOC, V78, P5222, DOI 10.1021/ja01601a025; GOTO Y, 1987, J BIOCHEM, V101, P319, DOI 10.1093/oxfordjournals.jbchem.a121916; HARUYAMA H, 1989, BIOCHEMISTRY-US, V28, P4301, DOI 10.1021/bi00436a027; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KUMAR S, 1990, J NEUROSCI RES, V27, P408, DOI 10.1002/jnr.490270320; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDBETTER JA, 1981, J EXP MED, V153, P1503, DOI 10.1084/jem.153.6.1503; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MONTELIONE GT, 1986, P NATL ACAD SCI USA, V83, P8594, DOI 10.1073/pnas.83.22.8594; PENG WW, 1982, SCIENCE, V215, P1102, DOI 10.1126/science.7063842; POLAND DC, 1965, BIOPOLYMERS, V3, P379, DOI 10.1002/bip.1965.360030404; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHELLMAN JOHN A., 1955, COMPT REND TRAV LAB CARLSBERG SER CHIM, V29, P223; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEDA T, 1985, BIOCHEMISTRY-US, V24, P6316, DOI 10.1021/bi00343a042; UPTON C, 1987, VIROLOGY, V160, P20, DOI 10.1016/0042-6822(87)90039-0; YAN H, 1991, J BIOL CHEM, V266, P12099	36	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11456	11461						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157676				2022-12-25	WOS:A1994NF96600071
J	JIANG, SW; EBERHARDT, NL				JIANG, SW; EBERHARDT, NL			THE HUMAN CHORIONIC SOMATOMAMMOTROPIN GENE ENHANCER IS COMPOSED OF MULTIPLE DNA ELEMENTS THAT ARE HOMOLOGOUS TO SEVERAL SV40 ENHANSONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL-LACTOGEN; TRANSCRIPTION; PITUITARY; EVOLUTION; SEQUENCE; TEF-1; SPECIFICITY; EXPRESSION; PREGNANCY; PROTEIN	Previous studies indicate that a human chorionic somatomammotropin (hCS) gene enhancer (CSEn) associated with the growth hormone (hGH) gene locus is involved in directing cell-specific expression of the hCS genes in placenta. In the current studies, we report a detailed structural analysis of this enhancer. CSEn stimulated transcription of a variety of promoters, including the hCS, human growth hormone, thymidine kinase, and Rous sarcoma virus promoters, in human choriocarcinoma cell lines (BeWo and JEG-3) but not HeLa cells or rat somatolactotrophes (GC). Maximal enhancer activity was confined to a 242-base pair DNA segment. Of several CSEn subfragments, only the En 57/242 subfragment retained activity (33.5% wild-type). The CSEn DNA sequence contained direct and inverted repeat motifs and sequences related to the SV40 enhansons, GT-IIC, GT-I, and SphI/SphII. DNase I footprint analysis revealed that most of these sites were protected by nuclear proteins derived from BeWo, JEG-3, HeLa, and GC cells. Site-specific block mutation of the GT-IIC-related and inverted repeat moths virtually abolished enhancer activity, and mutation of all but the GT-I-related motif resulted in significant loss (30-60%) of activity. These data demonstrate that the CS enhancer is comprised of multiple elements related to SV40 enhansons that interact cooperatively to generate enhancer function.	MAYO CLIN & MAYO FDN,DEPT MED,ENDOCRINE RES UNIT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic					NIDDK NIH HHS [DK41206] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041206] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; CHEN EY, 1989, GENOMICS, V4, P479, DOI 10.1016/0888-7543(89)90271-1; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FITZPATRICK SL, 1990, MOL ENDOCRINOL, V4, P1815, DOI 10.1210/mend-4-12-1815; HANDWERGER S, 1991, ENDOCR REV, V12, P329, DOI 10.1210/edrv-12-4-329; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; HIRT H, 1987, DNA-J MOLEC CELL BIO, V6, P59, DOI 10.1089/dna.1987.6.59; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; JJONES BK, 1992, ENDOCRINE SOC PROGRA, V74, P446; LOSARDO JE, 1990, J VIROL, V64, P1756, DOI 10.1128/JVI.64.4.1756-1763.1990; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; NACHTIGAL MW, 1993, J BIOL CHEM, V268, P8473; NEILSEN PV, 1979, AM J OBSTET GYNECOL, V135, P322; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; RODGERS BL, 1986, NUCLEIC ACIDS RES, V14, P7647; SCHIER AF, 1993, EMBO J, V12, P1111, DOI 10.1002/j.1460-2075.1993.tb05752.x; Snedecor G. W., 1980, STATISTICAL METHODS, P116; SOARES MJ, 1991, ENDOCR REV, V12, P402, DOI 10.1210/edrv-12-4-402; WALKER WH, 1991, ENDOCR REV, V12, P316, DOI 10.1210/edrv-12-4-316; WALKER WH, 1990, J BIOL CHEM, V265, P12940; WURZEL JM, 1982, DNA-J MOLEC CELL BIO, V1, P251, DOI 10.1089/dna.1.1982.1.251; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G	27	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10384	10392						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144621				2022-12-25	WOS:A1994NF01700033
J	AOKI, K; NAKAHARA, K; IKEGAWA, C; SETO, M; TAKAHASHI, T; MINOWADA, J; STROMINGER, JL; MAZIARZ, RT; KASAI, M				AOKI, K; NAKAHARA, K; IKEGAWA, C; SETO, M; TAKAHASHI, T; MINOWADA, J; STROMINGER, JL; MAZIARZ, RT; KASAI, M			NUCLEAR PROTEINS BINDING TO A NOVEL TARGET SEQUENCE WITHIN THE RECOMBINATION HOTSPOT REGIONS OF BCL-2 AND THE IMMUNOGLOBULIN-D(H) GENE FAMILY	ONCOGENE			English	Article							T-CELL LEUKEMIA; CHROMOSOMAL BREAKPOINT; FOLLICULAR LYMPHOMA; DNA-REPLICATION; TRANSLOCATION; T(14-18); MECHANISM; CONSENSUS; NEOPLASMS; CLONING	The chromosomal breakpoints of follicular lymphomas carrying the t(14;18)(q32;q21) are known to be clustered within a 150-bp region in the major breakpoint region (mbr) of the Bc1-2 oncogene. We have demonstrated that nuclear proteins specifically bind to a novel target sequence within this 150-bp region and a region of Dxp genes, members of the immunoglobulin (Ig) diversity (D(H)) gene family. One protein, designated BCLF-1, appears to be specifically expressed in lymphoid lineage cells. Two other proteins, BCLF-2 and -3, bind only to the complementary single strand of the target sequence. The manner in which these proteins interact with the target sequence is similar to the interaction of the ReHF-1 and -2 proteins to the signal-like sequence at the chromosomal breakpoint junctions in patients with the t(8;14)(q24;q11) and t(1;14)(p32;q11) translocations. It was further suggested that the BCLF-1 is quite similar to or identical to the ReHF-1. It is therefore hypothesized that these conserved target sequences found in recombination hotspot regions may define novel sequence motifs recognized by two classes of DNA binding proteins. One class of DNA binding proteins is specifically expressed in lymphoid cells while the other class binds to the complementary single strand DNA. These binding activities may play a crucial role in chromosomal translocation in lymphoid neoplasms.	NATL INST HLTH,DEPT IMMUN,1-23-1 TOYAMA,SHINJUKU KU,TOKYO 162,JAPAN; UNIV TOKYO,DEPT INTERNAL MED 1,BUNKYO KU,TOKYO 113,JAPAN; KYORIN UNIV,SCH MED,DEPT CLIN PATHOL,MITAKA,TOKYO 181,JAPAN; AICHI CANC CTR,CHEMOTHERAPY LAB,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,IMMUNOL LAB,CHIYODA KU,NAGOYA,AICHI 464,JAPAN; HAYASHIBARA BIOCHEM LABS INC,FUJISAKI CELL CTR,OKAYAMA 702,JAPAN; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138; OREGON HLTH SCI UNIV,DIV HEMATOL ONCOL,PORTLAND,OR 97201; VAMC,PORTLAND,OR 97207	University of Tokyo; Kyorin University; Aichi Cancer Center; Aichi Cancer Center; Hayashibara Biochemical Laboratories, Inc.; Harvard University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System								BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOEHM T, 1989, FASEB J, V3, P2344, DOI 10.1096/fasebj.3.12.2676678; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COTTER F, 1990, BLOOD, V76, P131; CRESCENZI M, 1988, P NATL ACAD SCI USA, V85, P4869, DOI 10.1073/pnas.85.13.4869; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GAUWERKY CE, 1988, P NATL ACAD SCI USA, V85, P8548, DOI 10.1073/pnas.85.22.8548; ICHIHARA Y, 1988, EMBO J, V7, P4141, DOI 10.1002/j.1460-2075.1988.tb03309.x; JAEGER U, 1993, BLOOD, V81, P1883; KASAI M, 1992, MOL CELL BIOL, V12, P4751, DOI 10.1128/MCB.12.10.4751; KASAI M, 1993, UNPUB; KOBAYASHI I, 1984, COLD SPRING HARB SYM, V49, P497, DOI 10.1101/SQB.1984.049.01.056; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; MAZIARZ RT, 1992, BLOOD, V79, P1523; MINOWADA J, 1988, Cancer Reviews, V10, P1; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; SETO M, 1991, JPN J CANCER RES, V82, P65, DOI 10.1111/j.1349-7006.1991.tb01747.x; SMITH GR, 1983, CELL, V34, P709, DOI 10.1016/0092-8674(83)90525-1; TAYLOR AF, 1988, REC BCD ENZYME ESCHE, P231; TSUJIMOTO Y, 1988, ONCOGENE, V2, P347; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; UMEK RM, 1989, BIOCHIM BIOPHYS ACTA, V1007, P1, DOI 10.1016/0167-4781(89)90123-1; WYATT RT, 1992, J EXP MED, V175, P1575, DOI 10.1084/jem.175.6.1575	28	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1109	1115						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134113				2022-12-25	WOS:A1994NC04800013
J	MASOLIVA, J; ARNOLD, KS; WAGNER, WD; PHILLIPS, DR; PITAS, RE; INNERARITY, TL				MASOLIVA, J; ARNOLD, KS; WAGNER, WD; PHILLIPS, DR; PITAS, RE; INNERARITY, TL			ISOLATION AND CHARACTERIZATION OF A PLATELET-DERIVED MACROPHAGE-BINDING PROTEOGLYCAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CHONDROITIN 4-SULFATE PROTEOGLYCAN; SMOOTH-MUSCLE CELLS; HERITABLE HYPERLIPIDEMIC RABBIT; ENDOTHELIAL-CELLS; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN FIBROBLASTS; RECEPTOR; ATHEROSCLEROSIS; DEGRADATION	A macromolecule in human platelet secretory products was demonstrated previously to inhibit the binding and uptake of acetoacetylated (AcAc) low density lipoproteins (LDL) by scavenger receptors on mouse peritoneal macrophages. In the current study, this macromolecule was purified to apparent homogeneity by DEAE-Sephacel chromatography, Sephacryl S-300 chromatography, and sucrose gradient centrifugation. SDS-polyacrylamide gel electrophoresis revealed a single band with an apparent molecular mass of approximately 120 kDa. Chemical analysis indicated that the macromolecule (designated platelet-derived macrophage-binding proteoglycan (PDMBP)) was a chondroitin 4-sulfate proteoglycan with an approximately 32-kDa core protein. A polyclonal antibody produced against this proteoglycan identified only PDMBP on Western blots of platelet secretory products and removed all ability of these products to inhibit the binding of AcAc LDL to macrophages. Treatment of purified PDMBP with protease or chondroitinase AC or A.BC abolished the ability of the proteoglycan to inhibit the binding of AcAc LDL to macrophages. Binding studies using radiolabeled PDMBP demonstrated that the proteoglycan bound directly to the macrophage cell surface and was competitively inhibited by AcAc LDL, acetyl-LDL, fucoidin, and unlabeled PDMBP. PDMBP inhibited binding of I-125-labeled AcAc LDL to macrophages but had no effect on binding to endothelial cells. The finding that PDMBP binds to the scavenger receptor on macrophages suggests a mechanism for the inhibition of foam cell formation and suggests that the receptor could be involved in the plasma clearance of chondroitin sulfate proteoglycans.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94141; COR THERAPEUT INC,S SAN FRANCISCO,CA 94080; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,WINSTON SALEM,NC 27157	University of California System; University of California San Francisco; Wake Forest University; Wake Forest Baptist Medical Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045848, P01HL047660] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47660, HL 45848] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACTON S, 1993, J BIOL CHEM, V268, P3530; BARBER AJ, 1972, BIOCHIM BIOPHYS ACTA, V286, P312, DOI 10.1016/0304-4165(72)90267-X; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BROWN MS, 1974, J BIOL CHEM, V249, P789; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; COHN ZA, 1965, J EXP MED, V121, P153, DOI 10.1084/jem.121.1.153; DODGSON KS, 1961, BIOCHEM J, V78, P312, DOI 10.1042/bj0780312; FITZGERALD LA, 1985, J BIOL CHEM, V260, P893; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HABERLAND ME, 1987, AM HEART J, V113, P573, DOI 10.1016/0002-8703(87)90635-1; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HUANG SS, 1982, J BIOL CHEM, V257, P1546; Innerarity T L, 1986, Methods Enzymol, V129, P542; KERBY GP, 1959, J LAB CLIN MED, V53, P708; KERBY GP, 1992, J LAB CLIN MED, V90, P1450; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KURIHARA Y, 1991, CURR OPIN LIPIDOL, V2, P295; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; NADER HB, 1991, J BIOL CHEM, V266, P10518; OKAYAMA M, 1986, BIOCHEM J, V233, P73, DOI 10.1042/bj2330073; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P3000, DOI 10.1073/pnas.82.9.3000; PERIN JP, 1988, BIOCHEM J, V255, P1007, DOI 10.1042/bj2551007; PHILLIPS DR, 1985, NATURE, V316, P746, DOI 10.1038/316746a0; PITAS RE, 1985, J CELL BIOL, V100, P103, DOI 10.1083/jcb.100.1.103; PITAS RE, 1990, J BIOL CHEM, V265, P12722; RADHAKRISHNAMURTHY B, 1980, J BIOL CHEM, V255, P7575; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SELDIN DC, 1984, ANAL BIOCHEM, V141, P291, DOI 10.1016/0003-2697(84)90459-7; SILVESTRI L, 1981, J BIOL CHEM, V256, P7383; STANTON LW, 1992, J BIOL CHEM, V267, P22446; STEIN O, 1980, BIOCHIM BIOPHYS ACTA, V620, P631, DOI 10.1016/0005-2760(80)90155-1; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053	39	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					10177	10183						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144520				2022-12-25	WOS:A1994NE05300116
J	NAG, B; ARIMILLI, S; KOUKIS, B; RHODES, E; BAICHWAL, V; SHARMA, SD				NAG, B; ARIMILLI, S; KOUKIS, B; RHODES, E; BAICHWAL, V; SHARMA, SD			INTRAMOLECULAR CHARGE HETEROGENEITY IN PURIFIED MAJOR HISTOCOMPATIBILITY CLASS-II ALPHA-POLYPEPTIDE AND BETA-POLYPEPTIDE CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESOLUTION 2-DIMENSIONAL ELECTROPHORESIS; N-LINKED OLIGOSACCHARIDES; ANTIGENIC PEPTIDE BINDING; T-CELL RECOGNITION; HLA-DR; TUNICAMYCIN INHIBITION; B-CELL; MOLECULES; COMPLEX; SEQUENCE	Major histocompatibility (MHC) class II antigens are heterodimeric cell surface glycoproteins consisting of an alpha and beta chain. Although one-dimensional SDS-polyacrylamide gel electrophoresis analysis of purified MHC class II antigens shows a single diffuse band for each chain, multiple spots of identical molecular size were observed for each chain when analyzed by two-dimensional electrophoresis. The basis of this heterogeneity has not been clearly defined and has been predicted partially to be due to glycosylation and/or phosphorylation of the mature protein. To investigate the role of the three N-linked oligosaccharides of the alpha and beta chains in determining the isoelectric point of each chain, affinity-purified MHC class II antigens from human and rat sources were deglycosylated using asparagine amidase. The complete enzymatic removal of all three N-linked oligosaccharides was confirmed by SDS-polyacrylamide gel electrophoresis as well as by four different lectin-linked Western blot analyses. Two-dimensional gel analysis of the deglycosylated molecules shows no significant difference from the fully glycosylated chains. We have expressed truncated forms of the HLA DR2 chains which lack the transmembrane and cytoplasmically exposed regions in Escherichia coli. Two-dimensional electrophoresis of these single chains also reveal multiple banding patterns. The two-dimensional banding patterns described are unaffected by exposure to acidic or basic conditions, increased gel running time in the first dimension, treatment of the proteins with alkaline phosphatase to remove any potential phosphorylation, or preincubation in the presence of iodoacetamide. Multiple forms of recombinant alpha and beta chains were also observed in Tris-glycine-urea gels which merged into a single band in the presence of SDS. In addition, partially fractionated bands from preparative isoelectric focusing gels, when refocused, showed an identical number of multiple spots spanning the same range of isoelectric points. These results together suggest that each polypeptide chain of MHC class II antigens may exist in multiconformational forms, and the observed charge heterogeneity is independent of glycosylation and phosphorylation of the proteins.			NAG, B (corresponding author), ANERGEN INC,REDWOOD CITY,CA 94063, USA.							ALLEN PM, 1987, IMMUNOL REV, V98, P171, DOI 10.1111/j.1600-065X.1987.tb00524.x; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BASHEERUDDIN K, 1985, APPL BIOCHEM BIOTECH, V11, P133, DOI 10.1007/BF02798545; BENOIST CO, 1983, P NATL ACAD SCI-BIOL, V80, P534, DOI 10.1073/pnas.80.2.534; BONTROP RE, 1990, J EXP MED, V172, P53, DOI 10.1084/jem.172.1.53; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; BUSS S, 1986, CELL, V47, P1071; BUSS S, 1987, IMMUNOL REV, V98, P95; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; CHARRON DJ, 1990, J EXP MED, V152, pS18; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CHICZ RM, 1993, NATURE, V178, P27; CHOI E, 1983, SCIENCE, V221, P283, DOI 10.1126/science.6407114; COWING C, 1983, P NATL ACAD SCI-BIOL, V80, P6000, DOI 10.1073/pnas.80.19.6000; CULLEN SE, 1976, TRANSPLANT REV-DENMA, V30, P236; CULLEN SE, 1981, J IMMUNOL, V127, P1478; CULLEN SE, 1975, TRANSPL P, V8, P237; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DORNMAIR K, 1989, COLD SPRING HARB SYM, V54, P409; ESTESS P, 1986, P NATL ACAD SCI USA, V83, P3594, DOI 10.1073/pnas.83.11.3594; FROHMAN M, 1985, J IMMUNOL, V134, P2269; FUKS A, 1977, TRANSPL P, V9, P1685; LEHLE L, 1976, FEBS LETT, V71, P167, DOI 10.1016/0014-5793(76)80922-2; MALISSEN M, 1983, SCIENCE, V221, P750, DOI 10.1126/science.6410508; NAG B, 1993, P NATL ACAD SCI USA, V90, P1604, DOI 10.1073/pnas.90.4.1604; NAG B, 1993, J IMMUNOL, V150, P1358; NAG B, 1991, J IMMUNOL METHODS, V142, P105, DOI 10.1016/0022-1759(91)90297-S; NAG B, 1992, J IMMUNOL, V148, P369; NAG B, 1992, J BIOL CHEM, V267, P22624; NEEL D, 1987, BIOCHEM J, V244, P433, DOI 10.1042/bj2440433; NEPOM BS, 1983, P NATL ACAD SCI-BIOL, V80, P6962, DOI 10.1073/pnas.80.22.6962; NEWCOMB JR, 1993, J IMMUNOL, V150, P499; O'Farrell P H, 1977, Methods Cell Biol, V16, P407; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1976, CELL, V9, P289, DOI 10.1016/0092-8674(76)90119-7; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PASSMORE D, 1992, J IMMUNOL METHODS, V155, P193, DOI 10.1016/0022-1759(92)90285-2; POBER JS, 1978, P NATL ACAD SCI USA, V75, P6002, DOI 10.1073/pnas.75.12.6002; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROTHENHAUSLER B, 1990, P NATL ACAD SCI USA, V87, P352, DOI 10.1073/pnas.87.1.352; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SHACKELFORD DA, 1980, J EXP MED, V151, P144, DOI 10.1084/jem.151.1.144; SHACKELFORD DA, 1983, J IMMUNOL, V130, P274; SWIEDLER SJ, 1985, J BIOL CHEM, V260, P4046; TAMPE R, 1991, SCIENCE, V254, P87, DOI 10.1126/science.1656526; TKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248, DOI 10.1016/S0006-291X(75)80086-6; WATTS TH, 1986, P NATL ACAD SCI USA, V83, P9660, DOI 10.1073/pnas.83.24.9660; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J	50	13	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					10061	10070						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144505				2022-12-25	WOS:A1994NE05300100
J	BERGSTEN, P; GRAPENGIESSER, E; GYLFE, E; TENGHOLM, A; HELLMAN, B				BERGSTEN, P; GRAPENGIESSER, E; GYLFE, E; TENGHOLM, A; HELLMAN, B			SYNCHRONOUS OSCILLATIONS OF CYTOPLASMIC CA2+ AND INSULIN RELEASE IN GLUCOSE-STIMULATED PANCREATIC-ISLETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BURSTING ELECTRICAL-ACTIVITY; BETA-CELLS; CYCLIC-AMP; B-CELLS; CA-2+; CALCIUM; ATP; CONDUCTANCE; LANGERHANS; ACTIVATION	The cytoplasmic Ca2+ concentration ([Ca2+](i)) was measured in single pancreatic mouse islets superfused in a system allowing concomitant recordings of insulin release. When glucose was raised from 3 to 11 mM, [Ca2+](i) responded by a transient lowering followed by a rise to an average level of 192 +/- 11 nM. In 77% of the islets the rise was associated with the gradual appearance of oscillations, which were either fast (2-7/min), slow (0.3-0.9/min), or a combination of both types. The characteristics of the fast [Ca2+](i) oscillations were those expected from a relationship with the electrical burst activity in islets. Accordingly, in most cases the fast oscillations were remarkably regular. The slow [Ca2+](i) oscillations had characteristics similar to the large amplitude ones in individual beta-cells. Whereas glucagon and dibutyryl cAMP could transform slow islet oscillations into fast ones, the alpha(2)-adrenergic agonist clonidine had the opposite effect. The rapid islet oscillations were also facilitated by elevated concentrations of extracellular Ca2+. Reinforcing the arguments for [Ca2+](i) oscillations as responsible for a pulsatile insulin secretion it was possible to demonstrate that the release of the hormone from single islets is synchronized with the slow [Ca2+](i) oscillations.	UPPSALA UNIV,BIOMEDICUM,DEPT MED CELL BIOL,S-75123 UPPSALA,SWEDEN	Uppsala University				Gylfe, Erik/0000-0002-8414-2107				AMMALA C, 1991, NATURE, V353, P849, DOI 10.1038/353849a0; ARKHAMMAR P, 1989, BIOCHEM BIOPH RES CO, V159, P223, DOI 10.1016/0006-291X(89)92426-1; BERGSTEN P, 1993, DIABETES, V42, P670, DOI 10.2337/diabetes.42.5.670; CHANCE B, 1975, ANAL BIOCHEM, V66, P498, DOI 10.1016/0003-2697(75)90617-X; COOK DL, 1983, METABOLISM, V32, P681, DOI 10.1016/0026-0495(83)90124-5; COOK DL, 1982, DIABETES, V31, P985, DOI 10.2337/diabetes.31.11.985; GARCIAMORALES P, 1984, BIOSCIENCE REP, V4, P511, DOI 10.1007/BF01122227; GILON P, 1992, J BIOL CHEM, V267, P20713; GRAPENGIESSER E, 1992, CELL CALCIUM, V13, P219, DOI 10.1016/0143-4160(92)90010-P; GRAPENGIESSER E, 1991, J BIOL CHEM, V266, P12207; GRAPENGIESSER E, 1989, ARCH BIOCHEM BIOPHYS, V268, P404, DOI 10.1016/0003-9861(89)90602-4; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYLFE E, 1991, CELL CALCIUM, V12, P229, DOI 10.1016/0143-4160(91)90023-8; GYLFE E, 1987, BRIT J PHARMACOL, V92, P281, DOI 10.1111/j.1476-5381.1987.tb11322.x; GYLFE E, 1988, J BIOL CHEM, V263, P5044; HAHN HJ, 1974, J BIOL CHEM, V249, P5275; HELLMAN B, 1990, CELL CALCIUM, V11, P413, DOI 10.1016/0143-4160(90)90053-W; HELLMAN B, 1965, ANN NY ACAD SCI, V131, P541, DOI 10.1111/j.1749-6632.1965.tb34819.x; HELLMAN B, 1992, BIOCHIM BIOPHYS ACTA, V1113, P295, DOI 10.1016/0304-4157(92)90003-S; HELLMAN B, 1975, ENDOCRINOLOGY, V97, P392, DOI 10.1210/endo-97-2-392; Hellman B., 1992, NUTR REGULATION INSU, P213; HENQUIN JC, 1982, PFLUG ARCH EUR J PHY, V393, P322, DOI 10.1007/BF00581418; LEFEBVRE PJ, 1987, DIABETOLOGIA, V30, P443, DOI 10.1007/BF00279610; LONGO EA, 1991, J BIOL CHEM, V266, P9314; RORSMAN P, 1991, NATURE, V349, P77, DOI 10.1038/349077a0; SANTOS RM, 1992, BIOCHEM BIOPH RES CO, V187, P872, DOI 10.1016/0006-291X(92)91278-X; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SMITH PA, 1990, FEBS LETT, V261, P187, DOI 10.1016/0014-5793(90)80667-8; STAGNER JI, 1992, DIABETES, V41, P93, DOI 10.2337/diabetes.41.1.93; SYKES JA, 1959, P SOC EXP BIOL MED, V100, P125, DOI 10.3181/00379727-100-24546; THELER JM, 1992, J BIOL CHEM, V267, P18110; VALDEOLMILLOS M, 1989, FEBS LETT, V259, P19, DOI 10.1016/0014-5793(89)81484-X; WANG JL, 1990, BIOCHEM BIOPH RES CO, V166, P813, DOI 10.1016/0006-291X(90)90882-N; WEBSTER HV, 1990, J IMMUNOL METHODS, V134, P95, DOI 10.1016/0022-1759(90)90116-D	34	230	245	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8749	8753						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132606				2022-12-25	WOS:A1994NB41100023
J	DAVIDSON, WS; SPARKS, DL; LUNDKATZ, S; PHILLIPS, MC				DAVIDSON, WS; SPARKS, DL; LUNDKATZ, S; PHILLIPS, MC			THE MOLECULAR-BASIS FOR THE DIFFERENCE IN CHARGE BETWEEN PRE-BETA AND ALPHA-MIGRATING HIGH-DENSITY-LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; ELECTROPHORETIC MOBILITY; CHOLESTEROL TRANSPORT; SERUM LIPOPROTEINS; PARTICLES; CHROMATOGRAPHY; HETEROGENEITY; MEMBRANES; CELLS	Several subspecies of human high density lipoprotein (HDL) exist, and particle surface charge is one parameter that can be used to distinguish them. For instance, pre-beta HDL has a lower negative surface charge than the bulk of plasma HDL resulting in slower migration when subjected to electrophoresis in an agarose gel at pH 8.6. The molecular basis for the variations in HDL particle surface charge have been established in this work. Quantitative analysis of electrophoretic mobilities in agarose gels indicates that the surface potentials of reconstituted pre-beta HDL and alpha-HDL(3) are -7.6 and -11.4 mV, respectively. The difference of 3.8 mV corresponds to an apparent le more net negative charge on alpha-migrating HDL(3). The contributions of the lipid and protein components to the charge of HDL(3) were defined using reconstituted particles (rHDL) containing various combinations of HDL(3) protein and lipid. The surface potentials of spherical and discoidal rHDL are not affected by the particle apoprotein composition. Thin layer chromatography of the HDL(3) phospholipid fraction from five normolipidemic subjects revealed that it consists of approximately 84% phosphatidylcholine, 12% sphingomyelin, and 4% phosphatidylinositol (PI) by weight. PI significantly affects the charge of discoidal rHDL and is responsible for similar to 0.7 mV of the surface potential difference between pre-beta and alpha-HDL. Reconstitution of spherical complexes containing apolipoprotein AI, palmitoyl-oleoyl phosphatidylcholine, and HDL(3) neutral lipid esters showed that particles containing a neutral lipid core migrate to an ct position in an agarose gel. The change in particle shape accounts for similar to 3 mV of the difference in surface potential between pre-beta and alpha-HDL. Overall, the charge of HDL particles is determined by 1) a direct contribution of negative charge from PI molecules in the surface of the lipoprotein and 2) the conformation of the resident apolipoprotein(s) which is influenced by the presence of neutral lipids and the particle shape. This quantitative understanding of surface charge provides a basis for understanding variations in function of HDL subspecies.	MED COLL PENN,DEPT BIOCHEM,PHILADELPHIA,PA 19129	Drexel University				Davidson, William/0000-0003-2756-2989; Phillips, Michael/0000-0002-7147-8007	NHLBI NIH HHS [HL07443, HL22633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007443, P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; FIEVET C, 1991, DIABETES METAB REV, V7, P155, DOI 10.1002/dmr.5610070304; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; FRANCONE OL, 1990, EUR HEART J, V11, P218, DOI 10.1093/eurheartj/11.suppl_E.218; HAVEL RJ, 1955, J CLIN INVEST, V34, P476; HIRZ R, 1970, BIOCHIM BIOPHYS ACTA, V207, P364, DOI 10.1016/0005-2795(70)90029-2; HUANG YD, 1993, ARTERIOSCLER THROMB, V13, P445, DOI 10.1161/01.ATV.13.3.445; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KAWANO M, 1993, BIOCHEMISTRY-US, V32, P5025, DOI 10.1021/bi00070a008; KUNITAKE ST, 1985, J LIPID RES, V26, P549; LEFEVRE M, 1988, J LIPID RES, V29, P1139; LUNDKATZ S, 1986, BIOCHEMISTRY-US, V25, P1562, DOI 10.1021/bi00355a016; MARCEL YL, 1984, EUR J BIOCHEM, V143, P467, DOI 10.1111/j.1432-1033.1984.tb08394.x; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MIIDA T, 1992, BIOCHEMISTRY-US, V31, P11112, DOI 10.1021/bi00160a022; NELSON GJ, 1972, BLOOD LIPIDS LIPOPRO, P317; NOWICKA G, 1990, J LIPID RES, V31, P1947; Patsch J. R, 1987, PLASMA LIPOPROTEINS, P221; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; RADER DJ, 1991, J LIPID RES, V32, P1849; SCANU AM, 1971, ANAL BIOCHEM, V44, P576, DOI 10.1016/0003-2697(71)90247-8; SHEN BW, 1977, P NATL ACAD SCI USA, V74, P837, DOI 10.1073/pnas.74.3.837; SKIPSKI VP, 1972, BLOOD LIPIDS LIPOPRO, P471; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; SPARKS DL, 1992, J LIPID RES, V33, P123; SPARKS DL, 1993, J BIOL CHEM, V268, P23250; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; SWANEY JB, 1986, METHOD ENZYMOL, V128, P613; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1; [No title captured]	33	91	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8959	8965						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132633				2022-12-25	WOS:A1994NB41100052
J	FLOCCO, MM; MOWBRAY, SL				FLOCCO, MM; MOWBRAY, SL			THE 1.9 ANGSTROM X-RAY STRUCTURE OF A CLOSED UNLIGANDED FORM OF THE PERIPLASMIC GLUCOSE/GALACTOSE RECEPTOR FROM SALMONELLA-TYPHIMURIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL CHANGE; GALACTOSE CHEMOSENSORY RECEPTOR; MALTODEXTRIN-BINDING-PROTEIN; ESCHERICHIA-COLI; ACTIVE-TRANSPORT; RIBOSE RECEPTOR; SUGAR BINDING; CHEMOTAXIS; RESOLUTION; LIGAND	The three-dimensional structure of a ligand-free closed form of the glucose/galactose binding protein from Salmonella typhimurium has been determined at a resolution of 1,9 Angstrom The crystallographic R-factor for the refined structure is 17.9%. The model contains all the atoms of the 309 residues of the protein sequence, a calcium ion, and 174 water molecules. The root mean square (r.m.s.) deviations for the whole molecule are: 0.010 A for bond lengths and 2.44 degrees for bond angles, indicating a good stereochemistry for the model. This structure shows that the protein is able to close in the absence of ligand, adopting a conformation similar to the liganded form but slightly more open. Water molecules satisfy the hydrogen bonding ability of the hydrophilic side chains of the binding site in a manner which is reminiscent of the sugars' hydrogen-bonding patterns. Since packing forces are weak, the crystallization event is unlikely to trigger a change from an open to a closed conformation. Instead, the latter must be one of the species in equilibrium in solution which is selected by packing in the crystal lattice.	SWEDISH UNIV AGR SCI,UPPSALA BIOMED CTR,DEPT MOLEC BIOL,S-75123 UPPSALA,SWEDEN	Swedish University of Agricultural Sciences			Mowbray, Sherry L/D-2141-2013					ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; ANRAKU Y, 1968, J BIOL CHEM, V243, P3116; ANRAKU Y, 1968, J BIOL CHEM, V243, P3123; BINNIE RA, 1992, PROTEIN SCI, V1, P1642, DOI 10.1002/pro.5560011212; BOOS W, 1972, J BIOL CHEM, V247, P917; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; JONES TA, 1992, O MANUAL VERSION 5 8; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LUCK LA, 1991, BIOCHEMISTRY-US, V30, P4248, DOI 10.1021/bi00231a021; LUCK LA, 1991, BIOCHEMISTRY-US, V30, P6484, DOI 10.1021/bi00240a019; MANSON MD, 1992, ADV MICROB PHYSIOL, V33, P277, DOI 10.1016/S0065-2911(08)60219-2; MCGOWAN EB, 1974, BIOCHEMISTRY-US, V13, P993, DOI 10.1021/bi00702a025; MILLER DM, 1980, J BIOL CHEM, V255, P2465; Mowbray S L, 1990, Receptor, V1, P41; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; MOWBRAY SL, 1983, J BIOL CHEM, V258, P7991; NEWCOMER ME, 1981, J BIOL CHEM, V256, P3218; OH BH, 1993, J BIOL CHEM, V268, P1138; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SACK JS, 1989, J MOL BIOL, V206, P193, DOI 10.1016/0022-2836(89)90532-9; SATO M, 1992, J APPL CRYSTALLOGR, V25, P348, DOI 10.1107/S0021889891012955; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; STEWART RC, 1987, CHEM REV, V87, P997, DOI 10.1021/cr00081a007; STRANGE PG, 1976, P NATL ACAD SCI USA, V73, P762, DOI 10.1073/pnas.73.3.762; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; YAGHMAI R, 1992, EMBO J, V12, P1897; ZOU JY, 1993, IN PRESS J MOL BIOL; ZUKIN RS, 1979, BIOCHEMISTRY-US, V18, P5599, DOI 10.1021/bi00592a012; ZUKIN RS, 1977, P NATL ACAD SCI USA, V74, P1932, DOI 10.1073/pnas.74.5.1932	35	105	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8931	8936						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132630				2022-12-25	WOS:A1994NB41100048
J	MOTOJIMA, K; GOTO, S				MOTOJIMA, K; GOTO, S			HISTIDYL PHOSPHORYLATION AND DEPHOSPHORYLATION OF P36 IN RAT-LIVER EXTRACT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LABILE HISTONE PHOSPHATES; GROWTH-FACTOR RECEPTOR; PROTEIN-KINASES; PEROXISOME-PROLIFERATOR; SIGNAL TRANSDUCTION; GENISTEIN; IDENTIFICATION; CLASSIFICATION; CLOFIBRATE; INHIBITOR	Protein histidine kinase (Motojima, K., and Goto, S. (1993) FEBS Lett. 319, 75-79) and phosphatase in rat liver extract were characterized. The histidine kinase was recovered mostly in the membrane and the phosphatase in the soluble fraction. The kinase and its substrate 36-kDa protein (P36) were co-solubilized from the membrane under conditions in which most of the other kinases, and their substrate proteins were not solubilized. The solubilized kinase and P36 were co-eluted after high pressure liquid chromatography gel filtration, showing an apparent molecular mass of 70-75 kDa. They were also co-eluted after ion exchange chromatography. These characteristics, together with its complete resistance to genistein, indicate that the rat liver histidine kinase is not cognate to the yeast enzyme (Huang, J., Nasr, M., Kim, Y., and Matthews, H. R. (1992) J. Biol. Chem. 267, 15511-15515). The phosphatase that dephosphorylates histidyl-phosphorylated P36 was also studied using rat liver subcellular fractions and in vitro phosphorylated P36 as the substrate. The characteristics of the phosphatase, that is, 1) Mg2+ requirement for activity, 2) apparent molecular mass of 45 kDa by high performance liquid chromatography gel filtration, and 3) resistance to 100 mu M okadaic acid, suggest that the primary phosphatase active in vitro is protein phosphatase 2C.			MOTOJIMA, K (corresponding author), TOHO UNIV, SCH PHARMACEUT SCI, DEPT BIOCHEM, MIYAMA 2-2-1, FUNABASHI, CHIBA 274, JAPAN.							AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; CHEN CC, 1977, BIOCHEMISTRY-US, V16, P4852, DOI 10.1021/bi00641a016; CHEN CC, 1974, BIOCHEMISTRY-US, V13, P3785, DOI 10.1021/bi00715a026; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; DEUTSCHER J, 1982, BIOCHEMISTRY-US, V21, P4867, DOI 10.1021/bi00263a006; FERRELL JE, 1991, METHOD ENZYMOL, V200, P430; FUKUNAGA K, 1993, J BIOL CHEM, V268, P133; HENNING WD, 1988, P NATL ACAD SCI USA, V85, P1432, DOI 10.1073/pnas.85.5.1432; HIRAGA A, 1981, EUR J BIOCHEM, V119, P503, DOI 10.1111/j.1432-1033.1981.tb05636.x; HUANG J, 1991, J BIOL CHEM, V257, P14477; HUANG JM, 1992, J BIOL CHEM, V267, P15511; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; JOHNSON LN, 1993, ANNU REV BIOPH BIOM, V22, P199, DOI 10.1146/annurev.bb.22.060193.001215; KALBITZER HR, 1982, BIOCHEMISTRY-US, V21, P2879, DOI 10.1021/bi00541a012; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KIM Y, 1993, ANAL BIOCHEM, V211, P28, DOI 10.1006/abio.1993.1227; KREIL G, 1964, BIOCHEM BIOPH RES CO, V16, P551, DOI 10.1016/0006-291X(64)90191-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lipmann F, 1941, ADV ENZYMOL REL S BI, V1, P99, DOI 10.1002/9780470122464.ch4; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MCCUNE BK, 1989, J BIOL CHEM, V264, P15501; MORGAN M, 1976, BIOCHEM J, V157, P687, DOI 10.1042/bj1570687; MOTOJIMA K, 1992, FEBS LETT, V308, P207, DOI 10.1016/0014-5793(92)81275-Q; MOTOJIMA K, 1992, BIOCHEM BIOPH RES CO, V188, P799, DOI 10.1016/0006-291X(92)91127-C; MOTOJIMA K, 1993, FEBS LETT, V319, P75, DOI 10.1016/0014-5793(93)80040-2; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; OGAWARA H, 1986, J ANTIBIOT, V39, P606, DOI 10.7164/antibiotics.39.606; OHKUMA S, 1982, P NATL ACAD SCI-BIOL, V79, P2758, DOI 10.1073/pnas.79.9.2758; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PETERSON G, 1991, BIOCHEM BIOPH RES CO, V179, P661, DOI 10.1016/0006-291X(91)91423-A; REDPATH NT, 1993, EUR J BIOCHEM, V213, P689, DOI 10.1111/j.1432-1033.1993.tb17809.x; SMITH DL, 1973, NATURE, V246, P103, DOI 10.1038/246103a0; SMITH DL, 1974, BIOCHEMISTRY-US, V13, P3780, DOI 10.1021/bi00715a025; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; THOEN C, 1985, BIOCHEM BIOPH RES CO, V131, P84, DOI 10.1016/0006-291X(85)91773-5; TOMONAGA T, 1992, BIOCHEM BIOPH RES CO, V182, P894, DOI 10.1016/0006-291X(92)91816-9; WIELAND T, 1956, CHEM BER-RECL, V89, P2476, DOI 10.1002/cber.19560891046	45	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9030	9037						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132640				2022-12-25	WOS:A1994NB41100063
J	POSTEL, EH; FERRONE, CA				POSTEL, EH; FERRONE, CA			NUCLEOSIDE DIPHOSPHATE KINASE ENZYME-ACTIVITY OF NM23-H2/PUF IS NOT REQUIRED FOR ITS DNA-BINDING AND IN-VITRO TRANSCRIPTIONAL FUNCTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TUMOR-METASTASIS; NM23 GENE; DROSOPHILA DEVELOPMENT; MAST-CELLS; EXPRESSION; PROTEIN; PRODUCT; DISEASE; RNA	nm23 genes encode proteins that participate in tumor metastasis regulation and in various fundamental cellular processes, although the mechanisms remain undefined. All Nm23 proteins contain nucleoside diphosphate kinase (NDPK) activity whose significance to these regulatory effects is not yet evident. The protein product of the human nm23-H2 gene functions in vitro both as a nucleoside diphosphate kinase enzyme (NDPK-B; Gilles, A.-M., Presecan, E., Vonica, A. and Lascu, I. (1991) J. Biol. Chem. 266, 8784-8789) and as a transcription factor (PuF; Postel, E. H., Berberich, S. J., Flint, S. J. and Ferrone, C. A (1993) Science 261, 478-480). To understand the significance of these two biochemical activities to NM23-H2 function, we have investigated the relationship between the DNA binding and transcriptional activity of NM23-H2 and its NDPK function. Using site-directed mutagenesis of the cDNA encoding NM23-H2, we have created a mutant substituting for the amino acid histidine 118, the presumed site of phosphorylation in the formation of the phosphoenzyme intermediate, the nonphosphorylatable amino acid phenylalanine. The H118F mutant protein is shown to be catalytically inactive as measured both in a radioisotopic assay that detects formation of the phosphorylated enzyme intermediate and in a coupled enzyme assay that indicates nucleoside diphosphate formation. These results confirm that histidine 118 is the critical residue for NDPK-B activity. In addition, the H118F mutant protein lacking enzymatic activity displayed normal DNA binding affinity for the c-myc promoter in electrophoretic mobility shift assays, and retained full transcriptional activity using the c-myc gene in vitro. These results indicate a lack of correlation between nucleoside diphosphate kinase activity of nm23-H2 on the one hand, and its DNA binding and transcriptional activity on the other, suggesting that the nm23-H2 gene encodes a bifunctional protein molecule.			POSTEL, EH (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08540, USA.				NCI NIH HHS [R01 CA55884] Funding Source: Medline; NIGMS NIH HHS [R01 GM37705] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037705] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal R P, 1978, Methods Enzymol, V51, P376; BACKER JM, 1993, ONCOGENE, V8, P497; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOMINAAR AA, 1993, EMBO J, V12, P2275, DOI 10.1002/j.1460-2075.1993.tb05881.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEAROLF CR, 1988, DEV BIOL, V129, P169, DOI 10.1016/0012-1606(88)90171-6; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; ENGEL M, 1993, INT J CANCER, V55, P375, DOI 10.1002/ijc.2910550306; FLORENES VA, 1992, CANCER RES, V52, P6088; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; HAUT M, 1991, J NATL CANCER I, V83, P712, DOI 10.1093/jnci/83.10.712; HEMMERICH S, 1992, BIOCHEMISTRY-US, V31, P4574, DOI 10.1021/bi00134a006; HEMMERICH S, 1992, BIOCHEMISTRY-US, V31, P4580, DOI 10.1021/bi00134a007; HIRAYAMA R, 1991, J NATL CANCER I, V83, P1249, DOI 10.1093/jnci/83.17.1249; KANTOR JD, 1993, CANCER RES, V53, P1971; KEIM D, 1992, J CLIN INVEST, V89, P919, DOI 10.1172/JCI115672; LACOMBE ML, 1991, EUR J CANCER, V27, P1302, DOI 10.1016/0277-5379(91)90101-I; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKSO M, 1992, CELL GROWTH DIFFER, V3, P873; LASCU I, 1992, J BIOL CHEM, V267, P12775; LEONE A, 1993, ONCOGENE, V8, P2325; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MUNOZDORADO J, 1993, J BACTERIOL, V175, P1176; MYEROFF LL, 1993, J NATL CANCER I, V85, P148; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; OKABEKADO J, 1988, J BIOL CHEM, V263, P10994; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STAHL JA, 1991, CANCER RES, V51, P445; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199	37	120	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8627	8630						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132589				2022-12-25	WOS:A1994NB41100002
J	SCHAEFER, A; MAGOCSI, M; STOCKER, U; KOSA, F; MARQUARDT, H				SCHAEFER, A; MAGOCSI, M; STOCKER, U; KOSA, F; MARQUARDT, H			EARLY TRANSIENT SUPPRESSION OF C-MYB MESSENGER-RNA LEVELS AND INDUCTION OF DIFFERENTIATION IN FRIEND-ERYTHROLEUKEMIA CELLS BY THE [CA-2+](I)-INCREASING AGENTS CYCLOPIAZONIC ACID AND THAPSIGARGIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ERYTHROID-DIFFERENTIATION; MESSENGER-RNA; GLOBIN GENES; CALCIUM; ERYTHROPOIETIN; ONCOGENE; COMMITMENT; RETICULUM; TURNOVER	Cyclopiazonic acid and thapsigargin, inhibitors of the endoplasmic reticulum Ca2+ pump were shown to elevate [Ca2+](i) in Friend erythroleukemia cells, line F4-6, at concentrations of 1-5 mu M and 0.5-2 nM, respectively. At the same concentrations, these agents induced a strong suppression of c-myb mRNA levels within 3 h, whereas c-myc expression remained unaffected. The c-myb expression recovered and approached pretreatment levels at 9-12 h of incubation. The decrease in c-myb mRNA was prevented in Ca2+-free medium. Treatment of F4-6 cells with EGTA led to a transient increase in c-myb mRNA with the same kinetics as the Ca2+ pump inhibitor-induced suppression, indicating that c-myb expression is bidirectionally regulated by changes in [Ca2+](i). Studies on the differentiation status of F4-6 cells following cyclopiazonic acid or thapsigargin exposure demonstrated a marked increase in P-globin mRNA synthesis at 60h and in hemoglobin production at 96 h. These results provide further evidence that a rise in the cytosolic Ca2+ concentration is capable, in Friend erythroleukemia cells, of inducing an early transient suppression of c-myb mRNA levels, which is followed by terminal erythroid differentiation.	FRAUNHOFER INST TOXICOL & MOLEC BIOL,D-21046 HAMBURG,GERMANY; NATL INST HEMATOL BLOOD TRANSFUS & IMMUNOL,H-1113 BUDAPEST,HUNGARY	Fraunhofer Gesellschaft	SCHAEFER, A (corresponding author), UNIV HAMBURG,SCH MED,DEPT TOXICOL,GRINDELALLEE 117,D-20146 HAMBURG,GERMANY.		Kósa, Ferenc/ABC-4078-2020	Kósa, Ferenc/0000-0002-2921-2379				BUSFIELD SJ, 1992, BLOOD, V80, P412; CATT KJ, 1989, ANNU REV MED, V40, P487; CHERN Y, 1990, J BIOL CHEM, V266, P2009; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CRAIG RW, 1984, CANCER RES, V44, P442; DANISH R, 1992, ONCOGENE, V7, P901; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FALETTO DL, 1985, J BIOL CHEM, V260, P4884; GILLO B, 1993, BLOOD, V81, P783; HENSOLD JO, 1991, BLOOD, V77, P1362; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KONKEL DA, 1979, CELL, V18, P865, DOI 10.1016/0092-8674(79)90138-7; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LACHMAN HM, 1984, NATURE, V310, P249; LUFTIG RB, 1977, J VIROL, V23, P799, DOI 10.1128/JVI.23.3.799-810.1977; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MARKS PA, 1987, CANCER RES, V47, P659; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; OSTERTAG W, 1972, NATURE-NEW BIOL, V239, P231, DOI 10.1038/newbio239231a0; PATEL HR, 1992, J BIOL CHEM, V267, P21300; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; SCHAEFER A, 1993, J BIOL CHEM, V268, P10876; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SIMONS M, 1993, J BIOL CHEM, V268, P627; SPIVAK JL, 1992, EXP HEMATOL, V20, P283; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; TIEMEIER DC, 1978, CELL, V14, P237, DOI 10.1016/0092-8674(78)90110-1; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; ZOBEL A, 1992, BIOCHEM BIOPH RES CO, V186, P715, DOI 10.1016/0006-291X(92)90805-U	36	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8786	8791						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132611				2022-12-25	WOS:A1994NB41100028
J	VRTOVSNIK, F; JOURDAIN, M; CHERQUI, G; LEFEBVRE, J; FRIEDLANDER, G				VRTOVSNIK, F; JOURDAIN, M; CHERQUI, G; LEFEBVRE, J; FRIEDLANDER, G			GLUCOCORTICOID INHIBITION OF NA-P-I COTRANSPORT IN RENAL EPITHELIAL-CELLS IS MEDIATED BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARATHYROID-HORMONE INHIBITION; PROXIMAL TUBULAR CELLS; OPOSSUM KIDNEY-CELLS; BORDER MEMBRANE-VESICLES; H+ EXCHANGE ACTIVITY; PHOSPHATE-TRANSPORT; RAT-KIDNEY; OK CELLS; COUPLED UPTAKES; DOWN-REGULATION	The effect and mechanism of action of glucocorticoids (GC) on Na-P-i cotransport were evaluated in opossum kidney cells. Dexamethasone (1-1000 nM) inhibited sodium-dependent P-i uptake in a time- and concentration dependent manner. Inhibition was maximal after a 6-h incubation with dexamethasone and was prevented by cycloheximide and actinomycin D. The effect was related to a 37% decrease of the V-max value after incubation with 100 nM dexamethasone. The effect of dexamethasone was mimicked by cortisol and blocked by GC receptor antagonists RU38486 and progesterone. GC affected neither glucose or alanine uptake nor Na/H exchange activity. Inhibition of P-i uptake persisted when Na/H was blocked by amiloride or dimethylamiloride. GC had no effect on basal or parathyroid hormone- and forskolin-stimulated intracellular cAMP content. Dexamethasone and extracellular cAMP, parathyroid hormone, or 3-isobutyl-1-methylxanthine had additive inhibitory effects on P-i uptake. Staurosporine, GF109203X, or calphostin C (three dissimilar inhibitors of protein kinase C (PKC)) and PKC down-regulation blunted the inhibitory effect of glucocorticoids on P-i uptake. GC increased both membrane-bound PKC activity and the membrane/cytosol PKC activity ratio. This is the first report of GC activation of PKC in renal cells, which appears to mediate the steroid inhibitory effect on P-i transport.	UNIV PARIS 07,FAC MED XAVIER BICHAT,INSERM,U251,F-75018 PARIS,FRANCE; UNIV PARIS 06,INSERM,U181,BIOCHIM BIOL CELLULAIRE LAB,F-75571 PARIS,FRANCE; CTR OSCAR LAMBRET,ENDOCRINOL EXPTL LAB,F-59000 LILLE,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UNICANCER; Centre Oscar Lambret	VRTOVSNIK, F (corresponding author), UNIV PARIS 07,FAC MED XAVIER BICHAT,DEPT PHYSIOL,F-75018 PARIS,FRANCE.			Vrtovsnik, Francois/0000-0003-1554-314X; Friedlander, Gerard/0000-0002-6854-4261				BAUM M, 1993, AM J PHYSIOL, V264, pF1027, DOI 10.1152/ajprenal.1993.264.6.F1027; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNSTEIN KL, 1990, J BIOL CHEM, V265, P7284; CAVERZASIO J, 1986, J BIOL CHEM, V261, P3233; CHEN TL, 1978, ENDOCRINOLOGY, V102, P589, DOI 10.1210/endo-102-2-589; COLE JA, 1987, AM J PHYSIOL, V253, pE221, DOI 10.1152/ajpendo.1987.253.2.E221; COLE JA, 1989, AM J PHYSIOL, V256, pF672, DOI 10.1152/ajprenal.1989.256.4.F672; DECOURCELLES DD, 1985, J BIOL CHEM, V260, P5762; DELAGE S, 1993, CANCER RES, V53, P2762; DUDEJA PK, 1987, BIOCHIM BIOPHYS ACTA, V905, P485, DOI 10.1016/0005-2736(87)90478-0; DURASIN I, 1984, RENAL PHYSIOL BIOCH, V7, P115; DUVAL D, 1983, BIOCHIM BIOPHYS ACTA, V737, P409, DOI 10.1016/0304-4157(83)90008-4; ELLIS D, 1988, IN VITRO CELL DEV B, V24, P811, DOI 10.1007/BF02623652; FREIBERG JM, 1982, P NATL ACAD SCI-BIOL, V79, P4932, DOI 10.1073/pnas.79.16.4932; FRICK A, 1981, PFLUG ARCH EUR J PHY, V392, P99, DOI 10.1007/BF00581256; FRIEDLANDER G, 1992, J CLIN INVEST, V90, P848, DOI 10.1172/JCI115960; FRIEDLANDER G, 1989, J BIOL CHEM, V264, P3935; FRIEDLANDER G, 1990, AM J PHYSIOL, V259, pF816, DOI 10.1152/ajprenal.1990.259.5.F816; GLUSMAN J, 1993, ENDOCRINOLOGY, V132, P261, DOI 10.1210/en.132.1.261; JOURDAIN M, 1992, AM J PHYSIOL, V263, pC1141, DOI 10.1152/ajpcell.1992.263.6.C1141; KALIMI MY, 1988, BIOCHEM BIOPH RES CO, V153, P365, DOI 10.1016/S0006-291X(88)81232-4; KAUFMANN M, 1991, ENDOCRINOLOGY, V128, P1819, DOI 10.1210/endo-128-4-1819; KINSELLA J, 1984, P NATL ACAD SCI-BIOL, V81, P630, DOI 10.1073/pnas.81.2.630; LEGOAS F, 1991, AM J PHYSIOL, V261, pF587, DOI 10.1152/ajprenal.1991.261.4.F587; MANGANIELLO V, 1972, J CLIN INVEST, V51, P2763, DOI 10.1172/JCI107096; MCLELLAN AR, 1992, J MOL ENDOCRINOL, V9, P237, DOI 10.1677/jme.0.0090237; MISHINA T, 1981, AM J PHYSIOL, V240, pF38, DOI 10.1152/ajprenal.1981.240.1.F38; NORONHABLOB L, 1986, J BIOL CHEM, V261, P2164; OBEID LM, 1990, J BIOL CHEM, V265, P2370; OKRET S, 1986, P NATL ACAD SCI USA, V83, P5899, DOI 10.1073/pnas.83.16.5899; Philibert D, 1985, ANTIPROGESTIN STEROI, P49; POLLOCK AS, 1986, AM J PHYSIOL, V250, pF217, DOI 10.1152/ajprenal.1986.250.2.F217; POUJEOL P, 1985, AM J PHYSIOL, V249, pF74, DOI 10.1152/ajprenal.1985.249.1.F74; QUAMME G, 1989, BIOCHIM BIOPHYS ACTA, V1013, P159, DOI 10.1016/0167-4889(89)90044-X; QUAMME G, 1989, BIOCHEM BIOPH RES CO, V158, P951, DOI 10.1016/0006-291X(89)92814-3; RIZZOLI R, 1987, J CELL PHYSIOL, V132, P517, DOI 10.1002/jcp.1041320314; ROBERTS KE, 1953, ENDOCRINOLOGY, V52, P324, DOI 10.1210/endo-52-3-324; RODAN SB, 1984, ENDOCRINOLOGY, V115, P951, DOI 10.1210/endo-115-3-951; SNEDECOR GW, 1972, STATISTICAL METHODS; SVEC F, 1981, J BIOL CHEM, V256, P5984; TODDTURLA KM, 1993, AM J PHYSIOL, V264, pF781, DOI 10.1152/ajprenal.1993.264.5.F781; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TURNER ST, 1982, AM J PHYSIOL, V243, pC227, DOI 10.1152/ajpcell.1982.243.5.C227; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; WEBSTER SK, 1986, AM J PHYSIOL, V251, pF576, DOI 10.1152/ajprenal.1986.251.4.F576; YONEMURA K, 1990, AM J PHYSIOL, V258, pF333, DOI 10.1152/ajprenal.1990.258.2.F333; YUN CHC, 1993, J BIOL CHEM, V268, P206	48	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8872	8877						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132623				2022-12-25	WOS:A1994NB41100040
J	FALNES, PO; CHOE, S; MADSHUS, IH; WILSON, BA; OLSNES, S				FALNES, PO; CHOE, S; MADSHUS, IH; WILSON, BA; OLSNES, S			INHIBITION OF MEMBRANE TRANSLOCATION OF DIPHTHERIA-TOXIN-A FRAGMENT BY INTERNAL DISULFIDE BRIDGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEIN; ESCHERICHIA-COLI; LOW PH; A-FRAGMENT; MITOCHONDRIA; CELLS; CYTOSOL; IMPORT; ENTRY; TRANSPORT	Fragment A of diphtheria toxin is translocated to the cytosol when the toxin is presented to receptor-positive cells. The toxin binds to cell surface receptors through its B-fragment, and after endocytotic uptake, the low endosomal pH triggers translocation of the A-fragment across the membrane. Translocation can also be induced at the level of the plasma membrane by exposure to low pH medium. Based on the diphtheria toxin crystal structure, we made five double cysteine mutants of the A-fragment, each expected to form an intramolecular disulfide bond. Four of the double cysteine mutants efficiently formed an intramolecular disulfide bridge, and these same mutants showed a strong reduction in their translocating ability. The inhibition of translocation was observed both when the toxin was endocytosed and when translocation was induced by exposing surface-bound toxin to low pH. The data indicate that extensive unfolding of the A-fragment is required for translocation.	NORWEGIAN RADIUM HOSP,INST CANC RES,DEPT BIOCHEM,N-0310 OSLO 3,NORWAY; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	University of Oslo; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Harvard University; Harvard Medical School			Falnes, Pål Ø./AAA-4581-2020	Falnes, Pal/0000-0001-8114-6025	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022021, R37AI022021] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-22021] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARIANSEN S, 1993, BIOCHEMISTRY-US, V32, P83, DOI 10.1021/bi00052a012; ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; CHEN WJ, 1987, J BIOL CHEM, V262, P15605; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; DUMONT ME, 1988, J BIOL CHEM, V263, P2087; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; ESBENSEN Y, 1993, BIOCHEM J, V294, P663; GLOVER LA, 1992, BIOCHEM J, V284, P609, DOI 10.1042/bj2840609; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; JIANG JX, 1970, BIOCHEMISTRY-US, V227, P680; KLAUSER T, 1992, EMBO J, V11, P2327, DOI 10.1002/j.1460-2075.1992.tb05292.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHER PA, 1986, P NATL ACAD SCI USA, V83, P9001, DOI 10.1073/pnas.83.23.9001; MCGILL S, 1989, EMBO J, V8, P2843, DOI 10.1002/j.1460-2075.1989.tb08431.x; MEKADA E, 1985, J BIOL CHEM, V260, P2148; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; NUNNARI J, 1992, Current Opinion in Cell Biology, V4, P573, DOI 10.1016/0955-0674(92)90074-M; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; SANDVIG K, 1986, J BIOL CHEM, V261, P1639; SANDVIG K, 1984, J CELL BIOL, V98, P963, DOI 10.1083/jcb.98.3.963; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; STENMARK H, 1992, BIOCHEM J, V281, P619, DOI 10.1042/bj2810619; TANI K, 1990, J BIOL CHEM, V265, P17341; UCHIDA T, 1972, SCIENCE, V175, P901, DOI 10.1126/science.175.4024.901; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WIEDLOCHA A, 1992, EMBO J, V11, P4835, DOI 10.1002/j.1460-2075.1992.tb05589.x	31	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8402	8407						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132565				2022-12-25	WOS:A1994NB40900086
J	FAURE, M; VOYNOYASENETSKAYA, TA; BOURNE, HR				FAURE, M; VOYNOYASENETSKAYA, TA; BOURNE, HR			CAMP AND BETA-GAMMA-SUBUNITS OF HETEROTRIMERIC G-PROTEINS STIMULATE THE MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY IN COS-7 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MAP KINASE; ADENYLYL CYCLASE; PHOSPHOLIPASE-C; ALPHA-SUBUNIT; EXPRESSION	Mitogen-activated protein kinases (MAPKs) are activated by a variety of extracellular stimuli, including agonists for G protein coupled receptors. Using transient transfection of COS-7 cells, we have studied the stimulation of a hemagglutinin-tagged p44(mapk) (p44(HA-mapk)) by receptors coupled to G(s), G(q), and G(i). Agonists that act via all three G proteins stimulated p44(HA-mapk) activity. A constitutively activated alpha(s) mutant, forskolin, and a cAMP analog also increased p(44HA-mapk) activity, indicating that cAMP in COS-7 cells, in contrast to other cell types, activates the MAPK pathway, Similarly, a constitutively activated alpha(q), mutant, overexpression of phospholipase C-beta 2, and a phorbol ester also stimulated p44(HA-mapk), suggesting that G(q)-coupled receptors stimulate the MAPK pathway by increasing phosphatidylinositol turnover and probably stimulating protein kinase C, In COS-7 cells, in contrast to Rat-1 cells, mutationally activated alpha(i) did not stimulate the MAPK pathway. G protein beta and gamma subunits, overexpressed together, did activate p44(HA-mapk); this finding suggests that in COS-7 cells G(i)-coupled receptors may stimulate the MAPK pathway through beta gamma. These unexpected results in COS-7 cells show that G proteins and second messengers regulate the MAPK pathway differently in different cell types.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCI NIH HHS [CA-54427] Funding Source: Medline; NIGMS NIH HHS [GM-27800] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027800, R37GM027800] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GRABER SG, 1992, J BIOL CHEM, V267, P13123; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAMY F, 1993, J BIOL CHEM, V268, P8398; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PARK D, 1992, J BIOL CHEM, V267, P16048; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SEGER R, 1992, J BIOL CHEM, V267, P14373; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936	43	448	450	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7851	7854						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132501				2022-12-25	WOS:A1994NB40900005
J	HUANG, Q; ALVARES, K; CHU, RY; BRADFIELD, CA; REDDY, JK				HUANG, Q; ALVARES, K; CHU, RY; BRADFIELD, CA; REDDY, JK			ASSOCIATION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AND HSP72	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; GLUCOCORTICOID RECEPTOR; BINDING-PROTEIN; FATTY-ACIDS; RAT-LIVER; MEMBER; IDENTIFICATION; FAMILY; SUPERFAMILY; COMPLEX	In an effort to understand the relationship between a 72-kDa heat shock protein (Hsp72) and peroxisome proliferator-activated receptors (PPARs), we have characterized their interaction using clofibric acid-Sepharose chromatography and co-immunoprecipitation with antisera raised against either rat PPAR (rPPAR) or Hsp72. First, we observed that both rPPAR and Hsp72 elute in a clofibrate-dependent manner from the clofibric acid-Sepharose matrix. Second, we found that immunoprecipitation of either protein from solution resulted in the precipitation of the other. This result was obtained from rat liver cytosol, from Spodoptera frugiperda (Sf9) insect cells expressing rPPAR, and from reticulocyte lysate rPPAR expression systems. These results suggest that Hsp72 and rPPAR form a complex in vivo and that Hsp72 may play a role in the folding, subcellular localization, and/or signaling pathway of PPARs.	NORTHWESTERN UNIV,SCH MED,DEPT PATHOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT PHARMACOL,CHICAGO,IL 60611	Northwestern University; Northwestern University				Alvares, Keith/0000-0003-3710-4367	NIGMS NIH HHS [GM23750] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750, R01GM023750] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVARES K, 1990, P NATL ACAD SCI USA, V87, P5293, DOI 10.1073/pnas.87.14.5293; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LALWANI ND, 1987, P NATL ACAD SCI USA, V84, P5242, DOI 10.1073/pnas.84.15.5242; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; NADLER SG, 1992, SCIENCE, V258, P484, DOI 10.1126/science.1411548; NIHEI T, 1993, CANCER RES, V53, P1702; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; REDDY JK, 1986, TRENDS PHARMACOL SCI, V7, P438, DOI 10.1016/0165-6147(86)90416-5; REDDY JK, 1975, SCIENCE, V190, P787, DOI 10.1126/science.1198095; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; REDDY JK, 1992, MECHANISM CARCINOGEN, P225; REXIN M, 1991, J BIOL CHEM, V266, P24601; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; THEVENIAU M, 1992, P NATL ACAD SCI USA, V89, P4314, DOI 10.1073/pnas.89.10.4314; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATOWICH SS, 1988, MOL CELL BIOL, V8, P393, DOI 10.1128/MCB.8.1.393; YEM AW, 1992, J BIOL CHEM, V267, P2868; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	30	54	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8493	8497						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132576				2022-12-25	WOS:A1994NB40900099
J	KERNER, J; ZALUZEC, E; GAGE, D; BIEBER, LL				KERNER, J; ZALUZEC, E; GAGE, D; BIEBER, LL			CHARACTERIZATION OF THE MALONYL-COA-SENSITIVE CARNITINE PALMITOYLTRANSFERASE (CPT(O)) OF A RAT-HEART MITOCHONDRIAL PARTICLE - EVIDENCE THAT THE CATALYTIC UNIT IS CPT(I)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER MEMBRANE; LIVER MITOCHONDRIA; BINDING-PROTEIN; OUTER-MEMBRANE; COENZYME-A; SITE; ACYLTRANSFERASE; PEROXISOMES; INHIBITION; ANTIBODIES	A post 30,000 x g particulate fraction was isolated from rat heart. This mixed membrane fraction is enriched in a carnitine palmitoyltransferase which is sensitive to both malonyl-CoA and etomoxiryl-CoA at concentrations that inhibit the malonyl-CoA-sensitive carnitine palmitoyltransferase (CPTo/CPT-I) of intact mitochondria. Tritiated etomoxiryl-CoA labels two proteins with the same molecular weight as the labeled proteins from rat heart mitochondria. Malonyl-CoA-sensitive carnitine palmitoyltransferase in the particulate fraction is stable to freeze-thawing, and the activity is not latent. These data show that the carnitine palmitoyltransferase associated with this particle is CPTo/CPT-I. Positive Western blots were obtained, with the particle using anti-CPTi/CPT-II at a molecular weight identical with the CPTi/CPT-II purified from rat heart mitochondria. Catalytic activity was purified to near homogeneity in approximately 40% yield. The purified protein has a molecular weight identical with CPTi/CPT-II, it cross-reacts with antibody against CPTiCPT-II, it is not inhibited by malonyl-CoA or etomoxiryl-CoA, and mass spectral analyses of the tryptic peptides give the same molecular masses as CPTi/CPT-II, and, when mixed with equal amounts of CPTi/CPT-II, one uniform spot is found by two-dimensional electrophoresis. These data indicate that the catalytic subunit of CPTo/CPT-I is the same as CPTi/CPT-II. The average inhibition of the CPT of frozen-thawed particles is 71% by 50 nM etomoxiryl-CoA and 62% by 50 nM malonyl-CoA. The inhibitor sensitivity, but not the catalytic activity, is lost by solubilization in 1% Triton X-114; removal of Triton X-114 using Extracti-Gel D restores etomoxiryl-CoA and malonyl-CoA sensitivity (both 50 nM) of CPT to an average of 77 and 48%, respectively. Consistent with previous reports, these results show that CPTo/CPT-I is NOT inactivated by detergents, rather detergents both desensitize it to malonyl-CoA and alter its V-max. These data show the assumption that CPTo/CPT-I is inactivated by detergents is untenable.			KERNER, J (corresponding author), MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018427] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 18427] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADRAIL D, 1990, J BIOL CHEM, V265, P18797; BERGSETH S, 1986, BIOCHEM SOC T, V14, P671, DOI 10.1042/bst0140671; BHAIRD NN, 1992, BIOCHEM J, V28, P637; BIEBER L, 1991, CURRENT CONCEPTS CAR, P129; BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; BILLECI TM, 1993, ANAL CHEM, V65, P1709, DOI 10.1021/ac00061a013; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRADY PS, 1987, BIOCHEM J, V241, P751, DOI 10.1042/bj2410751; BREMER J, 1983, PHYSIOL REV, V63, P1420, DOI 10.1152/physrev.1983.63.4.1420; CARBAL F, 1979, METHOD ENZYMOL, V56, P602; CATRAVAS GN, 1974, RADIAT RES, V58, P462, DOI 10.2307/3573915; Chung C, 1991, Protein Expr Purif, V2, P426, DOI 10.1016/1046-5928(91)90104-Q; CHUNG CD, 1993, J BIOL CHEM, V268, P4519; CHUNG CH, 1992, BIOCHEMISTRY-US, V31, P9777, DOI 10.1021/bi00155a034; CLARKE PRH, 1981, J BIOL CHEM, V256, P9869; DECHLERCQ PE, 1987, J BIOL CHEM, V262, P9812; DERRICK JP, 1989, BIOCHEM J, V262, P801, DOI 10.1042/bj2620801; ESSER V, 1993, J BIOL CHEM, V268, P5817; ESSER V, 1993, J BIOL CHEM, V268, P5810; FARRELL SO, 1984, J BIOL CHEM, V259, P13088; FIOL CJ, 1987, BIOCHIM BIOPHYS ACTA, V916, P482, DOI 10.1016/0167-4838(87)90195-6; GHADIMINEJAD I, 1990, FEBS LETT, V269, P406, DOI 10.1016/0014-5793(90)81204-2; GHADIMINEJAD I, 1990, BIOCHEM J, V270, P787, DOI 10.1042/bj2700787; GHADIMINEJAD I, 1992, INT J BIOCHEM, V24, P573, DOI 10.1016/0020-711X(92)90329-Y; GHADIMINEJAD I, 1991, BIOCHIM BIOPHYS ACTA, V1083, P166, DOI 10.1016/0005-2760(91)90038-J; HEALY MJ, 1988, BIOCHEM J, V249, P231, DOI 10.1042/bj2490231; HOPPEL CL, 1992, CURRENT CONCEPTS IN CARNITINE RESEARCH, P153; JUHASZ P, 1992, 40TH P ASMS C MASS S, P1913; KERNER J, 1990, BIOCHEMISTRY-US, V29, P4326, DOI 10.1021/bi00470a010; KIORPES TC, 1984, J BIOL CHEM, V259, P9750; KOLODZIEJ MP, 1990, BIOCHEM J, V272, P421, DOI 10.1042/bj2720421; KOLODZIEJ MP, 1992, BIOCHEM J, V282, P415, DOI 10.1042/bj2820415; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILLY K, 1992, BIOCHEM PHARMACOL, V43, P353, DOI 10.1016/0006-2952(92)90298-W; LILLY K, 1990, ARCH BIOCHEM BIOPHYS, V280, P167, DOI 10.1016/0003-9861(90)90532-4; LUND H, 1986, BIOCHIM BIOPHYS ACTA, V878, P243, DOI 10.1016/0005-2760(86)90152-9; Markwell M A, 1981, Methods Enzymol, V72, P296; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGARRY JD, 1978, J BIOL CHEM, V253, P4128; MCMILLIN JB, 1992, J MOL CELL CARDIOL, V24, P259, DOI 10.1016/0022-2828(92)93163-E; MOCK KK, 1992, RAPID COMMUN MASS SP, V6, P233, DOI 10.1002/rcm.1290060402; MURTHY MSR, 1990, BIOCHEM J, V268, P599, DOI 10.1042/bj2680599; MURTHY MSR, 1987, P NATL ACAD SCI USA, V84, P378, DOI 10.1073/pnas.84.2.378; MURTHY MSR, 1992, CURRENT CONCEPTS CAR, P192; PANDE SV, 1986, BIOCHIM BIOPHYS ACTA, V877, P223, DOI 10.1016/0005-2760(86)90298-5; RAMSAY RR, 1988, BIOCHEM J, V249, P239, DOI 10.1042/bj2490239; SAGGERSON D, 1992, ADV ENZYME REGUL, V32, P285; SCHOLTE HR, 1973, BIOCHIM BIOPHYS ACTA, V305, P413, DOI 10.1016/0005-2728(73)90187-4; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; Tanaka T, 1981, Methods Enzymol, V71 Pt C, P334; WILSON JE, 1983, METHOD ENZYMOL, V97, P469; WOELTJE KF, 1987, J BIOL CHEM, V262, P9822; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720; WOLDEGIORGIS G, 1992, ARCH BIOCHEM BIOPHYS, V295, P348, DOI 10.1016/0003-9861(92)90527-4; Yonetani T, 1967, METHODS ENZYMOL, V10, P332	55	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8209	8219						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132545				2022-12-25	WOS:A1994NB40900059
J	PISANI, FM; ROSSI, M				PISANI, FM; ROSSI, M			EVIDENCE THAT AN ARCHAEAL ALPHA-LIKE DNA-POLYMERASE HAS A MODULAR ORGANIZATION OF ITS ASSOCIATED CATALYTIC ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXONUCLEASE ACTIVE-SITE; I KLENOW FRAGMENT; ESCHERICHIA-COLI; 3'-5' EXONUCLEASE; SULFOLOBUS-SOLFATARICUS; AMINO-ACID; FUNCTIONAL DOMAINS; CRYSTAL-STRUCTURE; BINDING; IDENTIFICATION	In this study we report on the evidence that an alpha-like DNA polymerase purified from the thermoacidophilic archaeon Sulfolobus solfataricus has a modular organization of its associated catalytic activities (polymerase and 3'-5' exonuclease). This enzyme, a monomer of about 100 kDa whose complete primary structure is available, has a protease hypersensitive site that is likely to be cleaved by the action of endogenous proteases during the purification procedure. As a consequence of that, two proteolytic fragments of about 50 and 40 kDa, in addition to the intact 100 M)a molecular species, can be detected upon SDS-PAGE of highly purified S. solfataricus DNA polymerase samples. The amino-terminal microsequence analysis by Edman degradation has revealed that the 50- and the 40-kDa polypeptides correspond to the carboxyl- and the amino-terminal portion of the protein molecule, respectively. Using the bidimensional activity gel assay procedure, recently described by Longley and Mosbaugh (Longley, M. J., and Mosbaugh, D. W. (1991) Biochemistry 30, 2655-2664), we have demonstrated that the 50-kDa fragment retains a Mg2+ dependent DNA polymerizing activity, whereas the 40-kDa polypeptide is able to catalyze the excision of mispaired nucleotides at the 3'-OH terminus of a primer/ template DNA substrate in the presence of Mn2+ ions. On the other hand, the 100-kDa protein possess both activities. To date, this is the first report indicating, on the basis of direct functional data, that the polymerization and the 3'-5' exonuclease activity of a family B DNA polymerase can be ascribed to physically distinct modules of the enzyme molecule.			PISANI, FM (corresponding author), CNR,IST BIOCHIM PROT & ENZIMOL,VIA MARCONI 10,I-80125 NAPLES,ITALY.		Pisani, Francesca M./AAX-4025-2020					ANDREWS P, 1964, BIOCHEM J, V91, P222, DOI 10.1042/bj0910222; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BLANCO L, 1992, GENE, V112, P139, DOI 10.1016/0378-1119(92)90316-H; BLASCO MA, 1992, J BIOL CHEM, V267, P19427; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; BRENOWITZ S, 1991, J BIOL CHEM, V266, P7888; CARROLL SS, 1990, CHEM REV, V90, P1291, DOI 10.1021/cr00105a011; CATALANO CE, 1989, BIOCHEMISTRY-US, V28, P4374, DOI 10.1021/bi00436a038; CHEN M, 1989, P NATL ACAD SCI USA, V86, P6116, DOI 10.1073/pnas.86.16.6116; CHENG CH, 1993, BIOCHEMISTRY-US, V32, P8568, DOI 10.1021/bi00084a025; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; ESTEBAN JA, 1992, BIOCHEMISTRY-US, V31, P350, DOI 10.1021/bi00117a006; FREEMONT P S, 1986, Proteins Structure Function and Genetics, V1, P66, DOI 10.1002/prot.340010111; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2578; GIBBS JS, 1991, MOL CELL BIOL, V11, P4786, DOI 10.1128/MCB.11.9.4786; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; Joyce CM, 1991, CURR OPIN STRUC BIOL, V1, P123, DOI 10.1016/0959-440X(91)90020-T; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; KARAWYA E, 1983, ANAL BIOCHEM, V135, P318, DOI 10.1016/0003-2697(83)90689-9; KLENOW H, 1970, P NATL ACAD SCI USA, V65, P168, DOI 10.1073/pnas.65.1.168; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KONG HM, 1993, J BIOL CHEM, V268, P1965; Kornberg A., 1992, DNA REPLICATION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN IR, 1964, J BIOL CHEM, V239, P233; LONGLEY MJ, 1991, BIOCHEMISTRY-US, V30, P2655, DOI 10.1021/bi00224a014; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; MULLEN GP, 1990, J BIOL CHEM, V265, P14327; OLLIS DL, 1985, NATURE, V313, P726; PISANI FM, 1992, NUCLEIC ACIDS RES, V20, P2711, DOI 10.1093/nar/20.11.2711; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; REHAKRANTZ LJ, 1992, GENE, V112, P133, DOI 10.1016/0378-1119(92)90315-G; REISFELD RA, 1962, NATURE, V195, P281, DOI 10.1038/195281a0; RELLA R, 1990, ITAL J BIOCHEM, V39, P83; ROSSI M, 1986, SYST APPL MICROBIOL, V7, P337; SOENGAS MS, 1992, EMBO J, V11, P4227, DOI 10.1002/j.1460-2075.1992.tb05517.x; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867	45	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7887	7892						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132506				2022-12-25	WOS:A1994NB40900012
J	NAGAICH, AK; BHATTACHARYYA, D; BRAHMACHARI, SK; BANSAL, M				NAGAICH, AK; BHATTACHARYYA, D; BRAHMACHARI, SK; BANSAL, M			CA/TG SEQUENCE AT THE 5' END OF OLIGO(A)-TRACTS STRONGLY MODULATES DNA CURVATURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETOPLAST DNA; CURVED DNA; POTASSIUM-PERMANGANATE; DEOXYRIBONUCLEIC-ACID; ADENINE TRACTS; B-DNA; BENT; CONFORMATION; DUPLEXES; FRAGMENT	An analysis of the base pair doublet geometries in available crystal structures indicates that the often reported intrinsic curvature of DNA containing oligo-(d(A).d(T)) tracts may also depend on the nature of the flanking sequences. The presence of CA/TG doublet in particular at the 5' end of these tracts is expected to enhance their intrinsic bending property. To test this proposition, three oligonucleotides, d(GAAAAACCCCCC), d(CCCCCCAAAAAG), d(GAAAAATTTTTC), and their complementary sequences were synthesized to study the effect of various flanking sequences, at the 5' and 3' ends of the A-tracts, on the curvature of DNA in solution. An analysis of the polyacrylamide gel electrophoretic mobilities of these sequences under different conditions of salts and temperatures (below their melting points) clearly showed that the oligomer with CA/TG sequence in the center was always more retarded than the oligomer with AC/GT sequence, as well as the oligomer with AT/AT sequence. Hydroxyl radical probing of the sequences with AC/GT and CA/TG doublet junctions gives a similar cutting pattern in the A-tracts, which is quite different from that in the C-tracts, indicating that the oligo(A)-tracts have similar structures in the two oligomers. KMnO4 probing shows that the oligomer with a CA/TG doublet junction forms a kink that is responsible for its inherent curvature and unusual electrophoretic mobility. UV melting shows a reduced thermal stability of the duplex with CA/TG doublet junction, and circular dichroism (CD) studies indicate that a premelting transition occurs in the oligomer with CA/TG doublet step before global melting but not in the oligomer with AC/GT doublet step, which may correspond to thermally induced unbending of the oligomer. These observations indicate that the CA/TG doublet junction at the 5' end of the oligo(A)-tract has a crucial role in modulating the overall curvature in DNA.	INDIAN INST SCI,MOLEC BIOPHYS UNIT,BANGALORE 560012,KARNATAKA,INDIA; INDIAN INST SCI,CTR GENET ENGN,BANGALORE 560012,KARNATAKA,INDIA	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore								ABAGYAN RA, 1989, NUCLEIC ACIDS RES, V16, P989; BALAGURUMOORTHY P, 1992, NUCLEIC ACIDS RES, V20, P4061, DOI 10.1093/nar/20.15.4061; BANSAL M, 1991, MOL CONFORMATION BIO, P347; BERMAN HM, 1992, BIOPHYS J, V63, P751, DOI 10.1016/S0006-3495(92)81649-1; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BEUTEL BA, 1992, J MOL BIOL, V228, P803, DOI 10.1016/0022-2836(92)90865-H; BHATTACHARYA D, 1988, J BIOMOL STRUCT DYN, V6, P93, DOI 10.1080/07391102.1988.10506484; BHATTACHARYYA D, 1990, J BIOMOL STRUCT DYN, V8, P539, DOI 10.1080/07391102.1990.10507828; BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; BOSSI L, 1984, CELL, V39, P643, DOI 10.1016/0092-8674(84)90471-9; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BRAHMS S, 1990, NUCLEIC ACIDS RES, V18, P1559, DOI 10.1093/nar/18.6.1559; BURKHOFF AM, 1987, CELL, V48, P935, DOI 10.1016/0092-8674(87)90702-1; BURKHOFF AM, 1988, NATURE, V331, P455, DOI 10.1038/331455a0; CHAN SS, 1990, BIOCHEMISTRY-US, V29, P6161, DOI 10.1021/bi00478a008; CHEN JH, 1988, NUCLEIC ACIDS RES, V16, P6803, DOI 10.1093/nar/16.14.6803; DESANTIS P, 1990, BIOCHEMISTRY-US, V29, P9269, DOI 10.1021/bi00491a023; DIEKMANN S, 1985, J MOL BIOL, V186, P1, DOI 10.1016/0022-2836(85)90251-7; DIEKMANN S, 1992, J MOL BIOL, V225, P729, DOI 10.1016/0022-2836(92)90397-3; GOODSELL DS, 1993, P NATL ACAD SCI USA, V90, P2930, DOI 10.1073/pnas.90.7.2930; HAGERMAN PJ, 1984, P NATL ACAD SCI-BIOL, V81, P4632, DOI 10.1073/pnas.81.15.4632; HAGERMAN PJ, 1986, NATURE, V321, P449, DOI 10.1038/321449a0; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; HOWGATE P, 1968, J CHEM SOC C, P275, DOI 10.1039/j39680000275; IIDA S, 1971, BIOCHIM BIOPHYS ACTA, V240, P370, DOI 10.1016/0005-2787(71)90530-2; JERNIGAN RL, 1987, J BIOMOL STRUCT DYN, V4, P561, DOI 10.1080/07391102.1987.10507660; JIANG H, 1991, NUCLEIC ACIDS RES, V19, P6943, DOI 10.1093/nar/19.24.6943; KITCHIN PA, 1986, J BIOL CHEM, V261, P1302; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; LYUBCHENKO YL, 1993, BIOCHEMISTRY-US, V32, P4121, DOI 10.1021/bi00066a038; MARINI JC, 1982, P NATL ACAD SCI-BIOL, V79, P7664, DOI 10.1073/pnas.79.24.7664; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; MCCARTHY JG, 1991, NUCLEIC ACIDS RES, V19, P3421, DOI 10.1093/nar/19.12.3421; MCCARTHY JG, 1990, BIOCHEMISTRY-US, V29, P6071, DOI 10.1021/bi00477a027; MILTON DL, 1990, NUCLEIC ACIDS RES, V18, P817, DOI 10.1093/nar/18.4.817; NUSSINOV R, 1988, J BIOMOL STRUCT DYN, V6, P543, DOI 10.1080/07391102.1988.10506506; OLSON WK, 1993, J MOL BIOL, V232, P530, DOI 10.1006/jmbi.1993.1409; PARK YW, 1991, P NATL ACAD SCI USA, V88, P1551, DOI 10.1073/pnas.88.4.1551; PATEL DJ, 1987, UNUSUAL DNA STRUCTUR, P115; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; SRINIVASAN AR, 1987, J BIOMOL STRUCT DYN, V5, P459, DOI 10.1080/07391102.1987.10506409; STELLWAGEN NC, 1983, BIOCHEMISTRY-US, V22, P6186, DOI 10.1021/bi00295a023; ULANOVSKY LE, 1987, NATURE, V326, P720, DOI 10.1038/326720a0; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YANAGI K, 1991, J MOL BIOL, V217, P201, DOI 10.1016/0022-2836(91)90620-L; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850; ZHURKIN VB, 1991, P NATL ACAD SCI USA, V88, P7046, DOI 10.1073/pnas.88.16.7046; 1989, J MOL BIOL, V205, P787	49	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7824	7833						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8126009				2022-12-25	WOS:A1994NA03200120
J	TAKETANI, S; KOHNO, H; OKUDA, M; FURUKAWA, T; TOKUNAGA, R				TAKETANI, S; KOHNO, H; OKUDA, M; FURUKAWA, T; TOKUNAGA, R			INDUCTION OF PERIPHERAL-TYPE BENZODIAZEPINE RECEPTORS DURING DIFFERENTIATION OF MOUSE ERYTHROLEUKEMIA-CELLS - A POSSIBLE INVOLVEMENT OF THESE RECEPTORS IN HEME-BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; ERYTHROID DIFFERENTIATION; ENDOGENOUS LIGANDS; EXPRESSION; BINDING; PROTEIN; FERROCHELATASE; PURIFICATION; PORPHYRINS	To search for a possible role for peripheral-type benzodiazepine receptors (PBR) during erythroid differentiation, we cloned the PBR isoquinoline carboxamide-binding protein (PBR/IBP), an 18-kDa protein on PBR, from a mouse erythroleukemia (MEL) cell cDNA library. Sequence analysis revealed that PBR/IBP comprises 169 amino acid residues (M(r) 18,828), and has a high homology with PBR/IBP from other sources. The cDNA allows for the expression of active PBR/IBP, exhibiting a high affinity for isoquinoline carboxamide, [H-3]PK11195, with K-d of 0.80 and 1.56 nM. RNA blot analysis revealed that treatment of MEL cells with dimethyl sulfoxide led to an increase in PBR/IBP mRNA (?1.0 kilobases) for up to 72 h, with a concomitant induction of mRNAs for heme biosynthetic enzymes, coproporphyrinogen oxidase and ferrochelatase. The induction of PBR/IBP mRNA was also observed in MEL cells induced with diazepam. The binding activity of [H-3]PK11195 in MEL cells showed a high affinity with K-d of 0.69-2.13 nM, and increased during erythroid differentiation. The order of potency of different ligands to compete against [H-3]PK11195 binding in induced MEL cells was PK11195 > protoporphyrin IX > diazepam > coproporphyrinogen III > coproporphyrin III > estazolam. In contrast to the induction of PBR/IBP in induced MEL cells, the voltage-dependent anion channel (mitochondrial porin) associated with PBR remained unchanged. These results suggest that PBR/IBP on PBR may be involved in porphyrin transport and may even be a critical factor in erythroid-specific induction of heme biosynthesis.			TAKETANI, S (corresponding author), KANSAI MED UNIV,DEPT HYG,MORIGUCHI,OSAKA 570,JAPAN.							ANHALT RRH, 1986, J BIOL CHEM, V261, P576; ANHALT RRH, 1985, J PHARMACOL EXP THER, V233, P517; ANTKIEWICZMICHALUK L, 1988, J BIOL CHEM, V263, P17317; CLARKE GD, 1980, NATURE, V287, P160, DOI 10.1038/287160a0; DELBATLLE AM, 1979, CLIN SCI, V57, P63, DOI 10.1042/cs0570063; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUIDOTTI A, 1983, P NATL ACAD SCI-BIOL, V80, P3531, DOI 10.1073/pnas.80.11.3531; HA HJ, 1993, J BIOL CHEM, V268, P12143; HIRSCH JD, 1989, MOL PHARMACOL, V35, P164; KOHNO H, 1993, J BIOL CHEM, V268, P21359; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCABE RT, 1989, FEBS LETT, V244, P263, DOI 10.1016/0014-5793(89)80541-1; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; MUKHIN AG, 1989, P NATL ACAD SCI USA, V86, P9813, DOI 10.1073/pnas.86.24.9813; NAKAHASHI Y, 1990, BIOCHIM BIOPHYS ACTA, V1037, P321, DOI 10.1016/0167-4838(90)90032-B; PAPADOPOULOS V, 1990, J BIOL CHEM, V265, P3772; PAROLA AL, 1991, J BIOL CHEM, V266, P14082; PROULX KL, 1993, PROTEIN SCI, V2, P1092, DOI 10.1002/pro.5560020703; RIOND J, 1991, EUR J PHARM-MOLEC PH, V208, P307, DOI 10.1016/0922-4106(91)90076-T; RIOND J, 1991, EUR J BIOCHEM, V195, P305, DOI 10.1111/j.1432-1033.1991.tb15707.x; SAMBROOK T, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; SASSA S, 1976, J EXP MED, V143, P305, DOI 10.1084/jem.143.2.305; SNYDER SH, 1987, FASEB J, V1, P282, DOI 10.1096/fasebj.1.4.2820823; SPRENGEL R, 1989, J BIOL CHEM, V264, P20415; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; TAKETANI S, 1990, J BIOL CHEM, V265, P13981; VERMA A, 1988, MOL PHARMACOL, V34, P800; VERMA A, 1987, P NATL ACAD SCI USA, V84, P2256, DOI 10.1073/pnas.84.8.2256; WANG JKT, 1984, P NATL ACAD SCI-BIOL, V81, P3770, DOI 10.1073/pnas.81.12.3770	33	84	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7527	7531						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125973				2022-12-25	WOS:A1994NA03200078
J	LIU, LW; REZAIE, AR; CARSON, CW; ESMON, NL; ESMON, CT				LIU, LW; REZAIE, AR; CARSON, CW; ESMON, NL; ESMON, CT			OCCUPANCY OF ANION-BINDING EXOSITE-2 ON THROMBIN DETERMINES CA2+ DEPENDENCE OF PROTEIN-C ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; RECOMBINANT HUMAN THROMBOMODULIN; PROTHROMBIN FRAGMENT-2; BLOOD-COAGULATION; ANTITHROMBIN-III; ACTIVE-SITE; SPECIFICITY; CALCIUM; REGION; ANTICOAGULANT	Thrombomodulin (TM) binds thrombin to form a complex that activates the plasma anticoagulant zymogen protein C. TM is an integral membrane glycoprotein that contains a chondroitin sulfate moiety. Interaction with thrombin involves both the protein component of TM, specifically the growth factor-like repeats 4-6 (TM 4-6), and chondroitin sulfate. Removal of chondroitin sulfate decreases the affinity for thrombin approximate to 10-fold and shifts the Ca2+ dependence of protein C activation from simple saturation at greater than or equal to 500 mu M Ca2+ to a distinct optimum at approximate to 100 mu M Ca2+. Thrombin possesses two regions of high positive charge, anion binding exosites 1 and 2. Anion binding exosite 1 interacts with the growth factor region of TM while exosite 2 is involved in binding prothrombin activation fragment 2 or heparin. We demonstrate that recombinant TM, truncated at the membrane-spanning domain, or TM 4-6 can bind thrombin when fragment 2 is present either covalently attached (meizothrombin des-fragment 1) or in reversible association. With meizothrombin des-fragment 1, the Ca2+ dependence of protein C activation is independent of the presence of the chondroitin sulfate on TM. At 0.27 mM Ca2+, TM containing chondroitin sulfate binds thrombin (K-d(app) = 0.3 nM) approximate to 45 times tighter than meizothrombin des-fragment 1 (K-d(app) = 14 nM). However, the chondroitin-free form thrombin (K-d(app) = 2.4 nM) only approximate to 4 times tighter than meizothrombin des-fragment 1 (K-d(app) = 9.4 nM). These studies suggest that occupancy of anion binding exosite 2 by either chondroitin sulfate or fragment 2 alters thrombin conformation resulting in the altered Ca2+ dependence of protein C activation.	OKLAHOMA MED RES FDN,HOWARD HUGHES MED INST,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73104	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center					NHLBI NIH HHS [R37 HL30340] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030340] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BAJAJ SP, 1975, J BIOL CHEM, V250, P2150; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; DITTMAN WA, 1990, BLOOD, V75, P329; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON CT, 1974, J BIOL CHEM, V249, P7791; ESMON NL, 1988, CIRCULATION, V78, P317; JAKUBOWSKI HV, 1989, J BIOL CHEM, V264, P11117; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; KUROSAWA S, 1987, J BIOL CHEM, V262, P2206; MARTIN PD, 1993, 16TH C INT UN CRYST; MYRMEL KH, 1976, BIOCHEMISTRY-US, V15, P1767, DOI 10.1021/bi00653a027; OWEN WG, 1974, J BIOL CHEM, V249, P594; PARKINSON JF, 1992, BIOCHEM J, V283, P151, DOI 10.1042/bj2830151; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; PARKINSON JF, 1992, ADV EXP MED BIOL, V313, P177; PARKINSON JF, 1990, BIOCHEM BIOPH RES CO, V169, P177, DOI 10.1016/0006-291X(90)91451-W; REZAIE AR, 1994, J BIOL CHEM, V269, P3151; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; SCHOEN P, 1987, J BIOL CHEM, V262, P11268; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; SUGO T, 1984, J BIOL CHEM, V259, P5705; SUZUKI K, 1987, EMBO J, V6, P1891, DOI 10.1002/j.1460-2075.1987.tb02448.x; WALKER FJ, 1979, J BIOL CHEM, V254, P5618; WU QY, 1992, J BIOL CHEM, V267, P7083; YE J, 1993, J BIOL CHEM, V268, P2373; YE J, 1992, J BIOL CHEM, V267, P11023	33	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11807	11812						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163479				2022-12-25	WOS:A1994NG37700023
J	FINI, ME; STRISSEL, KJ; GIRARD, MT; MAYS, JW; RINEHART, WB				FINI, ME; STRISSEL, KJ; GIRARD, MT; MAYS, JW; RINEHART, WB			INTERLEUKIN-1-ALPHA MEDIATES COLLAGENASE SYNTHESIS STIMULATED BY PHORBOL 12-MYRISTATE 13-ACETATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNOVIAL CELL COLLAGENASE; MESSENGER-RNA; METALLOPROTEINASE EXPRESSION; RECEPTOR ANTAGONIST; SIGNAL TRANSDUCTION; FIBROBLASTS; GENE; STROMELYSIN; MATRIX; JUN	Stimulation of collagenase expression in cultures of normal diploid fibroblasts by the tumor promotor phorbol 12-myristate 13-acetate (PMA) occurs secondarily to synthesis of unknown intermediary proteins. We have investigated the hypothesis that a form of the cytokine interleukin 1 (IL-1) is one intermediate controlling PMA-stimulated collagenase expression. Treatment with an IL-1 receptor antagonist inhibits the constitutive synthesis of collagenase in early passage fibroblast cultures from rabbit. Radioimmunoassay demonstrates that, of the two known IL-1 forms, IL-1alpha and IL-1beta, only IL-1alpha is synthesized and released into the medium of corneal fibroblast cultures. PMA treatment of cells increases the level of IL-1alpha mRNA; this occurs prior to the increase in collagenase mRNA and corresponds with increased synthesis and release of IL-1alpha protein. Neutralizing antiserum to EL-1alpha inhibits constitutive collagenase synthesis. Reagents that inhibit the activity of IL-1alpha (IL-1 receptor antagonist or neutralizing antibody) also inhibit the PMA-mediated stimulation of collagenase synthesis. These results indicate that constitutive and PMA-stimulated expression of collagenase is regulated through an IL-1alpha intermediate. In vivo, regulation of the lytic phase of tissue remodeling through the IL-1alpha intermediate may ensure the recruitment of cells adjacent to the one that received the initial stimulus.	HARVARD UNIV,SCH MED,DEPT DERMATOL,BOSTON,MA 02129	Harvard University; Harvard Medical School	FINI, ME (corresponding author), MASSACHUSETTS GEN HOSP,HARVARD CUTANEOUS BIOL RES CTR,13TH ST,BOSTON,MA 02129, USA.				NEI NIH HHS [R01-EY08408, R01-EY09828] Funding Source: Medline; NIAMS NIH HHS [T32-AR07098] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009828, R01EY008408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007098] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; Alexander CM, 1991, CELL BIOL EXTRACELLU, P255; ALLEN RW, 1987, J BIOL CHEM, V262, P649; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANGEL P, 1985, J CELL BIOCHEM, V29, P351, DOI 10.1002/jcb.240290408; ANSEL JC, 1988, J IMMUNOL, V140, P2274; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BIRKEDALHANSEN H, 1992, MATRIX METALLOPROTEI; BISWAS C, 1979, CELL, V18, P1035, DOI 10.1016/0092-8674(79)90216-2; BORASCHI D, 1990, EUR J IMMUNOL, V20, P317, DOI 10.1002/eji.1830200213; BRINCKERHOFF CE, 1986, BIOCHEMISTRY-US, V25, P6378, DOI 10.1021/bi00369a006; BRINCKERHOFF CE, 1987, DEV DISEASES CARTILA, P299; CONCA W, 1991, J BIOL CHEM, V266, P16265; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; DARMIENTO J, 1992, CELL, V71, P955, DOI 10.1016/0092-8674(92)90391-O; DAYER JM, 1976, P NATL ACAD SCI USA, V73, P945, DOI 10.1073/pnas.73.3.945; DINARELLO CA, 1989, CRIT REV IMMUNOL, V9, P1; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DOANE KJ, 1991, EXP CELL RES, V195, P432, DOI 10.1016/0014-4827(91)90394-A; EISENBERG SP, 1991, P NATL ACAD SCI USA, V88, P5232, DOI 10.1073/pnas.88.12.5232; ELIAS JA, 1989, P NATL ACAD SCI USA, V86, P6171, DOI 10.1073/pnas.86.16.6171; ENK AH, 1993, J IMMUNOL, V150, P3698; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINI ME, 1990, J CELL SCI, V97, P373; FINI ME, 1987, BIOCHEMISTRY-US, V26, P6156, DOI 10.1021/bi00393a032; FINI ME, 1987, ARTHRITIS RHEUM, V30, P1254, DOI 10.1002/art.1780301108; FRISCH SM, 1987, P NATL ACAD SCI USA, V84, P2600, DOI 10.1073/pnas.84.9.2600; FURUTANI Y, 1985, NUCLEIC ACIDS RES, V13, P5869, DOI 10.1093/nar/13.16.5869; GIRARD MT, 1993, J CELL SCI, V104, P1001; GIRARD MT, 1991, INVEST OPHTH VIS SCI, V32, P2441; GROSS J, 1982, CELL BIOL EXTRACELLU, P217; GROSS RH, 1984, P NATL ACAD SCI-BIOL, V81, P1981, DOI 10.1073/pnas.81.7.1981; GUESDON F, 1993, J BIOL CHEM, V268, P4236; HULEIHEL M, 1990, EUR J IMMUNOL, V20, P731, DOI 10.1002/eji.1830200404; JOHNSONMULLER B, 1978, P NATL ACAD SCI USA, V75, P4417, DOI 10.1073/pnas.75.9.4417; KUMAR S, 1992, P NATL ACAD SCI USA, V89, P4683, DOI 10.1073/pnas.89.10.4683; KUTER I, 1989, J CELL SCI, V92, P423; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MCCACHREN SS, 1989, ARTHRITIS RHEUM, V32, P1639; NAKAGAWA M, 1992, DEV DYNAM, V195, P87, DOI 10.1002/aja.1001950203; NATHAN C, 1991, J CELL BIOL, V113, P25; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; SAKLATVALA J, 1991, AGENT ACTION SUPPL, V35, P35; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; UNEMORI EN, 1988, J BIOL CHEM, V263, P16252; WANG Z, 1993, J BIOL CHEM, V268, P16270; WERB Z, 1978, P NATL ACAD SCI USA, V75, P1839, DOI 10.1073/pnas.75.4.1839; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WERB Z, 1986, J CELL BIOL, V102, P679; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	53	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11291	11298						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157661				2022-12-25	WOS:A1994NF96600050
J	BRASIER, AR; KUMAR, A				BRASIER, AR; KUMAR, A			IDENTIFICATION OF A NOVEL DETERMINANT FOR BASIC DOMAIN-LEUCINE ZIPPER DNA-BINDING ACTIVITY IN THE ACUTE-PHASE INDUCIBLE NUCLEAR FACTOR-INTERLEUKIN-6 TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESSOR-OPERATOR INTERACTION; ANGIOTENSINOGEN GENE; C/EBP FAMILY; ACTIVATOR PROTEIN; RESPONSE ELEMENT; GCN4; MEMBER; EXPRESSION; EXCHANGE; NF-IL6	Nuclear factor-interleukin-6 (NF-IL6), a member of the CCAAT box/enhancer-binding protein (C/EBP) family, contains a basic domain leucine zipper (bZIP) DNA binding motif. Controlled protease digestion was used to probe free and DNA-complexed NF-IL6 protein. Digestion with trypsin in the absence of DNA produced the leucine zipper domain (containing residues 303-345). In contrast, digestion of NF-IL6.DNA complexes produced a stable domain, spanning residues 266-345, termed the tryptic core domain (TCD). The NH2-terminal boundary of the TCD is longer than tryptic peptides reported from C/EBP alpha.DNA complexes. Digestion of NF-IL6 with endoprotease Asp-N produced a domain smaller than the TCD (NF-IL6 bZIP domains (NFBD) (272-345)), a domain identified either in the absence or the presence of DNA. Both recombinant peptides bind acute-phase response element DNA in a sequence-specific fashion. The equilibrium disassociation constant (K-d) for the TCD was 36 +/- nM, whereas the K-d for NFBD (272-345) was 283 +/- 160 nM. Moreover, in comparison with the TCD, NFBD (272-345) formed unstable DNA complexes with a 15-fold faster off-rate. We conclude that the amino acids represented between 266 and 272 termed the complex stabilizing subdomain, influences DNA complex formation independent of DNA binding specificity, and may be one mechanism for heterogeneity of DNA interaction by C/EBP family members.	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555; UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	BRASIER, AR (corresponding author), UNIV TEXAS,MED BRANCH,DEPT MED,DIV ENDOCRINOL,GALVESTON,TX 77555, USA.				NHLBI NIH HHS [R29 HL45500] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045500] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASIER AR, 1990, MOL ENDOCRINOL, V4, P1921, DOI 10.1210/mend-4-12-1921; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CUENOUD B, 1993, SCIENCE, V259, P510, DOI 10.1126/science.8424173; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIULIAN GG, 1985, FED PROC, V44, P686; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KUMAR A, 1993, BIOCHEMISTRY-US, V32, P7466, DOI 10.1021/bi00080a018; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PU WT, 1991, P NATL ACAD SCI USA, V88, P6901, DOI 10.1073/pnas.88.16.6901; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANIUCHI H, 1969, J BIOL CHEM, V244, P4600; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WIDEN SG, 1991, BIOCHEMISTRY-US, V30, P6296, DOI 10.1021/bi00239a031; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WU C, 1985, NATURE, V317, P84, DOI 10.1038/317084a0	38	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10341	10351						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144615				2022-12-25	WOS:A1994NF01700027
J	LESSARD, IAD; PERHAM, RN				LESSARD, IAD; PERHAM, RN			EXPRESSION IN ESCHERICHIA-COLI OF GENES ENCODING THE E1-ALPHA AND E1-BETA SUBUNITS OF THE PYRUVATE-DEHYDROGENASE COMPLEX OF BACILLUS-STEAROTHERMOPHILUS AND ASSEMBLY OF A FUNCTIONAL E1 COMPONENT (ALPHA(2)BETA(2)) IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTI-ENZYME COMPLEX; MULTIENZYME COMPLEX; SEQUENCE-ANALYSIS; ACETYLTRANSFERASE COMPONENT; INTERDOMAIN SEGMENT; POLYPEPTIDE-CHAIN; GENOMIC SEQUENCES; SITE; PROTEIN; BINDING	The E1 alpha and E1 beta subunits of the pyruvate decarboxylase (E1) component of the pyruvate dehydrogenase multienzyme complex of Bacillus stearothermophilus were produced from two genes overexpressed separately in Escherichia coli. A functional E1 enzyme was generated from disrupted mixtures of cells containing the separately overexpressed E1 alpha and E1 beta genes. The purified E1 enzyme exhibited an apparent molecular mass of 150,000 Da, consistent with an alpha(2) beta(2) structure. The K-m for pyruvate and k(cat) (30 degrees C) were found to be 0.9 +/- 0.2 mu M and 0.47 +/- 0.03 s(-1), respectively. The purified E1 alpha subunit existed as a monomer (42,000 Da), whereas the E1 beta subunit existed mainly (95%) in a tetrameric form (145,000 Da). Mixing equimolar amounts of the pure recombinant E1 alpha and E1 beta subunits in vitro generated a functional E1 enzyme with a molecular mass and an E1 activity similar to those of the E1(alpha(2) beta(2)) enzyme purified from disrupted mixtures of cells containing individually expressed subunits. Mixing individual subunits in vitro with one of the subunits in excess resulted in complete assembly of the lesser subunit into the intact E1(alpha(2) beta 2()) enzyme. Thus, no chaperonin is needed in vitro to promote the assembly of the separate subunits to form the E1 component of the pyruvate dehydrogenase multienzyme complex of B. stearothermophilus.	UNIV CAMBRIDGE, CAMBRIDGE CTR MOLEC RECOGNIT, DEPT BIOCHEM, CAMBRIDGE CB2 1QW, ENGLAND	University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIYAMA SK, 1980, BIOCHEMISTRY-US, V19, P4208, DOI 10.1021/bi00559a011; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATE RL, 1980, J BIOL CHEM, V255, P7556; DANSON MJ, 1978, P NATL ACAD SCI USA, V75, P5386, DOI 10.1073/pnas.75.11.5386; DARDEL F, 1993, J MOL BIOL, V229, P1037, DOI 10.1006/jmbi.1993.1103; DAVIE JR, 1992, J BIOL CHEM, V267, P16601; DIEFENBACH RJ, 1992, FEBS LETT, V296, P95, DOI 10.1016/0014-5793(92)80411-9; DYDA F, 1993, BIOCHEMISTRY-US, V32, P6165, DOI 10.1021/bi00075a008; GRAHAM LD, 1989, BIOCHEMISTRY-US, V28, P1574, DOI 10.1021/bi00430a023; GREEN JDF, 1992, J BIOL CHEM, V267, P23484; GUEST JR, 1989, ANN N Y ACAD SCI, V573, P76; HACKERT ML, 1989, BIOCHEMISTRY-US, V28, P6816, DOI 10.1021/bi00443a006; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; HAWKINS CF, 1990, EUR J BIOCHEM, V191, P337, DOI 10.1111/j.1432-1033.1990.tb19128.x; HENDERSON CE, 1980, BIOCHEM J, V189, P161, DOI 10.1042/bj1890161; HORN F, 1983, J BIOL CHEM, V258, P6912; JAENICKE R, 1982, BIOCHEMISTRY-US, V21, P3378, DOI 10.1021/bi00257a020; KAHILOVA LS, 1977, BIOKHIMIYA, V42, P113; KALIA YN, 1993, J MOL BIOL, V230, P323, DOI 10.1006/jmbi.1993.1145; KOIKE K, 1992, BIOCHIM BIOPHYS ACTA, V1118, P223, DOI 10.1016/0167-4838(92)90279-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTEVI A, 1993, J MOL BIOL, V230, P1183, DOI 10.1006/jmbi.1993.1235; MATTEVI A, 1993, J MOL BIOL, V230, P1200, DOI 10.1006/jmbi.1993.1236; Mattevi A., 1992, CURR OPIN STRUC BIOL, V2, P877, DOI [10.1016/0959-440X(92)90114-M, DOI 10.1016/0959-440X(92)90114-M]; MATUDA S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P1, DOI 10.1016/0167-4781(91)90076-X; MILES JS, 1988, J MOL BIOL, V202, P97, DOI 10.1016/0022-2836(88)90522-0; MULLER YA, 1993, SCIENCE, V259, P965, DOI 10.1126/science.8438155; OLIVER RM, 1982, ELECTRON MICROS, V2, P1; PACKMAN LC, 1988, BIOCHEM J, V252, P79, DOI 10.1042/bj2520079; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; RADFORD SE, 1989, J BIOL CHEM, V264, P767; RADFORD SE, 1989, FEBS LETT, V250, P336, DOI 10.1016/0014-5793(89)80750-1; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P2221; REED LJ, 1990, J BIOL CHEM, V265, P8971; ROBIEN MA, 1992, BIOCHEMISTRY-US, V31, P3463, DOI 10.1021/bi00128a021; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; STEPP LR, 1985, BIOCHEMISTRY-US, V24, P7187, DOI 10.1021/bi00346a026; TEXTER FL, 1988, BIOCHEMISTRY-US, V27, P289, DOI 10.1021/bi00401a044; WILLIAMS DC, 1982, SCIENCE, V215, P687, DOI 10.1126/science.7036343; WYNN RM, 1992, J BIOL CHEM, V267, P1881; WYNN RM, 1992, J BIOL CHEM, V267, P12400	48	44	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10378	10383						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144620				2022-12-25	WOS:A1994NF01700032
J	MACDONALD, JIS; KENT, C				MACDONALD, JIS; KENT, C			IDENTIFICATION OF PHOSPHORYLATION SITES IN RAT-LIVER CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE; CHINESE-HAMSTER OVARY; MEMBRANE-ASSOCIATED CTP; RNA POLYMERASE-II; HEP G2 CELLS; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; PHOSPHORYLCHOLINE CYTIDYLYLTRANSFERASE; PROTEIN-KINASES; TRANSLOCATION	CTP:phosphocholine cytidylyltransferase (CT) is an important regulatory enzyme in phosphatidylcholine biosynthesis. The enzyme exists as a soluble, inactive form that is highly phosphorylated; activation of the enzyme is accompanied by dephosphorylation and translocation to the membrane. we have used a recombinant baculovirus clone to obtain CT labeled in vivo with (PO4)-P-32. The tryptic phosphopeptide pattern of the baculovirus-expressed CT was the same as for CT expressed in mammalian cells, indicating that insect cells modify the same phosphorylation sites as do mammalian cells. (PO4)-P-32-labeled, baculovirus-expressed CT was digested with trypsin and the peptides purified by reversed phase high performance liquid chromatography. Phosphoamino acid analysis of the complete protein as well as individual peptides revealed that only serine residues were phosphorylated. Sequence analysis of purified radioactive peptides revealed that phosphorylation of CT was confined to the carboxyl-terminal region and that all or nearly all Ser residues from Ser(315) to the carboxyl terminus were labeled. Ser(315), Ser(319), Ser(329), Ser(323), Ser(331), Ser(343), and Ser(347) all reside in potential sites for proline-directed kinases. Two other phosphorylated serine residues, Ser(315) and Ser(333), are found within protein kinase C consensus phosphorylation sites. Ser(321), Ser(322), Ser(333), Ser(345), Ser(346), Ser(350), Ser(352), and Ser(362) were also found to be phosphorylated. Serine(362) resides within a putative casein kinase II phosphorylation site, and there are five potential sites for phosphorylation by glycogen synthase kinase 3. Identification of these sites will allow investigations that focus on the establishment of the physiological function of phosphorylation at each site.	UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan								ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOU YH, 1991, J BIOL CHEM, V266, P7325; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5881, DOI 10.1021/bi00238a011; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5873, DOI 10.1021/bi00238a010; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DVIR A, 1993, J BIOL CHEM, V268, P10440; ESKO JD, 1981, J BIOL CHEM, V256, P7388; FELDMAN DA, 1987, J BIOL CHEM, V262, P9075; FELDMAN DA, 1993, J BIOL CHEM, V268, P3127; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; HATCH GM, 1991, BIOCHIM BIOPHYS ACTA, V1081, P25, DOI 10.1016/0005-2760(91)90245-D; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HOLMES CFB, 1987, FEBS LETT, V215, P21, DOI 10.1016/0014-5793(87)80106-0; JAMIL H, 1990, J BIOL CHEM, V265, P4332; JAMIL H, 1992, J BIOL CHEM, V267, P1752; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; KUPPUSWAMY D, 1993, J BIOL CHEM, V268, P19134; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LUCHE MM, 1993, ARCH BIOCHEM BIOPHYS, V301, P114, DOI 10.1006/abbi.1993.1122; MACDONALD JIS, 1993, PROTEIN EXPRES PURIF, V4, P1, DOI 10.1006/prep.1993.1001; MAK AS, 1991, J BIOL CHEM, V266, P19971; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MEYER HE, 1991, METHOD ENZYMOL, V201, P169; MORAND JN, 1989, J BIOL CHEM, V264, P13785; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; NAKAMURA S, 1993, J BIOL CHEM, V268, P11670; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SLEIGHT R, 1983, J BIOL CHEM, V258, P836; SWEITZER TD, 1994, IN PRESS ARCH BIOCH; TERCE F, 1992, BIOCHEM J, V282, P333, DOI 10.1042/bj2820333; VALTORTA F, 1992, J BIOL CHEM, V267, P7195; WANG YL, 1993, J BIOL CHEM, V268, P5512; WANG YL, 1993, J BIOL CHEM, V268, P5899; WATKINS JD, 1992, ARCH BIOCHEM BIOPHYS, V292, P360, DOI 10.1016/0003-9861(92)90003-F; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WEINHOLD PA, 1992, METHOD ENZYMOL, V209, P248; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; WEINHOLD PA, 1991, J BIOL CHEM, V266, P6093; WEINHOLD PA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P299, DOI 10.1016/0005-2760(89)90017-9; YAO ZM, 1990, J BIOL CHEM, V265, P4326	52	102	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10529	10537						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144639				2022-12-25	WOS:A1994NF01700053
J	JOST, JP; JOST, YC				JOST, JP; JOST, YC			TRANSIENT DNA DEMETHYLATION IN DIFFERENTIATING MOUSE MYOBLASTS CORRELATES WITH HIGHER ACTIVITY OF 5-METHYLDEOXYCYTIDINE EXCISION-REPAIR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROLEUKEMIA-CELLS; WIDE LOSS; METHYLATION; HYPOMETHYLATION; EXPRESSION; GENE; ACTIVATION; CYTOSINE; BREAKS; SITES	It has been recently shown that in developing chicken embryonic nuclear extracts there is a 5-methyldeoxycytidine excision repair activity (Jost, J. P. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 4684-4688). We show that in differentiating mouse myoblasts, a similar enzymatic reaction may be responsible for the genome-wide DNA demethylation (up to 50% of all CmCGG) occurring between the 3rd and 5th days of differentiation. Furthermore, in differentiating myoblasts, there is first a 50% transient decrease in DNA methyltransferase activity and a 90% drop in the rate of DNA synthesis, followed by an increase in 5-methyl-CpG endonuclease and 5-methyldeoxycytidine excision repair activities. As tested in vitro, the maximal activity of the 5-methyldeoxycytidine excision repair coincides with the maximal in vivo genome-wide DNA demethylation. We also find that 3-aminobenzamide, a potent inhibitor of ADP-ribosyltransferase, blocks the differentiation of myoblasts, the 5-methyldeoxycytidine excision repair activity, and the genome-wide demethylation.			JOST, JP (corresponding author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND.							ADAMS RLP, 1990, BIOCHEM J, V265, P309, DOI 10.1042/bj2650309; ADAMS RLP, 1990, FEBS LETT, V269, P29, DOI 10.1016/0014-5793(90)81111-Z; ALTHAUS FR, 1982, NATURE, V300, P366, DOI 10.1038/300366a0; BESTOR TH, 1984, MOL CELL BIOL, V4, P1800, DOI 10.1128/MCB.4.9.1800; CEDAR H, 1979, NUCLEIC ACIDS RES, V6, P2125, DOI 10.1093/nar/6.6.2125; CEDAR H, 1990, BIOCHIM BIOPHYS ACTA, V1049, P1, DOI 10.1016/0167-4781(90)90076-E; CHRISTMAN JK, 1977, EUR J BIOCHEM, V81, P53, DOI 10.1111/j.1432-1033.1977.tb11926.x; FARZANEH F, 1982, NATURE, V300, P362, DOI 10.1038/300362a0; FRANK D, 1991, NATURE, V351, P239, DOI 10.1038/351239a0; HOLLIDAY R, 1990, BIOL REV, V65, P431, DOI 10.1111/j.1469-185X.1990.tb01233.x; HUGHES BP, 1962, CLIN CHIM ACTA, V7, P597, DOI 10.1016/0009-8981(62)90137-7; JOHNSTONE AP, 1982, NATURE, V300, P368, DOI 10.1038/300368a0; JOST JP, 1993, P NATL ACAD SCI USA, V90, P4684, DOI 10.1073/pnas.90.10.4684; JOST JP, 1993, DNA METHYLATION MOL; LEWIS J, 1991, FEBS LETT, V285, P155, DOI 10.1016/0014-5793(91)80795-5; MANES C, 1981, NATURE, V293, P589, DOI 10.1038/293589a0; PAROUSH Z, 1990, CELL, V63, P1229, DOI 10.1016/0092-8674(90)90418-E; RAZIN A, 1988, P NATL ACAD SCI USA, V85, P9003, DOI 10.1073/pnas.85.23.9003; RAZIN A, 1984, P NATL ACAD SCI-BIOL, V81, P2275, DOI 10.1073/pnas.81.8.2275; RAZIN A, 1986, P NATL ACAD SCI USA, V83, P2827, DOI 10.1073/pnas.83.9.2827; ROCAMORA N, 1989, FEBS LETT, V247, P415, DOI 10.1016/0014-5793(89)81382-1; SALUZ HP, 1986, P NATL ACAD SCI USA, V83, P7167, DOI 10.1073/pnas.83.19.7167; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SZYF M, 1985, J BIOL CHEM, V260, P8653; SZYF M, 1991, J BIOL CHEM, V266, P10027; YOUNG PR, 1984, MOL CELL BIOL, V4, P898, DOI 10.1128/MCB.4.5.898	26	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					10040	10043						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144502				2022-12-25	WOS:A1994NE05300097
J	REGAN, LM; LAMPHEAR, BJ; HUGGINS, CF; WALKER, FJ; FAY, PJ				REGAN, LM; LAMPHEAR, BJ; HUGGINS, CF; WALKER, FJ; FAY, PJ			FACTOR-IXA PROTECTS FACTOR-VIIIA FROM ACTIVATED PROTEIN-C - FACTOR-IXA INHIBITS ACTIVATED PROTEIN-C-CATALYZED CLEAVAGE OF FACTOR-VIIIA AT ARG(562)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; COAGULATION FACTOR-V; FACTOR-XA; VONWILLEBRAND-FACTOR; A1/A3-C1-C2 DIMER; BLOOD-COAGULATION; SUBUNIT STRUCTURE; COFACTOR ACTIVITY; A2 SUBUNIT; INACTIVATION	Factor VIIIa is inactivated by both factor IXa and activated protein C. The latter protease rapidly attacked a site at Arg562 (A2 subunit), whereas both proteases slowly cleaved factor VIIIa at Arg336 (A1 subunit). Cofactor inactivation catalyzed by activated protein C was 8-fold faster than that catalyzed by factor IXa. Simultaneous reaction of factor VIIIa with the two enzymes resulted in a rate of inactivation intermediate to that observed for the individual proteases. Under these conditions, the activated protein C-catalyzed cleavage at Arg562 was inhibited such that cofactor inactivation resulted primarily from cleavage at Arg336. Substitution of factor IXa modified in its active site with 6-(dimethylamino)-2-naphthalenesulfonyl-glutamylglycylarginyl chloromethyl ketone (DEGR-IXa) for the native enzyme yielded a similar rate of activated protein C-catalyzed cleavage at the Al site, whereas cleavage at the A2 site was virtually eliminated. However, the inclusion of protein S resulted in a marked increase in cleavage at the A2 site that correlated with an increased rate of cofactor inactivation. Active site-modified activated protein C inhibited the factor IXa-dependent enhancement of factor VIIIa reconstitution from isolated subunits. In addition, the factor VIIIa-dependent fluorescence enhancement of DEGR-activated protein C was inhibited by EGR-IXa. These results indicate that factor IXa can reduce the rate of activated protein C-catalyzed cofactor inactivation by selectively blocking cleavage at the A2 domainal site, an effect reversed by protein S. One mechanism consistent with the reciprocal inhibitory effects of the proteases is that activated protein C and factor IXa occupy overlapping sites on the cofactor. Thus, factor IXa may protect factor VIIIa by preventing activated protein C binding.	UNIV ROCHESTER,MED CTR,SCH MED & DENT,DEPT MED,HEMATOL UNIT,POB 610,601 ELMWOOD AVE,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV CONNECTICUT,CTR HLTH,DEPT MED,FARMINGTON,CT 06032; UNIV CONNECTICUT,CTR HLTH,DEPT LAB MED,FARMINGTON,CT 06032; UNIV CONNECTICUT,CTR HLTH,AMER RED CROSS,BLOOD SERV,FARMINGTON,CT 06032	University of Rochester; University of Rochester; University of Connecticut; University of Connecticut; American Red Cross; University of Connecticut				Huggins, Christine/0000-0002-5873-1194	NHLBI NIH HHS [HL38199, HL40328] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040328, R01HL038199] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; BERTINA RM, 1984, BIOCHEM BIOPH RES CO, V125, P177, DOI 10.1016/S0006-291X(84)80351-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASILLAS G, 1971, COAGULATION, V4, P107; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1989, J BIOL CHEM, V264, P14005; FAY PJ, 1993, J BIOL CHEM, V268, P17861; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1991, J BIOL CHEM, V266, P2172; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; HEBB MJ, 1993, J BIOL CHEM, V268, P2872; KANE WH, 1988, BLOOD, V71, P539; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; MERTENS K, 1985, THROMB HAEMOSTASIS, V54, P654; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; PIETERS J, 1989, BLOOD, V74, P1021; RICK ME, 1990, J LAB CLIN MED, V115, P415; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1987, ARCH BIOCHEM BIOPHYS, V252, P322, DOI 10.1016/0003-9861(87)90037-3; WALKER FJ, 1990, J BIOL CHEM, V265, P1484; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	42	68	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9445	9452						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144529				2022-12-25	WOS:A1994NE05300011
J	BLOOMQUIST, BT; DARLINGTON, DN; MAINS, RE; EIPPER, BA				BLOOMQUIST, BT; DARLINGTON, DN; MAINS, RE; EIPPER, BA			RESP18, A NOVEL ENDOCRINE SECRETORY PROTEIN TRANSCRIPT, AND 4 OTHER TRANSCRIPTS ARE REGULATED IN PARALLEL WITH PROOPIOMELANOCORTIN IN MELANOTROPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROOPIOMELANOCORTIN GENE-EXPRESSION; CHAIN BINDING-PROTEIN; MESSENGER-RNA LEVELS; CHROMOGRANIN-B; SECRETOGRANIN-II; RAT PITUITARY; INSITU HYBRIDIZATION; ANTERIOR-PITUITARY; INTERMEDIATE LOBE; PROHORMONE CONVERTASES	The homogeneous nature of the rat intermediate pituitary makes it a powerful model system in which to study peptide hormone secretion. Adult male rats were treated with bromocriptine, a dopamine agonist, or haloperidol, a dopamine antagonist, for 3 weeks. In cDNA libraries prepared from the neurointermediate pituitaries of these rats, pro-opiomelanocortin (POMC) expression exhibited the expected decrease in response to bromocriptine, and increase in response to haloperidol. We report the identification of six transcripts that are coregulated with POMC in the intermediate pituitary by these dopaminergic agents. In addition to demonstrating parallel dopamine-regulated expression of carboxypeptidase E, chromogranin B, binding protein/glucose-regulated protein, and tenascin, two novel regulated transcripts are described. The expression of one of these novel transcripts, RESP18, is limited to neural and endocrine tissue. The RESP18 transcript is approximately 800 nucleotides in length; its cognate translation product is 20 +/- 1 kDa, contains a putative signal sequence, and has many characteristics of a secreted protein. Cell-free translation experiments in the presence of microsomal membranes demonstrate that the 20 +/- 1-kDa RESP18 protein is cleaved to an 18 +/- 1-kDa protein and sequestered within the lumen of the rough endoplasmic reticulum. Tissue in situ hybridization analysis shows that RESP18 mRNA is highly expressed in both the intermediate and anterior pituitary, as well as in the paraventricular and supraoptic nuclei of the hypothalamus.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; UNIV MARYLAND,DEPT SURG,BALTIMORE,MD 21201	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore			Darlington, Daniel/CAG-1917-2022		NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00097, DA-00266, DA-00098] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ARNAULD E, 1991, NEUROSCI LETT, V130, P12, DOI 10.1016/0304-3940(91)90216-G; AUTELITANO DJ, 1989, MOL CELL ENDOCRINOL, V67, P101, DOI 10.1016/0303-7207(89)90235-9; BENEDUM UM, 1987, EMBO J, V6, P1203, DOI 10.1002/j.1460-2075.1987.tb02355.x; BENJONATHAN N, 1990, NEUROENDOCRINE PERSP, V8, P1; BENSON D, 1993, NUCLEIC ACIDS RES, V21, P2963, DOI 10.1093/nar/21.13.2963; BHAT RV, 1992, J PHARMACOL EXP THER, V263, P343; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CETIN Y, 1991, CELL TISSUE RES, V264, P231, DOI 10.1007/BF00313960; CHRONWALL BM, 1988, ENDOCRINOLOGY, V123, P1992, DOI 10.1210/endo-123-4-1992; CHRONWALL BM, 1987, ENDOCRINOLOGY, V120, P1201, DOI 10.1210/endo-120-3-1201; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DILLEN L, 1993, NEUROCHEM INT, V22, P315, DOI 10.1016/0197-0186(93)90016-X; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; ENDO T, 1991, MOL ENDOCRINOL, V5, P905, DOI 10.1210/mend-5-7-905; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FISCHERCOLBRIE R, 1988, P NATL ACAD SCI USA, V85, P3240, DOI 10.1073/pnas.85.9.3240; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; GATCHALIAN CL, 1989, J CELL BIOL, V108, P1873, DOI 10.1083/jcb.108.5.1873; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDSMITH PC, 1979, J HISTOCHEM CYTOCHEM, V27, P1205, DOI 10.1177/27.8.383827; GUEST PC, 1989, BIOCHEM J, V257, P431, DOI 10.1042/bj2570431; HASSAN MN, 1986, LIFE SCI, V39, P513, DOI 10.1016/0024-3205(86)90507-2; HOLZBAUER M, 1985, MED BIOL, V63, P97; HUTTNER WB, 1987, TRENDS BIOCHEM SCI, V12, P361, DOI 10.1016/0968-0004(87)90166-6; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; HYDE JF, 1987, ENDOCRINOLOGY, V121, P1531, DOI 10.1210/endo-121-4-1531; JONES FS, 1988, P NATL ACAD SCI USA, V85, P2186, DOI 10.1073/pnas.85.7.2186; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KIM PS, 1993, J BIOL CHEM, V268, P4873; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUHL D, 1992, J CELL BIOL, V119, P1069, DOI 10.1083/jcb.119.5.1069; KUNKEL TA, 1987, CURR PROTOCOLS M S13, V13; LLOYD RV, 1992, LAB INVEST, V67, P394; MAINS RE, 1990, FRONT NEUROENDOCRIN, V11, P52; MAINS RE, 1990, TRENDS ENDOCRIN MET, V1, P388, DOI 10.1016/1043-2760(90)90097-M; MCKENNA PJ, 1987, BRIT J PSYCHIAT, V151, P288, DOI 10.1192/bjp.151.3.288; MILLINGTON WR, 1986, ENDOCRINOLOGY, V118, P2024, DOI 10.1210/endo-118-5-2024; MILLINGTON WR, 1989, NEUROENDOCRINE PERSP, V7, P1; MOORE HP, 1983, J CELL BIOL, V97, P810, DOI 10.1083/jcb.97.3.810; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; PARDY K, 1990, ENDOCRINOLOGY, V126, P2960, DOI 10.1210/endo-126-6-2960; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; PRITCHETT DB, 1987, P NATL ACAD SCI USA, V84, P5545, DOI 10.1073/pnas.84.16.5545; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; SAGA Y, 1991, GENE, V104, P177, DOI 10.1016/0378-1119(91)90248-A; SCAMMELL JG, 1990, J HISTOCHEM CYTOCHEM, V38, P949, DOI 10.1177/38.7.2192000; SCAMMELL JG, 1986, ENDOCRINOLOGY, V119, P1543, DOI 10.1210/endo-119-4-1543; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SHARIFI BG, 1992, J BIOL CHEM, V267, P23910; SITLANDMARKEN PA, 1990, J CLIN PSYCHIAT, V51, P68; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937; SWANSON LW, 1980, J COMP NEUROL, V194, P555, DOI 10.1002/cne.901940306; SWANSON LW, 1983, ANNU REV NEUROSCI, V6, P269, DOI 10.1146/annurev.ne.06.030183.001413; THIELE EA, 1990, ENDOCRINOLOGY, V126, P809, DOI 10.1210/endo-126-2-809; THIELE EA, 1990, THESIS J HOPKINS U B; TUCKER RP, 1993, J CELL SCI, V104, P69; VINCENT S, 1993, NUCLEIC ACIDS RES, V21, P1498, DOI 10.1093/nar/21.6.1498; VOLLMER G, 1992, CANCER RES, V52, P4642; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WAND GS, 1991, ENDOCRINOLOGY, V128, P1345, DOI 10.1210/endo-128-3-1345; WATOWICH SS, 1988, MOL CELL BIOL, V8, P393, DOI 10.1128/MCB.8.1.393; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; WIEDENMANN B, 1989, VIRCHOWS ARCH B, V58, P95, DOI 10.1007/BF02890062; YUN HY, 1993, ARCH BIOCHEM BIOPHYS, V301, P77, DOI 10.1006/abbi.1993.1117; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZIMMERMAN EA, 1984, PITUITARY HYPERFUNCT, P1	73	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9113	9122						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132649				2022-12-25	WOS:A1994NB41100075
J	GIDROL, X; CHRESTIN, H; TAN, HL; KUSH, A				GIDROL, X; CHRESTIN, H; TAN, HL; KUSH, A			HEVEIN, A LECTIN-LIKE PROTEIN FROM HEVEA-BRASILIENSIS (RUBBER TREE) IS INVOLVED IN THE COAGULATION OF LATEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; CELL-ADHESION; MOLECULES	Hevein, a lectin-like protein is the major protein of vacuolar structures called lutoids in the latex of rubber trees. We have shown both by in planta and ex planta studies that hevein is involved in the coagulation of latex by bringing together rubber particles. This polyvalent bridging between hevein and rubber particles is mediated by N-acetyl-D-glucosamine and involves a receptor glycoprotein of 22 kDa, which is localized on the surface of the rubber particles. The proposed role of hevein helps us to understand the mechanism of coagulation of latex and assigns a physiological intracellular function to one of the smallest lectins.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore				Gidrol, Xavier/0000-0002-4233-3749				ARCHER B. L., 1969, Journal of the Rubber Research Institute, V21, P560; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BOUTRY M, 1985, EMBO J, V4, P2159, DOI 10.1002/j.1460-2075.1985.tb03910.x; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BROEKAERT W, 1990, P NATL ACAD SCI USA, V87, P7633, DOI 10.1073/pnas.87.19.7633; BROGLIE KE, 1986, P NATL ACAD SCI USA, V83, P6820, DOI 10.1073/pnas.83.18.6820; BUTTERY BR, 1967, J EXP BOT, V17, P283; Chrestin H., 1989, PHYSL RUBBER TREE LA, P431; CHRISPEELS MJ, 1991, PLANT CELL, V3, P1, DOI 10.1105/tpc.3.1.1; CHYE ML, 1991, PLANT MOL BIOL, V16, P567, DOI 10.1007/BF00023422; Coupe M., 1989, PHYSL RUBBER TREE LA, P295; D'Auzac J., 1989, PHYSL RUBBER TREE LA, P257, DOI [10.1590/S0104-14282006000300015, DOI 10.1590/S0104-14282006000300015]; de Fay E, 1989, PHYSL RUBBER TREE LA, P3, DOI DOI 10.1111/J.1432-2277.2005.00166.X.; de Fay E., 1989, PHYSL RUBBER TREE LA, P407; DENNIS MS, 1989, J BIOL CHEM, V264, P18608; HANOWER P, 1976, PHYSIOL VEG, V14, P677; KUSH A, 1990, P NATL ACAD SCI USA, V87, P1787, DOI 10.1073/pnas.87.5.1787; Lis H., 1981, The biochemistry of plants. A comprehensive treatise. Volume 6. Proteins and nucleic acids., P371; MARTIN MN, 1991, PLANT PHYSIOL, V95, P469, DOI 10.1104/pp.95.2.469; MOIR GFJ, 1959, NATURE, V184, P1626, DOI 10.1038/1841626a0; RIBAILLIER D, 1971, PHYSL VEG, V2, P413; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; VANPARIJS J, 1991, PLANTA, V183, P258, DOI 10.1007/BF00197797; WALUJONO K, 1975, P INT RUBBER C KUALA, P518; WRIGHT HT, 1985, J MOL EVOL, V21, P133, DOI 10.1007/BF02100087	28	118	158	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9278	9283						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132664				2022-12-25	WOS:A1994NB41100095
J	GROEBE, DR; DUMM, JM; ABRAMSON, SN				GROEBE, DR; DUMM, JM; ABRAMSON, SN			IRREVERSIBLE INHIBITION OF NICOTINIC ACETYLCHOLINE-RECEPTORS BY THE BIPINNATINS - TOXIN ACTIVATION AND KINETICS OF RECEPTOR INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; AGONIST SITES; LOPHOTOXIN; LABEL; BRAIN	Bipinnatin-A, -B, and -C belong to a family of naturally occurring marine neurotoxins known as the lophotoxins. The lophotoxins are unique in that they irreversibly inhibit nicotinic acetylcholine receptors by forming a covalent bond with a tyrosine residue at position 190 in the alpha-subunit of the receptor. In this study, we show that the inhibitory activity of the bipinnatins against the nicotinic receptor increased with preincubation of the toxins in aqueous buffer prior to incubation with the receptor. The parent species of the bipinnatins displayed little, if any, affinity for the nicotinic receptor. Preincubation of the toxins appeared to produce a single, relatively stable, active toxin species that irreversibly inhibited the two acetylcholine-binding sites on the nicotinic receptor with two distinguishable apparent pseudo first-order rates. The difference in the rates of irreversible inhibition of the two binding sites on the receptor was exploited to selectively inhibit one site for the pharmacological investigation of the other. The bipinnatins preferentially inhibited the binding site near the alpha/delta-subunit interface that displays low affinity for metocurine and high affinity for acetylcholine. The bimolecular reaction constants for the interaction of the bipinnatins with the nicotinic receptor decreased in the order bipinnatin-B > bipinnatin-A > bipinnatin-C for both acetylcholine-binding sites. The ratio of the bimolecular reaction constants for the two binding sites on the receptor was not the same for the three bipinnatins. This indicates that the reaction of the bipinnatins with the nicotinic receptor is sensitive to differences in the structure of the two acetylcholine-binding sites. The bipinnatins may be useful in the design of novel drugs for the nicotinic receptor that exclusively inhibit one of the two binding sites and for the investigation of structural differences between the two acetylcholine binding sites of the receptor.	UNIV PITTSBURGH, SCH MED, DEPT PHARMACOL, PITTSBURGH, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NINDS NIH HHS [NS29951] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS029951, R55NS029951] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON SN, 1991, DRUG DEVELOP RES, V24, P297, DOI 10.1002/ddr.430240402; ABRAMSON SN, 1991, J MED CHEM, V34, P1798, DOI 10.1021/jm00110a007; ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; ABRAMSON SN, 1988, J BIOL CHEM, V263, P18568; ANAND R, 1991, J BIOL CHEM, V266, P11192; ASHANI Y, 1972, BIOCHIM BIOPHYS ACTA, V284, P427, DOI 10.1016/0005-2744(72)90139-8; BALANT LP, 1990, EUR J DRUG METAB PH, V15, P143, DOI 10.1007/BF03190197; BERMAN HA, 1989, J BIOL CHEM, V264, P3942; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; CONROY WG, 1992, NEURON, V9, P679, DOI 10.1016/0896-6273(92)90031-8; CULVER P, 1985, MOL PHARMACOL, V28, P436; CULVER P, 1984, J BIOL CHEM, V259, P3763; FENICAL W, 1981, SCIENCE, V212, P1512, DOI 10.1126/science.6112796; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; KITZ R, 1962, J BIOL CHEM, V237, P3245; KRANTZ A, 1991, BIOCHEMISTRY-US, V30, P4678, DOI 10.1021/bi00233a007; LANGDON RB, 1985, BRAIN RES, V359, P233, DOI 10.1016/0006-8993(85)91433-7; LUETJE CW, 1990, J NEUROCHEM, V55, P632, DOI 10.1111/j.1471-4159.1990.tb04180.x; MAIN AR, 1964, SCIENCE, V144, P992, DOI 10.1126/science.144.3621.992; OLEARY ME, 1992, J BIOL CHEM, V267, P8360; RAKITZIS ET, 1974, BIOCHEM J, V141, P601, DOI 10.1042/bj1410601; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SINE SM, 1980, J BIOL CHEM, V255, P144; SINE SM, 1991, J BIOL CHEM, V266, P10144; Taylor P., 1990, PHARMACOL BASIS THER, P166; VERNALLIS AB, 1993, NEURON, V10, P451, DOI 10.1016/0896-6273(93)90333-M	26	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8885	8891						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132625				2022-12-25	WOS:A1994NB41100042
J	BODE, AM; FOSTER, JD; NORDLIE, RC				BODE, AM; FOSTER, JD; NORDLIE, RC			GLYCOGENESIS FROM GLUCOSE AND UREAGENESIS IN ISOLATED-PERFUSED RAT LIVERS - INFLUENCE OF AMMONIUM ION, NORVALINE, AND ETHOXYZOLAMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSOMAL GLUCOSE-6-PHOSPHATASE SYSTEM; STREPTOZOTOCIN-DIABETIC RAT; CARBAMYL-PHOSPHATE; CARBONIC-ANHYDRASE; GLUTAMINASE; BIOSYNTHESIS; GLUCOKINASE; METABOLISM; PROTEIN; UREA	The probable involvement of hepatic carbamyl-P in the reciprocal relationship between hepatic ureagenesis and glycogenesis from glucose was explored. Isolated perfused liver preparations from 48-h fasted rats were employed. Moderate (9.2 mM) and relatively high levels of glucose (34 mM) were perfused. Hepatic glycogenesis, glucose-6-P, carbamyl-P and citrulline levels, hepatic urea formation, and ureagenesis based upon perfusate urea levels were measured. Experimental probes selected to modify hepatic ureagenesis and carbamyl-P production and utilization included: (a) NH4Cl, maintained at 5 mM by continuous infusion (NH4+ is a substrate for carbamyl-P synthase I and glutamate dehydrogenase); (b) norvaline, an inhibitor of ornithine transcarbamylase which catalyzes the first committed step in the urea cycle; and (c) ethoxyzolamide, an inhibitor of carbonic anhydrase which produces HCO3-, an essential substrate for carbamyl-P synthase I. NH4+ increased ureagenesis and decreased glycogenesis. The inclusion of norvaline with NH4+ decreased ureagenesis and increased glycogenesis. Ethoxyzolamide with or without NH4+ inhibited both ureagenesis and glycogenesis, and decreased the hepatic glucose-6-P level. Glycogenesis was greater at 34 mM than 9.2 mM glucose, increased in norvaline-containing preparations correlative with increased availability of carbamyl-P, and decreased when carbamyl-P formation was inhibited by ethoxyzolamide. Kinetic analysis indicated a K-m,K- Glc Of 31 mM for glucose phosphorylation preliminary to glycogenesis. Glycogen formation via the ''indirect pathway'' (i.e. involving extrahepatic glycolysis, transport of lactate to the liver, and glyconeogenesis therefrom) was quantitatively insufficient to account for the observed glycogenesis. Glucokinase is contraindicated by the inverse relationship between hepatic glycogenesis and ATP availability in the ethoxyzolamide-treated preparations. In contrast, carbamyl-P:glucose phosphotransferase activity of the glucose-6-phosphatase system has the characteristics to bridge hepatic ureagenesis and glycogenesis.	UNIV N DAKOTA,SCH MED,DEPT BIOCHEM & MOLEC BIOL,IRELAND RES LAB,GRAND FORKS,ND 58202; UNIV N DAKOTA,SCH MED,DEPT PHYSIOL,GRAND FORKS,ND 58202	University of North Dakota Grand Forks; University of North Dakota Grand Forks					NIDDK NIH HHS [DK07141] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK007141] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVARES FL, 1977, J BIOL CHEM, V252, P8404; ARION WJ, 1980, J BIOL CHEM, V255, P396; BODE AM, 1993, J BIOL CHEM, V268, P16298; COHEN NS, 1980, J BIOL CHEM, V255, P248; COHEN PP, 1962, ENZYMES, V6, P477; COHEN PP, 1964, MANOMETRIC TECHNIQUE, P149; DETHEUX M, 1991, EUR J BIOCHEM, V200, P553, DOI 10.1111/j.1432-1033.1991.tb16218.x; DIXON WJ, 1957, INTRO STATISTICAL AN, P19; DODGSON SJ, 1986, ARCH BIOCHEM BIOPHYS, V251, P198, DOI 10.1016/0003-9861(86)90066-4; DODGSON SJ, 1990, ARCH BIOCHEM BIOPHYS, V277, P410, DOI 10.1016/0003-9861(90)90597-R; DODGSON SJ, 1991, CARBONIC ANHYDRASES, P297; FOSTER JD, 1991, BIOCHIM BIOPHYS ACTA, V1118, P91, DOI 10.1016/0167-4838(91)90445-6; FOSTER JD, 1993, FASEB J, V7, pA848; Frieden C., 1963, ENZYMES 7, P3; HAUSSINGER D, 1986, BIOCHEM PHARMACOL, V35, P3317, DOI 10.1016/0006-2952(86)90429-6; HERS HG, 1976, ANNU REV BIOCHEM, V45, P167, DOI 10.1146/annurev.bi.45.070176.001123; Hohorst H.-J., 1965, METHOD ENZYMAT AN, P134, DOI DOI 10.1016/B978-0-12-395630-9.50025-6; HUE L, 1967, EUR J BIOCHEM, V2, P5056; JACOBSON GR, 1973, ENZYMES, V9, P225; Keppler D., 1974, METHODS ENZYM ANALYS, V3, P1127; KERSCHER L, 1985, METHOD ENZYMAT AN, V3, P444; Lehninger A. L., 1993, PRINCIPLES BIOCH, P514; LUECK JD, 1972, BIOCHEMISTRY-US, V11, P2792, DOI 10.1021/bi00765a010; LUECK JD, 1970, BIOCHEM BIOPH RES CO, V39, P190, DOI 10.1016/0006-291X(70)90776-X; MEHLER AH, 1992, TXB BIOCH, P478; MEIJER AJ, 1985, EUR J BIOCHEM, V148, P189, DOI 10.1111/j.1432-1033.1985.tb08824.x; MEIJER AJ, 1982, METABOLIC COMPARTMEN, P259; NATALE PJ, 1969, BIOCHEM BIOPH RES CO, V37, P512, DOI 10.1016/0006-291X(69)90945-0; Nordlie R C, 1974, Curr Top Cell Regul, V8, P33; NORDLIE RC, 1980, J BIOL CHEM, V255, P1834; OLSON MS, 1992, TXB BIOCH, P257; ROCHOVANSKY O, 1977, J BIOL CHEM, V252, P5287; ROGNSTAD R, 1985, BIOCHEM BIOPH RES CO, V130, P229, DOI 10.1016/0006-291X(85)90406-1; SCHIMKE RT, 1962, J BIOL CHEM, V237, P1921; SCHMIDT E, 1974, METHOD ENZYMAT AN, V2, P650; Smith E.L., 1975, ENZYMES, P293, DOI DOI 10.1016/S1874-6047(08)60213-9; SMITH EM, 1988, ARCH BIOCHEM BIOPHYS, V260, P740, DOI 10.1016/0003-9861(88)90504-8; SUKALSKI KA, 1986, J BIOL CHEM, V261, P6860; SZWEDA LI, 1990, J BIOL CHEM, V265, P20869; TREMBLAY GC, 1977, ARCH BIOCHEM BIOPHYS, V178, P264, DOI 10.1016/0003-9861(77)90191-6; VANDERCAMMEN A, 1991, EUR J BIOCHEM, V200, P545, DOI 10.1111/j.1432-1033.1991.tb16217.x; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P179; WATFORD M, 1988, TRENDS BIOCHEM SCI, V13, P329, DOI 10.1016/0968-0004(88)90099-0; WATFORD M, 1984, BIOCHEM J, V224, P207, DOI 10.1042/bj2240207	44	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7879	7886						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132505				2022-12-25	WOS:A1994NB40900011
J	GAO, GJ; FONDA, ML				GAO, GJ; FONDA, ML			IDENTIFICATION OF AN ESSENTIAL CYSTEINE RESIDUE IN PYRIDOXAL PHOSPHATASE FROM HUMAN ERYTHROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSYL PROTEIN PHOSPHATASE; WEIGHT ACID-PHOSPHATASE; TYROSINE-PHOSPHATASE; RAT-LIVER; INTERMEDIATE; EXPRESSION; CLONING; LOCALIZATION; PURIFICATION; MECHANISM	Pyridoxal-specific phosphatase purified from human erythrocytes was inactivated by a variety of thiol-specific reagents in a time- and concentration-dependent manner. The presence of pyridoxal phosphate, a substrate, or inorganic phosphate, a competitive inhibitor, protected the enzyme from inactivation. Phosphatase inactivated by disulfide reagents was reactivated by the addition of excess dithiothreitol, indicating that the inactivation was due to formation of a mixed disulfide between the reagent and a free cysteinyl residue at or near the active site of the enzyme. Incorporation of either 1 mol of 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB), 0.6 mol of iodo[H-3]acetate, or 0.6 mol of N-[H-3]ethylmaleimide per mol of subunit led to complete inactivation of the enzyme. High concentration of phosphate prevented the incorporation of DTNB and iodo[H-3]acetate. Amino acid analysis of carboxymethylated enzyme and DTNB titration of the denatured phosphatase indicated that there may be only 1 cysteinyl residue per subunit. Modification by iodoacetate did not affect the quaternary structure of the enzyme. The phosphatase modified by iodo[H-3]acetate was subjected to trypsin digestion, and the resulting peptides were separated on a reverse phase C-18 column. Two radioactive peaks were obtained and contained a peptide with the N-terminal sequence of Ala-Gln-Gly-Val-Leu-Phe-Asp-Cys(Cm)-Asp-Gly-Val-Leu-X -Asn-Gly. Most of the radioactivity was released with Cys(Cm). These results indicate that the cysteinyl residue in this sequence is at or near the active site and is essential for activity. Residues 5-12 and 15 of this peptide are identical with a sequence of a yeast alkaline p-nitrophenylphosphatase, and the peptide has little homology with other mammalian phosphatases.	UNIV LOUISVILLE,SCH MED,DEPT BIOCHEM,LOUISVILLE,KY 40292	University of Louisville								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ATTIAS J, 1973, BIOCHIM BIOPHYS ACTA, V321, P561, DOI 10.1016/0005-2744(73)90199-X; ATTIAS J, 1972, BIOCHIM BIOPHYS ACTA, V268, P422, DOI 10.1016/0005-2744(72)90338-5; BREWER CF, 1967, ANAL BIOCHEM, V18, P248, DOI 10.1016/0003-2697(67)90007-3; CAMICI G, 1989, J BIOL CHEM, V264, P2560; CHIARUGI P, 1992, FEBS LETT, V310, P9, DOI 10.1016/0014-5793(92)81134-8; CIRRI P, 1993, EUR J BIOCHEM, V214, P647, DOI 10.1111/j.1432-1033.1993.tb17965.x; CIRRI P, 1993, BIOCHIM BIOPHYS ACTA, V1161, P216, DOI 10.1016/0167-4838(93)90216-E; Coburn SP, 1988, CLIN PHYSL APPLICATI, P65; COLLIER HB, 1973, ANAL BIOCHEM, V56, P310, DOI 10.1016/0003-2697(73)90196-6; Ebadi M., 1986, VITAMIN B6 PYRIDOXAL, P449; FONDA ML, 1992, J BIOL CHEM, V267, P15978; FONDA ML, 1989, ALCOHOL CLIN EXP RES, V3, P804; FUJIMOTO S, 1984, J BIOCHEM, V96, P1079, DOI 10.1093/oxfordjournals.jbchem.a134925; GUAN KL, 1991, J BIOL CHEM, V266, P17026; KALLEN RG, 1985, TRANSAMINASES, P37; KANEKO Y, 1989, MOL GEN GENET, V220, P133, DOI 10.1007/BF00260867; KYAW A, 1980, BIOCHEM MED METAB B, V24, P27, DOI 10.1016/0006-2944(80)90083-6; LUMENG L, 1975, J BIOL CHEM, V250, P8126; MURAKAMI K, 1986, CHEM PHARM BULL, V34, P3320; OSTANIN K, 1992, J BIOL CHEM, V267, P22830; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; POT DA, 1992, J BIOL CHEM, V267, P140; POT DA, 1991, J BIOL CHEM, V266, P19688; ROIKO K, 1990, GENE, V89, P223, DOI 10.1016/0378-1119(90)90009-G; SARASWATHI S, 1963, J NEUROCHEM, V10, P127, DOI 10.1111/j.1471-4159.1963.tb11473.x; SMYTH DG, 1964, BIOCHEM J, V91, P589, DOI 10.1042/bj0910589; SPETH M, 1989, ARCH BIOCHEM BIOPHYS, V275, P202, DOI 10.1016/0003-9861(89)90365-2; STONE KL, 1989, PRACTICAL GUIDE PROT, P37; VAKILI B, 1981, BIOCHEM J, V194, P319, DOI 10.1042/bj1940319; VANETTEN RL, 1991, J BIOL CHEM, V266, P2313; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; WO YYP, 1992, J BIOL CHEM, V267, P10856; WORKU Y, 1984, FEBS LETT, V167, P235, DOI 10.1016/0014-5793(84)80133-7; ZHANG ZY, 1992, BIOCHEMISTRY-US, V31, P1701, DOI 10.1021/bi00121a018	35	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8234	8239						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132548				2022-12-25	WOS:A1994NB40900062
J	ITAKURA, M; IWASHINA, M; MIZUNO, T; ITO, T; HAGIWARA, H; HIROSE, S				ITAKURA, M; IWASHINA, M; MIZUNO, T; ITO, T; HAGIWARA, H; HIROSE, S			MUTATIONAL ANALYSIS OF DISULFIDE BRIDGES IN THE TYPE-C ATRIAL-NATRIURETIC-PEPTIDE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEARANCE RECEPTOR; GUANYLATE-CYCLASE; FUNCTIONAL EXPRESSION; BOVINE KIDNEY; CDNA; PURIFICATION; LUNG; PROLIFERATION; ACTIVATION; EFFICIENT	The type C receptor (ANP-C or NPR-C) for the natriuretic peptides was demonstrated, by site directed mutagenesis, to have an immunoglobulin-like disulfide bonding pattern that is very similar to that of the cytokine receptor superfamily, The mature form of ANP-C has a disulfide-linked homodimeric structure and contains 5 conserved cysteine residues per subunit, all in the extracellular domain. To identify the cysteine residue involved in the dimerization and further to determine the intramolecular disulfide bridges and their functional roles, cysteine to serine mutations of the 5 cysteine residues were constructed. An analysis of the mutant receptors expressed in COS-1 cells by I-125-ANP binding assay and by measuring difference in their electrophoretic mobilities on sodium dodecyl sulfate-polyacrylamide gels indicated that 1) the first 4 cysteine residues are joined sequentially, forming the Cys(104)-Cys(132) and Cys(209)-Cys(257) loops of 29 and 49 residues, respectively; 2) the two disulfide-linked loops are essential for the ligand binding activity; 3) the 5th cysteine residue Cys(469) is used in the formation of covalently linked dimers; and 4) the covalent association of the subunit through the disulfide bond involving Cys(469) has no apparent influence on ligand-receptor interactions. The intramolecular disulfide bond Cys(104)-Cys(132) was also confirmed by direct protein sequencing of tryptic fragments of purified ANP-C receptor. The secondary structural features revealed here will be useful in understanding the structure and function relationships of not only the dimeric ANP-C receptor, which has only a short cytoplasmic tail, but also the ANP-A (GC-A) and ANP-B (GC-B) receptor subtypes, which have a guanylate cyclase domain in their long cytoplasmic tail and have recently been shown to possess an oligomeric structure, since they have similarly spaced cysteine residues in their extracellular domains.	TOKYO INST TECHNOL,DEPT BIOL SCI,MIDORI KU,YOKOHAMA,KANAGAWA,JAPAN	Tokyo Institute of Technology								APPEL RG, 1992, AM J PHYSIOL, V262, pF911, DOI 10.1152/ajprenal.1992.262.6.F911; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CAHILL PA, 1993, J CELL PHYSIOL, V154, P28, DOI 10.1002/jcp.1041540105; CAHILL PA, 1991, BIOCHEM BIOPH RES CO, V179, P1606, DOI 10.1016/0006-291X(91)91758-5; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1991, ANNU REV BIOCHEM, V60, P553, DOI 10.1146/annurev.bi.60.070191.003005; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DEBOLD AJ, 1985, SCIENCE, V230, P767, DOI 10.1126/science.2932797; FULLER F, 1988, J BIOL CHEM, V263, P9395; IWATA T, 1991, J BIOCHEM-TOKYO, V110, P35, DOI 10.1093/oxfordjournals.jbchem.a123539; KACZMARSKI RS, 1991, BLOOD REV, V5, P193, DOI 10.1016/0268-960X(91)90036-C; KAWAGUCHI S, 1989, J HISTOCHEM CYTOCHEM, V37, P1739, DOI 10.1177/37.11.2553804; KOLLER KJ, 1992, CIRCULATION, V86, P1081, DOI 10.1161/01.CIR.86.4.1081; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEVIN ER, 1991, AM J PHYSIOL, V261, pR453, DOI 10.1152/ajpregu.1991.261.2.R453; LOWE DG, 1992, BIOCHEMISTRY-US, V31, P10421, DOI 10.1021/bi00158a001; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; LOWE DG, 1990, NUCLEIC ACIDS RES, V18, P3412, DOI 10.1093/nar/18.11.3412; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MIZUNO T, 1993, J BIOL CHEM, V268, P5162; OHYAMA Y, 1992, BIOCHEM BIOPH RES CO, V183, P743, DOI 10.1016/0006-291X(92)90546-W; PANDEY KN, 1990, J BIOL CHEM, V265, P12342; PORTER JG, 1989, J BIOL CHEM, V264, P14179; PORTER JG, 1990, BIOCHEM BIOPH RES CO, V171, P796, DOI 10.1016/0006-291X(90)91216-F; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SCHENK DB, 1987, P NATL ACAD SCI USA, V84, P1521, DOI 10.1073/pnas.84.6.1521; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SHIMONAKA M, 1987, J BIOL CHEM, V262, P5510; SHIMONAKA M, 1987, AM J PHYSIOL, V253, pF1058, DOI 10.1152/ajprenal.1987.253.5.F1058; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; UCHIDA K, 1989, BIOCHEM J, V263, P671, DOI 10.1042/bj2630671	33	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8314	8318						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132555				2022-12-25	WOS:A1994NB40900073
J	MARSTON, SB; FRASER, IDC; HUBER, PAJ; PRITCHARD, K; GUSEV, NB; TOROK, K				MARSTON, SB; FRASER, IDC; HUBER, PAJ; PRITCHARD, K; GUSEV, NB; TOROK, K			LOCATION OF 2 CONTACT SITES BETWEEN HUMAN SMOOTH-MUSCLE CALDESMON AND CA2+-CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; TROPONIN-I; CALMODULIN-BINDING; THIN-FILAMENTS; CA-2+ REGULATION; ACTIN; MYOSIN; MECHANISM; PROTEIN; EXPRESSION	We measured Ca2+-calmodulin binding to expressed human caldesmon fragments by three techniques: tryptophan fluorescence enhancement, change in fluorescence of TA-calmodulin, and cosedimentation with calmodulin- Sepharose. Ca2+-calmodulin bound with similar affinity to peptide M73 (C(714)SMWEKGNVFSSPGF(727), N terminus of domain 4b), to all the fragments of caldesmon containing this peptide, and also to H9 (Thr(726)-Val(793)), which did not contain this peptide (K-d = 0.2-0.8 mu M) We conclude that Ca2+-calmodulin binds at two sites on caldesmon; site A is the sequence (715)MWEKGNVFS(723) previously identified by Zhan et al. (Zhan, Q., Wong, S. S., and Wang, C.-L. A. (1991) J. Biol. Chem. 266, 21810-21814), and site B is located nearer the C terminus of caldesmon. Ca2+-calmodulin binding at site B is coupled to reversal of caldesmon inhibition of actin-tropomyosin activated myosin MgATPase, while calmodulin binding at site A has no detectable function. H9 did not displace M73 from Ca2+-calmodulin, while the other fragments did. High concentrations of M73 (>1000 x K-d) could not displace H9 bound to Ca2+-calmodulin-Sepharose. Thus sites A and B in calmodulin are functionally separate. Analysis of overlapping expressed fragments indicates that site B is located in the sequence Thr(726)-Leu(767), which includes Trp(749). The minimal Ca2+-calmodulin binding sequence could be (744)SRINEWLTK(752).	MOSCOW MV LOMONOSOV STATE UNIV, SCH BIOL, DEPT BIOCHEM, MOSCOW 119899, RUSSIA; NATL INST MED RES, LONDON NW7 1AA, ENGLAND	Lomonosov Moscow State University; MRC National Institute for Medical Research	MARSTON, SB (corresponding author), NATL HEART & LUNG INST, DEPT CARDIAC MED, DOVEHOUSE ST, LONDON SW3 6LY, ENGLAND.		Fraser, Iain DC/L-4735-2017; B.Gusev, Nikolai/D-7533-2012	Fraser, Iain DC/0000-0003-2272-3907; Torok, Katalin/0000-0002-3107-4534; Marston, Steven/0000-0001-6054-6070; Huber, Pia AJ/0000-0001-9823-7863				BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BARTEGI A, 1991, Biophysical Journal, V59, p56A; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CAMPBELL AP, 1991, J MOL BIOL, V222, P405, DOI 10.1016/0022-2836(91)90219-V; CHALOVICH JM, 1990, ANN NY ACAD SCI, V599, P85, DOI 10.1111/j.1749-6632.1990.tb42367.x; DALGARNO DC, 1982, FEBS LETT, V150, P54, DOI 10.1016/0014-5793(82)81303-3; FRASER IDC, 1994, IN PRESS J MUSC RES, V15; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GRABAREK Z, 1992, J MUSCLE RES CELL M, V13, P383, DOI 10.1007/BF01738034; HAYASHI K, 1992, P NATL ACAD SCI USA, V89, P12122, DOI 10.1073/pnas.89.24.12122; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HUBER PAJ, 1993, J MUSCLE RES CELL M, V14, P385, DOI 10.1007/BF00121289; HUMPHREY MB, 1992, GENE, V112, P197, DOI 10.1016/0378-1119(92)90376-Z; KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MARSTON SB, 1992, J BIOL CHEM, V267, P16796; MARSTON SB, 1983, PROG BIOPHYS MOL BIO, V41, P1, DOI 10.1016/0079-6107(83)90024-X; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MARSTON SB, 1991, BIOCHEM J, V279, P1; MARSTON SB, 1993, J BIOL CHEM, V268, P12317; MARSTON SB, 1994, IN PRESS J MUSCLE RE, V15; MEZGUELDI M, 1994, IN PRESS J MUSC RES, V15; NGAI SM, 1992, J BIOL CHEM, V267, P15715; PRITCHARD K, 1993, BIOCHEM BIOPH RES CO, V190, P668, DOI 10.1006/bbrc.1993.1100; PRITCHARD K, 1989, BIOCHEM J, V257, P839, DOI 10.1042/bj2570839; PRITCHARD K, 1991, BIOCHEM J, V277, P819, DOI 10.1042/bj2770819; PRITCHARD K, 1988, SARCOMERIC NONSARCOM, P649; REDWOOD CS, 1993, J BIOL CHEM, V268, P10969; REDWOOD CS, 1993, FEBS LETT, V327, P85, DOI 10.1016/0014-5793(93)81045-2; REDWOOD CS, 1993, J MUSCLE RES CELL M, V14, P241; REDWOOD CS, 1993, BIOPHYS J, V64, pA30; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; SHIRINSKY VP, 1988, BIOCHEM J, V255, P203; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; Straub FB, 1942, STUD I MED CHEM U SZ, V2, P3; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; TANAKA T, 1990, EUR J BIOCHEM, V188, P495, DOI 10.1111/j.1432-1033.1990.tb15427.x; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VOROTNIKOV AV, 1994, IN PRESS J MUSC RES, V15; WANG CLA, 1991, J BIOL CHEM, V266, P9166; ZHAN Q, 1991, J BIOL CHEM, V266, P21810	42	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8134	8139						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132538				2022-12-25	WOS:A1994NB40900048
J	MUH, U; MASSEY, V; WILLIAMS, CH				MUH, U; MASSEY, V; WILLIAMS, CH			LACTATE MONOOXYGENASE .1. EXPRESSION OF THE MYCOBACTERIAL GENE IN ESCHERICHIA-COLI AND SITE-DIRECTED MUTAGENESIS OF LYSINE-266	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; LACZ GENE; OXIDASE; MECHANISM; SEQUENCE; FLAVOCYTOCHROME-B2; FLAVOPROTEINS; INACTIVATION; RESOLUTION; OXIDATION	Lactate monooxygenase utilizes oxygen in the conversion of L-lactate to acetate, CO2, and water. The gene for the enzyme from Mycobacterium smegmatis had been cloned into Escherichia coli (Giegel, D. A., Williams, C. H., Jr., and Massey, V. (1990) J. Biol. Chem. 265, 6626-6632) and the derived amino acid sequence compared to glycolate oxidase and flavocytochrome b(2), enzymes of known three-dimensional structure (Lindqvist, Y., and Branden, C. I. (1989) J. Biol. Chem. 264, 3624-3628; Xia, Z. X., and Mathews, S. F. (1990) J. Mol. Biol. 212, 837-863). There is strong homology, especially around residues in the active site. The mechanism proposed for lactate monooxygenase involves an intermediate having a negative charge at the N(1)-position of the FMN. Based on the homology, lysine 266 is the residue suggested to neutralize that charge. Wild type enzyme and several forms of the enzyme altered at active site residues by site-directed mutagenesis have been expressed in E. coli and purification procedures developed. The properties determined for the recombinant wild type enzyme were, in every case, the same as those previously determined for the enzyme isolated from M. smegmatis. Mutation of lysine 266 to a methionine created K266M. The semiquinone showed spectral features different from those found in the wild type enzyme and was no longer thermodynamically stable. This indicates a redox potential for the enzyme-bound semiquinone/reduced flavin couple that is higher than the midpoint potential for the oxidized flavin/semiquinone couple. The two-electron redox potential was determined to be -180 mV at 25 degrees C, pH 7.0. In wild type enzyme, attack of the flavin ring by sulfite creates a negative charge at the FMN N(1)-position. In K266M, the stabilization of the sulfite adduct was 17,000-fold weaker (K-d similar to 10(-3) M) than in the wild type enzyme, with a rate of association that is lowered by 10,000-fold (k(on) = 1.2 M(-1) S-1). The rate of reduction with L-lactate is significantly decreased in K266M. Unexpectedly, binding of substrate and inhibitors is significantly weaker in K266M than in the wild type enzyme. In all properties involving a negative charge at position N(1) of the FMN, K266M is distinctly different from wild type enzyme. This makes it quite likely that lysine 266 serves the postulated role of interacting with this negative charge.	UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; DEPT VET AFFAIRS MED CTR, ANN ARBOR, MI 48105 USA	University of Michigan System; University of Michigan					NIGMS NIH HHS [GM 11106, GM 21444] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM011106, R01GM011106] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CHOONG YS, 1975, BIOCHEM J, V145, P37, DOI 10.1042/bj1450037; Clark W. M., 1960, OXIDATION REDUCTION; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; GHISLA S, 1976, BIOCHEMISTRY-US, V15, P1791, DOI 10.1021/bi00654a002; GHISLA S, 1975, J BIOL CHEM, V250, P577; GHISLA S, 1977, J BIOL CHEM, V252, P6729; GHISLA S, 1976, FLAVINS FLAVOPROTEIN, P213; Ghisla S., 1991, CHEM BIOCH FLAVOENZY, P243; GIEGEL DA, 1987, J BIOL CHEM, V262, P5705; GIEGEL DA, 1990, J BIOL CHEM, V265, P6626; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQVIST Y, 1989, J BIOL CHEM, V264, P3624; LOOMAN AC, 1987, EMBO J, V6, P2489, DOI 10.1002/j.1460-2075.1987.tb02530.x; MANSTEIN DJ, 1988, BIOCHEMISTRY-US, V27, P2300, DOI 10.1021/bi00407a009; MANSTEIN DJ, 1986, BIOCHEMISTRY-US, V25, P6807, DOI 10.1021/bi00370a012; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1977, J BIOL CHEM, V252, P5612; MASSEY V, 1979, J BIOL CHEM, V254, P9640; MASSEY V, 1969, J BIOL CHEM, V244, P3999; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; MUH U, 1994, J BIOL CHEM, V269, P7994; MUH U, 1994, J BIOL CHEM, V269, P7989; MUH U, 1993, THESIS U MICHIGAN; MULLER F, 1969, J BIOL CHEM, V244, P4007; OLINS PO, 1988, GENE, V73, P227, DOI 10.1016/0378-1119(88)90329-0; OLINS PO, 1989, J BIOL CHEM, V264, P16973; Ratledge C, 1982, BIOL MYCOBACTERIA; REID GA, 1988, EUR J BIOCHEM, V178, P329, DOI 10.1111/j.1432-1033.1988.tb14454.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHONBRUNN A, 1976, BIOCHEMISTRY-US, V15, P1798, DOI 10.1021/bi00654a003; STANKOVICH M, 1983, BIOCHEMISTRY-US, V22, P4466, DOI 10.1021/bi00288a018; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; SULLIVAN PA, 1977, BIOCHEM J, V165, P375, DOI 10.1042/bj1650375; TARTOF KD, 1987, FOCUS, V9, P12; WALSH C, 1973, J BIOL CHEM, V248, P7049; WALSH CT, 1972, J BIOL CHEM, V247, P6004; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M; XIA ZX, 1987, P NATL ACAD SCI USA, V84, P2629, DOI 10.1073/pnas.84.9.2629	39	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7982	7988						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132518				2022-12-25	WOS:A1994NB40900026
J	MANCHESTER, M; EVERITT, L; LOEB, DD; HUTCHISON, CA; SWANSTROM, R				MANCHESTER, M; EVERITT, L; LOEB, DD; HUTCHISON, CA; SWANSTROM, R			IDENTIFICATION OF TEMPERATURE-SENSITIVE MUTANTS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEASE THROUGH SATURATION MUTAGENESIS - AMINO-ACID SIDE-CHAIN REQUIREMENTS FOR TEMPERATURE SENSITIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC HIV-1 PROTEASE; CRYSTAL-STRUCTURE; BACTERIOPHAGE-T4 LYSOZYME; ASPARTIC PROTEINASES; VIRAL INFECTIVITY; ESCHERICHIA-COLI; RESOLUTION; INHIBITOR; MUTATIONS; HOMOLOGY	Human immunodeficiency virus type 1 encodes a protease whose activity is required for the production of infectious virus. An Escherichia coli expression and processing assay system was used to screen 285 protease mutants for temperature-sensitive activity. Fourteen protease mutants had a temperature-sensitive phenotype, and approximately half resulted from conservative amino acid substitutions. Of the 14 substitutions that conferred a temperature-sensitive phenotype, 11 substitutions occurred at 6 positions that represent 3 pairs of residues in the protease that contact each other in the three-dimensional structure. These mutants assist in pinpointing regions of the protease that are important for enzyme activity and stability.	UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT MICROBIOL & IMMUNOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill				Manchester, Marianne/0000-0002-7143-5744	NIAID NIH HHS [R01-AI25321] Funding Source: Medline; NIGMS NIH HHS [232-GM07092] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007092] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1987, BIOCHEMISTRY-US, V26, P3754, DOI 10.1021/bi00387a002; BAUM EZ, 1990, P NATL ACAD SCI USA, V87, P5573, DOI 10.1073/pnas.87.14.5573; DEBOUCK C, 1992, AIDS RES HUM RETROV, V8, P153, DOI 10.1089/aid.1992.8.153; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; GOLDENBERG DP, 1988, ANNU REV BIOPHYS BIO, V17, P481; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GRAY TM, 1987, J BIOL CHEM, V262, P16858; GRUTTER MG, 1979, NATURE, V277, P667, DOI 10.1038/277667a0; GRUTTER MG, 1987, J MOL BIOL, V197, P315, DOI 10.1016/0022-2836(87)90126-4; GUSTCHINA A, 1990, FEBS LETT, V269, P269, DOI 10.1016/0014-5793(90)81171-J; HUTCHISON CA, 1991, METHOD ENZYMOL, V202, P356; JASKOLSKI M, 1990, BIOCHEMISTRY-US, V29, P5889, DOI 10.1021/bi00477a002; JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0; LOEB DD, 1989, J VIROL, V63, P111, DOI 10.1128/JVI.63.1.111-121.1989; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; LOUIS JM, 1989, BIOCHEM BIOPH RES CO, V164, P30, DOI 10.1016/0006-291X(89)91678-1; Maniatis T, 1982, MOL CLONING LABORATO, P68; MATTHEWS BW, 1987, BIOCHEMISTRY-US, V26, P6885, DOI 10.1021/bi00396a001; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0; MULICHAK AM, 1993, J BIOL CHEM, V268, P13103; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; OHLENDORF DH, 1992, PROTEINS, V14, P382; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; PENG C, 1989, J VIROL, V63, P2550, DOI 10.1128/JVI.63.6.2550-2556.1989; Pettit Steve C., 1993, Perspectives in Drug Discovery and Design, V1, P69, DOI 10.1007/BF02171656; RAO JKM, 1991, BIOCHEMISTRY-US, V30, P4663, DOI 10.1021/bi00233a005; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; ROCKENBACH SK, 1990, AIDS RES HUM RETROV, V6, P543, DOI 10.1089/aid.1990.6.543; TONG L, 1993, P NATL ACAD SCI USA, V90, P8387, DOI 10.1073/pnas.90.18.8387; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WEBER IT, 1990, J BIOL CHEM, V265, P10492; WEBER IT, 1989, GENE, V85, P565, DOI 10.1016/0378-1119(89)90453-8; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	39	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7689	7695						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125995				2022-12-25	WOS:A1994NA03200102
J	TACCIOLI, GE; CHENG, HL; VARGHESE, AJ; WHITMORE, G; ALT, FW				TACCIOLI, GE; CHENG, HL; VARGHESE, AJ; WHITMORE, G; ALT, FW			A DNA-REPAIR DEFECT IN CHINESE-HAMSTER OVARY CELLS AFFECTS V(D)J RECOMBINATION SIMILARLY TO THE MURINE ACID MUTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-B CELLS; JUNCTIONAL SEQUENCES; RECEPTOR GAMMA; SCID MUTATION; GENES; MICE; MUTANTS; DEFICIENCY; RADIATION; SIGNAL	Lymphocyte antigen receptor variable regions are encoded by gene segments that are assembled by the site-specific variable (diversity) joining (V(D)J) recombination process. We have assayed the V-3 Chinese hamster ovary cell line, which has a double-strand DNA break repair (dsbr) defect, for the ability to carry out V(D)J recombination following transfection of constructs that encode the RAG-1 and RAG-2 proteins necessary to confer V(D)J recombination activity to non-lymphoid cells. The V-3 cells had substantially impaired ability to undergo V(D)J recombination of transiently introduced test substrates. Although these cells can initiate V(D)J recombination by introducing endonucleolytic scissions at the junctions of V(D)J recombination signal sequences and the flanking coding sequences, they have a greatly impaired ability to rejoin the coding sequences. Detailed characterization of attempted coding joins recovered from these cells indicated that the V(D)J recombination defect in V-3 is similar in phenotype to the murine severe combined immunodeficient (scid) defect and quite distinct from that found in other Chinese hamster ovary dsbr mutant cell lines. Somatic cell complementation analyses between homozygous scid mutant fibroblasts and V-3 cells confirmed that these mutations fall into the same genetic complementation group.	HARVARD UNIV, CHILDRENS HOSP, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, CTR BLOOD RES, BOSTON, MA 02115 USA; ONTARIO CANC INST, TORONTO M4X 1K9, ON, CANADA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; University of Toronto; University Toronto Affiliates; University Health Network Toronto					NIAID NIH HHS [AI20047] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020047, R37AI020047] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P271, DOI 10.1007/BF01538965; DISNEY JE, 1992, CYTOGENET CELL GENET, V59, P39, DOI 10.1159/000133196; FRIEDBERG EC, 1991, BIOESSAYS, V13, P295, DOI 10.1002/bies.950130607; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GELLERT M, 1992, ANNU REV GENET, V22, P425; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P173, DOI 10.1016/0168-9525(93)90164-D; JEGGO PA, 1990, MUTAT RES, V239, P1, DOI 10.1016/0165-1110(90)90028-A; KIENKER LJ, 1991, J EXP MED, V174, P769, DOI 10.1084/jem.174.4.769; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; ROBSON CN, 1988, MUTAT RES, V193, P157, DOI 10.1016/0167-8817(88)90046-6; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHULER W, 1991, EUR J IMMUNOL, V21, P589, DOI 10.1002/eji.1830210309; STAMATO TD, 1983, SOMAT CELL GENET, V9, P165, DOI 10.1007/BF01543175; Taccioli G E, 1992, Curr Top Microbiol Immunol, V182, P107; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; VARGHESE AJ, 1990, J CELL BIOCH SAB, V14; WEEDA G, 1993, BIOESSAYS, V15, P249, DOI 10.1002/bies.950150405; WHITMORE GF, 1989, INT J RADIAT BIOL, V56, P657, DOI 10.1080/09553008914551881	29	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7439	7442						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125964				2022-12-25	WOS:A1994NA03200065
J	TAKASUKA, T; SAKURAI, T; GOTO, K; FURUICHI, Y; WATANABE, T				TAKASUKA, T; SAKURAI, T; GOTO, K; FURUICHI, Y; WATANABE, T			HUMAN ENDOTHELIN RECEPTOR ET(B) - AMINO-ACID-SEQUENCE REQUIREMENTS FOR SUPER STABLE COMPLEX-FORMATION WITH ITS LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; CDNA; BINDING; ETB; IDENTIFICATION; CELLS; MEMBRANES; SUBTYPES; SITES	ET(B) type endothelin receptor (ET(B)R) forms a stable complex with its ligand endothelin-1 (ET-1). The ligand-receptor complex can survive in the presence of 2% SDS and migrate in SDS-polyacrylamide gel electrophoresis at reduced temperature. This is not the case for the ET(A) type endothelin receptor (ET(A)R). Most of ET(B)R from various animals, except rat, can form such a stable complex. Examination of stability in the ligand-receptor complex which was formed by chimeric receptors constructed from human ET(B)R and rat ET(B)R demonstrated that the region containing 29 amino acids in the N-terminal extracellular domain is responsible for the formation of such a stable complex. Site-directed mutagenesis focused on this particular region revealed that Asp(75) and Pro(93) are involved in the formation of the stable complex. This unique observation contributes to the elucidation of the structure of the stable ET(B)R.ET-1 complex at the molecular level.	NIPPON ROCHE RES CTR,DEPT MOLEC GENET,KAMAKURA,KANAGAWA 247,JAPAN; UNIV TSUKUBA,INST BASIC MED SCI,DEPT PHARMACOL,TSUKUBA,IBARAKI 305,JAPAN	Roche Holding; University of Tsukuba								ADACHI M, 1991, BIOCHEM BIOPH RES CO, V180, P1265, DOI 10.1016/S0006-291X(05)81332-4; ADACHI M, 1992, FEBS LETT, V311, P179, DOI 10.1016/0014-5793(92)81393-Z; AKIYAMA N, 1992, PROTEIN EXPRES PURIF, V3, P427, DOI 10.1016/S1046-5928(05)80046-4; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; CLOZEL M, 1989, J CLIN INVEST, V83, P1758, DOI 10.1172/JCI114078; ELSHOURBAGY NA, 1993, J BIOL CHEM, V268, P3873; ELSHOURBAGY NA, 1992, MOL PHARMACOL, V41, P465; FISCHLI W, 1989, LIFE SCI, V44, P1429, DOI 10.1016/0024-3205(89)90321-4; HORI S, 1992, ENDOCRINOLOGY, V130, P1885, DOI 10.1210/en.130.4.1885; HOSODA K, 1991, FEBS LETT, V287, P23, DOI 10.1016/0014-5793(91)80007-P; Innis MA, 1990, PCR PROTOCOLS GUIDE; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; MARTIN ER, 1989, BIOCHEM BIOPH RES CO, V162, P130, DOI 10.1016/0006-291X(89)91972-4; NAKAMUTA M, 1991, BIOCHEM BIOPH RES CO, V177, P34, DOI 10.1016/0006-291X(91)91944-8; NELSON CA, 1993, P NATL ACAD SCI USA, V90, P1227, DOI 10.1073/pnas.90.4.1227; OGAWA Y, 1991, BIOCHEM BIOPH RES CO, V178, P248, DOI 10.1016/0006-291X(91)91806-N; RUBANYI GM, 1991, FASEB J, V5, P2713, DOI 10.1096/fasebj.5.12.1916094; SAITO Y, 1991, J BIOL CHEM, V266, P23433; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAKURAI T, 1992, TRENDS PHARMACOL SCI, V13, P103; SOKOLOVSKY M, 1991, TRENDS BIOCHEM SCI, V16, P261, DOI 10.1016/0968-0004(91)90100-A; TAKASUKA T, 1992, J BIOCHEM-TOKYO, V112, P396, DOI 10.1093/oxfordjournals.jbchem.a123911; TAKASUKA T, 1992, J BIOCHEM-TOKYO, V111, P748, DOI 10.1093/oxfordjournals.jbchem.a123830; TAKASUKA T, 1991, BIOCHEM BIOPH RES CO, V176, P392, DOI 10.1016/0006-291X(91)90937-3; YANAGISAWA M, 1989, TRENDS PHARMACOL SCI, V10, P374; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	27	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7509	7513						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125970				2022-12-25	WOS:A1994NA03200075
J	FERBER, S; BELTRANDELRIO, H; JOHNSON, JH; NOEL, RJ; CASSIDY, LE; CLARK, S; BECKER, TC; HUGHES, SD; NEWGARD, CB				FERBER, S; BELTRANDELRIO, H; JOHNSON, JH; NOEL, RJ; CASSIDY, LE; CLARK, S; BECKER, TC; HUGHES, SD; NEWGARD, CB			GLUT-2 GENE-TRANSFER INTO INSULINOMA CELLS CONFERS BOTH LOW AND HIGH-AFFINITY GLUCOSE-STIMULATED INSULIN RELEASE - RELATIONSHIP TO GLUCOKINASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; ISLET CELLS; MESSENGER-RNAS; RAT; EXPRESSION; SECRETION; TRANSPORTER; METABOLISM; LIVER; LINE	The rat insulinoma cell line RIN 1046-38 loses glucose-stimulated insulin secretion as a function of time in culture. We found that the loss of glucose sensing in these cells was correlated with the loss of expression of GLUT-2 and glucokinase. Stable transfection of RIN cells with a plasmid containing the GLUT-2 cDNA conferred glucose-stimulated insulin release in intermediate but not high passage cells, with the near-maximal 3-fold increase occurring at 50 muM glucose. GLUT-2 expressing cells also exhibited a larger response to the combination of 5 mM glucose + 1 muM forskolin than untransfected cells (7.9 versus 1.6-2.7-fold, respectively). GLUT-2 expressing intermediate passage, but not high passage, RIN cells exhibited a 4-fold increase in glucokinase enzymatic activity relative to nonexpressing controls. Glucokinase activity was also increased by transfer of the GLUT-2 gene into intermediate passage RIN cells via recombinant adenovirus. Preincubation of GLUT-2 expressing intermediate passage RIN cells with 2-deoxyglucose to inhibit low K(m) hexokinases resulted in a glucose-stimulated insulin secretion response that was shifted toward the physiologic range. These studies indicate that GLUT-2 expression confers both a high and low affinity glucose-stimulated insulin secretion response to intermediate passage RIN cells.	UNIV TEXAS, SW MED CTR,GIFFORD LABS DIABET RES,RM 48222, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; VET AFFAIRS MED CTR, DALLAS, TX 75216 USA; UNIV MASSACHUSSETTS, MED CTR, WORCESTER, MA 01655 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Massachusetts System; University of Massachusetts Worcester; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Ferber, Sarah/0000-0003-2764-2786	NIDDK NIH HHS [P01-DK42582, R01-DK46492] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046492, P01DK042582] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; ASHLEY PL, 1985, BIOCHEMISTRY-US, V24, P4512, DOI 10.1021/bi00338a005; BECKER TC, 1994, IN PRESS METHODS CEL; CHEN C, 1993, DIABETES, V42, pA11; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; CLARK SA, 1990, ENDOCRINOLOGY, V127, P2779, DOI 10.1210/endo-127-6-2779; EFRAT S, 1993, DIABETES, V42, P901, DOI 10.2337/diabetes.42.6.901; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; EPSTEIN PN, 1992, P NATL ACAD SCI USA, V89, P12038, DOI 10.1073/pnas.89.24.12038; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HALBAN PA, 1983, BIOCHEM J, V212, P439, DOI 10.1042/bj2120439; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUGHES SD, 1992, P NATL ACAD SCI USA, V89, P688, DOI 10.1073/pnas.89.2.688; HUGHES SD, 1991, J BIOL CHEM, V266, P4521; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; JOHNSON JH, 1990, NEW ENGL J MED, V322, P653, DOI 10.1056/NEJM199003083221003; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; KUWAJIMA M, 1986, J BIOL CHEM, V261, P8849; LIANG Y, 1990, J BIOL CHEM, V265, P16863; LYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; NEWGARD CB, 1992, BIO-TECHNOL, V10, P1112, DOI 10.1038/nbt1092-1112; NEWGARD CB, 1990, BIOCHEM SOC T, V18, P851, DOI 10.1042/bst0180851; NEWGARD CB, 1992, DIABETES NUTR METAB, V5, P15; NISHI S, 1992, DIABETOLOGIA, V35, P743; PURRELLO F, 1993, DIABETES, V42, P199, DOI 10.2337/diabetes.42.1.199; QUAADE C, 1991, FEBS LETT, V280, P47, DOI 10.1016/0014-5793(91)80201-D; RANDLE PJ, 1993, DIABETOLOGIA, V36, P269, DOI 10.1007/BF00400227; SHELTON KD, 1992, MOL CELL BIOL, V12, P4578, DOI 10.1128/MCB.12.10.4578; TRUS M, 1980, DIABETES, V29, P1, DOI 10.2337/diabetes.29.1.1; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; YIN L, 1992, DIABETES, V41, P792	36	101	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11523	11529						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157682				2022-12-25	WOS:A1994NF96600081
J	LEHMANN, M; TSHISUAKA, B; FETZNER, S; ROGER, P; LINGENS, F				LEHMANN, M; TSHISUAKA, B; FETZNER, S; ROGER, P; LINGENS, F			PURIFICATION AND CHARACTERIZATION OF ISOQUINOLINE 1-OXIDOREDUCTASE FROM PSEUDOMONAS-DIMINUTA-7, A NOVEL MOLYBDENUM-CONTAINING HYDROXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDOPTERIN GUANINE DINUCLEOTIDE; ELECTRON-PARAMAGNETIC-RESONANCE; RHODOCOCCUS-SPEC B1; MICROBIAL-METABOLISM; XANTHINE-OXIDASE; SULFITE OXIDASE; NICOTINIC-ACID; FORMYLMETHANOFURAN DEHYDROGENASE; QUINOLINE-4-CARBOXYLIC ACID; QUINOLINE OXIDOREDUCTASE	Isoquinoline 1-oxidoreductase, which catalyzes the hydroxylation of isoquinoline to 1-oxo-1,2-dihydroisoquinoline with concomitant reduction of a suitable electron acceptor, was purified from the isoquinoline degrading bacterium Pseudomonas diminuta 7 to apparent homogeneity. The native enzyme was a heterodimer with a molecular mass of 95 kDa consisting of a 16- and a 80-kDa subunit. It contained 0.85 g atom molybdenum, 3.95 g atom iron, 3.9 g atom acid-labile sulfur, 2.1 mol of phosphate, and 1 mol of CMP/mol of enzyme. CMP and phosphate are suggested to originate from molybdopterin cytosine dinucleotide of the pterin molybdenum cofactor. It is assumed that the iron and the acid-labile sulfur are arranged in two (2Fe-2S) clusters. The isoelectric point of the isoquinoline 1-oxidoreductase was within the range of pH 6.2 to 6.8. Cytochrome c, ferricyanide, and several non-physiological electron acceptors served as oxidizing substrates, whereas O2 and NAD were not used. Isoquinoline 1-oxidoreductase revealed a high specificity toward the reducing substrates isoquinoline, 5-hydroxyisoquinoline, quinazoline, and phthalazine. Isoquinoline 1-oxidoreductase was inactivated by methanol, arsenite, p-hydroxymercuribenzoate, 1,10-phenanthroline, and cyanide. Additionally, the enzyme was inactivated upon incubation with its substrates isoquinoline, which slowly inhibited the enzyme in the absence of an electron acceptor, and 5-hydroxyisoquinoline, which rapidly and very effectively inactivated the enzyme in the presence as well as in the absence of the electron acceptors iodonitrotetrazolium chloride, phenazine methosulfate, or ferricyanide.	UNIV HOHENHEIM,INST MIKROBIOL 250,D-70593 STUTTGART,GERMANY	University Hohenheim				Fetzner, Susanne/0000-0002-7228-1871				AISLABIE J, 1989, APPL ENVIRON MICROB, V55, P3247, DOI 10.1128/AEM.55.12.3247-3249.1989; AMAYA Y, 1990, J BIOL CHEM, V265, P14170; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ARMSTRONG JM, 1964, BIOCHIM BIOPHYS ACTA, V86, P194; BABSON AL, 1973, CLIN CHEM, V19, P766; BAUDER R, 1990, BIOL CHEM H-S, V371, P1137, DOI 10.1515/bchm3.1990.371.2.1137; BAUER G, 1992, BIOL CHEM H-S, V373, P699, DOI 10.1515/bchm3.1992.373.2.699; BEHRMAN EJ, 1957, J BIOL CHEM, V228, P923; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BENNETT J L, 1985, Microbios Letters, V29, P147; BLASCHKE M, 1991, ARCH MICROBIOL, V155, P164, DOI 10.1007/BF00248612; BORNER G, 1991, FEBS LETT, V290, P31, DOI 10.1016/0014-5793(91)81218-W; BOTT G, 1991, BIOL CHEM H-S, V372, P381, DOI 10.1515/bchm3.1991.372.1.381; BRANZOLI U, 1974, J BIOL CHEM, V249, P4339; BRAY RC, 1988, Q REV BIOPHYS, V21, P299, DOI 10.1017/S0033583500004479; Britton HTS, 1931, J CHEM SOC, P1456, DOI 10.1039/jr9310001456; BUDER R, 1989, EUR J BIOCHEM, V185, P629, DOI 10.1111/j.1432-1033.1989.tb15159.x; CHERVENKA CH, 1969, MANUAL METHODS ANAL, P23; COUGHLAN MP, 1980, J BIOL CHEM, V255, P2694; COUGHLAN MP, 1969, J BIOL CHEM, V244, P2658; DAGLEY S, 1963, BIOCHIM BIOPHYS ACTA, V78, P577, DOI 10.1016/0006-3002(63)91023-0; DEBEYER A, 1993, BIOL CHEM H-S, V374, P101, DOI 10.1515/bchm3.1993.374.1-6.101; DILWORTH GL, 1983, ARCH BIOCHEM BIOPHYS, V221, P565, DOI 10.1016/0003-9861(83)90176-5; DIXON M, 1971, BIOCHIM BIOPHYS ACTA, V226, P259, DOI 10.1016/0005-2728(71)90093-4; FETZNER S, 1993, BIOL CHEM H-S, V374, P363, DOI 10.1515/bchm3.1993.374.1-6.363; FREUDENBERG W, 1988, FEMS MICROBIOL LETT, V52, P13; FRUNZKE K, 1991, BIOFORUM, V4, pP278; GEORGE GN, 1983, BIOCHEMISTRY-US, V22, P1013, DOI 10.1021/bi00274a003; GEORGE GN, 1983, BIOCHEMISTRY-US, V22, P5443, DOI 10.1021/bi00292a028; GRANT DJW, 1976, MICROBIOS, V15, P177; HAMES BD, 1990, GEL ELECTROPHORESIS, P36; HAWKES TR, 1984, BIOCHEM J, V218, P961, DOI 10.1042/bj2180961; HETTRICH D, 1991, BIOL CHEM H-S, V372, P513, DOI 10.1515/bchm3.1991.372.2.513; HILLE R, 1984, J BIOL CHEM, V259, P1570; HILLE R, 1983, J BIOL CHEM, V258, P4849; HIRSCHBERG R, 1971, J BACTERIOL, V108, P751, DOI 10.1128/JB.108.2.751-756.1971; HOCHSTEIN LI, 1965, BIOCHEM BIOPH RES CO, V21, P644, DOI 10.1016/0006-291X(65)90535-8; HOCHSTEIN LI, 1967, BIOCHIM BIOPHYS ACTA, V139, P56, DOI 10.1016/0005-2744(67)90113-1; HUND HK, 1990, BIOL CHEM H-S, V371, P1005, DOI 10.1515/bchm3.1990.371.2.1005; HUNT AL, 1958, BIOCHEM J, V69, P170, DOI 10.1042/bj0690170; JOHNSON JL, 1993, J BIOL CHEM, V268, P4848; JOHNSON JL, 1974, J BIOL CHEM, V249, P859; JOHNSON JL, 1990, ARCH BIOCHEM BIOPHYS, V283, P542, DOI 10.1016/0003-9861(90)90681-N; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; JOHNSON JL, 1974, J BIOL CHEM, V249, P5046; JOHNSON JL, 1991, BIOFACTORS, V3, P103; JOHNSON JL, 1991, FEMS MICROBIOL LETT, V77, P213; JOHNSON JL, 1976, J BIOL CHEM, V251, P5505; KANDA M, 1972, J BIOL CHEM, V247, P765; KARRASCH M, 1990, FEBS LETT, V274, P48, DOI 10.1016/0014-5793(90)81326-J; KOMAI H, 1969, J BIOL CHEM, V244, P1692; KRAMER SP, 1987, J BIOL CHEM, V262, P16357; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASSEY V, 1970, J BIOL CHEM, V245, P2837; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; MEYER O, 1986, FEMS MICROBIOL LETT, V39, P161, DOI 10.1111/j.1574-6968.1986.tb01858.x; MEYER O, 1982, J BIOL CHEM, V257, P1333; Morsdorf G., 1992, Biodegradation, V3, P61, DOI 10.1007/BF00189635; MOURA JJG, 1976, BIOCHEM BIOPH RES CO, V72, P782, DOI 10.1016/S0006-291X(76)80201-X; NAGEL M, 1989, FEMS MICROBIOL LETT, V59, P147; NAGEL M, 1990, ARCH MICROBIOL, V154, P605; PEREZVICENTE R, 1992, BIOCHIM BIOPHYS ACTA, V1117, P159, DOI 10.1016/0304-4165(92)90074-5; PESCHKE B, 1991, BIOL CHEM H-S, V372, P1081, DOI 10.1515/bchm3.1991.372.2.1081; PICK FM, 1971, EUR J BIOCHEM, V18, P65, DOI 10.1111/j.1432-1033.1971.tb01215.x; RAJAGOPALAN KV, 1968, J BIOL CHEM, V243, P3797; RAJAGOPALAN KV, 1968, J BIOL CHEM, V243, P3784; RAJAGOPALAN KV, 1964, J BIOL CHEM, V239, P1509; RAJAGOPALAN KV, 1962, J BIOL CHEM, V237, P922; ROGER P, 1990, BIOL CHEM H-S, V371, P511, DOI 10.1515/bchm3.1990.371.1.511; RUGER A, 1993, BIOL CHEM H-S, V374, P479, DOI 10.1515/bchm3.1993.374.7-12.479; SAUTER M, 1993, BIOL CHEM H-S, V374, P1037, DOI 10.1515/bchm3.1993.374.7-12.1037; SCHACH S, 1993, BIOL CHEM H-S, V374, P175, DOI 10.1515/bchm3.1993.374.1-6.175; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHELLENBERG KA, 1958, J BIOL CHEM, V231, P547; SCHICKLE H, SDRE01 PHARM B; SCHMIDT M, 1991, BIOL CHEM H-S, V372, P1015, DOI 10.1515/bchm3.1991.372.2.1015; SCHWARZ G, 1989, BIOL CHEM H-S, V370, P1183, DOI 10.1515/bchm3.1989.370.2.1183; SHUKLA O P, 1987, Biological Memoirs, V13, P115; SHUKLA OP, 1986, APPL ENVIRON MICROB, V51, P1332, DOI 10.1128/AEM.51.6.1332-1342.1986; SHUKLA OP, 1989, MICROBIOS, V59, P47; SIEGMUND I, 1990, FEMS MICROBIOL LETT, V67, P281, DOI 10.1111/j.1574-6968.1990.tb04033.x; STUBLEY C, 1979, XENOBIOTICA, V9, P475, DOI 10.3109/00498257909087261; TATE RL, 1974, CAN J MICROBIOL, V20, P695, DOI 10.1139/m74-106; TSHISUAKA B, 1993, BIOCHEMISTRY-US, V32, P12928, DOI 10.1021/bi00210a047; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8	85	44	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11254	11260						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157655				2022-12-25	WOS:A1994NF96600044
J	ZHANG, Y; AGARWAL, KC; BEYLOT, M; SOLOVIEV, MV; DAVID, F; REIDER, MW; ANDERSON, VE; TSERNG, KY; BRUNENGRABER, H				ZHANG, Y; AGARWAL, KC; BEYLOT, M; SOLOVIEV, MV; DAVID, F; REIDER, MW; ANDERSON, VE; TSERNG, KY; BRUNENGRABER, H			NONHOMOGENEOUS LABELING OF LIVER EXTRA-MITOCHONDRIAL ACETYL-COA - IMPLICATIONS FOR THE PROBING OF LIPOGENIC ACETYL-COA VIA DRUG ACETYLATION AND FOR THE PRODUCTION OF ACETATE BY THE LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED-RAT-LIVER; PEROXISOMAL FATTY-ACID; INTERMEDIARY METABOLISM; QUANTITATIVE-ANALYSIS; SUBSTRATE MIXTURE; BETA-OXIDATION; HEPATOCYTES; 3-BETA-HYDROXYSTEROL; ACETOACETATE; PURIFICATION	The labeling of liver extra-mitochondrial acetyl-CoA was investigated in isolated rat livers perfused with [2-C-13]acetate, [1-C-13]]octanoate, or [1,2,3,4-C-13(4)]docosanoate and with drugs that undergo acetylation (phenylaminobutyrate, paraaminobenzoate, and sulfamethoxazole; singly or in combination). The C-13 enrichment of mitochondrial acetyl-CoA was probed by the enrichment of R-beta-hydroxybutyrate. The latter was not enriched from [1,2,3,4-C-13(4)]docosanoate, thus excluding mitochondrial beta-oxidation of docosanoate. The C-13 enrichment of extra-mitochondrial acetyl-CoA was probed by the enrichments of acetylated drugs and of free acetate. In most cases, the four probes yielded different enrichments. Thus, extra-mitochondrial acetyl-CoA appears nonhomogeneous. Competition between drugs alters the labeling of individual acetyl-CoA sub. pools. The labeling pattern of acetylated drugs suggests the existence of more than the two N-acetyltransferases identified so far by others. Our data question the possibility of probing the pool of lipogenic acetyl-CoA via drug acetylation.	CASE WESTERN RESERVE UNIV, DEPT NUTR, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT BIOCHEM, CLEVELAND, OH 44106 USA; INSERM, U197, F-69008 LYON, FRANCE	Case Western Reserve University; Case Western Reserve University; Institut National de la Sante et de la Recherche Medicale (Inserm)				Anderson, Vernon Emmett/0000-0002-1699-7621	NIDDK NIH HHS [DK35543] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035543] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARANYAI JM, 1989, BIOCHEM J, V258, P121, DOI 10.1042/bj2580121; BRUNENGRABER H, 1978, EUR J BIOCHEM, V82, P373, DOI 10.1111/j.1432-1033.1978.tb12032.x; BRUNENGRABER H, 1973, J BIOL CHEM, V248, P2656; BRUNENGRABER H, 1993, FASEB J, V7, pA169; CONSOLI A, 1987, J CLIN INVEST, V80, P1303, DOI 10.1172/JCI113206; CRABTREE B, 1989, BIOCHEM J, V257, P673, DOI 10.1042/bj2570673; CRABTREE B, 1990, BIOCHEM J, V270, P219, DOI 10.1042/bj2700219; du Vigneaud V, 1938, J BIOL CHEM, V122, P349; ENDEMANN G, 1982, J BIOL CHEM, V257, P3434; GAVINO VC, 1987, J BIOL CHEM, V262, P6735; GRIGAT KP, 1979, BIOCHEM J, V177, P71, DOI 10.1042/bj1770071; HEIN DW, 1991, DRUG METAB DISPOS, V19, P933; HELLERSTEIN MK, 1991, J CLIN INVEST, V87, P1841, DOI 10.1172/JCI115206; HELLERSTEIN MK, 1991, AM J PHYSIOL, V261, pE479, DOI 10.1152/ajpendo.1991.261.4.E479; HEMMELGARN E, 1979, BIOCHIM BIOPHYS ACTA, V572, P298, DOI 10.1016/0005-2760(79)90045-6; HRYB DJ, 1979, BIOCHEM BIOPH RES CO, V87, P1200, DOI 10.1016/S0006-291X(79)80034-0; IZAI K, 1992, J BIOL CHEM, V267, P1027; JUNGERMANN K, 1986, ENZYME, V35, P161, DOI 10.1159/000469338; KAZ J, 1985, AM J PHYSIOL, V248, pR391; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LEIGHTON F, 1989, J BIOL CHEM, V264, P10347; MONTGOMERY JA, 1993, J BIOL CHEM, V268, P20185; PRASS RL, 1980, J BIOL CHEM, V255, P5215; RABKIN M, 1985, BIOCHEM J, V225, P761, DOI 10.1042/bj2250761; ROSIERS CD, 1988, ANAL BIOCHEM, V173, P96, DOI 10.1016/0003-2697(88)90165-0; ROSIERS CD, 1991, J BIOL CHEM, V266, P1574; SEUFERT CD, 1974, BIOCHEM BIOPH RES CO, V57, P901, DOI 10.1016/0006-291X(74)90631-7; SKORIN C, 1992, BIOCHEM J, V281, P561, DOI 10.1042/bj2810561; SOBOLL S, 1974, USE ISOLATED HEPATOC, P29; SOLING HD, 1985, EUR J BIOCHEM, V147, P111, DOI 10.1111/j.1432-1033.1985.tb08726.x; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; TSUNASAWA S, 1984, METHOD ENZYMOL, V106, P165; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; WATSON JA, 1970, J BIOL CHEM, V245, P5993; WEBER WW, 1980, ENZYMATIC BASIS DETO, P169; WICK MJ, 1990, BIOCHEM PHARMACOL, V40, P1389, DOI 10.1016/0006-2952(90)90408-D; YING Z, 1993, ANAL BIOCHEM, V212, P481, DOI 10.1006/abio.1993.1357; YUAN SS, 1984, J LABELLED COMPD RAD, V21, P525, DOI 10.1002/jlcr.2580210606	38	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11025	11029						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157628				2022-12-25	WOS:A1994NF96600012
J	ARREBOLA, R; OLMO, A; RECHE, P; GARVEY, EP; SANTI, DV; RUIZPEREZ, LM; GONZALEZPACANOWSKA, D				ARREBOLA, R; OLMO, A; RECHE, P; GARVEY, EP; SANTI, DV; RUIZPEREZ, LM; GONZALEZPACANOWSKA, D			ISOLATION AND CHARACTERIZATION OF A MUTANT DIHYDROFOLATE REDUCTASE-THYMIDYLATE SYNTHASE FROM METHOTREXATE-RESISTANT LEISHMANIA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; EXTRACHROMOSOMAL CIRCLES; HETEROLOGOUS EXPRESSION; CRYSTAL-STRUCTURES; DNA AMPLIFICATION; DRUG-RESISTANCE; H-REGION; SYNTHETASE; BINDING	The MTX-resistant Leishmania major promastigote cell line D7BR1000 displays extrachromosomal amplified R-region DNA, which contains the gene for dihydrofolate reductase-thymidylate synthase (DHFR-TS) (Garvey, E. P., and Santi, D, V. (1986) Science 233, 535-540). Now we report that these methotrexate (MTX)-resistant cells also possessed a structurally altered DHFR-TS. We have performed the cloning, expression, and characterization of the altered DHFR-TS gene. The DNA sequence of the altered DHFR-TS gene revealed a single base change in position 158 which resulted in the substitution of a methionine in position 53 of DHFR for an arginine. Steady-state measurements of the purified recombinant enzyme indicated that the mutation did not cause significant modifications in the K-m for DHFR or TS substrates but lowered the K-cat by 4-fold. Of greater interest, there was a modification in the effect on MTX inhibition of DHFR The initial inhibition complex appeared to have been unaffected by the alteration, but the subsequent slow-binding step of inhibition in the wild-type enzyme is absent in the altered enzyme. Consequently, the overall K-i for MTX was 30-fold greater for the mutant than for the wild-type enzyme. Transfection of L. major with the mutant DHFR-TS gene gives parasites that are capable of growing in medium containing 10 mM methotrexate, showing that the altered DHFR gene is in itself capable of conferring MTX resistance in Leishmania.	CSIC,INST PARASITOL & BIOMED LOPEZ NEYRA,E-18001 GRANADA,SPAIN; WELLCOME RES LABS,RES TRIANGLE PK,NC 27709; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Wellcome Research Laboratories; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Reche, Pedro A/B-1881-2013	Reche, Pedro A/0000-0003-3966-5838; Gonzalez-Pacanowska, Dolores/0000-0002-4303-5209; Ruiz-Perez, Luis M./0000-0001-7681-4471	NIAID NIH HHS [R01 AI 19358] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019358] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHRWEILER PM, 1988, J BACTERIOL, V170, P3301, DOI 10.1128/jb.170.7.3301-3304.1988; APPLEMAN JR, 1988, J BIOL CHEM, V263, P10304; BACCANARI D, 1975, BIOCHEMISTRY-US, V14, P5267, DOI 10.1021/bi00695a006; BETHELL GS, 1979, J BIOL CHEM, V254, P2572; BEVERLEY SM, 1984, CELL, V38, P431, DOI 10.1016/0092-8674(84)90498-7; BEVERLEY SM, 1986, P NATL ACAD SCI USA, V83, P2584, DOI 10.1073/pnas.83.8.2584; BLAKLEY RL, 1960, NATURE, V188, P231, DOI 10.1038/188231a0; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; BRUCHOVSKY N, 1982, DRUG HORMONE RESISTA, V1; CALLAHAN HL, 1992, J BIOL CHEM, V267, P24165; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; CODERRE JA, 1983, P NATL ACAD SCI-BIOL, V80, P2132, DOI 10.1073/pnas.80.8.2132; ELLENBERGER TE, 1989, J BIOL CHEM, V264, P15094; FERONE R, 1980, P NATL ACAD SCI-BIOL, V77, P5802, DOI 10.1073/pnas.77.10.5802; GALINDO I, 1989, MOL BIOCHEM PARASIT, V34, P245, DOI 10.1016/0166-6851(89)90053-4; GARRETT CE, 1984, MOL BIOCHEM PARASIT, V11, P257, DOI 10.1016/0166-6851(84)90070-7; GARVEY EP, 1985, P NATL ACAD SCI USA, V82, P7188, DOI 10.1073/pnas.82.21.7188; GARVEY EP, 1985, MOL BIOCHEM PARASIT, V17, P79, DOI 10.1016/0166-6851(85)90129-X; GARVEY EP, 1986, SCIENCE, V233, P535, DOI 10.1126/science.3726545; GRUMONT R, 1988, BIOCHEMISTRY-US, V27, P3776, DOI 10.1021/bi00410a039; Harrap K R, 1978, Antibiot Chemother (1971), V23, P228; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; IVANETICH KM, 1990, FASEB J, V4, P1591, DOI 10.1096/fasebj.4.6.2180768; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KATAKURA K, 1989, MOL BIOCHEM PARASIT, V34, P189, DOI 10.1016/0166-6851(89)90010-8; KAUR K, 1988, J BIOL CHEM, V263, P7020; LAWRIE JM, 1985, AM J TROP MED HYG, V34, P257, DOI 10.4269/ajtmh.1985.34.257; LEBOWITZ JH, 1991, GENE, V103, P119, DOI 10.1016/0378-1119(91)90402-W; MACIVOR RS, 1990, NUCLEIC ACIDS RES, V18, P7025; MATTHEWS DA, 1985, J BIOL CHEM, V260, P381; MEEK TD, 1985, BIOCHEMISTRY-US, V24, P678, DOI 10.1021/bi00324a021; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; OEFNER C, 1988, EUR J BIOCHEM, V174, P377, DOI 10.1111/j.1432-1033.1988.tb14108.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PENNER MH, 1985, J BIOL CHEM, V260, P5366; PETRILLOPEIXOTO ML, 1988, MOL CELL BIOL, V8, P5188, DOI 10.1128/MCB.8.12.5188; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEITZER BI, 1989, J BIOL CHEM, V264, P20786; SCHWEITZER BI, 1990, FASEB J, V4, P2441, DOI 10.1096/fasebj.4.8.2185970; SIRAWARAPORN W, 1990, BIOCHEMISTRY-US, V29, P10779, DOI 10.1021/bi00500a009; SRIMATKANDADA S, 1989, J BIOL CHEM, V264, P3524; STAMMERS DK, 1987, FEBS LETT, V218, P178, DOI 10.1016/0014-5793(87)81042-6; STONE SR, 1984, BIOCHEM PHARMACOL, V33, P175, DOI 10.1016/0006-2952(84)90472-6; THILLET J, 1988, J BIOL CHEM, V263, P12500; VOLZ KW, 1982, J BIOL CHEM, V257, P2528; WHITE TC, 1988, J BIOL CHEM, V263, P16977; Williams J W, 1979, Methods Enzymol, V63, P437; WILLIAMS JW, 1979, BIOCHEMISTRY-US, V18, P2567, DOI 10.1021/bi00579a021	50	31	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10590	10596						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144647				2022-12-25	WOS:A1994NF01700061
J	DEROSSI, D; JOLIOT, AH; CHASSAING, G; PROCHIANTZ, A				DEROSSI, D; JOLIOT, AH; CHASSAING, G; PROCHIANTZ, A			THE 3RD HELIX OF THE ANTENNAPEDIA HOMEODOMAIN TRANSLOCATES THROUGH BIOLOGICAL-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN; HOMEOBOX PEPTIDE; PROTEINS; GENES	The 60-amino acid long homeodomain of Antennapedia crosses biological membranes by an energy-independent mechanism, a phenomenon abolished by directed mutagenesis within the polypeptide C-terminal region. This finding led us to study the internalization of several chemically synthesized peptides derived from the third helix of the homeodomain. We report here that a polypeptide of 16 amino acids in length corresponding to the third helix of the homeodomain deleted of its N-terminal glutamate is still capable of translocating through the membrane. A longer peptide of 20 amino acids also translocates, whereas shorter peptides (15 amino acids) are not internalized by the cells. As is also the case for the entire homeodomain, the 20- and 16-amino acid long peptides are internalized at 4 degrees C, suggesting an energy-independent mechanism of translocation not involving classical endocytosis. The two translocated peptides can be recovered, intact, within the cells, strongly suggesting that they are not targeted to the lysosomal compartment. Finally, substitution of two tryptophans by two phenylalanines strongly diminishes translocation, raising the possibility that the internalization of the third helix is not solely based on its general hydrophobicity.	ECOLE NORMALE SUPER,CNRS,UNITE RECH 1414,F-75230 PARIS 05,FRANCE; UNIV PARIS 06,CNRS,UNITE RECH 493,F-75005 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite								BEAUMELLE B, 1992, J BIOL CHEM, V267, P11525; BLOCHGALLEGO E, 1993, J CELL BIOL, V120, P485, DOI 10.1083/jcb.120.2.485; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GLICK B, 1991, ANNU REV GENET, V25, P21; HOLLAND P, 1992, BIOESSAYS, V14, P267, DOI 10.1002/bies.950140412; HUNT P, 1992, ANNU REV CELL BIOL, V8, P227, DOI 10.1146/annurev.cb.08.110192.001303; JIANG JX, 1991, J BIOL CHEM, V266, P24003; JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864; JOLIOT AH, 1991, NEW BIOL, V3, P1121; LAFONT F, 1992, DEVELOPMENT, V114, P17; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LEROUX I, 1993, P NATL ACAD SCI USA, V90, P9120, DOI 10.1073/pnas.90.19.9120; MADUKE M, 1993, SCIENCE, V260, P364, DOI 10.1126/science.8385804; MOSKAUG JO, 1991, J BIOL CHEM, V266, P2652; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; OLSNES S, 1988, TRENDS BIOCHEM SCI, V13, P348, DOI 10.1016/0968-0004(88)90105-3; PAPINI E, 1993, J BIOL CHEM, V268, P1567; PEREZ F, 1992, J CELL SCI, V102, P717; PRICE M, 1992, NEURON, V8, P241, DOI 10.1016/0896-6273(92)90291-K; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; REISFELD RA, 1962, NATURE, V195, P281, DOI 10.1038/195281a0; SIMEONE A, 1992, EMBO J, V11, P2541, DOI 10.1002/j.1460-2075.1992.tb05319.x; VALLETTE FM, 1994, IN PRESS J BIOL CHEM	25	1648	1936	1	131	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10444	10450						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144628				2022-12-25	WOS:A1994NF01700041
J	KONIG, S; SCHELLENBERGER, A; NEEF, H; SCHNEIDER, G				KONIG, S; SCHELLENBERGER, A; NEEF, H; SCHNEIDER, G			SPECIFICITY OF COENZYME BINDING IN THIAMIN DIPHOSPHATE-DEPENDENT ENZYMES - CRYSTAL-STRUCTURES OF YEAST TRANSKETOLASE IN COMPLEX WITH ANALOGS OF THIAMIN DIPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYROPHOSPHATE; COLLECTION; DETECTOR; SYSTEM; SITE	The three-dimensional structures of complexes of yeast apotransketolase with the coenzyme analogs 6'-methyl, N1'-pyridyl, and N3'-pyridyl thiamin diphosphate, respectively, were determined with protein crystallographic methods. All three coenzyme analogs bind to the enzyme in a fashion highly similar to the cofactor thiamin diphosphate. Thus, either one of the hydrogen bonds of the pyrimidine ring nitrogens to the protein is sufficient for proper binding and positioning of the cofactor. The lack of catalytic activity of the N3'-pyridyl analog is not due to incorrect orientation of the pyrimidine ring, but results from the absence of the hydrogen bond between the N1' nitrogen atom and the conserved residue Glu(418). The structure analysis provides further evidence for the importance of this conserved interaction for enzymatic thiamin catalysis.	SWEDISH UNIV AGR SCI,CTR BIOMED,DEPT MOLEC BIOL,S-75124 UPPSALA,SWEDEN; UNIV HALLE WITTENBERG,INST BIOCHEM,DEPT BIOCHEM & BIOTECHNOL,D-06099 HALLE,GERMANY	Swedish University of Agricultural Sciences; Martin Luther University Halle Wittenberg			Koenig, Stephan/GRX-2480-2022	Schneider, Gunter/0000-0003-0622-5713				BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; CAVALIERI SW, 1975, ARCH BIOCHEM BIOPHYS, V171, P527, DOI 10.1016/0003-9861(75)90062-4; DYDA F, 1993, BIOCHEMISTRY-US, V32, P6165, DOI 10.1021/bi00075a008; GOLBIK R, 1991, BIOORG CHEM, V19, P10, DOI 10.1016/0045-2068(91)90039-R; HEINRICH PC, 1972, EUR J BIOCHEM, V30, P533, DOI 10.1111/j.1432-1033.1972.tb02124.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORDAN F, 1982, ANN NY ACAD SCI, V378, P14; KLUGER R, 1984, J BIOL CHEM, V259, P8960; KOCHETOV GA, 1982, METHOD ENZYMOL, V90, P209; LINDQVISTY, 1992, EMBO J, V11, P2373; MULLER YA, 1993, STRUCTURE, V1, P95, DOI 10.1016/0969-2126(93)90025-C; MULLERYA, 1993, SCIENCE, V259, P965; NEEF H, 1990, LIEBIGS ANN CHEM, P913; NILSSON U, 1993, FEBS LETT, V326, P145, DOI 10.1016/0014-5793(93)81779-Y; OBRIEN TA, 1980, J BIOL CHEM, V255, P3302; SATO M, 1992, J APPL CRYSTALLOGR, V25, P348, DOI 10.1107/S0021889891012955; SCHELLENBERGER A, 1967, H-S Z PHYSIOL CHEM, V348, P506, DOI 10.1515/bchm2.1967.348.1.506; SCHELLENBERGER A, 1967, ANGEW CHEM INT EDIT, V6, P1024, DOI 10.1002/anie.196710241; SCHELLENBERGER A, 1967, H-S Z PHYSIOL CHEM, V348, P501, DOI 10.1515/bchm2.1967.348.1.501; SCHELLENBERGER A, 1982, ANN NY ACAD SCI, V378, P51, DOI 10.1111/j.1749-6632.1982.tb31185.x; SCHNEIDER G, 1989, J BIOL CHEM, V264, P21619; SCHNEIDER G, 1993, BIOORG CHEM, V21, P109, DOI 10.1006/bioo.1993.1012; SUNDSTROM M, 1992, FEBS LETT, V313, P229, DOI 10.1016/0014-5793(92)81197-T; USMANOV RA, 1985, BIOCHEM INT, V10, P479; 1979, 4 DAR LAB SCI ENG CO	26	49	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10879	10882						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144674				2022-12-25	WOS:A1994NF01700101
J	LEIDICH, SD; DRAPP, DA; ORLEAN, P				LEIDICH, SD; DRAPP, DA; ORLEAN, P			A CONDITIONALLY LETHAL YEAST MUTANT BLOCKED AT THE FIRST STEP IN GLYCOSYL PHOSPHATIDYLINOSITOL ANCHOR SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOSPHATE MANNOSE SYNTHASE; CELL-SURFACE MOLECULES; SACCHAROMYCES-CEREVISIAE; BIOSYNTHESIS; MEMBRANE; PROTEIN; LYMPHOMA; GENE; DEFICIENT; THY-1	Glycosyl phosphatidylinositols (GPIs) anchor many proteins to the surface of eukaryotic cells and may also serve as sorting signals on proteins and participate in signal transduction. We have isolated a Saccharomyces cerevisiae GPI anchoring mutant, gpi1, using a colony screen for cells blocked in [H-3]inositol incorporation into protein. The gpi1 mutant is defective in vitro in the synthesis of N-acetylglucosaminyl phosphatidylinositol, the first intermediate in GPI synthesis, and is also temperature-sensitive for growth. Completion of the first step in GPI assembly is therefore required for growth of the unicellular eukaryote S. cerevisiae. GPI synthesis could therefore be exploited as a target for antifungal or antiparasitic agents.	UNIV ILLINOIS,DEPT BIOCHEM,ROGER ADAMS LAB 309,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign					NIGMS NIH HHS [GM46220] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046220] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CONZELMANN A, 1986, EMBO J, V5, P3291, DOI 10.1002/j.1460-2075.1986.tb04642.x; CONZELMANN A, 1990, EMBO J, V9, P653, DOI 10.1002/j.1460-2075.1990.tb08157.x; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; DOERING TL, 1989, J BIOL CHEM, V264, P11168; DOERING TL, 1991, SCIENCE, V252, P1851, DOI 10.1126/science.1829548; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FATEMI SH, 1986, CELL, V46, P653, DOI 10.1016/0092-8674(86)90340-5; HANSON BA, 1980, J LIPID RES, V21, P309; HIROSE S, 1992, J BIOL CHEM, V267, P5272; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; HUFFAKER TC, 1982, J BIOL CHEM, V257, P3203; HYMAN R, 1988, TRENDS GENET, V4, P5, DOI 10.1016/0168-9525(88)90120-5; KAMITANI T, 1993, J BIOL CHEM, V268, P20733; KEPES F, 1988, J BIOL CHEM, V263, P9155; Lee G. Richard, 1993, P1232; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; POPOLO L, 1993, J BACTERIOL, V175, P1879, DOI 10.1128/JB.175.7.1879-1885.1993; PUOTI A, 1991, J BIOL CHEM, V266, P21051; PUOTI A, 1991, J CELL BIOL, V113, P515, DOI 10.1083/jcb.113.3.515; Rose MD., 1990, METHODS YEAST GENETI; SMITH SW, 1974, J BIOL CHEM, V249, P3395; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; THOMAS LJ, 1991, J BIOL CHEM, V266, P23175; VAI M, 1991, J BIOL CHEM, V266, P12242; YEH ETH, 1988, CELL, V52, P665, DOI 10.1016/0092-8674(88)90404-7	38	140	143	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10193	10196						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144596				2022-12-25	WOS:A1994NF01700003
J	YANG, XD; MCDONOUGH, J; FYODOROV, D; MORRIS, M; WANG, F; DENERIS, ES				YANG, XD; MCDONOUGH, J; FYODOROV, D; MORRIS, M; WANG, F; DENERIS, ES			CHARACTERIZATION OF AN ACETYLCHOLINE-RECEPTOR ALPHA-3 GENE PROMOTER AND ITS ACTIVATION BY THE POU DOMAIN FACTOR SCIP/TST-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; CHICK CILIARY GANGLIA; RAT CENTRAL NEURONS; TRANSCRIPTION FACTOR; NICOTINIC RECEPTOR; HOMEOBOX GENE; FUNCTIONAL DIVERSITY; CPG ISLANDS; EXPRESSION; PROTEIN	Genes encoding neuronal nicotinic acetylcholine receptors exhibit restricted patterns of expression in the nervous system. We are interested in elucidating the molecular mechanisms responsible for establishing these patterns of expression. This paper presents the characterization of regulatory elements upstream of the neuronal nicotinic acetylcholine receptor alpha 3 gene. We have identified a GC-rich multistart site promoter adjacent to the alpha 3 coding region. Similar alpha 3 start sites were identified in PC12 cells and sympathetic ganglion neurons, suggesting similar control mechanisms in the clonal line and peripheral neurons. The start site region lacks TATA-like sequences but does contain initiator-like sequences. We show in transient transfection assays, that the POU domain transcription factor, SCI/Tst-1, specifically activates alpha 3 in a neural context. Other POU domain factors tested only weakly activated or repressed alpha 3. Unexpectedly, we found that alpha 3 basal activity and SCIP/Tst-1 activation of alpha 3 is not dependent on the SCIP/Tst-1 binding sites found upstream of the gene. In addition, mutations in the SCIP/Tst-1 coding region that prevent the factor from binding to DNA with high affinity do not obliterate alpha 3 activation. These results lead us to propose that alpha 3 activation by SCIP/Tst-1 is achieved via protein-protein interactions between SCIP/Tst-1 and a specific complement of transcription factors that act directly on the promoter.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT NEUROSCI, CLEVELAND, OH 44106 USA	Case Western Reserve University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029123] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS29123] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOULTER J, 1986, NATURE, V319, P368, DOI 10.1038/319368a0; BOULTER J, 1990, J BIOL CHEM, V265, P4472; BOYD RT, 1988, NEURON, V1, P495; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE PBS, 1990, NICOTINE PSYCHOPHARM, P158; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; COUTURIER S, 1990, J BIOL CHEM, V265, P17560; DENERIS ES, 1991, TRENDS PHARMACOL SCI, V12, P34, DOI 10.1016/0165-6147(91)90486-C; DENERIS ES, 1988, NEURON, V1, P45, DOI 10.1016/0896-6273(88)90208-5; DENERIS ES, 1989, J BIOL CHEM, V264, P6268; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUVOISIN RM, 1993, BRAZ J MED BIOL RES, V26, P137; DUVOISIN RM, 1989, NEURON, V3, P487, DOI 10.1016/0896-6273(89)90207-9; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HALVORSEN SW, 1990, J NEUROSCI, V10, P1711; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; JOHNSON WA, 1990, NATURE, V343, P467, DOI 10.1038/343467a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LEMOINE C, 1992, P NATL ACAD SCI USA, V89, P3285, DOI 10.1073/pnas.89.8.3285; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LU S, 1992, P NATL ACAD SCI USA, V89, P8053, DOI 10.1073/pnas.89.17.8053; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MATHIS JM, 1992, EMBO J, V11, P2551, DOI 10.1002/j.1460-2075.1992.tb05320.x; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCORMICK DA, 1987, J NEUROSCI, V7, P742; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MEIJER D, 1992, NUCLEIC ACIDS RES, V20, P2241, DOI 10.1093/nar/20.9.2241; MONUKI ES, 1993, MECH DEVELOP, V42, P15, DOI 10.1016/0925-4773(93)90095-F; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; MULLE C, 1990, J NEUROSCI, V10, P169; MULLE C, 1991, J NEUROSCI, V11, P2588; MULLE C, 1992, NEURON, V8, P937, DOI 10.1016/0896-6273(92)90208-U; MULLE C, 1992, NEURON, V8, P135, DOI 10.1016/0896-6273(92)90115-T; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PFAFFLE RW, 1992, SCIENCE, V257, P1118, DOI 10.1126/science.257.5073.1118; PORTEUS MH, 1991, NEURON, V7, P221, DOI 10.1016/0896-6273(91)90260-7; RADOVICK S, 1992, SCIENCE, V257, P1115, DOI 10.1126/science.257.5073.1115; ROGERS SW, 1992, J NEUROSCI, V12, P4611; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHOEPFER R, 1989, FEBS LETT, V257, P393, DOI 10.1016/0014-5793(89)81580-7; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SIMEONE A, 1988, NUCLEIC ACIDS RES, V16, P5379, DOI 10.1093/nar/16.12.5379; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOGAARDANDERSEN L, 1993, CELL, V75, P557, DOI 10.1016/0092-8674(93)90389-8; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TREACY MN, 1992, ANNU REV NEUROSCI, V15, P139, DOI 10.1146/annurev.ne.15.030192.001035; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	74	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10252	10264						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144606				2022-12-25	WOS:A1994NF01700016
J	YUN, HY; KEUTMANN, HT; EIPPER, BA				YUN, HY; KEUTMANN, HT; EIPPER, BA			ALTERNATIVE SPLICING GOVERNS SULFATION OF TYROSINE OR OLIGOSACCHARIDE ON PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE DOMAIN; PEPTIDE AMIDATION; MESSENGER-RNA; ATT-20 CELLS; FACTOR-VIII; PROTEIN; FORMS; EXPRESSION; MEMBRANE; SECRETION	Peptidylglycine alpha-amidating monooxygenase (PAM) catalyzes the COOH-terminal alpha-amidation of neuroendocrine peptides through the sequential action of monooxygenase and lyase domains contained within this bifunctional protein. Alternative splicing leads to the expression of soluble and integral membrane bifunctional PAM proteins as well as a soluble monofunctional monooxygenase. In order to determine how alternative splicing affects post-translational modification of PAM proteins, we investigated the sulfation of PAM proteins expressed in stably transfected hEK-293 cells. Metabolic labeling with [S-35]SO42- or [S-35]methionine and immunoprecipitation demonstrated that [S-35]SO42- was efficiently incorporated into PAM proteins that have the noncatalytic exon A region following the monooxygenase domain (PAM-1 and PAM-4) and into a soluble bifunctional PAM protein (PAM-3). Alkaline hydrolysis, radiosequencing, and deglycosylation experiments demonstrated the presence of a sulfated tyrosine (Tyr(965)) in the COOH-terminal domain of PAM-3 and multiple sulfated O-glycans in the exon A region of PAM-1 and PAM-4. A mutant PAM-3 protein in which Tyr(965) was changed to Ala(965) (PAM-3/Y965A) was not sulfated and exhibited monooxygenase and lyase activities similar to those of wild type PAM-3. Pulse-chase and temperature block experiments showed that the PAM-3/Y965A protein exits the trans-Golgi network faster than wild type PAM-3. Thus inclusion of exon A results in the sulfation of O-glycans, while elimination of the transmembrane domain results in the sulfation of Tyr(965).	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; MASSACHUSETTS GEN HOSP,ENDOCRINE UNIT,BOSTON,MA 02114	Johns Hopkins University; Harvard University; Massachusetts General Hospital					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032949, R56DK032949, R01DK032949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA000098] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00098] Funding Source: Medline; NIDDK NIH HHS [DK-32949] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BODANSZKY M, 1978, J MED CHEM, V21, P1030, DOI 10.1021/jm00208a006; BRAAS KM, 1992, ENDOCRINOLOGY, V130, P2778, DOI 10.1210/en.130.5.2778; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; EIPPER BA, 1992, J BIOL CHEM, V267, P4008; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1991, J BIOL CHEM, V266, P7827; EIPPER BA, 1993, PROTEIN SCI, V2, P489; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; FRIEDERICH E, 1988, J CELL BIOL, V107, P1655, DOI 10.1083/jcb.107.5.1655; GIBLIN P, 1989, P NATL ACAD SCI USA, V86, P998, DOI 10.1073/pnas.86.3.998; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; Hart Gerald W., 1992, Current Opinion in Cell Biology, V4, P1017, DOI 10.1016/0955-0674(92)90134-X; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V151, P417, DOI 10.1016/0006-291X(88)90609-2; HORTIN GL, 1989, P NATL ACAD SCI USA, V86, P1338, DOI 10.1073/pnas.86.4.1338; HUSTEN EJ, 1993, J BIOL CHEM, V268, P9709; HUSTEN EJ, 1991, J BIOL CHEM, V266, P17004; HUTTNER WB, 1984, METHOD ENZYMOL, V107, P200; HUTTNER WB, 1988, ANN REV PHYSL, V50, P353; IMAI Y, 1993, NATURE, V361, P555; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUKKOLA A, 1990, BIOCHEM BIOPH RES CO, V170, P264, DOI 10.1016/0006-291X(90)91269-X; KATO I, 1990, FEBS LETT, V269, P319, DOI 10.1016/0014-5793(90)81184-P; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P6115, DOI 10.1021/bi00478a001; KLEIN RS, 1992, J NEUROCHEM, V58, P2011, DOI 10.1111/j.1471-4159.1992.tb10941.x; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LEE RWH, 1985, P NATL ACAD SCI USA, V82, P6143, DOI 10.1073/pnas.82.18.6143; LEYTE A, 1991, J BIOL CHEM, V266, P740; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MALTESE JY, 1993, ENDOCRINOLOGY, V133, P2579, DOI 10.1210/en.133.6.2579; MALTESE JY, 1992, MOL ENDOCRINOL, V6, P1998, DOI 10.1210/me.6.12.1998; MAY V, 1986, ENDOCRINOLOGY, V118, P1284, DOI 10.1210/endo-118-4-1284; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; MILGRAM SL, 1994, IN PRESS J CELL SCI; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; OUAFIK L, 1992, MOL ENDOCRINOL, V6, P1571, DOI 10.1210/me.6.10.1571; OUAFIK L, 1989, J BIOL CHEM, V264, P5839; OYARCE AM, 1993, J NEUROCHEM, V60, P1105, DOI 10.1111/j.1471-4159.1993.tb03261.x; PERKINS SN, 1990, BIOCHEM BIOPH RES CO, V171, P926, DOI 10.1016/0006-291X(90)90772-F; PITTMAN DD, 1992, BIOCHEMISTRY-US, V31, P3315, DOI 10.1021/bi00128a003; RHODES CH, 1990, J HISTOCHEM CYTOCHEM, V38, P1301, DOI 10.1177/38.9.2387985; SMITH PL, 1993, J BIOL CHEM, V268, P795; STOFFERS DA, 1991, J BIOL CHEM, V266, P1701; TAKAHASHI K, 1990, BIOCHEM BIOPH RES CO, V169, P524, DOI 10.1016/0006-291X(90)90362-Q; TAUSK FA, 1992, MOL ENDOCRINOL, V6, P2185, DOI 10.1210/me.6.12.2185; YOUNG SD, 1989, J AM CHEM SOC, V111, P1933, DOI 10.1021/ja00187a088; YUN HY, 1993, ARCH BIOCHEM BIOPHYS, V301, P77, DOI 10.1006/abbi.1993.1117	49	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10946	10955						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144680				2022-12-25	WOS:A1994NF01700110
J	KHAN, MT; WANG, KKW; VILLALOBO, A; ROUFOGALIS, BD				KHAN, MT; WANG, KKW; VILLALOBO, A; ROUFOGALIS, BD			CHARACTERIZATION OF A NOVEL HIGH-MOLECULAR-MASS PROTEIN WITH PEPTIDASE ACTIVITY PURIFIED FROM THE HUMAN ERYTHROCYTE-MEMBRANE BY CALMODULIN AFFINITY-CHROMATOGRAPHY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE; RAT-LIVER; THERMOPLASMA-ACIDOPHILUM; SENSITIVE METHOD; TRITON X-100; PURIFICATION; BINDING; COMPLEX; PROTEASOME; QUANTITIES	A previously undescribed high molecular mass protein (HMP) from human erythrocyte membranes was solubilized by Triton X-100 and purified on a calmodulin-agarose column in the presence of Ca2+. It was shown to have a native molecular mass of 522-560 kDa, comprised of a single subunit of a molecular mass of 28 kDa (p28). The protein is associated with the lipid bilayer rather than with the cytoskeletal component of the membrane. The purified HMP showed peptidase-hydrolyzing activity toward substrates containing hydrophobic amino acids at the P1 position of the P2-P1 cleavage site. The activity was inhibited by serine proteinase inhibitors (leupeptin, phenylmethanesulfonyl fluoride) and chymotrypsin inhibitors in particular (chymostatin, N-tosyl-L-phenylalanine chloromethyl ketone). The enzyme exhibited maximal activity at slightly alkaline pH (7.5-8.5) and at 37-degrees-C and was stimulated over a narrow range of SDS concentrations (maximal at 0.05%). HMP was found to cross-react in Western blots with an antibody raised against the rabbit multicatalytic proteinase. The single subunit of HMP therefore contains both the catalytic activity and a sequence necessary for its association into a multimeric complex. The properties of the human erythrocyte membrane HMP described indicate that it is a novel peptidase related to the ubiquitous multicatalytic proteinase.	UNIV SYDNEY,DEPT PHARM,SYDNEY,NSW 2006,AUSTRALIA; CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN; UNIV BRITISH COLUMBIA,FAC PHARMACEUT SCI,VANCOUVER V6T 1Z3,BC,CANADA; PARK DAVIS CO,DIV PHARMACEUT RES,DEPT PHARMACOL,NEUROSCI SECT,ANN ARBOR,MI 48105	University of Sydney; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of British Columbia			Villalobo, Antonio/K-2902-2017; Villalobo, Antonio/O-9621-2019	Villalobo, Antonio/0000-0002-4200-374X; Wang, Kevin/0000-0002-9343-6473; Roufogalis, Basil/0000-0001-9123-5478				ARRIBAS J, 1990, J BIOL CHEM, V265, P13969; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CARDOZO C, 1992, BIOCHEMISTRY-US, V31, P7373, DOI 10.1021/bi00147a023; CLARK SJ, 1988, BIOCHIM BIOPHYS ACTA, V957, P243, DOI 10.1016/0167-4838(88)90279-8; DAHLMANN B, 1992, EUR J BIOCHEM, V208, P789, DOI 10.1111/j.1432-1033.1992.tb17249.x; DJABALLAH H, 1992, EUR J BIOCHEM, V209, P629, DOI 10.1111/j.1432-1033.1992.tb17329.x; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; GARDNER K, 1986, J BIOL CHEM, V261, P1339; HEARING VJ, 1976, ANAL BIOCHEM, V72, P113, DOI 10.1016/0003-2697(76)90512-1; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; KINOSHITA M, 1990, J BIOCHEM-TOKYO, V107, P440, DOI 10.1093/oxfordjournals.jbchem.a123064; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASON RW, 1990, BIOCHEM J, V265, P479, DOI 10.1042/bj2650479; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; MELLGREN RL, 1990, BIOCHIM BIOPHYS ACTA, V1040, P28, DOI 10.1016/0167-4838(90)90142-3; MYKLES DL, 1991, ARCH BIOCHEM BIOPHYS, V288, P543, DOI 10.1016/0003-9861(91)90233-9; MYKLES DL, 1989, ARCH BIOCHEM BIOPHYS, V274, P216, DOI 10.1016/0003-9861(89)90433-5; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SASAKI T, 1984, J BIOL CHEM, V259, P2489; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; WANG JH, 1985, CURR TOP CELL REGUL, V27, P419; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V267, P317, DOI 10.1016/0003-9861(88)90037-9; ZOLFAGHARI R, 1987, ARCH BIOCHEM BIOPHYS, V258, P42, DOI 10.1016/0003-9861(87)90320-1; ZWICKL P, 1991, FEBS LETT, V278, P217, DOI 10.1016/0014-5793(91)80120-R	31	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					10016	10021						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144498				2022-12-25	WOS:A1994NE05300093
J	NEGISHI, Y; NISHITA, Y; SAEGUSA, Y; KAKIZAKI, I; GALLI, I; KIHARA, F; TAMAI, K; MIYAJIMA, N; IGUCHIARIGA, SMM; ARIGA, H				NEGISHI, Y; NISHITA, Y; SAEGUSA, Y; KAKIZAKI, I; GALLI, I; KIHARA, F; TAMAI, K; MIYAJIMA, N; IGUCHIARIGA, SMM; ARIGA, H			IDENTIFICATION AND CDNA CLONING OF SINGLE-STRANDED-DNA BINDING-PROTEINS THAT INTERACT WITH THE REGION UPSTREAM OF THE HUMAN C-MYC GENE	ONCOGENE			English	Article							TRANSCRIPTIONAL ENHANCER; SACCHAROMYCES-CEREVISIAE; GEL-ELECTROPHORESIS; REPLICATION ORIGIN; MESSENGER-RNA; SEQUENCES; PROMOTER; ELEMENT; NUCLEAR; INITIATION	We have previously reported that a c-myc protein complex binds to the region upstream of the c-myc gene, where exist an origin of cellular DNA replication (ori) and a transcriptional enhancer. Both functions require a 21 bp long sequence, while the c-myc protein complex recognizes a 7 bp consensus therein. It was recently reported that single-stranded DNA binding proteins bound specifically to sequences that play roles in DNA replication or transcription. We examined for proteins binding to the single-stranded DNAs of the 21 bp element (myc(H-P)21). In a band shift assay with HL60 cells nuclear extract, probes of either the plus strand or the minus strand gave rise to specific signals. Mutation introduced within a short consensus (A/(T)CT(A)/T(A)/(T)T) present in both strands completely abolished binding in either case. Southwestern blotting analysis showed that proteins of molecular weight 105, 80, 50, 45, 40, 39.5 and 14 kDa bound sequence-specifically to either strand and 22 kDa to minus strand to the cognate A/(T)CT(A)/(T)A/(T)T consensus. These single-stranded DNA binding proteins were named MSSP, c-myc gene single strand binding proteins. We attempted to isolate the cDNAs encoding these proteins by screening a human cDNA library with the plus single-stranded oligonucleotide as a probe. Among several positive clones, we have characterized one, termed MSSP-1. MSSP-1 produced in E. coli as a fusion protein with GST specifically interacted with single-stranded TCTTAT (plus myc(H-P)21) and ACT-ATT (in minus myc(H-P)21), the consensus of which can be referred to as A/(T)CT(A)/T(A)/(T)T. Sequence analysis of MSSP-1 cDNA revealed that two domains thereof are homologous to the RNA binding motifs common to several ribonucleoproteins. Interestingly, the MSSP-1/GST fusion protein specifically recognized myc(H-P)21 not only in single-stranded but also in double-stranded forms. Binding properties of MSSP-1 imply its functions in DNA replication. Furthermore, when the AT stretch in the SV40 ori core was substituted by TCTTAT, MSSP-1 promoted viral DNA replication depending on the consensus sequences.	HOKKAIDO UNIV,FAC PHARMACEUT SCI,KITA 12 NISHI 6,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; MBL CO LTD,INA LABS,INA 396,JAPAN; INST PHYS & CHEM RES,TSUKUBA,IBARAKI 305,JAPAN; HOKKAIDO UNIV,COLL MED TECHNOL,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University; RIKEN; Hokkaido University			Kakizaki, Ikuko/AAO-5489-2020; Tamai, Katsuyuki/F-4743-2013; Ariga, Hiroyoshi/B-5895-2013	Kakizaki, Ikuko/0000-0002-6702-5830; Tamai, Katsuyuki/0000-0003-4094-3911; Ariga, Hiroyoshi/0000-0001-7384-2143				ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; BRUNEL F, 1991, NUCLEIC ACIDS RES, V19, P5237, DOI 10.1093/nar/19.19.5237; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; FINOCCHIARO LME, 1991, NUCLEIC ACIDS RES, V19, P4279, DOI 10.1093/nar/19.15.4279; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6501; GAILLARD C, 1990, J MOL BIOL, V215, P245, DOI 10.1016/S0022-2836(05)80343-2; GALLI I, 1992, NUCLEIC ACIDS RES, V20, P3333, DOI 10.1093/nar/20.13.3333; GALLI I, 1993, FEBS LETT, V318, P335, DOI 10.1016/0014-5793(93)80541-2; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4471; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOFFMANN J, 1991, CELL, V64, P951; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KITAURA H, 1991, FEBS LETT, V289, P1; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; KUMANO M, 1992, FEBS LETT, V309, P146, DOI 10.1016/0014-5793(92)81083-X; KUNO K, 1990, GENE, V95, P73, DOI 10.1016/0378-1119(90)90415-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MCWHINNEY C, 1990, NUCLEIC ACIDS RES, V18, P1233, DOI 10.1093/nar/18.5.1233; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MUKHERJEE R, 1990, NUCLEIC ACIDS RES, V18, P5713, DOI 10.1093/nar/18.19.5713; NEGISHI Y, 1992, ONCOGENE, V7, P543; PAN WT, 1990, J BIOL CHEM, V265, P7022; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; SIERAKOWSKA H, 1986, NUCLEIC ACIDS RES, V14, P5241, DOI 10.1093/nar/14.13.5241; SINGH H, 1988, CELL, V52, P514; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SWANSON MS, 1988, EMBO J, V11, P3519; TOMILIN NV, 1990, FEBS LETT, V263, P69, DOI 10.1016/0014-5793(90)80707-P; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; YEE HA, 1991, NUCLEIC ACIDS RES, V19, P949, DOI 10.1093/nar/19.4.949	49	58	60	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1133	1143						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134115				2022-12-25	WOS:A1994NC04800016
J	UDOVICHENKO, IP; CUNNICK, J; GONZALEZ, K; TAKEMOTO, DJ				UDOVICHENKO, IP; CUNNICK, J; GONZALEZ, K; TAKEMOTO, DJ			FUNCTIONAL EFFECT OF PHOSPHORYLATION OF THE PHOTORECEPTOR PHOSPHODIESTERASE INHIBITORY SUBUNIT BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; LIGHT-MEDIATED BREAKDOWN; AMINO-ACID SEQUENCE; CGMP PHOSPHODIESTERASE; GAMMA-SUBUNIT; INOSITOL TRISPHOSPHATE; GMP PHOSPHODIESTERASE; SYNTHETIC PEPTIDES; VISUAL EXCITATION	In rod outer segments the light activation of cGMP phosphodiesterase (PDEalphabetagamma2) is accomplished by removal of the gamma inhibitory subunit (PDEgamma) from the PDEalphabeta catalytic subunits. A light activation of the inositol signaling pathway also occurs, but there is little information linking these two signal transduction pathways. Here we report that protein kinase C (PKC) purified from bovine rod outer segment phosphorylates the bovine PDEgamma with incorporation of 0.9 +/- 0.1 mol of phosphate/mol of PDEgamma. Phosphorylation of PDEgamma increases its ability to inhibit PDEalphabeta catalytic activity (trypsin-activated PDE, tPDE) with an IC50 for phosphorylated PDEgamma of 26 +/- 4 pM and an IC50 of 60 +/- 5 pM for unphosphorylated PDEgamma. Inhibition of tPDE by PDEgamma is characterized by two values of K(d), K(d1) = 34 pm and K(d2) = 760 pM. Phosphorylation of PDEgamma by PKC eliminates the functional heterogeneity of the PDEgamma population resulting in a single value of K(d) = 23 pM. Free PDEgamma (without PDEalphabeta catalytic subunits) is a better substrate for PKC than PDEgamma in a complex with PDEalphabeta. Phosphorylation of free PDEgamma by PKC is characterized by a value of V(max) = 1,550 +/- 148 units/mg (K(m) = 21.0 +/- 1.9 muM). In contrast, phosphorylation of PDEgamma in PDEalphabetagamma2 complex has two values of V(max), V(max1) = 0.3 +/- 0.1 units/mg of PDEgamma (K(m1) = 0.4 +/- 0.2 muM) and V(max2) = 0.7 +/- 0.2 units/mg of PDEgamma (K(m2) = 4.6 +/- 0.9 muM). ROS PKC phosphorylates Thr35 in PDEgamma. We have previously reported (Morrison, D. F., Rider, M. A., and Takemoto, D. J. (1987) FEBS Lett. 222, 266-270; Lipkin, V. M., Udovichenko, I. P., Bodarenko, V. A., Yurovskaya, A. A., Telnykh, E. V., and Skiba, N. P. (1990) Biomed. Sci. (Lond.) 1, 305-308) that the central fragment of PDEgamma (24-45) is responsible for binding to PDE catalytic subunits. The new data suggests that this region of PDEgamma also includes the site for phosphorylation by PKC and that phosphorylation increases the ability of PDEgamma to inhibit PDE catalytic activity. This altered regulation of visual transduction may play a role in desensitization or light adaptation.	KANSAS STATE UNIV AGR & APPL SCI, DEPT BIOCHEM, WILLARD HALL, MANHATTAN, KS 66506 USA	Kansas State University			Cunnick, Jess/F-1715-2018		NCI NIH HHS [CA-09418] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009418] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BINDER BM, 1989, J BIOL CHEM, V264, P8857; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JE, 1984, NATURE, V311, P160, DOI 10.1038/311160a0; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAS ND, 1987, CELL STRUCT FUNCT, V12, P471, DOI 10.1247/csf.12.471; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; GEHM BD, 1990, BIOCHEMISTRY-US, V29, P5447, DOI 10.1021/bi00475a006; GHALAYINI A, 1984, BIOCHEM BIOPH RES CO, V124, P503, DOI 10.1016/0006-291X(84)91582-1; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GORMAN JJ, 1984, ANAL BIOCHEM, V136, P397, DOI 10.1016/0003-2697(84)90235-5; HANSEN RS, 1988, METHOD ENZYMOL, V159, P543; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4333, DOI 10.1073/pnas.88.10.4333; HAYASHI F, 1985, BIOCHEM BIOPH RES CO, V128, P954, DOI 10.1016/0006-291X(85)90139-1; HUANG KP, 1986, J BIOL CHEM, V261, P2134; KAPOOR CL, 1984, BIOCHEM BIOPH RES CO, V122, P1397, DOI 10.1016/0006-291X(84)91246-4; KELLEHER DJ, 1985, J CYCLIC NUCL PROT, V10, P579; KELLEHER DJ, 1986, J BIOL CHEM, V261, P4749; KINCAID RL, 1988, METHOD ENZYMOL, V159, P457; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lipkin V M, 1990, Biomed Sci, V1, P305; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; MORRISON DF, 1987, FEBS LETT, V222, P266, DOI 10.1016/0014-5793(87)80383-6; NEWTON AC, 1991, J BIOL CHEM, V266, P17725; NEWTON AC, 1993, TRENDS BIOCHEM SCI, V18, P275, DOI 10.1016/0968-0004(93)90032-I; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEGEL MR, 1961, THEORY PROBLEMS STAT; STRYER L, 1991, J BIOL CHEM, V266, P10711; SZUTS EZ, 1986, BIOCHEM J, V240, P929, DOI 10.1042/bj2400929; TUTEJA N, 1990, GENE, V88, P227, DOI 10.1016/0378-1119(90)90035-P; TUTEJA N, 1988, FEBS LETT, V232, P182, DOI 10.1016/0014-5793(88)80413-7; UDOVICHENKO IP, 1993, BIOCHEM J, V295, P49, DOI 10.1042/bj2950049; UDOVICHENKO IP, 1993, INVEST OPHTH VIS SCI, V34, P1325; WEYAND I, 1990, EUR J BIOCHEM, V193, P459, DOI 10.1111/j.1432-1033.1990.tb19360.x; WHALEN MM, 1989, BIOCHEM J, V259, P13, DOI 10.1042/bj2590013; WILDEN U, 1986, FEBS LETT, V207, P292, DOI 10.1016/0014-5793(86)81507-1; Williams LT, 1978, RECEPTOR BINDING STU; WITT JJ, 1975, ANAL BIOCHEM, V66, P253, DOI 10.1016/0003-2697(75)90743-5; WOLBRING G, 1991, EUR J BIOCHEM, V201, P601, DOI 10.1111/j.1432-1033.1991.tb16320.x	47	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9850	9856						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144577				2022-12-25	WOS:A1994NE05300071
J	LEITINGER, B; BROWN, JL; SPIESS, M				LEITINGER, B; BROWN, JL; SPIESS, M			TAGGING SECRETORY AND MEMBRANE-PROTEINS WITH A TYROSINE SULFATION SITE - TYROSINE SULFATION PRECEDES GALACTOSYLATION AND SIALYLATION IN COS-7 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI-APPARATUS; TYROSYLPROTEIN SULFOTRANSFERASE; ALPHA-1-PROTEINASE INHIBITOR; HELA-CELLS; TRANSPORT; SURFACE; GALACTOSYLTRANSFERASE; GLYCOSYLATION; EXPRESSION; PATHWAYS	Sulfation of proteins on tyrosines is a late Golgi modification that can be used to label proteins with [S-35]sulfate for the analysis of post-Golgi transport. To extend the use of this modification to proteins not naturally sulfated, we fused a tyrosine sulfation site, the carboxyl-terminal nonapeptide of cholecystokinin precursor, to the carboxyl terminus of two normally unsulfated proteins: alpha(1)-proteinase inhibitor, a secretory protein, and subunit H1 of the asialoglycoprotein receptor, a type II membrane protein. The tagged proteins were efficiently sulfated in transfected COS-7 and Madin-Darby canine kidney cells. Specifically in COS-7 cells, the proteins were sulfated before they were galactosylated and sialylated and were converted to the mature forms with a half-time of approximately 2-3 min. This is in contrast to other cell types in which tyrosine sulfation was found to be virtually the last modification of the Golgi apparatus. Our results suggest that tyrosine sulfation occurs before the trans-Golgi in transfected COS-7 cells.	UNIV BASEL,BIOZENTRUM,DEPT BIOCHEM,CH-4056 BASEL,SWITZERLAND; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262	University of Basel; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Spiess, Martin/0000-0001-7139-0550				ADRIAN TE, 1986, FEBS LETT, V196, P5, DOI 10.1016/0014-5793(86)80203-4; ARATANI Y, 1988, FEBS LETT, V235, P129, DOI 10.1016/0014-5793(88)81247-X; BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BRANTLY M, 1988, AM J MED, V84, P13; BRODBECK RM, 1992, J BIOL CHEM, V267, P294; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DUNPHY WG, 1983, J CELL BIOL, V97, P270, DOI 10.1083/jcb.97.1.270; DUNPHY WG, 1981, P NATL ACAD SCI-BIOL, V78, P7453, DOI 10.1073/pnas.78.12.7453; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FRIEDERICH E, 1988, J CELL BIOL, V107, P1655, DOI 10.1083/jcb.107.5.1655; GEFFEN I, 1992, INT REV CYTOL, V137B, P181; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; GRIMES M, 1992, J CELL BIOL, V117, P539, DOI 10.1083/jcb.117.3.539; HORTIN G, 1986, BIOCHEM BIOPH RES CO, V141, P326, DOI 10.1016/S0006-291X(86)80372-2; HUTTNER WB, 1984, METHOD ENZYMOL, V107, P200; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MEGA T, 1980, J BIOL CHEM, V255, P4057; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; NIEHRS C, 1992, J BIOL CHEM, V267, P15938; NIEHRS C, 1990, J BIOL CHEM, V265, P8525; NIEHRS C, 1990, J BIOL CHEM, V265, P9314; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; ROSA P, 1992, J BIOL CHEM, V267, P1227; ROSENQUIST GL, 1993, PROTEIN SCI, V2, P215; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SLOT JW, 1983, J HISTOCHEM CYTOCHEM, V31, P1049, DOI 10.1177/31.8.6863900; SPIESS M, 1985, J BIOL CHEM, V260, P1979; STROUS GJ, 1983, J CELL BIOL, V97, P723, DOI 10.1083/jcb.97.3.723; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X	35	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8115	8121						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132536				2022-12-25	WOS:A1994NB40900045
J	LIPPUNER, V; CHOUS, IT; SCOTT, SV; ETTINGER, WF; THEG, SM; GASSER, CS				LIPPUNER, V; CHOUS, IT; SCOTT, SV; ETTINGER, WF; THEG, SM; GASSER, CS			CLONING AND CHARACTERIZATION OF CHLOROPLAST AND CYTOSOLIC FORMS OF CYCLOPHILIN FROM ARABIDOPSIS-THALIANA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASE; BINDING PROTEIN CYCLOPHILIN; ESCHERICHIA-COLI; CYCLOSPORINE-A; ENDOPLASMIC-RETICULUM; PEPTIDYLPROLYL-CIS; PROLYL ISOMERASE; GENE; DNA; EXPRESSION	Cyclophilin (CyP), a protein with peptidyl-prolyl cistrans isomerase (rotamase) activity, is the specific cellular target of cyclosporin A, We have isolated cDNA clones of two genes (designated ROC1 and ROC4) encoding CyP homologs from Arabidopsis thaliana (L.). The protein products of these genes are distinct from a previously identified Arabidopsis CyP. ROC1 is expressed in all tested plant organs and encodes a protein which is highly similar to previously described cytosolic CyP isoforms of other plants. In contrast, ROC4 is expressed only in photosynthetic organs and encodes a protein which includes an amino-terminal extension with properties of known chloroplast transit peptides. In vitro import experiments using the putative precursor protein to ROC4 showed that the protein is imported into chloroplasts where it is processed to the predicted mature size. Rotamase assays and immunoblot analysis of subcellular fractions indicate the presence of a CyP isoform in the stroma of chloroplasts but not in the thylakoid membranes or thylakoid lumen. Together, these data show that ROC4 is a novel CyP isoform which is located in the stroma of chloroplasts. In vitro chloroplast import of precursors of other chloroplast proteins was unaffected by concentrations of cyclosporin A which completely inhibit rotamase activity of chloroplast stromal CyP. Thus, this activity is not essential for protein import into chloroplasts.	UNIV CALIF DAVIS,DIV BIOL SCI,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616; UNIV CALIF DAVIS,DIV BIOL SCI,PLANT BIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis; University of California System; University of California Davis				Gasser, Charles/0000-0001-5735-8175	NIGMS NIH HHS [GM07377] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007377] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BACHINGER HP, 1987, J BIOL CHEM, V262, P17144; BARTLING D, 1992, PLANT MOL BIOL, V19, P529, DOI 10.1007/BF00023405; BEERS EP, 1992, J BIOL CHEM, V267, P15432; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; BREIMAN A, 1992, J BIOL CHEM, V267, P21293; CLINE K, 1985, J BIOL CHEM, V260, P3691; CROUSE GF, 1983, METHOD ENZYMOL, V101, P78; DAVIS JM, 1989, J BIOL CHEM, V264, P8956; Davis R., 1980, ADV BACTERIAL GENETI; DELLACIOPPA G, 1988, EMBO J, V7, P1299, DOI 10.1002/j.1460-2075.1988.tb02944.x; ETTINGER WF, 1991, J CELL BIOL, V115, P321, DOI 10.1083/jcb.115.2.321; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOCHIM BIOPHYS ACTA, V791, P87, DOI 10.1016/0167-4838(84)90285-1; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FOOR F, 1992, NATURE, V360, P682; FRIEDMAN J, 1993, P NATL ACAD SCI USA, V90, P6815, DOI 10.1073/pnas.90.14.6815; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GASSER CS, 1989, PLANT CELL, V1, P15, DOI 10.1105/tpc.1.1.15; GASSER CS, 1990, P NATL ACAD SCI USA, V87, P9519, DOI 10.1073/pnas.87.24.9519; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; HAENDLER B, 1989, GENE, V83, P39, DOI 10.1016/0378-1119(89)90401-0; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARLOW D, 1988, ANTIBODIES LABORATOR, P61; HASEL KW, 1991, MOL CELL BIOL, V11, P3484, DOI 10.1128/MCB.11.7.3484; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; HERRLER M, 1992, FEBS LETT, V309, P231, DOI 10.1016/0014-5793(92)80779-G; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; Kranz A. R., 1987, ARABIDOPSIS INF SERV, V24; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MARIVET J, 1992, PLANT SCI, V84, P171, DOI 10.1016/0168-9452(92)90131-5; MEYEROWITZ EM, 1989, CELL, V56, P263, DOI 10.1016/0092-8674(89)90900-8; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID FX, 1978, P NATL ACAD SCI USA, V75, P4764, DOI 10.1073/pnas.75.10.4764; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; THEG SM, 1989, J BIOL CHEM, V264, P6730; Theg Steven M., 1993, Trends in Cell Biology, V3, P186, DOI 10.1016/0962-8924(93)90212-J; TITUS DE, 1991, PROMEGA PROTOCOLS AP, P59; TROPSCHUG M, 1988, J BIOL CHEM, V263, P14433; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; WALSH CT, 1992, J BIOL CHEM, V267, P13115	56	127	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7863	7868						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132503				2022-12-25	WOS:A1994NB40900008
J	YORK, JD; MAJERUS, PW				YORK, JD; MAJERUS, PW			NUCLEAR PHOSPHATIDYLINOSITOLS DECREASE DURING S-PHASE OF THE CELL-CYCLE IN HELA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SWISS 3T3 CELLS; INOSITOL POLYPHOSPHATE 1-PHOSPHATASE; GROWTH FACTOR-I; PHOSPHOLIPASE-C; PORE COMPLEX; DNA; DIACYLGLYCEROL; INHIBITION; MEMBRANE; KINASE	In the current study we have measured phosphatidylinositols during the cell cycle. HeLa cells were labeled with [H-3]myoinositol to a steady state, synchronized to the G1/S boundary, and the levels of phosphatidylinositol (PtdIns) lipids were measured at various times after release from the block. The levels of total cellular PtdIns, PtdIns(4)P, and PtdIns(4,5)P-2 relative to total cellular phospholipid did not vary throughout the cell cycle. We then isolated nuclei from synchronized cells using a non detergent method and found that the levels of nuclear PtdIns lipids decreased by over 50% at 2 and 4 h after release from the G1/S boundary (S-phase of the cell cycle) and returned to the original levels by 9 h. Separation of individual inositol containing nuclear lipids showed that PtdIns decreased by 50% while levels of PtdIns(4)P and PtdIns(4,B)P-2 decreased by 66%. Levels of the cytoplasmic PtdIns lipids remained constant throughout this period, This experiment indicates that there is specific nuclear PtdIns turnover that is activated during DNA synthesis.			YORK, JD (corresponding author), WASHINGTON UNIV, SCH MED, DIV HEMATOL ONCOL, ST LOUIS, MO 63110 USA.				NHGRI NIH HHS [HG 00304] Funding Source: Medline; NHLBI NIH HHS [HL 14147, HL 16634] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R37HL016634, R01HL016634] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000304] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AMES BN, 1960, J BIOL CHEM, V235, P769; BUNCE CM, 1988, ANAL BIOCHEM, V175, P67, DOI 10.1016/0003-2697(88)90362-4; COCCO L, 1989, BIOCHEM BIOPH RES CO, V159, P720, DOI 10.1016/0006-291X(89)90054-5; COCCO L, 1988, BIOCHEM BIOPH RES CO, V154, P1266, DOI 10.1016/0006-291X(88)90276-8; COCCO L, 1987, BIOCHEM J, V248, P765, DOI 10.1042/bj2480765; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DIVECHA N, 1993, BIOCHEM J, V289, P617, DOI 10.1042/bj2890617; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; FLEISCHMAN LF, 1988, AM J PHYSIOL, V255, pC531, DOI 10.1152/ajpcell.1988.255.4.C531; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GURR MI, 1963, BIOCHIM BIOPHYS ACTA, V70, P400; HOY CA, 1989, CYTOMETRY, V10, P718, DOI 10.1002/cyto.990100608; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; INHORN RC, 1988, J BIOL CHEM, V263, P14559; INHORN RC, 1987, J BIOL CHEM, V262, P15946; KAUFMANN SH, 1981, EXP CELL RES, V132, P105, DOI 10.1016/0014-4827(81)90088-4; KURIKI H, 1992, J BIOCHEM-TOKYO, V111, P283, DOI 10.1093/oxfordjournals.jbchem.a123750; MAJERUS PW, 1985, TRENDS BIOCHEM SCI, V10, P168, DOI 10.1016/0968-0004(85)90160-4; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MANZOLI FA, 1989, ADV ENZYME REGUL, V28, P25, DOI 10.1016/0065-2571(89)90061-7; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MARTELLI AM, 1994, IN PRESS EMBO J; NEUFELD EJ, 1985, J CELL BIOL, V101, P573, DOI 10.1083/jcb.101.2.573; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SMITH CD, 1983, J BIOL CHEM, V258, P9368; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SMITH MR, 1989, P NATL ACAD SCI USA, V86, P3659, DOI 10.1073/pnas.86.10.3659; SYLVIA V, 1988, CELL, V54, P651, DOI 10.1016/S0092-8674(88)80009-6	30	118	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7847	7850						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132500				2022-12-25	WOS:A1994NB40900004
J	ALBARRACIN, CT; PALFREY, HC; DUAN, WR; RAO, MC; GIBORI, G				ALBARRACIN, CT; PALFREY, HC; DUAN, WR; RAO, MC; GIBORI, G			PROLACTIN REGULATION OF THE CALMODULIN-DEPENDENT PROTEIN-KINASE-III ELONGATION FACTOR-II SYSTEM IN THE RAT CORPUS-LUTEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-CHAIN ELONGATION; MR 100,000 SUBSTRATE; PC12 CELLS; PHOSPHORYLATION; ESTRADIOL; RECEPTOR; PROGESTERONE; ESTROGEN; PSEUDOPREGNANCY; IDENTIFICATION	AM(r) 100,000 phosphoprotein in the corpus luteum was identified as elongation factor 2 (EF-2). Since prolactin (PRL) is necessary for optimal luteal development and protein synthesis, we determined whether this hormone affects the content and/or phosphorylation of EF-2 in the corpus luteum. PRL treatment enhanced the Ca2+/calmodulin (CaM) dependent phosphorylation of endogenous EF-2 in luteal cytoplasmic extracts. Immunoblot analysis revealed that PRL had no effect on EF-2 levels, but examination of luteal EF-2 by two dimensional isoelectric focusing/SDS-polyacrylamide gel electrophoresis showed that PRL increased the relative amount of the most basic dephosphorylated forms of EF-2. This suggests that PRL induces net dephosphorylation of the protein in vivo. Since EF-2 phosphorylation is regulated by both Ca2+/CaM-dependent kinase III (CaM kinase III) and protein phosphatase 2A, we examined the effect of PRL on both enzymes. Paradoxically, PRL enhanced the in vitro activity of CaM kinase III, possibly reflecting increased kinase levels, but had no effect on phosphatase activity. These results suggest that PRL maintains luteal EF-2 in a relatively dephosphorylated state in vivo by limiting the availability of Ca2+ and/or CaM to CaM kinase III. These data provide strong evidence for a role of the EF-2/CaM kinase III system in PRL action in the corpus luteum.	UNIV ILLINOIS, DEPT PHYSIOL & BIOPHYS, CHICAGO, IL 60612 USA; UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago					NICHD NIH HHS [HD-11119] Funding Source: Medline; NIGMS NIH HHS [GM-42715] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD011119, R37HD011119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042715] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBARRACIN CT, 1991, ENDOCRINOLOGY, V129, P1821, DOI 10.1210/endo-129-4-1821; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; ARMSTRON.DT, 1970, ENDOCRINOLOGY, V86, P634, DOI 10.1210/endo-86-3-634; ARMSTRON.DT, 1969, ENDOCRINOLOGY, V85, P393, DOI 10.1210/endo-85-3-393; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADY MJ, 1990, J NEUROCHEM, V54, P1034, DOI 10.1111/j.1471-4159.1990.tb02354.x; BRANTLEY KM, 1990, J STEROID BIOCHEM, V35, P367, DOI 10.1016/0022-4731(90)90242-K; DOHLER KD, 1974, ENDOCRINOLOGY, V94, P1595; GEHRKE L, 1981, J BIOL CHEM, V256, P2514; GIBORI G, 1988, RECENT PROG HORM RES, V44, P377; GIBORI G, 1977, ENDOCRINOLOGY, V100, P1483, DOI 10.1210/endo-100-6-1483; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; ILAN J, 1984, P NATL ACAD SCI-BIOL, V81, P1366, DOI 10.1073/pnas.81.5.1366; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KRASNOW JS, 1990, MOL ENDOCRINOL, V4, P13, DOI 10.1210/mend-4-1-13; MACKIE KP, 1989, J BIOL CHEM, V264, P1748; MCKERNS KW, 1977, BIOCHIM BIOPHYS ACTA, V478, P68, DOI 10.1016/0005-2787(77)90244-1; MITSUI K, 1993, J BIOL CHEM, V268, P13422; NAIRN AC, 1985, P NATL ACAD SCI USA, V82, P7939, DOI 10.1073/pnas.82.23.7939; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; NAIRN AC, 1987, J BIOL CHEM, V262, P14265; NYGARD O, 1991, J BIOL CHEM, V266, P16425; PALFREY HC, 1987, J BIOL CHEM, V262, P9785; PARMER TG, 1993, JJUN ANN M END SOC L; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; RAO MC, 1987, ENDOCRINOLOGY, V120, P1010, DOI 10.1210/endo-120-3-1010; REDPATH NT, 1993, EUR J BIOCHEM, V212, P511, DOI 10.1111/j.1432-1033.1993.tb17688.x; REDPATH NT, 1989, BIOCHEM J, V262, P69, DOI 10.1042/bj2620069; RILLEMA JA, 1992, ENDOCRINOLOGY, V131, P973, DOI 10.1210/en.131.2.973; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; SANCHEZCRIADO JE, 1988, J ENDOCRINOL, V117, P455, DOI 10.1677/joe.0.1170455; SMITH MS, 1976, ENDOCRINOLOGY, V98, P1370, DOI 10.1210/endo-98-6-1370; STEINSCHNEIDER A, 1991, ENDOCRINOLOGY, V128, P263, DOI 10.1210/endo-128-1-263; VENKITARAMAN AR, 1992, P NATL ACAD SCI USA, V89, P12083, DOI 10.1073/pnas.89.24.12083; WHELLY SM, 1974, BIOCHEMISTRY-US, V13, P341, DOI 10.1021/bi00699a019; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	38	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7772	7776						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8126003				2022-12-25	WOS:A1994NA03200113
J	NAKAHARA, DH; LINGAPPA, VR; CHUCK, SL				NAKAHARA, DH; LINGAPPA, VR; CHUCK, SL			TRANSLOCATIONAL PAUSING IS A COMMON STEP IN THE BIOGENESIS OF UNCONVENTIONAL INTEGRAL MEMBRANE AND SECRETORY PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; PRION PROTEIN; APOLIPOPROTEIN-B; TRANSMEMBRANE ORIENTATION; TOPOGENIC SEQUENCE; STOP TRANSFER; ER MEMBRANE; PRE-GOLGI; DEGRADATION; TRANSLATION	Signal, stop transfer, and signal-anchor sequences direct a nascent polypeptide to a single topology with respect to the membrane of the endoplasmic reticulum. However, other types of sequences direct nascent proteins, either transiently or permanently, to more than one topologic form. Pause transfer sequences direct nascent apolipoprotein B to pause during its translocation, resulting in nonintegrated, transmembrane intermediates that become fully translocated over time. The stop transfer effector sequence (STE) directs the nascent prion protein either to integrate at the hydrophobic domain which immediately follows (TM1) or to become fully translocated, in a manner dependent on cytosolic factors. Although the action of pause transfer sequences has been dissected into stop and restart steps, the mechanism of STE action is unknown. Using chimeric proteins expressed in vitro, we show that STE, inde- pendent of TM1, acts as a pause transfer sequence. We also demonstrate that translocational pausing at STE is a common step preceding either complete translocation or integration into the membrane of a chimeric protein containing STE and TM1. These findings have implications for the role of pausing in the biogenesis of both secretory and membrane proteins.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,BIOMED SCI GRAD PROGRAM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Lingappa, Vishwanath R./0000-0003-0962-6571	NIA NIH HHS [AG02132] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG002132] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CHUCK SL, 1993, J BIOL CHEM, V268, P22794; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; HAY B, 1987, BIOCHEMISTRY-US, V26, P8110, DOI 10.1021/bi00399a014; HAY B, 1987, MOL CELL BIOL, V7, P914, DOI 10.1128/MCB.7.2.914; KANG HS, 1991, J BIOL CHEM, V266, P5643; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; PERARA E, 1985, J CELL BIOL, V101, P2292, DOI 10.1083/jcb.101.6.2292; PERARA E, 1988, PROTEIN TRANSFER ORG, P3; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; REDMAN CM, 1966, P NATL ACAD SCI USA, V56, P608, DOI 10.1073/pnas.56.2.608; SATO R, 1990, J BIOL CHEM, V265, P11880; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1960, DOI 10.1073/pnas.84.7.1960; SIUTAMANGANO P, 1981, J BIOL CHEM, V256, P2094; SKACH WR, 1993, MECH INTRACELLULAR T, P19; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; YOST CS, 1983, CELL, V34, P759; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	29	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7617	7622						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125986				2022-12-25	WOS:A1994NA03200092
J	INOKUCHI, Y; YUYAMA, N; HIRASHIMA, A; NISHIKAWA, S; OHKAWA, J; TAIRA, K				INOKUCHI, Y; YUYAMA, N; HIRASHIMA, A; NISHIKAWA, S; OHKAWA, J; TAIRA, K			A HAMMERHEAD RIBOZYME INHIBITS THE PROLIFERATION OF AN RNA COLIPHAGE SP IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-Q-BETA; SELF-CLEAVAGE; IMMUNE-SYSTEM; TRIMMING PLASMID; VIRAL-INFECTION; EXPRESSION; SEQUENCE; PROTEIN; COMPLEMENTARY; CONSTRUCTION	Ribozymes are potentially powerful tools for the suppression of intracellular gene expression. However, the few reports that exist of their activities in bacteria have described mixed success. Chuat and Galibert (Chuat, J.- C., and Galibert, F. (1989) Biochem. Biophys. Res. Commun. 162, 1025-1029) failed to detect any trans-activities of hammerhead ribozymes in Escherichia coli, while Sioud and Drlica (Sioud, M., and Drlica, K. (1991) Proc. Natl. Acad. Sci. U. S. A. 88,7303-7307) reported complete inhibition of expression of the gene for a nonbacterial protein, HIV-1 integrase, by trans-acting hammerhead ribozymes in E. coli. It is of interest to determine whether ribozymes can really be used in natural bacterial systems (Altman, S. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10898-10900). We now report that a ribozyme designed to cleave the A2 gene of RNA coliphage SP, when transcribed from a plasmid in E. coli caused failure of the proliferation of progeny phage. Inactive ribozymes with altered catalytic sequences did not affect phage growth. These results indicate that it is mainly the catalytic activity of the ribozyme and not its function as an antisense molecule that is responsible for suppressing the proliferation of the RNA phage. Moreover, an analysis based on numbers of plaque-forming units and the function of the A2 protein indicated that antisense RNA may successfully compete with ribosomes in targeting mRNA while ribozymes in this study may not compete with ribosomes in naturally occurring bacterial transcription/translation-coupled systems.	IBARAKI UNIV, FAC AGR, AMI, IBARAKI 30003, JAPAN; TEIKYO UNIV, DEPT BIOSCI, UTSUNOMIYA 320, JAPAN; YAKULT CENT INST MICROBIOL RES, TOKYO 186, JAPAN; MINIST INT TRADE & IND, IND SCI & TECHNOL AGCY, NATL INST BIOSCI & HUMAN TECHNOL, TSUKUBA 305, JAPAN	Ibaraki University; Teikyo University; Yakult Honsha Company, Limited; National Institute of Advanced Industrial Science & Technology (AIST)								ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; ALTMAN S, 1993, P NATL ACAD SCI USA, V90, P10898, DOI 10.1073/pnas.90.23.10898; BUZAYAN JM, 1986, P NATL ACAD SCI USA, V83, P8859, DOI 10.1073/pnas.83.23.8859; CECH TR, 1990, ANGEW CHEM INT EDIT, V29, P759, DOI 10.1002/anie.199007591; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUAT JC, 1989, BIOCHEM BIOPH RES CO, V162, P1025, DOI 10.1016/0006-291X(89)90776-6; COLEMAN J, 1985, NATURE, V315, P601, DOI 10.1038/315601a0; COLEMAN J, 1984, CELL, V37, P429, DOI 10.1016/0092-8674(84)90373-8; DROPULIC B, 1992, J VIROL, V66, P1432; ENDO Y, 1990, J BIOL CHEM, V265, P2216; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ERICKSON RP, 1992, GENE REGULATION BIOL; FEDOR MJ, 1992, BIOCHEMISTRY-US, V31, P12042, DOI 10.1021/bi00163a012; FORSTER AC, 1987, CELL, V50, P9, DOI 10.1016/0092-8674(87)90657-X; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HIRASHIMA A, 1986, P NATL ACAD SCI USA, V83, P7726, DOI 10.1073/pnas.83.20.7726; HIRASHIMA A, 1989, J BIOCHEM-TOKYO, V106, P163; HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627; INOKUCHI Y, 1988, NUCLEIC ACIDS RES, V16, P6205, DOI 10.1093/nar/16.13.6205; KARNIK S, 1983, EMBO J, V2, P1521, DOI 10.1002/j.1460-2075.1983.tb01617.x; KOIZUMI M, 1988, FEBS LETT, V228, P228, DOI 10.1016/0014-5793(88)80004-8; MORI H, 1978, J BIOCHEM, V84, P681, DOI 10.1093/oxfordjournals.jbchem.a132173; MURRAY JAH, 1992, ANTISENSE RNA DNA; NISHIKAWA S, 1991, FUNDAMENTAL INVESTIG, P109; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; OHKAWA J, 1993, P NATL ACAD SCI USA, V90, P11302, DOI 10.1073/pnas.90.23.11302; Parker R., 1992, Gene regulation: biology of antisense RNA and DNA., P55; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; PRODY GA, 1986, SCIENCE, V231, P1577, DOI 10.1126/science.231.4745.1577; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SAXENA SK, 1990, J BIOL CHEM, V265, P17106; SHIMAYAMA T, 1993, NUCLEIC ACIDS RES, V21, P2605, DOI 10.1093/nar/21.11.2605; SIOUD M, 1991, P NATL ACAD SCI USA, V88, P7303, DOI 10.1073/pnas.88.16.7303; SYMONS RH, 1989, TRENDS BIOCHEM SCI, V14, P445, DOI 10.1016/0968-0004(89)90103-5; Taira K., 1992, Gene regulation: biology of antisense RNA and DNA., P35; TAIRA K, 1991, NUCLEIC ACIDS RES, V19, P5125, DOI 10.1093/nar/19.19.5125; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; van Duin J., 1988, BACTERIOPHAGES, P117, DOI [10.1007/978-1-4684-5424-6_4, DOI 10.1007/978-1-4684-5424-6_4]; WEERASINGHE M, 1991, J VIROL, V65, P5531, DOI 10.1128/JVI.65.10.5531-5534.1991; WINTER RB, 1983, CELL, V33, P877, DOI 10.1016/0092-8674(83)90030-2; YUYAMA N, 1992, BIOCHEM BIOPH RES CO, V186, P1271, DOI 10.1016/S0006-291X(05)81543-8	44	28	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11361	11366						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157667				2022-12-25	WOS:A1994NF96600059
J	NICKELS, JT; BUXEDA, RJ; CARMAN, GM				NICKELS, JT; BUXEDA, RJ; CARMAN, GM			REGULATION OF PHOSPHATIDYLINOSITOL 4-KINASE FROM THE YEAST SACCHAROMYCES-CEREVISIAE BY CDP-DIACYLGLYCEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+-ATPASE; PHOSPHOLIPID BIOSYNTHESIS; PLASMA-MEMBRANE; SYNTHASE ACTIVITY; KINETIC-ANALYSIS; MIXED MICELLES; MYO-INOSITOL-1-PHOSPHATE SYNTHASE; CELL-PROLIFERATION; STRUCTURAL GENE; PURIFICATION	Regulation of the 45- and 55-kDa forms of Saccharomyces cerevisiae membrane-associated phosphatidylinositol (PI) 4-kinase (ATP:phosphatidylinositol 4-phosphotransferase) by phospholipids was examined using Triton X-100/phospholipid-mixed micelles. CDP-diacylglycerol and phosphatidylglycerol inhibited 45-kDa PI 4-kinase activity in a dose-dependent manner. Kinetic analyses of the 45-kDa PI 4-kinase showed that phosphatidylglycerol was a competitive inhibitor with respect to PI (K(i) = 2 mol %), and CDP-diacylglycerol was a mixed type of inhibitor with respect to PI (K(i) = 4 mol %) and MgATP (K(i) = 5 mol %). 55-kDa PI 4-kinase activity was not significantly affected by phospholipids. The physiological relevance of CDP-diacylglycerol inhibition of 45-kDa PI 4-kinase activity was examined using plasma membranes from inositol auxotrophic (ino1) cells. Immunoblot analysis showed that 45-kDa PI 4-kinase expression in plasma membranes was not affected by inositol starvation of ino1 cells. However, both 45-kDa PI 4-kinase activity and its product PI 4-phosphate were reduced in plasma membranes from inositol-starved ino1 cells. The CDP-diacylglycerol concentration (9.6 mol %) in plasma membranes of inositol-starved ino1 cells was 12-fold higher than its concentration (0.8 mol %) in plasma membranes of inositol-supplemented cells. Plasma membranes of inositol-starved ino1 cells also had increased levels of phosphatidate, phosphatidylserine, phosphatidylethanolamine, and cardiolipin. However, these phospholipids did not affect pure 45-kDa PI 4-kinase activity. The concentration of CDP-diacylglycerol in plasma membranes of inositol-starved ino1 cells was in the range of the inhibitor constants determined for CDP-diacylglycerol by kinetic analyses using pure 45-kDa PI 4-kinase. These results raised the suggestion that 45-kDa PI 4-kinase activity may be regulated in vivo by CDP-diacylglycerol.	RUTGERS STATE UNIV, COOK COLL, NEW JERSEY AGR EXPT STN, DEPT FOOD SCI, NEW BRUNSWICK, NJ 08903 USA	Rutgers State University New Brunswick					NIGMS NIH HHS [GM-28140, GM-35655] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035655, R01GM028140] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, J BIOL CHEM, V264, P20181; BECKER GW, 1977, J BIOL CHEM, V252, P8684; BELUNIS CJ, 1988, J BIOL CHEM, V263, P18897; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUXEDA RJ, 1993, J BIOL CHEM, V268, P6248; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; CARMAN GM, 1983, CAN J MICROBIOL, V29, P1452, DOI 10.1139/m83-222; CARTER JR, 1966, J LIPID RES, V7, P678; CHANG YY, 1967, J LIPID RES, V8, P447; COLODZIN M, 1965, J BIOL CHEM, V240, P3771; CULBERTSON MR, 1975, GENETICS, V80, P23; DAHL C, 1987, P NATL ACAD SCI USA, V84, P4012, DOI 10.1073/pnas.84.12.4012; DAHL JS, 1985, BIOCHEM BIOPH RES CO, V133, P844, DOI 10.1016/0006-291X(85)91211-2; DEANJOHNSON M, 1989, J BIOL CHEM, V264, P1274; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; Dennis EA, 1983, ENZYMES, P307; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; FLANAGAN CA, 1992, J BIOL CHEM, V267, P24117; GREENBERG ML, 1988, MOL CELL BIOL, V8, P4773, DOI 10.1128/MCB.8.11.4773; HAID A, 1983, METHOD ENZYMOL, V96, P192; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HENRY SA, 1977, J BACTERIOL, V130, P472, DOI 10.1128/JB.130.1.472-484.1977; HJELMSTAD RH, 1991, BIOCHEMISTRY-US, V30, P1731, DOI 10.1021/bi00221a001; HOLLAND KM, 1988, J BACTERIOL, V170, P828, DOI 10.1128/jb.170.2.828-833.1988; HOMANN MJ, 1985, J BACTERIOL, V163, P1265, DOI 10.1128/JB.163.3.1265-1266.1985; JUND R, 1970, J BACTERIOL, V102, P607, DOI 10.1128/JB.102.3.607-615.1970; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; KATO H, 1989, J BIOL CHEM, V264, P3116; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; KINNEY AJ, 1990, J BACTERIOL, V172, P4115, DOI 10.1128/jb.172.7.4115-4117.1990; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KLIG LS, 1988, J BACTERIOL, V170, P1878, DOI 10.1128/jb.170.4.1878-1886.1988; KOLAND JG, 1986, J BIOL CHEM, V261, P5936; KUCHLER K, 1986, J BACTERIOL, V165, P901, DOI 10.1128/jb.165.3.901-910.1986; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESTER RL, 1968, J BIOL CHEM, V243, P4889; LICHTENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285, DOI 10.1016/0304-4157(83)90004-7; LIN YP, 1989, J BIOL CHEM, V264, P8641; MCKENZIE MA, 1982, J FOOD BIOCHEM, V6, P77, DOI 10.1111/j.1745-4514.1982.tb00297.x; MONK BC, 1991, J BACTERIOL, V173, P6826, DOI 10.1128/jb.173.21.6826-6836.1991; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NICKELS JT, 1992, J BIOL CHEM, V267, P16297; PATTON JL, 1992, ARCH BIOCHEM BIOPHYS, V292, P70, DOI 10.1016/0003-9861(92)90052-X; PAULUS H, 1960, J BIOL CHEM, V235, P1303; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; ROBSON RJ, 1983, ACCOUNTS CHEM RES, V16, P251, DOI 10.1021/ar00091a003; Segel IH., 1975, ENZYME KINETICS, P1, DOI 10.1016/0014-5793(75)80457-1; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; STEINER S, 1972, J BACTERIOL, V109, P81, DOI 10.1128/JB.109.1.81-88.1972; TALWALKAR RT, 1973, BIOCHIM BIOPHYS ACTA, V306, P412, DOI 10.1016/0005-2760(73)90180-X; TAMAI KT, 1990, BIOCHIM BIOPHYS ACTA, V1046, P214, DOI 10.1016/0005-2760(90)90192-Z; UNO I, 1988, NATURE, V333, P188, DOI 10.1038/333188a0; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	60	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11018	11024						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157627				2022-12-25	WOS:A1994NF96600011
J	STAPPEN, R; KRAMER, R				STAPPEN, R; KRAMER, R			KINETIC MECHANISM OF PHOSPHATE PHOSPHATE AND PHOSPHATE OH- ANTIPORTS CATALYZED BY RECONSTITUTED PHOSPHATE CARRIER FROM BEEF-HEART MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ASPARTATE GLUTAMATE CARRIER; TRANSPORT PROTEIN; SACCHAROMYCES-CEREVISIAE; INORGANIC-PHOSPHATE; CARNITINE CARRIER; LAC PERMEASE; SEQUENCE; EXCHANGE; PROTEOLIPOSOMES	In an optimized reconstituted system, the basic kinetic properties of the phosphate carrier from bovine heart mitochondria, e.g. the influence of membrane potential, pH, and proton gradient, were investigated for the two physiological modes of transport (P(i)-/P(i)- antiport and electroneutral, unidirectional phosphate transport). On the basis of these data, which closely resemble the function known from mitochondria, the reaction mechanism of the phosphate carrier was determined using bireactant initial velocity studies in both transport modes. Translocation occurred according to a simultaneous (sequential) mechanism, involving a ternary complex in transport catalysis. This mechanism indicates that the phosphate carrier falls into the same functional family as most other mitochondrial carriers. A detailed analysis of the different effects of pH on transport substrates and carrier protein in both possible transport modes, in combination with the identity of the kinetic mechanism in both modes, provides evidence that the unidirectional phosphate transport is catalyzed by P(i)-/OH- antiport rather than by P(i)-/H+ symport. We furthermore observed noncompetitive inhibition of phosphate transport by other anions. The consequences of this result with respect to a functional model of the carrier protein are discussed.	FORSCHUNGSZENTRUM JULICH,INST BIOTECHNOL 1,D-52425 JULICH,GERMANY	Helmholtz Association; Research Center Julich								AQUILA H, 1982, H-S Z PHYSIOL CHEM, V363, P345; AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; BISACCIA F, 1984, BIOCHIM BIOPHYS ACTA, V766, P386, DOI 10.1016/0005-2728(84)90254-8; BISACCIA F, 1993, BIOCHIM BIOPHYS ACTA, V1142, P139, DOI 10.1016/0005-2728(93)90095-W; Cleland W. W, 1970, ENZYMES, V2, P1; COTY WA, 1974, J BIOL CHEM, V249, P2593; DIERKS T, 1988, BIOCHIM BIOPHYS ACTA, V943, P231, DOI 10.1016/0005-2736(88)90555-X; FERREIRA GC, 1989, J BIOL CHEM, V264, P15628; FREITAG H, 1978, EUR J BIOCHEM, V83, P53, DOI 10.1111/j.1432-1033.1978.tb12067.x; GARCIA ML, 1983, BIOCHEMISTRY-US, V22, P2524, DOI 10.1021/bi00279a033; GENCHI G, 1988, BIOCHIM BIOPHYS ACTA, V936, P413, DOI 10.1016/0005-2728(88)90018-7; GREENBAUM NL, 1985, J BIOL CHEM, V260, P873; GUERIN B, 1990, J BIOL CHEM, V265, P19736; INDIVERI C, 1993, BIOCHIM BIOPHYS ACTA, V1143, P310, DOI 10.1016/0005-2728(93)90202-Q; INDIVERI C, 1991, BIOCHIM BIOPHYS ACTA, V1069, P110, DOI 10.1016/0005-2736(91)90110-T; INDIVERI C, 1991, EUR J BIOCHEM, V198, P339, DOI 10.1111/j.1432-1033.1991.tb16021.x; INDIVERI C, 1991, BIOCHIM BIOPHYS ACTA, V1065, P231, DOI 10.1016/0005-2736(91)90235-Z; INDIVERI C, 1994, IN PRESS BIOCH BIOPH; KABACK HR, 1990, TRENDS BIOCHEM SCI, V15, P309; KADENBACH B, 1978, FEBS LETT, V89, P161, DOI 10.1016/0014-5793(78)80545-6; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; KAPLAN RS, 1986, J BIOL CHEM, V261, P2767; KOLBE HVJ, 1985, J BIOL CHEM, V260, P5899; KRAMER R, 1982, BIOCHEMISTRY-US, V21, P1082; KRAMER R, 1986, BIOCHIM BIOPHYS ACTA, V863, P289, DOI 10.1016/0005-2736(86)90269-5; KRAMER R, 1992, MOL MECHANISMS BIOEN, V23, P359; KRAMER R, 1994, IN PRESS BIOCH BIOPH; KUAN J, 1993, CRIT REV BIOCHEM MOL, V28, P209, DOI 10.3109/10409239309086795; LANOUE KF, 1979, ANNU REV BIOCHEM, V48, P871, DOI 10.1146/annurev.bi.48.070179.004255; LANOUE KF, 1984, BIOENERGETICS, P221; LIGETI E, 1985, BIOCHEMISTRY-US, V24, P4423, DOI 10.1021/bi00337a025; LOLKEMA JS, 1991, BIOCHEMISTRY-US, V30, P1284, DOI 10.1021/bi00219a018; MCGIVAN JD, 1971, EUR J BIOCHEM, V20, P392, DOI 10.1111/j.1432-1033.1971.tb01405.x; PHELPS A, 1991, BIOCHEMISTRY-US, V30, P248, DOI 10.1021/bi00215a035; RUNSWICK MJ, 1987, EMBO J, V6, P1367, DOI 10.1002/j.1460-2075.1987.tb02377.x; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; Segel, 1975, ENZYME KINETICS BEHA, P274; SLUSE FE, 1989, ANION CARRIERS OF MITOCHONDRIAL MEMBRANES, P183; SLUSE FE, 1991, BIOCHIM BIOPHYS ACTA, V1058, P329, DOI 10.1016/S0005-2728(05)80128-8; SLUSE FE, 1979, EUR J BIOCHEM, V100, P3, DOI 10.1111/j.1432-1033.1979.tb02028.x; STAPPEN R, 1993, BIOCHIM BIOPHYS ACTA, V1149, P40, DOI 10.1016/0005-2736(93)90022-R; Walker J.E., 1992, CURR OPIN STRUC BIOL, V2, P519, DOI DOI 10.1016/0959-440X(92)90081-H; WEHRLE JP, 1989, J MEMBRANE BIOL, V111, P199, DOI 10.1007/BF01871006; WOHLRAB H, 1984, BIOCHEMISTRY-US, V23, P1057, DOI 10.1021/bi00301a004; WOHLRAB H, 1986, BIOCHIM BIOPHYS ACTA, V853, P115, DOI 10.1016/0304-4173(86)90007-8; WOHLRAB H, 1982, J BIOL CHEM, V257, P28	47	72	74	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11240	11246						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157653				2022-12-25	WOS:A1994NF96600042
J	VONMOLLARD, GF; STAHL, B; KHOKHLATCHEV, A; SUDHOF, TC; JAHN, R				VONMOLLARD, GF; STAHL, B; KHOKHLATCHEV, A; SUDHOF, TC; JAHN, R			RAB3C IS A SYNAPTIC VESICLE PROTEIN THAT DISSOCIATES FROM SYNAPTIC VESICLES AFTER STIMULATION OF EXOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEIN; SMG P25A; REGULATORY PROTEIN; LOCALIZATION; ASSOCIATION; GLUTAMATE; SEQUENCES; MEMBRANE; CLONING; BRAIN	Rab3 proteins are small GTP-binding proteins of the Ras superfamily. Four highly homologous Rab3 proteins termed Rab3A, Rab3B, Rab3C, and Rab3D have been described. Rab3A has previously been shown to be a constituent of synaptic vesicles in neurons that undergoes membrane dissociation-association cycles during synaptic vesicle recycling. Here we report that Rab3C copurifies with Rab3A during the isolation of synaptic vesicles. Organelles immunoisolated with monoclonal antibodies directed against Rab3A led to a coenrichment of Rab3A and Rab3C, demonstrating that both Rab3 proteins are colocalized on the same organelle. In isolated nerve terminals, stimulation of neurotransmitter release resulted in a dissociation of Rab3C from synaptic vesicle and/or recycling membranes. This dissociation parallels that of Rab3A observed under the same conditions. In contrast, no change was observed in the membrane-association of Rab5, a Rab protein localized on early endosomes. We conclude that in the nervous system Rab3C is localized on synaptic vesicles and, like Rab3A, cycles on and off the synaptic vesicle membrane in parallel with exocytotic release of neurotransmitter.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,BOYER CTR MOLEC MED,POB 9812,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			von Mollard, Gabriele Fischer/A-3935-2012; von Mollard, Gabriele Fischer/O-9778-2019	von Mollard, Gabriele Fischer/0000-0003-3236-1401; von Mollard, Gabriele Fischer/0000-0003-3236-1401; Jahn, Reinhard/0000-0003-1542-3498	NCI NIH HHS [P01 CA 46128] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BURGER PM, 1989, NEURON, V3, P715, DOI 10.1016/0896-6273(89)90240-7; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CORMONT M, 1993, J BIOL CHEM, V268, P19491; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; SCHNEIDER WJ, 1983, J CELL BIOL, V97, P1635, DOI 10.1083/jcb.97.5.1635; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; ZAHRAOUI A, 1988, NUCLEIC ACIDS RES, V16, P1204, DOI 10.1093/nar/16.3.1204	29	138	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					10971	10974						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157621				2022-12-25	WOS:A1994NF96600002
J	DALLASTA, V; ROSSI, PA; BUSSOLATI, O; GAZZOLA, GC				DALLASTA, V; ROSSI, PA; BUSSOLATI, O; GAZZOLA, GC			RESPONSE OF HUMAN FIBROBLASTS TO HYPERTONIC STRESS - CELL SHRINKAGE IS COUNTERACTED BY AN ENHANCED ACTIVE-TRANSPORT OF NEUTRAL AMINO-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN-FIBROBLASTS; ION-TRANSPORT; L-ARGININE; GLUTAMINE; VOLUME	Regulatory volume increase (RVI) has been studied in cultured human fibroblasts (CHF) incubated in a complete hypertonic growth medium (400 mosmol/kg). After the initial cell shrinkage induced by hypertonic treatment, cells recover their volume almost completely within 3 h. This RVI response is associated with a marked increase of the cell content of free amino acids. The cell content of potassium increases only slightly. Chromatographic analysis of the intracellular amino acid pool shows that the RVI-associated increase in cell amino acids is mainly a result of changes in the L-glutamine content. The intracellular accumulation of the analog 2-methylaminoisobutyric acid, a specific substrate of transport system A, is increased in CHF undergoing RVI. Hypertonic treatment causes an immediate and sustained cell hyperpolarization, as demonstrated by changes in the trans-membrane distribution ratio of L-arginine and in the fluorescence of the potential-sensitive dye bis-1,3,-diethylthiobarbiturate-trimethineoxonol. Because of cell hyperpolarization, at the end of RVI the trans-membrane gradient of the sodium electrochemical potential is higher than that of the control. The increase in the extracellular potassium concentration ([K+](out) = 40 mM) abolishes the hyperpolarization induced by hypertonic treatment and delays volume recovery. Cycloheximide suppresses RVI at a high but not at physiologic [K+](out). It is proposed that CHF counteract hypertonic shrinkage through an enhanced accumulation of substrates of transport system A sustained, initially, by an increase in the energy available for transport and, subsequently, also by the synthesis of new site A carriers.	UNIV PARMA,IST PATOL GEN,I-43100 PARMA,ITALY	University of Parma			Bussolati, Ovidio/B-7589-2013; Dall'Asta, Valeria/M-6698-2015	Bussolati, Ovidio/0000-0002-4301-2939; Dall'Asta, Valeria/0000-0001-8540-0916				BANNAI S, 1988, J CELL PHYSIOL, V137, P360, DOI 10.1002/jcp.1041370221; BODE BP, 1991, J BIOL CHEM, V266, P7376; BUSSOLATI O, 1989, AM J PHYSIOL, V256, pC930, DOI 10.1152/ajpcell.1989.256.4.C930; BUSSOLATI O, 1987, AM J PHYSIOL, V253, pC391, DOI 10.1152/ajpcell.1987.253.3.C391; BUSSOLATI O, 1992, J BIOL CHEM, V267, P8330; CHRISTENSEN HN, 1984, BIOCHIM BIOPHYS ACTA, V779, P255, DOI 10.1016/0304-4157(84)90012-1; DALLASTA V, 1991, J BIOL CHEM, V266, P1591; DALLASTA V, 1990, BIOCHIM BIOPHYS ACTA, V1052, P106, DOI 10.1016/0167-4889(90)90063-J; DARMAUN D, 1988, J CELL PHYSIOL, V134, P143, DOI 10.1002/jcp.1041340118; GAZZOLA G, 1991, Cellular Physiology and Biochemistry, V1, P131, DOI 10.1159/000154601; GAZZOLA GC, 1981, ANAL BIOCHEM, V115, P368, DOI 10.1016/0003-2697(81)90019-1; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; LAW RO, 1987, J PHYSIOL-LONDON, V386, P45, DOI 10.1113/jphysiol.1987.sp016521; MARCHHELLI R, 1992, J SCI FOOD AGR, V57, P217; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; SOLER C, 1993, BIOCHEM J, V289, P653, DOI 10.1042/bj2890653; SPRING KR, 1992, KIDNEY PHYSL PATHOPH, P147; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	18	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10485	10491						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144632				2022-12-25	WOS:A1994NF01700046
J	ERASO, P; PORTILLO, F				ERASO, P; PORTILLO, F			MOLECULAR MECHANISM OF REGULATION OF YEAST PLASMA-MEMBRANE H+-ATPASE BY GLUCOSE - INTERACTION BETWEEN DOMAINS AND IDENTIFICATION OF NEW REGULATORY SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; DIRECTED MUTAGENESIS; CA2+ PUMP; DNA; CONSEQUENCES; ACTIVATION; PROMOTER; SEQUENCE; BINDING; GROWTH	The carboxyl terminus of yeast plasma membrane H+-ATPase is an autoinhibitory domain, and its effect is counteracted by modification of the enzyme triggered by glucose metabolism (Portillo, F., Larrinoa, I. F., and Serrano, R. (1989) FEBS Lett. 247, 381-385). To identify interacting domains involved in this regulation, we have performed intragenic suppressor analysis. A double mutation at the carboxyl terminus (S911A/T912A) results in no activation of the ATPase by glucose and lack of yeast growth on this sugar (Portillo, F., Eraso, P., and Serrano, R. (1991) FEBS Lett. 287, 71-74). Random in vitro mutagenesis of this mutant ATPase gene resulted in 29 revertants. Six corresponded to full revertants of the initial double mutation. Fourteen suppressor (second-site) mutations are located within three functional domains of the enzyme. Four mutations (A165V, V169I/D170N, A350T, and A351T) are localized at the cytoplasmic ends of predicted transmembrane helices 2 and 4; six mutations (P536L, A565T, G587N, G648S, P669L,and G670S) map within the proposed ATP binding domain, and the other four substitutions (P890opa, S896F, R898K, and M907I) are located at the carboxyl terminus. These results demonstrate the interaction, direct or indirect, between these three domains far apart in the linear sequence of the ATPase. All the second-site mutations caused constitutive activation of the ATPase in the absence of glucose metabolism. Second site mutations at the carboxyl terminus were close to Ser-899 and suggested phosphorylation of this amino acid during glucose activation. Accordingly, the introduction of a negative charge, in a S899D mutant constructed by site-directed mutagenesis, partially mimics the glucose effect on the ATPase.			ERASO, P (corresponding author), UNIV AUTONOMA MADRID, FAC MED,CSIC,INST INVEST BIOMED,DEPT BIOQUIM, ARTURO DUPERIER 4, E-28029 MADRID, SPAIN.		Mazmela, Pilar Eraso/E-9248-2016	Mazmela, Pilar Eraso/0000-0002-6928-3219; Portillo Perez, Francisco/0000-0003-4922-346X				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CID A, 1988, J BIOL CHEM, V263, P14134; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; ERASO P, 1987, FEBS LETT, V224, P187, DOI 10.1016/0014-5793(87)80445-3; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; Freeman E. R., 1971, Computer designer's conference and exhibition (abstracts); GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GOFFEAU A, 1990, MONOVALENT CATIONS B, P155; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; Haynes R.H., 1981, MOL BIOL YEAST SACCH, P371; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; NA SQ, 1993, J BIOL CHEM, V268, P11792; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; PORTILLO F, 1991, FEBS LETT, V287, P71, DOI 10.1016/0014-5793(91)80018-X; PORTILLO F, 1989, FEBS LETT, V247, P381, DOI 10.1016/0014-5793(89)81375-4; RAO R, 1993, J BIOL CHEM, V268, P6708; Rose MD., 1990, METHODS YEAST GENETI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1990, BIOCHIM BIOPHYS ACTA, V1018, P195, DOI 10.1016/0005-2728(90)90247-2; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1992, ACTA PHYSIOL SCAND, V146, P131; SERRANO R, 1986, FEBS LETT, V208, P143, DOI 10.1016/0014-5793(86)81549-6; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; Serrano R, 1991, MOL CELLULAR BIOL YE, P523; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; WACH A, 1992, J BIOENERG BIOMEMBR, V24, P309; [No title captured]	36	95	96	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10393	10399						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144622				2022-12-25	WOS:A1994NF01700034
J	GACK, S; VALLON, R; SCHAPER, J; RUTHER, U; ANGEL, P				GACK, S; VALLON, R; SCHAPER, J; RUTHER, U; ANGEL, P			PHENOTYPIC ALTERATIONS IN FOS-TRANSGENIC MICE CORRELATE WITH CHANGES IN FOS/JUN-DEPENDENT COLLAGENASE TYPE-I EXPRESSION - REGULATION OF MOUSE METALLOPROTEINASES BY CARCINOGENS, TUMOR PROMOTERS, CAMP, AND FOS ONCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SYNOVIAL FIBROBLASTS; EPIDERMAL GROWTH-FACTOR; BONE-RESORBING AGENTS; C-FOS; MESSENGER-RNA; TISSUE INHIBITOR; GENE-EXPRESSION; RAT FIBROBLASTS; CYSTEINE SWITCH; INDUCED TRANSIN	Using specific cDNAs isolated from mouse fibroblasts we determined tissue-specific expression of different matrix metalloproteinase genes: both stromelysin-1 and collagenase IV are highly expressed in heart and lung, whereas collagenase I is expressed most abundantly in skeletal muscle, kidney, and bone. High basal level expression of stromelysin-2 is found in heart and kidney. Like in man and rat, the expressions of collagenase I, stromelysin-1, and stromelysin-2 are regulated by the tumor promoter 12-O-tetradecanoyl-phorbol 13-acetate and by UV irradiation, but not by cAMP. In contrast, the expression of the 72-kDa collagenase IV is not affected by either stimuli. We and others have shown previously that under cell culture conditions, the regulation of human collagenase I is regulated by the transcription factor Fos/Jun (AP-1). Here we show that in c-fos transgenic mice transcription of collagenase I is induced in thymus, spleen, and, most dominantly, in bone upon overexpression of Fos. Neither collagenase IV nor stromelysin-1 or stromelysin-2 expression is affected by c-Fos. The sites of induced collagenase I expression correlate with the sites of Fos-induced long-term cellular alterations in transgenic mice including bone remodeling and T cell development. In fact, in the developing bone tumors strongly enhanced levels of collagenase I transcripts were detectable. These results identify collagenase I as a Fos-regulated gene in vivo and suggest a possible role for Fos/Jun heterodimers in establishing the pathological phenotype of c-fos transgenic mice.	KERNFORSCHUNGSZENTRUM KARLSRUHE GMBH, INST GENET, D-76021 KARLSRUHE, GERMANY; HANNOVER MED SCH, INST MOLEK BIOL, D-30623 HANNOVER, GERMANY	Helmholtz Association; Karlsruhe Institute of Technology; Hannover Medical School			Piris, Miguel A/AAP-1445-2020	Piris, Miguel A/0000-0001-5839-3634				Alexander CM, 1989, CURR OPIN CELL BIOL, V1, P974, DOI 10.1016/0955-0674(89)90068-9; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Angel P, 1992, Matrix Suppl, V1, P156; BACHILLER D, 1990, Archiv fuer Geschwulstforschung, V60, P357; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; BRENNER CA, 1989, GENE DEV, V3, P848, DOI 10.1101/gad.3.6.848; BRINCKERHOFF CE, 1990, J BIOL CHEM, V265, P22262; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; CHIN JR, 1985, J BIOL CHEM, V260, P2367; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DELAISSE JM, 1988, ENDOCRINOLOGY, V123, P264, DOI 10.1210/endo-123-1-264; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; FRISCH SM, 1987, P NATL ACAD SCI USA, V84, P2600, DOI 10.1073/pnas.84.9.2600; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; FRISCH SM, 1990, ONCOGENE, V5, P75; GRANT GA, 1987, J BIOL CHEM, V262, P5886; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GROSS RH, 1984, P NATL ACAD SCI-BIOL, V81, P1981, DOI 10.1073/pnas.81.7.1981; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HEATH JK, 1984, BIOCHIM BIOPHYS ACTA, V802, P151, DOI 10.1016/0304-4165(84)90046-1; HEATH JK, 1990, BIOCHEM BIOPH RES CO, V168, P1171, DOI 10.1016/0006-291X(90)91152-I; HENRIET P, 1992, FEBS LETT, V310, P175, DOI 10.1016/0014-5793(92)81323-E; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KRAMER M, 1993, J BIOL CHEM, V268, P6734; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MARTIN GR, 1985, TRENDS BIOCHEM SCI, V10, P285, DOI 10.1016/0968-0004(85)90089-1; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; MURPHY G, 1985, J BIOL CHEM, V260, P3079; Murphy Gillian, 1993, P287; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; OSTROWSKI LE, 1988, MOL CARCINOGEN, V1, P13, DOI 10.1002/mc.2940010106; QUINN CO, 1990, J BIOL CHEM, V265, P22342; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; REPONEN P, 1992, J BIOL CHEM, V267, P7856; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; RUTHER U, 1988, CELL, V53, P847, DOI 10.1016/S0092-8674(88)90289-9; SAKAI M, 1989, CANCER RES, V49, P5633; SAKAMOTO S, 1985, BIOCHEM BIOPH RES CO, V133, P709, DOI 10.1016/0006-291X(85)90962-3; Sambrook J, 1989, MOL CLONING LABORATO; SCHONTHAL A, 1988, COLD SPRING HARB SYM, V53, P779, DOI 10.1101/SQB.1988.053.01.088; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Werb Z., 1989, TXB RHEUMATOLOGY, P300; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	70	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10363	10369						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144618				2022-12-25	WOS:A1994NF01700030
J	MARRERO, MB; PAXTON, WG; DUFF, JL; BERK, BC; BERNSTEIN, KE				MARRERO, MB; PAXTON, WG; DUFF, JL; BERK, BC; BERNSTEIN, KE			ANGIOTENSIN-II STIMULATES TYROSINE PHOSPHORYLATION OF PHOSPHOLIPASE C-GAMMA-1 IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; PROTEIN-KINASE; C-GAMMA; ACTIVATION; RECEPTOR; MOBILIZATION; RESIDUES; CALCIUM; ISOZYME; ALPHA	The receptor for angiotensin II (Ang II) has recently been cloned; it is a receptor with seven transmembrane spanning domains that stimulates phosphoinositide hydrolysis upon ligand binding. The physiologic effects of Ang II are important in the regulation of vascular function. In this study, we examined the ability of Ang II to regulate the enzymatic activity of phospholipase C (PLC) in rat aortic vascular smooth muscle cells (VSMC). In cultured VSMC, PLC-gamma 1 and PLC-delta 1 isozymes, but not PLC-beta 1, were identified by Western analysis. Ang II (10(-7) M)-stimulated PLC-gamma 1 phosphotyrosine phosphorylation with a maximum increase of 4.5-fold at 0.5 min. This followed the same time course as the Ang II-stimulated increase in inositol 1,4,5-trisphosphate (1,4,5-IP3) levels. 1,4,5-IP3 formation was inhibited 75% by the tyrosine kinase inhibitor genistein (120 mu M). Several growth factor receptors, such as the platelet-derived growth factor (PDGF) receptor are themselves tyrosine kinases and have been shown to phosphorylate PLC-gamma 1 and increase intracellular Ca2+ concentrations. The time course for PLC-gamma 1 phosphorylation, IP3 formation, and Ca2+ mobilization by PDGF differed from Ang II in VSMC. The kinetics of the PDGF effects were slower in onset and more prolonged than those of Ang II. In summary, these findings show that Ang II stimulates VSMC phosphoinositide hydrolysis in association with tyrosine phosphorylation of PLC-gamma 1 and support the concept that Ang II-stimulated tyrosine phosphorylation is responsible for early signal transduction events.	EMORY UNIV, DEPT PATHOL & LAB MED, ATLANTA, GA 30322 USA; EMORY UNIV, DEPT MED, DIV CARDIOL, ATLANTA, GA 30322 USA	Emory University; Emory University				Bernstein, Kenneth/0000-0001-8097-3272; Berk, Bradford/0000-0002-2767-4115	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044280, R01DK039777, R37DK039777, P50DK045215] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45215, DK44280, DK39777] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER RW, 1985, HYPERTENSION, V7, P447, DOI 10.1161/01.HYP.7.3.447; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BERK BC, 1987, J BIOL CHEM, V262, P5065; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BERK BC, 1986, SCIENCE, V232, P87, DOI 10.1126/science.3485309; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; EMORI Y, 1989, J BIOL CHEM, V264, P21885; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; GRIENDLING KK, 1991, J BIOL CHEM, V266, P15498; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HOMMA Y, 1993, BIOCHEM J, V290, P649, DOI 10.1042/bj2900649; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM UH, 1989, J BIOL CHEM, V264, P20167; KUMJIAN DA, 1991, J BIOL CHEM, V266, P3973; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SMITH JB, 1986, AM J PHYSIOL, V250, pF759, DOI 10.1152/ajprenal.1986.250.5.F759; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SRIVASTAVA SP, 1991, J BIOL CHEM, V266, P20337; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TAYLOR GD, 1992, BIOCHEM BIOPH RES CO, V188, P1176, DOI 10.1016/0006-291X(92)91355-T; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TSUDA T, 1991, FEBS LETT, V285, P44, DOI 10.1016/0014-5793(91)80721-E; WONG PC, 1990, J PHARMACOL EXP THER, V255, P584	35	201	203	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10935	10939						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144678				2022-12-25	WOS:A1994NF01700108
J	JANKNECHT, R; ZINCK, R; ERNST, WH; NORDHEIM, A				JANKNECHT, R; ZINCK, R; ERNST, WH; NORDHEIM, A			FUNCTIONAL DISSECTION OF THE TRANSCRIPTION FACTOR ELK-1	ONCOGENE			English	Note							ETS-RELATED PROTEIN; DNA-BINDING MOTIF; PUTATIVE ONCOGENE; FACTOR P62TCF; DOMAIN; EXPRESSION; KINASE; SRF; TRANSLOCATION; PROTOONCOGENE	The ternary complex factor Elk-1 belongs to the Ets oncoprotein family. We demonstrate that this transcription factor is localized predominantly in the nucleus, for which at least two regions of Elk-I are required. One of these regions is part of the N-terminal ETS-domain, while the other encompasses amino acids 137-157. In conjunction with the ETS-domain, which mediates autonomous binding of Elk-1 to some DNA target sequences, the conserved B-region is both necessary and sufficient for ternary complex formation with the c-fos serum response element and the serum response factor. However, the B-region must be linked to the ETS-domain by a spacer. Furthermore, the B-region impedes autonomous DNA-binding, possibly by masking the ETS-domain. A point mutation within the ETS-domain, homologous to the ts1.1 point mutation of v-Ets in the E26 virus, affects DNA-binding of Elk-1 in a temperature-dependent manner, which by analogy might be causative for the altered phenotype of ts1.1 E26. Finally we show that amino acids 83-428 contribute to Elk-1 mediated transactivation. In particular, the region 376-404 is indispensable for transactivation, while flanking amino acids on both sides are only required for enhancement of transcriptional efficacy.	HANNOVER MED SCH,INST MOLEC BIOL,D-30623 HANNOVER,GERMANY	Hannover Medical School				Janknecht, Ralf/0000-0003-1741-1562				BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1993, EUR J BIOCHEM, V216, P469, DOI 10.1111/j.1432-1033.1993.tb18165.x; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	29	87	87	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1273	1278						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134131				2022-12-25	WOS:A1994NC04800034
J	LIN, Q; MA, L; BURKHART, W; SPREMULLI, LL				LIN, Q; MA, L; BURKHART, W; SPREMULLI, LL			ISOLATION AND CHARACTERIZATION OF CDNA CLONES FOR CHLOROPLAST TRANSLATIONAL INITIATION FACTOR-III FROM EUGLENA-GRACILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; FACTOR-III; SECONDARY-STRUCTURE; COMPLEX FORMS; BINDING; GENE; DNA; IDENTIFICATION; PURIFICATION	A complete cDNA clone encoding Euglena gracilis chloroplast translational initiation factor 3 (IF-3chl) has been obtained. Analysis of the sequence indicates that the IF-3chl mRNA contains the spliced leader found at the 5' end of nuclear encoded mRNAs in E. gracilis. The open reading frame for IF-3chl encodes a 537-amino acid protein. IF-3chl appears to be divided into four domains. The first 140 amino acids correspond to a transit peptide required for the import of IF-3chl into the chloroplast. The mature form of IF-3chl encompasses domains 2-4 and is about twice the size of Escherichia coli IF-3. The second domain has no homology to other known proteins. It begins with a stretch of 35 residues, of which about 30% are proline. Downstream from this region is a stretch of about 25 amino acids with a repeating (GX)n motif followed by a very acidic region. The third domain comprises a region of about 175 residues and has between 31 and 37% homology to the IF-3s found in other organisms. The IF-3 homology domain is followed by an acidic region which has no detectable homology to other sequences. Analysis of E. gracilis genomic DNA suggests that there are about four copies of the IF-3chl gene, one of which is probably a pseudogene. The activity of IF-3chl is inducible by light. However, the IF-3chl mRNA is present in approximately equal amounts in both dark- and light-grown cells, suggesting that the light-dependent induction of IF-3chl activity is post-transcriptional.	UNIV N CAROLINA, DEPT CHEM, CHAPEL HILL, NC 27599 USA; GLAXO RES INST, DEPT STRUCT & BIOPHYS CHEM, RES TRIANGLE PK, NC 27709 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC RES CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; GlaxoSmithKline; University of North Carolina; University of North Carolina Chapel Hill			Ma, Lan/B-9295-2009	Ma, Lan/0000-0001-9034-5472	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024963] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24963] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BERKHOUT B, 1986, BIOCHIM BIOPHYS ACTA, V866, P144, DOI 10.1016/0167-4781(86)90111-9; BURKHART W, 1992, TECHNIQUES PROTEIN C, V4, P399; CANONACO MA, 1989, EUR J BIOCHEM, V182, P501, DOI 10.1111/j.1432-1033.1989.tb14856.x; Carmichael G G, 1980, Methods Enzymol, V65, P380; DEBELLIS D, 1992, BIOCHEMISTRY-US, V31, P11984, DOI 10.1021/bi00163a005; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIBBS SP, 1981, ANN NY ACAD SCI, V361, P193; GOTTESMAN MM, 1987, METHOD ENZYMOL, V151, P363; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; GUMPEL NJ, 1992, EUR J BIOCHEM, V210, P721, DOI 10.1111/j.1432-1033.1992.tb17473.x; HARTZ D, 1989, GENE DEV, V3, P1899, DOI 10.1101/gad.3.12a.1899; HARTZ D, 1990, GENE DEV, V4, P1790, DOI 10.1101/gad.4.10.1790; HENIKOFF S, 1991, NUCLEIC ACIDS RES, V19, P6565, DOI 10.1093/nar/19.23.6565; HU WS, 1993, GENE, V127, P79, DOI 10.1016/0378-1119(93)90619-E; HUNT AG, 1987, PLANT MOL BIOL, V8, P23, DOI 10.1007/BF00016431; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; KELLER M, 1992, NUCLEIC ACIDS RES, V20, P1711, DOI 10.1093/nar/20.7.1711; KIMURA M, 1983, FEBS LETT, V160, P78, DOI 10.1016/0014-5793(83)80940-5; KRAUS BL, 1986, J BIOL CHEM, V261, P4781; KRAUS BL, 1988, PLANT PHYSIOL, V88, P993, DOI 10.1104/pp.88.4.993; LEFORTTRAN M, 1981, BER DEUT BOT GES, V94, P463; MA L, 1992, J BIOL CHEM, V267, P18356; MA L, 1990, J BIOL CHEM, V265, P13560; MCCARTHY SA, 1984, PLANT SCI LETT, V35, P61, DOI 10.1016/0304-4211(84)90158-5; MONTANDON PE, 1990, NUCLEIC ACIDS RES, V18, P75, DOI 10.1093/nar/18.1.75; MURAYAMA Y, 1993, PLANT MOL BIOL, V22, P767, DOI 10.1007/BF00027363; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; NISHIKAWA K, 1983, BIOCHIM BIOPHYS ACTA, V748, P285, DOI 10.1016/0167-4838(83)90306-0; PON CL, 1974, P NATL ACAD SCI USA, V71, P4950, DOI 10.1073/pnas.71.12.4950; RAWSON JRY, 1979, BIOCHIM BIOPHYS ACTA, V563, P1, DOI 10.1016/0005-2787(79)90002-9; ROTH MJ, 1985, J BIOL CHEM, V260, P9326; SACERDOT C, 1982, EMBO J, V1, P311, DOI 10.1002/j.1460-2075.1982.tb01166.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHASHIDHARA LS, 1992, J BIOL CHEM, V267, P12885; STERN AI, 1964, PLANT PHYSIOL, V39, P220, DOI 10.1104/pp.39.2.220; TESSIER LH, 1991, EMBO J, V10, P2621, DOI 10.1002/j.1460-2075.1991.tb07804.x; VANKNIPPENBERG PH, 1990, RIBOSOME, P265; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WANG CC, 1991, J BIOL CHEM, V266, P17079; WICKSTROM E, 1980, ARCH BIOCHEM BIOPHYS, V200, P296, DOI 10.1016/0003-9861(80)90357-4; WOODCOCK E, 1980, ARCH MICROBIOL, V124, P33, DOI 10.1007/BF00407025; WU DY, 1991, DNA CELL BIOL, V10, P233, DOI 10.1089/dna.1991.10.233	45	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9436	9444						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144528				2022-12-25	WOS:A1994NE05300010
J	MIGEON, JC; NATHANSON, NM				MIGEON, JC; NATHANSON, NM			DIFFERENTIAL REGULATION OF CAMP-MEDIATED GENE-TRANSCRIPTION BY M1 AND M4 MUSCARINIC ACETYLCHOLINE-RECEPTORS - PREFERENTIAL COUPLING OF M4 RECEPTORS TO G(I)ALPHA-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE ACTIVITY; RAT OLFACTORY-BULB; DEPENDENT PROTEIN-KINASE; CELL-SPECIFIC EXPRESSION; CYCLIC-AMP ACCUMULATION; GTP-BINDING PROTEIN; NEUROBLASTOMA-CELLS; HYDROLYSIS; CLONING; STIMULATION	We have used a luciferase reporter gene under the transcriptional control of a cAMP response element as a sensitive monitor of the regulation by muscarinic acetylcholine receptors (mAChRs) of intracellular cAMP levels and cAMP-regulated gene expression. Treatment with the muscarinic agonist carbachol results in an increase in luciferase activity in JEG-3 cells transiently transfected with mouse ml (8-10-fold) and chick m4 (3-5-fold) mAChRs. Control experiments indicate that these responses are not due to a calcium-mediated pathway and are dependent upon a functional protein kinase A. The m1 and m4 responses are not sensitive to pertussus toxin and the m4 response was potentiated by it. Thus, these responses do not result from direct stimulation of adenylate cyclase by betagamma subunits released from pertussis toxin-sensitive G-proteins. Atropine treatment of cells transfected with high levels of m4 mAChR, but not m1, causes an elevation in basal levels of cAMP response element-mediated luciferase expression in the absence of agonist. This suggests that the m4 receptor is spontaneously active and can cause constitutive inhibition of adenylyl cyclase that is relieved by atropine treatment. Surprisingly, the m4 receptor exhibits little if any agonist-induced inhibition of luciferase expression at either low or high levels of receptor expression. JEG-3 cells express G(i)alpha-1 and G(i)alpha-3 but not G(i)alpha-2. Cotransfection of G(i)alpha subunits with m4 demonstrates that the m4 receptor requires G(i)alpha-2 for optimal agonist-mediated inhibition. Even in the presence of G(i)alpha-2, high levels of receptor increased luciferase expression at high concentrations of agonist. Thus, the m4 mAChR can undergo a switch in functional coupling from inhibition to stimulation of adenylyl cyclase. This switch is dependent on the level of receptor expression, the subtypes of G-proteins coexpressed with the receptor, and the concentration of agonist. Furthermore, we demonstrate that the G(i)alpha-2 G-protein alpha subunit preferentially couples the m4 mAChR to inhibition of adenylyl cyclase in JEG-3 cells.	UNIV WASHINGTON,DEPT PHARMACOL,SJ30,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL30639] Funding Source: Medline; NIGMS NIH HHS [GM07108] Funding Source: Medline; NINDS NIH HHS [NS26920] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026920] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BAUMGOLD J, 1992, J NEUROCHEM, V58, P1754, DOI 10.1111/j.1471-4159.1992.tb10050.x; BAUMGOLD J, 1989, BIOCHEM BIOPH RES CO, V154, P1137; BEALS CR, 1987, P NATL ACAD SCI USA, V84, P7886, DOI 10.1073/pnas.84.22.7886; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; DAY RN, 1989, J BIOL CHEM, V264, P431; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; EASON MG, 1992, J BIOL CHEM, V267, P15795; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FELDER CC, 1989, FEBS LETT, V245, P75, DOI 10.1016/0014-5793(89)80195-4; FELDER CC, 1989, J BIOL CHEM, V264, P20356; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; HANF R, 1993, J PHYSIOL-LONDON, V461, P743, DOI 10.1113/jphysiol.1993.sp019539; HUGHES AR, 1984, P NATL ACAD SCI-BIOL, V81, P5680, DOI 10.1073/pnas.81.18.5680; JANSSON CC, 1991, BIOCHIM BIOPHYS ACTA, V1095, P255, DOI 10.1016/0167-4889(91)90108-A; JONES DT, 1987, J BIOL CHEM, V262, P14241; JONES SVP, 1991, MOL PHARMACOL, V40, P242; KUBO T, 1986, FEBS LETT, V209, P367, DOI 10.1016/0014-5793(86)81144-9; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; LIM K, 1989, BIOTECHNIQUES, V7, P576; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUETJE CW, 1987, BIOCHEMISTRY-US, V26, P4876, DOI 10.1021/bi00389a040; MATESIC DF, 1991, FEBS LETT, V284, P184, DOI 10.1016/0014-5793(91)80680-2; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MONTMAYEUR JP, 1993, MOL ENDOCRINOL, V7, P161, DOI 10.1210/me.7.2.161; NATHANSON NM, 1992, METHODS NEUROSCI, V9, P116; OLIANAS MC, 1990, J NEUROCHEM, V55, P1083, DOI 10.1111/j.1471-4159.1990.tb04603.x; OLIANAS MC, 1991, J PHARMACOL EXP THER, V259, P680; OLIANAS MC, 1992, J NEUROCHEM, V58, P1723, DOI 10.1111/j.1471-4159.1992.tb10046.x; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PEI L, 1991, MOL ENDOCRINOL, V5, P521, DOI 10.1210/mend-5-4-521; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; SHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; SPIEGEL AM, 1990, G RPTEINS SIGNAL TRA, P186; TIETJE KM, 1990, J BIOL CHEM, V265, P2828; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WOODFORD TA, 1989, J BIOL CHEM, V264, P13321	43	72	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9767	9773						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144570				2022-12-25	WOS:A1994NE05300059
J	PROKIPCAK, RD; HERRICK, DJ; ROSS, J				PROKIPCAK, RD; HERRICK, DJ; ROSS, J			PURIFICATION AND PROPERTIES OF A PROTEIN THAT BINDS TO THE C-TERMINAL CODING REGION OF HUMAN C-MYC MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; SULFATE-POLYACRYLAMIDE GELS; 3' UNTRANSLATED REGION; SODIUM DODECYL-SULFATE; BETA-TUBULIN; POSTTRANSCRIPTIONAL REGULATION; CELL-DIFFERENTIATION; ONCOGENE EXPRESSION; OXIDATION-REDUCTION; GENE-EXPRESSION	The short half-life of c-myc mRNA is influenced by sequences in the 3'-untranslated region and the C-terminal part of the coding region. In cell-free extracts, a polysomal protein binds to RNA corresponding to the coding region stability determinant. This and other observations suggest that the protein is bound to polysome-associated c-myc mRNA and protects the mRNA from a ribosome-associated endoribonuclease (Bernstein, P. L., Herrick, D. J., Prokipcak, R. D., and Ross, J. (1992) Genes and Dev. 6, 642-654). Here, we describe a four-step purification of the binding protein: solubilization from ribo somes, ammonium sulfate precipitation, RNA affinity chromatography, and reverse-phase high performance liquid chromatography. The 7O-kDa protein can be renatured from solutions containing sodium dodecyl sulfate or organic solvents, greatly facilitating its purification. Protein binding to c-myc coding region RNA is blocked by diamide and N-ethylmaleimide, indicating a requirement for sulfhydryl groups. The protein also binds to N-myc coding region RNA but with approximately 5-fold lower affinity than to the comparable c-myc region. Excess c-myc competitor RNA induces 8-fold destabilization of c-myc mRNA in cell-free mRNA decay extracts. In contrast, N-myc coding region competitor RNA has no effect on c-nye mRNA half-life. Therefore, the protein we have purified probably affects c-myc mRNA metabolism with high specificity.	UNIV WISCONSIN, MCARDLE LAB CANC RES, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT PATHOL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NCI NIH HHS [CA07175, CA63676, CA23076] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063676, P30CA007175, P01CA023076] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BISHOP JO, 1974, NATURE, V250, P199, DOI 10.1038/250199a0; BONNIEU A, 1988, ONCOGENE RES, V3, P155; BONNIEU A, 1990, ONCOGENE, V5, P1585; BRADFIELD CA, 1991, MOL PHARMACOL, V39, P13; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1990, METHOD ENZYMOL, V181, P202; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; BROWN PH, 1989, J BIOL CHEM, V264, P13383; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHEN CYA, 1992, MOL CELL BIOL, V12, P5748, DOI 10.1128/MCB.12.12.5748; CLEVELAND D W, 1989, New Biologist, V1, P121; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; GAY DA, 1989, P NATL ACAD SCI USA, V86, P5763, DOI 10.1073/pnas.86.15.5763; GAY DA, 1987, CELL, V50, P671, DOI 10.1016/0092-8674(87)90325-4; GRIEP AE, 1986, P NATL ACAD SCI USA, V83, P5539, DOI 10.1073/pnas.83.15.5539; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HARGROVE JL, 1991, BIOESSAYS, V13, P667, DOI 10.1002/bies.950131209; HARRELL CM, 1991, P NATL ACAD SCI USA, V88, P4166, DOI 10.1073/pnas.88.10.4166; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HERRICK DJ, 1994, IN PRESS MOL CELL BI, V14; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KINDY MS, 1986, J BIOL CHEM, V261, P2865; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRDOFFRINGA IA, 1991, NUCLEIC ACIDS RES, V19, P2387, DOI 10.1093/nar/19.9.2387; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MASTERS PS, 1988, J VIROL, V62, P2658, DOI 10.1128/JVI.62.8.2658-2664.1988; MATTAJ IW, 1989, CELL, V57, P1, DOI 10.1016/0092-8674(89)90164-5; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; OLSEN HS, 1990, SCIENCE, V247, P845, DOI 10.1126/science.2406903; PARIA BC, 1992, P NATL ACAD SCI USA, V89, P10051, DOI 10.1073/pnas.89.21.10051; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; ROSS J, 1987, J BIOL CHEM, V262, P9374; RYFFEL GU, 1975, BIOCHEMISTRY-US, V14, P1379, DOI 10.1021/bi00678a006; SACHS AB, 1985, MOL CELL BIOL, V5, P1993, DOI 10.1128/MCB.5.8.1993; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WISDOM R, 1990, J BIOL CHEM, V265, P19015; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; YEN TJ, 1988, MOL CELL BIOL, V8, P1224, DOI 10.1128/MCB.8.3.1224; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931	85	104	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9261	9269						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132663				2022-12-25	WOS:A1994NB41100093
J	TAGUCHI, T; SEKO, A; KITAJIMA, K; MUTO, Y; INOUE, S; KHOO, KH; MORRIS, HR; DELL, A; INOUE, Y				TAGUCHI, T; SEKO, A; KITAJIMA, K; MUTO, Y; INOUE, S; KHOO, KH; MORRIS, HR; DELL, A; INOUE, Y			STRUCTURAL STUDIES OF A NOVEL TYPE OF PENTAANTENNARY LARGE GLYCAN UNIT IN THE FERTILIZATION-ASSOCIATED CARBOHYDRATE-RICH GLYCOPEPTIDE ISOLATED FROM THE FERTILIZED-EGGS OF ORYZIAS-LATIPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; DE-N-GLYCOSYLATION; UNFERTILIZED EGGS; SIALYL-LEX; FREE SIALOOLIGOSACCHARIDES; HUMAN-GRANULOCYTES; ZONA-PELLUCIDA; STORAGE POOL; MEDAKA FISH	In a previous report (Kitajima, K., Inoue, S., and Inoue, Y. (1989) Dev. Biol. 132, 544-553), we found the presence of a heavily glycosylated polyprotein, ''H-hyosophorin,'' isolated from the unfertilized eggs of Oryzias latipes. We now report our detailed analysis of the structure of the N-glycan chain in L-hyosophorin, the smallest repeating unit of H-hyosophorin, which was isolated from the fertilized eggs of O. latipes and formed from H-hyosophorin upon fertilization. The N-glycan structures were defined by a combination of compositional analysis, methylation analysis, selective chemical degradation (i.e. mild methanolysis, periodate-Smith degradation, and hydrazinolysis nitrous acid deamination), enzymatic (endo-beta-galactosidase, peptide:N-glycanase and Newcastle disease virus sialidase) digestion, and instrumental analyses (one- and two-dimensional proton nuclear magnetic resonance spectroscopy and fast atom bombardment mass spectrometry) which revealed novel and unique features: (a) the presence of highly branched poly-N-acetyllactosamino pentaantennary structures; (b) the presence of a beta-galactosylated Lewis X antigenic epitope, Gal beta 1 --> 4 Gal beta 1 --> 4 (Fuc alpha 1 --> 3)GlcNAc beta 1 -->; (c) the presence of a beta-galactosylated sialyl Lewis X structure, Gal beta 1 --> 4(Neu5Ac alpha 2 --> 3)Gal beta 1 --> 4(Fuc alpha 1 --> 3)GlcNAc beta 1 -->; (d) the presence of Gal beta 1 --> 4Gal beta 1 --> and Gal beta 1 -->; 4Gal beta 1 --> 4Gal beta 1 --> as the major and minor groupings, respectively; and (e) the presence of the branched Gal residues, --> 4GlcNAc beta 1 --> 3(Gal beta 1 --> 4) Gal beta 1 -->. This study represents the first detailed investigation regarding the nature of highly branched complex asparagine-linked pentaantennary glycans in glycoproteins. The unique expression of such bulky multiantennary glycan units on proteins could be essential during early embryogenesis.	UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, TOKYO 113, JAPAN; SHOWA UNIV, SCH PHARMACEUT SCI, TOKYO 142, JAPAN; IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AZ, ENGLAND	University of Tokyo; Showa University; Imperial College London			Khoo, Kay-Hooi/E-1989-2019	Khoo, Kay-Hooi/0000-0003-2906-406X; Taguchi, Tomohiko/0000-0003-0464-6370	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; BROCKHAUSEN I, 1989, J BIOL CHEM, V264, P11211; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; DELL A, 1994, IN PRESS GLYCOBIOLOG; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FUKUDA M, 1981, P NATL ACAD SCI-BIOL, V78, P6299, DOI 10.1073/pnas.78.10.6299; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1984, J BIOL CHEM, V259, P4782; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; HAKOMORI S, 1982, TERATOCARCINOMA EMBR, P179; INOUE S, 1989, J BIOL CHEM, V264, P18520; INOUE Y, 1993, POLYSIALIC ACID MICR, P171; ISHII K, 1989, J BIOL CHEM, V264, P1623; IWASAKI M, 1992, J BIOL CHEM, V267, P24287; KAMADA Y, 1987, EUR J BIOCHEM, V163, P497, DOI 10.1111/j.1432-1033.1987.tb10896.x; KITAGAWA H, 1989, BIOCHEMISTRY-US, V28, P8891, DOI 10.1021/bi00448a031; KITAJIMA K, 1989, DEV BIOL, V132, P544, DOI 10.1016/0012-1606(89)90249-2; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MURAMATSU H, 1983, J BIOCHEM-TOKYO, V94, P799, DOI 10.1093/oxfordjournals.jbchem.a134422; MURAMATSU T, 1978, P NATL ACAD SCI USA, V75, P2315, DOI 10.1073/pnas.75.5.2315; NIMTZ M, 1993, EUR J BIOCHEM, V213, P39, DOI 10.1111/j.1432-1033.1993.tb17732.x; NOGUCHI S, 1992, EUR J BIOCHEM, V209, P883, DOI 10.1111/j.1432-1033.1992.tb17361.x; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PIERCE M, 1986, J BIOL CHEM, V261, P772; PRIEM B, 1990, GLYCOCONJUGATE J, V7, P121, DOI 10.1007/BF01050375; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; SAWADA R, 1993, J BIOL CHEM, V268, P12675; SEKO A, 1991, BIOCHEM BIOPH RES CO, V180, P1165, DOI 10.1016/S0006-291X(05)81318-X; SEKO A, 1989, J BIOL CHEM, V264, P15922; SEKO A, 1991, J BIOL CHEM, V266, P22110; SHIMODA Y, 1993, GLYCOCONJUGATE J, V10, P264, DOI 10.1007/BF01209938; SPOONCER E, 1984, J BIOL CHEM, V259, P4792; SVENNERHOLM L, 1963, METHOD ENZYMOL, V6, P459, DOI 10.1016/0076-6879(63)06206-6; TAGUCHI T, 1993, J BIOL CHEM, V268, P2353; UCHIDA Y, 1977, J BIOCHEM-TOKYO, V82, P1425, DOI 10.1093/oxfordjournals.jbchem.a131830; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WOODWARD JR, 1992, GLYCOBIOLOGY, V2, P241, DOI 10.1093/glycob/2.3.241; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772; YUREWICZ EC, 1987, J BIOL CHEM, V262, P564	42	40	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8762	8771						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132608				2022-12-25	WOS:A1994NB41100025
J	LI, RS; ABRAHAMSEN, MS; JOHNSON, RR; MORRIS, DR				LI, RS; ABRAHAMSEN, MS; JOHNSON, RR; MORRIS, DR			COMPLEX INTERACTIONS AT A GC-RICH DOMAIN REGULATE CELL TYPE-DEPENDENT ACTIVITY OF THE ORNITHINE DECARBOXYLASE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; TRANSCRIPTIONAL ACTIVATION; RESPONSE ELEMENT; RETINOIC ACID; MAMMALIAN-CELLS; GENE-EXPRESSION; SP1; MECHANISMS; CLONING; FAMILY	Regulation of ornithine decarboxylase (ODC) is critical to the control of cellular growth, differentiation, and carcinogenesis. A GC-rich region in the ODC promoter contains two overlapping protein binding sites that interact to regulate basal level expression in some cell types. A perfect binding motif for transcription factor Sp1 (CCCCGCCCC) is located at nucleotides -114 to -106 relative to the site of transcriptional initiation, binds strongly to purified Spl protein, and forms several complexes when incubated with nuclear extracts. Only one of these complexes is recognized by Sp1-specific antibody. A new protein-binding motif (GCCCCTCCCCC, located at -110 to -100) partially overlaps with the Spl site and analysis by DNase I protection showed that a new protein (''NF-ODC1'') and the Sp1-like proteins interact with the ODC promoter in a mutually exclusive manner. Mutation of the NF-ODC1 binding motif strongly enhanced ODC promoter strength in some cell types, but had little or no influence in others. The effect of mutating the Sp1 site also varied with cell type. These cell type specificities did not correlate with the levels of Sp1 and NF-ODC1, binding activities in nuclear extracts. These results show that regulation of the ODC promoter by the Sp1 family is cell type specific and modulated by a negative effector that we have termed NF-ODC1.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; MONTANA STATE UNIV,DEPT VET MOLEC BIOL,BOZEMAN,MT 59717	University of Washington; University of Washington Seattle; Montana State University System; Montana State University Bozeman			Morris, David/G-4503-2011; Li, Runsheng/AFR-9519-2022	Li, Runsheng/0000-0003-1563-1844	NCI NIH HHS [CA39053] Funding Source: Medline; NIDCR NIH HHS [DE08229] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039053] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008229] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABRAHAMSEN MS, 1990, MOL CELL BIOL, V10, P5525, DOI 10.1128/MCB.10.10.5525; ABRAHAMSEN MS, 1992, J BIOL CHEM, V267, P18866; ABRAHAMSEN MS, 1991, PERSPECTIVES CELL RE, P107; ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; AMMOENDOLA R, 1992, J BIOL CHEM, V267, P17944; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BHAT G, 1987, EMBO J, V6, P2045, DOI 10.1002/j.1460-2075.1987.tb02469.x; BRABANT M, 1988, P NATL ACAD SCI USA, V85, P2200, DOI 10.1073/pnas.85.7.2200; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; CORNWELL MM, 1993, J BIOL CHEM, V268, P19505; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DARROW AL, 1990, MOL CELL BIOL, V10, P5883, DOI 10.1128/MCB.10.11.5883; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FITZGERALD MC, 1989, DNA-J MOLEC CELL BIO, V8, P623, DOI 10.1089/dna.1.1989.8.623; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HANNINK M, 1990, ONCOGENE, V5, P1843; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; HENTHORN P, 1989, NUCLEIC ACIDS RES, V17, P6545; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KATZ A, 1988, J BIOL CHEM, V263, P7604; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LEHMANN JM, 1992, MOL CELL BIOL, V12, P2976, DOI 10.1128/MCB.12.7.2976; LEONARD J, 1992, P NATL ACAD SCI USA, V89, P6247, DOI 10.1073/pnas.89.14.6247; LUK GD, 1984, NEW ENGL J MED, V311, P80, DOI 10.1056/NEJM198407123110202; MATSUZAWA Y, 1991, ONCOGENE, V6, P1561; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MORRIS DR, 1991, J CELL BIOCHEM, V46, P102, DOI 10.1002/jcb.240460203; MOSHIER JA, 1993, CANCER RES, V53, P2618; MOSHIER JA, 1992, NUCLEIC ACIDS RES, V20, P2581, DOI 10.1093/nar/20.10.2581; PALVIMO JJ, 1991, NUCLEIC ACIDS RES, V19, P3921, DOI 10.1093/nar/19.14.3921; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; QUINN PG, 1993, J BIOL CHEM, V268, P16999; ROBIDOUX S, 1992, MOL CELL BIOL, V12, P3797; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J, 1989, MOL CLONING LABORATO; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TAN SH, 1992, NUCLEIC ACIDS RES, V20, P251, DOI 10.1093/nar/20.2.251; VERMA AK, 1988, CANCER RES, V48, P2168; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; WEN L, 1989, J BIOL CHEM, V264, P9016; WINOTO A, 1989, EMBO J, V8, P729, DOI 10.1002/j.1460-2075.1989.tb03432.x; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773	56	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7941	7949						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132514				2022-12-25	WOS:A1994NB40900020
J	COGHLAN, VM; LANGEBERG, LK; FERNANDEZ, A; LAMB, NJC; SCOTT, JD				COGHLAN, VM; LANGEBERG, LK; FERNANDEZ, A; LAMB, NJC; SCOTT, JD			CLONING AND CHARACTERIZATION OF AKAP-95, A NUCLEAR-PROTEIN THAT ASSOCIATES WITH THE REGULATORY SUBUNIT OF TYPE-II CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; CYCLIC-AMP; CATALYTIC SUBUNITS; SUBCELLULAR-LOCALIZATION; ANCHORING PROTEINS; HEPATOMA-CELLS; GOLGI-COMPLEX; BOVINE BRAIN; RII; EXPRESSION	The subcellular location of the type II cAMP-depend- ent protein kinase is dictated by the interaction of the regulatory subunit (RII) with A-kinase anchor proteins (AKAPs). Using an interaction cloning strategy with RII alpha as a probe, we have isolated cDNAs encoding a novel 761-amino acid protein (named AKAP 95) that con- tains both RII- and DNA-binding domains. Deletion analysis and peptide studies revealed that the RII-binding domain of AKAP 95 is located between residues 642 and 659 and includes a predicted amphipathic helix. Zinc overlay and DNA binding studies suggest that the DNA-binding domain is composed of two CC/HH-type zinc fingers between residues 464 and 486 and residues 553 and 576. The AKAP was detected in a nuclear matrix fraction, and immunofluorescence using purified anti-AKAP 95 antibodies revealed a distinct nuclear staining in a variety of cell types. Direct overlay of fluorescein isothiocyanate-labeled RII alpha onto fixed rat embryo fibroblasts showed that high-affinity binding sites for RII exist in the nucleus and that these sites are blocked by an anchoring inhibitor peptide. Furthermore, AKAP 95 was detected in preparations of RII that were purified from cellular extracts using cAMP-agarose. The results suggest that AKAP 95 could play a role in targeting type II cAMP-dependent protein kinase for cAMP-responsive nuclear events.	CNRS,CTR RECH BIOCHIM MACROMOLEC,F-34033 MONTPELLIER,FRANCE; OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201	Centre National de la Recherche Scientifique (CNRS); Oregon Health & Science University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048231, R37GM048231] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44239] Funding Source: Medline; NIGMS NIH HHS [GM48231] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BYUS CV, 1982, J CELL BIOL, V93, P727, DOI 10.1083/jcb.93.3.727; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, TRENDS BIOCHEM SCI, V17, P246, DOI 10.1016/0968-0004(92)90402-U; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; COGHLAN VM, 1993, MOL CELL BIOCHEM, V128, P309, DOI 10.1007/BF01076780; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; CORBIN JD, 1975, J BIOL CHEM, V250, P218; CORBIN JD, 1977, J BIOL CHEM, V252, P3854; CUMMING R, 1981, NEUROSCIENCE, V6, P953, DOI 10.1016/0306-4522(81)90176-7; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; FLETCHER WH, 1986, J BIOL CHEM, V261, P5504; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HAKES DJ, 1991, P NATL ACAD SCI USA, V88, P6186, DOI 10.1073/pnas.88.14.6186; HAKES DJ, 1991, J BIOL CHEM, V266, P11131; HARPER JF, 1985, VITAM HORM, V42, P197; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; JOACHIM S, 1990, EUR J CELL BIOL, V51, P76; JOLY JC, 1989, J CELL BIOL, V109, P2289, DOI 10.1083/jcb.109.5.2289; KAPTEIN R, 1991, CURR OPIN STRUC BIOL, V2, P109; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KUETTEL MR, 1985, J CELL BIOL, V101, P965, DOI 10.1083/jcb.101.3.965; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB NJC, 1991, EMBO J, V10, P1523, DOI 10.1002/j.1460-2075.1991.tb07672.x; LEISER M, 1986, J BIOL CHEM, V261, P1904; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; NICKERSON JA, 1992, J CELL BIOL, V116, P977, DOI 10.1083/jcb.116.4.977; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; NILAVER G, 1989, TECHNIQUES IMMUNOCYT, V4, P199; RUBIN CS, 1972, J BIOL CHEM, V247, P6135; RUBIN CS, 1979, J BIOL CHEM, V254, P3797; SALVATORI S, 1990, BIOCHEM J, V267, P679, DOI 10.1042/bj2670679; SAMBROOK J, 1989, MOL CLON LABORATORY; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JD, 1992, NEWS PHYSIOL SCI, V7, P143; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SIKORSKA M, 1988, J BIOL CHEM, V263, P3005; STAUFENBIEL M, 1984, J CELL BIOL, V98, P1886, DOI 10.1083/jcb.98.5.1886; STOFKOHAHN RE, 1992, FEBS LETT, V302, P274, DOI 10.1016/0014-5793(92)80458-S; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUTHERLAND EW, 1972, SCIENCE, V177, P401, DOI 10.1126/science.177.4047.401; VANDRIEL R, 1991, J CELL BIOCHEM, V47, P311, DOI 10.1002/jcb.240470405; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455	59	114	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7658	7665						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125992				2022-12-25	WOS:A1994NA03200098
J	SHIPLEY, JM; CLARK, J; CREW, AJ; BIRDSALL, S; ROCQUES, PJ; GILL, S; CHELLY, J; MONACO, AP; ABE, S; GUSTERSON, BA; COOPER, CS				SHIPLEY, JM; CLARK, J; CREW, AJ; BIRDSALL, S; ROCQUES, PJ; GILL, S; CHELLY, J; MONACO, AP; ABE, S; GUSTERSON, BA; COOPER, CS			THE T(X18)(P11.2Q11.2) TRANSLOCATION FOUND IN HUMAN SYNOVIAL SARCOMAS INVOLVES 2 DISTINCT LOCI ON THE X-CHROMOSOME	ONCOGENE			English	Article							BREAKPOINT; LIBRARIES	A high proportion of synovial sarcomas contain the reciprocal translocation t(X;18)(p11.2;q11.2). We have previously localized the breakpoint on the X chromosome between the X chromosome marker DXS255 and an ornithine aminotransferase (OAT) pseudogene region designated OATL2. Subsequently by fluorescence in situ hybridization (FISH) we provided evidence that YACs corresponding to the OATL2 locus spanned the breakpoint. In order to confirm the position of this breakpoint cosmids corresponding to the OATL2 region were isolated. Most of these cosmids mapped to four cosmid contigs designated C1-C4. Analysis of two contigs, C1-and C4, using FISH established that in four of six synovial sarcomas examined the breakpoint occurs between these two contigs: C1 lies distal to the breakpoint while C4 is proximal. In contrast we provide evidence that the breakpoint in the remaining two tumours mapped to a second pseudogene region called OATL1 that is telomeric to the OATL2 locus. This heterogeneity of the breakpoint position on the X chromosome explains why in previous mapping studies there have been discrepancies between the results obtained by different laboratories.	INST CANC RES, MOLEC CARCINOGENESIS SECT, SUTTON SM2 5NG, SURREY, ENGLAND; JOHN RADCLIFFE HOSP, IMPERIAL CANC RES FUND, HUMAN GENET LAB, OXFORD OX3 9DU, ENGLAND; HOKKAIDO UNIV, FAC SCI, CHROMOSOME RES UNIT, SAPPORO, HOKKAIDO, JAPAN	University of London; Institute of Cancer Research - UK; University of Oxford; Hokkaido University	SHIPLEY, JM (corresponding author), INST CANC RES, CELL BIOL & EXPTL PATHOL SECT, 15 COTSWOLD RD, SUTTON SM2 5NG, SURREY, ENGLAND.		gusterson, barry a/D-3752-2009; Monaco, Anthony P/A-4495-2010; Chelly, Jamel/J-7528-2015	Monaco, Anthony P/0000-0001-7480-3197; Chelly, Jamel/0000-0002-0939-8719; Shipley, Janet/0000-0001-6748-8678				BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BAXENDALE S, 1991, NUCLEIC ACIDS RES, V19, P6651, DOI 10.1093/nar/19.23.6651; COOPER CS, 1993, ADV CANCER RES, V60, P75; COOPER CS, 1991, CARCINOGENESIS, V12, P155, DOI 10.1093/carcin/12.2.155; CORY S, 1985, EMBO J, V4, P675, DOI 10.1002/j.1460-2075.1985.tb03682.x; Coulson Alan, 1988, P19; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELEEUW B, 1993, ONCOGENE, V8, P1457; DELEEUW B, 1993, GENE CHROMOSOME CANC, V6, P182, DOI 10.1002/gcc.2870060309; Enzinger RM., 2011, SOFT TISSUE TUMORS, P1178; GERAGHTY MT, 1993, GENOMICS, V16, P440, DOI 10.1006/geno.1993.1208; GILGENKRANTZ S, 1990, ONCOGENE, V5, P1063; GREIG GM, 1993, HUM MOL GENET, V2, P1611; KNIGHT JC, 1992, HUM MOL GENET, V1, P633, DOI 10.1093/hmg/1.8.633; KNIGHT JC, 1992, INT J ONCOL, V1, P747; LAFRENIERE RG, 1991, GENOMICS, V10, P276, DOI 10.1016/0888-7543(91)90512-D; LIMON J, 1991, GENE CHROMOSOME CANC, V3, P338, DOI 10.1002/gcc.2870030504; LITTLE PFR, 1987, DNA CLONING PRACTICA, V3, P19; NIZETIC D, 1991, P NATL ACAD SCI USA, V88, P3233, DOI 10.1073/pnas.88.8.3233; NOJIMA T, 1990, ACTA PATHOL JAPON, V40, P486; REEVES BR, 1989, ONCOGENE, V4, P373; RUBIN CM, 1988, P NATL ACAD SCI USA, V85, P2795, DOI 10.1073/pnas.85.8.2795; SHENG WW, 1987, CANCER GENET CYTOGEN, V29, P179, DOI 10.1016/0165-4608(87)90048-3; SHIPLEY JM, 1993, CYTOGENET CELL GENET, V64, P233, DOI 10.1159/000133585; SMITH S, 1987, CANCER GENET CYTOGEN, V26, P179, DOI 10.1016/0165-4608(87)90147-6; SONOBE H, 1992, LAB INVEST, V67, P498; TACHIBANA K, 1993, GENE, V124, P231, DOI 10.1016/0378-1119(93)90398-M; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; WAHL GM, 1987, P NATL ACAD SCI USA, V84, P2160, DOI 10.1073/pnas.84.8.2160	29	53	55	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1994	9	5					1447	1453						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152806				2022-12-25	WOS:A1994NH40100017
J	ADLER, V; UNLAP, T; KRAFT, AS				ADLER, V; UNLAP, T; KRAFT, AS			A PEPTIDE ENCODING THE C-JUN DELTA-DOMAIN INHIBITS THE ACTIVITY OF A C-JUN AMINO-TERMINAL PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC INHIBITOR; V-JUN; TRANSCRIPTIONAL ACTIVATION; PHOSPHORYLATION; ONCOGENE; AP-1; MEMBER; FAMILY	Evidence suggests that the c-Jun protooncogene delta (delta) domain (amino acids 31-60) helps regulate the transcriptional activating capacity of c-Jun by modulating the amino-terminal phosphorylation of this protein. By using a peptide encoding the delta domain and purified amino-terminal c-Jun protein kinase, we demonstrate that the delta domain peptide inhibits phosphorylation of the amino terminus of both c-Jun and the related protein JunD. The delta domain peptide inhibited the activation of the c-Jun amino-terminal protein kinase by phorbol esters in permeabilized U937 leukemic cells. Mutation of c-Jun followed by transfection into U937 leukemic cells demonstrated that partial deletions of the delta domain are sufficient to block phosphorylation of the amino terminus of c-Jun. In vitro deletion of the amino-terminal (amino acids 31-44) half of the delta domain inhibited the phosphorylation of c-Jun. However, deletion of the carboxyl-terminal (amino acids 45-60) half only partially inhibited c-Jun phosphorylation. Therefore, these results indicate that the delta domain sequence is an important regulator of c-Jun amino-terminal phosphorylation.	UNIV ALABAMA,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42533] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, J BIOL CHEM, V267, P17001; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; DEFIZE LHK, 1993, J CELL BIOCHEM, V17, P298; FRANKLIN CC, 1993, CELL GROWTH DIFFER, V4, P377; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507	20	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11186	11191						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157646				2022-12-25	WOS:A1994NF96600034
J	COLAMONICI, OR; PORTERFIELD, B; DOMANSKI, P; CONSTANTINESCU, S; PFEFFER, LM				COLAMONICI, OR; PORTERFIELD, B; DOMANSKI, P; CONSTANTINESCU, S; PFEFFER, LM			COMPLEMENTATION OF THE INTERFERON-ALPHA RESPONSE IN RESISTANT CELLS BY EXPRESSION OF THE CLONED SUBUNIT OF THE INTERFERON-ALPHA RECEPTOR - A CENTRAL ROLE OF THIS SUBUNIT IN INTERFERON - SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; CLONING; CDNA; HORMONE; KINASE; LINES	A subunit of the interferon alpha receptor (IFNalphaR) that confers biologic response to and specific ''binding''1 for IFNalpha8 has recently been cloned. We have explored the biological consequences of expressing the cloned IFNalphaR subunit in human cells resistant to IFNalpha and in mouse cell lines nonresponsive to human IFNalpha. The expression of the cloned IFNalphaR subunit in the human IFNalpha-resistant K-562 cell line restored sensitivity to the antiviral effect of not only IFNalpha8 but also IFNalpha2 and IFNalphaCon1. In mouse L-929 cells the expression of the cloned receptor subunit markedly increased antiviral sensitivity to human type I IFNs. In either human K-562 or mouse L-929 cells these effects were observed without a detectable increase in the binding for any of the subtypes of IFNalpha tested. We propose that the cloned IFNalphaR subunit functions as a transducer subunit for the IFNalphaR. This concept is supported by the finding that the cloned receptor protein, when it is expressed in Cos cells, has an M(r) of 75 kDa, which is different from the main IFNalpha-binding proteins, the alpha and beta subunits of the IFNalphaR. This report also suggests that alterations at the receptor level could be involved in IFNalpha resistance in some cell lines.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago	COLAMONICI, OR (corresponding author), UNIV TENNESSEE CTR HLTH SCI,DEPT PATHOL,800 MADISON AVE,MEMPHIS,TN 38163, USA.		Constantinescu, Stefan N/E-5277-2012	Constantinescu, Stefan N./0000-0002-8599-2699; Pfeffer, Lawrence/0000-0003-2809-1234	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036716] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36716] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUET M, 1980, NATURE, V284, P459, DOI 10.1038/284459a0; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, CELL, V61, P753, DOI 10.1016/0092-8674(90)90182-E; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BENOIT P, 1993, J IMMUNOL, V150, P707; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; COLAMONICI OR, 1986, MOL CELL BIOL, V6, P1847, DOI 10.1128/MCB.6.5.1847; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; COLAMONICI OR, 1991, PHARMACOL THERAPEUT, V52, P227, DOI 10.1016/0163-7258(91)90010-J; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; KESSLER DS, 1988, EMBO J, V7, P3779, DOI 10.1002/j.1460-2075.1988.tb03262.x; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFER LM, 1990, CANCER RES, V50, P2654; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; PFEFFER LM, 1987, J BIOL CHEM, V262, P3665; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VANDENBROECKE C, 1988, J INTERFERON RES, V8, P803; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L	25	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9598	9602						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144546				2022-12-25	WOS:A1994NE05300033
J	NORDSTEDT, C; NASLUND, J; THYBERG, J; MESSAMORE, E; GANDY, SE; TERENIUS, L				NORDSTEDT, C; NASLUND, J; THYBERG, J; MESSAMORE, E; GANDY, SE; TERENIUS, L			HUMAN NEUTROPHIL PHAGOCYTIC GRANULES CONTAIN A TRUNCATED SOLUBLE FORM OF THE ALZHEIMER BETA/A4 AMYLOID PRECURSOR PROTEIN (APP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; INHIBITORY PROPERTIES; HUMAN-PLATELETS; SECRETED FORM; KUNITZ DOMAIN; NEXIN-II; DISEASE; CELLS; CDNA; IDENTIFICATION	We have characterized the molecular species and subcellular distribution of Alzheimer beta/A4 amyloid precursor protein (APP) in neutrophilic granulocytes purified from human peripheral blood. APP was readily detectable in these cells. Immunochemical analysis with a panel of antibodies revealed that this APP species lacked the transmembrane and cytoplasmic domains previously demonstrated in cell-associated APP. However, it contained a protease inhibitor domain of the Kunitz type, indicating that neutrophil APP is a potent inhibitor of certain serine proteases. Upon subcellular fractionation, APP was primarily localized to azurophilic granules, which are neutrophil-specific phagocytic organelles assigned to enzymatic digestion of invading microbes and dead or injured tissue. Apparently, in the neutrophil, a nonsecretory organelle stores truncated, soluble APP, a species previously found only in blood plasma and cerebrospinal fluid or in conditioned medium of cultured cells. Soluble APP in neutrophils may therefore have intracellular functions in addition to its previously described extracellular functions. These findings also indicate that there are previously uncharacterized cell-specific differences in processing, trafficking, and storage of the APP molecule. Finally, the precise subcellular localization of APP to neutrophil-specific phagocytic organelles is suggestive of a role for APP in the nonimmunological host defense.	KAROLINSKA INST, MED NOBEL INST, DEPT CELL & MOLEC BIOL, S-17177 STOCKHOLM, SWEDEN; KAROLINSKA INST, HUDDINGE UNIV HOSP, DEPT GERIATR MED, S-14186 HUDDINGE, SWEDEN; CORNELL UNIV, MED CTR, COLL MED, DEPT NEUROL & NEUROSCI, NEW YORK, NY 10021 USA	Karolinska Institutet; Karolinska Institutet; Cornell University	NORDSTEDT, C (corresponding author), KAROLINSKA INST, DEPT CLIN NEUROSCI, DRUG ADDICT RES SECT, S-17176 STOCKHOLM, SWEDEN.				NHLBI NIH HHS [HL49571-01] Funding Source: Medline; NIA NIH HHS [AG 11508] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011508, R55AG011508] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BUSH AI, 1990, J BIOL CHEM, V265, P15977; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GABAY JE, 1986, J EXP MED, V164, P1407, DOI 10.1084/jem.164.5.1407; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HALLET MB, 1989, NEUTROPHIL CELLULAR; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; MIYAZAKI K, 1993, NATURE, V362, P839, DOI 10.1038/362839a0; MONNING U, 1990, FEBS LETT, V277, P261, DOI 10.1016/0014-5793(90)80861-C; MONNING U, 1992, J BIOL CHEM, V267, P23950; MUSTARD JF, 1989, METHOD ENZYMOL, V169, P3; NORDSTEDT C, 1993, J BIOL CHEM, V268, P608; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEUERT P, 1992, NATURE, V359, P325; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SINHA S, 1990, J BIOL CHEM, V265, P8983; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; SPITZNAGEL JK, 1974, LAB INVEST, V30, P774; STORRIE B, 1990, GUIDE PROTEIN PURIFI; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; VANNOSTRAND WE, 1989, NATURE, V341, P546; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WUNDERLICH D, 1992, J IMMUNOL METHODS, V147, P1	40	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9805	9810						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144573				2022-12-25	WOS:A1994NE05300064
J	AYOUBI, TAY; CREEMERS, JWM; ROEBROEK, AJM; VANDEVEN, WJM				AYOUBI, TAY; CREEMERS, JWM; ROEBROEK, AJM; VANDEVEN, WJM			EXPRESSION OF THE DIBASIC PROPROTEIN PROCESSING ENZYME FURIN IS DIRECTED BY MULTIPLE PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILISIN-LIKE PROTEASE; GENE-EXPRESSION; BETA-SUBUNIT; YEAST KEX2; TRANSCRIPTION; ENDOPROTEASE; SEQUENCE; CDNA; CLEAVAGE; PROTEINS	The prototype mammalian proprotein processing enzyme furin is shown to be encoded by three distinct FUR mRNA isoforms which differ only in their 5'-untranslated regions. By primer extension analysis, the transcription start sites of the three mRNA isoforms were defined. The genomic regions located immediately up stream of the three alternative transcriptional start sites were shown to possess promoter activity in transfection experiments using the luciferase encoding gene as reporter. In a liver cell line, the P1 promoter appeared to be the strongest; in a lung cell line, the P1A promoter. Human FUR promoter P1 but not P1A or P1B was transactivated by transcription factor C/EBP beta. Other members of this family of bZIP transcription factors, C/EBP alpha and C/EBP delta, were not able to transactivate the P1 promoter. Promoter P1A and P1B have characteristics of promoters of housekeeping genes. They lack TATA or CAAT boxes upstream of the transcription start site but are very GC-rich and contain several SP1 sites. Promoter P1, on the other hand, has a TATA box in the proximal promoter region. In electromobility shift assays and DNase I footprinting analysis, transcription factor SP1 was found to bind to the proximal region of the P1 promoter. Altogether, our results indicate that expression of the human FUR gene is directed by alternative promoters, housekeeping (GC-rich) as well as regulated (TATA-containing) promoters, suggesting that their differential use may be a mechanism to modulate levels of the furin enzyme.			AYOUBI, TAY (corresponding author), UNIV LEUVEN,CTR HUMAN GENET,MOLEC ONCOL LAB,HERESTR 49,B-3000 LOUVAIN,BELGIUM.							BARR PJ, 1991, DNA CELL BIOL, V10, P319, DOI 10.1089/dna.1991.10.319; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CARR FE, 1987, J BIOL CHEM, V262, P981; CREEMERS JWM, 1992, FEBS LETT, V300, P82, DOI 10.1016/0014-5793(92)80169-H; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KASAI Y, 1992, MOL CELL BIOL, V12, P2884, DOI 10.1128/MCB.12.6.2884; KIM JG, 1992, MOL CELL BIOL, V12, P5631; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KLIMPEL KR, 1992, P NATL ACAD SCI US, V89; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MISUMI Y, 1990, NUCLEIC ACIDS RES, V18, P6719, DOI 10.1093/nar/18.22.6719; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; ROBIDOUX S, 1992, MOL CELL BIOL, V12, P3796, DOI 10.1128/MCB.12.9.3796; Roebroek A. J. M., 1992, MOL BIOL LIFE SCI AD, V11, P127; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SCHALKEN JA, 1987, J CLIN INVEST, V80, P1545, DOI 10.1172/JCI113240; SCHIBLER U, 1987, ANNU REV GENET, V21, P237, DOI 10.1146/annurev.ge.21.120187.001321; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VANDENOUWELAND AMW, 1989, NUCLEIC ACIDS RES, V17, P7101, DOI 10.1093/nar/17.17.7101; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; WASLEY LC, 1993, J BIOL CHEM, V268, P8458; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; WOLF O, 1987, J BIOL CHEM, V262, P16596	45	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9298	9303						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132667				2022-12-25	WOS:A1994NB41100098
J	SHELNESS, GS; MORRISROGERS, KC; INGRAM, MF				SHELNESS, GS; MORRISROGERS, KC; INGRAM, MF			APOLIPOPROTEIN B48-MEMBRANE INTERACTIONS - ABSENCE OF TRANSMEMBRANE LOCALIZATION IN NONHEPATIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; BETA-N-ACETYLGLUCOSAMINIDASE; LOW-DENSITY LIPOPROTEINS; PROTEIN TRANSLOCATION; MICROSOMAL-MEMBRANES; SEQUENCE; IDENTIFICATION; PURIFICATION; OLIGOSACCHARIDES; RECONSTITUTION	Apolipoprotein B (apoB) is essential for the hepatic assembly and secretion of triglyceride-rich very low density lipoproteins. Recent studies have revealed that in both hepatic and nonhepatic cells a large percentage of newly synthesized apoB polypeptides engage in transmembrane interactions with the endoplasmic reticulum (ER). These apoB-membrane interactions have been implicated in the processes of lipoprotein assembly and regulation. To identify domains of apoB that are responsible for its transmembrane localization, overlapping 300 amino acid segments of human apoB48 (amino-terminal 48% of apoB) and two control proteins, human complement component C3 and mouse CD4, were appended to the amino-terminal 77 amino acids of a soluble secretory precursor protein and expressed in COS-1 cells. While the integral membrane protein CD4 conferred predictable transmembrane orientation on the hybrid protein, as evidenced by its partial protease accessibility in intact microsomes, all of the apoB-containing proteins and the soluble secretory control, C3, were fully protease-resistant, consistent with their complete translocation into the ER. To determine if conformational properties of apoB are responsible for its transmembrane interactions with the ER, proteins containing the entire amino-terminal similar to 50% of apoB (apoB50) were expressed in COS-1 cells. Irrespective of whether targeting and translocation initiation were directed by a heterologous signal peptide or the native apoB signal peptide, apoB50 appeared to undergo complete membrane translocation into a protease inaccessible compartment. These results demonstrate that the amino-terminal 50% of apoB lacks autonomous signals or properties that can fully block ER membrane translocation or promote any other form of stable transmembrane assembly in nonhepatic cells.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,MOLEC GENET RES & TRAINING PROGRAM,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center	SHELNESS, GS (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT COMPARAT MED,WINSTON SALEM,NC 27157, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049373] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-O5404] Funding Source: Medline; NHLBI NIH HHS [HL49373] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BOREN J, 1993, BIOCHEM SOC T, V21, P487, DOI 10.1042/bst0210487; BOREN J, 1993, ARTERIOSCLER THROMB, V18, P1748; BRIZZARD B, 1994, IN PRESS BIOTECHNIQU; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHUCK SL, 1993, J BIOL CHEM, V268, P22794; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; DIXON JL, 1992, J CELL BIOL, V117, P1161, DOI 10.1083/jcb.117.6.1161; DIXON JL, 1993, J LIPID RES, V34, P167; ESSER V, 1988, J BIOL CHEM, V263, P13282; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GILMORE R, 1991, Current Opinion in Cell Biology, V3, P580, DOI 10.1016/0955-0674(91)90026-U; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; Higuchi R., 1989, PCR TECHNOLOGY, P61; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; KNOTT TJ, 1986, NUCLEIC ACIDS RES, V14, P7501, DOI 10.1093/nar/14.18.7501; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PARNES JR, 1987, IMMUNOL REV, V100, P109, DOI 10.1111/j.1600-065X.1987.tb00529.x; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; PEASE RJ, 1993, CIRCULATION, V88, P177; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; Sambrook J, 1989, MOL CLONING LABORATO; SASAVAGE NL, 1982, J BIOL CHEM, V257, P678; SCHEELE G, 1983, METHOD ENZYMOL, V96, P94; SHELNESS GS, 1993, J BIOL CHEM, V268, P5201; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; WALTER P, 1979, P NATL ACAD SCI USA, V76, P1795, DOI 10.1073/pnas.76.4.1795; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WILKINSON J, 1993, J LIPID RES, V34, P815; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	52	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9310	9318						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132669				2022-12-25	WOS:A1994NB41100100
J	COELHOSAMPAIO, T; VOSS, EW				COELHOSAMPAIO, T; VOSS, EW			ANTI-METATYPE ANTIBODIES STABILIZE THE FLUORESCEIN SINGLE-CHAIN ANTIBODY-4-4-20 COMPLEX AGAINST DISSOCIATION BY HYDROSTATIC-PRESSURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; FAB COMPLEX; AFFINITY; PROTEINS; IDIOTYPE; DNA	Hydrostatic pressure was used to promote dissociation of fluorescein (Fl) from single-chain antibody 4-4-20 (SCA 4-4-20). Fl fluorescence intensity was quenched by 97% upon binding to SCA 4-4-20. Increasing pressure to 2.4 kbar enhanced Fl fluorescence from the remaining 3% to 14-17%. The capacity of anti-metatype antibodies (anti-Met), which specifically recognize liganded anti-Fl antibodies, to protect against pressure-induced Fl dissociation was tested. Both polyclonal and monoclonal anti-Met antibodies protected against Fl dissociation, reducing the fluorescence intensity at 2.4 kbar from 14-17% to 6-8%. Additive effects of anti-Met antibodies in protection against pressure-induced Fl dissociation were suggested by the fact that a 2-fold molar excess polyclonal anti-Met reagent promoted additional protection relative to an equimolar amount. On the other hand, combination of different monoclonal anti-Met antibodies did not promote additive protection, suggesting recognition of overlapping metatopes by these monoclonals. The complex formed by SCA 4-4-20 and the Fl analog HPF was more sensitive to pressure than the Fl-SCA 4-4-20 complex. Addition of both polyclonal and monoclonal anti Met antibodies reduced the Fl fluorescence recovery at 2.4 kbar from 75% to 40-55%. In order to directly study binding of anti-Met antibodies to mAb 4-4-20, monoclonal anti-Met antibody 3A5-1 was labeled with 2-dimethylaminonaphthalene-5-sulfonyl chloride (2,5-Dns Cl) and Dns fluorescence anisotropy measured. Unliganded mAb 4-4-20 did not bind to 2,5-Dns-3A5-1 as indicated by the absence of measurable changes in Dns fluorescence anisotropy upon increasing mAb concentration. Addition of mAb 4-4-20 bound to Fl produced a sigmoidal increase in Dns anisotropy, compatible with association of the primary im immune complex and 3A5-1. An affinity constant, K-0.5, of 1.5 x 10(-7) M and a cooperativity coefficient (n) of 3.1 were calculated for formation of the Fl-mAb 4-4-20 complex. The HPF mAb 4-4-20 complex was also recognized by 2,5-Dns-3A5-1 but with lower affinity, indicating that the monoclonal anti-Met 3A5-1 distinguished between mAb 4-4-20 liganded to different haptens.	UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign								BEDZYK WD, 1992, BIOCHIM BIOPHYS ACTA, V1119, P27, DOI 10.1016/0167-4838(92)90229-7; BEDZYK WD, 1990, J BIOL CHEM, V265, P18615; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; COELHOSAMPAIO T, 1993, BIOCHEMISTRY-US, V32, P10929, DOI 10.1021/bi00092a001; DENZIN LK, 1991, J BIOL CHEM, V266, P14095; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HERRON JN, 1981, J BIOCHEM BIOPH METH, V5, P1, DOI 10.1016/0165-022X(81)90029-4; HERRON JN, 1984, FLUORESCEIN HAPTEN I, P49; Karush F, 1978, IMMUNOGLOBULINS, P85; KRANZ DM, 1983, MOL IMMUNOL, V20, P1313, DOI 10.1016/0161-5890(83)90162-1; KRANZ DM, 1981, MOL IMMUNOL, V18, P889, DOI 10.1016/0161-5890(81)90012-2; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; PALADINI AA, 1981, BIOCHEMISTRY-US, V20, P2587, DOI 10.1021/bi00512a034; REINITZ DM, 1984, MOL IMMUNOL, V21, P775, DOI 10.1016/0161-5890(84)90164-0; RUMBLEY CA, 1993, J BIOL CHEM, V268, P13667; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; SMITH RG, 1990, MOL IMMUNOL, V27, P463, DOI 10.1016/0161-5890(90)90171-U; VOSS EW, 1988, MOL IMMUNOL, V25, P751, DOI 10.1016/0161-5890(88)90111-3; VOSS EW, 1989, MOL IMMUNOL, V26, P971, DOI 10.1016/0161-5890(89)90115-6; VOSS EW, 1992, MOL IMMUNOL, V29, P241, DOI 10.1016/0161-5890(92)90105-7; VOSS EW, 1993, MOL IMMUNOL, V30, P949, DOI 10.1016/0161-5890(93)90020-C; WEBER G, 1983, Q REV BIOPHYS, V16, P89, DOI 10.1017/S0033583500004935; Weber G., 1992, PROTEIN INTERACTIONS; WEBER G, 1987, NATO ASI SER C, V197, P401; WEIDNER KM, 1992, J BIOL CHEM, V267, P10281; WEIDNER KM, 1993, MOL IMMUNOL, V30, P1003, DOI 10.1016/0161-5890(93)90125-U; WEIDNER KM, 1991, J BIOL CHEM, V266, P2513	28	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8146	8152						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132540				2022-12-25	WOS:A1994NB40900050
J	KOKEN, SEC; GREIJER, AE; VERHOEF, K; VANWAMEL, J; BUKRINSKAYA, AG; BERKHOUT, B				KOKEN, SEC; GREIJER, AE; VERHOEF, K; VANWAMEL, J; BUKRINSKAYA, AG; BERKHOUT, B			INTRACELLULAR ANALYSIS OF IN-VITRO MODIFIED HIV TAT PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DNA-BINDING ACTIVITY; TRANS-ACTIVATION; MUTATIONAL ANALYSIS; FUNCTIONAL DOMAINS; N-ACETYLCYSTEINE; RNA STRUCTURE; TYPE-1; INVITRO; CELLS	Human immunodeficiency viruses HIV-1 and HIV-2 encode a Tat protein that specifically activates transcription from the viral long terminal repeat. To characterize the properties of the Tat proteins, we have expressed them in Escherichia coli. The purified Tat protein was biochemically analyzed and tested for activity upon electroporation into human cell lines. This protein electroporation was used for the intracellular analysis of in vitro modified Tat protein. Our results indicate that the transcriptionally active form of the Tat protein is a monomer. Furthermore, we found that Tat activity is dramatically inhibited by preincubation of the protein with strongly reducing agents. In contrast, no inhibitory effect was measured upon incubation with metal-chelating reagents. These results suggest that the cysteine residues of Tat are involved in the formation of intramolecular disulfide bonds.	UNIV AMSTERDAM, DEPT VIROL, 1105 AZ AMSTERDAM, NETHERLANDS	University of Amsterdam								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BALHORN R, 1992, ARCH BIOCHEM BIOPHYS, V296, P384, DOI 10.1016/0003-9861(92)90588-N; BALHORN R, 1991, BIOCHEMISTRY-US, V30, P175, DOI 10.1021/bi00215a026; BERKHOUT B, 1990, NUCLEIC ACIDS RES, V18, P1839, DOI 10.1093/nar/18.7.1839; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; BOGERD HP, 1993, J VIROL, V67, P5030, DOI 10.1128/JVI.67.8.5030-5034.1993; BRAKE DA, 1990, J VIROL, V64, P962, DOI 10.1128/JVI.64.2.962-965.1990; CHANDRA A, 1988, FEBS LETT, V236, P282, DOI 10.1016/0014-5793(88)80038-3; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; EMERMAN M, 1987, EMBO J, V6, P3755, DOI 10.1002/j.1460-2075.1987.tb02710.x; FELBER BK, 1988, SCIENCE, V239, P184, DOI 10.1126/science.3422113; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; GARCIA JA, 1988, EMBO J, V7, P3143, DOI 10.1002/j.1460-2075.1988.tb03181.x; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HAUBER J, 1987, P NATL ACAD SCI USA, V84, P6364, DOI 10.1073/pnas.84.18.6364; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; HAYASHI T, 1993, J BIOL CHEM, V268, P1138; KALEBIC T, 1991, P NATL ACAD SCI USA, V88, P986, DOI 10.1073/pnas.88.3.986; KAMINE J, 1991, VIROLOGY, V182, P570, DOI 10.1016/0042-6822(91)90598-6; KASHANCHI F, 1992, NUCLEIC ACIDS RES, V20, P4673, DOI 10.1093/nar/20.17.4673; KIM YS, 1993, J VIROL, V67, P3739, DOI 10.1128/JVI.67.7.3739-3747.1993; KOBAYASHI Y, 1991, BIOPOLYMERS, V31, P1213, DOI 10.1002/bip.360311009; KUBOTA S, 1990, AIDS RES HUM RETROV, V6, P919, DOI 10.1089/aid.1990.6.919; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; Maniatis T., 1982, MOL CLONING; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MYERS G, 1990, HUMAN RETROVIRUSES A; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; PHILPOTT CC, 1993, J BIOL CHEM, V268, P17655; RAPPAPORT J, 1989, New Biologist, V1, P101; RHIM H, 1993, J VIROL, V67, P1110, DOI 10.1128/JVI.67.2.1110-1121.1993; RICE AP, 1990, J VIROL, V64, P1864, DOI 10.1128/JVI.64.4.1864-1868.1990; RICE AP, 1990, J VIROL, V64, P6018, DOI 10.1128/JVI.64.12.6018-6026.1990; RICE AP, 1991, VIROLOGY, V185, P451, DOI 10.1016/0042-6822(91)90797-F; ROEDERER M, 1991, AIDS RES HUM RETROV, V7, P563, DOI 10.1089/aid.1991.7.563; ROTH EJ, 1993, J BIOL CHEM, V267, P16390; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; RUBEN S, 1989, J VIROL, V63, P1; SADAIE MR, 1988, P NATL ACAD SCI USA, V85, P9224, DOI 10.1073/pnas.85.23.9224; SANGER F, 1953, NATURE, V171, P1025, DOI 10.1038/1711025a0; SCHIAVO G, 1990, INFECT IMMUN, V58, P4136, DOI 10.1128/IAI.58.12.4136-4141.1990; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; SLICE LW, 1992, BIOCHEMISTRY-US, V31, P1206; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAAL FJT, 1993, AIDS RES HUM RETROV, V9, P299, DOI 10.1089/aid.1993.9.299; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STEFFY K, 1991, MICROBIOL REV, V55, P193, DOI 10.1128/MMBR.55.2.193-205.1991; STUURMAN N, 1992, EXP CELL RES, V200, P285, DOI 10.1016/0014-4827(92)90174-7; TONGSTARKSEN SE, 1993, VIROLOGY, V195, P826, DOI 10.1006/viro.1993.1438; VERHOEF K, 1993, ANAL BIOCHEM, V210, P210, DOI 10.1006/abio.1993.1176; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	53	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8366	8375						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132560				2022-12-25	WOS:A1994NB40900081
J	ALVES, PC; VIDEIRA, A				ALVES, PC; VIDEIRA, A			DISRUPTION OF THE GENE CODING FOR THE 21.3-KDA SUBUNIT OF THE PERIPHERAL ARM OF COMPLEX-I FROM NEUROSPORA-CRASSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; BOVINE HEART-MITOCHONDRIA; ACYL-CARRIER PROTEIN; ENCODED SUBUNITS; SENSITIVE METHOD; BINDING PROTEIN; REDUCTASE; DEHYDROGENASE; SEQUENCES; INVITRO	A21.3-kDa subunit of the peripheral arm of complex I from Neurospora is encoded by a single chromosomal gene, nuo-21.3b. It is located on linkage group V of the fungal genome, linked to inl. We have isolated and characterized a genomic clone containing this nuclear gene. A DNA fragment containing a portion of the coding region of the gene and upstream flanking sequences was introduced by transformation into a wild-type strain of Neurospora crassa. A single copy transformant was selected and crossed with another strain, leading to inactivation of nuo-21.3b through repeat-induced point mutations. We have analyzed random progeny from this cross and isolated two mutant strains lacking the 21.3-kDa subunit of complex I. One of them was further characterized. Our results suggest that most, if not all, other subunits of complex I are present in the mitochondria of the mutant and assembled in a structure similar to complex I, representing Lambda 25% of the amounts of enzyme found in the wild type. Nevertheless, a major intermediate, containing proteins of the peripheral arm of complex I, accumulates in the mutant mitochondria. This indicates that the absence of the 21.3-kDa polypeptide results in a disturbed assembly of the enzyme complex, suggesting a role for this polypeptide. We observed similar rates of rotenone-sensitive NADH:ubiquinone oxide-reductase activity in mitochondrial membranes from the mutant and wild-type strains and discuss the possibility that this electron transfer is independent of the more hydrophobic part of complex I. Transformation of the mutant with the intact gene and flanking sequences restored the wild-type phenotype.	UNIV PORTO, INST CIENCIAS BIOMED ABEL SALAZAR, P-4000 OPORTO, PORTUGAL	Universidade do Porto			Videira, Arnaldo/H-8150-2013	Videira, Arnaldo/0000-0001-7267-4459				[Anonymous], [No title captured]; AZEVEDO JE, 1992, BIOCHEM J, V288, P29, DOI 10.1042/bj2880029; AZEVEDO JE, 1993, BIOCHEM J, V293, P501, DOI 10.1042/bj2930501; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; DUARTE M, 1993, BIOCHIM BIOPHYS ACTA, V1172, P327, DOI 10.1016/0167-4781(93)90223-Z; EARLEY FGP, 1987, FEBS LETT, V219, P108, DOI 10.1016/0014-5793(87)81200-0; FILSER M, 1988, BIOCHEM PHARMACOL, V37, P2551, DOI 10.1016/0006-2952(88)90245-6; FINEL M, 1992, BIOCHEMISTRY-US, V31, P11425, DOI 10.1021/bi00161a022; FRIEDRICH T, 1989, EUR J BIOCHEM, V180, P173, DOI 10.1111/j.1432-1033.1989.tb14629.x; HALL RE, 1990, J BIOL CHEM, V265, P16484; Hatefi Y, 1978, Methods Enzymol, V53, P11; HEINRICH H, 1992, BIOCHEMISTRY-US, V31, P11420, DOI 10.1021/bi00161a021; HOFHAUS G, 1991, J MOL BIOL, V221, P1027, DOI 10.1016/0022-2836(91)80190-6; HOFHAUS G, 1993, EMBO J, V12, P3043, DOI 10.1002/j.1460-2075.1993.tb05973.x; Lee S.B., 1988, FUNGAL GENET REP, V35, P23, DOI [10.4148/1941-4765.1531, DOI 10.4148/1941-4765.1531]; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERRIL CR, 1990, METHOD ENZYMOL, V182, P477; NEHLS U, 1992, J MOL BIOL, V227, P1032, DOI 10.1016/0022-2836(92)90519-P; Perkins DD, 1986, FUNGAL GENET NEWSL, V33, P35; PILKINGTON SJ, 1993, BIOCHEM SOC T, V21, P26, DOI 10.1042/bst0210026; PREIS D, 1991, BIOCHIM BIOPHYS ACTA, V1090, P133, DOI 10.1016/0167-4781(91)90049-R; RAGAN CI, 1987, CURR TOP BIOENERG, V15, P1; RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3; SACKMANN U, 1991, EUR J BIOCHEM, V200, P463, DOI 10.1111/j.1432-1033.1991.tb16205.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT M, 1992, FEBS LETT, V313, P8, DOI 10.1016/0014-5793(92)81172-I; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SELKER EU, 1988, P NATL ACAD SCI USA, V85, P6870, DOI 10.1073/pnas.85.18.6870; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Staben C, 1989, FUNGAL GENET NEWSL, V36, P79, DOI DOI 10.4148/1941-4765.1519; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROPSCHUG M, 1988, J BIOL CHEM, V263, P14433; TUSCHEN G, 1990, J MOL BIOL, V213, P845, DOI 10.1016/S0022-2836(05)80268-2; VIDEIRA A, 1993, BIOCHEM J, V291, P729, DOI 10.1042/bj2910729; VIDEIRA A, 1989, EUR J BIOCHEM, V181, P493, DOI 10.1111/j.1432-1033.1989.tb14751.x; VIDEIRA A, 1990, BIOCHEM BIOPH RES CO, V171, P1168, DOI 10.1016/0006-291X(90)90807-Y; VIDEIRA A, 1990, BIOCHEM BIOPH RES CO, V166, P280, DOI 10.1016/0006-291X(90)91942-L; VIDEIRA A, 1990, J BIOL CHEM, V265; VOLLMER SJ, 1986, P NATL ACAD SCI USA, V83, P4869, DOI 10.1073/pnas.83.13.4869; WALKER JE, 1992, J MOL BIOL, V226, P1051, DOI 10.1016/0022-2836(92)91052-Q; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WALLACE DC, 1993, TRENDS GENET, V9, P128, DOI 10.1016/0168-9525(93)90207-X; WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x; Werner S, 1981, Methods Biochem Anal, V27, P109, DOI 10.1002/9780470110478.ch3; WERNER S, 1977, EUR J BIOCHEM, V79, P103, DOI 10.1111/j.1432-1033.1977.tb11788.x; ZAUNER R, 1985, EUR J BIOCHEM, V150, P447, DOI 10.1111/j.1432-1033.1985.tb09042.x	48	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7777	7784						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8126004				2022-12-25	WOS:A1994NA03200114
J	KOO, JS; SPREMULLI, LL				KOO, JS; SPREMULLI, LL			EFFECT OF THE SECONDARY STRUCTURE IN THE EUGLENA-GRACILIS CHLOROPLAST RIBULOSE-BISPHOSPHATE CARBOXYLASE/OXYGENASE MESSENGER-RNA ON TRANSLATIONAL INITIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RIBOSOMAL-PROTEIN; GENE-EXPRESSION; SEQUENCE; REGION; BINDING; RECOGNITION; MUTAGENESIS; EXTENSION; ENHANCER	The results reported in the previous paper indicate that the translational start site of the Euglena gracilis chloroplast mRNA for the large subunit of ribulose-bisphosphate carboxylase/oxygenase (rbcL) is not defined by primary sequence elements (Koo, J. S., and Spremulli, L. L. (1994) J. Biol. Chem. 269, 7494-7500). In the work presented here, the effects of secondary structure in the 5'-untranslated leader of the rbcL mRNA have been examined. Only weak secondary structure can be detected in the 5'-untranslated leader of the rbcL message by enzymatic and computer analysis. Further reduction of the weak secondary structure of this message by site-directed mutagenesis does not significantly affect the ability of this message to participate in initiation complex formation. The secondary structure near the translational start site was increased by the introduction of an inverted repeat sequence and by site-directed mutagenesis. Messages with increased secondary structure are much less active in initiation complex formation if the structural element introduced is within similar to 10 nucleotides of the start codon. These results suggest that the translational start site in this chloroplast mRNA is specified by the presence of an AUG codon in an unstructured or weakly structured region of the mRNA. No specific sequences around the start codon, either upstream or immediately downstream, were found to have important information directing the chloroplast ribosome to the start site of this mRNA.	UNIV N CAROLINA, DEPT CHEM, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill					NIGMS NIH HHS [GM24963] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024963] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTUVIA S, 1989, J MOL BIOL, V210, P265, DOI 10.1016/0022-2836(89)90329-X; ASANO K, 1991, J BIOL CHEM, V266, P24549; BONI IV, 1991, NUCLEIC ACIDS RES, V19, P155, DOI 10.1093/nar/19.1.155; DEBOER HA, 1990, METHOD ENZYMOL, V185, P103; DESMIT MH, 1990, PROG NUCLEIC ACID RE, V38, P1; DESMIT MH, 1990, P NATL ACAD SCI USA, V87, P7668, DOI 10.1073/pnas.87.19.7668; FRANZETTI B, 1992, J BIOL CHEM, V267, P19075; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GALLIE DR, 1989, P NATL ACAD SCI USA, V86, P129, DOI 10.1073/pnas.86.1.129; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GOLD L, 1987, ESCHERICHIA COLI SAL, P1302; GREN EJ, 1984, BIOCHIMIE, V66, P1, DOI 10.1016/0300-9084(84)90188-3; GROSS G, 1990, J BIOL CHEM, V265, P17627; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HAHN V, 1988, PLANT MOL BIOL, V10, P459, DOI 10.1007/BF00014951; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; HARTZ D, 1991, J MOL BIOL, V218, P99, DOI 10.1016/0022-2836(91)90876-8; HARTZ D, 1991, J MOL BIOL, V218, P83, DOI 10.1016/0022-2836(91)90875-7; KNAPP G, 1989, METHOD ENZYMOL, V180, P192; KOO JS, 1994, J BIOL CHEM, V269, P7494; KOZAK M, 1980, CELL, V19, P79, DOI 10.1016/0092-8674(80)90390-6; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASO MRV, 1993, J BIOL CHEM, V268, P6453; LOECHEL S, 1991, NUCLEIC ACIDS RES, V19, P6905, DOI 10.1093/nar/19.24.6905; LOWMAN HB, 1986, J BIOL CHEM, V261, P5396; MACHE R, 1990, PLANT SCI, V72, P1, DOI 10.1016/0168-9452(90)90180-V; Maniatis T., 1982, MOL CLONING; MCCARTHY JEG, 1990, TRENDS GENET, V6, P78, DOI 10.1016/0168-9525(90)90098-Q; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MUNSON LM, 1984, J MOL BIOL, V177, P663, DOI 10.1016/0022-2836(84)90043-3; OLINS PO, 1989, J BIOL CHEM, V264, P16973; RONEY WB, 1988, THESIS U N CAROLINA; SANTALUCIA J, 1992, SCIENCE, V256, P217, DOI 10.1126/science.1373521; SCHAUDER B, 1989, GENE, V78, P59, DOI 10.1016/0378-1119(89)90314-4; SCHULZ VP, 1990, J MOL BIOL, V211, P427, DOI 10.1016/0022-2836(90)90363-Q; SHELNESS GS, 1985, J BIOL CHEM, V260, P8637; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SKRIPKIN EA, 1990, J MOL BIOL, V211, P447, DOI 10.1016/0022-2836(90)90364-R; SPANJAARD RA, 1989, GENE, V80, P345, DOI 10.1016/0378-1119(89)90298-9; SPRENGART ML, 1990, NUCLEIC ACIDS RES, V18, P1719, DOI 10.1093/nar/18.7.1719; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; VARY CPH, 1984, NUCLEIC ACIDS RES, V12, P6763, DOI 10.1093/nar/12.17.6763; WANG CC, 1989, NUCLEIC ACIDS RES, V17, P9735, DOI 10.1093/nar/17.23.9735; WIKSTROM PM, 1992, J MOL BIOL, V224, P949, DOI 10.1016/0022-2836(92)90462-S; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; ZHANG JR, 1992, P NATL ACAD SCI USA, V89, P2605, DOI 10.1073/pnas.89.7.2605; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	48	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7501	7508						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125969				2022-12-25	WOS:A1994NA03200074
J	BERBERICH, S; COLE, M				BERBERICH, S; COLE, M			THE MDM-2 ONCOGENE IS TRANSLOCATED AND OVEREXPRESSED IN A MURINE PLASMACYTOMA CELL-LINE EXPRESSING WILD-TYPE P53	ONCOGENE			English	Note							C-MYC; BURKITT-LYMPHOMA; GENE; PROTEIN; MUTATION; REQUIRES; TUMORS; RAS	The cellular p53 protein has been demonstrated to possess growth-inhibitory activity. Recent work suggests that the murine double minute gene (mdm-2) encodes a protein that may function as a cellular regulator or mediator of p53 function. We were interested in determining if the mdm-2 gene was overexpressed in mouse tumor cells, in particular mouse plasmacytomas that harbor wild type-p53 protein. A novel chromosomal translocation of the mdm-2 gene was detected in the SP2 cell line, that is derived from plasmacytoma MOPC21. The translocation results in a head-to-head arrangement of the mdm-2 gene (chromosome 10) with the immunoglobulin CK gene (chromosome 6), analogous to the translocations that activate the c-mye gene in murine plasmacytomas. Based on Northern blot analysis, the translocation induces a 10-fold elevation of mdm-2 RNA. Primer extension assays demonstrate that the 5' end of the mdm-2 RNA from the translocated gene is colinear with the 5' mdm-2 mRNA from an unrearranged gene, suggesting that the mRNA and encoded protein are unaltered. This chromosomal translocation represents the first example in which mdm-2 overexpression is activated by a genetic alteration other than gene amplification.	WRIGHT STATE UNIV,KETTERING MED CTR,CLIN MOLEC GENET LAB,DAYTON,OH 45435; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Wright State University Dayton; Princeton University	BERBERICH, S (corresponding author), WRIGHT STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,DAYTON,OH, USA.							BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUMBACH WR, 1987, MOL CELL BIOL, V7, P664, DOI 10.1128/MCB.7.2.664; BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; COWAN NJ, 1974, J MOL BIOL, V90, P691, DOI 10.1016/0022-2836(74)90533-6; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GUTIERREZ MI, 1992, CANCER RES, V52, P1032; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; LADANYI M, 1993, CANCER RES, V53, P16; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEACH FS, 1993, CANCER RES, V53, P2231; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PERLMUTTER RM, 1984, NATURE, V307, P473, DOI 10.1038/307473a0; WIMAN KG, 1991, ONCOGENE, V6, P1633; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	22	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1469	1472						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152809				2022-12-25	WOS:A1994NH40100020
J	KEEN, N; ELSTON, R; CRAWFORD, L				KEEN, N; ELSTON, R; CRAWFORD, L			INTERACTION OF THE E6 PROTEIN OF HUMAN PAPILLOMAVIRUS WITH CELLULAR PROTEINS	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; LARGE TUMOR-ANTIGEN; CERVICAL-CARCINOMA; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; TYPE-16; P53; E7; KERATINOCYTES; TRANSCRIPTION	The E6 proteins of the oncogenic Human Papillomavirus (HPV) types 16 and 18 are known to bind two cellular proteins, the tumour suppressor protein p53 and a 100 kDa protein named E6-AP. In this paper we describe the expression and purification of biologically active E6 fusion proteins and their specific association with additional cellular proteins. HPV16E6 specifically associated with at least seven cellular proteins which have been designated pp212, pp182, p100, p81, p75, p53 and p33 respectively, on the basis of molecular mass and phosphorylation. We have also shown that the complex of cellular proteins associated with HPV16, 18, 6 and 11 E6 proteins contains a protein kinase. This protein kinase phosphorylated exogenous histone H1 and the E6 associated protein pp182.	UNIV CAMBRIDGE,DEPT PATHOL,DIV VIROL,CAMBRIDGE CB2 1QP,CAMBS,ENGLAND; UNIV CAMBRIDGE,DEPT PATHOL,IMPERIAL CANC RES FUND,TUMOUR VIRUS GRP,CAMBRIDGE CB2 1QP,ENGLAND	University of Cambridge; University of Cambridge	KEEN, N (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,CAMBS,ENGLAND.							BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GUIS D, 1988, J VIROL, V62, P665; Harlow E., 1988, ANTIBODIES LABORATOR, P341; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LAMBERTI C, 1990, EMBO J, V9, P1907, DOI 10.1002/j.1460-2075.1990.tb08317.x; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LIANG XH, 1993, ONCOGENE, V8, P2645; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Maniatis T., 1982, MOL CLONING; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MUNGER K, 1989, J VIROL, V63, P4417; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; TOMMASINO M, 1993, ONCOGENE, V8, P195; Vousden K H, 1990, Semin Cancer Biol, V1, P415; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WATANABE S, 1989, J VIROL, V63, P965, DOI 10.1128/JVI.63.2.965-969.1989; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; 1991, PHARM ANALECTS, V19, P1	39	56	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1493	1499						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152813				2022-12-25	WOS:A1994NH40100024
J	RUVINOV, SB; MILES, EW				RUVINOV, SB; MILES, EW			THERMAL INACTIVATION OF TRYPTOPHAN SYNTHASE - STABILIZATION BY PROTEIN-PROTEIN INTERACTION AND PROTEIN-LIGAND INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DODECAMERIC GLUTAMINE-SYNTHETASE; AMINO-ACID SUBSTITUTIONS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; ALPHA-SUBUNIT; BETA-SUBUNIT; ALPHA-2-BETA-2 COMPLEX; BIENZYME COMPLEX; FLEXIBLE LOOP; SCANNING CALORIMETRY	This study investigates effects of ligands on thermal inactivation of the tryptophan synthase alpha and beta(2) subunits alone and in the alpha(2) beta(2) complex. Addition of pyridoxal phosphate to the apo-beta(2) subunit increases the temperature of one-half inactivation (T-i) from 52 to 77 degrees C. Ligands that promote association of the alpha and holo-beta(2) subunits markedly stabilize the more temperature-labile alpha subunit in the alpha(2) beta(2) complex from irreversible thermal denaturation. The combination of a beta(2) subunit ligand (L-serine) with an a subunit ligand (alpha-glycerol 3-phosphate) raises the inactivation temperature (T-i) of the alpha subunit in the holo-alpha(2) beta(2) complex from 54 to 66 degrees C. In contrast, values of T-i for inactivation of the alpha and beta subunits in the holo-alpha(2) beta(2) complex are more similar to respective values for the isolated alpha subunit (50 degrees C) and holo-beta(2) subunit (77 degrees C). Surprisingly, the addition of L- serine results in a larger decrease in the T-i of the beta(2) subunit in the holo-alpha(2) beta(2) complex (78 degrees C --> 64 degrees C) than in T-i of the holo-beta(2) subunit alone (77 degrees C --> 71 degrees C). The observation that ligands have different effects on the isolated and associated subunits provides evidence that the alpha and beta(2) subunits do not fully dissociate during thermal inactivation of the alpha(2) beta(2) complex at pH 7.8 and at similar to 0.1 ionic strength. Our results demonstrate that linkage between protein-ligand interactions and protein-protein interactions affects the conformational stability of the tryptophan synthase alpha(2) beta(2) complex.	NIDDK, BIOCHEM PHARMACOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BRANDTS JF, 1989, BIOCHEMISTRY-US, V28, P8588, DOI 10.1021/bi00447a048; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; BRZOVLC P, 1991, INT UNION B, V199, P277; CHAFFOTTE AF, 1983, BIOCHEMISTRY-US, V22, P2708, DOI 10.1021/bi00280a019; CREIGHTO.TE, 1970, EUR J BIOCHEM, V13, P1, DOI 10.1111/j.1432-1033.1970.tb00892.x; CREIGHTON TE, 1966, J BIOL CHEM, V241, P980; EDGE V, 1988, BIOCHEMISTRY-US, V27, P8081, DOI 10.1021/bi00421a017; GINSBURG A, 1991, BIOCHEMISTRY-US, V30, P9421, DOI 10.1021/bi00103a005; HOUBEN KF, 1990, BIOCHEMISTRY-US, V29, P2421, DOI 10.1021/bi00461a028; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KANZAKI H, 1991, ARCH BIOCHEM BIOPHYS, V284, P174, DOI 10.1016/0003-9861(91)90280-V; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KIRSCHNER K, 1991, BIOCHEMISTRY-US, V30, P472, DOI 10.1021/bi00216a024; LANE AN, 1981, EUR J BIOCHEM, V120, P379, DOI 10.1111/j.1432-1033.1981.tb05715.x; LANE AN, 1983, EUR J BIOCHEM, V129, P561; LANE AN, 1991, BIOCHEMISTRY-US, V30, P479, DOI 10.1021/bi00216a025; LANE AN, 1984, EMBO J, V3, P279, DOI 10.1002/j.1460-2075.1984.tb01797.x; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LIM WK, 1992, ARCH BIOCHEM BIOPHYS, V292, P34, DOI 10.1016/0003-9861(92)90047-Z; MATTHEWS CR, 1980, BIOCHEMISTRY-US, V19, P1290, DOI 10.1021/bi00548a004; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1989, J BIOL CHEM, V264, P6280; MILES EW, 1991, J BIOL CHEM, V266, P10715; OGASAHARA K, 1984, INT J PEPT PROT RES, V24, P147; REMETA D P, 1992, Biophysical Journal, V61, pA213; REMETA DP, 1993, BIOPHYS J, V64, pA175; RUVINOV SB, 1992, FEBS LETT, V299, P197, DOI 10.1016/0014-5793(92)80246-D; SCHNEIDER WP, 1981, P NATL ACAD SCI-BIOL, V78, P2169, DOI 10.1073/pnas.78.4.2169; SUGISAKI Y, 1990, THERMOCHIM ACTA, V163, P117, DOI 10.1016/0040-6031(90)80386-D; YANG XJ, 1992, PROTEIN EXPRES PURIF, V3, P347, DOI 10.1016/1046-5928(92)90011-K; YANG XJ, 1992, J BIOL CHEM, V267, P7520; YANOFSKY C, 1977, P NATL ACAD SCI USA, V74, P286, DOI 10.1073/pnas.74.1.286; YANOFSKY C, 1972, ENZYMES, V7, P1; YUTANI K, 1982, INT J PEPT PROT RES, V20, P331; YUTANI K, 1984, ARCH BIOCHEM BIOPHYS, V229, P448, DOI 10.1016/0003-9861(84)90174-7; ZETINA CR, 1980, J MOL BIOL, V137, P401, DOI 10.1016/0022-2836(80)90165-5; ZETINA CR, 1980, J BIOL CHEM, V255, P4381; ZOLKIEWSKI M, 1992, BIOCHEMISTRY-US, V31, P11991, DOI 10.1021/bi00163a006	43	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11703	11706						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163467				2022-12-25	WOS:A1994NG37700008
J	COTE, HCF; STEVENS, WK; BAJZAR, L; BANFIELD, DK; NESHEIM, ME; MACGILLIVRAY, RTA				COTE, HCF; STEVENS, WK; BAJZAR, L; BANFIELD, DK; NESHEIM, ME; MACGILLIVRAY, RTA			CHARACTERIZATION OF A STABLE FORM OF HUMAN MEIZOTHROMBIN DERIVED FROM RECOMBINANT PROTHROMBIN (R155A, R271A, AND R284A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; BOVINE FACTOR-V; FACTOR-XA; FACTOR-IX; PHOSPHOLIPID-BINDING; CATALYZED ACTIVATION; PROTEIN-C; EXPRESSION; THROMBIN; INTERMEDIATE	Meizothrombin is a transient intermediate produced during the activation of prothrombin by the prothrombinase complex. Because meizothrombin is very sensitive to further activation and autolysis, its isolation is possible only in the presence of active site thrombin inhibitors. This complicates studies of the activities and functions of meizothrombin. As a model, we have expressed a mutant human prothrombin cDNA (R155A, R271A, R284A) with three of the cleavage sites modified so that they are no longer cleaved by factor Xa or thrombin. Several stable baby hamster kidney cell lines were isolated that secreted up to 20 mug/ml of carboxylated mutant prothrombin. After purification, the mutant prothrombin was activated by the prothrombinase complex or by ecarin, resulting in the formation of a meizothrombin-like molecule. Electrophoretic analysis and NH2-terminal sequence analysis were consistent with cleavage of a single bond between Arg320-Ile321 and proper processing of the prepropeptide. The meizothrombin was stable for weeks at 4-degrees-C. Activation in the presence of dansylarginine N-(3-ethyl-1,5-pentanediyl) amide confirmed the conversion of prothrombin via meizothrombin. Compared with human plasma-derived thrombin, recombinant meizothrombin demonstrated approximately 7% clotting activity, 100% p-toluene-sulfonylarginine methyl ester esterase activity, and approximately 35% S2238 amidolytic activity, and could attenuate fibrinolysis.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1Z3,BC,CANADA; QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA; QUEENS UNIV,DEPT MED,KINGSTON K7L 3N6,ONTARIO,CANADA	University of British Columbia; Queens University - Canada; Queens University - Canada			Cote, Helene/K-7896-2012					ANSON DS, 1985, NATURE, V315, P683, DOI 10.1038/315683a0; BAJZAR L, 1993, J BIOL CHEM, V268, P8608; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; BUSBY S, 1985, NATURE, V316, P271, DOI 10.1038/316271a0; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10360; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; ESMON CT, 1974, J BIOL CHEM, V249, P7798; FALKNER FG, 1992, THROMB HAEMOSTASIS, V68, P119; FRANZA BR, 1975, J BIOL CHEM, V250, P7057; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRINNELL BW, 1987, BIOTECHNOLOGY, V5, P1188; JORGENSEN MJ, 1987, J BIOL CHEM, V262, P1; KAUFMAN RJ, 1986, J BIOL CHEM, V261, P9622; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; MACGILLIVRAY RTA, ANN NY ACAD SCI, V485, P73; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1990, BLOOD, V76, P1; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P6886; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; OWEN WG, 1974, J BIOL CHEM, V249, P594; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PEI G, 1991, J BIOL CHEM, V266, P9598; PRENDERGAST FG, 1977, J BIOL CHEM, V252, P840; ROSING J, 1988, THROMB HAEMOSTASIS, V60, P355; ROSING J, 1986, J BIOL CHEM, V261, P4224; ROSING J, 1980, J BIOL CHEM, V255, P274; SEARLE PF, 1985, MOL CELL BIOL, V5, P1480, DOI 10.1128/MCB.5.6.1480; STEVENS WK, 1993, BIOCHEMISTRY-US, V32, P2787, DOI 10.1021/bi00062a008; WOLF DL, 1991, J BIOL CHEM, V266, P13726; WU QY, 1992, J BIOL CHEM, V267, P7083; YAN SCB, 1990, BIO-TECHNOL, V8, P655, DOI 10.1038/nbt0790-655	42	53	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11374	11380						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157669				2022-12-25	WOS:A1994NF96600061
J	PENG, SB; ZHANG, Y; TSAI, SJ; XIE, XS; STONE, DK				PENG, SB; ZHANG, Y; TSAI, SJ; XIE, XS; STONE, DK			RECONSTITUTION OF RECOMBINANT 33-KDA SUBUNIT OF THE CLATHRIN-COATED VESICLE H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON TRANSLOCATING COMPLEX; KIDNEY; INHIBITORS; PUMP	Evidence suggests that the ATP hydrolytic sector of the clathrin-coated vesicle proton-translocating ATPase is composed of four subunits of molecular masses of 70, 58, 40, and 33 kDa (Xie, X. S., and Stone, D. K. (1988) J. Biol. Chem. 263, 9859-9867). We have now expressed recombinant 33-kDa polypeptide in Escherichia coli and in Spodoptera frugiperda (Sf9) cells. This subunit, renatured and purified from both sources, lacks intrinsic ATPase activity. Co-reconstitution of these recombinant 33-kDa polypeptides and recombinant 40-kDa subunit to a biochemically prepared 70-58-kDa subcomplex results in a 6-fold stimulation of calcium-activated, N-ethylmaleimide-sensitive ATPase activity, documenting the essential role of the 33- and 40-kDa components in vacuolar type proton pump function and furthering the aim of reconstitution of a purely recombinant hydrolytic core.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV MOLEC TRANSPORT,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK RO1 33627] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033627] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERN RA, 1990, KIDNEY, P318; FERNANDEZ JM, 1991, BIOPHYS J, V59, P1022, DOI 10.1016/S0006-3495(91)82317-7; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GLUCK S, 1988, AM J PHYSIOL, V254, pF71, DOI 10.1152/ajprenal.1988.254.1.F71; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; HO MN, 1993, J BIOL CHEM, V268, P18286; Innis MA, 1990, PCR PROTOCOLS GUIDE; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTSSON JP, 1991, BIOCHIM BIOPHYS ACTA, V1065, P261, DOI 10.1016/0005-2736(91)90238-4; MOFFATT BA, 1987, CELL, V49, P221, DOI 10.1016/0092-8674(87)90563-0; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; PENG SB, 1993, J BIOL CHEM, V268, P23519; QIAGEN, 1992, QIAEXPRESSIONIST; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SEIDMAN JG, 1989, SHORT PROTOCOLS MOL; STONE DK, 1984, J BIOL CHEM, V259, P2701; STONE DK, 1988, KIDNEY INT, V33, P403; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Summers MD, 1987, TEXAS AGR EXPT STATI; SUN SZ, 1987, J BIOL CHEM, V262, P14790; XIE XS, 1986, J BIOL CHEM, V261, P2492; XIE XS, 1988, J BIOL CHEM, V263, P9859; XIE XS, 1993, J BIOL CHEM, V268, P25063	26	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11356	11360						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157666				2022-12-25	WOS:A1994NF96600058
J	TOUHARA, K; INGLESE, J; PITCHER, JA; SHAW, G; LEFKOWITZ, RJ				TOUHARA, K; INGLESE, J; PITCHER, JA; SHAW, G; LEFKOWITZ, RJ			BINDING OF G-PROTEIN BETA-GAMMA-SUBUNITS TO PLECKSTRIN HOMOLOGY DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADRENERGIC-RECEPTOR KINASE; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; CDNA	Ligand-induced activation of many receptors leads to dissociation of the alpha- and beta gamma-subunit complexes of heterotrimeric G proteins, both of which regulate a variety of effector molecules involved in cellular signaling processes. In one case, a cytosolic enzyme, the beta-adrenergic receptor kinase (beta ARK) binds to the dissociated, prenylated, membrane-anchored beta gamma-subunits of heterotrimeric G proteins (G beta gamma) and is thereby targeted to its membrane-bound receptor substrate. Quite recently, numerous proteins involved in cellular signal transduction have been shown to contain sequences homologous with a ''domain'' originally identified in the protein ''pleckstrin'' (pleckstrin homology domain; PH domain) and subsequently found in the G beta gamma interaction region of the beta ARK sequence. Here we demonstrate that glutathione S-transferase-fusion proteins, containing sequences encompassing the PH domain of nine proteins from this group, bind G beta gamma to varying extents. Binding of G beta gamma to these fusion proteins was documented either by a direct binding assay or by ability to block G beta gamma-mediated membrane translocation of beta ARK1. G beta gamma binding to these fusion proteins was inhibited by the alpha subunit of G(o) (G(o) alpha), indicating that the binding of G beta gamma to G alpha and the PH domain-containing fusion proteins is mutually exclusive. Studies with a series of truncated PH domains derived from the Ras-guanine-nucleotide releasing factor indicate that the G beta gamma binding domain includes only the C-terminal portion of the PH domain and sequences just distal to this. Protein protein interactions between G beta gamma and PH domain-containing proteins may play a significant role in cellular signaling analogous to that previously demonstrated for Src homology 2 and 3 domains.	DUKE UNIV,MED CTR,DEPT MED,HOWARD HUGHES MED RES INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,HOWARD HUGHES MED RES INST,DURHAM,NC 27710; UNIV FLORIDA,J HILLIS MILLER HLTH CTR,DEPT NEUROSCI,GAINESVILLE,FL 32610	Duke University; Duke University; State University System of Florida; University of Florida			Lefkowitz, Robert/AAW-2649-2021; Pitcher, Julie/ABH-2078-2020		NHLBI NIH HHS [HL16037] Funding Source: Medline; NINDS NIH HHS [R01 NS22695] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022695] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; Dayhoff M.O., 1978, ATLAS PROTEIN SEQ ST; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FRY MJ, 1993, PROTEIN SCI, V2, P1785, DOI 10.1002/pro.5560021102; HASLAM RJ, 1993, NATURE, V363, P310; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEVANON D, 1990, GENOMICS, V7, P65, DOI 10.1016/0888-7543(90)90519-Z; LUPAS AN, 1992, FEBS LETT, V314, P105, DOI 10.1016/0014-5793(92)80952-D; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MMUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEITSCH MC, 1993, TRENDS BIOCHEM SCI, V18, P292, DOI 10.1016/0968-0004(93)90038-O; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SHAW G, 1993, BIOCHEM BIOPH RES CO, V195, P1145, DOI 10.1006/bbrc.1993.2164; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMONDS WF, 1993, TRENDS BIOCHEM SCI, V18, P315; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; VETRIS D, 1993, NATURE, V361, P236; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449	34	456	466	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10217	10220						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144601				2022-12-25	WOS:A1994NF01700009
J	WAGA, S; BAUER, G; STILLMAN, B				WAGA, S; BAUER, G; STILLMAN, B			RECONSTITUTION OF COMPLETE SV40 DNA-REPLICATION WITH PURIFIED REPLICATION FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; CELL NUCLEAR ANTIGEN; POLYMERASE-ALPHA-PRIMASE; LAGGING STRAND SYNTHESIS; T-ANTIGEN; SACCHAROMYCES-CEREVISIAE; INVITRO REPLICATION; EXCISION REPAIR; PROTEIN-A; LIGASE-I	The identification and purification of human cell proteins required for the production of form I DNA following DNA replication from the simian virus 40 (SV40) origin is described. Using these proteins, complete SV40 DNA replication was reconstituted with only purified DNA replication factors: SV40 large tumor antigen (TAg), replication protein A (RPA), DNA topoisomerases I and II, DNA polymerase alpha-primase, replication factor C (RFC), the proliferating cell nuclear antigen (PCNA), DNA polymerase delta, maturation factor 1 (MF1), and DNA ligase I. MF1, a 5' to 3' exonuclease and DNA ligase I were both identified as essential components for production of covalently closed circular relaxed (form I) DNA. MF1 is probably the same exonuclease previously shown by others to function during DNA synthesis on artificial DNA templates or in conjunction with DNA polymerase alpha from the SV40 origin. Combined with these previous studies, our results suggest that MF1 functions to remove an RNA primer attached to every Okazaki fragment during lagging strand DNA synthesis. Interestingly, whereas mammalian DNA ligase I functioned in the reconstituted replication system, mammalian DNA ligase III did not substitute and the phage T4 DNA ligase functioned inefficiently, suggesting that DNA ligase I has a specific role as a replicative DNA ligase in eukaryotic cells.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory				Waga, Shou/0000-0003-4986-8735; Stillman, Bruce/0000-0002-9453-4091	NCI NIH HHS [CA13106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; BARNES DE, 1990, P NATL ACAD SCI USA, V87, P6679, DOI 10.1073/pnas.87.17.6679; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; CREISSEN D, 1982, NATURE, V296, P271, DOI 10.1038/296271a0; DEAN FB, 1991, J BIOL CHEM, V266, P5062; DEAN FB, 1992, J BIOL CHEM, V267, P14129; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; EKI T, 1992, J BIOL CHEM, V267, P7284; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FUNNELL BE, 1986, J BIOL CHEM, V261, P5616; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HENDERSON LM, 1985, P NATL ACAD SCI USA, V82, P2044, DOI 10.1073/pnas.82.7.2044; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; JOHNSTON LH, 1978, NATURE, V274, P891, DOI 10.1038/274891a0; KENNY MK, 1988, J BIOL CHEM, V263, P9809; KESTI T, 1993, J BIOL CHEM, V268, P10238; KONRAD EB, 1974, P NATL ACAD SCI USA, V71, P2048, DOI 10.1073/pnas.71.5.2048; LANFORD RE, 1988, VIROLOGY, V167, P72, DOI 10.1016/0042-6822(88)90055-4; LEE MYW, 1984, BIOCHEMISTRY-US, V2, P1906; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1991, J BIOL CHEM, V266, P594; LEHMANN AR, 1988, CANCER RES, V48, P6343; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; LONN U, 1989, CARCINOGENESIS, V10, P981, DOI 10.1093/carcin/10.6.981; Maniatis T., 1982, MOL CLONING; MELENDY T, 1991, J BIOL CHEM, V266, P1942; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MELENDY T, 1992, NUCLEIC ACIDS MOL BI, V6, P129; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11018; NETHANEL T, 1992, J VIROL, V66, P6634, DOI 10.1128/JVI.66.11.6634-6640.1992; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; NISHIDA C, 1988, J BIOL CHEM, V263, P501; OGAWA T, 1984, MOL GEN GENET, V193, P231, DOI 10.1007/BF00330673; OLIVERA BM, 1968, J MOL BIOL, V36, P261, DOI 10.1016/0022-2836(68)90380-X; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; PROGENT C, 1992, EMBO J, V11, P2925; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; SIMANIS V, 1985, VIROLOGY, V144, P80; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; TOMKINSON AE, 1991, J BIOL CHEM, V266, P21728; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	80	355	357	3	118	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10923	10934						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144677				2022-12-25	WOS:A1994NF01700107
J	HENKEMEYER, M; MARENGERE, LEM; MCGLADE, J; OLIVIER, JP; CONLON, RA; HOLMYARD, DP; LETWIN, K; PAWSON, T				HENKEMEYER, M; MARENGERE, LEM; MCGLADE, J; OLIVIER, JP; CONLON, RA; HOLMYARD, DP; LETWIN, K; PAWSON, T			IMMUNOLOCALIZATION OF THE NUK RECEPTOR TYROSINE KINASE SUGGESTS ROLES IN SEGMENTAL PATTERNING OF THE BRAIN AND AXONOGENESIS	ONCOGENE			English	Article							CELL-ADHESION MOLECULE; IMMUNOGLOBULIN SUPERFAMILY; MOUSE DEVELOPMENT; NERVOUS-SYSTEM; INT-1 PROTOONCOGENE; ECTOPIC EXPRESSION; NEURITE OUTGROWTH; XENOPUS EMBRYOS; PROTEIN-KINASES; OPTIC CHIASM	Neural kinase (Nuk) encodes a murine receptor-like tyrosine kinase belonging to the Eph/Elk/Eck family. Protein localization studies indicate that during early embryogenesis Nuk is confined to the developing nervous system, where it marks segments along the axis of the neural tube in the hindbrain (rhombomeres r2, r3 and r5) and specific morphological bulges of the midbrain and forebrain. Subcellular localization of Nuk indicates that this receptor is concentrated at sites of cell-cell contact, often involving migrating neuronal cells or their extensions. Most notably, high levels of Nuk protein are found within initial axon outgrowths and associated nerve fibers. The axonal localization of Nuk is transient and is not detected after migrations have ceased, suggesting a role for this tyrosine kinase during the early pathfinding and/or fasciculation stages of axonogenesis. The subcellular localization of Nuk, as well as the presence of fibronectin type III and immunoglobulin-like adhesive domains on the extracellular region, suggest this receptor tyrosine kinase may function to regulate specific cell-cell interactions during early development of the murine nervous system.	UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto	HENKEMEYER, M (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA.		Pawson, Tony J/E-4578-2013	Henkemeyer, Mark/0000-0002-7525-1061				BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BOHME B, 1993, ONCOGENE, V8, P2857; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BURNS FR, 1991, NEURON, V7, P209, DOI 10.1016/0896-6273(91)90259-3; Carpenter M.B., 1985, CORE TEXT NEUROANATO, V3rd; CHAN J, 1991, ONCOGENE, V6, P1057; CHITNIS AB, 1990, J NEUROSCI, V10, P1892; CONLON RA, 1992, DEVELOPMENT, V116, P357; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DETRICK RJ, 1990, NEURON, V4, P493, DOI 10.1016/0896-6273(90)90108-R; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; EDELMAN GM, 1988, BIOCHEMISTRY-US, V27, P3533, DOI 10.1021/bi00410a001; Edelman GM, 1985, CELL CONTACT ADHESIO; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FIGDOR MC, 1993, NATURE, V363, P630, DOI 10.1038/363630a0; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUJIMORI T, 1990, DEVELOPMENT, V110, P97; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; GODEMENT P, 1990, NEURON, V5, P173, DOI 10.1016/0896-6273(90)90307-2; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GRENNINGLOH G, 1990, COLD SH Q B, V55, P327; Grumet M, 1991, Curr Opin Neurobiol, V1, P370, DOI 10.1016/0959-4388(91)90055-C; Guild SR, 1927, AM J ANAT, V39, P57, DOI 10.1002/aja.1000390103; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; HATTA K, 1987, DEV BIOL, V120, P215, DOI 10.1016/0012-1606(87)90119-9; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HENDRIKS DM, 1973, S AFR MED J, V47, P2294; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; Kaufman M. H, 1990, POSTIMPLANTATION MAM, P81; KEYNES R, 1990, NEURON, V4, P1, DOI 10.1016/0896-6273(90)90438-L; KLEIN R, 1990, DEVELOPMENT, V109, P845; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LANDMESSER L, 1992, NEURON, V8, P291, DOI 10.1016/0896-6273(92)90296-P; LETWIN K, 1988, ONCOGENE, V3, P621; LEVITT P, 1981, J NEUROSCI, V1, P27, DOI 10.1523/JNEUROSCI.01-01-00027.1981; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LIESI P, 1985, EMBO J, V4, P1163, DOI 10.1002/j.1460-2075.1985.tb03755.x; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; LOGAN C, 1992, DEV GENET, V13, P345, DOI 10.1002/dvg.1020130505; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; NAKANISHI S, 1983, DEV BIOL, V95, P305, DOI 10.1016/0012-1606(83)90031-3; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PORTEUS MH, 1991, NEURON, V7, P221, DOI 10.1016/0896-6273(91)90260-7; PRICE M, 1991, NATURE, V351, P748, DOI 10.1038/351748a0; PRICE M, 1992, NEURON, V8, P241, DOI 10.1016/0896-6273(92)90291-K; PUELLES L, 1987, J COMP NEUROL, V266, P247, DOI 10.1002/cne.902660210; RUGH R, 1968, MOUSE ITS REPRODUCTI; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SHER AE, 1971, ACTA OTO-LARYNGOL, P1; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SRETAVAN DW, 1990, J NEUROSCI, V10, P1995; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; THEILER K, 1989, HOUSE MOUSE; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TOSNEY KW, 1985, DEV BIOL, V109, P193, DOI 10.1016/0012-1606(85)90360-4; TOSNEY KW, 1985, J NEUROSCI, V5, P2336; TOSNEY KW, 1984, J NEUROSCI, V4, P2518; VANDEWATER TR, 1991, ANN NY ACAD SCI, V630, P116; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILSON SW, 1990, DEVELOPMENT, V108, P121; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4	89	190	195	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1001	1014						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134103				2022-12-25	WOS:A1994NC04800001
J	SCHUMACHER, RJ; HURST, R; SULLIVAN, WP; MCMAHON, NJ; TOFT, DO; MATTS, RL				SCHUMACHER, RJ; HURST, R; SULLIVAN, WP; MCMAHON, NJ; TOFT, DO; MATTS, RL			ATP-DEPENDENT CHAPERONING ACTIVITY OF RETICULOCYTE LYSATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; GLUCOCORTICOID RECEPTOR-HSP90 COMPLEX; REGULATED EIF-2-ALPHA KINASE; VIRUS TRANSFORMING PROTEIN; PROGESTERONE-RECEPTOR; STEROID-RECEPTORS; UNCOATING ATPASE; BINDING-PROTEIN; HSP90; PURIFICATION	We have developed an assay for chaperone-mediated protein renaturation using thermally denatured Firefly luciferase. Dilution of denatured luciferase (>99% loss of activity) into reticulocyte lysate typically results in recovery of 5-15% activity. Addition of an ATP-regenerating system increases yields to >60%, while heat shock or the addition of denatured proteins inhibits the chaperoning activity. Reticulocyte lysate contains abundant quantities of the heat shock proteins, hsp90 and hsp70, and a 60-kDa protein homologous to the yeast stress protein, STI1. Immune isolated samples of these three proteins support recovery of up to 35% of luciferase activity in an ATP-dependent manner, suggesting that these or associated proteins are involved in the renaturation of luciferase. Furthermore, we observed a correlation between luciferase renaturation activity and the levels of hsp70 and hsp90 in reticulocyte lysate preparations. Purified hsp90 and hsp70, along with an ATP-regenerating system, are able to renature luciferase to greater than 20% of its original activity. This renaturation is most efficient when hsp90 and hsp70 are at about a 2:1 ratio and at concentrations similar to those found in reticulocyte lysate. This study provides evidence for an ATP-dependent chaperoning activity in reticulocyte lysate that involves a cooperative action of hsp70 and hsp90.	OKLAHOMA STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,STILLWATER,OK 74078	Oklahoma State University System; Oklahoma State University - Stillwater	SCHUMACHER, RJ (corresponding author), MAYO GRAD SCH,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD009140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES004299, R01ES004299] Funding Source: NIH RePORTER; NCRR NIH HHS [RR07077] Funding Source: Medline; NICHD NIH HHS [HD09140] Funding Source: Medline; NIEHS NIH HHS [ES04299] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALNEMRI ES, 1993, P NATL ACAD SCI USA, V90, P6839, DOI 10.1073/pnas.90.14.6839; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BENSAUDE O, 1990, P89; BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DENIS M, 1987, J BIOL CHEM, V262, P11803; DUBOIS MF, 1991, J BIOL CHEM, V266, P9707; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; ERNST V, 1978, J BIOL CHEM, V253, P7163; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAITANARIS GA, 1990, CELL, V61, P1013, DOI 10.1016/0092-8674(90)90066-N; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREENE LE, 1990, J BIOL CHEM, V265, P6682; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HONORE B, 1992, J BIOL CHEM, V267, P8485; HUNT T, 1972, J MOL BIOL, V66, P471, DOI 10.1016/0022-2836(72)90427-5; IANNOTTI AM, 1988, ARCH BIOCHEM BIOPHYS, V264, P54, DOI 10.1016/0003-9861(88)90569-3; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANKS KW, 1992, BIOCHEM BIOPH RES CO, V184, P394, DOI 10.1016/0006-291X(92)91206-6; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MATTINGLY JR, 1993, J BIOL CHEM, V268, P3925; MATTS RL, 1992, J BIOL CHEM, V267, P18160; MATTS RL, 1993, BIOCHEMISTRY-US, V32, P7323, DOI 10.1021/bi00080a001; MATTS RL, 1992, J BIOL CHEM, V267, P18168; MATTS RL, 1991, J BIOL CHEM, V266, P12695; MIYATA Y, 1991, J BIOL CHEM, V266, P8779; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; NADEAU K, 1992, PROTEIN SCI, V1, P970, DOI 10.1002/pro.5560010802; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; NGUYEN VT, 1989, J BIOL CHEM, V264, P10487; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; NIMMESGERN E, 1993, FEBS LETT, V331, P25, DOI 10.1016/0014-5793(93)80290-B; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PEATTIE DA, 1992, BIOCHEMISTRY-US, V89, P10974; PELHAM H, 1988, NATURE, V332, P776, DOI 10.1038/332776a0; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PINTO M, 1991, J BIOL CHEM, V266, P13941; PUSKIN AV, 1982, BIOCHIM BIOPHYS ACTA, V704, P379; RAABE T, 1991, NUCLEIC ACIDS RES, V19, P6645, DOI 10.1093/nar/19.23.6645; RENOIR JM, 1984, BIOCHEMISTRY-US, V23, P6016, DOI 10.1021/bi00320a018; ROSE DW, 1987, BIOCHEMISTRY-US, V26, P6583, DOI 10.1021/bi00395a003; RYAN C, 1992, PROTEIN SCI, V1, P980, DOI 10.1002/pro.5560010803; SANCHEZ ER, 1988, MOL ENDOCRINOL, V2, P756, DOI 10.1210/mend-2-8-756; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P7325, DOI 10.1021/bi00147a017; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID SL, 1985, J BIOL CHEM, V260, P57; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SCHUH S, 1985, J BIOL CHEM, V260, P4292; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; YEM AW, 1992, J BIOL CHEM, V267, P2868	83	124	124	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9493	9499						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144534				2022-12-25	WOS:A1994NE05300018
J	ZAHEDI, K; PRADA, AE; DAVIS, AE				ZAHEDI, K; PRADA, AE; DAVIS, AE			TRANSCRIPTIONAL REGULATION OF THE C1-INHIBITOR GENE BY GAMMA-INTERFERON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATE VIRUS INDUCIBILITY; INDUCED NUCLEAR FACTORS; BINDING PROTEIN GENE; MAJOR LATE PROMOTER; HUMAN C1 INHIBITOR; RNA POLYMERASE-II; CELL-LINE; STIMULATED GENES; HUMAN MONOCYTES; CDNA CLONING	Treatment of the hepatoma cell line, Hep3B, with gamma-interferon (IFN) enhanced expression of C1 inhibitor (C1INH) mRNA, primarily due to an enhanced transcription rate. Hep3B cells transfected with reporter constructs containing various regions of the C1INH gene between positions -1182 and +587, and stimulated with gamma-IFN, expressed increased levels of chloramphenicol acetyltransferase in the presence of the first intron and as few as 12 bases of the 5'-flanking region. However, a 66% reduction in the inducibility of the constructs was observed when the upstream region between -582 and -252 was eliminated. Successive deletions mapped the first intron IFN-responsive elements to a region between +368 and +410. The data indicate that both the upstream and the first intron sequences can independently enhance induction of C1INH gene expression. Examination of the immediate upstream sequence of the C1INH gene reveals the absence of a TATA box. The promoter of the C1INH gene was mapped to a region within 81 bases of the upstream sequence and the first exon. Further examination indicated two regions that were potentially important for promoter activity as follows: 1) a G-C-rich region from -81 to -49, and 2) an initiator element at -3 to +5. The results indicate that the upstream sequences including -81 to -49 and the H-DNA region between -48 and -17 are not necessary for promoter activity. The initiator element from -3 to +5 is sufficient and necessary for promoter function.	UNIV CINCINNATI,COLL MED,DEPT PEDIAT,CINCINNATI,OH 45229	University System of Ohio; University of Cincinnati	ZAHEDI, K (corresponding author), CHILDRENS HOSP RES FDN,DIV NEPHROL,3333 BURNET AVE,CINCINNATI,OH 45229, USA.		Zahedi, Kamyar/AAQ-3428-2021		NICHD NIH HHS [HD22082] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022082, R37HD022082] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BOCK SC, 1986, BIOCHEMISTRY-US, V25, P4292, DOI 10.1021/bi00363a018; CARTER PE, 1988, EUR J BIOCHEM, V173, P163, DOI 10.1111/j.1432-1033.1988.tb13980.x; CARTER PE, 1991, EUR J BIOCHEM, V197, P301, DOI 10.1111/j.1432-1033.1991.tb15911.x; DALE TC, 1989, EMBO J, V8, P831, DOI 10.1002/j.1460-2075.1989.tb03444.x; DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595, DOI 10.1146/annurev.iy.06.040188.003115; DAVIS AE, 1986, P NATL ACAD SCI USA, V83, P3161, DOI 10.1073/pnas.83.10.3161; DECKER T, 1991, MOL CELL BIOL, V11, P5147, DOI 10.1128/MCB.11.10.5147; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; FABER PW, 1993, J BIOL CHEM, V268, P9296; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; GARFINKEL S, 1990, J BIOL CHEM, V265, P10309; HAMILTON AO, 1987, BIOCHEM J, V242, P809, DOI 10.1042/bj2420809; HAUPT H, 1970, EUR J BIOCHEM, V17, P254, DOI 10.1111/j.1432-1033.1970.tb01161.x; HEDA GD, 1990, BLOOD, V75, P2401; KATZ Y, 1989, J IMMUNOL, V142, P2041; KOHWI Y, 1991, GENE DEV, V5, P2547, DOI 10.1101/gad.5.12b.2547; LAPIN DF, 1992, BIOCHEM J, V281, P437; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LOTZ M, 1987, J IMMUNOL, V139, P3382; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MIRKOVITCH J, 1992, MOL CELL BIOL, V12, P1; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MORRIS KM, 1982, J CLIN INVEST, V70, P906, DOI 10.1172/JCI110687; NAF D, 1991, P NATL ACAD SCI USA, V88, P1369, DOI 10.1073/pnas.88.4.1369; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; RANDAZZO BP, 1985, J IMMUNOL, V135, P1313; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAFER B, 1991, J BIOL CHEM, V266, P10989; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT B, 1991, IMMUNOLOGY, V74, P677; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STEEL DM, 1991, BIOCHEM J, V277, P477, DOI 10.1042/bj2770477; WANG IM, 1993, J IMMUNOL, V151, P2646; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; WRIGHT TM, 1991, J EXP MED, V173, P417, DOI 10.1084/jem.173.2.417; YAN C, 1992, P NATL ACAD SCI USA, V89, P8859, DOI 10.1073/pnas.89.19.8859; ZURAW BL, 1990, J BIOL CHEM, V265, P12664	48	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9669	9674						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144555				2022-12-25	WOS:A1994NE05300044
J	KOMALAVILAS, P; LINCOLN, TM				KOMALAVILAS, P; LINCOLN, TM			PHOSPHORYLATION OF THE INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR BY CYCLIC GMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; RECONSTITUTED LIPID VESICLES; TRISPHOSPHATE RECEPTOR; RAT AORTA; RELAXING FACTOR; NITRIC-OXIDE; CALCIUM FLUX; CA-2+ LEVELS; PURIFICATION; CGMP	Cyclic GMP (cGMP) inhibits intracellular calcium ([Ca2+](i)) mobilization in vascular smooth muscle cells by a mechanism that is not well understood. Because several studies suggest that cGMP inhibits inositol 1,4,5-trisphosphate (IP3) action, we examined the effects of cGMP-dependent protein kinase on IP3 receptor phosphorylation. The purified IP3 receptor was phosphorylated using either the cGMP- or cAMP-dependent protein kinase in vitro. Phosphorylation was time-dependent and stoichiometric using both kinases. Two-dimensional phosphopeptide mapping high performance liquid chromatography analysis, and amino acid analysis showed that identical sites were phosphorylated using either kinase, and identified serine 1755 as the site of phosphorylation. The synthetic peptide corresponding to serine 1755 (GRRESLTSFG) was phosphorylated with a K-m in the range of 30-40 mu m by both kinases. The kinetic analysis revealed that this peptide substrate is the best substrate described for cGMP kinase to date. Vascular smooth muscle cells prelabeled with [P-32]orthophosphate and treated with atrial natriuretic peptide or sodium nitroprusside to elevate cGMP also resulted in increased labeling of the IP3 receptor. Phosphorylation of IP3 receptor by cGMP kinase may regulate the function of IP3 receptor in vascular smooth muscle cells and contribute to the effect of cGMP to regulate intracellular calcium levels.	UNIV ALABAMA, DEPT PATHOL, DIV MOLEC & CELLULAR PATHOL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham					NHLBI NIH HHS [HL 34646] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034646] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BIRD GS, 1993, J BIOL CHEM, V268, P17917; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; CHEN XL, 1992, AM J PHYSIOL, V263, pC468, DOI 10.1152/ajpcell.1992.263.2.C468; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; COLLINS P, 1986, J PHYSIOL-LONDON, V381, P427, DOI 10.1113/jphysiol.1986.sp016336; Corbin J D, 1974, Methods Enzymol, V38, P287; CORNWELL TL, 1988, J PHARMACOL EXP THER, V247, P524; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; CORNWELL TL, 1991, MOL PHARMACOL, V40, P923; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; GRUETTER CA, 1979, J CYCLIC NUCL PROT, V5, P211; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; HIRATA M, 1990, J BIOL CHEM, V265, P1268; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; JIN JG, 1993, AM J PHYSIOL, V264, pG470, DOI 10.1152/ajpgi.1993.264.3.G470; JOHNSON RM, 1985, MOL PHARMACOL, V27, P333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINCOLN TM, 1983, ADV CYCL NUCL RES<D>, V15, P139; LINCOLN TM, 1989, PHARMACOL THERAPEUT, V41, P479, DOI 10.1016/0163-7258(89)90127-7; LINCOLN TM, 1977, J BIOL CHEM, V252, P4269; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MARKS AR, 1990, J BIOL CHEM, V265, P20719; MAYRLEITNER M, 1991, CELL CALCIUM, V12, P505, DOI 10.1016/0143-4160(91)90032-A; MEISHERI KD, 1986, AM J PHYSIOL, V250, pC171, DOI 10.1152/ajpcell.1986.250.1.C171; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RAPOPORT RM, 1986, CIRC RES, V58, P407, DOI 10.1161/01.RES.58.3.407; RASHATWAR SS, 1987, P NATL ACAD SCI USA, V84, P5685, DOI 10.1073/pnas.84.16.5685; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; RUTH P, 1993, P NATL ACAD SCI USA, V90, P2623, DOI 10.1073/pnas.90.7.2623; SMITH JB, 1983, J CELL PHYSIOL, V114, P284, DOI 10.1002/jcp.1041140306; SUGDEN PH, 1976, BIOCHEM J, V159, P409, DOI 10.1042/bj1590409; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; VROLIX M, 1988, BIOCHEM J, V255, P855, DOI 10.1042/bj2550855; WALAAS SI, 1986, J NEUROSCI, V6, P954; Walter U, 1989, REV PHYSL BIOCH PHAR, V113, P41; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0	46	197	200	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8701	8707						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132598				2022-12-25	WOS:A1994NB41100015
J	WIPPLER, J; KOUNS, WC; SCHLAEGER, EJ; KUHN, H; HADVARY, P; STEINER, B				WIPPLER, J; KOUNS, WC; SCHLAEGER, EJ; KUHN, H; HADVARY, P; STEINER, B			THE INTEGRIN ALPHA(IIB)-BETA(3), PLATELET GLYCOPROTEIN IIB-IIIA, CAN FORM A FUNCTIONALLY ACTIVE HETERODIMER COMPLEX WITHOUT THE CYSTEINE-RICH REPEATS OF THE BETA(3) SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED HUMAN-PLATELETS; AMINO-ACID POLYMORPHISM; LIGAND-BINDING SITE; GPIIB-IIIA; GLANZMANN THROMBASTHENIA; FIBRINOGEN RECEPTOR; CELL-ADHESION; GAMMA-CHAIN; ELECTRON-MICROSCOPY; CYTOPLASMIC DOMAIN	Integrin alpha(IIb)-beta(3) binds fibrinogen via the recognition sequence Arg-Gly-Asp-Ser (RGDS). We have used the baculovirus/insect cell expression system to study the structural requirements for the formation of a functionally active fragment of alpha(IIb)-beta(3). A tandem baculovirus transfer vector was constructed containing the cDNA coding for the heavy chain of human alpha(IIb) (alpha(IIbH), amino acids 1-874) and the cDNA coding for a truncated form of human beta(3) (t beta(3); amino acids 1-469). Sf9 insect cells were infected with the corresponding baculovirus, and the produced soluble recombinant proteins were purified using an RGD-like affinity column. The bound receptor fragments were specifically eluted with RGDS and existed as a heterodimeric complex (rec alpha(IIbH)-t beta(3)) with an apparent M(r) of 160,000, In an immunocapture assay, the monoclonal antibody pl-55, which only recognizes the functionally active form of alpha(IIb)-beta(3), bound to the purified complex. Rec alpha(IIbH)-t beta(3) specifically bound I-125-fibrinogen with an affinity comparable with that of purified platelet alpha(IIb)-beta(3). Electron micrographs of rotary-shadowed rec alpha(IIb)-B-3 showed that the complex had the characteristic globular head, but the two rodlike tails were 4-6 nm shorter than those found in intact alpha(IIb)-beta(3). Thus, the cysteine-rich repeats of beta(3) are not required for assembly, stability, and functional activity of this integrin.			WIPPLER, J (corresponding author), F HOFFMANN LA ROCHE LTD, PRECLIN RES, DIV PHARMA, PRPV BAU 69-330, GRENZACHERSTSR 124, CH-4002 BASEL, SWITZERLAND.							ALIG L, 1992, J MED CHEM, V35, P4393, DOI 10.1021/jm00101a017; BAJT ML, 1992, J BIOL CHEM, V267, P22211; BAJT ML, 1992, J BIOL CHEM, V267, P3789; BEER J, 1989, J BIOL CHEM, V264, P17564; BENNETT JS, 1993, J BIOL CHEM, V268, P3580; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BODARY SC, 1989, J BIOL CHEM, V264, P18859; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; COOK JJ, 1992, BIOCHIM BIOPHYS ACTA, V1119, P312, DOI 10.1016/0167-4838(92)90219-4; DSOUZA SE, 1988, J BIOL CHEM, V263, P3943; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FRACHET P, 1992, BIOCHEMISTRY-US, V31, P2408, DOI 10.1021/bi00123a028; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GULINO D, 1992, J BIOL CHEM, V267, P1001; GULINO D, 1990, J BIOL CHEM, V265, P9575; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Inlow D., 1989, J TISSUE CULTURE MET, V12, P13; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOUNS WC, 1991, BLOOD, V78, P3215; KOUNS WC, 1992, J BIOL CHEM, V267, P18844; KOUNS WC, 1991, THROMB RES, V63, P343, DOI 10.1016/0049-3848(91)90137-L; KOUNS WC, 1992, BLOOD, V80, P2529; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM SCT, 1989, BLOOD, V73, P1513; LAM SCT, 1987, J BIOL CHEM, V262, P947; LAM SCT, 1992, J BIOL CHEM, V267, P5649; LANZA F, 1992, J CLIN INVEST, V89, P1995, DOI 10.1172/JCI115808; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; Luckow V. A, 1991, Recombinant DNA technology and applications., P97; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LYMAN S, 1990, BLOOD, V75, P2343; MCEVER RP, 1982, BLOOD, V59, P80; MUNSON PJ, 1980, ANAL BIOCHEM, V102, P318; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; NEWMAN PJ, 1991, P NATL ACAD SCI USA, V88, P3160, DOI 10.1073/pnas.88.8.3160; NEWMAN PJ, 1993, THROMB HAEMOSTASIS, V69, P1017; NEWMAN PJ, 1989, J CLIN INVEST, V83, P1778, DOI 10.1172/JCI114082; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PARISE LV, 1985, J BIOL CHEM, V260, P698; PLOW EF, 1985, BLOOD, V66, P724; PLOW EF, 1981, J BIOL CHEM, V256, P9477; PONCZ M, 1987, J BIOL CHEM, V262, P8476; Possee RD., 1992, BACULOVIRUS EXPRESSI; ROSA JP, 1989, J BIOL CHEM, V264, P12596; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SAVAGE B, 1990, J BIOL CHEM, V265, P11766; Schlaeger E.-J., 1993, Biotechnology Techniques, V7, P183; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; STEINER B, 1991, J BIOL CHEM, V266, P14986; STEINER B, 1993, J BIOL CHEM, V268, P6870; STEINER B, 1989, J BIOL CHEM, V264, P13102; SUMMERS MD, 1987, MANUAL METHODS BACIL; TAYLOR DB, 1992, J BIOL CHEM, V267, P11729; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; WANG RG, 1992, J CLIN INVEST, V90, P2038, DOI 10.1172/JCI116084	69	67	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8754	8761						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132607				2022-12-25	WOS:A1994NB41100024
J	CHEN, DG; STALLCUP, MR				CHEN, DG; STALLCUP, MR			THE HORMONE-BINDING ROLE OF 2 CYSTEINES NEAR THE C-TERMINUS OF THE MOUSE GLUCOCORTICOID RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; DEPENDENT TRANSCRIPTIONAL ACTIVATION; HUMAN ESTROGEN-RECEPTOR; STEROID-BINDING; DEXAMETHASONE 21-MESYLATE; FUNCTIONAL DOMAINS; POINT MUTATIONS; MAMMALIAN-CELLS; AMINO-ACID; WILD-TYPE	Previous biochemical analyses with covalent affinity labels and thiol-blocking reagents suggested possible roles for one methionine residue and multiple cysteine residues in binding of steroid to the 250-amino acid hormone-binding domain at the C-terminal end of mammalian glucocorticoid receptors. To test the functional roles of these residues in the receptor's ability to bind hormone and activate transcription of target genes, the mouse glucocorticoid receptor cDNA was specifically mutated to cause single amino acid substitutions for methionine 610 and for each of the 5 cysteines (at positions 628, 644, 649, 671, and 742) in the hormone-binding domain. Among these 6 residues, only mutations in cysteine 671 and cysteine 742 caused substantial reductions in function. In transient transfection assays, the concentration of dexamethasone required for half maximal activation of a glucocorticoid-responsive reporter gene was increased by 10-40-fold by changing cysteine 742 to serine or cysteine 671 to serine or alanine. At saturating concentrations of dexamethasone, the mutant receptors activated the reporter gene to the same extent as the wild type receptor, indicating that the mutations affected only the hormone-binding function of the receptor and not its ability to bind DNA or activate transcription once the hormone was bound.	UNIV SO CALIF,DEPT PATHOL,LOS ANGELES,CA 90033; UNIV SO CALIF,DEPT BIOCHEM & MOLEC BIOL,LOS ANGELES,CA 90033	University of Southern California; University of Southern California					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043093] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43093] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; BYRAVAN S, 1991, MOL ENDOCRINOL, V5, P752, DOI 10.1210/mend-5-6-752; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CARLSTEDTDUKE J, 1988, J BIOL CHEM, V263, P6842; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; CHAKRABORTI PK, 1992, J BIOL CHEM, V267, P11366; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DANIELSEN M, 1989, CANCER RES, V49, pS2286; DANIELSEN M, 1984, MOL CELL BIOL, V4, P449, DOI 10.1128/MCB.4.3.449; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Ham J, 1989, CURR OPIN CELL BIOL, V1, P503, DOI 10.1016/0955-0674(89)90012-4; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LIU ES, 1991, NUCLEIC ACIDS RES, V19, P5425, DOI 10.1093/nar/19.19.5425; MA WJ, 1992, J BIOL CHEM, V267, P22728; OMALLEY BW, 1992, MOL ENDOCRINOL, V6, P1359, DOI 10.1210/me.6.9.1359; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; REESE JC, 1992, J BIOL CHEM, V267, P9868; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLATTER LK, 1992, MOL ENDOCRINOL, V6, P132, DOI 10.1210/me.6.1.132; SIMONS SS, 1987, J BIOL CHEM, V262, P9676; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH LI, 1988, BIOCHEMISTRY-US, V27, P3747, DOI 10.1021/bi00410a034; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WESTPHAL HM, 1984, EMBO J, V3, P1493, DOI 10.1002/j.1460-2075.1984.tb02001.x	38	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7914	7918						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132510				2022-12-25	WOS:A1994NB40900016
J	LEE, MGS; RUSSELL, DG; DALESANDRO, PA; VANDERPLOEG, LHT				LEE, MGS; RUSSELL, DG; DALESANDRO, PA; VANDERPLOEG, LHT			IDENTIFICATION OF MEMBRANE-ASSOCIATED PROTEINS IN TRYPANOSOMA-BRUCEI ENCODING AN INTERNAL, EARLRAEE AMINO-ACID REPEAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORM; ANTIGENIC VARIATION; AFRICAN TRYPANOSOMES; GEL-ELECTROPHORESIS; REPETITIVE PROTEINS; CULTURE FORMS; SURFACE-COAT; DNA; PURIFICATION; PARASITE	Differential screening of expression libraries with nonimmune and day 4-6 immune serum from naive rats infected with the protozoan Trypanosoma lewisi was used to identify potential cell surface protein coding genes. Several T. lewisi cDNAs that resulted were partially characterized and used to clone the homologues from Trypanosoma brucei. The nucleotide sequence of the cDNAs encoding the Tb-29 genes of the parasitic protozoan T. brucei obtained by this method (3557 nucleotides for Tb-291 and 8729 nucleotides for Tb-292) encoded predicted open reading frames of 1070 and 2550 amino acids, respectively. The Tb-29 proteins encoded a large domain with an octapeptide (EARLRAEE) repeat (79 repeats in Tb-291 and 60 in Tb-292), which shared significant similarity with the octapeptide repeat of the S-antigen of isolate NF7 of Plasmodium falciparum. The predicted amino acid sequence of the Tb-292 protein encoded potential transmembrane domains (eight in total). Indirect immunofluorescence using confocal image analysis and immunoelectron microscopy located the EARLRAEE proteins to a membranous network. The Tb-29 proteins were most abundantly distributed to the area surrounding the nucleus, the region between the nucleus and the flagellar pocket, and the region immediately underneath the flagellar pocket membrane. The subcellular distribution of Tb-29 proteins suggests that these proteins may provide a constituent associated with the cell's vesicular transport system.	WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	LEE, MGS (corresponding author), COLUMBIA UNIV, DIV TROP MED, NEW YORK, NY 10032 USA.		Russell, David G/N-5280-2019; Russell, David G/D-4533-2009	Russell, David G/0000-0002-9748-750X; Russell, David G/0000-0002-9748-750X	NIAID NIH HHS [AI21784, AI26889, AI34207] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026889, R01AI021784, R01AI034207] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLACK S, 1989, MOL BIOCHEM PARASIT, V37, P65, DOI 10.1016/0166-6851(89)90103-5; BOEDTKER H, 1971, BIOCHIM BIOPHYS ACTA, V240, P448, DOI 10.1016/0005-2787(71)90539-9; BONE GJ, 1956, NATURE, V178, P308, DOI 10.1038/178308a0; BORST P, 1987, SCIENCE, V235, P658, DOI 10.1126/science.3544215; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BORST P, 1991, TRENDS GENET, V7, P307, DOI 10.1016/0168-9525(91)90406-G; BRUN R, 1979, ACTA TROP, V36, P289; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Clayton C.E., 1988, Genetic Engineering, V7, P1; CLAYTON CE, 1989, J BIOL CHEM, V264, P15088; COPPENS I, 1988, P NATL ACAD SCI USA, V85, P6753, DOI 10.1073/pnas.85.18.6753; COPPENS I, 1987, J PROTOZOOL, V34, P465, DOI 10.1111/j.1550-7408.1987.tb03216.x; COWMAN AF, 1985, CELL, V40, P775, DOI 10.1016/0092-8674(85)90337-X; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; DALESANDRO PA, 1980, EXP PARASITOL, V50, P384, DOI 10.1016/0014-4894(80)90041-7; ENGLUND PT, 1982, ANNU REV BIOCHEM, V51, P695, DOI 10.1146/annurev.bi.51.070182.003403; FAIRLAMB AH, 1978, J CELL BIOL, V76, P293, DOI 10.1083/jcb.76.2.293; GIANNINI MSH, 1987, J PARASITOL, V73, P144, DOI 10.2307/3282358; GIANNINI SH, 1979, EXP PARASITOL, V47, P342, DOI 10.1016/0014-4894(79)90087-0; GIANNINI SH, 1984, INFECT IMMUN, V43, P617, DOI 10.1128/IAI.43.2.617-621.1984; GOTTESDIENER K, 1990, MOL CELL BIOL, V10, P6079, DOI 10.1128/MCB.10.11.6079; HAJDUK SL, 1989, J BIOL CHEM, V264, P5210; KEMP DJ, 1987, ANNU REV MICROBIOL, V41, P181, DOI 10.1146/annurev.mi.41.100187.001145; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGRETH SG, 1975, J PROTOZOOL, V22, P40, DOI 10.1111/j.1550-7408.1975.tb00943.x; LEE MG, 1987, MOL CELL BIOL, V7, P357, DOI 10.1128/MCB.7.1.357; LEE MG, 1990, NUCLEIC ACIDS RES, V18, P4252, DOI 10.1093/nar/18.14.4252; LEE MGS, 1990, MOL CELL BIOL, V10, P4506, DOI 10.1128/MCB.10.9.4506; LETRANT N, 1983, J BIOL CHEM, V258, P125; LONGACRE S, 1983, MOL CELL BIOL, V3, P399, DOI 10.1128/MCB.3.3.399; MANDLIN I, 1988, TROPENMED PARASITOL, V39, P56; MELLORS A, 1989, PARASITOL TODAY, V5, P239, DOI 10.1016/0169-4758(89)90255-X; MOWATT MR, 1987, MOL CELL BIOL, V7, P2838, DOI 10.1128/MCB.7.8.2838; PETERSON DS, 1986, NATURE, V322, P566, DOI 10.1038/322566a0; RUSSELL DG, 1992, J CELL SCI, V103, P1193; SAMAD A, 1988, MOL BIOCHEM PARASIT, V29, P159, DOI 10.1016/0166-6851(88)90071-0; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHNEIDER A, 1988, SCIENCE, V241, P459, DOI 10.1126/science.3393912; SHAPIRO SZ, 1989, J PROTOZOOL, V36, P344, DOI 10.1111/j.1550-7408.1989.tb05524.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERPLOEG LHT, 1982, NUCLEIC ACIDS RES, V10, P593, DOI 10.1093/nar/10.2.593; VANDERPLOEG LHT, 1990, FRONTIERS MOL BIOL G, P51; VICKERMAN K, 1969, J PROTOZOOL, V16, P54, DOI 10.1111/j.1550-7408.1969.tb02233.x; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; VICKERMAN K, 1969, J CELL SCI, V5, P163; WEBSTER P, 1989, EUR J CELL BIOL, V49, P295; WEBSTER P, 1988, J CELL BIOL, V106, P279, DOI 10.1083/jcb.106.2.279; WEBSTER P, 1993, PARASITOL TODAY, V9, P201, DOI 10.1016/0169-4758(93)90008-4; WEBSTER P, 1989, EUR J CELL BIOL, V49, P303; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359	52	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8408	8415						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132566				2022-12-25	WOS:A1994NB40900087
J	GLOVER, JR; ANDREWS, DW; SUBRAMANI, S; RACHUBINSKI, RA				GLOVER, JR; ANDREWS, DW; SUBRAMANI, S; RACHUBINSKI, RA			MUTAGENESIS OF THE AMINO TARGETING SIGNAL OF SACCHAROMYCES-CEREVISIAE 3-KETOACYL-COA THIOLASE REVEALS CONSERVED AMINO-ACIDS REQUIRED FOR IMPORT INTO PEROXISOMES IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL PRESEQUENCE; PROTEINS; YEAST; PEPTIDE; ENZYME; GENE	Saccharomyces cerevisiae peroxisomal 3-ketoacyl-CoA thiolase is a soluble matrix protein that does not end in a consensus peroxisomal targeting signal-1. The amino terminus of S. cerevisiae peroxisomal thiolase is conserved in 6 of 11 residues with the amino terminus of rat thiolase B, shown to act as a peroxisomal targeting signal 2 (Swinkels, B. W., Gould, S. J., Bodnar, A, G., Rachu- binski, R. A., and Subramani, S. (1991) EMBO J. 10, 3255-3262). Unlike mammalian peroxisomal thiolases, there is no extensive cleavage of S. cerevisiae thiolase upon import into peroxisomes. We demonstrate by in vivo expression that the amino terminal 16 amino acids of S. cerevisiae thiolase are necessary and sufficient for targeting to peroxisomes. This result implies that yeast, like mammalian cells, can target proteins to the peroxi- somal matrix by at least two different routes. We also demonstrate by targeted mutagenesis and in vivo expression of mutated thiolase genes that three amino acids conserved in the amino termini of all known thio- lases are critical for efficient targeting of S. cerevisiae thiolase to peroxisomes.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	GLOVER, JR (corresponding author), MCMASTER UNIV,DEPT BIOCHEM,HAMILTON L8N 3Z5,ON,CANADA.			Andrews, David/0000-0002-9266-7157	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041737, R37DK041737] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41737] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AITCHISON JD, 1992, YEAST, V8, P721, DOI 10.1002/yea.320080905; AITCHISON JD, 1991, J BIOL CHEM, V266, P23197; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; HIJIKATA M, 1987, J BIOL CHEM, V262, P8151; JANIAK F, 1994, IN PRESS BIOCH J; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIN AS, 1990, MOL CELL BIOL, V10, P1399, DOI 10.1128/MCB.10.4.1399; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; NEEDLEMAN RB, 1975, ANAL BIOCHEM, V64, P545, DOI 10.1016/0003-2697(75)90466-2; NUTTLEY WM, 1994, J BIOL CHEM, V269, P556; NUTTLEY WM, 1993, YEAST, V9, P507, DOI 10.1002/yea.320090506; OSUMI T, 1992, BIOCHEM BIOPH RES CO, V186, P811, DOI 10.1016/0006-291X(92)90818-6; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; SEUBERT W, 1968, BIOCHIM BIOPHYS ACTA, V164, P498, DOI 10.1016/0005-2760(68)90180-X; SIKORSKI RS, 1989, GENETICS, V122, P19; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; TAGER JM, 1985, BIOCHEM BIOPH RES CO, V126, P1269, DOI 10.1016/0006-291X(85)90322-5; WANG TW, 1992, NUCLEIC ACIDS RES, V20, P3495, DOI 10.1093/nar/20.13.3495	22	127	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7558	7563						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125978				2022-12-25	WOS:A1994NA03200083
J	DAIHO, T; KANAZAWA, T				DAIHO, T; KANAZAWA, T			REDUCTION OF DISULFIDE BONDS IN SARCOPLASMIC-RETICULUM CA2+-ATPASE BY DITHIOTHREITOL CAUSES INHIBITION OF PHOSPHOENZYME ISOMERIZATION IN CATALYTIC CYCLE - THIS REDUCTION REQUIRES BINDING OF BOTH PURINE NUCLEOTIDE AND CA2+ TO ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; CA-2+-ATPASE; VESICLES	Sarcoplasmic reticulum vesicles were treated with 6 mM dithiothreitol in the presence of 2 mM ATP and 0.1 mM Ca2+ at 25-degrees-C and pH 7.0 for various periods. The Ca2+-ATPase was inhibited almost completely in 100 min. The content of the sulfhydryl group, which was measured in 2.5% SDS with 5,5'-dithiobis(2-nitrobenzoic acid), increased during the treatment. Extrapolation of the plot of the Ca2+-ATPase activity versus the increment of the sulfhydryl group showed that reduction of two disulfide bonds per phosphorylation site leads to a complete inhibition of the enzyme. This reduction required binding of both Ca2+ (with a high affinity) and a purine nucleotide to the enzyme. Adenosine 5'-(beta,gamma-methylene) triphosphate (a nonhydrolyzable ATP analog) was also effective for the reduction, while phosphorylation of the enzyme with acetyl phosphate or P(i) did not trigger the reduction. These results indicate that formation of a substrate-enzyme-calcium complex is responsible for the dithiothreitol-induced disulfide bond reduction. The partial reactions of the Ca2+-ATPase were examined with the vesicles that had been treated with dithiothreitol in the presence of ATP and Ca2+ for 100-200 min. Neither isomerization of the unphosphorylated enzyme from the low Ca2+ affinity form to the high Ca2+ affinity form nor phosphorylation of the enzyme with ATP or P(i) was inhibited. In contrast, isomerization of the phosphoenzyme intermediate from the ADP-sensitive form to the ADP-insensitive form was strongly inhibited. These results show that the observed inhibition of the Ca2+-ATPase is due to a selective blockage of the phosphoenzyme isomerization.	ASAHIKAWA MED COLL,DEPT BIOCHEM,ASAHIKAWA 078,JAPAN	Asahikawa Medical College								ABRAMSON JJ, 1978, J MEMBRANE BIOL, V44, P233, DOI 10.1007/BF01944223; ANDERSEN JP, 1977, BIOCHIM BIOPHYS ACTA, V485, P188, DOI 10.1016/0005-2744(77)90206-6; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; DAIHO T, 1993, BIOCHEMISTRY-US, V32, P10021, DOI 10.1021/bi00089a018; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FRIEDMAN Z, 1970, FEBS LETT, V11, P69, DOI 10.1016/0014-5793(70)80494-X; GEORGOUSSI Z, 1985, BIOCHEM BIOPH RES CO, V126, P1196, DOI 10.1016/0006-291X(85)90312-2; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; HASSELBACH W, 1974, BIOCHEM SOC SPEC PUB, V4, P159; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; KAWASHIMA T, 1990, J BIOL CHEM, V265, P10993; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MURPHY AJ, 1976, BIOCHEMISTRY-US, V15, P4492, DOI 10.1021/bi00665a025; Mutoh Yoshinobu, 1992, Journal of UOEH, V14, P253; PANET R, 1970, EUR J BIOCHEM, V14, P440, DOI 10.1111/j.1432-1033.1970.tb00308.x; THORLEYLAWSON DA, 1977, BIOCHEM J, V167, P739, DOI 10.1042/bj1670739	22	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11060	11064						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157632				2022-12-25	WOS:A1994NF96600017
J	JUST, I; FRITZ, G; AKTORIES, K; GIRY, M; POPOFF, MR; BOQUET, P; HEGENBARTH, S; VONEICHELSTREIBER, C				JUST, I; FRITZ, G; AKTORIES, K; GIRY, M; POPOFF, MR; BOQUET, P; HEGENBARTH, S; VONEICHELSTREIBER, C			CLOSTRIDIUM-DIFFICILE TOXIN-B ACTS ON THE GTP-BINDING PROTEIN-RHO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOTULINUM ADP-RIBOSYLTRANSFERASE; BOVINE BRAIN CYTOSOL; ACTIVATING PROTEIN; ESCHERICHIA-COLI; PARTIAL-PURIFICATION; MAMMALIAN-CELLS; GENE-PRODUCT; C2 TOXIN; RAS; GDP	Clostridium difficile toxin B exhibits cytotoxic activity that is characterized by the disruption of the microfilamental cytoskeleton. Here we studied whether the GTP-binding Rho protein, which reportedly participates in the regulation of the actin cytoskeleton, is involved in the toxin action. Toxin B treatment of Chinese hamster ovary cells reveals a time- and concentration-dependent decrease in the ADP-ribosylation of Rho by Clostridium botulinum C3 exoenzyme in the cell lysate. Disruption of the microfilament system induced by C. botulinum C2 toxin or cytochalasin D does not cause impaired ADP-ribosylation of Rho. Toxin B exhibits its effects on Rho not only in intact cells but also when added to cell lysates. Besides endogenous Rho, RhoA-glutathione S-transferase (Rho-GST) fusion protein added to cell lysate showed decreased ADP-ribosylation after toxin B treatment. Immunoblot analysis reveals identical amounts of Rho-GST and no change in molecular mass after toxin B treatment compared with controls. ADP-ribosylation of Rho-GST purified from toxin B-treated cell lysate is inhibited, indicating a modification of Rho itself. Finally, transfection of rhoA DNA under the control of a strong promoter into cells protects them from the activity of toxin B. Altogether, the data indicate that C. difficile toxin B acts directly or indirectly on Rho proteins to inhibit ADP-ribosylation and suggest that the cytotoxic effect of toxin B involves Rho.	INST PASTEUR,UNITE TOXINES BACTERIENNES,F-75724 PARIS 15,FRANCE; UNIV MAINZ,INST MED MICROBIOL,D-55101 MAINZ,GERMANY	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Johannes Gutenberg University of Mainz	JUST, I (corresponding author), UNIV SAARLAND,INST PHARMACOL & TOXIKOL,D-66421 HOMBURG,GERMANY.		Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; BARTLETT JG, 1990, REV INFECT DIS, V12, pS243, DOI 10.1093/clinids/12.Supplement_2.S243; BETTE P, 1991, TOXICON, V29, P877, DOI 10.1016/0041-0101(91)90224-F; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CIESIELSKITRESKA J, 1989, EUR J CELL BIOL, V48, P191; CIESIELSKITRESKA J, 1991, EUR J CELL BIOL, V56, P68; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; FIORENTINI C, 1991, TOXICON, V29, P543, DOI 10.1016/0041-0101(91)90050-2; FIORENTINI C, 1989, TOXICON, V27, P1209, DOI 10.1016/0041-0101(89)90029-9; FLORIN I, 1986, MICROB PATHOGENESIS, V1, P373, DOI 10.1016/0882-4010(86)90069-0; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GARRETT MD, 1991, BIOCHEM J, V276, P833, DOI 10.1042/bj2760833; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HARTENSTEIN JH, 1993, PERSPECTIVES MED CHE, P99; HIDIKA H, 1984, BIOCHEMISTRY-US, V23, P5036; ISOMURA M, 1990, BIOCHEM BIOPH RES CO, V169, P652, DOI 10.1016/0006-291X(90)90380-6; JUST I, 1992, J BIOL CHEM, V267, P10274; JUST I, 1992, BIOCHEM BIOPH RES CO, V183, P931, DOI 10.1016/S0006-291X(05)80279-7; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; KIKUCHI A, 1992, BIOCHEMISTRY-US, V31, P12863; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYERLY D M, 1988, Clinical Microbiology Reviews, V1, P1; MITCHELL MJ, 1987, INFECT IMMUN, V55, P1610, DOI 10.1128/IAI.55.7.1610-1615.1987; MORII N, 1991, J BIOL CHEM, V266, P7646; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; OHISHI I, 1980, INFECT IMMUN, V30, P668; OTTLINGER ME, 1988, EXP CELL RES, V174, P215, DOI 10.1016/0014-4827(88)90156-5; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; POPOFF MR, 1991, INFECT IMMUN, V59, P3673, DOI 10.1128/IAI.59.10.3673-3679.1991; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLDATI T, 1991, CELL, V66, P277, DOI 10.1016/0092-8674(91)90618-9; SUGAI M, 1992, J BIOL CHEM, V267, P2600; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEDA T, 1990, J BIOL CHEM, V265, P9373; VONEICHELSTREIB.C, 1993, GENETICS MOL BIOL AN, P264; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8; WIEGERS W, 1991, EUR J CELL BIOL, V54, P237; YAMAMOTO J, 1990, MOL BRAIN RES, V8, P105, DOI 10.1016/0169-328X(90)90054-H	48	171	173	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10706	10712						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144660				2022-12-25	WOS:A1994NF01700077
J	ARLT, G; BROOKS, DA; ISBRANDT, D; HOPWOOD, JJ; BIELICKI, J; BRADFORD, TM; BINDLOSSPETHERBRIDGE, CA; VONFIGURA, K; PETERS, C				ARLT, G; BROOKS, DA; ISBRANDT, D; HOPWOOD, JJ; BIELICKI, J; BRADFORD, TM; BINDLOSSPETHERBRIDGE, CA; VONFIGURA, K; PETERS, C			JUVENILE FORM OF MUCOPOLYSACCHARIDOSIS-VI (MAROTEAUX-LAMY SYNDROME) - A C-TERMINAL EXTENSION CAUSES INSTABILITY BUT INCREASES CATALYTIC EFFICIENCY OF ARYLSULFATASE-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL ACID-PHOSPHATASE; CULTURED HUMAN-FIBROBLASTS; ALPHA-L-IDURONIDASE; N-ACETYLGALACTOSAMINE-4-SULFATASE; PROTEIN; MATURATION; SULFATASE; GENE; PURIFICATION; BIOSYNTHESIS	A deficiency of the enzyme arylsulfatase B results in the lysosomal storage disorder Maroteaux-Lamy syndrome or mucopolysaccharidosis type VI. Severe, intermediate and mild forms of this autosomal recessively inherited disease can be clinically differentiated. To determine the molecular defect in a patient with the intermediate form of the disorder, DNA fragments generated from the patient's mRNA by reverse transcription and subsequent amplification by the polymerase chain reaction were subcloned and sequenced. The mRNA transcribed from one allele contains a 244-base pair deletion causing a frameshift and a truncation of the open reading frame. The C-terminal third of the encoded mutant polypeptide has a nonsense sequence. This mutation is due to a deletion of exon 5 in this allele. A silent A to G transition at nucleotide 1191 was present in the same allele, and the second allele was characterized by a T to C transition at nucleotide 1600 causing a mutation of the translational stop codon to a glutamine codon (*534Q) and extending the encoded polypeptide by 50 amino acids. Stable expression of the *534Q allele in LTK- cells resulted in a mutant precursor 4 kDa larger than the wild-type precursor. The majority of the mutant precursor appears to be degraded before reaching the trans Golgi. This is consistent with an altered polypeptide structure, where a number of missing or masked epitopes were observed in an enzyme immunobinding assay using a panel of monoclonal antibodies. Immunoquantification analysis showed that epitopes were most likely masked, as missing epitopes could be reformed by binding the mutant protein to a polyclonal antibody of arylsulfatase B. It is suggested that the additional amino acids at the C terminus of the arylsulfatase B polypeptide induce a protein conformational change. *534Q mutant polypeptide escaping degradation is sorted to dense lysosomes. The mutant polypeptide has an approximately 9-fold higher catalytic efficiency than wild-type arylsulfatase B.	UNIV GOTTINGEN,GOSSLERSTR 12D,W-3400 GOTTINGEN,GERMANY; ADELAIDE MED CTR WOMEN & CHILDREN,DEPT CHEM PATHOL,LYSOSOMAL DIS RES UNIT,ADELAIDE,SA 5006,AUSTRALIA	University of Gottingen; Womens & Childrens Hospital Australia			Bradford, Tessa/G-8387-2011; Brooks, Doug A/K-6714-2012	Bradford, Tessa/0000-0003-0607-1398; , Tessa/0000-0003-1442-8449; Brooks, Doug/0000-0001-9098-3626; Isbrandt, Dirk/0000-0002-4720-1016				BROOKS DA, 1991, J INHERIT METAB DIS, V14, P5, DOI 10.1007/BF01804381; BROOKS DA, 1991, AM J HUM GENET, V48, P710; BROOKS DA, 1992, BIOCHEM MED METAB B, V47, P211, DOI 10.1016/0885-4505(92)90028-W; CHELLY J, 1990, CELL, V63, P1239, DOI 10.1016/0092-8674(90)90419-F; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1625; GIBSON GJ, 1987, BIOCHEM J, V248, P755, DOI 10.1042/bj2480755; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HOPWOOD JJ, 1986, BIOCHEM J, V234, P507, DOI 10.1042/bj2340507; JIN WD, 1992, AM J HUM GENET, V50, P795; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; LEMANSKY P, 1985, J BIOL CHEM, V260, P9023; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LITJENS T, 1991, BIOCHEM INT, V24, P209; Litjens Tom, 1992, Human Mutation, V1, P397, DOI 10.1002/humu.1380010509; MATALON R, 1974, BIOCHEM BIOPH RES CO, V61, P1450, DOI 10.1016/S0006-291X(74)80446-8; MODARESSI S, 1993, BIOL CHEM H-S, V374, P327, DOI 10.1515/bchm3.1993.374.1-6.327; MYEROWITZ R, 1981, J BIOL CHEM, V256, P3044; Neufeld EF, 1989, METABOLIC BASIS INHE, P1565; OBRIEN JF, 1974, BIOCHEM BIOPH RES CO, V60, P1170, DOI 10.1016/0006-291X(74)90435-5; PETERS C, 1990, J BIOL CHEM, V265, P3374; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUCHMAN EH, 1990, GENOMICS, V6, P149, DOI 10.1016/0888-7543(90)90460-C; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STECKEL F, 1983, J BIOL CHEM, V258, P4322; Strauss W. M., 1990, CURRENT PROTOCOLS MO; VONFIGURA K, 1977, EUR J BIOCHEM, V80, P525; VONFIGURA K, 1983, P NATL ACAD SCI-BIOL, V80, P6066; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; WICKER G, 1991, J BIOL CHEM, V266, P21386; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	31	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9638	9643						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144552				2022-12-25	WOS:A1994NE05300039
J	HOUGH, RF; BASS, BL				HOUGH, RF; BASS, BL			PURIFICATION OF THE XENOPUS-LAEVIS DOUBLE-STRANDED-RNA ADENOSINE-DEAMINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNWINDING MODIFYING ACTIVITY; MAMMALIAN-CELLS; PROTEIN-KINASE; MESSENGER-RNA; BINDING; CHROMATOGRAPHY; SUBSTRATE; MECHANISM; EGGS; GELS	A double-stranded RNA adenosine deaminase that catalyzes the conversion of adenosines to inosines in duplex RNA substrates was purified to near homogeneity from Xenopus laevis eggs. The final specific activity was approximately 2.0 nmol of inosine min-1 mg-1 at 25-degrees-C and pH 7.9 with a 794-base pair RNA substrate. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed a single major approximately 120-kDa protein band by silver staining. The purified enzyme migrated with an apparent molecular mass of 90 +/- 10 kDa during high performance liquid chromatography. Gel filtration of the partially purified enzyme gave an apparent molecular mass of 210 +/- 20 kDa, suggesting that the enzyme may dimerize or associate with other cellular components. Substrate modification was inhibited by excess substrate, thiol reagents, heparin, and moderate concentrations of monovalent cations.	UNIV UTAH, DEPT BIOCHEM, 50 N MED DR, SALT LAKE CITY, UT 84132 USA	Utah System of Higher Education; University of Utah					NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30CA42014] Funding Source: Medline; NIGMS NIH HHS [GM 44073] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BASS BL, 1993, RNA WORLD, P383; Bass Brenda L., 1992, Seminars in Developmental Biology, V3, P425; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2846, DOI 10.1128/MCB.13.5.2846; BISCHOFF JR, 1989, VIROLOGY, V172, P106, DOI 10.1016/0042-6822(89)90112-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN L, 1993, BIOESSAYS, V15, P33, DOI 10.1002/bies.950150106; Cleland W W, 1979, Methods Enzymol, V63, P500; FUKUDA K, 1993, INT J BIOCHEM, V25, P183, DOI 10.1016/0020-711X(93)90005-Y; GALABRU J, 1989, EUR J BIOCHEM, V178, P581, DOI 10.1111/j.1432-1033.1989.tb14485.x; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; HAINES DS, 1991, J CELL BIOCHEM, V46, P9, DOI 10.1002/jcb.240460104; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HUNTER T, 1975, J BIOL CHEM, V250, P409; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; MORRISSEY LM, 1991, MOL CELL BIOL, V11, P3719, DOI 10.1128/MCB.11.7.3719; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NISHIKURA K, 1991, EMBO J, V10, P3523, DOI 10.1002/j.1460-2075.1991.tb04916.x; OCHS D, 1983, ANAL BIOCHEM, V135, P470, DOI 10.1016/0003-2697(83)90714-5; OSTROVE S, 1990, METHOD ENZYMOL, V182, P357; POLSON AG, 1991, BIOCHEMISTRY-US, V30, P11507, DOI 10.1021/bi00113a004; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; SHARMEEN L, 1991, P NATL ACAD SCI USA, V88, P8096, DOI 10.1073/pnas.88.18.8096; SKEIKY YAW, 1991, J MOL BIOL, V218, P517, DOI 10.1016/0022-2836(91)90698-6; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770	38	98	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9933	9939						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144588				2022-12-25	WOS:A1994NE05300082
J	SAKANO, S; IWAMA, A; INAZAWA, J; ARIYAMA, T; OHNO, M; SUDA, T				SAKANO, S; IWAMA, A; INAZAWA, J; ARIYAMA, T; OHNO, M; SUDA, T			MOLECULAR-CLONING OF A NOVEL NONRECEPTOR TYROSINE KINASE, HYL (HEMATOPOIETIC CONSENSUS TYROSINE-LACKING KINASE)	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; CELL ANTIGEN RECEPTOR; PROTEIN-KINASE; CONSERVED FEATURES; CATALYTIC DOMAIN; MESSENGER-RNAS; FAMILY; GENE; SEQUENCE	We identified a novel non-receptor tyrosine kinase from a human megakaryoblastic cell line, UT-7, by means of a PCR-based cloning method. The HYL gene contained a SH2 and SH3 domain and a tyrosine kinase catalytic domain. The deduced amino acid sequence of the protein encoded by this gene was most homologous to CSK (c-src kinase). This gene and CSK shared some unique structural properties such as the absence of a myristylation signal and phosphorylation sites of tyrosine residues corresponding to tyrosines 416 and 527 of chicken p60c-src. Unlike CSK, the SH3 domain of HYL was unique since the ALYDY motif was absent. Northern blot analysis revealed a 2.2 kb transcript in various myeloid cell lines but not in adult tissues except for the brain and the lung, whereas CSK mRNA was ubiquitously expressed. The expression of HYL was upregulated when these myeloid cells were differentiated by induction with phorbol myristate acetate. We named this gene, hematopoietic consensus tyrosine-lacking kinase, HYL. The HYL gene was assigned to chromosome 19 at band p13. It is suggested that HYL plays a significant role in the signal transduction of hematopoietic cells.	KUMAMOTO UNIV, SCH MED,INST MOLEC EMBRYOL & GENET, DEPT DIFFERENTIAT,2-2-1 HONJO, KUMAMOTO 860, JAPAN; ASAHI CHEM IND CO LTD, FUNDAMENTAL RES LAB LIFE SCI, FUJI, SHIZUOKA 416, JAPAN; KYOTO PREFECTURAL UNIV MED, DEPT HYG HEMATOL & ONCOL UNIT, KYOTO 602, JAPAN	Kumamoto University; Kyoto Prefectural University of Medicine			Suda, Toshio/H-6761-2013	Suda, Toshio/0000-0001-7540-1771				ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; INAZAWA J, 1991, GENOMICS, V10, P1075, DOI 10.1016/0888-7543(91)90202-P; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; KOMATSU N, 1991, CANCER RES, V51, P341; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; Maniatis T., 1982, MOL CLONING; MATUDA M, 1992, MOL CELL BIOL, V12, P3482; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1991, J BIOL CHEM, V266, P24249; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PARTANEN J, 1991, ONCOGENE, V6, P2013; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TABILIO A, 1983, CANCER RES, V43, P4569; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TREVILLYAN JM, 1986, BIOCHIM BIOPHYS ACTA, V888, P286, DOI 10.1016/0167-4889(86)90228-4; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	44	60	67	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1155	1161						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134117				2022-12-25	WOS:A1994NC04800018
J	WOLCOTT, RG; FRANKS, BS; HANNUM, DM; HURST, JK				WOLCOTT, RG; FRANKS, BS; HANNUM, DM; HURST, JK			BACTERICIDAL POTENCY OF HYDROXYL RADICAL IN PHYSIOLOGICAL ENVIRONMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED DAMAGE; ESCHERICHIA-COLI; AMINO-ACIDS; HYDROGEN-PEROXIDE; AQUEOUS-SOLUTION; RATE CONSTANTS; OXYGEN; SUPEROXIDE; OXIDATION; NEUTROPHILS	Rates of radiolytic inactivation of bacteria suspended in N2O-saturated solutions were dramatically increased over normal background levels when the media contained chloride or bicarbonate ions. The bacteria could be protected from this enhanced toxicity by the addition of free radical scavengers (ethanol, ascorbate, hydrogen peroxide, mannitol, glucose, EDTA, picolinic acid), indicating that the lethal reactions were extracellular in origin. Prior irradiation of chloride-containing solutions led to formation of hypochlorous acid, which was identified by detection of ring-chlorinated products when reacted with fluorescein. Prolonged irradiation of other solutions did not lead to accumulation of bactericidal agents; however, irradiation of bicarbonate-containing solutions in the presence of the spin trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO) led to formation of the EPR-detectable DMPO.CO3- adduct. The results are interpreted in terms of formation of secondary radicals, among which the carbonate and chlorine radicals are uniquely toxic to bacteria. From rate comparisons of the solution components, it was concluded that the reactions involving chloride ion are unlikely to be expressed in biological environments, but that the CO3- radical could be an important intermediary oxidant in peroxide-inflicted cellular damage, particularly in spatially confined environments such as the leukocyte phagosome.	WASHINGTON STATE UNIV,DEPT CHEM,PULLMAN,WA 99164; OREGON GRAD INST SCI & TECHNOL,DEPT CHEM BIOCHEM & MOLEC BIOL,PORTLAND,OR 97291	Washington State University					NIAID NIH HHS [AI 15834] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015834] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS GE, 1972, RADIAT RES, V49, P278, DOI 10.2307/3573266; ADAMS GE, RADIAT RES, V49, P290; ALBRICH JM, 1982, FEBS LETT, V144, P157, DOI 10.1016/0014-5793(82)80591-7; ALTMAN PL, 1971, BLOOD OTHER BODY BOD; [Anonymous], 1989, STANDARD METHODS EXA, V17th; BARRETTE WC, 1988, J BACTERIOL, V170, P3655, DOI 10.1128/jb.170.8.3655-3659.1988; BARTON DHR, 1991, TETRAHEDRON LETT, V32, P311, DOI 10.1016/S0040-4039(00)92615-7; BERLETT BS, 1990, P NATL ACAD SCI USA, V87, P389, DOI 10.1073/pnas.87.1.389; BOIVIN J, 1990, TETRAHEDRON LETT, V31, P6869, DOI 10.1016/S0040-4039(00)97193-4; BRITIGAN BE, 1986, J BIOL CHEM, V261, P4429; BRUSTAD T, 1976, RADIAT RES, V66, P215, DOI 10.2307/3574392; BUETTNER GR, 1978, BIOCHEM BIOPH RES CO, V83, P69, DOI 10.1016/0006-291X(78)90398-4; BUXTON GV, 1986, RADIAT PHYS CHEM, V27, P241; BUXTON GV, 1988, J PHYS CHEM REF DATA, V17, P513, DOI 10.1063/1.555805; CHEN SN, 1973, RADIAT RES, V56, P40, DOI 10.2307/3573789; CHEVION M, 1988, FREE RADICAL BIO MED, V5, P27, DOI 10.1016/0891-5849(88)90059-7; COPE VW, 1972, J CHEM SOC CHEM COMM, P227, DOI 10.1039/c39720000227; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; GABIG TG, 1984, J BIOL CHEM, V259, P3166; GRABNER G, 1973, INT J RADIAT PHYS CH, V5, P393, DOI 10.1016/0020-7055(73)90002-8; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P61; HARBOUR JR, 1978, PHOTOCHEM PHOTOBIOL, V28, P231, DOI 10.1111/j.1751-1097.1978.tb07700.x; HECKEL E, 1966, BERICH BUNSEN GESELL, V70, P149; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; HURST JK, 1984, J BIOL CHEM, V259, P4812; JACOBS GP, 1985, INT J RADIAT BIOL, V47, P621, DOI 10.1080/09553008514550861; JAYSON GG, 1973, J CHEM SOC FARAD T 1, V69, P1597, DOI DOI 10.1039/F19736901597; JOHNS HE, 1988, PHYSICS RADIOLOGY, P217; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; Koppenol W. H., 1985, ADV FREE RADICALS BI, V1, P91, DOI DOI 10.1016/8755-9668(85)90005-5; Latimer W.M., 1952, OXIDATION POTENTIALS; LILIE J, 1978, RADIAT PHYS CHEM, V11, P225, DOI 10.1016/0146-5724(78)90101-2; MATSUYAMA A, 1967, RADIAT RES, V30, P687, DOI 10.2307/3572136; MICHELSON AM, 1977, PHOTOCHEM PHOTOBIOL, V25, P55, DOI 10.1111/j.1751-1097.1977.tb07424.x; MICHELSON AM, 1984, OXYGEN RADICALS CHEM, P831; NETA P, 1988, J PHYS CHEM REF DATA, V17, P1027, DOI 10.1063/1.555808; SAMUNI A, 1978, RADIAT RES, V76, P624, DOI 10.2307/3574810; SARGENT FP, 1976, CAN J CHEM, V54, P275, DOI 10.1139/v76-041; Simic MG, 1988, OXYGEN RADICALS BIOL; SUTTON HC, 1989, FREE RADICAL BIO MED, V6, P53, DOI 10.1016/0891-5849(89)90160-3; THOMAS JK, 1965, T FARADAY SOC, V61, P702, DOI 10.1039/tf9656100702; WALLING C, 1975, ACCOUNTS CHEM RES, V8, P125, DOI 10.1021/ar50088a003; WARD JF, 1970, INT J RADIAT BIOL RE, V18, P381, DOI 10.1080/09553007014551221; WEEKS JL, 1966, J PHYS CHEM-US, V70, P2100, DOI 10.1021/j100879a005; WINTERBOURN CC, 1985, BIOCHEM J, V228, P583, DOI 10.1042/bj2280583	45	59	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9721	9728						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144563				2022-12-25	WOS:A1994NE05300052
J	ACKERMANN, EJ; KEMPNER, ES; DENNIS, EA				ACKERMANN, EJ; KEMPNER, ES; DENNIS, EA			CA2+-INDEPENDENT CYTOSOLIC PHOSPHOLIPASE A(2) FROM MACROPHAGE-LIKE P388D(1) CELLS - ISOLATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-INDEPENDENT PHOSPHOLIPASE-A2; RADIATION INACTIVATION; PURIFICATION; LINE; PHOSPHOFRUCTOKINASE; MEMBRANE; LYSOPHOSPHOLIPASE; RAT; PROTEINS; BRAIN	A novel form of an ATP-regulated, oligomeric, Ca2(+-) independent phospholipase A(2)(iPLA(2)) has been purified from the cytosol of the murine macrophage-like cell line P388D(1). The purification procedure included ammonium sulfate precipitation and sequential column chromatography on octyl-Sepharose, ATP-agarose, Mono Q fast protein liquid chromatography (FPLC), and hydroxyapatite FPLC. The resulting enzyme preparation was purified over 400,000-fold with a final specific activity of approximately 5 mu mol/min/mg using a mixed micelle assay system of Triton X-100 and dipalmitoyl phosphatidylcholine (PC). The purified enzyme was Ca2+-independent and did not show a preference for either sn-2 arachidonic acid or sn-1 alkyl-ether containing phospholipids when utilizing mixed micelles as substrate. It was found to hydrolyze dipalmitoyl-PC similar to 4-fold faster than 1-palmitoyl-2-arachidonyl-PC and similar to 15-fold faster than 1-O-hexadecyl-2-arachidonyl-PC. Triton X-100 increased the P388D(1) iPLA(2) activity with optimal activity found at a Triton/phospholipid molar ratio of 4:1. The purified enzyme was activated 2-6-fold by ATP as well as other di- and triphosphate nucleosides. This activation was sensitive to the concentration of Triton X-100 present in the assay. SDS-polyacrylamide gel electrophoresis carried out on the purified enzyme yielded a single major band at a molecular weight of about 80,000. However, radiation inactivation experiments, carried out on the cell homogenate, demonstrated a target size of 337 +/- 25 kDa, indicating that the catalytically active iPLA(2) exists as a large oligomeric complex, either through self-aggregation or association of the enzyme with other proteins.	UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA; NIH, BETHESDA, MD 20892 USA	University of California System; University of California San Diego; National Institutes of Health (NIH) - USA			Dennis, Edward A./M-5554-2019	Dennis, Edward A./0000-0003-3738-3140	NICHD NIH HHS [HD 26171] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACKERMANN L, 1993, FASEB J, V7, pA1265; CAO YZ, 1987, J BIOL CHEM, V262, P16927; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; DOLE VP, 1956, J CLIN INVEST, V35, P150, DOI 10.1172/JCI103259; FOE LG, 1985, J BIOL CHEM, V260, P726; FORD DA, 1991, J CLIN INVEST, V88, P331, DOI 10.1172/JCI115296; GASSAMADIAGNE A, 1989, J BIOL CHEM, V264, P9470; HARMON JT, 1985, METHOD ENZYMOL, V117, P65; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P14526; HAZEN SL, 1993, J BIOL CHEM, V268, P9892; HIRASHIMA Y, 1992, J NEUROCHEM, V59, P708, DOI 10.1111/j.1471-4159.1992.tb09426.x; IBRAHIM SA, 1967, BIOCHIM BIOPHYS ACTA, V137, P413, DOI 10.1016/0005-2760(67)90122-1; KEMPNER ES, 1991, METHOD ENZYMOL, V197, P280; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISTER MD, 1988, J BIOL CHEM, V263, P7506; LISTER MD, 1989, J BIOL CHEM, V264, P8520; MIZUNO M, 1991, BIOCHIM BIOPHYS ACTA, V1084, P21, DOI 10.1016/0005-2760(91)90050-R; PIERIK AJ, 1988, BIOCHIM BIOPHYS ACTA, V962, P345, DOI 10.1016/0005-2760(88)90264-0; PIND S, 1991, BIOCHEM CELL BIOL, V69, P346, DOI 10.1139/o91-054; RAMADOSS CS, 1976, ARCH BIOCHEM BIOPHYS, V175, P487, DOI 10.1016/0003-9861(76)90536-1; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; ROSS MI, 1985, ARCH BIOCHEM BIOPHYS, V238, P247, DOI 10.1016/0003-9861(85)90162-6; SIMPSON CJ, 1991, BIOCHEM BIOPH RES CO, V180, P197, DOI 10.1016/S0006-291X(05)81276-8; STAFFORD RE, 1993, BIOCHIM BIOPHYS ACTA, V1167, P43, DOI 10.1016/0005-2760(93)90215-U; TANAKA Y, 1989, ARCH BIOCHEM BIOPHYS, V272, P210, DOI 10.1016/0003-9861(89)90212-9; ULEVITCH RJ, 1988, J BIOL CHEM, V263, P3079; VORA S, 1985, BIOCHEM J, V229, P333, DOI 10.1042/bj2290333; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZHANG Y, 1988, J BIOL CHEM, V263, P9965; ZHANG YY, 1991, METHOD ENZYMOL, V197, P456	32	231	238	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9227	9233						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132660				2022-12-25	WOS:A1994NB41100089
J	BLOCKI, FA; LOGAN, MSP; BAOLI, C; WACKETT, LP				BLOCKI, FA; LOGAN, MSP; BAOLI, C; WACKETT, LP			REACTION OF RAT-LIVER GLUTATHIONE S-TRANSFERASES AND BACTERIAL DICHLOROMETHANE DEHALOGENASE WITH DIHALOMETHANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY-CHROMATOGRAPHY; SEQUENCE-ANALYSIS; INORGANIC HALIDE; CDNA CLONE; DETOXIFICATION; PROTEINS; FORMALDEHYDE; SUBSTITUTION; METABOLISM; EXPRESSION	Dichloromethane dehalogenase from Methylophilus sp. DM11 is a glutathione S-transferase homolog that is specifically active with dihalomethane substrates. This bacterial enzyme and rat liver glutathione S transferases were purified to investigate their relative reactivity with CH2Cl2 and related substrates. Rat liver alpha class glutathione transferases were inactive and mu class enzymes showed low activity (7-23 nmol/min/mg of protein) with CH2Cl2. theta class glutathione transferase 5-5 from rat liver and Methylophilus sp. dichloromethane dehalogenase showed specific activities of greater than or equal to 1 mu mol/ min/mg of protein. Apparent K-cat/K-m were determined to be 3.3 x 10(4) and 6.0 x 10(4) L M(-1) s(-1) for the two enzymes, respectively. Dideutereo-dichloromethane was processed to dideutereo-formaldehyde, consistent with a nucleophilic halide displacement mechanism, The possibility of a GSCH(2)X reaction intermediate (GS, glutathione; X, halide) was probed using CH2ClF to generate a more stable halomethylglutathione species (GSCH(2)F). The reaction of CH2ClF with dichloromethane dehalogenase produced a kinetically identifiable intermediate that decomposed to formaldehyde at a similar rate to synthetic HOCH2CH2SCH2F. F-19-NMR revealed the transient formation of an intermediate identified as GSCH(2)F by its chemical shift, its triplet resonance, and H-F coupling constant consistent with a fluoromethylthioether. Its decomposition was matched by a stoichiometric formation of fluoride. These studies indicated that the bacterial dichloromethane dehalogenase directs a nucleophilic attack of glutathione on CH2Cl2 to produce a halomethylthioether intermediate. This focuses attention on the mechanism used by theta class glutathione transferases to generate a halomethylthioether from relatively unreactive dihalomethanes.	UNIV MINNESOTA, DEPT BIOCHEM, ST PAUL, MN 55108 USA; UNIV MINNESOTA, INST ADV STUDIES BIOL PROC TECHNOL, ST PAUL, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041235] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41235] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED AE, 1978, BIOCHEM PHARMACOL, V27, P2021, DOI 10.1016/0006-2952(78)90061-8; AHMED AE, 1976, DRUG METAB DISPOS, V4, P357; ANDERS MW, 1985, BIOACTIVATION FOREIG, P253; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; BLOCKI FA, 1993, PROTEIN SCI, V2, P2095, DOI 10.1002/pro.5560021210; BLOCKI FA, 1992, NATURE, V360, P269, DOI 10.1038/360269a0; BLOCKI FA, 1993, THESIS U MINNESOTA; BOGGS JE, 1960, J AM CHEM SOC, V82, P3517, DOI 10.1021/ja01499a010; BOHME H, 1949, LIEBIGS ANN CHEM, V563, P54; BOYER TD, 1983, BIOCHEM PHARMACOL, V32, P1843, DOI 10.1016/0006-2952(83)90048-5; BOYER TD, 1985, BIOCH PHARM TOXICOLO, V1, P297; DIKS RMM, 1991, BIOPROCESS ENG, V6, P93, DOI 10.1007/BF00369061; DING GJF, 1986, J BIOL CHEM, V261, P7952; DING GJF, 1985, J BIOL CHEM, V260, P3268; Gunsalus I C, 1978, Methods Enzymol, V52, P166; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HINE J, 1958, J AM CHEM SOC, V80, P824, DOI 10.1021/ja01537a018; HINE J, 1956, J AM CHEM SOC, V78, P2282, DOI 10.1021/ja01591a069; HOUSTON ME, 1989, J CHEM SOC CHEM COMM, P761, DOI 10.1039/c39890000761; INOUE M, 1981, BIOCHIM BIOPHYS ACTA, V659, P362, DOI 10.1016/0005-2744(81)90062-0; Jakoby W B, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P383; JAKOBY WB, 1977, TRENDS BIOCHEM SCI, V2, P229, DOI 10.1016/0968-0004(77)90116-5; JI X, 1992, BIOCHEMISTRY-US, V31, P1019; JOHNSON WW, 1993, J BIOL CHEM, V268, P11508; KOHLERSTAUB D, 1985, J BACTERIOL, V162, P676, DOI 10.1128/JB.162.2.676-681.1985; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROCHE SD, 1990, J BACTERIOL, V172, P164, DOI 10.1128/JB.172.1.164-171.1990; LIU SX, 1992, J BIOL CHEM, V267, P4296; LOGAN MSP, 1993, BIOCHEM BIOPH RES CO, V197, P853, DOI 10.1006/bbrc.1993.2557; MANNERVIK B, 1982, J BIOL CHEM, V257, P9909; MANOHARAN TH, 1992, J MOL BIOL, V226, P319, DOI 10.1016/0022-2836(92)90949-K; MARUYAMA H, 1984, J BIOL CHEM, V259, P2449; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; PATTINSON N, 1980, J CHROMATOGR, V187, P409, DOI 10.1016/S0021-9673(00)80473-2; PATTINSON N, 1981, ANAL BIOCHEM, V115, P424, DOI 10.1016/0003-2697(81)90028-2; PATTINSON NR, 1981, BIOCHIM BIOPHYS ACTA, V667, P70, DOI 10.1016/0005-2795(81)90067-2; PEMBLE SE, 1992, BIOCHEM J, V287, P957, DOI 10.1042/bj2870957; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; ROBERTS AL, 1992, ENVIRON SCI TECHNOL, V26, P2263, DOI 10.1021/es00035a027; ROGIERS V, 1991, BIOCHEM PHARMACOL, V42, P491, DOI 10.1016/0006-2952(91)90310-2; SCHOLTZ R, 1988, J BACTERIOL, V170, P5698, DOI 10.1128/jb.170.12.5698-5704.1988; SIMONS PC, 1977, ANAL BIOCHEM, V82, P334, DOI 10.1016/0003-2697(77)90169-5; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; STUCKI G, 1981, ARCH MICROBIOL, V130, P366, DOI 10.1007/BF00414602; STUCKI G, 1981, MICROBIAL DEGRADATIO, P131; Wackett Lawrence P., 1992, Biodegradation, V3, P19, DOI 10.1007/BF00189633; WIDERSTEIN M, 1992, BIOCHEM J, V285, P377, DOI 10.1042/bj2850377; ZHANG PH, 1992, BIOCHEMISTRY-US, V31, P10185, DOI 10.1021/bi00157a005	49	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8826	8830						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132617				2022-12-25	WOS:A1994NB41100034
J	MICANOVIC, R; PROCYK, R; LIN, WH; MATSUEDA, GR				MICANOVIC, R; PROCYK, R; LIN, WH; MATSUEDA, GR			ROLE OF HISTIDINE-373 IN THE CATALYTIC ACTIVITY OF COAGULATION-FACTOR-XIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; FIBRIN; ACTIVATION; TRANSGLUTAMINASE; EXPRESSION; MECHANISM; SEQUENCE; CLEAVAGE; PROTEINS; ENZYMES	Factor XIII catalysis proceeds via formation of thioester acyl enzyme intermediate involving an active site cysteine residue at position 314. The contribution of other residues to catalysis has not been established. Earlier studies of the pH dependence of factor XIII activity suggested the existence of a putative active site histidine. We used chemical modification and oligonucle otide directed site-specific mutagenesis to investigate the role of histidines. Photo-oxidation with methylene blue resulted in a complete loss of catalytic activity under conditions that oxidized histidine but did not affect the essential cysteine. Single substitution of each of the 14 histidine residues in the a subunit of factor XIII by asparagine or alanine led to mutants with catalytic activities generally not significantly different from the wild-type recombinant enzyme. The only exceptions were the H373N and H373A mutants that were poorly expressed, had no detectable rate of [C-14]putrescine in corporation into dimethylcasein, and failed to cross-link fibrin gamma-chains. Thus, the a subunit His-373 may function in the active site of factor XIII, by analogy with papain's mechanism, as a histidinium cation that increases the nucleophilicity of the essential Cys-314. Decreased expression levels of His-373 mutants also indicate that this residue may be critical for enzyme stability.			MICANOVIC, R (corresponding author), BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,H3124,POB 4000,PRINCETON,NJ 08543, USA.							BISHOP P, 1993, THROMB HAEMOSTASIS, V69, P1235; BISHOP PD, 1990, J BIOL CHEM, V265, P13888; BISHOP PD, 1990, BIOCHEMISTRY-US, V29, P1861, DOI 10.1021/bi00459a028; BLOMBACK B, 1985, THROMB RES, V37, P613, DOI 10.1016/0049-3848(85)90094-5; BOARD PG, 1990, THROMB HAEMOSTASIS, V63, P235; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; CULLEN BR, 1984, NATURE, V307, P241, DOI 10.1038/307241a0; CURTIS CG, 1974, BIOCHEMISTRY-US, V13, P3774, DOI 10.1021/bi00715a024; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GOLDENBERG DP, 1988, ANNU REV BIOPHYS BIO, V17, P481; GREENBERG CS, 1988, BIOCHEM J, V256, P1013, DOI 10.1042/bj2561013; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GRUNDMANN U, 1986, P NATL ACAD SCI USA, V83, P8024, DOI 10.1073/pnas.83.21.8024; HOLBROOK JJ, 1973, BIOCHEM J, V135, P901, DOI 10.1042/bj1350901; HORNYAK TJ, 1989, BIOCHEMISTRY-US, V28, P7326, DOI 10.1021/bi00444a027; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P6900, DOI 10.1021/bi00370a025; JAGADEESWARAN P, 1990, GENE, V86, P279, DOI 10.1016/0378-1119(90)90291-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS SD, 1976, BIOCHEMISTRY-US, V15, P5009, DOI 10.1021/bi00668a010; LORAND L, 1972, ANAL BIOCHEM, V50, P623, DOI 10.1016/0003-2697(72)90074-7; MCDONAGH J, 1972, BIOCHIM BIOPHYS ACTA, V257, P135, DOI 10.1016/0005-2795(72)90262-0; McDonagh J, 1987, HEMOSTASIS THROMBOSI, P289; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; MUSZBEK L, 1993, THROMB HAEMOSTASIS, V69, P282; PARAMESWARAN KN, 1981, BIOCHEMISTRY-US, V20, P3703, DOI 10.1021/bi00516a006; POLGAR L, 1974, FEBS LETT, V47, P15, DOI 10.1016/0014-5793(74)80415-1; PROCYK R, 1992, BIOCHEMISTRY-US, V31, P2273, DOI 10.1021/bi00123a009; PROCYK R, 1993, THROMB RES, V71, P127, DOI 10.1016/0049-3848(93)90179-R; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARTZ ML, 1973, J BIOL CHEM, V248, P1395; SWIGERT S, 1963, NATURE, V198, P797, DOI 10.1038/198797a0; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019; TOKUNAGA F, 1993, J BIOL CHEM, V268, P262; Westhead E W, 1972, Methods Enzymol, V25, P401, DOI 10.1016/S0076-6879(72)25035-2	36	35	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9190	9194						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132656				2022-12-25	WOS:A1994NB41100084
J	REID, RJD; BODLEY, JW; ANDERSON, D				REID, RJD; BODLEY, JW; ANDERSON, D			IDENTIFICATION OF BACTERIOPHAGE-PHI-29 PROHEAD RNA DOMAINS NECESSARY FOR IN-VITRO DNA-GP3 PACKAGING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; RESTRICTION FRAGMENTS; PHENOTYPIC SELECTION; DNA; SIZE	Functional domains of the bacteriophage phi 29 prohead RNA (pRNA) that are essential for in vitro packaging of DNA-gp3 into the prohead were mapped using pRNA mutants. Oligonucleotide-directed mutant pRNAs were produced that contained deletions and sequence alterations but were predicted to retain the overall secondary structure of wild type pRNA. Mutant pRNAs were compared to wild-type pRNA for prohead binding in a competition assay and for DNA packaging in the defined in vitro system. The prohead binding site was previously localized to residues 22-84 on the 120-residue domain I of pRNA by ribonuclease footprinting (Reid, R. J. D., Bodley, J. W., and Anderson, D. (1994) J. Biol. Chem. 269, 5157-5162). Mutations of pRNA within the prohead bind ing site resulted in substantial loss of prohead binding capacity, while mutations outside of the footprint had moderate effects on prohead binding. DNA gp3 packaging activity was correlated with pRNA binding activity for mutations within the footprint. This mutational analysis showed that both sequence and secondary structure of residues 40-91 of pRNA were crucial for prohead binding and that elements of the A helix formed from residues 1-28 and 117-92 were needed for DNA packaging functions other than prohead binding.	UNIV MINNESOTA,DEPT MICROBIOL & ORAL SCI,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT GENET & CELL BIOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Reid, Robert/AAR-1560-2020	Reid, Robert/0000-0002-7424-3537				BAILEY S, 1990, J BIOL CHEM, V265, P22365; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; GRIMES S, 1990, J MOL BIOL, V215, P559, DOI 10.1016/S0022-2836(05)80168-8; GRIMES S, 1989, J MOL BIOL, V209, P101, DOI 10.1016/0022-2836(89)90173-3; GRIMES S, 1989, J MOL BIOL, V209, P91, DOI 10.1016/0022-2836(89)90172-1; GUO PX, 1987, NUCLEIC ACIDS RES, V15, P7081, DOI 10.1093/nar/15.17.7081; GUO PX, 1987, SCIENCE, V236, P690, DOI 10.1126/science.3107124; GUO PX, 1991, VIROLOGY, V183, P366, DOI 10.1016/0042-6822(91)90149-6; GUO PX, 1986, P NATL ACAD SCI USA, V83, P3505, DOI 10.1073/pnas.83.10.3505; HALL KB, 1992, NUCLEIC ACIDS RES, V20, P4283, DOI 10.1093/nar/20.16.4283; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; REID RJD, 1994, J BIOL CHEM, V269, P5157; WICHITWECHKARN J, 1989, NUCLEIC ACIDS RES, V17, P3459, DOI 10.1093/nar/17.9.3459; WICHITWECHKARN J, 1992, J MOL BIOL, V223, P991, DOI 10.1016/0022-2836(92)90257-K; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	16	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9084	9089						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132646				2022-12-25	WOS:A1994NB41100071
J	SAAVEDRAALANIS, VM; RYSAVY, P; ROSENBERG, LE; KALOUSEK, F				SAAVEDRAALANIS, VM; RYSAVY, P; ROSENBERG, LE; KALOUSEK, F			RAT-LIVER MITOCHONDRIAL PROCESSING PEPTIDASE - BOTH ALPHA-SUBUNIT AND BETA-SUBUNIT ARE REQUIRED FOR ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C REDUCTASE; YEAST MITOCHONDRIA; TARGETING PEPTIDES; PROTEASE; PROTEINS; MATRIX; CLEAVAGE; FAMILY; IMPORT; METALLOENDOPEPTIDASES	Most nuclearly encoded mitochondrial proteins are synthesized with an amino-terminal leader peptide that is cleaved by the mitochondrial processing peptidase (MPP). Purified rat liver MPP, like the Neurospora and yeast enzymes, consists of two nonidentical subunits, alpha (55 kDa) and beta (50 kDa). To confirm the functional authenticity of the recently cloned and sequenced cDNAs for the alpha and beta-MPP subunits from rat liver and to study each subunit's participation in MPP activity, we have subcloned and expressed separately in Escherichia coli the mature sequence of each subunit as a fusion protein with the maltose binding protein. After induction, about 80% of each expressed fusion protein was insoluble in aggregates or inclusion bodies, and 20% remained soluble in the supernatant. The fusion proteins in the soluble fraction were purified by affinity chromatography and treated with factor Xa, and the MPP subunits were purified to homogeneity. When mixed together, these subunits showed no activity, suggesting that they might be misfolded. Therefore, a reconstitution protocol was developed which consisted of denaturation in urea, dithiothreitol, and 2-mercaptoethanol, followed by renaturation by dilution and dialysis under reducing conditions. With this procedure, active MPP was recovered from the mixed subunits, and it could be demonstrated that both alpha- and beta-MPP subunits were necessary for activity. Reconstituted recombinant MPP resembled the native rat liver enzyme as judged by its molecular weight, its inhibition by EDTA, and its ability to process a variety of mitochondrial precursor proteins appropriately to either an intermediate or a mature form.	YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA	Yale University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009527] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09527] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GELI V, 1990, J BIOL CHEM, V265, P19216; GENCIC S, 1991, EUR J BIOCHEM, V199, P123, DOI 10.1111/j.1432-1033.1991.tb16099.x; GLICK B, 1991, ANNU REV GENET, V25, P21; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; ISAYA G, 1991, J CELL BIOL, V113, P65, DOI 10.1083/jcb.113.1.65; JANSEN R, 1989, GENOMICS, V4, P198, DOI 10.1016/0888-7543(89)90300-5; JENSEN RE, 1988, EMBO J, V7, P3863, DOI 10.1002/j.1460-2075.1988.tb03272.x; KALOUSEK F, 1993, TRENDS BIOCHEM SCI, V18, P249, DOI 10.1016/0968-0004(93)90174-L; KALOUSEK F, 1988, P NATL ACAD SCI USA, V85, P7536, DOI 10.1073/pnas.85.20.7536; KALOUSEK F, 1992, EMBO J, V11, P2803, DOI 10.1002/j.1460-2075.1992.tb05347.x; KITADA S, 1993, BIOCHEM BIOPH RES CO, V190, P289, DOI 10.1006/bbrc.1993.1044; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PACES V, 1993, P NATL ACAD SCI USA, V90, P5355, DOI 10.1073/pnas.90.11.5355; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; ROSENBERG LE, 1986, ANN NY ACAD SCI, V488, P99; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SCHULTE U, 1989, NATURE, V339, P147, DOI 10.1038/339147a0; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WEISS H, 1990, TRENDS BIOCHEM SCI, V15, P178, DOI 10.1016/0968-0004(90)90155-5; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; YANG M, 1991, J BIOL CHEM, V266, P6416	37	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9284	9288						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132665				2022-12-25	WOS:A1994NB41100096
J	SETTE, C; IONA, S; CONTI, M				SETTE, C; IONA, S; CONTI, M			THE SHORT-TERM ACTIVATION OF A ROLIPRAM-SENSITIVE, CAMP-SPECIFIC PHOSPHODIESTERASE BY THYROID-STIMULATING HORMONE IN THYROID FRTL-5 CELLS IS MEDIATED BY A CAMP-DEPENDENT PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; PROTEIN-KINASE; HUMAN-PLATELETS; OKADAIC ACID; RAT ADIPOCYTES; SERTOLI-CELL; INSULIN; AMP; DESENSITIZATION	To elucidate the mechanism causing the transient accumulation of intracellular cAMP in the FRTL-5 thyroid cell line, the short-term effect of thyroid-stimulating hormone (TSH) on phosphodiesterase (PDE) activity was studied. Together with an increase in cAMP levels, TSH produced a significant increase in total PDE activity as early as 3 min, with a maximal stimulation reached after 15 min. This short-term increase in PDE activity was dependent on the TSH concentration (ED(50) = 4 x 10(-11) M TSH). Forskolin and dibutyryl cAMP produced an even larger stimulation than that produced by TSH, suggesting that the effect of TSH is mediated by cAMP. To determine the properties of the PDE forms activated by TSR, antibodies specific for the cAMP-PDEs were used to immunoprecipitate the PDEs present in control cells, and cells incubated for 15 min in the presence of 10 nw TSH. Comparison of the activity recovered in the immunoprecipitation pellets demonstrated that TSH produced more than a 2.5-fold increase in the cAMP-PDE form(s) recognized by this antibody. Conversely, the activity remaining in the supernatants was not affected by the TSH treatment. Most of the activity recovered in the immunoprecipitation pellets (90%) was inhibited by 10 mu M Rolipram, an inhibitor specific for the high affinity cAMP-PDEs. No TSH stimulation of the Rolipram-insensitive PDE activity could be observed under these conditions. Western blot analyses with two different cAMP-PDE specific antibodies showed that a 15-min stimulation with TSH induced the appearance of a new band with electrophoretic mobility slower than the polypeptide present in unstimulated cells. The appearance of this band did not require ongoing protein synthesis because it occurred in the presence of cycloheximide. Metabolic [P-32]orthophosphate labeling of intact FRTL-5 cells indicated that the TSH treatment caused an increased P-32 incorporation into a polypeptide that co-purified with the stimulated PDE activity and had an electrophoretic mobility identical to that of the cAMP-PDE. Okadaic acid, a potent inhibitor of protein phosphatase 1 and protein phosphatase 2A, elicited a potentiation of the TSH-stimulated PDE activity. The stimulation of a PDE with the same immunological properties and Rolipram sensitivity as the cAMP-PDE stimulated by TSH in the intact cells was reproduced, in a cell-free system, by incubating soluble extracts from FRTL-5 cells with the catalytic subunit of cAMP-dependent protein kinase. These data provide evidence that TSH produces a rapid activation of a cAMP-PDE in the FRTL-5 cells through a cAMP-dependent phosphorylation.			SETTE, C (corresponding author), STANFORD MED CTR, DEPT GYNECOL & OBSTET, DIV REPROD BIOL, STANFORD, CA 94305 USA.		Sette, Claudio/S-4307-2019	Sette, Claudio/0000-0003-2864-8266	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20788] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTSCHULER D, 1993, J BIOL CHEM, V268, P7527; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BALL EH, 1980, J BIOL CHEM, V255, P2962; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG HC, 1986, J BIOL CHEM, V261, P989; CLARK RB, 1989, MOL PHARMACOL, V36, P343; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COLLINS S, 1992, TRENDS BIOCHEM SCI, V17, P37, DOI 10.1016/0968-0004(92)90425-9; CONTI M, 1982, ENDOCRINOLOGY, V110, P1189, DOI 10.1210/endo-110-4-1189; CONTI M, 1981, BIOCHEM BIOPH RES CO, V98, P1044, DOI 10.1016/0006-291X(81)91216-X; CORBIN JD, 1985, J BIOL CHEM, V260, P8731; DAVIS CW, 1984, BIOCHIM BIOPHYS ACTA, V797, P354, DOI 10.1016/0304-4165(84)90257-5; DEGERMAN E, 1990, P NATL ACAD SCI USA, V87, P533, DOI 10.1073/pnas.87.2.533; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GETTYS TW, 1987, J BIOL CHEM, V262, P333; GETTYS TW, 1988, J BIOL CHEM, V263, P10359; GRANT PG, 1988, P NATL ACAD SCI USA, V85, P9071, DOI 10.1073/pnas.85.23.9071; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LAZAROWSKI ER, 1990, J BIOL CHEM, V265, P13118; LOPEZAPARICIO P, 1992, BIOCHEM BIOPH RES CO, V186, P517, DOI 10.1016/S0006-291X(05)80838-1; MACPHEE CH, 1988, J BIOL CHEM, V263, P10353; MADELIAN V, 1991, AM SOC NEUROCHEM, V22; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; NARINDRASORASAK S, 1982, J BIOL CHEM, V257, P4618; NEMOZ G, 1985, BIOCHEM PHARMACOL, V34, P2997, DOI 10.1016/0006-2952(85)90029-2; ROBERTSON DW, 1986, J MED CHEM, V29, P635, DOI 10.1021/jm00155a009; SHIBATA H, 1991, J BIOL CHEM, V266, P17948; SMITH CJ, 1991, J BIOL CHEM, V266, P13385; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; SWINNENJV, 1991, J BIOL CHEM, V266, P18370; TAKAHASHI S, 1990, ENDOCRINOLOGY, V126, P736, DOI 10.1210/endo-126-2-736; TAKAHASHI S, 1991, END SOC ABSTR, P1045; TAKAHASHI SI, 1991, J BIOL CHEM, V266, P7834; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; VALETTE L, 1990, BIOCHEM BIOPH RES CO, V169, P864, DOI 10.1016/0006-291X(90)91973-V	43	175	175	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9245	9252						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132662				2022-12-25	WOS:A1994NB41100091
J	SHIN, JM; SACHS, G				SHIN, JM; SACHS, G			IDENTIFICATION OF A REGION OF THE H,K-ATPASE ALPHA-SUBUNIT ASSOCIATED WITH THE BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; INTRACELLULAR-TRANSPORT; H+/K+-ATPASE; NA,K-ATPASE	The gastric H,K-ATPase consists of an alpha, beta heterodimer. To determine which part of the alpha subunit is associated with the beta subunit, hog gastric vesicles were trypsinized, which left most of the beta subunit undigested. The vesicles were solubilized with either C(12)E(8) (polyoxyethylene 8 lauryl ester) or Nonidet P-40 and then passed over a wheat germ agglutinin column, which retained the beta subunit. Among the fragments of membrane spanning segments obtained by digestion in the absence of K+, only one peptide fragment of the alpha subunit coeluted with the beta subunit, representing only the M7 and M8 membrane spanning segments of the alpha subunit along with their extracytoplasmic connecting loop. With K+ present during digestion, the fragments at 19-21 kDa and at 9.4 kDa were retained on the column, representing the M7 to C-terminal end and the M5/loop/M6 sector of the enzyme. These results provide biochemical evidence that a region of the alpha subunit containing the M7/ loop/M8 sector is bound to the beta subunit under both digestion conditions; but when the C-terminal 180-amino acid sector of the alpha subunit remains intact, as found in the presence of K+, there is an additional retention of the M5/loop/M6 sector of the alpha subunit.	WADSWORTH VET ADM MED CTR, LOS ANGELES, CA 90073 USA; UNIV CALIF LOS ANGELES, DEPT MED & PHYSIOL, LOS ANGELES, CA 90073 USA	University of California System; University of California Los Angeles					NCRR NIH HHS [1S10RR0554-01] Funding Source: Medline; NIDDK NIH HHS [R01 DK 40165] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; CHOW DC, 1992, AM J PHYSIOL, V263, pC39, DOI 10.1152/ajpcell.1992.263.1.C39; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; GREEN NM, 1989, BIOCHEM SOC T, V17, P970; HALL K, 1990, BIOCHEMISTRY-US, V29, P701, DOI 10.1021/bi00455a016; HORISBERGER JD, 1991, ANNU REV PHYSIOL, V53, P565, DOI 10.1146/annurev.physiol.53.1.565; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; JAUNIN P, 1992, J BIOL CHEM, V267, P577; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; LANE LK, 1986, BIOCHEM BIOPH RES CO, V138, P185, DOI 10.1016/0006-291X(86)90264-0; LEMAS MV, 1992, J BIOL CHEM, V267, P20987; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERCIER F, 1993, BIOCHIM BIOPHYS ACTA, V1149, P151, DOI 10.1016/0005-2736(93)90036-Y; MILLER RP, 1990, BIOCHEMISTRY-US, V29, P1524, DOI 10.1021/bi00458a025; OKAMOTO CT, 1990, BIOCHIM BIOPHYS ACTA, V1037, P360, DOI 10.1016/0167-4838(90)90038-H; RABON EC, 1990, ANNU REV PHYSIOL, V52, P321; RABON EC, 1990, BIOCHIM BIOPHYS ACTA, V1039, P277, DOI 10.1016/0167-4838(90)90260-M; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHIN JM, 1993, BIOCHIM BIOPHYS ACTA, V1148, P223, DOI 10.1016/0005-2736(93)90133-K; SHULL GE, 1986, NATURE, V321, P429, DOI 10.1038/321429a0; TEUBEIT MJ, 1993, J BIOL CHEM, V268, P13914; TOH BH, 1990, P NATL ACAD SCI USA, V87, P6418, DOI 10.1073/pnas.87.16.6418; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X	27	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8642	8646						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132592				2022-12-25	WOS:A1994NB41100006
J	HILL, DR; HLADUN, SL; SCHERER, S; POTTS, M				HILL, DR; HLADUN, SL; SCHERER, S; POTTS, M			WATER-STRESS PROTEINS OF NOSTOC COMMUNE (CYANOBACTERIA) ARE SECRETED WITH UV-A/B-ABSORBING PIGMENTS AND ASSOCIATE WITH 1,4-BETA-D-XYLANXYLANOHYDROLASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GEL-ELECTROPHORESIS; GLYCOPROTEINS; UTEX-584; PROTEOLYSIS; CULTURES; SEQUENCE; CELLS; ASSAY	Acidic water stress polypeptides (Wsp) with molecular masses of 33, 37 and 39 kDa are the most abundant soluble proteins in the cyanobacterium Nostoc commune. Wsp polypeptides and UV-A/B-absorbing pigments are secreted by cells, accumulate in the extracellular glycan sheath, and are released from desiccated colonies upon rehydration. No evidence was obtained for either glycosylation, phosphorylation, or acylation of Wsp polypeptides. NH2-terminal amino acid sequences of the 33, 37-, and 39-kDa polypeptides were identical: Ala-Leu-Tyr-Gly-Tyr-Thr-Ile-Gly-Glu-Gln-X-Ile-Gln-Asn-Pro-Ser-Asn-Pro-Ser-Asn-Gly-Lys-Gln. This consensus NH2-terminal sequence and an internal sequence (Glu-Ala-Arg-Val-Thr-Gly-Pro-Thr-Thr-Pro-Ile-Asp) showed homologies with the sequences of carbohydrate-modifying enzymes. Purified Wsp polypeptides associate with a 1,4-beta-D-xylanxylanohydrolase activity that was inhibited specifically by Wsp antiserum. In the absence of salt, Wsp polypeptides, and the water-soluble UV-A/B-absorbing pigments, form multimeric complexes through strong ionic interactions. A possible role is suggested for Wsp polypeptides in the synthesis and/or modification of a xylose-containing UV-A/B-absorbing pigment.	VIRGINIA POLYTECH INST & STATE UNIV, DEPT BIOCHEM & ANAEROB MICROBIOL, BLACKSBURG, VA 24061 USA; TECH UNIV MUNICH, INST MIKROBIOL, D-85350 FREISING, GERMANY	Virginia Polytechnic Institute & State University; Technical University of Munich			Scherer, Siegfried/I-1320-2013	Scherer, Siegfried/0000-0002-0394-9890				BIELY P, 1985, ANAL BIOCHEM, V144, P142, DOI 10.1016/0003-2697(85)90095-8; CARDEMIL L, 1979, J BIOL CHEM, V254, P736; Chaplin M.F., 1986, MASS SPECTROM, P1; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CROWE JH, 1987, BIOCHEM J, V242, P1, DOI 10.1042/bj2420001; CROWE JH, 1992, ANNU REV PHYSIOL, V54, P579, DOI 10.1146/annurev.ph.54.030192.003051; FAIRCHILD CD, 1991, J BACTERIOL, V173, P2985, DOI 10.1128/JB.173.9.2985-2992.1991; GARCIAPICHEL F, 1991, J PHYCOL, V27, P395, DOI 10.1111/j.0022-3646.1991.00395.x; Gros E., 1967, METHOD ENZYMOL, V11, P238; HASELBECK A, 1988, TOP BIOCH, V8, P1; LECHNER J, 1989, ANNU REV BIOCHEM, V58, P173, DOI 10.1146/annurev.bi.58.070189.001133; LUTHI E, 1990, APPL ENVIRON MICROB, V56, P1017; Maniatis T, 1989, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; OSHANNESSY DJ, 1987, ANAL BIOCHEM, V163, P204, DOI 10.1016/0003-2697(87)90114-X; PEAT A, 1988, PROTOPLASMA, V146, P72, DOI 10.1007/BF01405915; PEAT A, 1987, FEMS MICROBIOL LETT, V43, P223, DOI 10.1111/j.1574-6968.1987.tb02127.x; PERINI F, 1982, ANAL BIOCHEM, V123, P357, DOI 10.1016/0003-2697(82)90458-4; POTTS M, 1993, J BIOL CHEM, V268, P7632; POTTS M, 1985, ARCH MICROBIOL, V141, P51, DOI 10.1007/BF00446739; POTTS M, 1985, J BACTERIOL, V164, P1025, DOI 10.1128/JB.164.3.1025-1031.1985; POTTS M, 1984, FEMS MICROBIOL LETT, V24, P193, DOI 10.1111/j.1574-6968.1984.tb01303.x; RIETHMAN HC, 1988, J BACTERIOL, V170, P2433, DOI 10.1128/jb.170.6.2433-2440.1988; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; SCANLAN DJ, 1988, METHOD ENZYMOL, V167, P599; SCHERER S, 1991, MICROBIAL ECOL, V22, P271, DOI 10.1007/BF02540229; SCHERER S, 1986, OECOLOGIA, V68, P585, DOI 10.1007/BF00378775; SCHERER S, 1988, PLANT PHYSIOL, V88, P1055, DOI 10.1104/pp.88.4.1055; SCHERER S, 1989, J BIOL CHEM, V264, P12546; STULP BK, 1987, FEMS MICROBIOL LETT, V41, P241; TARANTO PA, 1993, BIOCHIM BIOPHYS ACTA, V1168, P228, DOI 10.1016/0005-2760(93)90129-W; TERADA I, 1990, J BIOL CHEM, V265, P6576; WHITTON BA, 1979, PHYCOLOGIA, V18, P278, DOI 10.2216/i0031-8884-18-3-278.1; WIRTH SJ, 1990, J MICROBIOL METH, V12, P197, DOI 10.1016/0167-7012(90)90031-Z; WONG KKY, 1988, MICROBIOL REV, V52, P305, DOI 10.1128/MMBR.52.3.305-317.1988; ZLOTNICK GW, 1986, ANAL BIOCHEM, V153, P121, DOI 10.1016/0003-2697(86)90069-2	36	68	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7726	7734						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125999				2022-12-25	WOS:A1994NA03200107
J	QIU, XQ; JAKES, KS; FINKELSTEIN, A; SLATIN, SL				QIU, XQ; JAKES, KS; FINKELSTEIN, A; SLATIN, SL			SITE-SPECIFIC BIOTINYLATION OF COLICIN IA - A PROBE FOR PROTEIN CONFORMATION IN THE MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR LIPID BILAYERS; VOLTAGE-DEPENDENT CHANNEL; ION CHANNEL; FRAGMENT; IDENTIFICATION; TRANSLOCATION; SEQUENCE; DOMAIN; DNA	Channel-forming colicins are Escherichia coli proteins that form voltage-dependent channels in lipid bilayer membranes and are lethal to sensitive strains of E. coli. Experiments with colicin E1 have led to a model of voltage dependence based on the insertion of alpha-helical segments of the protein into the membrane in response to cis-positive voltages. This model was tested on the partly homologous colicin Ia protein, which offers certain advantages over colicin E1 as a model channel, it is active at neutral pH and exhibits comparatively well-defined single channel conductance. We describe here the creation of a specific probe for locating a particular amino acid residue on one side or the other of a planar lipid bilayer membrane, by using the biotin-streptavidin system. Site-directed mutagenesis was used to change lysine 544 of colicin Ia to cysteine. This placed a unique cysteine at a site expected, by homology to colicin E1, to cross the membrane from the cis to the trans side in association with the opening of the channel. This unique cysteine was biotinylated chemically, so that it could serve as a target for streptavidin. Incubation of the biotinylated mutant colicin with streptavidin blocked its killing activity, in vivo; incubation of wild-type colicin, which lacks cysteine, with streptavidin, did not affect its activity. Channels formed by the biotinylated mutant protein in planar lipid bilayers were abolished by streptavidin added to the cis side of the membrane, if the channels were closed, but not if they were open. Trans streptavidin had no effect on either open or closed channels. Thus, when the channel is closed, residue 544 of colicin Ia is accessible to cis streptavidin in the closed state, but the opening of the channel eliminates this accessibility.	ALBERT EINSTEIN COLL MED,DEPT PHYSIOL & BIOPHYS,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NIGMS NIH HHS [GM 29210-16] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029210, R37GM029210] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS CK, 1991, J GEN PHYSIOL, V98, P77, DOI 10.1085/jgp.98.1.77; BAYER EA, 1989, BIOCHEM J, V259, P369, DOI 10.1042/bj2590369; COLLARINI M, 1987, EUR BIOPHYS J BIOPHY, V14, P147, DOI 10.1007/BF00253839; CRAMER WA, 1990, MOL MICROBIOL, V4, P519, DOI 10.1111/j.1365-2958.1990.tb00619.x; DANKERT JR, 1982, J BIOL CHEM, V257, P3857; ENEA V, 1982, VIROLOGY, V122, P222, DOI 10.1016/0042-6822(82)90395-6; GREEN NM, 1971, BIOCHEM J, V125, P781, DOI 10.1042/bj1250781; JAKES K, 1974, J BIOL CHEM, V249, P438; JAKES KS, 1990, J BIOL CHEM, V265, P6984; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKEY JH, 1992, FEBS LETT, V307, P26, DOI 10.1016/0014-5793(92)80895-N; LAZDUNSKI CJ, 1988, BIOCHIM BIOPHYS ACTA, V947, P445, DOI 10.1016/0304-4157(88)90003-2; LIU Q R, 1986, Proteins Structure Function and Genetics, V1, P218, DOI 10.1002/prot.340010304; MANKOVICH JA, 1986, J BACTERIOL, V168, P228, DOI 10.1128/jb.168.1.228-236.1986; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P8529, DOI 10.1021/bi00489a004; Montal M, 1974, Methods Enzymol, V32, P545; NOGUEIRA RA, 1988, J MEMBRANE BIOL, V105, P143, DOI 10.1007/BF02009167; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; RAYMOND L, 1986, J MEMBRANE BIOL, V92, P255, DOI 10.1007/BF01869394; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Savage D, 1992, AVIDIN BIOTIN CHEM H; SCHEIN SJ, 1978, NATURE, V276, P159, DOI 10.1038/276159a0; SLATIN S, 1986, BIOPHYS J, V49, pA412; SLATIN SL, 1986, J MEMBRANE BIOL, V92, P247, DOI 10.1007/BF01869393; SLATIN SL, 1988, INT J BIOCHEM, V20, P737, DOI 10.1016/0020-711X(88)90058-4; YAMADA M, 1982, P NATL ACAD SCI-BIOL, V79, P2827, DOI 10.1073/pnas.79.9.2827; ZHANG YL, 1992, PROTEIN SCI, V1, P1666, DOI 10.1002/pro.5560011215	28	43	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7483	7488						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125966				2022-12-25	WOS:A1994NA03200071
J	GOWING, E; ROHER, AE; WOODS, AS; COTTER, RJ; CHANEY, M; LITTLE, SP; BALL, MJ				GOWING, E; ROHER, AE; WOODS, AS; COTTER, RJ; CHANEY, M; LITTLE, SP; BALL, MJ			CHEMICAL CHARACTERIZATION OF A-BETA-17-42 PEPTIDE, A COMPONENT OF DIFFUSE AMYLOID DEPOSITS OF ALZHEIMER-DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SENILE PLAQUES; COMPLEMENT ACTIVATION; PREAMYLOID DEPOSITS; DOWNS-SYNDROME; PROTEIN; CORTEX	A peptide corresponding to the amino acid sequence of Abeta17-42 (LVFFAEDVGSNKGAIIGLMVGGWIA) was isolated from Alzheimer Disease patient brains containing large deposits of diffuse-type amyloid. Brain homogenates were lysed in SDS and submitted to high speed centrifugations. Abeta peptides were purified by size exclusion chromatography on Superose 12 and TSK 3000 SW columns. An Abeta peptide with M(r) of 3,000 was recovered that on automatic gas-phase Edman degradation yielded the amino acid sequence of Abeta starting at residue 17 (Leu). The 3-kDa peptide was subsequently hydrolyzed with trypsin and reacted with CNBr, and the resulting peptides were separated by reverse phase high pressure liquid chromatography and characterized by amino acid analyses, peptide microsequencing, and mass spectrometry. Hydrolysis of beta-amyloid precursor protein 695 at Lys612-Leu613 or at Lys16-Leu17 of its Abeta1-42 derivative prevents the generation of neurotoxic Abeta filaments, thus leading to the formation of Abeta17-42 localized in the diffuse amyloid deposits. An outstanding feature in the pathology of Alzheimer Disease is that the predominant Abeta peptides have their C termini at position 42, whether in the cores of the neuritic plaques, in the vascular walls, or in the diffuse deposits. Based on these observations, we postulate that the accumulation of insoluble Abeta(N-42) in Alzheimer Disease is due to the anomalous processing of the C-terminal region.	WAYNE STATE UNIV, SCH MED, DEPT ANAT & CELL BIOL, DETROIT, MI 48201 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, MIDDLE ATLANTIC MASS SPECT LAB, BALTIMORE, MD 21205 USA; ELI LILLY & CO, LILLY RES LAB, INDIANAPOLIS, IN 46285 USA; OREGON HLTH SCI UNIV, DEPT PATHOL, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT NEUROL, PORTLAND, OR 97201 USA	Wayne State University; Johns Hopkins University; Eli Lilly; Oregon Health & Science University; Oregon Health & Science University					NATIONAL INSTITUTE ON AGING [P30AG008017] Funding Source: NIH RePORTER; NIA NIH HHS [AG08017] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; DOVEY HF, 1993, NEUROREPORT, V4, P1039, DOI 10.1097/00001756-199308000-00011; GEARING M, 1993, J NEUROPATH EXP NEUR, V52, P22, DOI 10.1097/00005072-199301000-00004; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; HUNG AY, 1993, J BIOL CHEM, V268, P22959; IKEDA S, 1990, HUM PATHOL, V21, P1221, DOI 10.1016/S0046-8177(06)80034-1; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; LUE LF, 1992, DEMENTIA, V3, P308, DOI 10.1159/000107031; MASLIAH E, 1990, AM J PATHOL, V137, P1293; MASLIAH E, 1993, J NEUROPATH EXP NEUR, V52, P619, DOI 10.1097/00005072-199311000-00009; MCKENZIE JE, 1992, NEUROSCI LETT, V143, P23, DOI 10.1016/0304-3940(92)90224-U; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; OGHGAMI T, 1991, ACTA NEUROPATHOL, V81, P242; POTTER H, 1992, PROG BRAIN RES, V94, P447; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J BIOL CHEM, V268, P3072; ROHER AE, 1993, J NEUROCHEM, V61, P1916, DOI 10.1111/j.1471-4159.1993.tb09834.x; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SNOW AD, 1990, AM J PATHOL, V137, P1253; SNOW AD, 1994, IN PRESS AM J PATHOL, V144; SPARGO E, 1992, J NEUROL SCI, V111, P26, DOI 10.1016/0022-510X(92)90108-W; SPARKS DL, 1993, J NEUROPATH EXP NEUR, V52, P135, DOI 10.1097/00005072-199303000-00006; TAGLIAVINI F, 1988, NEUROSCI LETT, V93, P191, DOI 10.1016/0304-3940(88)90080-8; ULRICH J, 1990, ACTA NEUROL SCAND, V82, P5; VERGA L, 1989, NEUROSCI LETT, V105, P294, DOI 10.1016/0304-3940(89)90636-8; WISNIEWSKI HM, 1989, ACTA NEUROPATHOL, V78, P337, DOI 10.1007/BF00688170; YAMAGUCHI H, 1988, ACTA NEUROPATHOL, V77, P113; YAMAGUCHI H, 1989, AM J PATHOL, V135, P593	36	205	222	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					10987	10990						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157623				2022-12-25	WOS:A1994NF96600006
J	KULICH, SM; YAHR, TL; MENDEMUELLER, LM; BARBIERI, JT; FRANK, DW				KULICH, SM; YAHR, TL; MENDEMUELLER, LM; BARBIERI, JT; FRANK, DW			CLONING THE STRUCTURAL GENE FOR THE 49-KDA FORM OF EXOENZYME-S (EXOS) FROM PSEUDOMONAS-AERUGINOSA STRAIN 388	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLTRANSFERASE ACTIVITY; HEAT-LABILE ENTEROTOXIN; DIPHTHERIA-TOXIN; ESCHERICHIA-COLI; CHOLERA-TOXIN; CRYSTAL-STRUCTURE; ENZYMIC ACTIVITY; EXOTOXIN-A; PROTEINS; SEQUENCE	We report the purification and proteolytic characterization of the 49-kDa form of exoenzyme S and the cloning of the structural gene for the 49-kDa form of exoenzyme S (exoS). The 49-kDa form of exoenzyme S was purified from SDS-polyacrylamide gels. Conditions were established that allowed efficient trypsin digestion of the 49-kDa form of exoenzyme S. Amino acid sequence determination of the amino terminus and tryptic peptides of the 49-kDa form of exoenzyme S allowed the generation of degenerate oligonucleotides, which were used to amplify DNA encoding an amino-terminal sequence and an internal sequence of the 49-kDa form of exoenzyme S. These DNA fragments were used to clone the entire structural gene for the 49-kDa form of exoenzyme S (exoS) from a cosmid library of Pseudomonas aeruginosa strain 388. The 49-kDa form of exoenzyme S (ExoS) is predicted to be a 453 amino acid protein. The predicted amino acid sequence indicates that ExoS is secreted from Pseudomonas without cleavage of an aminoterminal sequence. BESTFIT analysis identified three regions of alignment between ExoS and the active site of Escherichia coli heat-labile enterotoxin. One region of homology appears to be shared among several members of the family of bacterial ADP-ribosyltransferases.	MED COLL WISCONSIN, PROT NUCLEIC ACID FACIL, DEPT MICROBIOL, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, PROT NUCLEIC ACID FACIL, DEPT BIOCHEM, MILWAUKEE, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin			Kulich, Scott/G-3592-2010	Yahr, Timothy/0000-0001-9054-8704	NIAID NIH HHS [AI01087, AI31665] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI001087, R01AI031665, R29AI031665] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BARBIERI JT, 1989, J BACTERIOL, V171, P4362, DOI 10.1128/JB.171.8.4362-4369.1989; BODEY GP, 1983, REV INFECT DIS, V5, P279; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; CHUNG DW, 1977, INFECT IMMUN, V16, P832, DOI 10.1128/IAI.16.3.832-841.1977; COBURN J, 1989, INFECT IMMUN, V57, P996, DOI 10.1128/IAI.57.3.996-998.1989; COBURN J, 1989, J BIOL CHEM, V264, P9004; COBURN J, 1991, J BIOL CHEM, V266, P6438; COBURN J, 1991, INFECT IMMUN, V59, P4259, DOI 10.1128/IAI.59.11.4259-4262.1991; COBURN J, 1992, CURR TOP MICROBIOL, V175, P133; DRAZIN R, 1971, J BIOL CHEM, V246, P1504; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; HENDERSON LE, 1979, ANAL BIOCHEM, V93, P153, DOI 10.1016/S0003-2697(79)80129-3; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; IGLEWSKI BH, 1978, P NATL ACAD SCI USA, V75, P3211, DOI 10.1073/pnas.75.7.3211; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; IGLEWSKI BH, 1988, HDB TOXINS, V4, P249; IGLEWSKI WJ, 1990, ADP RIBOSYLATING TOX, P511; INOUE S, 1991, BIOCHEM BIOPH RES CO, V174, P459, DOI 10.1016/0006-291X(91)91438-I; KANDEL J, 1974, J BIOL CHEM, V249, P2088; KULICH SM, 1993, INFECT IMMUN, V61, P307, DOI 10.1128/IAI.61.1.307-313.1993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBET Y, 1991, INFECT IMMUN, V59, P2870, DOI 10.1128/IAI.59.9.2870-2879.1991; LORY S, 1980, INFECT IMMUN, V28, P494; Maniatis T., 1982, MOL CLONING; MEADE HM, 1982, J BACTERIOL, V149, P114, DOI 10.1128/JB.149.1.114-122.1982; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; MEKALANOS JJ, 1979, J BIOL CHEM, V254, P5855; Nicas T I, 1985, Antibiot Chemother (1971), V36, P40; NICAS TI, 1985, EUR J CLIN MICROBIOL, V4, P175, DOI 10.1007/BF02013593; NICAS TI, 1985, CAN J MICROBIOL, V31, P387, DOI 10.1139/m85-074; NICAS TI, 1984, INFECT IMMUN, V45, P270; NICOSIA A, 1986, P NATL ACAD SCI USA, V83, P4361; POPOFF M, 1990, NUCLEIC ACIDS RES, V18, P1291, DOI 10.1093/nar/18.5.1291; RIVIERE LE, 1991, TECH PROTEIN CHEM, V2, P170; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SOKOL PA, 1990, MICROB PATHOGENESIS, V8, P243, DOI 10.1016/0882-4010(90)90051-Q; STROM MS, 1991, J BACTERIOL, V173, P1175, DOI 10.1128/jb.173.3.1175-1180.1991; VASIL ML, 1977, INFECT IMMUN, V16, P353, DOI 10.1128/IAI.16.1.353-361.1977; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WEST SEH, 1988, NUCLEIC ACIDS RES, V16, P9323, DOI 10.1093/nar/16.19.9323; Wood R E, 1976, Hosp Pract, V11, P91; WOODS DE, 1985, EUR J CLIN MICROBIOL, V4, P163, DOI 10.1007/BF02013591; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	47	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10431	10437						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144626				2022-12-25	WOS:A1994NF01700039
J	CHAN, AML; MCGOVERN, ES; CATALANO, G; FLEMING, TP; MIKI, T				CHAN, AML; MCGOVERN, ES; CATALANO, G; FLEMING, TP; MIKI, T			EXPRESSION CDNA CLONING OF A NOVEL ONCOGENE WITH SEQUENCE SIMILARITY TO REGULATORS OF SMALL GTP-BINDING PROTEINS	ONCOGENE			English	Article							SIGNAL TRANSDUCTION; VAV PROTOONCOGENE; SACCHAROMYCES-CEREVISIAE; TRANSFORMING ACTIVITY; GENE-PRODUCT; CELL-CYCLE; PROTO-DBL; CANCER; CDC24; RECEPTOR	We generated a cDNA expression library from a human mammary epithelial cell line for detection of novel oncogenes by focus formation assay in NIH3T3 cells. A morphologically unique focus was identified and the transforming plasmid was isolated. The transforming gene, designated TIM, encoded a predicted protein species of 60 kDa containing a Dbl-Homology (DH) motif. This motif is also present in other growth regulatory molecules including Bcr, Cdc24, Vav, Ras-grf, and Ect2 which have been implicated as regulators of small GTP-binding proteins. NIH3T3 cells transfected with TIM expression plasmid showed altered growth properties in vitro and were tumorigenic when injected into nude mice. The 6.5 kilobasepair (kb) transcript of the TIM gene was mainly expressed in kidney, liver, pancreas, lung, and placenta. By analysing a panel of human-hamster somatic celt hybrids, we localized the TIM gene to human chromosome 7.			CHAN, AML (corresponding author), NCI, CELLULAR & MOLEC BIOL LAB, BLDG 37, 1E24, BETHESDA, MD 20892 USA.		Chan, Andrew/AAC-1145-2020; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew/0000-0001-9923-5464; Chan, Andrew Man-Lok/0000-0001-9923-5464				ADAMS JM, 1992, ONCOGENE, V7, P611; BOS JL, 1989, CANCER RES, V49, P4682; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN AML, 1993, ONCOGENE, V8, P1329; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; DOWNWARD J, 1992, NATURE, V358, P282, DOI 10.1038/358282a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Maniatis T., 1982, MOL CLONING; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; RON D, 1991, NEW BIOL, V3, P372; RON D, 1989, ONCOGENE, V4, P1067; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	33	53	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1057	1063						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134109				2022-12-25	WOS:A1994NC04800008
J	CHAN, TA; CHU, CA; RAUEN, KA; KROIHER, M; TATAREWICZ, SM; STEELE, RE				CHAN, TA; CHU, CA; RAUEN, KA; KROIHER, M; TATAREWICZ, SM; STEELE, RE			IDENTIFICATION OF A GENE ENCODING A NOVEL PROTEIN-TYROSINE KINASE CONTAINING SH2 DOMAINS AND ANKYRIN-LIKE REPEATS	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; BUDDING STRAIN L4; DROSOPHILA-MELANOGASTER; DEVELOPMENTAL MECHANISMS; SEQUENCE-ANALYSIS; NERVOUS-SYSTEM; LEUKEMIA-CELLS; DNA-SEQUENCE; SRC GENE; HYDRA	Using the polymerase chain reaction with primers corresponding to conserved regions in the kinase domain of protein-tyrosine kinases, we amplified segments of several protein-tyrosine kinase genes from Hydra vulgaris, a member of the ancient metazoan phylum Cnidaria. Characterization of cDNA clones for one of these genes, HTK16, revealed that it encodes a non-receptor protein-tyrosine kinase with two SH2 domains but no SH3 domain. In this regard the predicted HTK16 protein resembles two mammalian non-receptor protein-tyrosine kinases, the products of the ZAP-70 and syk genes. However, the HTK16 protein contains five ankyrin-like repeats, a structural motif which has not previously been found in protein-tyrosine kinases. The HTK16 protein also contains a potential tyrosine phosphorylation site in its carboxyl-terminal tail which resembles the phosphorylation site in members of the src family. RNA hybridization analysis indicates that the HTK16 gene is expressed in epithelial cells, cells which also express the Hydra homologue of the src protein. Our finding of the HTK16 gene in Hydra indicates that diversification of genes encoding non-receptor protein-tyrosine kinases was a very early event in metazoan evolution.	UNIV CALIF IRVINE, DEPT BIOL CHEM, IRVINE, CA 92717 USA; UNIV CALIF IRVINE, CTR DEV BIOL, IRVINE, CA 92717 USA	University of California System; University of California Irvine; University of California System; University of California Irvine			Chan, Timothy A/ABD-5850-2021		NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009755] Funding Source: NIH RePORTER; NCRR NIH HHS [R01 RR09755-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; Bode H.R., 1983, P291; BODE HR, 1978, PROG BIOPHYS MOL BIO, V33, P189; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOSCH TCG, 1989, MOL CELL BIOL, V9, P4141, DOI 10.1128/MCB.9.10.4141; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; DAVID CN, 1973, ROUX ARCH DEV BIOL, V171, P259, DOI 10.1007/BF00577724; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; GODDARD JM, 1986, P NATL ACAD SCI USA, V83, P2172, DOI 10.1073/pnas.83.7.2172; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; GRIMMELIKHUIJZEN CJP, 1982, HISTOCHEMISTRY, V73, P499, DOI 10.1007/BF00493364; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HENKEMEYER MJ, 1988, MOL CELL BIOL, V8, P843, DOI 10.1128/MCB.8.2.843; HOLSTEIN TW, 1990, NATURE, V346, P21, DOI 10.1038/346021b0; HUANG CC, 1985, J MOL BIOL, V181, P175, DOI 10.1016/0022-2836(85)90083-X; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KATZEN AL, 1991, MOL CELL BIOL, V11, P226, DOI 10.1128/MCB.11.1.226; KHANDJIAN EW, 1987, BIO-TECHNOL, V5, P165, DOI 10.1038/nbt0287-165; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LENHOFF H M, 1970, Laboratory Animals (London), V4, P139, DOI 10.1258/002367770781036463; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MACAULEY A, 1990, New Biologist, V2, P828; MANO H, 1990, ONCOGENE, V5, P1781; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OTTILIE S, 1992, ONCOGENE, V7, P1625; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAMAKRISHNAN L, 1989, BIOCHIM BIOPHYS ACTA, V989, P209, DOI 10.1016/0304-419X(89)90043-7; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; RUBIN DI, 1982, DEV BIOL, V89, P332, DOI 10.1016/0012-1606(82)90322-0; Sambrook J, 1989, MOL CLONING LABORATO; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHISHIDO E, 1991, FEBS LETT, V289, P235, DOI 10.1016/0014-5793(91)81078-M; SHORT JM, 1992, METHOD ENZYMOL, V216, P495; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; TAKANO J, 1984, J EMBRYOL EXP MORPH, V80, P155; TAKANO J, 1983, J EMBRYOL EXP MORPH, V78, P141; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	60	31	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1253	1259						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134129				2022-12-25	WOS:A1994NC04800031
J	HORIO, Y; SUZUKI, H; UEDA, R; KOSHIKAWA, T; SUGIURA, T; ARIYOSHI, Y; SHIMOKATA, K; TAKAHASHI, T; TAKAHASHI, T				HORIO, Y; SUZUKI, H; UEDA, R; KOSHIKAWA, T; SUGIURA, T; ARIYOSHI, Y; SHIMOKATA, K; TAKAHASHI, T; TAKAHASHI, T			PREDOMINANTLY TUMOR-LIMITED EXPRESSION OF A MUTANT ALLELE IN A JAPANESE FAMILY CARRYING A GERMLINE P53 MUTATION	ONCOGENE			English	Note							LI-FRAUMENI SYNDROME; CANCER-PRONE FAMILY; CELL LUNG-CANCER; MESSENGER-RNA; BREAST-CANCER; WILD-TYPE; GENE; SARCOMA; ABNORMALITIES; LESIONS	Germline mutations of p53 have been implicated as a cause of cancer susceptibility in the Li-Fraumeni syndrome. Since inactivation of p53 has been suggested to play an important causative role in lung cancer, the present study of the prevalence of germline mutations in 148 patients with this neoplasm was performed. None of 138 randomly chosen patients were found to carry such mutations, while a single patient had a nonsense mutation at codon 213 among 10 patients selected for early onset and/or occurrence of multiple primary cancers. In contrast to the previous report of biallelic expression of p53 in a case with a germline missense mutation, preferential expression of the wild-type allele was observed in the heterozygous state in both normal lung and peripheral blood lymphocytes of our case, whereas expression of mutant mRNA was readily detectable in her lung cancer in the absence of the remaining wild-type allele. Interestingly, the family history of the proband showed a mild aggregation of adulthood cancers and a high prevalence of stomach cancer, a rare component in American families affected by the syndrome. These observations suggest the presence of heterogeneity with regard to molecular and clinical features of germline p53 mutations.	AICHI CANC CTR,RES INST,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR HOSP,CLIN LABS,CHIKUSA KU,NAGOYA 464,JAPAN; AICHI CANC CTR HOSP,DEPT INTERNAL MED,CHIKUSA KU,NAGOYA 464,JAPAN; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 1,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Nagoya University			Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001; Horio, Yoshitsugu/0000-0003-4661-6399				CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DAAR IO, 1988, MOL CELL BIOL, V8, P802, DOI 10.1128/MCB.8.2.802; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FELIX CA, 1993, ONCOGENE, V8, P1203; FREBOURG T, 1992, J CLIN INVEST, V90, P1637, DOI 10.1172/JCI116034; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; HORIO Y, 1993, CANCER RES, V53, P1; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KUROISHI T, 1992, JPN J CLIN ONCOL, V22, P365; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LI FP, 1992, J NATL CANCER I, V84, P1156, DOI 10.1093/jnci/84.15.1156; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LYNCH HT, 1978, CANCER, V41, P2055, DOI 10.1002/1097-0142(197805)41:5<2055::AID-CNCR2820410554>3.0.CO;2-X; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MAQUAT LE, 1981, CELL, V27, P543, DOI 10.1016/0092-8674(81)90396-2; MATSUDA R, 1993, AM J PATHOL, V142, P339; MINNA JD, 1991, MOL MECHANISMS THEIR, P63; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRONG LC, 1987, JNCI-J NATL CANCER I, V79, P1213; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; SUZUKI H, 1992, CANCER RES, V52, P734; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; UCHINO S, 1993, INT J CANCER, V54, P759, DOI 10.1002/ijc.2910540509; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; 1992, CANCER INCIDENCE 5 C, V6, P876	30	53	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1231	1235						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134126				2022-12-25	WOS:A1994NC04800027
J	YAN, W; FRANCKLYN, C				YAN, W; FRANCKLYN, C			CYTOSINE-73 IS A DISCRIMINATOR NUCLEOTIDE IN-VIVO FOR HISTIDYL-TRANSFER RNA IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCEPTOR STEM; TRIOSEPHOSPHATE ISOMERASE; MAJOR DETERMINANT; IDENTITY INVIVO; AMINOACYLATION; SYNTHETASE; RECOGNITION; SPECIFICITY; ANTICODON; CLEAVAGE	The acceptor helix of histidine tRNAs in Escherichia coli is capped by a unique base pair in which the cytosine at the discriminator position is paired with an extra guanosine at -1. In previous in vitro studies, the presence of the G-1:C73 base pair was found to be required to obtain both optimal histidylation by histidyl-tRNA synthetase and accurate 5' processing by RNase P. We investigated the role of G-1:C 73 in histidine tRNA identity and found that nucleotide substitutions conferred mischarging by other amino acids in a pattern that correlated with the discriminator base and not with the extra nucleotide at -1. As shown by primer extension experiments, the relatively minor role of the -1 nucleotide in vivo could be attributed to altered RNase P processing. These studies show that interactions of tRNAs in vivo both with RNase P during tRNA biosynthesis and with the pool of aminoacyl-tRNA synthetases can modulate the effects of substitutions at recognition nucleotides, eliciting changes in transfer RNA identity.	UNIV VERMONT, COLL MED, DEPT BIOCHEM, HLTH SCI COMPLEX B409, BURLINGTON, VT 05405 USA	University of Vermont					NIGMS NIH HHS [GM 48146] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048146] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1982, Journal of Molecular and Applied Genetics, V1, P419; ASAHARA H, 1993, J MOL BIOL, V231, P219, DOI 10.1006/jmbi.1993.1277; BURKARD U, 1988, J BIOL CHEM, V263, P9578; BURKARD U, 1988, J BIOL CHEM, V263, P2447; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CHATTAPADHYAY R, 1990, BIOCHEMISTRY-US, V29, P4263, DOI 10.1021/bi00470a001; CROTHERS D, 1972, P NATL ACAD SCI USA, V69, P63; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; FRANCKLYN C, 1992, SCIENCE, V255, P1121, DOI 10.1126/science.1546312; FRANCKLYN C, 1990, P NATL ACAD SCI USA, V87, P8655, DOI 10.1073/pnas.87.21.8655; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; GREEN CJ, 1988, J BIOL CHEM, V263, P652; HARADA F, 1972, FEBS LETT, V19, P352, DOI 10.1016/0014-5793(72)80078-4; HASEGAWA T, 1989, BIOCHEM BIOPH RES CO, V163, P1534, DOI 10.1016/0006-291X(89)91154-6; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; HIMENO H, 1990, NUCLEIC ACIDS RES, V18, P6815, DOI 10.1093/nar/18.23.6815; HOLM PS, 1992, NUCLEIC ACIDS RES, V20, P421, DOI 10.1093/nar/20.3.421; HOOPER ML, 1972, FEBS LETT, V22, P149, DOI 10.1016/0014-5793(72)80241-2; HOU YM, 1989, BIOCHEMISTRY-US, V28, P4942, DOI 10.1021/bi00438a005; HOU YM, 1989, BIOCHEMISTRY-US, V28, P6800, DOI 10.1021/bi00443a003; HOU YM, 1993, P NATL ACAD SCI USA, V90, P6776, DOI 10.1073/pnas.90.14.6776; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; KIRSEBOM LA, 1992, NUCLEIC ACIDS RES, V20, P425, DOI 10.1093/nar/20.3.425; KLEINA LG, 1990, J MOL BIOL, V213, P705, DOI 10.1016/S0022-2836(05)80257-8; KOMATSOULIS GA, 1993, BIOCHEMISTRY-US, V32, P7435, DOI 10.1021/bi00080a014; KOMIVES EA, 1991, BIOCHEMISTRY-US, V30, P3011, DOI 10.1021/bi00226a005; MCCLAIN WH, 1990, P NATL ACAD SCI USA, V87, P9260, DOI 10.1073/pnas.87.23.9260; MCCLAIN WH, 1991, P NATL ACAD SCI USA, V88, P6147, DOI 10.1073/pnas.88.14.6147; MCCLAIN WH, 1988, J MOL BIOL, V202, P697, DOI 10.1016/0022-2836(88)90551-7; MCLAIN WH, 1993, J MOL BIOL, V234, P257; MILELR JH, 1972, EXPT MOL GENETICS; MURGOLA EJ, 1983, MOL GEN GENET, V191, P132, DOI 10.1007/BF00330900; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; ORELLANA O, 1986, MOL CELL BIOL, V6, P525, DOI 10.1128/MCB.6.2.525; PALLANCK L, 1992, J BIOL CHEM, V267, P7221; PUTZ J, 1991, SCIENCE, V252, P1696, DOI 10.1126/science.2047878; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIMMEL P, 1989, BIOCHEMISTRY-US, V28, P2747, DOI 10.1021/bi00433a001; SCHULMAN LH, 1991, PROG NUCLEIC ACID RE, V41, P23; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SHERMAN JM, 1992, NUCLEIC ACIDS RES, V20, P1547, DOI 10.1093/nar/20.7.1547; SHERMAN JM, 1992, J MOL BIOL, V228, P1055, DOI 10.1016/0022-2836(92)90314-A; SHI JP, 1991, J BIOL CHEM, V266, P2705; SHIMURA Y, 1972, FEBS LETT, V22, P144, DOI 10.1016/0014-5793(72)80240-0; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; STIRLING DA, 1989, MOL MICROBIOL, V3, P1025, DOI 10.1111/j.1365-2958.1989.tb00253.x; STRAUS D, 1985, P NATL ACAD SCI USA, V82, P2014, DOI 10.1073/pnas.82.7.2014; YARUS M, 1972, NATURE-NEW BIOL, V239, P106, DOI 10.1038/newbio239106a0	56	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					10022	10027						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144499				2022-12-25	WOS:A1994NE05300094
J	ZHENG, YW; YEN, TSB				ZHENG, YW; YEN, TSB			NEGATIVE REGULATION OF HEPATITIS-B VIRUS GENE-EXPRESSION AND REPLICATION BY OXIDATIVE STRESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; KAPPA-B; ACTIVATION; PROTEIN; TRANSCRIPTION; RESPONSES; RECOGNIZE; ANTIGEN; CELLS	We present data demonstrating that hydrogen peroxide markedly decreases release of progeny hepatitis B virus particles in cultured cells. The presence of reduced glutathione prevents this effect. Hydrogen peroxide also decreases secretion of the hepatitis B virus surface and e antigens, with a concomitant decrease in the steady-state levels of the corresponding viral transcripts. This effect is specific to viral gene expression, since hydrogen peroxide at the concentration used does not have any significant effect on the overall pattern of host cell protein synthesis nor on the secretion of growth hormone from a co-transfected plasmid. Since hepatitis E virus can cause acute and chronic hepatitis and since inflammatory cells release significant amounts of reactive oxygen species, including hydrogen peroxide, this phenomenon may be of pathophysiological importance in the viral life cycle.	UNIV CALIF SAN FRANCISCO,VET ADM MED CTR,DEPT PATHOL 113B,SAN FRANCISCO,CA 94121	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)								AHERN H, 1991, ASM NEWS, V57, P627; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BRUSS V, 1991, P NATL ACAD SCI USA, V88, P1059, DOI 10.1073/pnas.88.3.1059; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GILLES PN, 1992, J VIROL, V66, P3955, DOI 10.1128/JVI.66.6.3955-3960.1992; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HOLLINGER FB, 1990, VIROLOGY, P2171; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; MONDELLI M, 1982, J IMMUNOL, V129, P2773; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; OU JH, 1990, J VIROL, V64, P4578, DOI 10.1128/JVI.64.9.4578-4581.1990; PENNA A, 1991, J EXP MED, V174, P1565, DOI 10.1084/jem.174.6.1565; PENNA A, 1992, J VIROL, V66, P1193, DOI 10.1128/JVI.66.2.1193-1198.1992; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDERSCHAULIES S, 1992, J VIROL, V66, P5534, DOI 10.1128/JVI.66.9.5534-5541.1992; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHIBANUMA M, 1991, CELL GROWTH DIFFER, V2, P583; SIFLINGERBIRNBOIM A, 1992, LAB INVEST, V67, P24; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; VALENZUELA P, 1980, ANIMAL VIRUS GENETIC, P57; YAGINUMA K, 1989, J VIROL, V63, P2914, DOI 10.1128/JVI.63.7.2914-2920.1989; YEN TSB, 1993, SEMIN VIROL, V4, P33; ZHOU DX, 1990, J BIOL CHEM, V265, P20731	27	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8857	8862						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132621				2022-12-25	WOS:A1994NB41100038
J	APARICIO, JF; CAFFREY, P; MARSDEN, AFA; STAUNTON, J; LEADLAY, PF				APARICIO, JF; CAFFREY, P; MARSDEN, AFA; STAUNTON, J; LEADLAY, PF			LIMITED PROTEOLYSIS AND ACTIVE-SITE STUDIES OF THE FIRST MULTIENZYME COMPONENT OF THE ERYTHROMYCIN-PRODUCING POLYKETIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-DEHYDROGENASE COMPLEX; FATTY-ACID SYNTHASE; SACCHAROPOLYSPORA-ERYTHRAEA; MULTIFUNCTIONAL ENZYME; DOMAIN-STRUCTURE; ORGANIZATION; SEQUENCE; PROTEINS; BIOSYNTHESIS; QUANTITIES	The domain structure of the 6-deoxyerythronolide B synthase 1 component of the erythromycin-producing polyketide synthase from Saccharopolyspora erythraea has been investigated using limited proteolysis and active-site labeling. Trypsin, elastase, endoproteinase Glu-C, and endoproteinase Arg-C were used to cleave the multienzyme, and the sizes of the resulting fragments were assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The location of fragments within the primary structure was established by N-terminal sequence analysis. The cleavage pattern followed domain boundaries previously predicted on the basis of sequence alignments, but many predicted interdomain regions were not cleaved, even under the harshest conditions used. Initial proteolysis generated three large fragments: an N-terminal fragment (about 60 kDa) housing an acyltransferase-acyl carrier protein di-domain; a central fragment (about 90 kDa) containing a ketosynthase-acyltransferase di-domain; and a C-terminal fragment (about 220 kDa) containing the remaining six domains of the multienzyme, including the third acyltransferase. The intact multienzyme behaves as a dimer of molecular mass 660 kDa on gel filtration; and the C-terminal fragment remains dimeric. However, the N-terminal and central fragments appear to be monomeric species. After proteolysis of the multienzyme, the N-terminal di-domain was found to be specifically labeled after incubation with [C-14]propionyl-CoA, providing the first evidence for its proposed role as a ''loading domain'' for the propionate starter unit. In contrast, the other two fragments were specifically acylated by [C-14]methylmalonyl-CoA, indicating that both the other two acyltransferases remain enzymatically active after proteolysis.	UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,CAMBS,ENGLAND; UNIV CAMBRIDGE,DEPT ORGAN CHEM,CAMBRIDGE CB2 1QW,CAMBS,ENGLAND; UNIV CAMBRIDGE,CAMBRIDGE CTR MOLEC RECOGNIT,CAMBRIDGE CB2 1QW,CAMBS,ENGLAND	University of Cambridge; University of Cambridge; University of Cambridge			Caffrey, Patrick/B-1409-2008; Aparicio, Jesús F./K-8686-2014	Aparicio, Jesús F./0000-0003-4242-4701; Leadlay, Peter/0000-0002-3247-509X				BEVITT DJ, 1992, EUR J BIOCHEM, V204, P39, DOI 10.1111/j.1432-1033.1992.tb16603.x; BLEILE DM, 1979, P NATL ACAD SCI USA, V76, P4385, DOI 10.1073/pnas.76.9.4385; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAFFREY P, 1992, FEBS LETT, V304, P225, DOI 10.1016/0014-5793(92)80624-P; COGGINS JR, 1986, MULTIDOMAIN PROTEINS, P1; Corcoran JW, 1981, ANTIBIOTICS, P132; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; DONADIO S, 1992, GENE, V111, P51, DOI 10.1016/0378-1119(92)90602-L; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; EDELMAN GM, 1973, SCIENCE, V180, P830, DOI 10.1126/science.180.4088.830; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSDEN AFA, 1994, IN PRESS SCIENCE; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; ROBERTS GA, 1993, EUR J BIOCHEM, V214, P305, DOI 10.1111/j.1432-1033.1993.tb17925.x; ROSSMANN MG, 1981, ANNU REV BIOCHEM, V50, P497, DOI 10.1146/annurev.bi.50.070181.002433; RUBENSTEIN DS, 1991, J BIOL CHEM, V266, P11252; SENO ET, 1986, BACTERIA, V9, P231; STEPHENS PE, 1983, EUR J BIOCHEM, V133, P481, DOI 10.1111/j.1432-1033.1983.tb07490.x; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WITKOWSKI A, 1991, EUR J BIOCHEM, V198, P571, DOI 10.1111/j.1432-1033.1991.tb16052.x	26	88	94	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8524	8528						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132579				2022-12-25	WOS:A1994NB40900104
J	HORI, H; FENNA, RE; KIMURA, S; IKEDASAITO, M				HORI, H; FENNA, RE; KIMURA, S; IKEDASAITO, M			AROMATIC SUBSTRATE MOLECULES BIND AT THE DISTAL HEME POCKET OF MYELOPEROXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLEEN GREEN HEMEPROTEIN; HORSERADISH-PEROXIDASE; LIGAND-BINDING; CHLORINATING ACTIVITY; SPECTRAL PROPERTIES; PROSTHETIC GROUP; LACTOPEROXIDASE; COMPLEXES; RESONANCE; CHLORIDE	Binding of aromatic substrate molecules to myeloperoxidase has been investigated by EPR spectroscopy and model building. Binding of aromatic substrate molecules, such as phenol, p-cresol, resorcinol, and 4-amino salicylate, replaces the original rhombic high spin EPR spectrum of the ferric enzyme (g = 6.74, 5.18, and 1.97) by another high spin signal (g = 7.04, 4.87, and 1.93) indicating that these substrate molecules bind near the heme center of the enzyme. Salicylhydroxamic acid and benzohydroxamic acid complexes of myeloperoxidase showed EPR spectra composed of high spin (g = 6.99, 4.93, and 1.95) and low spin (2.66, 2.22, and 1.81) signals. The hydroxamic side chains of these two substrates seem to interact with the heme iron. Model building based on the three-dimensional structure of the enzyme (Zeng, J., and Fenna, R. E. (1992) J. Mel. Biol. 226, 185-207) revealed the presence of a hydrophobic pocket at the entrance of the distal heme cavity where the aromatic ring of these substrates can bind. Moreover, the six-membered ring portion of salicylhydroxamic acid and benzohydroxamic acid could bind to this hydrophobic pocket with the hydroxamic side chain placed between the imidazole of the distal His and the heme iron. The EPR results on lactoperoxidase and intestinal peroxidase also suggest the presence of an aromatic substrate binding site similar to that of myeloperoxidase.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; OSAKA UNIV,FAC ENGN SCI,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN; UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,MIAMI,FL 33101; NCI,MOLEC CARCINOGENESIS LAB,BETHESDA,MD 20892	Case Western Reserve University; Osaka University; University of Miami; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Ikeda-Saito, Masao/K-2703-2015; Ikeda-Saito, Masao/A-5992-2008		NCRR NIH HHS [RR05695] Funding Source: Medline; NIGMS NIH HHS [GM49149, GM39492] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049149, R01GM039492] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABCOCK GT, 1985, BIOCHIM BIOPHYS ACTA, V828, P58, DOI 10.1016/0167-4838(85)90009-3; BAKKENIST ARJ, 1978, BIOCHIM BIOPHYS ACTA, V524, P45, DOI 10.1016/0005-2744(78)90101-8; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V784, P177, DOI 10.1016/0167-4838(84)90125-0; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V791, P75, DOI 10.1016/0167-4838(84)90283-8; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V788, P1, DOI 10.1016/0167-4838(84)90290-5; BRACETE AM, 1991, BIOCHIM BIOPHYS ACTA, V1080, P264, DOI 10.1016/0167-4838(91)90012-O; CALS MM, 1991, EUR J BIOCHEM, V198, P733, DOI 10.1111/j.1432-1033.1991.tb16073.x; DUGAD LB, 1990, J BIOL CHEM, V265, P7173; ERMAN JE, 1992, J AM CHEM SOC, V114, P6592, DOI 10.1021/ja00042a068; GUPTA RK, 1979, BIOCHEM BIOPH RES CO, V89, P1334, DOI 10.1016/0006-291X(79)92155-7; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HORI H, 1990, BIOCHEMISTRY-US, V29, P7106, DOI 10.1021/bi00482a023; IKEDASAITO M, 1985, J BIOL CHEM, V260, P1688; IKEDASAITO M, 1989, J BIOL CHEM, V264, P4559; IKEDASAITO M, 1985, FEBS LETT, V184, P52, DOI 10.1016/0014-5793(85)80651-7; IKEDASAITO M, 1985, J BIOL CHEM, V260, P8301; IKEDASAITO M, 1990, ARCH BIOCHEM BIOPHYS, V283, P351, DOI 10.1016/0003-9861(90)90653-G; IKEDASAITO M, 1991, J BIOL CHEM, V266, P3611; KETTLE AJ, 1992, J BIOL CHEM, V267, P8319; KIMURA S, 1988, PROTEINS, V3, P113, DOI 10.1002/prot.340030206; KIMURA S, 1978, ARCH BIOCHEM BIOPHYS, V189, P14, DOI 10.1016/0003-9861(78)90108-X; LAMAR GN, 1992, BIOCHEMISTRY-US, V31, P9158, DOI 10.1021/bi00153a007; MAGUIRE RJ, 1971, CAN J BIOCHEM CELL B, V49, P1165, DOI 10.1139/o71-167; MODI S, 1989, BIOCHIM BIOPHYS ACTA, V996, P214, DOI 10.1016/0167-4838(89)90250-1; MORRISON M, 1976, ANNU REV BIOCHEM, V45, P861, DOI 10.1146/annurev.bi.45.070176.004241; SCHONBAUM GR, 1973, J BIOL CHEM, V248, P502; SMULEVICH G, 1991, BIOCHEMISTRY-US, V30, P772, DOI 10.1021/bi00217a029; TAMURA M, 1971, BIOCHIM BIOPHYS ACTA, V243, P239, DOI 10.1016/0005-2795(71)90081-X; THANABAL V, 1989, BIOCHEMISTRY-US, V28, P7038, DOI 10.1021/bi00443a039; THANABAL V, 1987, J AM CHEM SOC, V109, P7516, DOI 10.1021/ja00258a043; WEVER R, 1981, BIOCHIM BIOPHYS ACTA, V661, P235, DOI 10.1016/0005-2744(81)90009-7; WEVER R, 1991, J BIOL CHEM, V266, P24308; YOSHIMURA T, 1984, ARCH BIOCHEM BIOPHYS, V230, P466, DOI 10.1016/0003-9861(84)90427-2; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5; ZUURBIER KWM, 1990, BIOCHIM BIOPHYS ACTA, V1037, P140, DOI 10.1016/0167-4838(90)90159-D	35	56	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8388	8392						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132563				2022-12-25	WOS:A1994NB40900084
J	MARQUEZ, LA; DUNFORD, HB				MARQUEZ, LA; DUNFORD, HB			CHLORINATION OF TAURINE BY MYELOPEROXIDASE - KINETIC EVIDENCE FOR AN ENZYME-BOUND INTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; HALOGENATION REACTIONS; ISOLATED NEUTROPHILS; HYPOCHLOROUS ACID; CHLORIDE; CHLOROPEROXIDASE; MECHANISM; OXIDANT; SPLEEN; CHLORAMINES	The chlorination of taurine by the myeloperoxidase-H2O2-Cl- system was investigated under steady state conditions. By systematically varying the pH and the concentrations of H2O2, Cl-, and taurine such that chloride inhibition and the unwanted formation of inactive compound II intermediate are minimized, rate data were found to fit a mechanism involving an enzyme-bound chlorinating intermediate. The mechanism we propose is as follows. [GRAPHICS] The kinetic parameters determined at pH 4.7 are: k(1) = (3.3 +/- 0.2) x 10(7) M(-1) S-1, k(2) = (2.8 +/- 1.2) x 10(6) M(-1) S-1, and k(3) = (4.4 +/- 0.2) x 10(5) M(-1) S-1. The rate constant for compound I formation (k(1)) is of the same order of magnitude as the value (1.8 x 10(7) M(-1) S-1) obtained using transient state techniques in a previous study by our group. The value of k(3) is 2 orders of magnitude greater than the nonenzymatic reaction between HOCl and taurine at the same pH. The results of this study indicate that the chlorination reaction mediated by the myeloperoxidase system in vivo may involve an enzyme intermediate species rather than free HOCl. Not only does this mechanism offer the advantage of substrate specificity but also of speed compared to the non-enzymatic reaction. This mechanism can also explain how the indiscriminate oxidation reactions by HOCl are prevented in the leukocyte. The fast formation of taurine monochloramine, a relatively nontoxic and stable compound compared to HOCl, is consistent with the proposed role of taurine in the neutrophil, that of protecting certain targets including myeloperoxidase from the attack by potent chlorinated oxidants.	UNIV ALBERTA,DEPT CHEM,EDMONTON T6G 2G2,AB,CANADA	University of Alberta			Marquez-Curtis, Leah A/M-7152-2015	Marquez-Curtis, Leah A/0000-0002-4047-2227				AGNER K, 1958, ACTA CHEM SCAND, V12, P89, DOI 10.3891/acta.chem.scand.12-0089; Agner K., 1972, STRUCTURE FUNCTION O, P329; ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; ANDREWS PC, 1982, J BIOL CHEM, V257, P13240; BAKKENIST ARJ, 1980, BIOCHIM BIOPHYS ACTA, V613, P337, DOI 10.1016/0005-2744(80)90088-1; BARBEAU A, 1978, TAURINE NEUROLOGICAL; BARON DN, 1969, CLIN SCI, V37, P205; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V788, P1, DOI 10.1016/0167-4838(84)90290-5; BRAUER G, 1960, HDB PREPARATIVE INOR, V1, P272; COCHRANE CG, 1983, J CLIN INVEST, V71, P754, DOI 10.1172/JCI110823; COTTON ML, 1973, CAN J CHEM, V51, P582, DOI 10.1139/v73-088; DAVIS JC, 1981, J BIOL CHEM, V256, P5992; DAVIS JC, 1984, INORG CHIM A-BIOINOR, V93, pL49, DOI 10.1016/S0020-1693(00)88148-7; DUNFORD HB, 1987, ARCH BIOCHEM BIOPHYS, V252, P292, DOI 10.1016/0003-9861(87)90034-8; FUKADA K, 1982, CLIN CHEM, V28, P1758; GRISHAM MB, 1984, J BIOL CHEM, V259, P404; HAGER LP, 1970, BIOCH PHAGOCYTIC PRO, P67; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HARRISON JE, 1976, CANCER ENZYMOLOGY, P305; HAYES KC, 1981, ANNU REV NUTR, V1, P401, DOI 10.1146/annurev.nu.01.070181.002153; HELD AM, 1978, BIOCHEM BIOPH RES CO, V81, P878, DOI 10.1016/0006-291X(78)91433-X; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; IKEDASAITO M, 1985, J BIOL CHEM, V260, P1688; JENSEN MS, 1973, J CELL BIOL, V56, P379, DOI 10.1083/jcb.56.2.379; KETTLE AJ, 1988, BIOCHIM BIOPHYS ACTA, V957, P185, DOI 10.1016/0167-4838(88)90271-3; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTION, P409; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; KURIYAMA K, 1985, SULFUR AMINO ACIDS B, P449; LAMBEIR AM, 1983, J BIOL CHEM, V258, P3558; LEARN DB, 1990, J LEUKOCYTE BIOL, V48, P174, DOI 10.1002/jlb.48.2.174; LEWIS CPL, 1990, BIOCHEM PHARMACOL, V39, P431, DOI 10.1016/0006-2952(90)90047-O; LIBBY RD, 1982, J BIOL CHEM, V257, P5030; LOMBARDINI JB, 1992, ADV EXP MED BIOL, V315; MARQUEZ LA, 1990, THESIS U ALBERTA; MCLOUGHLIN DM, 1991, BIOCHEM SOC T, V19, P73, DOI 10.1042/bst0190073; MORRISON M, 1976, ANNU REV BIOCHEM, V45, P861, DOI 10.1146/annurev.bi.45.070176.004241; NAKAMORI K, 1990, CHEM PHARM BULL, V38, P3116, DOI 10.1248/cpb.38.3116; NASKALSKI JW, 1977, BIOCHIM BIOPHYS ACTA, V485, P291, DOI 10.1016/0005-2744(77)90165-6; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; Oja SS, 1985, TAURINE BIOL ACTIONS; SCHRAUFSTATTER IU, 1990, J CLIN INVEST, V85, P554, DOI 10.1172/JCI114472; SCHRAUFSTATTER IU, 1984, J CLIN INVEST, V73, P1175, DOI 10.1172/JCI111303; SCHULTZ J, 1962, ARCH BIOCHEM BIOPHYS, V96, P465, DOI 10.1016/0003-9861(62)90321-1; Soupart P., 1962, AMINO ACID POOLS, P220; STELMASZYNSKA T, 1974, EUR J BIOCHEM, V45, P305, DOI 10.1111/j.1432-1033.1974.tb03555.x; STELMASZYNSKA T, 1992, INT J BIOCHEM, V24, P121, DOI 10.1016/0020-711X(92)90237-U; SVENSSON BE, 1987, BIOCHEM J, V242, P673, DOI 10.1042/bj2420673; Thomas E L, 1986, Methods Enzymol, V132, P569; Thomas E L, 1986, Methods Enzymol, V132, P585; THOMAS EL, 1983, J CLIN INVEST, V72, P441, DOI 10.1172/JCI110992; TRACHTMAN H, 1993, BIOCHEM BIOPH RES CO, V191, P759, DOI 10.1006/bbrc.1993.1282; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5; WRIGHT CE, 1986, ANNU REV BIOCHEM, V55, P427, DOI 10.1146/annurev.bi.55.070186.002235; Zgliczynski J. M., 1980, RETICULOENDOTHELIAL, V2, P255; ZGLICZYNSKI JM, 1971, BIOCHIM BIOPHYS ACTA, V235, P419, DOI 10.1016/0005-2744(71)90281-6; ZGLICZYNSKI JM, 1977, P SOC EXP BIOL MED, V154, P418	57	125	125	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7950	7956						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132515				2022-12-25	WOS:A1994NB40900021
J	JORDAN, ET; GOLDSTEIN, IJ				JORDAN, ET; GOLDSTEIN, IJ			THE SEQUENCE OF A 2ND MEMBER OF THE LIMA-BEAN LECTIN GENE FAMILY AND THE EXPRESSION AND CHARACTERIZATION OF RECOMBINANT LECTIN IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASEOLUS-LUNATUS; ADENINE BINDING; CONCANAVALIN-A; SEED LECTIN; PEA LECTIN; PROTEINS; PHYTOHEMAGGLUTININ; ELECTROPHORESIS; CARBOHYDRATE; RESOLUTION	The lima bean lectin recognizes terminal alpha-D GalNAc groups and agglutinates human type A erythrocytes. We have cloned a portion of the gene encoding the (alpha subunit of the lima bean lectin. The clone was obtained using the polymerase chain reaction and verified from a genomic clone encoding the mature protein of 253 amino acids. The deduced amino acid sequence has significant overall homology with other leguminous plant lectins and contains all of the known peptide sequences isolated from lima bean lectin (LBL). Southern blot analysis reveals the presence of several genes which hybridize to the cloned gene and which we propose are genes included in the lima bean lectin gene family. We report here the sequence, expression, and characterization of LBL 2, the second member of this gene family. Milligram quantities of soluble active recombinant lima bean lectin (LBL) were obtained from Escherichia coli, using the T7 RNA polymerase expression system. SDS polyacrylamide gel electrophoresis and Western blot analysis indicate expression of one protein band of about 27 kDa in induced E. coli cells. This protein crossreacts with polyclonal antibodies raised against seed lectin (sLBL) and gave a reaction of identity with seed lectin by Ouchterlony double diffusion, specifically agglutinates type A blood cells, and is specifically inhibited by D-GalNAc. The isoelectric point of rLBL is 5.86, whereas those of the seed lectin subunits were determined to be 5.86, 5.58, and 5.20 (previously designated alpha, beta, alpha(r), respectively). rLBL binds to hydrophobic ligands independent of sugar binding, an observation similar to results obtained with sLBL. However, despite the similar activities described, several significant differences between recombinant and native lima bean lectin were found, including mobility on gel filtration, aggregation in solution, and its CD spectrum. These differences may be due to a number of factors, which will be discussed.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIGMS NIH HHS [GM 29470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARANGO R, 1992, EUR J BIOCHEM, V205, P575, DOI 10.1111/j.1432-1033.1992.tb16815.x; ARANGO R, 1990, FEBS LETT, V264, P104; BOYD WC, 1949, J IMMUNOL, V62, P333; CARRINGTON DM, 1985, NATURE, V313, P64, DOI 10.1038/313064a0; CLAUSEN J, 1969, IMMUNOCHEMICAL TEC 3, V1; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DEWENDA Z, 1989, EMBO J, V8, P2189; DOBRES MS, 1989, PLANT PHYSIOL, V89, P833, DOI 10.1104/pp.89.3.833; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; ELLISTON K, 1988, ARCHITECTURE EUKARYO, P21; GALBRAIT.W, 1972, BIOCHEMISTRY-US, V11, P3976, DOI 10.1021/bi00771a022; GOLDBERG RB, 1983, CELL, V33, P465, DOI 10.1016/0092-8674(83)90428-2; HARADA JJ, 1990, J BIOL CHEM, V265, P4997; HOFFMAN LM, 1985, EMBO J, V4, P883, DOI 10.1002/j.1460-2075.1985.tb03714.x; Hurn B A, 1980, Methods Enzymol, V70, P104; IMBRIEMILLIGAN C, 1989, J BIOL CHEM, V264, P16793; JOSIC D, 1984, ANAL BIOCHEM, V142, P473, DOI 10.1016/0003-2697(84)90492-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORIS R, 1993, BIOCHEMISTRY-US, V32, P8772, DOI 10.1021/bi00085a007; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MALIARIK MJ, 1988, J BIOL CHEM, V263, P11274; Maniatis T., 1982, MOL CLONING; MATSUDA H, 1990, MOL IMMUNOL, V27, P571, DOI 10.1016/0161-5890(90)90076-C; MISAKI A, 1977, J BIOL CHEM, V252, P6995; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ROBERTS DD, 1986, PHYTOCHEMISTRY, V25, P589, DOI 10.1016/0031-9422(86)88004-9; ROBERTS DD, 1982, J BIOL CHEM, V257, P1274; ROBERTS DD, 1983, ARCH BIOCHEM BIOPHYS, V224, P479, DOI 10.1016/0003-9861(83)90235-7; ROBERTS DD, 1984, J BIOL CHEM, V259, P903; ROBERTS DD, 1982, J BIOL CHEM, V257, P9198; RUDDON RW, 1974, P NATL ACAD SCI USA, V71, P1848, DOI 10.1073/pnas.71.5.1848; SCHNELL DJ, 1987, EUR J BIOCHEM, V167, P227, DOI 10.1111/j.1432-1033.1987.tb13327.x; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211; SHERMAN F, 1982, MOL BIOL YEAST SACCH, P301; Steczko J, 1991, Protein Expr Purif, V2, P221, DOI 10.1016/1046-5928(91)90075-T; STUBBS ME, 1986, J BIOL CHEM, V261, P6141; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANBOGELEN RA, 1990, ELECTROPHORESIS, V11, P1131, DOI 10.1002/elps.1150111205; VODKIN LO, 1981, PLANT PHYSIOL, V68, P766, DOI 10.1104/pp.68.3.766; YAMAUCHI D, 1990, FEBS LETT, V260, P127, DOI 10.1016/0014-5793(90)80083-U; YARWOOD A, 1985, FEBS LETT, V184, P104, DOI 10.1016/0014-5793(85)80663-3; YOUNG NM, 1992, J MOL BIOL, V228, P924, DOI 10.1016/0022-2836(92)90875-K	45	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7674	7681						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125994				2022-12-25	WOS:A1994NA03200100
J	KOO, JS; SPREMULLI, LL				KOO, JS; SPREMULLI, LL			ANALYSIS OF THE TRANSLATIONAL INITIATION REGION ON THE EUGLENA-GRACILIS CHLOROPLAST RIBULOSE-BISPHOSPHATE CARBOXYLASE/OXYGENASE (RBCL) MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCES; PHENOTYPIC SELECTION; EUKARYOTIC RIBOSOMES; SECONDARY STRUCTURE; COMPLEX FORMS; BINDING-SITE; FACTOR-III; GENE	The chloroplast mRNAs from Euglena gracilis fall into two classes. One group of mRNAs from this organelle contains a Shine-Dalgarno sequence 5' to the start codon, while the other group of mRNAs does not have a conserved sequence signal in the 5'-untranslated region. To investigate the start signals for E. gracilis chloroplast mRNAs that do not carry a Shine-Dalgarno sequence, 30 S initiation complex formation has been studied using a series of transcripts carrying the wild-type translational start site of ribulose-bisphosphate carboxylase/oxygenase (rbcL) or mutated derivatives of this site. Mutation of the start codon of the rbcL gene indicates that the chloroplast 30 S subunit is recognizing only the correct AUG codon. The analysis of the messages from a series of deletion mutants shows that a minimum of Lambda 20 residues 5' to the AUG codon is required for activity. Maximal activity requires the full 55-base leader sequence. Surprisingly, a transcript carrying the inverse complement of 48 bases in the leader is Lambda 60% as active as the wild-type message in promoting initiation complex formation. Introduction of a Shine-Dalgarno sequence in the 5'-leader increases the activity of the mRNA only Lambda 1.4-2-fold. The presence of an oligodeoxynucleotide containing a strong Shine-Dalgarno sequence does not significantly inhibit the formation of initiation complexes at the rbcL start site. Similar results are obtained when initiation complexes are formed with initiation factors from either E. gracilis chloroplasts or Escherichia coli.	UNIV N CAROLINA, DEPT CHEM, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill			Koo, J Peter/AAE-6700-2019		NIGMS NIH HHS [GM24963] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024963] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BHANGU R, 1992, BIOCHEMISTRY-US, V31, P5937, DOI 10.1021/bi00140a033; BONHAMSMITH PC, 1989, NUCLEIC ACIDS RES, V17, P2057, DOI 10.1093/nar/17.5.2057; BORISOVA GP, 1979, NUCLEIC ACIDS RES, V6, P1761, DOI 10.1093/nar/6.5.1761; CANONACO MA, 1989, EUR J BIOCHEM, V182, P501, DOI 10.1111/j.1432-1033.1989.tb14856.x; CHRISTOPHER DA, 1989, NUCLEIC ACIDS RES, V17, P7591, DOI 10.1093/nar/17.19.7591; COPERTINO DW, 1991, NUCLEIC ACIDS RES, V19, P6491, DOI 10.1093/nar/19.23.6491; DESMIT MH, 1990, PROG NUCLEIC ACID RE, V38, P1; DESMIT MH, 1990, P NATL ACAD SCI USA, V87, P7668, DOI 10.1073/pnas.87.19.7668; DRETZEN G, 1981, ANAL BIOCHEM, V112, P295, DOI 10.1016/0003-2697(81)90296-7; ECKHARDT H, 1981, BIOCHEMISTRY-US, V20, P2075, DOI 10.1021/bi00511a002; EVSTAFIEVA AG, 1983, EMBO J, V2, P799, DOI 10.1002/j.1460-2075.1983.tb01503.x; GINGRICH JC, 1985, J BIOL CHEM, V260, P6162; GOLD JC, 1985, J BIOL CHEM, V260, P4897; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GRAVES MC, 1983, ARCH BIOCHEM BIOPHYS, V222, P192, DOI 10.1016/0003-9861(83)90516-7; GRAVES MC, 1980, ARCH BIOCHEM BIOPHYS, V204, P444, DOI 10.1016/0003-9861(80)90055-7; GREN EJ, 1984, BIOCHIMIE, V66, P1, DOI 10.1016/0300-9084(84)90188-3; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; GUALERZI CO, 1990, RIBOSOME, P281; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HUI A, 1987, P NATL ACAD SCI USA, V84, P4762, DOI 10.1073/pnas.84.14.4762; JACOB WF, 1987, P NATL ACAD SCI USA, V84, P4757, DOI 10.1073/pnas.84.14.4757; KOO JS, 1994, J BIOL CHEM, V269, P7501; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAUS BL, 1986, J BIOL CHEM, V261, P4781; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MA L, 1992, J BIOL CHEM, V267, P18356; MA L, 1990, J BIOL CHEM, V265, P13560; Maniatis T., 1982, MOL CLONING; MCCARTHY JEG, 1990, TRENDS GENET, V6, P78, DOI 10.1016/0168-9525(90)90098-Q; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; Roney W.B., 1991, NATO ASI Series Series H Cell Biology, V55, P197; SCHMITT M, 1982, EUR J BIOCHEM, V125, P389, DOI 10.1111/j.1432-1033.1982.tb06695.x; SCHNEIDER TD, 1986, J MOL BIOL, V188, P415, DOI 10.1016/0022-2836(86)90165-8; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; STEEGE DA, 1982, J BIOL CHEM, V257, P430; STEITZ JA, 1969, NATURE, V224, P957, DOI 10.1038/224957a0; STORMO GD, 1982, NUCLEIC ACIDS RES, V10, P2971, DOI 10.1093/nar/10.9.2971; SUTTLE DP, 1973, BIOCHEM BIOPH RES CO, V51, P376, DOI 10.1016/0006-291X(73)91268-0; WANG CC, 1989, NUCLEIC ACIDS RES, V17, P9735, DOI 10.1093/nar/17.23.9735; WANG CC, 1991, J BIOL CHEM, V266, P17079; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	44	17	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7494	7500						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125968				2022-12-25	WOS:A1994NA03200073
J	LAEGREID, A; MEDVEDEV, A; NONSTAD, U; BOMBARA, MP; RANGES, G; SUNDAN, A; ESPEVIK, T				LAEGREID, A; MEDVEDEV, A; NONSTAD, U; BOMBARA, MP; RANGES, G; SUNDAN, A; ESPEVIK, T			TUMOR-NECROSIS-FACTOR RECEPTOR P75 MEDIATES CELL-SPECIFIC ACTIVATION OF NUCLEAR FACTOR KAPPA-B AND INDUCTION OF HUMAN CYTOMEGALOVIRUS ENHANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; VIRUS ENHANCER; PROTEIN-KINASE; TNF RECEPTORS; EXPRESSION; BINDING; 55-KDA; ALPHA; STIMULATION	The functional role of human tumor necrosis factor receptor (TNFR) p75 was studied by the use of TNFR p75-specific agonistic antibodies. Human SW480T adenocarcinoma cells, stably transfected with a reporter construct containing beta-galactosidase under the control of human cytomegalovirus immediate early enhancer, were stimulated with anti-TNFR p75 polyclonal antiserum or monoclonal antibodies followed by measurement of beta-galactosidase activity and analysis by electrophoretic mobility shift assays. It was found that cross-linking of TNFR p75 led to strong induction of the human cytomegalovirus enhancer as well as activation of nuclear factor-kappa B (NF-kappa B). Stimulation of TNFR p75 also mediated activation of NF-kappa B in human KYM-1 rhabdomyosarcoma cells but not in other cell types such as U937 and HL-60 monocytic cells or in Eahy 926 endothelial cells. NF-kappa B activation induced by TNFR p75 was delayed approximately 15 min compared with NF-kappa B activation induced by TNFR p55, indicating that the two TNFRs activate NF-kappa B through different signaling pathways. The data presented in this study identify intracellular responses mediated by TNFR p75 which have not been reported previously and suggest that TNFR p75-induced activation of NF-kappa B is strictly cell type-specific.	UNIV TRONDHEIM,INST CANC RES,N-7005 TRONDHEIM,NORWAY; UNIV TRONDHEIM,CTR MOLEC BIOL,UNIGEN,N-7005 TRONDHEIM,NORWAY; MILES INC,INST INFLAMMAT & EXPTL MED,W HAVEN,CT 06516									ABE Y, 1993, J IMMUNOL, V150, P5070; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CAMERINI D, 1991, J IMMUNOL, V147, P3165; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; Edgell CJ, 1983, P NATL ACAD SCI USA, V80, P734; EMEIS JJ, 1988, BLOOD, V71, P1669; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ERIKSTEIN BK, 1991, EUR J IMMUNOL, V21, P1033, DOI 10.1002/eji.1830210426; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; ESPEVIK T, 1994, IN PRESS ORGAN METAB; GALLOWAY CJ, 1992, EUR J IMMUNOL, V22, P3045, DOI 10.1002/eji.1830221143; GHAZAL P, 1992, P NATL ACAD SCI USA, V89, P7630, DOI 10.1073/pnas.89.16.7630; GHAZAL P, 1987, P NATL ACAD SCI USA, V84, P3658, DOI 10.1073/pnas.84.11.3658; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; GRILLI M, 1993, INT REV CYTOL, V143, P1; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Kronke M, 1992, Immunol Ser, V56, P189; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LIABAKKNB, 1993, J IMMUNOL METHODS, V163, P145; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MEAGER A, 1991, J IMMUNOL METHODS, V144, P141, DOI 10.1016/0022-1759(91)90239-C; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; NAUME B, 1991, J IMMUNOL, V146, P3045; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; SAMBUCETTI LC, 1989, EMBO J, V8, P4251, DOI 10.1002/j.1460-2075.1989.tb08610.x; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STAMMINGER T, 1990, J GEN VIROL, V71, P105, DOI 10.1099/0022-1317-71-1-105; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; VANDENABEELE P, 1992, J EXP MED, V176, P1015, DOI 10.1084/jem.176.4.1015; VANLINT J, 1992, J BIOL CHEM, V267, P25916; VANVOORHIS WC, 1983, J EXP MED, V158, P126, DOI 10.1084/jem.158.1.126	39	79	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7785	7791						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8126005				2022-12-25	WOS:A1994NA03200115
J	TSYGANKOV, AY; SPANA, C; ROWLEY, RB; PENHALLOW, RC; BURKHARDT, AL; BOLEN, JB				TSYGANKOV, AY; SPANA, C; ROWLEY, RB; PENHALLOW, RC; BURKHARDT, AL; BOLEN, JB			ACTIVATION-DEPENDENT TYROSINE PHOSPHORYLATION OF FYN-ASSOCIATED PROTEINS IN T-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; AMINO-TERMINAL DOMAIN; SIGNAL TRANSDUCTION; CROSS-LINKING; KINASE P56LCK; SH3 DOMAINS; ZETA-CHAIN; STIMULATION; CD4; INHIBITION	While previous studies have implicated the tyrosine protein kinase p60(fyn) in antigenic activation of T lymphocytes, it is clear that signal transduction initiated through the antigen receptor requires the concerted actions of several proteins. Here, we report our finding that the activation of p60(fyn) following TcR cross-linking results in the tyrosine phosphorylation of two Fyn-associated proteins of 82 and 116 kDa. In the cells analyzed, p116 appears to represent one of the major substrates of T-cell antigen receptor mediated tyrosine phosphorylation In activated T-cells, the interaction of these proteins is specific for p60(fyn) since neither p56(lck) nor p62(c-yes) were found to detectably associate with p82 or p116. Furthermore, the p60(fyn)-p82/p116 complex could be dissociated and then reconstituted in vitro using purified recombinant Fyn. Using this technique we demonstrated that both p82 and p116 were capable of binding to the Fyn SH2 domain while p82 was to some extent capable of independent binding to the Fyn SH3 domain. An association between p60(fyn) and phosphoproteins possibly related to the T-cell p82 and p116 was also observed in other hematopoietic cells. Thus, the activation-induced phosphorylation of the p60(fyn)-associated proteins p116 and p82 and the wide distribution of potentially similar p60(fyn)-associated proteins in hematopoietic cells suggest that p116 and p82 may play a role as physiological substrates and/or regulators of p60(fyn).			TSYGANKOV, AY (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, SIGNAL TRANSDUCT LAB, H4112, PRINCETON, NJ 08543 USA.		Tsygankov, Alexander Y/K-6205-2017					APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; ARNI S, 1993, ONCOGENE, V8, P2485; BELL GM, 1992, MOL CELL BIOL, V12, P5548, DOI 10.1128/MCB.12.12.5548; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CARMO AM, 1993, EUR J IMMUNOL, V23, P2196, DOI 10.1002/eji.1830230922; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; DASILVA AJ, 1992, MOL IMMUNOL, V29, P1417, DOI 10.1016/0161-5890(92)90215-J; DESEAU V, 1987, J CELL BIOCHEM, V35, P113, DOI 10.1002/jcb.240350205; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KOYASU S, 1992, J BIOL CHEM, V267, P3375; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LUO KX, 1991, METHOD ENZYMOL, V201, P149; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PLUZNIK DH, 1982, EXP HEMATOL, V10, P211; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SPANA C, 1993, PROTEIN EXPRES PURIF, V4, P390, DOI 10.1006/prep.1993.1051; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TSYGANKOV AY, 1994, J LEUKOCYTE BIOL, V55, P289, DOI 10.1002/jlb.55.3.289; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TSYGANKOV AY, 1992, CELL IMMUNOL, V140, P97, DOI 10.1016/0008-8749(92)90179-S; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WENG ZG, 1993, J BIOL CHEM, V268, P14956	42	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7792	7800						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8126006				2022-12-25	WOS:A1994NA03200116
J	WATANABE, D; YAMADA, K; NISHINA, Y; TAJIMA, Y; KOSHIMIZU, U; NAGATA, A; NISHIMUNE, Y				WATANABE, D; YAMADA, K; NISHINA, Y; TAJIMA, Y; KOSHIMIZU, U; NAGATA, A; NISHIMUNE, Y			MOLECULAR-CLONING OF A NOVEL CA2+-BINDING PROTEIN (CALMEGIN) SPECIFICALLY EXPRESSED DURING MALE MEIOTIC GERM-CELL DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; MUSCLE SARCOPLASMIC-RETICULUM; RO/SS-A AUTOANTIGEN; MOUSE SPERMATOGENESIS; ENDOPLASMIC-RETICULUM; TRANSLATIONAL CONTROL; GENE-EXPRESSION; SERTOLI CELLS; MESSENGER-RNA; CPG ISLANDS	During mammalian spermatogenesis, many specific molecules are expressed. We have recently identified a 93-kDa male meiotic germ cell-specific antigen (Meg 1) exclusively expressed in germ cells from the pachytene spermatocyte to the spermatid stage using the monoclonal antibody TRA 369 (Watanabe, D., Sawada, K., Koshimizu, U., Kagawa, T., and Nishimune, Y. (1992) Mol. Reprod. Dev. 33, 307-312). In this study, we cloned a cDNA representing this antigen from a mouse testis cDNA expression library, using the monoclonal antibody TRA 369. Northern blotting showed that this transcript was 2.3 kilobases in length and was expressed only in the testis and not in other somatic tissues or in the ovary. The expression of the mRNA was first detected at the pachytene spermatocyte stage of male germ cell development, and this expression was correlated with the expression of the protein. Sequence analysis of the cDNA revealed that the predicted protein consists of 611 amino acids, including a hydrophobic NH2 terminus characteristic of a signal peptide, two sets of internal repetitive sequences (four repeats of IPDPSAVKPEDWDD and GEWXPPMIPNPXYQ), and a hydrophilic COOH terminus. The deduced amino acid sequence has 58% homology with dog calnexin (the ER membrane phosphoprotein of pancreatic cells) and significant partial homology with calreticulin (high affinity Ca2+-binding protein of the ER membrane) at the repetitive sequence. Furthermore, we demonstrated the Ca-45(2+) binding ability of this antigen by a Ca-45(2+) overlay assay, and the name calmegin is proposed for this antigen. Calmegin is a novel Ca2+-binding protein that is specifically expressed in spermatogenesis. The highly regulated, specific, and abundant expression of calmegin suggests that it has important roles in spermatogenesis.	OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT NUTR & PHYSIOL CHEM,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University								ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; ARIEL M, 1991, P NATL ACAD SCI USA, V88, P2317, DOI 10.1073/pnas.88.6.2317; BAKSH S, 1991, J BIOL CHEM, V266; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAGOSTINO A, 1987, MOL CELL BIOL, V7, P1250, DOI 10.1128/MCB.7.3.1250; ERICKSON RP, 1990, TRENDS GENET, V6, P264, DOI 10.1016/0168-9525(90)90209-O; FENDERSON BA, 1984, DEV BIOL, V103, P117, DOI 10.1016/0012-1606(84)90013-7; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GAUNT SJ, 1982, DEV BIOL, V89, P92, DOI 10.1016/0012-1606(82)90297-4; GOLD B, 1983, DEV BIOL, V98, P392, DOI 10.1016/0012-1606(83)90368-8; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MCCAULIFFE DP, 1990, J CLIN INVEST, V86, P332, DOI 10.1172/JCI114704; MCCAULIFFE DP, 1990, J CLIN INVEST, V85, P1379, DOI 10.1172/JCI114582; MILLETTE CF, 1981, J CELL SCI, V48, P367; MILNER RE, 1991, J BIOL CHEM, V266, P7155; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; MUKAI H, 1991, BIOCHEM BIOPH RES CO, V179, P1325, DOI 10.1016/0006-291X(91)91718-R; NAKAMURA M, 1991, BIOCHEM BIOPH RES CO, V176, P1358, DOI 10.1016/0006-291X(91)90436-B; OBRIEN DA, 1984, DEV BIOL, V101, P307, DOI 10.1016/0012-1606(84)90144-1; OBRIEN DA, 1987, BIOL REPROD, V37, P147, DOI 10.1095/biolreprod37.1.147; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; RAPPOLD GA, 1987, EMBO J, V6, P1975, DOI 10.1002/j.1460-2075.1987.tb02460.x; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; TREVES S, 1990, BIOCHEM J, V271, P473, DOI 10.1042/bj2710473; VERNON RB, 1989, BIOL REPROD, V40, P1329, DOI 10.1095/biolreprod40.6.1329; WADA I, 1991, J BIOL CHEM, V266; WATANABE D, 1992, MOL REPROD DEV, V33, P307, DOI 10.1002/mrd.1080330312; WILLISON K, 1987, TRENDS GENET, V3, P351, DOI 10.1016/0168-9525(87)90296-4	37	104	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7744	7749						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8126001				2022-12-25	WOS:A1994NA03200109
J	BOGAZZI, F; HUDSON, LD; NIKODEM, VM				BOGAZZI, F; HUDSON, LD; NIKODEM, VM			A NOVEL HETERODIMERIZATION PARTNER FOR THYROID-HORMONE RECEPTOR - PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							9-CIS RETINOIC ACID; RXR-BETA; RESPONSE ELEMENTS; GENE; BINDING	Retinoid-like receptors play a central role in hormonal responses by forming heterodimers with other nuclear hormone receptors. In this study we have identified the peroxisome proliferator-activated receptor (PPAR) as a new thyroid hormone receptor (THR) auxiliary nuclear protein, heterodimerizing with THR in solution. Although these heterodimers do not recognize a classical thyroid hormone response element (TRE) characterized by direct repeat separated by four nucleotides (DR + 4), PPAR behaves as a dominant negative regulator of thyroid hormone (TH) action. However a TH-dependent positive effect is elicited by selective interaction of the THR beta-PPAR but not the THR alpha-PPAR heterodimer with a novel TRE (DR + 2). The critical region of THR beta was mapped to 3 amino acids in the distal box of the DNA binding domain. Hence, PPAR can positively or negatively influence TH action depending on TRE structure and THR isotype.	NIDDK,MECHANISMS GENE REGULAT SECT,GENET & BIOCHEM BRANCH,BETHESDA,MD 20892; NINCDS,VIRAL & MOLEC PATHOGENESIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)			BOGAZZI, FAUSTO/I-2087-2012	BOGAZZI, FAUSTO/0000-0001-5975-4411				BERNDT JA, 1992, J BIOL CHEM, V267, P14730; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; FARSETTI A, 1991, J BIOL CHEM, V266, P23226; GREEN S, 1993, NATURE, V361, P590, DOI 10.1038/361590a0; HALLENBECK PL, 1993, J BIOL CHEM, V268, P3825; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	18	118	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11683	11686						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163464				2022-12-25	WOS:A1994NG37700003
J	DUKES, ID; MCINTYRE, MS; MERTZ, RJ; PHILIPSON, LH; ROE, MW; SPENCER, B; WORLEY, JF				DUKES, ID; MCINTYRE, MS; MERTZ, RJ; PHILIPSON, LH; ROE, MW; SPENCER, B; WORLEY, JF			DEPENDENCE ON NADH PRODUCED DURING GLYCOLYSIS FOR BETA-CELL GLUCOSE SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DNA STRAND BREAKS; PANCREATIC-ISLETS; POLY(ADP-RIBOSE) SYNTHETASE; ELECTRICAL-ACTIVITY; INSULIN RELEASE; INHIBITION; STREPTOZOTOCIN; METABOLISM; SECRETION; PHOSPHATE	An increase in cytosolic ATP following glucose metabolism by pancreatic beta-cells is the key signal initiating insulin secretion by causing blockade of ATP-dependent K+ channels (K(APT)). This induces membrane depolarization, leading to an elevation in cytosolic Ca2+ ([Ca2+]i) and insulin secretion. In this report we identify the critical metabolic step by which glucose initiates changes in beta-cell K(ATP) channel activity, membrane potential, and [Ca2+]i. The signal stems from the glycolytic production of NADH during the oxidation of glyceraldehyde 3-phosphate, which is subsequently processed into ATP by mitochondria via the operation of discrete shuttle systems.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago	DUKES, ID (corresponding author), GLAXO RES INST,RES TRIANGLE PK,NC 27709, USA.							ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ASHCROFT SJH, 1991, ISLETS LANGERHANS BI, P117; Atwater I, 1980, Horm Metab Res Suppl, VSuppl 10, P100; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; CLARKE DD, 1991, NEUROCHEM RES, V16, P1055, DOI 10.1007/BF00965850; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; DUGGLEBY RG, 1974, J BIOL CHEM, V249, P175; DUKES ID, 1993, AM J PHYSIOL, V264, pE348, DOI 10.1152/ajpendo.1993.264.3.E348; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; GILON P, 1992, J BIOL CHEM, V267, P20713; GIROIX MH, 1991, DIABETES, V40, P227, DOI 10.2337/diabetes.40.2.227; HALESTRAP AP, 1976, BIOCHEM J, V156, P181, DOI 10.1042/bj1560181; HARRIS RA, 1992, TXB BIOCH, P308; HUTTON JC, 1980, DIABETOLOGIA, V18, P395; KEAHEY HH, 1989, DIABETES, V38, P188, DOI 10.2337/diabetes.38.2.188; KIRANADI B, 1991, FEBS LETT, V283, P93, DOI 10.1016/0014-5793(91)80561-G; MACDONALD MJ, 1990, ARCH BIOCHEM BIOPHYS, V279, P104, DOI 10.1016/0003-9861(90)90468-E; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MALAISSE WJ, 1993, AM J PHYSIOL, V264, pE428, DOI 10.1152/ajpendo.1993.264.3.E428; MALAISSE WJ, 1993, ACTA DIABETOL, V30, P1, DOI 10.1007/BF00572865; MISLER S, 1992, PFLUG ARCH EUR J PHY, V424, P289; NOWAK T, 1981, BIOCHEMISTRY-US, V20, P6901, DOI 10.1021/bi00527a025; ONISHI H, 1993, J NEUROL SCI, V114, P205, DOI 10.1016/0022-510X(93)90299-E; RAGAN CI, 1973, J BIOL CHEM, V248, P6876; ROE MW, 1993, J BIOL CHEM, V268, P9953; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SENER A, 1978, BIOCHEM J, V176, P217, DOI 10.1042/bj1760217; SENER A, 1992, J BIOL CHEM, V267, P13251; SMOLEN P, 1992, J MEMBRANE BIOL, V127, P9; SUGANO T, 1974, BIOCHIM BIOPHYS ACTA, V347, P340, DOI 10.1016/0005-2728(74)90074-7; TRENTHAM DR, 1968, BIOCHEM J, V109, P603, DOI 10.1042/bj1090603; UCHIGATA Y, 1982, J BIOL CHEM, V257, P6084; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P94; YAMAMOTO H, 1981, NATURE, V294, P284, DOI 10.1038/294284a0	35	127	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					10979	10982						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157622				2022-12-25	WOS:A1994NF96600004
J	GEIGER, O; THOMASOATES, JE; GLUSHKA, J; SPAINK, HP; LUGTENBERG, BJJ				GEIGER, O; THOMASOATES, JE; GLUSHKA, J; SPAINK, HP; LUGTENBERG, BJJ			PHOSPHOLIPIDS OF RHIZOBIUM CONTAIN NODE-DETERMINED HIGHLY UNSATURATED FATTY-ACID MOIETIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST-ATOM-BOMBARDMENT; ACYL-CARRIER PROTEIN; SYM PLASMID PRL1JI; HOST SPECIFICITY; ESCHERICHIA-COLI; AGROBACTERIUM-TUMEFACIENS; MASS-SPECTROMETRY; MELILOTI 1021; LEGUMINOSARUM; PHOSPHATIDYLETHANOLAMINE	In Rhizobium leguminosarum the nodABC and nodFEL operons are involved in the production of lipooligosaccharide signals, which mediate host specificity. A nodE-determined highly unsaturated C18.4 fatty acid (trans-2,trans-4,trans-6,cis-11-octadecatetraenoic acid) is essential for the ability of the signals to induce nodule primordia (Spaink, H. P., Sheeley, D. M., van Brussel, A. A. N., Glushka, J., York, W. S., Tak, T., Geiger, O., Kennedy, E. P., Reinhold, V. N., and Lugtenberg, B. J. J. (1991) Nature 354, 125-130) and preinfection thread structures (van Brussel, A. A. N., Bakhuizen, R., van Spronsen, P. C., Spaink, H. P., Tak, T., Lugtenberg, B. J. J., and Kijne, J. W. (1992) Science 257, 70-72) on the host plant Vicia sativa. We presently focus on the question of how these lipooligosaccharide signals are synthesized in Rhizobium. Here we show that after the induction of the nodFE genes, even in the absence of the nodABC genes, the trans-2,trans-4,trans-6,cis-11-octadecatetraenoic acid, which has a characteristic absorbance maximum of 303 nm, is synthesized; this shows that the biosynthesis of the unusual fatty acid is not dependent on the synthesis of the lipooligosaccharides. This finding also suggests that the biosynthesis of the unusual fatty acid is completed before it is linked to the sugar backbone of the lipooligosaccharide. In an attempt to identify the lipid fraction with which the unusual C18:4 fatty acid is associated, we found that it is linked to the sn-2 position of the phospholipids. Even when lipooligosaccharide signals are produced in a wild type Rhizobium cell, a fraction of the unusual fatty acid is still bound to all major phospholipids. These findings offer interesting possibilities. 1) The phospholipids might be biosynthetic intermediates for the synthesis of lipooligosaccharide signals, and 2) phospholipids, containing nodFE-derived fatty acids, might have a signal function of their own.	LEIDEN UNIV, INST MOLEC PLANT SCI, 2333 AL LEIDEN, NETHERLANDS; UNIV UTRECHT, DEPT MASS SPECTROMETRY, 3508 TB UTRECHT, NETHERLANDS; COMPLEX CARBOHYDRATE RES CTR, ATHENS, GREECE	Leiden University; Leiden University - Excl LUMC; Utrecht University			Spaink, Herman P./S-3586-2017; Geiger, Otto/F-6356-2019	Spaink, Herman P./0000-0003-4128-9501; Geiger, Otto/0000-0002-7794-1568				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; COLE MJ, 1991, ANAL CHEM, V63, P1032, DOI 10.1021/ac00010a020; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; FUKUDA MN, 1985, J BIOL CHEM, V260, P1067; GEIGER O, 1991, J BACTERIOL, V173, P3021, DOI 10.1128/JB.173.9.3021-3024.1991; GEIGER O, 1991, J BACTERIOL, V173, P2872, DOI 10.1128/JB.173.9.2872-2878.1991; GUPTA SD, 1991, J BIOL CHEM, V266, P9983; HOLLINGSWORTH RI, 1989, J BIOL CHEM, V264, P9300; HOOYKAAS PJJ, 1981, NATURE, V291, P351, DOI 10.1038/291351a0; HUANG ZH, 1992, J AM SOC MASS SPECTR, V3, P71, DOI 10.1016/1044-0305(92)85020-K; HUBAC C, 1992, J GEN MICROBIOL, V138, P1973, DOI 10.1099/00221287-138-9-1973; JACKOWSKI S, 1986, J BIOL CHEM, V261, P1328; JENSEN NJ, 1986, LIPIDS, V21, P580, DOI 10.1007/BF02534056; JOSEY DP, 1979, J APPL BACTERIOL, V46, P343, DOI 10.1111/j.1365-2672.1979.tb00830.x; Kates M., 1986, TECHNIQUES LIPIDOLOG; KENNEDY EP, 1987, ESCHERICHIA COLI SAL, P672; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MILLER KJ, 1988, J BACTERIOL, V170, P4569, DOI 10.1128/jb.170.10.4569-4575.1988; PATTON GM, 1990, METHOD ENZYMOL, V187, P195; PATTON GM, 1982, J LIPID RES, V23, P190; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; ROCK CO, 1982, J BIOL CHEM, V257, P10759; SHEARMAN CA, 1986, EMBO J, V5, P647, DOI 10.1002/j.1460-2075.1986.tb04262.x; SPAINK HP, 1989, EMBO J, V8, P2811, DOI 10.1002/j.1460-2075.1989.tb08427.x; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; SPAINK HP, 1987, NATURE, V328, P337, DOI 10.1038/328337a0; SPAINK HP, 1989, PLANT MOL BIOL, V12, P59, DOI 10.1007/BF00017448; SPAINK HP, 1987, PLANT MOL BIOL, V9, P27, DOI 10.1007/BF00017984; SPAINK HP, 1993, CURR PLANT SCI BIOT, V14, P151; THOMPSON EA, 1983, LIPIDS, V18, P602, DOI 10.1007/BF02534669; VANBRUSSEL AAN, 1992, SCIENCE, V257, P70, DOI 10.1126/science.257.5066.70; VANBRUSSEL AAN, 1977, J GEN MICROBIOL, V101, P51, DOI 10.1099/00221287-101-1-51; ZAAT SAJ, 1987, J BACTERIOL, V169, P198, DOI 10.1128/jb.169.1.198-204.1987	33	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11090	11097						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157634				2022-12-25	WOS:A1994NF96600021
J	KRAMER, W; WESS, G; NECKERMANN, G; SCHUBERT, G; FINK, J; GIRBIG, F; GUTJAHR, U; KOWALEWSKI, S; BARINGHAUS, KH; BOGER, G; ENHSEN, A; FALK, E; FRIEDRICH, M; GLOMBIK, H; HOFFMANN, A; PITTIUS, C; URMANN, M				KRAMER, W; WESS, G; NECKERMANN, G; SCHUBERT, G; FINK, J; GIRBIG, F; GUTJAHR, U; KOWALEWSKI, S; BARINGHAUS, KH; BOGER, G; ENHSEN, A; FALK, E; FRIEDRICH, M; GLOMBIK, H; HOFFMANN, A; PITTIUS, C; URMANN, M			INTESTINAL-ABSORPTION OF PEPTIDES BY COUPLING TO BILE-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; RAT SMALL-INTESTINE; SALT-BINDING POLYPEPTIDES; TRANSPORT-SYSTEM; VESICLES; PROTEIN; INSULIN; IDENTIFICATION; CHARGE	Poor intestinal absorption of peptides greatly limits their use as drugs for the treatment of chronic diseases. Since bile acids are efficiently absorbed by an active, Na+-dependent transport system in the ileum of mammals, model peptides of different chain length were attached to the 3-position of modified 3 beta-(omega-amino-alkoxy)-7 alpha,12 alpha-dihydroxy-5 beta-cholan-24-oic acid. These peptide-bile acid conjugates inhibited Na+-dependent [H-3]taurocholate uptake into brush-border membrane vesicles isolated from rabbit ileum in a concentration-dependent manner. Furthermore, photoaffinity labeling of the bile acid-binding proteins of M(r) 93,000 and 14,000, identified as the protein components of the ileal Na+-dependent bile acid transport system in rabbit ileum (Kramer, W., Girbig, F., Gutjahr, U., Kowalewski, S., Jouvenal, K., Muller, G., Tripler D., and Wess, G. (1993) J. Biol. Chem. 268, 18035-18046) by the photoreactive taurocholate analogue, (3,3-azo-7 alpha,12 alpha-dihydroxy-5 beta[7 beta,-12 beta-H-3]cholan-24-oyl)-2-aminoethanesulfonic acid, was inhibited by the peptide-bile acid conjugates. In contrast, the parent peptides and amino acids neither had a significant effect on [H-3]taurocholate uptake by ileal brush-border membrane vesicles nor on photoaffinity labeling of the ileal bile acid-binding membrane proteins. The inhibitory effect of peptide-bile acid conjugates on [H-3]taurocholate transport and photoaffinity labeling of the bile acid-binding proteins in rabbit ileal vesicles decreased with increasing chain length of the attached peptide radical. By in vivo ileum perfusion in anesthetized rats an intestinal absorption of the bile acid conjugate S3744 of the fluorescent oxaprolylpeptide 4-nitrobenzo-2-ora-1,3-diazol-beta-Ala-Phe-5-Opr-Gly (S1037) and secretion of the intact compound into bile could be demonstrated, whereas the parent peptide S1037 or its t-butylester S4404 were not absorbed. The intestinal absorption of S3744 showed a similar temperature dependence as [H-3]taurocholate absorption and was inhibited by the presence of taurocholate indicating a carrier-mediated uptake of S3744 via the ileal bile acid transporter. In conclusion, these results indicate that oligopeptides can be made enterally absorbable by coupling to modified bile acid molecules making use of the specific intestinal absorption pathway for bile acids. This finding may be of great importance for the design and development of orally active peptide drugs.			KRAMER, W (corresponding author), HOECHST AG, SBU METAB, D-65926 FRANKFURT, GERMANY.							ALDINI R, 1982, J LIPID RES, V23, P1167; ANWER MS, 1985, AM J PHYSIOL, V249, pG479, DOI 10.1152/ajpgi.1985.249.4.G479; Atherton E., 1987, PEPTIDES ANAL SYNTHE, V9, P1; Bergmann M, 1932, BER DTSCH CHEM GES, V65, P1192, DOI 10.1002/cber.19320650722; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND E, 1952, J AM CHEM SOC, V74, P1849, DOI 10.1021/ja01127a505; BURCKHARDT G, 1983, J BIOL CHEM, V258, P3618; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; FUJII S, 1985, J PHARM PHARMACOL, V37, P545, DOI 10.1111/j.2042-7158.1985.tb03064.x; HARDISON WGM, 1991, HEPATOLOGY, V13, P68, DOI 10.1002/hep.1840130111; HO NFH, 1987, ANN NY ACAD SCI, V507, P315, DOI 10.1111/j.1749-6632.1987.tb45811.x; HOLMES CP, 1993, PERSPECTIVES MED CHE, P489; HOPFER U, 1973, J BIOL CHEM, V248, P25; HOUBENWEYL, 1974, METHODEN ORGANISCHEN, V15; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KRAMER W, 1992, J BIOL CHEM, V267, P18598; KRAMER W, 1982, EUR J BIOCHEM, V129, P13, DOI 10.1111/j.1432-1033.1982.tb07015.x; KRAMER W, 1993, FALK SYMP, V68, P161; KRAMER W, 1992, BIOCHIM BIOPHYS ACTA, V1111, P93, DOI 10.1016/0005-2736(92)90278-T; KRAMER W, 1993, J BIOL CHEM, V268, P18035; KRAMER W, 1990, J CHROMATOGR, V521, P199, DOI 10.1016/0021-9673(90)85044-V; KRAMER W, 1987, BIOCHIM BIOPHYS ACTA, V905, P65, DOI 10.1016/0005-2736(87)90009-5; KRAMER W, 1988, BIOCHEM PHARMACOL, V37, P2427, DOI 10.1016/0006-2952(88)90370-X; KRAMER W, 1989, J LIPID RES, V30, P1281; KRAMER W, 1983, J LIPID RES, V24, P910; KRAMER W, 1983, J BIOL CHEM, V258, P3623; KRAMER W, 1980, H-S Z PHYSIOL CHEM, V361, P1307; KRAMER W, 1979, EUR J BIOCHEM, V102, P1, DOI 10.1111/j.1432-1033.1979.tb06257.x; KRAMER W, 1981, IDENTIFIZIERUNG GALL, P1; KRAMER W, 1993, HEPATOLOGY, V18, P299; KRCHNAK V, 1988, COLLECT CZECH CHEM C, V53, P2542, DOI 10.1135/cccc19882542; LACK L, 1967, BIOCHIM BIOPHYS ACTA, V135, P1065, DOI 10.1016/0005-2736(67)90078-8; LACK L, 1979, ENVIRON HEALTH PERSP, V33, P79, DOI 10.2307/3429075; LEE V H L, 1989, Advanced Drug Delivery Reviews, V4, P171, DOI 10.1016/0169-409X(89)90018-5; LEE VHL, 1988, CRIT REV THER DRUG, V5, P69; LIN MC, 1988, J MEMBRANE BIOL, V106, P1, DOI 10.1007/BF01871762; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; Matthews DM, 1991, PROTEIN ABSORPTION D; MERGLER M, 1988, TETRAHEDRON LETT, V29, P4005, DOI 10.1016/S0040-4039(00)80405-0; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MERRIFIELD RB, 1988, ANAL BIOCHEM, V174, P399, DOI 10.1016/0003-2697(88)90039-5; Russell-Jones G.J., 1988, P INT S CONTROLLED R, V15, P142; SAFFRAN M, 1986, SCIENCE, V233, P1081, DOI 10.1126/science.3526553; SCHMASSMANN A, 1990, GASTROENTEROLOGY, V99, P1092, DOI 10.1016/0016-5085(90)90630-J; SCHWARZ LR, 1975, EUR J BIOCHEM, V55, P617, DOI 10.1111/j.1432-1033.1975.tb02199.x; SMITH PL, 1992, ADV DRUG DELIVER REV, V8, P253, DOI 10.1016/0169-409X(92)90005-B; STEPHAN ZF, 1992, BIOCHEM PHARMACOL, V43, P1969, DOI 10.1016/0006-2952(92)90640-5; VLAHCEVIC ZR, 1990, HEPATOLOGY TXB LIVER, P341; WESS G, 1993, TETRAHEDRON LETT, V34, P817, DOI 10.1016/0040-4039(93)89020-Q; WESS G, 1992, TETRAHEDRON LETT, V33, P195, DOI 10.1016/0040-4039(92)88048-A; WESS G, 1993, TETRAHEDRON LETT, V34, P819, DOI 10.1016/0040-4039(93)89021-H; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILSON FA, 1981, AM J PHYSIOL, V241, pG83, DOI 10.1152/ajpgi.1981.241.2.G83; ZIV E, 1981, LIFE SCI, V29, P803, DOI 10.1016/0024-3205(81)90036-9; [No title captured]	55	81	102	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10621	10627						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144651				2022-12-25	WOS:A1994NF01700066
J	NISHIKI, T; KAMATA, Y; NEMOTO, Y; OMORI, A; ITO, T; TAKAHASHI, M; KOZAKI, S				NISHIKI, T; KAMATA, Y; NEMOTO, Y; OMORI, A; ITO, T; TAKAHASHI, M; KOZAKI, S			IDENTIFICATION OF PROTEIN-RECEPTOR FOR CLOSTRIDIUM-BOTULINUM TYPE-B NEUROTOXIN IN RAT-BRAIN SYNAPTOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE FATTY-ACIDS; TETANUS TOXIN; BINDING; GANGLIOSIDES; PURIFICATION; QUANTITIES; MEMBRANES; CLEAVAGE; CALCIUM	The protein receptor for Clostridium botulinum type B neurotoxin was purified 340-fold from rat synaptosomes by successive chromatography on DEAE-Sepharose, phenyl-Toyopearl, and heparin-Toyopearl columns. I-125-Labeled neurotoxin bound to lipid vesicles containing the protein receptor and ganglioside G(T1b) or G(D1a). The reconstituted receptor showed the same affinities as the native receptor on synaptosomes. Chemical crosslinking of I-125-toxin to the receptor in the presence of gangliosides resulted in formation of a cross-linked product of 161 kDa under reducing conditions. Crosslinking was specific, as it was inhibited by the presence of excess unlabeled toxin. A monoclonal antibody against the purified 58-kDa receptor protein and a monoclonal antibody against the heavy chain (103 kDa) of the neurotoxin reacted with the cross-linked product of 161 kDa in immunoblotting experiments. We determined partial amino acid sequences of the 58-kDa protein, which were identical to synaptotagmin, a synaptic vesicle membrane protein. In addition, the monoclonal antibody against the 58-kDa receptor protein recognized recombinant rat synaptotagmin. These results suggest that synaptotagmin in association with ganglioside G(T1b) or G(D1a)receptor for C. botulinum type B neurotoxin at the nerve terminals.	UNIV OSAKA PREFECTURE,COLL AGR,DEPT VET SCI,SAKAI,OSAKA 593,JAPAN; MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN	Osaka Metropolitan University								BAKRY N, 1991, J PHARMACOL EXP THER, V258, P830; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; EVANS DM, 1986, EUR J BIOCHEM, V154, P409, DOI 10.1111/j.1432-1033.1986.tb09413.x; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; HIGASHI H, 1992, J BIOL CHEM, V267, P9831; HUTTNER WB, 1993, NATURE, V365, P104, DOI 10.1038/365104a0; IKEDA S, 1991, EUR J PHARM-MOLEC PH, V208, P199, DOI 10.1016/0922-4106(91)90096-Z; IWAMORI M, 1978, BIOCHIM BIOPHYS ACTA, V528, P257; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; KITAMURA M, 1980, BIOCHIM BIOPHYS ACTA, V628, P328, DOI 10.1016/0304-4165(80)90382-7; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOZAKI S, 1987, INFECT IMMUN, V55, P3051, DOI 10.1128/IAI.55.12.3051-3056.1987; KOZAKI S, 1984, FEMS MICROBIOL LETT, V21, P219; KOZAKI S, 1979, N-S ARCH PHARMACOL, V308, P67, DOI 10.1007/BF00499721; KOZAKI S, 1977, INFECT IMMUN, V18, P761, DOI 10.1128/IAI.18.3.761-766.1977; KOZAKI S, 1974, INFECT IMMUN, V10, P750, DOI 10.1128/IAI.10.4.750-756.1974; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; OGASAWARA J, 1991, FEMS MICROBIOL LETT, V79, P351, DOI 10.1111/j.1574-6968.1991.tb04554.x; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; REVERCHON S, 1987, GENE, V55, P125, DOI 10.1016/0378-1119(87)90255-1; Sakagichi G, 1983, PHARMACOL THERAPEUT, V19, P165; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1992, J BIOL CHEM, V267, P23479; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SCHNEIDER WJ, 1980, J BIOL CHEM, V255, P11142; Simpson L.L., 1989, BOTULINUM NEUROTOXIN; SIMPSON LL, 1971, J NEUROCHEM, V18, P1751, DOI 10.1111/j.1471-4159.1971.tb03750.x; SIMPSON LL, 1986, ANNU REV PHARMACOL, V26, P427, DOI 10.1146/annurev.pa.26.040186.002235; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUGIYAMA H, 1980, MICROBIOL REV, V44, P419, DOI 10.1128/MMBR.44.3.419-448.1980; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TAKAMIZAWA K, 1986, FEBS LETT, V201, P229, DOI 10.1016/0014-5793(86)80614-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WADSWORTH JDF, 1990, BIOCHEM J, V268, P123, DOI 10.1042/bj2680123; WHITTAKER VP, 1959, BIOCHEM J, V72, P694, DOI 10.1042/bj0720694; [No title captured]	42	263	292	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10498	10503						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144634				2022-12-25	WOS:A1994NF01700048
J	SUZUKI, M; IZUTA, S; YOSHIDA, S				SUZUKI, M; IZUTA, S; YOSHIDA, S			DNA-POLYMERASE-ALPHA OVERCOMES AN ERROR-PRONE PAUSE SITE IN THE PRESENCE OF REPLICATION PROTEIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SINGLE-STRANDED-DNA; DROSOPHILA-MELANOGASTER; BINDING-PROTEIN; INVITRO; FIDELITY; PRIMASE; INITIATION; IDENTIFICATION; MUTAGENESIS; SPECIFICITY	Eukaryotic DNA polymerase alpha pauses at some sites on the natural DNA template of M13mp2. Terminal misincorporations of dA or dG, in place of dT, by DNA polymerase alpha have been reported to be within one of the pause sites, pause site II (positions 6269 and 6270 (Fry, M., and Loeb, L.A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 763-767)). The DNA products arrested within pause site II (position 6270) were separated, annealed with synthetic templates, and further elongated by DNA polymerase alpha. It was confirmed that a considerable amount of terminal misincorporation of dG in place of dT occurred at this position. When M13mp2 DNA was coated with various amounts of replication protein-A (RP-A), however, DNA polymerase alpha was able to overcome the pause site II, whereas pause bands at other sites barely decreased. In contrast, Escherichia coli single-stranded DNA-binding protein did not specifically abolish the arrested band at pause site II, though it generally suppressed the reaction. Since RP-A hardly increased the elongation frequency from the primer carrying a 3'-mismatched terminal deoxynucleotide, the reduction of arrested products by RP-A may be attributed to the change in the incorporation mode from noncomplementary to complementary deoxynucleotides within pause site II and may not be due to the reinitiation from the mismatched 3'-terminal deoxynucleotide. To confirm this, we amplified the reaction products at pause site III by means of a polymerase chain reaction method and showed that the complementary strand to pause site II, which was elongated in the presence of RP-A, did not carry any detectable misinsertion. Therefore, the error-prone step of the DNA synthesis catalyzed by DNA polymerase a may be readily avoided by RP-A.	NAGOYA UNIV,SCH MED,DIS MECHANISM & CONTROL RES INST,CANC CELL BIOL LAB,SHOWA KU,NAGOYA 466,JAPAN	Nagoya University			Suzuki, Motoshi/I-7246-2014	Suzuki, Motoshi/0000-0003-0682-5006				ABBOTTS J, 1988, J BIOL CHEM, V263, P15094; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; CARTY MP, 1992, MUTAT RES, V274, P29, DOI 10.1016/0921-8777(92)90041-Z; COTTERILL SM, 1987, P NATL ACAD SCI USA, V84, P5635, DOI 10.1073/pnas.84.16.5635; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; FAIRMAN M, 1988, BIOCHIM BIOPHYS ACTA, V951, P382, DOI 10.1016/0167-4781(88)90110-8; FAY PJ, 1982, J BIOL CHEM, V257, P5692; FRY M, 1992, P NATL ACAD SCI USA, V89, P763, DOI 10.1073/pnas.89.2.763; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HILLEBRAND GG, 1985, J BIOL CHEM, V260, P3116; HOFFMANN JS, 1993, CANCER RES, V53, P2895; HOPFIELD JJ, 1980, P NATL ACAD SCI-BIOL, V77, P5248, DOI 10.1073/pnas.77.9.5248; KAGUNI LS, 1982, P NATL ACAD SCI-BIOL, V79, P983, DOI 10.1073/pnas.79.4.983; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; LOEB LA, 1986, PROG NUCLEIC ACID RE, V33, P57, DOI 10.1016/S0079-6603(08)60020-3; LOEB LA, 1982, ANNU REV BIOCHEM, V52, P429; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; REYLAND ME, 1987, J BIOL CHEM, V262, P10824; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAAPER RM, 1988, P NATL ACAD SCI USA, V85, P8126, DOI 10.1073/pnas.85.21.8126; SUZUKI M, 1993, BIOCHEM MOL BIOL INT, V29, P645; TAMAI K, 1988, BIOCHIM BIOPHYS ACTA, V950, P263, DOI 10.1016/0167-4781(88)90122-4; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; WATSON JD, 1987, MOL BIOL GENE, pCH12; WEAVER DT, 1982, J BIOL CHEM, V257, P2075; WEISMANSHOMER P, 1989, BIOCHEM BIOPH RES CO, V164, P1149, DOI 10.1016/0006-291X(89)91789-0; WOLD MS, 1989, J BIOL CHEM, V264, P2801	33	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10225	10228						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144602				2022-12-25	WOS:A1994NF01700011
J	BEELMAN, CA; PARKER, R				BEELMAN, CA; PARKER, R			DIFFERENTIAL-EFFECTS OF TRANSLATIONAL INHIBITION IN CIS AND IN TRANS ON THE DECAY OF THE UNSTABLE YEAST MFA2 MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INHIBITORS; SACCHAROMYCES-CEREVISIAE; POLY(A) TAIL; INITIATION; ACID; DEGRADATION; INSTABILITY; STABILITY; REGION; GROWTH	Several observations in eukaryotic cells suggest that the processes of translation and mRNA turnover are interrelated. To understand this relationship, we examined the effects of translational inhibition on the decay of the unstable yeast MFA2 mRNA, which is degraded in a 5' to 3' direction following deadenylation (1). Although inhibition of translation in cis stabilizes several unstable mammalian transcripts, inhibiting translation of the MFA2 mRNA in cis, by the insertion of a large stem-loop structure in the 5'-untranslated region (UTR), did not affect the half-life, deadenylation rate, or appearance of specific decay intermediates. Therefore, efficient translational elongation on the MFA2 mRNA is not a requirement for the normal rate, or mechanism, of degradation of this transcript. In contrast, inhibition of translation in trans, by the addition of cycloheximide, stabilized the deadenylated form of MFA2 mRNA. Furthermore, the MFA2 transcripts that were not translated due to a stem-loop in the 5'-UTR were also stabilized in the presence of cycloheximide, suggesting that cycloheximide is likely to affect mRNA stability indirectly. These results suggest possible relationships between the mechanisms of mRNA decay and the translational process.	UNIV ARIZONA,DEPT MOLEC & CELLULAR BIOL,TUCSON,AZ 85721	University of Arizona					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045443, R37GM045443] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45443] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; BAIM SB, 1988, MOL CELL BIOL, V8, P1591, DOI 10.1128/MCB.8.4.1591; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CAPONIGRO G, 1993, MOL CELL BIOL, V13, P5141, DOI 10.1128/MCB.13.9.5141; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; CIGAN AM, 1988, MOL CELL BIOL, V8, P2964, DOI 10.1128/MCB.8.7.2964; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; FELICI F, 1989, MOL CELL BIOL, V9, P3260, DOI 10.1128/MCB.9.8.3260; GALLIE DR, 1990, GENE DEV, V4, P1149, DOI 10.1101/gad.4.7.1149; GRAFI G, 1993, MOL CELL BIOL, V13, P3487, DOI 10.1128/MCB.13.6.3487; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LAIRDOFFRINGA IA, 1990, MOL CELL BIOL, V10, P6132, DOI 10.1128/MCB.10.12.6132; LASO MRV, 1993, J BIOL CHEM, V268, P6453; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; PELTZ SW, 1992, MOL CELL BIOL, V12, P5778, DOI 10.1128/MCB.12.12.5778; PELTZ SW, 1993, CONTROL MESSENGER RN, P318; PLATT T, 1972, EXPT MOL GENETICS, P352; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SAPPRSTEIN S, 1994, MOL CELL BIOL, V2, P1438; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; WELLINGTON CL, 1993, MOL CELL BIOL, V13, P5034, DOI 10.1128/MCB.13.8.5034; WISDOM R, 1990, J BIOL CHEM, V265, P19015; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; ZUCKER M, 1981, NUCLEIC ACIDS RES, V9, P133	37	141	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9687	9692						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144558				2022-12-25	WOS:A1994NE05300047
J	CIECHANOVER, A; SHKEDY, D; OREN, M; BERCOVICH, B				CIECHANOVER, A; SHKEDY, D; OREN, M; BERCOVICH, B			DEGRADATION OF THE TUMOR-SUPPRESSOR PROTEIN-P53 BY THE UBIQUITIN-MEDIATED PROTEOLYTIC SYSTEM REQUIRES A NOVEL SPECIES OF UBIQUITIN-CARRIER PROTEIN, E2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; N-END RULE; CONJUGATING ENZYME; E6 ONCOPROTEIN; P53; MUTANT; LIGASE; TRANSFORMATION; PURIFICATION; ASSOCIATION	The tumor suppressor protein p53 is extremely unstable in most cell lines. In contrast, many mutant and oncogenic species of the protein are stable. The degradation of p53 in vivo requires metabolic energy; however, the proteolytic system(s) involved have not been identified. The ubiquitin system has been implicated in the degradation of p53 in vitro. The degradation is stimulated significantly by the human papillomavirus (HPV) oncoprotein E6 that associates with p53 and facilitates conjugate formation and subsequent degradation. Complex formation between E6 and p53 is promoted by a cellular protein designated E6-associated protein (E6-AP). Initial dissection of the conjugation process have demonstrated a role for the ubiquitin-activating enzyme, E1, but the ubiquitin-carrier protein (E2, UBC) and the ubiquitin protein ligase, E3, have not been identified. In this study, we report that a novel species of ubiquitin-carrier protein designated E2-F1 (Blumenfeld, N., Gonen, H., Mayer, A., Smith, C., Siegel, N. R., Schwartz, A. L., and Ciechanover, A. (1994) J. Biol. Chem. 269,9574-9581) is involved in the conjugation and degradation of p53. This E2 enzyme recognizes non-''N-end rule'' protein substrates and appears to mediate their conjugation via a novel species of E3. The process of recognition appears to be selective; E2-F1 is not required for the conjugation and degradation of human N-myc. The involvement of E2-F1 in the in vitro process appears to be physiologically meaningful and to reproduce the in vivo process; mutant species of p53 that do not interact with E6 and are stable in vivo are not recognized by the cell free system.	TECHNION ISRAEL INST TECHNOL,FAC MED,RAPPAPORT INST RES MED SCI,IL-31096 HAIFA,ISRAEL; WEIZMANN INST SCI,DEPT IMMUNOL CHEM,IL-76100 REHOVOT,ISRAEL	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Weizmann Institute of Science	CIECHANOVER, A (corresponding author), TECHNION ISRAEL INST TECHNOL,FAC MED,DEPT BIOCHEM,POB 9649,IL-31096 HAIFA,ISRAEL.		Ciechanover, Aaron J/C-9166-2017					BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; BOISSEL JP, 1988, J BIOL CHEM, V263, P8443; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; ELIYAHU D, 1988, ONCOGENE, V3, P313; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GONEN H, 1991, J BIOL CHEM, V266, P19221; GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HELLER H, 1990, J BIOL CHEM, V265, P6532; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSTON NL, 1991, BIOCHEMISTRY-US, V30, P7514, DOI 10.1021/bi00244a021; KULKA RG, 1988, J BIOL CHEM, V263, P15726; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; REISS Y, 1988, J BIOL CHEM, V263, P2693; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J, 1989, MOL CLONING LABORATO; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; SHANKLIN J, 1987, P NATL ACAD SCI USA, V84, P359, DOI 10.1073/pnas.84.2.359; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; SUNG P, 1991, EMBO J, V10, P2187, DOI 10.1002/j.1460-2075.1991.tb07754.x; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	38	96	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9582	9589						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144545				2022-12-25	WOS:A1994NE05300031
J	FINGAR, DC; BIRNBAUM, MJ				FINGAR, DC; BIRNBAUM, MJ			A ROLE FOR RAF-1 IN THE DIVERGENT SIGNALING PATHWAYS MEDIATING INSULIN-STIMULATED GLUCOSE-TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; 3T3-L1 ADIPOCYTES; MAP KINASE; C-FOS; DIFFERENTIAL REGULATION; MOLECULAR MECHANISM; GENE-EXPRESSION; SKELETAL-MUSCLE; ADIPOSE-CELLS; PHORBOL ESTER	Downstream mediators of insulin signaling are thought to include multiple cytoplasmic serine/threonine kinases such as the product of the cellular proto-oncogene c-raf-1. To investigate a role for the Raf-1 protein kinase in insulin-stimulated glucose transport, a gene encoding an oncogenically activated Raf-1 mutant was introduced into 3T3-L1 fibroblasts by retroviral gene transfer. Expression of activated Raf-1 in differentiated 3T3-L1 adipocytes markedly increases hexose uptake compared to control adipocytes or those infected with the retroviral vector. Basal 2-deoxyglucose uptake in adipocytes expressing activated Raf-1 is approximately 40-fold higher than in parental adipocytes, and insulin further increases uptake about 1.2-fold. As determined by the plasma membrane ''sheet'' assay, Raf-1-expressing adipocytes contain greatly elevated levels of the ubiquitous glucose transporter (GLUT1) on the cell surface in the absence or presence of insulin. Total cellular GLUT1 protein is increased about 5-fold. In contrast, activated Raf-1 affects neither the expression of the ''insulin-responsive'' glucose transporter (GLUT4) nor its cellular distribution; GLUT4 is virtually undetectable on the plasma membrane in the absence of insulin and translocates normally following the addition of hormone. These data suggest that activation of Raf-1 mediates the chronic effect of insulin on hexose uptake but is not sufficient for the rapid translocation of GLUT4. Moreover, the differential effects of activated Raf-1 expression on the two transporter isoforms define divergent signaling pathways by which insulin regulates glucose transport in cultured adipocytes.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM CELL & DEV BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School				Birnbaum, Morris/0000-0001-9972-8680	NIDDK NIH HHS [DK39519] Funding Source: Medline; NIGMS NIH HHS [GM07226] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007226] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; DEHERREROS AG, 1989, J BIOL CHEM, V264, P9885; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DICKENS M, 1992, BIOCHEM J, V287, P201, DOI 10.1042/bj2870201; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FINGAR DC, 1994, IN PRESS ENDOCRINOLO; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HAINQUE B, 1990, J BIOL CHEM, V265, P7982; HASPEL HC, 1985, J BIOL CHEM, V260, P7219; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUDSON AW, 1992, J CELL BIOL, V116, P785, DOI 10.1083/jcb.116.3.785; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LENORMAND P, 1993, J CELL BIOL, V122, P107; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; NISHIMURA H, 1993, J BIOL CHEM, V268, P8514; OSTEROP APR, 1992, J BIOL CHEM, V267, P1464; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; TABARINI D, 1985, P NATL ACAD SCI USA, V82, P4369, DOI 10.1073/pnas.82.13.4369; TOBE K, 1992, J BIOL CHEM, V267, P21089; TORDJMAN KM, 1990, BIOCHEM J, V271, P201, DOI 10.1042/bj2710201; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	58	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					10127	10132						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144513				2022-12-25	WOS:A1994NE05300109
J	PASTOR, R; BERNAL, J; RODRIGUEZPENA, A				PASTOR, R; BERNAL, J; RODRIGUEZPENA, A			UNLIGANDED C-ERBA THYROID-HORMONE RECEPTOR INDUCES TRKB EXPRESSION IN NEUROBLASTOMA-CELLS	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; THYROID-HORMONE; NEUROTROPHIC FACTOR; 3,5,3'-TRIIODOTHYRONINE RECEPTOR; MORPHOLOGICAL-DIFFERENTIATION; BRAIN-DEVELOPMENT; RETINOIC ACID; GENE ENCODES; PC12 CELLS	Neurotrophins are responsible for the differentiation and survival of neurons in the developing and in the adult nervous system. They bind to specific membrane receptors with tyrosine kinase activity whose prototype is the product of the trkA proto-oncogene. TrkB, a member of this family, is the receptor for the neurotrophins brain derived growth factor (BDNF) and neurotrophins-3, 4/5. In this study, we show that stable expression of the c-erbA proto-oncogene, which encodes the alpha1-isoform of the nuclear receptor for thyroid hormone (Tralpha1) induces the expression of trkB mRNA with a concomitant decrease to undetectable levels of trkA and trkC mRNAs in the mouse neuroblastoma N2a cell line. trkB induction by c-erbA is ligand independent, since addition of T3 had no effect. The induced trkB transcript encodes a functional gp145trkB protein, which is phosphorylated on tyrosine in response to BDNF. Furthermore, induction of trkB mRNA is also caused by transient expression of either TR alpha1 or beta1 isoforms. Our results are compatible with the idea that there are certain pathways which are under control of unliganded thyroid hormone receptor, and that one of these pathways results in regulation of trk expression.	UNIV AUTONOMA MADRID,FAC MED,CONSEJO SUPER INVEST CIENTIFICAS,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Bernal, Juan/J-6086-2014	Bernal, Juan/0000-0002-5867-4951; Rodriguez-Pena, Angeles/0000-0002-2515-4626				ALTIN JG, 1992, NEUROTROPHIC FACTORS, P129; BARBACID M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P115, DOI 10.1016/0304-419X(91)90010-I; Barbacid Mariano, 1993, P123; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BERNAL J, 1984, ENDOCRINOLOGY, V114, P677, DOI 10.1210/endo-114-2-677; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Clos J, 1990, GROWTH FACTORS, V3, P205, DOI 10.3109/08977199009043905; COLLAZO D, 1992, NEURON, V9, P643, DOI 10.1016/0896-6273(92)90028-C; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DIAZNIDO J, 1988, J CELL BIOL, V106, P2057, DOI 10.1083/jcb.106.6.2057; DUSSAULT JH, 1987, ANNU REV PHYSIOL, V49, P321, DOI 10.1146/annurev.ph.49.030187.001541; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORREST D, 1991, EMBO J, V10, P269, DOI 10.1002/j.1460-2075.1991.tb07947.x; GLOWACKA D, 1990, J NEUROSCI RES, V25, P453, DOI 10.1002/jnr.490250403; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; KAPLAN DR, 1993, NEURON, V11, P1; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MELLSTROM B, 1991, MOL ENDOCRINOL, V5, P1339, DOI 10.1210/mend-5-9-1339; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MUNOZ A, 1990, MOL ENDOCRINOL, V4, P312, DOI 10.1210/mend-4-2-312; MUNOZ A, 1993, J CELL BIOL, V121, P423, DOI 10.1083/jcb.121.2.423; PATTERSON PH, 1993, NEURON S, V10, P123; PEREZCASTILLO A, 1985, ENDOCRINOLOGY, V117, P2457, DOI 10.1210/endo-117-6-2457; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; Sambrook J, 1989, MOL CLONING LABORATO; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SHEA TB, 1985, DEV BRAIN RES, V21, P307, DOI 10.1016/0165-3806(85)90220-2; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0	45	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1081	1089						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134111				2022-12-25	WOS:A1994NC04800010
J	SANZ, L; BERRA, E; MUNICIO, MM; DOMINGUEZ, I; LOZANO, J; JOHANSEN, T; MOSCAT, J; DIAZMECO, MT				SANZ, L; BERRA, E; MUNICIO, MM; DOMINGUEZ, I; LOZANO, J; JOHANSEN, T; MOSCAT, J; DIAZMECO, MT			ZETA-PKC PLAYS A CRITICAL ROLE DURING STROMELYSIN PROMOTER ACTIVATION BY PLATELET-DERIVED GROWTH-FACTOR THROUGH A NOVEL PALINDROMIC ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HYDROLYZING PHOSPHOLIPASE-C; XENOPUS-LAEVIS OOCYTES; GENE-EXPRESSION; MESSENGER-RNA; PHOSPHATIDYLCHOLINE HYDROLYSIS; TRANSCRIPTIONAL ACTIVATION; MEDIATED HYDROLYSIS; RAT FIBROBLASTS; FOS	Stromelysin is a metalloproteinase with the widest substrate specificity that plays a critical role in the induction of the metastatic phenotype in cancer cells. The mechanisms whereby growth factors and oncogenes control stromelysin expression are beginning to be characterized. We have recently demonstrated that protein kinase C isotypes down-regulatable by chronic exposure to phorbol esters are not involved in stromelysin gene expression in response to platelet-derived growth factor, ras oncogene, and phosphatidylcholine-hydrolyzing phospholipase C. We also identified a region in the stromelysin promoter, distinct from the 12-O-tetradecanoylphorbol-13-acetate-responsive element, responsible for the promoter activity in response to these stimulants. In this paper, we further characterize that promoter fragment and demonstrate that the region encompassing nucleotides -1218 to -1202, including the palindromic sequence ACTAGT, is necessary and sufficient for the control of stromelysin gene expression. The involvement of zeta-protein kinase C but not of c-raf in the stimulation of stromelysin promoter activity in response to platelet-derived growth factor is also demonstrated here. All these data suggest the existence of a bifurcation downstream of ras in the signaling mechanisms leading to stromelysin expression and DNA synthesis.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC SEVERO OCHOA,CANTO BLANCO,E-28049 MADRID,SPAIN; UNIV TROMSO,INST MED BIOL,DEPT BIOCHEM,N-9037 TROMSO,NORWAY	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); UiT The Arctic University of Tromso			Moscat, Jorge/A-7011-2009; Berra, Edurne/F-9692-2011; Lozano, José/C-2760-2014; Johansen, Terje/N-2971-2015	Berra, Edurne/0000-0002-3820-5744; Lozano, José/0000-0002-8187-2833; Johansen, Terje/0000-0003-1451-9578; Diaz-Meco, Maria/0000-0003-0147-0998; /0000-0001-9617-4141				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DEHERREROS AG, 1991, J BIOL CHEM, V266, P6825; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; DIAZMECO MT, 1991, J BIOL CHEM, V266, P22597; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIAZMECO MT, 1992, MOL CELL BIOL, V12, P302, DOI 10.1128/MCB.12.1.302; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; EXTON JH, 1990, J BIOL CHEM, V265, P1; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MURPHY G, 1985, BIOCHIM BIOPHYS ACTA, V831, P49, DOI 10.1016/0167-4838(85)90148-7; OKADA Y, 1986, J BIOL CEHM, V261, P1425; OSTROWSKI LE, 1988, MOL CARCINOGEN, V1, P13, DOI 10.1002/mc.2940010106; OWEN RD, 1990, P NATL ACAD SCI USA, V87, P3866, DOI 10.1073/pnas.87.10.3866; PRICE BD, 1989, J BIOL CHEM, V264, P16638; QUINONES S, 1989, J BIOL CHEM, V264, P8339; SAUS J, 1988, J BIOL CHEM, V263, P6742; SCHMID TM, 1986, J BIOL CHEM, V261, P4184; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843	38	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					10044	10049						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144503				2022-12-25	WOS:A1994NE05300098
J	KONRAD, M; MERZ, WE				KONRAD, M; MERZ, WE			REGULATION OF N-GLYCOSYLATION - LONG-TERM EFFECT OF CYCLIC-AMP MEDIATES ENHANCED SYNTHESIS OF THE DOLICHOL PYROPHOSPHATE CORE OLIGOSACCHARIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; ASPARAGINE-LINKED OLIGOSACCHARIDES; ALPHA-SUBUNIT GENE; ENDOPLASMIC-RETICULUM; BETA-SUBUNIT; RAT-LIVER; PROTEIN GLYCOSYLATION; PHOSPHATE-MANNOSE; DEVELOPMENTAL-CHANGE; SYNTHASE ACTIVITY	The influence of 8-bromo-cAMP on N-glycosylation in JEG-3 choriocarcinoma cells was investigated using the octanoyl-tripeptide (OTP; N-octanoyl-asparagyl-I-125- tyrosyl-threonine amide) as glycosyl acceptor. In cells pretreated with 8-bromo-cAMP (2.5 nM to 1 mM), the amount of glycosylated OTP released into the culture medium was increased up to 35-foId. Under the same conditions, a 23-fold higher quantity of the glycoprotein hormone human chorionic gonadotropin was secreted. Preincubation of 10-90 min with 250 mu M 8-bromo-cAMP caused only a 2-fold increase of the total amount of glycosylated OTP, whereas it was approximately 20-fold higher when the pretreatment was extended to 40 h. This strongly suggests involvement of gene activation rather than cAMP-mediated phosphorylation. The specific activity of the oligosaccharyltransferase, as well as the mRNA levels of ribophorin I and II (presumptive subunits of the enzyme), remained unchanged. In pulse-chase experiments, [H-3]mannose incorporation into dolichol-linked Glc(3)Man(9)(GlcNAc)(2) was up to 20-fold higher in cells pretreated with 8-bromo-cAMP (250 mu M, 40 h). The radioactivity was chased from the lipid-linked oligosaccharide pool and shifted to the glycoprotein fraction 10 times more rapidly in the pretreated cells. The flux of [H-3]mannose through the dolichol phosphate mannose pool was only slightly affected by the 8-bromo-cAMP pretreatment. Our investigations show that the oligosaccharyltransferase activity in JEG-3 cells is not rate-limiting. N-Glycosylation seems to be controlled by the amount of lipid-linked core oligosaccharide. The size of the lipid-linked core oligosaccharide pool, as well as the flux through, is markedly increased by pretreat ment with 8-bromo cAMP.	UNIV HEIDELBERG,DEPT BIOCHEM 2,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg								ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; ALBANESE C, 1991, MOL ENDOCRINOL, V5, P693, DOI 10.1210/mend-5-5-693; BANERJEE DK, 1985, BIOCHEM BIOPH RES CO, V126, P123, DOI 10.1016/0006-291X(85)90580-7; BANERJEE DK, 1987, P NATL ACAD SCI USA, V84, P6389, DOI 10.1073/pnas.84.18.6389; BARINAGA M, 1985, NATURE, V314, P279, DOI 10.1038/314279a0; BEEBE JS, 1989, ENDOCRINOLOGY, V124, P1613, DOI 10.1210/endo-124-4-1613; BERGER P, 1990, J ENDOCRINOL, V125, P301, DOI 10.1677/joe.0.1250301; BLITHE DL, 1990, J BIOL CHEM, V265, P21951; CARSON DD, 1987, BIOCHEMISTRY-US, V26, P1598, DOI 10.1021/bi00380a017; CARSON DD, 1981, J BIOL CHEM, V256, P1552; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DSOUZA C, 1992, ANAL BIOCHEM, V203, P211, DOI 10.1016/0003-2697(92)90305-Q; DUTT A, 1986, ENDOCRINOLOGY, V118, P661, DOI 10.1210/endo-118-2-661; FENSTERMAKER RA, 1989, MOL ENDOCRINOL, V3, P1070, DOI 10.1210/mend-3-7-1070; FENSTERMAKER RA, 1990, MOL ENDOCRINOL, V4, P1480, DOI 10.1210/mend-4-10-1480; FRANC JL, 1984, BIOCHEM BIOPH RES CO, V118, P910, DOI 10.1016/0006-291X(84)91481-5; FREEZE HH, 1990, J CELL BIOCHEM, V43, P27, DOI 10.1002/jcb.240430104; FRIEDMAN G, 1986, BIOCHIM BIOPHYS ACTA, V877, P112, DOI 10.1016/0005-2760(86)90125-6; FUH VL, 1989, MOL ENDOCRINOL, V3, P1148, DOI 10.1210/mend-3-7-1148; HARFORD JB, 1980, BIOCHEM J, V188, P481, DOI 10.1042/bj1880481; HARFORD JB, 1977, BIOCHEM BIOPH RES CO, V76, P1036, DOI 10.1016/0006-291X(77)90960-3; HASHIMOTO S, 1984, P NATL ACAD SCI-BIOL, V81, P6637, DOI 10.1073/pnas.81.21.6637; HILF G, 1989, BIOCHEM BIOPH RES CO, V159, P26, DOI 10.1016/0006-291X(89)92399-1; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUBBARD SC, 1980, J BIOL CHEM, V255, P1782; IUSEM ND, 1984, ENDOCRINOLOGY, V114, P1448, DOI 10.1210/endo-114-4-1448; KEAN EL, 1985, J BIOL CHEM, V260, P2561; KEAN EL, 1982, J BIOL CHEM, V257, P7952; KEAN EL, 1992, BIOCHEM CELL BIOL, V70, P413, DOI 10.1139/o92-064; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOUSVELARI EE, 1983, P NATL ACAD SCI-BIOL, V80, P7146, DOI 10.1073/pnas.80.23.7146; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRMAN M A, 1991, Glycobiology, V1, P553, DOI 10.1093/glycob/1.6.553; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCAS JJ, 1978, BIOCHIM BIOPHYS ACTA, V528, P475, DOI 10.1016/0005-2760(78)90037-1; LUCAS JJ, 1977, J BIOL CHEM, V252, P4330; MARCANTONIO EE, 1984, J CELL BIOL, V99, P2254, DOI 10.1083/jcb.99.6.2254; MARTELL RE, 1990, ENDOCRINOLOGY, V126, P2757, DOI 10.1210/endo-126-5-2757; MATZUK MM, 1989, J BIOL CHEM, V264, P2409; MATZUK MM, 1988, J BIOL CHEM, V263, P17106; MERZ WE, 1988, BIOCHEM BIOPH RES CO, V156, P1271, DOI 10.1016/S0006-291X(88)80770-8; MERZ WE, 1991, GBF MONOG SERIES, V15, P57; MILSTED A, 1987, DNA-J MOLEC CELL BIO, V6, P213, DOI 10.1089/dna.1987.6.213; NIELSEN DA, 1985, J BIOL CHEM, V260, P3585; ODATAMAI S, 1985, J BIOL CHEM, V260, P57; PAN YT, 1990, BIOCHEMISTRY-US, V29, P8077, DOI 10.1021/bi00487a013; Patterson M K Jr, 1979, Methods Enzymol, V58, P141; ROSENWALD AG, 1990, J BIOL CHEM, V265, P14544; SARKAR M, 1984, BIOCHEM J, V219, P429, DOI 10.1042/bj2190429; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; SCHMITT JW, 1979, J BIOL CHEM, V254, P2291; SHARMA C, 1988, BIOCHEM BIOPH RES CO, V155, P615, DOI 10.1016/S0006-291X(88)80539-4; SIBLEY CP, 1991, MOL ENDOCRINOL, V5, P582, DOI 10.1210/mend-5-4-582; STORRING PL, 1980, J ENDOCRINOL, V84, P295, DOI 10.1677/joe.0.0840295; TONG PSL, 1983, EXP CELL RES, V149, P215, DOI 10.1016/0014-4827(83)90393-2; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WIEST DL, 1990, J CELL BIOL, V110, P1501, DOI 10.1083/jcb.110.5.1501; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105	59	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8659	8666						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132594				2022-12-25	WOS:A1994NB41100009
J	SHIH, HM; TOWLE, HC				SHIH, HM; TOWLE, HC			DEFINITION OF THE CARBOHYDRATE RESPONSE ELEMENT OF THE RAT S-14 GENE - CONTEXT OF THE CACGTG MOTIF DETERMINES THE SPECIFICITY OF CARBOHYDRATE REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; TRANSCRIPTION FACTOR BINDS; MAJOR LATE PROMOTER; DNA-BINDING; THYROID-HORMONE; C-FOS; S14 GENE; SACCHAROMYCES-CEREVISIAE; MESSENGER RNAS14; TERNARY COMPLEX	Transcription of the S-14 gene in primary hepatocytes is stimulated in response to increased carbohydrate metabolism. We have demonstrated previously that a 30-base pair (bp) segment of the S-14 gene from -1457 to -1428 is a carbohydrate response element (ChoRE). This element contains a (5')CACGTG motif that is essential for control. DNase I footprinting experiments with liver nuclear extract revealed two factors binding within the S-14 ChoRE. In transient transfection experiments, mutation of the upstream site between -1457 and -1450 did not affect the response to elevated glucose, whereas the downstream 21-bp site between -1448 and -1428 was sufficient to mediate the glucose induction. Electrophoretic mobility shift assays indicated that the hepatic factor binding to this site in vitro is closely related or identical to the major late transcription factor (MLTF). However, replacement of the 21-bp S-14 ChoRE with the authentic MLTF binding site from the adenovirus major late promoter failed to elicit the glucose response. By systematically exchanging bases between the functional S-14 and nonresponsive adenovirus sites, the sequence (5')CACGTGNNNGCC was found to be essential for carbohydrate regulation. A segment containing this specific motif from the rat fatty acid synthase gene, another carbohydrate-responsive gene in hepatocytes, conferred a carbohydrate response when linked to the S-14 promoter. Thus, the context of the CACGTG motif provides the specificity for regulation by carbohydrate metabolism.	UNIV MINNESOTA,INST HUMAN GENET,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities			Shih, Hsiu-Ming/S-7023-2018		NIDDK NIH HHS [DK 26919] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026919] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BRADSHAW MS, 1988, MOL ENDOCRINOL, V2, P1286, DOI 10.1210/mend-2-12-1286; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; FISHER F, 1992, EMBO J, V11, P4103, DOI 10.1002/j.1460-2075.1992.tb05503.x; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JUMP DB, 1990, J BIOL CHEM, V265, P3474; JUMP DB, 1985, ENDOCRINOLOGY, V117, P2259, DOI 10.1210/endo-117-6-2259; JUMP DB, 1984, J BIOL CHEM, V259, P2789; LEGRAVEREND C, 1993, NUCLEIC ACIDS RES, V21, P1735, DOI 10.1093/nar/21.8.1735; LIAW C, 1983, BIOCHEMISTRY-US, V22, P213, DOI 10.1021/bi00270a031; LIU ZR, 1993, J BIOL CHEM, V268, P12787; MARIASH CN, 1981, J CLIN INVEST, V68, P1485, DOI 10.1172/JCI110401; MARIASH CN, 1986, J BIOL CHEM, V261, P9583; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHIH HM, 1992, J BIOL CHEM, V267, P13222; Sirito Mario, 1992, Gene Expression, V2, P231; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1986, J BIOL CHEM, V261, P7621; VAULONT S, 1989, MOL CELL BIOL, V9, P4409, DOI 10.1128/MCB.9.10.4409; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505	45	110	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9380	9387						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132677				2022-12-25	WOS:A1994NB41100110
J	PRITCHARD, KA; OBANION, MK; MIANO, JM; VLASIC, N; BHATIA, UG; YOUNG, DA; STEMERMAN, MB				PRITCHARD, KA; OBANION, MK; MIANO, JM; VLASIC, N; BHATIA, UG; YOUNG, DA; STEMERMAN, MB			INDUCTION OF CYCLOOXYGENASE-2 IN RAT VASCULAR SMOOTH-MUSCLE CELLS IN-VITRO AND IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-H SYNTHASE; HUMAN-ENDOTHELIAL-CELLS; ANGIOTENSINOGEN MESSENGER-RNA; LOW-DENSITY LIPOPROTEIN; IMMEDIATE-EARLY GENE; GROWTH-FACTOR; HUMAN-FIBROBLASTS; ARACHIDONIC-ACID; ARTERIAL INJURY; 3T3 CELLS	Prostaglandins are synthesized from arachidonic acid by the rate limiting enzyme cyclooxygenase (prostaglandin G/H synthase). Active cyclooxygenase is encoded by two distinct and independently regulated genes, termed cyclooxygenase-1 (cox1) and cyclooxygenase-2 (cox2). In this investigation, we examined the expression of cox1 and coxa mRNA in rat aorta following balloon deendothelialization (BDE) in vivo and in rat aortic smooth muscle cells (SMC) after serum stimulation in vitro. Two h after BDE, rat aortic cox2 mRNA levels increased greater than 50-fold relative to the lowest detectable levels on days 2 and 14. No message was detectable in non-BDE control rat aortas. Similar to the results found in vivo, cultured SMC exhibited a greater than 45-fold increase in cox2 mRNA levels after a 2-h exposure to serum. This increase was transient because cox2 levels declined at 4 and 8 h. In contrast, minimal changes in cox1 mRNA levels were observed after BDE or serum treatments. Increased levels of cox2 mRNA and corresponding protein synthesis led to an accumulation of total cyclooxygenase protein, which remained elevated 24 h after serum stimulation. Serum-treated SMC also generated greater amounts of cyclooxygenase-dependent metabolites than quiescent SMC as evidenced by marked increases in prostaglandin E(2) content in conditioned media, This increase is associated with a 2.5-3.0-fold increased rate of arachidonic acid conversion to prostaglandin E(2). Our data indicate that injury and serum stimulation differentially regulate mRNA and protein expression of two distinct cox genes in vascular SMC in vivo and in vitro. The findings suggest that the prostanoid responses after vascular injury are, in part, mediated by acute increases in cox2 mRNA and cyclooxygenase-2 protein.	UNIV ROCHESTER,SCH MED,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Rochester; University of Rochester	PRITCHARD, KA (corresponding author), NEW YORK MED COLL,DEPT EXPTL PATHOL,VALHALLA,NY 10595, USA.		; Miano, Joseph/L-5634-2018	O'Banion, M. Kerry/0000-0003-1246-3363; Miano, Joseph/0000-0001-7522-3207	NHLBI NIH HHS [1-PO HL43023R1, HL25316] Funding Source: Medline; NIDDK NIH HHS [DK1677] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043023, R01HL025316] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKAHOSHI T, 1988, J CLIN INVEST, V82, P1219, DOI 10.1172/JCI113719; ALBRIGHTSON CR, 1985, J IMMUNOL, V135, P1872; BRINKMAN HJM, 1990, THROMB HAEMOSTASIS, V63, P291; CASSIS LA, 1988, HYPERTENSION, V11, P591, DOI 10.1161/01.HYP.11.6.591; CASSIS LA, 1988, CIRC RES, V62, P1259, DOI 10.1161/01.RES.62.6.1259; CHERVU A, 1989, J VASC SURG, V10, P129, DOI 10.1067/mva.1989.0100129; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; GOLDBERG ID, 1979, SCIENCE, V205, P920, DOI 10.1126/science.472713; GUTSTEIN WH, 1991, MECH AGEING DEV, V57, P205, DOI 10.1016/0047-6374(91)90047-4; HABENICHT AJR, 1985, J CLIN INVEST, V75, P1381, DOI 10.1172/JCI111839; HABENICHT AJR, 1986, P NATL ACAD SCI USA, V83, P1344, DOI 10.1073/pnas.83.5.1344; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOLLAND JA, 1988, AM J PATHOL, V132, P474; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KENT RS, 1983, J CLIN INVEST, V72, P455, DOI 10.1172/JCI110993; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1993, J BIOL CHEM, V268, P5425; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEROY EC, 1984, J CLIN INVEST, V74, P1003, DOI 10.1172/JCI111467; LIBBY P, 1989, AM REV RESPIR DIS, V140, P1114, DOI 10.1164/ajrccm/140.4.1114; LIBBY P, 1988, J CLIN INVEST, V81, P487, DOI 10.1172/JCI113346; LIN LL, 1992, J BIOL CHEM, V267, P23451; LOESBERG C, 1985, EXP CELL RES, V160, P117, DOI 10.1016/0014-4827(85)90241-1; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MIANO JM, 1993, AM J PATHOL, V142, P715; MIANO JM, 1990, AM J PATHOL, V137, P761; MIANO JM, 1993, ARTERIOSCLER THROMB, V13, P211, DOI 10.1161/01.ATV.13.2.211; MIANO JM, 1991, CIRCULATION, V84, P342; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; NILSSON J, 1984, ATHEROSCLEROSIS, V53, P77, DOI 10.1016/0021-9150(84)90107-2; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OBANION MK, 1991, J BIOL CHEM, V266, P23261; PASH JM, 1988, FASEB J, V2, P2613, DOI 10.1096/fasebj.2.10.2968288; PASRICHA PJ, 1992, PROSTAGLANDINS, V43, P5, DOI 10.1016/0090-6980(92)90060-7; RAZ A, 1989, ADV EXP MED BIOL, V259, P1; RAZ A, 1988, J BIOL CHEM, V263, P3022; RYSECK RP, 1992, CELL GROWTH DIFFER, V3, P443; STEMERMAN MB, 1973, AM J PATHOL, V73, P7; TAHARA K, 1991, J BIOL CHEM, V266, P440; TANNENBAUM CS, 1990, J CELL PHYSIOL, V144, P77, DOI 10.1002/jcp.1041440111; TAUBMAN MB, 1992, CIRC RES, V70, P314, DOI 10.1161/01.RES.70.2.314; TSAI AL, 1991, ADV PROSTAG THROMB L, V21, P141; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WINN VD, 1993, J LIPID MEDIATOR, V6, P101; WU KK, 1991, P NATL ACAD SCI USA, V88, P2384, DOI 10.1073/pnas.88.6.2384; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; ZYGLEWSKA T, 1992, BIOCHIM BIOPHYS ACTA, V1131, P78, DOI 10.1016/0167-4781(92)90101-5	52	141	143	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8504	8509						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132578				2022-12-25	WOS:A1994NB40900101
J	SCHENKMAN, S; CHAVES, LB; DECARVALHO, LCP; EICHINGER, D				SCHENKMAN, S; CHAVES, LB; DECARVALHO, LCP; EICHINGER, D			A PROTEOLYTIC FRAGMENT OF TRYPANOSOMA-CRUZI TRANS-SIALIDASE LACKING THE CARBOXYL-TERMINAL DOMAIN IS ACTIVE, MONOMERIC, AND GENERATES ANTIBODIES THAT INHIBIT ENZYMATIC-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAMINIDASE ACTIVITIES; MAMMALIAN-CELLS; ACID; PROTEINS; TRYPOMASTIGOTES; SEQUENCES; BACTERIAL; INVASION; ANTIGENS; INVITRO	trans-Sialidase isolated from trypomastigote forms of Trypanosoma cruzi, the protozoan parasite that causes Chagas' disease, is multimeric and heterogeneous in size. We show here that limited proteolysis of trans-sialidase with papain yields a single monomeric polypeptide chain of 70 kDa that conserves full enzymatic activity on soluble and membrane-bound substrates. The papain fragment lacks most of the 12-amino acid repeats of the carboxyl-terminal domain that comprises about 50% of the native trans-sialidase. When injected into rabbits, the papain-generated fragment induces antibodies that inhibit trans-sialidase activity and trypomastigote sialylation. The repeats are also not required for the stability of the enzyme or for the correct folding during the biosynthesis in Escherichia coli, but seem essential for trans-sialidase oligomerization. We conclude that trans-sialidase is composed of two structurally and functionally independent domains.	NYU MED CTR,MICHAEL HEIDELBERGER DIV IMMUNOL,NEW YORK,NY 10016; ESCOLA PAULISTA MED,DEPT MICROBIOL IMMUNOL & PARASITOL,SAO PAULO,SP,BRAZIL	New York University; Universidade Federal de Sao Paulo (UNIFESP)			Schenkman, Sergio/A-9227-2013; Chaves, Luciana Botelho/N-7925-2019; Chaves, Luciana/D-6689-2012	Schenkman, Sergio/0000-0001-9353-8480; Chaves, Luciana Botelho/0000-0002-5137-610X; Chaves, Luciana/0000-0002-5137-610X	FOGARTY INTERNATIONAL CENTER [R03TW000227] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW00227-01] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		BUSCHIAZZO A, 1992, MOL BIOCHEM PARASIT, V54, P125, DOI 10.1016/0166-6851(92)90105-S; CAMPETELLA O, 1992, PARASITOL TODAY, V8, P378, DOI 10.1016/0169-4758(92)90175-2; CAZZULO JJ, 1992, FASEB J, V6, P3259, DOI 10.1096/fasebj.6.14.1426764; CHAVES LB, 1993, MOL BIOCHEM PARASIT, V61, P97, DOI 10.1016/0166-6851(93)90162-Q; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COTE GL, 1990, GLYCOCONJUGATE J, V7, P145, DOI 10.1007/BF01050377; CROSS GAM, 1993, ANNU REV MICROBIOL, V47, P384; DECARVALHO LCP, 1993, J EXP MED, V177, P465, DOI 10.1084/jem.177.2.465; ENGSTLER M, 1992, MOL BIOCHEM PARASIT, V54, P21, DOI 10.1016/0166-6851(92)90091-W; ENGSTLER M, 1993, PARASITOL TODAY, V9, P222, DOI 10.1016/0169-4758(93)90018-B; ENGSTLER M, 1992, HOPPESEYLERS Z PHYSL, V373, P843; HALL BF, 1993, J EUKARYOT MICROBIOL, V40, P207, DOI 10.1111/j.1550-7408.1993.tb04905.x; MACINA RA, 1989, FEBS LETT, V2, P365; PARODI AJ, 1992, EMBO J, V11, P1705, DOI 10.1002/j.1460-2075.1992.tb05221.x; PASSANITI A, 1988, J BIOL CHEM, V263, P7591; PAULSON JC, 1987, METHOD ENZYMOL, V138, P162; PEREIRA MEA, 1991, J EXP MED, V174, P179, DOI 10.1084/jem.174.1.179; PIRAS MM, 1987, MOL BIOCHEM PARASIT, V22, P135, DOI 10.1016/0166-6851(87)90043-0; POLLEVICK GD, 1993, MOL BIOCHEM PARASIT, V59, P171, DOI 10.1016/0166-6851(93)90018-S; POLLOCK JJ, 1970, BIOCHEMISTRY-US, V9, P3913, DOI 10.1021/bi00822a009; PREVIATO JO, 1985, MOL BIOCHEM PARASIT, V16, P85, DOI 10.1016/0166-6851(85)90051-9; PRIOLI RP, 1990, J IMMUNOL, V144, P4384; PRIOLI RP, 1992, MOL BIOCHEM PARASIT, V52, P85, DOI 10.1016/0166-6851(92)90038-L; ROGGENTIN P, 1989, GLYCOCONJUGATE J, V6, P349, DOI 10.1007/BF01047853; ROSENBERG I, 1991, MOL BIOCHEM PARASIT, V46, P303, DOI 10.1016/0166-6851(91)90054-A; SCHAUER R, 1983, H-S Z PHYSIOL CHEM, V364, P1053, DOI 10.1515/bchm2.1983.364.2.1053; SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M; SCHENKMAN S, 1992, J EXP MED, V175, P1635, DOI 10.1084/jem.175.6.1635; SCHENKMAN S, 1993, MOL BIOCHEM PARASIT, V59, P293, DOI 10.1016/0166-6851(93)90227-O; SCHENKMAN S, 1992, J EXP MED, V175, P567, DOI 10.1084/jem.175.2.567; SCHENKMAN S, 1993, PARASITOL TODAY, V9, P218, DOI 10.1016/0169-4758(93)90017-A; UEMURA H, 1992, EMBO J, V11, P3837, DOI 10.1002/j.1460-2075.1992.tb05476.x; ZINGALES B, 1987, MOL BIOCHEM PARASIT, V26, P135, DOI 10.1016/0166-6851(87)90137-X	33	63	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7970	7975						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132517				2022-12-25	WOS:A1994NB40900024
J	SEEGERT, D; STREHLOW, I; KLOSE, B; LEVY, DE; SCHINDLER, C; DECKER, T				SEEGERT, D; STREHLOW, I; KLOSE, B; LEVY, DE; SCHINDLER, C; DECKER, T			A NOVEL INTERFERON ALPHA-REGULATED, DNA-BINDING PROTEIN PARTICIPATES IN THE REGULATION OF THE IFP53/TRYPTOPHANYL-TRANSFER-RNA SYNTHETASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; IFN-GAMMA; INDOLEAMINE 2,3-DIOXYGENASE; TYROSINE PHOSPHORYLATION; CYTOPLASMIC ACTIVATION; MOLECULAR-CLONING; HUMAN FIBROBLASTS; RESPONSE ELEMENT; EXPRESSION; INDUCTION	We have investigated the transcriptional response of the IFP53/tryptophanyl-tRNA synthetase gene to interferon-alpha (IFN-alpha). A single gamma-interferon activation site (GAS) in proximity to the transcription start sites was found to mediate the response of the IFP53 gene to IFN-alpha. This DNA element bound two distinct protein factors, alpha-interferon activation factor 1 (AAF1) and AAF2, which were rapidly activated in the cytoplasm of IFN-alpha-treated HeLa cells. AAF1, like the gamma-interferon activation factor, bound to the GAS from different IFN-responsive promoters and contained the 91-kDa ISGF3 protein (p91). However, in complexes with the IFP53 or Ly6A/E GAS, p91 was the only ISGF3 protein, whereas in the case of the GBP GAS, the 48-kDa protein (p48) was also present. AAF2 was found to preferentially bind to the IFP53 GAS, but not at all to the GBP GAS, and contained no ISGF3 protein. Therefore, GAS-binding regulatory factors in the IFN-alpha response can either consist of proteins found in ISGF3 or be formed by distinct proteins that are similarly linked to IFN-alpha-induced signal transduction.	VIENNA BIOCTR,INST MICROBIOL & GENET,DEPT CELL BIOL & MICROBIOL,A-1030 VIENNA,AUSTRIA; FRAUNHOFER INST TOXICOL & MOLEC BIOL,D-30625 HANNOVER,GERMANY; NYU,SCH MED,DEPT PATHOL,NEW YORK,NY 10016; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,DIV MOLEC MED,NEW YORK,NY 10032	Vienna Biocenter (VBC); Fraunhofer Gesellschaft; New York University; Columbia University			Levy, David/AAG-6202-2019; Levy, David/GPS-4945-2022	Levy, David/0000-0002-7320-7788; 				AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; BUWITT U, 1992, EMBO J, V11, P489, DOI 10.1002/j.1460-2075.1992.tb05079.x; DAI W, 1990, J BIOL CHEM, V265, P19871; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DAVID M, 1993, J BIOL CHEM, V268, P6593; DECKER T, 1991, MOL CELL BIOL, V11, P5147, DOI 10.1128/MCB.11.10.5147; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; Demaeyer E., 1988, INTERFERONS OTHER RE; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EILERS A, 1993, MOL CELL BIOL, V13, P3245, DOI 10.1128/MCB.13.6.3245; EILERS A, 1994, IN PRESS MOL CELL BI; FROLOVA LY, 1993, GENE, V128, P237, DOI 10.1016/0378-1119(93)90568-N; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GOLUB EI, 1989, NUCLEIC ACIDS RES, V9, P3047; HASSANAIN HH, 1993, J BIOL CHEM, V268, P5077; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KISSELEV L, 1993, TRENDS BIOCHEM SCI, V18, P263, DOI 10.1016/0968-0004(93)90178-P; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PARRINGTON J, 1993, EUR J BIOCHEM, V214, P617, DOI 10.1111/j.1432-1033.1993.tb17961.x; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; RUBIN BY, 1991, J BIOL CHEM, V266, P24245; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sambrook J, 1989, MOL CLONING LABORATO; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STREHLOW I, 1993, J BIOL CHEM, V268, P16590; STREHLOW I, 1992, NUCLEIC ACIDS RES, V20, P3865, DOI 10.1093/nar/20.15.3865; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; YUAN J, 1994, IN PRESS MOL CELL BI	50	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8590	8595						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132584				2022-12-25	WOS:A1994NB40900113
J	ALBERTS, AS; ARIAS, J; HAGIWARA, M; MONTMINY, MR; FERAMISCO, JR				ALBERTS, AS; ARIAS, J; HAGIWARA, M; MONTMINY, MR; FERAMISCO, JR			RECOMBINANT CYCLIC-AMP RESPONSE ELEMENT-BINDING PROTEIN (CREB) PHOSPHORYLATED ON SER-133 IS TRANSCRIPTIONALLY ACTIVE UPON ITS INTRODUCTION INTO FIBROBLAST NUCLEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE INDUCES EXPRESSION; CATALYTIC SUBUNIT; C-FOS; SOMATOSTATIN GENE; AP-1 ACTIVITY; LIVING CELLS; INDUCTION; DEPHOSPHORYLATION; PHOSPHATASES; ISOFORMS	To date, it has not been possible to determine whether the single phosphorylation of the cyclic AMP response element binding factor (CREB) at Ser-133 is sufficient for the transcriptional activation by cAMP-mediated pathways. Previous in vivo studies investigating this point have relied upon transfection of cyclic AMP-dependent kinase (cAPK) or its activation by treatment of cells with cell-permeable cAMP analogs. However, as numerous cellular proteins, including CREB, are substrates for activated cAPK, the possibility remains that cAPK substrates other than CREB are required for the transcriptional activity of CRE-containing promoters. To further address this, we compared the activity of recombinant CREB phosphorylated on Ser-133 in both cell-free transcription assays and in vivo after introduction of the same preparations into fibroblasts by microinjection. The activity of phosphorylated CREB, non-phosphorylated CREB, and a mutant form of CREB, containing Ala substituted for Ser at position 133, was found to be nearly identical in cell-free in vitro transcription assays. In contrast, we found that only the phosphorylated CREB microinjected into fibroblasts resulted in the stimulation of expression of CRE regulated genes. These results suggest that phosphorylation of CREB on Ser-133 directly stimulates its ability to transactivate gene expression in intact cells.	UNIV CALIF SAN DIEGO, CTR CANC, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR CANC, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; SALK INST BIOL STUDIES, CLAYTON FDN LABS PEPTIDE BIOL, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Salk Institute					NIGMS NIH HHS [R01 GM 37828] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037828] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ALBERTS AS, 1993, DNA CELL BIOL, V12, P935, DOI 10.1089/dna.1993.12.935; ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LECOCQ R, 1990, ELECTROPHORESIS, V11, P200, DOI 10.1002/elps.1150110303; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MANDELL RB, 1992, EXP CELL RES, V198, P164, DOI 10.1016/0014-4827(92)90163-3; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MEINKOTH JL, 1991, MOL CELL BIOL, V11, P1759, DOI 10.1128/MCB.11.3.1759; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; RIABOWOL KT, 1988, COLD SPRING HARB SYM, V53, P85, DOI 10.1101/SQB.1988.053.01.013; RIABOWOL KT, 1988, NATURE, V336, P83, DOI 10.1038/336083a0; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; STRUHL K, 1993, CURR BIOL, V3, P220, DOI 10.1016/0960-9822(93)90338-O; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; SUN PQ, 1992, MOL ENDOCRINOL, V6, P1858, DOI 10.1210/me.6.11.1858; THORBURN AM, 1993, BIOTECHNIQUES, V14, P356; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	39	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7623	7630						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125987				2022-12-25	WOS:A1994NA03200093
J	MOON, KY; SHIN, KS; SONG, WK; CHUNG, CH; HA, DB; KANG, MS				MOON, KY; SHIN, KS; SONG, WK; CHUNG, CH; HA, DB; KANG, MS			A CANDIDATE MOLECULE FOR THE MATRIX ASSEMBLY RECEPTOR TO THE N-TERMINAL 29-KDA FRAGMENT OF FIBRONECTIN IN CHICK MYOBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; CELL-ADHESION; MONOCLONAL-ANTIBODIES; PLASMA FIBRONECTIN; SURFACE-PROTEINS; BINDING PROTEIN; DIFFERENTIATION; MUSCLE; DOMAIN; MYOGENESIS	Myoblast surface proteins with binding activity toward the N-terminal 29-kDa fragment of fibronectin were identified by two different experimental techniques: one involves radioiodination of the cell surface proteins, followed by solubilization with Triton X-100 and affinity purification on a Sepharose column conjugated with the 29-kDa fragment, and the other involves cross-linking of the 29-kDa fragment to the cells metabolically labeled with [S-35]methionine, followed by immunoprecipitation with anti-29-kDa IgG. Both approaches revealed that primary cultures of chick myoblasts contain the 66- and 48-kDa proteins that bind to the 29-kDa fragment. These binding proteins were then purified to apparent homogeneity by two successive chromatographies of the solubilized extracts of 12-day-old embryonic muscle on wheat germ agglutinin-agarose and 29-kDa fragment-Sepharose columns. However, the 48-kDa protein was found to be derived from contaminating fibroblasts upon immunoblot analysis of the myogenic cell lines, rat L8E63 and mouse C2A3, and cultured fibroblasts using the antibody raised against the 66-kDa protein. Anti-66-kDa IgG inhibited the binding of the I-125-29. kDa protein to the primary culture of myoblasts in a dose-dependent manner. On the other hand, the same antibody showed little or no effect on the initial binding of I-125-fibronectin to the cell surface, but dramatically inhibited its incorporation into deoxycholate-insoluble matrices. Furthermore, Fab fragments of anti-66-kDa IgG completely blocked the incorporation of fluoresceinated fibronectin into matrices but not its binding to the cell surface. These results suggest that fibronectin matrix assembly is mediated at least in part by the interaction of the 66-kDa protein with the N-terminal type I domain of fibronectin.	SEOUL NATL UNIV, COLL NAT SCI, DEPT MOLEC BIOL, SEOUL 151742, SOUTH KOREA	Seoul National University (SNU)			Shin, Ki Soon/AAK-1939-2020	Shin, Ki Soon/0000-0002-5701-3596				AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BLYSTONE SD, 1992, J BIOL CHEM, V267, P3968; CHEN LB, 1978, CELL, V14, P377, DOI 10.1016/0092-8674(78)90123-X; CHIQUET M, 1979, J BIOL CHEM, V254, P5475; CHIQUET M, 1981, DEV BIOL, V88, P220, DOI 10.1016/0012-1606(81)90166-4; CHUNG CY, 1990, J CELL PHYSIOL, V142, P392, DOI 10.1002/jcp.1041420224; ENGEL L, 1990, DEV BIOL, V140, P196, DOI 10.1016/0012-1606(90)90067-S; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; HAUSMAN RE, 1986, DEV BIOL, V113, P40, DOI 10.1016/0012-1606(86)90106-5; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1909, FIBRONECTIN, P546; KAUFMAN SJ, 1977, P NATL ACAD SCI USA, V74, P3888, DOI 10.1073/pnas.74.9.3888; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIMPER AH, 1991, J BIOL CHEM, V266, P9697; LOWREY AA, 1989, EXP CELL RES, V183, P1, DOI 10.1016/0014-4827(89)90414-X; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCDONALD JA, 1988, ANNU REV CELL BIOL, V4, P183, DOI 10.1146/annurev.cb.04.110188.001151; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MCKEOWNLONGO PJ, 1987, J CELL BIOL, V105, P44; MCKEOWNLONGO PJ, 1988, FIBRONECTIN, P163; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; MOSHER DF, 1991, ANN NY ACAD SCI, V614, P167, DOI 10.1111/j.1749-6632.1991.tb43701.x; NEFF NT, 1982, J CELL BIOL, V95, P654, DOI 10.1083/jcb.95.2.654; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; PODLESKI TR, 1979, EXP CELL RES, V122, P317, DOI 10.1016/0014-4827(79)90308-2; PONTREMOLI S, 1987, P NATL ACAD SCI USA, V84, P398, DOI 10.1073/pnas.84.2.398; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; SCHWARZBAUER JE, 1987, P NATL ACAD SCI USA, V84, P754, DOI 10.1073/pnas.84.3.754; SEKIGUCHI K, 1983, J BIOL CHEM, V258, P3967; SMALHEISER NR, 1987, P NATL ACAD SCI USA, V84, P6457, DOI 10.1073/pnas.84.18.6457; SOLURSH M, 1988, DEVELOPMENT, V104, P41; THIERY JP, 1989, FIBRONECTIN, P181; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER DC, 1974, DEV BIOL, V37, P63, DOI 10.1016/0012-1606(74)90170-5; WALSH FS, 1981, DEV BIOL, V81, P229, DOI 10.1016/0012-1606(81)90286-4; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	43	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7651	7657						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125991				2022-12-25	WOS:A1994NA03200097
J	WILLIAMS, AC; BROWNE, SJ; MANNING, AM; DAFFADA, P; COLLARD, TJ; PARASKEVA, C				WILLIAMS, AC; BROWNE, SJ; MANNING, AM; DAFFADA, P; COLLARD, TJ; PARASKEVA, C			TRANSFECTION AND EXPRESSION OF MUTANT P53 PROTEIN DOES NOT ALTER THE IN-VIVO OR IN-VITRO GROWTH-CHARACTERISTICS OF THE AA/C1 HUMAN ADENOMA DERIVED CELL-LINE, INCLUDING SENSITIVITY TO TRANSFORMING GROWTH-FACTOR-BETA-1	ONCOGENE			English	Note							WILD-TYPE P53; POLYPOSIS COLI PATIENTS; GENE-MUTATIONS; CANCER CELLS; COLORECTAL-CANCER; SUPPRESSES GROWTH; RAS; CARCINOMAS; PROMOTER; INVITRO	Mutation of the p53 gene is thought to be a late event in human colorectal carcinogenesis, involved in the malignant conversion of the adenoma to the carcinoma. One of the questions that we hoped to address was whether, in vivo, a single mutational event in one p53 gene is sufficient to confer a significant growth advantage on a colonic epithelial cell. Such a growth advantage could result either from an increase in growth rate and/or loss of response to inhibitory growth signals naturally present in the colonic crypt. We therefore introduced the pC53-SCX3 143 (Val-Ala) p53 mutation into a non tumorigenic adenoma derived cell line, AA/C1, which contained a truncating APC mutation, activating K-ras mutation but was wild-type for the p53 protein. High levels of mutant p53 protein were detected in the pC53-SCX3 transfected AA/C1 cell lines but was found not to affect either the in vitro (colony forming efficiency, anchorage independence) or in vivo (tumorigenicity in nude mice) growth, when compared to vector control or the parental AA/C1 cell line. In addition, to test whether the cells become less sensitive to inhibitory growth factors, the response of the cell lines to the naturally occurring growth inhibitor TGF beta was also investigated. Even though TGF beta had previously been implicated in the control of growth of intestinal epithelium, expression of the mutant p53 protein did not affect the sensitivity of the parental AA/C1 cell line to TGF beta. Under the experimental conditions tested expression of the 143 (Val-Ala) p53 protein was unable to affect the in vitro or in vivo growth characteristics of the adenoma derived AA/C1 cell line. When compared to other studies, these results suggest that the genetic background of the individual recipient cell may greatly influence the effect of expression of a particular p53 mutation.			WILLIAMS, AC (corresponding author), UNIV BRISTOL,SCH MED SCI,DEPT PATHOL & MICROBIOL,CRC,COLORECTAL TUMOUR BIOL RES GRP,UNIV WALK,BRISTOL BS8 1TD,ENGLAND.			Williams, Ann/0000-0002-6009-7137				AVERY A, 1993, BRIT J CANCER, V68, P137, DOI 10.1038/bjc.1993.301; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BODNER SM, 1992, ONCOGENE, V7, P743; CAJOT JF, 1992, CANCER RES, V52, P6956; CARDER P, 1993, ONCOGENE, V8, P1397; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FARR CJ, 1988, ONCOGENE, V3, P673; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; ISAACS WB, 1991, CANCER RES, V51, P4716; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LEIBOVITZ A, 1976, CANCER RES, V36, P3562; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MANNING AM, 1991, ONCOGENE, V6, P1471; MATOZAKI T, 1992, CANCER RES, V52, P4335; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARASKEVA C, 1988, INT J CANCER, V41, P908; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; REISS M, 1993, CANCER RES, V53, P899; RIDGWAY PJ, 1993, ONCOGENE, V8, P1069; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; TAKAHASHI K, 1992, JPN J CANCER RES, V83, P358, DOI 10.1111/j.1349-7006.1992.tb00115.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WHITEHEAD RH, 1991, INT J CANCER, V48, P693, DOI 10.1002/ijc.2910480511; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; WILLIAMS AC, 1992, INT J CANCER, V52, P785, DOI 10.1002/ijc.2910520519; WILLSON JKV, 1987, CANCER RES, V47, P2704; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WUYLLIE FS, 1993, MOL CARCINOGEN, V7, P83; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	52	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1479	1485						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152811				2022-12-25	WOS:A1994NH40100022
J	MUHLRAD, A; CHEUNG, P; PHAN, BC; MILLER, C; REISLER, E				MUHLRAD, A; CHEUNG, P; PHAN, BC; MILLER, C; REISLER, E			DYNAMIC PROPERTIES OF ACTIN - STRUCTURAL-CHANGES INDUCED BY BERYLLIUM FLUORIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN SUBFRAGMENT-1; SLIDING MOVEMENT; F-ACTIN; MUSCLE-CONTRACTION; FLUORESCENT-PROBE; BINDING; ATP; POLYMERIZATION; FILAMENTS; COMPLEXES	Beryllium fluoride (BeFx) has been widely used as a phosphate analogue in nucleotide-binding proteins. It was found to bind tightly to F- but not G-actin (Combeau C., and Carlier M. F. (1988) J. Biol. Chem. 263, 17429-17436) and to affect the three-dimensional structure of filaments by stabilizing the subdomain 2 region of the actin protomer (Orlova, A., and Egelman, E. H. (1992) J. Mol. Biol. 227, 1043-1053). In this work we examined the BeFx-induced structural and functional changes in G- and F-actin by using proteolysis, chemical modifications, ATPase, and in vitro motility assays. The results of proteolysis studies show that BeFx binds also to MgADP-G-actin and renders its subdomain 2 region more similar to that in MgATP-G-actin. This is manifested in enhanced subtilisin and decreased tryptic digestions in subdomain 2 of G-actin. BeFx had a strong effect on the proteolysis of MgADP-F-actin: both the tryptic and sub digestions in subdomain 2 were completely inhibited. Significant protection against proteolysis in this region was observed even at 1:14 molar ratios of BeFx to actin indicating cooperative effects on the structure of the actin filament. A similar although milder effect of phosphate on the proteolysis of F-actin suggests that BeFx acts as a phosphate analogue in this system. BeFx also induces changes in the subdomain 1 region of F-actin. This is revealed via reduced rates of Cys-374 alkylation with 7-diethylamino-3-(4'-maleimidylphenyl)-4-methylcoumarin and an increased subtilisin cleavage near the C terminus of actin in the presence of BeFx. The BeFx-induced structural changes in actin have little effect on its interactions with myosin. BeFx inhibits only slightly the actin-activated ATPase activity of S1 by decreasing V-max without affecting K-M. Additionally, the binding of BeFx to actin does not change the sliding velocity of actin filaments in the in vitro motility assays. The BeFx-induced specific and distinct changes in G- and F-actin point to the dynamic nature of actin structure and the local differences between monomeric and polymeric forms of actin.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; HEBREW UNIV JERUSALEM, HADASSAH SCH DENT MED, DEPT ORAL BIOL, IL-91010 JERUSALEM, ISRAEL	University of California System; University of California Los Angeles; Hebrew University of Jerusalem	MUHLRAD, A (corresponding author), UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA.				NCI NIH HHS [CA-9056] Funding Source: Medline; NHLBI NIH HHS [HL 07386] Funding Source: Medline; NIAMS NIH HHS [R01 AR022031, AR22031] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR022031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; CARLIER MF, 1986, BIOCHEMISTRY-US, V25, P7789, DOI 10.1021/bi00372a001; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; CHANTLER PD, 1975, EUR J BIOCHEM, V60, P67, DOI 10.1111/j.1432-1033.1975.tb20976.x; COMBEAU C, 1988, J BIOL CHEM, V263, P17429; COOK RK, 1993, J BIOL CHEM, V268, P2410; DREWES G, 1993, EUR J BIOCHEM, V212, P247, DOI 10.1111/j.1432-1033.1993.tb17656.x; DREWES G, 1991, J BIOL CHEM, V266, P5508; FRIEDEN C, 1985, BIOCHEMISTRY-US, V24, P4192, DOI 10.1021/bi00336a056; FRIEDEN C, 1980, J BIOL CHEM, V255, P8991; GODFREY JE, 1970, BIOCHEMISTRY-US, V9, P886, DOI 10.1021/bi00806a025; HEGYI G, 1974, EUR J BIOCHEM, V44, P7, DOI 10.1111/j.1432-1033.1974.tb03452.x; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; JACOBSON GR, 1976, P NATL ACAD SCI USA, V73, P2742, DOI 10.1073/pnas.73.8.2742; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KHAITLINA SY, 1991, FEBS LETT, V279, P49, DOI 10.1016/0014-5793(91)80247-Z; KONNO K, 1987, BIOCHEMISTRY-US, V26, P3582, DOI 10.1021/bi00386a050; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MIKI M, 1982, BIOCHEMISTRY-US, V21, P3661, DOI 10.1021/bi00258a021; MOCKRIN SC, 1981, J BIOL CHEM, V256, P8228; NONOMURA Y, 1975, J BIOCHEM, V78, P1101, DOI 10.1093/oxfordjournals.jbchem.a130988; ORLOVA A, 1992, J MOL BIOL, V227, P1047; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PHAN CB, 1993, BIOCHEMISTRY-US, V32, P7713; PROCHNIEWICZ E, 1990, J MOL BIOL, V216, P761, DOI 10.1016/0022-2836(90)90397-5; PROCHNIEWICZ E, 1993, BIOPHYS J, V65, P113, DOI 10.1016/S0006-3495(93)81057-9; RICHARD JE, 1986, J MOL BIOL, V191, P273; SCHUTT CE, 1992, P NATL ACAD SCI USA, V89, P319, DOI 10.1073/pnas.89.1.319; SCHUTT CE, 1992, FEBS LETT, V325, P59; SCHWYTER D, 1989, BIOCHEMISTRY-US, V28, P5889, DOI 10.1021/bi00440a027; SCHWYTER DH, 1990, J CELL BIOL, V111, P465, DOI 10.1083/jcb.111.2.465; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STRZELECKAGOLASZEWSKA H, 1993, EUR J BIOCHEM, V211, P731, DOI 10.1111/j.1432-1033.1993.tb17603.x; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; TAKASHI R, 1988, BIOCHEMISTRY-US, V27, P938, DOI 10.1021/bi00403a015; TIRION MM, 1993, J MOL BIOL, V230, P186, DOI 10.1006/jmbi.1993.1135; WANGER M, 1987, BIOCHIM BIOPHYS ACTA, V914, P105, DOI 10.1016/0167-4838(87)90052-5; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WERBER MM, 1992, BIOCHEMISTRY-US, V31, P7190, DOI 10.1021/bi00146a023	40	101	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11852	11858						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163484				2022-12-25	WOS:A1994NG37700030
J	HENRICKSEN, LA; UMBRICHT, CB; WOLD, MS				HENRICKSEN, LA; UMBRICHT, CB; WOLD, MS			RECOMBINANT REPLICATION PROTEIN-A - EXPRESSION, COMPLEX-FORMATION, AND FUNCTIONAL-CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; CELL NUCLEAR ANTIGEN; LARGE-TUMOR-ANTIGEN; CYCLE-DEPENDENT PHOSPHORYLATION; POLYMERASE-ALPHA-PRIMASE; CASEIN KINASE-II; LARGE T-ANTIGEN; BINDING-PROTEIN; SV40 ORIGIN; TOPOISOMERASE-II	Replication protein A (RPA) is a multisubunit, single-stranded DNA-binding protein that is absolutely required for replication of SV40 DNA. The three cDNAs encoding the subunits of human replication protein A (70, 32, and 14 kDa) have been expressed individually and in combination in Escherichia coli. When subunits were expressed individually, appropriately sized polypeptides were synthesized, but were found to be either insoluble or aggregated with other proteins. We examined the interactions between individual RPA subunits by expressing pairs of subunits and determining if they formed stable complexes. Only the 32- and 14-kDa subunits formed a soluble complex when coexpressed. This complex was purified and characterized. The 32.14 kDa subcomplex did not have any effect on DNA replication and was not phosphorylated efficiently in vitro. We believe that the 32.14-kDa subcomplex may be a precursor in the assembly of the complete RPA complex. Coexpression of all three subunits of RPA resulted in a significant portion of each polypeptide forming a soluble complex. We have purified recombinant RPA complex from E. coli and demonstrated that it has properties similar to those of human RPA. Recombinant human RPA has the same subunit composition and the same activities as the authentic complex from human cells. Recombinant human RPA binds single-stranded DNA and is capable of supporting SV40 DNA replication in vitro. In addition, recombinant RPA became phosphorylated when incubated under replication conditions.	UNIV IOWA, DEPT BIOCHEM, 51 NEWTON RD, IOWA CITY, IA 52242 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA	University of Iowa; Johns Hopkins University			Wold, Marc/F-5806-2010	Wold, Marc/0000-0002-4580-1624	NATIONAL CANCER INSTITUTE [K11CA001469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044721] Funding Source: NIH RePORTER; NCI NIH HHS [5 K11 CAO1469-04] Funding Source: Medline; NIGMS NIH HHS [GM44721] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; ATRAZHEV A, 1992, EUR J BIOCHEM, V210, P855, DOI 10.1111/j.1432-1033.1992.tb17489.x; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; BROWN GW, 1992, P NATL ACAD SCI USA, V89, P10227, DOI 10.1073/pnas.89.21.10227; BULLOCK PA, 1989, P NATL ACAD SCI USA, V86, P3944, DOI 10.1073/pnas.86.11.3944; CARMICHAEL EP, 1993, MOL CELL BIOL, V13, P408, DOI 10.1128/MCB.13.1.408; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11380; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; CORBETT AH, 1992, J BIOL CHEM, V267, P20513; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; CRIPPSWOLFMAN J, 1989, J BIOL CHEM, V264, P19478; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DONALDSON RW, 1987, P NATL ACAD SCI USA, V84, P759, DOI 10.1073/pnas.84.3.759; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; EKI T, 1992, J BIOL CHEM, V267, P7284; ERDILE LF, 1991, COLD SH Q B, V56, P303; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FAIRMAN M, 1988, BIOCHIM BIOPHYS ACTA, V951, P382, DOI 10.1016/0167-4781(88)90110-8; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; FRORATH B, 1991, BIOTECHNIQUES, V11, P364; GASSER SM, 1992, ANTON LEEUW INT J G, V62, P15, DOI 10.1007/BF00584459; GEORGAKI A, 1992, FEBS LETT, V308, P240, DOI 10.1016/0014-5793(92)81283-R; HAFFEY ML, 1990, J VIROL, V64, P5008, DOI 10.1128/JVI.64.10.5008-5018.1990; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; HOESS A, 1988, BIO-TECHNOL, V6, P1214, DOI 10.1038/nbt1088-1214; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1992, J BIOL CHEM, V267, P462; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; KENNY MK, 1990, J BIOL CHEM, V265, P769; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEE SH, 1991, J BIOL CHEM, V266, P594; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MELENDY T, 1991, J BIOL CHEM, V266, P1942; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MITSIS PG, 1993, BIOCHEMISTRY-US, V32, P5257, DOI 10.1021/bi00070a038; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11008; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11018; MURAKAMI Y, 1986, P NATL ACAD SCI USA, V83, P2869, DOI 10.1073/pnas.83.9.2869; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; NAKAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P4292, DOI 10.1093/nar/19.15.4292; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; ROBERTS JM, 1989, P NATL ACAD SCI USA, V86, P3939, DOI 10.1073/pnas.86.11.3939; SAIJO M, 1992, BIOCHEMISTRY-US, V31, P359, DOI 10.1021/bi00117a007; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SEO YS, 1991, J BIOL CHEM, V266, P13161; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMMES P, 1992, J BIOL CHEM, V267, P6063; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; UMBRICHT CB, 1993, J BIOL CHEM, V268, P6131; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; VIRSHUP DM, 1989, P NATL ACAD SCI USA, V86, P3584, DOI 10.1073/pnas.86.10.3584; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950	95	516	529	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11121	11132						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157639				2022-12-25	WOS:A1994NF96600026
J	KALLIO, PJ; PALVIMO, JJ; MEHTO, M; JANNE, OA				KALLIO, PJ; PALVIMO, JJ; MEHTO, M; JANNE, OA			ANALYSIS OF ANDROGEN RECEPTOR-DNA INTERACTIONS WITH RECEPTOR PROTEINS PRODUCED IN INSECT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYLMETHIONINE DECARBOXYLASE GENE; GLUCOCORTICOID RECEPTOR; PROGESTERONE-RECEPTOR; RESPONSIVE ELEMENT; STEROID-BINDING; TRANSCRIPTIONAL ACTIVATION; BACULOVIRUS SYSTEM; HORMONE RECEPTOR; ESCHERICHIA-COLI; EXPRESSION	Wild-type rat androgen receptor and four of its deletion mutants were produced in insect cells using the baculovirus expression system. Inclusion of androgen, but not estrogen, progesterone, or glucocorticoid, in culture medium increased the yield of soluble androgen receptors, although the majority of receptors still remained in the insoluble form (Xie, Y.-B., Sui, Y.-P., Shan, L.-X., Palvimo, J. J., Phillips, D. M., and Janne, O. A. (1992) J. Biol. Chem. 267, 4939-4948). The wild-type receptor interacted with an androgen response element (ARE) with a 2-6-fold higher affinity (K(D) = 0.5 nM) than mutants with deletions outside the DNA-binding domain (DELTA40-147, DELTA38-296, DELTA46-408, and DELTA788-902 mutants), suggesting that sequences flanking the DNA-binding region influence the stability of receptor-DNA complexes. Changes in spacing (n = 3) between the two ARE half-sites by a single nucleotide (n - 1, n + 1) or by 10 bases (n + 10) abolished the full-length receptor's ability to form stable complexes with DNA. Binding to AREs with altered spacing could not be restored by antisera against the N-terminal domain of the receptor that stabilize androgen receptor-DNA interactions with many naturally occurring strong and weak AREs. Methylation interference and 1,10-phenanthroline copper footprinting analyses revealed that the receptor binds to DNA as a dimer. Dimer formation was demonstrated directly by mixing full-length and DELTA46-408 mutant receptors, which resulted in the formation of. heterodimeric receptor-DNA complexes. The half-time of dissociation of the wild-type receptor from a consensus ARE sequence was about 3 min at 22-degrees-C. Collectively, androgen receptor binds to DNA with properties similar to, but not identical with, those of glucocorticoid receptor, indicating that regions outside the DNA-binding domain are important to ensure androgen specificity of transcriptional regulation.	UNIV HELSINKI,DEPT PHYSIOL,POB 9,SF-00014 HELSINKI,FINLAND	University of Helsinki				Palvimo, Jorma/0000-0003-2373-0578				ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BROWN M, 1990, J BIOL CHEM, V265, P11238; BURNSTEIN KL, 1993, J CELL BIOCHEM, V51, P130, DOI 10.1002/jcb.240510203; CHALEPAKIS G, 1990, DNA CELL BIOL, V9, P355, DOI 10.1089/dna.1990.9.355; CHANG CS, 1992, P NATL ACAD SCI USA, V89, P5946, DOI 10.1073/pnas.89.13.5946; CHRISTENSEN K, 1991, MOL ENDOCRINOL, V5, P1755, DOI 10.1210/mend-5-11-1755; CROSSLEY M, 1992, SCIENCE, V257, P377, DOI 10.1126/science.1631558; CROZAT A, 1992, ENDOCRINOLOGY, V130, P1131, DOI 10.1210/en.130.3.1131; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DAHLMANWRIGHT K, 1992, BIOCHEMISTRY-US, V31, P9040, DOI 10.1021/bi00152a047; DEVOS P, 1991, J BIOL CHEM, V266, P3439; DROUIN J, 1993, EMBO J, V12, P145, DOI 10.1002/j.1460-2075.1993.tb05640.x; DROUIN J, 1992, MOL ENDOCRINOL, V6, P1299, DOI 10.1210/me.6.8.1299; ELASHRY D, 1989, MOL ENDOCRINOL, V3, P1545, DOI 10.1210/mend-3-10-1545; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FREEDMAN LP, 1993, ENDOCR REV, V51, P130; ISOMAA V, 1982, ENDOCRINOLOGY, V111, P833, DOI 10.1210/endo-111-3-833; JANNE OA, 1993, CLIN CHEM, V39, P346; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; KADONAGA JT, 1991, METHOD ENZYMOL, V208, P10; KUIPER GGJM, 1993, BIOCHEM J, V291, P95, DOI 10.1042/bj2910095; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARIC SC, 1992, J BIOL CHEM, V267, P18915; MARINEZ E, 1989, EMBO J, V8, P3781; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; PALVIMO JJ, 1991, NUCLEIC ACIDS RES, V19, P3921, DOI 10.1093/nar/19.14.3921; Papavassiliou A G, 1994, Methods Mol Biol, V30, P43; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; RODRIGUEZ R, 1989, MOL ENDOCRINOL, V3, P356, DOI 10.1210/mend-3-2-356; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHAUER M, 1989, P NATL ACAD SCI USA, V86, P1123, DOI 10.1073/pnas.86.4.1123; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; SRINIVASAN G, 1992, MOL ENDOCRINOL, V6, P857, DOI 10.1210/me.6.6.857; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TAN J, 1992, J BIOL CHEM, V67, P4456; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; WONG P, 1993, J BIOL CHEM, V268, P5021; XIE YB, 1992, J BIOL CHEM, V267, P4939	48	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11514	11522						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157681				2022-12-25	WOS:A1994NF96600080
J	RADIC, Z; DURAN, R; VELLOM, DC; LI, Y; CERVENANSKY, C; TAYLOR, P				RADIC, Z; DURAN, R; VELLOM, DC; LI, Y; CERVENANSKY, C; TAYLOR, P			SITE OF FASCICULIN INTERACTION WITH ACETYLCHOLINESTERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENDROASPIS-ANGUSTICEPS VENOM; ANTICHOLINESTERASE TOXINS; TORPEDO-CALIFORNICA; SNAKE-VENOM; BINDING; MUTAGENESIS; INHIBITION; PROTEIN; LIGANDS	Fasciculin, a 6750-Da peptide from the venom of Dendroaspis, is known to inhibit reversibly mammalian and fish acetylcholinesterases at picomolar concentrations, but is a relatively weak inhibitor of avian, reptile, and insect acetylcholinesterases and mammalian butyrylcholinesterases. An examination of fasciculin association with several mutant forms of recombinant DNA-derived acetylcholinesterase from mouse shows that it interacts with a cluster of residues near the rim of the gorge on the enzyme. The aromatic residues, Trp286, Tyr72, and Tyr124, have the most marked influence on fasciculin binding, whereas Asp74, a charged residue in the vicinity of the binding site that affects the binding of low molecular weight inhibitors, has little influence on fasciculin binding. The 3 aromatic residues are unique to the susceptible acetylcholinesterases and, along with Asp74, constitute part of the peripheral anionic site. Fasciculin falls in the family of three-loop toxins that include the receptor blocking alpha-toxins and cardiotoxins. From this basic structural motif, a binding site has evolved on fasciculin to be highly specific for the peripheral site on acetylcholinesterase. Acetylthiocholine affects rates of fasciculin binding at concentrations causing substrate inhibition. In the case of the mutant cholinesterases where rates of fasciculin dissociation are more rapid, steady state kinetic parameters also show acetylthiocholine-fasciculin competition to be consistent with occupation at a peripheral or substrate inhibition site rather than the active center.	CLEMENTE ESTABLE,INST INVEST BIOL,MONTEVIDEO 11600,URUGUAY	Instituto de Investigaciones Biologicas Clemente Estable Uruguay	RADIC, Z (corresponding author), UNIV CALIF SAN DIEGO,DEPT PHARMACOL,SAN DIEGO,CA 92103, USA.		Durán, Rosario/GQH-8502-2022	Duran, Rosario/0000-0002-8575-9651	NIGMS NIH HHS [GM-18360] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360, R01GM018360] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMANN WW, 1949, P SOC EXP BIOL MED, V72, P1; Aldridge W. N., 1972, ENZYME INHIBITORS SU; BLABER LC, 1962, BIOCHEM PHARMACOL, V11, P113, DOI 10.1016/0006-2952(62)90098-9; BOLGER MB, 1979, BIOCHEMISTRY-US, V18, P3622, DOI 10.1021/bi00583a029; Cervenansky C., 1991, P303; CERVENANSKY C, 1991, Toxicon, V29, P1163; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; ENDO T, 1987, PHARMACOL THERAPEUT, V34, P403, DOI 10.1016/0163-7258(87)90002-7; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1577, DOI 10.1021/bi00405a027; GNATT A, 1994, J NEUROCHEM, V62, P749; GRECO WR, 1979, J BIOL CHEM, V254, P2104; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; HODGE AS, 1992, MOL PHARMACOL, V41, P937; HUNTER A, 1945, J BIOL CHEM, V157, P427; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; KARLSSON E, 1985, PHARMACOL THERAPEUT, V30, P259, DOI 10.1016/0163-7258(85)90051-8; KRUPKA RM, 1961, J AM CHEM SOC, V83, P1448, DOI 10.1021/ja01467a042; LEDU MH, 1992, J BIOL CHEM, V267, P22122; LIN WW, 1987, ASIA PAC J PHARMACOL, V2, P79; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; MAULET Y, 1991, CHOLINESTERASES STRU, P186; MILLARD CB, 1992, BIOCHEM BIOPH RES CO, V189, P1280, DOI 10.1016/0006-291X(92)90212-4; MUTERO A, 1992, NEUROREPORT, V3, P39, DOI 10.1097/00001756-199201000-00010; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; RADIC Z, 1984, BIOCHEM PHARMACOL, V33, P671, DOI 10.1016/0006-2952(84)90324-1; RADIC Z, 1992, BIOCHEMISTRY-US, V31, P9760, DOI 10.1021/bi00155a032; RADIC Z, 1991, MOL PHARMACOL, V39, P98; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; RODRIGUEZITHURRALDE D, 1983, NEUROCHEM INT, V5, P267, DOI 10.1016/0197-0186(83)90028-1; ROSENBERRY TL, 1977, BIOCHEMISTRY-US, V16, P3870, DOI 10.1021/bi00636a024; ROSENBERRY TL, 1979, BIOCHEMISTRY-US, V18, P3622; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; VILJOEN CC, 1973, J BIOL CHEM, V248, P4915; WEISE C, 1990, EMBO J, V9, P3885, DOI 10.1002/j.1460-2075.1990.tb07607.x	37	116	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11233	11239						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157652				2022-12-25	WOS:A1994NF96600041
J	SHIRATORI, Y; OKWU, AK; TABAS, I				SHIRATORI, Y; OKWU, AK; TABAS, I			FREE-CHOLESTEROL LOADING OF MACROPHAGES STIMULATES PHOSPHATIDYLCHOLINE BIOSYNTHESIS AND UP-REGULATION OF CTP - PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE; ACYL COENZYME-A; PLASMA-MEMBRANE SPHINGOMYELIN; MOUSE PERITONEAL-MACROPHAGES; HAMSTER OVARY CELLS; FATTY-ACIDS; ATHEROSCLEROTIC LESIONS; CULTURED FIBROBLASTS; TRANSFERASE-ACTIVITY	Atheroma macrophages accumulate large amounts of free cholesterol (FC) as well as cholesteryl ester (CE). An important adaptive response to FC loading might be increased cellular phospholipid to accommodate the excess FC. To explore this idea, J774 macrophages were incubated for 48 h without lipid, with acetyl-low density lipoprotein to induce mostly CE loading, or with acetyl-low density lipoprotein plus an acyl-CoA:cholesterol O-acyltransferase inhibitor (58035) to induce marked FC loading. The total phospholipid content approximately doubled in FC-loaded versus control or CE-loaded macrophages, with phosphatidylcholine showing the largest increase (approximately 2.5-fold versus control). Electron micrographs revealed the presence of multiple intracellular membrane whorls in the FC-loaded macrophages but not in the control or CE-loaded macrophages. [H-3]Choline incorporation into phosphatidylcholine was also greater in FC-loaded macrophages versus control or CE-loaded macrophages, whereas [H-3]phosphatidylcholine degradation was similar in all of the macrophages. In these experiments and in others that used non-lipoprotein cholesterol, there was a very close correlation between cellular FC content and phosphatidylcholine biosynthesis. To determine the mechanism of increased phosphatidylcholine synthesis, FC-loaded and CE-loaded macrophages were pulsed with [H-3]choline, then chased and assayed for labeled phosphatidylcholine biosynthetic precursors. The only major differences were a 2-fold greater disappearance of label from [H-3]choline phosphate and a 5-fold greater appearance of label in CDP-[H-3]choline in the FC-loaded macrophages. These data suggest a stimulation of CTP:phosphocholine cytidylyltransferase (CT), which was confirmed by microsomal CT assays. Further studies revealed that the increase in phosphatidylcholine biosynthesis in FC-loaded macrophages was: (a) reversible under conditions of high density lipoprotein3-mediated cellular cholesterol efflux; (b) not blocked by cycloheximide-induced protein synthesis inhibition; and (c) not associated with increased CT mRNA levels. Thus, FC loading of macrophages leads to an increase in phosphatidylcholine mass which is caused by increased phosphatidylcholine biosynthesis. The mechanism appears to be FC-mediated post-translational activation of CT. This adaptive response may be important for atheroma macrophage survival, and disruption of the response may lead to macrophage necrosis and lesion progression.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, 630 W 168 ST, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT ANAT & CELL BIOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University			Shiratori, Yoshimune/I-6206-2014		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039703, P50HL021006] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-39703, HL-21006] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOTTALICO LA, 1991, J BIOL CHEM, V266, P22866; BRASITUS TA, 1988, J BIOL CHEM, V263, P8592; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1975, J BIOL CHEM, V250, P4025; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BUCK RC, 1951, AMA ARCH PATHOL, V51, P224; CHOBANIAN AV, 1966, J CLIN INVEST, V45, P932, DOI 10.1172/JCI105408; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORNELL RB, 1992, METHOD ENZYMOL, V209, P267; CORNELL RB, 1983, BIOCHIM BIOPHYS ACTA, V750, P504, DOI 10.1016/0005-2760(83)90191-1; EXTON JH, 1990, J BIOL CHEM, V265, P1; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOWLER S, 1980, ACTA MED SCAND, P151; FUGLER L, 1985, J BIOL CHEM, V260, P4098; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GERRITY RG, 1981, AM J PATHOL, V103, P181; GUPTA AK, 1991, J LIPID RES, V32, P125; GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408; HARA A, 1990, JPN J EXP MED, V60, P311; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOUWELING M, 1991, BIOCHEM J, V278, P347, DOI 10.1042/bj2780347; ISHIDATE K, 1992, METHOD ENZYMOL, V209, P121; JACKSON RL, 1976, ATHEROSCLER REV, V1, P1; KATZ S S, 1976, Journal of Clinical Investigation, V58, P200; KHOO JC, 1989, BIOCHIM BIOPHYS ACTA, V1012, P215, DOI 10.1016/0167-4889(89)90099-2; KRIEGER M, 1978, P NATL ACAD SCI USA, V75, P5052, DOI 10.1073/pnas.75.10.5052; KUDCHODKAR BJ, 1983, ATHEROSCLEROSIS, V46, P353, DOI 10.1016/0021-9150(83)90184-3; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LANGE Y, 1979, BIOCHIM BIOPHYS ACTA, V556, P388, DOI 10.1016/0005-2736(79)90127-5; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; LIM PH, 1983, BIOCHIM BIOPHYS ACTA, V753, P74, DOI 10.1016/0005-2760(83)90100-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBERG B, 1985, ATHEROSCLEROSIS, V56, P93, DOI 10.1016/0021-9150(85)90087-5; MCCANDLESS EL, 1956, ARCH BIOCHEM BIOPHYS, V62, P402, DOI 10.1016/0003-9861(56)90138-2; MCGOOKEY DJ, 1983, J CELL BIOL, V97, P1156, DOI 10.1083/jcb.97.4.1156; MOCK T, 1986, BIOCHEM CELL BIOL, V64, P413, DOI 10.1139/o86-058; MORRIS MD, 1982, AM J PATHOL, V108, P140; NAGAWA Y, 1979, BIOCHIM BIOPHYS ACTA, V553, P307; OKWU AK, 1994, IN PRESS J LIPID RES; PELECH SL, 1983, J BIOL CHEM, V258, P6782; POST M, 1984, BIOCHIM BIOPHYS ACTA, V795, P552, DOI 10.1016/0005-2760(84)90185-1; PRITCHARD PH, 1981, BIOCHEM J, V196, P261, DOI 10.1042/bj1960261; RAPP JH, 1983, J LIPID RES, V24, P1329; ROBENEK H, 1988, ARTERIOSCLEROSIS, V8, P57, DOI 10.1161/01.ATV.8.1.57; ROONEY SA, 1990, BIOCHIM BIOPHYS ACTA, V1044, P385, DOI 10.1016/0005-2760(90)90085-C; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROTHBLAT GH, 1982, J BIOL CHEM, V257, P4775; SCHAEFER HE, 1976, VERH DTSCH GES PATHO, V60, P259; SCHAFFNER T, 1980, AM J PATHOL, V100, P57; SCHMITZ G, 1991, J LIPID RES, V32, P1539; SCHMITZ G, 1990, J LIPID RES, V31, P1741; SHIO H, 1979, LAB INVEST, V41, P160; SHORE ML, 1955, AM J PHYSIOL, V181, P527, DOI 10.1152/ajplegacy.1955.181.3.527; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; STEIN O, 1992, BIOCHIM BIOPHYS ACTA, V1126, P291, DOI 10.1016/0005-2760(92)90243-O; STEIN Y, 1963, BIOCHIM BIOPHYS ACTA, V70, P33, DOI 10.1016/0006-3002(63)90716-9; STEVENS VL, 1986, BIOCHEMISTRY-US, V25, P4287, DOI 10.1021/bi00363a017; TABAS I, 1993, J BIOL CHEM, V268, P20419; TABAS I, 1987, J BIOL CHEM, V262, P12175; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; TANGIRALA RK, 1993, J BIOL CHEM, V268, P9653; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; TIJBURG LBM, 1988, BIOCHIM BIOPHYS ACTA, V959, P1, DOI 10.1016/0005-2760(88)90143-9; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VANCE DE, 1991, BIOCH CELL BIOL, V29, P87; WANG YL, 1993, J BIOL CHEM, V268, P5899; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; WEINHOLD PA, 1992, METHOD ENZYMOL, V209, P248; WEINHOLD PA, 1991, J BIOL CHEM, V266, P6093; Weinhouse S, 1940, ARCH PATHOL, V29, P31; WHITLON DS, 1985, BIOCHIM BIOPHYS ACTA, V835, P369, DOI 10.1016/0005-2760(85)90293-0; WRIGHT PS, 1985, J BIOL CHEM, V260, P7919; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; YEAGLE PL, 1983, BIOCHIM BIOPHYS ACTA, V727, P39, DOI 10.1016/0005-2736(83)90366-8; ZILVERSMIT DB, 1954, CIRCULATION, V9, P581, DOI 10.1161/01.CIR.9.4.581	82	89	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11337	11348						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157665				2022-12-25	WOS:A1994NF96600056
J	SPORENO, E; PAONESSA, G; SALVATI, AL; GRAZIANI, R; DELMASTRO, P; CILIBERTO, G; TONIATTI, C				SPORENO, E; PAONESSA, G; SALVATI, AL; GRAZIANI, R; DELMASTRO, P; CILIBERTO, G; TONIATTI, C			ONCOSTATIN-M BINDS DIRECTLY TO GP130 AND BEHAVES AS INTERLEUKIN-6 ANTAGONIST ON A CELL-LINE EXPRESSING GP130 BUT LACKING FUNCTIONAL ONCOSTATIN-M RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; SIGNAL TRANSDUCER; PURIFICATION; CYTOKINES; INVITRO; IDENTIFICATION	Oncostatin M (OM) and interleukin 6 (IL-6) are functionally related cytokines, which trigger similar biological responses because they share gp130 as a common signal transducing transmembrane receptor. While IL-6 recruits gp130 only upon binding to its specific receptor subunit (IL-6Ralpha), reconstitution and cross-linking experiments on cell membranes suggest that OM can directly interact with gp130 and that this interaction is necessary but not sufficient to stimulate cells. However, the issue of the direct binding between gp130 and OM, in the absence of any additional membrane component, remained essentially unclarified. In this paper we show that, uniquely among the family of cytokines that transduce through gp130, OM directly binds in vitro with a 10(-8) M affinity sgp130, a soluble form of gp130. Moreover, titration of sgp130 with OM inhibits the formation of a ternary complex comprising IL-6, sIL-6Ralpha, and sgp130. These in vitro properties of OM are consistent with the additional finding that on human hepatoma Hep3B cells, which express gp130 but not functional OM receptors, OM does not mimic IL-6 activity, but rather behaves, at high doses, as an IL-6 antagonist.	IST RIC BIOL MOLEC P ANGELETTI,DEPT GENET,VIA PONTINA KM 30600,I-00040 POMEZIA,ITALY; IST RIC BIOL MOLEC P ANGELETTI,DEPT IMMUNOL,I-00040 POMEZIA,ITALY				Ciliberto, Gennaro/J-4131-2017	Ciliberto, Gennaro/0000-0003-2851-8605				ARCONE R, 1988, NUCLEIC ACIDS RES, V16, P3195, DOI 10.1093/nar/16.8.3195; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BROWN TJ, 1987, J IMMUNOL, V139, P2977; BRUCE AG, 1992, J IMMUNOL, V149, P1271; BUSH GL, 1991, J BIOL CHEM, V266, P13811; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FIORILLO MT, 1992, EUR J IMMUNOL, V22, P2609, DOI 10.1002/eji.1830221021; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRAHAM FL, 1973, VIROLOGY, V52, P6777; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; LINSLEY PS, 1989, J BIOL CHEM, V264, P4282; LIU JW, 1992, J BIOL CHEM, V267, P16763; LU T, 1993, ANAL BIOCHEM, V213, P318, DOI 10.1006/abio.1993.1427; MIYAJIMA A, 1993, BLOOD, V82, P1960; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NARAZAKI M, 1993, BLOOD, V82, P1120, DOI 10.1182/blood.V82.4.1120.bloodjournal8241120; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; SAVINO R, 1994, IN PRESS EMBO J; SPORENO E, 1994, IN PRESS CYTOKINE; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STOYAN T, 1993, EUR J BIOCHEM, V216, P239, DOI 10.1111/j.1432-1033.1993.tb18138.x; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TAGA T, 1993, FASEB J, V7, P3387; TONIATTI C, 1990, EMBO J, V9, P4467, DOI 10.1002/j.1460-2075.1990.tb07897.x; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YASUKAWA K, 1992, IMMUNOL LETT, V31, P123, DOI 10.1016/0165-2478(92)90138-E; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x; YIN TG, 1993, J IMMUNOL, V151, P2555; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	42	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					10991	10995						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157624				2022-12-25	WOS:A1994NF96600007
J	TANAKA, Y; TASHJIAN, AH				TANAKA, Y; TASHJIAN, AH			THIMEROSAL POTENTIATES CA2+ RELEASE MEDIATED BY BOTH THE INOSITOL 1,4,5-TRISPHOSPHATE AND THE RYANODINE RECEPTORS IN SEA-URCHIN EGGS - IMPLICATIONS FOR MECHANISTIC STUDIES ON CA2+ SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; INDUCED CALCIUM RELEASE; SARCOPLASMIC-RETICULUM; ENDOPLASMIC-RETICULUM; HAMSTER EGGS; CA-2+ RELEASE; INTRACELLULAR CALCIUM; XENOPUS OOCYTES; TRISPHOSPHATE; STORES	Two intracellular Ca2+ release pathways are modulated by Ca2+ itself, namely Ca-induced Ca2+ release (classical CICR), and Ca2+-sensitized inositol 1,4,5-trisphosphate (InsP3)-induced Ca2+ release (CSIICR). Both of these pathways are thought to be important in generating cytosolic Ca2+ oscillations. Caffeine and the sulfhydryl reagent thimerosal (TMS) are frequently used as selective modulators of CICR and CSIICR, respectively. We have studied the modes of action of caffeine and TMS in sea urchin egg homogenates using the Ca2+ indicator fluo-3. Cyclic ADP-ribose (cADPR), the only known endogenous compound to cause Ca2+ release via the ryanodine receptor, was used as an agonist for the classical CICR pathway. cADPR and InsP3 each alone caused release of sequestered Ca2+. Coaddition of caffeine dose-dependently and dramatically enhanced Ca2+ release induced by cADPR. InsP3-induced Ca2+ release was not affected by caffeine, but it was amplified by TMS, indicating the existence of the CSIICR pathway in this preparation. Surprisingly, cADPR-induced Ca2+ release was also markedly potentiated by TMS. TMS alone caused a slow increase in Ca2+ release which was not inhibited by heparin and/or procaine, indicating that TMS-induced Ca2+ release was not due to the actions of endogenous agonists (InsP3 or cADPR) on their receptors. All observed actions of TMS were abolished by dithiothreitol. We conclude: 1) both the InsP3- and cADPR-controlled Ca2+ release pathways are potentiated by TMS, while caffeine is specific for the cADPR pathway, indicating that TMS cannot be used as a selective reagent for probing the CSIICR mechanism; and 2) the action of TMS on intracellular Ca2+ release is independent of endogenous Ca2+ channel agonists, suggesting a novel action of TMS possibly on intravesicular Ca2+ handling.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School					NIDDK NIH HHS [DK 11011] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; BROWN GR, 1992, BIOCHEM J, V282, P309, DOI 10.1042/bj2820309; CLAPPER DL, 1985, J BIOL CHEM, V260, P3947; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; DELISLE S, 1992, J BIOL CHEM, V267, P7963; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GALIONE A, 1992, TRENDS PHARMACOL SCI, V13, P304, DOI 10.1016/0165-6147(92)90096-O; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GILCHRIST JSC, 1992, J BIOL CHEM, V267, P20850; HENSON JH, 1989, J CELL BIOL, V109, P149, DOI 10.1083/jcb.109.1.149; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; ISLAM MS, 1992, FEBS LETT, V296, P287, DOI 10.1016/0014-5793(92)80306-2; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; KNUDSON CM, 1993, J BIOL CHEM, V268, P12637; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; KUBOTA HY, 1987, DEV BIOL, V119, P129, DOI 10.1016/0012-1606(87)90214-4; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1993, J BIOL CHEM, V268, P293; LEE HC, 1991, J BIOL CHEM, V266, P2276; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MINTA A, 1989, J BIOL CHEM, V264, P8171; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MIYAZAKI S, 1992, FEBS LETT, V309, P180, DOI 10.1016/0014-5793(92)81090-9; MIYAZAKI S, 1986, DEV BIOL, V118, P259, DOI 10.1016/0012-1606(86)90093-X; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; PARKER I, 1991, J PHYSIOL-LONDON, V433, P229, DOI 10.1113/jphysiol.1991.sp018423; RANDRIAMAMPITA C, 1991, CELL REGUL, V2, P513, DOI 10.1091/mbc.2.7.513; RASMUSSEN H, 1984, PHYSIOL REV, V64, P938, DOI 10.1152/physrev.1984.64.3.938; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; SAYERS LG, 1993, BIOCHEM J, V289, P883, DOI 10.1042/bj2890883; SHARP AH, 1993, J NEUROSCI, V13, P3051; STAUDERMAN KA, 1991, BIOCHEM J, V278, P643, DOI 10.1042/bj2780643; SWANN K, 1991, FEBS LETT, V278, P175, DOI 10.1016/0014-5793(91)80110-O; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TANAKA Y, 1993, BIOCHEMISTRY-US, V32, P12062, DOI 10.1021/bi00096a017; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THORN P, 1992, PFLUG ARCH EUR J PHY, V422, P173, DOI 10.1007/BF00370417; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.neuro.12.1.227; VERMA A, 1990, BIOCHEM BIOPH RES CO, V172, P811, DOI 10.1016/0006-291X(90)90747-B; VERMA A, 1992, MOL BIOL CELL, V3, P621, DOI 10.1091/mbc.3.6.621; WAGNER KA, 1993, BIOCHEM J, V292, P175, DOI 10.1042/bj2920175; WALSETH TF, 1993, J BIOL CHEM, V268, P26686; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; WHITAKER M, 1993, DEVELOPMENT, V117, P1; ZAIDI NF, 1989, J BIOL CHEM, V264, P21737; ZAIDI NF, 1989, J BIOL CHEM, V264, P21725	67	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11247	11253						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157654				2022-12-25	WOS:A1994NF96600043
J	HERSCHER, CJ; REGA, AF; GARRAHAN, PJ				HERSCHER, CJ; REGA, AF; GARRAHAN, PJ			THE DEPHOSPHORYLATION REACTION OF THE CA2+-ATPASE FROM PLASMA-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL MEMBRANES; TRANSPORT ADENOSINE-TRIPHOSPHATASE; SARCOPLASMIC-RETICULUM ATPASE; HUMAN ERYTHROCYTE-MEMBRANES; MAGNESIUM-IONS; PHOSPHORYLATED INTERMEDIATE; CALCIUM; PHOSPHOENZYME; CA-2+; ADP	The breakdown of phosphoenzyme (EP) of the Ca2+-ATPase from pig red blood cell membranes was studied at 37 degrees C by means of a rapid chemical quenching technique. When the enzyme was phosphorylated with [gamma-P-32]ATP in media without added MgCl2, all the EP formed disappeared along two single exponential curves, a rapid one with k(app) = 90 +/- 10 s(-1) and a slow one with k(app) = 0.7 +/- 0.3 s(-1). The amount of EP involved in each reaction was close to 50% of the EP present at the beginning. Only EP of rapid breakdown could account for the steady-state hydrolysis of ATP observed under the same experimental conditions. ADP accelerated the slow reaction 45-fold (k(app) = 31 +/- 9 s(-1)) with K-0.5 = 740 +/- 120 mu M as if this reaction represented the decay of CaE(1)P, which donated its phosphate to water slowly in the forward direction and rapidly to ADP in the reverse direction of the cycle. Combination of Mg2+ with K-0.5 = 26.3 +/- 5.0 mu M at a single class of site in E(1) before phosphorylation increased EP of rapid breakdown at the expense of ADP-sensitive EP so that, at nonlimiting concentrations of Mg2+ in the phosphorylation media, all EP decomposed at high rate. Rapid decomposition was observed even with enough CDTA to chelate most of the Mg2+ remaining from phosphorylation, suggesting that the role of Mg2+ during dephosphorylation was to accelerate the transition CaE(1)P --> CaE(2)P, preparing EP for hydrolysis. The combination of ATP at a single class of site with K-m = 845 +/- 231 mu M accelerated the hydrolysis of CaE(2)P. Calmodulin alone had no effects on dephosphorylation but enhanced acceleration of hydrolysis of CaE(2)P by ATP making the decay of EP under these conditions the fastest among those measured. Comparison of the rates of dephosphorylation of EP made in the presence of Mg2+ with those of steady-state Ca2+-ATPase activity with and without calmodulin showed that the transition CaE(1)P --> CaE(2)P and decomposition of CaE(2)P by hydrolysis are compatible with their role as obligatory intermediate reactions in the cycle of hydrolysis of ATP by the Ca2+-ATPase.			HERSCHER, CJ (corresponding author), UNIV BUENOS AIRES,FAC FARM & BIOQUIM,INST QUIM & FIS BIOL,RA-1113 BUENOS AIRES,ARGENTINA.							ADAMO HP, 1990, BIOCHEM BIOPH RES CO, V169, P700, DOI 10.1016/0006-291X(90)90387-3; ADAMO HP, 1990, J BIOL CHEM, V265, P3789; ADAMO HP, 1988, J BIOL CHEM, V263, P17548; CARIDE AJ, 1986, BIOCHIM BIOPHYS ACTA, V863, P165, DOI 10.1016/0005-2736(86)90256-7; FROEHLICH JP, 1975, J BIOL CHEM, V250, P2013; FUKUSHIMA Y, 1978, J BIOL CHEM, V253, P6853; GARRAHAN PJ, 1978, BIOCHIM BIOPHYS ACTA, V513, P59, DOI 10.1016/0005-2736(78)90111-6; GARRAHAN PJ, 1976, BIOCHIM BIOPHYS ACTA, V448, P121, DOI 10.1016/0005-2736(76)90081-X; GIETZEN K, 1980, BIOCHEM J, V99, P147; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; INESI G, 1970, ARCH BIOCHEM BIOPHYS, V138, P285, DOI 10.1016/0003-9861(70)90309-7; JEFFERY DA, 1981, BIOCHEM J, V194, P481, DOI 10.1042/bj1940481; KANAZAWA T, 1971, J BIOCHEM-TOKYO, V70, P95, DOI 10.1093/oxfordjournals.jbchem.a129631; KRATJE RB, 1983, BIOCHIM BIOPHYS ACTA, V731, P40, DOI 10.1016/0005-2736(83)90395-4; LUDI H, 1987, J PHYSIOL-LONDON, V390, P367; LUNDAHL P, 1975, BIOCHIM BIOPHYS ACTA, V379, P304, DOI 10.1016/0005-2795(75)90033-1; MUALLEM S, 1981, BIOCHIM BIOPHYS ACTA, V647, P73, DOI 10.1016/0005-2736(81)90296-0; NAKAMURA Y, 1986, J BIOL CHEM, V261, P3090; ORLOWSKI S, 1988, J BIOL CHEM, V263, P17576; PELUFFO RD, 1992, J BIOL CHEM, V267, P6596; POST RL, 1972, J BIOL CHEM, V247, P6530; REGA A, 1986, CA2PLUS PUMP PLASMA; REGA AF, 1980, BIOCHIM BIOPHYS ACTA, V596, P487, DOI 10.1016/0005-2736(80)90140-6; REGA AF, 1978, BIOCHIM BIOPHYS ACTA, V507, P182, DOI 10.1016/0005-2736(78)90386-3; REGA AF, 1975, J MEMBRANE BIOL, V22, P313, DOI 10.1007/BF01868177; RICHARDS DE, 1978, BIOCHIM BIOPHYS ACTA, V511, P194, DOI 10.1016/0005-2736(78)90313-9; ROSSI JPFC, 1985, BIOCHIM BIOPHYS ACTA, V816, P379, DOI 10.1016/0005-2736(85)90505-X; ROSSI RC, 1989, BIOCHIM BIOPHYS ACTA, V981, P85, DOI 10.1016/0005-2736(89)90085-0; ROSSI RC, 1985, SODIUM PUMP, P443; TAKISAWA H, 1983, J BIOL CHEM, V258, P2986; YAMADA S, 1986, J BIOCHEM-TOKYO, V100, P1329, DOI 10.1093/oxfordjournals.jbchem.a121839	31	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10400	10406						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144623				2022-12-25	WOS:A1994NF01700035
J	WONG, H; DAVIS, RC; THUREN, T; GOERS, JW; NIKAZY, J; WAITE, M; SCHOTZ, MC				WONG, H; DAVIS, RC; THUREN, T; GOERS, JW; NIKAZY, J; WAITE, M; SCHOTZ, MC			LIPOPROTEIN-LIPASE DOMAIN FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; LOW-DENSITY-LIPOPROTEIN; HEPATIC LIPASE; PANCREATIC LIPASE; TRIACYLGLYCEROL LIPASE; CATALYTIC TRIAD; GENE FAMILY; PROTEINS; BINDING; INACTIVATION	Human lipoprotein lipase (LPL) monomer consists of two domains, a larger NH2-terminal domain that contains catalytic residues and a smaller COOH-terminal domain that modulates substrate specificity and is a major determinant of heparin binding. Analyses of NH2-terminal domain function were performed after site-directed mutagenesis of the putative active-site serine residue, while COOH-terminal domain function was assessed following reaction with a monoclonal antibody. The native enzyme and mutant LPL in which serine 132 was replaced with alanine, cysteine, or glycine were transiently expressed in COS-7 cells. Mutant proteins were synthesized and secreted at levels comparable to native LPL; however, none of the mutants retained enzymatic activity. The mutant with alanine replacing serine 132 was purified and shown to be inactive with both esterase and lipase substrates; however, binding to a 1,2-didodecanoyl-sn-glycero-3-phosphatidylcholine monolayer was comparable to native LPL, These results are consistent with a catalytic, and not a lipid binding, role for serine 132. To investigate the function of the smaller COOH-terminal domain, LPL lipolytic and esterolytic activities as well as heparin binding properties were determined after reaction with a monoclonal antibody specific for this domain. Lipolytic activity was inhibited by the monoclonal antibody, whereas esterolytic activity was only marginally affected, indicating that the LPL COOH-terminal domain is required for lipolysis, perhaps by promoting interaction with insoluble substrates. Also, the affinity of antibody-reacted LPL for heparin was not significantly different from that of LPL alone, suggesting that (i) the heparin-binding site is physically distinct from the COOH-terminal domain region required for lipolysis and (ii) binding of antibody did not cause dimer dissociation. A model is proposed for the two LPL domains fulfilling different roles in the lipolytic process.	UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; WAKE FOREST UNIV,DEPT MED,WINSTON SALEM,NC 27103; CALIF POLYTECH STATE UNIV SAN LUIS OBISPO,DEPT CHEM,SAN LUIS OBISPO,CA 93407	University of California System; University of California Los Angeles; Wake Forest University; California State University System; California Polytechnic State University San Luis Obispo	WONG, H (corresponding author), VET ADM WADSWORTH MED CTR,LIPID RES LAB,BLDG 113,RM 312,LOS ANGELES,CA 90073, USA.				NHLBI NIH HHS [HL28481] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BENZEEV O, 1987, BIOCHIM BIOPHYS ACTA, V919, P13, DOI 10.1016/0005-2760(87)90212-8; Borgstrom B., 1984, P151; BOWNES M, 1992, J LIPID RES, V33, P777; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; CHAILLAN C, 1992, BIOCHEM BIOPH RES CO, V184, P206, DOI 10.1016/0006-291X(92)91179-T; CHAPUS C, 1976, BIOCHEMISTRY-US, V15, P4980, DOI 10.1021/bi00668a006; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; DAVIS RC, 1990, J BIOL CHEM, V265, P6291; DEREWENDA ZS, 1991, BIOCHEM CELL BIOL, V69, P842, DOI 10.1139/o91-125; DEREWENDA ZS, 1991, J BIOL CHEM, V266, P23112; DOOLITTLE MH, 1987, J LIPID RES, V28, P1326; EMMERICH J, 1992, J BIOL CHEM, V267, P4161; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P14418; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P9481; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOERS JW, 1987, ANAL BIOCHEM, V168, P27; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; KOMAROMY MC, 1987, P NATL ACAD SCI USA, V84, P1526, DOI 10.1073/pnas.84.6.1526; LIU MS, 1992, BIOCHIM BIOPHYS ACTA, V1128, P113, DOI 10.1016/0005-2760(92)90264-V; Macritchie F, 1978, Adv Protein Chem, V32, P283, DOI 10.1016/S0065-3233(08)60577-X; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; OLIVECRONA T, 1985, J BIOL CHEM, V260, P6888; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PETERSON J, 1992, J LIPID RES, V33, P1165; RIETSCH J, 1977, J BIOL CHEM, V252, P4313; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAXENA U, 1993, J BIOL CHEM, V268, P14812; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SHIRAI K, 1984, BIOCHIM BIOPHYS ACTA, V795, P1; TASHIRO J, 1992, FEBS LETT, V298, P36, DOI 10.1016/0014-5793(92)80017-B; VAINIO P, 1983, J BIOL CHEM, V258, P5477; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; Verger R., 1984, P83; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; WONG H, 1991, P NATL ACAD SCI USA, V88, P11290, DOI 10.1073/pnas.88.24.11290; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	45	56	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10319	10323						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144612				2022-12-25	WOS:A1994NF01700024
J	JORDAN, KL; HAAS, AR; LOGAN, TJ; HALL, DJ				JORDAN, KL; HAAS, AR; LOGAN, TJ; HALL, DJ			DETAILED ANALYSIS OF THE BASIC DOMAIN OF THE E2F1 TRANSCRIPTION FACTOR INDICATES THAT IT IS UNIQUE AMONG BHLH PROTEINS	ONCOGENE			English	Article							DNA-BINDING ACTIVITY; LEUCINE ZIPPER; MINOR GROOVE; CYCLIN-A; C-MYC; HELIX; DIMERIZATION; COMPLEX; BOX; SPECIFICITY	The E2F1 transcription factor binds to sites within the promoters of a number of cell cycle regulated genes through a basic-helix-loop-helix motif (bHLH). It is shown here that the basic region of E2F1 is distinct from that of all other bHLH proteins. The center of the basic region contains a helix breaking proline-glycine pair, (P122, G123), implying a turn within this region. This is in contrast to the known bHLH containing proteins where the basic region is alpha-helical. Substitution of P122 and G123 with alanines results in a significant reduction in DNA binding levels, with the predicted formation of an alpha-helix. Also in contrast to other bHLH proteins, mutations generated in conserved basic residues of E2F1 do not effect DNA binding. In addition, a single leucine (191) between helix no. 2 and the leucine zipper is required for DNA binding while the leucine zipper itself is not necessary. Finally, E2F1 interacts with ail of the G-residues in the sequence GGCGG-GAAA while the A-residues are not required for DNA binding. The uniqueness of the E2F1 DNA binding domain is likely to play a role in its binding a DNA site that is distinct from that of all other bHLH proteins (CACGTG).	THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOLEC BIOL,233 S 10TH ST,PHILADELPHIA,PA 19107	Jefferson University			Jordan-Sciutto, Kelly L/A-1046-2007		NCI NIH HHS [CA51170] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051170] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; FISHER F, 1992, EMBO J, V11, P4103, DOI 10.1002/j.1460-2075.1992.tb05503.x; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HALL DJ, 1990, ONCOGENE, V5, P47; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; JONES N, 1992, CELL, V70, P351; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEVINS JR, 1992, SCIENCE, V258, P424; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722	34	36	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1177	1185						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134120				2022-12-25	WOS:A1994NC04800021
J	LELONG, C; SETIF, P; LAGOUTTE, B; BOTTIN, H				LELONG, C; SETIF, P; LAGOUTTE, B; BOTTIN, H			IDENTIFICATION OF THE AMINO-ACIDS INVOLVED IN THE FUNCTIONAL INTERACTION BETWEEN PHOTOSYSTEM-I AND FERREDOXIN FROM SYNECHOCYSTIS SP-PCC-6803 BY CHEMICAL CROSS-LINKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEINS; NADP+ REDUCTASE; ANABAENA PCC-7119; LINKED COMPLEX; 2FE-2S FERREDOXIN; ELECTRON-TRANSFER; BINDS FERREDOXIN; 2.5-A RESOLUTION; SP PCC-6803; PSI-E	Ferredoxin isolated from the cyanobacterium Synechocystis sp. PCC 6803 has been chemically cross-linked to purified photosystem I from the same organism. The reaction was catalyzed by N-ethyl-3-(3-dimethylaminopropyl) carbodiimide in the presence of N-hydroxysulfosuccinimide. A short reaction time and neutral pH values can be used in the presence of the two reagents, ensuring the integrity of both of the proteins and the iron-sulfur cluster of the ferredoxin. The only covalent complex detected comprised ferredoxin and the photosystem I (PSI)-D subunit, as identified by antibodies probing after electrophoresis. Electron paramagnetic resonance measurements of this covalent complex have shown that the cross-linked ferredoxin was entirely photoreducible by photosystem I and that the molar ratio of ferredoxin to PSI was close to 1. Extensive sequencing of the peptides obtained after proteolysis of the purified cross-linked product led to the identification of a covalent bond between glutamic acid 93 of ferredoxin and lysine 106 of the PSI-D subunit.	CEA SACLAY, DEPT BIOL CELLULAIRE & MOLEC,CNRS,URA 1290, SERV BIOENERGET, F-91191 GIF SUR YVETTE, FRANCE	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								ANDERSEN B, 1992, PHYSIOL PLANTARUM, V84, P154, DOI 10.1111/j.1399-3054.1992.tb08778.x; ANDERSEN B, 1992, FEBS LETT, V311, P169, DOI 10.1016/0014-5793(92)81391-X; BOTTIN H, 1992, BIOCHIM BIOPHYS ACTA, V1101, P48, DOI 10.1016/0167-4838(92)90465-P; CARRAWAY KL, 1970, BIOCHIM BIOPHYS ACTA, V200, P564, DOI 10.1016/0005-2795(70)90112-1; CARRAWAY KL, 1968, BIOCHIM BIOPHYS ACTA, V160, P272, DOI 10.1016/0005-2795(68)90102-5; CHITNIS PR, 1989, J BIOL CHEM, V264, P18381; COLVERT KK, 1988, PHOTOSYNTH RES, V17, P231, DOI 10.1007/BF00035450; DEPASCALIS AR, 1993, PROTEIN SCI, V2, P1126, DOI 10.1002/pro.5560020707; DOLLA A, 1989, BIOCHIM BIOPHYS ACTA, V975, P395, DOI 10.1016/S0005-2728(89)80348-2; FRIEDMAN M, 1970, J BIOL CHEM, V245, P3868; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; GUIGLIARELLI B, 1989, J BIOL CHEM, V264, P6025; HERVAS M, 1992, PHOTOCHEM PHOTOBIOL, V56, P319, DOI 10.1111/j.1751-1097.1992.tb02166.x; HIRASAWA M, 1991, ARCH BIOCHEM BIOPHYS, V286, P171, DOI 10.1016/0003-9861(91)90024-D; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; HURLEY JK, 1993, BIOCHEMISTRY-US, V32, P9346, DOI 10.1021/bi00087a013; JACOBSON BL, 1993, BIOCHEMISTRY-US, V32, P6788, DOI 10.1021/bi00077a033; KE B, 1973, P NATL ACAD SCI USA, V70, P2941, DOI 10.1073/pnas.70.10.2941; KNAFF DB, 1991, BIOCHIM BIOPHYS ACTA, V1056, P93, DOI 10.1016/S0005-2728(05)80277-4; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; LAGOUTTE B, 1992, EUR J BIOCHEM, V205, P1175, DOI 10.1111/j.1432-1033.1992.tb16888.x; MATSUBARA H, 1988, METHOD ENZYMOL, V167, P387; MERATI G, 1987, FEBS LETT, V215, P37, DOI 10.1016/0014-5793(87)80109-6; ORTEGA JM, 1993, BIOCHEMISTRY-US, V32, P1141, DOI 10.1021/bi00055a020; PUEYO JJ, 1991, BIOCHIM BIOPHYS ACTA, V1059, P149, DOI 10.1016/S0005-2728(05)80199-9; PUEYO JJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P367, DOI 10.1016/0003-9861(92)90697-U; REILLY P, 1988, J BIOL CHEM, V263, P17658; Rogers L.J, 1987, CYANOBACTERIA, P35; ROGNER M, 1990, J BIOL CHEM, V265, P6189; ROSEN D, 1983, BIOCHEMISTRY-US, V22, P335, DOI 10.1021/bi00271a016; ROUSSEAU F, 1993, EMBO J, V12, P1755, DOI 10.1002/j.1460-2075.1993.tb05823.x; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V537, P255, DOI 10.1016/0005-2795(78)90509-3; RYPNIEWSKI WR, 1991, BIOCHEMISTRY-US, V30, P4126, DOI 10.1021/bi00231a003; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SONOIKE K, 1993, BIOCHIM BIOPHYS ACTA, V1141, P52, DOI 10.1016/0005-2728(93)90188-L; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; TSUKIHARA T, 1990, J MOL BIOL, V216, P399, DOI 10.1016/S0022-2836(05)80330-4; TSUKIHARA T, 1981, J BIOCHEM-TOKYO, V90, P1763, DOI 10.1093/oxfordjournals.jbchem.a133654; WAGNER R, 1982, BIOCHIM BIOPHYS ACTA, V680, P317, DOI 10.1016/0005-2728(82)90145-1; WALKER MC, 1990, ARCH BIOCHEM BIOPHYS, V281, P76, DOI 10.1016/0003-9861(90)90415-U; ZANETTI G, 1988, BIOCHEMISTRY-US, V27, P3753, DOI 10.1021/bi00410a035; ZANETTI G, 1987, EUR J BIOCHEM, V169, P143, DOI 10.1111/j.1432-1033.1987.tb13591.x; ZANETTI G, 1984, J BIOL CHEM, V259, P6153; ZILBER AL, 1988, PLANT PHYSIOL, V88, P810, DOI 10.1104/pp.88.3.810	44	83	87	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					10034	10039						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144501				2022-12-25	WOS:A1994NE05300096
J	THOMPSON, HL; MARSHALL, CJ; SAKLATVALA, J				THOMPSON, HL; MARSHALL, CJ; SAKLATVALA, J			CHARACTERIZATION OF 2 DIFFERENT FORMS OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE INDUCED IN POLYMORPHONUCLEAR LEUKOCYTES FOLLOWING STIMULATION BY N-FORMYLMETHIONYL-LEUCYL-PHENYLALANINE OR GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE THREONINE KINASE; RABBIT SKELETAL-MUSCLE; TUMOR-NECROSIS-FACTOR; ERK-1 GENE-PRODUCT; MAP KINASE; RESPIRATORY BURST; HUMAN-NEUTROPHILS; SIGNAL TRANSDUCTION; PHOSPHORYLATION; RECEPTOR	Incubation of polymorphonuclear leukocytes with chemoattractants, granulocyte-macrophage colony-stimulating factor (GM-CSF), or phorbol 12-myristate 13-acetate (PMA) activated both mitogen-activated protein kinase kinase (MAPKK) and mitogen-activated protein kinase (MAPK). Activation by chemoattractants was rapid and transient, being maximal by 1 min and decreasing by 10 min. The order of efficacy was formyl-met-leu-phe > C5a > > LTB4 > interleukin 8 > platelet-activating factor. In contrast, activation by GM-CSF or PMA was slow and sustained being maximal at 5 min and with little decrease by 30 min. Sustained MAPK activation required continuous activation of the MAPKK. The MAPKK induced by N-formylmethionyl-leucyl-phenylalanine, GM-CSF, or PMA was resolved into two forms by anion exchange chromatography (Mono Q). Both corresponded to a 45-kDa MAPKK antigen by Western blotting and were inactivated by serine/threonine protein phosphatase 2A. Rechromatography of both forms after dephosphorylation resulted in the antigen's eluting slightly earlier on the Mono Q gradient than when in the active state. However, the two peaks remained separate, suggesting that they are not merely different phosphoforms of the same enzyme. The MAPK cascade is a signaling pathway common to many polymorphonuclear leukocyte stimulants, which may be activated transiently or in a sustained manner.	INST CANC RES, CHESTER BEATTY LABS, LONDON SW3 6JB, ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	THOMPSON, HL (corresponding author), BABRAHAM INST, DEPT DEV & SIGNALLING, CYTOKINE LAB, BABRAHAM CB2 4AT, CAMBS, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ASHWORTH A, 1992, ONCOGENE, V7, P2555; BAGGIOLINI M, 1990, TRENDS BIOCHEM SCI, V15, P69, DOI 10.1016/0968-0004(90)90179-F; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DEVRIESSMITS AMM, 1993, SCIENCE, V357, P602; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOMEZCAMBRONERO J, 1992, P NATL ACAD SCI USA, V89, P7551, DOI 10.1073/pnas.89.16.7551; GOMEZCAMBRONERO J, 1990, ADV EXP MED BIOL, V314, P35; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HSUAN JJ, 1989, BIOCHEM J, V259, P519, DOI 10.1042/bj2590519; HUGHES DA, 1993, NATURE, V364, P349, DOI 10.1038/364349a0; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; JAISWAL RK, 1993, J BIOL CHEM, V268, P7055; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MCCOLL SR, 1990, J IMMUNOL, V145, P3047; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; OHTA S, 1992, EUR J BIOCHEM, V206, P895, DOI 10.1111/j.1432-1033.1992.tb16998.x; OKUDA K, 1992, BLOOD, V79, P2880; OMANN GM, 1987, PHYSIOL REV, V67, P285, DOI 10.1152/physrev.1987.67.1.285; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; RAINES MA, 1992, BLOOD, V79, P3350; RICHTER J, 1989, J IMMUNOL, V142, P3199; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATOH T, 1992, J BIOL CHEM, V267, P2537; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SEGER R, 1992, J BIOL CHEM, V267, P14373; SKLAR LA, 1986, ADV IMMUNOL, V39, P95; SOZERI O, 1992, ONCOGENE, V7, P2259; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; THOMPSON HL, 1993, BIOCHEM J, V290, P483, DOI 10.1042/bj2900483; TORRES M, 1993, J IMMUNOL, V150, P1563; WEINGARTEN R, 1990, IMMUNOL LETT, V26, P1, DOI 10.1016/0165-2478(90)90167-O; WU J, 1992, BIOCHEM J, V285, P701, DOI 10.1042/bj2850701; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; WYMANN MP, 1987, J BIOL CHEM, V262, P12048; XING MZ, 1992, J BIOL CHEM, V267, P25966	50	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9486	9492						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144533				2022-12-25	WOS:A1994NE05300017
J	LOH, C; ROMEO, C; SEED, B; BRUDER, JT; RAPP, U; RAO, A				LOH, C; ROMEO, C; SEED, B; BRUDER, JT; RAPP, U; RAO, A			ASSOCIATION OF RAF WITH THE CD3 DELTA-CHAIN AND GAMMA-CHAIN OF THE T-CELL RECEPTOR-CD3 COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SERINE-THREONINE KINASE; PDGF BETA-RECEPTOR; ANTIGEN RECEPTOR; GROWTH-FACTOR; SIGNAL TRANSDUCTION; ZETA-CHAIN; PHOSPHOLIPASE-C; MONOCLONAL-ANTIBODY; BINDING-SITE	Protein kinases and phosphatases play an important role in signal transduction. In the T cell, activation via the T cell receptor-CD3 complex results in rapid tyrosine phosphorylation of proteins, as well as subsequent increases in serine/threonine phosphorylation. The Raf serine/threonine kinase has been implicated in many receptor signaling pathways, including those of platelet-derived growth factor, epidermal growth factor, insulin, and interleukin-2 receptors. We show here that Raf is associated with the T cell receptor-CD3 complex in unstimulated murine T cells. Using a COS cell expression system, we show that a hypophosphorylated form of Raf specifically associates with the CD3 gamma and delta chains but not with the CD3 epsilon or zeta chains. These results suggest that Raf mediates signal transduction from the gamma and delta chains of the T cell receptor-CD3 complex, analogous to the role played by ZAP-70 in signal transduction mediated by the zeta chain.	DIV TUMOR VIROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA; NCI, FREDERICK CANC RES & DEV CTR, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21702 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027849, R37AI027849] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27849] Funding Source: Medline; NIGMS NIH HHS [GM46227] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANIYASH M, 1988, J BIOL CHEM, V263; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CANTRELL D, 1987, NATURE, V325, P540, DOI 10.1038/325540a0; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; DASGUPTA JD, 1992, J EXP MED, V175, P285, DOI 10.1084/jem.175.1.285; DAVIES AA, 1987, J BIOL CHEM, V262, P10918; DYEMECKI SM, 1990, SCIENCE, V247, P332; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYET C, 1991, P NATL ACAD SCI USA, V88, P2346, DOI 10.1073/pnas.88.6.2346; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MASLINSKI W, 1992, J BIOL CHEM, V267, P15281; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NARDONE J, 1993, IN PRESS P NATL ACAD; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RAO A, 1984, J EXP MED, V159, P479, DOI 10.1084/jem.159.2.479; RAPP UR, 1991, ONCOGENE, V6, P495; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WONG JGP, 1990, J BIOL CHEM, V265, P4685; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	62	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8817	8825						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132616				2022-12-25	WOS:A1994NB41100033
J	UCHIDA, C; FUNAI, T; ODA, T; OHBAYASHI, K; ICHIYAMA, A				UCHIDA, C; FUNAI, T; ODA, T; OHBAYASHI, K; ICHIYAMA, A			REGULATION BY GLUCAGON OF SERINE-PYRUVATE/ALANINE-GLYOXYLATE AMINOTRANSFERASE GENE-EXPRESSION IN CULTURED RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; NUCLEAR FACTOR CREB; PROTEIN-KINASE-C; CYCLIC-AMP; GLUCOCORTICOID RECEPTOR; SOMATOSTATIN GENE; MULTIHORMONAL REGULATION; MITOCHONDRIAL SERINE; DEPENDENT ACTIVATION; LIVER MITOCHONDRIA	The effects of glucagon on serine:pyruvate/alanine: glyoxylate aminotransferase (SPT/AGT) gene expression were studied in primary cultured rat hepatocytes. When hepatocytes had been precultured for 16-18 h under serum- and hormone-free conditions, the addition of glucagon caused (after a lag period of about 2 h) a remarkable increase in the cellular level of SPT/AGT mRNA by 4 h in a time- and dose-dependent manner. The induced mRNA was that far mitochondrial SPT/AGT, as judged by ribonuclease protection analysis. A nuclear run-on assay revealed that activation of transcription is responsible for the increase in mitochondrial SPT/AGT mRNA and that the maximal rate of transcription occurs 1.5 h after glucagon addition, The effect of glucagon was mimicked by 8-bromo-cAMP and suppressed by N-[2-(p-bromocinnamylamino) ethyl]-5-isoquinolinesulfonamide, an inhibitor of cAMP-dependent protein kinase (protein kinase A), while both 12-O-tetradecanoylphorbol-13-acetate and A23187 were without effect in elevating the SPT/AGT mRNA level, suggesting that the cAMP/protein kinase A system is involved in the regulation of SPT/AGT gene expression. In hepatocytes precultured for 16-18 h under serum- and hormone-free conditions, the glucagon-induced transcription was severely inhibited by cycloheximide. When the preculture was for 2 h, on the other hand, the activation of transcription by glucagon was more rapid, and the inhibition by cycloheximide was less than that observed with cells precultured for 16-18 h, suggesting that a short-lived protein factor is involved in the hormonal regulation. The glucagon-induced expression of the SPT/AGT gene was also turned off by dexamethasone.			UCHIDA, C (corresponding author), HAMAMATSU UNIV SCH MED, DEPT BIOCHEM, 3600 HANDA CHO, HAMAMATSU, SHIZUOKA 43131, JAPAN.							BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHRIST B, 1990, BIOL CHEM H-S, V371, P395, DOI 10.1515/bchm3.1990.371.1.395; CORVERA S, 1984, BIOCHIM BIOPHYS ACTA, V804, P434, DOI 10.1016/0167-4889(84)90071-5; DEAN DC, 1989, MOL CELL BIOL, V9, P1498, DOI 10.1128/MCB.9.4.1498; EXTON JH, 1985, AM J PHYSIOL, V248, pE633, DOI 10.1152/ajpendo.1985.248.6.E633; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; IHRA H, 1990, J BIOL CHEM, V265, P22441; MARZLUFF WF, 1973, BIOCHEMISTRY-US, V12, P3440, DOI 10.1021/bi00742a013; MATSUDA T, 1990, J BIOCHEM-TOKYO, V108, P778, DOI 10.1093/oxfordjournals.jbchem.a123280; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; MIYAJIMA H, 1989, J BIOCHEM-TOKYO, V105, P500, DOI 10.1093/oxfordjournals.jbchem.a122695; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORI M, 1992, GENOMICS, V13, P686, DOI 10.1016/0888-7543(92)90142-F; NAKAMURA T, 1987, J BIOL CHEM, V262, P727; NODA C, 1988, J BIOL CHEM, V263, P14764; NOGUCHI T, 1978, BIOCHEM J, V170, P173, DOI 10.1042/bj1700173; NORTHROP JP, 1992, J EXP MED, V175, P1235, DOI 10.1084/jem.175.5.1235; ODA T, 1981, BIOCHEM BIOPH RES CO, V102, P568, DOI 10.1016/0006-291X(81)91557-6; ODA T, 1993, GENOMICS, V17, P59, DOI 10.1006/geno.1993.1283; ODA T, 1984, J BIOCHEM, V95, P815, DOI 10.1093/oxfordjournals.jbchem.a134673; ODA T, 1982, J BIOCHEM, V91, P219, DOI 10.1093/oxfordjournals.jbchem.a133679; ODA T, 1987, EUR J BIOCHEM, V168, P537, DOI 10.1111/j.1432-1033.1987.tb13451.x; ODA T, 1990, J BIOL CHEM, V265, P7513; PETERSEN OH, 1986, NATURE, V323, P18, DOI 10.1038/323018a0; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; RUNGE D, 1991, EUR J BIOCHEM, V198, P641, DOI 10.1111/j.1432-1033.1991.tb16062.x; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SILVER G, 1990, J BIOL CHEM, V265, P3134; STALLCUP MR, 1983, J BIOL CHEM, V258, P2802; TANAKA K, 1978, J BIOCHEM-TOKYO, V84, P937, DOI 10.1093/oxfordjournals.jbchem.a132207; TANG EKY, 1992, BIOCHEM J, V283, P341, DOI 10.1042/bj2830341; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; WAKELAM MJO, 1986, NATURE, V323, P68, DOI 10.1038/323068a0; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOKOTA S, 1984, HISTOCHEMISTRY, V80, P591, DOI 10.1007/BF02400977; YOKOTA S, 1991, BIOMED RES-TOKYO, V12, P53, DOI 10.2220/biomedres.12.53	44	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8849	8856						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132620				2022-12-25	WOS:A1994NB41100037
J	WOJCIKIEWICZ, RJH; FURUICHI, T; NAKADE, S; MIKOSHIBA, K; NAHORSKI, SR				WOJCIKIEWICZ, RJH; FURUICHI, T; NAKADE, S; MIKOSHIBA, K; NAHORSKI, SR			MUSCARINIC RECEPTOR ACTIVATION DOWN-REGULATES THE TYPE-I INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR BY ACCELERATING ITS DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; CEREBELLAR GRANULE CELLS; TRISPHOSPHATE RECEPTOR; FUNCTIONAL EXPRESSION; ENDOPLASMIC-RETICULUM; INTRACELLULAR CA-2+; INHIBITION; SH-SY5Y; BINDING; STIMULATION	Stimulation of SH-SY5Y human neuroblastoma cells with carbachol, a muscarinic agonist, down-regulates the type I inositol 1,4,5 trisphosphate (InsP(3)) receptor by > 90% with maximal and half-maximal effects after similar to 6 h and similar to 1 h, respectively. Examination of the mechanistic basis of this down-regulation revealed that carbachol increased the rate of type I InsP(3) receptor degradation (radiolabeled immunoprecipitable receptor was lost from cells with half-times of > 8 h and similar to 1 h in the absence and presence of carbachol, respectively) and that the concentration of type I InsP(3) receptor mRNA, despite a transient decrease after 3 h, did not correlate with levels of the receptor. Only those muscarinic receptor subtypes coupled to stimulation of phosphoinositide hydrolysis were capable of causing type I InsP(3) receptor down-regulation. Ca2+ mobilization was pivotal to the mechanism of receptor down-regulation, since perturbation of Ca2+ homeostasis with either EGTA or thapsigargin blocked the ability of carbachol to accelerate receptor degradation. Studies with thapsigargin also revealed that both functional InsP(3)-sensitive Ca2+ stores and persistent elevation of InsP(3) concentration were required for down-regulation to occur. In conclusion, phosphoinositidase C-linked muscarinic receptors down-regulate the type I InsP(3) receptor by accelerating its degradation. It appears that this process is initiated by persistent discharge of intracellular Ca2+ stores via the channels formed by tetramerically complexed type I InsP(3) receptors.	UNIV LEICESTER,DEPT CELL PHYSIOL & PHARMACOL,LEICESTER LE1 9HN,ENGLAND; UNIV TOKYO,INST MED SCI,DEPT MOLEC NEUROBIOL,MINATO KU,TOKYO 108,JAPAN	University of Leicester; University of Tokyo			Mikoshiba, Katsuhiko/N-7943-2015	Furuichi, Teiichi/0000-0002-9676-1888	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADFORD PG, 1992, J BIOL CHEM, V267, P20959; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; CHALLISS RAJ, 1993, METH NEUROSCI, V18, P224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FERRIS CD, 1992, J NEUROSCI, V12, P1567; FUKAMAUCHI F, 1991, J NEUROCHEM, V56, P716, DOI 10.1111/j.1471-4159.1991.tb08210.x; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1993, RECEPTOR CHANNEL, V1, P11; GERSHENGORN MC, 1986, ANNU REV PHYSIOL, V48, P515; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; LAMBERT DG, 1990, BIOCHEM J, V265, P555, DOI 10.1042/bj2650555; LAMBERT DG, 1990, BIOCHEM PHARMACOL, V40, P2291, DOI 10.1016/0006-2952(90)90725-Z; MAGNUSSON A, 1993, FEBS LETT, V323, P229, DOI 10.1016/0014-5793(93)81345-Z; MCGOWAN EB, 1989, BIOCHEM BIOPH RES CO, V158, P432, DOI 10.1016/S0006-291X(89)80065-8; MENNITI FS, 1991, MOL PHARMACOL, V40, P727; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MITCHELL FM, 1993, BIOCHEM J, V293, P495, DOI 10.1042/bj2930495; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; NAKADE S, 1991, BIOCHEM J, V277, P125, DOI 10.1042/bj2770125; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Sambrook J, 1989, MOL CLONING LABORATO; STEEL MC, 1993, MOL PHARMACOL, V43, P694; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOBIN AB, 1992, MOL PHARMACOL, V42, P1042; WALL SJ, 1991, MOL PHARMACOL, V40, P783; WATRAS J, 1991, J NEUROSCI, V11, P3239; WHITHAM EM, 1991, EUR J PHARM-MOLEC PH, V206, P181, DOI 10.1016/S0922-4106(05)80017-3; WOJCIKIEWICZ RJH, 1992, J NEUROCHEM, V59, P383, DOI 10.1111/j.1471-4159.1992.tb08916.x; WOJCIKIEWICZ RJH, 1991, J BIOL CHEM, V266, P22234; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3; WOJCIKIEWICZ RJH, 1994, IN PRESS J NEUROCHEM	40	127	128	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7963	7969						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132516				2022-12-25	WOS:A1994NB40900023
J	GOMEZPUERTAS, P; SATRUSTEGUI, J; BOGONEZ, E				GOMEZPUERTAS, P; SATRUSTEGUI, J; BOGONEZ, E			SYNAPTIC VESICLES ISOLATED FROM P-32 PRELABELED SYNAPTOSOMES CONTAIN A PHOSPHOPROTEIN OF APPARENT M(R) 65,000 (PP65), A POSSIBLE SUBSTRATE FOR PKC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RAT CORTICAL SYNAPTOSOMES; NEUROTRANSMITTER RELEASE; PHORBOL ESTER; BRAIN SYNAPTOSOMES; NORADRENALINE RELEASE; INTACT SYNAPTOSOMES; MEMBRANE-PROTEINS; GLUTAMATE RELEASE; PHASE-SEPARATION	the present study, we have investigated the subcellular localization of pp65, a synaptosomal phosphoprotein of apparent M(r)65,000. The results obtained strongly support that pp65 is localized to synaptic vesicles. The solubility properties of pp65, especially its partitioning into the detergent phase of Triton X-114, indicated that it is tightly associated with the membrane of synaptic vesicles. pp65 is multiply phosphorylated exclusively on serine. By studying the decay of labeled phosphate following incubation of P-32-prelabeled synaptosomes in the presence of cold inorganic phosphate, we have found that pp65 shows an unusually high turnover of phosphate. Exposure of synaptosomes to 1 mu m phorbol 12-myristate 13-acetate prior to prelabeling with P-32(i) led to a reduction in the steady state phosphorylation of pp65, and tryptic/chymotryptic mapping was shown to selectively affect phosphopeptide 4. Identical results were obtained following incubation of synaptosomes with the protein kinase C (PKC) inhibitor, GF109203 X. These results indicated that one of the protein kinases involved in steady state phosphorylation of pp65 is PKC dependent or is PKC itself. Several characteristics of pp65 reported in the present study suggest a regulatory role in nerve terminal function.	UNIV AUTONOMA MADRID, CONSEJO SUPER INVEST CIENT, CTR BIOL MOLEC SEVERO OCHOA, DEPT BIOL MOLEC, E-28049 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Satrustegui, Jorgina/R-6732-2019; Gomez-Puertas, Paulino/G-8821-2014	Gomez-Puertas, Paulino/0000-0003-3131-729X; Satrustegui Gil Delgado, Jorgina/0000-0003-3377-2667				ABDULGHANI M, 1991, P NATL ACAD SCI USA, V88, P1803, DOI 10.1073/pnas.88.5.1803; ADAMVIZI V, 1983, J NEUROCHEM, V41, P780, DOI 10.1111/j.1471-4159.1983.tb04808.x; AGUILERA J, 1993, J NEUROCHEM, V60, P709, DOI 10.1111/j.1471-4159.1993.tb03205.x; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOGONEZ E, 1992, NEUROSCI LETT, V142, P123, DOI 10.1016/0304-3940(92)90354-A; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUXBAUM JD, 1987, J NEUROCHEM, V49, P1161, DOI 10.1111/j.1471-4159.1987.tb10007.x; DEKKER LV, 1989, J NEUROCHEM, V52, P24, DOI 10.1111/j.1471-4159.1989.tb10893.x; DEKKER LV, 1989, NATURE, V342, P74, DOI 10.1038/342074a0; DELORENZO RJ, 1979, P NATL ACAD SCI USA, V76, P1838, DOI 10.1073/pnas.76.4.1838; DIAZGUERRA MJM, 1988, BIOCHIM BIOPHYS ACTA, V970, P157, DOI 10.1016/0167-4889(88)90174-7; DUNKLEY PR, 1986, J NEUROCHEM, V46, P1692; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; GOMEZPUERTAS P, 1991, J NEUROCHEM, V56, P2039, DOI 10.1111/j.1471-4159.1991.tb03464.x; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HELL JW, 1988, EMBO J, V7, P3023, DOI 10.1002/j.1460-2075.1988.tb03166.x; HOOPER NM, 1991, BIOCHEM J, V280, P745, DOI 10.1042/bj2800745; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; IPATA PL, 1968, BIOCHEMISTRY-US, V7, P507, DOI 10.1021/bi00842a004; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JOHNSTON PA, 1991, NEURON, V7, P101, DOI 10.1016/0896-6273(91)90078-E; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; KOSHLAND DE, 1987, TRENDS BIOCHEM SCI, V12, P225, DOI 10.1016/0968-0004(87)90114-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCMAHON HT, 1991, BIOCHIM BIOPHYS ACTA, V1059, P243, DOI 10.1016/S0005-2728(05)80210-5; NICHOLS RA, 1987, J NEUROCHEM, V48, P615, DOI 10.1111/j.1471-4159.1987.tb04137.x; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; ODA T, 1991, J NEUROCHEM, V56, P1263, DOI 10.1111/j.1471-4159.1991.tb11420.x; ROBINSON PJ, 1991, FEBS LETT, V282, P388, DOI 10.1016/0014-5793(91)80520-D; ROBINSON PJ, 1992, J BIOL CHEM, V267, P21637; ROBINSON PJ, 1983, J NEUROCHEM, V41, P909, DOI 10.1111/j.1471-4159.1983.tb09034.x; ROBINSON PJ, 1991, MOL NEUROBIOL, V5, P87, DOI 10.1007/BF02935541; ROBINSON PJ, 1991, NEUROSCI RES COMMUN, V9, P167; RODNIGHT R, 1986, J PHYSIOLOGY PARIS, V81, P340; SIHRA TS, 1992, J BIOL CHEM, V267, P1983; Thomas P, 1992, Curr Opin Neurobiol, V2, P308, DOI 10.1016/0959-4388(92)90120-A; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; Wharton DC., 1967, METHOD ENZYMOL, P245; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; WILKINSON RJ, 1989, NEUROCHEM INT, V15, P191, DOI 10.1016/0197-0186(89)90100-9; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249	46	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7564	7570						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125979				2022-12-25	WOS:A1994NA03200084
J	HOUWELING, M; JAMIL, H; HATCH, GM; VANCE, DE				HOUWELING, M; JAMIL, H; HATCH, GM; VANCE, DE			DEPHOSPHORYLATION OF CTP PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE IS NOT REQUIRED FOR BINDING TO MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED RAT HEPATOCYTES; CHOLINE-PHOSPHATE CYTIDYLTRANSFERASE; CHINESE-HAMSTER OVARY; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; FATTY-ACIDS; HELA-CELLS; ENDOPLASMIC-RETICULUM; OKADAIC ACID; PHOSPHORYLCHOLINE CYTIDYLYLTRANSFERASE; INDUCED INHIBITION	The sequence of the reversible phosphorylation and activation of CTP:phosphocholine cytidylyltransferase was investigated. Treatment of primary rat hepatocytes with oleic acid or phospholipase C caused a significant increase in the activity and amount of particulate cytidylyltransferase which correlated with decreased cytidylyltransferase activity and protein in the cytosol. The increase in membrane associated cytidylyltransferase is accompanied by a decrease in the phosphorylation of the enzyme. Reversal of membrane association resulted in an increased amount of phosphorylated cytidylyltransferase in the cytosol. We wished to determine if dephosphorylation of the enzyme were a prerequisite for its translocation from the cytosol to the membranes. In vitro studies with membranes from oleic acid- or phospholipase C-treated cells showed that phosphorylated cytosolic cytidylyltransferase associated with these membranes with negligible dephosphorylation. Incubation of hepatocytes with oleic acid for different periods of time demonstrated that cytidylyltransferase associated with membranes in an active, phosphorylated form and was subsequently dephosphorylated. This result was supported by comparison of phosphopeptide maps of P-32-labeled cytidylyltransferase obtained from cytosolic, as well as membrane fractions of control, oleic acid-treated, or phospholipase C-treated cells. These studies revealed dephosphorylation on some sites and phosphorylation on other sites. Our data strengthen the hypothesis that a change in the lipid composition of membranes can mediate the initial binding of cytidylyltransferase to the membrane and that subsequently the enzyme becomes dephosphorylated.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,AB,CANADA	University of Alberta	HOUWELING, M (corresponding author), UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON T6G 2S2,AB,CANADA.							AEBERHARD EE, 1986, BIOCHIM BIOPHYS ACTA, V875, P6, DOI 10.1016/0005-2760(86)90004-4; ANDERSON KE, 1985, BIOCHIM BIOPHYS ACTA, V835, P360, DOI 10.1016/0005-2760(85)90292-9; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; CHANDER A, 1988, BIOCHIM BIOPHYS ACTA, V958, P343, DOI 10.1016/0005-2760(88)90219-6; COOK HW, 1985, CAN J BIOCHEM CELL B, V63, P145, DOI 10.1139/o85-021; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P26, DOI 10.1016/0005-2760(87)90214-1; DAVIS RA, 1979, J BIOL CHEM, V254, P2010; HATCH GM, 1992, J BIOL CHEM, V267, P15751; HATCH GM, 1990, BIOCHIM BIOPHYS ACTA, V1042, P374, DOI 10.1016/0005-2760(90)90167-V; HATCH GM, 1991, BIOCHIM BIOPHYS ACTA, V1081, P25, DOI 10.1016/0005-2760(91)90245-D; HOUWELING M, 1991, BIOCHEM J, V278, P347, DOI 10.1042/bj2780347; HOUWELING M, 1993, EUR J BIOCHEM, V214, P927, DOI 10.1111/j.1432-1033.1993.tb17996.x; JAMIL H, 1993, BIOCHEM J, V291, P419, DOI 10.1042/bj2910419; JAMIL H, 1990, J BIOL CHEM, V265, P4332; JAMIL H, 1992, J BIOL CHEM, V267, P1752; KENNEDY EP, 1988, LIPIDS MEMBRANES PAS, P171; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; KISS Z, 1992, ARCH BIOCHEM BIOPHYS, V296, P457, DOI 10.1016/0003-9861(92)90597-P; MOCK T, 1986, BIOCHEM CELL BIOL, V64, P413, DOI 10.1139/o86-058; PADDON HB, 1980, BIOCHIM BIOPHYS ACTA, V620, P636, DOI 10.1016/0005-2760(80)90156-3; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P433, DOI 10.1016/0005-2760(84)90169-3; PELECH SL, 1983, J BIOL CHEM, V258, P6782; PELECH SL, 1981, J BIOL CHEM, V256, P8283; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; SANGHERA JS, 1989, J BIOL CHEM, V264, P1215; SLACK BE, 1991, J BIOL CHEM, V266, P24503; SLEIGHT R, 1983, J BIOL CHEM, V258, P836; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; TIJBURG LBM, 1990, BIOCHIM BIOPHYS ACTA, V1004, P1; UTAL AK, 1991, J BIOL CHEM, V266, P24084; Vance D E, 1981, Methods Enzymol, V71 Pt C, P576; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; WATKINS JD, 1992, ARCH BIOCHEM BIOPHYS, V292, P360, DOI 10.1016/0003-9861(92)90003-F; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WEINHOLD PA, 1984, J BIOL CHEM, V259, P315; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; YAO ZM, 1990, J BIOL CHEM, V265, P4326	38	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7544	7551						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125976				2022-12-25	WOS:A1994NA03200081
J	YAMAMOTO, H; LAMPHIER, MS; FUJITA, T; TANIGUCHI, T; HARADA, H				YAMAMOTO, H; LAMPHIER, MS; FUJITA, T; TANIGUCHI, T; HARADA, H			THE ONCOGENIC TRANSCRIPTION FACTOR IRF-2 POSSESSES A TRANSCRIPTIONAL REPRESSION AND A LATENT ACTIVATION DOMAIN	ONCOGENE			English	Article							INTERFERON-BETA GENE; NF-KAPPA-B; IFN-INDUCIBLE GENES; REGULATORY ELEMENTS; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; VIRUS INDUCTION; ALPHA PROMOTER; LEXA GENE; EXPRESSION	IRF-1 and IRF-2 are two structurally related transcription factors originally identified as regulators of the type I interferon (IFN) system. IRF-1 functions as an activator whereas IRF-2 binds to the same cis-elements and can repress IRF-1 action. More recently these two factors have been shown to act in a mutually antagonistic manner to regulate cell growth; overexpression of the repressor IRF-2 leads to cell transformation, whereas concomitant overexpression of IRF-1 leads to reversion. Previous studies have identified DNA-binding domains in IRF-1 and IRF-2 and an activation domain in IRF-1. In the present study we show that IRF-2 also possesses a transcriptional repression domain in its carboxyl terminal region. We further observe that a LexA-IRF2 fusion can inhibit the function of an activator positioned nearby in the promoter. Thus, repression by IRF-2 may involve both competition with IRF-1 for binding to the promoter as well as the 'silencing' of nearby activators. Furthermore, we demonstrate the presence of a latent activation domain in the central region of IRF-2 and speculate that IRF-2 may contribute to gene activation under certain conditions.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN	Osaka University			Harada, Hisashi/H-2815-2019	Harada, Hisashi/0000-0001-5993-1289				AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; CLEMENS MJ, 1985, BIOCHEM J, V226, P345, DOI 10.1042/bj2260345; COHEN L, 1991, CELL GROWTH DIFFER, V2, P323; Demaeyer E., 1988, INTERFERONS OTHER RE; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; HAGGARTY A, 1991, CELL GROWTH DIFFER, V2, P503; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HORII T, 1981, CELL, V23, P689, DOI 10.1016/0092-8674(81)90432-3; ITOH S, 1989, NUCLEIC ACIDS RES, V17, P8372, DOI 10.1093/nar/17.20.8372; ITOH S, 1991, GENOMICS, V10, P1097, DOI 10.1016/0888-7543(91)90208-V; JAYNES J, 1988, EMBO J, V10, P1427; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KUHL D, 1987, CELL, V50, P1057, DOI 10.1016/0092-8674(87)90172-3; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MARKHAM BE, 1981, NUCLEIC ACIDS RES, V9, P4149, DOI 10.1093/nar/9.16.4149; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SALTMAN DL, 1993, GENOMICS, V16, P726, DOI 10.1006/geno.1993.1254; SEN GC, 1992, J BIOL CHEM, V267, P5017; TAMM I, 1987, INTERFERON, V9, P14; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VILCEK J, 1990, PEPTIDE GROWTH FACTO, V2, P3; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156	48	65	67	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1423	1428						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152803				2022-12-25	WOS:A1994NH40100014
J	MOUTIN, MJ; CUILLEL, M; RAPIN, C; MIRAS, R; ANGER, M; LOMPRE, AM; DUPONT, Y				MOUTIN, MJ; CUILLEL, M; RAPIN, C; MIRAS, R; ANGER, M; LOMPRE, AM; DUPONT, Y			MEASUREMENTS OF ATP BINDING ON THE LARGE CYTOPLASMIC LOOP OF THE SARCOPLASMIC-RETICULUM CA2+-ATPASE OVEREXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; PLASMA-MEMBRANE; CATALYTIC SITE; FLUORESCEIN ISOTHIOCYANATE; ADENOSINE 5'-TRIPHOSPHATE; FUNCTIONAL CONSEQUENCES; SKELETAL-MUSCLE; CA-ATPASE; ION PUMPS; H+-ATPASE	The large cytoplasmic loop of the sarcoplasmic reticulum Ca2+-ATPase (LCL), situated between Lys329 and Phe740, is believed to contain both its phosphorylation and ATP binding domains. A cDNA fragment coding for this amino acid sequence was generated in vitro and cloned in vector pQE8 which allowed the overexpression in Escherichia coli of this Ca2+-ATPase domain fused with a cluster of 6 histidines at its NH2 terminus. The fusion protein produced in an insoluble form within bacteria was solubilized in 4 M urea, purified on immobilized Ni2+, and then renatured by elimination of urea. More than 4 mg of purified renatured fusion protein was obtained from 500 ml of culture. ATP binding on the refolded protein was demonstrated by two methods: 1) detection of ATP-induced intrinsic fluorescence change and 2) binding of the fluorescent ATP analogue 2',3'-O-(2,4,6-trinitrophenyl)adenosine-5'-triphosphate (TNP-ATP) and its chase by ATP. It is shown that the LCL protein has one single TNP-ATP binding site having a dissociation constant (K(d)) of 1.6-1.9 muM. Both methods yielded a K(d) for ATP around 200 muM. Binding of other nucleotides was detected with a sequence of K(d) identical to that found for native Ca2+-ATPase: ATP < ADP < GTP < AMP < ITP. A Mg2+ binding site was also found on the LCL protein (K(d) = 100 muM at pH 7.2). The fluorescence of bound TNP-ATP was found to be highly dependent on Mg2+ binding on this site.	ECOLE POLYTECH, ECOLE NATL SUPER TECHN AVANCEES,INSERM,U275LOA, CTR YVETTE, F-91128 PALAISEAU, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Polytechnique de Paris	MOUTIN, MJ (corresponding author), CEA, DBMS BMC, CNRS, URA 520, BIOPHYS MOLEC & CELLULAIRE LAB, F-38054 GRENOBLE, FRANCE.		LOMPRE, Anne-Marie/H-2872-2013; Moutin, Marie-Jo/P-7518-2017	Moutin, Marie-Jo/0000-0003-2681-9818				AINSWORTH S, 1977, STEADY STATE ENZYME, P38; BIGELOW DJ, 1992, BIOCHIM BIOPHYS ACTA, V1113, P323, DOI 10.1016/0304-4157(92)90005-U; BISHOP JE, 1987, J BIOL CHEM, V262, P4658; BLACKWELL JR, 1991, FEBS LETT, V295, P10, DOI 10.1016/0014-5793(91)81372-F; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; CHAMPEIL P, 1986, FEBS LETT, V206, P86; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; DAVIDSON GA, 1987, J BIOL CHEM, V262, P7041; de Meis L, 1973, J Biol Chem, V248, P3691; DEJESUS F, 1993, FEBS LETT, V332, P229, DOI 10.1016/0014-5793(93)80638-B; DUFOUR JP, 1988, METHOD ENZYMOL, V157, P513; DUPONT Y, 1985, J BIOL CHEM, V260, P7241; DUPONT Y, 1977, EUR J BIOCHEM, V72, P185, DOI 10.1111/j.1432-1033.1977.tb11238.x; DUPONT Y, 1982, BIOCHEM BIOPH RES CO, V106, P1272, DOI 10.1016/0006-291X(82)91250-5; DUPONT Y, 1978, NATURE, V273, P396, DOI 10.1038/273396a0; DUPONT Y, 1983, FEBS LETT, V156, P93, DOI 10.1016/0014-5793(83)80255-5; ENOUF J, 1988, J BIOL CHEM, V263, P13922; FERREIRA ST, 1989, J BIOL CHEM, V264, P15392; Fiske CH, 1925, J BIOL CHEM, V66, P375; FORGE V, 1993, J BIOL CHEM, V268, P10953; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GREEN NM, 1992, ACTA PHYSIOL SCAND, V146, P59; GREEN NM, 1989, BIOCHEM SOC T, V17, P819, DOI 10.1042/bst0170819; GUILLAIN F, 1982, J BIOL CHEM, V257, P7366; GUILLAIN F, 1980, J BIOL CHEM, V255, P2072; HASSELBACH W, 1963, BIOCHEM Z, V339, P94; Hochuli E, 1990, Genet Eng (N Y), V12, P87; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMPRE AM, 1989, FEBS LETT, V249, P35, DOI 10.1016/0014-5793(89)80010-9; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; NOJIMA H, 1977, J MOL BIOL, V116, P429, DOI 10.1016/0022-2836(77)90078-X; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; PICK U, 1981, EUR J BIOCHEM, V121, P187, DOI 10.1111/j.1432-1033.1981.tb06448.x; RONJAT M, 1986, THESIS U GRENOBLE GR; RONZANI N, 1979, EUR J BIOCHEM, V101, P593, DOI 10.1111/j.1432-1033.1979.tb19754.x; SERRANO R, 1990, BIOCHIM BIOPHYS ACTA, V1018, P195, DOI 10.1016/0005-2728(90)90247-2; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SUZUKI H, 1990, BIOCHEMISTRY-US, V29, P7040, DOI 10.1021/bi00482a013; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; VANWINKLE WB, 1981, J BIOL CHEM, V256, P2268; WACH A, 1990, EUR J BIOCHEM, V189, P675, DOI 10.1111/j.1432-1033.1990.tb15536.x; WATANABE T, 1982, J BIOL CHEM, V257, P1510; ZAK B, 1961, CLIN CHIM ACTA, V6, P665, DOI 10.1016/0009-8981(61)90112-7	52	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11147	11154						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157641				2022-12-25	WOS:A1994NF96600029
J	DAVIDSON, D; FOURNEL, M; VEILLETTE, A				DAVIDSON, D; FOURNEL, M; VEILLETTE, A			ONCOGENIC ACTIVATION OF P59(FYN) TYROSINE PROTEIN-KINASE BY MUTATION OF ITS CARBOXYL-TERMINAL SITE OF TYROSINE PHOSPHORYLATION, TYROSINE-528	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTANT MICE; SH3 DOMAINS; T-CELLS; P56LCK; FYN; TRANSFORMATION; ANTIGEN; GENE; RECEPTOR; REGION	As a result of alternative splicing, the Src-related tyrosine protein kinase p59(fyn) consists of two distinct isoforms termed FynB and FynT. Whereas the first product accumulates principally in brain, the second is expressed in hemopoietic cells, especially in T-lymphocytes. There is increasing evidence that the Fyn proteins are critical for normal functions of neuronal and lymphoid cells. To better understand the regulation of the catalytic function of p59(fyn), we have tested the effects of mutating the major site of in vivo tyrosine phosphorylation, tyrosine 528, on the biological and biochemical properties of this enzyme. Our studies showed that a tyrosine 528 --> phenylalanine (Y528F) mutation converted either Fyn isoform into a dominant oncoprotein, capable of full transformation of rodent fibroblasts. However, while both Y528F p54(fynT) and Y528F p59(fynB) were able to transform NTH 3T3 cells, activated FynT molecules were consistently more efficient at this process. It was also found that expression of wild-type p59(fyn) or kinase-defective Y528F Fyn molecules failed to provoke transformation of NIH 3T3 cells, implying that the transforming capabilities of Y528F Fyn relied on deregulated catalytic activity. Contrary to an earlier study (Cheng, S. H., Espino, P. C., Marshall, J., Harvey, R, Merrill, J., and Smith, A. E, (1991) J. Virol. 65, 170-179), these findings showed that mutation of the conserved carboxyl-terminal tyrosine residue markedly stimulated the catalytic function of p59(fyn) in vivo, implying that dephosphorylation of tyrosine 528 is sufficient to produce biologically relevant activation of the Fyn kinase. Moreover, our results provided further indication that the two Fyn isoforms possess distinct biochemical activities that may dictate functional differences in normal cell physiology.	MCGILL UNIV,CTR CANC,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL H3G 1Y6,PQ,CANADA; MONTREAL GEN HOSP,DEPT MED,DIV MED ONCOL,MONTREAL H3G 1A4,PQ,CANADA	McGill University; McGill University; McGill University; McGill University; McGill University								ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COOKE M P, 1989, New Biologist, V1, P66; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HOMMA Y, 1992, J BIOL CHEM, V267, P3778; HORAK ID, 1990, ONCOGENE, V5, P597; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LUO K, 1990, ONCOGENE, V5, P803; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PIWINICAWORMS H, 1987, CELL, V49, P75; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SARTOR O, 1993, J BIOL CHEM, V268, P21014; SEMBA K, 1990, MOL CELL BIOL, V10, P3095, DOI 10.1128/MCB.10.6.3095; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; STANNERS CP, 1971, NATURE-NEW BIOL, V230, P52, DOI 10.1038/newbio230052a0; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; SUGIE K, 1991, P NATL ACAD SCI USA, V88, P9132, DOI 10.1073/pnas.88.20.9132; TAUEN LKT, 1992, MOL CELL BIOL, V12, P5438; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; VEILLETTE A, 1992, ONCOGENE, V7, P971; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; ZIEGLER SF, 1989, MOL CELL BIOL, V9, P2724, DOI 10.1128/MCB.9.6.2724	42	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10956	10963						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144681				2022-12-25	WOS:A1994NF01700111
J	ELKHOURY, J; THOMAS, CA; LOIKE, JD; HICKMAN, SE; CAO, L; SILVERSTEIN, SC				ELKHOURY, J; THOMAS, CA; LOIKE, JD; HICKMAN, SE; CAO, L; SILVERSTEIN, SC			MACROPHAGES ADHERE TO GLUCOSE-MODIFIED BASEMENT-MEMBRANE COLLAGEN-IV VIA THEIR SCAVENGER RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NON-ENZYMATIC GLUCOSYLATION; GLYCOSYLATION END-PRODUCTS; HUMAN-MONOCYTES; CELL-LINE; BINDING; IDENTIFICATION; COMPLICATIONS; DEGRADATION; ADHESION; PROTEINS	Scavenger receptors have been reported to mediate macrophage adhesion to serum coated plastic surfaces. We report here that scavenger receptors promote the divalent cation independent adhesion of human monocytes and macrophages to surfaces coated with non-enzymatically glycated collagen IV but not to surfaces coated with native collagen IV. Ligands for scavenger receptor types I and II blocked adhesion of monocytes and macrophages to non-enzymatically glycated collagen IV but had no effect on adhesion of these cells to albumin-coated surfaces. U937 human promonocyte-like cells transfected with cDNA encoding bovine scavenger receptor I or II adhered to surfaces coated with glycated-collagen IV but not to surfaces coated with native collagen IV. A synthetic peptide homologous to the domain of bovine scavenger receptor that binds modified low density lipoproteins (residues 327-343) inhibited the adhesion of U937 cells transfected with cDNA encoding bovine scavenger receptor II to glycated collagen IV, whereas a control peptide from the alpha helical domain of scavenger receptor II (residues 121-137) had no effect on adhesion of these cells. Macrophages plated on surfaces coated with glycated collagen IV were unable to endocytose acetylated low density lipoproteins from the medium, suggesting that their scavenger receptors were occupied in binding these cells to the substrate. These findings suggest new roles for scavenger receptors in the accelerated development of vascular lesions observed in diabetics.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PHYSIOL & CELLULAR BIOPHYS,NEW YORK,NY 10032	Columbia University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032210, P50HL021006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020516, R01AI020516] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-21006, HL-32210] Funding Source: Medline; NIAID NIH HHS [AI-20516] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACTON S, 1993, J BIOL CHEM, V268, P3530; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; COHEN MP, 1981, BIOCHEM BIOPH RES CO, V100, P1549, DOI 10.1016/0006-291X(81)90695-1; DAVIS GE, 1992, EXP CELL RES, V200, P242, DOI 10.1016/0014-4827(92)90170-D; EBLE AS, 1983, J BIOL CHEM, V258, P9406; FRAZER I, 1993, NATURE, V364, P343; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GREENBERG S, 1991, J IMMUNOL METHODS, V139, P115, DOI 10.1016/0022-1759(91)90358-M; HAYASHI K, 1991, BIOCHIM BIOPHYS ACTA, V1082, P152; JONES BM, 1989, J IMMUNOL METHODS, V125, P41, DOI 10.1016/0022-1759(89)90076-8; KIRSTEIN M, 1990, P NATL ACAD SCI USA, V87, P9010, DOI 10.1073/pnas.87.22.9010; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; KULL FC, 1983, APPL BIOCHEM BIOTECH, V8, P97, DOI 10.1007/BF02778090; LOIKE JD, 1991, P NATL ACAD SCI USA, V88, P1044, DOI 10.1073/pnas.88.3.1044; LOIKE JD, 1986, AM J PHYSIOL, V251, pC128, DOI 10.1152/ajpcell.1986.251.1.C128; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MICHL J, 1983, J EXP MED, V157, P1746, DOI 10.1084/jem.157.6.1746; PALKAMA T, 1991, IMMUNOLOGY, V74, P432; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TARSIO JF, 1988, DIABETES, V37, P532, DOI 10.2337/diabetes.37.5.532; TOBIAS JW, 1987, BLOOD, V69, P1265; VLASSARA H, 1985, P NATL ACAD SCI USA, V82, P5588, DOI 10.1073/pnas.82.17.5588; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; ZHANG HF, 1993, J BIOL CHEM, V268, P5535	26	151	156	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10197	10200						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144597				2022-12-25	WOS:A1994NF01700004
J	MALITSCHEK, B; WITTBRODT, J; FISCHER, P; LAMMERS, R; ULLRICH, A; SCHARTL, M				MALITSCHEK, B; WITTBRODT, J; FISCHER, P; LAMMERS, R; ULLRICH, A; SCHARTL, M			AUTOCRINE STIMULATION OF THE XMRK RECEPTOR TYROSINE KINASE IN XIPHOPHORUS MELANOMA-CELLS AND IDENTIFICATION OF A SOURCE FOR THE PHYSIOLOGICAL LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; SIMIAN SARCOMA-VIRUS; FMS PROTO-ONCOGENE; GROWTH-FACTOR; EGF RECEPTOR; MALIGNANT TRANSFORMATION; MESSENGER-RNA; FOREIGN GENES; VECTORS; SIS	The melanoma-inducing gene of Xiphophorus fish encodes the Xmrk receptor tyrosine kinase. Using a highly specific antiserum produced against the recombinant receptor expressed with a baculovirus, it is shown that Xmrk is the most abundant phosphotyrosine protein in fish melanoma and thus highly activated in the tumors. Studies on a melanoma cell line revealed that these cells produce an activity that considerably stimulates receptor autophosphorylation. The stimulating activity induces receptor down-regulation and can be depleted from the melanoma cell supernatant by the immobilized recombinant receptor protein. The fish melanoma cells can thus be considered autocrine tumor cells providing a source for future purification and characterization of the Xmrk ligand.	UNIV WURZBURG,BIOCTR,THEODOR BOVERI INST,DEPT PHYSIOL CHEM 1,D-97074 WURZBURG,GERMANY; UNIV BASEL,BIOCTR,DEPT CELL BIOL,CH-4056 BASEL,SWITZERLAND; MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY	University of Wurzburg; University of Basel; Max Planck Society			Wittbrodt, Joachim/D-4735-2014	Wittbrodt, Joachim/0000-0001-8550-7377; Schartl, Manfred/0000-0001-9882-5948				ADAM D, 1993, SCIENCE, V259, P816, DOI 10.1126/science.8430335; ADAM D, 1991, ONCOGENE, V6, P73; AHUJA MR, 1976, PROG EXP TUMOR RES, V20, P380; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARK AJL, 1985, P NATL ACAD SCI USA, V82, P8374, DOI 10.1073/pnas.82.24.8374; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EARP HS, 1986, J BIOL CHEM, V261, P4777; GREENFIELD C, 1988, EMBO J, V7, P139, DOI 10.1002/j.1460-2075.1988.tb02793.x; HELDIN CH, 1987, BIOCHIM BIOPHYS ACTA, V907, P219, DOI 10.1016/0304-419X(87)90007-2; JAYE M, 1985, SCIENCE, V228, P882, DOI 10.1126/science.3890179; JINNO Y, 1988, NUCLEIC ACIDS RES, V16, P4957, DOI 10.1093/nar/16.11.4957; JOHNSSON A, 1985, NATURE, V317, P438, DOI 10.1038/317438a0; KAPLAN PL, 1982, P NATL ACAD SCI-BIOL, V79, P485, DOI 10.1073/pnas.79.2.485; LEE DC, 1985, MOL CELL BIOL, V5, P3644, DOI 10.1128/MCB.5.12.3644; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LUCKOW VA, 1988, VIROLOGY, V167, P56, DOI 10.1016/0042-6822(88)90054-2; MALITSCHEK B, 1991, BIOTECHNIQUES, V11, P177; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; OZANNE B, 1980, J CELL PHYSIOL, V105, P163, DOI 10.1002/jcp.1041050118; RANKIN C, 1988, GENE, V70, P39, DOI 10.1016/0378-1119(88)90102-3; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SCHARTL M, 1990, GENETICS, V126, P1083; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SODERQUIST AM, 1984, J BIOL CHEM, V259, P2586; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; SUMMERS MD, 1988, TEXAS AGR EXPT STATI, V1555, P10; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAKAMATSU Y, 1981, CANCER RES, V41, P679; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5	37	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10423	10430						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144625				2022-12-25	WOS:A1994NF01700038
J	OHYAMA, Y; OZONO, K; UCHIDA, M; SHINKI, T; KATO, S; SUDA, T; YAMAMOTO, O; NOSHIRO, M; KATO, Y				OHYAMA, Y; OZONO, K; UCHIDA, M; SHINKI, T; KATO, S; SUDA, T; YAMAMOTO, O; NOSHIRO, M; KATO, Y			IDENTIFICATION OF A VITAMIN-D-RESPONSIVE ELEMENT IN THE 5'-FLANKING REGION OF THE RAT 25-HYDROXYVITAMIN D-3 24-HYDROXYLASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN OSTEOCALCIN GENE; D RECEPTOR INTERACTION; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; KIDNEY MITOCHONDRIA; THYROID-HORMONE; BONE TURNOVER; RETINOIC ACID; DNA; EXPRESSION; SEQUENCES	The 5'-flanking region of the rat vitamin D-3 24-hydroxylase (P450cc24) gene was examined and a vitamin D-responsive element (VDRE) responsible for the 1 alpha,25-dihydroxyvitamin D-3 (1,25-(OH)(2)D-3) enhancement was identified. Unidirectional deletion analyses of the 5'-flanking region indicated that the region [-167/-102] is involved in vitamin D responsiveness. Further functional analyses showed that the segment [-204/-129] conferred the hormone responsiveness in an orientation-independent manner when it was placed upstream to the heterologous thymidine kinase promoter or the rabbit beta-globin promoter. The segment [-204/-129] contained two direct repeat motifs homologous to other VDREs found in the osteocalcin and osteopontin genes. Synthetic oligonucleotides containing the putative VDRE were used for functional analyses and gel mobility shift assays. The proximal [-151/-137], but not the distal [-169/-155] direct repeat activated the transcription in response to 1,25-(OH)(2)D-3 through the beta-globin promoter. Furthermore, the proximal direct repeat formed a complex with the vitamin D receptor and a nuclear accessory factor(s) from COS cells (or retinoid X receptor) in the presence of 1,25-(OH)(2)D-3. These results indicate that a direct repeat motif, AGGTGAgt-gAGGGCG, located at -151 base pairs upstream in the antisense strand binds to a heterologous dimer consisting of the VDR occupied with 1,25-(OH)(2)D-3 and the nuclear accessory factor and that it plays a critical role in mediating the vitamin D enhancement of the rat P450cc24 gene expression.	OSAKA MED CTR MATERNAL & CHILD HLTH, IZUMI, OSAKA 59002, JAPAN; KUREHA CHEM IND CO LTD, BIOMED RES LABS, SHINJUKU KU, TOKYO 169, JAPAN; SHOWA UNIV, SCH DENT, DEPT BIOCHEM, SHINAGAWA KU, TOKYO 142, JAPAN; TOKYO UNIV AGR, FAC AGR, DEPT AGR CHEM, SETAGAYA KU, TOKYO 156, JAPAN; HIROSHIMA UNIV, SCH DENT, DEPT BIOCHEM, MINAMI KU, HIROSHIMA 734, JAPAN	Showa University; Tokyo University of Agriculture; Hiroshima University	OHYAMA, Y (corresponding author), HIROSHIMA UNIV, FAC SCI, GRAD DEPT GENE SCI, 1-3-1 KAGAMIYAMA, HIGASHIHIROSHIMA 724, JAPAN.							BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BROMMAGE R, 1985, ENDOCR REV, V6, P491, DOI 10.1210/edrv-6-4-491; CHEN ML, 1993, ENDOCRINOLOGY, V132, P1782, DOI 10.1210/en.132.4.1782; DARWISH HM, 1992, P NATL ACAD SCI USA, V89, P603, DOI 10.1073/pnas.89.2.603; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097; GILL RK, 1993, P NATL ACAD SCI USA, V90, P2984, DOI 10.1073/pnas.90.7.2984; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MACDONALD PN, 1991, J BIOL CHEM, V266, P18808; MANO H, 1993, BIOCHEM BIOPH RES CO, V191, P943, DOI 10.1006/bbrc.1993.1308; MARKOSE ER, 1990, P NATL ACAD SCI USA, V87, P1701, DOI 10.1073/pnas.87.5.1701; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; NAKAMURA T, 1992, CALCIFIED TISSUE INT, V50, P221, DOI 10.1007/BF00296286; NAKAMURA T, 1992, BONE, V13, P229, DOI 10.1016/8756-3282(92)90202-8; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OHYAMA Y, 1993, BIOCHEMISTRY-US, V32, P76, DOI 10.1021/bi00052a011; OHYAMA Y, 1991, FEBS LETT, V278, P195, DOI 10.1016/0014-5793(91)80115-J; OHYAMA Y, 1989, FEBS LETT, V255, P405, DOI 10.1016/0014-5793(89)81133-0; OHYAMA Y, 1991, J BIOL CHEM, V266, P8690; OZONO K, 1990, J BIOL CHEM, V265, P21881; OZONO K, 1991, J BONE MINER RES, V6, P1021; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; Sambrook J, 1989, MOL CLONING LABORATO; SHINKI T, 1992, J BIOL CHEM, V267, P13757; SONE T, 1991, J BIOL CHEM, V266, P23296; SONE T, 1991, MOL ENDOCRINOL, V5, P1578, DOI 10.1210/mend-5-11-1578; SUDA T, 1990, ANNU REV NUTR, V10, P195, DOI 10.1146/annurev.nu.10.070190.001211; TANAKA Y, 1974, SCIENCE, V183, P1198, DOI 10.1126/science.183.4130.1198; UCHIDA M, 1993, J BONE MINER RES, V8, pS171; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	39	193	199	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10545	10550						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144641				2022-12-25	WOS:A1994NF01700055
J	LAINE, RO; SHAY, NF; KILBERG, MS				LAINE, RO; SHAY, NF; KILBERG, MS			NUCLEAR RETENTION OF THE INDUCED MESSENGER-RNA FOLLOWING AMINO ACID-DEPENDENT TRANSCRIPTIONAL REGULATION OF MAMMALIAN RIBOSOMAL-PROTEINS L17 AND S25	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATIONAL CONTROL; RAT-LIVER; CELLS; EXPRESSION; IDENTIFICATION; GENES; TRANSPORT; YEAST	An amino acid starvation-induced mRNA, increased up to 4-fold in the absence of amino acids, was identified previously as rat 60 S subunit ribosomal protein L17. The data presented here demonstrate that among ribosomal proteins, L17, as well as the smaller subunit ribosomal protein S25, are uniquely regulated by amino acid deprivation of cells; the increase in L17 and S25 mRNA content in response to substrate starvation is not shared by the 11 other ribosomal proteins tested. When rat Fao hepatoma cells were incubated in the presence of actinomycin D, the L17 mRNA level decayed below the basal level, regardless of medium amino acid content, and nuclear run-off assays confirmed that nutrient starvation leads to enhanced transcription of the L17 ribosomal protein gene. Likewise, the induction of S25 mRNA also was prevented in the presence of actinomycin D. Furthermore, the induction of L17 and S25 mRNA content was blocked by cycloheximide, demonstrating the requirement for a newly synthesized protein in the signaling pathway. Northern analysis with RNA isolated from cytoplasmic, polysomal, and nuclear enriched fractions indicated that the starvation-dependent increase in the S25 and L17 mRNAs is retained within the nucleus and not is available for translation. Amino acid refeeding of the cells caused the translocation of the stored nuclear mRNAs to the polysomal fraction.	UNIV FLORIDA,J HILLIS MILLER HLTH CTR,DEPT BIOCHEM & MOLEC BIOL,BOX 100245,GAINESVILLE,FL 32610	State University System of Florida; University of Florida					NIDDK NIH HHS [DK-31580] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031580] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; ADELMAN RR, 1974, METHOD ENZYMOL, V31, P201; AMALDI F, 1989, TRENDS BIOCHEM SCI, V14, P175, DOI 10.1016/0968-0004(89)90269-7; ANGERER LM, 1992, DEV BIOL, V149, P27, DOI 10.1016/0012-1606(92)90261-E; BURMEISTER LA, 1991, J BIOL CHEM, V266, P22905; CARDINALI B, 1993, NUCLEIC ACIDS RES, V21, P2301, DOI 10.1093/nar/21.10.2301; CHAN SO, 1992, MOL CELL BIOCHEM, V117, P71; CHESTER KA, 1989, BIOCHIM BIOPHYS ACTA, V1009, P297, DOI 10.1016/0167-4781(89)90119-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE SD, 1992, FASEB J, V6, P3146, DOI 10.1096/fasebj.6.13.1397836; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; DESJARDIN LE, 1993, J BIOL CHEM, V268, P6953; ENGLESBERG E, 1986, J MEMBRANE BIOL, V91, P199, DOI 10.1007/BF01868814; FALIKS D, 1982, NUCLEIC ACIDS RES, V10, P789, DOI 10.1093/nar/10.3.789; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; GUIDOTTI GG, 1978, BIOCHIM BIOPHYS ACTA, V515, P239; HARALSON MA, 1975, J BIOL CHEM, V250, P8618; HENRY JL, 1993, CANCER RES, V53, P1403; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; KILBERG MS, 1986, TRENDS BIOCHEM SCI, V11, P183, DOI 10.1016/0968-0004(86)90138-6; KILBERG MS, 1994, FASEB J, V8, P13, DOI 10.1096/fasebj.8.1.8299885; KITAGAWA M, 1991, FEBS LETT, V283, P210, DOI 10.1016/0014-5793(91)80590-Y; KONDOH N, 1992, CANCER RES, V52, P791; LAINE RO, 1991, J BIOL CHEM, V266, P16969; LI ML, 1992, FEBS LETT, V298, P142, DOI 10.1016/0014-5793(92)80041-E; LI ML, 1991, GENE, V107, P329, DOI 10.1016/0378-1119(91)90335-9; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; Meyuhas O., 1984, RECOMBINANT DNA CELL, P243; NIEUWINT RTM, 1985, CURR GENET, V10, P1, DOI 10.1007/BF00418486; POGUEGEILE K, 1991, MOL CELL BIOL, V11, P3842, DOI 10.1128/MCB.11.8.3842; SHAY NF, 1991, J BIOL CHEM, V265, P17844; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SUZUKI K, 1991, BIOCHEM BIOPH RES CO, V178, P322, DOI 10.1016/0006-291X(91)91817-V	34	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9693	9697						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144559				2022-12-25	WOS:A1994NE05300048
J	LIAUDET, E; GARCIA, M; ROCHEFORT, H				LIAUDET, E; GARCIA, M; ROCHEFORT, H			CATHEPSIN-D MATURATION AND ITS STIMULATORY EFFECT ON METASTASIS ARE PREVENTED BY ADDITION OF KDEL RETENTION SIGNAL	ONCOGENE			English	Article						CATHEPSIN-D OVEREXPRESSION; METASTASIS; PROTEOLYSIS; KDEL SIGNAL	BREAST-CANCER-CELLS; LUMINAL ER PROTEINS; FACTOR-II RECEPTOR; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; LYSOSOMAL PROENZYMES; AUTOCRINE GROWTH; GOLGI-COMPLEX; MCF7 CELLS; SECRETION	Cathepsin D is overexpressed in most primary breast cancers where its concentration is correlated with increased metastatic potential. To investigate the possible role and mechanism of this lysosomal protease in metastasis, we transfected low-metastatic rat tumor cells with wild-type human cathepsin D, or mutated forms obtained by insertion of a KDEL peptide signal responsible for ER retention, or a control KDAS peptide. The overexpressed pro-cathepsin D in wild-type and KDAS clones was normally sorted and maturated in lysosomes. In KDEL clones, pro-cathepsin D was mostly retained in the ER or partially secreted by high-producer clones but was not maturated. While overexpressed cathepsin D increased experimental metastasis in athymic mice, the pro-cathepsin/D-KDEL was totally ineffective. Moreover, the effect of cathepsin D on metastasis did not seem to be due to saturation of the mannose-6-phosphate receptor since the secretion of two other rat lysosomal enzymes was unaffected by cathepsin D overexpression. We conclude that pro-cathepsin D overexpression facilitates tumor metastasis only when maturated into an active enzyme.	INSERM,U148,UNITE HORMONES & CANC,60 RUE NAVACELLES,F-34090 MONTPELLIER,FRANCE; UNIV MONTPELLIER 1,F-34090 MONTPELLIER,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier			Liaudet-Coopman, Emmanuelle/N-4744-2017	Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690				BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BLASI F, 1990, CELL DIFFER DEV, V32, P247, DOI 10.1016/0922-3371(90)90037-W; BRAULKE T, 1987, J CELL BIOL, V104, P1735, DOI 10.1083/jcb.104.6.1735; BRIOZZO P, 1988, CANCER RES, V48, P3688; BROUILLET JP, 1991, CLIN BIOCHEM, V24, P491, DOI 10.1016/S0009-9120(05)80008-6; BROUILLET JP, 1993, EUR J CANCER, V29A, P1248, DOI 10.1016/0959-8049(93)90066-O; BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; CAPONY F, 1990, BIOCHEM BIOPH RES CO, V171, P972, DOI 10.1016/0006-291X(90)90779-M; CAPONY F, 1989, CANCER RES, V49, P3904; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; DIMENT S, 1985, J BIOL CHEM, V260, P5311; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; FREISS G, 1988, CANCER RES, V48, P3709; GARCIA M, 1990, ONCOGENE, V5, P1809; GARCIA M, 1985, CANCER RES, V45, P709; GOTTESMAN MM, 1990, SEMINARS CANCER BIOL; GRASSEL S, 1992, BIOCHEM BIOPH RES CO, V182, P276, DOI 10.1016/S0006-291X(05)80141-X; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; IOANNOU YA, 1992, J CELL BIOL, V119, P1137, DOI 10.1083/jcb.119.5.1137; KIESS W, 1987, J BIOL CHEM, V262, P12745; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Maniatis T., 1982, MOL CLONING; MAREEL MM, 1991, MECHANISMS INVASION; MATHIEU M, 1991, MOL ENDOCRINOL, V5, P815, DOI 10.1210/mend-5-6-815; MONTCOURRIER P, 1993, CR ACAD SCI III-VIE, V316, P421; MONTCOURRIER P, 1990, CANCER RES, V50, P6045; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; ROCHEFORT H, 1992, EUR J CANCER, V28A, P1780, DOI 10.1016/0959-8049(92)90003-K; SPYRATOS F, 1989, LANCET, V2, P1115; TANDON AK, 1990, NEW ENGL J MED, V322, P297, DOI 10.1056/NEJM199002013220504; THORPE SM, 1989, CANCER RES, V49, P6008; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; WESTLEY B, 1980, CELL, V20, P352; YAMASHITA T, 1980, INT J CANCER, V26, P435, DOI 10.1002/ijc.2910260408	42	71	71	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1145	1154						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134116				2022-12-25	WOS:A1994NC04800017
J	LU, YM; USSERY, GD; MUNCASTER, MM; GALLIE, BL; BLANCK, G				LU, YM; USSERY, GD; MUNCASTER, MM; GALLIE, BL; BLANCK, G			EVIDENCE FOR RETINOBLASTOMA PROTEIN (RB) DEPENDENT AND INDEPENDENT IFN-GAMMA RESPONSES - RB COORDINATELY RESCUES IFN-GAMMA INDUCTION OF MHC CLASS-II GENE-TRANSCRIPTION IN NONINDUCIBLE BREAST-CARCINOMA CELLS	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; MALIGNANT PHENOTYPE; DERMAL FIBROBLASTS; SURFACE EXPRESSION; MESSENGER-RNAS; TUMOR-CELLS; CHAIN GENE; HLA-DR; C-FOS; ANTIGENS	The class II major histocompatibility (MHC) genes encode cell surface heterodimers that present processed antigen to CD4 positive T-cells. The class II genes are expressed constitutively on B-cells and can be induced by IFN-gamma on a variety of other cell types. Because the class II genes are aberrantly expressed on many mesenchymal tumors, which are frequently defective for the retinoblastoMa tumor suppressor protein (RB), we investigated the role of RB in the regulation of HLA-DR and -DP. The RB defective breast carcinomas cell line, MDA-468-S4 (S4), as well as S4 subclones reconstituted with RB coding sequences under the control of a zinc inducible promoter, were treated with IFN-gamma and examined for DR and DP expression. Surface DR is not inducible in S4 cells, but inducibility is rescued by RB. DP is only slightly inducible in S4, but inducible to a much higher level in the RB positive subclones of S4. IFN-gamma induction of DR and DP mRNAs are correspondingly dependent on RB. IFN-gamma receptors are present on S4 cells, and the guanylate binding protein and ICAM-1 genes respond to IFN-gamma, ruling out the possibility that all IFN-gamma signal transduction pathways are defective in S4 cells. These data indicate RB regulates the coordinate response of class II genes to IFN-gamma. Possible roles for RB in this process are discussed, as well as the role of the class II-noninducible phenotype in tumor rejection.	UNIV S FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33612; UNIV TORONTO,DEPT MOLEC GENET,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA; HOSP SICK CHILDREN,DIV IMMUNOL & CANC RES,TORONTO M5G 1X8,ONTARIO,CANADA	State University System of Florida; University of South Florida; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Blanck, George/A-5365-2012	Gallie, Brenda/0000-0002-9697-9211				ACCOLLA RS, 1983, J EXP MED, V157, P1053, DOI 10.1084/jem.157.3.1053; ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P4387, DOI 10.1093/nar/19.16.4387; ANDERSSON M, 1987, J IMMUNOL, V138, P3960; ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BASTA PV, 1987, J IMMUNOL, V138, P1275; BERNARD DJ, 1992, BRIT J CANCER, V66, P88, DOI 10.1038/bjc.1992.222; BLANCK G, 1990, HUM IMMUNOL, V29, P150, DOI 10.1016/0198-8859(90)90078-4; BLANCK G, 1992, J FLORIDA MED ASS, V79, P97; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; BURGERT HG, 1987, P NATL ACAD SCI USA, V84, P1356, DOI 10.1073/pnas.84.5.1356; CALMAN AF, 1987, J IMMUNOL, V139, P2489; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLEMENTS VK, 1992, J IMMUNOL, V149, P2391; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; COX JH, 1990, SCIENCE, V247, P715, DOI 10.1126/science.2137259; DECASTRO JAL, 1989, IMMUNOL TODAY, V10, P239, DOI 10.1016/0167-5699(89)90261-2; DETRICK B, 1988, CANCER RES, V48, P1633; FILMUS J, 1987, MOL CELL BIOL, V7, P251, DOI 10.1128/MCB.7.1.251; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GLADSTONE P, 1978, NATURE, V271, P459, DOI 10.1038/271459a0; HAMMEL PA, 1992, MOL CELL BIOL, V12, P3431; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUME CR, 1989, HUM IMMUNOL, V26, P288, DOI 10.1016/0198-8859(89)90007-4; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LIOU HC, 1990, SCIENCE, V24, P1581; MAUER DH, 1987, TISSUE ANTIGENS, V31, P174; MOLLER P, 1989, AM J PATHOL, V135, P73; MUNCASTER MM, 1992, CANCER RES, V52, P654; NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493; ONO SJ, 1991, P NATL ACAD SCI USA, V88, P4309, DOI 10.1073/pnas.88.10.4309; ONO SJ, 1991, J EXP MED, V173, P629, DOI 10.1084/jem.173.3.629; OSTRANDROSENBERG S, 1990, J IMMUNOL, V144, P4068; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SCOTLANDI K, 1992, ANTICANCER RES, V12, P767; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SRIKUMAR P, 1991, CELL, V65, P1053; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YANG Z, 1988, EMBO J, V7, P1965, DOI 10.1002/j.1460-2075.1988.tb03034.x; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	48	59	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1015	1019						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134104				2022-12-25	WOS:A1994NC04800002
J	SANGADALA, S; WALTERS, FS; ENGLISH, LH; ADANG, MJ				SANGADALA, S; WALTERS, FS; ENGLISH, LH; ADANG, MJ			A MIXTURE OF MANDUCA-SEXTA AMINOPEPTIDASE AND PHOSPHATASE ENHANCES BACILLUS-THURINGIENSIS INSECTICIDAL CRYIA(C) TOXIN BINDING AND (RB+-K+)-RB-86 EFFLUX IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; DELTA-ENDOTOXINS; HELIOTHIS-VIRESCENS; MIDGUT; SPECIFICITY; RESISTANCE; RECEPTOR; IDENTIFICATION; QUANTITIES; MECHANISM	CryIA(c) delta-endotoxin, a member of the CryI family of Bacillus thuringiensis insecticidal proteins, specifically recognizes and binds with high affinity to target proteins in the midgut of susceptible insects. Protein blots of Manduca sexta brush-border membranes probed with I-125-CryIA(c) identify a major binding protein of 120 kDa and a minor binding protein of 65 kDa. Monoclonal antibodies were raised against the 120-kDa toxin binding protein. Using isoelectric focusing and monoclonal antibodies (2B3, 8G1, and 12B8) 120- and 65-kDa brush-border proteins were isolated. Labeled CryIA(c) and monoclonal antibodies probed to blots of the affinity-selected proteins recognized the 120- and 65-kDa proteins. When reconstituted into phospholipid vesicles, antibody-selected proteins increased toxin binding (35%) and enhanced toxin-induced Rb-86+ release up to 1000-fold. The 120-kDa protein was identified as aminopeptidase N (EC 3.4.11.2). A CryIA(c)-sensitive phosphatase was also present in the 120/65-kDa protein mixture. These findings provide the first identification of B. thuringiensis toxin binding proteins, although confirmation is needed in vivo.	UNIV GEORGIA, DEPT ENTOMOL, ATHENS, GA 30602 USA; ECOGEN INC, LANGHORNE, PA 19047 USA	University System of Georgia; University of Georgia								Adang M. J., 1991, Biotechnology for biological control of pests and vectors., P3; BARBARAT B, 1986, J BIOL CHEM, V261, P4455; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0; ENGLISH L, 1992, INSECT BIOCHEM MOLEC, V22, P1, DOI 10.1016/0965-1748(92)90093-T; ENGLISH LH, 1989, INSECT BIOCHEM, V19, P145, DOI 10.1016/0020-1790(89)90085-1; ENGLISH LH, 1991, INSECT BIOCHEM, V21, P177, DOI 10.1016/0020-1790(91)90048-J; FERRE J, 1991, P NATL ACAD SCI USA, V88, P5119, DOI 10.1073/pnas.88.12.5119; GARCZYNSKI SF, 1991, APPL ENVIRON MICROB, V57, P2816, DOI 10.1128/AEM.57.10.2816-2820.1991; GOULD F, 1992, P NATL ACAD SCI USA, V89, P7986, DOI 10.1073/pnas.89.17.7986; Harlow E., 1988, ANTIBODIES LABORATOR, P1; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KNOWLES BH, 1991, P ROY SOC B-BIOL SCI, V245, P31, DOI 10.1098/rspb.1991.0084; KNOWLES BH, 1987, BIOCHIM BIOPHYS ACTA, V924, P509, DOI 10.1016/0304-4165(87)90167-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERRIL CR, 1980, ANAL BIOCHEM, V105, P361; NILSSON BO, 1987, J IMMUNOL METHODS, V99, P67; ODDOU P, 1991, EUR J BIOCHEM, V188, P209; OLSEN J, 1989, FEBS LETT, V251, P275, DOI 10.1016/0014-5793(89)81470-X; PLAKIDOUDYMOCK S, 1993, BIOCHEM J, V290, P59, DOI 10.1042/bj2900059; PLAKIDOUDYMOCK S, 1993, BIOCHIM BIOPHYS ACTA, V1145, P105, DOI 10.1016/0005-2736(93)90386-E; SACCHI VF, 1986, FEBS LETT, V204, P213, DOI 10.1016/0014-5793(86)80814-6; TAKEDA S, 1993, COMP BIOCHEM PHYS B, V104, P81, DOI 10.1016/0305-0491(93)90341-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VADLAMUDI RK, 1993, J BIOL CHEM, V268, P12334; VANRIE J, 1990, SCIENCE, V247, P72, DOI 10.1126/science.2294593; VANRIE J, 1989, EUR J BIOCHEM, V186, P239, DOI 10.1111/j.1432-1033.1989.tb15201.x; VANRIE J, 1990, APPL ENVIRON MICROB, V56, P1378, DOI 10.1128/AEM.56.5.1378-1385.1990; WATT VM, 1989, J BIOL CHEM, V264, P5480; WOLFERSBERGER MG, 1990, EXPERIENTIA, V46, P475, DOI 10.1007/BF01954236; YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0	31	254	276	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					10088	10092						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144508				2022-12-25	WOS:A1994NE05300103
J	ADELI, K				ADELI, K			REGULATED INTRACELLULAR DEGRADATION OF APOLIPOPROTEIN-B IN SEMIPERMEABLE HEPG2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; TREATED RAT HEPATOCYTES; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; G2 CELLS; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; PROTEIN-DEGRADATION; CYSTEINE PROTEASE; HEPATOMA-CELLS; SECRETION	A digitonin-permeabilized HepG2 cell system has been developed and used to characterize the pathway responsible for apolipoprotein B-100 (apoB) degradation. Degradation of S-35-labeled apoB occurred after an initial lag period and resulted in the loss of approximately 75.8% of apoB after 2 h of chase. The degradation rate in permeabilized cells was slower than that in intact cells, but approximately the same percentage of apoB was lost over 2 h of chase. The loss of intact apoB in permeabilized cells coincided with the appearance of a number of degradation fragments, including 335- and 70-kDa fragments. The detection of a 70-kDa fragment was a sensitive indicator of degradation. ApoB degradation was inhibited at temperatures below 37 degrees C and maximally activated at 42 degrees C. Degradation was also pH dependent, with inhibition at pH greater than or equal to 7.5. ApoB decay was stimulated by ATP supplementation but not GTP and was inhibited in the presence of energy inhibitors. Degradation was not significantly affected by cycloheximide. However, the stability of the 70-kDa fragment was prolonged with cycloheximide. Preincubation of cells with brefeldin A and nocodazole, as well as monensin, did not diminish the degradation of intact apoB or the appearance of the 70-kDa fragment, suggesting a lack of requirement for intracellular transport from the endoplasmic reticulum. Among the various protease inhibitors tested, degradation was most sensitive to N-acetylleucylleucylnorleucinal (ALLN), which abolished the generation of the 70-kDa fragment in a dose-dependent manner. ALLN-sensitive degradation of apoB was unaffected by the calcium ionophore, A23187. Interestingly, degradation of unglycosylated apoB, detected in tunicamycin-pretreated cells, occurred earlier, resulted in generation of additional fragments, and was largely uninhibited by ALLN. In summary, apoB degradation occurs in permeabilized HepG2 cells by a temperature- and pH-sensitive, pre-Golgi degradation system and is catalyzed by a calcium-independent, ALLN sensitive protease. Specificity of the initial apoB cleavage may require the proper N-linked glycosylation of the protein in the endoplasmic reticulum.			ADELI, K (corresponding author), UNIV WINDSOR,DEPT CHEM & BIOCHEM,400 SUNSET ST,WINDSOR N9B 3P4,ON,CANADA.			Adeli, Khosrow/0000-0002-5839-5709				ADELI K, 1990, FEBS LETT, V263, P345, DOI 10.1016/0014-5793(90)81410-P; ADELI K, 1992, BIOCHEM CELL BIOL, V70, P1301, DOI 10.1139/o92-177; AMITAY R, 1992, J BIOL CHEM, V267, P20694; BAUER HC, 1985, BIOCHEM BIOPH RES CO, V128, P368, DOI 10.1016/0006-291X(85)91688-2; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1992, J BIOL CHEM, V267, P9858; CARTWRIGHT IJ, 1993, J BIOL CHEM, V268, P20937; DASHTI N, 1989, J LIPID RES, V30, P1365; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1991, J BIOL CHEM, V266, P5080; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GAY RJ, 1968, CLIN CHEM, V14, P740; GODA Y, 1989, FASEB J, V3, P2488, DOI 10.1096/fasebj.3.13.2680705; INOUE S, 1992, J BIOL CHEM, V267, P9080; INOUE S, 1991, J BIOL CHEM, V266, P13311; KAPTEIN A, 1991, BIOCHEM J, V278, P557, DOI 10.1042/bj2780557; KATZ J, 1985, J CELL BIOCHEM, V28, P207, DOI 10.1002/jcb.240280304; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE A, 1990, J BIOL CHEM, V265, P14001; LEONARD DA, 1987, J BIOL CHEM, V262, P7914; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LUSIS AJ, 1987, J BIOL CHEM, V262, P7594; MEIGS TE, 1992, J BIOL CHEM, V267; Murachi T. M., 1983, CALCIUM CELL FUNCTIO, V4, P377; OLDEN K, 1978, CELL, V13, P461, DOI 10.1016/0092-8674(78)90320-3; OMURA T, 1970, J BIOCHEM-TOKYO, V67, P249, DOI 10.1093/oxfordjournals.jbchem.a129248; PULLINGER CR, 1989, J LIPID RES, V30, P1065; SASKI T, 1990, J ENZYM INHIB, V3, P195; SATO R, 1990, J BIOL CHEM, V265, P11880; SPARKS JD, 1992, J CLIN INVEST, V89, P1418, DOI 10.1172/JCI115731; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; STRUCK DK, 1978, J BIOL CHEM, V255, P5332; SUITAMANGANO P, 1982, J BIOL CHEM, V257, P11463; THERIAULT A, 1992, BIOCHEM BIOPH RES CO, V186, P617, DOI 10.1016/0006-291X(92)90791-I; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; URADE R, 1992, J BIOL CHEM, V267, P15152; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WILKSTROM L, 1992, J BIOL CHEM, V267, P5; YE SQ, 1993, J BIOL CHEM, V268, P8497	44	110	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9166	9175						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132654				2022-12-25	WOS:A1994NB41100081
J	FORCE, WR; TILLMAN, JB; SPRUNG, CN; SPINDLER, SR				FORCE, WR; TILLMAN, JB; SPRUNG, CN; SPINDLER, SR			HOMODIMER AND HETERODIMER DNA-BINDING AND TRANSCRIPTIONAL RESPONSIVENESS TO TRIIODOTHYRONINE (T-3) AND 9-CIS-RETINOIC ACID ARE DETERMINED BY THE NUMBER AND ORDER OF HIGH-AFFINITY HALF-SITES IN A T-3 RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; RAT GROWTH-HORMONE; RETINOID-X-RECEPTOR; NUCLEAR RECEPTORS; GENE; PROTEIN; BETA; RXR; 3,5,3'-TRIIODOTHYRONINE; PROMOTER	T-3 (triiodothyronine) response elements (TREs) consist of pairs of strong and weak (S and W), 10-nucleotide Ts receptor (TR) monomer binding sites (half-sites). We report that the number and order of S and W half-sites in a direct repeat TRE determines whether it mediates ligand-dependent or independent transcriptional activation or inhibition in the presence of TR or TR and 9-cis-retinoic acid receptor (RXR); and whether a TRE is preferentially bound by TR homodimers, TR-RXR heterodimers, or CV1 cell TR accessory protein (TRAP)-TR heterodimers. TR homodimers bound equally to TREs composed of the 5'-S and 3'-W (SW) and the opposite (WS) arrangement of half-sites. TR-RXR gamma heterodimers bound SW better than WS. TR-TRAP heterodimers bound WS better than SW. Transcription of a reporter gene cis-linked to WS responded to unliganded TR and RXR, and either ligand stimulated expression 2-fold more. Reporter expression cis-linked to SW was not altered by unliganded receptors, and Ts stimulated transcription only in the presence of both TR and RXR. SS was strongly activated by liganded, but not by unliganded TR. SS was activated by unliganded TR and RXR gamma together, and Ts further stimulated transcription a-fold. Under these conditions, transcription was inhibited 60% by 9-cis-retinoic acid.	UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521	University of California System; University of California Riverside				Tillman, John/0000-0003-2912-2370	NIDDK NIH HHS [DK40164] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040164] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEEBE JS, 1991, MOL ENDOCRINOL, V5, P85, DOI 10.1210/mend-5-1-85; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRENT GA, 1989, J BIOL CHEM, V264, P178; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CRONE DE, 1990, J BIOL CHEM, V265, P10851; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DARLING DS, 1993, J BIOL CHEM, V268, P10221; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; ING NH, 1992, J BIOL CHEM, V267, P17617; KIM HS, 1992, MOL ENDOCRINOL, V6, P1489, DOI 10.1210/me.6.9.1489; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MADER S, 1993, J BIOL CHEM, V268, P591; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MURRAY MB, 1988, J BIOL CHEM, V263, P12770; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; STRAIT KA, 1992, MOL ENDOCRINOL, V6, P1874, DOI 10.1210/me.6.11.1874; TILLMAN JB, 1993, MOL CELL ENDOCRINOL, V95, P101, DOI 10.1016/0303-7207(93)90034-H; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YEN PM, 1992, J BIOL CHEM, V267, P3565; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	51	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8863	8871						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132622				2022-12-25	WOS:A1994NB41100039
J	GHAZIZADEH, S; BOLEN, JB; FLEIT, HB				GHAZIZADEH, S; BOLEN, JB; FLEIT, HB			PHYSICAL AND FUNCTIONAL ASSOCIATION OF SRC-RELATED PROTEIN-TYROSINE KINASES WITH FC-GAMMA-RII IN MONOCYTIC THP-1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; LYMPHOCYTES-B; CROSS-LINKING; HIGH-AFFINITY; U937 CELLS; IGG FC; ACTIVATION; PHOSPHORYLATION; CD4; HETEROGENEITY	Aggregation of Fc gamma RII (CD 32), a low affinity receptor for immunoglobulin G (IgG), on the monocytic cell line THP-1 induces protein tyrosine kinase (PTK) activity. Several distinct cellular proteins, including Fc gamma RII itself, are phosphorylated on tyrosine following crosslinking of the receptor. Fc gamma RII lacks intrinsic PTK activity. In this report we demonstrate that a kinase activity was coprecipitated with Fc gamma RII in THP-1 cells. The kinetics of the receptor associated kinase activity paralleled the appearance of tyrosine phosphorylation events observed following Fc gamma RII activation of THP-1 cells. Several proteins were associated with the receptor. Reimmunoprecipitation analysis demonstrated that lyn gene products were among the proteins coprecipitated with Fc gamma RII. p59(hck) (Hck) and p56(lyn) (Lyn) were the most abundant Src-related PTKs (Src-PTKs) in THP-1 cells. Enzymatic activity of both kinases, as measured by an in vitro ki nase assay, was increased following specific cross-linking of Fc gamma RII. Furthermore, Fc gamma RII was specifically associated with both enzymes following its engagement and served as a substrate for both of these kinases. The association of Fc gamma RII with Src-PTK was specific for Fc gamma RII activation of THP-1 cells, since activation of cells via the high affinity Fc gamma receptor, Fc gamma RI (CD 64), did not result in association of Fc gamma RII with Hck or Lyn. Our data demonstrate a functional and physical association of Fc gamma RII with lick and Lyn consistent with the involvement of Src-PTK in Fc gamma RII-mediated signal transduction.	SUNY STONY BROOK, DEPT PATHOL, STONY BROOK, NY 11794 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, PRINCETON, NJ 08543 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Bristol-Myers Squibb					NCI NIH HHS [CA38055] Funding Source: Medline; NCRR NIH HHS [RR05736] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R23CA038055, R01CA038055] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; ANDERSON CL, 1990, J EXP MED, V171, P1333, DOI 10.1084/jem.171.4.1333; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; EISEMAN E, 1992, NATURE, V355, P78; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; GHAZIZADEH S, 1994, J IMMUNOL, V152, P30; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUNZIKER W, 1990, NATURE, V345, P628, DOI 10.1038/345628a0; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; INDIK Z, 1991, J CLIN INVEST, V88, P1766, DOI 10.1172/JCI115496; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KOLANUS W, 1992, EMBO J, V11, P4861, DOI 10.1002/j.1460-2075.1992.tb05592.x; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOONEY RJ, 1986, J IMMUNOL, V136, P1641; MUSTELIN T, 1990, ONCOGENE, V5, P809; ODIN JA, 1991, SCIENCE, V254, P1785, DOI 10.1126/science.1837175; RANKIN BM, 1993, J IMMUNOL, V150, P605; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIGLEY KP, 1989, EUR J IMMUNOL, V19, P481, DOI 10.1002/eji.1830190311; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SALCEDO TW, 1993, J EXP MED, V177, P1475, DOI 10.1084/jem.177.5.1475; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHOLL PR, 1992, J IMMUNOL, V149, P1751; UNKELESS JC, 1988, ANNU REV IMMUNOL, V6, P251, DOI 10.1146/annurev.iy.06.040188.001343; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; VANDEWINKEL JGJ, 1991, J LEUKOCYTE BIOL, V49, P511, DOI 10.1002/jlb.49.5.511; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1991, CELL REGUL, V2, P979, DOI 10.1091/mbc.2.12.979; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	162	204	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8878	8884						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132624				2022-12-25	WOS:A1994NB41100041
J	JOHNSON, JD; NAKKULA, RJ; VASULKA, C; SMILLIE, LB				JOHNSON, JD; NAKKULA, RJ; VASULKA, C; SMILLIE, LB			MODULATION OF CA2+ EXCHANGE WITH THE CA2+-SPECIFIC REGULATORY SITES OF TROPONIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE STOPPED-FLOW; MAGNESIUM BINDING; CALCIUM; PROBE; DANSYLAZIRIDINE; CALMODULIN; RESOLUTION; AFFINITY	Calcium (Ca2+) binding to the N-terminal Ca2+-specific sites on troponin C (TnC) regulate the contraction-relaxation cycle of skeletal muscle. A mutant TnC (F29W) and dansylaziridine-labeled TnC undergo large fluorescence increases when Ca2+ binds to their Ca2+-specific sites (half-maximal at pCa 5.8). calmidazolium and the additional mutation of Met-82 to Gln (F29W,M82Q) increased Ca2+ affinity at these Ca2+ sites by similar to 4-fold (half-maximal at pCa similar to 6.4). Calmidazolium and the M82Q mutation decreased the rate of Ca2+ dissociation from the Ca2+-specific sites similar to 3.4-fold (from similar to 462 +/- 84/s to similar to 138 +/- 30/s) at 22 degrees C. Ca2+ associated with the Ca2+-specific sites of these proteins at 1-2 x 10(8) M(-1) s(-1) at 4 degrees C. These drug- and mutation-induced increases in Ca2+ affinity occur solely from large decreases in the Ca2+ off-rate without an effect on the Ca2+ on rate. Thus, Ca2+ can bind to the Ca2+-specific sites of TnC as rapidly as it can diffuse to the protein, consistent with the extreme speed of skeletal muscle contraction. Drugs and/or site-directed mutagenesis can modify the Ca2+ sensitivity and the rate of Ca2+ exchange with TnC's Ca2+-specific sites to perhaps alter the rate of relaxation and/or the rate of rise of tension.	UNIV ALBERTA,DEPT BIOCHEM,MED RES COUNCIL,PROT STRUCT & FUNCT GRP,EDMONTON T6G 2H7,AB,CANADA	University of Alberta	JOHNSON, JD (corresponding author), OHIO STATE UNIV,MED CTR,DEPT MED BIOCHEM,333 HAMILTON HALL,1645 NEIL AVE,COLUMBUS,OH 43210, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033727] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK33727] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAYLEY P, 1984, BIOCHEM BIOPH RES CO, V120, P185, DOI 10.1016/0006-291X(84)91431-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLOSE R, 1965, J PHYSIOL-LONDON, V180, P542, DOI 10.1113/jphysiol.1965.sp007716; ELSALEH SC, 1987, J BIOL CHEM, V262, P17240; GRABAREK Z, 1992, J MUSCLE RES CELL M, V13, P383, DOI 10.1007/BF01738034; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; IIO T, 1981, J BIOCHEM-TOKYO, V90, P163, DOI 10.1093/oxfordjournals.jbchem.a133446; IIO T, 1980, J BIOCHEM-TOKYO, V88, P547, DOI 10.1093/oxfordjournals.jbchem.a133002; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; JOHNSON JD, 1978, J BIOL CHEM, V253, P6451; JOHNSON JD, 1978, J BIOL CHEM, V253, P3775; KASTURI R, 1993, J BIOL CHEM, V268, P7958; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; Potter J. D., 1981, REGULATION MUSCLE CO, P241; POTTER JD, 1975, J BIOL CHEM, V250, P4628; ROSENFELD SS, 1985, J BIOL CHEM, V260, P242; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SOLARO RJ, 1986, J PHARMACOL EXP THER, V238, P502; TRIGOGONZALEZ G, 1992, BIOCHEMISTRY-US, V31, P7009, DOI 10.1021/bi00146a001; WAHR PA, 1993, BIOPHYS J, V64, pA24	23	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8919	8923						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132628				2022-12-25	WOS:A1994NB41100046
J	NORRIS, FA; MAJERUS, PW				NORRIS, FA; MAJERUS, PW			HYDROLYSIS OF PHOSPHATIDYLINOSITOL 3,4-BISPHOSPHATE BY INOSITOL POLYPHOSPHATE 4-PHOSPHATASE ISOLATED BY AFFINITY ELUTION CHROMATOGRAPHY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; HUMAN PLATELETS; PHOSPHOINOSITIDE 3-KINASE; ACTIVATED NEUTROPHILS; BOVINE BRAIN; RAT-LIVER; PATHWAY; 3-PHOSPHATE; THROMBIN; PDGF	Inositol polyphosphate 4-phosphatase is a monomeric 110-kDa protein that hydrolyzes two substrates in the inositol phosphate pathway. Inositol 3,4-bisphosphate is converted to inositol 3-phosphate, and inositol 1,3,4-trisphosphate is converted to inositol 1,3-bisphosphate. We have exploited the fact that inositol hexasulfate inhibits the enzyme to devise an affinity elution scheme from a Mono S cation exchange column that resulted in an 11,300-fold purified preparation of rat brain 4-phosphatase, The resulting 4-phosphatase hydrolyzed phosphatidylinositol 3,4-bisphosphate to phosphatidylinositol 3-phosphate with a first order rate constant 120-fold greater than that for inositol 3,4 bisphosphate and 900-fold greater than that for inositol 1,3,4-trisphosphate. This is now the third example wherein the same enzyme hyrolyzes both an inositol lipid and its analogous inositol phosphate.	WASHINGTON UNIV,SCH MED,DEPT BIOL CHEM,DIV HEMATOL ONCOL,ST LOUIS,MO 63110	Washington University (WUSTL)	NORRIS, FA (corresponding author), WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV HEMATOL ONCOL,ST LOUIS,MO 63110, USA.				NHGRI NIH HHS [HG 00304] Funding Source: Medline; NHLBI NIH HHS [HL 14147, HL 16634] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016634, P50HL014147, R01HL016634] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000304] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AMES BN, 1960, J BIOL CHEM, V235, P769; BANSAL VS, 1990, J BIOL CHEM, V265, P1806; BANSAL VS, 1987, J BIOL CHEM, V262, P9444; BREARLEY CA, 1993, BIOCHEM J, V290, P145, DOI 10.1042/bj2900145; CALDWELL KK, 1991, J BIOL CHEM, V266, P18378; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; CUNNINGHAM TW, 1991, BIOCHEM BIOPH RES CO, V175, P568, DOI 10.1016/0006-291X(91)91603-A; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; GAUDETTE DC, 1993, J BIOL CHEM, V268, P13773; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LIPS DL, 1989, J BIOL CHEM, V264, P19911; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MARECEK JF, 1991, TETRAHEDRON LETT, V32, P1863, DOI 10.1016/S0040-4039(00)85982-1; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NOLAN RD, 1990, J BIOL CHEM, V265, P2441; PITTET D, 1989, J BIOL CHEM, V264, P18489; SCOPES RK, 1977, BIOCHEM J, V161, P253, DOI 10.1042/bj1610253; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; SULTAN C, 1991, J BIOL CHEM, V266, P23554; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; von der Haar F, 1974, Methods Enzymol, V34, P163; YAMAMOTO K, 1990, J BIOL CHEM, V265, P22086; YORK JD, 1990, P NATL ACAD SCI USA, V87, P9548, DOI 10.1073/pnas.87.24.9548	30	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8716	8720						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132601				2022-12-25	WOS:A1994NB41100018
J	SCHNEIDER, A; OPPLIGER, W; JENO, P				SCHNEIDER, A; OPPLIGER, W; JENO, P			PURIFIED INNER MEMBRANE PROTEASE-I OF YEAST MITOCHONDRIA IS A HETERODIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MICROSOMAL SIGNAL PEPTIDASE; COLI LEADER PEPTIDASE; ESCHERICHIA-COLI; PURIFICATION	Inner membrane protease I is bound to the outer face of the yeast mitochondrial inner membrane and mediates the proteolytic maturation of cytochrome b(2) and cytochrome oxidase subunit II. We have previously shown that one of its subunits is a 21.4-kDa integral membrane protein encoded by the nuclear IMP1 gene. We have now purified the active protease approximately 300-fold from yeast mitochondria. It has an apparent molecular weight of 35,000 and contains not only Imp1p but also a previously unrecognized 19-kDa subunit. Partial amino acid sequencing identifies this subunit as the product of the recently described IMP2 gene (Nunnari, J., Fox, T., and Walter, P. (1993) Science 262, 1997-2004).			SCHNEIDER, A (corresponding author), UNIV BASEL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND.							BAKER RK, 1987, BIOCHEMISTRY-US, V26, P8561, DOI 10.1021/bi00400a010; BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; DETERS D, 1976, ANAL BIOCHEM, V70, P263, DOI 10.1016/S0003-2697(76)80067-X; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; HALPIN C, 1989, EMBO J, V8, P3917, DOI 10.1002/j.1460-2075.1989.tb08572.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HORST M, 1993, EMBO J, V12, P3035, DOI 10.1002/j.1460-2075.1993.tb05972.x; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANDIJL JM, 1990, MOL GEN GENET, V223, P233, DOI 10.1007/BF00265059; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; ZWIZINSKI C, 1980, J BIOL CHEM, V255, P7973	14	29	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8635	8638						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132591				2022-12-25	WOS:A1994NB41100004
J	SINE, SM; QUIRAM, P; PAPANIKOLAOU, F; KREIENKAMP, HJ; TAYLOR, P				SINE, SM; QUIRAM, P; PAPANIKOLAOU, F; KREIENKAMP, HJ; TAYLOR, P			CONSERVED TYROSINES IN THE ALPHA-SUBUNIT OF THE NICOTINIC ACETYLCHOLINE-RECEPTOR STABILIZE QUATERNARY AMMONIUM GROUPS OF AGONISTS AND CURARIFORM ANTAGONISTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN BC3H-1 CELLS; BINDING-SITE; DELTA-SUBUNIT; CHOLINERGIC RECEPTOR; MOUSE FIBROBLASTS; MUSCLE-CELLS; AMINO-ACIDS; ACTIVATION; LIGAND; MUTAGENESIS	Studies with site directed labeling reagents have identified residues near the ligand binding pocket of the nicotinic acetylcholine receptor. Among these residues are three conserved tyrosines, Tyr-93, Tyr-190, and Tyr-198 of the alpha subunit. Previous studies combined mutagenesis, expression in Xenopus oocytes, and dose-response analysis to examine contributions of these tyrosines to agonist affinity. In this study, we prepared a series of mutants at each position, expressed them in 293 HEK cells, and studied binding of agonists and antagonists to mutant receptors on intact cells. We show that all three tyrosines contribute to binding of agonists, and that each tyrosine contributes roughly equally to the binding energy. Although the contributions are roughly equivalent, the nature of the contribution is not equivalent at each position. For Tyr-93 and Tyr-190 the aromatic hydroxyl is essential, whereas for Tyr-198 aromaticity of the side chain is essential. Nearly identical results were obtained for the elementary quaternary ligand tetramethylammonium, indicating that these tyrosines contribute to stabilization of the quaternary ammonium portion of agonist. Tyr-190 and Tyr-198 also contribute to binding of the competitive antagonist dimethyl-d-tubocurarine; the side chain specificity for binding supports tyrosine interactions with one of two quaternary ammonium groups in dimethyl-d-tubocurarine. Y190F, in addition to altering binding affinity, also affects the equilibrium between activatable and desensitized receptor states.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	SINE, SM (corresponding author), MAYO CLIN & MAYO FDN, DEPT PHYSIOL, RECEPTOR BIOL LAB, ROCHESTER, MN 55905 USA.			Kreienkamp, Hans-Jurgen/0000-0002-8871-9970	NIGMS NIH HHS [GM 24437] Funding Source: Medline; NINDS NIH HHS [NS 31744] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS031744, R01NS031744] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; COHEN JB, 1991, J BIOL CHEM, V266, P23354; CZAJKOWSKI C, 1991, J BIOL CHEM, V266, P22603; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DILGER J, 1992, BIOPHYS J, V57, P723; DILGER JP, 1992, PFLUG ARCH EUR J PHY, V420, P479, DOI 10.1007/BF00374622; FRANKE C, 1993, BIOPHYS J, V64, P339, DOI 10.1016/S0006-3495(93)81374-2; GALZI JL, 1991, FEBS LETT, V294, P198, DOI 10.1016/0014-5793(91)80668-S; GALZI JL, 1990, J BIOL CHEM, V265, P10430; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; OLEARY ME, 1992, J BIOL CHEM, V267, P8360; PAULING P, 1973, CHEM-BIOL INTERACT, V6, P351, DOI 10.1016/0009-2797(73)90056-2; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1987, J PHYSIOL-LONDON, V385, P325, DOI 10.1113/jphysiol.1987.sp016496; SINE SM, 1982, J BIOL CHEM, V257, P8106; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1986, J PHYSIOL-LONDON, V373, P129, DOI 10.1113/jphysiol.1986.sp016039; SINE SM, 1984, BIOPHYS J, V46, P277, DOI 10.1016/S0006-3495(84)84022-9; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1990, J GEN PHYSIOL, V96, P395, DOI 10.1085/jgp.96.2.395; SINE SM, 1991, J BIOL CHEM, V266, P13679; SINE SM, 1988, J BIOL CHEM, V263, P18052; SINE SM, 1981, J BIOL CHEM, V256, P6692; SUSSMAN JL, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P95; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; WEILAND G, 1977, J BIOL CHEM, V252, P7648	30	128	128	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8808	8816						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132615				2022-12-25	WOS:A1994NB41100032
J	WAGNER, ACC; WISHART, MJ; MULDERS, SM; BLEVINS, PM; ANDREWS, PC; LOWE, AW; WILLIAMS, JA				WAGNER, ACC; WISHART, MJ; MULDERS, SM; BLEVINS, PM; ANDREWS, PC; LOWE, AW; WILLIAMS, JA			GP-3, A NEWLY CHARACTERIZED GLYCOPROTEIN ON THE INNER SURFACE OF THE ZYMOGEN GRANULE MEMBRANE, UNDERGOES REGULATED SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PANCREATIC LIPASE; ELECTROPHORETIC TRANSFER; TRITON X-114; ATP-DIPHOSPHOHYDROLASE; NITROCELLULOSE SHEETS; POLYACRYLAMIDE GELS; MAJOR GLYCOPROTEIN; PHASE-SEPARATION; PHOSPHOLIPASE-C; RAT PANCREAS	We have recently reported the cloning of the rat zymogen granule membrane glycoprotein GP-3 and the related pancreatic secretory lipase (Wishart, M. J., Andrews, P. C., Nichols, R., Blevins, G. T., Logsdon, C. D., and Williams, J. A (1993) J. Biol. Chem. 268, 10303-10311). Specific antipeptide antibodies were generated against both GP-3 and secretory lipase and used for the biochemical and physiological characterization of GP-3. Western blotting confirmed that GP-3 was found exclusively in zymogen granule membranes and was absent from zymogen granule content which contains the majority of secretory lipase. Extraction of zymogen granule membranes with Triton X-114 showed GP-3 to be significantly more hydrophobic than lipase. The GP-3 amino acid sequence contains one potential N-linked glycosylation site at Asn-336. The loss of concanavalin A labeling after both chemical deglycosylation with trifluoromethanesulfonic acid and enzymatic deglycosylation with N-glycanase showed GP-3 to possess a small N-linked oligosaccharide side chain. Digestion of intact and permeabilized zymogen granules with the nonspecific protease Pronase localized GP-3 to the inner surface of zymogen granule membranes. Since GP-3 is resident on the inner surface of the zymogen granule membrane, it should appear on the outer cellular surface after exocytosis. Although membrane attachment of GP-3 was resistant to treatment with phosphatidylinositol-specific phospholipase C, we observed that GP-3 is released into the pancreatic juice and that secretion of GP-3 was greatly enhanced by cholecystokinin.	UNIV MICHIGAN, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT BIOCHEM, ANN ARBOR, MI 48109 USA; STANFORD UNIV, DEPT MED, STANFORD, CA 94305 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Stanford University				Andrews, Philip/0000-0001-6843-5420; Williams, John/0000-0002-6063-7615	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933, R01DK043294, R01DK045722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008322] Funding Source: NIH RePORTER; NIDDK NIH HHS [P-30-DK-34933, DK 45722] Funding Source: Medline; NIGMS NIH HHS [5T32-GM08322] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAUDOIN AR, 1983, EUR J CELL BIOL, V29, P218; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BURNHAM DB, 1985, BIOCHEM J, V227, P743, DOI 10.1042/bj2270743; CHOW M, 1992, Current Opinion in Cell Biology, V4, P629, DOI 10.1016/0955-0674(92)90082-N; COYNE KE, 1993, J BIOL CHEM, V268, P6689; DELISLE RC, 1984, AM J PHYSIOL, V246, pG411, DOI 10.1152/ajpgi.1984.246.4.G411; ERICKSON PF, 1982, J IMMUNOL METHODS, V51, P241, DOI 10.1016/0022-1759(82)90263-0; FERGUSON MAJ, 1992, BIOCHEM J, V284, P297, DOI 10.1042/bj2840297; FUKUOKA SI, 1992, P NATL ACAD SCI USA, V89, P1189, DOI 10.1073/pnas.89.4.1189; FUKUOKA SI, 1991, P NATL ACAD SCI USA, V88, P2898, DOI 10.1073/pnas.88.7.2898; FUKUOKA SI, 1990, NUCLEIC ACIDS RES, V18, P5900, DOI 10.1093/nar/18.19.5900; GILLER T, 1992, J BIOL CHEM, V267, P16509; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GRUSBY MJ, 1990, CELL, V60, P451, DOI 10.1016/0092-8674(90)90596-7; HAVINGA JR, 1985, EUR J CELL BIOL, V39, P70; HOOPS TC, 1991, J BIOL CHEM, V266, P4257; HORVATH E, 1989, J NEUROSCI RES, V24, P398, DOI 10.1002/jnr.490240309; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEL D, 1984, BIOCHIM BIOPHYS ACTA, V769, P611, DOI 10.1016/0005-2736(84)90060-9; LEBEL D, 1988, BIOCHEM BIOPH RES CO, V154, P818, DOI 10.1016/0006-291X(88)90213-6; LEBEL D, 1980, J BIOL CHEM, V255, P1227; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; PAQUET MR, 1982, EUR J CELL BIOL, V28, P20; POSNETT DN, 1989, METHOD ENZYMOL, V178, P739; PRYDE JG, 1986, BIOCHEM J, V233, P525, DOI 10.1042/bj2330525; PRYDE JG, 1986, TRENDS BIOCHEM SCI, V11, P160, DOI 10.1016/0968-0004(86)90132-5; PUTNAM WS, 1989, AM J PHYSIOL, V256, pG698, DOI 10.1152/ajpgi.1989.256.4.G698; RINDLER MJ, 1990, EUR J CELL BIOL, V53, P154; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; RONZIO RA, 1978, BIOCHIM BIOPHYS ACTA, V508, P65, DOI 10.1016/0005-2736(78)90189-X; RUCKER RB, 1993, J NUTR, V123, P977; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; Scheele George A., 1993, P121; SPICER SS, 1992, J HISTOCHEM CYTOCHEM, V40, P1, DOI 10.1177/40.1.1370305; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER ACC, 1992, AM J PHYSIOL, V263, pC1172, DOI 10.1152/ajpcell.1992.263.6.C1172; WANG K, 1989, METHOD ENZYMOL, V172, P687, DOI 10.1016/S0076-6879(89)72038-3; Williams John A., 1993, P167; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WISHART MJ, 1993, J BIOL CHEM, V268, P10303	42	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9099	9104						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132647				2022-12-25	WOS:A1994NB41100073
J	WANG, YB; HAHN, TM; TSAI, SY; WOO, SLC				WANG, YB; HAHN, TM; TSAI, SY; WOO, SLC			FUNCTIONAL-CHARACTERIZATION OF A UNIQUE LIVER GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PHENYLALANINE-HYDROXYLASE; TISSUE-SPECIFIC EXPRESSION; SERINE DEHYDRATASE GENE; NUCLEAR FACTOR-IV; HUMAN ALPHA-1-ANTITRYPSIN GENE; DNA-BINDING PROTEINS; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; RAT-LIVER; CHLORAMPHENICOL ACETYLTRANSFERASE	Human phenylalanine hydroxylase (PAH) is specifically expressed in the liver to convert L phenylalanine to L-tyrosine. Deficiency of the PAH enzyme causes classic phenylketonuria, a common genetic disorder. The human PAH gene has a TATA-less promoter with multiple transcriptional initiation sites. A 9-kilobase DNA fragment 5'-flanking to the human BAH gene is sufficient to confer tissue- and developmental stage-specific expression of a reporter gene in transgenic mice. Deletion studies showed that the -121-base pair proximal promoter still retained a significant level of activity in hepatic cells. At least two protein binding sites, PAH-A and PAH-B, were identified in the proximal region of the human PAH promoter using rat liver nuclear extract. The PAH-A site covers a unique palindromic sequence, and the PAH-B site contains CCCTCCC repeats. Both elements are ubiquitous and essential regulatory elements for transcriptional activity. Nuclear protein factors that bind to the PAH-A and -B sites are detected in different cell types and are distinct from previously characterized transcription factors. No tissue-specific transcription factor binding sites have been detected within the proximal promoter region of the human PAH gene. These results suggest that the BAH gene promoter has a unique organization of regulatory elements for its tissue-specific expression in comparison with other liver gene promoters.	BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine				Wang, Yibin/0000-0003-0852-0767	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD017711, R01HD017711] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-17711] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AZIZKHAN JC, 1986, BIOCHEMISTRY-US, V25, P6228, DOI 10.1021/bi00368a059; BALKE MC, 1990, MOL CELL BIOL, V10, P6632; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BOAM DSW, 1989, BIOCHEM J, V264, P233, DOI 10.1042/bj2640233; BROOKS AR, 1991, J BIOL CHEM, V266, P7848; CHOW BKC, 1991, J BIOL CHEM, V266, P18927; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CITRON BA, 1992, P NATL ACAD SCI USA, V89, P1181; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COSTA RH, 1991, NUCLEIC ACIDS RES, V19, P4139, DOI 10.1093/nar/19.15.4139; COSTA RH, 1988, MOL CELL BIOL, V8, P81, DOI 10.1128/MCB.8.1.81; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; DESIMONE V, 1992, BIOCHIM BIOPHYS ACTA, V1132, P119, DOI 10.1016/0167-4781(92)90001-G; DESIMONE V, 1987, EMBO J, V6, P2759, DOI 10.1002/j.1460-2075.1987.tb02570.x; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; DILELLA AG, 1986, BIOCHEMISTRY-US, V25, P743, DOI 10.1021/bi00352a001; Eisensmith Randy C., 1992, Human Mutation, V1, P13, DOI 10.1002/humu.1380010104; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAYSON DR, 1988, SCIENCE, V239, P786, DOI 10.1126/science.3257586; GREENGARD O, 1977, PEDIATR RES, V11, P669, DOI 10.1203/00006450-197705000-00009; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; HSIEH MC, 1979, J EXP ZOOL, V208, P161, DOI 10.1002/jez.1402080204; Kaufman S., 1976, ADV NEUROCHEM, P1; KILEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448; KONECKI DS, 1992, BIOCHEMISTRY-US, V31, P8363, DOI 10.1021/bi00150a033; KWOK SCM, 1985, BIOCHEMISTRY-US, V24, P556, DOI 10.1021/bi00324a002; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LAI E, 1992, SEMIN LIVER DIS, V12, P246, DOI 10.1055/s-2007-1007396; LAIMINS L, 1982, P NATL ACAD SCI USA, V79, P6563; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LI Y, 1987, MOL CELL BIOL, V8, P4362; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LOU R, 1992, CELL, V71, P231; LUCERO MA, 1989, NUCLEIC ACIDS RES, P2281; MARIE P, 1989, SCIENCE, V244, P343; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGEE MM, 1972, BIOCHEM J, V127, P669, DOI 10.1042/bj1270669; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; NODA C, 1990, BIOCHEM BIOPH RES CO, V168, P335, DOI 10.1016/0006-291X(90)91713-3; NODA C, 1990, J BIOCHEM-TOKYO, V108, P622, DOI 10.1093/oxfordjournals.jbchem.a123253; OGAWA H, 1988, P NATL ACAD SCI USA, V85, P5809, DOI 10.1073/pnas.85.16.5809; PUGE BF, 1991, GENE DEV, V5, P1935; RAIHA NCR, 1973, PEDIATR RES, V7, P1; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; REIJNEN MJ, 1992, P NATL ACAD SCI USA, V89, P6300, DOI 10.1073/pnas.89.14.6300; ROBSON KJH, 1982, P NATL ACAD SCI-BIOL, V79, P4701, DOI 10.1073/pnas.79.15.4701; Scriver Charles R., 1993, Developmental Brain Dysfunction, V6, P11; SCRIVER CR, 1980, ANNU REV GENET, V14, P179, DOI 10.1146/annurev.ge.14.120180.001143; SCRIVER CR, 1989, METABOLIC BASIS INHE, V2, P495; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHEN RF, 1987, NUCLEIC ACIDS RES, V15, P8399, DOI 10.1093/nar/15.20.8399; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SMALE S, 1991, GENE DEV, V5, P1935; SU Y, 1990, BIOCHEM BIOPH RES CO, V170, P892, DOI 10.1016/0006-291X(90)92175-Y; SU Y, 1992, GENE, V120, P301, DOI 10.1016/0378-1119(92)90110-B; SVENSSON E, 1994, IN PRESS EUR J HUM G; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; TRAVIS A, 1991, MOL CELL BIOL, V11, P5756, DOI 10.1128/MCB.11.11.5756; TRONCHE F, 1990, MOL BIOL MED, V7, P173; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; WANG YB, 1992, J BIOL CHEM, V267, P15105; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; YEOH GCT, 1988, DIFFERENTIATION, V38, P42, DOI 10.1111/j.1432-0436.1988.tb00590.x	73	21	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9137	9146						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132651				2022-12-25	WOS:A1994NB41100078
J	ZHAO, ZZ; LAROCQUE, R; HO, WT; FISCHER, EH; SHEN, SH				ZHAO, ZZ; LAROCQUE, R; HO, WT; FISCHER, EH; SHEN, SH			PURIFICATION AND CHARACTERIZATION OF PTP2C, A WIDELY DISTRIBUTED PROTEIN-TYROSINE-PHOSPHATASE CONTAINING 2 SH2 DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE SIMILARITY; HUMAN-PLACENTA; RECEPTOR; KINASE; IDENTIFICATION; EXPRESSION; CORKSCREW; ENCODES; BINDING; TORSO	PTP2C, a widely distributed protein tyrosine phosphatase (PTP) containing two SH2 domains, was expressed as a recombinant enzyme in Escherichia coli and purified to near homogeneity. The purified enzyme and a truncated form lacking the SH2 domains (Delta SH2-PTP2C) have been characterized with four commonly used substrates. Both forms showed pH optima of around neutrality for protein substrates but below 5.5 for a peptide substrate and para-nitrophenylphosphate. The dependence of the enzymes on ionic strength varied with the nature of the substrates involved. Like its analog PTP1C, PTP2C displayed a specific activity of less than 0.1% of that observed with other known PTPs toward protein substrates. Deletion of the SH2 domains increased its activity by 12-45-fold, depending on the substrates used. Limited trypsinolysis which cleaved about 4 kDa from the carboxyl terminus resulted in a 2-5-fold activation of the full-length enzyme but was es sentially without effect on the truncated enzyme. Both forms showed similar responses to effecters including activators (e.g. anionic phospholipids) or inhibitors (e.g. vanadate, molybdate, or Zn2+). PTP2C and Delta SH2-PTP2C were phosphorylated in vitro by mitogen-activated protein kinase, protein kinase C, and various protein tyrosine kinases; in the latter case, they underwent au todephosphorylation. No significant effect of the phosphorylation reactions on enzyme activity could be ob served in vitro.	NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, MOLEC BIOL SECT, MONTREAL H4P 2R2, PQ, CANADA	National Research Council Canada	ZHAO, ZZ (corresponding author), UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07902] Funding Source: Medline; NIGMS NIH HHS [GM42508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAUM G, 1993, ANAL BIOCHEM, V211, P50, DOI 10.1006/abio.1993.1231; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; HIRAGA A, 1992, EUR J BIOCHEM, V209, P195, DOI 10.1111/j.1432-1033.1992.tb17277.x; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POT DA, 1991, J BIOL CHEM, V266, P19688; ROBETS DV, 1977, ENZYME KINETICS, P109; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STIDIES FW, 1990, METHOD ENZYMOL, V185, P60; SUGIMOTO S, 1993, J BIOL CHEM, V268, P11221; TONKS NK, 1991, METHOD ENZYMOL, V201, P427; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251; ZHAO ZZ, 1991, BIOCHEM BIOPH RES CO, V176, P1454, DOI 10.1016/0006-291X(91)90450-L; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816	35	79	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8780	8785						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132610				2022-12-25	WOS:A1994NB41100027
J	NEUENSCHWANDER, PF; MORRISSEY, JH				NEUENSCHWANDER, PF; MORRISSEY, JH			ROLES OF THE MEMBRANE-INTERACTIVE REGIONS OF FACTOR VIIA AND TISSUE FACTOR - THE FACTOR VIIA GLA DOMAIN IS DISPENSABLE FOR BINDING TO TISSUE FACTOR BUT IMPORTANT FOR ACTIVATION OF FACTOR-X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; COAGULATION FACTOR-XA; BOVINE FACTOR-X; BLOOD-COAGULATION; COFACTOR FUNCTION; CELLULAR RECEPTOR; PROTEIN; CALCIUM; COMPLEX; PHOSPHOLIPIDS	The roles of the putative membrane-interactive regions of factor VIIa (fVIIa) and tissue factor (TF) have been examined. Enzymatic removal of the 4-carboxyglutamic acid (Gla) domain of fVIIa had no effect on hydrolysis of a tripeptidyl chromogenic substrate in the absence or presence of TF. Additionally, Gla-domainless fVIIa (GdVIIa) was similar to native fVIIa in activating factor X in the absence of TF and phospholipid. However, GdVIIa in complex with recombinant soluble TF (sTF) was 76-fold less efficient in factor X activation than was fVIIa.sTF. The difference increased to 740-fold using TF relipidated in vesicles composed of 80% phosphatidylcholine and 20% phosphatidylserine (TF/PCPS). While Gla domain deletion produced a 10(3)-fold increase in the K-d for binding to TF/PCPS, the K-d for binding to TF/PC increased only 20-fold, and that for sTF in the absence of phospholipid increased 10-fold. K-d values for GdVIIa binding to TF/PCPS, TF/PC, or sTF were nearly identical. Thus, most of the binding energy required for formation of the fVIIa.TF complex was present even after Gla domain deletion. Both fVIIa and GdVIIa were capable of binding sTF in the presence of excess divalent metal-ion chelator, suggesting Ca2+-independent binding or the presence of a novel very high affinity Ca2+ binding site in fVIIa. The results demonstrate that the effect of the Gla domain on the K-d is apparent only in the presence of PS, and that interactions involving the fVIIa Gla domain and phospholipid are critical for efficient proteolysis of factor X on a membrane surface.	OKLAHOMA MED RES FDN, CARDIOVASC BIOL RES PROGRAM, OKLAHOMA CITY, OK 73104 USA	Oklahoma Medical Research Foundation			Morrissey, James H/H-4933-2011; Morrissey, James H./GLR-5645-2022	Morrissey, James H/0000-0002-1570-1569; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008710, R01HL047014] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32 HL08710, R01 HL47014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BACH R, 1988, BIOCHEMISTRY-US, V27, P4227, DOI 10.1021/bi00412a004; Bevington P. R., 1969, DATA REDUCTION ERROR; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; BROZE GJ, 1985, J BIOL CHEM, V260, P917; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; CROMPTON IE, 1986, BIOCHEM J, V239, P221, DOI 10.1042/bj2390221; CUTSFORTH GA, 1989, BIOCHEMISTRY-US, V28, P7453, DOI 10.1021/bi00444a045; DAHLBACK B, 1990, J BIOL CHEM, V265; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FIORE MM, 1994, J BIOL CHEM, V269, P143; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; Jesty J, 1988, Thromb Res, V50, P745, DOI 10.1016/0049-3848(88)90333-7; Jesty J, 1976, Methods Enzymol, V45, P95; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; MANN KG, 1984, PROG HEMOST THROMB, V7, P1; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MORITA T, 1986, J BIOL CHEM, V261, P4015; MORRISON SA, 1983, BIOCHEMISTRY-US, V22, P4053, DOI 10.1021/bi00286a010; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; MORRISSEY JH, 1988, THROMB RES, V50, P481, DOI 10.1016/0049-3848(88)90197-1; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NEMERSON Y, 1988, BLOOD, V71, P1; NEUENSCHWANDER P, 1988, BLOOD, V72, P1761; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; RAPAPORT SI, 1991, ANN NY ACAD SCI, V614, P51, DOI 10.1111/j.1749-6632.1991.tb43691.x; RAWALASHEIKH R, 1992, BLOOD, V79, P398; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; ROY S, 1991, J BIOL CHEM, V266, P4665; ROY S, 1991, J BIOL CHEM, V266, P22063; RUF W, 1992, J BIOL CHEM, V267, P6375; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; RUF W, 1991, J BIOL CHEM, V266, P16256; SAKAI T, 1990, J BIOL CHEM, V265, P1890; SCHIODT J, 1992, FEBS LETT, V306, P265, DOI 10.1016/0014-5793(92)81014-D; SKOGEN WF, 1984, J BIOL CHEM, V259, P2306; SMITH RL, 1973, J BIOL CHEM, V248, P2418; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016; WILDGOOSE P, 1990, P NATL ACAD SCI USA, V87, P7290, DOI 10.1073/pnas.87.18.7290; WILDGOOSE P, 1992, THROMB HAEMOSTASIS, V67, P679; ZUR M, 1978, J BIOL CHEM, V253, P2203	53	106	116	3	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8007	8013						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132522				2022-12-25	WOS:A1994NB40900030
J	VENNSTROM, B; RAYNOSCHECK, C; JANSSON, L; DOEDERLEIN, G; LHOTAK, V; JOHNSSON, A; BEUG, H				VENNSTROM, B; RAYNOSCHECK, C; JANSSON, L; DOEDERLEIN, G; LHOTAK, V; JOHNSSON, A; BEUG, H			RETROVIRAL CAPTURE OF C-ERBB PROTOONCOGENE SEQUENCES - RAPID EVOLUTION OF DISTINCT VIRAL GENOMES CARRYING MUTANT V-ERBB GENES WITH DIFFERENT TRANSFORMING CAPACITIES	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; GROWTH-FACTOR RECEPTOR; ROUS-SARCOMA VIRUS; TISSUE-SPECIFIC TRANSFORMATION; SINGLE REPLICATION CYCLE; LARGE DELETION MUTANTS; LEUKOSIS VIRUS; EGF RECEPTOR; NUCLEOTIDE-SEQUENCE; CELL-TRANSFORMATION	The evolution of oncogene-transducing retorviruses was followed by studying the genomes of five new, erbB carrying retroviruses. These viruses, isolated from cells of one chicken infected with Rous Associated virus 1 (RAV-1), had captured c-erbB sequences as a consequence of RAV-1 integration into the host genome. Their genome structures were distinct; however, their v-erbB genes had sustained identical 5' and 3' deletions and the v-erbB-env junctions were identical at the nucleotide level. The results therefore strongly suggest that all five viruses originate from the same capture event. Sequence analyses of the v-erbB genes from three of these viruses revealed that one of them had undergone no further mutation and lacked detectable capacity to transform cells, therefore probably representing an 'early' form of transducing virus. The two other v-erbB genes contained distinct mutations and differed in their potential to induce fibroblast- and erythroblast transformation; they therefore probably represent later derivatives of the virus that captured the erbB oncogene. The data suggest that the initial retrovirus rapidly underwent many alterations after capture of c-erbB sequences, already in the RAV-1 infected bird as well as during subsequent in vitro isolation procedures. The changes involve both major rearrangements of the genome as well as point mutations that activated the erbB oncogene.	KAROLINSKA INST,DEPT MED CELL BIOL,S-10401 STOCKHOLM,SWEDEN; SQUIBB FORRESTRAL GREENS,DEPT MOLEC BIOL,PLAINSBORO,NJ 08536; EMBL,HEIDELBERG,GERMANY; MT SINAI HOSP,TORONTO M5G 1X5,ON,CANADA; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Karolinska Institutet; European Molecular Biology Laboratory (EMBL); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	VENNSTROM, B (corresponding author), KAROLINSKA INST,DEPT MOLEC BIOL,S-10401 STOCKHOLM,SWEDEN.			Sanchez-Pardo Echevarria, Jesus/0000-0002-3683-5371				BEUG H, 1978, CELL, V14, P843, DOI 10.1016/0092-8674(78)90340-9; BEUG H, 1986, J VIROL, V57, P1127, DOI 10.1128/JVI.57.3.1127-1138.1986; BEUG H, 1981, VIROLOGY, V111, P201, DOI 10.1016/0042-6822(81)90665-6; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; CHOI OR, 1986, MOL CELL BIOL, V6, P1751, DOI 10.1128/MCB.6.5.1751; COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DOUGHERTY JP, 1988, J VIROL, V62, P2817, DOI 10.1128/JVI.62.8.2817-2822.1988; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; GAMETT DC, 1986, P NATL ACAD SCI USA, V83, P6053, DOI 10.1073/pnas.83.16.6053; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GOODWIN RG, 1986, MOL CELL BIOL, V6, P3128, DOI 10.1128/MCB.6.9.3128; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; GRAF T, 1980, P NATL ACAD SCI-BIOL, V77, P389, DOI 10.1073/pnas.77.1.389; HAYMAN MJ, 1984, NATURE, V309, P460, DOI 10.1038/309460a0; HAYMAN MJ, 1983, CELL, V32, P579, DOI 10.1016/0092-8674(83)90477-4; HIHARA H, 1983, J NATL CANCER I, V70, P891; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HUANG CC, 1986, CELL, V44, P935, DOI 10.1016/0092-8674(86)90016-4; HUANG CC, 1985, J MOL BIOL, V181, P175, DOI 10.1016/0022-2836(85)90083-X; JANSSON M, 1987, ONCOGENE, V1, P167; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KAWAI S, 1987, J VIROL, V61, P1665, DOI 10.1128/JVI.61.5.1665-1669.1987; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KILLISCH I, 1992, J CELL SCI, V103, P211; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LEE EB, 1990, ONCOGENE, V5, P1165; LEE EB, 1993, ONCOGENE, V8, P1317; LEUTZ A, 1988, J BIOL CHEM, V263, P3905; MAIHLE N J, 1988, Biochimica et Biophysica Acta, V948, P287; MAIHLE NJ, 1988, MOL CELL BIOL, V8, P4868, DOI 10.1128/MCB.8.11.4868; MILES BD, 1985, J VIROL, V54, P295, DOI 10.1128/JVI.54.2.295-303.1985; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6024, DOI 10.1073/pnas.87.16.6024; PELLEY RJ, 1989, P NATL ACAD SCI USA, V86, P7164, DOI 10.1073/pnas.86.18.7164; PELLEY RJ, 1988, J VIROL, V62, P1840, DOI 10.1128/JVI.62.5.1840-1844.1988; PRIVALSKY ML, 1984, VIROLOGY, V135, P356, DOI 10.1016/0042-6822(84)90192-2; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; RAINES MA, 1985, P NATL ACAD SCI USA, V82, P2127; ROBINSON HL, 1985, J VIROL, V55, P617, DOI 10.1128/JVI.55.3.617-622.1985; ROYERPOKORA B, 1978, CELL, V13, P751, DOI 10.1016/0092-8674(78)90225-8; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SCOTTING P, 1987, ONCOGENE RES, V1, P265; SHU HKG, 1991, J VIROL, V65, P6173, DOI 10.1128/JVI.65.11.6173-6180.1991; SHU HKG, 1990, P NATL ACAD SCI USA, V87, P9103, DOI 10.1073/pnas.87.23.9103; SORGE J, 1982, Journal of Molecular and Applied Genetics, V1, P547; SWAIN A, 1992, SCIENCE, V255, P841, DOI 10.1126/science.1371365; UHL E., 1936, Acta Pathologica et Microbiologica Scandinavica, V13, P434; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; VOYNOW SL, 1985, J VIROL, V55, P79, DOI 10.1128/JVI.55.1.79-85.1985; VOYNOW SL, 1985, J VIROL, V55, P67, DOI 10.1128/JVI.55.1.67-78.1985; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	62	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1307	1320						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152791				2022-12-25	WOS:A1994NH40100001
J	LAZAROWSKI, ER; HARDEN, TK				LAZAROWSKI, ER; HARDEN, TK			IDENTIFICATION OF A URIDINE NUCLEOTIDE-SELECTIVE G-PROTEIN-LINKED RECEPTOR THAT ACTIVATES PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION SYSTEMS; BETA-ADRENERGIC RECEPTORS; CANINE CEREBRAL-ARTERIES; FRTL-5 THYROID-CELLS; EXTRACELLULAR ATP; ADENYLATE-CYCLASE; P2-PURINERGIC RECEPTORS; PYRIMIDINE NUCLEOTIDES; INOSITOL TRISPHOSPHATE; URACIL NUCLEOTIDES	Incubation of C6-2B rat glioma cells with UDP or UTP resulted in a time- and concentration-dependent increase in the accumulation of inositol phosphates. In contrast, ATP, ADP, and analogs of these nucleotides known to be effective agonists at P-2U-, P-2X-, P-2Y-, P,(2T)-, and P-2Z-purinergic receptors all had no effect on inositol phosphate levels in C6-2B cells. Pyrimidine nucleotides stimulated inositol phosphate accumulation with an order of potency of UDP > 5-BrUTP > UTP > dTDP > UDP glucose. K-0.5 values for UDP, 5-BrUTP, and UTP were 2.3 +/- 0.5, 9 +/- 3, and 57 +/- 10 mu M, respectively. A similar uridine nucleotide selectivity was observed for arachidonic acid release presumably occurring as a consequence of activation of phospholipase A(2). Cross-desensitization and additivity experiments indicated that UDP and UTP interact with the same population of receptors. The effect of uridine nucleotides on inositol phosphate accumulation was inhibited markedly by pretreatment of cells with pertussis toxin. UDP also caused a guanine nudeotide-dependent increase in inositol lipid hydrolysis in streptolysin-O-permeabilized cells. Taken together these results describe the existence of a novel uridine nucleotide receptor that is not activated by adenine nucleotides. This receptor is pharmacologically distinct from the previously described P-2U- and other P-2-purinergic receptors, and likely is a member of a new class of receptors for extracellular nucleotides.	UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NHLBI NIH HHS [HL32322] Funding Source: Medline; NIGMS NIH HHS [GM38213, GM29536] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029536, R01GM029536, R01GM038213] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BOYER JL, 1993, J PHARMACOL EXP THER, V267, P1140; BROWN HA, 1991, MOL PHARMACOL, V40, P648; Burnstock G., 1978, CELL MEMBRANE RECEPT, Vpp, P107; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; DEVELLIS J, 1974, SCIENCE, V186, P1221, DOI 10.1126/science.186.4170.1221; DEVELLIS J, 1973, TISSUE CULTURE NERVO, P231; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; DUBYAK GR, 1988, J BIOL CHEM, V263, P18108; FINE J, 1989, BIOCHEM J, V263, P371, DOI 10.1042/bj2630371; FISHMAN PH, 1981, MOL PHARMACOL, V20, P310; FREDERICH RC, 1983, J CYCLIC NUCL PROT, V9, P103; GOETZ U, 1971, J PHARMACOL EXP THER, V178, P210; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HARDEBO JE, 1983, GEN PHARMACOL, V14, P133, DOI 10.1016/0306-3623(83)90082-4; HARDEBO JE, 1987, BLOOD VESSELS, V24, P150; Harden T. Kendall, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P11; HARDEN TK, 1989, INOSITOL LIPIDS CELL, P113; HAUSSINGER D, 1987, EUR J BIOCHEM, V167, P65; HOMBURGER V, 1980, J BIOL CHEM, V255, P436; HUGHES PJ, 1989, J BIOL CHEM, V264, P19871; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KEPPLER D, 1970, ANAL BIOCHEM, V38, P105, DOI 10.1016/0003-2697(70)90160-0; LAZAROWSKI ER, 1994, AM J PHYSIOL, V266, pC406, DOI 10.1152/ajpcell.1994.266.2.C406; LIN WW, 1993, NEUROCHEM RES, V18, P681, DOI 10.1007/BF00966782; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MACDONALD G, 1984, CLIN EXP PHARMACOL P, V11, P381, DOI 10.1111/j.1440-1681.1984.tb00283.x; MARTIN TFJ, 1989, INOSITOL LIPIDS CELL, P81; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; NAKAHATA N, 1987, BIOCHEM J, V241, P337, DOI 10.1042/bj2410337; OKAJIMA F, 1989, J BIOL CHEM, V264, P13029; OKAJIMA F, 1987, J BIOL CHEM, V262, P13483; PFEILSCHIFTER J, 1990, BIOCHEM J, V272, P469, DOI 10.1042/bj2720469; RALEVIC V, 1991, CIRC RES, V69, P1583, DOI 10.1161/01.RES.69.6.1583; SAKAI K, 1979, JPN J PHARMACOL, V29, P243, DOI 10.1254/jjp.29.243; SATO K, 1992, BIOCHEM J, V283, P281, DOI 10.1042/bj2830281; SEIFERT R, 1989, TRENDS PHARMACOL SCI, V10, P365, DOI 10.1016/0165-6147(89)90009-6; SEIFERT R, 1989, EUR J BIOCHEM, V181, P277, DOI 10.1111/j.1432-1033.1989.tb14722.x; SHIRASAWA Y, 1983, STROKE, V14, P347, DOI 10.1161/01.STR.14.3.347; SIEFERT R, 1989, BIOCHEM J, V259, P813; STUTCHFIELD J, 1990, FEBS LETT, V262, P256, DOI 10.1016/0014-5793(90)80204-V; URQUILLA PR, 1978, STROKE, V9, P133, DOI 10.1161/01.STR.9.2.133; VONKUGELGEN I, 1987, N-S ARCH PHARMACOL, V336, P556, DOI 10.1007/BF00169313; VONKUGELGEN I, 1990, N-S ARCH PHARMACOL, V341, P538, DOI 10.1007/BF00171734; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; YAMADA M, 1992, CIRC RES, V70, P477, DOI 10.1161/01.RES.70.3.477	47	94	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11830	11836						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163481				2022-12-25	WOS:A1994NG37700027
J	BALBOA, MA; FIRESTEIN, BL; GODSON, C; BELL, KS; INSEL, PA				BALBOA, MA; FIRESTEIN, BL; GODSON, C; BELL, KS; INSEL, PA			PROTEIN-KINASE C-ALPHA MEDIATES PHOSPHOLIPASE-D ACTIVATION BY NUCLEOTIDES AND PHORBOL ESTER IN MADIN-DARBY CANINE KIDNEY-CELLS - STIMULATION OF PHOSPHOLIPASE-D IS INDEPENDENT OF ACTIVATION OF POLYPHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE-C AND PHOSPHOLIPASE A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; ARACHIDONIC-ACID RELEASE; PHOSPHATIDYLCHOLINE HYDROLYSIS; PHOSPHATIDIC-ACID; PHOSPHOINOSITIDE HYDROLYSIS; DEPENDENT ACTIVATION; DIFFERENT MECHANISMS; HUMAN-NEUTROPHILS; MDCK-D1 CELLS; D PATHWAY	Protein kinase C (PKC) has been implicated in the activation of phospholipase D (PLD) in a number of systems. By antisense technology, we have ''knocked out'' alpha and beta isoforms of PKC to study the role of these isoforms in PLD activation in Madin-Darby canine kidney (MDCK) cells. To this end, we have studied PLD activation by phorbol 12-myristate 13 acetate (PMA), ATP, UTP, and 2-methylthio-ATP in cells labeled with [H-3]palmitic acid. [H-3]Phosphatidylethanol (PEt) production catalyzed by PLD in the presence of ethanol was time- and concentration-dependent in PMA- and nucleotide stimulated cells. In Ca2+-free medium, [H-3]PEt accumulation was diminished for all stimuli assayed. Treatment of cells with chelerythrine, an inhibitor of PKC, and phorbol ester down-regulation of PKC inhibited [H-3]PEt production by both PMA and nucleotides. In cells transfected with antisense PKCalpha or both PKCalpha and PKCbeta, PLD activation was inhibited by both PMA and nucleotides, whereas in cells transfected with antisense PKCbeta, PLD activation was similar to that of control cells. Moreover, inhibition of polyphosphoinositide-specific PLC (by neomycin) or of release of arachidonic acid and arachidonic acid metabolites (by nordihydroguaiaretic acid or by indomethacin) failed to decrease [H-3]PEt accumulation in PMA- and nucleotide-stimulated MDCK-D1 cells. From these data, we conclude that in MDCK-D1 cells PMA and nucleotide receptors utilize PKCalpha to regulate PLD activity and that PLD activation is independent of the activation of polyphosphoinositide-specific PLC and phospholipase A(2)-mediated release of arachidonic acid or arachidonic acid metabolites.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL 0636,LA JOLLA,CA 92093	University of California System; University of California San Diego			Balboa, María A./V-9493-2018	Balboa, María A./0000-0002-2130-5298; Godson, Catherine/0000-0003-0655-1041; Firestein, Bonnie/0000-0002-1679-3565	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL035018] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 35018] Funding Source: Medline; NIGMS NIH HHS [GM 31487] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGWU DE, 1991, J IMMUNOL, V146, P3895; AGWU DE, 1989, J BIOL CHEM, V264, P1405; BALBOA MA, 1992, J EXP MED, V176, P9, DOI 10.1084/jem.176.1.9; BALSINDE J, 1992, BIOCHIM BIOPHYS ACTA, V1136, P75, DOI 10.1016/0167-4889(92)90087-R; BALSINDE J, 1991, J BIOL CHEM, V266, P18726; BENAV P, 1993, EUR J BIOCHEM, V215, P455, DOI 10.1111/j.1432-1033.1993.tb18054.x; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BILLAH MM, 1991, BIOCHEM SOC T, V19, P324, DOI 10.1042/bst0190324; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COCKCROFT S, 1984, BIOCHIM BIOPHYS ACTA, V795, P37, DOI 10.1016/0005-2760(84)90102-4; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; COOK SJ, 1991, BIOCHIM BIOPHYS ACTA, V1092, P265, DOI 10.1016/0167-4889(91)90166-U; COOPER CL, 1989, J BIOL CHEM, V264, P6202; DIVIRGILIO F, 1984, NATURE, V310, P691, DOI 10.1038/310691a0; DUBYAK GR, 1993, BIOCHEM J, V292, P121, DOI 10.1042/bj2920121; ELDAR H, 1993, J BIOL CHEM, V268, P12560; EXTON JH, 1990, J BIOL CHEM, V265, P9761; FIRESTEIN B L, 1991, Society for Neuroscience Abstracts, V17, P81; FIRESTEIN BL, 1993, PHARMACOLOGIST, V35, P140; FOSTER KA, 1987, BIOCHEM SOC T, V15, P418, DOI 10.1042/bst0150418; GODSON C, 1990, J BIOL CHEM, V265, P8369; GODSON C, 1993, J BIOL CHEM, V268, P11946; GODSON C, 1991, FASEB J, V5, pA834; HALENDA SP, 1990, BIOCHEM J, V267, P479, DOI 10.1042/bj2670479; Heller M, 1978, Adv Lipid Res, V16, P267; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HUANG CF, 1992, J BIOL CHEM, V267, P16859; HUANG CF, 1990, J BIOL CHEM, V265, P14858; HUANG FL, 1989, J BIOL CHEM, V264, P4238; HUANG R, 1991, J BIOL CHEM, V266, P1652; HUWILER A, 1991, BIOCHEM J, V279, P441, DOI 10.1042/bj2790441; JONES GA, 1993, J BIOL CHEM, V268, P20845; KANAHO Y, 1992, J BIOL CHEM, V267, P23554; KANAHO Y, 1991, J IMMUNOL, V146, P3536; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KNAUSS TC, 1990, J BIOL CHEM, V265, P14457; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; KUSNER DJ, 1993, J BIOL CHEM, V268, P19973; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIPSKY JJ, 1982, J PHARMACOL EXP THER, V220, P287; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; LISCOVITCH M, 1989, J BIOL CHEM, V264, P1450; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MARTINSON EA, 1989, J BIOL CHEM, V264, P14748; MEIER KE, 1985, AM J PHYSIOL, V246, pC69; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MULLMANN TJ, 1993, J LEUKOCYTE BIOL, V53, P630, DOI 10.1002/jlb.53.6.630; NISHIZUUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P826; OCONNOR SE, 1991, TRENDS PHARMACOL SCI, V12, P137, DOI 10.1016/0165-6147(91)90530-6; PACHTER JA, 1992, J BIOL CHEM, V267, P9826; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; ROBISON TW, 1990, TOXICOL APPL PHARM, V105, P113, DOI 10.1016/0041-008X(90)90363-Y; SCHWERTZ DW, 1984, J PHARMACOL EXP THER, V231, P48; SLIVKA SR, 1988, J BIOL CHEM, V263, P12242; SLIVKA SR, 1987, J BIOL CHEM, V262, P4200; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; TETTENBORN CS, 1988, BIOCHEM BIOPH RES CO, V155, P249, DOI 10.1016/S0006-291X(88)81076-3; WEISS BA, 1991, J BIOL CHEM, V266, P2126; WIJKANDER J, 1989, FEBS LETT, V244, P51, DOI 10.1016/0014-5793(89)81160-3; YANG SF, 1967, J BIOL CHEM, V242, P477; YOUNG Y, 1987, BIOCHEM J, V244, P755	65	138	139	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10511	10516						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144636				2022-12-25	WOS:A1994NF01700050
J	HOLZ, RW; BRONDYK, WH; SENTER, RA; KUIZON, L; MACARA, IG				HOLZ, RW; BRONDYK, WH; SENTER, RA; KUIZON, L; MACARA, IG			EVIDENCE FOR THE INVOLVEMENT OF RAB3A IN CA2+-DEPENDENT EXOCYTOSIS FROM ADRENAL CHROMAFFIN CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; CATECHOLAMINE SECRETION; ENDOPLASMIC-RETICULUM; GOLGI-COMPLEX; RAS; EXPRESSION; VESICLES; PATHWAY; INVITRO; YEAST	Bovine chromaffin cells are nondividing primary secretory cells that store and secrete catecholamine and a variety of proteins including chromogranins, opiate peptides, and opiate precursors. A transient transfection technique based upon the expression of human growth hormone as a reporter for the regulated secretory pathway was used to study the role of a Ras-like, GTP-binding protein, Rab3a, in Ca2+-dependent exocytosis. Immunocytochemistry and flow cytometry revealed that growth hormone and Rab proteins were coexpressed in the same cells. Overexpression of the wild type protein and expression of a mutant protein Rab3aQ81L both inhibited nicotinic agonist-stimulated exocytosis in intact cells. Expression of Rab3aQ81L also inhibited Ca2+-dependent secretion from permeabilized cells. Two other mutants, Rab3aN135I and Rab3aT36N, which correspond to dominant acting mutants of Ras, caused limited and no inhibition, respectively, of agonist-stimulated exocytosis. These data provide direct evidence that Rab3a plays an important role in Ca(2+-)triggered exocytosis. We suggest that Rab3a is an inhibitor of secretion, perhaps as part of a pre-fusion complex with secretory vesicles. Elevated Ca2+ may trigger exocytosis by overcoming the inhibition by Rab3a.	UNIV VERMONT,DEPT PATHOL,BURLINGTON,VT 05405	University of Vermont	HOLZ, RW (corresponding author), UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109, USA.				NCI NIH HHS [R01 CA56300] Funding Source: Medline; NEI NIH HHS [F32EY06411] Funding Source: Medline; NIDDK NIH HHS [R01-DK 27959] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056300] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [F32EY006411] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027959] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BADER MF, 1989, J BIOL CHEM, V264, P16426; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BITTNER MA, 1992, J BIOL CHEM, V267, P16226; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; BITTNER MA, 1986, J BIOL CHEM, V261, P182; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; BURSTEIN E, 1989, MOL CELL BIOL, V9, P4807, DOI 10.1128/MCB.9.11.4807; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; CORCORAN JJ, 1990, AM J PHYSIOL, V259, pC161, DOI 10.1152/ajpcell.1990.259.1.C161; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HOLZ RW, 1982, J NEUROCHEM, V39, P635, DOI 10.1111/j.1471-4159.1982.tb07940.x; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MA WJ, 1992, J BIOL CHEM, V267, P22728; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; NGSEE JK, 1993, MOL BIOL CELL, V4, P747, DOI 10.1091/mbc.4.7.747; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; OHARAIMAIZUMI M, 1992, J NEUROCHEM, V58, P2275, DOI 10.1111/j.1471-4159.1992.tb10974.x; OLOFSSON B, 1988, ONCOGENE, V3, P231; PADFIELD PJ, 1992, P NATL ACAD SCI USA, V89, P1656, DOI 10.1073/pnas.89.5.1656; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SANO K, 1989, BIOCHEM BIOPH RES CO, V158, P377, DOI 10.1016/S0006-291X(89)80058-0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SENYSHYN J, 1992, FEBS LETT, V309, P41, DOI 10.1016/0014-5793(92)80735-Y; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VITALE N, 1993, J BIOL CHEM, V268, P14175; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WICKPW, 1993, J BIOL CHEM, V268, P10983; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8	38	206	208	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10229	10234						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144603				2022-12-25	WOS:A1994NF01700012
J	OMOTE, H; PARK, MY; MAEDA, M; FUTAI, M				OMOTE, H; PARK, MY; MAEDA, M; FUTAI, M			THE ALPHA/BETA SUBUNIT INTERACTION IN H+-ATPASE (ATP SYNTHASE) - AN ESCHERICHIA-COLI ALPHA-SUBUNIT MUTATION (ARG-ALPHA-296 -] CYS) RESTORES COUPLING EFFICIENCY TO THE DELETERIOUS BETA-SUBUNIT MUTANT (SER-BETA-174 -] PHE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; GLYCINE-RICH SEQUENCE; UNCD MUTANTS; B-SUBUNIT; F1-ATPASE; RESIDUES; BINDING; DNA; SITE; IDENTIFICATION	The Ser-beta 174 residue of the Escherichia coli H+-ATPase beta subunit has been shown to be near the catalytic site together with Gly-beta 149, Gly-beta 172, Glu-beta 192, and Val-beta 198 (Iwamoto, A., Park, M.-Y., Maeda, M., and Futai, M. (1993) J. Biol. Chem. 268, 3156-3160). In this study, we introduced various residues at position 174 and found that the larger the side chain volume of the residue introduced, the lower the enzyme activity became. The Phe-beta 174 mutant was defective in energy coupling between catalysis and transport, whereas the Leu-beta 174 mutant could couple efficiently, although both mutants had essentially the same ATPase activities (similar to 10% of the wild type). The defective energy coupling of the Phe-beta 174 mutant was suppressed by the second mutation (Arg-alpha 296 --> Cys) in the alpha subunit. The Cys-alpha 296/Phe-beta 174 mutant had essentially the same membrane ATPase activity as the Phe-beta 174 single mutant when assayed under the conditions that stabilize the double mutant enzyme. These results indicate the importance of the alpha/beta interaction, especially that between the regions near Arg-alpha 296 and Ser-beta 174, for energy coupling in the H+-ATPase. The 2 residues (Ser-beta 174 and Arg-alpha 296) may be located nearby at the interface of the two subunits. About 1 mol of N-[C-14]ethylmaleimide could bind to 1 mol of the alpha subunit of Cys-alpha 296/Phe-beta 174 or Cys-alpha 296 mutant ATPase, but could not inhibit the enzyme activity. This is the first intersubunit mutation/suppression approach to ATPase catalysis and its energy coupling.			OMOTE, H (corresponding author), OSAKA UNIV,INST SCI & IND RES,DEPT ORGAN CHEM & BIOCHEM,IBARAKI,OSAKA 567,JAPAN.		OMOTE, Hiroshi/B-1635-2011					CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; CROSS RL, 1982, J BIOL CHEM, V257, P2101; DUNCAN TM, 1985, J BIOL CHEM, V260, P4901; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; FUTAI M, 1992, J EXP BIOL, V172, P443; HATEFI Y, 1982, P NATL ACAD SCI-BIOL, V79, P1756, DOI 10.1073/pnas.79.6.1756; HSU SY, 1987, FEBS LETT, V218, P222, DOI 10.1016/0014-5793(87)81050-5; IDA K, 1991, J BIOL CHEM, V266, P5424; IWAMOTO A, 1993, J BIOL CHEM, V268, P3156; IWAMOTO A, 1991, J BIOL CHEM, V266, P16350; KANAZAWA H, 1980, J BIOCHEM-TOKYO, V88, P695, DOI 10.1093/oxfordjournals.jbchem.a133022; KANAZAWA H, 1980, P NATL ACAD SCI-BIOL, V77, P7005, DOI 10.1073/pnas.77.12.7005; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KUMAMOTO CA, 1987, J BIOL CHEM, V262, P3060; KUMAMOTO CA, 1986, J BIOL CHEM, V261, P37; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGGIO MB, 1987, J BIOL CHEM, V262, P8981; MAGGIO MB, 1988, J BIOL CHEM, V263, P4619; MORIYAMA Y, 1991, J BIOL CHEM, V266, P22141; NAKAJIMA H, 1979, J BIOCHEM-TOKYO, V85, P303, DOI 10.1093/oxfordjournals.jbchem.a132325; NAKAMOTO RK, 1993, J BIOL CHEM, V268, P867; NOUMI T, 1986, J BIOL CHEM, V261, P9196; NOUMI T, 1984, J BIOL CHEM, V259, P71; NOUUMI T, 1984, J BIOL CHEM, V259, P10076; OMOTE H, 1992, J BIOL CHEM, V267, P20571; PAGAN J, 1990, ARCH BIOCHEM BIOPHYS, V277, P283, DOI 10.1016/0003-9861(90)90580-R; PARSONAGE D, 1988, FEBS LETT, V232, P111, DOI 10.1016/0014-5793(88)80397-1; PARSONAGE D, 1987, J BIOL CHEM, V262, P6301; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SENIOR AE, 1993, J BIOL CHEM, V268, P6989; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; SOGA S, 1989, ARCH BIOCHEM BIOPHYS, V268, P643, DOI 10.1016/0003-9861(89)90332-9; TAKEYAMA M, 1990, J BIOL CHEM, V265, P21279; TURINA P, 1993, J BIOL CHEM, V268, P6978; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	41	28	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10265	10269						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144607				2022-12-25	WOS:A1994NF01700017
J	WISNIEWSKI, JR; SCHULZE, E				WISNIEWSKI, JR; SCHULZE, E			HIGH-AFFINITY INTERACTION OF DIPTERAN HIGH-MOBILITY GROUP (HMG) PROTEINS-1 WITH DNA IS MODULATED BY COOH-TERMINAL REGIONS FLANKING THE HMG BOX DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL-PROTEINS; TRANSCRIPTION FACTOR; BINDING PROPERTIES; RNA-POLYMERASE; CRUCIFORM DNA; HISTONE; FLUORESCENCE; CHROMATIN; INVITRO; SITE	The cells of the dipteran insects Chironomus and Drosophila contain high mobility group (HMG) 1 proteins that are homologous to the HMG1 protein of mammals but comprise one instead of two DNA-binding HMG boxes. Mobility shift assays have revealed that Chironomus cHMG1a and cHMG1b bind double strand and four-way junction DNA in a similar way at apparent dissociation constants in the range of 7.5-20 x 10(-9) M. Both proteins are monomeric and highly asymmetric molecules in solution. cHMG1a and cHMG1b exhibit Stokes' radii of 2.4 and 2.3 nm, respectively, and both show a frictional ratio of 1.5. Despite these similarities in their hydrodynamic properties, the binding site of cHMG1a on DNA is similar to 1.5 of the size found for the cHMG1b. Enzymatically and chemically prepared peptides of cHMG1a as well as bacterially expressed cHMG1a with terminal deletions and point substitutions showed that sequences flanking the folded domain that constitutes the HMG box are essential for the interaction of the HMG box with DNA. In particular, changes in the number of positive and negative charges, respectively, within basic and acidic domains modulated the DNA binding affinity of the cHMG1a protein. The alteration of fluorescence of the Trp residues suggest that this modulation is due to interaction of the acidic domain with the positively charged HMG box.			WISNIEWSKI, JR (corresponding author), UNIV GOTTINGEN, INST ZOOL 3, DEPT DEV BIOL, HOLUMBOLDTALLEE 34A, D-37073 GOTTINGEN, GERMANY.							ACKERS GK, 1975, PROTEINS, V3, P1; BIANCHI ME, 1988, EMBO J, V7, P843, DOI 10.1002/j.1460-2075.1988.tb02883.x; BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BONNE C, 1982, J BIOL CHEM, V257, P2722; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JW, 1986, J BIOL CHEM, V261, P1349; BUSTIN M, 1985, BIOCHEM BIOPH RES CO, V133, P633, DOI 10.1016/0006-291X(85)90952-0; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; BUTLER AP, 1985, J BIOL CHEM, V260, P613; CARBALLO M, 1983, EMBO J, V2, P1759, DOI 10.1002/j.1460-2075.1983.tb01654.x; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; CARY PD, 1983, EUR J BIOCHEM, V131, P367, DOI 10.1111/j.1432-1033.1983.tb07272.x; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DUGUET M, 1978, J BIOL CHEM, V253, P1660; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GOODWIN GH, 1975, EUR J BIOCHEM, V54, P427, DOI 10.1111/j.1432-1033.1975.tb04153.x; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NICOLAS RH, 1982, HMG CHROMOSOMAL PROT, P41; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; REECK GR, 1982, NATURE, V300, P76, DOI 10.1038/300076a0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARZ G, 1983, J MOL BIOL, V163, P467, DOI 10.1016/0022-2836(83)90069-4; SHEFLIN LG, 1993, BIOCHEMISTRY-US, V32, P3238, DOI 10.1021/bi00064a005; SHEFLIN LG, 1989, BIOCHEMISTRY-US, V28, P5658, DOI 10.1021/bi00439a048; SHOOTER KV, 1974, EUR J BIOCHEM, V47, P263, DOI 10.1111/j.1432-1033.1974.tb03690.x; SINGH J, 1990, BIOCHEMISTRY-US, V29, P6295, DOI 10.1021/bi00478a026; TREMETHICK DJ, 1988, NUCLEIC ACIDS RES, V16, P11107, DOI 10.1093/nar/16.23.11107; WAGNER CR, 1992, MOL CELL BIOL, V12, P1915, DOI 10.1128/MCB.12.5.1915; WATANABE F, 1989, FEBS LETT, V249, P147, DOI 10.1016/0014-5793(89)80612-X; WATT F, 1988, NUCLEIC ACIDS RES, V16, P1471, DOI 10.1093/nar/16.4.1471; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WISNIEWSKI JR, 1992, J BIOL CHEM, V267, P17170	38	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10713	10719						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144661				2022-12-25	WOS:A1994NF01700078
J	CHOI, KH; WALL, C; HANRATTY, R; KELLER, G				CHOI, KH; WALL, C; HANRATTY, R; KELLER, G			ISOLATION OF A GENE ENCODING A NOVEL RECEPTOR TYROSINE KINASE FROM DIFFERENTIATED EMBRYONIC STEM-CELLS	ONCOGENE			English	Note							GROWTH-FACTOR RECEPTOR; C-KIT; SIGNAL TRANSDUCTION; ENZYMATIC AMPLIFICATION; MESSENGER-RNAS; SEQUENCES; IDENTIFICATION; ANGIOGENESIS; EXPRESSION; MUTATIONS	A mouse gene encoding a receptor tyrosine kinase, designated Embryonic receptor kinase (EmRK2), was isolated from embryoid bodies (EBs) generated by differentiating embryonic stem (ES) cells in culture for 6 days. Sequence analysis of EmRK2 cDNA clones predicts a receptor with a 755 amino acid extracellular region with seven immunoglobulin-like domains, a transmembrane region, and a 552 amino acid cytoplasmic region containing the kinase domain. The kinase domain is interrupted by a stretch of hydrophilic amino acids, the kinase insert. EmRK2 is expressed in embryoid bodies, in whole embryos at day 10 and 12 of gestation, and in the embryonic yolk sac and the fetal liver. On the basis of sequence homology, EmRK2 is likely to be the mouse homologue of human flt, a receptor for vascular endothelial growth factor, and as such, could encode an endothelial cell specific receptor tyrosine kinase.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	CHOI, KH (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,1400 JACKSON ST,DENVER,CO 80206, USA.			Keller, Gordon/0000-0001-9309-9297				BREIER G, 1992, DEVELOPMENT, V114, P521; CHOI KG, 1993, P NATL ACAD SCI USA, V90, P5747, DOI 10.1073/pnas.90.12.5747; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EVANS M, NATURE, V292, P154; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEN Z, 1991, ONCOGENE, V6, P953; GALLAND F, 1993, ONCOGENE, V8, P1233; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MULLER AJ, 1989, MOL CELL BIOL, V9, P5234, DOI 10.1128/MCB.9.11.5234; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; OELRICHS RB, 1993, ONCOGENE, V8, P11; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; REITH AD, 1990, GENE DEV, V4, P3900; RISAU W, 1988, DEVELOPMENT, V102, P471; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SHIBUYA M, 1990, ONCOGENE, V5, P519; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAGNER RC, 1980, ADV MICROCIRCULAT, V9, P45; WANG R, 1992, DEVELOPMENT, V114, P303; WILES MV, 1991, DEVELOPMENT, V111, P259; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZAGURSKY RJ, 1985, GENE ANAL TECH, V2, P89, DOI 10.1016/0735-0651(85)90011-1	39	9	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1261	1266						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134130				2022-12-25	WOS:A1994NC04800032
J	HERBER, B; TRUSS, M; BEATO, M; MULLER, R				HERBER, B; TRUSS, M; BEATO, M; MULLER, R			INDUCIBLE REGULATORY ELEMENTS IN THE HUMAN CYCLIN-D1 PROMOTER	ONCOGENE			English	Article							CELL-CYCLE; CANDIDATE ONCOGENE; FOS JUN; DNA; GENE; FIBROBLASTS; IDENTIFICATION; EXPRESSION; COMPLEXES; FAMILY	To be able to elucidate the function of cyclin D1 in the control of cell cycle progression and its role as an oncogene in tumourigenesis, it is of paramount importance to understand the mechanisms involved in the regulation of its expression. In the present study, we have cloned the human cyclin D1 gene and analysed the structure and function of 3kb of its 5'-flanking region. Several regulatory regions involved in both basal level and serum-induced expression were identified, two of which turned out to be of particular interest. One of these regions is involved in serum induction and is located 848-944 bp upstream of the initiation site. In agreement with this result, in vivo footprinting revealed a novel, strongly inducible protein binding site around positions -928 to -921. A second constitutively occupied binding site was mapped to a potential CRE at position -52. Cotransfection experiments showed that the cyclin D1 promoter is inducible by c-Jun, and that this induction is mediated predominantly through the protected putative CRE at -52.	UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, EMIL MANNKOPFF STR 2, D-35037 MARBURG, GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016; Beato, Miguel/B-5564-2015	Müller, Rolf/0000-0003-3339-4248; Beato, Miguel/0000-0002-2878-2222				ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOOD L, 1992, NUCLEIC ACIDS RES, V20, P4934, DOI 10.1093/nar/20.18.4934; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LAMMIE GA, 1991, ONCOGENE, V6, P439; Lew D J, 1992, Trends Cell Biol, V2, P77, DOI 10.1016/0962-8924(92)90076-Y; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LUCIBELLO F C, 1991, Critical Reviews in Oncogenesis, V2, P259; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PRUNELL A, 1982, EMBO J, V1, P173, DOI 10.1002/j.1460-2075.1982.tb01143.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	46	251	257	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1295	1304						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134134				2022-12-25	WOS:A1994NC04800037
J	KATZ, ML; CHRISTIANSON, JS; NORBURY, NE; GAO, CL; SIAKOTOS, AN; KOPPANG, N				KATZ, ML; CHRISTIANSON, JS; NORBURY, NE; GAO, CL; SIAKOTOS, AN; KOPPANG, N			LYSINE METHYLATION OF MITOCHONDRIAL ATP SYNTHASE SUBUNIT-C STORED IN TISSUES OF DOGS WITH HEREDITARY CEROID-LIPOFUSCINOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORAGE BODY PROTEIN; BATTENS DISEASE; CARNITINE	Certain forms of ceroid lipofuscinosis, a hereditary degenerative disease, are characterized by accumulation of large amounts of subunit c of mitochondrial ATP synthase in lysosomal storage bodies of numerous tissues. The subunit c protein appears to constitute a major fraction of the total storage body protein. In previous studies it was demonstrated that hydrolysates of total storage body protein from affected humans and sheep contain significant amounts of epsilon-N-trimethyllysine (TML). This finding suggested that one or both of the two lysine residues of subunit c might be methylated in the stored form of the protein. The normal subunit c protein from mitochondria does not appear to be methylated. Using a putative canine model for the juvenile form of ceroid lipofuscinosis, analyses were conducted to determine whether lysosomal storage of subunit c was accompanied by lysine methylation of this protein. In affected dogs, as in humans and sheep with hereditary ceroid lipofuscinosis, the storage bodies were found to contain large amounts of subunit c protein, as indicated by polyacrylamide gel electrophoresis and partial amino acid sequence analysis. The subunit c protein partially purified from isolated storage bodies was found to contain lysine and TML in an almost equimolar ratio. Normal subunit c contains 2 lysine residues, one at position 7 and the other at position 43. Removal of the first 7 residues of the partially purifIed protein through sequential Edman degradation resulted in a dramatic increase in the TML to Lysine ratio in the residual protein. This suggests that lysine residue 43 is methylated. Confirmation that residue 43 of the stored protein is TML was obtained by amino acid sequence analysis after cleavage of the protein with trypsin. This finding strongly suggests that specific methylation of lysine residue 43 of mitochondrial ATP synthase plays a central role in the lysosomal storage of this protein.	INDIANA UNIV,SCH MED,DEPT PATHOL,INDIANAPOLIS,IN 46223; NATL VET INST,N-0033 OSLO,NORWAY	Indiana University System; Indiana University-Purdue University Indianapolis; Norwegian Veterinary Institute	KATZ, ML (corresponding author), UNIV MISSOURI,MASON INST OPHTHALMOL,COLUMBIA,MO 65212, USA.		Christianson, J Scott/E-7349-2018	Christianson, J Scott/0000-0002-7937-208X	NEI NIH HHS [EY08813] Funding Source: Medline; NINDS NIH HHS [NS30171, NS30155] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030155, R01NS030171] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; Boustany R M, 1988, Am J Med Genet Suppl, V5, P47; BRONSON RT, 1993, ANN NEUROL, V33, P381, DOI 10.1002/ana.410330408; Dyken P R, 1988, Am J Med Genet Suppl, V5, P69; FEARNLEY IM, 1990, BIOCHEM J, V268, P751, DOI 10.1042/bj2680751; Goebel H H, 1988, Am J Med Genet Suppl, V5, P127, DOI 10.1002/ajmg.1320310617; HALL NA, 1991, BIOCHEM J, V275, P269, DOI 10.1042/bj2750269; Jolly R D, 1988, Am J Med Genet Suppl, V5, P159, DOI 10.1002/ajmg.1320310619; JOLLY RD, 1980, NEUROPATH APPL NEURO, V6, P195, DOI 10.1111/j.1365-2990.1980.tb00290.x; KATZ ML, 1992, BIOCHIM BIOPHYS ACTA, V1138, P97, DOI 10.1016/0925-4439(92)90048-R; KATZ ML, 1984, EXP EYE RES, V38, P137, DOI 10.1016/0014-4835(84)90098-8; KATZ ML, 1991, AM J PATHOL, V138, P323; KOMINAMI E, 1992, J BIOCHEM, V111, P278, DOI 10.1093/oxfordjournals.jbchem.a123749; Koppang N, 1988, Am J Med Genet Suppl, V5, P117, DOI 10.1002/ajmg.1320310616; LABADIE J, 1976, BIOCHEM J, V160, P85, DOI 10.1042/bj1600085; Paik W. K., 1980, PROTEIN METHYLATION; Palmer D N, 1988, Am J Med Genet Suppl, V5, P141, DOI 10.1002/ajmg.1320310618; PALMER DN, 1993, J INHERIT METAB DIS, V16, P292, DOI 10.1007/BF00710268; PALMER DN, 1992, AM J MED GENET, V42, P561, DOI 10.1002/ajmg.1320420428; PALMER DN, 1990, LIPOFUSCIN CEROID PI, P211; Park I. K., 1990, PROTEIN METHYLATION, P1; REBOUCHE CJ, 1991, AM J CLIN NUTR, V54, pS1147, DOI 10.1093/ajcn/54.6.1147s; SEBALD W, 1981, CURR TOP BIOENERG, V12, P1; SEBALD W, 1979, FUNCTION MOL ASPECTS, P63; Zimmerman HM, 1976, PROGR NEUROPATHOLOGY, V3, P203	25	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9906	9911						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144584				2022-12-25	WOS:A1994NE05300078
J	SIVARAM, P; CHOI, SY; CURTISS, LK; GOLDBERG, IJ				SIVARAM, P; CHOI, SY; CURTISS, LK; GOLDBERG, IJ			AN AMINO-TERMINAL FRAGMENT OF APOLIPOPROTEIN-B BINDS TO LIPOPROTEIN-LIPASE AND MAY FACILITATE ITS BINDING TO ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FIBROBLAST GROWTH-FACTOR; LOW-DENSITY LIPOPROTEINS; RECEPTOR-RELATED PROTEIN; HEPARAN-SULFATE; PLASMA-LIPOPROTEINS; SURFACE; IDENTIFICATION; EMULSION; B-100	Lipoprotein lipase (LPL), the principal enzyme which hydrolyzes triglycerides in circulating plasma lipoproteins, functions while bound to the luminal surface of endothelial cells. LPL is a heparin-binding protein and has been assumed to associate with endothelial cell heparan sulfate proteoglycans (HSPG). Recently, using ligand blotting and affinity chromatography we identified a 116-kDa heparin-releasable LPL-binding protein (hrp-116) from endothelial cells which was not a HSPG (Sivaram, P., Klein, M. G., and Goldberg, I. J. (1992) J. Biol. Chem. 267,16517-16522). This suggested that, like a number of other heparin-binding proteins, LPL binding to cells also involves non-HSPG proteins. Using heparin-agarose affinity chromatography, a 116-kDa LPL-binding protein was purified from endothelial cell extracts. Microsequencing of peptides generated by Lys-C protease digestion revealed complete homology with four different regions in the NH2-terminal part of human apolipoprotein B (apoB). Western blots using anti-apoB monoclonal antibodies (mAb) that recognize the NH2-terminal region of apoB confirmed that a 116-kDa fragment of apoB was present on endothelial cell membranes. Further evidence that LPL associates with the NH2-terminal region of apoB was obtained by showing 1) that an NH2-terminal fragment of apoB obtained from apoB-transfected CHO cells bound LPL on ligand blots and 2) that NH 2-terminal fragments of apoB generated by thrombin digestion of low density lipoprotein bind LPL. Evidence that the NH2-terminal region of apoB mediates LPL interaction with endothelial cells was obtained using monoclonal antibodies. mAb3 and mAb19, which recognize epitopes near the NH2 terminus of apoB, inhibited I-125-LPL binding to cells by 60-65%. In contrast, mAb47, which has determinants at the COOH-terminal end of apoB, inhibited LPL binding by only about 10%. The inhibitory effects of mAb3 and mAb19 were abolished following treatment of cells with heparin, which removes the 116-kDa LPL-binding protein. Furthermore, incubation of I-125-LPL in medium containing an NH2-terminal apoB fragment reduced LPL binding to cells. These data suggest that an NH2-terminal fragment of apoB that binds to endothelial surfaces facilitates LPL binding to cells.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, 630 W 168TH ST, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, SPECIALIZED CTR RES ARTERIOSCLEROSIS, NEW YORK, NY 10032 USA; SCRIPPS RES INST, LA JOLLA, CA 92037 USA	Columbia University; Columbia University; Scripps Research Institute					NHLBI NIH HHS [HL 21006, HL 45095] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045095, R37HL045095, P50HL021006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATHA DH, 1984, P NATL ACAD SCI-BIOL, V81, P1030, DOI 10.1073/pnas.81.4.1030; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CURTISS LK, 1982, J BIOL CHEM, V257, P5213; DECKELBAUM RJ, 1990, BIOCHEMISTRY-US, V29, P1136, DOI 10.1021/bi00457a006; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; FORGEZ P, 1986, BIOCHEM BIOPH RES CO, V140, P250, DOI 10.1016/0006-291X(86)91083-1; GOLDBERG IJ, 1986, J CLIN INVEST, V78, P1523, DOI 10.1172/JCI112744; JACKSON RL, 1985, FEBS LETT, V190, P297, DOI 10.1016/0014-5793(85)81304-1; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; LOETSCHER H, 1990, CELL, V61, P352; MAHLEY RW, 1979, BIOCHIM BIOPHYS ACTA, V575, P81, DOI 10.1016/0005-2760(79)90133-4; MCKEONE BJ, 1993, J CLIN INVEST, V91, P1926, DOI 10.1172/JCI116411; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P3; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; Olivecrona Thomas, 1993, Current Opinion in Lipidology, V4, P187, DOI 10.1097/00041433-199306000-00003; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SAXENA U, 1991, J BIOL CHEM, V266, P17516; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SHIMADA K, 1985, J CLIN INVEST, V75, P1308, DOI 10.1172/JCI111831; SHIMADA K, 1981, BIOCHIM BIOPHYS ACTA, V710, P117; SIVARAM P, 1992, J BIOL CHEM, V267, P16517; SIVARAM P, 1993, ANAL BIOCHEM, V214, P511, DOI 10.1006/abio.1993.1531; SOCORRO L, 1985, PREP BIOCHEM, V15, P133, DOI 10.1080/10826068508062267; STINS MF, 1993, J LIPID RES, V34, P1853; TENG BB, 1990, J BIOL CHEM, V265, P20616; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; WEISGRABER KH, 1987, J BIOL CHEM, V262; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YOUNG SG, 1987, J BIOL CHEM, V262, P16604	37	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9409	9412						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144523				2022-12-25	WOS:A1994NE05300004
J	TANSEY, MG; LUBYPHELPS, K; KAMM, KE; STULL, JT				TANSEY, MG; LUBYPHELPS, K; KAMM, KE; STULL, JT			CA2+-DEPENDENT PHOSPHORYLATION OF MYOSIN LIGHT-CHAIN KINASE DECREASES THE CA2+ SENSITIVITY OF LIGHT-CHAIN PHOSPHORYLATION WITHIN SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RABBIT MESENTERIC-ARTERY; PHOTOBLEACHING RECOVERY; F-ACTIN; CALMODULIN; CONTRACTION; RELAXATION; DIFFUSION; SKELETAL; BINDING	Myosin light chain kinase (MLCK) is phosphorylated in contracting smooth muscle. The rate of phosphorylation of MLCK is slower than the rates of increase in cytosolic Ca2+ concentrations and phosphorylation of the regulatory light chain of myosin in intact tracheal smooth muscle cells in culture. In permeable cells, increasing the Ca2+ concentration increased the extent of myosin light chain and MLCK phosphorylation. The Ca2+ concentration required for half-maximal phosphorylation was 500 nM for MLCK and 250 nM for myosin light chain. Addition of KN-62 or a synthetic peptide CK II, inhibitors of multifunctional Ca2+/calmodulin-dependent protein kinase II activity, abolished MLCK phosphorylation. Under these conditions, the Ca2+ concentration required for half-maximal light chain phosphorylation decreased to 170 nM. Thus, the Ca2+ concentrations required for MLCK phosphorylation are greater than those required for light chain phosphorylation in smooth muscle cells. Furthermore, phosphorylation of MLCK decreases the Ca2+ sensitivity of light chain phosphorylation. These results can be explained by a regulatory scheme in which calmodulin available for myosin light chain kinase activation is limiting. This is supported by the retention of calmodulin when tracheal smooth muscle cells and tissues are permeabilized in relaxing solution and by the low mobility of rhodamine-calmodulin in intact tracheal smooth muscle cells.	UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Luby-Phelps, Katherine/0000-0002-8378-1409	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR007354] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032607, R37HL026043, R23HL032607, R01HL026043] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR07354] Funding Source: Medline; NHLBI NIH HHS [HL 32607, HL 26043] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOWMAN BF, 1992, J BIOL CHEM, V267, P5346; COHEN DM, 1978, J GEN PHYSIOL, V72, P369, DOI 10.1085/jgp.72.3.369; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; ELSON EL, 1989, METHOD CELL BIOL, V30, P307; FUJIWARA T, 1989, J PHYSIOL-LONDON, V408, P535, DOI 10.1113/jphysiol.1989.sp017474; GARDNER JP, 1989, PFLUG ARCH EUR J PHY, V414, P484, DOI 10.1007/BF00585061; GOUGH AH, 1993, J CELL BIOL, V121, P1095, DOI 10.1083/jcb.121.5.1095; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAI CM, 1989, ANNU REV PHYSIOL, V51, P285, DOI 10.1146/annurev.physiol.51.1.285; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HASHIMOTO Y, 1990, ARCH BIOCHEM BIOPHYS, V278, P41, DOI 10.1016/0003-9861(90)90228-Q; HINRICHSEN RD, 1993, P NATL ACAD SCI USA, V90, P1585, DOI 10.1073/pnas.90.4.1585; HOU L, 1990, BIOPHYS J, V58, P31, DOI 10.1016/S0006-3495(90)82351-1; IKEBE M, 1990, J BIOL CHEM, V265, P8975; ITOH T, 1986, J PHYSIOL-LONDON, V376, P231, DOI 10.1113/jphysiol.1986.sp016151; KAMM KE, 1989, J BIOL CHEM, V264, P21223; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; KUBOTA Y, 1992, AM J PHYSIOL, V262, pC405, DOI 10.1152/ajpcell.1992.262.2.C405; LUBYPHELPS K, 1985, J CELL BIOL, V101, P1245, DOI 10.1083/jcb.101.4.1245; MEISHERI KD, 1985, CALCIUM CONTRACTILIT, P191; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER JR, 1983, MOL PHARMACOL, V24, P235; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; MORELAND RS, 1986, AM J PHYSIOL, V251, pC892, DOI 10.1152/ajpcell.1986.251.6.C892; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PROVANCE DW, 1993, J CELL SCI, V106, P565; REMBOLD CM, 1988, CIRC RES, V63, P593, DOI 10.1161/01.RES.63.3.593; RUEGG JC, 1984, FEBS LETT, V170, P383, DOI 10.1016/0014-5793(84)81349-6; SIMON JR, 1988, BIOPHYS J, V54, P801, DOI 10.1016/S0006-3495(88)83018-2; STULL JT, 1978, J BIOL CHEM, V253, P5932; STULL JT, 1983, FED PROC, V42, P21; STULL JT, 1990, J BIOL CHEM, V265, P16683; STULL JT, 1986, ENZYMES, V17, P113; TANG DC, 1992, J BIOL CHEM, V267, P11839; TANG DC, 1993, FEBS LETT, V331, P272, DOI 10.1016/0014-5793(93)80351-T; TANSEY MG, 1992, J BIOL CHEM, V267, P12511; TAYLOR DA, 1988, J BIOL CHEM, V263, P14456; TAYLOR DA, 1989, J BIOL CHEM, V264, P6207; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325	43	146	149	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9912	9920						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144585				2022-12-25	WOS:A1994NE05300079
J	DEBOLAND, AR; MORELLI, S; BOLAND, R				DEBOLAND, AR; MORELLI, S; BOLAND, R			1,25(OH)(2)-VITAMIN D-3 SIGNAL-TRANSDUCTION IN CHICK MYOBLASTS INVOLVES PHOSPHATIDYLCHOLINE HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPASE-D ACTIVATION; MUSCLE CALCIUM-UPTAKE; SKELETAL-MUSCLE; HL-60 GRANULOCYTES; PHOSPHATIDIC-ACID; 12-O-TETRADECANOYLPHORBOL 13-ACETATE; PHOSPHOINOSITIDE HYDROLYSIS; DIACYLGLYCEROL FORMATION; ENDOTHELIAL-CELLS	1,25-Dihydroxyvitamin D-3 (1,25(OH)(2)D-3) rapidly stimulates the biphasic formation of diacylglycerol (DAG) in chick myoblasts. Neomycin (0.5 mM), an inhibitor of phosphoinositide hydrolysis, abolished the first phase (1 min) but had no effect on the second 1,25(OH)(2)D-3-induced DAG peak (5 min). In myoblasts prelabeled with [H-3]choline, 1,25(OH)(2)D-3 increased the release of [H-3]choline (maximally at 5 min), with a concomitant decrease in phosphatidylcholine and the absence of significant changes in phosphocholine. 1,25(OH)(2)D-3 caused a significant increase in phosphatidylethanol (PEt) formation in myoblasts in the presence of 1.5% ethanol. The effects of 1,25(OH)(2)D-3 were time- and dose-dependent (10(-11) to 10(-8) M) and specific as 25OHD(3) and 24,25(OH)(2)D-3 failed to accumulate PEt. 12-O-Tetradecanoylphorbol-13-acetate also stimulated PEt formation. The combination of 1,25(OH)(2)D-3 and 12-O-tetradecanoylphorbol-13-acetate was more effective than either compound alone. Neither the PKC inhibitor H-7 nor PKC down-regulation blocked the hormone-induced increase in PEt. The effects of 1,25(OH)(2)D-3 were, however, inhibited in the absence of extracellular Ca2+ (+EGTA) and by nifedipine and verapamil, whereas the Ca2+ ionophore A23181 also increased PEt generation. The data support the notion that 1,25(OH)(2)D-3 triggers the hydrolysis of phosphatidylcholine in myoblasts through a Ca2+-dependent, PKC-independent, phospholipase D-catalyzed mechanism.	UNIV NACL SUR,DEPT BIOL,RA-8000 BAHIA BLANCA,ARGENTINA	National University of the South								ANTHES JC, 1989, BIOCHEM BIOPH RES CO, V163, P657, DOI 10.1016/0006-291X(89)92187-6; BELLIDO T, 1993, MOL CELL ENDOCRINOL, V90, P231, DOI 10.1016/0303-7207(93)90156-E; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOLAND R, 1986, ENDOCR REV, V7, P434, DOI 10.1210/edrv-7-4-434; CABOT MC, 1988, BIOCHIM BIOPHYS ACTA, V959, P46, DOI 10.1016/0005-2760(88)90148-8; CABOT MC, 1988, FEBS LETT, V233, P153, DOI 10.1016/0014-5793(88)81374-7; DEBOLAND AR, 1987, ENDOCRINOLOGY, V120, P1858, DOI 10.1210/endo-120-5-1858; EXTON JH, 1990, J BIOL CHEM, V265, P1; FERNANDEZ LM, 1990, CALCIFIED TISSUE INT, V47, P314, DOI 10.1007/BF02555915; FOLCH J, 1957, J BIOL CHEM, V226, P497; GIULIANI DL, 1984, CALCIFIED TISSUE INT, V36, P200, DOI 10.1007/BF02405318; GRILLONE LR, 1988, J BIOL CHEM, V263, P2658; GUY GR, 1982, CANCER RES, V42, P1980; IRVING HR, 1987, J BIOL CHEM, V262, P3440; JALINK K, 1990, J BIOL CHEM, V265, P12232; KESTER M, 1992, J CELL PHYSIOL, V150, P578, DOI 10.1002/jcp.1041500319; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; LISCOVITCH M, 1989, J BIOL CHEM, V264, P1450; LISCOVITCH M, 1987, BIOCHEM J, V241, P81, DOI 10.1042/bj2410081; MARTIN TW, 1989, BIOCHEM BIOPH RES CO, V165, P319, DOI 10.1016/0006-291X(89)91072-3; MARTIN TW, 1988, BIOCHIM BIOPHYS ACTA, V962, P282, DOI 10.1016/0005-2760(88)90258-5; MASSHEIMER V, 1992, BIOCHEM J, V281, P349, DOI 10.1042/bj2810349; MORELLI S, 1993, BIOCHEM J, V289, P675, DOI 10.1042/bj2890675; MUIR JG, 1987, J CELL PHYSIOL, V130, P382, DOI 10.1002/jcp.1041300311; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OLSON SC, 1991, J BIOL CHEM, V266, P17236; ONEILL MC, 1972, J CELL BIOL, V52, P52, DOI 10.1083/jcb.52.1.52; PAI JK, 1988, J BIOL CHEM, V263, P12472; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; POLVERINO AJ, 1988, BIOCHIM BIOPHYS ACTA, V970, P75, DOI 10.1016/0167-4889(88)90224-8; PUTNEY JW, 1980, NATURE, V284, P345, DOI 10.1038/284345a0; QIAN Z, 1990, J BIOL CHEM, V265, P3607; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; TAKAI T, 1979, J BIOL CHEM, V254, P9761; TAKUWA N, 1987, BIOCHEM J, V243, P647, DOI 10.1042/bj2430647	38	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8675	8679						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132595				2022-12-25	WOS:A1994NB41100011
J	HARAGUCHI, Y; CHUNG, AB; NEILL, S; WALLACE, DC				HARAGUCHI, Y; CHUNG, AB; NEILL, S; WALLACE, DC			OXBOX AND REBOX, OVERLAPPING PROMOTER ELEMENTS OF THE MITOCHONDRIAL F0F1-ATP SYNTHASE BETA-SUBUNIT GENE - OXBOX/REBOX IN THE ATPSYN-BETA PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE ADP/ATP TRANSLOCATOR; OXIDATIVE-PHOSPHORYLATION; DIFFERENTIAL EXPRESSION; TRANSCRIPTIONAL CONTROL; NUCLEAR GENES; SEQUENCE; DNA; GENOME; CELLS	Three positive (PR1-3) and one negative (NR1) transcriptional control domain have been tentatively mapped in the promoter of the human F0F1-ATP synthase beta subunit gene (ATPsyn beta) in the context of expression in myogenic cells. Lipofection of promoter-chloramphenicol acetyltransferase fusion constructs into C2C12 myogenic cells revealed that two of the three positive domains (PR1 and PR2) function in both myoblasts and myotubes, whereas the third positive domain (PR3) and the sole negative domain (NR1) seem to function only in myotubes. PR1 contains a cluster of four CCAAT cis-elements, PR2 is a small 44-base pair region containing an SP1-like motif, and PR3 is a region previously shown to be recognized by both OXBOX- and REBOX-binding factors. By site-directed polymerase chain reaction linker mutations, the activity of the OXBOX/REBOX cis-element in myoblasts is shown to be masked by flanking sequences in PR3. The negative domain, NR1, is located between 300 and 1,000 base pairs upstream from the OXBOX/REBOX elements in a region containing multiple ALu repeats. Mobility gel shift analysis of DNA-protein complexes using competitor DNAs verified the involvement of both OXBOX- and REBOX-binding factors in PR3. Similar experiments show SP1-specific binding at PR2. These data with observations of OXBOX and REBOX-specific binding of an OXBOX/REBOX-like region within the conserved sequence block C of the human mitochondrial DNA D-loop sequence are consistent with the idea that OXBOX and REBOX DNA-binding factors coordinate the expression of mitochondrial energy genes in highly oxidative tissues by working with well characterized general transcription factors such as SP1 and CCAAT DNA-binding proteins, which exist in the nucleus, and MTF, which exists in the mitochondrion.	EMORY UNIV,SCH MED,DEPT GENET & MOLEC MED,ATLANTA,GA 30322	Emory University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045572] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45572] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; CHODOSH LA, 1988, CURRENT PROTOCOLS MO; CHUNG AB, 1992, J BIOL CHEM, V267, P21154; CHUNG AB, 1993, THESIS EMORY U GRADU; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; HEDDI A, 1993, J BIOL CHEM, V268, P12156; IZQUIERDO JM, 1990, J BIOL CHEM, V265, P9090; KAGAWA Y, 1990, INT J BIOCHEM, V22, P219; KINGSTON RE, 1988, CURRENT PROTOCOLS MO; LI K, 1989, J BIOL CHEM, V264, P13998; LI K, 1990, J BIOL CHEM, V265, P20585; LUCIAKOVA K, 1992, EUR J BIOCHEM, V207, P252; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MIGNOTTE F, 1991, BIOL CELL, V71, P67, DOI 10.1016/0248-4900(91)90052-O; NECKELMANN N, 1989, GENOMICS, V5, P829, DOI 10.1016/0888-7543(89)90125-0; OHTA S, 1988, J BIOL CHEM, V263, P11257; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; STEPIEN G, 1992, J BIOL CHEM, V267, P14592; SUZUKI H, 1991, J BIOL CHEM, V266, P2333; TOMURA H, 1990, J BIOL CHEM, V265, P6525; TORRONI A, 1990, J BIOL CHEM, V265, P20589; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	27	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9330	9334						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132672				2022-12-25	WOS:A1994NB41100103
J	FONTES, EPB; EAGLE, PA; SIPE, PS; LUCKOW, VA; HANLEYBOWDOIN, L				FONTES, EPB; EAGLE, PA; SIPE, PS; LUCKOW, VA; HANLEYBOWDOIN, L			INTERACTION BETWEEN A GEMINIVIRUS REPLICATION PROTEIN AND ORIGIN DNA IS ESSENTIAL FOR VIRAL REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLDEN MOSAIC-VIRUS; CASSAVA LATENT VIRUS; B-GENOME COMPONENT; MAIZE STREAK VIRUS; WHEAT DWARF VIRUS; COAT PROTEIN; NUCLEOTIDE-SEQUENCE; SYMPTOM DEVELOPMENT; INITIATOR PROTEINS; TRANSGENIC PLANTS	The geminivirus, tomato golden mosaic virus (TGMV), encodes one protein, AL1, that is absolutely required for viral DNA replication. AL1 interacts with the TGMV DNA genome by binding specifically to the viral origin of replication. We have investigated the nature and significance of AL1/origin interactions in vitro and in vivo by using competitive DNA binding and transient replication assays. Competition assays established that a 13-base pair (bp) element (5'-GGTAGTAAGGTAG) containing two 5-bp direct repeat motifs separated by a 3-bp central core constitutes a high affinity AL1 binding site. DNAs containing intact 3' repeat sequences plus core (TAAGGTAG and ccTAGTAAGGTAG) were stronger competitors for AL1 binding than DNAs containing intact 5' repeat sequences plus core (GGTAGTAA and GGTAGTA-AccTAG), thereby demonstrating that AL1 interacts differently with the repeat motifs. Replication in tobacco protoplasts established that the AL1 binding site is an essential cis-acting element for viral replication. No replication was detected for DNAs containing mutations in either of the repeat motifs of the AL1 recognition sequence when AL1 was provided in trans from a plant gene expression vector. In contrast, a DNA with a mutation in the 5' repeat motif (ccTAGTAAGGTAG) replicated when both AL1 and AL3, a TGMV protein involved in viral DNA accumulation, were provided in trans. No replication was detected for a DNA containing a mutation in the 3' repeat motif (GGTAGTAAccTAG) in the presence of AL1 and AL3. The in vitro and in vivo results suggest that binding of AL1 to the 3' repeat element is an essential step in DNA replication, while binding to the 5' repeat element may serve to enhance viral replication.	N CAROLINA STATE UNIV,DEPT BIOCHEM,RALEIGH,NC 27695; MONSANTO CO,CORP RES,ST LOUIS,MO 63198	University of North Carolina; North Carolina State University; Monsanto			Fontes, Elizabeth/K-3159-2012	Fontes, Elizabeth/0000-0002-7986-1369				ACCOTTO GP, 1989, EMBO J, V8, P1033, DOI 10.1002/j.1460-2075.1989.tb03470.x; AN GH, 1985, PLANT PHYSIOL, V79, P568, DOI 10.1104/pp.79.2.568; BISARO DM, 1982, NUCLEIC ACIDS RES, V10, P4913, DOI 10.1093/nar/10.16.4913; BOULTON MI, 1993, VIROLOGY, V192, P85, DOI 10.1006/viro.1993.1010; BRIDDON RW, 1989, VIROLOGY, V172, P628, DOI 10.1016/0042-6822(89)90205-5; BROUGH CL, 1988, J GEN VIROL, V69, P503, DOI 10.1099/0022-1317-69-3-503; CORUZZI G, 1984, EMBO J, V3, P1671, DOI 10.1002/j.1460-2075.1984.tb02031.x; DAVIES JW, 1989, TRENDS GENET, V5, P77, DOI 10.1016/0168-9525(89)90030-9; ELMER JS, 1988, PLANT MOL BIOL, V10, P225, DOI 10.1007/BF00027399; ELMER JS, 1988, NUCLEIC ACIDS RES, V16, P7043, DOI 10.1093/nar/16.14.7043; ETESSAMI P, 1991, J GEN VIROL, V72, P1005, DOI 10.1099/0022-1317-72-5-1005; FARIA J C, 1990, Phytopathology, V80, P983; FONTES EPB, 1992, PLANT CELL, V4, P597, DOI 10.1105/tpc.4.5.597; FRISCHMUTH S, 1991, VIROLOGY, V185, P596, DOI 10.1016/0042-6822(91)90530-O; FRISCHMUTH T, 1993, VIROLOGY, V196, P666, DOI 10.1006/viro.1993.1523; GILBERTSON RL, 1993, J GEN VIROL, V74, P23, DOI 10.1099/0022-1317-74-1-23; HALEY A, 1992, VIROLOGY, V188, P905, DOI 10.1016/0042-6822(92)90551-Y; HAMILTON WDO, 1984, EMBO J, V3, P2197, DOI 10.1002/j.1460-2075.1984.tb02114.x; HANLEYBOWDOIN L, 1990, P NATL ACAD SCI USA, V87, P1446, DOI 10.1073/pnas.87.4.1446; HANLEYBOWDOIN L, 1988, NUCLEIC ACIDS RES, V16, P10511, DOI 10.1093/nar/16.22.10511; HARRISON BD, 1985, ANNU REV PHYTOPATHOL, V23, P55, DOI 10.1146/annurev.py.23.090185.000415; HEYRAUD F, 1993, EMBO J, V12, P4445, DOI 10.1002/j.1460-2075.1993.tb06130.x; HOWARTH AJ, 1989, J GEN VIROL, V70, P2717, DOI 10.1099/0022-1317-70-10-2717; ILYINA TV, 1992, NUCLEIC ACIDS RES, V20, P3279, DOI 10.1093/nar/20.13.3279; JUNGHANS H, 1990, BIOTECHNIQUES, V8, P176; KAY R, 1987, SCIENCE, V236, P1299, DOI 10.1126/science.236.4806.1299; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; KOONIN EV, 1992, J GEN VIROL, V73, P2763, DOI 10.1099/0022-1317-73-10-2763; Kornberg A., 1992, DNA REPLICATION; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P482; LAZAROWITZ SG, 1989, EMBO J, V8, P1023, DOI 10.1002/j.1460-2075.1989.tb03469.x; LAZAROWITZ SG, 1991, VIROLOGY, V180, P70, DOI 10.1016/0042-6822(91)90010-9; LAZAROWITZ SG, 1992, PLANT CELL, V4, P799, DOI 10.1105/tpc.4.7.799; LAZAROWITZ SG, 1992, CRIT REV PLANT SCI, V11, P327, DOI [10.1080/07352689209382350, 10.1080/713608038]; LIN HJL, 1992, J VIROL, V66, P5443, DOI 10.1128/JVI.66.9.5443-5452.1992; MORRIS B, 1990, NUCLEIC ACIDS RES, V18, P197, DOI 10.1093/nar/18.1.197; MULLINEAUX PM, 1985, PLANT MOL BIOL, V5, P125, DOI 10.1007/BF00020095; MYERS RM, 1981, CELL, V25, P373, DOI 10.1016/0092-8674(81)90056-8; PARSONS R, 1992, J VIROL, V66, P1933, DOI 10.1128/JVI.66.4.1933-1942.1992; PILARTZ M, 1992, VIROLOGY, V189, P800, DOI 10.1016/0042-6822(92)90610-2; REVINGTON GN, 1989, PLANT CELL, V1, P985, DOI 10.1105/tpc.1.10.985; ROGERS SG, 1986, CELL, V45, P593, DOI 10.1016/0092-8674(86)90291-6; RUSHING AE, 1987, PHYTOPATHOLOGY, V77, P1231, DOI 10.1094/Phyto-77-1231; Sambrook J, 1989, MOL CLONING LABORATO; SAUNDERS K, 1991, NUCLEIC ACIDS RES, V19, P2325, DOI 10.1093/nar/19.9.2325; SCHALK HJ, 1989, EMBO J, V8, P359, DOI 10.1002/j.1460-2075.1989.tb03385.x; STANLEY J, 1985, J GEN VIROL, V66, P1055, DOI 10.1099/0022-1317-66-5-1055; STANLEY J, 1990, P NATL ACAD SCI USA, V87, P6291, DOI 10.1073/pnas.87.16.6291; STENGER DC, 1991, P NATL ACAD SCI USA, V88, P8029, DOI 10.1073/pnas.88.18.8029; SUNTER G, 1990, VIROLOGY, V179, P69, DOI 10.1016/0042-6822(90)90275-V; SUNTER G, 1993, VIROLOGY, V195, P275, DOI 10.1006/viro.1993.1374; SUNTER G, 1989, VIROLOGY, V173, P647, DOI 10.1016/0042-6822(89)90577-1; THOMASHOW MF, 1980, CELL, V19, P729, DOI 10.1016/S0092-8674(80)80049-3; THOMMES P, 1993, FEBS LETT, V319, P95, DOI 10.1016/0014-5793(93)80044-U; TIMMERMANS MCP, 1992, NUCLEIC ACIDS RES, V20, P4047, DOI 10.1093/nar/20.15.4047; TOWNSEND R, 1985, EMBO J, V4, P33, DOI 10.1002/j.1460-2075.1985.tb02313.x; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; VONARNIM A, 1992, VIROLOGY, V186, P286, DOI 10.1016/0042-6822(92)90083-2; WANG PZ, 1993, EMBO J, V12, P45, DOI 10.1002/j.1460-2075.1993.tb05630.x; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086	60	205	215	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8459	8465						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132573				2022-12-25	WOS:A1994NB40900094
J	DEVITRY, C				DEVITRY, C			CHARACTERIZATION OF THE GENE OF THE CHLOROPLAST RIESKE IRON-SULFUR PROTEIN IN CHLAMYDOMONAS-REINHARDTII - INDICATIONS FOR AN UNCLEAVED LUMEN TARGETING SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C REDUCTASE; AMINO-ACID-SEQUENCE; MEMBRANE-PROTEINS; COMPLEMENTARY-DNA; TRANSIT PEPTIDES; COMPLEX; CLONING; ORGANIZATION; IMPORT; CDNA	The sequence of the nuclear gene encoding the Rieske iron-sulfur protein of the cytochrome b(6) f complex of Chlamydomonas reinhardtii has been established. Comparison of genomic clones and amplified cDNA indicates that the petC gene is interrupted by four introns within the coding sequence of the mature protein. The nucleotide sequence predicts a precursor protein of 206 amino acid residues with a transit peptide of 29 amino acids. The transit peptide is shorter than that of higher plants and has a basic region typical for the transfer through the chloroplast envelope, but no hydrophobic segment at the C-terminal end as is found in proteins transferred through the thylakoid membrane. The mature protein shows a high degree of homology with that of higher plants and has an N-terminal hydrophobic segment as in other Rieske proteins. Biochemical data (Breyton, C., de Vitry, C., and Popot, J.-L. (1994) J. Biol. Chem. 269, 7597-7602) indicate that the chloroplast Rieske protein of C. reinhardtii is an extrinsic membrane protein. Therefore, this N-terminal hydrophobic segment is not a transmembrane segment but may act as an uncleaved N-terminal thylakoid membrane transfer signal sequence. There are other examples of uncleaved hydrophobic membrane transfer signal in secreted proteins, although these are rare.			DEVITRY, C (corresponding author), INST BIOL PHYSICOCHIM,CTR NATL RECH SCI,URA 1187,13 RUE PIERRE & MARIE CURIE,F-75005 PARIS,FRANCE.							BARTLING D, 1990, BOT MAG TOKYO, V2, P119; BECKMANN JD, 1987, J BIOL CHEM, V262, P8901; BRANDT U, 1993, J BIOL CHEM, V268, P8387; BREYTON C, 1994, J BIOL CHEM, V269, P7597; BUSCHLEN S, 1991, FEBS LETT, V284, P257, DOI 10.1016/0014-5793(91)80698-3; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3342, DOI 10.1021/bi00128a006; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DRAPIER D, 1992, PLANT CELL, V4, P283, DOI 10.2307/3869540; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FONG SE, 1992, CURR GENET, V21, P527, DOI 10.1007/BF00351664; FRANZEN LG, 1990, FEBS LETT, V260, P165, DOI 10.1016/0014-5793(90)80094-Y; FRANZEN LG, 1989, PLANT MOL BIOL, V12, P463, DOI 10.1007/BF00017585; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; GLICK BS, 1992, TRENDS BIOCHEM SCI, V17, P453, DOI 10.1016/0968-0004(92)90487-T; GOLDSCHMIDTCLERMONT M, 1986, PLANT MOL BIOL, V6, P13, DOI 10.1007/BF00021302; HAGEMAN J, 1990, PLANT CELL, V2, P479, DOI 10.1105/tpc.2.5.479; Hallick RB, 1989, PLANT MOL BIOL REP, V7, P266, DOI [10.1007/BF02668635, DOI 10.1007/BF02668635]; HARNISCH U, 1985, EUR J BIOCHEM, V149, P95, DOI 10.1111/j.1432-1033.1985.tb08898.x; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HAUSKA G, 1988, J BIOENERG BIOMEMBR, V20, P211, DOI 10.1007/BF00768395; HIGUCHI R, 1988, NATURE, V332, P543, DOI 10.1038/332543a0; KALLAS T, 1988, P NATL ACAD SCI USA, V85, P5794, DOI 10.1073/pnas.85.16.5794; KIRWIN PM, 1988, J BIOL CHEM, V263, P18128; KNAFF DB, 1993, PHOTOSYNTH RES, V35, P117, DOI 10.1007/BF00014743; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; LEMAIRE C, 1986, BIOCHIM BIOPHYS ACTA, V851, P229, DOI 10.1016/0005-2728(86)90130-1; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MADUENO F, 1992, PLANT MOL BIOL, V20, P289, DOI 10.1007/BF00014496; MALKIN R, 1992, PHOTOSYNTH RES, V33, P121, DOI 10.1007/BF00039175; MAYES SR, 1991, PLANT MOL BIOL, V17, P287; MAYFIELD SP, 1989, PLANT MOL BIOL, V12, P683, DOI 10.1007/BF00044159; MCREYNOLDS L, 1978, NATURE, V273, P723, DOI 10.1038/273723a0; MERCHANT S, 1990, J BIOL CHEM, V265, P12372; MERCHANT S, 1987, J BIOL CHEM, V262, P9062; MEYER TF, 1984, P NATL ACAD SCI-BIOL, V81, P6110, DOI 10.1073/pnas.81.19.6110; PALMITER RD, 1978, P NATL ACAD SCI USA, V75, P94, DOI 10.1073/pnas.75.1.94; PFEFFERKORN B, 1986, FEBS LETT, V206, P233, DOI 10.1016/0014-5793(86)80987-5; POPOT JL, 1990, ANNU REV BIOPHYS BIO, V19, P369; Poyton Robert O., 1992, Trends in Cell Biology, V2, P369, DOI 10.1016/0962-8924(92)90049-S; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Rochaix J. D., 1988, PLANT MOL BIOL PRACT, P253; SALTER AH, 1992, PLANT MOL BIOL, V20, P569, DOI 10.1007/BF00040617; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, FEBS LETT, V219, P161, DOI 10.1016/0014-5793(87)81210-3; SEGUIREAL B, 1992, FEBS LETT, V313, P2, DOI 10.1016/0014-5793(92)81171-H; SILFLOW CD, 1985, MOL CELL BIOL, V5, P2389, DOI 10.1128/MCB.5.9.2389; STEPPUHN J, 1987, MOL GEN GENET, V210, P171, DOI 10.1007/BF00337775; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; USUI S, 1990, BIOCHEM BIOPH RES CO, V167, P575, DOI 10.1016/0006-291X(90)92063-6; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WIDGER WR, 1991, PHOTOSYNTH RES, V30, P71, DOI 10.1007/BF00042005; WIDGER WR, 1991, CELL CULTURE SOMATIC, V7, P149; WRIGHT HT, 1990, J MOL BIOL, V213, P513; YE RD, 1988, J BIOL CHEM, V263, P4869; YE RD, 1987, J BIOL CHEM, V262, P3718; YUN CH, 1990, EUR J BIOCHEM, V194, P399, DOI 10.1111/j.1432-1033.1990.tb15633.x; ZIMMER WE, 1988, J BIOL CHEM, V263, P19370	59	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7603	7609						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125984				2022-12-25	WOS:A1994NA03200090
J	KNAPP, S; DELLEKARTH, G; FRIEDL, J; PURTSCHER, B; MITTERBAUER, G; DOMER, PH; JAEGER, U				KNAPP, S; DELLEKARTH, G; FRIEDL, J; PURTSCHER, B; MITTERBAUER, G; DOMER, PH; JAEGER, U			GUANINE-RICH (GGNNGG) ELEMENTS AT CHROMOSOMAL BREAKPOINTS INTERACT WITH A LOOP-FORMING, SINGLE-STRANDED DNA-BINDING PROTEIN	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; ACUTE LEUKEMIAS; MINISATELLITE DNA; CLUSTER REGION; TRANSLOCATION; RECOMBINATION; GENE; SEQUENCES; ORGANIZATION; MECHANISM	Proto-oncogene-activation is frequently preceded by chromosomal translocations. Several models suggest that DNA single-strands and loops may serve as intermediates in the process of illegitimate recombination. Guanine-rich, repetitive elements are preferred sites of chromosomal exchange and can undergo conformational changes which result in the generation of single-stranded DNA. Here we describe a single-stranded DNA-binding protein which binds specifically to guanine-rich elements at the breakpoints of human reciprocal translocations, including the t(14;18), t(2;8), t(9;22), t(15;17) and t(4;11) in leukemia and lymphoma. The primitive binding consensus consists of two guanine-residues on either side separated by a spacer of at least two nucleotides (GGN-NGG). Binding activity is unaltered by a spacer length of up to 46 nucleotides. These data suggest that the protein has the unique ability to form or stabilize DNA-loops and may thus play a general role in recombination.	UNIV VIENNA,DEPT MED 1,DIV HEMATOL,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DEPT CLIN CHEM & LAB MED,A-1090 VIENNA,AUSTRIA; NORTHWESTERN UNIV,NW MEM HOSP,MOLEC DIAGNOST LAB,CHICAGO,IL 60611	University of Vienna; University of Vienna; Northwestern Memorial Hospital; Northwestern University			Knapp, Sylvia/J-3973-2013	Knapp, Sylvia/0000-0001-9016-5244				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BALAGURUMOORTHY P, 1992, NUCLEIC ACIDS RES, V20, P4061, DOI 10.1093/nar/20.15.4061; BELL GI, 1980, NUCLEIC ACIDS RES, V8, P4091, DOI 10.1093/nar/8.18.4091; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; CAMERINIOTERO RD, 1993, CELL, V73, P217, DOI 10.1016/0092-8674(93)90224-E; CHANG KS, 1992, BLOOD, V79, P554; CHEN SJ, 1989, ONCOGENE, V4, P195; COGGINS LW, 1992, GENE, V121, P279, DOI 10.1016/0378-1119(92)90132-9; COLLICK A, 1991, NUCLEIC ACIDS RES, V23, P6399; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; GERSTEIN RM, 1990, CELL, V63, P537, DOI 10.1016/0092-8674(90)90450-S; GODISKA R, 1990, CELL, V61, P1237, DOI 10.1016/0092-8674(90)90688-B; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; HANSEN SR, 1993, CELL, V73, P1403; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; ICHIHARA Y, 1988, EMBO J, V7, P4141, DOI 10.1002/j.1460-2075.1988.tb03309.x; JAEGER U, 1993, BLOOD, V81, P1833; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; LIEBER MR, 1992, CELL, V70, P873, DOI 10.1016/0092-8674(92)90237-7; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P6461, DOI 10.1093/nar/20.24.6461; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MITANI K, 1990, J BIOL CHEM, V265, P15203; NGAN BY, 1989, BLOOD, V73, P1759; OHSHIMA A, 1992, P NATL ACAD SCI USA, V89, P1016, DOI 10.1073/pnas.89.3.1016; RABBITTS PH, 1988, ONCOGENE, V3, P99; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; RIGGINS GJ, 1992, NAT GENET, V2, P186, DOI 10.1038/ng1192-186; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SMITH GR, 1983, CELL, V34, P709, DOI 10.1016/0092-8674(83)90525-1; STEINMETZ M, 1986, CELL, V44, P895, DOI 10.1016/0092-8674(86)90012-7; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; WAHLS WP, 1990, CELL, V60, P95, DOI 10.1016/0092-8674(90)90719-U; WYATT RT, 1992, J EXP MED, V175, P1575, DOI 10.1084/jem.175.6.1575	38	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1501	1505						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152814				2022-12-25	WOS:A1994NH40100025
J	KUNDRA, V; SOKER, S; ZETTER, BR				KUNDRA, V; SOKER, S; ZETTER, BR			EXCESS EARLY SIGNALING ACTIVITY INHIBITS CELLULAR CHEMOTAXIS TOWARD PDGF-BB	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; SIMIAN SARCOMA-VIRUS; V-SIS; PHOSPHATIDYLINOSITOL-3 KINASE; TYROSINE KINASES; PROTEIN-KINASES; TRANSFORMATION; ONCOGENE; SRC; TRANSDUCTION	Chemotaxis, directed migration toward a gradient of a soluble substance, requires a cell to spatially distinguish the concentration of a chemoattractant at one end relative to its opposite end. Platelet-derived growth factor (PDGF) is a potent mitogen and chemoattractant. In the current study, we attempted to interfere with PDGF-BB mediated chemotaxis by abnormal expression of potential early components of the signaling cascade. We find that expression of the PDGF homolog v-Sis prevents cellular migration toward PDGF-BB, indicating that autocrine production of a PDGF receptor ligand will prevent the chemotactic response to exogenously added ligand. In addition, while it is known that PDGF receptor mutants incapable of activating tyrosine kinase activity cannot transduce a signal for mitogenesis or chemotaxis, the effects of excess tyrosine kinase activity on PDGF mediated chemotaxis have not been tested. We demonstrate that cells expressing constitutively active tyrosine kinase genes such as v-fms, v-fes, or v-src fail to migrate toward PDGF-BB whereas expression of the serine/threonine kinase v-mos does not block the chemotactic response. The results demonstrate that chemotaxis may be prevented by excess production of either ligand, receptor activity, or downstream signaling molecule. In addition, our results show that the signals that mediate chemotaxis are separable from those that regulate unstimulated random motility in the same cells.	HARVARD UNIV, CHILDRENS HOSP, SCH MED, PROGRAM BIOL & BIOMED SCI, BOSTON, MA 02115 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT SURG, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA037393, R37CA037393] Funding Source: NIH RePORTER; NCI NIH HHS [CA37393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; FUKUI Y, 1991, ONCOGENE, V6, P407; GROTENDORST GR, 1981, P NATL ACAD SCI-BIOL, V78, P3669, DOI 10.1073/pnas.78.6.3669; GROTENDORST GR, 1984, CELL, V36, P279, DOI 10.1016/0092-8674(84)90221-6; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; Kaplan D R, 1992, Cancer Treat Res, V63, P265; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEE BA, 1992, J CELL BIOL, V118, P1057, DOI 10.1083/jcb.118.5.1057; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; QUI F, 1988, EMBO J, V7, P1003; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; STROOBANT P, 1984, EMBO J, V3, P2963, DOI 10.1002/j.1460-2075.1984.tb02241.x; SUDOL M, 1993, NEUROCHEM INT, V22, P369, DOI 10.1016/0197-0186(93)90019-2; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; YOUNG JC, 1984, J VIROL, V52, P913, DOI 10.1128/JVI.52.3.913-918.1984	36	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1994	9	5					1429	1435						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152804				2022-12-25	WOS:A1994NH40100015
J	TAKASE, K; KAKINUMA, S; YAMATO, I; KONISHI, K; IGARASHI, K; KAKINUMA, Y				TAKASE, K; KAKINUMA, S; YAMATO, I; KONISHI, K; IGARASHI, K; KAKINUMA, Y			SEQUENCING AND CHARACTERIZATION OF THE NTP GENE-CLUSTER FOR VACUOLAR-TYPE NA+-TRANSLOCATING ATPASE OF ENTEROCOCCUS-HIRAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BOUND ATPASE; VESICLE PROTON PUMP; ION MOTIVE ATPASES; H+-ATPASE; STREPTOCOCCUS-FAECALIS; SULFOLOBUS-ACIDOCALDARIUS; ACIDOTHERMOPHILIC ARCHAEBACTERIUM; SACCHAROMYCES-CEREVISIAE; METHANOSARCINA-BARKERI; ALPHA-SUBUNIT	We have previously reported the DNA and amino acid sequences for the three genes (ntpA, ntpB, and ntpK) encoding the A, B, and K (proteolipid) subunits, respectively, of Na+-translocating ATPase of a eubacterium Enterococcus hirae (Kakinuma, Y., Kakinuma, S., Takase, K., Konishi, K., Igarashi, K., and Yamato, I. (1993) Biochem. Biophys. Res. Commun. 195,1063-1069). In this paper we report the entire nucleotide sequence of the ntp gene cluster coding for this multisubunit enzyme. The cluster contained eight other genes; the order of these 11 genes was ntpF, -I, -K, -E, -C, -G, -A, -B, -D, -H, and -J, encoding proteins with predicted molecular weights of 14,255, 75,619, 16,036, 22,699, 38,162, 11,409, 65,766, 51,139, 27,093, 7,164, and 48,869, respectively. The deduced amino acid sequences of these products suggested that NtpI and NtpJ are hydrophobic proteins and others are hydrophilic. The ntpI gene product, which possesses six membrane-spanning segments in its carboxyl-terminal half, resembled the 116-kDa subunit of vacuolar (V)-ATPase in clathrin-coated vesicles. In addition, the NtpE, NtpC, NtpG, and NtpD proteins resembled bovine kidney ATPase E subunit, Saccharomyces cerevisiae Vma6p, Manduca sexta V-ATPase 14-kDa subunit, and Sulfolobus acidocaldarius gamma subunit, respectively, although the similarities between their amino acid sequences were moderate. Other gene products (NtpF and NtpH) did not show significant sequence similarity to other V-ATPase subunits. Since NtpA, NtpB, and NtpK are homologous counterparts of V-ATPase, these findings suggest that the molecular architecture of E. hirae Na+-ATPase complex corresponds to the V-type H+-ATPase complex distributed in various eukaryotic endomembrane systems. The sequence of the NtpJ product was similar to those of K+ transport systems of S. cerevisiae (Trk1 and Trk2); its meaning will be discussed. This is the first demonstration of a eukaryotic V-ATPase-like Na+ pump in bacteria.	BRISTOL MEYERS SQUIBB RES INST,MEGURO KU,TOKYO 153,JAPAN; CHIBA UNIV,FAC PHARMACEUT SCI,INAGE KU,CHIBA 263,JAPAN; TOYAMA MED & PHARMACEUT UNIV,FAC MED,DEPT BIOCHEM,TOYAMA,TOYAMA 93001,JAPAN	Chiba University; University of Toyama	TAKASE, K (corresponding author), SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL,2641 YAMAZAKI,NODA,CHIBA 278,JAPAN.			Igarashi, Kazuei/0000-0003-3751-3187				ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ARAI H, 1987, J BIOL CHEM, V262, P11006; BAUERLE C, 1993, J BIOL CHEM, V268, P12794; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BIRD CR, 1985, EMBO J, V4, P1381, DOI 10.1002/j.1460-2075.1985.tb03790.x; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; CHU CP, 1992, J BACTERIOL, V174, P1619, DOI 10.1128/jb.174.5.1619-1625.1992; COZENS AL, 1987, J MOL BIOL, V194, P359, DOI 10.1016/0022-2836(87)90667-X; DENDA K, 1990, J BIOL CHEM, V265, P21509; DENDA K, 1988, J BIOL CHEM, V263, P6012; DENDA K, 1988, J BIOL CHEM, V263, P17251; DENDA K, 1989, J BIOL CHEM, V264, P7119; DEVOS WM, 1990, J BIOL CHEM, V265, P22554; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FOURY F, 1990, J BIOL CHEM, V265, P18554; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; GLUCK S, 1987, J BIOL CHEM, V262, P15780; HEEFNER DL, 1982, P NATL ACAD SCI-BIOL, V79, P2798, DOI 10.1073/pnas.79.9.2798; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; HO MN, 1993, J BIOL CHEM, V268, P18286; IHARA K, 1991, ARCH BIOCHEM BIOPHYS, V286, P111, DOI 10.1016/0003-9861(91)90015-B; INATOMI K, 1989, BIOCHEM BIOPH RES CO, V162, P1585, DOI 10.1016/0006-291X(89)90856-5; INATOMI K, 1986, J BACTERIOL, V167, P837, DOI 10.1128/jb.167.3.837-841.1986; INATOMI KI, 1989, J BIOL CHEM, V264, P10954; KAESTNER KH, 1988, J BIOL CHEM, V263, P1282; KAKINUMA Y, 1991, FEBS LETT, V292, P64, DOI 10.1016/0014-5793(91)80835-Q; KAKINUMA Y, 1990, FEBS LETT, V261, P135, DOI 10.1016/0014-5793(90)80654-2; KAKINUMA Y, 1990, J BACTERIOL, V172, P1732, DOI 10.1128/jb.172.4.1732-1735.1990; KAKINUMA Y, 1985, J BIOL CHEM, V260, P2086; KAKINUMA Y, 1990, FEBS LETT, V271, P97, DOI 10.1016/0014-5793(90)80381-R; KAKINUMA Y, 1990, FEBS LETT, V271, P102, DOI 10.1016/0014-5793(90)80382-S; KAKINUMA Y, 1993, BIOCHEM BIOPH RES CO, V195, P1063, DOI 10.1006/bbrc.1993.2152; KAKINUMA Y, 1993, ALKALI CATION TRANSP, P277; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; KONISHI J, 1987, J BIOCHEM, V102, P1379, DOI 10.1093/oxfordjournals.jbchem.a122184; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MARMUR J, 1962, J MOL BIOL, V5, P109, DOI 10.1016/S0022-2836(62)80066-7; MUKOHATA Y, 1987, J BIOCHEM-TOKYO, V102, P797, DOI 10.1093/oxfordjournals.jbchem.a122118; NANBA T, 1987, J BIOCHEM-TOKYO, V102, P591, DOI 10.1093/oxfordjournals.jbchem.a122092; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON N, 1988, PLANT PHYSIOL, V86, P1, DOI 10.1104/pp.86.1.1; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; PADAN E, 1993, ALKALI CATION TRANSP, P3; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PERIN MS, 1991, J BIOL CHEM, V266, P3877; REA PA, 1987, J BIOL CHEM, V262, P14745; SCHAFER G, 1992, ANN NY ACAD SCI, V671, P293, DOI 10.1111/j.1749-6632.1992.tb43804.x; SCHLOSSER A, 1991, J BACTERIOL, V173, P3170; SHIBATA C, 1992, J BACTERIOL, V174, P6117, DOI 10.1128/JB.174.19.6117-6124.1992; TAKASE K, 1993, J BIOL CHEM, V268, P11610; WANG SY, 1988, J BIOL CHEM, V263, P17638; WARD JM, 1992, PLANT PHYSIOL, V99, P170, DOI 10.1104/pp.99.1.170	59	105	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11037	11044						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157629				2022-12-25	WOS:A1994NF96600014
J	BERNARD, OA; MAUCHAUFFE, M; MECUCCI, C; VANDENBERGHE, H; BERGER, R				BERNARD, OA; MAUCHAUFFE, M; MECUCCI, C; VANDENBERGHE, H; BERGER, R			A NOVEL GENE, AF-1P, FUSED TO HRX IN T(1,11)(P32,Q23), IS NOT RELATED TO AF-4, AF-9 NOR ENL	ONCOGENE			English	Article							ACUTE LEUKEMIAS; CHROMOSOME TRANSLOCATIONS; DROSOPHILA-TRITHORAX; DIRECT CLONING; PCR PRODUCTS; 11Q23; T(11-19)(Q23-P13); BREAKPOINTS; TRANSLATION; TRANSCRIPT	Most of the translocations affecting the chromosome band 11q23, frequently seen in human acute leukemias, involve a restricted area of the HRX gene. We have characterized two t(1;11)(p32;q11) translocations which fuse the HRX gene to a novel gene, AF-1p on chromosome 1p32, in two myeloid leukemias. The der (11) chromosome expresses the 1368 N-terminal amino acids of HRX, including the AT-hook, snRNP and methyltransferase similarities, fused to almost all the AF-1p product. The predicted wild type AF-1p product is a 98 kDa acidic protein which does not exhibit similarity to the AF4, AF-9 and ENL gene products. It is highly similar to the murine eps 15 gene product, which encodes a cytoplasmic phosphoprotein. Our data indicate that AF-lp defines another class of genes fused to HRX in 11q23 abnormalities.	INST GENET MOLEC, CNRS, SDI NO 15954 I, F-75010 PARIS, FRANCE; POLICLIN MONTELUCE, INST HEMATOL, I-06100 PERUGIA, ITALY; CTR HUMAN GENET, B-3000 LOUVAIN, BELGIUM	Centre National de la Recherche Scientifique (CNRS)	BERNARD, OA (corresponding author), INST NATL SANTE & RECH MED, U301, 27 RUE JULIETTE DODU, F-75010 PARIS, FRANCE.		Bernard, Olivier A./E-5721-2016	Bernard, Olivier/0000-0002-0463-9747				CHEN CS, 1993, BLOOD, V81, P2386; CHERIF D, 1993, GENE CHROMOSOME CANC, V6, P107, DOI 10.1002/gcc.2870060207; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIMINO G, 1992, CANCER RES, V52, P3811; CIMINO G, 1993, BLOOD, V82, P544; CIMINO G, 1991, CANCER RES, V51, P6712; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; KOBAYASHI H, 1993, GENE CHROMOSOME CANC, V7, P204, DOI 10.1002/gcc.2870070404; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LANOTTE M, 1991, BLOOD, V77, P1080; LECONIAT M, 1993, CR ACAD SCI III-VIE, V316, P692; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MATSUOKA Y, 1967, P SOC EXP BIOL MED, V125, P1246; MCCABE NR, 1992, P NATL ACAD SCI USA, V89, P11794, DOI 10.1073/pnas.89.24.11794; MITELMAN F, 1993, GENOME PRIORITY REPO, V1, P700; MORGAN GJ, 1992, BLOOD, V80, P2172; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NICHOLS J, 1992, BLOOD, V80, P2953; RABBITTS TH, 1991, ADV IMMUNOL, V50, P119; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SAIT SNJ, 1993, GENE CHROMOSOME CANC, V7, P28, DOI 10.1002/gcc.2870070105; Sambrook J, 1989, MOL CLONING LABORATO; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VANDERPOEL SZ, 1991, P NATL ACAD SCI USA, V88, P10735; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YOUNG BD, 1992, BAILLIERE CLIN HAEM, V5, P881, DOI 10.1016/S0950-3536(11)80050-8	37	120	126	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1039	1045						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134107				2022-12-25	WOS:A1994NC04800005
J	DUTCZAK, WJ; BALLATORI, N				DUTCZAK, WJ; BALLATORI, N			TRANSPORT OF THE GLUTATHIONE-METHYLMERCURY COMPLEX ACROSS LIVER CANALICULAR MEMBRANES ON REDUCED GLUTATHIONE CARRIERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT TRANSPORT; RAT-LIVER; BILIARY TRANSPORT; PLASMA-MEMBRANES; S-CONJUGATE; VESICLES; BILE; MECHANISMS; SECRETION; TAUROCHOLATE	Methylmercury transport across liver canalicular membranes into bile, a major route of excretion of this toxic compound, is dependent upon intracellular GSH, and a glutathione-methylmercury complex (CH3Hg.SG) has been detected in liver tissue and bile. To examine whether the CH3Hg.SG complex is itself transported across the canalicular membrane and to identify the transport system involved, studies were performed in isolated rat liver canalicular plasma membrane vesicles. Uptake of (CH3Hg.SG)-Hg-203 (10 muM) into an osmotically active space was temperature-sensitive and unaffected by either ATP (5 mM) or an inwardly directed Na+ gradient (100 mM); however, CH3Hg.SG uptake was enhanced by a valinomycin-induced K+ diffusion potential (inside-positive) indicating that its transport was electrogenic. Transport of CH3Hg.SG exhibited saturation kinetics with both high affinity (K(m) = 12 +/- 2 muM, V(max) = 0.23 +/- 0.02 nmol.mg-1.20 s-1) and low affinity (K(m) = 1.47 +/- 0.22 mM, V(max) = 1.23 +/- 0.14 nmol.mg-1.20 s-1) components. Uptake of this complex was inhibited by GSH, the GSH analog ophthalmic acid, S-methyl, S-ethyl, S-butyl, S-hexyl, S-octyl, and S-dinitrophenyl glutathione, but not by GSSG, bile acids, amino acids, and P-glycoprotein inhibitors. Furthermore, GSH competitively inhibited (K(i) = 83 muM) and trans-stimulated CH3Hg-SG uptake into the canalicular vesicles. These studies provide the first kinetic characterization of a transport system for glutathione-mercaptides and indicate that CH3Hg.SG is not a substrate for the ATP-dependent, canalicular GSSG or glutathione S-conjugate carriers, but appears to be a substrate for canalicular carriers that also transport GSH. Because efflux systems for GSH are found in all mammalian cells, transport of glutathione-metal complexes by such carriers may be a common mechanism for the removal of methylmercury and possibly other metals from cells.	UNIV ROCHESTER,SCH MED,DEPT ENVIRONM MED,ROCHESTER,NY 14642	University of Rochester					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK039165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006484, P30ES001247] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-39165] Funding Source: Medline; NIEHS NIH HHS [ES-01247, ES-06484] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABERG B, 1969, ARCH ENVIRON HEALTH, V19, P478, DOI 10.1080/00039896.1969.10666872; AKERBOOM T, 1984, EUR J BIOCHEM, V141, P211, DOI 10.1111/j.1432-1033.1984.tb08177.x; AKERBOOM TPM, 1991, J BIOL CHEM, V266, P13147; BALLATORI N, 1985, AM J PHYSIOL, V248, pG238, DOI 10.1152/ajpgi.1985.248.2.G238; BALLATORI N, 1991, DRUG METAB REV, V23, P83, DOI 10.3109/03602539109029757; BALLATORI N, 1986, J BIOL CHEM, V261, P6216; BALLATORI N, 1983, AM J PHYSIOL, V244, pG435, DOI 10.1152/ajpgi.1983.244.4.G435; BALLATORI N, 1982, SCIENCE, V216, P61, DOI 10.1126/science.7063871; BALLATORI N, 1985, FUND APPL TOXICOL, V5, P816, DOI 10.1016/0272-0590(85)90165-4; FERNANDEZCHECA JC, 1993, J BIOL CHEM, V268, P10836; FERNANDEZCHECA JC, 1992, J BIOL CHEM, V267, P1667; GARCIARUIZ C, 1992, J BIOL CHEM, V267, P22256; HINCHMAN CA, 1991, J BIOL CHEM, V266, P22179; INOUE M, 1984, J BIOL CHEM, V259, P4998; INOUE M, 1983, EUR J BIOCHEM, V134, P467, DOI 10.1111/j.1432-1033.1983.tb07590.x; INSKIP MJ, 1985, J APPL TOXICOL, V5, P113, DOI 10.1002/jat.2550050302; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; KOBAYASHI K, 1990, J BIOL CHEM, V265, P7737; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGOS L, 1978, BIOCHEM PHARMACOL, V27, P2203, DOI 10.1016/0006-2952(78)90078-3; MEIER PJ, 1984, J BIOL CHEM, V259, P614; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MULLER M, 1991, J BIOL CHEM, V266, P18920; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; NORSETH T, 1971, ARCH ENVIRON HEALTH, V22, P568, DOI 10.1080/00039896.1971.10665903; OMATA S, 1978, BIOCHEM PHARMACOL, V27, P1700; ORLOWSKI M, 1963, BIOCHIM BIOPHYS ACTA, V73, P676; REFSVIK T, 1978, ACTA PHARMACOL TOX, V42, P135; REFSVIK T, 1975, ACTA PHARMACOL TOX, V36, P67; SCHARSCHMIDT BF, 1979, J LAB CLIN MED, V93, P790; SIMMONS TW, 1992, J PHARMACOL EXP THER, V262, P1182; SIMPSON RB, 1961, J AM CHEM SOC, V83, P4711, DOI 10.1021/ja01484a005; TORIBARA TY, 1985, INT J APPL RADIAT IS, V36, P903, DOI 10.1016/0020-708X(85)90025-0	33	86	87	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9746	9751						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144567				2022-12-25	WOS:A1994NE05300056
J	HU, NP; GUTSMANN, A; HERBERT, DC; BRADLEY, A; LEE, WH; LEE, EYHP				HU, NP; GUTSMANN, A; HERBERT, DC; BRADLEY, A; LEE, WH; LEE, EYHP			HETEROZYGOUS RB-1(DELTA-20)/+ MICE ARE PREDISPOSED TO TUMORS OF THE PITUITARY-GLAND WITH A NEARLY COMPLETE PENETRANCE	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; BLADDER-CARCINOMA CELLS; SV40 LARGE-T; SUSCEPTIBILITY GENE; INTERMEDIATE LOBE; CELLULAR PROTEINS; MOLECULAR-CLONING; ENCODED PROTEIN; BINDING PROTEIN; CDC2 KINASE	Humans with a germline mutation of the RB gene are predisposed to retinoblastoma with a 90% penetrance and are at higher risk for other rare tumors. We have established a mouse strain carrying a germ-line mutation of the Rh-1 gene. Here we describe a nearly 100% incidence of spontaneous pituitary tumors which arise in Rb-1 heterozygous mice from ages 2 to 11 months. Histological and immunological analysis indicate that these tumors originate from the intermediate lobe of the pituitary gland, which is a vestigial structure in adult humans. Progression of the tumors can be followed by the elevated level of a specific proteotytic product of pro-opiomelanocortin prohormone, alpha-melanocyte stimulating hormone, in the circulating blood of the tumor-bearing animals. Multiple foci are frequently seen in the tiny intermediate lobe of the pituitary gland which contains approximately 1.5 x 10(5) cells. The tumor tissues invariably lose expression of full-length Rb protein due to loss of the single wild-type Rb-1 allele. The Rb knock out mouse strain provides a unique model for addressing tissue-specific tumor predisposition by inactivation of a ubiquitously expressed tumor suppressor gene.	UNIV TEXAS,HLTH SCI CTR,CTR MOLEC MED,INST BIOTECHNOL,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute				Bradley, Allan/0000-0002-2349-8839				BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CASTRO MG, 1989, J NEUROCHEM, V52, P1619, DOI 10.1111/j.1471-4159.1989.tb09217.x; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHANG CY, 1993, CELL GROWTH DIFFER, V4, P1057; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DONOSO LA, 1985, ARCH OPHTHALMOL-CHIC, V103, P855, DOI 10.1001/archopht.1985.01050060115039; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; Eipper B A, 1980, Endocr Rev, V1, P1; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GLASER T, 1990, SCIENCE, V250, P823, DOI 10.1126/science.2173141; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLMES RL, 1974, PITUITARY GLAND COMP, P5; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KYRITSIS AP, 1984, NATURE, V307, P471, DOI 10.1038/307471a0; LAMBERTS SWJ, 1982, J CLIN ENDOCR METAB, V54, P286, DOI 10.1210/jcem-54-2-286; LEE EYH, 1991, DIVERSE MUTATIONS LE; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEE WH, 1991, COLD SH Q B, V56, P211; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MATSUNAGA E, 1980, HUM GENET, V56, P127; MAYOL X, 1993, ONCOGENE, V8, P2561; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MIRSHAHI M, 1986, CANCER-AM CANCER SOC, V57, P1497, DOI 10.1002/1097-0142(19860415)57:8<1497::AID-CNCR2820570810>3.0.CO;2-H; NEVINS JR, 1992, SCIENCE, V258, P424; PENNY RJ, 1978, NEUROENDOCRINOLOGY, V25, P193, DOI 10.1159/000122741; PEREZ FM, 1990, ENDOCRINOLOGY, V127, P1877, DOI 10.1210/endo-127-4-1877; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROBERTS JL, 1980, BIOCHEM, V17, P3609; RODRIGUES MM, 1987, OPHTHALMOLOGY, V94, P378; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P139; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; VOGEL F, 1979, HUM GENET, V52, P1; VOSS JW, 1992, CELL, V70, P527, DOI 10.1016/0092-8674(92)90422-9; WANG NP, 1993, ONCOGENE, V8, P279; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WINGSTRAND KG, 1966, PITUITARY GLAND, P1; XU HJ, 1989, ONCOGENE, V4, P807	67	234	236	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1021	1027						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134105				2022-12-25	WOS:A1994NC04800003
J	MAZOYER, S; LALLE, P; MOYRETLALLE, C; MARCAIS, C; SCHRAUB, S; FRAPPAZ, D; SOBOL, H; OZTURK, M				MAZOYER, S; LALLE, P; MOYRETLALLE, C; MARCAIS, C; SCHRAUB, S; FRAPPAZ, D; SOBOL, H; OZTURK, M			2 GERM-LINE MUTATIONS AFFECTING THE SAME NUCLEOTIDE AT CODON-257 OF P53 GENE, A RARE SITE FOR MUTATIONS	ONCOGENE			English	Note							TUMOR-SUPPRESSOR GENE; BREAST-CANCER; FAMILY; NEOPLASMS; PROTEIN; PATIENT	Codon 257 of the p53 gene is an extremely rare target for somatic mutations (accounting for only two of 1600 published mutations). We report here two constitutional mutations both affecting the second nucleotide of codon 257. A thymine to adenine transversion resulting in an amino acid change from leucine to glutamine was found in one proband who developed multiple independent malignant tumors (osteosarcoma, phyllodes tumor, soft-tissue sarcoma). Her mother died of early-onset breast cancer. In the other case, a deletion resulting in a frameshift in the C-terminal coding region of p53 was found in a woman who was diagnosed with breast cancer at age 34. This woman belongs to a family with features of Li-Fraumeni syndrome. In both cases, the p53 mutations identified in the proband was found in other members of the family. Codon 257, even if rarely mutated in somatic cells, may thus be an important target for germ-line mutations.	CTR LEON BERARD,ONCOL MOLEC LAB,INSERM,CJF 9302,28 PROMENADE BULLUKIAN,F-69008 LYON,FRANCE; CTR HOSP REG BESANCON,REGISTRE TUMEURS DOUBS,F-25000 BESANCON,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Universite de Franche-Comte; CHU Besancon			Mazoyer, Sylvie/N-7559-2017; Moyret-Lalle, Caroline/G-2742-2013; ozturk, mehmet/G-3330-2014; LALLE, Philippe/G-7734-2018; OZTURK, MEHMET/AAS-7241-2021	Moyret-Lalle, Caroline/0000-0002-8359-2018; OZTURK, MEHMET/0000-0002-6092-9706; Mazoyer, Sylvie/0000-0002-2135-0160				BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BRUGIERES L, 1993, CANCER RES, V53, P452; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; EELES RA, 1993, ONCOGENE, V8, P1269; FELIX CA, 1993, ONCOGENE, V8, P1203; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ICHIKAWA A, 1992, BLOOD, V79, P2701; KRESS S, 1992, CANCER RES, V52, P3220; LI FP, 1988, CANCER RES, V48, P5358; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; SOBOL H, 1992, HUM GENET, V89, P381; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001	16	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1237	1239						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134127				2022-12-25	WOS:A1994NC04800028
J	YAN, SD; SCHMIDT, AM; ANDERSON, GM; ZHANG, JH; BRETT, J; ZOU, YS; PINSKY, D; STERN, D				YAN, SD; SCHMIDT, AM; ANDERSON, GM; ZHANG, JH; BRETT, J; ZOU, YS; PINSKY, D; STERN, D			ENHANCED CELLULAR OXIDANT STRESS BY THE INTERACTION OF ADVANCED GLYCATION END-PRODUCTS WITH THEIR RECEPTORS BINDING-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LIPID-PEROXIDATION; TRANSCRIPTION FACTOR; GLYCOSYLATION; ACTIVATION; GLUCOSE; SURFACE; COMPLICATIONS; GENERATION; ANTIBODIES	Attack by reactive oxygen intermediates, common to many kinds of cell/tissue injury, has been implicated in the development of diabetic and other vascular diseases. Such oxygen-free radicals can be generated by advanced glycation end products (AGEs), which are nonenzymatically glycated and oxidized proteins. Since cellular interactions of AGEs are mediated by specific cellular binding proteins, receptor for AGE (RAGE) and the lactoferrin-like polypeptide (LF-L), we tested the hypothesis that AGE ligands tethered to the complex of RAGE and LF-L could induce oxidant stress. AGE albumin or AGEs immunoisolated from diabetic plasma resulted in induction of endothelial cell (EC) oxidant stress, including the generation of thiobarbituric acid reactive substances (TBARS) and resulted in the activation of NF-kappaB, each of which was blocked by antibodies to AGE receptor polypeptides and by antioxidants. Infusion of AGE albumin into normal animals led to the appearance of malondialdehyde determinants in the vessel wall and increased TBARS in the tissues, activation of NF-kappaB, and induction of heme oxygenase mRNA. AGE-induced oxidant stress was inhibited by pretreatment of animals with either antibodies to the AGE receptor/binding proteins or antioxidants. These data indicate that interaction of AGEs with cellular targets, such as ECs, leads to oxidant stress resulting in changes in gene expression and other cellular properties, potentially contributing to the development of vascular lesions. Further studies will be required to dissect whether oxidant stress occurs on the cell surface or at an intracellular locus.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; MERCK SHARP & DOHME LTD, W POINT, PA 19486 USA	Columbia University; Merck & Company	YAN, SD (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT PHYSIOL & CELLULAR BIOPHYS, 630 W 168 ST, NEW YORK, NY 10032 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042507, R01HL042833] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42833, HL42507] Funding Source: Medline; NIA NIH HHS [AG00602] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALLA G, 1992, J BIOL CHEM, V267, P18148; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BORCH RF, 1971, J AM CHEM SOC, V93, P2897, DOI 10.1021/ja00741a013; BRETT J, 1993, AM J PATHOL, V143, P1699; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; DAVID GS, 1974, BIOCHEMISTRY-US, V13, P1014, DOI 10.1021/bi00702a028; DENEKE SM, 1985, J APPL PHYSIOL, V58, P571, DOI 10.1152/jappl.1985.58.2.571; DENNERY PA, 1990, AM J RESP CELL MOL, V3, P137, DOI 10.1165/ajrcmb/3.2.137; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ESMON NL, 1982, J BIOL CHEM, V257, P859; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; GODIN DV, 1988, MOL CELL BIOCHEM, V84, P223, DOI 10.1007/BF00421057; GODING JW, 1976, J IMMUNOL METHODS, V13, P215, DOI 10.1016/0022-1759(76)90068-5; GUTTERIDGE JMC, 1981, BIOCHEM J, V199, P259, DOI 10.1042/bj1990259; HABERLAND ME, 1985, P NATL ACAD SCI USA, V82, P2693, DOI 10.1073/pnas.82.9.2693; HICKS M, 1989, ARCH BIOCHEM BIOPHYS, V268, P249, DOI 10.1016/0003-9861(89)90586-9; HORIUCHI S, 1986, J BIOL CHEM, V261, P4962; HUNT JV, 1990, DIABETES, V39, P1420, DOI 10.2337/diabetes.39.11.1420; JAIN SK, 1991, DIABETES, V40, P1241, DOI 10.2337/diabetes.40.10.1241; KAGEYAMA H, 1988, CANCER RES, V48, P4795; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; MULLARKEY CJ, 1990, BIOCHEM BIOPH RES CO, V173, P932, DOI 10.1016/S0006-291X(05)80875-7; NAKAYAMA H, 1991, J IMMUNOL METHODS, V140, P119; NEEPER M, 1992, J BIOL CHEM, V267, P14998; OBERLEY LW, 1988, FREE RADICAL BIO MED, V5, P113, DOI 10.1016/0891-5849(88)90036-6; REHMAN J, 1989, COMP BIOCH PHYSL B, V93, P929; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; SAKURAI T, 1990, BIOCHIM BIOPHYS ACTA, V1043, P27, DOI 10.1016/0005-2760(90)90106-8; SATO Y, 1979, BIOCHEM MED METAB B, V21, P104, DOI 10.1016/0006-2944(79)90061-9; SCHMIDT AM, 1994, J BIOL CHEM, V269, P9882; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SCHMIDT AM, 1993, J CLIN INVEST, V91, P2155, DOI 10.1172/JCI116442; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SELL DR, 1989, J BIOL CHEM, V264, P21597; STITES D, 1982, BASIC CLIN IMMUNOL, P34; TESFAMARIAM B, 1992, AM J PHYSIOL, V263, pH321, DOI 10.1152/ajpheart.1992.263.2.H321; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; WAUTIER JL, 1992, 7TH INT S BIOL VASC, P45; YANG Z, 1991, J EXP MED, V174, P515, DOI 10.1084/jem.174.3.515	44	1076	1125	1	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9889	9897						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144582				2022-12-25	WOS:A1994NE05300076
J	KIM, ML; VOSS, EW				KIM, ML; VOSS, EW			QUANTITATION OF INTERACTION ANTI-METATYPE MONOCLONAL-ANTIBODIES SPECIFIC FOR THE VARIABLE REGIONS OF A HIGH-AFFINITY LIGANDED MONOCLONAL-ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCYL ANTIBODIES; IDIOTYPE FAMILY; BINDING	Four hamster monoclonal anti-metatype antibodies were characterized in terms of their binding properties with liganded murine monoclonal single-chain anti-fluorescein antibody 4-4-20. Based on induced delays in the rate of ligand (fluorescein) dissociation upon the binding of each monoclonal anti-Met antibody, apparent K-d values were determined for monoclonal antibodies 3A5-1, P1E11, 4A6, and 2C3 (3.6 x 10(-8), 3.6 x 10(-8), 5.0 x 10(-8), and 2.6 x 10(-7) M, respectively). The interaction of hamster monoclonal antibody 3A5-1 with liganded SCA 4-4-20 and IgG 4-4-20 was also evaluated on the basis of deuterium oxide exchange to assess the relative ability of each antibody to stabilize the intrinsic dynamics of the variable domains of the single-chain molecule. The results indicated a correlation between the apparent K-d of the monoclonal anti-Met antibody and the degree of delay in the rate of ligand dissociation from the primary antibody.	UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign								BATES RM, 1985, MOL IMMUNOL, V22, P871, DOI 10.1016/0161-5890(85)90072-0; BEDZYK WD, 1990, J BIOL CHEM, V265, P133; BEDZYK WD, 1990, J BIOL CHEM, V265, P18615; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; COELHOSAMPAIO T, 1993, BIOCHEMISTRY-US, V32, P10929, DOI 10.1021/bi00092a001; DENZIN LK, 1992, J BIOL CHEM, V267, P8925; DENZIN LK, 1991, J BIOL CHEM, V266, P14095; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.biophys.21.1.243; HERRON JN, 1986, BIOCHEMISTRY-US, V25, P4602, DOI 10.1021/bi00364a022; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; KRANZ DM, 1982, J BIOL CHEM, V257, P6987; KRANZ DM, 1981, J BIOL CHEM, V256, P4433; KRANZ DM, 1981, MOL IMMUNOL, V18, P889, DOI 10.1016/0161-5890(81)90012-2; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; SWINDLEHURST CA, 1991, BIOPHYS J, V59, P619, DOI 10.1016/S0006-3495(91)82277-9; TETIN SY, 1992, BIOCHEMISTRY-US, V48, P12029; VOSS EW, 1988, MOL IMMUNOL, V25, P751, DOI 10.1016/0161-5890(88)90111-3; VOSS EW, 1980, MOL IMMUNOL, V17, P505, DOI 10.1016/0161-5890(80)90090-5; WATT RM, 1977, IMMUNOCHEMISTRY, V14, P533, DOI 10.1016/0019-2791(77)90308-1; Weber G, 1975, Adv Protein Chem, V29, P1, DOI 10.1016/S0065-3233(08)60410-6; WEIDNER KM, 1992, J BIOL CHEM, V267, P10281; WEIDNER KM, 1993, MOL IMMUNOL, V30, P1003, DOI 10.1016/0161-5890(93)90125-U; WEIDNER KM, 1991, J BIOL CHEM, V266, P2513; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4	24	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8695	8700						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132597				2022-12-25	WOS:A1994NB41100014
J	MARFATIA, SM; LUE, RA; BRANTON, D; CHISHTI, AH				MARFATIA, SM; LUE, RA; BRANTON, D; CHISHTI, AH			IN-VITRO BINDING-STUDIES SUGGEST A MEMBRANE-ASSOCIATED COMPLEX BETWEEN ERYTHROID P55, PROTEIN-4.1, AND GLYCOPHORIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TYROSINE-PHOSPHATASE; EZRIN; IDENTIFICATION; BAND-4.1; HOMOLOGY; DOMAIN; KINASE; TALIN; LOCALIZATION; CALMODULIN	p55 is a palmitoylated peripheral membrane phosphoprotein of human erythrocytes. Primary structure of p55 includes a single copy of the SH3 motif, a COOH-terminal guanylate kinase domain, and an NH2-terminal domain of unknown function. Although the function of p55 is not known, interest in this component has been heightened by its similarity to the Drosophila tumor suppressor discs-large (dlg). In this report we provide evidence for the direct association of p55 with the NH2-terminal 30-kDa domain of protein 4.1, a key component of the erythroid membrane skeleton. In addition, p55 also binds to the cytoplasmic domain of glycophorin C, a transmembrane protein of red blood cells. We also provide evidence demonstrating the direct association of the 30-kDa domain of protein 4.1 with the cytoplasmic domain of glycophorin C. Taken together, these results suggest the existence of a novel ternary complex at the erythroid plasma membrane involving protein 4.1, p55, and glycophorin C. Since isoforms of protein 4.1, p55, and glycophorin C are present in many non erythroid cells, the binding interactions may be prototypical of similar associations that modulate cytoskeletal-membrane linkage of broad significance.	TUFTS UNIV,ST ELIZABETHS MED CTR,SCH MED,DEPT BIOMED RES,BOSTON,MA 02135; HARVARD UNIV,BIOL LABS,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138	St. Elizabeth's Medical Center; Tufts University; Harvard University					NHLBI NIH HHS [HL17411, HL37462, HL51445] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL017411, R01HL051445, R56HL051445, P01HL037462] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLOISIO N, 1993, BLOOD, V82, P1323, DOI 10.1182/blood.V82.4.1323.bloodjournal8241323; BENNETT V, 1989, BIOCHIM BIOPHYS ACTA, V988, P107, DOI 10.1016/0304-4157(89)90006-3; BRYANT PJ, 1991, CELL, V66, P451; BRYANTPJ, 1992, CELL, V68, P621; DAS AK, 1992, BIOCHIM BIOPHYS ACTA, V1108, P128, DOI 10.1016/0005-2736(92)90016-F; DISCHER D, 1993, J BIOL CHEM, V268, P7186; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GOEBL MG, 1992, TRENDS BIOCHEM SCI, V17, P99, DOI 10.1016/0968-0004(92)90244-4; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; KELLY GM, 1991, J BIOL CHEM, V266, P12469; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LETO TL, 1984, J BIOL CHEM, V259, P4603; LETO TL, 1986, MEMBRANE SKELETONS C, P201; LING E, 1988, J BIOL CHEM, V263, P2209; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; OHANIAN V, 1984, EUR J BIOCHEM, V144, P375, DOI 10.1111/j.1432-1033.1984.tb08474.x; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; REID ME, 1989, RED CELL, P553; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SATO N, 1992, J CELL SCI, V103, P131; SHAHROKH Z, 1991, J BIOL CHEM, V266, P12082; TANAKA T, 1991, J BIOL CHEM, V266, P1134; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	27	154	154	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8631	8634						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132590				2022-12-25	WOS:A1994NB41100003
J	LEE, PY; HRUBY, DE				LEE, PY; HRUBY, DE			PROTEOLYTIC CLEAVAGE OF VACCINIA VIRUS VIRION PROTEINS - MUTATIONAL ANALYSIS OF THE SPECIFICITY DETERMINANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; CORE PROTEINS; POLYPEPTIDE; MATURATION; POLIOVIRUS; POLYPROTEIN; SITE; MUTAGENESIS; BIOGENESIS; PRECURSOR	Previous studies have suggested that cleavage of vaccinia virus core protein precursors occurs within the consensus tripeptide motif -A-G down arrow X-. As an approach to delineate the sequence and structural features of the precursor polypeptides that are responsible for directing site-specific scission within this element, site-directed mutagenesis procedures were employed in concert with an in vivo trans-processing assay of the P25K: FLAG reporter plasmid. The results obtained suggest that residue occupancy at the P1' site (following the nomenclature of Schechter and Berger (Schechter, I., and Berger, A. (1976) Biochem. Biophys. Res. Commun. 27, 157-162), the positions at the amino and carboxyl-proximal residues are indicated as P1, P2, etc., and P1', P2', etc., respectively) was extremely permissive, with only a proline substitution blocking cleavage. In contrast, the permissible occupancy of the P1 (serine or alanine) and P2 (cysteine, serine, or asparagine) sites was extremely restricted. Analysis of P1/P2 double mutants supported this conclusion and suggested additional levels of combinatorial stringency. Insertion or deletion of sequences immediately adjacent (amino or carboxyl-terminal) to the -A-G-X- motif completely abrogated cleavage, suggesting the presence of additional important structural determinants. Mutation of the conserved proline or basic amino acid residues in these regions had no effect on cleavage, whereas it appeared that the presence of a hydrophobic residue in the P4 site was required.	OREGON STATE UNIV, CTR GENE RES & BIOTECHNOL, DEPT MICROBIOL, CORVALLIS, OR 97331 USA	Oregon State University					NIAID NIH HHS [AI-29367] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029367] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON CW, 1990, VIROLOGY, V177, P259, DOI 10.1016/0042-6822(90)90479-B; BINNS MM, 1989, VIROLOGY, V170, P288, DOI 10.1016/0042-6822(89)90380-2; BINNS MM, 1988, J GEN VIROL, V69, P1275, DOI 10.1099/0022-1317-69-6-1275; BLAIR WS, 1990, J VIROL, V64, P1784, DOI 10.1128/JVI.64.4.1784-1793.1990; BLAIR WS, 1991, J VIROL, V65, P6111, DOI 10.1128/JVI.65.11.6111-6123.1991; DEGROOT RJ, 1990, EMBO J, V9, P2631, DOI 10.1002/j.1460-2075.1990.tb07445.x; DEWALT PG, 1989, J VIROL, V63, P3444, DOI 10.1128/JVI.63.8.3444-3452.1989; DOUGHERTY WG, 1989, VIROLOGY, V182, P17; GORDON J, 1991, VIROLOGY, V181, P671, DOI 10.1016/0042-6822(91)90901-M; HRUBY DE, 1979, J VIROL, V29, P705, DOI 10.1128/JVI.29.2.705-715.1979; KATZ E, 1970, P NATL ACAD SCI USA, V66, P677, DOI 10.1073/pnas.66.3.677; KAY J, 1990, BIOCHIM BIOPHYS ACTA, V1048, P1, DOI 10.1016/0167-4781(90)90015-T; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE PY, 1993, J VIROL, V67, P4252, DOI 10.1128/JVI.67.7.4252-4263.1993; LOPEZOTIN C, 1989, J BIOL CHEM, V264, P9107; PALLAI PV, 1989, J BIOL CHEM, V264, P9738; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SILVER M, 1982, VIROLOGY, V117, P341, DOI 10.1016/0042-6822(82)90474-3; TRITCH RJ, 1991, J VIROL, V65, P922, DOI 10.1128/JVI.65.2.922-930.1991; VANSLYKE JK, 1991, J GEN VIROL, V72, P411, DOI 10.1099/0022-1317-72-2-411; VANSLYKE JK, 1993, VIRUS GENES, V7, P311, DOI 10.1007/BF01703388; VANSLYKE JK, 1991, VIROLOGY, V183, P467, DOI 10.1016/0042-6822(91)90976-I; WEBSTER A, 1989, J GEN VIROL, V70, P3225, DOI 10.1099/0022-1317-70-12-3225; WHITEHEAD SS, 1994, IN PRESS VIROLOGY; YANG WP, 1988, VIROLOGY, V167, P578, DOI 10.1016/0042-6822(88)90120-1; YPMAWONG MF, 1987, J VIROL, V61, P3181, DOI 10.1128/JVI.61.10.3181-3189.1987; YPMAWONG MF, 1988, J BIOL CHEM, V263, P17846; ZHANG L, 1993, GENE, V129, P197, DOI 10.1016/0378-1119(93)90269-9	29	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8616	8622						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132587				2022-12-25	WOS:A1994NB40900117
J	IZUMI, M; MIYAZAWA, H; HARAKAWA, S; YATAGAI, F; HANAOKA, F				IZUMI, M; MIYAZAWA, H; HARAKAWA, S; YATAGAI, F; HANAOKA, F			IDENTIFICATION OF A POINT MUTATION IN THE CDNA OF THE CATALYTIC SUBUNIT OF DNA-POLYMERASE-ALPHA FROM A TEMPERATURE-SENSITIVE MOUSE FM3A CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE ESSENTIAL GENE; PRIMASE P49 SUBUNIT; SACCHAROMYCES-CEREVISIAE; HEAT-LABILE; I GENE; DROSOPHILA-MELANOGASTER; NUCLEOTIDE-SEQUENCE; TSFT20 STRAIN; MUTANT; REPLICATION	DNA polymerase at is a key enzyme in eukaryotic chromosomal DNA replication. tsFT20 is a temperature-sensitive mutant cell line derived from mouse mammary carcinoma FM3A cells, and the cells contain heat-labile DNA polymerase alpha and are arrested at the S phase at the nonpermissive temperature. We isolated cDNA of the catalytic subunit of DNA polymerase alpha from tsFT20 cells. DNA sequence analysis revealed that the cDNA from tsFT20 has a single mutation, a cytosine to thymine substitution that changes amino acid 1180 from serine to phenylalanine. We have also shown that tsFT20 cells could be rescued by transfection with the wild-type cDNA. These results demonstrate that the point mutation in the gene of DNA polymerase cu causes the temperatue-sensitive phenotype of tsFT20 cells and provide additional evidence that DNA polymerase cu is essential for chromosomal replication in mamma lian cells. We also detected mutation sites in one spontaneous and six N-methyl-N'-nitro-N-nitrosoguanidine-induced growth revertants of tsFT20 cells by single strand conformation polymorphism analyses and direct sequencing. All revertant cell lines had a second point mutation adjacent to the first mutation site in tsFT20 cells.	INST PHYS & CHEM RES,CELLULAR PHYSIOL LAB,WAKO,SAITAMA 35101,JAPAN; INST PHYS & CHEM RES,BIODESIGN RES GRP,WAKO,SAITAMA 35101,JAPAN; INST PHYS & CHEM RES,DIV RADIOISOTOPE TECHNOL,WAKO,SAITAMA 35101,JAPAN	RIKEN; RIKEN; RIKEN								ADLER DA, 1991, GENOMICS, V9, P642, DOI 10.1016/0888-7543(91)90357-K; AGUILERA A, 1988, GENETICS, V119, P779; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BUDD M, 1987, P NATL ACAD SCI USA, V84, P2838, DOI 10.1073/pnas.84.9.2838; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COTTERILL S, 1992, NUCLEIC ACIDS RES, V20, P4325, DOI 10.1093/nar/20.16.4325; COULONDRE C, 1977, J MOL BIOL, V117, P577, DOI 10.1016/0022-2836(77)90059-6; DAMAGNEZ V, 1991, MOL GEN GENET, V226, P182, DOI 10.1007/BF00273602; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; EKI T, 1987, EXP CELL RES, V171, P24, DOI 10.1016/0014-4827(87)90248-5; EKI T, 1990, J BIOL CHEM, V265, P26; FOIANI M, 1989, MOL CELL BIOL, V9, P3081, DOI 10.1128/MCB.9.7.3081; GONG SS, 1990, NUCLEIC ACIDS RES, V18, P3509, DOI 10.1093/nar/18.12.3509; HIROSE F, 1991, NUCLEIC ACIDS RES, V19, P4991, DOI 10.1093/nar/19.18.4991; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; IZUMI M, 1991, EXP CELL RES, V197, P229, DOI 10.1016/0014-4827(91)90427-V; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; LUCCHINI G, 1988, MOL GEN GENET, V212, P459, DOI 10.1007/BF00330850; LUCCHINI G, 1990, GENE, V90, P99, DOI 10.1016/0378-1119(90)90444-V; LUCCHINI G, 1987, EMBO J, V6, P737, DOI 10.1002/j.1460-2075.1987.tb04815.x; MIYAZAWA H, 1993, J BIOL CHEM, V268, P8111; MURAKAMI Y, 1986, EXP CELL RES, V163, P135, DOI 10.1016/0014-4827(86)90565-3; MURAKAMI Y, 1985, P NATL ACAD SCI USA, V82, P1761, DOI 10.1073/pnas.82.6.1761; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PIZZAGALLI A, 1988, P NATL ACAD SCI USA, V85, P3772, DOI 10.1073/pnas.85.11.3772; PRUSSAK CE, 1989, J BIOL CHEM, V264, P4957; Sambrook J, 1989, MOL CLONING LABORATO; SPICER EK, 1988, J BIOL CHEM, V263, P7478; SPINARDI L, 1991, NUCLEIC ACIDS RES, V19, P4009, DOI 10.1093/nar/19.14.4009; TAKADATAKAYAMA R, 1991, J BIOL CHEM, V266, P15716; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TSAI YJ, 1979, BIOCHEM BIOPH RES CO, V91, P1190, DOI 10.1016/0006-291X(79)92005-9; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WONG SW, 1986, J BIOL CHEM, V261, P7958; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x	40	14	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7639	7644						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125989				2022-12-25	WOS:A1994NA03200095
J	KRATZKE, RA; OTTERSON, GA; HOGG, A; COXON, AB; GERADTS, J; COWELL, JK; KAYE, FJ				KRATZKE, RA; OTTERSON, GA; HOGG, A; COXON, AB; GERADTS, J; COWELL, JK; KAYE, FJ			PARTIAL INACTIVATION OF THE RB PRODUCT IN A FAMILY WITH INCOMPLETE PENETRANCE OF FAMILIAL RETINOBLASTOMA AND BENIGN RETINAL TUMORS	ONCOGENE			English	Article							LARGE T-ANTIGEN; GENE-PRODUCT; SUSCEPTIBILITY GENE; CELLULAR PROTEINS; MOLECULAR-CLONING; BINDING PROTEIN; EXPRESSION; MUTATIONS; IDENTIFICATION; TRANSCRIPTION	While familial retinoblastoma has served as the paradigm for the two-hit theory of tumorigenesis and for the concept of the tumor suppressor gene, the etiology of incomplete penetrance of familial retinoblastoma is poorly understood. To address the molecular basis for this phenotype we have studied the functional properties of a mutant Rb gene identified in a kindred with incomplete penetrance of familial retinoblastoma and evidence for regressed retinal lesions (retinomas). In contrast to all previously isolated RB mutant proteins, we demonstrated that the mutant product from this kindred retained the wildtype properties of nuclear localization, the ability to undergo hyperphosphorylation in vivo, and the capacity to suppress growth of RB((-)) cells. Protein binding ('pocket') activity, however, was defective defining a new class of RB mutant with partial inactivation. The presence of this unique RB mutant in the germline of obligate carriers with incomplete penetrance and regressed retinal lesions suggests a molecular basis for this phenotype and supports the hypothesis that a minimum 'RB threshold' level of protein binding activity is required to suppress tumorigenesis.	USN,NCI,MED ONCOL BRANCH,BETHESDA,MD 20889; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20889; INST CHILD HLTH,IMPERIAL CANC RES FUND,LONDON WC1N 1EH,ENGLAND; MOLEC ONCOL INC,GAITHERSBURG,MD 20878	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; Uniformed Services University of the Health Sciences - USA; Cancer Research UK; University of London; University College London			kaye, frederic/E-2437-2011	Cowell, John/0000-0002-2079-5950				BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHAR DH, 1974, AM J OPHTHALMOL, V78, P5, DOI 10.1016/0002-9394(74)90003-8; CHEN PL, 1992, CELL GROWTH DIFFER, V3, P119; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DESTREE OHJ, 1992, DEV BIOL, V153, P141, DOI 10.1016/0012-1606(92)90098-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YK, 1987, SCIENCE, V236, P218; Gallie B L, 1977, Prog Clin Biol Res, V16, P229; GALLIE BL, 1982, BRIT J CANCER, V45, P513, DOI 10.1038/bjc.1982.87; GALLIE BL, 1979, IMMUNOLOGY IMMUNOPAT; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HASHIMOTO T, 1991, ONCOGENE, V6, P463; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HOGG A, 1992, ONCOGENE, V7, P1445; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KRATZKE RA, 1992, J BIOL CHEM, V267, P25998; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MAYOL X, 1993, ONCOGENE, V8, P2561; MEHRA KS, 1965, BRIT J OPHTHALMOL, V49, P381, DOI 10.1136/bjo.49.7.381; MUNCASTER MM, 1992, CANCER RES, V52, P654; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; ONADIM Z, 1993, BRIT J CANCER, V68, P958, DOI 10.1038/bjc.1993.461; OTTERSON GA, 1993, ONCOGENE, V8, P949; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; STEWARD JK, 1956, BRIT J OPHTHALMOL, V40, P449; STIRDIVANT SM, 1992, J BIOL CHEM, V267, P14846; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WUSTENBERG W, 1950, Klin Monbl Augenheilkd Augenarztl Fortbild, V117, P423; YOKOTA J, 1988, ONCOGENE, V3, P471	60	60	62	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1321	1326						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152792				2022-12-25	WOS:A1994NH40100002
J	HAGTING, A; KUNJI, ERS; LEENHOUTS, KJ; POOLMAN, B; KONINGS, WN				HAGTING, A; KUNJI, ERS; LEENHOUTS, KJ; POOLMAN, B; KONINGS, WN			THE DIPEPTIDE AND TRIPEPTIDE TRANSPORT PROTEIN OF LACTOCOCCUS-LACTIS - A NEW-TYPE OF BACTERIAL PEPTIDE TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; RABBIT SMALL-INTESTINE; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; SALMONELLA-TYPHIMURIUM; STREPTOCOCCUS-CREMORIS; OLIGOPEPTIDE PERMEASE; BINDING PROTEIN; GENE FUSIONS; SYSTEM	Lactococcus lactis takes up di- and tripeptides via a proton motive force-dependent carrier protein. The gene (dtpT) encoding the di-tripeptide transport protein of L. lactis was cloned by complementation of a dipeptide transport-deficient and proline auxotrophic Escherichia coli strain. Functional expression of the dipeptide transport gene was demonstrated by uptake studies of alanyl-[C-14]glutamate and other peptides in E. coli cells. The di-tripeptide transport protein catalyzes proton motive force-driven peptide uptake and dipeptide exchange activity. The nucleotide sequence of dtpT was determined and the translated sequence corresponds with a protein of 463 amino acid residues. Hydropathy profiling indicates that the protein could form 12 membrane-spanning segments with the amino and carboxyl termini at the outer surface of the membrane. A secondary structure model is presented which is substantiated by analysis of DtpT-PhoA fusion constructs. Amino acid sequence comparisons showed no significant homology with other bacterial peptide transport systems nor with any other known protein. Flanking regions of the di-tripeptide transport gene were used to delete dtpT from the chromosome of L. lactis. Genetic and biochemical characterization of this mutant indicates that DtpT is the only transport protein in L. lactis for hydrophilic di- and tripeptides.	UNIV GRONINGEN,DEPT MICROBIOL,9751 NN HAREN,NETHERLANDS; UNIV GRONINGEN,DEPT GENET,9751 NN HAREN,NETHERLANDS	University of Groningen; University of Groningen			Kunji, Edmund/AAH-2362-2020; Konings, Wilhelmus N./C-7063-2013; Poolman, Bert/D-1882-2012	Kunji, Edmund/0000-0002-0610-4500; 				ADLER HI, 1967, P NATL ACAD SCI USA, V57, P321, DOI 10.1073/pnas.57.2.321; ALLOING G, 1990, MOL MICROBIOL, V4, P633, DOI 10.1111/j.1365-2958.1990.tb00632.x; BERTELOOT A, 1981, BIOCHIM BIOPHYS ACTA, V649, P179, DOI 10.1016/0005-2736(81)90405-3; CHOMCZYNSKI P, 1984, BIOCHEM BIOPH RES CO, V122, P340, DOI 10.1016/0006-291X(84)90480-7; DANIEL H, 1992, J BIOL CHEM, V267, P9565; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FRANCOIS V, 1987, GENE, V56, P99, DOI 10.1016/0378-1119(87)90162-4; GANAPATHY V, 1981, J BIOL CHEM, V256, P118; GASSON MJ, 1983, J BACTERIOL, V154, P1; GIBSON MM, 1987, MOL GEN GENET, V207, P120, DOI 10.1007/BF00331499; GOODELL EW, 1987, J BACTERIOL, V169, P3861, DOI 10.1128/jb.169.8.3861-3865.1987; GUTIERREZ C, 1989, NUCLEIC ACIDS RES, V17, P3999, DOI 10.1093/nar/17.10.3999; HARLOW E, 1988, ANTIBODIES LABORATOR; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1986, METHOD ENZYMOL, V125, P365; HILES ID, 1987, J MOL BIOL, V195, P125, DOI 10.1016/0022-2836(87)90332-9; HOLO H, 1989, APPL ENVIRON MICROB, V55, P3119, DOI 10.1128/AEM.55.12.3119-3123.1989; KASHIWAGI K, 1992, J BACTERIOL, V174, P4331, DOI 10.1128/JB.174.13.4331-4337.1992; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P4658; KRAMER W, 1992, EUR J BIOCHEM, V204, P923, DOI 10.1111/j.1432-1033.1992.tb16713.x; KRAMER W, 1990, BIOCHIM BIOPHYS ACTA, V1028, P174, DOI 10.1016/0005-2736(90)90152-E; KRAMER W, 1987, BIOCHIM BIOPHYS ACTA, V905, P65, DOI 10.1016/0005-2736(87)90009-5; KRAMER W, 1988, BIOCHEM PHARMACOL, V37, P2427, DOI 10.1016/0006-2952(88)90370-X; KUNJI ERS, 1993, J BACTERIOL, V175, P2052, DOI 10.1128/JB.175.7.2052-2059.1993; LAW BA, 1978, J GEN MICROBIOL, V105, P113, DOI 10.1099/00221287-105-1-113; Leenhouts K, 1993, PLASMIDS PRACTICAL A, P65; LEENHOUTS KJ, 1990, APPL ENVIRON MICROB, V56, P2726, DOI 10.1128/AEM.56.9.2726-2735.1990; LEENHOUTS KJ, 1991, APPL ENVIRON MICROB, V57, P2562, DOI 10.1128/AEM.57.9.2562-2567.1991; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUDWIG W, 1985, J GEN MICROBIOL, V131, P543; MAEGHER RB, 1977, CELL, V10, P521; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; MANSON MD, 1986, NATURE, V321, P253, DOI 10.1038/321253a0; MATHIOPOULOS C, 1991, MOL MICROBIOL, V5, P1903, DOI 10.1111/j.1365-2958.1991.tb00814.x; MATTHEWS DM, 1980, CURR TOP MEMBR TRANS, V14, P331; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; Miller J.H., 1972, EXPT MOL GENETICS; OKANO T, 1986, J BIOL CHEM, V261, P14130; OLSON ER, 1991, J BACTERIOL, V173, P234, DOI 10.1128/jb.173.1.234-244.1991; Payne J. W., 1980, MICROORGANISMS NITRO, P211; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEREGO M, 1991, MOL MICROBIOL, V5, P173, DOI 10.1111/j.1365-2958.1991.tb01838.x; POOLMAN B, 1989, J BACTERIOL, V171, P244, DOI 10.1128/jb.171.1.244-253.1989; POOLMAN B, 1988, J BACTERIOL, V170, P700, DOI 10.1128/jb.170.2.700-707.1988; POOLMAN B, 1987, J BACTERIOL, V169, P1460, DOI 10.1128/jb.169.4.1460-1468.1987; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; RUDNER DZ, 1991, J BACTERIOL, V173, P1388, DOI 10.1128/jb.173.4.1388-1398.1991; SAMBROOK J, 1989, MOL CLONING LABORTOR; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMID EJ, 1989, J BACTERIOL, V171, P6135, DOI 10.1128/jb.171.11.6135-6140.1989; SMID EJ, 1989, J BACTERIOL, V171, P292, DOI 10.1128/jb.171.1.292-298.1989; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; TOLNER B, 1992, MOL MICROBIOL, V6, P2845, DOI 10.1111/j.1365-2958.1992.tb01464.x; TYNKKYNEN S, 1993, J BACTERIOL, V175, P7533; VANDEGUCHTE M, 1992, FEMS MICROBIOL LETT, V88, P73, DOI 10.1016/0378-1097(92)90685-H; VANDERVOSSEN JMBM, 1985, APPL ENVIRON MICROB, V50, P540, DOI 10.1128/AEM.50.2.540-542.1985; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VOSMAN B, 1983, J BACTERIOL, V156, P920, DOI 10.1128/JB.156.2.920-921.1983; WILSON D, 1989, BIOCHIM BIOPHYS ACTA, V986, P123, DOI 10.1016/0005-2736(89)90280-0	60	106	108	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11391	11399						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157671				2022-12-25	WOS:A1994NF96600063
J	LAWRENCE, JC; ZHANG, JN				LAWRENCE, JC; ZHANG, JN			CONTROL OF GLYCOGEN-SYNTHASE AND PHOSPHORYLASE BY AMYLIN IN RAT SKELETAL-MUSCLE - HORMONAL EFFECTS ON THE PHOSPHORYLATION OF PHOSPHORYLASE AND ON THE DISTRIBUTION OF PHOSPHATE IN THE SYNTHASE SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; EPITROCHLEARIS MUSCLES; MOLECULAR MECHANISM; INSULIN RESISTANCE; SEQUENCE-ANALYSIS; SOLEUS MUSCLE; INVIVO; GLUCOSE; INVITRO; METABOLISM	The effects of amylin and insulin on the phosphorylation of glycogen synthase and phosphorylase were investigated using rat diaphragms incubated with P-32i. Muscles were incubated with insulin (200 nM) or amylin (200 nM) for 30 min before extracts were prepared. The P-32 contents of the enzymes were determined after immunoprecipitation and SDS-polyacrylamide gel electrophoresis. Amylin increased both the activity ratio (-AMP/+AMP) and the P-32 content of phosphorylase by approximately 2-fold. Insulin alone was without significant effect on phosphorylase, but insulin blocked the effect of amylin on increasing the phosphorylation of phosphorylase. Insulin increased the glycogen synthase activity ratio (low glucose-6-P/high glucose-6-P) by approximately 80%. Amylin decreased this ratio from 0.14 to 0.08 and increased the phosphorylation of synthase by approximately 40%. To investigate changes in phosphorylation of different sites in the synthase, the enzyme was subjected to exhaustive proteolysis with trypsin, and P-32-labeled fragments were separated by reverse phase high performance liquid chromatography. Insulin decreased the P-32 contents of sites 3(a + b + c) and 2(a + b), which appears to account for the increase in synthase activity. Amylin increased phosphorylation of sites 1a, 1b, and 3(a + b + c), but not sites 2(a + b). With insulin plus amylin, phosphorylation of none of the sites was significantly changed. The results indicate that the effects of amylin on glycogen synthase must involve more than activation of cAMP-dependent protein kinase, as this kinase phosphorylates site 2 and does not phosphorylate sites 3(a + b + c).			LAWRENCE, JC (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA.				NIAMS NIH HHS [AR41180] Funding Source: Medline; NIDDK NIH HHS [DK28312] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARON AD, 1988, AM J PHYSIOL, V255, pE769, DOI 10.1152/ajpendo.1988.255.6.E769; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; Cohen P., 1986, ENZYMES, VXVII, P461; Cooper G J, 1989, Prog Growth Factor Res, V1, P99, DOI 10.1016/0955-2235(89)90004-5; CRYER PE, 1993, AM J PHYSIOL, V264, pE149, DOI 10.1152/ajpendo.1993.264.2.E149; DANIEL PM, 1975, J PHYSIOL-LONDON, V247, P273, DOI 10.1113/jphysiol.1975.sp010931; DEEMS RO, 1991, BIOCHEM BIOPH RES CO, V174, P716, DOI 10.1016/0006-291X(91)91476-S; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; Fischer E. H., 1971, CURR TOP CELL REGUL, V4, P211; FRONTONI S, 1991, DIABETES, V40, P568, DOI 10.2337/diabetes.40.5.568; GAMMELTOFT S, 1984, PHYSIOL REV, V64, P1321, DOI 10.1152/physrev.1984.64.4.1321; GILBOE DP, 1972, ANAL BIOCHEM, V47, P20, DOI 10.1016/0003-2697(72)90274-6; Goldberg A L, 1975, Methods Enzymol, V39, P82; GUINOVART JJ, 1979, FEBS LETT, V106, P284, DOI 10.1016/0014-5793(79)80515-3; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; JASPERS SR, 1989, ARCH BIOCHEM BIOPHYS, V268, P630, DOI 10.1016/0003-9861(89)90330-5; JUE T, 1989, P NATL ACAD SCI USA, V86, P1439, DOI 10.1073/pnas.86.5.1439; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KREUTTER DK, 1993, AM J PHYSIOL, V264, pE606, DOI 10.1152/ajpendo.1993.264.4.E606; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARNER J, 1990, ADV ENZYMOL RAMB, V63, P173; LAWRENCE JC, 1990, J BIOL CHEM, V265, P2324; LAWRENCE JC, 1983, J BIOL CHEM, V258, P710; LAWRENCE JC, 1992, ANNU REV PHYSIOL, V54, P177, DOI 10.1146/annurev.ph.54.030192.001141; LEIGHTON B, 1990, BIOCHEM J, V269, P19, DOI 10.1042/bj2690019; LEIGHTON B, 1988, NATURE, V335, P632, DOI 10.1038/335632a0; LUSKEY KL, 1992, DIABETES CARE, V15, P297, DOI 10.2337/diacare.15.2.297; MAYER SE, 1970, J BIOL CHEM, V245, P3153; NAKIELNY S, 1991, EUR J BIOCHEM, V199, P713, DOI 10.1111/j.1432-1033.1991.tb16175.x; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; PICTON C, 1982, EUR J BIOCHEM, V124, P37, DOI 10.1111/j.1432-1033.1982.tb05903.x; POULTER L, 1988, EUR J BIOCHEM, V175, P497, DOI 10.1111/j.1432-1033.1988.tb14222.x; RINK TJ, 1993, TRENDS PHARMACOL SCI, V14, P113, DOI 10.1016/0165-6147(93)90081-T; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROACH PJ, 1993, FASEB J, V7, pA1161; SHEORAIN VS, 1985, J BIOL CHEM, V260, P1567; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH RL, 1988, J BIOL CHEM, V263, P658; SMITH RL, 1985, J BIOL CHEM, V260, P273; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; TUKEY JW, 1949, BIOMETRICS, V5, P99, DOI 10.2307/3001913; WANG YH, 1993, J BIOL CHEM, V268, P23876; YOUNG AA, 1992, AM J PHYSIOL, V263, pE274, DOI 10.1152/ajpendo.1992.263.2.E274; YOUNG AA, 1991, FEBS LETT, V281, P149, DOI 10.1016/0014-5793(91)80380-L; YOUNG DA, 1990, AM J PHYSIOL, V259, pE457, DOI 10.1152/ajpendo.1990.259.3.E457; ZHANG JN, 1989, J BIOL CHEM, V264, P17513	51	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11595	11600						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157693				2022-12-25	WOS:A1994NF96600092
J	ROSENTHAL, JA; HSU, SH; SCHNEIDER, D; GENTILE, LN; MESSIER, NJ; VASLET, CA; HAWROT, E				ROSENTHAL, JA; HSU, SH; SCHNEIDER, D; GENTILE, LN; MESSIER, NJ; VASLET, CA; HAWROT, E			FUNCTIONAL EXPRESSION AND SITE-DIRECTED MUTAGENESIS OF A SYNTHETIC GENE FOR ALPHA-BUNGAROTOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; TORPEDO-CALIFORNICA; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; SNAKE; NEUROTOXIN; PROTEIN; SEQUENCE; BINDING; RESOLUTION	In order to explore the structure-function relationships of the curaremimetic alpha-neurotoxins we have constructed and cloned a synthetic gene for Bungarus multicinctus alpha-bungarotoxin which is expressed in Escherichia coli. The recombinant alpha-bungarotoxin is expressed as a fusion protein with alpha-bungarotoxin linked to the COOH-terminal end of the T7 Gene 9-encoded coat protein. After treatment of the fusion protein with Factor Xa protease, a recombinant alpha-bungarotoxin is released that co-migrates with authentic alpha-bungarotoxin upon reverse-phase high performance liquid chromatography and ion-exchange chromatography. Final yields of active recombinant alpha-bungarotoxin were about 0.4 mg/liter of starting bacterial culture. The recombinant alpha-bungarotoxin contains 10 additional residues linked to the NH2-terminal Ile of the alpha-bungarotoxin sequence due apparently to the inaccessibility of the engineered cleavage site to Factor Xa. Nevertheless, the recombinant alpha-bungarotoxin is capable of binding to the nicotinic acetylcholine receptor with an apparent affinity that is only decreased approximately 1.7-fold from that of authentic alpha-bungarotoxin. Alanine substitution of a residue, Asp30, highly conserved among alpha-neurotoxins and previously suggested to play a key role in receptor recognition, resulted in a recombinant alpha-bungarotoxin whose receptor binding activity is indistinguishable from authentic alpha-bungarotoxin.	BROWN UNIV, DIV BIOL & MED, MOLEC & BIOCHEM PHARMACOL SECT, PROVIDENCE, RI 02912 USA	Brown University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032629, T32GM007601] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07601, GM32629] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARD DA, 1982, ACTA CRYSTALLOGR A, V38, P186, DOI 10.1107/S0567739482000436; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; BASUS VJ, 1988, BIOCHEMISTRY-US, V27, P2763, DOI 10.1021/bi00408a016; BOYOT P, 1990, FEBS LETT, V266, P87, DOI 10.1016/0014-5793(90)81513-N; CHANG CC, 1971, BIOCHIM BIOPHYS ACTA, V251, P334, DOI 10.1016/0005-2795(71)90120-6; CHANGEUX JP, 1992, TRENDS PHARMACOL SCI, V13, P299, DOI 10.1016/0165-6147(92)90094-M; CHIAPPINELLI VA, 1993, NATURAL SYNTHETIC NE, P65; CORRAN PH, 1989, HPLC MACROMOLECULES, P127; CZAJKOWSKI C, 1989, ARCH BIOCHEM BIOPHYS, V272, P412, DOI 10.1016/0003-9861(89)90235-X; DUCANCEL F, 1989, PROTEIN ENG, V3, P139, DOI 10.1093/protein/3.2.139; ENDO T, 1987, PHARMACOL THERAPEUT, V34, P403, DOI 10.1016/0163-7258(87)90002-7; FIORDALISI JJ, 1991, BIOCHEMISTRY-US, V30, P10337, DOI 10.1021/bi00106a035; FIORDALISI JJ, 1992, PROTEIN EXPRES PURIF, V3, P282, DOI 10.1016/1046-5928(92)90002-E; GALLAGHER MJ, 1992, J BIOL CHEM, V267, P13958; GIBBS CS, 1991, BIOCHEMISTRY-US, V30, P5329, DOI 10.1021/bi00236a001; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HERVE M, 1992, EUR J BIOCHEM, V208, P125, DOI 10.1111/j.1432-1033.1992.tb17165.x; HOWELL ML, 1989, J BIOL CHEM, V264, P15268; KOHNO T, 1990, METHOD ENZYMOL, V185, P187; KOSEN PA, 1988, BIOCHEMISTRY-US, V27, P2775, DOI 10.1021/bi00408a018; LENTZ TL, 1991, BIOCHEMISTRY-US, V30, P10949, DOI 10.1021/bi00109a020; LOVE RA, 1986, PROTEIN ENG, V1, P37, DOI 10.1093/protein/1.1.37; LOW BW, 1979, SNAKE VENOMS, P213; MENEZ A, 1992, P ROY SOC EDINB B, V99, P83, DOI 10.1017/S0269727000013075; OSWALD RE, 1991, BIOCHEMISTRY-US, V30, P4901, DOI 10.1021/bi00234a010; PARK CS, 1991, P NATL ACAD SCI USA, V88, P2046, DOI 10.1073/pnas.88.6.2046; PILLET L, 1993, J BIOL CHEM, V268, P909; SEELY PJ, 1991, PROTEIN REFOLDING, P206; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TSERNOGLOU D, 1978, MOL PHARMACOL, V14, P710; TSERNOGLOU D, 1976, FEBS LETT, V68, P1, DOI 10.1016/0014-5793(76)80390-0; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WILSON PT, 1985, P NATL ACAD SCI USA, V82, P8790, DOI 10.1073/pnas.82.24.8790; WU SH, 1983, ARCH BIOCHEM BIOPHYS, V227, P111, DOI 10.1016/0003-9861(83)90353-3	36	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11178	11185						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157645				2022-12-25	WOS:A1994NF96600033
J	CORIN, SJ; JUHASZ, O; ZHU, L; CONLEY, P; KEDES, L; WADE, R				CORIN, SJ; JUHASZ, O; ZHU, L; CONLEY, P; KEDES, L; WADE, R			STRUCTURE AND EXPRESSION OF THE HUMAN SLOW-TWITCH SKELETAL-MUSCLE TROPONIN-I GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTORS; MESSENGER-RNA; CDNA CLONE; ACTIN GENE; PROMOTER; SEQUENCE; UPSTREAM; ENHANCER; ELEMENTS	The contractile protein troponin I is encoded by a multigene family whose members are expressed differentially in various classes of muscle fibers. In vertebrates, the ''slow'' isoform of troponin I is expressed during early heart and skeletal muscle development but is restricted to slow twitch skeletal muscle in the adult. This diverse expression pattern offers an opportunity to study the regulation of a single gene within different developmental contexts. To initiate such studies, we have cloned the gene encoding the human slow twitch skeletal muscle isoform of troponin I and have identified 5'-flanking sequences required for its expression in skeletal muscle cells. The slow troponin I gene spans 12.5 kilobases and is divided into nine exons. In contrast to many muscle-specific genes, the troponin I promoter does not contain consensus CCAAT or TATA elements. Moreover, the sequence from -9 to +11 resembles an ''initiator element'' previously shown to direct transcription of some tissue-specific genes lacking TATA boxes (Smale, S. T, and Baltimore, D. (1989) Cell 57, 103-113; Brand, N. J., Petkovich, M., and Ghambon, P. (1990) Nucleic Acids Res. 18, 6799-6806; Weis, L., and Reinberg, D. (1992) FASEB J. 6, 3300-3309). A transcriptional fusion construct, comprising 4.2 kilobases of troponin I 5'-flanking DNA linked to the bacterial chloramphenicol acetyltransferase gene, exhibited cell type-specific and developmentally regulated expression. A muscle-specific enhancer regulated slow troponin I promoter activity.	UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,PROGRAM MOLEC & CELLULAR BIOL,BALTIMORE,MD 21201; COR THERAPEUT,S SAN FRANCISCO,CA 94080; UNIV SO CALIF,SCH MED,INST MED GENET,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MED,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT BIOCHEM & MOLEC BIOL,LOS ANGELES,CA 90033	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Southern California; University of Southern California; University of Southern California								ARNOTT S, 1980, NATURE, V283, P743, DOI 10.1038/283743a0; BALDWIN AS, 1985, P NATL ACAD SCI USA, V82, P8080, DOI 10.1073/pnas.82.23.8080; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; CHODOSH L, 1988, CURRENT PROTOCOLS MO, V2; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORZA L, 1993, DEV BIOL, V156, P253, DOI 10.1006/dbio.1993.1074; GREENE JM, 1989, CURRENT PROTOCOLS MO, V1; GUNNING P, 1991, FASEB J, V5, P3064, DOI 10.1096/fasebj.5.15.1835946; HANIFORD DB, 1983, NATURE, V302, P632, DOI 10.1038/302632a0; HASTINGS KEM, 1991, J BIOL CHEM, V266, P19659; HEILIG JS, 1989, CURRENT PROTOCOLS MO, V1; INNIS MA, 1990, PCR PROTOCOLS; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KINGSTON RE, 1989, CURRENT PROTOCOLS MO, V1; KOPPE RI, 1989, J BIOL CHEM, V264, P14327; LAMINS L, 1982, P NATL ACAD SCI USA, V79, P6453; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; NIKOVITS W, 1990, MOL CELL BIOL, V10, P3468, DOI 10.1128/MCB.10.7.3468; NIKOVITS W, 1986, NUCLEIC ACIDS RES, V14, P3377, DOI 10.1093/nar/14.8.3377; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; Rosenthal N, 1989, CURR OPIN CELL BIOL, V1, P1094, DOI 10.1016/S0955-0674(89)80056-0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SASSONECORSI P, 1985, NATURE, V313, P458, DOI 10.1038/313458a0; SCHIAFFINO S, 1993, TRENDS CARDIOVAS MED, V3, P12, DOI 10.1016/1050-1738(93)90022-X; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; SUTHERLAND CJ, 1993, DEV DYNAM, V196, P25, DOI 10.1002/aja.1001960104; WADE R, 1990, DEV BIOL, V142, P270, DOI 10.1016/0012-1606(90)90348-M; WADE R, 1990, GENOMICS, V7, P346, DOI 10.1016/0888-7543(90)90168-T; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	47	67	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10651	10659						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144655				2022-12-25	WOS:A1994NF01700070
J	DOIRON, B; CUIF, MH; KAHN, A; DIAZGUERRA, MJM				DOIRON, B; CUIF, MH; KAHN, A; DIAZGUERRA, MJM			RESPECTIVE ROLES OF GLUCOSE, FRUCTOSE, AND INSULIN IN THE REGULATION OF THE LIVER-SPECIFIC PYRUVATE-KINASE GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							POST-TRANSCRIPTIONAL REGULATION; RAT HEPATOCYTES; GLUCOKINASE GENE; PRIMARY CULTURES; EXPRESSION; STIMULATION; PHOSPHORYLATION; INDUCTION; PROTEIN; CELLS	The L-type pyruvate kinase (L-PK) is a key enzyme of the glycolytic pathway mainly expressed in the liver. Rat liver contains a regulatory protein that inhibits glucokinase (GK) activity. The effect of this protein is greatly reinforced by the fructose 6-phosphate and antagonized by the fructose 1-phosphate (Van Schaftingen, E. (1989) fur. J. Biochem. 179, 179-184). In hepatocytes, fructose in low concentrations is phosphorylated into fructose 1-phosphate, and therefore is able to activate GK in the absence of insulin via the regulatory protein in the liver. In primary culture of rat hepatocytes, 0.2 mM fructose in the presence of 20 or 40 mM glucose stimulated the activity of the L-PK gene promoter fused with the chloramphenicol acetyltransferase reporter gene, regardless of the addition of insulin, through the glucose/insulin response element. A constitutive GK expression vector co-transfected with the L-PK/ chloramphenicol acetyltransferase construct is also able to confer an insulin-independent glucose responsiveness in hepatocytes. Thus, the insulin effect on glucose-dependent activation of the L-PK promoter is, under these experimental conditions, to permit glucose phosphorylation through the stimulation of the GK synthesis. In the presence of glucose, the L-PK promoter can also be activated by a post-translational GK activation, mediated by a low concentration of fructose acting via the regulatory protein of glucokinase.	INST COCHIN GENET MOLEC, INSERM, U129, F-75014 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Díaz-Guerra, María José M/M-2855-2014	Díaz-Guerra, María José M/0000-0003-3843-3912				BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; DAVIES DR, 1990, EUR J BIOCHEM, V192, P283, DOI 10.1111/j.1432-1033.1990.tb19225.x; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DECAUX JF, 1991, J BIOL CHEM, V266, P3432; DETHEUX M, 1993, FEBS LETT, V321, P111, DOI 10.1016/0014-5793(93)80089-D; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; GIFFHORNKATZ S, 1986, EUR J BIOCHEM, V159, P513, DOI 10.1111/j.1432-1033.1986.tb09916.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANNER D, 1990, J BIOL CHEM, V265, P10173; HAYZER DJ, 1990, BIOCHEM J, V270, P261, DOI 10.1042/bj2700261; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; KOGAWA M, 1983, ACTA ENDOCRINOL-COP, V103, P385, DOI 10.1530/acta.0.1030385; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MARIE S, 1993, J BIOL CHEM, V268, P23881; MATSUDA T, 1990, J BIOCHEM-TOKYO, V108, P778, DOI 10.1093/oxfordjournals.jbchem.a123280; MUNNICH A, 1987, J BIOL CHEM, V262, P17065; NOGUCHI T, 1985, J BIOL CHEM, V260, P4393; NOUSPIKEL T, 1992, EUR J BIOCHEM, V210, P365, DOI 10.1111/j.1432-1033.1992.tb17430.x; Sambrook J, 1989, MOL CLONING LABORATO; SLEIN MW, 1963, METHOD ENZYMAT AN, P1238; Van den Berghe G, 1986, Prog Biochem Pharmacol, V21, P1; VANDERCAMMEN A, 1990, EUR J BIOCHEM, V191, P483, DOI 10.1111/j.1432-1033.1990.tb19147.x; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P173; VANSCHAFTINGEN E, 1991, FASEB J, V5, P326, DOI 10.1096/fasebj.5.3.2001793; VANSCHAFTINGEN E, 1992, ADV ENZYME REGUL, V32, P133; VAULONT S, 1986, J BIOL CHEM, V261, P7621	27	82	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10213	10216						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144600				2022-12-25	WOS:A1994NF01700008
J	MORII, H; KOGA, Y				MORII, H; KOGA, Y			ASYMMETRICAL TOPOLOGY OF DIETHER-TYPE AND TETRAETHER-TYPE POLAR LIPIDS IN MEMBRANES OF METHANOBACTERIUM-THERMOAUTOTROPHICUM CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHER LIPIDS; ARCHAEBACTERIUM; PHOSPHOLIPIDS; PSEUDOMUREIN; PURIFICATION; WOLFEI; ACID	We investigated the distribution of diether polar lipids between the inner and outer leaflets of the membrane of Methanobacterium thermoautotrophicum comparing the orientation of tetraether polar lipids, which constitute a monolayer in the same membrane. Three kinds of reactions were employed for intact cells or protoplasts and unsealed membrane fragments prepared from the organism: glycosidase digestion for glycolipids, NaIO4 oxidation for glycolipids and inositol lipids, and trinitrophenylation for aminophospholipids. The results indicated that (a) most gentiobiose residues of both diether and tetraether polar lipids were exposed on the outside of the cells; (b) serine and inositol residues of both diether and tetraether polar lipids were mainly oriented to the cytoplasmic surface of the membrane; and (c) approximately 80% of archaetidylethanolamine (diether type) was distributed in the outer leaflet of the membrane bilayer, while only 25% of the ethanolamine residue of gentiobiosyl caldarchaetidylethanolamine (tetraether type) was oriented to the outer surface of the membrane. These results, except for ethanolamine lipids, are consistent with the hypothesis that the tetraether polar lipids are synthesized from the corresponding diether polar lipid precursors that have been already substituted by polar groups in the membrane by head-to-head condensation without rearrangement of lipids.	UNIV OCCUPAT & ENVIRONM HLTH,DEPT CHEM,YAHATANISHI KU,KITAKYUSHU,FUKUOKA 807,JAPAN	University of Occupational & Environmental Health - Japan								BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BISHOP DG, 1977, EUR J BIOCHEM, V80, P381, DOI 10.1111/j.1432-1033.1977.tb11893.x; DEMANT EJF, 1979, EUR J BIOCHEM, V95, P613, DOI 10.1111/j.1432-1033.1979.tb13002.x; DEROSA M, 1983, J MEMBRANE SCI, V16, P287, DOI 10.1016/S0376-7388(00)81316-2; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; ELFERINK MGL, 1992, J BIOL CHEM, V267, P1375; FUHRHOP JH, 1986, SYST APPL MICROBIOL, V7, P272; GASCARD P, 1991, BIOCHIM BIOPHYS ACTA, V1069, P27, DOI 10.1016/0005-2736(91)90100-M; KIENER A, 1987, J BACTERIOL, V169, P1010, DOI 10.1128/jb.169.3.1010-1016.1987; KONIG H, 1983, H-S Z PHYSIOL CHEM, V364, P627, DOI 10.1515/bchm2.1983.364.1.627; Langworthy T.A., 1985, BACTERIA, V8, P459; LO SL, 1990, BIOCHEM BIOPH RES CO, V167, P238, DOI 10.1016/0006-291X(90)91756-I; MORII H, 1993, FEMS MICROBIOL LETT, V109, P283, DOI 10.1111/j.1574-6968.1993.tb06182.x; MORII H, 1992, J FERMENT BIOENG, V73, P6, DOI 10.1016/0922-338X(92)90222-G; MORII H, 1988, AGR BIOL CHEM TOKYO, V52, P3149, DOI 10.1080/00021369.1988.10869195; NISHIHARA M, 1989, BIOCHEMISTRY-US, V28, P95, DOI 10.1021/bi00427a014; NISHIHARA M, 1987, J BIOCHEM-TOKYO, V101, P1007, DOI 10.1093/oxfordjournals.jbchem.a121942; NISHIHARA M, 1988, J LIPID RES, V29, P384; NISHIHARA M, 1987, J BIOCHEM-TOKYO, V101, P997, DOI 10.1093/oxfordjournals.jbchem.a121969; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; PATON JC, 1978, J BACTERIOL, V135, P393, DOI 10.1128/JB.135.2.393-401.1978; ROTHMAN JE, 1977, J MOL BIOL, V110, P603, DOI 10.1016/S0022-2836(77)80114-9	22	19	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10492	10497						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144633				2022-12-25	WOS:A1994NF01700047
J	SHAINSKAYA, A; KARLISH, SJD				SHAINSKAYA, A; KARLISH, SJD			EVIDENCE THAT THE CATION OCCLUSION DOMAIN OF NA/K-ATPASE CONSISTS OF A COMPLEX OF MEMBRANE-SPANNING SEGMENTS - ANALYSIS OF LIMIT MEMBRANE-EMBEDDED TRYPTIC FRAGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SARCOPLASMIC-RETICULUM; FUNCTIONAL EXPRESSION; TRANSMEMBRANE DOMAIN; PLASMA-MEMBRANE; ALPHA-SUBUNITS; RAPID RELEASE; RB+-OCCLUSION; BETA-SUBUNIT; NA+,K+-ATPASE	Digestion of renal Na/K-ATPase with trypsin, in the presence of rubidium and absence of calcium ions, produces so called ''19-kDa membranes,'' containing a C-terminal 19-kDa and smaller fragments (8-12 kDa) of the alpha chain, and a beta chain either intact or split into two fragments (Karlish, S. J. D., Goldshleger, R., and Stein, W. D. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 4566-4570). Cation occlusion is intact. The cation sites are thought to be located within trans-membrane segments, but the identity and number of segments involved is unknown. Analysis of Ca2+-induced sensitization of 19-kDa membranes to proteolysis, and characterization of the limit membrane-embedded fragments, has provided some insight into this question. Calcium ions have been shown to compete with two rubidium ions for occlusion sites on 19-kDa membranes, with a high affinity (K-D approximate to 2.8 mu M, pH 7.5, 20 degrees C). The kinetics of displacement of rubidium by calcium ions indicate that competition is direct and is not an allosteric antagonism. At 37 degrees C, reversible displacement of rubidium ions by calcium ions is followed by an irreversible thermal inactivation of rubidium occlusion. Calcium ions partially protect rubidium occlusion sites against modification by the carboxyl reagent, N,N'-dicyclohexylcarbodiimide. We propose that calcium ions, like rubidium ions, recognize carboxyl groups at the entrance to the cation sites, but the calcium ions do not become occluded and thus fail to protect 19-kDa membranes against further proteolysis or thermal inactivation. Upon displacement of occluded rubidium, trypsin digests the Ca2+-bound and thermally inactivated 19-kDa membranes, and all of the membrane-embedded fragments are truncated or are split in these conditions. A related finding is that the C-terminal sequence of the 19-kDa fragment (and alpha chain), E-T-Y-Y, is digested by carboxypeptidase Y only when the rubidium occlusion is inactivated. Identification of the limit tryptic fragments indicates that polypeptide loops and the C-terminal tail of the 19-kDa fragment, N and C termini of the smaller fragments of the alpha chain, and both N and C termini of a 16-kDa fragment of the beta chain are split by proteolytic enzymes upon displacement of occluded rubidium. We conclude that all fragments of 19-kDa membranes form a complex, which is stabilized and protected against proteolytic enzymes upon occlusion of rubidium ions, and which relaxes upon displacement of occluded rubidium. The cation occlusion ''cage'' presumably consists of ligating groups from several trans-membrane segments. The interactions between the rubidium occlusion sites and protected segments of the protein are necessarily reciprocal, and so they must also affect properties of rubidium occlusion. These interactions may be either direct or indirect such as those between the 16-kDa fragment of the beta chain and occlusion sites within transmembrane segments of the alpha chain. The arrangement of the limit tryptic fragments in the membrane is discussed within the framework of possible topological models. The results are suggestive of a 10-segment model of the alpha chain but do not exclude certain 8-segment models.	WEIZMANN INST SCI, DEPT BIOCHEM, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science					NIGMS NIH HHS [GM32286] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032286] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTOLOVIC R, 1991, EUR J BIOCHEM, V199, P195, DOI 10.1111/j.1432-1033.1991.tb16109.x; ARGUELLO JM, 1991, J BIOL CHEM, V266, P14627; BAYER R, 1990, BIOCHEMISTRY-US, V29, P2251, DOI 10.1021/bi00461a007; BURGENERKAIRUZ P, 1991, FEBS LETT, V290, P83, DOI 10.1016/0014-5793(91)81231-V; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DAVID P, 1991, J BIOL CHEM, V266, P14896; DAVID P, 1992, J BIOL CHEM, V267, P1141; DEWEER P, 1988, ANNU REV PHYSIOL, V50, P225, DOI 10.1146/annurev.physiol.50.1.225; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P433; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; FORBUSH B, 1988, J BIOL CHEM, V263, P7970; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GLYNN IM, 1985, J PHYSIOL-LONDON, V368, P453, DOI 10.1113/jphysiol.1985.sp015868; GOLDSHLEGER R, 1990, J MEMBRANE BIOL, V113, P139, DOI 10.1007/BF01872888; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; GOLDSHLEGER R, 1993, 7TH P INT C SOD PUMP; GOLDSHLEGGER R, 1987, J PHYSIOL-LONDON, V387, P331, DOI 10.1113/jphysiol.1987.sp016576; HENAO F, 1992, J BIOL CHEM, V267, P10302; JAISSER F, 1992, J BIOL CHEM, V267, P16895; Jorgensen P L, 1974, Methods Enzymol, V32, P277; JORGENSEN PL, 1982, J BIOL CHEM, V257, P7435; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MODYANOV N, 1992, ACTA PHYSIOL SCAND, V146, P49; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; OR E, 1993, J BIOL CHEM, V268, P16929; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P269, DOI 10.1016/0014-5793(87)80676-2; PALMGREN MG, 1991, J BIOL CHEM, V266, P20470; PEDEMONTE CH, 1986, J BIOL CHEM, V261, P3632; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHANI M, 1987, BIOCHIM BIOPHYS ACTA, V904, P13, DOI 10.1016/0005-2736(87)90081-2; SHANISEKLER M, 1988, J BIOL CHEM, V263, P19331; THIBAULT D, 1993, BIOCHEMISTRY-US, V32, P2813, DOI 10.1021/bi00062a012; VANHUYSSE JW, 1993, BIOCHEMISTRY-US, V32, P819, DOI 10.1021/bi00054a012; VASSALO PM, 1986, J BIOL CHEM, V261, P16957	41	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10780	10789						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144667				2022-12-25	WOS:A1994NF01700089
J	HONG, JX; HAUN, RS; TSAI, SC; MOSS, J; VAUGHAN, M				HONG, JX; HAUN, RS; TSAI, SC; MOSS, J; VAUGHAN, M			EFFECT OF ADP-RIBOSYLATION FACTOR AMINO-TERMINAL DELETIONS ON ITS GTP-DEPENDENT STIMULATION OF CHOLERA-TOXIN ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING; PROTEIN ACTIVATORS; ADENYLATE-CYCLASE; BOVINE BRAIN; EXPRESSION; MEMBRANES	It has been proposed that the amino-terminal domain of ADP-ribosylation factor (ARF) is critical for its stimulation of cholera toxin ADP-ribosyltransferase activity. In this study, recombinant ARF1 (rARF1), rDELTA13ARF1 (recombinant ARF1 lacking the first 13 amino acids) and rPKA14ARF1 (recombinant ARF1 in which the first 14 amino acids were replaced by the first 7 amino acids of the cAMP-dependent protein kinase catalytic subunit) were used to assess the effect of the amino terminus on the ability of ARF to enhance ADP-ribosylation of agmatine by the cholera toxin A subunit. The GTP-dependent ARF activities of rDELTA13ARF1 and rPKA14ARF1 were similar to that of rARF1, whereas the GTP requirement for half-maximal activation of cholera toxin A, was somewhat higher for rARF1 than it was for rDELTA13ARF1 and rPKA14ARF1. These results are consistent with the view that the amino terminus of ARF1 is not critical for its action as a GTP-dependent activator of cholera toxin.			HONG, JX (corresponding author), NHLBI,CELLULAR METAB LAB,ROOM 5N-307,BLDG 10,BETHESDA,MD 20892, USA.							BALCH WE, 1992, J BIOL CHEM, V267, P13053; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; HAUN RS, 1992, BIOTECHNIQUES, V13, P515; HAUN RS, 1993, J BIOL CHEM, V268, P7064; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KHAN R, 1992, J BIOL CHEM, V267, P13039; KUNZ BC, 1993, BIOCHEMISTRY-US, V32, P6643, DOI 10.1021/bi00077a017; LEE CM, 1992, J BIOL CHEM, V267, P9028; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MOSS J, 1981, P NATL ACAD SCI USA, V78, P4806; MURTAGH JJ, 1992, J BIOL CHEM, V267, P9654; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1992, J BIOL CHEM, V267, P17766; SERVENTI IM, 1993, J BIOL CHEM, V268, P4863; SERVENTI IM, 1991, J BIOL CHEM, V268, P23053; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSAI SC, 1987, P NATL ACAD SCI USA, V84, P5139, DOI 10.1073/pnas.84.15.5139; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1991, J BIOL CHEM, V266, P8213; TSAI SC, 1993, J BIOL CHEM, V268, P10820; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P6272; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WALKER MW, 1992, J BIOL CHEM, V267, P3230; WEISS O, 1989, J BIOL CHEM, V264, P21066	29	49	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9743	9745						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144566				2022-12-25	WOS:A1994NE05300055
J	LARSSON, LG; PETTERSSON, M; OBERG, F; NILSSON, K; LUSCHER, B				LARSSON, LG; PETTERSSON, M; OBERG, F; NILSSON, K; LUSCHER, B			EXPRESSION OF MAD, MXI1, MAX AND C-MYC DURING INDUCED-DIFFERENTIATION OF HEMATOPOIETIC-CELLS - OPPOSITE REGULATION OF MAD AND C-MYC	ONCOGENE			English	Note							DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; MESSENGER-RNA; ONCOGENE; PROTEIN; FOS; COTRANSFORMATION; ONCOPROTEIN; INTERFERON; DOMAINS	The Myc proto-oncoprotein family is considered to play an important role in the control of cell growth and differentiation. It appears that the interaction of Myc with its heterodimeric partner Max is essential for Myc function. Recently two other partners of Max, called Mad and Mxi1, have been identified. In an effort to gain insight into the network of these four proteins we have started to analyse the expression of the c-myc, max, mad and mxi1 genes at the mRNA level during hematopoietic cell growth and differentation. In the human myeloid cell lines U-937, HL-60 and ML-1 c-myc expression was down-regulated as shown previously after induction of differentiation, whereas the expression of max was only slightly affected. In contrast to these two genes the expression of mad was induced upon differentiation in the three cell lines by TPA, retinoic acid, vitamin D3, dimethyl sulfoxide, and interferon-gamma and remained elevated for at least 3 days. A kinetic analysis showed that the induction of mad in U-937 in response to TPA was rapid (15 min) and at least in part transcriptional, reminiscent of immediate early genes. The expression of mxi1 was induced in U-937 by some inducers but not in HL-60 or ML-1. Its induction occurred slowly, peaking around 48 h. These analysis thus suggest that the expression of mad and c-myc is inversely regulated during induced hematopoietic differentiation.	UNIV UPPSALA,UNIV HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital	LARSSON, LG (corresponding author), HANNOVER MED SCH,INST MOLEK BIOL,KONSTANTY GUTSCHOW STR 8,D-30623 HANNOVER,GERMANY.		Larsson, Lars-Gunnar/D-9747-2012; Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMATI B, 1993, CELL, V72, P235; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KREZNER L, 1992, NATURE, V359, P426; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LARSSON LG, 1991, LEUKEMIA LYMPHOMA, V4, P193, DOI 10.3109/10428199109068065; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MILLER LJ, 1986, J IMMUNOL, V137, P2891; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; Nilsson K., 1980, INT S NEW TRENDS HUM, P271; OBERG F, 1991, P NATL ACAD SCI USA, V88, P5567, DOI 10.1073/pnas.88.13.5567; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; REDDY CD, 1992, ONCOGENE, V7, P2085; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; TODD RF, 1981, J IMMUNOL, V126, P1435; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; WATT SM, 1991, BLOOD, V78, P63; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	40	170	171	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1247	1252						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134128				2022-12-25	WOS:A1994NC04800030
J	SAIKUMAR, P; GABRIEL, JL; REDDY, EP				SAIKUMAR, P; GABRIEL, JL; REDDY, EP			THE MYB ONCOGENE PRODUCT INDUCES DNA-BENDING	ONCOGENE			English	Article							GENE V-MYB; C-MYB; BINDING DOMAIN; ESCHERICHIA-COLI; PROTO-ONCOGENE; TRANSCRIPTIONAL ACTIVATORS; CELLULAR PROGENITOR; TRANSFORMING GENE; TRANS-ACTIVATION; RNA-POLYMERASE	The nuclear oncogene v-myb and its cellular counterpart c-myb code for proteins that bind to DNA in a sequence specific manner and act as regulators of transcription. The Myb protein contains DNA binding and transregulatory domains which are important for its function. The DNA binding domain of Myb protein has been shown to contain three imperfectly conserved repeats of 50-52 aminoacids that constitute the amino terminal end. In this communication, we show that Myb protein induces conformational change in DNA after protein-DNA complex formation. Circular permutation assays indicate that Myb protein induces DNA bending at the site of binding. Phasing analysis confirm the DNA bending and allowed the detection of relative orientation of bend. Myb proteins which comprise only DNA-binding domains either with three repeats or two repeats also bend DNA in the same orientation as the larger proteins with both DNA-binding and transactivating domains. However, the transactivating region seems to influence the magnitude of bend angle. We used molecular modeling to analyse the structure of Myb-DNA complex formation resulting in the bending of DNA. Data presented here show that Myb protein, like other transcriptional regulators, bends DNA upon binding allowing the interaction of regulatory elements.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [P01CA052009, P30CA012227] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 12227, CA 52009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; BAUR CP, 1988, J MOL BIOL, V203, P1009, DOI 10.1016/0022-2836(88)90125-8; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DASGUPTA P, 1990, P NATL ACAD SCI USA, V87, P8090, DOI 10.1073/pnas.87.20.8090; DEVARGAS LM, 1989, SCIENCE, V244, P1457; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; FRIED MG, 1983, NUCLEIC ACIDS RES, V11, P141, DOI 10.1093/nar/11.1.141; GABRIEL JL, 1993, P NATL ACAD SCI USA, V90, P4186, DOI 10.1073/pnas.90.9.4186; GABRIEL JL, 1991, J THEOR BIOL, V151, P541, DOI 10.1016/S0022-5193(05)80369-8; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GARTENBERG MR, 1991, J MOL BIOL, V219, P217, DOI 10.1016/0022-2836(91)90563-L; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOBER JW, 1990, GENE DEV, V4, P1494, DOI 10.1101/gad.4.9.1494; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GROTEWOLD E, 1991, P NATL ACAD SCI USA, V88, P4587, DOI 10.1073/pnas.88.11.4587; HEUMANN H, 1988, EMBO J, V7, P4379, DOI 10.1002/j.1460-2075.1988.tb03336.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; JU QD, 1990, MOL CELL BIOL, V10, P5226, DOI 10.1128/MCB.10.10.5226; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KERPPOLA T, 1991, CELL, V66, P1; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KOSTREWA D, 1991, NATURE, V349, P178, DOI 10.1038/349178a0; LEPRINCE D, 1983, EMBO J, V2, P1073, DOI 10.1002/j.1460-2075.1983.tb01548.x; MAROCCO A, 1989, MOL GEN GENET, V216, P183, DOI 10.1007/BF00334354; MCALLISTER CF, 1989, J BIOL CHEM, V264, P10451; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PECK LJ, 1981, NATURE, V292, P375, DOI 10.1038/292375a0; RHODES D, 1981, NATURE, V292, P378, DOI 10.1038/292378a0; ROJO F, 1991, EMBO J, V10, P3429, DOI 10.1002/j.1460-2075.1991.tb04907.x; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SALVO JJ, 1987, NUCLEIC ACIDS RES, V15, P9771, DOI 10.1093/nar/15.23.9771; SALVO JJ, 1988, EMBO J, V7, P3609, DOI 10.1002/j.1460-2075.1988.tb03239.x; SNYDER UK, 1989, NATURE, V341, P255, DOI 10.1038/341255a0; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WILLIAMS JS, 1988, MOL CELL BIOL, V8, P2763, DOI 10.1128/MCB.8.7.2763; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0; ZINKEL SS, 1991, J MOL BIOL, V219, P201, DOI 10.1016/0022-2836(91)90562-K	69	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1279	1287						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134132				2022-12-25	WOS:A1994NC04800035
J	DASSO, LLT; TAYLOR, CW				DASSO, LLT; TAYLOR, CW			INTERACTIONS BETWEEN CA2+-MOBILIZING RECEPTORS AND THEIR G-PROTEINS IN HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; CYTOPLASMIC FREE CALCIUM; HUMAN-PLATELETS; FURA-2-LOADED HEPATOCYTES; GUANINE-NUCLEOTIDES; ADENYLATE-CYCLASE; RAT HEPATOCYTES; PHOSPHOLIPASE-C; BINDING; AGONIST	In hepatocytes, different receptors that share an ability to stimulate inositol 1,4,5-trisphosphate formation by activating guanine nucleotide-binding proteins (G proteins) evoke Ca2+ signals that are characteristic of the receptor that evoked them. High affinity, guanine nucleotide-sensitive binding of agonists to their receptors provides a convenient means of assessing receptor-G protein interactions. We used these methods to examine the extent to which different Ca2+-mobilizing receptors share G protein pools. Although our earlier results (Dasso, L. L. T., and Taylor, C. W. (1992) Mol. Pharmacol. 42, 453-457) showed that activated V-1-vasopressin receptors prevented alpha(1)-adrenoreceptors from associating with G proteins, our present results show that neither alpha(1)-adrenergic agonists nor angiotensin II influences the interaction between V-1 receptors and their G proteins, This asymmetric scavenging of G proteins by alpha(1)-adrenoreceptors and V-1 receptors is not a consequence of there being more of the latter and may result either from V-1 receptors binding more tightly to G proteins or from their ability to interact with a second G protein pool. We speculate that the different interactions among V-1 receptors, alpha(1)-adrenoreceptors, and their G proteins contribute to the differently shaped Ca2+ spikes evoked by these receptors.	DEPT PHARMACOL,CAMBRIDGE CB2 1QJ,CAMBS,ENGLAND				Taylor, Colin/G-2447-2010	Taylor, Colin/0000-0001-7771-1044	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAMSON SN, 1987, MOL PHARMACOL, V31, P103; Bockaert J, 1991, Curr Opin Neurobiol, V1, P32, DOI 10.1016/0959-4388(91)90008-U; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS G M, 1986, P311; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DASSO LLT, 1992, MOL PHARMACOL, V42, P453; DASSO LLT, 1991, BIOCHEM J, V280, P791, DOI 10.1042/bj2800791; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; FAIN JN, 1985, FEBS LETT, V192, P251, DOI 10.1016/0014-5793(85)80118-6; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FUXE K, 1988, ACTA PHYSIOL SCAND, V134, P317, DOI 10.1111/j.1748-1716.1988.tb08497.x; GOODHARDT M, 1982, J BIOL CHEM, V257, P1577; GOPALAKRISHNAN V, 1988, ENDOCRINOLOGY, V123, P922, DOI 10.1210/endo-123-2-922; GRAESER D, 1993, MOL PHARMACOL, V43, P434; GRANDT R, 1986, BIOCHEM J, V237, P669, DOI 10.1042/bj2370669; HAN C, 1987, MOL PHARMACOL, V32, P505; HOUSLAY MD, 1986, BIOCHEM J, V238, P109, DOI 10.1042/bj2380109; KAWANISHI T, 1989, J BIOL CHEM, V264, P12859; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1992, SCIENCE, V358, P424; LEE TWT, 1986, BIOCHEMISTRY-US, V25, P7009, DOI 10.1021/bi00370a038; MAY DC, 1988, BIOCHEMISTRY-US, V27, P4888, DOI 10.1021/bi00413a045; MOHELL N, 1985, EUR J PHARMACOL, V115, P231, DOI 10.1016/0014-2999(85)90695-8; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEUBIG RR, 1985, MOL PHARMACOL, V28, P475; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SANCHEZBUENO A, 1993, BIOCHEM J, V291, P163, DOI 10.1042/bj2910163; SANCHEZBUENO A, 1993, BIOCHEM J, V291, P169, DOI 10.1042/bj2910169; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TAYLOR CW, 1990, BIOCHEM J, V272, P1; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; TOLKOVSKY AM, 1978, BIOCHEMISTRY-US, V17, P3811, DOI 10.1021/bi00611a021; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; WOODS NM, 1987, CELL CALCIUM, V8, P79, DOI 10.1016/0143-4160(87)90038-8	37	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8647	8652						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132593				2022-12-25	WOS:A1994NB41100007
J	MILLER, MW; HANOVER, JA				MILLER, MW; HANOVER, JA			FUNCTIONAL NUCLEAR-PORES RECONSTITUTED WITH BETA-1-4 GALACTOSE-MODIFIED O-LINKED N-ACETYLGLUCOSAMINE GLYCOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE-EXTRACTS; XENOPUS EGGS; PROTEIN IMPORT; DNA-REPLICATION; COMPLEX GLYCOPROTEINS; ASSEMBLY INVITRO; TRANSPORT; IDENTIFICATION; GLYCOSYLATION; ENVELOPE	Nuclear pore proteins bearing O-linked N-acetylglucosamine (GlcNAc) are involved in nuclear transport, although a role for their glycosylation is not established. Xenopus egg extracts capable of reforming functional nuclei in vitro yielded nuclei with impaired transport and reduced nuclear pore density when depleted of wheat germ agglutinin-binding proteins. Many of the nuclear pores remaining in wheat germ agglutinin-depleted nuclei showed a striking loss of internal structure. Nuclear transport and normal nuclear pore structure were restored by the addition of nuclear pore glycoproteins from rat liver or Xenopus eggs. Glycoproteins modified by the addition of galactose to O-linked GlcNAc were also competent for assembling normal nuclear pores and restoring nuclear transport. Aphidicolin-sensitive DNA synthesis was unaffected by the removal or modification of O-linked GlcNAc glycoproteins. These data argue against a requirement for a lectin-like recognition of O-linked GlcNAc glycoproteins in nuclear pore assembly, nuclear transport, or DNA synthesis.	NIDDKD,BIOCHEM & METAB LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; CARMOFONSECA M, 1991, EUR J CELL BIOL, V55, P17; CARROLL SM, 1981, J BIOL CHEM, V256, P8357; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CORDES V, 1991, EUR J CELL BIOL, V55, P31; COX LS, 1992, J CELL SCI, V101, P43; DABAUVALLE MC, 1990, CHROMOSOMA, V100, P56, DOI 10.1007/BF00337603; DABAUVALLE MC, 1991, BIOL CELL, V72, P25, DOI 10.1016/0248-4900(91)90074-W; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FORBES DJ, 1983, CELL, V34, P13, DOI 10.1016/0092-8674(83)90132-0; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KELLY WG, 1993, J BIOL CHEM, V268, P10416; LENO GH, 1991, METHOD CELL BIOL, V36, P561; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1988, CELL BIOL INT REP, V12, P833, DOI 10.1016/0309-1651(88)90091-4; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; NEWMEYER DD, 1986, J CELL BIOL, V103, P2091, DOI 10.1083/jcb.103.6.2091; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; PARK MK, 1987, P NATL ACAD SCI USA, V84, P6462, DOI 10.1073/pnas.84.18.6462; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; REICHELT R, 1990, J CELL BIOL, V110, P883, DOI 10.1083/jcb.110.4.883; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; ROGERS GN, 1986, J BIOL CHEM, V261, P5947; SADLER JE, 1979, J BIOL CHEM, V254, P2112; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; STERNEMARR R, 1992, J CELL BIOL, V116, P271, DOI 10.1083/jcb.116.2.271; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; TRAYER IP, 1971, J BIOL CHEM, V246, P6666; VIGERS GPA, 1991, J CELL BIOL, V112, P545, DOI 10.1083/jcb.112.4.545; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WHYTOCK S, 1988, J MICROSC-OXFORD, V151, P115, DOI 10.1111/j.1365-2818.1988.tb04618.x; WOLFF B, 1988, EXP CELL RES, V178, P318, DOI 10.1016/0014-4827(88)90402-8; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	54	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9289	9297						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132666				2022-12-25	WOS:A1994NB41100097
J	MIYAZAWA, K; SHIMOMURA, T; NAKA, D; KITAMURA, N				MIYAZAWA, K; SHIMOMURA, T; NAKA, D; KITAMURA, N			PROTEOLYTIC ACTIVATION OF HEPATOCYTE GROWTH-FACTOR IN RESPONSE TO TISSUE-INJURY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE CHAIN FORM; SCATTER FACTOR; MESSENGER-RNA; MOLECULAR-CLONING; EPITHELIAL-CELLS; HEPATOPOIETIN-A; RAT HEPATOCYTES; PURIFICATION; RECEPTOR; LIVER	Hepatocyte growth factor (HGF) is a potent mitogen for hepatocytes and renal tubular epithelial cells and may play an important role in regeneration following hepatic and renal injury. HGF is first synthesized as a single chain precursor which is then converted to a heterodimeric form by proteolytic processing. This proteolytic conversion is required for HGF to function as a mitogen. In this study, we examined whether the proteolytic activation of HGF occurred in response to hepatic and renal injury. HGF remained as an inactive single chain form in the liver, kidney, lung, and spleen of normal rats. The production of HGF markedly increased in the liver after hepatotoxin treatment and in the kidney after nephrotoxin treatment. A significant portion of the increased HGF was converted to the active heterodimeric form, whereas in other tissues, conversion did not occur although the production of HGF increased in some of them. Furthermore, an enzymatic activity that converts the single chain form of HGF to the active heterodimeric form was detected in the injured liver but not in the normal liver. These results indicate that HGF is proteolytically activated in response to tissue injury, and this activation is mediated by an enzymatic activity which is induced exclusively in the injured tissues. Thus, the proteolytic activation system functions in vivo as a mechanism for localizing HGF activities to injured tissues.	KANSAI MED UNIV, INST LIVER RES, MORIGUCHI, OSAKA 570, JAPAN; MITSUBISHI KASEI CORP, RES CTR, MIDORI KU, YOKOHAMA 227, JAPAN	Kansai Medical University			MIYAZAWA, KEIJI/I-9713-2014					ASAMI O, 1991, J BIOCHEM-TOKYO, V109, P8; BIRCH HE, 1986, J BIOL CHEM, V261, P8077; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; COULOMBE JJ, 1963, CLIN CHEM, V9, P102; DIRENZO MF, 1991, ONCOGENE, V6, P1997; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HERNANDEZ J, 1992, J CELL PHYSIOL, V150, P116, DOI 10.1002/jcp.1041500116; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; IGAWA T, 1993, AM J PHYSIOL, V265, pF63; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KAPLAN AP, 1988, METHOD ENZYMOL, V163, P3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; OKAJIMA A, 1990, EUR J BIOCHEM, V193, P375, DOI 10.1111/j.1432-1033.1990.tb19349.x; OKAJIMA A, 1993, EUR J BIOCHEM, V213, P113, DOI 10.1111/j.1432-1033.1993.tb17740.x; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SHIMA N, 1991, BIOCHEM BIOPH RES CO, V180, P1151, DOI 10.1016/S0006-291X(05)81187-8; SHIMOMURA T, 1992, CYTOTECHNOLOGY, V8, P219, DOI 10.1007/BF02522039; SHIMOMURA T, 1993, J BIOL CHEM, V268, P22927; STRAIN AJ, 1991, J CLIN INVEST, V87, P1853, DOI 10.1172/JCI115207; TAJIMA H, 1992, J BIOCHEM-TOKYO, V111, P401, DOI 10.1093/oxfordjournals.jbchem.a123769; TAMURA M, 1993, J BIOL CHEM, V268, P8140; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; TSUBOUCHI H, 1991, HEPATOLOGY, V13, P1; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WROBLEWSKI F, 1956, P SOC EXP BIOL MED, V91, P569; ZARNEGAR R, 1989, CANCER RES, V49, P3314	38	216	222	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8966	8970						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132634				2022-12-25	WOS:A1994NB41100053
J	LETEURTRE, F; KOHLHAGEN, G; FESEN, MR; TANIZAWA, A; KOHN, KW; POMMIER, Y				LETEURTRE, F; KOHLHAGEN, G; FESEN, MR; TANIZAWA, A; KOHN, KW; POMMIER, Y			EFFECTS OF DNA METHYLATION ON TOPOISOMERASE-I AND TOPOISOMERASE-II CLEAVAGE ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC PROTOONCOGENE; CPG BINDING-PROTEIN; HEAT-SHOCK GENES; ANTITUMOR DRUGS; CYTOSINE METHYLATION; SV40 DNA; SITES; SEQUENCE; CAMPTOTHECIN; CHROMATIN	DNA methylation is deregulated during oncogenesis. Since several major anti-cancer drugs act on topoisomerases, we investigated the effects of cytosine methylation on topoisomerase cleavage activities. Both topoisomerase I and II cleavage patterns were modified by CpG methylation in c-myc gene DNA fragments. Topoisomerase II changes, mainly cleavage reduction, occurred for methylation sites within 7 base pairs from the topoisomerase II breaks and were different for VM-26 and azatoxin. For topoisomerase I, cleavage enhancement as well as suppression were observed. Using synthetic methylated oligonucleotides, we show that hemimethylation is sufficient to alter topoisomerase I activity. Cytosine methylation on the scissile strand within the topoisomerase I consensus sequence had strong effects. Cleavage was stimulated by methylation at position -4 and was strongly inhibited by methylation at position -3 (with position -1 being the enzyme linked nucleotide). This inhibitory effect was attributed to the presence of a methyl group in the major groove, since the transition uracil to thymine also inhibited cleavage. Altogether these results suggest an interaction of topoisomerase I with the DNA major grove at positions -3 and -4. In addition, DNA methylation may have profound effects on the activity of topoisomerases and may alter the distribution of cleavage sites produced by anticancer drugs in chromatin.	NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,MOLEC PHARMACOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Francois, Leteurtre/0000-0001-7373-6180				[Anonymous], DEV CANC CHEMOTHERAP; BEDNARIK DP, 1991, NEW BIOL, V3, P969; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P4553, DOI 10.1093/nar/18.15.4553; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; CULOTTA V, 1988, CELL, V52, P585, DOI 10.1016/0092-8674(88)90471-0; DARBY MK, 1986, EMBO J, V5, P2257, DOI 10.1002/j.1460-2075.1986.tb04493.x; EDWARDS KA, 1982, NUCLEIC ACIDS RES, V10, P2565, DOI 10.1093/nar/10.8.2565; FLEISCHMANN G, 1984, P NATL ACAD SCI-BIOL, V81, P6958, DOI 10.1073/pnas.81.22.6958; GILMOUR DS, 1987, MOL CELL BIOL, V7, P141, DOI 10.1128/MCB.7.1.141; HAUSHEER FH, 1989, CARCINOGENESIS, V10, P1131, DOI 10.1093/carcin/10.6.1131; HODGESGARCIA Y, 1992, BIOCHEMISTRY-US, V31, P7595, DOI 10.1021/bi00148a022; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIEH T-S, 1992, Current Opinion in Cell Biology, V4, P396, DOI 10.1016/0955-0674(92)90004-V; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JAXEL C, 1991, J BIOL CHEM, V266, P20418; JAXEL C, 1988, NUCLEIC ACIDS RES, V16, P11157, DOI 10.1093/nar/16.23.11157; KAS E, 1992, EMBO J, V11, P705, DOI 10.1002/j.1460-2075.1992.tb05103.x; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KITAMURA Y, 1992, P NATL ACAD SCI USA, V89, P5532, DOI 10.1073/pnas.89.12.5532; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; KREUZER KN, 1984, J BIOL CHEM, V259, P5339; KROEGER PE, 1992, BIOCHEMISTRY-US, V31, P2492, DOI 10.1021/bi00124a008; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LETEURTRE F, 1993, BIOCHEMISTRY-US, V32, P8955, DOI 10.1021/bi00085a029; LETEURTRE F, 1992, CANCER RES, V52, P4478; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LUND K, 1990, J BIOL CHEM, V265, P13856; MAKOS M, 1993, CANCER RES, V53, P2719; MALINEN T, 1991, BLOOD, V77, P2435; MINFORD J, 1986, BIOCHEMISTRY-US, V25, P9, DOI 10.1021/bi00349a002; NELKIN BD, 1991, BLOOD, V77, P2431; NYCE J, 1989, CANCER RES, V49, P5829; NYCE J, 1993, P NATL ACAD SCI USA, V90, P2960, DOI 10.1073/pnas.90.7.2960; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; ONO T, 1989, MUTAT RES, V219, P39, DOI 10.1016/0921-8734(89)90039-8; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; PARKER LH, 1993, J MOL BIOL, V231, P6, DOI 10.1006/jmbi.1993.1252; POMMIER Y, 1992, CANCER RES, V52, P3125; POMMIER Y, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P215; POMMIER Y, 1991, J MOL BIOL, V222, P909, DOI 10.1016/0022-2836(91)90585-T; POMMIER Y, 1993, CAUSES CONSEQUENCES, P277; Pommier Y, 1993, CANCER CHEMOTHERAPY, P214; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; RIOU JF, 1989, BIOCHEMISTRY-US, V28, P9104, DOI 10.1021/bi00449a022; RIOU JF, 1986, BIOCHEM BIOPH RES CO, V137, P154, DOI 10.1016/0006-291X(86)91189-7; RIOU JF, 1986, BIOCHEM PHARMACOL, V35, P4409, DOI 10.1016/0006-2952(86)90756-2; ROWE TC, 1986, MOL CELL BIOL, V6, P985, DOI 10.1128/MCB.6.4.985; SASAKI T, 1992, MOL CELL BIOL, V12, P3819, DOI 10.1128/MCB.12.9.3819; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; STEVNSNER T, 1989, J BIOL CHEM, V264, P10110; STEWART AF, 1990, CELL, V60, P141; SUETAKE I, 1993, NUCLEIC ACIDS RES, V21, P2125, DOI 10.1093/nar/21.9.2125; TAN KB, 1989, J NATL CANCER I, V81, P1732, DOI 10.1093/jnci/81.22.1732; UDVARDY A, 1986, J MOL BIOL, V191, P231, DOI 10.1016/0022-2836(86)90260-3; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; YU BW, 1993, J BIOL CHEM, V268, P19586; ZWELLING LA, 1985, CANCER METAST REV, V4, P263, DOI 10.1007/BF00048092	66	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7893	7900						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132507				2022-12-25	WOS:A1994NB40900013
J	RANCANO, C; RUBIO, T; CORREAS, I; ALONSO, MA				RANCANO, C; RUBIO, T; CORREAS, I; ALONSO, MA			GENOMIC STRUCTURE AND SUBCELLULAR-LOCALIZATION OF MAL, A HUMAN T-CELL-SPECIFIC PROTEOLIPID PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; NERVOUS-SYSTEM MYELIN; TRANSMEMBRANE PROTEINS; ENDOPLASMIC-RETICULUM; CHROMAFFIN GRANULES; MEMBRANE-PROTEIN; PROLINE RESIDUES; PROTON CHANNEL; GENE; SEQUENCE	Genomic DNA clones containing the T-cell-specific human MAL gene were isolated. Restriction and sequence analysis revealed four exons and three introns. Each hydrophobic segment of MAL together with its adjacent hydrophilic sequence correlates closely with one exon of the gene. RNase protection analysis revealed that the previously described MAL mRNA, which contains the sequences present in the four exons, is the mRNA species predominant in T-cells. A remarkable similarity was found between the hydrophobicity pattern of MAL and those of the peripheral membrane protein 22 (PMP-22) and the 16-kDa proteolipid of vacuolar H+-ATPases. Direct evidence supporting that MAL is a proteolipid was obtained by extracting bacterial lysates expressing recombinant MAL protein with lipophilic solvents used to extract lipids. The use of two different antibodies raised against distinct peptides from the MAL molecule has allowed the localization of MAL in the endoplasmic reticulum of T-cells. This subcellular localization is in agreement with the presence of a RWKSS motif in the COOH-terminal tail of MAL, next to its last putative transmembrane domain, that fits with one of the consensus sequences (RXKXX) for residency in the endoplasmic reticulum for transmembrane proteins. A possible function for MAL protein in T-cells is discussed based on its subcellular localization and the unique lipid-like properties of the proteolipid proteins.	UNIV AUTONOMA MADRID,CONSEJO SUPER INVEST CIENT,CTR BIOL MOLEC SEVERO OCHOA,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Correas, Isabel/O-4061-2018; Alonso, Miguel A/J-3945-2016	Correas, Isabel/0000-0002-2286-186X; Alonso, Miguel A/0000-0002-7001-8826				ALONSO MA, 1987, P NATL ACAD SCI USA, V84, P1997, DOI 10.1073/pnas.84.7.1997; ALONSO MA, 1988, IMMUNOGENETICS, V27, P91, DOI 10.1007/BF00351081; BIRMAN S, 1990, FEBS LETT, V261, P303, DOI 10.1016/0014-5793(90)80577-6; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; BULINSKI JC, 1986, METHOD ENZYMOL, V184, P453; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DERMIETZEL R, 1989, FEBS LETT, V253, P1, DOI 10.1016/0014-5793(89)80917-2; DIEHL HJ, 1986, P NATL ACAD SCI USA, V83, P9807, DOI 10.1073/pnas.83.24.9807; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FILLINGAME RH, 1991, J BACTEIROL, V173, P2639; FINBOW ME, 1992, PROTEIN ENG, V5, P7, DOI 10.1093/protein/5.1.7; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; HARLOW E, 1988, ANTIBODIES LABORATOR; HASEBE M, 1992, BIOCHEM BIOPH RES CO, V183, P856, DOI 10.1016/0006-291X(92)90562-Y; INGRAHAM HA, 1986, MOL CELL BIOL, V6, P2923, DOI 10.1128/MCB.6.8.2923; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JONGSTRA J, 1987, J EXP MED, V165, P601, DOI 10.1084/jem.165.3.601; KANAZAWA H, 1983, MICROBIOL REV, V47, P285; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURSEN RA, 1984, P NATL ACAD SCI-BIOL, V81, P2912, DOI 10.1073/pnas.81.9.2912; LEITCH B, 1990, EXP CELL RES, V190, P218, DOI 10.1016/0014-4827(90)90189-H; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; MAELICKE A, 1988, TRENDS BIOCHEM SCI, V13, P199, DOI 10.1016/0968-0004(88)90081-3; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MEAGHER L, 1990, NUCLEIC ACIDS RES, V18, P6712, DOI 10.1093/nar/18.22.6712; MILLER MD, 1989, J IMMUNOL, V143, P2907; MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1990, J BIOL CHEM, V265, P20390; NELSON N, 1992, Current Opinion in Cell Biology, V4, P654, DOI 10.1016/0955-0674(92)90086-R; NODA M, 1983, NATURE, V305, P818, DOI 10.1038/305818a0; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; POPOT JL, 1991, J MEMBRANE BIOL, V120, P233, DOI 10.1007/BF01868534; ROSENBERG AH, 1987, GENE AMST, V56, P215; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANSOM MSP, 1992, PROTEIN ENG, V5, P53, DOI 10.1093/protein/5.1.53; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SCHANBERG LE, 1991, P NATL ACAD SCI USA, V88, P603, DOI 10.1073/pnas.88.2.603; SCHLESINGER MJ, 1981, ANNU REV BIOCHEM, V50, P193, DOI 10.1146/annurev.bi.50.070181.001205; SCHNEIDER A, 1992, NATURE, V358, P758, DOI 10.1038/358758a0; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; SLAVUTSKY I, 1986, CANCER GENET CYTOGEN, V21, P335, DOI 10.1016/0165-4608(86)90214-1; SMADJA N, 1983, CANCER GENET CYTOGEN, V8, P1, DOI 10.1016/0165-4608(83)90060-2; SMITH MW, 1988, J MOL EVOL, V27, P45, DOI 10.1007/BF02099729; SNIPES GJ, 1992, J CELL BIOL, V117, P225, DOI 10.1083/jcb.117.1.225; SPREYER P, 1991, EMBO J, V10, P3661, DOI 10.1002/j.1460-2075.1991.tb04933.x; SPURR NK, 1991, CYTOGENET CELL GENET, V58, P142, DOI 10.1159/000133162; STOFFEL W, 1984, P NATL ACAD SCI-BIOL, V81, P5012, DOI 10.1073/pnas.81.16.5012; SUTER U, 1992, NATURE, V356, P241, DOI 10.1038/356241a0; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	63	43	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8159	8164						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132541				2022-12-25	WOS:A1994NB40900052
J	OOHASHI, T; SUGIMOTO, M; MATTEI, MG; NINOMIYA, Y				OOHASHI, T; SUGIMOTO, M; MATTEI, MG; NINOMIYA, Y			IDENTIFICATION OF A NEW COLLAGEN-IV CHAIN, ALPHA-6(IV), BY CDNA ISOLATION AND ASSIGNMENT OF THE GENE TO CHROMOSOME XQ22, WHICH IS THE SAME LOCUS FOR COL4A5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; ALPORT SYNDROME; GOODPASTURE ANTIGEN; GLOBULAR DOMAIN; X-CHROMOSOME; LOCALIZATION; REGION; ALPHA-1(IV); MUTATIONS; PROMOTER	To date, five distinct alpha chains have been identified in basement membrane collagen IV. We have cloned a gene encoding a new a chain belonging to basement membrane collagen IV by cDNA isolation under low stringency conditions. Isolation of overlapping clones and the technique of 5' rapid amplification of cDNA ends enabled us to derive the primary structure of the entire polypeptide. The deduced collagen polypeptide contained 1678 amino acid residues, including a 21-residue signal peptide, a 24-residue amino-terminal NC domain, a central 1405-residue collagenous (COL1) domain, and a 228-residue carboxyl-terminal NC1 domain. We have designated this newly found alpha chain as the alpha 6(IV) chain. The gene was mapped to chromosome Xq22 by in situ hybridization of metaphase lymphocytes. This is the same region of chromosome X where the gene coding for the alpha 5(IV) collagen chain (COL4A5) resides. Mutations in COL4A5 have been characterized in more than 50 patients with Alport syndrome. However, some of the X-linked cases of Alport syndrome are not apparently caused by COL4A5 mutations. The gene we describe in this paper therefore seems to be a candidate for mutations in this group of Alport syndrome patients.	OKAYAMA UNIV,SCH MED,DEPT MOLEC BIOL & BIOCHEM,OKAYAMA 700,JAPAN; OKAYAMA UNIV,SCH MED,DEPT OPHTHALMOL,OKAYAMA 700,JAPAN; HOP ENFANTS LA TIMONE,GRP HOSP TIMONE,INST SANTE & RECH MED,UNITE 242,MARSEILLE 13385,FRANCE	Okayama University; Okayama University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille			Oohashi, Toshitaka/B-1599-2011	Oohashi, Toshitaka/0000-0002-9302-1913	NATIONAL EYE INSTITUTE [R01EY007334] Funding Source: NIH RePORTER; NEI NIH HHS [EY07334] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BUTKOWSKI RJ, 1989, KIDNEY INT, V35, P1195, DOI 10.1038/ki.1989.110; BUTKOWSKI RJ, 1990, J LAB CLIN MED, V115, P365; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GUNWAR S, 1991, J BIOL CHEM, V266, P14088; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; JOHANSSON C, 1991, CONNECT TISSUE RES, V25, P229, DOI 10.3109/03008209109029159; JUNQUIERA LC, 1986, BASIC HISTOLOGY; KAMAGATA Y, 1992, J BIOL CHEM, V267, P23753; LANGEVELD JPM, 1991, J BIOL CHEM, V266, P2622; Maniatis T., 1982, MOL CLONING; MARIYAMA M, 1992, J BIOL CHEM, V267, P1253; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MORRISON KE, 1991, AM J HUM GENET, V49, P545; MYERS JC, 1990, AM J HUM GENET, V46, P1024; OVERBEEK PA, 1981, BIOCHIM BIOPHYS ACTA, V656, P195, DOI 10.1016/0005-2787(81)90087-3; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; Rohrbach DH, 1993, MOL CELLULAR ASPECTS; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEBOLD B, 1987, EUR J BIOCHEM, V168, P569, DOI 10.1111/j.1432-1033.1987.tb13455.x; SMEETS HJM, 1992, KIDNEY INT, V42, P83, DOI 10.1038/ki.1992.264; SOININEN R, 1988, J BIOL CHEM, V263, P17217; SOININEN R, 1987, FEBS LETT, V225, P188; SUGIMOTO M, 1993, FEBS LETT, V330, P122, DOI 10.1016/0014-5793(93)80256-T; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TRYGGVASON K, 1993, KIDNEY INT, V43, P38, DOI 10.1038/ki.1993.8; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564; YAMAGUCHI N, 1991, INVEST OPHTH VIS SCI, V32, P2924; ZHOU J, 1991, GENOMICS, V9, P1, DOI 10.1016/0888-7543(91)90214-Y	32	87	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7520	7526						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125972				2022-12-25	WOS:A1994NA03200077
J	KIRSCH, T; WUTHIER, RE				KIRSCH, T; WUTHIER, RE			STIMULATION OF CALCIFICATION OF GROWTH-PLATE CARTILAGE MATRIX VESICLES BY BINDING TO TYPE-II AND TYPE-X COLLAGENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN EPIPHYSEAL CARTILAGE; BOUND ALKALINE-PHOSPHATASE; CII ANNEXIN-V; ANCHORIN-CII; CHONDROCYTE MEMBRANES; CALCIUM CHANNELS; PROTEINS; IDENTIFICATION; ASSOCIATION; IMMUNOLOCALIZATION	Matrix vesicles (MV), microstructures which rapidly accumulate Ca2+ and induce mineral formation in vitro, are linked to type II and X collagens and proteoglycans in the hypertrophic cartilage. However, the roles of these matrix proteins on MV function are not known. This led us to investigate the influence of type II and X collagen binding on Ca2+ uptake by MV. MV isolated from chicken growth plate cartilage were treated with pure bacterial collagenase and 1 M NaCl in synthetic cartilage lymph to selectively and completely remove associated type II and X collagens. Uptake of Ca-45(2+) by these collagen-depleted vesicles was markedly reduced. Further treatment with detergent, which disrupted the membrane, restored Ca2+ uptake, indicating that the vesicle membrane structure and the nucleational core inside the vesicle lumen were still intact after the collagenase and 1 M NaCl treatments. Readdition of either native type II or X collagen to the collagenase, 1 M NaCl-treated MV stimulated their Ca2+ uptake to levels similar to those of untreated vesicles. Pepsin-treated type II and X collagens were less effective in stimulating Ca2+ uptake, indicating that non-triple helical domains of these collagens were involved. The pepsin treatment of these collagens also decreased their binding to annexin V (anchorin CII), one of three annexins found in MV, suggesting that annexin V is involved in mediating the binding of type II and X collagens to the MV surface. Furthermore, treatment of collagenase, 1 M NaCl-treated MV with chymotrypsin, which damaged annexin V as well as many other MV proteins, prevented the stimulation of Ca2+ uptake by these collagens. Thus, the interaction between type II and X collagens with MV activates the influx of Ca2+ into MV and may play an important role in calcification of the vesicles.	UNIV S CAROLINA, DEPT CHEM & BIOCHEM, COLUMBIA, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NIAMS NIH HHS [AR 18193] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKISAKA T, 1988, CALCIFIED TISSUE INT, V42, P383, DOI 10.1007/BF02556357; ALI SY, 1970, P NATL ACAD SCI USA, V67, P1513, DOI 10.1073/pnas.67.3.1513; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; Anderson H. C., 1990, PATHOLOGY REV, P13, DOI 10.1007/978-1-4612-0485-5_2; ANDERSON HC, 1969, J CELL BIOL, V41, P59, DOI 10.1083/jcb.41.1.59; BAGINSKI ES, 1973, CLIN CHIM ACTA, V46, P49, DOI 10.1016/0009-8981(73)90101-0; BONUCCI E, 1967, J ULTRA MOL STRUCT R, V20, P33, DOI 10.1016/S0022-5320(67)80034-0; CYBORON GW, 1981, J BIOL CHEM, V256, P7262; GENGE B, 1992, BONE MINER, V17, P202, DOI 10.1016/0169-6009(92)90737-X; GENGE BR, 1992, J BONE MINER RES, V7, P807, DOI 10.1002/jbmr.5650070710; GENGE BR, 1990, J BIOL CHEM, V265, P4703; GENGE BR, 1989, J BIOL CHEM, V264, P10917; GENGE BR, 1988, J BIOL CHEM, V263, P18513; HALE JE, 1987, J BIOL CHEM, V262, P1916; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; KIRSCH T, 1990, BIOCHEM J, V265, P453, DOI 10.1042/bj2650453; KIRSCH T, 1991, EUR J BIOCHEM, V196, P575, DOI 10.1111/j.1432-1033.1991.tb15852.x; KIRSCH T, 1992, BONE MINER, V18, P107, DOI 10.1016/0169-6009(92)90851-4; KIRSCH T, 1992, FEBS LETT, V310, P143, DOI 10.1016/0014-5793(92)81316-E; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCLEAN FM, 1987, J BIOL CHEM, V262, P10481; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MOLLENHAUER J, 1983, EMBO J, V2, P45, DOI 10.1002/j.1460-2075.1983.tb01378.x; MOLLENHAUER J, 1984, J CELL BIOL, V98, P1572, DOI 10.1083/jcb.98.4.1572; PFAFFLE M, 1988, EMBO J, V7, P2335, DOI 10.1002/j.1460-2075.1988.tb03077.x; REGISTER TC, 1986, J BIOL CHEM, V261, P9354; ROJAS E, 1992, BONE MINER, V17, P214, DOI 10.1016/0169-6009(92)90739-Z; ROJAS E, 1990, J BIOL CHEM, V265, P21207; SAUER GR, 1989, BONE MINER, V7, P233, DOI 10.1016/0169-6009(89)90080-9; SCHMID TM, 1987, STRUCTURE FUNCTION C, P223; SHIMOKOMAKI M, 1980, FEBS LETT, V121, P51, DOI 10.1016/0014-5793(80)81265-8; Von der Mark K., 1986, RHEUMATOLOGY, V10; VONDERMARK K, 1985, ANN NY ACAD SCI, V460, P214; WARNER GP, 1983, CALCIFIED TISSUE INT, V35, P327, DOI 10.1007/BF02405054; WU LNY, 1989, J BIOL CHEM, V264, P21346; WU LNY, 1993, J BIOL CHEM, V268, P25084; WU LNY, 1991, J BIOL CHEM, V266, P1195; WU LNY, 1991, J BIOL CHEM, V266, P1187; WUTHIER RE, 1975, BIOCHIM BIOPHYS ACTA, V409, P128, DOI 10.1016/0005-2760(75)90087-9; WUTHIER RE, 1989, CONNECT TISSUE RES, V22, P653, DOI 10.3109/03008208909114117; WUTHIER RE, 1977, CALC TISS RES, V24, P163, DOI 10.1007/BF02223311	42	100	103	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11462	11469						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157677				2022-12-25	WOS:A1994NF96600072
J	ISMAILOV, II; MCDUFFIE, JH; BENOS, DJ				ISMAILOV, II; MCDUFFIE, JH; BENOS, DJ			PROTEIN-KINASE A PHOSPHORYLATION AND G-PROTEIN REGULATION OF PURIFIED RENAL NA+ CHANNELS IN PLANAR BILAYER-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE SODIUM-CHANNEL; SUBUNIT; A6; VASOPRESSIN	Purified bovine renal epithelial Na+ channels incorporated into planar lipid bilayer membranes were used to evaluate the biophysical consequences of its phosphorylation by protein kinase A (PKA). We also studied the effects of pertussis toxin-induced ADP-ribosylation on single channel activity of nonphosphorylated and PKA phosphorylated channels. PKA-induced phosphorylation resulted in a significant increase in single channel open probability (P-o) with no change in single channel conductance, as well as increased the probability of multiple channel openings in the bilayer. Further, PKA conferred a voltage sensitivity to channel gating without affecting open channel conduction properties. PKA-phosphorylated Na+ channels were inhibited by subsequent ADP-ribosylation with pertussis toxin (PTX). Addition of guanosine 5'-3-O-(thio)triphosphate reversed this inhibition. However, exposure of nonphosphorylated Na+ channels to PTX increased channel open probability by a factor of 3-5. These results demonstrate that a cAMP-dependent pathway is an important regulatory element for amiloride-sensitive Na+ channels and that the effects of PTX-induced ADP-ribosylation of the channel-associated Gi protein on function depend upon the previous phosphorylation state of the protein.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 37206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ O, 1985, J ELECTROPHYSIOL TEC, V12, P159; AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; BARBRY P, 1990, BIOCHEMISTRY-US, V29, P1039, DOI 10.1021/bi00456a028; BARBRY P, 1990, P NATL ACAD SCI USA, V87, P7347, DOI 10.1073/pnas.87.19.7347; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; BENOS DJ, 1992, REV PHYSIOL BIOCH P, V120, P31, DOI 10.1007/BFb0036122; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CANTIELLO HF, 1990, J BIOL CHEM, V265, P21624; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; KEMENDY AE, 1992, AM J PHYSIOL, V263, pC825, DOI 10.1152/ajpcell.1992.263.4.C825; LINGUEGLIA E, 1993, EUR J BIOCHEM, V216, P679, DOI 10.1111/j.1432-1033.1993.tb18188.x; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; MARUNAKA Y, 1991, AM J PHYSIOL, V260, pC1071, DOI 10.1152/ajpcell.1991.260.5.C1071; OH Y, 1993, AM J PHYSIOL, V264, pC1489, DOI 10.1152/ajpcell.1993.264.6.C1489; OH YS, 1993, AM J PHYSIOL, V265, pC85, DOI 10.1152/ajpcell.1993.265.1.C85; OH YS, 1993, PROTEIN EXPRES PURIF, V4, P312, DOI 10.1006/prep.1993.1040; OHARA A, 1993, AM J PHYSIOL, V264, pC352, DOI 10.1152/ajpcell.1993.264.2.C352; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; PRAT AG, 1993, AM J PHYSIOL, V265, pC218, DOI 10.1152/ajpcell.1993.265.1.C218; SARIBANSOHRABY S, 1984, SCIENCE, V225, P745, DOI 10.1126/science.6463652; SARIBANSOHRABY S, 1988, J BIOL CHEM, V263, P13875; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; STAUB O, 1992, J CELL BIOL, V119, P1497, DOI 10.1083/jcb.119.6.1497	25	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10235	10241						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144604				2022-12-25	WOS:A1994NF01700013
J	KITAZUME, S; KITAJIMA, K; INOUE, S; INOUE, Y; TROY, FA				KITAZUME, S; KITAJIMA, K; INOUE, S; INOUE, Y; TROY, FA			DEVELOPMENTAL EXPRESSION OF TROUT EGG POLYSIALOGLYCOPROTEINS AND THE PREREQUISITE ALPHA-2,6-SIALYL, AND ALPHA-2,8-SIALYL AND ALPHA-2,8-POLYSIALYLTRANSFERASE ACTIVITIES REQUIRED FOR THEIR SYNTHESIS DURING OOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; ESCHERICHIA-COLI K1; ENDO-N-ACETYLNEURAMINIDASE; RAINBOW-TROUT; SIALIC ACIDS; POLYSIALIC ACID; CARBOHYDRATE UNITS; MASS-SPECTROMETRY; POLY(SIALIC ACID); UNFERTILIZED EGGS	The developmental expression of the alpha 2,6- and alpha 2,8-linked sialic acid (Sia) residues in trout egg polysialoglycoproteins (PSGPs) was studied by correlating the temporal expression of these sugar residues, and the prerequisite sialyltransferases responsible for their synthesis, during oogenesis. The following new findings are reported. 1) Disialylated glycoproteins were identified in ovaries 4-6 months prior to ovulation. Three months prior to ovulation, a second more highly sialylated glycoprotein appeared. Structural studies confirmed that the two glycoproteins were discrete molecular species, designated PSGP(low Sia) and PSGP(high Sia), which differed only in their Sia content. PSGP(low Sia) contained mostly disialyl (Sia alpha 2,8-Sia alpha 2,6-) side chains, whereas PSGP(high Sia) contained alpha 2,8-linked oligo/polySia side chains ranging in length from 2 to over 20 Sia residues. The average degree of polymerization (DP(HV)) was 6. 2) Biosynthetic studies using CMP-[C-14]Neu5Ac indicated that three sialyltransferase activities were responsible for synthesis of the polysialyl residues of PSGPs: (i) alpha-N-acetylgalactosaminide alpha 2,6-sialyltransferase (alpha 2,6-ST), which catalyzed formation of the Sia residues alpha 2,6-linked to the proximal GalNAc residues in asialo-PSGP; (ii) alpha 2,6-sialoside alpha 2,8-sialyltransferase (alpha 2,8-ST or ''initiase''), which catalyzed transfer of the first alpha 2,8-Sia residue to the alpha 2,6-linked Sia residue; and (iii) an alpha 2,8-polysialyltransferase (alpha 2,8-polyST or ''polymerase''), responsible for synthesis of the alpha 2,8-linked poly/oligo Sia chains in PSGP(high Sia). Expression of these enzyme activities increased in accordance with the developmental appearance of each PSGP. 3) Structural characterization of the [C-14]Sia-labeled side chains of each PSGP at different stages of development confirmed that synthesis of the disialyl unit containing a single alpha 2,8-Sia residue occurred before alpha 2,8-polysialylation. 4). In ovaries, 96% of the sialyltransferase activities were found in the Golgi-derived immature cortical vesicles or as soluble enzymes released from the fragile vesicles. Less than 4% of the activities were localized in the membrane (Golgi) fraction. In mature eggs, the sialyltransferases were also detected as soluble enzymes, and within the cortical vesicles.	UNIV CALIF DAVIS, SCH MED, DEPT BIOL CHEM, DAVIS, CA 95616 USA; UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, TOKYO 113, JAPAN; SHOWA UNIV, SCH PHARMACEUT SCI, TOKYO 142, JAPAN	University of California System; University of California Davis; University of Tokyo; Showa University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009352] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-09352] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARRY GT, 1957, NATURE, V179, P206, DOI 10.1038/179206a0; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; Corfield A.P., 1982, Cell Biology Monographs, V10, P5; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DUBOIS M, 1956, ANAL CHEM, V135, P243; FINNE J, 1982, J BIOL CHEM, V257, P1966; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; GLICK MC, 1991, ADV NEUROBLASTOMA RE, V3, P267; GROGAN T, 1994, IN PRESS US CAN ACAD; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; INOUE S, 1987, DEV BIOL, V123, P442, DOI 10.1016/0012-1606(87)90402-7; INOUE S, 1986, J BIOL CHEM, V261, P5256; INOUE S, 1978, BIOCHEM BIOPH RES CO, V83, P1018, DOI 10.1016/0006-291X(78)91497-3; INOUE S, 1979, CARBOHYD RES, V74, P361, DOI 10.1016/S0008-6215(00)84795-3; INOUE S, 1980, BIOCHEM BIOPH RES CO, V93, P162, DOI 10.1016/S0006-291X(80)80260-9; INOUE Y, 1993, POLYSIALIC ACID MICR, P335; IWASAKI M, 1984, BIOCHEM INT, V8, P573; IWASAKI M, 1984, BIOCHEMISTRY-US, V23, P305, DOI 10.1021/bi00297a020; IWASAKI M, 1990, J BIOL CHEM, V265, P2596; Iwasaki M., 1985, GLYCOCONJUGATE J, V2, P209, DOI [10.1007/BF01049269, DOI 10.1007/BF01049269]; JAMES WM, 1987, BIOCHEM BIOPH RES CO, V148, P817, DOI 10.1016/0006-291X(87)90949-1; KITAJIMA K, 1986, J BIOL CHEM, V261, P5262; KITAJIMA K, 1988, DEV BIOL, V129, P270, DOI 10.1016/0012-1606(88)90181-9; KITAJIMA K, 1988, J BIOL CHEM, V263, P18269; KITAJIMA K, 1988, BIOCHEMISTRY-US, V27, P741; KITAZUME S, 1992, ANAL BIOCHEM, V202, P25, DOI 10.1016/0003-2697(92)90200-Q; KUNDIG FD, 1971, J BIOL CHEM, V246, P2543; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; MANZI AE, 1990, J BIOL CHEM, V265, P8094; MCCOY RD, 1985, J BIOL CHEM, V260, P2695; MOOLENAAR CECK, 1990, CANCER RES, V50, P1102; NADANO D, 1986, J BIOL CHEM, V261, P1550; NOMOTO H, 1982, ARCH BIOCHEM BIOPHYS, V218, P335, DOI 10.1016/0003-9861(82)90352-6; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAVELKA MS, 1991, J BACTERIOL, V173, P4603, DOI 10.1128/jb.173.15.4603-4610.1991; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; REGAN CM, 1991, INT J BIOCHH, V23, P515; ROHR TE, 1980, J BIOL CHEM, V255, P2332; Rosenberg A, 1976, BIOL ROLES SIALIC AC, P295; ROTH J, 1992, SCIENCE, V256, P673, DOI 10.1126/science.1585182; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SADLER JE, 1979, J BIOL CHEM, V254, P5934; SADOUL R, 1983, NATURE, V304, P347, DOI 10.1038/304347a0; SARFF LD, 1975, LANCET, V1, P1099; SATO C, 1993, J BIOL CHEM, V268, P23675; SCHAEFER HF, 1989, CHIMIA, V43, P1; SCHAUER R, 1987, METHOD ENZYMOL, V138, P132, DOI 10.1016/0076-6879(87)38012-7; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; SHIMAMURA M, 1983, BIOCHEMISTRY-US, V22, P959, DOI 10.1021/bi00273a039; SHIMODA Y, 1994, IN PRESS BIOCHEMISTR, V32; SORIMACHI H, 1988, J BIOL CHEM, V263, P17678; SORIMACHI H, 1990, J MOL BIOL, V211, P35, DOI 10.1016/0022-2836(90)90009-B; STEENBERGEN SM, 1990, MOL MICROBIOL, V4, P603, DOI 10.1111/j.1365-2958.1990.tb00629.x; SUNSHINE J, 1987, P NATL ACAD SCI USA, V84, P5986, DOI 10.1073/pnas.84.16.5986; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TAGUCHI T, 1993, J BIOL CHEM, V268, P2353; TERADA T, 1993, J BIOL CHEM, V268, P2640; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; TROY FA, 1979, J BIOL CHEM, V254, P7377; TROY FA, 1975, J BIOL CHEM, V250, P156; TROY FA, 1979, ANNU REV MICROBIOL, V33, P529; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VIMR ER, 1984, P NATL ACAD SCI-BIOL, V81, P1971, DOI 10.1073/pnas.81.7.1971; WEISGERBER C, 1991, Glycobiology, V1, P357, DOI 10.1093/glycob/1.4.357; YANG P, 1992, J CELL BIOL, V116, P487; YE J, 1994, METHOD ENZYMOL, V230, P460; YU S, 1990, ARCH BIOCHEM BIOPHYS, V283, P167; ZUBER C, 1992, J BIOL CHEM, V267, P9965	70	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10330	10340						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144614				2022-12-25	WOS:A1994NF01700026
J	LISZEWSKI, MK; TEDJA, I; ATKINSON, JP				LISZEWSKI, MK; TEDJA, I; ATKINSON, JP			MEMBRANE COFACTOR PROTEIN (CD46) OF COMPLEMENT - PROCESSING DIFFERENCES RELATED TO ALTERNATIVELY SPLICED CYTOPLASMIC DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARR VIRUS RECEPTOR; HUMAN LYMPHOCYTES-B; ENDOPLASMIC-RETICULUM; LIGAND-BINDING; GENE-CLUSTER; C3D RECEPTOR; CELL-DAMAGE; SYSTEM; MCP; IDENTIFICATION	Membrane cofactor protein (MCP, CD46), a widely distributed regulatory protein, inhibits complement activation on host cells and serves as a measles virus receptor. Most cells express four isoforms (with one of two cytoplasmic tails, CYT-1 or CYT-2). Previously, we noted that MCP precursors had variable intracellular processing. Therefore, we characterized the intracellular trans port of individual MCP isoforms. Transfectants were used for pulse chase analyses. MCP isoforms bearing CYT-1 chased into their mature, surface forms with a half-life (t(1/2)) of 10-13 min while those with CYT-2 required 35-40 min. The precursor of a tail-less mutant possessed a t(1/2) of 160-165 min. Chimeras were constructed that added both tails in opposite orientation onto the isoform (i.e. CYT 1+2 or CYT 2+1). Chimera 1+2 precursor processed with a t(1/2) of 35-37 min, similar to CYT-2. Chimera 2+1 had a t(1/2) of 15-19 min, more closely resembling CYT-1. Thus, in both cases the carboxyl-terminal tail controlled the processing rate. Deletions were made in the beginning, middle, and carboxyl terminus of CYT-1. Deletion of the first or middle six amino acids had no effect on the processing rate, However, deletion of the terminal tetrapeptide (FTSL) slowed the rate to 30-32 min, suggesting that this sequence facilitates exit from the endoplasmic reticulum.	ST LOUIS UNIV, SCH MED, DEPT INTERNAL MED, DIV RHEUMATOL, ST LOUIS, MO 63110 USA	Saint Louis University				Atkinson, John/0000-0002-2514-3441				ADAMS EM, 1991, J IMMUNOL, V147, P3005; BALLARD LL, 1988, J IMMUNOL, V141, P3923; DINGWALL C, 1992, Current Biology, V2, P503, DOI 10.1016/0960-9822(92)90687-6; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; FRADE R, 1985, P NATL ACAD SCI USA, V82, P1490, DOI 10.1073/pnas.82.5.1490; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GETHING M J, 1991, Current Opinion in Cell Biology, V3, P610, DOI 10.1016/0955-0674(91)90030-3; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Kelley William L., 1992, Current Opinion in Cell Biology, V4, P984, DOI 10.1016/0955-0674(92)90130-5; KLICKSTEIN LB, 1988, J EXP MED, V168, P1699, DOI 10.1084/jem.168.5.1699; KRYCH M, 1991, P NATL ACAD SCI USA, V88, P4353, DOI 10.1073/pnas.88.10.4353; LISZEWSKI MK, 1991, ANNU REV IMMUNOL, V9, P431, DOI 10.1146/annurev.iy.09.040191.002243; LISZEWSKI MK, 1989, BIOTECHNIQUES, V7, P13; LUBLIN DM, 1991, J EXP MED, V174, P35, DOI 10.1084/jem.174.1.35; LUBLIN DM, 1988, J EXP MED, V168, P181, DOI 10.1084/jem.168.1.181; MANCHESTER M, 1994, P NATL ACAD SCI USA, V91, P2161, DOI 10.1073/pnas.91.6.2161; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; NEMEROW GR, 1985, J VIROL, V55, P347, DOI 10.1128/JVI.55.2.347-351.1985; OGLESBY TJ, 1992, J EXP MED, V175, P1547, DOI 10.1084/jem.175.6.1547; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; POST TW, 1991, J EXP MED, V174, P93, DOI 10.1084/jem.174.1.93; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SEYA T, 1989, BIOCHEM J, V264, P581, DOI 10.1042/bj2640581; SEYA T, 1990, J EXP MED, V172, P1673, DOI 10.1084/jem.172.6.1673	29	60	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10776	10779						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144666				2022-12-25	WOS:A1994NF01700088
J	ZHANG, L; HIGUCHI, M; TOTPAL, K; CHATURVEDI, MM; AGGARWAL, BB				ZHANG, L; HIGUCHI, M; TOTPAL, K; CHATURVEDI, MM; AGGARWAL, BB			STAUROSPORINE INDUCES THE CELL-SURFACE EXPRESSION OF BOTH FORMS OF HUMAN TUMOR-NECROSIS-FACTOR RECEPTORS ON MYELOID AND EPITHELIAL-CELLS AND MODULATES LIGAND-INDUCED CELLULAR-RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-KINASE INHIBITOR; GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE; FACTOR-ALPHA; MOLECULAR-CLONING; SOLUBLE RECEPTORS; POTENT INHIBITOR; RESISTANT CELLS; DNA-SYNTHESIS; TNF RECEPTOR	Staurosporine, an inhibitor of protein kinase C, is commonly used to inhibit the growth factor-induced signal transduction pathway at the post-receptor level. In this report, we examined the effect of staurosporine on the constitutive expression of tumor necrosis factor (TNF) receptors in K562, a human erythroblastoid leukemic cell line. Exposure of these cells to staurosporine enhanced cell surface expression of TNF receptors by almost 7-fold in a dose- and time-dependent fashion. Maximum induction occurred at a concentration of 20 nM of the agent for 16 h at 37 degrees C. Induction of the TNF receptor was found to be temperature dependent. No induction was observed at 22 or at 4 degrees C, suggesting the role of cell metabolism. Scatchard analysis indicated an increase in receptor number without any change in receptor affinity. TNF receptors were induced by staurosporine on a wide variety of human cells of both epithelial (primarily p60 receptors) and myeloid (mainly p80 receptor) origin.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN IMMUNOL & BIOL THERAPY,CYTOKINE RES LAB,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Aggarwal, Bharat B/G-3388-2013					AGARWALBB, 1986, J BIOL CHEM, V261, P13652; AGGARWAL BB, 1987, J BIOL CHEM, V262, P10000; AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; AGGARWAL BB, 1991, TUMOR NECROSIS FACTO, P1; AGGARWAL BB, 1987, J BIOL CHEM, V262; AIYER RA, 1988, CRC HDB CYTOLYTIC LY, P105; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BISHOP WR, 1990, BIOCHEM PHARMACOL, V40, P2129, DOI 10.1016/0006-2952(90)90245-G; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; COMBADIERE C, 1993, BIOCHEM J, V289, P695, DOI 10.1042/bj2890695; DAIBATA M, 1991, J IMMUNOL, V147, P292; DEAN NM, 1989, BIOCHEM BIOPH RES CO, V165, P795, DOI 10.1016/S0006-291X(89)80036-1; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; DING AH, 1989, J BIOL CHEM, V264, P3924; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ERIKSTEIN BK, 1991, EUR J IMMUNOL, V21, P1033, DOI 10.1002/eji.1830210426; FRIEDMAN BA, 1990, CANCER RES, V50, P533; GATANAGA T, 1990, P NATL ACAD SCI USA, V87, P8781, DOI 10.1073/pnas.87.22.8781; GOROSPE M, 1993, J BIOL CHEM, V268, P6214; HELLER R, 1992, VANO, V70, P47; HIGUCHI M, 1993, J BIOL CHEM, V268, P5624; HIGUCHI M, 1992, J BIOL CHEM, V267, P20892; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; HOHMANN HP, 1992, J BIOL CHEM, V267, P2065; HOLTMANN H, 1987, J IMMUNOL, V139, P1161; KALTHOFF H, 1993, J BIOL CHEM, V268, P2762; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Maniatis T., 1989, MOL CLONING COLD SPR, P11; MIYAMOTO K, 1993, CANCER RES, V53, P1555; MORIOKA H, 1985, AGR BIOL CHEM TOKYO, V49, P1959, DOI 10.1080/00021369.1985.10867017; NAKANO H, 1987, J ANTIBIOT, V40, P706, DOI 10.7164/antibiotics.40.706; OHMICHI M, 1992, BIOCHEMISTRY-US, V31, P4034, DOI 10.1021/bi00131a019; PANG XP, 1989, ENDOCRINOLOGY, V125, P599; PEETRE C, 1988, EUR J HAEMATOL, V41, P414; PENNICA D, 1992, J BIOL CHEM, V267, P21172; POUTEU F, 1990, J EXP MED, V172, P599; ROUBEY RAS, 1991, J IMMUNOL, V146, P3557; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; RUGGIERO V, 1987, J IMMUNOL, V138, P661; SATO W, 1990, BIOCHEM BIOPH RES CO, V173, P1252, DOI 10.1016/S0006-291X(05)80921-0; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHEURICH P, 1989, J EXP MED, V170, P947, DOI 10.1084/jem.170.3.947; SECKINGER P, 1989, J BIOL CHEM, V264, P11966; SECRIST JP, 1990, J BIOL CHEM, V265, P20394; SHISHEVA A, 1993, J BIOL CHEM, V268, P6463; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STAUBER GB, 1989, J BIOL CHEM, V264, P3573; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; TOTPAL K, 1991, CANCER RES, V51, P4266; TOTPAL K, 1992, CANCER RES, V52, P2557; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; UMEZAWA K, 1990, FEBS LETT, V260, P198, DOI 10.1016/0014-5793(90)80102-O; VANOSTADE X, 1993, NATURE, V361, P266; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; VILCEK J, 1991, J BIOL CHEM, V266, P7313; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	62	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10270	10279						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144608				2022-12-25	WOS:A1994NF01700018
J	BELLUSCI, S; MOENS, G; GAUDINO, G; COMOGLIO, P; NAKAMURA, T; THIERY, JP; JOUANNEAU, J				BELLUSCI, S; MOENS, G; GAUDINO, G; COMOGLIO, P; NAKAMURA, T; THIERY, JP; JOUANNEAU, J			CREATION OF AN HEPATOCYTE GROWTH-FACTOR SCATTER FACTOR AUTOCRINE LOOP IN CARCINOMA-CELLS INDUCES INVASIVE PROPERTIES ASSOCIATED WITH INCREASED TUMORIGENICITY	ONCOGENE			English	Article							ANCHORAGE-INDEPENDENT GROWTH; TYROSINE KINASE-ACTIVITY; EPITHELIAL-CELLS; MET PROTOONCOGENE; C-MET; EXTRACELLULAR-MATRIX; FACTOR RECEPTOR; RAT; IDENTIFICATION; EXPRESSION	Exogenous HGF/SF converts subconfluent cultures of NBT-II epithelial carcinoma cells into mobile fibroblast-like cells while being only mitogenic for cells maintained at high density. To investigate the potential rote of such factor in tumor progression, we generated HGF/SF-producing NBT-II cells by transfection with an expression plasmid containing human HGF/SF cDNA. HGF/SF-producing cells also exhibit a fibroblastic phenotype. Media conditioned by these cells are potent inducers of in vitro tubulogenesis which can be inhibited with specific anti-HGF/SF antibodies; these antibodies are also able to reverse the scattered phenotype of the HGF/SF-producing cells. In addition spheroids of HGF/SF-producing cells are dispersed into 3D collagen gels suggesting an increase of invasive properties of these cells. When injected in nude mice, these HGF/SF-producing cells induce tumors appearing more rapidly than did those obtained with untransfected cells. These results show that HGF/SF can promote motility and invasive properties of NBT-II bladder carcinoma cells and also confers a tumorigenic advantage when acting as an autocrine factor.	UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,I-10126 TURIN,ITALY; OSAKA UNIV,SCH MED,BIOMED RES CTR,DIV BIOCHEM,SUITA,OSAKA 565,JAPAN	University of Turin; Osaka University	BELLUSCI, S (corresponding author), ECOLE NORMALE SUPER,PHYSIOPATHOL DEV LAB,CNRS,URA 1337,46 RUE ULM,F-75231 PARIS 05,FRANCE.		Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Comoglio, Paolo/0000-0002-7056-5328; Thiery, Jean Paul/0000-0003-0478-5020	NATIONAL CANCER INSTITUTE [R01CA049417] Funding Source: NIH RePORTER; NCI NIH HHS [2RO1 CA 49417-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ADAMS JC, 1991, J CELL SCI, V98, P385; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOYER B, 1989, J CELL BIOL, V109, P1495, DOI 10.1083/jcb.109.4.1495; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; COLBEREGARAPIN F, 1981, J MOL BIOL, V105, P1; Cowin P, 1985, CELL CONTACT, P427; DEFRANCES MC, 1992, DEVELOPMENT, V116, P387; DIRENZO MF, 1991, ONCOGENE, V6, P1997; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GAVRILOVIC J, 1990, CELL REGUL, V1, P1003, DOI 10.1091/mbc.1.13.1003; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; JIANG WG, 1993, CLIN EXP METASTAS, V11, P235, DOI 10.1007/BF00121166; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; JOUANNEAU J, 1994, P NATL ACAD SCI USA, V91, P286, DOI 10.1073/pnas.91.1.286; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KENWORTHY P, 1992, BRIT J CANCER, V66, P243, DOI 10.1038/bjc.1992.251; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SPORN MB, 1985, NATURE, V327, P239; STERN CD, 1990, DEVELOPMENT, V110, P1271; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TOYOSHIMA K, 1971, JNCI-J NATL CANCER I, V47, P979; TSAO MS, 1993, CELL GROWTH DIFFER, V4, P571; TUCKER GC, 1991, INVAS METAST, V11, P297; TUCKER GC, 1991, J CELL SCI, V100, P371; UEHARA Y, 1992, J CELL BIOL, V117, P889, DOI 10.1083/jcb.117.4.889; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001	54	192	201	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1091	1099						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134112				2022-12-25	WOS:A1994NC04800011
J	KHAN, WA; BLOBE, GC; RICHARDS, AL; HANNUN, YA				KHAN, WA; BLOBE, GC; RICHARDS, AL; HANNUN, YA			IDENTIFICATION, PARTIAL-PURIFICATION, AND CHARACTERIZATION OF A NOVEL PHOSPHOLIPID-DEPENDENT AND FATTY ACID-ACTIVATED PROTEIN-KINASE FROM HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED HUMAN-PLATELETS; RAT-BRAIN; SPHINGOSINE INHIBITION; ALLOSTERIC REGULATION; PHOSPHATIDIC-ACID; KINETIC-ANALYSIS; LEUKEMIC-CELLS; OLEIC-ACID; C-EPSILON; DIACYLGLYCEROL	A novel lipid-dependent protein kinase in human platelets was partially purified and characterized. This enzyme was calcium-independent and was selective for phosphatidic acid as a cofactor/activator with initial activation observed at approximately 2 mol % and peak activity achieved at 4 mol % phosphatidic acid. In the presence of phosphatidylserine, enzyme activation was observed with concentrations of phosphatidic acid as low as 0.5 mol % with peak activity at 2 mol %. Other anionic phospholipids also activated the enzyme but to a lesser extent and with less potency. Enzyme activity was independent of diacylglycerol or phorbol esters and the enzyme did not bind [H-3]phorbol dibutyrate. In a soluble protein kinase assay, the enzyme was activated by cis-unsaturated fatty acids with maximum activation occurring at 5-10 muM sodium oleate. Western blot analysis showed that this enzyme did not cross-react immunologically with antibodies raised against the currently identified isoenzymes of protein kinase C. A number of additional biochemical criteria distinguished this enzyme from known isoenzymes of protein kinase C. These biochemical and immunologic data define a novel lipid-dependent protein kinase in human platelets. The role of this enzyme in signal transduction as a phosphatidic acid-activated enzyme and as a possible target for cis-unsaturated fatty acids is discussed.	DUKE UNIV,MED CTR,DEPT MED,BOX 3355,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University			Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43707] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; CRABOS M, 1992, BIOCHEM J, V288, P891, DOI 10.1042/bj2880891; ELIAS L, 1985, J BIOL CHEM, V260, P7023; ELTOUNY S, 1990, J BIOL CHEM, V265, P16437; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, J BIOL CHEM, V262, P13620; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HANNUN YA, 1990, J BIOL CHEM, V265, P2962; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; KARNIGUIAN A, 1990, BIOCHEM J, V268, P325, DOI 10.1042/bj2680325; KHAN WA, 1993, J BIOL CHEM, V268, P5063; KHAN WA, 1992, J BIOL CHEM, V267, P3605; Kitano T, 1986, Methods Enzymol, V124, P349; KLEMM DJ, 1988, EXP HEMATOL, V16, P855; KLEMM DJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P496, DOI 10.1016/0003-9861(88)90154-3; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KROLL MH, 1989, J CELL PHYSIOL, V139, P558, DOI 10.1002/jcp.1041390315; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; MURPHY CT, 1991, BIOCHIM BIOPHYS ACTA, V1133, P46, DOI 10.1016/0167-4889(91)90240-X; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SANO K, 1983, J BIOL CHEM, V262, P13620; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SEIFERT R, 1987, BIOCHEM BIOPH RES CO, V149, P762, DOI 10.1016/0006-291X(87)90433-5; SIESS W, 1983, J BIOL CHEM, V258, P4683; TSUKUDA M, 1988, BIOCHEM BIOPH RES CO, V155, P1387, DOI 10.1016/S0006-291X(88)81295-6; WERNER MH, 1991, MOL PHARMACOL, V39, P547; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; YOSHIDA K, 1992, P NATL ACAD SCI USA, V89, P6443, DOI 10.1073/pnas.89.14.6443	32	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9729	9735						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144564				2022-12-25	WOS:A1994NE05300053
J	RHIE, G; BEALE, SI				RHIE, G; BEALE, SI			REGULATION OF HEME OXYGENASE ACTIVITY IN CYANIDIUM-CALDARIUM BY LIGHT, GLUCOSE, AND PHYCOBILIN PRECURSORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIVERDIN-IX-ALPHA; CHLOROPHYLL SYNTHESIS; ARABIDOPSIS-THALIANA; PARTIAL-PURIFICATION; EUGLENA-GRACILIS; BIOSYNTHESIS; PHYCOCYANIN; PROTEIN; ALGA; APOPROTEIN	Cyanobacteria, red algae, and cryptophytes contain Phycobiliproteins which function as photosynthetic light-harvesting pigments. The chromophores of phycobiliproteins are phycobilins, open-chain tetrapyrroles that are synthesized from protoheme. The first step of phycobilin formation is the conversion of protoheme to biliverdin IXalpha in a reaction that is catalyzed by heme oxygenase. In the unicellular red alga, Cyanidium caldarium, light is required for the accumulation of phycobiliproteins. It has been reported previously that the synthesis of the apoprotein components of allophycocyanin and phycocyanin is induced by light in C. caldarium, that the phycobilin precursors, delta-aminolevulinic acid (ALA), protoporphyrin IX, and protoheme can substitute for light, and that the regulation is exerted at the level of mRNA synthesis. We have determined that a key enzyme of phycobilin formation is induced by light in C. caldarium. Extractable heme oxygenase activity is low in dark-grown cells, and it increases approximately 6-fold during the first 24 h after the cells are illuminated. After 24 h, the activity decreases to a level approximately equal to the initial activity. Heme oxygenase is induced in unilluminated cells by administration of ALA. D-Glucose, which is known to inhibit phycocyanin accumulation in C. caldarium, inhibits the induction of heme oxygenase by light or ALA. Induction of heme oxygenase by light or ALA is blocked by cycloheximide, an inhibitor of cytoplasmic protein synthesis, but not by chloramphenicol, an inhibitor of chloroplast protein synthesis. Rifampicin, an inhibitor of algal chloroplast RNA synthesis, and gabaculine, a competitive inhibitor of ALA biosynthesis, block the induction of heme oxygenase by light but not by ALA. These results indicate that heme oxygenase in C. caldarium is induced by phycobilin precursors. The induction by light and the repression of the induction by D-glucose are probably indirect effects mediated by the effects of light and D-glucose on phycobilin precursor formation. The results also indicate that heme oxygenase is encoded by a nuclear gene and is synthesized on cytoplasmic ribosomes.	BROWN UNIV, DIV BIOL & MED, PROVIDENCE, RI 02912 USA	Brown University								ALLEN MB, 1959, ARCH MIKROBIOL, V32, P270, DOI 10.1007/BF00409348; BEALE SI, 1984, ARCH BIOCHEM BIOPHYS, V235, P371, DOI 10.1016/0003-9861(84)90210-8; BEALE SI, 1983, PLANT PHYSIOL, V71, P263, DOI 10.1104/pp.71.2.263; BEALE SI, 1971, PLANT PHYSIOL, V47, P230, DOI 10.1104/pp.47.2.230; BEALE SI, 1993, CHEM REV, V93, P785, DOI 10.1021/cr00018a008; BEALE SI, 1990, PLANT PHYSIOL, V93, P1273, DOI 10.1104/pp.93.4.1273; BEALE SI, 1991, J BIOL CHEM, V266, P22328; BEALE SI, 1991, J BIOL CHEM, V266, P22333; BEALE SI, 1991, J BIOL CHEM, V266, P22341; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN SB, 1984, BIOCHEM J, V217, P265, DOI 10.1042/bj2170265; BROWN SB, 1984, BIOCHEM J, V220, P861, DOI 10.1042/bj2200861; COLE WJ, 1967, J AM CHEM SOC, V89, P3643, DOI 10.1021/ja00990a055; CORNEJO J, 1988, J BIOL CHEM, V263, P11915; DOEMEL WN, 1971, J GEN MICROBIOL, V67, P17, DOI 10.1099/00221287-67-1-17; DOUGLAS SE, 1993, IN PRESS J MAR BIOTE; DWARKI VJ, 1987, J BIOL CHEM, V262, P16958; FAIRCHILD CD, 1992, P NATL ACAD SCI USA, V89, P7017, DOI 10.1073/pnas.89.15.7017; HORTNER H, 1982, EUR J BIOCHEM, V128, P179; HOUGHTON JD, 1989, CARLSBERG RES COMMUN, V54, P131, DOI 10.1007/BF02907183; HOUGHTON JD, 1988, BIOCHEM J, V254, P907, DOI 10.1042/bj2540907; KONCZ C, 1992, PLANT MOL BIOL, V20, P963, DOI 10.1007/BF00027166; KONCZ C, 1990, EMBO J, V9, P1337, DOI 10.1002/j.1460-2075.1990.tb08248.x; LIN S, 1990, PLANT PHYSIOL, V93, P772, DOI 10.1104/pp.93.2.772; MCDONAGH AF, 1980, BIOCHEM J, V189, P193, DOI 10.1042/bj1890193; NICHOLS KE, 1960, NATURE, V188, P870, DOI 10.1038/188870b0; ORSAT B, 1992, FEBS LETT, V303, P181, DOI 10.1016/0014-5793(92)80514-H; REINBOTHE S, 1991, PLANT PHYSIOL BIOCH, V29, P297; REINBOTHE S, 1992, NATO ADV SCI I A-LIF, V226, P43; REITH M, 1993, PLANT CELL, V5, P645; RHIE GE, 1992, J BIOL CHEM, V267, P16088; SECKBACH J, 1991, J PHYCOL, V27, P794, DOI 10.1111/j.0022-3646.1991.00794.x; STEINMULLER K, 1984, PLANT PHYSIOL, V76, P935, DOI 10.1104/pp.76.4.935; TROXLER RF, 1978, BIOCHEM J, V172, P569, DOI 10.1042/bj1720569; TROXLER RF, 1979, ARCH BIOCHEM BIOPHYS, V195, P53, DOI 10.1016/0003-9861(79)90326-6; TROXLER RF, 1972, BIOCHEMISTRY-US, V11, P4235, DOI 10.1021/bi00773a007; TROXLER RF, 1966, PLANT PHYSIOL, V41, P491, DOI 10.1104/pp.41.3.491; TROXLER RF, 1989, J BIOL CHEM, V264, P20596; TURNER L, 1992, PLANT PHYSIOL BIOCH, V30, P309	39	20	23	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9620	9626						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144549				2022-12-25	WOS:A1994NE05300036
J	DAVIS, JP; ZHOU, MM; VANETTEN, RL				DAVIS, JP; ZHOU, MM; VANETTEN, RL			KINETIC AND SITE-DIRECTED MUTAGENESIS STUDIES OF THE CYSTEINE RESIDUES OF BOVINE LOW-MOLECULAR-WEIGHT PHOSPHOTYROSYL PROTEIN PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC ACID-PHOSPHATASE; TYROSINE PHOSPHATASES; PURIFICATION; LIVER; HEART; EXPRESSION; RECEPTOR; CLONING; LAR; INTERMEDIATE	The roles of the 8 conserved cysteines and 1 arginine in the low molecular weight phosphotyrosyl protein phosphatases were investigated using site-directed mutagenesis of the recombinant bovine heart enzyme. Single mutants of cysteine to serine were studied for each cysteine; alanine replacements were also made for Cys-12, Cys-17, and Arg-18. The CD spectra of the purified proteins were effectively superimposable, consistent with the conclusion that no major structural alterations had occurred, but H-1 NMR spectroscopy did reveal some spectral shifts in the aromatic region. Kinetic analysis of the mutant proteins demonstrated that only Cys-12, Cys-17, and Arg-18 had significantly altered catalytic activity toward the substrate p-nitrophenyl phosphate at pH 5. The Cys-12 and Arg-18 mutants were effectively inactive. Thus, it is concluded that Cys-12 is the catalytic nucleophile, and Arg-18 presumably serves an essential function in substrate binding. The C17S mutant had 6% residual activity compared with wild type protein, whereas the C17A mutant had 37% activity. Consistent with the observed activity of the Cys-17 mutant, a covalent phosphocysteine intermediate was trapped and identified by P-31 NMR, Further kinetic analysis of C17A using several aryl phosphate monoester substrates with different leaving group pK(alpha), values indicated that no change in the rate-determining step of the catalytic mechanism had occurred, that is, dephosphorylation of the covalent phosphoenzyme intermediate remains rate-limiting. The C17A mutant had a 4-fold higher phosphate K-i and slightly higher K-m values for p-nitrophenyl phosphate suggesting that Cys-17 may be important for optimal positioning of the substrate phosphate moiety.	PURDUE UNIV, DEPT CHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIAID NIH HHS [AI 27713] Funding Source: Medline; NIGMS NIH HHS [GM 27003] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027003] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BITTENCOURT HMS, 1976, BIOCHIM BIOPHYS ACTA, V438, P153, DOI 10.1016/0005-2744(76)90231-X; BOIVIN P, 1987, INT J BIOCHEM, V19, P613, DOI 10.1016/0020-711X(87)90227-8; BOIVIN P, 1986, BIOCHEM BIOPH RES CO, V134, P557, DOI 10.1016/S0006-291X(86)80456-9; BUNTON CA, 1967, J ORG CHEM, V32, P2806, DOI 10.1021/jo01284a037; CAMICI G, 1989, J BIOL CHEM, V264, P2560; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHERNOFF J, 1985, ARCH BIOCHEM BIOPHYS, V240, P135, DOI 10.1016/0003-9861(85)90016-5; CHIARUGI P, 1992, FEBS LETT, V310, P9, DOI 10.1016/0014-5793(92)81134-8; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; CIRRI P, 1993, FEBS LETT, V214, P647; DAVIS JP, 1992, OCT ASBMB FALL S STR, P99; DISSING J, 1991, J BIOL CHEM, V266, P20619; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HEINRIKSON RL, 1969, J BIOL CHEM, V244, P299; Innis MA, 1990, PCR PROTOCOLS GUIDE; KIRBY AJ, 1967, J AM CHEM SOC, V89, P415, DOI 10.1021/ja00978a044; KLEPPE K, 1971, J MOL BIOL, V56, P341, DOI 10.1016/0022-2836(71)90469-4; KNACK I, 1981, H-S Z PHYSIOL CHEM, V362, P1119, DOI 10.1515/bchm2.1981.362.2.1119; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIDLER PM, 1982, ARCH BIOCHEM BIOPHYS, V216, P512, DOI 10.1016/0003-9861(82)90240-5; LAU KHW, 1989, BIOCHEM J, V257, P23, DOI 10.1042/bj2570023; LAWRENCE GL, 1981, ARCH BIOCHEM BIOPHYS, V206, P122, DOI 10.1016/0003-9861(81)90073-4; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBLAD RL, 1991, CHEM REAGENTS PROTEI, P8; LUTZ RA, 1985, CLIN CHEM, V31, P656; MANAO G, 1992, J PROTEIN CHEM, V11, P333, DOI 10.1007/BF01024871; OKADA M, 1986, BIOCHEM J, V239, P155, DOI 10.1042/bj2390155; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; POT DA, 1991, J BIOL CHEM, V266, P19688; RAMPONI G, 1989, FEBS LETT, V250, P469, DOI 10.1016/0014-5793(89)80778-1; SAINI MS, 1981, J BIOL CHEM, V256, P453; SALL DJ, 1993, J MED CHEM, V36, P2350, DOI 10.1021/jm00068a012; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TAGA EM, 1982, ARCH BIOCHEM BIOPHYS, V214, P505, DOI 10.1016/0003-9861(82)90054-6; TONKS NK, 1988, J BIOL CHEM, V263, P6731; WAHEED A, 1988, BIOCHEMISTRY-US, V27, P4265, DOI 10.1021/bi00412a010; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; WO YYP, 1992, J BIOL CHEM, V267, P10856; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHANG ZY, 1990, ARCH BIOCHEM BIOPHYS, V282, P39, DOI 10.1016/0003-9861(90)90084-C; ZHANG ZY, 1991, BIOCHEMISTRY-US, V30, P8954, DOI 10.1021/bi00101a006; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516; ZHANG ZY, 1992, BIOCHEMISTRY-US, V31, P1701, DOI 10.1021/bi00121a018; ZHOU MM, 1993, BIOCHEMISTRY-US, V32, P8479, DOI 10.1021/bi00084a012	47	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8734	8740						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132604				2022-12-25	WOS:A1994NB41100021
J	BETTS, JC; AGRANOFF, AB; NABEL, GJ; SHAYMAN, JA				BETTS, JC; AGRANOFF, AB; NABEL, GJ; SHAYMAN, JA			DISSOCIATION OF ENDOGENOUS CELLULAR CERAMIDE FROM NF-KAPPA-B ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SPHINGOMYELIN TURNOVER; PHOSPHOLIPASE-C; PROTEIN-KINASE; HL-60 CELLS; SPHINGOSINE; DIFFERENTIATION; DIACYLGLYCEROL; GROWTH	The participation of cell ceramide in tumor necrosis factor (TNF)-alpha-stimulated NF-kappa B activation in Jurkat T cells and HL-60 cells was studied. TNF-alpha readily stimulated NF-kappa B activity in both cell lines as assayed by electrophoretic mobility shift assay and the use of a human immunodeficiency virus-chloramphenicol acetyltransferase reporter construct. However, TNF-alpha stimulation did not increase cell ceramide levels in either cell line. The exogenous addition of a short chain ceramide, N-acetylsphingosine, to Jurkat cells had no effect on NF-kappa B activity. When Jurkat T cells were exposed to the glucosylceramide synthase inhibitor, 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, endogenous ceramide levels increased 4-fold. The increase in ceramide, however, did not result in NF-kappa B activation nor did it potentiate TNF-alpha or phorbol ester-stimulated activity. We conclude that TNF-alpha-induced NF-kappa B activation occurs in Jurkat and HL-60 cell lines that do not demonstrate an increase in TNF-alpha-induced ceramide. Increasing ceramide levels by the addition of short chain ceramides or the use of a glucosylceramide synthase inhibitor can be dissociated from activation of NF-kappa B by TNF-alpha.	UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan					NIAID NIH HHS [AI 29179] Funding Source: Medline; NIDDK NIH HHS [DK41487] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041487] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE A, 1992, EUR J BIOCHEM, V210, P765, DOI 10.1111/j.1432-1033.1992.tb17479.x; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; CLARK MA, 1988, BIOCHEM J, V250, P125, DOI 10.1042/bj2500125; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; KIM MY, 1991, J BIOL CHEM, V266, P484; LADENSON RC, 1993, J BIOL CHEM, V268, P7650; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PAUL P, 1992, ANAL BIOCHEM, V204, P265, DOI 10.1016/0003-2697(92)90237-2; PREISS J, 1986, J BIOL CHEM, V261, P8597; RADIN NS, 1993, ADV LIPID RES, V26, P183; RADIN NS, 1993, NEUROPROTOCOLS, V3, P145; RAINES MA, 1993, J BIOL CHEM, V268, P14572; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968; SHAYMAN JA, 1990, J BIOL CHEM, V265, P12135; YOUNES A, 1992, J BIOL CHEM, V267, P842	24	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8455	8458						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132572				2022-12-25	WOS:A1994NB40900093
J	CASTELLS, MC; WU, XY; ARM, JP; AUSTEN, KF; KATZ, HR				CASTELLS, MC; WU, XY; ARM, JP; AUSTEN, KF; KATZ, HR			CLONING OF THE GP49B GENE OF THE IMMUNOGLOBULIN SUPERFAMILY AND DEMONSTRATION THAT ONE OF ITS 2 PRODUCTS IS AN EARLY-EXPRESSED MAST-CELL SURFACE PROTEIN ORIGINALLY DESCRIBED AS GP49	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING TRANSCRIPTION FACTORS; CONNECTIVE-TISSUE-TYPE; SULFATE-E-PROTEOGLYCAN; ADHESION MOLECULE; MESSENGER-RNA; ALPHA-CHAIN; W/WV MICE; RECEPTOR; FIBROBLASTS; ANTIGEN	gp49 was originally defined as a 49-kDa surface glycoprotein preferentially expressed on mouse interleukin-3-dependent, bone marrow-derived mast cells, which are immature progenitor cells. A previously cloned cDNA (gp49A) indicated that gp49 was a member of the immunoglobulin (Ig) superfamily, and genomic DNA analysis indicated that two genes might encode a gp49 family. We have now characterized a 5.6 kilobase pair gene, gp49B, that encodes two novel gp49 cDNAs, gp49B1 and gp49B2. The two cDNAs are identical except that gp49B2 is missing exon 6, which encodes a predicted transmembrane domain. In contrast to gp49A, gp49B1 and gp49B2 have 32 additional amino acids at their C termini containing 4 of the 6 consensus amino acids of the antigen receptor homology 1 motif found on several signal transducing members of the Ig superfamily. When COS-7 cells were transfected with either the gp49B1 or gp49B2 cDNA, only the gp49B1 transfectants bound the B23.1 monoclonal antibody that originally defined gp49. Reverse transcriptase-polymerase chain reaction analysis of the transfectants established that both transcripts were expressed, suggesting that the product of the gp49B2 transcript was not inserted in the plasma membrane, Thus, cloning of the gp49B gene has established the organization of one of the gp49 genes and provided evidence of alternate splicing of transcripts from that gene.	BRIGHAM & WOMENS HOSP, DEPT RHEUMATOL IMMUNOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital	CASTELLS, MC (corresponding author), HARVARD UNIV, SCH MED,DEPT MED,SEELEY G MUDD BLDG,RM 607, 250 LONGWOOD AVE, BOSTON, MA 02115 USA.				NIAID NIH HHS [AI-22531, AI-07306, AI-32101] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022531, R01AI022531, T32AI007306, R01AI032101] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1986, B MATH BIOL, V48, P603, DOI 10.1016/S0092-8240(86)90010-8; AMIGORENA S, 1992, NATURE, V358, P337, DOI 10.1038/358337a0; ARM JP, 1991, J BIOL CHEM, V266, P15966; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DAYTON ET, 1988, P NATL ACAD SCI USA, V85, P569, DOI 10.1073/pnas.85.2.569; GALLI SJ, 1982, J CELL BIOL, V95, P435, DOI 10.1083/jcb.95.2.435; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; HOGARTH PM, 1991, J IMMUNOL, V146, P369; KATZ HR, 1989, J IMMUNOL, V142, P919; KATZ HR, 1990, J IMMUNOL, V145, P3412; KATZ HR, 1992, J IMMUNOL, V148, P868; KATZ HR, 1983, P NATL ACAD SCI-BIOL, V80, P5916, DOI 10.1073/pnas.80.19.5916; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KENNELLY PJ, 1991, J BIOL CHEM, V266, P1555; LEVISCHAFFER F, 1986, P NATL ACAD SCI USA, V83, P6485, DOI 10.1073/pnas.83.17.6485; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; ODIN JA, 1991, SCIENCE, V254, P1785, DOI 10.1126/science.1837175; ORKIN SH, 1992, BLOOD, V80, P575; OTSU K, 1987, J EXP MED, V165, P615, DOI 10.1084/jem.165.3.615; RAPPAPORT EF, 1993, EXP HEMATOL, V21, P689; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; RAZIN E, 1984, J IMMUNOL, V132, P1479; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; REYES AA, 1991, MOL CELL BIOL, V11, P1654, DOI 10.1128/MCB.11.3.1654; REYNOLDS DS, 1988, J BIOL CHEM, V263, P12783; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TEPLER I, 1989, J BIOL CHEM, V264, P5912; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS AF, 1987, IMMUNOL TODAY, V8, P298, DOI 10.1016/0167-5699(87)90016-8; YE ZS, 1992, J IMMUNOL, V149, P897; ZON LI, 1991, J BIOL CHEM, V266, P22948	35	96	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8393	8401						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132564				2022-12-25	WOS:A1994NB40900085
J	POON, PP; STORMS, RK				POON, PP; STORMS, RK			THYMIDYLATE SYNTHASE IS LOCALIZED TO THE NUCLEAR PERIPHERY IN THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN RIBONUCLEOTIDE REDUCTASE; TRANSFER-RNA; CELL-CYCLE; BIOSYNTHETIC-ENZYMES; BETA-GALACTOSIDASE; ESCHERICHIA-COLI; GENE-EXPRESSION; MITOCHONDRIAL; DEOXYRIBONUCLEOTIDE; PROTEIN	To date, the organization of DNA precursor synthesis within eukaryotic cells remains unresolved. Previous studies have suggested the existence of a multienzyme complex that is responsible for DNA precursor synthesis and is associated with sites of replication within the nucleus. Contrasting this, other studies have proposed that DNA precursor synthesis occurs outside the nucleus. To further these studies, we have addressed the location where thymidylate synthase resides in yeast. Subcellular fractionation experiments indicate thymidylate synthase is associated with purified nuclei. Consistent with this, immunofluorescence analysis suggests that thymidylate synthase is situated at the nuclear periphery.	CONCORDIA UNIV, DEPT BIOL, MONTREAL H3G 1M8, PQ, CANADA	Concordia University - Canada			Storms, Reginald/B-2405-2013					AMMERER G, 1983, METHOD ENZYMOL, V101, P192; ANDREWS BJ, 1992, NATURE, V355, P393, DOI 10.1038/355393a0; AYUSAWA D, 1983, J BIOL CHEM, V258, P48; BABA M, 1987, J ELECTRON MICR TECH, V5, P249, DOI 10.1002/jemt.1060050305; BISSON LF, 1981, J BIOL CHEM, V256, P2456; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CELLA R, 1991, EUR J BASIC APPL HIS, V35, P61; CHATTON B, 1988, J BIOL CHEM, V263, P52; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; FRANKE WW, 1974, INT REV CYTOL, P71; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GILLMAN EC, 1991, MOL CELL BIOL, V11, P2382, DOI 10.1128/MCB.11.5.2382; GREENWOOD MT, 1986, J BACTERIOL, V168, P1336, DOI 10.1128/jb.168.3.1336-1342.1986; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HALL MN, 1990, P NATL ACAD SCI USA, V87, P6954, DOI 10.1073/pnas.87.18.6954; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HARVEY G, 1988, J CELL PHYSIOL, V134, P25, DOI 10.1002/jcp.1041340104; IDE GJ, 1981, CURR GENET, V4, P85, DOI 10.1007/BF00365686; JOHNSON L F, 1992, Current Opinion in Cell Biology, V4, P149, DOI 10.1016/0955-0674(92)90025-8; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; Kornberg A, 1992, DNA REPLICATION, P53; KUCERA R, 1986, EXP CELL RES, V167, P417, DOI 10.1016/0014-4827(86)90182-5; KUNZ BA, 1991, ANNU REV GENET, V25, P339, DOI 10.1146/annurev.ge.25.120191.002011; LEEDS JM, 1985, MOL CELL BIOL, V5, P3443, DOI 10.1128/MCB.5.12.3443; LI JM, 1989, J CELL BIOL, V109, P1411, DOI 10.1083/jcb.109.4.1411; LOHR D, 1988, YEAST PRACTICAL APPR, P125; MATHEWS CK, 1991, J THEOR BIOL, V152, P25, DOI 10.1016/S0022-5193(05)80502-8; MATHEWS CK, 1988, TRENDS BIOCHEM SCI, V13, P394, DOI 10.1016/0968-0004(88)90182-X; MCINTOSH EM, 1988, MOL CELL BIOL, V8, P4616, DOI 10.1128/MCB.8.11.4616; MCNEIL JB, 1980, CURR GENET, V2, P17, DOI 10.1007/BF00445690; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; OVADI J, 1991, J THEOR BIOL, V152, P1, DOI 10.1016/S0022-5193(05)80500-4; PERLMAN D, 1981, CELL, V25, P525, DOI 10.1016/0092-8674(81)90071-4; POON PP, 1993, THESIS CONCORDIA U M; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; REDDY GPV, 1980, P NATL ACAD SCI-BIOL, V77, P3312; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; ROSE AM, 1992, MOL CELL BIOL, V12, P5652, DOI 10.1128/MCB.12.12.5652; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT J, 1989, METHOD CELL BIOL, V32, P1; SHERMAN F, 1991, METHODS BIOL, V196, P1; SIKORSKA M, 1990, BIOCHEM CELL BIOL, V68, P880, DOI 10.1139/o90-130; STORMS RK, 1979, J BACTERIOL, V4, P73; TAYLOR GR, 1987, J BIOL CHEM, V262, P5298; WICKREMASINGHE RG, 1983, BIOCHIM BIOPHYS ACTA, V740, P243, DOI 10.1016/0167-4781(83)90132-X; WU M, 1987, J BIOL CHEM, V262, P12275	51	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8341	8347						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132557				2022-12-25	WOS:A1994NB40900077
J	SANTOSO, S; KALB, R; KROLL, H; WALKA, M; KIEFEL, V; MUELLERECKHARDT, C; NEWMAN, PJ				SANTOSO, S; KALB, R; KROLL, H; WALKA, M; KIEFEL, V; MUELLERECKHARDT, C; NEWMAN, PJ			A POINT MUTATION LEADS TO AN UNPAIRED CYSTEINE RESIDUE AND A MOLECULAR-WEIGHT POLYMORPHISM OF A FUNCTIONAL PLATELET BETA(3) INTEGRIN SUBUNIT - THE SR-A ALLOANTIGEN SYSTEM OF GPIIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLYCOPROTEIN-IIIA; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; AMINO-ACID POLYMORPHISM; GLANZMANN THROMBASTHENIA; MONOCLONAL-ANTIBODY; IIB; POLYPEPTIDE; SEQUENCE; EPITOPES; PROTEIN	Recently, we described a low frequency platelet alloantigen on human platelet membrane glycoprotein (GP) IIIa, termed Sr-a, that was involved in neonatal alloimmune thrombocytopenia. To identify the molecular nature of the Sr-a alloantigen, we analyzed the nucleotide sequence of polymerase chain reaction-amplified GPIIIa mRNA, and found a C-2004-->T substitution in seven Sr-a positive individuals which results in an Arg(636) --> Cys polymorphism within the cysteine-rich region of GPIIIa. Analysis of allele-specific recombinant forms of GPIIIa that differed only at amino acid residue 636 showed that anti Sr-a alloantibodies reacted with the Cys(636), but not the Arg(636), recombinant form of GPIIIa. Interestingly, under reducing conditions, the Cys(636) form of GPIIIa migrated with a slightly increased apparent molecular weight compared with the Arg(636) form. Following treatment with Endoglycosidase H, both allelic forms of GPIIIa exhibited the same mobility, however the Sr-a epitope was lost. Sr-a positive platelets express the same number of GPIIb-IIIa complexes on their surface as wild-type Sr-a negative platelets, and also aggregate normally in response to a variety of platelet agonists. Based upon these results, we conclude that 1) GPIIIa residue 636 specifically controls the formation and expression of the Sr-a alloantigenic determinant, and 2) an unpaired cysteine residue alters the N-linked glycosylation pattern of the extracellular domain of GPIIIa, but affects neither the degree of surface expression nor the adhesive function of the GPIIb-IIIa complex.	BLOOD CTR SE WISCONSIN INC,BLOOD RES INST,MILWAUKEE,WI 53233; MED COLL WISCONSIN,DEPT CELLULAR BIOL,MILWAUKEE,WI 53233; MED COLL WISCONSIN,DEPT PHARMACOL,MILWAUKEE,WI 53233	Versiti Blood Center of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	SANTOSO, S (corresponding author), JUSTUS LIEBIG UNIV,INST CLIN IMMUNOL & TRANSFUS MED,LANGHANSSTR 7,D-35392 GIESSEN,GERMANY.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044612] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-44612] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASTER RH, 1989, PLATELET IMMUNOBIOLO, P387; BEER J, 1989, J BIOL CHEM, V264, P17564; BOGAERT T, 1987, CELL, V51, P929, DOI 10.1016/0092-8674(87)90580-0; BURK CD, 1991, J CLIN INVEST, V87, P270, DOI 10.1172/JCI114982; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; DESIMONE DW, 1988, J BIOL CHEM, V263, P5333; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; GOLDBERGER A, 1991, BLOOD, V78, P681; KALOMIRIS EL, 1985, BIOCHEMISTRY-US, V24, P5430, DOI 10.1021/bi00341a022; KEKOMAKI R, 1992, TRANSFUSION MED, V2, P27, DOI 10.1111/j.1365-3148.1992.tb00131.x; KEKOMAKI R, 1993, BRIT J HAEMATOL, V83, P306, DOI 10.1111/j.1365-2141.1993.tb08286.x; KIEFEL V, 1987, BLOOD, V70, P1722; KIEFEL V, 1991, BRIT J HAEMATOL, V79, P256, DOI 10.1111/j.1365-2141.1991.tb04530.x; KIEFEL V, 1990, LABORATORY METHODS I, P241; KIEFFER N, 1990, ANNU REV CELL BIOL, V6, P329; KOUNS WC, 1991, BLOOD, V78, P3215; KROLL H, 1990, BLOOD, V76, P2296; KUIJPERS RWAM, 1993, BLOOD, V81, P70; KUIJPERS RWAM, 1992, J CLIN INVEST, V89, P381, DOI 10.1172/JCI115596; LYMAN S, 1990, BLOOD, V75, P2343; MCEVER RP, 1982, BLOOD, V59, P80; MCFARLAND JG, 1991, BLOOD, V78, P2276; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mueller-Eckhardt C, 1990, Transfus Med Rev, V4, P98, DOI 10.1016/S0887-7963(90)70254-4; NEWMAN PJ, 1991, THROMB HAEMOSTASIS, V66, P111; NEWMAN PJ, 1991, P NATL ACAD SCI USA, V88, P3160, DOI 10.1073/pnas.88.8.3160; NEWMAN PJ, 1985, MOL IMMUNOL, V22, P719, DOI 10.1016/0161-5890(85)90103-8; NEWMAN PJ, 1989, J CLIN INVEST, V83, P1778, DOI 10.1172/JCI114082; NEWMAN PJ, 1985, BLOOD, V65, P227; NEWMAN PJ, 1988, J CLIN INVEST, V82, P739, DOI 10.1172/JCI113656; NIEWIAROWSKI S, 1989, BIOCHIM BIOPHYS ACTA, V983, P91, DOI 10.1016/0005-2736(89)90384-2; SANTOSO S, 1989, BRIT J HAEMATOL, V72, P191, DOI 10.1111/j.1365-2141.1989.tb07682.x; SANTOSO S, 1993, J CLIN INVEST, V92, P2427, DOI 10.1172/JCI116849; SMITH JW, 1993, J IMMUNOL METHODS, V158, P77, DOI 10.1016/0022-1759(93)90260-E; TSUJI T, 1986, J BIOCHEM-TOKYO, V100, P1387, DOI 10.1093/oxfordjournals.jbchem.a121845; WANG L, 1991, P JPN ACAD B-PHYS, V67, P102, DOI 10.2183/pjab.67.102; WANG RG, 1992, J CLIN INVEST, V90, P2038, DOI 10.1172/JCI116084; WANG RG, 1993, BLOOD, V82, P3386; ZIMRIN AB, 1990, J BIOL CHEM, V265, P8590	39	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8439	8444						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132570				2022-12-25	WOS:A1994NB40900091
J	TORRI, AF; KUNKEL, TA; ENGLUND, PT				TORRI, AF; KUNKEL, TA; ENGLUND, PT			A BETA-LIKE DNA-POLYMERASE FROM THE MITOCHONDRION OF THE TRYPANOSOMATID CRITHIDIA-FASCICULATA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETOPLAST DNA; DEOXYRIBONUCLEIC-ACID; CATALYTIC SUBUNIT; XENOPUS-LAEVIS; REPLICATION; GAMMA; PURIFICATION; MINICIRCLES; FIDELITY; SITES	The mitochondrial DNA in Crithidia fasciculata, a trypanosomatid parasite, is known as kinetoplast DNA. Kinetoplast DNA has a very unusual structure, consisting of several thousand minicircles and a few dozen maxicircles, all topologically interlocked into a giant network. There is one network within each cell's single mitochondrion. We previously purified a 43-kDa DNA polymerase from C. fasciculata mitochondria (Torri, A. F., and Englund, P. T. (1992) J. Biol. Chem. 267, 4786-4792). This enzyme has properties very different from those of a DNA polymerase gamma, the conventional mitochondrial polymerase. In addition to its small size, it is nonprocessive, has no detectable exonuclease activity, and has very low fidelity. In all of these respects, the polymerase resembles a DNA polymerase beta, a gap-filling enzyme thought to function in DNA repair in the nucleus of other eukaryotes. We speculate that this enzyme may have been specially imported into the C. fasciculata mitochondrion to repair the many gaps found in minicircles following their replication. This is the first example of a beta-like polymerase from the mitochondrion of any eukaryote.	NIEHS,MOLEC GENET LAB,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	TORRI, AF (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205, USA.		Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788	NIGMS NIH HHS [GM 13604, GM 27608] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027608, R01GM027608, F32GM013604] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNE R, 1990, TRENDS GENET, V6, P177, DOI 10.1016/0168-9525(90)90173-4; COSGROVE WB, 1970, J PROTOZOOL, V17, P172, DOI 10.1111/j.1550-7408.1970.tb02350.x; FERGUSON M, 1992, CELL, V70, P621, DOI 10.1016/0092-8674(92)90431-B; FOURY F, 1989, J BIOL CHEM, V264, P20552; INSDORF NF, 1989, J BIOL CHEM, V264, P21498; INSDORF NF, 1989, J BIOL CHEM, V264, P21491; KITCHIN PA, 1984, J BIOL CHEM, V259, P5532; Kornberg A., 1992, DNA REPLICATION; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1992, J BIOL CHEM, V267, P18251; KUNKEL TA, 1989, BIOCHEMISTRY-US, V28, P988, DOI 10.1021/bi00429a011; MELENDY T, 1988, CELL, V55, P1083, DOI 10.1016/0092-8674(88)90252-8; PAPANICOLAOU C, 1986, J MOL BIOL, V189, P435, DOI 10.1016/0022-2836(86)90315-3; RAY DS, 1987, PLASMID, V17, P177, DOI 10.1016/0147-619X(87)90026-6; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; RYAN KA, 1988, ANNU REV MICROBIOL, V42, P339, DOI 10.1146/annurev.mi.42.100188.002011; Sambrook J, 1989, MOL CLONING LABORATO; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; STALKER DM, 1976, BIOCHEMISTRY-US, V15, P3114, DOI 10.1021/bi00659a027; STRAUSS P, 1993, FASEB J, V7, P1394; STUART K, 1992, INT REV CYTOL, V141, P65, DOI 10.1016/S0074-7696(08)62063-X; TORRI AF, 1992, J BIOL CHEM, V267, P4786; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; YAMAGUCHI M, 1980, NATURE, V285, P45, DOI 10.1038/285045a0; YAMAGUCHI M, 1980, J BIOL CHEM, V255, P7002	28	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8165	8171						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132542				2022-12-25	WOS:A1994NB40900053
J	CARNERO, A; CUADRADO, A; DELPESO, L; LACAL, JC				CARNERO, A; CUADRADO, A; DELPESO, L; LACAL, JC			ACTIVATION OF TYPE-D PHOSPHOLIPASE BY SERUM STIMULATION AND RAS-INDUCED TRANSFORMATION IN NIH3T3 CELLS	ONCOGENE			English	Article							PROTEIN-KINASE-C; SWISS 3T3 CELLS; PHOSPHATIDYLCHOLINE BREAKDOWN; PHOSPHATIDATE PHOSPHOHYDROLASE; 2ND MESSENGERS; POINT MUTATION; HYDROLYSIS; CHOLINE; DIACYLGLYCEROL; ONCOGENE	Mitogenic stimulation of NIH3T3 fibroblasts with growth factors or ras oncogenes is associated with an increase in the levels of phosphorylcholine and diacylglycerol. Both metabolites could be generated as a result of direct activation of a phosphatidylcholine-specific phospholipase C (PC-PLC) or by a more complex pathway, involving activation of phospholipase D followed by choline kinase and phosphatidic acid-hydrolase. We show evidence indicating that the generation of phosphorylcholine and diacylglycerol follow independent mechanisms in both serum-treated and in ras-transformed NIH3T3 cells. No significant activation of a PC-PLC enzyme was observed. Instead, activation of a phosphatidylcholine-specific phospholipase D (PC-PLD) was detected. Moreover, while a fivefold constitutive activation of the endogenous PLD activity and a twofold increase on the levels of phosphatidic acid were observed in uas-transformed cells, very small alterations on these parameters were detected at late times after serum stimulation of quiescent cells. Thus, cell proliferation induced by uas oncogenes in fibroblasts cells may be functionally linked to activation of a PC-PLD enzyme. The differences found in the activation of this enzyme between ras-transformed and normal cells may constitute an important difference in mitogenic signalling between normal and transformed cells.	CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			del Peso, Luis/K-9391-2014; IBIS, CANCER/P-3323-2015; Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	del Peso, Luis/0000-0003-4014-5688; Lacal, Juan Carlos/0000-0002-1908-2777; Carnero, Amancio/0000-0003-4357-3979; Cuadrado, Antonio/0000-0002-3444-9012; Cuadrado, Antonio/0000-0002-4039-7140				BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337; BLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; CANNON JG, 1988, PHARMACEUT RES, V5, P359, DOI 10.1023/A:1015955527100; CARNERO A, 1993, J CELL BIOCHEM, V52, P440, DOI 10.1002/jcb.240520408; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; COOK SJ, 1991, BIOCHIM BIOPHYS ACTA, V1092, P265, DOI 10.1016/0167-4889(91)90166-U; COOK SJ, 1991, BIOCHEM J, V280, P431, DOI 10.1042/bj2800431; CORVEN EJ, 1989, CELL, V59, P45; CUADRADO A, 1993, ONCOGENE, V8, P2959; DALY PF, 1987, J BIOL CHEM, V262, P14875; DUGAN LL, 1986, J CHROMATOGR, V378, P317, DOI 10.1016/S0378-4347(00)80728-8; EXTON JH, 1990, J BIOL CHEM, V265, P1; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; KOUL O, 1987, ARCH BIOCHEM BIOPHYS, V253, P453, DOI 10.1016/0003-9861(87)90199-8; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MURRAY JJ, 1990, BIOCHEM J, V270, P63, DOI 10.1042/bj2700063; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; PREISS J, 1986, J BIOL CHEM, V261, P8597; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; WARDEN CH, 1985, J BIOL CHEM, V260, P6006; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0	38	94	94	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1387	1395						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152799				2022-12-25	WOS:A1994NH40100010
J	MONTE, D; BAERT, JL; DEFOSSEZ, PA; DELAUNOIT, Y; STEHELIN, D				MONTE, D; BAERT, JL; DEFOSSEZ, PA; DELAUNOIT, Y; STEHELIN, D			MOLECULAR-CLONING AND CHARACTERIZATION OF HUMAN ERM, A NEW MEMBER OF THE ETS FAMILY CLOSELY-RELATED TO MOUSE PEA3 AND ER81 TRANSCRIPTION FACTORS	ONCOGENE			English	Article							DNA-BINDING MOTIF; GENE FAMILY; C-FOS; MESSENGER-RNAS; ACTIVATION; PROTEIN; ONCOGENE; DOMAIN; EXPRESSION; SEQUENCES	The ets-related transcription factors PEA3 and ER81 have recently been isolated and characterized in the mouse. They share 95% identity in a 85 amino acid (AA) domain termed the ETS domain which is responsible for DNA binding, and therefore they form an Ets family group. By screening a human testis cDNA library with a probe containing the mouse PEA3 ETS domain, we isolated a 2.2 kb clone containing a 510 AA open reading frame. Since the ETS domain, which is localized in the carboxy terminal region of the encoded protein, is 95% and 96% identical to that of PEA3 and ER81, respectively, we named this new member 'Ets Related Molecule PEA3-like' (ERM). Although the first 120 AA in the amino-terminal region of ERM share 47% identity with PEA3 and 66% with ER81, ERM contains a central region of approximate to 35 AA not found in the two mouse proteins. Gel shift analysis indicates that the full-length ERM protein is able to bind specifically to an oligonucleotide containing the consensus nucleotide core sequence GGAA recognized by the Ets proteins. Moreover, in vitro translation of 83 AA of the ERM ETS domain led to the production of a truncated protein which also binds to DNA. Though differential expression is observed in primary tumors and normal lymphocytes do not express ERM, this gene is almost ubiquitously expressed in human normal tissues. ERM mRNA is highly expressed in brain as well as in placenta and, to a lesser degree, in lung, pancreas, and heart. Moreover, almost all human cell lines tested express it at varying levels. In mouse tissues, we showed that PEA3 and ER81 mRNAs display restricted expression, whereas ERM is almost ubiquitously expressed as observed for human tissues. Altogether these results indicate that ERM is clearly a new ets family member and not the human equivalent of PEA3 or ER81.	INST PASTEUR,UNITE ONCOL MOLEC,CNRS,URA 1160,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				Defossez, Pierre-Antoine/0000-0002-6463-9263; monte, didier/0000-0002-0613-6203				BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; GEGONNE A, 1992, NEW BIOL, V4, P512; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAGET MP, 1993, NUCLEIC ACIDS RES, V21, P5987, DOI 10.1093/nar/21.25.5987; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1992, ONCOGENE, V7, P9; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MONTE D, 1992, BLOOD, V79, P2670; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZHAO HF, 1991, J BIOL CHEM, V266, P583	36	117	119	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1397	1406						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152800				2022-12-25	WOS:A1994NH40100011
J	KOGA, T; YOSHIDA, Y; CAI, JQ; ISLAM, MO; IMAI, S				KOGA, T; YOSHIDA, Y; CAI, JQ; ISLAM, MO; IMAI, S			PURIFICATION AND CHARACTERIZATION OF 240-KDA CGMP-DEPENDENT PROTEIN-KINASE SUBSTRATE OF VASCULAR SMOOTH-MUSCLE - CLOSE RESEMBLANCE TO INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECONSTITUTED LIPID VESICLES; CYCLIC-GMP; PLASMA-MEMBRANE; TRISPHOSPHATE RECEPTOR; SARCOPLASMIC-RETICULUM; INSP3 RECEPTOR; CA-2+ PUMP; PHOSPHORYLATION; CALCIUM; CELLS	The 240-kDa, cGMP-dependent protein kinase substrate protein obtained from porcine aortic smooth muscle, whose phosphorylation was closely associated with stimulation of plasma membrane Ca2+-pump ATPase (Yoshida, Y., Sun, H.-T., Cai, J.-Q., and Imai, S. (1991) J. Biol. Chem. 266, 19819-19825), was purified to near homogeneity by three successive chromatographic runs with calmodulin-, concanavalin A-, and heparin-Sepharose columns from microsomes solubilized with Triton X-100. The purified protein was found to bind inositol 1,4,5-trisphosphate (InsP3) in a specific, heparin-inhibitable manner with a K(d) of 2.0 nM and B(max) 450 pmol/mg protein (the binding of inositol 1,3,4,5-tetrakisphosphate was much weaker). In sedimentation experiments on a linear sucrose density gradient the InsP3 binding activity was always with the 240-kDa protein. Protein kinase G phosphorylated the InsP3 receptor purified from the rat cerebellum as well as the 240-kDa protein. Sialic acid content of the protein measured with Limulus polyphemus agglutinin was not significantly different from that of the cerebellar InsP3 receptor. Thus, 240-kDa protein closely resembles InsP3 receptor and may be a type of InsP3 receptor. The only difference was the behavior on SDS-polyacrylamide gel electrophoresis. The 240-kDa protein presented itself as two polypeptides with similar but slightly differing M(r) values, both of which were phosphorylated by protein kinase G.	NIIGATA UNIV,DEPT PHARMACOL,NIIGATA 951,JAPAN	Niigata University								BALTENSPERGER K, 1988, EUR J BIOCHEM, V172, P7, DOI 10.1111/j.1432-1033.1988.tb13848.x; BALTENSPERGER K, 1990, BIOCHEMISTRY-US, V29, P9753, DOI 10.1021/bi00493a035; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CASNELLI.JE, 1974, P NATL ACAD SCI USA, V71, P1891, DOI 10.1073/pnas.71.5.1891; CASNELLIE JE, 1980, J BIOL CHEM, V255, P3770; CORNWELL TL, 1991, MOL PHARMACOL, V40, P923; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1992, J BIOL CHEM, V267, P7036; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUKAWA KI, 1988, J BIOL CHEM, V263, P8058; FURUKAWA KI, 1987, J BIOCHEM-TOKYO, V101, P287, DOI 10.1093/oxfordjournals.jbchem.a121904; HINGORANI SR, 1991, ANAL BIOCHEM, V194, P204, DOI 10.1016/0003-2697(91)90169-T; IMAI S, 1990, J BIOCHEM-TOKYO, V107, P755, DOI 10.1093/oxfordjournals.jbchem.a123121; IVES HE, 1980, J BIOL CHEM, V255, P3777; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINCOLN TM, 1983, METHOD ENZYMOL, V99, P62; LINCOLN TM, 1989, PHARMACOL THERAPEUT, V41, P479, DOI 10.1016/0163-7258(89)90127-7; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; MOUREY RJ, 1990, BIOCHEM J, V272, P383, DOI 10.1042/bj2720383; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PARKS TP, 1987, ARCH BIOCHEM BIOPHYS, V255, P361, DOI 10.1016/0003-9861(87)90404-8; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POPESCU LM, 1985, EUR J PHARMACOL, V107, P393, DOI 10.1016/0014-2999(85)90269-9; QUINTON TM, 1992, BIOCHEM BIOPH RES CO, V184, P893, DOI 10.1016/0006-291X(92)90675-B; RAEYMAEKERS L, 1988, BIOCHEM J, V252, P269, DOI 10.1042/bj2520269; RAPOPORT RM, 1982, P NATL ACAD SCI-BIOL, V79, P6470, DOI 10.1073/pnas.79.21.6470; RESTREPO D, 1990, SCIENCE, V249, P1166, DOI 10.1126/science.2168580; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TWORT CHC, 1988, CIRC RES, V62, P961, DOI 10.1161/01.RES.62.5.961; VROLIX M, 1988, BIOCHEM J, V255, P855, DOI 10.1042/bj2550855; WALAAS SI, 1986, J NEUROSCI, V6, P954; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; YAMAMOTO H, 1989, J NEUROCHEM, V53, P917, DOI 10.1111/j.1471-4159.1989.tb11792.x; YOSHIDA Y, 1992, J BIOCHEM-TOKYO, V111, P559, DOI 10.1093/oxfordjournals.jbchem.a123796; YOSHIDA Y, 1991, J BIOL CHEM, V266, P19819	50	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11640	11647						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157697				2022-12-25	WOS:A1994NF96600099
J	LOUNSBURY, KM; BEDDOW, AL; MACARA, IG				LOUNSBURY, KM; BEDDOW, AL; MACARA, IG			A FAMILY OF PROTEINS THAT STABILIZE THE RAN/TC4 GTPASE IN ITS GTP-BOUND CONFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN CYTOSOL; CHROMOSOME CONDENSATION; BINDING PROTEIN; SUBSEQUENT BINDING; RCC1; REGULATOR; MITOSIS; GENES; DNA; COMPLEMENTATION	Ran/TC4, referred to here as Ran1, is a 25-kilodalton nuclear GTP-binding protein with an acidic C terminus that lacks any consensus prenylation sites. Here, we use a nitrocellulose overlay assay to identify potential effector proteins that bind specifically and with high affinity to the GTP-bound form of Ran1. GTP-Ran1 is shown to bind a variety of proteins, present in many eukaryotic tissues and cell extracts. A 28-kDa protein is cytosolic, whereas others, consisting of proteins of 86-300 kDa, are primarily localized in the nucleus. Binding is highly specific and is not detected by other small GTPases, such as c-Ha-Ras or Rab3A. Both deletion of the C-terminal -DEDDDL acidic sequence or alteration of the N terminus of Ran1 inhibits binding. However, these altered forms of Ran1 maintain the capacity to bind guanyl nucleotides and interact with the nucleotide exchange factor. The Ran1-binding proteins potently inhibit release of GTP from Ran1. These proteins can therefore maintain Ran1 in the ''on'' state and are potential down-stream effectors for Ran1-dependent cellular processes.	UNIV VERMONT,COLL MED,VERMONT COMPREHENS CANC CTR,BURLINGTON,VT 05405	University of Vermont	LOUNSBURY, KM (corresponding author), UNIV VERMONT,COLL MED,DEPT PATHOL,MED ALUMNI BLDG,BURLINGTON,VT 05405, USA.				NATIONAL CANCER INSTITUTE [P30CA022435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007122] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA22435] Funding Source: Medline; NIEHS NIH HHS [EST3207122] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; BRESSAN A, 1991, GENE, V103, P201, DOI 10.1016/0378-1119(91)90274-F; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; COMPTON DA, 1992, J CELL BIOL, V116, P1395, DOI 10.1083/jcb.116.6.1395; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FLEISCHMANN M, 1991, MOL GEN GENET, V227, P417, DOI 10.1007/BF00273932; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; KHOSRAVIFAR R, 1992, CELL GROWTH DIFFER, V3, P461; KORNBERG A, 1959, METHOD ENZYMOL, V1, P451; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NAKAYASU H, 1991, P NATL ACAD SCI USA, V88, P10312, DOI 10.1073/pnas.88.22.10312; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; NISHITANI H, 1990, J BIOCHEM-TOKYO, V107, P228, DOI 10.1093/oxfordjournals.jbchem.a123031; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; OHTSUBO M, 1991, EMBO J, V10, P1265, DOI 10.1002/j.1460-2075.1991.tb08068.x; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; SASAKI T, 1990, J BIOL CHEM, V265, P2333; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; UCHIDA S, 1990, MOL CELL BIOL, V10, P557; UEDA T, 1990, J BIOL CHEM, V265, P9373; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; YONEDA Y, 1988, SCIENCE, V242, P276	35	104	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11285	11290						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157660				2022-12-25	WOS:A1994NF96600049
J	MINOWA, T; MINOWA, MT; MOURADIAN, MM				MINOWA, T; MINOWA, MT; MOURADIAN, MM			NEGATIVE MODULATOR OF THE RAT D(2) DOPAMINE-RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; MOLECULAR-CLONING; PROMOTER REGION; EXPRESSION; SP1; D1; DNA; AFFINITY; FAMILY; TARGET	The rat D2 dopamine receptor gene is transcribed from a TATA-less promoter that has an initiator-like sequence and several putative Sp1 binding sites. The main activator of this gene is between nucleotides -75 and -29, and a strong negative modulator is located between bases -217 and -76 (Minowa, T., Minowa, M. T., and Mouradian, M. M. (1992) Biochemistry 31, 8389-8396). In the present investigation, a small deletion series within this negative modulator fused with the reporter gene for chloramphenicol acetyltransferase was used to transfect the D2-expressing cells, NB41A3. Two cis-acting functional DNA sequences were identified: a 41-base pair segment between nucleotides -116 and -76 (D2Neg-B), which decreased transcription from the D2 promoter by about 45%, and a 26-base pair segment between nucleotides -160 and -135 (DNeg-A), which, in the presence of the downstream negative modulator, reduced transcription down to the level of a promoterless vector. DNase I footprinting, gel mobility shift, and competitive cotransfection experiments suggested that D2Neg-A functions without trans-acting factors, whereas D2Neg-B interacts with nuclear factors at its Sp1 binding sequences. Gel supershift with anti-Sp1 antibody and UV cross-linking experiments revealed that a novel 130-kDa factor as well as Sp1 interact with D2Neg-B in NB41A3 cells. This novel protein recognizing Sp1 binding sequences in the D2 gene negative modulator is also found in nuclear extract from the rat striatum.	NINCDS,EXPTL THERAPEUT BRANCH,GENET PHARMACOL UNIT,BLDG 10,RM 5C116,9000 ROCKVILLE PIKE,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)				Mouradian, M. Maral/0000-0002-9937-412X				Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CRESS I, 1987, RECEPTOR BIOCH METHO, V8; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LEE T, 1978, NATURE, V274, P897, DOI 10.1038/274897a0; MAY E, 1992, J VIROL, V66, P3347, DOI 10.1128/JVI.66.6.3347-3354.1992; MINOWA MT, 1993, J BIOL CHEM, V268, P23544; MINOWA T, 1992, BIOCHEMISTRY-US, V31, P8389, DOI 10.1021/bi00151a001; MONSMA FJ, 1990, P NATL ACAD SCI USA, V87, P6723, DOI 10.1073/pnas.87.17.6723; MOURADIAN MM, 1988, ANN NEUROL, V24, P372, DOI 10.1002/ana.410240304; PIERCE AJ, 1992, NUCLEIC ACIDS RES, V20, P6583, DOI 10.1093/nar/20.24.6583; Sambrook J, 1989, MOL CLONING LABORATO; SCHACHTER M, 1980, NATURE, V286, P157, DOI 10.1038/286157a0; SEEMAN P, 1980, PHARMACOL REV, V32, P229; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0	31	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11656	11662						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157698				2022-12-25	WOS:A1994NF96600101
J	MOOKHTIAR, KA; KALINOWSKI, SS; ZHANG, DL; POULTER, CD				MOOKHTIAR, KA; KALINOWSKI, SS; ZHANG, DL; POULTER, CD			YEAST SQUALENE SYNTHASE - A MECHANISM FOR ADDITION OF SUBSTRATES AND ACTIVATION BY NADPH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESQUALENE PYROPHOSPHATE; MOLECULAR-CLONING; POTENT INHIBITOR; SYNTHETASE; PURIFICATION; SOLUBILIZATION; LIVER; GENE; BIOSYNTHESIS; DIPHOSPHATE	Squalene synthase catalyzes the condensation of two molecules of farnesyl diphosphate (FPP) to give presqualene diphosphate (PSPP) and the subsequent reductive rearrangement of PSPP to squalene. Previous studies of the mechanism of addition of FPP to the enzyme have led to conflicting interpretations of initial velocity measurements (Beytia, E., Qureshi, A. A., and Porter, J. W. (1973) J. Biol. Chem. 248,1856-1867; Agnew, W. S., and Popjak, G. (1978) J. Biol. Chem. 253,4566-4573). Initial velocities for synthesis of PSPP and squalene were measured over a wider range of FPP and NADPH concentrations than previously reported, using a soluble form of recombinant enzyme. In the absence of NADPH, PSPP formation was activated by FPP at concentrations above approximately 0.5 muM. At fixed levels of NADPH, the dependence of initial rates of PSPP and squalene synthesis on FPP concentrations indicated that the C-15 substrate added by a sequential mechanism. In addition, NADPH stimulated synthesis of PSPP by 40-fold at saturating levels of the cofactor. This stimulation is, at least in part, by reduction of PSPP to squalene.	UNIV UTAH,DEPT CHEM,SALT LAKE CITY,UT 84112; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT METAB DIS,PRINCETON,NJ 08543	Utah System of Higher Education; University of Utah; Bristol-Myers Squibb					NIGMS NIH HHS [GM 25521] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025521] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGNEW WS, 1978, J BIOL CHEM, V253, P4566; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BAXTER A, 1992, J BIOL CHEM, V267, P11705; BEYTIA E, 1973, J BIOL CHEM, V248, P1856; BILLER SA, 1988, J MED CHEM, V31, P1869, DOI 10.1021/jm00118a001; BILLER SA, 1991, J MED CHEM, V34, P1912, DOI 10.1021/jm00110a024; BILLER SA, 1991, J AM CHEM SOC, V113, P8522, DOI 10.1021/ja00022a050; CIOSEK CP, 1993, J BIOL CHEM, V268, P24832; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DAVISSON VJ, 1985, METHOD ENZYMOL, V110, P130; DEMONTELLANO PRO, 1976, J AM CHEM SOC, V98, P2018; DEMONTELLANO PRO, 1977, BIOCHEMISTRY-US, V16, P2680; DEMPSEY ME, 1974, ANNU REV BIOCHEM, V43, P967, DOI 10.1146/annurev.bi.43.070174.004535; FAUST JR, 1979, P NATL ACAD SCI USA, V76, P5018, DOI 10.1073/pnas.76.10.5018; FEGUEUR M, 1991, CURR GENET, V20, P365, DOI 10.1007/BF00317063; JENNINGS SM, 1991, P NATL ACAD SCI USA, V88, P6038, DOI 10.1073/pnas.88.14.6038; JIANG GJ, 1993, J BIOL CHEM, V268, P12818; KUSWIKRABIEGA G, 1987, J BIOL CHEM, V262, P1505; MATSUOKA S, 1991, J BIOL CHEM, V266, P3464; MCKENZIE TL, 1992, J BIOL CHEM, V267, P21368; POULTER CD, 1990, ACCOUNTS CHEM RES, V23, P70, DOI 10.1021/ar00171a003; POULTER CD, 1989, J AM CHEM SOC, V111, P3734, DOI 10.1021/ja00192a036; ROBINSON GW, 1993, MOL CELL BIOL, V13, P2706, DOI 10.1128/MCB.13.5.2706; RODRIGUEZ CL, 1990, THESIS U UTAH; SASIAK K, 1988, ARCH BIOCHEM BIOPHYS, V260, P622, DOI 10.1016/0003-9861(88)90490-0; SCHLOSS JV, 1984, BIOCHEMISTRY-US, V23, P4572, DOI 10.1021/bi00315a010; SHECHTER I, 1971, J BIOL CHEM, V246, P7690; SHECHTER I, 1992, J BIOL CHEM, V267, P8628; WEINSTEIN JD, 1986, ARCH BIOCHEM BIOPHYS, V245, P44, DOI 10.1016/0003-9861(86)90188-8; ZHANG DL, 1993, ARCH BIOCHEM BIOPHYS, V304, P133, DOI 10.1006/abbi.1993.1331	30	29	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11201	11207						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157649				2022-12-25	WOS:A1994NF96600037
J	BENEVIDES, JM; WEISS, MA; THOMAS, GJ				BENEVIDES, JM; WEISS, MA; THOMAS, GJ			RAMAN SPECTRAL STUDIES OF NUCLEIC-ACIDS .47. AN ALTERED SPECIFICITY MUTATION IN THE LAMBDA-REPRESSOR INDUCES GLOBAL REORGANIZATION OF THE PROTEIN-DNA INTERFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPERATOR-BINDING DOMAIN; N-TERMINAL DOMAIN; TURN-HELIX MOTIF; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; WILD-TYPE; RECOGNITION; SPECTROSCOPY; STABILITY; COMPLEX	The lambda repressor exhibits structural characteristics of lock and key complementarity through the helix-turn-helix motif, and of induced fit by virtue of DNA-dependent folding of the N-terminal arm. In both cases, molecular recognition is mediated by direct contacts between amino acids and DNA bases. The extent to which such contacts function as discrete elements in a protein-DNA recognition code is not known. Because of the relevance of protein recognition to the broader issue of protein design, and because the lambda system serves as a prototype for gene regulation, we have employed laser Raman and H-1 NMR spectroscopy to compare free and operator-bound structures of A repressor variants which are known to exhibit altered DNA-binding specificities. Ex perimental design is based upon a previous biochemical study of mutations in the repressor N-terminal arm (K4Q) and helix-turn-helix motif (G48S) (Nelson, H. C, M., and Sauer, R. T. (1986) J. Mol. Biol. 192, 27-38). These mutations, which were originally isolated by loss of function (K4Q) and second-site reversion (G48S), are of particular interest in light of their complex effects on sequence specificity at multiple positions in the operator site (Benson, N., Adams, C., and Youderian, P. (1992) Genetics 130, 17-26). Laser Raman and H-1 NMR spectra of repressor variants carrying one (G48S) or two mutations (K4Q/G48S) are similar to those of the native wild type repressor and are in accord with the x-ray crystal structure. Remarkably, however, the complexes of wild type and mutant repressors exhibit extensive differences both in the global DNA structure and in the environments of key functional groups along the major groove. By demonstrating that single amino acid substitutions can induce global reorganization of a protein-DNA interface, the present results establish that repressor-operator recognition in solution cannot be explained in terms of a simple recognition code.	UNIV MISSOURI,SCH BIOL SCI,DIV CELL BIOL & BIOPHYS,KANSAS CITY,MO 64110; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	University of Missouri System; University of Missouri Kansas City; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018758] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18758] Funding Source: Medline; NICHD NIH HHS [HD26465] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEAMER LJ, 1992, J MOL BIOL, V227, P177, DOI 10.1016/0022-2836(92)90690-L; BENEVIDES JM, 1991, BIOCHEMISTRY-US, V30, P5955, DOI 10.1021/bi00238a020; BENEVIDES JM, 1991, BIOCHEMISTRY-US, V30, P4381, DOI 10.1021/bi00232a003; BENEVIDES JM, 1984, NUCLEIC ACIDS RES, V12, P5913, DOI 10.1093/nar/12.14.5913; BENSON N, 1992, GENETICS, V130, P17; CLARKE ND, 1991, SCIENCE, V254, P267, DOI 10.1126/science.1833818; DIJKSTRA S, 1991, J MOL STRUCT, V242, P283, DOI 10.1016/0022-2860(91)87142-5; ELIASON JL, 1985, P NATL ACAD SCI USA, V82, P2339, DOI 10.1073/pnas.82.8.2339; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ERFURTH SC, 1972, P NATL ACAD SCI USA, V69, P938, DOI 10.1073/pnas.69.4.938; EVERTSZ EM, 1991, BIOCHEMISTRY-US, V30, P1149, DOI 10.1021/bi00218a037; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; HECHT MH, 1985, J MOL BIOL, V186, P53, DOI 10.1016/0022-2836(85)90256-6; HECHT MH, 1985, J CELL BIOCHEM, V29, P217, DOI 10.1002/jcb.240290306; HECHT MH, 1983, P NATL ACAD SCI-BIOL, V80, P2676, DOI 10.1073/pnas.80.9.2676; HOCH JC, 1987, J MAG RESON, V72, P324; HOGAN M, 1983, NATURE, V304, P752, DOI 10.1038/304752a0; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KIM J, 1993, P NATL ACAD SCI USA, V90, P4513, DOI 10.1073/pnas.90.10.4513; LAW SM, 1993, J MOL BIOL, V230, P161, DOI 10.1006/jmbi.1993.1133; LETELLIER R, 1986, J BIOMOL STRUCT DYN, V3, P671, DOI 10.1080/07391102.1986.10508455; Li Y, 1981, Prog Clin Biol Res, V64, P271; Nelson H C, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 1, P441; NELSON HCM, 1986, J MOL BIOL, V192, P27, DOI 10.1016/0022-2836(86)90461-4; NELSON HCM, 1985, CELL, V42, P549, DOI 10.1016/0092-8674(85)90112-6; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; PABO CO, 1979, P NATL ACAD SCI USA, V76, P1608, DOI 10.1073/pnas.76.4.1608; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; REILLY KE, 1992, BIOCHEMISTRY-US, V31, P3118, DOI 10.1021/bi00127a012; SARAI A, 1989, P NATL ACAD SCI USA, V86, P6513, DOI 10.1073/pnas.86.17.6513; Sauer R T, 1990, Adv Protein Chem, V40, P1, DOI 10.1016/S0065-3233(08)60286-7; SAUER RT, 1986, BIOCHEMISTRY-US, V25, P5992, DOI 10.1021/bi00368a024; SAUER RT, 1982, NATURE, V298, P447, DOI 10.1038/298447a0; SAUER RT, 1987, NEW FRONTIERS STUDY, P177; SENGUPTA PK, 1987, BIOPOLYMERS, V26, pS99, DOI 10.1002/bip.360260011; SHIMON LJW, 1993, J MOL BIOL, V232, P826, DOI 10.1006/jmbi.1993.1434; SIAMWIZA MN, 1975, BIOCHEMISTRY-US, V14, P4870, DOI 10.1021/bi00693a014; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; SUSI H, 1974, BIOCHIM BIOPHYS ACTA, V312, P311; THOMAS GJ, 1986, BIOCHEMISTRY-US, V25, P6768, DOI 10.1021/bi00370a007; THOMAS GJ, 1988, NUCLEIC ACIDS MOL BI, V2, P1; WEISS MA, 1987, BIOCHEMISTRY-US, V26, P890, DOI 10.1021/bi00377a033; WEISS MA, 1984, BIOCHEMISTRY-US, V23, P5090, DOI 10.1021/bi00317a002; WEISS MA, 1987, BIOCHEMISTRY-US, V26, P897, DOI 10.1021/bi00377a034; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8020, DOI 10.1021/bi00487a004; WEISS MA, 1990, J MAGN RESON, V86, P626, DOI 10.1016/0022-2364(90)90041-7	47	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10869	10878						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144673				2022-12-25	WOS:A1994NF01700100
J	CRICK, DC; SCOCCA, JR; RUSH, JS; FRANK, DW; KRAG, SS; WAECHTER, CJ				CRICK, DC; SCOCCA, JR; RUSH, JS; FRANK, DW; KRAG, SS; WAECHTER, CJ			INDUCTION OF DOLICHYL-SACCHARIDE INTERMEDIATE BIOSYNTHESIS CORRESPONDS TO INCREASED LONG-CHAIN CIS-ISOPRENYLTRANSFERASE ACTIVITY DURING THE MITOGENIC RESPONSE IN MOUSE B-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE N-ACETYLGLUCOSAMINE-1-PHOSPHATE TRANSFERASE; HAMSTER OVARY CELLS; ROUGH ENDOPLASMIC-RETICULUM; PROTEIN GLYCOSYLATION; SEA-URCHIN; BRAIN; CHOLESTEROL; LYMPHOCYTES; KINASE; DIFFERENTIATION	There are large increases in the rates of Glc(3)-Man(9)GlcNAc(2)-P-P-Dol (Oligo-P-P-Dol) biosynthesis and protein N-glycosylation during the proliferative response of murine B lymphocytes (B cells) to bacterial lipopolysaccharide (LPS). To learn more about the regulation of dolichyl-saccharide biosynthesis, the possible relationships between developmental changes in specific steps in dolichyl phosphate (Dol-P) and N-acetyl-glucosaminylpyrophosphoryldolichol (GlcNAc-P-P-Dol) biosynthesis and the induction of Oligo-P-P-Dol biosynthesis were investigated. These studies describe an impressive induction of long chain cis-isoprenyltransferase (cis-IPTase) activity, an enzyme system required for the chain elongation stage in de novo Dol-P synthesis, which corresponded to the striking increase in the rate of Oligo-P-P-Dol biosynthesis in LPS-activated B cells. The cellular level and specific activity of cis-IPTase increase 15-fold in LPS-treated cells with relatively unaltered affinity for isopentenyl pyrophosphate. The rates of Dol-P and Oligo-P-P-Dol synthesis increased substantially when cis-IPTase activity was induced, suggesting a regulatory relationship between the level of cis-IPTase activity and lipid intermediate synthesis. Distinctly different developmental patterns were observed for cis-IPTase and HMG-CoA reductase activity, and when sterol biosynthesis was drastically inhibited by lovastatin, the rate of synthesis of Dol-P was slightly higher in the presence of the drug. Modest elevations in the cellular levels of dolichol kinase, Dol-P phosphatase, and UDP-GlcNAc:Dol-P N-acetylglucosaminylphosphoryltransferase (L-G1PT) activities were also observed, but these changes were relatively small compared with the increases in cis-IPTase activity and the rates of Dol-P, GlcNAc-P-P-Dol, and Oligo-P-P-Dol synthesis. The expression of the L-G1PT gene is an early event in the developmental program for Oligo-P-P-Dol synthesis, but GlcNAc-P-P-Dol formation is apparently not rate-limiting. In summary, large increases in cis-IPTase activity and the rate of Dol-P biosynthesis appear to play a key regulatory role in the induction of Oligo-P-P-Dol biosynthesis during the proliferative response of B cells to LPS, and the biosynthetic pathways for Dol-P and cholesterol are regulated independently in dividing B cells.	UNIV KENTUCKY,COLL MED,ALBERT B CHANDLER MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205	University of Kentucky; Johns Hopkins University			Crick, Dean/H-8251-2017	Crick, Dean/0000-0001-9281-7058	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036065, R01GM036570] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36570, GM36065] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BHAT NR, 1991, J NEUROCHEM, V56, P339, DOI 10.1111/j.1471-4159.1991.tb02600.x; BURTON WA, 1981, J BIOL CHEM, V256, P632; CARSON DD, 1981, J BIOL CHEM, V256, P1552; CIOSEK CP, 1993, J BIOL CHEM, V268, P24832; CRICK DC, 1991, J NEUROCHEM, V57, P1354, DOI 10.1111/j.1471-4159.1991.tb08301.x; CRICK DC, 1994, J NEUROCHEM, V62, P247; CRICK DC, 1992, GLYCOBIOLOGY, V2; CRICK DC, 1993, GLYCOBIOLOGY, V3; CUMMINGS RD, 1992, GLYCOCONJUGATES COMP, P333; EGGENS I, 1990, J EXP PATHOL, V71, P219; EULLINS, 1991, IN VITRO CELL DEV, V27, pA120; HARFORD JB, 1977, BIOCHEM BIOPH RES CO, V76, P1036, DOI 10.1016/0006-291X(77)90960-3; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HUBBARD SC, 1980, J BIOL CHEM, V255, P1782; JAMES MJ, 1980, BIOCHIM BIOPHYS ACTA, V619, P432, DOI 10.1016/0005-2760(80)90094-6; KAIDEN A, 1991, SOMAT CELL MOLEC GEN, V17, P15, DOI 10.1007/BF01233202; KAIDEN A, 1991, TRENDS GLYCOSCI GLYC, V3, P275; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; KELLER RK, 1979, J BIOL CHEM, V254, P9966; KRAG SS, 1977, J BIOL CHEM, V252, P2621; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRMAN M A, 1991, Glycobiology, V1, P553, DOI 10.1093/glycob/1.6.553; LENNARZ WJ, 1985, TRENDS BIOCHEM SCI, V10, P248, DOI 10.1016/0968-0004(85)90144-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCAS JJ, 1977, J BIOL CHEM, V252, P4330; MELCHERS F, 1974, EUR J IMMUNOL, V4, P181, DOI 10.1002/eji.1830040306; PAN YT, 1990, BIOCHEMISTRY-US, V29, P8077, DOI 10.1021/bi00487a013; POTTER JER, 1981, J BIOL CHEM, V256, P2371; RIP JW, 1985, PROG LIPID RES, V24, P269, DOI 10.1016/0163-7827(85)90008-6; RODRIGUEZVICO F, 1989, ANAL BIOCHEM, V183, P275, DOI 10.1016/0003-2697(89)90479-X; ROSSIGNOL DP, 1981, J BIOL CHEM, V256, P538; RUSH J S, 1991, Glycobiology, V1, P229, DOI 10.1093/glycob/1.2.229; RUSH JS, 1988, ARCH BIOCHEM BIOPHYS, V267, P305, DOI 10.1016/0003-9861(88)90036-7; RUSH JS, 1991, ARCH BIOCHEM BIOPHYS, V284, P63, DOI 10.1016/0003-9861(91)90264-J; RUSH JS, 1987, ARCH BIOCHEM BIOPHYS, V259, P567, DOI 10.1016/0003-9861(87)90523-6; SAGAMI H, 1993, J BIOL CHEM, V268, P10109; Sambrook J, 1989, MOL CLONING LABORATO; SCOCCA JR, 1990, J BIOL CHEM, V265, P20621; SHOHAT M, 1973, EUR J IMMUNOL, V3, P680, DOI 10.1002/eji.1830031106; SINENSKY M, 1990, J BIOL CHEM, V265, P19937; SPIRO MJ, 1986, J BIOL CHEM, V261, P4725; SUMBILLA C, 1985, METHOD ENZYMOL, V111, P471; VOLPE JJ, 1987, DEV BRAIN RES, V31, P193, DOI 10.1016/0165-3806(87)90117-9; WAECHTER CJ, 1983, J BIOL CHEM, V258, P5117; WAECHTER CJ, 1989, NEUROBIOLOGY GLYCOCO, P127; WALDMAN BC, 1987, J CELL PHYSIOL, V131, P302, DOI 10.1002/jcp.1041310303; WHITE DA, 1981, ARCH BIOCHEM BIOPHYS, V208, P30, DOI 10.1016/0003-9861(81)90119-3; ZHU JF, 1993, GLYCOBIOLOGY, V3; ZHU XY, 1990, J BIOL CHEM, V265, P14250; ZHU XY, 1992, J BIOL CHEM, V267, P8895; [No title captured]	53	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10559	10565						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144643				2022-12-25	WOS:A1994NF01700057
J	LI, CY; WATKINS, JA; GLASS, J				LI, CY; WATKINS, JA; GLASS, J			THE H+-ATPASE FROM RETICULOCYTE ENDOSOMES RECONSTITUTED INTO LIPOSOMES ACTS AS AN IRON TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOCYTIC VESICLES; ADENOSINE-TRIPHOSPHATASE; TRANSFERRIN; MEMBRANE; SUBUNIT; MOBILIZATION; BINDING; F1	The H+-ATPase from reticulocyte endosomes was purified and reconstituted into liposomes, and protein-dependent iron transport was observed. Reconstitution of the H+-ATPase into liposomes was performed by sonicating a lipid mixture, with a composition similar to the reticulocyte plasma membrane, in a buffer containing ferric citrate. The nonencapsulated iron:citrate was removed by gel filtration and the proteoliposomes diluted into 1 mM FerroZine. Upon addition of ascorbate, an initial efflux of 2.9 +/- 0.3 x 10(-2) mu mol of iron/mg of ATPase/min and 56 +/- 7% of total internal Fe(II) was detected by formation of the Fe(II)-FerroZine complex with an absorbance at 562 nm or radioactivity of Fe-59(II)-FerroZine following separation using gel filtration. Both thiosulfate and ferrocyanide could substitute for ascorbate. Citrate or EGTA could substitute for FerroZine. The initial rate of Fe(II) efflux was decreased by 41 or 17% using 100 mu M of the cation channel inhibitor N,N'-dicyclohexylcarbodiimide or 70 mu M of the ATP hydrolysis inhibitor N-ethylmaleimide, respectively, but was unaffected by the presence of ATP. The amount of iron transported was decreased 51 or 39% by 100 mu M N,N'-dicyclohexylcarbodiimide or 70 mu M of the ATPase inhibitor 7-chloro-4-nitrobenz-2-oxa-1,3-dazole. The amount of Fe(III) transport was 80% lower than Fe(II) when reductants were not present internally or externally although the apparent rate constants were identical when ascorbate was externally present. These results suggest that this vacuolar H+-ATPase may transport iron.	LOUISIANA STATE UNIV,CTR MED,CTR EXCELLENCE CANC RES TREATMENT & EDUC,DEPT MED,DIV HEMATOL ONCOL,SHREVEPORT,LA 71130	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK037866, R01DK037866] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-37866] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; CHEN JW, 1984, BIOCHIM BIOPHYS ACTA, V777, P151, DOI 10.1016/0005-2736(84)90508-X; CHOE HR, 1987, BLOOD, V70, P1035; COWART RE, 1993, ANAL BIOCHEM, V211, P151, DOI 10.1006/abio.1993.1246; EGYED A, 1988, BRIT J HAEMATOL, V68, P483, DOI 10.1111/j.1365-2141.1988.tb04241.x; FENG Y, 1992, J BIOL CHEM, V267, P5817; HAMAZAKI S, 1992, EXP HEMATOL, V20, P436; HANADA H, 1991, BIOCHEM BIOPH RES CO, V176, P1062, DOI 10.1016/0006-291X(91)90391-J; INMAN RS, 1993, J BIOL CHEM, V268, P8521; KOHLBRENNER WE, 1982, J BIOL CHEM, V257, P3441; LI CY, 1993, FASEB J, V7, pA817; LI CY, 1993, BIOPHYS J, V64, pA335; LI CY, 1991, FASEB J, V5, pA749; LI CY, 1991, BLOOD, V78, pA87; LIPPE G, 1991, BIOCHEM BIOPH RES CO, V181, P764, DOI 10.1016/0006-291X(91)91256-C; MORGAN EH, 1988, BIOCHIM BIOPHYS ACTA, V943, P428, DOI 10.1016/0005-2736(88)90374-4; NUMA MS, 1991, EUR J CELL BIOL, V56, P19; NUNEZ MT, 1990, J BIOL CHEM, V265, P6688; SENIOR AE, 1980, J BIOL CHEM, V255, P7211; SIMPSON RJ, 1987, BIOCHIM BIOPHYS ACTA, V898, P187, DOI 10.1016/0005-2736(87)90037-X; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016; SUUN SZ, 1987, J BIOL CHEM, V262, P14790; THORSTENSEN K, 1988, J BIOL CHEM, V263, P16837; WATKINS JA, 1992, BIOCHEMISTRY-US, V31, P5820, DOI 10.1021/bi00140a018; WHITE MD, 1976, BIOCHIM BIOPHYS ACTA, V436, P567, DOI 10.1016/0005-2736(76)90441-7	25	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10242	10246						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144605				2022-12-25	WOS:A1994NF01700014
J	PANIGRAHI, GB; SADOWSKI, PD				PANIGRAHI, GB; SADOWSKI, PD			INTERACTION OF THE NH2-TERMINAL AND COOH-TERMINAL DOMAINS OF THE FLP RECOMBINASE WITH THE FLP RECOGNITION TARGET SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST PLASMID; 2-MU CIRCLE; DNA; PROTEIN; SITE; CONTACTS; BINDING; CLEAVAGE; GROOVES	The FLP protein that is encoded by the 2-mu M plasmid of yeast Saccharomyces cerevisiae is a 45-kDa site-specific recombinase that belongs to the Int family of recombination proteins. FLP catalyzes a recombination event within the plasmid by binding specifically to each of three 13-base pair (bp) symmetry elements of the FLP recognition target (FRT). We have shown previously that partial proteolysis of the FLP protein by proteinase H resulted in a COOH-terminal fragment of size 32 kDa (P32) and an NH2-terminal fragment of 13 kDa (P13). In this study we have used footprinting with dimethyl sulfate to show that P32 binds specifically to the outer 9 bp of the 13 bp symmetry element. Binding of P13 alone to the FRT site was not detectable in this assay. However, when P13 and P32 were incubated together with the FRT site, protection of the remaining 4-bp region of the symmetry element was observed. To confirm these results we used bromodeoxyuridine (BrdU)-dependent UV cross-linking. P32 became crosslinked to the substrate that contained BrdU substitutions in the outer 9 bp of a 13-bp symmetry element, but not to one with the BrdU substitutions in the inner 4 bp. Reciprocally P13 cross-linked to the latter substrate but not the former. Cross-linking was both BrdU and ultraviolet light dependent. This study indicates that the COOH-terminal domain (P32) of FLP recognizes the outer 9 bp of the 13-bp symmetry element, whereas its NH2-terminal domain (P13) is needed for protection of the inner 4 bp of each symmetry element.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ON,CANADA	University of Toronto								ABDELMEGUID SS, 1984, P NATL ACAD SCI-BIOL, V81, P2001, DOI 10.1073/pnas.81.7.2001; ANDREWS BJ, 1987, J MOL BIOL, V193, P345, DOI 10.1016/0022-2836(87)90223-3; ANDREWS BJ, 1985, CELL, V40, P795, DOI 10.1016/0092-8674(85)90339-3; BEATTY LG, 1988, J MOL BIOL, V204, P283, DOI 10.1016/0022-2836(88)90576-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROACH JR, 1980, CELL, V21, P501, DOI 10.1016/0092-8674(80)90487-0; BRUCKNER RC, 1986, J BIOL CHEM, V261, P1798; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; HARTLEY JL, 1980, NATURE, V286, P860, DOI 10.1038/286860a0; HOESS R, 1990, J MOL BIOL, V216, P873, DOI 10.1016/S0022-2836(99)80007-2; HUTCHINSON F, 1973, Q REV BIOPHYS, V6, P201, DOI 10.1017/S0033583500001141; PAN G, 1991, J BIOL CHEM, V226, P11347; PAN GH, 1993, J BIOL CHEM, V268, P22546; PAN GH, 1993, MOL CELL BIOL, V13, P3167, DOI 10.1128/MCB.13.6.3167; PAN GH, 1992, J BIOL CHEM, V267, P12397; PANIGRAHI GB, 1992, NUCLEIC ACIDS RES, V20, P5927, DOI 10.1093/nar/20.22.5927; PANIGRAHI GB, 1991, BIOCHEMISTRY-US, V30, P9761, DOI 10.1021/bi00104a028; SENECOFF JF, 1988, J MOL BIOL, V201, P405, DOI 10.1016/0022-2836(88)90147-7	18	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10940	10945						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144679				2022-12-25	WOS:A1994NF01700109
J	SALTO, R; BABE, LM; LI, J; ROSE, JR; YU, ZH; BURLINGAME, A; DEVOSS, JJ; SUI, ZH; DEMONTELLANO, PO; CRAIK, CS				SALTO, R; BABE, LM; LI, J; ROSE, JR; YU, ZH; BURLINGAME, A; DEVOSS, JJ; SUI, ZH; DEMONTELLANO, PO; CRAIK, CS			IN-VITRO CHARACTERIZATION OF NONPEPTIDE IRREVERSIBLE INHIBITORS OF HIV PROTEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS-1; TYPE-2; SITE; INACTIVATION; CONSTRUCTION; INFECTIVITY; MATURATION; PROTEINASE; ENZYMES; DESIGN	The irreversible inhibition of human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-8) proteases by 1,2-epoxy-3-(p-nitrophenoxy)propane (EPNP) and eight haloperidol derivatives has been studied. EPNP specifically inhibits HIV-1 and HIV-2 proteases with a stoichiometry of one EPNP molecule/dimeric enzyme. The site of modification of HIV-2 protease by EPNP has been unambiguously identified as Asp-25 using high performance tandem mass spectrometry. The haloperidol derivatives assayed consist of epoxides, ynones, and alpha,beta- unsaturated ketones. The K-inact values for these haloperidol derivatives range from 10.7 to 521 mu m for HIV-1 protease and from 8.6 to 283 mu m for the HIV-2 enzyme, being in some cases similar to 1000-fold more potent irreversible inhibitors of HIV proteases than EPNP This potency results from the haloperidol character of the compounds and the chemical reactivity of the groups capable of forming a covalent bond with the enzyme. Covalent modification of HIV-2 protease by a radiolabeled epoxide derivative of haloperidol, UCSF 84, is prevented by EPNP and the peptidomimetic transition state analog U-85548. In similar experiments, incorporation of UCSF 84 into HIV-1 protease is partially prevented by these active-site inhibitors. In contrast, a mutant HIV-1 protease, HIV-1 PR C95M, in which Cys-95 has been replaced by Met, is labeled 50% less than HIV-1 protease and is fully protected by EPNP and U-85548. These results indicate the presence of 2 reactive residues in HTV-1 protease: Cys-95 and another located in the active site of the enzyme. The alpha,beta-unsaturated ketone derivative of halo peridol, UCSF 191, which is stable over a broad pH range, was used to study the pH profile of inactivation of HPV-1 and HIV-2 proteases. Comparison of the profiles of inactivation of wild-type HTV-1 protease, HPV-1 PR C95M, and HIV-1 PR C67L as well as HIV-2 protease (which has no cysteine residues) reveals the contribution of Cys-95 to the reactivity of these irreversible inhibitors. The inhibitors UCSF 70, UCSF 84, UCSF 115, UCSF 142, and UCSF 191 reduce p55(gag) polyprotein processing when assayed in a mammalian cell line that produces HIV-1 viral particles lacking the envelope.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Salto, Rafael/A-6486-2011	Salto, Rafael/0000-0002-7044-3611	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM039552] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 07175, GM39552] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472; BABE LM, 1990, UCLA SYM BI, V110, P71; CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430; DESJARLAIS RL, 1990, P NATL ACAD SCI USA, V87, P6644, DOI 10.1073/pnas.87.17.6644; DEVOSS J, 1994, IN PRESS J MED CHEM; FRANCHINI G, 1988, AIDS RES HUM RETROV, V4, P243, DOI 10.1089/aid.1988.4.243; GRANT SK, 1992, BIOORG MED CHEM LETT, V2, P1441, DOI 10.1016/S0960-894X(00)80528-4; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; JAMES MNG, 1977, NATURE, V267, P808, DOI 10.1038/267808a0; KARLSTROM AR, 1993, ARCH BIOCHEM BIOPHYS, V304, P163, DOI 10.1006/abbi.1993.1334; KNOWLES JR, 1987, SCIENCE, V236, P1252; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0; LEGRICE SFJ, 1989, J BIOL CHEM, V264, P14902; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MEEK TD, 1989, P NATL ACAD SCI USA, V86, P1841, DOI 10.1073/pnas.86.6.1841; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; MULICHAK AM, 1993, J BIOL CHEM, V268, P13103; PAGE KA, 1990, J VIROL, V64, P5270, DOI 10.1128/JVI.64.11.5270-5276.1990; PICHUANTES S, 1990, J BIOL CHEM, V265, P13890; RICH DH, 1990, J MED CHEM, V33, P1285, DOI 10.1021/jm00167a003; RICHMAN DD, 1993, ANNU REV PHARMACOL, V33, P149, DOI 10.1146/annurev.pa.33.040193.001053; RITTENHOUSE J, 1990, BIOCHEM BIOPH RES CO, V171, P60, DOI 10.1016/0006-291X(90)91356-W; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; ROESTORFF P, 1984, J BIOMED MASS SPECTR, V11, P601; ROSE JR, 1993, J BIOL CHEM, V268, P11939; RUTENBER E, 1993, J BIOL CHEM, V268, P15343; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SUI ZH, 1993, SYNTHESIS-STUTTGART, P803; TANG J, 1971, J BIOL CHEM, V246, P4510; TOMASSELLI AG, 1990, BIOCHEMISTRY-US, V29, P264, DOI 10.1021/bi00453a036; TOMASSELLI AG, 1990, J BIOL CHEM, V265, P14675; TOTH MV, 1990, INT J PEPT PROT RES, V36, P544	35	39	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10691	10698						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144659				2022-12-25	WOS:A1994NF01700075
J	BURKS, RT; KESSIS, TD; CHO, KR; HEDRICK, L				BURKS, RT; KESSIS, TD; CHO, KR; HEDRICK, L			MICROSATELLITE INSTABILITY IN ENDOMETRIAL CARCINOMA	ONCOGENE			English	Article							GENE-MUTATIONS; P53	Microsatellite instability (MI), detected as electrophoretic shifts in allele sizes of microsatellite DNA sequences, has been identified in some colorectal carcinomas. Investigators have previously attributed such microsatellite instability to replication errors (RER). The colorectal carcinomas with RER have been found to arise either sporadically or in association with the hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Because endometrial carcinoma is also commonly associated with HNPCC, we studied 30 cases of endometrial carcinoma to characterize the presence of MI in these neoplasms. Seven cases (23%) showed MI. Four cases showed both Type I (large shifts) and Type II (small shifts) mutation patterns and the remaining three cases showed Type I mutations only. We conclude that MI frequently occurs in endometrial cancers and that this type of genetic alteration may be an important pathogenetic feature of this tumor type.	JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205	Johns Hopkins University				Cho, Kathleen/0000-0003-0500-9998				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; ENOMOTO T, 1990, CANCER RES, V50, P6139; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; IGNARTROWBRIDGE D, 1992, AM J OBSTET GYNECOL, V167, P227, DOI 10.1016/S0002-9378(11)91663-9; IMAMURA T, 1992, INT J CANCER, V51, P47, DOI 10.1002/ijc.2910510110; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LYNCH HT, 1985, CANCER, V56, P934, DOI 10.1002/1097-0142(19850815)56:4<934::AID-CNCR2820560439>3.0.CO;2-I; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; OKAMOTO A, 1991, CANCER RES, V51, P5632; PELOYPELTOMAKI P, 1993, SCIENCE, V260, P810; RISINGER JI, 1992, MOL CARCINOGEN, V5, P250, DOI 10.1002/mc.2940050403; Rousseau Francois, 1992, Human Mutation, V1, P91, DOI 10.1002/humu.1380010202; SASAKI H, 1993, CANCER RES, V53, P1906; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122	19	214	219	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1163	1166						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134118				2022-12-25	WOS:A1994NC04800019
J	FORCE, WR; SPINDLER, SR				FORCE, WR; SPINDLER, SR			3,5,3'-L-TRIIODOTHYRONINE (THYROID HORMONE)-INDUCED PROTEIN-DNA INTERACTIONS IN THE THYROID-HORMONE RESPONSE ELEMENTS AND CELL-TYPE-SPECIFIC ELEMENTS OF THE RAT GROWTH-HORMONE GENE REVEALED BY IN-VIVO DIMETHYL SULFATE FOOTPRINTING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; LIGATION MEDIATED PCR; AUXILIARY PROTEIN; NUCLEAR PROTEINS; BINDING-SITES; T3 RECEPTOR; POU-DOMAIN; PROMOTER; PITUITARY; EXPRESSION	The cell type-specific element and 3,5,3'-L-triiodothyronine (thyroid hormone) (T3) response element of the rat growth hormone gene act synergistically to produce cell type-specific, T3-regulated expression. Pit-1 is a pituitary cell type-specific transcription factor that binds the cell type-specific element and is essential to its activity. T3 receptors bind as homodimers and heterodimers to the T3 response element and are essential for its activity. Here, we report the use of ligation-mediated polymerase chain reaction in vivo dimethyl sulfate footprinting to study the effects of T3 on protein-DNA interactions in the rat growth hormone gene promoter in vivo. T3-responsive guanine methylation was detected only in and near the T3 response element and the Pit-1 binding sites. The results indicate that within 2 h, T3 induces occupancy of the T3 response element and Pit-1 sites by their respective trans-acting factors in vivo.	UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521	University of California System; University of California Riverside					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040164] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40164] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; BANCROFT FC, 1969, J CELL BIOL, V43, P432, DOI 10.1083/jcb.43.3.432; BANCROFT FC, 1970, IN VITRO CELL DEV B, V6, P180; BRENT GA, 1989, J BIOL CHEM, V264, P178; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BRENT GA, 1988, MOL ENDOCRINOL, V2, P792, DOI 10.1210/mend-2-9-792; CASANOVA JN, 1985, J BIOL CHEM, V60, P11744; CATANZARO DF, 1987, MOL ENDOCRINOL, V1, P90, DOI 10.1210/mend-1-1-90; COPP RP, 1989, MOL ENDOCRINOL, V3, P790, DOI 10.1210/mend-3-5-790; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; CREW MD, 1986, J BIOL CHEM, V261, P5018; DALMAN FC, 1990, J BIOL CHEM, V265, P3615; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DAVIS KD, 1992, J BIOL CHEM, V267, P3185; EVANS RM, 1982, P NATL ACAD SCI-BIOL, V79, P7659, DOI 10.1073/pnas.79.24.7659; FERL RJ, 1987, J BIOL CHEM, V262, P7947; FORCE WR, 1994, J BIOL CHEM, V269, P8863; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GARCIAVILLALBA P, 1993, BIOCHEM BIOPH RES CO, V191, P580, DOI 10.1006/bbrc.1993.1257; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GUERIN SL, 1988, MOL ENDOCRINOL, V2, P1101, DOI 10.1210/mend-2-11-1101; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; HROMAS R, 1988, NUCLEIC ACIDS RES, V19, P953; INGRAHAM HA, 1990, ANNU REV PHYSIOL, V52, P773; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KIM HS, 1992, MOL ENDOCRINOL, V6, P1489, DOI 10.1210/me.6.9.1489; KING IN, 1993, J BIOL CHEM, V268, P495; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; KOLCHINSKY AM, 1976, NUCLEIC ACIDS RES, V3, P11, DOI 10.1093/nar/3.1.11; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIRA SA, 1993, MOL ENDOCRINOL, V7, P694, DOI 10.1210/me.7.5.694; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; NELSON C, 1986, NATURE, V322, P557, DOI 10.1038/322557a0; NYBORG JK, 1986, J BIOL CHEM, V261, P5685; NYBORG JK, 1985, ENDOCRINOLOGY, V116, P2361, DOI 10.1210/endo-116-6-2361; PAN WT, 1990, J BIOL CHEM, V265, P7022; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; SALUZ H, 1989, P NATL ACAD SCI USA, V86, P2602, DOI 10.1073/pnas.86.8.2602; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; SCHAUFELE F, 1990, J BIOL CHEM, V265, P14592; SPINDLER SR, 1982, J BIOL CHEM, V257, P1627; STRAIT KA, 1992, MOL ENDOCRINOL, V6, P1874, DOI 10.1210/me.6.11.1874; TANSEY WP, 1993, J BIOL CHEM, V268, P14906; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; TASHJIAN AH, 1972, 4TH P INT C END, P648; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; VOZ ML, 1992, MOL CELL BIOL, V12, P3991, DOI 10.1128/MCB.12.9.3991; WEST BL, 1987, MOL CELL BIOL, V7, P1193, DOI 10.1128/MCB.7.3.1193; WIGHT PA, 1988, MOL ENDOCRINOL, V2, P536, DOI 10.1210/mend-2-6-536; WILLIAMS GR, 1991, J BIOL CHEM, V266, P19636; YE ZS, 1988, J BIOL CHEM, V263, P7821; YE ZS, 1987, J BIOL CHEM, V262, P6313; YEN PM, 1992, J BIOL CHEM, V267, P23248; YEN PM, 1992, J BIOL CHEM, V267, P3656; YU LY, 1977, J BIOL CHEM, V252, P3870; ZHANG X, 1992, NATURE, V358, P581; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	69	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9682	9686						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144557				2022-12-25	WOS:A1994NE05300046
J	YANG, ZY; ENGEL, JD				YANG, ZY; ENGEL, JD			BIOCHEMICAL-CHARACTERIZATION OF THE DEVELOPMENTAL STAGE-SPECIFIC AND TISSUE-SPECIFIC ERYTHROID TRANSCRIPTION FACTOR, NF-E4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN GENE; NUCLEAR-PROTEIN FACTORS; DOMINANT CONTROL REGION; BINDING-PROTEIN; GEL-ELECTROPHORESIS; CELL LINES; PROMOTER; ENHANCER; EXPRESSION; ELEMENT	Analysis of the nuclear factors responsible for erythroid gene regulation has led to the cloning of several transcriptional regulatory proteins with clear lines of evidence suggesting or demonstrating their roles in tissue-specific gene expression. However, the erythroid cell lineage-restricted proteins that have been characterized to date do not differ significantly in activity during the distinct developmental stages of erythropoiesis, a characteristic that might be expected for a nuclear factor that actively participates in the differential regulation of various alpha- or beta-type globin genes (called globin gene switching) at distinct stages of embryonic development. We reported previously the identification of such a differentially expressed DNA binding activity, which appeared to be present in mature definitive (adult) erythroid cells but absent in immature definitive or primitive (embryonic) erythroid cells. Here we detail the biochemical properties of this erythroid tissue- and developmental stage-specific DNA binding activity (called nuclear factor-erythroid 4; NF-E4), which contains characteristics of a molecule that may be intimately involved in globin gene switching.	NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA	Northwestern University					NHLBI NIH HHS [HL 24415] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024415] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA Y, 1974, BIKEN J, V17, P105; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANTONIOU M, 1988, EMBO J, V7, P377, DOI 10.1002/j.1460-2075.1988.tb02824.x; BARTON MC, 1993, GENE DEV, V7, P1796, DOI 10.1101/gad.7.9.1796; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; BROWN JL, 1974, J BIOL CHEM, V249, P3960; BRUNS GAP, 1973, PHILOS T ROY SOC B, V266, P225, DOI 10.1098/rstb.1973.0050; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CATALA F, 1989, NUCLEIC ACIDS RES, V17, P3811, DOI 10.1093/nar/17.10.3811; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHOI OR, 1986, NATURE, V323, P731, DOI 10.1038/323731a0; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; DOLAN M, 1981, CELL, V24, P669, DOI 10.1016/0092-8674(81)90093-3; DOLAN M, 1983, J BIOL CHEM, V258, P3983; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EMERSON BM, 1989, CELL, V57, P1189, DOI 10.1016/0092-8674(89)90056-1; EMERSON BM, 1987, P NATL ACAD SCI USA, V84, P4786, DOI 10.1073/pnas.84.14.4786; EMERSON BM, 1985, CELL, V41, P21, DOI 10.1016/0092-8674(85)90057-1; EMERSON BM, 1984, P NATL ACAD SCI-BIOL, V81, P95, DOI 10.1073/pnas.81.1.95; ENGEL JD, 1991, SEMIN HEMATOL, V28, P158; FOLEY KP, 1992, GENE DEV, V6, P730, DOI 10.1101/gad.6.5.730; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALLARDA JL, 1989, GENE DEV, V3, P1845, DOI 10.1101/gad.3.12a.1845; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HESSE JE, 1986, P NATL ACAD SCI USA, V83, P4312, DOI 10.1073/pnas.83.12.4312; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JENDRISAK J, 1987, METHOD ENZYMOL, V152, P359; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LEONARD MW, 1993, DEVELOPMENT, V119, P519; LEWIS CD, 1988, GENE DEV, V2, P863, DOI 10.1101/gad.2.7.863; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; MANTOVANI R, 1988, NUCLEIC ACIDS RES, V16, P4299, DOI 10.1093/nar/16.10.4299; MILLER LJ, 1993, MOL CELL BIOL, V13, P2776; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NICKOL JM, 1988, P NATL ACAD SCI USA, V85, P2548, DOI 10.1073/pnas.85.8.2548; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PRUZINA S, 1991, NUCLEIC ACIDS RES, V19, P1413, DOI 10.1093/nar/19.7.1413; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; XIAO JH, 1987, GENE DEV, V1, P794, DOI 10.1101/gad.1.8.794; YAMAMOTO M, 1985, P NATL ACAD SCI USA, V82, P3702, DOI 10.1073/pnas.82.11.3702; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANG ZY, 1991, JH S CONT M, P249	60	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					10079	10087						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144507				2022-12-25	WOS:A1994NE05300102
J	HURLEY, MM; ABREU, C; GRONOWICZ, G; KAWAGUCHI, H; LORENZO, J				HURLEY, MM; ABREU, C; GRONOWICZ, G; KAWAGUCHI, H; LORENZO, J			EXPRESSION AND REGULATION OF BASIC FIBROBLAST GROWTH-FACTOR MESSENGER-RNA LEVELS IN MOUSE OSTEOBLASTIC MC3T3-E1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY ENDOTHELIAL-CELLS; FACTOR GENE-EXPRESSION; MESSENGER-RNA; FACTOR-BETA; EXTRACELLULAR-MATRIX; ALKALINE-PHOSPHATASE; NUCLEOTIDE-SEQUENCE; COLLAGEN-SYNTHESIS; DNA-SYNTHESIS; BONE-CELLS	Basic fibroblast growth factor (bFGF) is a potent mitogen for bone cells and is a constituent of the bone matrix. We have found that osteoblastic MC3T3-E1 cells expressed bFGF mRNA transcript of 4.5 kilobases (kb). We examined factors that regulate the expression of bFGF mRNA and protein in MC3T3-E1 cells. Treatment of MC3T3-E1 cells with bFGF (10 nM) for 4-48 h induced another 7-kb bFGF transcript at 4 h. Treatment of MC3T3-E1 cells with TGF beta (10 ng/ml) also induced the 7-kb transcript of bFGF mRNA. In contrast, heparin, parathyroid hormone, and interleukin-1 had no effect on bFGF mRNA. Western blot analyses revealed that MC3T3-E1 cells produced a 24-kDa bFGF protein, which was increased by TGF beta. Immunofluorescence showed that bFGF protein was localized to the cytoplasm in serum deprived MC3T3-E1 cells. Treatment of these cultures with medium containing fetal calf serum or TGF beta caused increased cytoplasmic staining for bFGF and marked shape change. Furthermore, in the cells treated with TGF beta there was both nuclear and cytoplasmic staining for the protein. These data demonstrate that bFGF mRNA and protein are expressed in osteoblastic cells and are regulated by treatment with TGF beta and bFGF. Production of bFGF may be important as an autocrine and paracrine mediator of bone cell replication, differentiation, and function.	UNIV CONNECTICUT,CTR HLTH,DEPT ORTHOPED,FARMINGTON,CT 06030; NEWINGTON VET HOSP,DEPT MED,NEWINGTON,CT 06470	University of Connecticut	HURLEY, MM (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT MED,DIV ENDOCRINOL & METAB,FARMINGTON,CT 06030, USA.			Gronowicz, Gloria/0000-0001-7158-3598	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042362, P01AR038933, R01AR042368] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-42362, AR-38933, AR-42368] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; AZIZKHAN JC, 1980, P NATL ACAD SCI-BIOL, V77, P2762, DOI 10.1073/pnas.77.5.2762; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CANALIS E, 1988, J CLIN INVEST, V81, P1572, DOI 10.1172/JCI113490; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3987; GLOBUS RK, 1989, ENDOCRINOLOGY, V124, P1539, DOI 10.1210/endo-124-3-1539; GLOBUS RK, 1988, ENDOCRINOLOGY, V123, P98, DOI 10.1210/endo-123-1-98; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; Gospodarowicz D, 1990, CLIN ORTHOP RELAT R, V257, P231; HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665; Hill DJ, 1992, GROWTH FACTORS, V6, P277, DOI 10.3109/08977199209021540; HIRAKI Y, 1988, AIOCH BIOPHYS AC, V966, P91; HORTON WE, 1989, J CELL PHYSIOL, V141, P8, DOI 10.1002/jcp.1041410103; HURLEY MM, 1993, J BIOL CHEM, V268, P5588; HURLEY MM, 1992, ENDOCRINOLOGY, V130, P2675, DOI 10.1210/en.130.5.2675; IBBOTSON KJ, 1989, J BONE MINER RES, V4, P37; INOUE H, 1989, J CELL PHYSIOL, V138, P329, DOI 10.1002/jcp.1041380216; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KUROKAWA T, 1987, FEBS LETT, V213, P189, DOI 10.1016/0014-5793(87)81489-8; LOGAN A, 1990, J ENDOCRINOL, V125, P339, DOI 10.1677/joe.0.1250339; MCCARTHY TL, 1989, ENDOCRINOLOGY, V125, P2118, DOI 10.1210/endo-125-4-2118; MIGNATTI P, 1991, J CELL BIOCHEM, V47, P201, DOI 10.1002/jcb.240470303; MOENNER M, 1986, P NATL ACAD SCI USA, V83, P5024, DOI 10.1073/pnas.83.14.5024; MORRISON R, 1981, J BIOL CHEM, V266, P728; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MURPHY PR, 1988, MOL ENDOCRINOL, V2, P591, DOI 10.1210/mend-2-7-591; NODA M, 1989, J CELL BIOL, V109, P2529, DOI 10.1083/jcb.109.5.2529; NUGENT MA, 1992, J BIOL CHEM, V267, P21256; PLOUET J, 1989, J CELL PHYSIOL, V141, P392, DOI 10.1002/jcp.1041410221; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RODAN SB, 1989, J BIOL CHEM, V264, P19934; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SANDBERG M, 1988, DEV BIOL, V130, P324, DOI 10.1016/0012-1606(88)90438-1; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SEYEDIN SM, 1985, P NATL ACAD SCI USA, V82, P2267, DOI 10.1073/pnas.82.8.2267; SHEN V, 1989, BONE MINER, V7, P205, DOI 10.1016/0169-6009(89)90078-0; SHIMASAKI S, 1988, BIOCHEM BIOPH RES CO, V157, P256, DOI 10.1016/S0006-291X(88)80041-X; SHING Y, 1984, SCIENCE, V223, P1926; STERNFELD MD, 1988, J CELL PHYSIOL, V136, P297, DOI 10.1002/jcp.1041360212; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WEEKS DL, 1989, CELL, V1, P861; WEICH HA, 1991, J CELL BIOCHEM, V47, P158, DOI 10.1002/jcb.240470209	51	104	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9392	9396						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132679				2022-12-25	WOS:A1994NB41100112
J	BARTELS, F; BERGEL, H; BIGALKE, H; FREVERT, J; HALPERN, J; MIDDLEBROOK, J				BARTELS, F; BERGEL, H; BIGALKE, H; FREVERT, J; HALPERN, J; MIDDLEBROOK, J			SPECIFIC ANTIBODIES AGAINST THE ZN2+-BINDING DOMAIN OF CLOSTRIDIAL NEUROTOXINS RESTORE EXOCYTOSIS IN CHROMAFFIN CELLS TREATED WITH TETANUS OR BOTULINUM A NEUROTOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIC-STRENGTH SOLUTION; LIGHT CHAIN; NEUROTRANSMITTER RELEASE; INHIBITS EXOCYTOSIS; TOXIN; PROTEINS; GANGLIOSIDES; ZINC	Although tetanus and botulinum A neurotoxins are ineffective in cultured chromaffin cells, they will inhibit carbachol-induced release of noradrenaline provided they gain access to the cytosol either through artificial pores generated in the plasma membrane or by binding to incorporated exogenous gangliosides. The block of exocytosis persists for weeks followed by a slow recovery of cell function. When specific anti-botulinum A toxin antibodies are introduced into cells through pores after manifestation of the block by botulinum A neurotoxin, restoration of exocytotic function is accelerated and fully reestablished within 4 days. The same time course of restoration is seen with anti-tetanus toxin antibodies in cells poisoned by tetanus toxin. Since the light chains of the toxins are enzymatically active, we have introduced polyclonal and monoclonal anti-light chain antibodies into the cytosol. Of all light chain antibodies tested, only those directed against the peptide homologous to the zinc-binding sequence, which is present in both neurotoxins, restored exocytosis regardless of which toxin caused the block. These results indicate that the zinc-binding domain is directly involved in the interaction of the light chains with their substrates and that the toxins have to be present continuously to maintain the block.	MED SCH HANNOVER,INST TOXICOL,D-30625 HANNOVER,GERMANY; PHARMATEC,D-60486 FRANKFURT,GERMANY; US FDA,PUBL HLTH SERV,BETHESDA,MD 20892; USA,MED RES INST INFECT DIS,DIV TOXICOL,FREDERICK,MD 21701	Hannover Medical School; United States Public Health Service; US Food & Drug Administration (FDA)								AHNERTHILGER G, 1989, FEBS LETT, V242, P245, DOI 10.1016/0014-5793(89)80478-8; AHNERTHILGER G, 1989, J NEUROCHEM, V52, P1751, DOI 10.1111/j.1471-4159.1989.tb07253.x; ALDERSON K, 1991, NEUROLOGY, V41, P1800, DOI 10.1212/WNL.41.11.1800; AMBACHE N, 1948, NATURE, V161, P482, DOI 10.1038/161482b0; BARTELS F, 1992, INFECT IMMUN, V60, P302, DOI 10.1128/IAI.60.1.302-307.1992; BERGEY GK, 1987, J NEUROPHYSIOL, V57, P121, DOI 10.1152/jn.1987.57.1.121; BITTNER MA, 1989, J BIOL CHEM, V264, P10354; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; CURTIS D R, 1968, Brain Research, V10, P208, DOI 10.1016/0006-8993(68)90123-6; DASGUPTA BR, 1984, TOXICON, V22, P415, DOI 10.1016/0041-0101(84)90085-0; DUCHEN LW, 1968, Q J EXP PHYSIOL CMS, V53, P84, DOI 10.1113/expphysiol.1968.sp001948; HABERMANN E, 1988, J NEUROCHEM, V51, P522, DOI 10.1111/j.1471-4159.1988.tb01069.x; HABIG WH, 1986, J NEUROCHEM, V47, P930; JAHN R, 1993, J NEUROCHEM, V61, P12, DOI 10.1111/j.1471-4159.1993.tb03533.x; KENIMER JG, 1983, INFECT IMMUN, V42, P942, DOI 10.1128/IAI.42.3.942-948.1983; KOSAKI S, 1981, JPN J MED SCI BIOL, V34, P61; LAMBERT H, 1990, BIOCHEM CELL BIOL, V68, P729, DOI 10.1139/o90-105; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; LIVETT BG, 1984, PHYSIOL REV, V64, P1103, DOI 10.1152/physrev.1984.64.4.1103; MARXEN P, 1990, TOXICON, V28, P1077, DOI 10.1016/0041-0101(90)90146-X; MARXEN P, 1989, TOXICON, V27, P849, DOI 10.1016/0041-0101(89)90097-4; MARXEN P, 1991, TOXICON, V29, P181, DOI 10.1016/0041-0101(91)90102-W; MARXEN P, 1989, NEUROSCI LETT, V107, P261, DOI 10.1016/0304-3940(89)90828-8; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; OLSEN KM, 1987, CLIN PHARMACY, V6, P570; PENNER R, 1986, NATURE, V324, P76, DOI 10.1038/324076a0; PESTRONK A, 1978, SCIENCE, V199, P1223, DOI 10.1126/science.204007; SANDERS D, 1992, N-S ARCH PHARMACOL, V346, P358; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1992, EMBO J, V11, P3577, DOI 10.1002/j.1460-2075.1992.tb05441.x; SCHIAVO G, 1992, J BIOL CHEM, V267, P23479; SPAUN J, 1970, B WORLD HEALTH ORGAN, V42, P523; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; WRIGHT JF, 1992, J BIOL CHEM, V267, P9053	34	42	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8122	8127						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132537				2022-12-25	WOS:A1994NB40900046
J	DAHNKE, T; TSAI, MD				DAHNKE, T; TSAI, MD			MECHANISM OF ADENYLATE KINASE - THE CONSERVED ASPARTATE-140 AND ASPARTATE-141 ARE IMPORTANT FOR TRANSITION-STATE STABILIZATION INSTEAD OF SUBSTRATE-INDUCED CONFORMATIONAL-CHANGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; X-RAY; SITE; PHOSPHOLIPASE-A2; CATALYSIS; PROTEINS; NMR	The goal of this work is to evaluate the quantitative contribution of Asp-140 and Asp-141 to conformational (changes and/or substrate stabilization in the catalysis by chicken muscle adenylate kinase (AK), by use of kinetic and structural analysis of the single alanine mutants D140A and D141A as well as the salt bridge double mutants R138M,D140A and R132M,D14A. The single mutants D140A and D141A displayed small increases in K-m (6-12-fold) and moderate decreases in k(cat) (17-78-fold). Kinetic analysis with the slowly reacting substrate system MgATP and dAMP suggested that the decrease in k(cat) is not caused by a decrease in the conformational step(s) relative to the chemical step. Most of the kinetic constants of the double mutants R138M,D140A and R132M,D141A are similar to those of the single mutants R138M and R132M, respectively. Detailed analysis by two-dimensional NMR indicated no appreciable changes in the conformations of the free enzyme or the complex with MgAP(5)A (where AP(5)A is P-1,P-5-bis(5'-adenosyl)pentaphosphate), for both single and double mutants. These results taken together suggest that Asp-140 and Asp-141 are unimportant for substrate-induced conformational changes in AK; their roles are mainly to assist Arg-138 and Arg-132 in stabilizing the transition state. The structural results also suggest that AK is a flexible enzyme.	OHIO STATE UNIV,DEPT CHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210	Ohio State University; Ohio State University			Tsai, Ming-Daw/G-4689-2019	Tsai, Ming-Daw/0000-0003-1374-0414	NCRR NIH HHS [RR01458] Funding Source: Medline; NIGMS NIH HHS [GM43268] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043268] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; BYEON IJL, 1993, BIOCHEMISTRY-US, V32, P12508, DOI 10.1021/bi00097a031; CLELAND WW, 1986, INVESTIGATION RATE 1, V1, P791; DAHNKE T, 1992, BIOCHEMISTRY-US, V31, P3818; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; DUPUREUR CM, 1992, BIOCHEMISTRY-US, V31, P6402, DOI 10.1021/bi00143a007; DUPUREUR CM, 1992, J AM CHEM SOC, V114, P2748, DOI 10.1021/ja00033a076; DUTILH CE, 1975, EUR J BIOCHEM, V53, P91, DOI 10.1111/j.1432-1033.1975.tb04045.x; HAASE GHW, 1989, J MOL BIOL, V207, P151, DOI 10.1016/0022-2836(89)90446-4; KISHI F, 1986, J BIOL CHEM, V261, P2942; LI YS, 1993, J AM CHEM SOC, V115, P8523, DOI 10.1021/ja00072a001; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; Pace C N, 1986, Methods Enzymol, V131, P266; PACE CN, 1990, TRENDS BIOCHEM SCI, V15, P14, DOI 10.1016/0968-0004(90)90124-T; RHOADS DG, 1968, J BIOL CHEM, V243, P3963; SANDERS CR, 1989, BIOCHEMISTRY-US, V28, P9028, DOI 10.1021/bi00449a011; SCHULZ GE, 1987, COLD SPRING HARB SYM, V52, P429, DOI 10.1101/SQB.1987.052.01.050; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SHI ZT, 1993, BIOCHEMISTRY-US, V32, P6450, DOI 10.1021/bi00076a019; TANIZAWA Y, 1987, J BIOCHEM-TOKYO, V101, P1289, DOI 10.1093/oxfordjournals.jbchem.a121993; TIAN G, 1990, BIOCHEMISTRY-US, V29, P4296, DOI 10.1021/bi00470a006; TIAN G, 1988, BIOCHEMISTRY-US, V27, P5544, DOI 10.1021/bi00415a024; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002; YAN HG, 1990, BIOCHEMISTRY-US, V29, P6385, DOI 10.1021/bi00479a007; YAN HG, 1990, BIOCHEMISTRY-US, V29, P10956, DOI 10.1021/bi00501a013	26	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8075	8081						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	8132532				2022-12-25	WOS:A1994NB40900040
J	HEI, YJ; PELECH, SL; CHEN, XS; DIAMOND, J; MCNEILL, JH				HEI, YJ; PELECH, SL; CHEN, XS; DIAMOND, J; MCNEILL, JH			PURIFICATION AND CHARACTERIZATION OF A NOVEL RIBOSOMAL S6 KINASE FROM SKELETAL-MUSCLE OF INSULIN-TREATED RATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; NERVE GROWTH-FACTOR; SEA STAR OOCYTES; 3T3 CELLS; PHOSPHORYLATION SITES; XENOPUS OOCYTES; MAP KINASES; MITOGEN; IDENTIFICATION; RAPAMYCIN	The predominant 40 S ribosomal protein S6 kinase in skeletal muscle extracts from insulin-treated rats was purified over 10,000-fold to near homogeneity with similar to 4.5% recovery of starting activity. This S6 kinase was resolved from the catalytic subunit of cAMP-dependent protein kinase only by the seventh and final column chromatography step. The purified S6 kinase migrated as a tight doublet of similar to 31 kDa on an SDS-polyacrylamide gel, and it was eluted from gel filtration columns with a similar apparent M(r), which indicated that the enzyme exists as a monomer. This S6 kinase was immunologically distinct from the other known insulin-activated S6 kinases, i.e. p70(S6K) and p90(rsk). It was inhibited by [ethylenebis(oxyethylenenitrilo)]tetraacetic acid and beta-glycerophosphate at concentrations routinely used to stabilize p70(S6K) and p90(rsk). In addition to S6, phosvitin was also a substrate, whereas myelin basic protein, casein, protamine, and histones were poorly phosphorylated if at all by the purified S6 kinase. The purified enzyme was inactivated upon incubation with serine/threonine-specific protein phosphatase 2A, which indicated that it may be an intermediary component in a cascade of insulin-activated protein kinases.	UNIV BRITISH COLUMBIA,FAC PHARMACEUT SCI,DIV PHARMACOL & TOXICOL,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,FAC MED,DEPT MED,BIOMED RES CTR,VANCOUVER V6T 1Z3,BC,CANADA; KINETEK BIOTECHNOL CORP,VANCOUVER V5Z 1A1,BC,CANADA	University of British Columbia; University of British Columbia								ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BLENIS J, 1991, CANCER CELL-MON REV, V3, P445; BRANDON SD, 1991, J BIOL CHEM, V266, P380; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CICIRELLI MF, 1988, FEBS LETT, V241, P195, DOI 10.1016/0014-5793(88)81060-3; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; COBB MH, 1986, J BIOL CHEM, V261, P2994; DAHMUS ME, 1981, J BIOL CHEM, V256, P3319; DELGRANDE RW, 1982, EUR J BIOCHEM, V123, P421; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUVERNAY VH, 1978, BIOCHEMISTRY-US, V17, P2045, DOI 10.1021/bi00604a003; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON E, 1991, J BIOL CHEM, V266, P5249; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HANSSON A, 1985, EUR J BIOCHEM, V151, P97, DOI 10.1111/j.1432-1033.1985.tb09073.x; HECHT LB, 1988, BIOCHEM BIOPH RES CO, V152, P1200, DOI 10.1016/S0006-291X(88)80412-1; HEI YJ, 1993, J BIOL CHEM, V268, P13203; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; JENO P, 1989, J BIOL CHEM, V264, P1293; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOZMA SC, 1989, EMBO J, V8, P4125, DOI 10.1002/j.1460-2075.1989.tb08597.x; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KOZMA SC, 1992, REV PHYSIOL BIOCH P, V119, P123; KRIEG J, 1988, J BIOL CHEM, V263, P11473; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE HA, 1992, EMBO J, V11, P1743, DOI 10.1002/j.1460-2075.1992.tb05226.x; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LEPEUCH CJ, 1983, P NATL ACAD SCI-BIOL, V80, P6858; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDA Y, 1987, J BIOL CHEM, V262, P2832; MERRIL CR, 1979, P NATL ACAD SCI USA, V76, P4335, DOI 10.1073/pnas.76.9.4335; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; MUTOH T, 1988, J BIOL CHEM, V263, P15853; NAKAJO S, 1983, BIOCHEM BIOPH RES CO, V113, P1010, DOI 10.1016/0006-291X(83)91099-9; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PELECH SL, 1993, CURR BIOL, V3, P513, DOI 10.1016/0960-9822(93)90043-N; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PELECH SL, 1991, J BIOL CHEM, V266, P8696; PERISIC O, 1983, J BIOL CHEM, V258, P3998; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; PRICE DJ, 1991, J BIOL CHEM, V266, P16281; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; SANGHERA JS, 1992, BIOCHEM J, V283, P829, DOI 10.1042/bj2830829; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SOMMERCORN J, 1993, J CLIN INVEST, V91, P509, DOI 10.1172/JCI116229; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; SWEET LJ, 1990, MOL CELL BIOL, V10, P2413, DOI 10.1128/MCB.10.5.2413; TABARINI D, 1987, BIOCHEM BIOPH RES CO, V144, P891, DOI 10.1016/S0006-291X(87)80048-7; TAO M, 1980, J BIOL CHEM, V255, P2563; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; TRAUGH JA, 1986, PROG NUCLEIC ACID RE, V33, P195; WETTENHALL REH, 1984, J BIOL CHEM, V259, P2084	74	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7816	7823						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8126008				2022-12-25	WOS:A1994NA03200119
J	ISHIBASHI, T; NAKABEPPU, Y; SEKIGUCHI, M				ISHIBASHI, T; NAKABEPPU, Y; SEKIGUCHI, M			ARTIFICIAL CONTROL OF NUCLEAR TRANSLOCATION OF DNA-REPAIR METHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE ACTIVITY; DEFICIENT HUMAN-CELLS; ESCHERICHIA-COLI; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; ALKYLATING-AGENTS; ESTROGEN-RECEPTOR; GLUCOCORTICOID RECEPTOR; CELLULAR-RESISTANCE; PROTEIN; EXPRESSION	We constructed a recombinant plasmid carrying a chimeric cDNA that encodes a fusion protein, ER:MGMT, composed of the ligand-binding domain of the human estrogen receptor and the human O-6-methylguanine-DNA methyltransferase. By introducing this plasmid into the methyltransferase-deficient human cell line HeLa MR, a system was established in which nuclear translocation of the ER:MGMT fusion protein can be controlled by estrogen. On in situ immunostaining using anti-MGMT, the cytoplasm of ER:MGMT-carrying cells was preferentially stained and nuclear staining occurred only when the cells were exposed to estrogen. The estrogen-dependent nuclear translocation of ER: MGMT was confirmed by Western blotting analysis of fractionated cell extracts. The fusion protein was translocated into the nucleus within 1 h after estrogen treatment and remained there unless estrogen was removed. The methyltransferase activity of the fusion protein was as active as the authentic methyltransferase enzyme, regardless of the presence or absence of estrogen. The ER:MGMT-producing cells were sensitive to (1-(4-amino-2-methyl-5-pyrimi- dinyl)methyl-3-(2- chloroethyl)-3-nitrosourea (ACNU) in the absence of estrogen, and estrogen treatment rendered the cells as resistant to ACNU as the ordinary Mer(+) cell line, HeLa S3, thereby indicating that translocation of the methyltransferase into the nucleus is a prerequisite for repair of the chromosomal DNA damaged by alkylating agents. Taking advantage of the artificial control of cellular localization of the fusion protein, we examined the timing of the nuclear translocation required to execute efficient DNA repair. We obtained evidence that the methyltransferase must repair the DNA damage as soon as the DNA is exposed to ACNU, in order to avoid cell cycle arrest at the G(2) phase.	KYUSHU UNIV, MED INST BIOREGULAT, DEPT BIOCHEM, FUKUOKA 812, JAPAN	Kyushu University			Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X				BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRENT TP, 1987, CANCER RES, V47, P3384; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0; DOLAN ME, 1985, CANCER RES, V45, P6413; DOLAN ME, 1990, P NATL ACAD SCI USA, V87, P5368, DOI 10.1073/pnas.87.14.5368; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; ECKERT RL, 1982, CANCER RES, V42, P139; FUKUHARA M, 1992, JPN J CANCER RES, V83, P72, DOI 10.1111/j.1349-7006.1992.tb02354.x; GERSON SL, 1986, CARCINOGENESIS, V7, P745, DOI 10.1093/carcin/7.5.745; GOTH R, 1974, P NATL ACAD SCI USA, V71, P639, DOI 10.1073/pnas.71.3.639; HAYAKAWA H, 1990, J MOL BIOL, V213, P739, DOI 10.1016/S0022-2836(05)80260-8; ISHIZAKI K, 1986, MUTAT RES, V166, P135, DOI 10.1016/0167-8817(86)90011-8; ISHIZAKI K, 1987, MUTAT RES, V184, P121, DOI 10.1016/0167-8817(87)90068-X; KARRAN P, 1985, P NATL ACAD SCI USA, V82, P5285, DOI 10.1073/pnas.82.16.5285; KOIKE G, 1990, J BIOL CHEM, V265, P14754; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; LOVELESS A, 1969, NATURE, V223, P206, DOI 10.1038/223206a0; LUDLUM DB, 1990, MUTAT RES, V233, P117, DOI 10.1016/0027-5107(90)90156-X; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; NAKATSURU Y, 1993, P NATL ACAD SCI USA, V90, P6468, DOI 10.1073/pnas.90.14.6468; OLSSON M, 1980, J BIOL CHEM, V255, P569; PEGG AE, 1990, CANCER RES, V50, P6119; PEGG AE, 1983, J BIOL CHEM, V258, P2327; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; ROBINS P, 1983, NUCLEIC ACIDS RES, V11, P7743, DOI 10.1093/nar/11.22.7743; SAIJO N, 1980, CANCER CHEMOTH PHARM, V4, P165; SAMSON L, 1986, P NATL ACAD SCI USA, V83, P5607, DOI 10.1073/pnas.83.15.5607; SASSANFAR M, 1991, J BIOL CHEM, V266, P2767; SIBGHATULLAH, 1992, BIOCHEMISTRY-US, V31, P7998, DOI 10.1021/bi00149a034; SINGER B, 1982, ANNU REV BIOCHEM, V51, P655, DOI 10.1146/annurev.bi.51.070182.003255; SUKUMAR S, 1991, ORIGINS OF HUMAN CANCER, P153; SWANN PF, 1990, MUTAT RES, V233, P81, DOI 10.1016/0027-5107(90)90153-U; TAKAHASHI K, 1988, J BIOL CHEM, V263, P13490; TOBEY RA, 1975, NATURE, V254, P245, DOI 10.1038/254245a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WOOD ML, 1991, ORIGINS OF HUMAN CANCER, P137; YAGI T, 1984, CARCINOGENESIS, V5, P593, DOI 10.1093/carcin/5.5.593	43	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7645	7650						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125990				2022-12-25	WOS:A1994NA03200096
J	NAMCIU, S; LIEBERMAN, MA; STAVNEZER, E				NAMCIU, S; LIEBERMAN, MA; STAVNEZER, E			INDUCTION OF THE C-SKI PROTOONCOGENE BY PHORBOL ESTER CORRELATES WITH INDUCTION OF MEGAKARYOCYTE DIFFERENTIATION	ONCOGENE			English	Article							LEUKEMIA-CELL-LINE; HEL CELLS; EXPRESSION; PHENOTYPE; SEQUENCE; PRODUCT; CULTURE; GROWTH; MUSCLE; GENE	Overexpression of v-ski blocks the terminal differentiation of chicken erythroblasts, and in cooperation with v-sea causes transformation of these cells, indicating that c-ski may play a role in regulating either proliferation or differentiation in hematopoietic cells. We examined c-ski expression in four different myeloid cell lines which can be induced to differentiate by exposure to phorbol 12-myristate 13-acetate (PMA). Two of the cell lines are multipotent and have the ability to differentiate into either erythrocytes or megakaryocytes (K562 and HEL cells), one cell line differentiates exclusively into megakaryocytes (CHRF-288-11), and the fourth cell line differentiates into either monocytes or granulocytes (HL-60). Our findings indicate that c-ski mRNA is up regulated by PMA only in those cell lines which respond by differentiating along the megakaryocyte lineage. The extent of differentiation and the observed increase in c-ski mRNA levels are positively correlated with the PMA concentration used to induce differentiation. Experiments in which CHRF-288-11 cells were treated with the protein kinase C (PKC) activator bryostatin 1 indicate that c-ski mRNA induction is not a general effect of PKC activation. The results strongly suggest that c-ski expression is correlated with megakaryocyte maturation.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT BIOCHEM,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT MICROBIOL,CINCINNATI,OH 45267	University of Cincinnati; University of Cincinnati; University of Cincinnati					NATIONAL CANCER INSTITUTE [R01CA043600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007250] Funding Source: NIH RePORTER; NCI NIH HHS [CA43600] Funding Source: Medline; NIEHS NIH HHS [T32-ES07250] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BERKOW RL, 1985, BIOCHEM BIOPH RES CO, V131, P1109, DOI 10.1016/0006-291X(85)90205-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRENCH BT, 1990, CANCER CHEMOTH PHARM, V27, P171, DOI 10.1007/BF00685709; FUGMAN DA, 1990, BLOOD, V75, P1252; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HOFFMAN R, 1989, BLOOD, V74, P1196; KABNOUDIAS A, 1992, EXP HEMATOL, V20, P43; LARSEN J, 1992, ONCOGENE, V7, P1903; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; LONG MW, 1990, J CLIN INVEST, V85, P1072, DOI 10.1172/JCI114538; LOZZIO BB, 1981, P SOC EXP BIOL MED, V166, P546; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MCKINNON RD, 1987, MOL CELL BIOL, V7, P2148, DOI 10.1128/MCB.7.6.2148; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MILNER RM, 1983, NUCLEIC ACIDS RES, V11, P4597; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; PAPAYANNOPOULOU T, 1987, BLOOD, V70, P1764; PRASAD VS, 1991, J IMMUNOL, V147, P4200; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; STAEHELI P, 1989, MOL CELL BIOL, V9, P4038; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; TAKAHASHI T, 1991, BRIT J HAEMATOL, V78, P480, DOI 10.1111/j.1365-2141.1991.tb04476.x; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7	36	32	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1407	1416						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152801				2022-12-25	WOS:A1994NH40100012
J	BRAESCHANDERSEN, S; STAMENKOVIC, I				BRAESCHANDERSEN, S; STAMENKOVIC, I			SIALYLATION OF THE B-LYMPHOCYTE MOLECULE CD22 BY ALPHA-2,6-SIALYLTRANSFERASE IS IMPLICATED IN THE REGULATION OF CD22-MEDIATED ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; SURFACE EXPRESSION; ANTIGEN; PROTEIN; SIALYLTRANSFERASE; GLYCOSYLATION; ACTIVATION; RECEPTOR; CLONING; LIVER	The B cell surface receptor CD22 binds several sialoglycoproteins containing sialic acid in alpha 2,6 linkage, on the surface of B and T lymphocytes. Because lymphocytes adhere tightly to fibroblasts transfected with CD22 cDNA, it would appear reasonable to suggest that regulatory mechanisms might have evolved which prevent undesired CD22-mediated leukocyte aggregation. Here we provide evidence for the existence of at least one mechanism that might regulate CD22 interaction with ligands on adjacent cells. We demonstrate that sialylation of CD22 by beta-galactoside alpha 2,6-sialyltransferase abrogates CD22-mediated lymphocyte adhesion, and that adhesion can be restored by removal of alpha 2,6-linked sialic acid residues from the CD22 molecule. Taken together, our results suggest that alpha 2,6-sialyltransferase can both promote and inhibit CD22-ligand interactions. These observations provide the first direct evidence that receptor-ligand interactions mediated by an Ig superfamily molecule are under the control of a specific glycosyltransferase.	HARVARD UNIV,SCH MED,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP E,DEPT PATHOL RES,BOSTON,MA 02129	Harvard University; Harvard Medical School	BRAESCHANDERSEN, S (corresponding author), MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02129, USA.				NCI NIH HHS [CA55735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P10242, DOI 10.1073/pnas.89.21.10242; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; DORKEN B, 1986, J IMMUNOL, V136, P4470; ERIKSTEIN BK, 1992, EUR J IMMUNOL, V22, P1149, DOI 10.1002/eji.1830220507; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; PAULSON JC, 1977, J BIOL CHEM, V252, P8624; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PEZZUTTO A, 1988, J IMMUNOL, V140, P1791; POWELL LD, 1993, J BIOL CHEM, V268, P7019; SCHWARTZALBIEZ R, 1991, INT IMMUNOL, V3, P623, DOI 10.1093/intimm/3.7.623; SGROI D, 1993, J BIOL CHEM, V268, P7011; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; WANG XC, 1993, J BIOL CHEM, V268, P4355; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137	19	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11783	11786						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163475				2022-12-25	WOS:A1994NG37700019
J	HOJIMA, Y; MORGELIN, MM; ENGEL, J; BOUTILLON, MM; VANDERREST, M; MCKENZIE, J; CHEN, GC; RAFI, N; ROMANIC, AM; PROCKOP, DJ				HOJIMA, Y; MORGELIN, MM; ENGEL, J; BOUTILLON, MM; VANDERREST, M; MCKENZIE, J; CHEN, GC; RAFI, N; ROMANIC, AM; PROCKOP, DJ			CHARACTERIZATION OF TYPE-I PROCOLLAGEN N-PROTEINASE FROM FETAL BOVINE TENDON AND SKIN - PURIFICATION OF THE 500-KILODALTON FORM OF THE ENZYME FROM BOVINE TENDON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO TENDONS; COLLAGEN FIBRILS; C-PROTEINASE; TERMINAL PROPEPTIDE; PC-COLLAGEN; CLEAVAGE; COPOLYMERIZATION; HOMOTRIMER; INHIBITION; PNCOLLAGEN	Procollagen N-proteinase (EC 3.4.24.14) is the enzyme that specifically cleaves the NH2-terminal propeptides from type I procollagen. Two forms of N-proteinase with apparent molecular sizes of 300 and 500 kDa were found in partially purified preparations from fetal bovine tendon extracts. The 500-kDa form of enzyme was purified 16,000-fold with a recovery of 8% from the extracts of the tendons by six purification steps. The purified enzyme was a neutral, Ca2+-dependent proteinase (5-10 mM) that was inhibited by metal chelators. The 500-kDa enzyme contained unreduced polypeptides of 58, 125, 170, and 190 kDa which were separated by polyacrylamide gel electrophoresis in sodium dodecyl sulfate. Electron microscopic study indicated that the enzyme molecules were generally globular and had diameters of 33 +/- 4 m. Other properties of the 500-kDa enzyme were: 1) the K(m) for type I procollagen is 35 nM at pH 7.5 and 35-degrees-C, and the k(cat) is 290 h-1; 2) the activation energy for reaction with type I procollagen is 10,050 cal mol-1; 3) the isoelectric point is 3.8; 4) the enzyme cleaves the NH2-terminal propeptides of type II procollagen as well as type I procollagen but not of type III procollagen; and 5) the enzyme specifically cleaves a -Pro-Gln- bond in the pro(alpha1(I) chain and an -Ala-Gln- bond in the pro-alpha2(I) chain. The bovine N-proteinase with a mass of 300 kDa was found to be similar to the 500-kDa enzyme and appeared to be a degraded form of the 500-kDa enzyme generated during purification. The N-proteinase from fetal bovine skin extracts also contained 300-kDa and 500-kDa enzyme forms.	THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,233 S 10TH ST,PHILADELPHIA,PA 19107; UNIV BASEL,BIOCTR,CH-4056 BASEL,SWITZERLAND; UNIV LYON 1,ECOLE NORMALE SUPER LYON,F-69622 VILLEURBANNE,FRANCE	Jefferson University; University of Basel; Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; Universite Claude Bernard Lyon 1								BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; CURRAN S, 1982, BIOCHEMISTRY-US, V21, P1482, DOI 10.1021/bi00536a003; DEHM P, 1971, BIOCHIM BIOPHYS ACTA, V240, P358, DOI 10.1016/0005-2787(71)90529-6; DOMBROWSKI KE, 1989, BIOCHEMISTRY-US, V28, P7107, DOI 10.1021/bi00443a048; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; ENGEL J, 1987, METHOD ENZYMOL, V145, P1; FESSLER JH, 1978, ANNU REV BIOCHEM, V47, P129, DOI 10.1146/annurev.bi.47.070178.001021; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; HALILA R, 1986, BIOCHEM J, V239, P47, DOI 10.1042/bj2390047; HALILA R, 1984, BIOCHEMISTRY-US, V23, P1251, DOI 10.1021/bi00301a036; HOJIMA Y, 1989, J BIOL CHEM, V264, P11336; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HOJIMA Y, 1992, MATRIX METALLOPROTEI, P97; HORLEIN D, 1978, FEBS LETT, V89, P279, DOI 10.1016/0014-5793(78)80236-1; Hulmes DJS, 1992, ESSAYS BIOCHEM, V27, P49; HULMES DJS, 1989, J MOL BIOL, V210, P337, DOI 10.1016/0022-2836(89)90335-5; KADLER KE, 1990, ANN NY ACAD SCI, V580, P214, DOI 10.1111/j.1749-6632.1990.tb17930.x; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KESSLER E, 1989, EUR J BIOCHEM, V186, P115, DOI 10.1111/j.1432-1033.1989.tb15184.x; KOHN LD, 1974, P NATL ACAD SCI USA, V71, P40, DOI 10.1073/pnas.71.1.40; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPIERE CM, 1971, P NATL ACAD SCI USA, V68, P3054, DOI 10.1073/pnas.68.12.3054; LEUNG MKK, 1979, J BIOL CHEM, V254, P224; MCBRIDE DJ, 1992, MATRIX, V12, P256; MIYAHARA M, 1984, J BIOL CHEM, V259, P9891; NAGASE H, 1983, J BIOL CHEM, V258, P7490; NJIEHA FK, 1982, BIOCHEMISTRY-US, V21, P757, DOI 10.1021/bi00533a028; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; RAUTERBERG J, 1972, EUR J BIOCHEM, V27, P231, DOI 10.1111/j.1432-1033.1972.tb01831.x; ROMANIC AM, 1991, J BIOL CHEM, V266, P12703; ROMANIC AM, 1992, J BIOL CHEM, V267, P22265; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; TANZAWA K, 1985, J BIOL CHEM, V260, P1120; TORREBLANCO A, 1992, J BIOL CHEM, V267, P2650; TORREBLANCO A, 1992, J BIOL CHEM, V267, P4968; TUDERMAN L, 1982, EUR J BIOCHEM, V125, P545, DOI 10.1111/j.1432-1033.1982.tb06716.x; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; Vesterberg O., 1971, METHODS ENZYMOLOGY, V22, P389; WATSON RB, 1992, J BIOL CHEM, V267, P9093; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0; WOZNEY J, 1981, NATURE, V294, P129, DOI 10.1038/294129a0; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	42	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11381	11390						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	8157670				2022-12-25	WOS:A1994NF96600062
J	CASE, RD; PICCIONE, E; WOLF, G; BENETT, AM; LECHLEIDER, RJ; NEEL, BG; SHOELSON, SE				CASE, RD; PICCIONE, E; WOLF, G; BENETT, AM; LECHLEIDER, RJ; NEEL, BG; SHOELSON, SE			SH-PTP2/SYP SH2 DOMAIN BINDING-SPECIFICITY IS DEFINED BY DIRECT INTERACTIONS WITH PLATELET-DERIVED GROWTH-FACTOR BETA-RECEPTOR, EPIDERMAL GROWTH-FACTOR RECEPTOR, AND INSULIN-RECEPTOR SUBSTRATE-1-DERIVED PHOSPHOPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; AUTOPHOSPHORYLATION SITES; EGF RECEPTOR; PROTEIN; KINASE; IDENTIFICATION; SRC	Signaling by tyrosine kinases involves direct associations between proteins with Src homology 2 (SH2) domains and sites of tyrosine phosphorylation. Specificity in signaling pathways results in part from inherent selectivity in interactions between particular SH2 domains and phosphopeptide sequences. The cytoplasmic phosphotyrosine phosphatase SH-PTP2 (Syp, PTP 1D, PTP-2C) contains two SH2 domains (N and C) which mediate its association with and activation by the platelet-derived growth factor (PDGF) and epidermal growth factor receptors and IRS-1. We have developed a competitive phosphopeptide binding assay to analyze specificity of the SH-PTP2 N-SH2 domain for phosphorylation sites of these phosphoproteins. The sequence surrounding Tyr(1009) bound with greatest affinity (ID50 = 14 mu M) of eight PDGF receptor-derived phosphopeptides tested. No peptides corresponding to known epidermal growth factor receptor phosphorylation sites bound with high affinity. However, an alternative sequence surrounding Tyr(954) bound tightly (ID50 = 21 mu M). Of the 13 IRS-1-related peptides analyzed, sequences surrounding Tyr(546), Tyr(895), and Tyr(1172) bound with highest affinity (ID50 = 11, 4, and 1 mu M, respectively). Alternative phosphopeptides generally bound with much weaker affinity (ID50 > 150 mu M). These findings are consistent with recent mutational analyses of the PDGF receptor and predict site-specific interactions between SH-PTP2 and each of these phosphoproteins. Comparisons between peptide sequences suggest that the N-terminal SH2 domain of SH-PTP2 binds with highest affinity to phosphotyrosine (pY) followed by a beta-branched residue (Val, Ile, Thr) at pY+1 and a hydrophobic residue (Val, Leu, Ile) at pY+3 positions. Peptide truncation studies also indicate that residues outside of the pY-1 to pY+4 motif are required for high affinity interactions.	HARVARD UNIV, SCH MED, JOSLIN DIABET CTR, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02215 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, MOLEC MED UNIT, BOSTON, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KASHISHIAN A, 1992, EMBO J, V11, P1382; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LASZLO B, 1993, CELL, V73, P611; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1994, IN PRESS MOL CELL BI; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TOBE K, 1993, J BIOL CHEM, V268, P11167; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WILLIAMS KP, 1993, J BIOL CHEM, V268, P5361; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	132	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10467	10474						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144631				2022-12-25	WOS:A1994NF01700044
J	ERIKSSON, I; SANDBACK, D; EK, B; LINDAHL, U; KJELLEN, L				ERIKSSON, I; SANDBACK, D; EK, B; LINDAHL, U; KJELLEN, L			CDNA CLONING AND SEQUENCING OF MOUSE MASTOCYTOMA GLUCOSAMINYL N-DEACETYLASE/N-SULFOTRANSFERASE, AN ENZYME INVOLVED IN THE BIOSYNTHESIS OF HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE SULFOTRANSFERASE; ESCHERICHIA-COLI; PROTEIN; PURIFICATION; TRANSFERASE; MEMBRANES	A 110-kDa protein involved in heparin biosynthesis in mouse mastocytoma cells was previously shown to express both glucosaminyl N-deacetylase and N-sulfotransferase activity. In this study, the complete nucleotide sequence corresponding to this protein is reported. The mRNA, estimated to contain 3.9 kilobases encodes a protein with an M(r) of 101,092. The predicted domain structure of the protein resembles those of previously characterized Golgi proteins with an N-terminal cytoplasmic tail, a single membrane-spanning domain, and a large catalytic domain linked to the transmembrane domain through a ''stem region.'' Comparison of the deduced amino acid sequence of the mouse mastocytoma protein and a previously cloned similar enzyme from rat liver demonstrated that while large portions of the proteins, corresponding essentially to the putative catalytic domains, were closely related, other portions, in particular in the N-terminal parts, were markedly different. The divergence was not due to species differences since two separate mouse transcripts could be identified that hybridized with probes specific for the two proteins. Also, functional differences were noted since the mastocytoma enzyme, contrary to the liver enzyme, requires a polycation cofactor for expression of N-deacetylase activity. The results are discussed in relation to the structural properties of heparin and heparan sulfate.	SWEDISH UNIV AGR SCI,DEPT VET MED CHEM,S-75007 UPPSALA,SWEDEN; SWEDISH UNIV AGR SCI,DEPT CELL RES,S-75007 UPPSALA,SWEDEN; UNIV UPPSALA,CTR BIOMED,DEPT MED & PHYSIOL CHEM,S-75123 UPPSALA,SWEDEN	Swedish University of Agricultural Sciences; Swedish University of Agricultural Sciences; Uppsala University			Kjellen, Lena/F-1362-2011					BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; DEVREUX J, 1984, NUCLEIC ACIDS RES, V12, P387; HARLOW E, 1988, ANTIBODIES LABORATOR, P78; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; ISHIHARA M, 1993, J BIOL CHEM, V268, P20091; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KJELLEN L, 1992, ADV EXP MED BIOL, V313, P107; KJELLEN L, 1989, BIOCHEM J, V263, P105, DOI 10.1042/bj2630105; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; Lindahl U., 1989, HEPARIN, P159; Machamer C E, 1991, Trends Cell Biol, V1, P141, DOI 10.1016/0962-8924(91)90001-P; NAVIA JL, 1983, ANAL BIOCHEM, V135, P134, DOI 10.1016/0003-2697(83)90741-8; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; Sambrook J, 1989, MOL CLONING LABORATO; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938	23	125	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10438	10443						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144627				2022-12-25	WOS:A1994NF01700040
J	FRIEDMAN, SL; YAMASAKI, G; WONG, L				FRIEDMAN, SL; YAMASAKI, G; WONG, L			MODULATION OF TRANSFORMING GROWTH-FACTOR-BETA RECEPTORS OF RAT LIPOCYTES DURING THE HEPATIC WOUND-HEALING RESPONSE - ENHANCED BINDING AND REDUCED GENE-EXPRESSION ACCOMPANY CELLULAR ACTIVATION IN CULTURE AND IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT-STORING CELLS; BASEMENT-MEMBRANE MATRIX; KUPFFER CELLS; LIVER FIBROGENESIS; MESSENGER-RNA; MUSCLE-CELLS; FACTOR-BETA-1; PROLIFERATION; CLONING; PROTEIN	Activation of lipocytes, characterized by increased proliferation and fibrogenesis, is a central feature of the hepatic wound healing response. We have examined whether modulation of receptors for transforming growth factor beta (TGF-beta) contributes to the fibrogenic behavior of activated lipocytes. Isolated lipocytes were maintained in a quiescent state by culturing the cells in suspension, where they displayed minimal specific binding for TGF-beta 1 and only a small amount of type III (betaglycan) receptor by affinity labeling. In contrast, lipocytes activated by growth on uncoated plastic displayed saturable binding of TGF-beta 1 (K-d = 28 pM, 7,730 receptors/ cell), and receptors types I, II, and III. Binding activity in quiescent and activated cells correlated with responsiveness to TGF-beta 1; TGF-beta 1 induced cellular fibronectin mRNA expression only in activated and not quiescent cells. Despite the absence of binding in quiescent cells, type II receptor was detectable by immunoblot. By RNase protection assay, mRNAs for receptor types II and III were greater in quiescent than activated cells. In freshly isolated lipocytes from animals with liver injury caused by the administration of carbon tetrachloride, a rapid but transient increase in mRNA for receptor types I (similar to 3.2 fold), II (similar to 1.5-fold), and III (similar to 3-fold) was observed, with peaks at 12 h for type I receptor, 1 h for type II receptor, and 6 h for type III receptor; mRNA induction was followed by down-regulation for all receptors. The modest changes in mRNAs compared with marked alterations in binding activity during mesenchymal cell activation suggest that TGF-beta receptors may be regulated in vivo in part by a post-translational mechanism.			FRIEDMAN, SL (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,LIVER CTR LAB & MED SERV,BLDG 40,RM 4102,SAN FRANCISCO,CA 94110, USA.				NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P30AM026743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037340] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM26743] Funding Source: Medline; NIDDK NIH HHS [DK37340] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMENDARIZBORUNDA J, 1989, MATRIX, V9, P150, DOI 10.1016/S0934-8832(89)80034-4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BACHEM MG, 1989, FEBS LETT, V257, P134, DOI 10.1016/0014-5793(89)81804-6; BACHEM MG, 1992, J CLIN INVEST, V89, P19, DOI 10.1172/JCI115561; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; Ben-Ze'ev A, 1985, Cell Muscle Motil, V6, P23; BUTZOW R, 1993, J CELL BIOL, V122, P721, DOI 10.1083/jcb.122.3.721; CASTILLA A, 1991, NEW ENGL J MED, V324, P933, DOI 10.1056/NEJM199104043241401; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; EWTON DZ, 1988, J BIOL CHEM, V263, P4029; FALK LA, 1991, BLOOD, V77, P1248; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FRIEDMAN SL, 1992, HEPATOLOGY, V15, P234, DOI 10.1002/hep.1840150211; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FRIEDMAN SL, 1989, J CLIN INVEST, V84, P1780, DOI 10.1172/JCI114362; FRIEDMAN SL, 1989, J BIOL CHEM, V264, P10756; FRIEDMAN SL, 1985, P NATL ACAD SCI USA, V82, P8681, DOI 10.1073/pnas.82.24.8681; FRIEDMAN SL, 1993, AM J PHYSIOL, V264, P947; FRIEDMAN SL, 1993, METHODS TOXICOL, V1, P292; GEERTS A, 1989, J HEPATOL, V9, P59, DOI 10.1016/0168-8278(89)90076-7; GIRARDI AJ, 1956, VIROLOGY, V2, P532, DOI 10.1016/0042-6822(56)90009-5; GOODMAN LV, 1989, J BIOL CHEM, V264, P5241; GRESSNER AM, 1990, SEMIN LIVER DIS, V10, P30, DOI 10.1055/s-2008-1040455; HORN T, 1986, J HEPATOL, V3, P333, DOI 10.1016/S0168-8278(86)80486-X; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LEMARRE J, 1991, J CLIN INVEST, V87, P39; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MAHER JJ, 1988, J CLIN INVEST, V82, P450, DOI 10.1172/JCI113618; MAHER JJ, 1990, J CLIN INVEST, V86, P1641, DOI 10.1172/JCI114886; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MATSUOKA M, 1990, HEPATOLOGY, V11, P599, DOI 10.1002/hep.1840110412; MEYER DH, 1992, HEPATOLOGY, V16, P204, DOI 10.1002/hep.1840160131; MILANI S, 1989, HEPATOLOGY, V10, P84, DOI 10.1002/hep.1840100117; MILANI S, 1991, AM J PATHOL, V139, P1221; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; NAKATSUKASA H, 1990, J CLIN INVEST, V85, P1833, DOI 10.1172/JCI114643; PARALKAR VM, 1991, DEV BIOL, V143, P303, DOI 10.1016/0012-1606(91)90081-D; PINZANI M, 1989, J CLIN INVEST, V84, P1786, DOI 10.1172/JCI114363; PROCTOR E, 1982, GASTROENTEROLOGY, V83, P1183; RAMADORI G, 1991, HEPATOLOGY, V14, P875, DOI 10.1002/hep.1840140520; RAMADORI G, 1987, J HEPATOL, V4, P190, DOI 10.1016/S0168-8278(87)80079-X; RAMADORI G, 1992, ROENTEROLOGY, V103, P1313; RHOADS DD, 1986, MOL CELL BIOL, V6, P2774, DOI 10.1128/MCB.6.8.2774; RIZZINO A, 1988, CANCER RES, V48, P4266; ROCKEY DC, 1992, J SUBMICR CYTOL PATH, V24, P193; SANGER F, 1982, J MOL BIOL, V162, P729, DOI 10.1016/0022-2836(82)90546-0; SCHAFER S, 1987, HEPATOLOGY, V7, P680, DOI 10.1002/hep.1840070411; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; TSUJI T, 1990, P NATL ACAD SCI USA, V87, P8835, DOI 10.1073/pnas.87.22.8835; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WEINER FR, 1990, HEPATOLOGY, V11, P111, DOI 10.1002/hep.1840110119; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; ZERBE O, 1988, EXP MOL PATHOL, V49, P87, DOI 10.1016/0014-4800(88)90023-8	61	158	161	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10551	10558						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144642				2022-12-25	WOS:A1994NF01700056
J	MONTEIRO, PB; LATARO, RC; FERRO, JA; REINACH, FDC				MONTEIRO, PB; LATARO, RC; FERRO, JA; REINACH, FDC			FUNCTIONAL ALPHA-TROPOMYOSIN PRODUCED IN ESCHERICHIA-COLI - A DIPEPTIDE EXTENSION CAN SUBSTITUTE THE AMINO-TERMINAL ACETYL GROUP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTOMYOSIN SUBFRAGMENT-1 ATPASE; RABBIT SKELETAL-MUSCLE; HELIX DIPOLE MODEL; TROPONIN-TROPOMYOSIN; ACID SEQUENCE; F-ACTIN; BINDING; COMPONENTS; STABILIZATION; ABSENCE	Unlike the muscle protein, alpha-tropomyosin expressed in Escherichia coli does not bind actin, does not exhibit head-to-tail polymerization, and does not inhibit actomyosin ATPase activity in the absence of troponin. The only chemical difference between recombinant and muscle tropomyosins is that the first methionine is not acetylated in the recombinant protein (Hitchcock-DeGregori, S. E., and Heald, R. W. (1987) J. Biol. Chem. 262, 9730-9735). We expressed three fusion tropomyosins in E. coli with 2, 3, and 17 amino acids fused to its amino terminus. Ah three fusions restored actin binding, head-to-tail polymerization, and the capacity to inhibit the actomyosin ATPase to these unacetylated tropomyosins. Unlike larger fusions, the small fusions of 2 and 3 amino acids do not interfere with regulatory function. Therefore the presence of a fused dipeptide at the amino terminus of unacetylated tropomyosin is sufficient to replace the function of the N-acetyl group present in muscle tropomyosin. A structural interpretation for the function of the acetyl group, based on our results and the coiled coil structure of tropomyosin, is presented.	UNIV SAO PAULO,INST QUIM,DEPT BIOQUIM,BR-01498 SAO PAULO,SP,BRAZIL; UNIV ESTADUAL PAULISTA,DEPT TECNOL,BR-14870 JABOTICABAL,SP,BRAZIL	Universidade de Sao Paulo; Universidade Estadual Paulista			Ferro, Jesus Aparecido A/C-8251-2013	Ferro, Jesus Aparecido A/0000-0002-3966-1303				CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; CHO YJ, 1990, J BIOL CHEM, V265, P538; COTE GP, 1981, J BIOL CHEM, V256, P1999; EBASHI S, 1971, J BIOCHEM, V69, P441, DOI 10.1093/oxfordjournals.jbchem.a129486; FAIRMAN R, 1989, PROTEINS, V5, P1, DOI 10.1002/prot.340050102; FARAH CS, 1994, J BIOL CHEM, V269, P4878; GOODING C, 1987, NUCLEIC ACIDS RES, V15, P8105, DOI 10.1093/nar/15.19.8105; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HEELEY DH, 1989, BIOCHEM J, V258, P831, DOI 10.1042/bj2580831; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; HILL LE, 1992, J BIOL CHEM, V267, P16106; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; HODGES R S, 1992, Current Biology, V2, P122, DOI 10.1016/0960-9822(92)90241-2; HODGES RS, 1981, J BIOL CHEM, V256, P1214; ISERHARDT SV, 1988, ARQ BIOL TECNOL, V31, P52; JOHNSON KA, 1978, BIOCHEMISTRY-US, V17, P3432, DOI 10.1021/bi00610a002; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; MAK AS, 1983, J BIOL CHEM, V258, P4330; MAK AS, 1981, BIOCHEM BIOPH RES CO, V101, P208, DOI 10.1016/S0006-291X(81)80032-0; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MEISTEIR A, 1965, BIOCH AMINO ACIDS, P28; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PATO MD, 1981, J BIOL CHEM, V256, P602; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; QUAGGIO RB, 1993, PROTEIN SCI, V2, P1053, DOI 10.1002/pro.5560020618; REINACH FC, 1982, J CELL BIOL, V95, P78, DOI 10.1083/jcb.95.1.78; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENDER PM, 1971, FEBS LETT, V17, P106, DOI 10.1016/0014-5793(71)80575-6; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; SODEK J, 1978, J BIOL CHEM, V253, P1129; STONE D, 1978, J BIOL CHEM, V253, P1137; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TALBOT JA, 1982, ACCOUNTS CHEM RES, V15, P224, DOI 10.1021/ar00079a006; TSAO TC, 1951, BIOCHEM J, V49, P27, DOI 10.1042/bj0490027; YANG YZ, 1979, J BIOL CHEM, V254, P7137; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	40	191	192	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10461	10466						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144630				2022-12-25	WOS:A1994NF01700043
J	WOLODKO, WT; FRASER, ME; JAMES, MNG; BRIDGER, WA				WOLODKO, WT; FRASER, ME; JAMES, MNG; BRIDGER, WA			THE CRYSTAL-STRUCTURE OF SUCCINYL-COA SYNTHETASE FROM ESCHERICHIA-COLI AT 2.5-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHETASE; ALPHA-SUBUNIT; MACROMOLECULAR CRYSTALLOGRAPHY; WEISSENBERG CAMERA; PORCINE HEART; CATALYSIS; SEQUENCE; PROTEINS; PRECURSOR; CLONING	The x-ray crystal structure of succinyl-CoA synthetase (SCS) from Escherichia coli has been determined by the method of multiple isomorphous replacement to a resolution of 2.5 Angstrom. Crystals of SCS are tetragonal with a space group of P4(3)22 and unit cell dimensions of a = b = 98.47 Angstrom and c = 400.6 Angstrom. One molecule of SCS (142 kDa) is contained in the asymmetric unit. The current model has been refined to a conventional R factor of 21.6% with root mean square deviations from ideal stereochemistry of 0.022 Angstrom for bond lengths and 3.25 degrees for bond angles. The quaternary organization of the E. coli enzyme is an alpha(2) beta(2) heterotetramer. In this tetramer, the alpha-subunits interact only with the beta-subunits, whereas the beta-subunits interact to form the dimer of alpha beta-dimers. The two active site pockets are located at regions of contact between alpha- and beta subunits. One molecule of coenzyme A is bound to each alpha-subunit at a typical nucleotide-binding motif, and His-246 of each alpha-subunit is phosphorylated. This phosphohistidine, a catalytic intermediate, is stabilized by two helix dipoles (the ''power'' helices), one from each of the two subunit types. A short segment of the beta-subunit from one cup-dimer is in close proximity to the CoA-binding site of the other cup-dimer, providing a possible rationale for the overall tetrameric structure.	UNIV ALBERTA, DEPT BIOCHEM, EDMONTON T6G 2H7, AB, CANADA; UNIV ALBERTA, MRC, CANADA GRP PROT STRUCT & FUNCT, EDMONTON T6G 2H7, AB, CANADA	University of Alberta; University of Alberta				Fraser, Marie/0000-0001-8501-1494				ALLEN FH, 1983, ACCOUNTS CHEM RES, V16, P146, DOI 10.1021/ar00089a001; BAILEY DL, 1993, PROTEIN SCI, V2, P1255, DOI 10.1002/pro.5560020808; BEARD LN, 1968, ACTA CRYSTALL B-STRU, VB 24, P1529, DOI 10.1107/S0567740868004590; BOWMAN CM, 1975, J BIOL CHEM, V250, P5609; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; Brtinger A. T., 1990, X PLOR VERSION 2 1; BUCK D, 1989, BIOCHEM J, V260, P737, DOI 10.1042/bj2600737; BUCK D, 1985, BIOCHEMISTRY-US, V24, P6245, DOI 10.1021/bi00343a031; COLLIER GE, 1978, J BIOL CHEM, V253, P4938; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; ELSHOURBAGY NA, 1990, J BIOL CHEM, V265, P1430; HENNING WD, 1988, P NATL ACAD SCI USA, V85, P1432, DOI 10.1073/pnas.85.5.1432; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; HIGASHI T, 1989, J APPL CRYSTALLOGR, V22, P9, DOI 10.1107/S0021889888009562; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; JIA ZC, 1993, NATURE, V361, P94, DOI 10.1038/361094a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KIM YH, 1993, J BIOL CHEM, V268, P18513; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MAJUMDAR R, 1990, BIOCHEM CELL BIOL, V68, P292, DOI 10.1139/o90-040; MOFFET FJ, 1972, J BIOL CHEM, V247, P8139; MOFFET FJ, 1973, CAN J BIOCHEM CELL B, V51, P44, DOI 10.1139/o73-007; NISHIMURA JS, 1986, ADV ENZYMOL RAMB, V58, P141; OTWINOWSKI Z, 1990, 1990 AM CRYST ASS AN; PEARSON PH, 1975, J BIOL CHEM, V250, P8524; PHILLIPS GN, 1979, J AM CHEM SOC, V101, P7120, DOI 10.1021/ja00517a081; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; REED SI, 1989, J CELL SCI, P29; SAKABE N, 1983, J APPL CRYSTALLOGR, V16, P542, DOI 10.1107/S0021889883010973; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; TEHERANI JA, 1975, J BIOL CHEM, V250, P3883; TRONRUD DE, 1992, ACTA CRYSTALLOGR A, V48, P912, DOI 10.1107/S0108767392005415; VELLIEUX FMD, 1993, P NATL ACAD SCI USA, V90, P2355, DOI 10.1073/pnas.90.6.2355; WANG SP, 1993, P NATL ACAD SCI USA, V90, P630, DOI 10.1073/pnas.90.2.630; WANG T, 1972, BIOCHEMISTRY-US, V11, P2067, DOI 10.1021/bi00761a011; WILLIAMS SP, 1987, BIOCHEMISTRY-US, V26, P4483, DOI 10.1021/bi00388a046; WINN SI, 1981, PHILOS T ROY SOC B, V293, P121, DOI 10.1098/rstb.1981.0066; WOLODKO WT, 1987, BIOCHEM CELL BIOL, V65, P452, DOI 10.1139/o87-058; WOLODKO WT, 1981, P NATL ACAD SCI-BIOL, V78, P2140, DOI 10.1073/pnas.78.4.2140; WOLODKO WT, 1984, J BIOL CHEM, V259, P5316; WOLODKO WT, 1986, BIOCHEMISTRY-US, V25, P5420, DOI 10.1021/bi00367a012	41	127	129	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10883	10890						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	8144675				2022-12-25	WOS:A1994NF01700102
J	CHUNDURU, SK; CODY, V; LUFT, JR; PANGBORN, W; APPLEMAN, JR; BLAKLEY, RL				CHUNDURU, SK; CODY, V; LUFT, JR; PANGBORN, W; APPLEMAN, JR; BLAKLEY, RL			METHOTREXATE-RESISTANT VARIANTS OF HUMAN DIHYDROFOLATE-REDUCTASE - EFFECTS OF PHE31 SUBSTITUTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; HYDROPHOBIC INTERACTIONS; VERTEBRATE SOURCES; CRYSTAL-STRUCTURE; HYDRIDE TRANSFER; TRANSIENT-STATE; FUNCTIONAL-ROLE; BONE-MARROW; BINDING	Substitution of glycine or alanine for phenylalanine 31 in human dihydrofolate reductase produces variants that are inhibited less by methotrexate (MTX) than the previously reported serine variant. The 100 times decrease in MTX affinity for the glycine variant is due to slower binding, and to inability of the initial complex to isomerize to a nondissociating conformer. A polar group at position 31 is unnecessary for resistance, but residues larger than serine confer no resistance. The glycine variant best fulfills criteria for gene therapy: low K(m) for H-2folate, high k(cat), and good stability. Although k(cat) is unaltered by these mutations, the rate of hydride transfer is greatly decreased. Presteady-state measurements have enabled a complete catalytic scheme to be constructed for the glycine variant that predicts observed steady-state behavior. The crystal structures of inhibitor complexes of the serine, alanine, and glycine mutants and of the wild-type enzyme show that the mutations cause little perturbation of the protein backbone, of side chains of residues at the active site, or of the bound inhibitor. A molecule of bound water occupies the space vacated by the phenyl group.	ST JUDE CHILDRENS RES HOSP, DEPT MOLEC PHARMACOL, 332 N LAUDERDALE, POB 318, MEMPHIS, TN 38101 USA; MED FDN BUFFALO INC, BUFFALO, NY 14203 USA	St Jude Children's Research Hospital					NCI NIH HHS [P30 CA 21765, R01 CA 31922] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031922, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHRWEILER PM, 1991, BIOCHEMISTRY-US, V30, P7801, DOI 10.1021/bi00245a020; APPLEMAN JR, 1988, J BIOL CHEM, V263, P10304; APPLEMAN JR, 1990, J BIOL CHEM, V265, P2740; APPLEMAN JR, 1988, J BIOL CHEM, V263, P9187; APPLEMAN JR, 1989, J BIOL CHEM, V264, P2625; BEARD WA, 1989, J BIOL CHEM, V264, P9391; BENKOVIC SJ, 1988, SCIENCE, V239, P1105, DOI 10.1126/science.3125607; BLAKLEY RL, 1985, BIOCHEMISTRY-US, V24, P4772, DOI 10.1021/bi00339a010; CODY V, 1992, ANTI-CANCER DRUG DES, V7, P483; COREY CA, 1990, BLOOD, V75, P337; DAVIES JF, 1990, BIOCHEMISTRY-US, V29, P9467, DOI 10.1021/bi00492a021; DELCAMP TJ, 1983, BIOCHEMISTRY-US, V22, P633, DOI 10.1021/bi00272a017; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; FREI B, 1991, BIOTECHNIQUES, V19, P420; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; KING EL, 1956, J PHYS CHEM-US, V60, P1375, DOI 10.1021/j150544a010; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LI LY, 1992, BIOCHEMISTRY-US, V31, P7826, DOI 10.1021/bi00149a012; LI M, 1992, HUM GENE THER, V3, P381, DOI 10.1089/hum.1992.3.4-381; MARGOSIAK SA, 1993, ARCH BIOCHEM BIOPHYS, V305, P499, DOI 10.1006/abbi.1993.1453; MCTIGUE MA, 1992, BIOCHEMISTRY-US, V31, P7264, DOI 10.1021/bi00147a009; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; OEFNER C, 1988, EUR J BIOCHEM, V174, P377, DOI 10.1111/j.1432-1033.1988.tb14108.x; PRENDERGAST NJ, 1988, BIOCHEMISTRY-US, V27, P3664, DOI 10.1021/bi00410a022; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEITZER BI, 1989, J BIOL CHEM, V264, P20786; SRIMATKANDADA S, 1989, J BIOL CHEM, V264, P3524; STONE SR, 1984, BIOCHEM PHARMACOL, V33, P175, DOI 10.1016/0006-2952(84)90472-6; STONE SR, 1986, BIOCHIM BIOPHYS ACTA, V869, P275, DOI 10.1016/0167-4838(86)90067-1; STUBER D, 1986, P839; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; TAIRA K, 1988, J MED CHEM, V31, P129, DOI 10.1021/jm00396a019; THILLET J, 1988, J BIOL CHEM, V263, P12500; TSAY JT, 1990, BIOCHEMISTRY-US, V29, P6428, DOI 10.1021/bi00479a014; WILLIAMS DA, 1987, J EXP MED, V166, P210, DOI 10.1084/jem.166.1.210; WILLIAMS JW, 1979, BIOCHEMISTRY-US, V18, P2567, DOI 10.1021/bi00579a021; WILLIAMS JW, 1980, BIOCHEM PHARMACOL, V29, P589, DOI 10.1016/0006-2952(80)90381-0; WU YD, 1987, J AM CHEM SOC, V109, P2226, DOI 10.1021/ja00241a074	39	63	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9547	9555						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144541				2022-12-25	WOS:A1994NE05300026
J	HAGLER, J; LUO, Y; SHUMAN, S				HAGLER, J; LUO, Y; SHUMAN, S			FACTOR-DEPENDENT TRANSCRIPTION TERMINATION BY VACCINIA RNA-POLYMERASE - KINETIC COUPLING AND REQUIREMENT FOR ATP HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS EARLY TRANSCRIPTION; MESSENGER-RNA; ESCHERICHIA-COLI; (GUANINE-7-)METHYLTRANSFERASE COMPLEX; CAPPING ENZYME; ELONGATION; VIRIONS; INVITRO; PURIFICATION; PROMOTER	Transcription termination during synthesis of vaccinia early mRNAs occurs downstream of a UUUUUNU signal in the nascent transcript and requires a virus-encoded termination factor (VTF), which is identical with the vaccinia mRNA capping enzyme. Using purified transcription complexes halted at defined sites on linear DNA templates, we have examined the order and timing of events during a single round of elongation and termination. We find that although cap synthesis occurs by the time the nascent RNA is 31 nucleotides long, capping enzyme is not stably associated with the elongation complex at this stage. Stable interaction, defined by the formation of a termination-competent complex, requires a longer nascent RNA, eg. 51 nucleotides, but does not depend on prior transcription of the termination signal. The acquisition of termination competence correlates temporally with the physical association of capping enzyme/VTF with the elongation complex, as revealed by UV cross-linking of the capping enzyme large subunit to the nascent RNA chain. Subsequent induction of termination and transcript release by capping enzyme requires energy, specifically the hydrolysis of ATP. The choice of termination site is flexible and is determined by a kinetic balance between the rate of polymerase elongation and the rate of signaling. Signaling rate is related directly to the concentration of hydrolyzable ATP. An apparent lower limit of 33 nucleotides between the 5' boundary of the termination signal and the most proximal termination site implies that the UUUUUNU signal must be extruded from the RNA polymerase before it can be acted upon by VTF. Similarities between VTF-dependent termination and rho-dependent termination underscore an evolutionarily conserved mechanism for RNA signal transduction to the elongating RNA polymerase.			HAGLER, J (corresponding author), MEM SLOAN KETTERING CANC CTR,MOLEC BIOL PROGRAM,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM 42498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS JA, 1989, J BIOL CHEM, V264, P3223; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BAJSZAR G, 1983, J VIROL, V45, P62; BAROUDY BM, 1980, J BIOL CHEM, V255, P4372; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14266; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; DISSINGER S, 1992, J MOL BIOL, V219, P11; EARL PL, 1990, J VIROL, V64, P2448, DOI 10.1128/JVI.64.5.2448-2451.1990; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P121, DOI 10.1021/bi00116a018; GERSHON PD, 1990, P NATL ACAD SCI USA, V87, P4401, DOI 10.1073/pnas.87.11.4401; GERSHOWITZ A, 1978, J VIROL, V27, P399, DOI 10.1128/JVI.27.2.399-408.1978; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HAGLER J, 1992, J VIROL, V66, P2982, DOI 10.1128/JVI.66.5.2982-2989.1992; HAGLER J, 1992, J BIOL CHEM, V267, P7644; HAGLER J, 1992, P NATL ACAD SCI USA, V89, P10009; INK BS, 1989, J VIROL, V63, P4632, DOI 10.1128/JVI.63.11.4632-4644.1989; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; KATES J, 1970, J MOL BIOL, V50, P1, DOI 10.1016/0022-2836(70)90100-2; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; LI J, 1993, J BIOL CHEM, V268, P20016; LI J, 1993, J BIOL CHEM, V268, P2773; LIBBY RT, 1989, EMBO J, V8, P3153, DOI 10.1002/j.1460-2075.1989.tb08469.x; LUO Y, 1991, J BIOL CHEM, V266, P13303; LUO Y, 1993, J BIOL CHEM, V268, P21253; LUO Y, 1991, VIROLOGY, V185, P432, DOI 10.1016/0042-6822(91)90793-B; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MOSS B, 1991, J BIOL CHEM, V266, P1355; PAOLETTI E, 1978, VIROLOGY, V87, P317, DOI 10.1016/0042-6822(78)90137-X; REINES D, 1989, J BIOL CHEM, V264, P10799; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; ROHRMANN G, 1986, CELL, V46, P1029, DOI 10.1016/0092-8674(86)90702-6; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SHUMAN S, 1980, J BIOL CHEM, V255, P5396; SHUMAN S, 1990, J BIOL CHEM, V265, P11960; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; SHUMAN S, 1988, J BIOL CHEM, V263, P6220; SPENCER E, 1980, J BIOL CHEM, V255, P5388; STEINMETZ EJ, 1990, J BIOL CHEM, V265, P18408; VENKATESAN S, 1980, J BIOL CHEM, V255, P903; VEOMETT GE, 1973, ICN UCL S MOL BIOL, P127; WATANABE Y, 1974, FEBS LETT, V41, P331, DOI 10.1016/0014-5793(74)81241-X; WU SY, 1993, P NATL ACAD SCI USA, V90, P6606, DOI 10.1073/pnas.90.14.6606	45	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					10050	10060						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144504				2022-12-25	WOS:A1994NE05300099
J	MYMRYK, JS; SHIRE, K; BAYLEY, ST				MYMRYK, JS; SHIRE, K; BAYLEY, ST			INDUCTION OF APOPTOSIS BY ADENOVIRUS TYPE-5 E1A IN RAT-CELLS REQUIRES A PROLIFERATION BLOCK	ONCOGENE			English	Article							WILD-TYPE P53; CELLULAR PROTEIN; HOST-CELL; DNA; DEGRADATION; SUPPRESSOR; BINDING; ANTIGEN; 19-KDA; GENE	Infection with Ad5dl520EIB-, an adenovirus producing only the 243 residue EIA protein and lacking the EIB region, caused apoptosis in normal rat kidney (NRK) cells as judged by the production of nucleosomal DNA fragments. Apoptosis occurred only when the celts were growth-inhibited by cell-cell contacts in confluent cultures or by serum starvation and not when they were actively growing. In uninfected cultures, apoptosis also occurred at confluency, but more slowly than after infection. Studies with EIA deletion mutants of dl520E1B- showed that the regions of the EIA protein essential for induction of apoptosis were those in exon 1 required for binding to the cellular proteins p300 and pRb. Mutants defective at inducing apoptosis were previously found to be defective at inducing baby rat kidney cells to synthesize cellular DNA. In our experiments, cells underwent apoptosis when stimulated by E1A to proliferate under conditions where proliferation was blocked. It is possible that it was the proliferation block opposing the induction of proliferation that led directly to apoptosis. Circumstances leading to induction of apoptosis by c-myc (Evan et al., 1992) are similar and can be interpreted in a similar way.	MCMASTER UNIV,DEPT BIOL,HAMILTON L8S 4K1,ONTARIO,CANADA; MCMASTER UNIV,DEPT BIOCHEM,HAMILTON L8S 4K1,ONTARIO,CANADA	McMaster University; McMaster University								BARBEAU D, 1992, BIOCHEM CELL BIOL, V70, P1123, DOI 10.1139/o92-158; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; DHALLUIN JC, 1979, J VIROL, V32, P61, DOI 10.1128/JVI.32.1.61-71.1979; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EZOE H, 1981, J VIROL, V40, P20, DOI 10.1128/JVI.40.1.20-27.1981; FATT RBL, 1982, J VIROL, V42, P969, DOI 10.1128/JVI.42.3.969-977.1982; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOWE JA, 1992, VIROLOGY, V186, P15, DOI 10.1016/0042-6822(92)90057-V; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MYMRYK JS, 1993, J GEN VIROL, V74, P2131, DOI 10.1099/0022-1317-74-10-2131; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; SUBRAMANIAN T, 1984, J BIOL CHEM, V259, P1777; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; WILLIAMS G T, 1992, Trends in Cell Biology, V2, P263, DOI 10.1016/0962-8924(92)90198-V; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	33	102	105	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1187	1193						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134121				2022-12-25	WOS:A1994NC04800022
J	SMITH, DM; TRAN, HM; SOO, VW; MCQUISTON, SA; TARTAGLIA, LA; GOEDDEL, DV; EPSTEIN, LB				SMITH, DM; TRAN, HM; SOO, VW; MCQUISTON, SA; TARTAGLIA, LA; GOEDDEL, DV; EPSTEIN, LB			ENHANCED SYNTHESIS OF TUMOR NECROSIS FACTOR-INDUCIBLE PROTEINS, PLASMINOGEN-ACTIVATOR INHIBITOR-2, MANGANESE SUPEROXIDE-DISMUTASE, AND PROTEIN 28/5.6, IS SELECTIVELY TRIGGERED BY THE 55-KDA TUMOR-NECROSIS-FACTOR RECEPTOR IN HUMAN-MELANOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-DIMENSIONAL GEL-ELECTROPHORESIS; FACTOR TNF RECEPTOR; FACTOR-ALPHA; MONOCLONAL-ANTIBODIES; SYNERGISTIC INDUCTION; HUMAN-FIBROBLASTS; INTERFERON-GAMMA; EXPRESSION; CLONING; BINDING	We have demonstrated that A375 melanoma cells express mRNA for both types of tumor necrosis factor (TNF) receptors and receptor proteins on their plasma membranes. Specific agonist and blocking antibodies to either 55-kDa (TNF-R1) or 75-kDa (TNF-R2) TNF receptors combined with two-dimensional gel analysis were employed to determine which receptor type is responsible for mediating the induction of individual melanoma proteins. Our results indicate that the enhanced synthesis of proteins 21/>7 (M(r)/pI), 28/5.6, and 41/5.7 is selectively induced through TNF-R1. TNF induces these proteins; antagonist antibody to TNF-R1 prevents their induction by TNF, and TNF-R1 agonist induces them in the absence of TNF. Identification of these proteins by immunoblot analysis proved that 21/>7 is manganese superoxide dismutase, protein 28/5.6 is unrelated to 27/28-kDa heat shock protein, and protein 41/5.7 is plasminogen activator inhibitor-2. Furthermore, TNF cytotoxicity for A375 cells is also mediated by TNF-R1. These studies indicate that TNF-R1 is a critical signaling receptor for TNF action on A375 cells and demonstrate the potential use of TNF-R1 antibodies to selectively block or enhance specific effects of TNF on melanoma cells.	UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; Roche Holding; Genentech; University of California System; University of California San Francisco					NCI NIH HHS [CA 4446, CA 27903] Funding Source: Medline; NIA NIH HHS [AG08938] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA027903, R01CA027903] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG008938] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARRIGO AP, 1990, MOL CELL BIOL, V10, P3857; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; BERESINI MH, 1990, ELECTROPHORESIS, V11, P232, DOI 10.1002/elps.1150110307; BERESINI MH, 1988, J IMMUNOL, V140, P485; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; BROUCKAERT P, 1992, LYMPHOKINE CYTOK RES, V11, P193; CAMUSSI G, 1991, EUR J BIOCHEM, V202, P3, DOI 10.1111/j.1432-1033.1991.tb16337.x; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CHURCH SL, 1992, DEV BIOL, V149, P177, DOI 10.1016/0012-1606(92)90274-K; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; DUFFY MJ, 1992, CLIN EXP METASTAS, V10, P145, DOI 10.1007/BF00132746; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; EPSTEIN LB, 1991, CYTOKINES PRACTICAL; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GHER G, 1992, J IMMUNOL, V149, P911; GRAY PW, 1990, P NATL ACAD SCI USA, V87, P7380, DOI 10.1073/pnas.87.19.7380; GREENBLATT MS, 1992, BLOOD, V80, P1339; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; HALL SC, 1993, P NATL ACAD SCI USA, V90, P1927, DOI 10.1073/pnas.90.5.1927; HARRIS CA, 1991, J IMMUNOL, V147, P149; HIGUCHI M, 1992, BIOCHEM BIOPH RES CO, V182, P638, DOI 10.1016/0006-291X(92)91780-T; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JAATTELA M, 1991, LAB INVEST, V64, P724; JOHNSON SE, 1990, J BIOL CHEM, V265, P6642; KRONKE M, 1991, TUMOR NECROSIS FACTO, P189; KRUPPA G, 1992, J IMMUNOL, V148, P3152; KWEE JK, 1991, CANCER LETT, V57, P199, DOI 10.1016/0304-3835(91)90157-D; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER A, 1992, 8TH P INT C IMM BUD, P236; LOPEZ MF, 1991, 2D PAGE 91, P313; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; MONTGOMERY AMP, 1993, CANCER RES, V53, P693; NAKAMURA M, 1992, THROMB RES, V65, P709, DOI 10.1016/0049-3848(92)90110-V; OBERLEY LW, 1983, SUPEROXIDE DISMUTASE, V2, P127; OSTADE XV, 1993, NATURE, V361, P266; OTTER T, 1987, ANAL BIOCHEM, V162, P370, DOI 10.1016/0003-2697(87)90406-4; PATTON WF, 1990, BIOTECHNIQUES, V8, P518; PENNICA D, 1992, BIOCHEMISTRY-US, V31, P1134, DOI 10.1021/bi00119a023; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PYTEL BA, 1990, J CELL PHYSIOL, V144, P416, DOI 10.1002/jcp.1041440308; QUAX PHA, 1991, J CELL BIOL, V115, P191, DOI 10.1083/jcb.115.1.191; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH DM, 1992, TUMOR NECROSIS FACTOR : STRUCTURE-FUNCTION RELATIONSHIP AND CLINICAL APPLICATION, P173; SMITH DM, 1991, 2D PAGE 91, P145; SUMIYOSHI K, 1992, INT J CANCER, V50, P345, DOI 10.1002/ijc.2910500303; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; VANDENABEELE P, 1992, J EXP MED, V176, P1015, DOI 10.1084/jem.176.4.1015; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WISPE JR, 1989, BIOCHIM BIOPHYS ACTA, V994, P30, DOI 10.1016/0167-4838(89)90058-7; WONG GHW, 1992, J IMMUNOL, V149, P3350; YANAGA F, 1992, FEBS LETT, V314, P297, DOI 10.1016/0014-5793(92)81493-6	59	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9898	9905						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144583				2022-12-25	WOS:A1994NE05300077
J	VOLLAND, C; URBANGRIMAL, D; GERAUD, G; HAGUENAUERTSAPIS, R				VOLLAND, C; URBANGRIMAL, D; GERAUD, G; HAGUENAUERTSAPIS, R			ENDOCYTOSIS AND DEGRADATION OF THE YEAST URACIL PERMEASE UNDER ADVERSE CONDITIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE ATPASE; COLI SHUTTLE VECTORS; SACCHAROMYCES-CEREVISIAE; ALPHA-FACTOR; CATABOLITE INACTIVATION; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; RESTRICTION SITES; UBIQUITIN PATHWAY; TRANSPORT-SYSTEM	Yeast uracil permease follows the secretory pathway to the plasma membrane and is phosphorylated on serine residues in a post-Golgi compartment. The protein was found to be rather stable in growing cells, but its turnover rate (half-life of about 7 h) was much faster than that of most yeast proteins. Several adverse conditions triggered the rapid degradation of uracil permease, and so a loss of uracil uptake. Turnover was rapid when yeast cells were starved of either nitrogen, phosphate, or carbon, and as they approached the stationary growth phase. Rapid permease degradation was also promoted by the inhibition of protein synthesis. The degradation of uracil permease in response to several stresses was strikingly slower in the two mutants, end3 and end4, that are deficient in the internalization step of receptor-mediated endocytosis. Thus, internalization is the first step in the permease degradative pathway. Uracil permease is degraded in the vacuole, since pep4 mutant cells lacking vacuolar protease activities accumulated large amounts of uracil permease, which was located within the vacuole by immunofluorescence. We have yet to determine whether adverse conditions enhance permease endocytosis and subsequent degradation or divert internalized uracil permease from a recycling to a degradative pathway.	UNIV PARIS 07, INST JACQUES MONOD, 2 PL JUSSIEU, F-75251 PARIS 05, FRANCE	UDICE-French Research Universities; Universite Paris Cite			Haguenauer-Tsapis, Rosine/C-5446-2012					AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BENITO B, 1991, BIOCHIM BIOPHYS ACTA, V1063, P265, DOI 10.1016/0005-2736(91)90381-H; BUSTURIA A, 1986, J GEN MICROBIOL, V132, P379; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CHEVALLIER MR, 1982, MOL CELL BIOL, V2, P977, DOI 10.1128/MCB.2.8.977; CHIRIO MC, 1990, EUR J BIOCHEM, V194, P293, DOI 10.1111/j.1432-1033.1990.tb19456.x; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; DEJUAN C, 1986, FEBS LETT, V207, P258, DOI 10.1016/0014-5793(86)81500-9; DULIC V, 1991, METHOD ENZYMOL, V194, P697; ERASO P, 1987, FEBS LETT, V224, P193, DOI 10.1016/0014-5793(87)80446-5; FINLEY D, 1992, MOL CELLULAR BIOL YE, V2, P539; GANCEDO JM, 1982, MOL CELL BIOCHEM, V43, P89, DOI 10.1007/BF00423096; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRENSON M, 1969, EUR J BIOCHEM, V11, P249, DOI 10.1111/j.1432-1033.1969.tb00767.x; HARE JF, 1990, BIOCHIM BIOPHYS ACTA, V1031, P71, DOI 10.1016/0304-4157(90)90003-U; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HUNT T, 1991, NATURE, V349, P100, DOI 10.1038/349100a0; JENNESS DD, 1986, CELL, V46, P345, DOI 10.1016/0092-8674(86)90655-0; JUND R, 1977, J MEMBRANE BIOL, V36, P233, DOI 10.1007/BF01868153; JUND R, 1988, EUR J BIOCHEM, V171, P417, DOI 10.1111/j.1432-1033.1988.tb13806.x; KUCHLER K, 1993, J CELL BIOL, V120, P1203, DOI 10.1083/jcb.120.5.1203; LACROUTE F, 1968, J BACTERIOL, V95, P824, DOI 10.1128/JB.95.3.824-832.1968; LAGUNAS R, 1982, J BACTERIOL, V152, P19; LASZLO L, 1990, FEBS LETT, V261, P365, DOI 10.1016/0014-5793(90)80593-8; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; MARSH M, 1993, CURR BIOL, V3, P30, DOI 10.1016/0960-9822(93)90142-B; MECHLER B, 1982, BIOCHEM BIOPH RES CO, V107, P770, DOI 10.1016/0006-291X(82)90590-3; MORI S, 1992, J BIOL CHEM, V267, P6429; PANARETOU B, 1992, EUR J BIOCHEM, V206, P635, DOI 10.1111/j.1432-1033.1992.tb16968.x; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PIPER RC, 1992, J CELL BIOL, V117, P729, DOI 10.1083/jcb.117.4.729; RAMOS J, 1989, J BACTERIOL, V171, P3545, DOI 10.1128/jb.171.6.3545-3548.1989; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; RIEZMAN H, 1986, TRENDS BIOCHEM SCI, V11, P325, DOI 10.1016/0968-0004(86)90290-2; Riezman Howard, 1993, Trends in Cell Biology, V3, P273, DOI 10.1016/0962-8924(93)90056-7; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SHULMAN RW, 1977, J BIOL CHEM, V252, P1344; SILVE S, 1991, MOL CELL BIOL, V11, P1114, DOI 10.1128/MCB.11.2.1114; SIMEON A, 1992, FEBS LETT, V301, P231, DOI 10.1016/0014-5793(92)81254-J; SINGER B, 1990, J CELL BIOL, V110, P1911, DOI 10.1083/jcb.110.6.1911; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; THEVELEIN JM, 1991, MOL MICROBIOL, V5, P1301, DOI 10.1111/j.1365-2958.1991.tb00776.x; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; VEINOTDREBOT LM, 1989, J BIOL CHEM, V264, P19473; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; VOLLAND C, 1992, J BIOL CHEM, V267, P23767; WICHMANN H, 1992, CELL, V71, P1131, DOI 10.1016/S0092-8674(05)80062-5; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; WOOLFORD JL, 1991, MOL CELLULAR BIOL YE, V1, P587; ZANOLARI B, 1991, MOL CELL BIOL, V11, P5251, DOI 10.1128/MCB.11.10.5251; [No title captured]	58	232	234	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9833	9841						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	8144575				2022-12-25	WOS:A1994NE05300069
J	COOK, GA; MYNATT, RL; KASHFI, K				COOK, GA; MYNATT, RL; KASHFI, K			YONETANI-THEORELL ANALYSIS OF HEPATIC CARNITINE PALMITOYLTRANSFERASE-I INHIBITION INDICATES 2 DISTINCT INHIBITORY BINDING-SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; MALONYL-COA; APPARENT-KI; ACTIVE-SITE; SENSITIVITY; ACYLTRANSFERASE; AFFINITY; INSULIN; VALUES	Analysis of inhibitor studies indicates that carnitine palmitoyltransferase-I has two separate sites for inhibitor binding. One site is located on the cytoplasmic side of the mitochondrial outer membrane. Malonyl-CoA, the most important physiological inhibitor of carnitine palmitoyltransferase-I, binds primarily to this site, but it can also bind to another site. A second inhibitory site is located at the active site of carnitine palmitoyltransferase-I. Coenzyme A, a product/inhibitor of carnitine palmitoyltransferase-I binds primarily at this site and can inhibit carnitine palmitoyltransferase-I at physiological concentrations, but can also attenuate malonyl-CoA inhibition. Analogs of malonyl-CoA and other simpler compounds containing two carbonyl groups but no coenzyme A moiety inhibit only at the cytoplasmic she, indicating that this site has an absolute requirement for two carbonyl groups but has no absolute requirement for a coenzyme A moiety. Inhibitors acting through the active site included the active-site-directed inhibitor (+)-hemipalmitoylcarpitinium. These studies support the existence of two regulatory binding sites for the control of hepatic fatty acid oxidation: (a) the active site, for regulation by the inhibitory binding of coenzyme A and acetyl-CoA, and (b) a separate regulatory malonyl-CoA-binding site that is physically separated from the active site.			COOK, GA (corresponding author), UNIV TENNESSEE,CTR HLTH SCI,COLL MED,DEPT PHARMACOL,874 UNION AVE,MEMPHIS,TN 38163, USA.		Mynatt, Randall L/N-1980-2017	Mynatt, Randall L/0000-0003-4399-0019	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007641, R01HL040929] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL07641, HL-40929] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; BIRD MI, 1984, BIOCHEM J, V222, P639, DOI 10.1042/bj2220639; BREMER J, 1981, BIOCHIM BIOPHYS ACTA, V665, P628, DOI 10.1016/0005-2760(81)90282-4; BREMER J, 1983, PHYSIOL REV, V63, P1420, DOI 10.1152/physrev.1983.63.4.1420; COOK GA, 1980, BIOCHEM J, V192, P955, DOI 10.1042/bj1920955; COOK GA, 1984, J BIOL CHEM, V259, P2030; COOK GA, 1987, J BIOL CHEM, V262, P2050; DECLERCQ PE, 1985, J BIOL CHEM, V260, P2516; ESSER V, 1993, J BIOL CHEM, V268, P5817; FRITZ IB, 1963, J LIPID RES, V4, P279; GAMBLE MS, 1985, J BIOL CHEM, V260, P9516; GANDOUR RD, 1992, J ORG CHEM, V57, P3426, DOI 10.1021/jo00038a035; GANDOUR RD, 1993, J MED CHEM, V36, P237, DOI 10.1021/jm00054a007; GHADIMINEJAD I, 1991, BIOCHIM BIOPHYS ACTA, V1083, P166, DOI 10.1016/0005-2760(91)90038-J; GRANTHAM BD, 1986, BIOCHEM J, V233, P589, DOI 10.1042/bj2330589; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; KASHFI K, 1992, BIOCHEM J, V282, P909, DOI 10.1042/bj2820909; KASHFI K, 1988, BIOCHEM SOC T, V16, P1010, DOI 10.1042/bst0161010; KASHFI K, 1991, BIOCHEM BIOPH RES CO, V176, P600; KIORPES TC, 1984, J BIOL CHEM, V259, P9750; KOLODZIEJ MP, 1993, FEBS LETT, V327, P294, DOI 10.1016/0014-5793(93)81007-M; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; MILLS SE, 1983, BIOCHEM J, V214, P83, DOI 10.1042/bj2140083; MURTHY MSR, 1987, P NATL ACAD SCI USA, V84, P378, DOI 10.1073/pnas.84.2.378; PARSONS DF, 1966, ANN NY ACAD SCI, V137, P643, DOI 10.1111/j.1749-6632.1966.tb50188.x; SAGGERSON ED, 1981, FEBS LETT, V129, P225, DOI 10.1016/0014-5793(81)80170-6; STEPHENS TW, 1987, BIOCHEM J, V243, P405, DOI 10.1042/bj2430405; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720; WOLDEGIORGIS G, 1992, ARCH BIOCHEM BIOPHYS, V295, P348, DOI 10.1016/0003-9861(92)90527-4; YONETANI T, 1982, METHOD ENZYMOL, V87, P500	30	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8803	8807						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132614				2022-12-25	WOS:A1994NB41100031
J	NAKANISHI, M; KAGAWA, Y; NARITA, Y; HIRATA, H				NAKANISHI, M; KAGAWA, Y; NARITA, Y; HIRATA, H			PURIFICATION AND RECONSTITUTION OF AN INTESTINAL NA+-DEPENDENT NEUTRAL L-ALPHA-AMINO ACID TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; RAT-BRAIN; EXPRESSION CLONING; FUNCTIONAL-CHARACTERIZATION; GLUTAMATE TRANSPORTER; SYSTEM; PROTEIN; SOLUBILIZATION; IDENTIFICATION; GLYCOPROTEIN	Using an improved reconstitution method, we have purified an Na+-dependent neutral L-alpha-amino acid transporter from rabbit small intestine to apparent homogeneity. The preparation solubilized with octaethylene glycol dodecyl ether (C(12)E(8)) was purified by successive chromatographies on DEAE-Toyopearl and lentil lectin-Sepharose 4B columns. The transport activity was assayed by reconstitution of the protein into liposomes. The specific activity of the final preparation was 1364-fold that of brush border membrane vesicles. On sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the active fractions gave one band of 90 kDa. Kinetic analysis using proteoliposomes reconstituted with the purified fraction showed that alanine transport was mediated by high affinity system with K-t value of 0.19 mM and J(max) value of 2.8 nmol/mg protein/s. Analysis of the amino acid composition of the purified transporter revealed that the transporter is very hydrophobic protein. From its specific activities for transport of individual amino acids this transporter was concluded to possess broad specificity for neutral L-alpha-amino acids. Furthermore, inhibition study of other amino acids allowed us to identify this transport pathway as the intestinal system B.	JICHI MED SCH,DEPT BIOCHEM,MINAMIKWACHI,TOCHIGI 32904,JAPAN; NAGOYA CITY UNIV,SCH MED,DEPT BIOCHEM,MIZUHO KU,NAGOYA,AICHI 467,JAPAN; HIMEJI INST TECHNOL,FAC SCI,DEPT LIFE SCI,HIMEJI,HYOGO 67812,JAPAN	Jichi Medical University; Nagoya City University; University of Hyogo								BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BOYD CAR, 1987, AMINO ACID TRANSPORT, P123; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; DANIEL H, 1991, J BIOL CHEM, V266, P19917; DUDECK KL, 1987, J BIOL CHEM, V262, P12565; FAFOURNOUX P, 1989, J BIOL CHEM, V264, P4805; FASS SJ, 1977, J BIOL CHEM, V252, P583; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAMMERMAN MR, 1977, J BIOL CHEM, V252, P591; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; IM WB, 1980, J BIOL CHEM, V255, P764; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, FEBS LETT, V89, P47, DOI 10.1016/0014-5793(78)80519-5; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KOEPSELL H, 1986, REV PHYSIOL BIOCH P, V104, P65, DOI 10.1007/BFb0031013; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZCORCUERA B, 1991, J BIOL CHEM, V266, P24809; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAENZ DD, 1992, J BIOL CHEM, V267, P1510; MAENZ DD, 1992, J BIOL CHEM, V267, P22079; MCCORMICK JI, 1988, P NATL ACAD SCI USA, V85, P7877, DOI 10.1073/pnas.85.21.7877; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; NAKANISHI M, 1993, BIOCHIM BIOPHYS ACTA, V1151, P193, DOI 10.1016/0005-2736(93)90104-8; NISHINO H, 1978, P NATL ACAD SCI USA, V75, P3856, DOI 10.1073/pnas.75.8.3856; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; RADIAN R, 1986, J BIOL CHEM, V261, P5437; RADIAN R, 1985, J BIOL CHEM, V260, P1859; RAJENDRAN VM, 1987, J BIOL CHEM, V262, P14974; SCHALI C, 1986, BIOCHEM J, V235, P189, DOI 10.1042/bj2350189; SIGRISTNELSON K, 1975, J BIOL CHEM, V250, P5674; STEVENS BR, 1987, J BIOL CHEM, V262, P6546; STEVENS BR, 1982, J MEMBRANE BIOL, V66, P213, DOI 10.1007/BF01868496; STEVENS BR, 1984, ANNU REV PHYSIOL, V46, P417; STEVENS BR, 1992, AM J PHYSIOL, V263, pR458, DOI 10.1152/ajpregu.1992.263.3.R458; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TAMARAPPOO BK, 1992, J BIOL CHEM, V267, P2370; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	41	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9325	9329						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132671				2022-12-25	WOS:A1994NB41100102
J	ROBERTS, DL; BENNETT, DW; FORST, SA				ROBERTS, DL; BENNETT, DW; FORST, SA			IDENTIFICATION OF THE SITE OF PHOSPHORYLATION ON THE OSMOSENSOR, ENVZ OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 REGULATORY COMPONENTS; PORIN GENE-EXPRESSION; OMPC GENES; TRANSCRIPTIONAL ACTIVATOR; PROTEIN-KINASE; OSMOREGULATORY EXPRESSION; ENVIRONMENTAL SENSOR; SIGNAL TRANSDUCTION; DNA-BINDING; K-12	EnvZ is a membrane-bound histidine kinase that functions as an osmotic sensor capable of phosphorylating the regulator protein OmpR in Escherichia coli. To characterize the site of phosphorylation biochemically, we overexpressed a 36-kDa truncated EnvZ protein (Glu-106 to Gly-450) that formed inclusion bodies in the cell. After solubilization, the inclusion body form of EnvZ was cleaved into two major fragments with molecular weights of 25,000 and 10,000. The 25-kDa fragment, EnvZ(c), was purified and found to exist as a dimer. N-terminal sequence analysis established that cleavage had occurred at Arg-214, indicating that EnvZ(c) contained most of the cytoplasmic domain of EnvZ. After labeling EnvZ(c) with [gamma-P-32]ATP, the protein was proteo proteolytically digested, and the resulting peptides were separated by reverse phase chromatography using high performance liquid chromatography. One major radioactive peptide containing greater than 90% of the recovered peptide-associated radioactivity was isolated. Amino acid analysis of this purified peptide indicated that the composition was consistent with a peptide that contained His-243. The amino acid sequence of this peptide was determined to be MAGVSHDLRTP (residues 238-248). These results indicate that His-243 is the major site of phosphorylation on EnvZ and represents the first biochemical characterization of the site of phosphorylation of a membrane histidine kinase of the two-component regulatory family of molecules in bacteria.	UNIV WISCONSIN,DEPT BIOL SCI,MILWAUKEE,WI 53201; UNIV WISCONSIN,DEPT CHEM,MILWAUKEE,WI 53201	University of Wisconsin System; University of Wisconsin Milwaukee; University of Wisconsin System; University of Wisconsin Milwaukee					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM044671] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44671] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1989, J BIOL CHEM, V264, P14090; AIBA H, 1989, J BIOL CHEM, V264, P8563; AIBA H, 1990, FEBS LETT, V261, P19, DOI 10.1016/0014-5793(90)80626-T; Alphen W V, 1977, J Bacteriol, V131, P623; BRISSETTE RE, 1991, J BACTERIOL, V173, P601, DOI 10.1128/jb.173.2.601-608.1991; CUI JS, 1993, J BIOL CHEM, V268, P5040; ELLIOTT JI, 1978, ARCH BIOCHEM BIOPHYS, V190, P351, DOI 10.1016/0003-9861(78)90285-0; FORST S, 1990, J BACTERIOL, V172, P3473, DOI 10.1128/jb.172.6.3473-3477.1990; FORST S, 1987, J BIOL CHEM, V262, P16433; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; FORST S, 1988, ANNU REV CELL BIOL, V4, P21, DOI 10.1146/annurev.cb.04.110188.000321; HALL MN, 1981, J MOL BIOL, V151, P1, DOI 10.1016/0022-2836(81)90218-7; HARLOCKER SL, 1993, J BACTERIOL, V175, P1956, DOI 10.1128/JB.175.7.1956-1960.1993; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; IGO M M, 1990, New Biologist, V2, P5; IGO MM, 1989, GENE DEV, V3, P598, DOI 10.1101/gad.3.5.598; IGO MM, 1988, J BACTERIOL, V170, P5971, DOI 10.1128/jb.170.12.5971-5973.1988; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; JO YL, 1986, J BIOL CHEM, V261, P15253; MATSUYAMA SI, 1986, J BACTERIOL, V168, P1309, DOI 10.1128/jb.168.3.1309-1314.1986; MIZUNO T, 1982, J BIOL CHEM, V257, P13692; MIZUNO T, 1990, MOL MICROBIOL, V4, P1077, DOI 10.1111/j.1365-2958.1990.tb00681.x; NAKASHIMA K, 1991, J BIOL CHEM, V266, P10775; NINFA AJ, 1991, J BIOL CHEM, V266, P6888; NORIOKA S, 1986, J BIOL CHEM, V261, P7113; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; RAMPERSAUD A, 1989, J BIOL CHEM, V264, P18693; RAMPERSAUD A, 1991, J BACTERIOL, V173, P6882, DOI 10.1128/jb.173.21.6882-6888.1991; RUSSO FD, 1991, J MOL BIOL, V222, P567, DOI 10.1016/0022-2836(91)90497-T; SLAUCH JM, 1988, J BACTERIOL, V170, P439, DOI 10.1128/jb.170.1.439-441.1988; SLAUCH JM, 1989, J MOL BIOL, V210, P281, DOI 10.1016/0022-2836(89)90330-6; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; SWANSON RV, 1993, MOL MICROBIOL, V8, P435, DOI 10.1111/j.1365-2958.1993.tb01588.x; TAYLOR RK, 1983, J MOL BIOL, V166, P273, DOI 10.1016/S0022-2836(83)80085-0; WAUKAU J, 1992, J BACTERIOL, V174, P1522, DOI 10.1128/jb.174.5.1522-1527.1992; YANG Y, 1993, J MOL BIOL, V231, P335, DOI 10.1006/jmbi.1993.1286; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057	37	45	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8728	8733						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	8132603				2022-12-25	WOS:A1994NB41100020
J	MO, HQ; VANDAMME, EJM; PEUMANS, WJ; GOLDSTEIN, IJ				MO, HQ; VANDAMME, EJM; PEUMANS, WJ; GOLDSTEIN, IJ			ISOLATION AND CHARACTERIZATION OF AN N-ACETYL-D-GALACTOSAMINE-BINDING LECTIN FROM DUTCH IRIS BULBS WHICH RECOGNIZES THE BLOOD-GROUP-A DISACCHARIDE (GALNAC-ALPHA-1-3GAL)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BANDEIRAEA-SIMPLICIFOLIA SEEDS; NIGRA L BARK; AFFINITY-CHROMATOGRAPHY; CARBOHYDRATE; PROTEINS; OLIGOSACCHARIDES; PURIFICATION	A blood group type A disaccharide (GalNAc alpha 1-3Gal)binding lectin has been purified from Dutch Iris (Iris x hollandica) bulbs to electrophoretic homogeneity by consecutive affinity chromatography on columns of immobilized asialofetuin-Sepharose 4B and Synsorb A disaccharide (GalNAc alpha 1-3Gal beta-O-(CH2)(8)CONH-Synsorb). This lectin agglutinates both native and trypsin-treated rabbit erythrocytes, but not human erythrocytes, irrespective of blood group type.	UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; KATHOLIEKE UNIV LEUVEN, FYTOPATHOL & PLANTENBESCHERMING LAB, B-3001 LOUVAIN, BELGIUM	University of Michigan System; University of Michigan; KU Leuven			Van Damme, Els/U-3904-2019; Van Damme, Els J/B-4410-2015	Van Damme, Els/0000-0001-9848-766X; 	NIGMS NIH HHS [GM 29470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN MH, 1992, J AM SOC MASS SPECTR, V3, P18, DOI 10.1016/1044-0305(92)85014-B; Andrews PC, 1992, TECHNIQUES PROTEIN C, VIII, P515; AXELSSON K, 1969, ACTA CHEM SCAND, V23, P1815, DOI 10.3891/acta.chem.scand.23-1815; BAKER DA, 1983, BIOCHEMISTRY-US, V22, P2741, DOI 10.1021/bi00280a023; CROWLEY JF, 1982, METHOD ENZYMOL, V83, P368; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; EDGE ASB, 1987, J BIOL CHEM, V262, P16135; FRIEDMAN M, 1970, J BIOL CHEM, V245, P3868; GOLDSTEIN IJ, 1980, NATURE, V285, P66, DOI 10.1038/285066b0; HAMMOND KS, 1976, ANAL BIOCHEM, V74, P292, DOI 10.1016/0003-2697(76)90210-4; HAYES CE, 1974, J BIOL CHEM, V249, P1904; IYER PNS, 1976, ARCH BIOCHEM BIOPHYS, V177, P330, DOI 10.1016/0003-9861(76)90444-6; KAKU H, 1990, ARCH BIOCHEM BIOPHYS, V277, P255, DOI 10.1016/0003-9861(90)90576-K; KOBATA A, 1992, J CHROMATOGR, V597, P111, DOI 10.1016/0021-9673(92)80101-Y; KONAMI Y, 1983, H-S Z PHYSIOL CHEM, V364, P397, DOI 10.1515/bchm2.1983.364.1.397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIENER IE, 1986, LECTINS PROPERTRIES; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; RINDERLE SJ, 1989, J BIOL CHEM, V264, P16123; ROBERTS DD, 1984, J BIOL CHEM, V259, P903; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211; SHIBATA S, 1982, J BIOL CHEM, V257, P9324; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SO LL, 1967, J BIOL CHEM, V242, P1917; SUNDARI CS, 1991, BIOCHIM BIOPHYS ACTA, V1065, P35; TOLLEFSEN SE, 1983, J BIOL CHEM, V258, P5165; TOWNSEND RR, 1986, BIOCHEMISTRY-US, V25, P5716, DOI 10.1021/bi00367a055; WARREN L, 1959, J BIOL CHEM, V234, P1971; WU AM, 1992, J BIOL CHEM, V267, P19130; WU JH, 1993, MOL IMMUNOL, V30, P333, DOI 10.1016/0161-5890(93)90062-G; YAMASHITA K, 1992, BIOCHEMISTRY-US, V31, P11647, DOI 10.1021/bi00161a052; YAMASHITA K, 1992, J BIOL CHEM, V267, P25414	33	20	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7666	7673						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125993				2022-12-25	WOS:A1994NA03200099
J	MURDZAINGLIS, DL; MODRIANSKY, M; PATEL, HV; WOLDEGIORGIS, G; FREEMAN, KB; GARLID, KD				MURDZAINGLIS, DL; MODRIANSKY, M; PATEL, HV; WOLDEGIORGIS, G; FREEMAN, KB; GARLID, KD			SINGLE MUTATION IN UNCOUPLING PROTEIN OF RAT BROWN ADIPOSE-TISSUE MITOCHONDRIA ABOLISHES GDP SENSITIVITY OF H+ TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-SITE; FATTY-ACID ACTIVATION; RECONSTITUTION; TRANSLOCATION; MECHANISM; SEQUENCE; CARRIER	The uncoupling protein is one of a family of mitochondrial transport proteins involved in energy metabolism. It dissipates oxidative energy to generate heat, either by catalyzing proton transport directly or by catalyzing fatty acid anion transport, thus enabling fatty acids to act as cycling protonophores. This transport process is tightly regulated by purine nucleotides. We have expressed uncoupling protein in yeast and examined its proton transport activity after its reconstitution into proteoliposomes. A directed change of Arg(276) to Leu or Gln completely abolished nucleotide inhibition of protonophoretic action of the reconstituted mutant uncoupling proteins without affecting the transport process. Arg(276) is the first residue of functional importance to be identified in uncoupling protein. Mutation of the homologous residue in the yeast ADP/ATP translocator prevented the growth of yeast on a nonfermentable carbon source, presumably by interfering with nucleotide exchange (Nelson, D. R., Lawson, J. E., Klingenberg, M., and Douglas, M. G. (1993) J. Mol. Biol. 230, 1159-1170). Demonstration of the essential role of a single homologous residue in protein-nucleotide interaction within these two transporters is the first direct evidence that uncoupling protein and the ADP/ATP translocator belong to the same gene family.	OREGON GRAD INST SCI & TECHNOL,DEPT CHEM BIOCHEM & MOLEC BIOL,PORTLAND,OR 97291; MCMASTER UNIV,DEPT BIOCHEM,HAMILTON L8N 3Z5,ON,CANADA	McMaster University			Modriansky, Martin/A-6338-2008	Modriansky, Martin/0000-0001-7692-0338; Garlid, Keith/0000-0002-6777-1235	NHLBI NIH HHS [HL 43814] Funding Source: Medline; NIGMS NIH HHS [GM 31086] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; CASTEILLA L, 1989, NUCLEIC ACIDS RES, V17, P2131, DOI 10.1093/nar/17.5.2131; CUNNINGHAM SA, 1986, EUR J BIOCHEM, V157, P415, DOI 10.1111/j.1432-1033.1986.tb09683.x; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; JEZEK P, 1987, FEBS LETT, V211, P89, DOI 10.1016/0014-5793(87)81280-2; JEZEK P, 1990, J BIOL CHEM, V265, P19303; JEZEK P, 1990, J BIOL CHEM, V265, P19296; KAMP F, 1992, P NATL ACAD SCI USA, V89, P11367, DOI 10.1073/pnas.89.23.11367; KATIYAR SS, 1989, P NATL ACAD SCI USA, V86, P2559, DOI 10.1073/pnas.86.8.2559; KLINGENBERG M, 1985, EMBO J, V4, P3087, DOI 10.1002/j.1460-2075.1985.tb04049.x; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MAYINGER P, 1992, BIOCHEMISTRY-US, V31, P10536, DOI 10.1021/bi00158a017; MURDZAINGLIS DL, 1991, J BIOL CHEM, V266, P11871; MURDZAINGLIS DL, 1993, FASEB J, V7, pA1108; NEDERGAARD J, 1992, NEW COMPREHENSIVE BI, V23, P385; NELSON DR, 1993, J MOL BIOL, V230, P1159, DOI 10.1006/jmbi.1993.1233; OROSZ DE, 1993, ANAL BIOCHEM, V210, P7, DOI 10.1006/abio.1993.1143; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; STRIELEMAN PJ, 1985, J BIOL CHEM, V260, P3402; WINKLER E, 1992, EUR J BIOCHEM, V203, P295, DOI 10.1111/j.1432-1033.1992.tb19859.x	22	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7435	7438						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125963				2022-12-25	WOS:A1994NA03200064
J	TORDAI, A; FRANKLIN, RA; PATEL, H; GARDNER, AM; JOHNSON, GL; GELFAND, EW				TORDAI, A; FRANKLIN, RA; PATEL, H; GARDNER, AM; JOHNSON, GL; GELFAND, EW			CROSS-LINKING OF SURFACE IGM STIMULATES THE RAS/RAF-1/MEK/MAPK CASCADE IN HUMAN B-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MAP KINASE; TYROSINE PHOSPHORYLATION; MEMBRANE IMMUNOGLOBULIN; ANTIGEN RECEPTOR; CELL ACTIVATION; EXPRESSION; S6; IDENTIFICATION; PROLIFERATION	The mechanism by which mitogen-activated protein kinase (MAPK) is activated in human B cells following cross-linking of the antigen receptor was investigated. Following anti-IgM antibody and phorbol 12-myristate 13-acetate (PMA) stimulation, we demonstrate the activation of Res, Raf-1, and MAPK/ERK kinase (MEK), all of which are thought to participate in an important signaling cascade that leads to MAPK activation. We detected the kinase activities of Raf-1 and MEK toward purified recombinant substrates for each in this pathway (MEK for Raf-1 and MAPK for MEK). Following stimulation with either anti-IgM or PMA, Ras activation was observed, and the ability of Raf-1 to phosphorylate recombinant kinase-inactive MEK was increased by approximately 10-fold. Similarly, MEK activity toward kinase-active or -inactive recombinant MAPK also increased upon anti-IgM or PMA treatment. Furthermore, the activation of both MAPK and p(90rsk) was demonstrated under identical conditions in the B cells. We conclude that activation of B lymphocytes through the antigen receptor stimulates distinct members of the Ras/Raf-1/MEK cascade and this mechanism is likely to be responsible for MAPK and p(90rsk) activation in these cells.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI,DENVER,CO 80206	National Jewish Health				Franklin, Richard A./0000-0003-0299-9578; Gardner, Anne/0000-0001-7095-772X	NIAID NIH HHS [R01-AI29704, P01-AI29903] Funding Source: Medline; NIDDK NIH HHS [DK37871] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI029903, R01AI029704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ALVEREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; CAMBIER JC, 1992, FASEB J, V6, P3207, DOI 10.1096/fasebj.6.13.1397843; CASILLAS A, 1991, J BIOL CHEM, V266, P19088; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEUNG RK, 1991, J BIOL CHEM, V266, P8667; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FRANKLIN RA, 1993, J IMMUNOL, V151, P1802; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GARDNER AM, 1994, IN PRESS METHODS ENZ; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GLENNEY JR, 1992, BIOCHIM BIOPHYS ACTA, V1134, P113, DOI 10.1016/0167-4889(92)90034-9; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOLD MR, 1992, BIOCHEM J, V287, P269, DOI 10.1042/bj2870269; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; JELINEK DF, 1987, ADV IMMUNOL, V40, P1, DOI 10.1016/S0065-2776(08)60237-0; KLEMSZ MJ, 1989, J IMMUNOL, V143, P1032; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARX J, 1993, SCIENCE, V260, P1588, DOI 10.1126/science.8503004; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; ROIFMAN CM, 1992, BIOCHEM BIOPH RES CO, V183, P411, DOI 10.1016/0006-291X(92)90496-8; ROIFMAN CM, 1991, J IMMUNOL, V146, P2965; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SEGER R, 1992, J BIOL CHEM, V267, P14373; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TERADA N, 1993, J BIOL CHEM, V268, P12062; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	46	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7538	7543						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	8125975				2022-12-25	WOS:A1994NA03200080
